PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	PAYNE, DW; SHACKLETON, C; TOMS, H; BENSHLOMO, I; KOL, S; DEMOURA, M; STRAUSS, JF; ADASHI, EY				PAYNE, DW; SHACKLETON, C; TOMS, H; BENSHLOMO, I; KOL, S; DEMOURA, M; STRAUSS, JF; ADASHI, EY			A NOVEL NONHEPATIC HYDROXYCHOLESTEROL 7-ALPHA-HYDROXYLASE THAT IS MARKEDLY STIMULATED BY INTERLEUKIN-1-BETA - CHARACTERIZATION IN THE IMMATURE RAT OVARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE-MEDIATED REGULATION; BILE-ACID SYNTHESIS; DENSITY-LIPOPROTEIN RECEPTOR; CELL-CELL INTERACTION; CHOLESTEROL 7-ALPHA-HYDROXYLASE; ANDROGEN BIOSYNTHESIS; MESSENGER-RNA; MITOCHONDRIAL CYTOCHROME-P-450; STEROID-HORMONES; GRANULOSA-CELLS	During studies on the regulation of rat ovarian steroidogenic enzymes by interleukin-1 beta (IL-1 beta), we observed substantial metabolism of 25-hydroxycholesterol to two unusual polar products. This unexpected effect was observed both in isolated granulosa cells and in whole ovarian dispersates and was also induced by tumor necrosis factor alpha but not by insulin-like growth factor I or follicle-stimulating hormone. The effect was dependent on time and the dose of IL-1 beta and was blocked by an IL-1 receptor antagonist, The formation of the polar metabolites was inhibited by ketoconazole and trilostane, but not by aminoglutethimide. Subsequent purification of these novel metabolites and analysis by gas chromatography/mass spectrometry, NMR, and high performance liquid chromatography revealed them to be related 7 alpha-hydroxylated hydroxycholesterols (cholest-4-ene-7 alpha,25-diol-3-one and cholest-5-ene-3 beta,7 alpha 25-triol). IL-1 beta-stimulated ovarian 7 alpha-hydroxylase activity (3-10 pmol/min/mg of cellular protein) was nearly 4-fold that of control levels using 25-hydroxycholesterol as substrate, Activities at or below control levels were observed when IL-1 beta-treated cell sonicates were boiled or assayed in the presence of NADH (rather than NADPH), indicating that involvement of a nonenzymatic process was unlikely, IL-1 beta-stimulated 7 alpha-hydroxylase activity was inhibited to basal levels by a 10-fold excess of unlabeled 25- or 27-hydroxycholesterol, but not by cholesterol, pregnenolone, progesterone, testosterone, or dehydroepiandrosterone, suggesting that ovarian 7 alpha-hydroxylase is specific for hydroxycholesterols, Furthermore, when IL-1 beta-treated ovarian cultures were incubated with radiolabeled cholesterol or testosterone, no 7 alpha-hydroxylated products were observed, We were also unable to detect any mRNA transcripts for liver cholesterol 7 alpha-hydroxylase in IL-1 beta-stimulated ovarian cultures, This study describes an ovarian hydroxycholesterol 7 alpha-hydroxylase that differs from liver cholesterol 7 alpha-hydroxylase and from other nonhepatic progestin/androgen 7 alpha-hydroxylases, The novel finding of the regulation of a 7 alpha-hydroxylase by IL-1 beta (and tumor necrosis factor alpha) suggests a unique role for cytokines in the regulation of cholesterol metabolism in the ovary and possibly other tissues.	CHILDRENS HOSP OAKLAND, RES INST, OAKLAND, CA 94609 USA; UNIV LONDON, UNIV LONDON QUEEN MARY & WESTFIELD COLL, LONDON E1 4NS, ENGLAND; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of London; Queen Mary University London; University of Pennsylvania	PAYNE, DW (corresponding author), UNIV MARYLAND, SCH MED,DEPT OBSTET GYNECOL,DIV REPROD ENDOCRINOL, 655 W BALTIMORE ST, RM 11-010, BALTIMORE, MD 21201 USA.		Kol, Shahar/R-7180-2019	Kol, Shahar/0000-0002-2899-5295	NICHD NIH HHS [HD-O6274, HD-19998, HD-30288] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030288, R01HD019998] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADASHI EY, 1990, AM J OBSTET GYNECOL, V162, P889, DOI 10.1016/0002-9378(90)91289-O; ADASHI EY, 1989, J BIOL CHEM, V264, P11591; AKWA Y, 1992, BIOCHEM J, V288, P959, DOI 10.1042/bj2880959; ALSEMA GJ, 1982, J STEROID BIOCHEM, V17, P31, DOI 10.1016/0022-4731(82)90588-X; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDREANI CL, 1991, J BIOL CHEM, V266, P6761; ARINGER L, 1981, BIOMED MASS SPECTROM, V8, P183, DOI 10.1002/bms.1200080502; AXELSON M, 1992, J BIOL CHEM, V267, P1701; AYAKI Y, 1989, J BIOL CHEM, V264, P3818; BAKOS JT, 1993, J STEROID BIOCHEM, V46, P415, DOI 10.1016/0960-0760(93)90096-F; BAX A, 1981, J MAGN RESON, V44, P542, DOI 10.1016/0022-2364(81)90287-0; BENSHLOMO I, 1994, BIOL REPROD, V94, P1463; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHAN YL, 1987, J BIOL CHEM, V262, P1111; DECAPRIO J, 1992, J LIPID RES, V33, P441; DEXTER RN, 1967, J CLIN ENDOCR METAB, V27, P473, DOI 10.1210/jcem-27-4-473; DUELAND S, 1992, J BIOL CHEM, V267, P22695; EINARSSON K, 1992, J LIPID RES, V33, P1591; FALKE HE, 1975, MOL CELL ENDOCRINOL, V3, P375, DOI 10.1016/0303-7207(75)90037-4; FEINGOLD KR, 1993, J LIPID RES, V34, P2147; GUPTA A, 1986, J BIOL CHEM, V261, P8348; HARDARDOTTIR I, 1994, LYMPHOKINE CYTOK RES, V13, P161; HERNANDEZ ER, 1988, ENDOCRINOLOGY, V122, P1603, DOI 10.1210/endo-122-4-1603; HURWITZ A, 1991, ENDOCRINOLOGY, V129, P1250, DOI 10.1210/endo-129-3-1250; HURWITZ A, 1992, J CLIN INVEST, V89, P1746, DOI 10.1172/JCI115777; HURWITZ A, 1991, ENDOCRINOLOGY, V129, P3427, DOI 10.1210/endo-129-6-3427; HURWITZ A, 1992, ENDOCRINOLOGY, V131, P1643, DOI 10.1210/en.131.4.1643; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; INANO H, 1971, BIOCHEMISTRY-US, V10, P1503; JAVITT NB, 1990, J LIPID RES, V31, P1527; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KHALIL MW, 1994, J STEROID BIOCHEM, V48, P545, DOI 10.1016/0960-0760(94)90206-2; KHALIL MW, 1993, J STEROID BIOCHEM, V46, P585, DOI 10.1016/0960-0760(93)90186-Z; KIRK DN, 1990, J CHEM SOC PERK T 2, P1567, DOI 10.1039/p29900001567; KLEBE RJ, 1984, IN VITRO CELL DEV B, V20, P127; KOKIA E, 1992, ENDOCRINOLOGY, V130, P3095, DOI 10.1210/en.130.5.3095; KOKIA E, 1995, FERTIL STERIL, V63, P176, DOI 10.1016/S0015-0282(16)57314-2; KOKIA E, 1993, ENDOCRINOLOGY, V133, P2391, DOI 10.1210/en.133.5.2391; KUIPERS F, 1989, LIPIDS, V24, P759, DOI 10.1007/BF02544580; LEIGHTON JK, 1991, MOL CELL BIOL, V11, P2049, DOI 10.1128/MCB.11.4.2049; MARTIN KO, 1993, J LIPID RES, V34, P581; MITTON JR, 1971, EUR J BIOCHEM, V20, P569, DOI 10.1111/j.1432-1033.1971.tb01429.x; MORFIN R, 1994, J STEROID BIOCHEM, V50, P91, DOI 10.1016/0960-0760(94)90176-7; PAYNE DW, 1991, SERONO SYMP, P190; PAYNE DW, 1988, BIOL REPROD, V39, P581, DOI 10.1095/biolreprod39.3.581; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PINKERTON FD, 1993, BIOCHEM BIOPH RES CO, V193, P1091, DOI 10.1006/bbrc.1993.1737; POTTS GO, 1978, STEROIDS, V32, P257, DOI 10.1016/0039-128X(78)90010-7; PRINCEN HMG, 1986, J CLIN INVEST, V78, P1064, DOI 10.1172/JCI112662; RENNERT H, 1990, ENDOCRINOLOGY, V127, P738, DOI 10.1210/endo-127-2-738; SHACKLETON CHL, 1986, J CHROMATOGR, V379, P91, DOI 10.1016/S0378-4347(00)80683-0; SONDERFAN AJ, 1989, ENDOCRINOLOGY, V125, P857, DOI 10.1210/endo-125-2-857; SRINIVASAN G, 1993, RECEPTOR, V3, P99; STRAKA MS, 1990, J BIOL CHEM, V265, P7145; STRAUSS JF, 1981, ADV LIPID RES, V18, P99; STRAVITZ RT, 1993, J BIOL CHEM, V268, P13987; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; SUDJANASUGIAMAN E, 1994, BIOCHEM BIOPH RES CO, V202, P896, DOI 10.1006/bbrc.1994.2014; SWELL L, 1981, BIOCHIM BIOPHYS ACTA, V663, P163, DOI 10.1016/0005-2760(81)90202-2; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; TINT GS, 1978, J LIPID RES, V19, P956; TOAFF ME, 1982, ENDOCRINOLOGY, V111, P1785, DOI 10.1210/endo-111-6-1785; TOLL A, 1994, EUR J BIOCHEM, V224, P309, DOI 10.1111/j.1432-1033.1994.00309.x; VLAHCEVIC ZR, 1991, HEPATOLOGY, V13, P590, DOI 10.1002/hep.1840130331	66	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18888	18896		10.1074/jbc.270.32.18888	http://dx.doi.org/10.1074/jbc.270.32.18888			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642545	hybrid			2022-12-25	WOS:A1995RN95400032
J	JUGEAUBRY, CE; GORLABAJSZCZAK, A; PERNIN, A; LEMBERGER, T; WAHLI, W; BURGER, AG; MEIER, CA				JUGEAUBRY, CE; GORLABAJSZCZAK, A; PERNIN, A; LEMBERGER, T; WAHLI, W; BURGER, AG; MEIER, CA			PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR MEDIATES CROSS-TALK WITH THYROID-HORMONE RECEPTOR BY COMPETITION FOR RETINOID-X RECEPTOR - POSSIBLE ROLE OF A LEUCINE ZIPPER-LIKE HEPTAD REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; RESISTANCE; DIMERIZATION; EXPRESSION; ISOFORMS; ELEMENT; GENE; DNA	The peroxisome proliferator-activated receptors (PPAR) and thyroid hormone receptors (TR) are members of the nuclear receptor superfamily, which regulate lipid metabolism and tissue differentiation. In order to bind to DNA and activate transcription, PPAR requires the formation of heterodimers with the retinoid X receptor (RXR). In addition to activating transcription through its own response elements, PPAR is able to selectively down-regulate the transcriptional activity of TR, but not vitamin D receptor. The molecular basis of this functional interaction has not been fully elucidated. By means of site-directed mutagenesis of hPPAR alpha we mapped its inhibitory action on TR to a leucine zipper-like motif in the ligand binding domain of PPAR, which is highly conserved among all subtypes of this receptor and mediates heterodimerization with RXR. Replacement of a single leucine by arginine at position 433 of hPPAR alpha (L433R) abolished heterodimerization of PPAR with RXR and consequently its trans-activating capacity. However, a similar mutation of a leucine residue to arginine at position 422 showed no alteration of heterodimerization, DNA binding, or transcriptional activation. The dimerization deficient mutant L433R was no longer able to inhibit TR action, demonstrating that the selective inhibitory effect of PPAR results from the competition for RXR as well as possibly for other TR-auxiliary proteins. In contrast, abolition of DNA binding by a mutation in the P-box of PPAR (C122S) did not eliminate the inhibition of TR trans-activation, indicating that competition for DNA binding is not involved. Additionally, no evidence for the formation of PPAR:TR heterodimers was found in co-immunoprecipitation experiments. In summary, we have demonstrated that PPAR selectively inhibits the transcriptional activity of TRs by competition for RXR and possibly non-RXR TR-auxiliary proteins. In contrast, this functional interaction is independent of the formation of PPAR:TR heterodimers or competition for DNA binding.	UNIV HOSP GENEVA,DIV ENDOCRINOL,THYROID UNIT,CH-1211 GENEVA,SWITZERLAND; UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND; GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OVATES,SWITZERLAND; UNIV HOSP GENEVA,DEPT MED,MED CLIN 2,CH-1211 GENEVA,SWITZERLAND	University of Geneva; University of Lausanne; GlaxoSmithKline; University of Geneva			Lemberger, Thomas/A-7301-2008; Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009	Lemberger, Thomas/0000-0002-2499-4025; Wahli, Walter/0000-0002-5966-9089				AUFLIEGNER M, MOL CELL BIOL, V13, P5725; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; DARLING DS, 1993, J BIOL CHEM, V268, P10221; FALCONE M, 1994, EUR J ENDOCRINOL, V130, P97, DOI 10.1530/eje.0.1300097; FALCONE M, 1992, ENDOCRINOLOGY, V131, P2419, DOI 10.1210/en.131.5.2419; FLUG F, 1987, J BIOL CHEM, V262, P6373; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MEIER CA, 1983, J CLIN INVEST, V92, P1986; MEIERHEUSLER SC, 1995, MOL CELL ENDOCRINOL, V107, P55, DOI 10.1016/0303-7207(94)03422-P; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; SHER T, 1993, BIOCHEMISTRY-US, V32, P8898; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V315, P555, DOI 10.1006/abbi.1994.1536; YEN PM, 1992, J BIOL CHEM, V267, P3565	23	134	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18117	18122		10.1074/jbc.270.30.18117	http://dx.doi.org/10.1074/jbc.270.30.18117			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629123	hybrid			2022-12-25	WOS:A1995RM26600074
J	KOLAKOWSKI, LF; LU, B; GERARD, C; GERARD, NP				KOLAKOWSKI, LF; LU, B; GERARD, C; GERARD, NP			PROBING THE MESSAGE-ADDRESS SITES FOR CHEMOATTRACTANT BINDING TO THE C5A RECEPTOR - MUTAGENESIS OF HYDROPHILIC AND PROLINE RESIDUES WITHIN THE TRANSMEMBRANE SEGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; LIGAND-BINDING; INTERLEUKIN-8 RECEPTOR; CYSTEINE RESIDUE-110; SUBTYPE SPECIFICITY; BOVINE RHODOPSIN; AMINO TERMINUS; ANAPHYLATOXIN; IDENTIFICATION	The C5a anaphylatoxin ligand receptor interaction on polymorphonuclear granulocytes stimulates chemotaxis, degranulation, and the oxidative burst. The receptor is a member of the large G-protein-coupled family. The ligand is a cationic peptide of 72 amino acids derived from the C5 component of complement and has been shown to have a number of structural requirements for interaction with the receptor. In order to probe the potential interaction sites between ligand and receptor, we constructed a series of mutated receptor molecules, targeting cysteines, prolines, and additional amino acids of interest because of combinations of charge or hydrophobicity and putative location with respect to the membrane. Transfected mutant receptors were analyzed for cell surface expression, ligand binding, and ligand-activated phospholipase C activity. The receptors created can be placed generally in four distinct classes: those which bind and signal like the natural receptor; those which bind but fail to transduce signals; those which are expressed but neither bind nor transduce signal; and those which are not expressed at the cell surface.	CHILDRENS HOSP,INA SUE PERLMUTTER LAB,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PEDIAT,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA; HARVARD UNIV,CTR BLOOD RES,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,THORNDIKE LAB,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R37HL036162] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL71910, HL36162] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BAYRAMASHVILI DI, 1984, EUR J BIOCHEM, V142, P583, DOI 10.1111/j.1432-1033.1984.tb08326.x; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GERARD C, 1985, J BIOL CHEM, V260, P2613; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD G, 1979, J RETICULOENDOTHEL S, V26, P711; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HENDERSON R, 1990, PHILOS T ROY SOC B, V326, P379, DOI 10.1098/rstb.1990.0019; HUUANG HV, 1988, BIOTECHNOLOGY, V10, P269; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAWAI M, 1991, J MED CHEM, V34, P2068, DOI 10.1021/jm00111a022; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEONG SR, 1994, J BIOL CHEM, V269, P19343; MERY L, 1994, J BIOL CHEM, V269, P3457; MOLLISON KW, 1989, P NATL ACAD SCI USA, V86, P292, DOI 10.1073/pnas.86.1.292; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHWYZER R, 1980, PROC R SOC SER B-BIO, V210, P5, DOI 10.1098/rspb.1980.0115; Schwyzer R, 1977, Ann N Y Acad Sci, V297, P3, DOI 10.1111/j.1749-6632.1977.tb41843.x; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STRADER CD, 1988, J BIOL CHEM, V263, P10267; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; TOTA MR, 1990, J BIOL CHEM, V265, P16891; VALOVE FM, 1994, ENDOCRINOLOGY, V135, P2657, DOI 10.1210/en.135.6.2657; VOGT W, 1986, Complement, V3, P177; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; YANCEY KB, 1989, J INVEST DERMATOL, V92, P184, DOI 10.1111/1523-1747.ep12276710; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	46	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18077	18082		10.1074/jbc.270.30.18077	http://dx.doi.org/10.1074/jbc.270.30.18077			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629117	hybrid			2022-12-25	WOS:A1995RM26600068
J	LAIDLER, V; CHADDOCK, AM; KNOTT, TG; WALKER, D; ROBINSON, C				LAIDLER, V; CHADDOCK, AM; KNOTT, TG; WALKER, D; ROBINSON, C			A SECY HOMOLOG IN ARABIDOPSIS-THALIANA - SEQUENCE OF A FULL-LENGTH CDNA CLONE AND IMPORT OF THE PRECURSOR PROTEIN INTO CHLOROPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; MEMBRANE-PROTEINS; PLASTID GENOME; EXPORT GENE; MATURATION; PEPTIDES; OPERON; MUTANT; LUMEN	Proteins are translocated across the thylakoid membrane by two distinct pathways in higher plant chloroplasts, one of which is related to prokaryotic Sec-dependent translocation mechanisms. SecY is an essential, hydrophobic component of the membrane-bound translocase complex in bacteria, and we report here the nucleotide sequence of a full-length cDNA encoding a homolog of SecY from Arabidopsis thaliana. The predicted protein of 551 residues includes an amino-terminal extension of approximately 120 residues when compared with other SecY proteins. The deduced sequence of the mature protein, cpSecY, is 41% identical with SecY from Synechococcus and 33% identical with the Escherichia coli protein. The extension serves to target the protein into chloroplasts; transcription-translation of the cDNA yields a 58-kDa precursor protein which is imported into pea chloroplasts, processed to a product of 46 kDa, and targeted into the thylakoid membrane.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick				Walker, Denise/0000-0003-1534-1679				AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; DOUGLAS SE, 1992, FEBS LETT, V298, P93, DOI 10.1016/0014-5793(92)80029-G; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; FLACHMANN R, 1993, J BIOL CHEM, V268, P7514; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; NAKAI M, 1994, J BIOL CHEM, V269, P31338; NAKAI M, 1992, BIOCHIM BIOPHYS ACTA, V1171, P113, DOI 10.1016/0167-4781(92)90150-X; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P1895, DOI 10.1073/pnas.86.6.1895; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	23	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17664	17667		10.1074/jbc.270.30.17664	http://dx.doi.org/10.1074/jbc.270.30.17664			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629062	hybrid			2022-12-25	WOS:A1995RM26600007
J	RANA, B; XIE, YH; MISCHOULON, D; BUCHER, NLR; FARMER, SR				RANA, B; XIE, YH; MISCHOULON, D; BUCHER, NLR; FARMER, SR			THE DNA-BINDING ACTIVITY OF C/EBP TRANSCRIPTION FACTORS IS REGULATED IN THE G(1) PHASE OF THE HEPATOCYTE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-REGENERATION; GENE-EXPRESSION; PHOSPHOENOLPYRUVATE CARBOXYKINASE; 3T3-L1 PREADIPOCYTES; INDUCTION-PATTERNS; ACTIVATOR PROTEIN; DIFFERENTIATION; FAMILY; ISOFORMS; PROMOTER	We have isolated the promoter of the rat C/EBP alpha gene and find a high degree of homology with the mouse gene, particularly in putative regulatory domains. Transactivation of this promoter by ectopic expression of rat C/EBP beta occurs through a C/EBP regulatory domain at position -170 to -195. An oligonucleotide corresponding to this domain binds to complexes expressed in rat liver that comprise C/EBP alpha-C/EBP beta heterodimers (alpha beta) as well as C/EBP beta complexed with itself and/or other unidentified nuclear factors (beta 1, beta 2, and beta 3). The DNA binding activity of these complexes changes both qualitatively and quantitatively following partial hepatectomy. Within 2-5 h postsurgery, the binding activity of the alpha beta complexes drops severalfold, reaching a nadir by 20 h. During the ensuing 3-8 days, as regeneration nears completion, this activity slowly returns to normal quiescent liver levels. Western blot analysis shows 3 major C/EBP alpha polypeptide species (42, 40, and 30 kDa), whose abundance in general parallels the decrease and recovery in DNA binding activity. In contrast to C/EBP alpha behavior, the DNA binding activity of the beta complexes is transiently induced severalfold during the early G(1) period between 2 and 6 h posthepatectomy. The major C/EBP beta polypeptide is the 32-kDa LAP protein, whereas the LIP protein (21 kDa) is weakly expressed. Both remain essentially constant throughout the course of regeneration, suggesting that changes in DNA binding activity may reflect changes in the complexed proteins rather than the C/EBP beta polypeptides themselves. In primary hepatocyte cultures, under growth supporting conditions, in the absence of growth factors proliferation is negligible; C/EBP alpha is abundantly expressed at the outset, but is then extensively down-regulated. Epidermal growth factor causes further decay of C/EBP alpha polypeptides and DNA binding activity, and down-regulates C/EBP beta DNA binding activity as well. Addition of transforming growth factor beta completely antagonizes the effects of epidermal growth factor on C/EBP beta activity, and partially overcomes the effect on C/EBP alpha. These results demonstrate that the DNA binding activity of C/EBP alpha and C/EBP beta complexes is regulated in the regenerating liver, and in hepatocyte cultures responding to growth factors that regulate their proliferation.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118	Boston University; Boston University				Farmer, Stephen/0000-0003-2483-2795	NATIONAL CANCER INSTITUTE [R01CA039099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045048] Funding Source: NIH RePORTER; NCI NIH HHS [CA39099] Funding Source: Medline; NIDDK NIH HHS [DK45048] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM T, 1992, J BIOL CHEM, V267, P5021; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BUCHER NLR, 1991, J GASTROEN HEPATOL, V6, P615, DOI 10.1111/j.1440-1746.1991.tb00921.x; BUCHER NLR, 1978, CIBA F S, V55, P95; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIEHL AM, 1994, HEPATOLOGY, V19, P447; FAUSTO N, 1989, HEPATOLOGY, P49; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FRIEDMAN JM, 1984, J MOL BIOL, V179, P37, DOI 10.1016/0022-2836(84)90305-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Higgins GM, 1931, ARCH PATHOL, V12, P186; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MCGOWAN JA, 1981, J CELL PHYSIOL, V108, P353, DOI 10.1002/jcp.1041080309; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MOHN KL, 1990, J BIOL CHEM, V265, P21914; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VASSEURCOGNET M, 1993, CURR OPIN GENET DEV, V3, P238, DOI 10.1016/0959-437X(93)90029-O; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; XANTHOPOULOS KG, 1989, P NATL ACAD SCI USA, V86, P4117, DOI 10.1073/pnas.86.11.4117	45	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18123	18132		10.1074/jbc.270.30.18123	http://dx.doi.org/10.1074/jbc.270.30.18123			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629124	hybrid			2022-12-25	WOS:A1995RM26600075
J	ALLEVATO, G; BILLESTRUP, N; GOUJON, L; GALSGAARD, ED; NORSTEDT, G; POSTELVINAY, MC; KELLY, PA; NIELSEN, JH				ALLEVATO, G; BILLESTRUP, N; GOUJON, L; GALSGAARD, ED; NORSTEDT, G; POSTELVINAY, MC; KELLY, PA; NIELSEN, JH			IDENTIFICATION OF PHENYLALANINE-346 IN THE RAT GROWTH-HORMONE RECEPTOR AS BEING CRITICAL FOR LIGAND-MEDIATED INTERNALIZATION AND DOWN-REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; MUTATIONAL ANALYSIS; INSULINOMA CELLS; BINDING-PROTEIN; SEQUENCE; ADIPOCYTES; JAK2; PHOSPHORYLATION; MUTAGENESIS	The functional significance of growth hormone (GH) receptor (GHR) internalization is unknown; therefore, we have analyzed domains and individual amino acids in the cytoplasmic region of the rat GHR required for ligand-mediated receptor internalization, receptor down-regulation, and transcriptional signaling, When various mutated GHR cDNAs were transfected stably into Chinese hamster ovary cells or transiently into monkey kidney (COS-7) cells, internalization of the GHR was found to be dependent upon a domain located between amino acids 318 and 380, Mutational analysis of aromatic residues in this domain revealed that phenylalanine 346 is required for internalization. Receptor down-regulation in transiently transfected COS-7 cells was also dependent upon the phenylalanine 346 residue of the GHR, since no GH-induced down-regulation was observed in cells expressing the F346A GHR mutant. in contrast, the ability to stimulate transcription of the serine protease inhibitor 2.1 promoter by the GHR was not affected by the phenylalanine 346 to alanine mutation, These results demonstrate that phenylalanine 346 is essential for GHR internalization and down-regulation but not for transcriptional signaling, suggesting that ligand-mediated endocytosis is not a prerequisite for GH-induced gene transcription.	HAGEDORN RES INST, DK-2820 GENTOFTE, DENMARK; FAC MED NECKER ENFANTS MALAD, UNITE 344, F-75730 PARIS 15, FRANCE; NOVUM, KAROLINSKA INST, CTR BIOTECHNOL, S-14157 HUDDINGE, SWEDEN	Novo Nordisk; Hagedorn Research Institute; UDICE-French Research Universities; Universite Paris Cite; Karolinska Institutet			Kelly, Paul/A-7951-2008	Billestrup, Nils/0000-0002-4968-8067; Nielsen, Jens Hoiriis/0000-0001-8252-3048				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; ESHET R, 1984, ACTA ENDOCRINOL-COP, V107, P9, DOI 10.1530/acta.0.1070009; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOBIE PE, 1991, J BIOL CHEM, V266, P22645; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; PAQUEREAU L, 1992, EUR J BIOCHEM, V209, P1053, DOI 10.1111/j.1432-1033.1992.tb17381.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; ROUPAS P, 1986, MOL CELL ENDOCRINOL, V47, P81, DOI 10.1016/0303-7207(86)90018-3; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; SAVION N, 1981, J BIOL CHEM, V256, P1149; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WAKSHULL EM, 1985, P NATL ACAD SCI USA, V82, P8513, DOI 10.1073/pnas.82.24.8513; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YANKNER BA, 1982, ANNU REV BIOCHEM, V51, P845, DOI 10.1146/annurev.bi.51.070182.004213; YOON JB, 1990, J BIOL CHEM, V265, P19947	39	81	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17210	17214		10.1074/jbc.270.29.17210	http://dx.doi.org/10.1074/jbc.270.29.17210			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615519	hybrid			2022-12-25	WOS:A1995RK68900026
J	HIGAZI, AA; COHEN, RL; HENKIN, J; KNISS, D; SCHWARTZ, BS; CINES, DB				HIGAZI, AA; COHEN, RL; HENKIN, J; KNISS, D; SCHWARTZ, BS; CINES, DB			ENHANCEMENT OF THE ENZYMATIC-ACTIVITY OF SINGLE-CHAIN UROKINASE PLASMINOGEN-ACTIVATOR BY SOLUBLE UROKINASE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND UROKINASE; PRO-UROKINASE; POTENTIATION; INHIBITION; MONOCYTES; CELLS; MODEL	Single-chain urokinase (scuPA), the unique form of urokinase secreted by cells, is converted to an active two-chain molecule through the cleavage of a single peptide bond by plasmin and other specific proteinases. Although scuPA may express limited enzymatic activity, its contribution to plasminogen activation on cell surfaces remains uncertain. Further, although it is well known that scuPA binds to a specific extracellular urokinase type plasminogen activator receptor, the effect of this interaction on the enzymatic activity of scuPA has not been described. In the present paper we report that the binding of scuPA to cellular and to recombinant soluble urokinase-type plasminogen activator receptors (suPAR) increases its catalytic activity as measured by the cleavage of a urokinase-specific chromogenic substrate. suPAR increased the V-max of scuPA 5-fold with little change in its K-m. suPAR also stimulated the plasminogen activator activity of scuPA by decreasing its K-m for Glu-plasminogen from 1.15 mu M to 0.022 mu M and by increasing the k(cat) of this reaction from 0.0015 to 0.022 s(-1). Preincubation of scuPA with suPAR also enhances its susceptibility to inhibition by plasminogen activator inhibitor type 1, consistent with exposure of its catalytic site. The activity of scuPA bound to suPAR is not accompanied by cleavage of scuPA, which continues to migrate as a single band in SDS-polyacrylamide gel electrophoresis under reducing conditions. Moreover, suPAR increases the plasminogen activator activity of a plasmin-insensitive variant, scuPA (scuPA-Glu(158)), as well. Enhancement of scuPA activity by suPAR is both prevented and reversed by its aminoterminal fragment (amino acids 1-135), which competes for receptor binding, suggesting that continued binding to the receptor is required for expression of scuPA's enzymatic activity. Thus, our data suggest that scuPA may undergo a reversible transformation between a la tent and an active state. The urokinase receptor may induce or stabilize scuPA in its active conformation, thereby contributing to the initiation of plasminogen activation on cell surfaces.	GENENTECH INC,S SAN FRANCISCO,CA 94080; ABBOTT LABS,ABBOTT PK,IL 60064; OHIO STATE UNIV,DEPT OBSTET & GYNECOL,COLUMBUS,OH 43210; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706	Roche Holding; Genentech; Abbott Laboratories; University System of Ohio; Ohio State University; University of Wisconsin System; University of Wisconsin Madison	HIGAZI, AA (corresponding author), HOSP UNIV PENN,DEPT PATHOL & LAB MED,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049517, P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40387, HL50970, HL49517] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DISS EM, 1992, AM J OBSTET GYNECOL, V167, P1046, DOI 10.1016/S0002-9378(12)80036-6; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ELLIS V, 1987, J BIOL CHEM, V262, P14998; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; HARVEY SR, 1988, CLIN EXP METASTAS, V6, P431, DOI 10.1007/BF01784375; HIGAZI AA, 1992, BIOCHEM J, V282, P863, DOI 10.1042/bj2820863; KASAI S, 1985, J BIOL CHEM, V260, P2382; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SW, 1994, J BIOL CHEM, V269, P2411; LIU JN, 1992, J BIOL CHEM, V267, P15289; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MIZUKAMI IF, 1994, CLIN IMMUNOL IMMUNOP, V71, P96, DOI 10.1006/clin.1994.1057; NELLES L, 1987, J BIOL CHEM, V262, P5682; PANNELL R, 1987, BLOOD, V69, P22; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333	20	81	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17375	17380		10.1074/jbc.270.29.17375	http://dx.doi.org/10.1074/jbc.270.29.17375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615542	hybrid			2022-12-25	WOS:A1995RK68900053
J	THOMSON, RB; IGARASHI, P; BIEMESDERFER, D; KIM, R; ABUALFA, A; SOLEIMANI, M; ARONSON, PS				THOMSON, RB; IGARASHI, P; BIEMESDERFER, D; KIM, R; ABUALFA, A; SOLEIMANI, M; ARONSON, PS			ISOLATION AND CDNA CLONING OF KSP-CADHERIN, A NOVEL KIDNEY-SPECIFIC MEMBER OF THE CADHERIN MULTIGENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; L-CAM; POLYACRYLAMIDE GELS; CYTOPLASMIC DOMAIN; SEQUENCE-ANALYSIS; NERVOUS-SYSTEM; RNA ISOLATION; T-CADHERIN	Cadherins are recognized as the principal mediators of homotypic cellular recognition and, play a demonstrated role in the morphogenic direction of tissue development. We report here the identification of a structurally unique, kidney-specific member of the cadherin multigene family (Ksp-cadherin). cDNA cloning and molecular analysis of the 130-kDa protein confirmed that it was novel and indicated that it most closely resembled members of the LI-cadherin/HPT-1 cadherin subgroup. The predicted protein possesses the definitive cadherin-specific sequence motifs LDRE, DXND, and DXD in well conserved sequential arrangement, and the characteristic cysteine residues found in the last ectodomains of almost all known cadherins. Like LI-cadherin and HPT-1, Ksp-cadherin lacks the prosequence and HAV adhesion recognition sequence typical of most classical cadherins, and possesses a truncated cytoplasmic domain (18-22 amino acids). When expressed in a transient Vaccinia/T7 expression system, Ksp-cadherin displayed the classic calcium sensitivity to trypsin proteolysis that is observed in all cadherins. Immunolocalization studies and Northern analysis indicated that expression of Ksp-cadherin was kidney-specific and limited to the basolateral membranes of renal tubular epithelial cells. In summary, we have identified and cloned a novel, kidney-specific member of the cadherin multigene family that we propose be designated Ksp-cadherin.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEPHROL SECT,NEW HAVEN,CT 06510	Yale University				Igarashi, Peter/0000-0001-8698-1185; soleimani, m/0000-0002-3446-8870	NIDDK NIH HHS [DK 17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOTA S, 1988, NUCLEIC ACIDS RES, V16, P315; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; DANTZIG AH, 1994, SCIENCE, V264, P430, DOI 10.1126/science.8153632; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; GALLIN WJ, 1987, P NATL ACAD SCI USA, V84, P2808, DOI 10.1073/pnas.84.9.2808; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GRASSL SM, 1986, J BIOL CHEM, V261, P8778; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; HARTMANN KKP, 1990, ENDOCRINOLOGY, V127, P2038, DOI 10.1210/endo-127-4-2038; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HILDEBRANDT F, 1991, BIOCHIM BIOPHYS ACTA, V1129, P105, DOI 10.1016/0167-4781(91)90221-7; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; HYAFIL F, 1981, CELL, V26, P446; IGARASHI P, 1991, BIOCHEM J, V280, P71, DOI 10.1042/bj2800071; KASHGARIAN M, 1985, KIDNEY INT, V28, P899, DOI 10.1038/ki.1985.216; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIAW CW, 1990, EMBO J, V9, P2701, DOI 10.1002/j.1460-2075.1990.tb07456.x; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; NOUWEN EJ, 1993, KIDNEY INT, V44, P147, DOI 10.1038/ki.1993.225; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P560; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SOLEIMANI M, 1989, KIDNEY INT, V35, P464; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VOLLER A, 1979, GUIDE ABSTRACTS MICR, P1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415; XIANG YY, 1994, CANCER RES, V54, P3034	54	89	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17594	17601		10.1074/jbc.270.29.17594	http://dx.doi.org/10.1074/jbc.270.29.17594			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615566	hybrid			2022-12-25	WOS:A1995RK68900083
J	LUTTRELL, LM; VANBIESEN, T; HAWES, BE; KOCH, WJ; TOUHARA, K; LEFKOWITZ, RJ				LUTTRELL, LM; VANBIESEN, T; HAWES, BE; KOCH, WJ; TOUHARA, K; LEFKOWITZ, RJ			G(BETA-GAMMA) SUBUNITS MEDIATE MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION BY THE TYROSINE KINASE INSULIN-LIKE GROWTH-FACTOR-1 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BC3H-1 MURINE MYOCYTES; PERTUSSIS TOXIN; GTP-BINDING; FIBROBLASTS; CELLS; INVOLVEMENT; P21(RAS); PATHWAY	The receptors for insulin-like growth factor 1 (IGF1) and insulin are related heterotetrameric proteins which, like the epidermal growth factor (EGF) receptor, possess intrinsic ligand-stimulated tyrosine protein kinase activity, In Rat 1 fibroblasts, stimulation of mitogen-activated protein (MAP) kinase via the IGF1 receptor and the G(i)-coupled receptor for lysophosphatidic acid (LPA), but not via the EGF receptor, is sensitive both to pertussis toxin treatment and to cellular expression of a specific G(beta gamma) subunit-binding peptide, The IGF1, LPA, and EGF receptor-mediated signals are all sensitive to inhibitors of tyrosine protein kinases, require p21(ras) activation, and are independent of protein kinase C. These data suggest that some tyrosine kinase growth factor receptors (e.g. IGF1 receptor) and classical G protein-coupled receptors (e.g. LPA receptor) employ a similar mechanism for mitogenic signaling that involves both tyrosine phosphorylation and G(beta gamma) subunits derived from pertussis toxin-sensitive G proteins.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL 16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DUBLER RE, 1985, ARCH BIOCHEM BIOPHYS, V236, P119, DOI 10.1016/0003-9861(85)90611-3; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1991, MOL CELL BIOL, V8, P4822; GOREN HJ, 1985, CAN J PHYSIOL PHARM, V63, P1017, DOI 10.1139/y85-167; HEYWORTH CM, 1986, BIOCHEM J, V235, P145, DOI 10.1042/bj2350145; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KELLERER M, 1991, BIOCHEM J, V276, P103, DOI 10.1042/bj2760103; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1993, FEBS LETT, V334, P143, DOI 10.1016/0014-5793(93)81700-A; OMICHI M, 1994, J BIOL CHEM, V269, P3783; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANOBBERGHENSCH.E, 1983, EXP CELL RES, V147, P369; VILA MD, 1990, BIOCHEMISTRY-US, V29, P8735, DOI 10.1021/bi00489a033; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1; WINITZ S, 1993, J BIOL CHEM, V268, P19196	41	192	192	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16495	16498		10.1074/jbc.270.28.16495	http://dx.doi.org/10.1074/jbc.270.28.16495			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622449	hybrid			2022-12-25	WOS:A1995RJ34700004
J	STOCKERT, RJ; POTVIN, B; TAO, L; STANLEY, P; WOLKOFF, AW				STOCKERT, RJ; POTVIN, B; TAO, L; STANLEY, P; WOLKOFF, AW			HUMAN HEPATOMA-CELL MUTANT DEFECTIVE IN CELL-SURFACE PROTEIN TRAFFICKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; LOW-DENSITY-LIPOPROTEIN; HAMSTER OVARY CELLS; RECEPTOR-MEDIATED ENDOCYTOSIS; HUMAN ASIALOGLYCOPROTEIN RECEPTOR; SEMLIKI FOREST VIRUS; GALACTOSYL RECEPTORS; GOLGI-COMPLEX; END4 MUTANT; TEMPERATURE	To isolate a mutant liver cell defective in the endocytic pathway, a selection strategy using toxic ligands for two distinct membrane receptors was devised, Ovalbumin-gelonin and asialoorosomucoid (ASOR)-gelonin were incubated with mutagenized HuH-7 cells, and a rare survivor termed trafficking mutant 1 (Trf1) was isolated, Trf1 cells were stably 3-fold more resistant than the parental HuH-7 to both toxic conjugates, The anterograde steps of intracellular endocytic processing of ASOR, including internalization, endosomal acidification, and ligand degradation, were unaltered in Trf1 cells, In contrast, retrograde diacytosis of asialoglycoprotein receptor (ASGR). ASOR complex back to the cell surface was enhanced by about 250%, Selective labeling revealed an approximately 46% reduction in cell surface-associated ASGR in Trf1 cells, although their total cellular ASGR content was essentially equivalent to that in HuH-7. Similar results were obtained with the transferrin receptor. Binding of I-125-ASOR and I-125-transferrin was reduced in Trf1 cells to 49 +/- 2.5% and 30 +/- 2%, respectively, of HuH-7 cells. The methionine transporter was also reduced in Trf1 cells, as revealed by a 2-fold reduction in V-max with no change in apparent K-m. Pretreatment with monensin, sodium azide, or colchicine reduced surface binding of I-125-ASOR;, HuH-7 cells by 50% but had no effect on binding to Trf1 cells. This result is predicted for a cell that expresses only State 1 ASGRs, which are resistant to modulation by metabolic and cytoskeletal inhibitors in contrast to State 2, which are responsive to these agents (Weigel, P. H., and Oka, J. A. (1984) J. Biol. Chem. 259, 1150-1154), The Trf1 mutant, having lost the ability to express State 2 receptors, provides genetic evidence for the existence of these two receptor subpopulations and an approach to identifying the biochemical mechanism by which they are generated.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	STOCKERT, RJ (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,1300 MORRIS PK AVE,ULLMANN 517,BRONX,NY 10461, USA.			Stanley, Pamela/0000-0001-5704-3747	NIDDK NIH HHS [DK41918, DK41296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041918, P30DK041296] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUCCI M, 1994, SOMAT CELL MOLEC GEN, V20, P47, DOI 10.1007/BF02257485; CAIN CC, 1991, J BIOL CHEM, V266, P11746; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CLARKE BL, 1987, BIOCHEM J, V262, P277; COLBAUGH PA, 1993, ADV CELL MOL BIOL M, V1, P169; EALEY PA, 1988, J MOL ENDOCRINOL, V1, pR1, DOI 10.1677/jme.0.001R001; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1984, EMBO J, V3, P2677, DOI 10.1002/j.1460-2075.1984.tb02193.x; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HARFORD J, 1988, J CELL BIOL, V96, P1824; HAYNES PA, 1994, J BIOL CHEM, V269, P33152; KAO CY, 1992, J CELL BIOL, V117, P701, DOI 10.1083/jcb.117.4.701; KIELIAN M, 1990, J VIROL, V64, P4614, DOI 10.1128/JVI.64.10.4614-4624.1990; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; KRIEGER M, 1983, P NATL ACAD SCI-BIOL, V80, P5607, DOI 10.1073/pnas.80.18.5607; LAMBERT JM, 1985, J BIOL CHEM, V260, P2035; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; MALMSTROM K, 1991, J BIOL CHEM, V266, P24025; MARNELL MH, 1984, J CELL BIOL, V99, P1907, DOI 10.1083/jcb.99.6.1907; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCABEE DD, 1990, J BIOL CHEM, V265, P629; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MCGRAW TE, 1991, HDB EXPT PHARM, V100, P11; NOVAK DA, 1994, BIOCHEM J, V301, P671, DOI 10.1042/bj3010671; OKA JA, 1983, J BIOL CHEM, V258, P253; PARK JE, 1991, SOMAT CELL MOLEC GEN, V17, P137, DOI 10.1007/BF01232971; PHALEN T, 1991, J CELL BIOL, V112, P615, DOI 10.1083/jcb.112.4.615; RAY B, 1982, MOL CELL BIOL, V2, P535, DOI 10.1128/MCB.2.5.535; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SEGE RD, 1984, NATURE, V307, P742, DOI 10.1038/307742a0; STANLEY P, 1985, MOL CELL BIOL, V5, P923, DOI 10.1128/MCB.5.5.923; STOCKERT RJ, 1980, LAB INVEST, V43, P556; STOCKERT RJ, 1980, J BIOL CHEM, V255, P9028; STOCKERT RJ, 1993, J BIOL CHEM, V268, P19540; STOCKERT RJ, 1990, J BIOL CHEM, V265, P1841; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WANG RH, 1990, J BIOL CHEM, V265, P20179; WEIGEL PH, 1980, J BIOL CHEM, V255, P6111; WEIGEL PH, 1984, J BIOL CHEM, V259, P1150; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; WEIGEL PH, 1993, ENDOCYTIC COMPONENTS, P125; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; WEISS P, 1994, HEPATOLOGY, V19, P432; WELLNER RB, 1984, J BIOL CHEM, V259, P2788; WILSON RB, 1993, J BIOL CHEM, V268, P25357; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375	49	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16107	16113		10.1074/jbc.270.27.16107	http://dx.doi.org/10.1074/jbc.270.27.16107			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608173	hybrid			2022-12-25	WOS:A1995RH22600036
J	GRIECO, D; SANTORO, M; DATHAN, NA; FUSCO, A				GRIECO, D; SANTORO, M; DATHAN, NA; FUSCO, A			ACTIVATED RET ONCOGENE PRODUCTS INDUCE MATURATION OF XENOPUS OOCYTES	ONCOGENE			English	Article						RET/PTC; RAS; MPF	TRANSFORMING GENE; TYROSINE KINASE; PROTEIN-KINASE; RAS PROTEINS; PROTOONCOGENE; CARCINOMAS; EXPRESSION; MUTATIONS; FUSION	The RET proto-oncogene encodes a transmembrane receptor of the tyrosine kinase family, recently found to be the gene responsible for the multiple endocrine neoplasia type 2A and 2B syndromes, RET was found specifically activated, by gene rearrangement, in human thyroid carcinomas of the papillary subtype, In most cases the activation consisted of an in frame fusion of the RET tyrosine-kinase domain, at the carboxy-terminus, with heterologous genes at the amino-terminus. These chimeric oncogenes are collectively named RET/PTC, Two forms of these gene products, RET/PTC1 and RET/PTC3, have been tested for their ability to induce meiotic maturation in Xenopus oocytes, Injection of RET/PTC mRNAs into immature oocytes induced maturation-promoting-factor (MPF) activation and germinal vesicle breakdown (GVBD), The injected oocytes expressed polypeptides recognized by an anti-RET gene product antibody as well as by an anti-phosphotyrosine antibody, indicating activation of the tyrosine-kinase domain, The RET/PTC induced maturation was dependent on endogenous ras; in fact, the coinjection of RET/PTC mRNA with a neutralizing anti-ras antibody blocked oocytes maturation without interfering with the accumulation and tyrosine-phosphorylation of the RET/PTC protein.	UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	GRIECO, D (corresponding author), COLUMBIA UNIV,INST CANC RES,701 W 168TH ST,NEW YORK,NY 10032, USA.			Fusco, Alfredo/0000-0003-3332-5197; GRIECO, Domenico/0000-0002-7131-5742				AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; LANZI C, 1992, ONCOGENE, V7, P2189; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALLER JL, 1985, P NATL ACAD SCI USA, V82, P272, DOI 10.1073/pnas.82.2.272; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OPRESKO LK, 1990, J CELL BIOL, V111, P1661, DOI 10.1083/jcb.111.4.1661; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1994, ONCOGENE, V9, P509; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SPIVAK JG, 1994, MOL CELL BIOL, V4, P1631; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0	31	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					113	117						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624118				2022-12-25	WOS:A1995RJ29500014
J	ZABNER, J; FASBENDER, AJ; MONINGER, T; POELLINGER, KA; WELSH, MJ				ZABNER, J; FASBENDER, AJ; MONINGER, T; POELLINGER, KA; WELSH, MJ			CELLULAR AND MOLECULAR BARRIERS TO GENE-TRANSFER BY A CATIONIC LIPID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-TRANSPORT DEFECT; ALKALINE-PHOSPHATASE; LIPOSOME COMPLEXES; MAMMALIAN-CELLS; EXPRESSION; DNA; DELIVERY; ADENOVIRUS; EFFICIENT; VESICLES	Cationic lipids are widely used for gene transfer in vitro and show promise as a vector for in vivo gene therapy applications. However, there is limited understanding of the cellular and molecular mechanisms involved, We investigated the individual steps in cationic lipid-mediated gene transfer to cultured cell lines, We used DMRIE/DOPE (a 1:1 mixture of N-[1-(2,3-dimyristyloxy)propyl]-N,N-dimethyl-N-(2-hydroxyethyl)ammonium bromide (DMRIE) and dioleoyl phosphatidylethanolamine (DOPE)) as a model lipid because of its efficacy and because it is being used for clinical trials in humans, The data show that cationic lipid mediated gene transfer is an inefficient process, Part of the inefficiency may result from the fact that the population of lipid-DNA complexes was very heterogeneous, even under conditions that have been optimized to produce the best transfection, Inefficiency was not due to inability of the complex to enter the cells because most cells took up the DNA, However, in contrast to previous speculation, the results indicate that endocytosis was the major mechanism of entry, After endocytosis, the lipid-DNA aggregated into large perinuclear complexes, which often showed a highly ordered tubular structure, Although much of the DNA remained aggregated in a vesicular compartment, there was at least a small amount of DNA in the cytoplasm of most cells, That observation plus results from direct injection of DNA and lipid-DNA into the nucleus and cytoplasm indicate that movement of DNA from the cytoplasm to the nucleus may be one of the most important limitations to successful gene transfer, Finally, before transcription can occur, the data show that lipid and DNA must dissociate, These results provide new insights into the physical limitations to cationic lipid-mediated gene transfer and suggest that attention to specific steps in the cellular process may further improve the efficiency of transfection and increase its use in a number of applications.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYS & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa				Zabner, Joseph/0000-0002-9606-1339; Welsh, Michael/0000-0002-1646-6206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BOLTON PH, 1978, NUCLEIC ACIDS RES, V5, P4891; CANONICO AE, 1994, AM J RESP CELL MOL, V10, P24, DOI 10.1165/ajrcmb.10.1.8292378; CANTRELL CE, 1979, MOL PHARMACOL, V15, P322; CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CHIN D J, 1990, New Biologist, V2, P1091; COGGINS LW, 1995, ELECTRON MICROS, P1; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DUZGUNES N, 1989, BIOCHEMISTRY-US, V28, P9179, DOI 10.1021/bi00449a033; FARHOOD H, 1992, BIOCHIM BIOPHYS ACTA, V1111, P239, DOI 10.1016/0005-2736(92)90316-E; FASBENDER AJ, 1995, IN PRESS AM J PHYSL; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER P L, 1990, Advanced Drug Delivery Reviews, V5, P163, DOI 10.1016/0169-409X(90)90015-K; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; GAO X, 1993, NUCLEIC ACIDS RES, V21, P2867, DOI 10.1093/nar/21.12.2867; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GRAHAM FL, 1992, VACCINES NEW APPROAC, P363; HAZINSKI TA, 1991, AM J RESP CELL MOL, V4, P206, DOI 10.1165/ajrcmb/4.3.206; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HORWITZ MS, 1990, VIROLOGY, P01679; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670; LOGAN J, 1993, PEDIATR PULM, V9, P245; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MOSS B, 1991, J BIOL CHEM, V266, P1355; MURPHY RF, 1985, P NATL ACAD SCI USA, V82, P8523, DOI 10.1073/pnas.82.24.8523; NABEL GJ, 1994, HUM GENE THER, V5, P57, DOI 10.1089/hum.1994.5.1-57; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; RUBIN J, 1994, HUM GENE THER, V5, P1385, DOI 10.1089/hum.1994.5.11-1385; SMITH JG, 1993, BIOCHIM BIOPHYS ACTA, V1154, P327, DOI 10.1016/0304-4157(93)90004-8; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; VOGELZANG NJ, 1994, HUM GENE THER, V5, P1357, DOI 10.1089/hum.1994.5.11-1357; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; YOSHIMURA K, 1993, J BIOL CHEM, V268, P2300; YOSHIMURA K, 1992, NUCLEIC ACIDS RES, V20, P3233, DOI 10.1093/nar/20.12.3233; ZABNER J, 1994, HUM GENE THER, V5, P585, DOI 10.1089/hum.1994.5.5-585; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3	47	1226	1302	0	108	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18997	19007		10.1074/jbc.270.32.18997	http://dx.doi.org/10.1074/jbc.270.32.18997			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642560	hybrid			2022-12-25	WOS:A1995RN95400048
J	LIANG, QW; FULCO, AJ				LIANG, QW; FULCO, AJ			TRANSCRIPTIONAL REGULATION OF THE GENES ENCODING CYTOCHROMES P450(BM-1) AND P450(BM-3) IN BACILLUS-MEGATERIUM BY THE BINDING OF BM3R1 REPRESSOR TO BARBIE BOX ELEMENTS AND OPERATOR SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; SEQUENCE; P-450BM-3; PROTEIN; DNA	We previously reported (Liang, and., He, J.-S., and Fulco, A. J. (1995) J. Biol. Chem. 270, 4438-4450) that Bm3R1, a repressor regulating the expression of P450(BM-3) in Bacillus megaterium, could bind to Barbie box sequences in the 5'-flanking regions of barbiturate inducible genes. We've now shown that pentobarbital does not inhibit in vitro binding of Bm3R1 to the P450(BM-3) and P450(BM-3) Barbie boxes (BB3 and BB1), although the palindromic operator sequence (O-III) of P450(BM-3) did have a strong competitive effect on such binding. G39E-Bm3R1, a mutant of Bm3R1, did not bind to either Barbie box. In the presence of Bm3R1, portions of the regulatory regions of P450(BM-3) and P450(BM-1) were protected from DNase I digestion. These included 11 of the 15 base pairs of BB3 plus 7 base pairs 3' to BB3, BB1 plus 16 base pairs 3' to BB1, and, in the 5'-flanking region of P450(BM-1), segments covering most of two palindromic sequences (O-II and O-III) of 24 and 52 base pairs. These DNase I-protected regions (including O-III) showed considerable sequence identity, especially in a conserved poly(A) motif. Barbiturates did not inhibit binding of Bm3R1 to O-I . O-II in vitro while G39E-Bm3R1 did not bind. The regulatory effects of Bm3R1 on P450(BM-1) and P450(BM-3) were also evaluated in vivo using heterologous chloramphenicol acetyltransferase constructs and Western blotting. In the G39E mutant strain, both P450(BM-1) and P450(BM-3) were constitutively expressed, and the regulatory proteins Bm1P1 and Bm3P1, although still pentobarbital-inducible, had significantly higher basal levels of synthesis, In toto, our results show that Bm3R1 represses both P450(BM-1) and P450(BM-3) expression and that it may effect this by coordinate binding to operator and Barbie box sequences to produce looping of the P450(BM-1) and P450(BM-3) regulatory regions through protein-protein interaction.	UNIV CALIF LOS ANGELES,SCH MED,STRUCT BIOL & MOLEC MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM23913] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023913] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; ENGLISH N, 1994, J BIOL CHEM, V269, P26836; FERNANDEZ LM, 1994, CYTOCHROME P450, P663; FOURNIER T, 1994, J BIOL CHEM, V44, P27175; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; HAHN CN, 1991, J BIOL CHEM, V266, P17031; Harlow E., 1988, ANTIBODIES LAB MANUA, V2nd, P479; HE JS, 1991, J BIOL CHEM, V266, P7864; HE JS, 1989, BIOCHIM BIOPHYS ACTA, V1009, P301, DOI 10.1016/0167-4781(89)90120-6; HE JS, 1995, IN PRESS J BIOL CHEM; IMANAKA T, 1982, J BACTERIOL, V149, P824, DOI 10.1128/JB.149.3.824-830.1982; JAISWAL AK, 1990, NUCLEIC ACIDS RES, V18, P4237, DOI 10.1093/nar/18.14.4237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; NARHI LO, 1986, J BIOL CHEM, V261, P7160; PADMANABAN G, 1994, CYTOCHROME P450, P133; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SHAW GC, 1992, J BIOL CHEM, V267, P5515; SHAW GC, 1993, J BIOL CHEM, V268, P2997; SHERVINGTON A, 1994, CYTOCHROME P450, P137; UPADHYA P, 1992, NUCLEIC ACIDS RES, V20, P557, DOI 10.1093/nar/20.3.557; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEN LP, 1989, J BIOL CHEM, V264, P10996	24	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18606	18614		10.1074/jbc.270.31.18606	http://dx.doi.org/10.1074/jbc.270.31.18606			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629191	hybrid			2022-12-25	WOS:A1995RM64200071
J	TSUMOTO, K; OGASAHARA, K; UEDA, Y; WATANABE, K; YUTANI, K; KUMAGAI, I				TSUMOTO, K; OGASAHARA, K; UEDA, Y; WATANABE, K; YUTANI, K; KUMAGAI, I			ROLE OF TYR RESIDUES IN THE CONTACT REGION OF ANTILYSOZYME MONOCLONAL-ANTIBODY HYHEL10 FOR ANTIGEN-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; FAB FRAGMENT; AMINO-ACIDS; COMPLEX; RECOGNITION; PROTEINS; SITES; SUBSTITUTIONS; MUTAGENESIS; RESOLUTION	It has been shown that Tyr residues are unusually localized in the regions of antibodies responsible for contact with antigens (Padlan, E. A. (1990) Proteins Struct. Funct. Genet. 7, 112-124). In order to clarify the role of these Tyr residues in antigen binding, the interaction between hen egg white lysozyme (HEL) and its monoclonal antibody HyHEL10, whose structure has been well studied in complex with its antigen, was investigated. Four Tyr residues in the VH chain (HTyr-33, HTyr-50, HTyr-53, and HTyr-58) were replaced with Ala, Leu, Phe, or Trp, and the interactions between these mutant Fv fragments and HEL were studied by inhibition assay of the enzymatic activity of HEL and isothermal titration calorimetry. Twelve mutant Fv fragments could be expressed, but two mutants (HY50W and HY58W) could not be obtained in the Escherichia coli expression system, and a further two mutants (HY33A and HY50A) could not be purified by affinity chromatography. It was shown by inhibition assay that Tyr residues at each mutated site made positive contributions to the interaction to different degrees. Thermodynamic studies showed that the role of Tyr residues in antigen binding was to obtain enthalpic energy. The roles of Tyr residues in antibody HyHEL10 for the association with antigen, HEL, can be summarized as follows: 1) formation of hydrogen bonds by the hydroxyl group, 2), creating more favorable interactions through the aromatic ring and decreasing the entropic loss upon binding, and 3) allowing hydrophobic interaction through the side chain. The four Tyr residues studied here were found to play significant roles in the association in various ways.	UNIV TOKYO, FAC ENGN, DEPT CHEM & BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN; OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN	University of Tokyo; Osaka University								AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; CONNELLY PR, 1994, P NATL ACAD SCI USA, V91, P1964, DOI 10.1073/pnas.91.5.1964; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; CYGLER M, 1987, J BIOL CHEM, V262, P643; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; HERRON JN, 1986, BIOCHEMISTRY-US, V25, P4602, DOI 10.1021/bi00364a022; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; Imoto T., 1972, ENZYMES, V7, P665; ITO W, 1993, J BIOL CHEM, V268, P16639; JANIN J, 1990, J BIOL CHEM, V265, P16027; Kabat EA, 1991, SEQUENCES PROTEINS I; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROKI R, 1992, J BIOL CHEM, V267, P24297; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; NOVOTNY J, 1991, MOL IMMUNOL, V28, P201, DOI 10.1016/0161-5890(91)90062-O; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Sambrook J, 1989, MOL CLONING LABORATO; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; TELLO D, 1993, BIOCHEM SOC T, V21, P943, DOI 10.1042/bst0210943; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; TSUMOTO K, 1994, BIOCHEM BIOPH RES CO, V201, P546, DOI 10.1006/bbrc.1994.1736; UEDA Y, 1993, GENE, V129, P129; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P1421, DOI 10.1021/bi00120a019; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	39	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18551	18557		10.1074/jbc.270.31.18551	http://dx.doi.org/10.1074/jbc.270.31.18551			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629185	hybrid			2022-12-25	WOS:A1995RM64200063
J	VANDENBERG, RJ; ARRIZA, JL; AMARA, SG; KAVANAUGH, MP				VANDENBERG, RJ; ARRIZA, JL; AMARA, SG; KAVANAUGH, MP			CONSTITUTIVE ION FLUXES AND SUBSTRATE-BINDING DOMAINS OF HUMAN GLUTAMATE TRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-BRAIN; XENOPUS-OOCYTES; GLIAL-CELL; EXPRESSION; CARRIER; CLONING; SODIUM; ACID	Application of L-glutamate activates ionic currents in voltage clamped Xenopus oocytes expressing cloned human excitatory amino acid transporters (EAATs). However, even in the absence of L-glutamate, the membrane conductance of oocytes expressing EAAT1 was significantly increased relative to oocytes expressing EAAT2 or control oocytes. Whereas transport mediated by EAAT2 is blocked by the non-transported competitive glutamate analog kainate (K-i = 14 mu M), EAAT1 is relatively insensitive K-i > 3 mM). Substitution of a block of 76 residues from EAAT2 into EAAT1, in which 18 residues varied from EAAT1, conferred high affinity kainate binding to EAAT1, and application of kainate to oocytes expressing the chimeric transporter blocked a pre-existing monovalent cation conductance that displayed a permeability sequence K+ > Na+ > Li+ >> choline(+). The results identify a structural domain of glutamate transporters that influences kainate binding and demonstrate the presence of a constitutive ion-selective pore in the transporter.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,HOWARD HUGHES MED INST,PORTLAND,OR 97201	Oregon Health & Science University; Howard Hughes Medical Institute; Oregon Health & Science University			Vandenberg, Robert John/E-6018-2016	Vandenberg, Robert John/0000-0003-1523-4814; Amara, Susan/0000-0001-8914-1106	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033273, R01NS033270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33273, NS33270] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BOUVIER M, 1994, SEMIN NEUROSCI, V6, P117; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CAMMACK JN, 1994, NEURON, V13, P946; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FAIRMAN WA, 1995, IN PRESS NAUTRE; FRANCIOLINI F, 1987, J GEN PHYSIOL, V90, P453, DOI 10.1085/jgp.90.4.453; JOHNSTON GAR, 1979, J NEUROCHEM, V32, P121, DOI 10.1111/j.1471-4159.1979.tb04518.x; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; LAUGER P, 1980, J MEMBRANE BIOL, V57, P63; LESTER HA, 1994, ANNU REV PHARMACOL, V34, P219; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; Sonders M. S., 1994, Society for Neuroscience Abstracts, V20, P627; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, IN PRESS NEURON; WALLACE B, 1990, J BACTERIOL, V172, P3214, DOI 10.1128/jb.172.6.3214-3220.1990	24	88	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17668	17671		10.1074/jbc.270.30.17668	http://dx.doi.org/10.1074/jbc.270.30.17668			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629063	Green Published, hybrid			2022-12-25	WOS:A1995RM26600008
J	KENDREW, SG; HARDING, SE; HOPWOOD, DA; MARSH, ENG				KENDREW, SG; HARDING, SE; HOPWOOD, DA; MARSH, ENG			IDENTIFICATION OF A FLAVIN-NADH OXIDOREDUCTASE INVOLVED IN THE BIOSYNTHESIS OF ACTINORHODIN - PURIFICATION AND CHARACTERIZATION OF THE RECOMBINANT ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; STREPTOMYCES-COELICOLOR; ANTIBIOTIC ACTINORHODIN; POLYKETIDE SYNTHASE; HYBRID ANTIBIOTICS; GENES; EXPRESSION	The biosynthesis of the polyketide antibiotic actinorhodin by Streptomyces coelicolor involves the oxidative dimerization and hydroxylation of a precursor, most likely dihydrokalafungin, as the final steps in its formation. Mutations in the actVB gene block these last steps, and the mutants secrete kalafungin as a shunt product. To investigate the role of the actVB gene in these transformations, we have overexpressed the gene in Escherichia coli and purified and characterized the recombinant protein. ActVB was shown to catalyze the reduction of FMN by NADH to give NAD and FMNH(2), which, unusually, is released into solution. The protein contains no chromogenic cofactors and exhibits no requirements for added metal ions. The reaction obeys simple kinetics and proceeds through the formation of a ternary complex; K-m values for FMN and NADH are 1.5 and 7.3 mu M, respectively, and k(cat) is about 5 s(-1). FAD and riboflavin are also substrates for the enzyme, although they have much higher K-m values. The subunit structure of the enzyme was investigated by analytical ultracentrifugation, which showed the protein to exist in rapid equilibrium between monomer and dimer forms. The possible role of this oxidoreductase in the oxidative chemistry of actinorhodin biosynthesis is discussed.	UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND; UNIV NOTTINGHAM,DEPT APPL BIOCHEM & FOOD SCI,SUTTON LE12 5RD,LEICS,ENGLAND; JOHN INNES CTR PLANT SCI RES,DEPT GENET,NORWICH NR4 7UH,NORFOLK,ENGLAND	University of Cambridge; University of Cambridge; University of Nottingham; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Marsh, Neil/G-7553-2016	Marsh, Neil/0000-0003-1713-1683; Harding, Stephen E./0000-0002-7798-9692	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLANC V, 1994, Patent No. 08014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLE SP, 1987, J ANTIBIOT, V40, P340, DOI 10.7164/antibiotics.40.340; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FUJII I, 1987, J BIOCHEM, V101, P11, DOI 10.1093/oxfordjournals.jbchem.a121881; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; GORSTALLMAN CP, 1981, J ORG CHEM, V46, P455, DOI 10.1021/jo00315a046; GRAMAJO HC, 1991, J BACTERIOL, V173, P6475, DOI 10.1128/jb.173.20.6475-6483.1991; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; Mann J., 1987, SECONDARY METABOLISM; MARSDEN AFA, 1994, SCIENCE, V263, P378, DOI 10.1126/science.8278811; MARSH EN, 1993, BIOCHEM J, V290, P551, DOI 10.1042/bj2900551; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MORRISON PT, 1989, J BACTERIOL, V171, P3641, DOI 10.1128/jb.171.7.3641-3649.1989; OHagan D., 1991, POLYKETIDE METABOLIT; PRIETO MA, 1994, J BIOL CHEM, V269, P22823; Sambrook J, 1989, MOL CLONING LABORATO; SHEN B, 1993, SCIENCE, V262, P1535, DOI 10.1126/science.8248801; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WILSON K, 1994, PRINCIPLES TECHNIQUE, P223; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994	27	68	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17339	17343		10.1074/jbc.270.29.17339	http://dx.doi.org/10.1074/jbc.270.29.17339			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615536	hybrid			2022-12-25	WOS:A1995RK68900047
J	YANG, W; JACKOWSKI, S				YANG, W; JACKOWSKI, S			LIPID ACTIVATION OF CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE IS REGULATED BY THE PHOSPHORYLATED CARBOXYL-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHINESE-HAMSTER OVARY; PHOSPHOLIPASE-C TREATMENT; CULTURED RAT HEPATOCYTES; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; HELA-CELLS; ENDOPLASMIC-RETICULUM; FEEDBACK-REGULATION; INDUCED INHIBITION; MAMMALIAN-CELLS; FATTY-ACIDS	The role of the phosphorylated carboxyl-terminal domain of CTP:phosphocholine cytidylyltransferase (CT) in the regulation of enzyme activity was investigated by comparing the catalytic properties of wild-type CT to two mutant proteins with altered carboxyl-terminal phosphorylation domains. CT isolated from a baculovirus expression system was extensively phosphorylated at multiple sites in the carboxyl terminal domain, The CT[S315A] mutant lacked a major CT phosphorylation site, and the carboxyl-terminal deletion mutant, CT[Delta 312-367], was not phosphorylated, The higher activities of CT[Delta 312-367] and CT[S315A] relative to CT were attributed to differences in the sensitivities of the enzymes to lipid activators. The rank order of the apparent K-m values for activation by either phosphatidylcholine/oleic acid or phosphatidylcholine/diacylglycerol was CT > CT[S315A] > CT[Delta 312-367]. In addition, CT exhibited negative cooperativity in its activation by phosphatidylcholine/oleic acid (n(H) = 0.64) and phosphatidylcholine/diacylglycerol (n(H) = 0.74) vesicles, whereas CT[Delta 312-367] and CT[S315A] did not. These data support the concept that the phosphorylation of the CT carboxyl-terminal domain interferes with the activation of CT by lipid regulators.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [T32 CA09346, CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, T32CA009346] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P37, DOI 10.1016/0005-2760(87)90215-3; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; CRAIG L, 1994, J BIOL CHEM, V269, P3311; Dixon M., 1979, ENZYMES, Vthird; HATCH GM, 1992, J BIOL CHEM, V267, P15751; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JAMIL H, 1990, BIOCHEM J, V270, P749, DOI 10.1042/bj2700749; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; LIANG P, 1994, CURRENT PROTOCOLS MO; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; PADDON HB, 1980, BIOCHIM BIOPHYS ACTA, V620, P636, DOI 10.1016/0005-2760(80)90156-3; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1982, J BIOL CHEM, V257, P4198; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1981, J BIOL CHEM, V256, P8283; RUTHERFORD MS, 1993, GENOMICS, V18, P698, DOI 10.1016/S0888-7543(05)80377-5; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; WANG YL, 1993, J BIOL CHEM, V268, P5512; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WIEDER T, 1994, FEBS LETT, V345, P207, DOI 10.1016/0014-5793(94)00433-1; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; YAO ZM, 1990, J BIOL CHEM, V265, P4326	40	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16503	16506		10.1074/jbc.270.28.16503	http://dx.doi.org/10.1074/jbc.270.28.16503			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622451	hybrid			2022-12-25	WOS:A1995RJ34700006
J	BHALERAO, J; TYLZANOWSKI, P; FILIE, JD; KOZAK, CA; MERREGAERT, J				BHALERAO, J; TYLZANOWSKI, P; FILIE, JD; KOZAK, CA; MERREGAERT, J			MOLECULAR-CLONING, CHARACTERIZATION, AND GENETIC-MAPPING OF THE CDNA CODING FOR A NOVEL SECRETORY PROTEIN OF MOUSE - DEMONSTRATION OF ALTERNATIVE SPLICING IN SKIN AND CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM-ALBUMIN; CALCIUM-BINDING PROTEINS; EXTRACELLULAR-MATRIX; MESSENGER-RNA; SEQUENCE; EXPRESSION; DIFFERENTIATION; CHROMOSOME-3; PROFILAGGRIN; INVOLUCRIN	A novel 85-kDa protein secreted by the mouse stromal osteogenic cell line MN7 was identified using two-dimensional polyacrylamide gel electrophoresis (Mathieu, E., Meheus, L., Raymackers, J., and Merregaert, J. (1994) J. Bone Miner. Res. 9, 903-913). Degenerate primers were used to isolate the cDNA coding for this protein, The full-length cDNA clone is 1.9 kilobases (kb) and codes for a protein of 559 amino acid residues, The DNA and deduced amino acid sequences have no counterparts in public data bases, but a structural similarity involving typical cysteine doublets can be observed to serum albumin family proteins and to Endo16 (a calcium-binding protein of sea urchin), Northern blot analysis revealed the presence of a 1.9-kb transcript in various tissues, and a shorter transcript of 1.5 kb, derived by alternative splicing in tail, front paw and skin of embryonic mice. The gene for the p85 protein, termed Ecm1 (for extracellular matrix protein 1), is a single-copy gene, which was localized to the region on mouse chromosome 3 known to contain at least one locus associated with developmental disorders of the skin, soft coat (soc), Alternative splicing may serve as a mechanism for generating functional diversity in the Ecm1 gene.	UNIV ANTWERP, DEPT BIOCHEM, MOLEC BIOTECHNOL LAB, B-2610 Antwerp, BELGIUM; NIAID, BETHESDA, MD 20892 USA	University of Antwerp; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Tylzanowski, Przemko/G-8881-2013	Tylzanowski, Przemko/0000-0003-0769-559X				ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; APPEL RD, 1993, ELECTROPHORESIS, V14, P1232, DOI 10.1002/elps.11501401185; Ayad S, 1994, EXTRACELLULAR MATRIX; BACKENDORF C, 1992, NAT GENET, V2, P91, DOI 10.1038/ng1092-91; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P259; BROWN JR, 1976, FED PROC, V35, P2141; BURR DB, 1989, AM J ANAT, V186, P186, DOI 10.1002/aja.1001860208; CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704; DARLINGTON GJ, 1986, MOL CELL BIOL, V6, P969, DOI 10.1128/MCB.6.4.969; Dickson Ian R., 1993, P249; DOOLEY TP, 1992, GENOMICS, V13, P866, DOI 10.1016/0888-7543(92)90171-N; DORIN JR, 1990, GENOMICS, V8, P420, DOI 10.1016/0888-7543(90)90027-R; DUGAICZYK A, 1982, P NATL ACAD SCI-BIOL, V79, P71, DOI 10.1073/pnas.79.1.71; FERRARI S, 1987, J BIOL CHEM, V262, P8325; GANG A, 1992, AM J RESP CELL MOL, V7, P104, DOI 10.1165/ajrcmb/7.1.104; GATES RE, 1982, BIOCHEM BIOPH RES CO, V105, P57, DOI 10.1016/S0006-291X(82)80010-7; Green EL, 1981, GENETICS PROBABILITY, P77; GREEN MC, 1989, GENETIC VARIANTS STR, P212; HARDER T, 1992, GENE, V113, P269, DOI 10.1016/0378-1119(92)90406-F; HEGYI H, 1993, COMPUT APPL BIOSCI, V9, P371; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; Heinegard Dick, 1993, P189; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JOKINEN M, 1981, EUR J BIOCHEM, V114, P393, DOI 10.1111/j.1432-1033.1981.tb05159.x; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; LEE SC, 1993, J INVEST DERMATOL, V100, P65, DOI 10.1111/1523-1747.ep12354504; MALLEINGERIN F, 1993, P NATL ACAD SCI USA, V90, P3289, DOI 10.1073/pnas.90.8.3289; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MATHIEU E, 1994, J BONE MINER RES, V9, P903; MATHIEU E, 1992, CALCIFIED TISSUE INT, V50, P362, DOI 10.1007/BF00301635; MATHIEU E, 1994, J BONE MINER RES, V9, P183; MATHIEU E, 1993, THESIS U ANTWERP BEL; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Murphy Gillian, 1993, P287; NAKISA RC, 1993, DOTPLOT PROGRAM GRAP; NASH JHE, 1993, COMPUT APPL BIOSCI, V9, P469; OBRIEN SJ, 1991, CYTOGENET CELL GENET, V58, P1124, DOI 10.1159/000133725; OSMAN N, 1992, J IMMUNOL, V148, P1570; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PONGOR S, 1993, NUCLEIC ACIDS RES, V21, P3111, DOI 10.1093/nar/21.13.3111; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; Putnam E., 1975, 3 SERUM ALBUMIN, VSecond, P133, DOI [10.1016/B978-0-12-568401-9.50010-4, DOI 10.1016/B978-0-12-568401-9.50010-4]; Rigoutsos I., 1994, IEEE Computational Science and Engineering, V1, P60, DOI 10.1109/99.326666; ROSENTHAL DS, 1992, J INVEST DERMATOL, V98, P343, DOI 10.1111/1523-1747.ep12499802; ROTHNAGEL JA, 1994, GENOMICS, V23, P450, DOI 10.1006/geno.1994.1522; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAMBROOK J, 1969, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; Schubert D, 1992, Trends Cell Biol, V2, P63, DOI 10.1016/0962-8924(92)90057-T; SELDIN MF, 1993, MAMM GENOME, V4, pS47, DOI 10.1007/BF00360829; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SIMON M, 1989, AM J HUM GENET, V45, P910; SOLTYSIKESPANOLA M, 1994, DEV BIOL, V165, P73, DOI 10.1006/dbio.1994.1235; SONNHAMMER ELL, 1994, PROTEIN SCI, V3, P482; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VOGELAAR NJ, 1991, J MOL BIOL, V220, P545, DOI 10.1016/0022-2836(91)90097-P; VOLZ A, 1993, GENOMICS, V18, P92, DOI 10.1006/geno.1993.1430; Von Der Mark Klaus, 1993, P211; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L; YANG F, 1985, P NATL ACAD SCI USA, V82, P7994, DOI 10.1073/pnas.82.23.7994; YONEDA K, 1992, J BIOL CHEM, V267, P18060; ZABEL BU, 1985, P NATL ACAD SCI USA, V82, P469, DOI 10.1073/pnas.82.2.469	76	40	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16385	16394		10.1074/jbc.270.27.16385	http://dx.doi.org/10.1074/jbc.270.27.16385			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608209	hybrid			2022-12-25	WOS:A1995RH22600076
J	TSEN, GS; NAPIER, A; HALFTER, W; COLE, GJ				TSEN, GS; NAPIER, A; HALFTER, W; COLE, GJ			IDENTIFICATION OF A NOVEL ALTERNATIVELY SPLICED AGRIN MESSENGER-RNA THAT IS PREFERENTIALLY EXPRESSED IN NONNEURONAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACETYLCHOLINE-RECEPTOR; EXTRACELLULAR-MATRIX; ORGANIZING PROTEIN; CULTURED MYOTUBES; AGGREGATION; RNA; COMPONENTS; MOLECULES; MUSCLE; GENE	A novel agrin isoform was identified based on the isolation of an agrin cDNA from E9 chick brain that lacked 21 base pairs (bp) in the NH2-terminal encoding region of the agrin mRNA. Reverse transcription-polymerase chain reaction (RT-PGR) of E9 chick brain mRNA confirmed the existence of this agrin isoform in brain, although the novel splice variant represents a minor fraction of agrin mRNA in brain. However, upon analysis of chick brain astrocyte mRNA, smooth muscle mRNA, and cardiac muscle mRNA by RT-PCR, we show that this novel agrin isoform is the predominant agrin isoform in these non-neuronal cell populations. We extended our analyses to examine the expression of this agrin mRNA isoform during chick development and show that the agrin mRNA lacking this 21-bp exon is up-regulated with brain development, consistent with the increase in glial number during brain development, while the agrin isoform that does not undergo splicing and thus contains the 21-bp exon is down-regulated in brain development. Because the 21-bp exon is inserted in the region of chick agrin which encodes the putative signal sequence of agrin, with the signal peptidase site immediately preceding the putative first amino acid of the mature protein being deleted as a result of splicing, these data raise the interesting possibility that the presence or absence of this alternatively spliced exon may differentially regulate processing of the agrin protein in neuronal and non-neuronal cells, respectively.	OHIO STATE UNIV,CTR NEUROBIOTECHNOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT CELL BIOL NEUROBIOL & ANAT,COLUMBUS,OH 43210; UNIV PITTSBURGH,DEPT NEUROBIOL,PITTSBURGH,PA 15261	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BURG MA, 1995, J NEUROSCI RES, V41, P49, DOI 10.1002/jnr.490410107; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; GODFREY EW, 1991, EXP CELL RES, V195, P99, DOI 10.1016/0014-4827(91)90504-N; GORDON H, 1993, J NEUROSCI, V13, P586; HOCH W, 1994, J CELL BIOL, V126, P1, DOI 10.1083/jcb.126.1.1; KELLY MM, 1995, DEV BRAIN RES, V85, P31, DOI 10.1016/0165-3806(94)00185-3; MA E, 1994, J NEUROSCI, V14, P2943; MAGILLSOLC C, 1988, J CELL BIOL, V107, P1825, DOI 10.1083/jcb.107.5.1825; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; NITKIN RM, 1990, J CELL BIOL, V111, P1161, DOI 10.1083/jcb.111.3.1161; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1992, J NEUROSCI, V12, P3535; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH MA, 1994, NEURON, V12, P795, DOI 10.1016/0896-6273(94)90332-8; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; THOMAS WS, 1993, DEV BIOL, V158, P523, DOI 10.1006/dbio.1993.1210; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; WALLACE BG, 1990, J NEUROSCI, V10, P3576; WALLACE BG, 1989, J NEUROSCI, V9, P1294	30	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					15934	15937		10.1074/jbc.270.27.15934	http://dx.doi.org/10.1074/jbc.270.27.15934			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608145	hybrid			2022-12-25	WOS:A1995RH22600006
J	GALIS, ZS; SUKHOVA, GK; LIBBY, P				GALIS, ZS; SUKHOVA, GK; LIBBY, P			MICROSCOPIC LOCALIZATION OF ACTIVE PROTEASES BY IN-SITU ZYMOGRAPHY - DETECTION OF MATRIX METALLOPROTEINASE ACTIVITY IN VASCULAR TISSUE	FASEB JOURNAL			English	Article						EXTRACELLULAR MATRIX DEGRADATION; FLUORESCENT ASSAY; ATHEROSCLEROSIS	DEGRADING METALLOPROTEINASES; ATHEROSCLEROTIC PLAQUES; EXPRESSION; PROCOLLAGENASE; THROMBOSIS; METASTASIS	Many physiological and pathological processes involve tissue remodeling due in part to degradation of extracellular matrix, Several factors limit current approaches used for detection of matrix-degrading enzymes in tissues, Matrix metalloproteinases (MMPs), enzymes specialized in catabolism of extracellular matrix constituents, require processing from inactive zymogen precursors to gain enzymatic function, Presently available antibodies do not distinguish between precursor and proteolytically processed forms of MMPs. Also, ubiquitous tissue inhibitors of metalloproteinases (TIMPs) could prevent matrix degradation by MMPs even if the enzymes were in an active form, For these reasons immunocytochemistry does not provide information regarding the functional state of these enzymes, Biochemical studies of tissue extracts preclude localization and entail the possibility of artifactual activation of the enzymes consequent to tissue disruption, To obviate these problems, we have adapted substrate zymography to frozen tissue sections to assess net proteolytic activity in situ, We report here the details and the validation of this methodology, Initial experiments defined casein fluorescently labeled with resorufin as a useful substrate for detecting stromelysin, and fluoresceinated gelatin or autoradiographic emulsion as suitable for detecting gelatinolytic activity by this approach, Either TIMP-1 or the Zn chelator 1,10-phenanthroline reduced the zymographic activity in cryosections of atheroma from humans or rabbits, Inhibitors of serine proteases did not reduce the extent of substrate lysis substantially. In situ zymography preserves the fine morphological details of the tissue and can complement the study of enzyme expression by other microscopic techniques, such as immunocytochemistry, This approach may prove generally applicable for the detection of protease activity in tissue sections permitting exploration of the roles of these enzymes in pathobiology.	BRIGHAM & WOMENS HOSP,VASC MED & ATHEROSCLEROSIS UNIT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034636, R37HL034636] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34636-10] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; CHENG GC, 1993, CIRCULATION, V87, P1179, DOI 10.1161/01.CIR.87.4.1179; CONSTANTINIDES P, 1989, PATHOBIOLOGY HUMAN A, P393; DAVIES MJ, 1993, BRIT HEART J, V69, P377; EISEN AZ, 1970, J INVEST DERMATOL, V55, P359, DOI 10.1111/1523-1747.ep12260483; FUSTER V, 1990, CIRCULATION, V82, P47; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; GROSS J, 1962, P NATL ACAD SCI USA, V48, P1014, DOI 10.1073/pnas.48.6.1014; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HERRON GS, 1986, J BIOL CHEM, V261, P2810; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SOUTHGATE KM, 1992, BIOCHEM J, V288, P93, DOI 10.1042/bj2880093; STETLERSTEVENSO.WG, 1993, FASEB J, V7, P1434; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	20	239	251	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					974	980		10.1096/fasebj.9.10.7615167	http://dx.doi.org/10.1096/fasebj.9.10.7615167			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615167				2022-12-25	WOS:A1995RK89900021
J	SARGE, KD				SARGE, KD			MALE GERM CELL-SPECIFIC ALTERATION IN TEMPERATURE SET-POINT OF THE CELLULAR STRESS-RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-SHOCK FACTOR; MOUSE SPERMATOGENIC CELLS; AMINO-ACID-ANALOGS; DNA-BINDING; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; PROTEINS; ACTIVATION; EXPRESSION; OLIGOMERIZATION	Heat shock factor (HSF), a transcriptional regulator with heat-activatable DNA binding ability, mediates the stress-induced expression of eukaryotic heat shock protein genes, Previous results from this laboratory demonstrated that a preparation of mixed male germ cell types from mouse testis exhibited a lower temperature threshold for activation of HSF1 DNA binding relative to other mouse cell types (Sarge, K. D., Pray, A. E., and Goodson, M. L. (1995) Nature 374, 126), The purpose of the present study was to determine whether the phenomenon of reduced HSF1 activation temperature is common to all testis cell types, both somatic and germ cell types, or whether it is a special property of male germ cells, The results show that a purified population of pachytene spermatocytes, one of the male germ cell types, exhibits a profile of reduced HSF1 activation temperature identical to that observed for the mixed germ cell preparation, with a threshold HSF1 activation temperature of 35 degrees C, Activation of HSF1 DNA binding in male germ cells by incubation at 38 degrees C is accompanied by the classic cellular stress response parameters of heat-induced HSF1 phosphorylation and increased expression of the hsp72 stress protein, In contrast, a preparation of somatic testis cell types exhibits HSF1 activation only at temperatures of 42 degrees C and above, a profile identical to that observed for mouse liver cells and mammalian cell lines, These results demonstrate that the phenomenon of reduced HSF1 activation temperature is a unique property of male germ cell types within the mammalian testis and demonstrate that HSF1 activated at this lower temperature threshold is fully capable of mediating a productive cellular stress response in these cell types.			SARGE, KD (corresponding author), UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT BIOCHEM,800 ROSE ST,LEXINGTON,KY 40536, USA.							ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ALLEN RL, 1988, MOL CELL BIOL, V8, P828, DOI 10.1128/MCB.8.2.828; ALLEN RL, 1988, MOL CELL BIOL, V8, P3260, DOI 10.1128/MCB.8.8.3260; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; CLOS J, 1993, NATURE, V364, P252, DOI 10.1038/364252a0; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; Eddy EM, 1993, MOL BIOL MALE REPROD, P181; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; HARRISON RG, 1948, J PHYSIOL-LONDON, V107, pP48; HECHT NB, 1992, CELL MOL BIOL TESTIS, P464; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KINGSTON RE, 1991, HORMONAL CONTROL GEN, P377; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEMAIRE L, 1991, LIFE SCI, V48, P365, DOI 10.1016/0024-3205(91)90557-R; LIS J, 1992, TRANSCRIPTIONAL REGU, P907; LIU AYC, 1994, J BIOL CHEM, V269, P14768; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1995, NATURE, V374, P126, DOI 10.1038/374126a0; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; ZAKERI ZF, 1990, J CELL BIOL, V111, P1785, DOI 10.1083/jcb.111.5.1785; ZORGNIOTTI AW, 1989, TEMPERATURE ENV EFFE	37	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18745	18748		10.1074/jbc.270.32.18745	http://dx.doi.org/10.1074/jbc.270.32.18745			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642523	hybrid			2022-12-25	WOS:A1995RN95400010
J	SEEDORF, K; SHEARMAN, M; ULLRICH, A				SEEDORF, K; SHEARMAN, M; ULLRICH, A			RAPID AND LONG-TERM EFFECTS OF PROTEIN-KINASE-C ON RECEPTOR TYROSINE KINASE PHOSPHORYLATION AND DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SWISS 3T3 CELLS; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; PHORBOL ESTERS; EGF RECEPTOR; S6 KINASE; SERINE PHOSPHORYLATION; CHIMERIC RECEPTOR	Rapid and long term effects of protein kinase C alpha activation on receptor tyrosine kinase signaling parameters were investigated in human 293 embryonic fibroblasts and mouse NIH 3T3 cells, Within minutes of phorbol 12-myristate 13-acetate treatment, epidermal growth factor receptor and HER2 tyrosine phosphorylation was decreased, while platelet derived growth factor receptor and insulin receptor autophosphorylation was upregulated, These effects are not mediated by protein kinase C-dependent receptor tyrosine kinase phosphorylation but apparently by activation or inactivation of receptor tyrosine kinase specific phosphatases, as indicated by neutralization of these phenomena upon treatment of cells with sodium orthovanadate. In contrast to these short term effects, sustained activation of protein kinase C alpha by phorbol 12-myristate 13-acetate results in translocation of protein kinase C from the cytosol to the membrane fraction where it forms stable complexes with all receptor tyrosine kinases investigated, Ligand-induced receptor tyrosine kinase/protein kinase C association in NIH 3T3 fibroblasts is accompanied by a mobility shift of the receptor, indicating phosphorylation by activated protein kinase C. This phenomenon correlates with the disappearance of receptor tyrosine kinases from the cell surface, implying that this interaction plays a role in the process of receptor internalization and degradation, Interestingly, ligand-stimulated receptor down-regulation is also enhanced by overexpression of phospholipase C gamma, which strongly indicates a role for this common receptor tyrosine kinase substrate in negative regulation of growth factor signals.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society								AHN NG, 1991, J BIOL CHEM, V266, P4220; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOWEN S, 1991, J BIOL CHEM, V266, P1162; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHIN JE, 1993, J BIOL CHEM, V268, P6338; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DECKER SJ, 1985, J BIOL CHEM, V260, P2003; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; FENDLY BM, 1990, CANCER RES, V50, P1550; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HACHIYA HL, 1987, J BIOL CHEM, V262, P6417; HARING H, 1986, BIOCHEM J, V234, P59; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HOUSLAY MD, 1989, BRIT MED BULL, V45, P264, DOI 10.1093/oxfordjournals.bmb.a072316; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HUCKLE WR, 1990, ENDOCRINOLOGY, V127, P1697, DOI 10.1210/endo-127-4-1697; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IWASHITA S, 1992, CELL SIGNAL, V4, P123, DOI 10.1016/0898-6568(92)90076-K; JACOBS S, 1986, J BIOL CHEM, V261, P934; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; KASUGA K, 1989, FEBS LETT, V254, P22; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LACAL JC, 1990, MOL CELL BIOL, V10, P2983, DOI 10.1128/MCB.10.6.2983; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRIS JDH, 1988, ONCOGENE, V4, P27; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON P, 1993, J BIOL CHEM, V268, P15536; NEMENOFF RA, 1986, ARCH BIOCHEM BIOPHYS, V245, P196, DOI 10.1016/0003-9861(86)90205-5; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1992, SCIENCE, V233, P305; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; OBERMAIER B, 1987, DIABETOLOGIA, V30, P93; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, J BIOL CHEM, V263, P12721; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOZERI O, 1992, ONCOGENE, V7, P2259; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WEINSTEIN IB, 1988, CANCER RES, V48, P4135	79	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18953	18960		10.1074/jbc.270.32.18953	http://dx.doi.org/10.1074/jbc.270.32.18953			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642554	hybrid			2022-12-25	WOS:A1995RN95400042
J	SUGAYA, T; NISHIMATSU, SI; TANIMOTO, K; TAKIMOTO, E; YAMAGISHI, T; IMAMURA, K; GOTO, S; IMAIZUMI, K; HISADA, Y; OTSUKA, A; UCHIDA, H; SUGIURA, M; FUKUTA, K; FUKAMIZU, A; MURAKAMI, K				SUGAYA, T; NISHIMATSU, SI; TANIMOTO, K; TAKIMOTO, E; YAMAGISHI, T; IMAMURA, K; GOTO, S; IMAIZUMI, K; HISADA, Y; OTSUKA, A; UCHIDA, H; SUGIURA, M; FUKUTA, K; FUKAMIZU, A; MURAKAMI, K			ANGIOTENSIN-II TYPE 1A RECEPTOR-DEFICIENT MICE WITH HYPOTENSION AND HYPERRENINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SECRETION; RENIN	Angiotensin (AT) II, the bioactive octapeptide in the renin-angiotensin system that plays a key role in cardiovascular homeostasis, exerts its multiple effects through the different types of AT receptors, AT1a, AT1b, and AT2. Previously, we showed chronic hypotension in angiotensinogen (the precursor of AT)-deficient mice and a dramatic increase in renin mRNA levels in its kidney, but it remains unclear which types of AT receptors regulate the blood pressure and renin gene expression, In order to elucidate the physiological roles of AT1a receptor, we generated mutant mice with a targeted replace ment of the AT1a receptor loci by the lacZ gene, In the heterozygous mutant mice, the strong lacZ staining was found in the glomerulus and juxtaglomerular apparatus of the renal cortex, which coincided with that of the signals detected by in situ hybridization, Chronic hypotension was observed in the heterozygous and homozygous mutant mice, with 10 and 22 mm Mg lower systolic blood pressure, respectively, than that of wild-type littermates. Both the levels of renin mRNA in the kidney and plasma renin activity were markedly increased only in the homozygous mutant mice, These results demonstrated that an AT1a-mediated signal transduction pathway is, at least in part, involved in the regulation of blood pressure and renin gene expression.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; NATL INST ANIM HLTH,TSUKUBA,IBARAKI 305,JAPAN; TANABE SEIYAKU CO LTD,LEAD GENERAT RES LABS,KASHIMA,OSAKA 532,JAPAN	University of Tsukuba; University of Tsukuba; National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan; Mitsubishi Tanabe Pharma Corporation			Nishimatsu, Shin-ichiro/C-4188-2012; fukamizu, akiyoshi/J-5350-2012; Tanimoto, Keiji/B-2600-2014	fukamizu, akiyoshi/0000-0002-8786-6020; Tanimoto, Keiji/0000-0003-1971-6546				BLAIRWEST JR, 1971, AM J PHYSIOL, V220, P1309; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; GASC JM, 1994, HYPERTENSION, V24, P531, DOI 10.1161/01.HYP.24.5.531; Hall JE, 1990, HYPERTENSION PATHOPH, P1105; HATAE T, 1994, MOL CELL BIOCHEM, V131, P43, DOI 10.1007/BF01075723; HEALY DP, 1995, AM J PHYSIOL-RENAL, V268, pF220, DOI 10.1152/ajprenal.1995.268.2.F220; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; PINET F, 1987, J CLIN INVEST, V80, P724, DOI 10.1172/JCI113127; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; Tanimoto Keiji, 1993, Journal of Reproduction and Development, V39, P19; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; VANDONGEN R, 1974, AM J PHYSIOL, V226, P277, DOI 10.1152/ajplegacy.1974.226.2.277; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458	18	337	341	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18719	18722		10.1074/jbc.270.32.18719	http://dx.doi.org/10.1074/jbc.270.32.18719			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642517	hybrid			2022-12-25	WOS:A1995RN95400003
J	MOODIE, SA; PARIS, M; VILLAFRANCA, E; KIRSHMEIER, P; WILLUMSEN, BM; WOLFMAN, A				MOODIE, SA; PARIS, M; VILLAFRANCA, E; KIRSHMEIER, P; WILLUMSEN, BM; WOLFMAN, A			DIFFERENT STRUCTURAL REQUIREMENTS WITHIN THE SWITCH-II REGION OF THE RAS PROTEIN FOR INTERACTIONS WITH SPECIFIC DOWNSTREAM TARGETS	ONCOGENE			English	Article						RAS; PI-3 KINASE; DOWNSTREAM TARGETS	NUCLEOTIDE-FREE; GTP HYDROLYSIS; P21; DOMAIN; GAP; NEUROFIBROMATOSIS; IDENTIFICATION; ACTIVATION; EXPRESSION; MUTATIONS	Ras proteins function through the formation of specific complexes with Raf-1, B-raf, PI-3 kinase and RalGDS. These interactions all require Ras-GTP with an intact effector binding domain (Switch I region). We have examined the requirements of the Switch II region (amino acids 60-72) for the production of stable interactions between Ras and its downstream effecters. A point mutation at position 65 or 64 combined with additional mutations at either position 65 or 71 rendered nucleotide-free Ras protein unable to stably interact with Ras specific guanine nucleotide exchange factors. Ha-Ras containing point mutations at positions 65 and 71 possessed a twofold higher affinity for B-raf and consequently MEK1. The point mutation at 64, in combination with additional point mutations at either position 65 or 71, resulted in a protein which failed to interact with either PI-3 kinase or neurofibromin, though these Ras mutants effectively bound both Raf-1 and B-raf. An activated form of Ras, Q61L-Ras, associated with all effector proteins independent of the bound guanine nucleotide. Q61L-Ras-GDP was almost as effective as wild type Ras-GMPPNP in the in vitro activation of MEK1 and MAP kinase. Competitive studies with the catalytic domain of neurofibromin, NF1-GRD, demonstrated that its interaction with Ras-GMPPNP is mutually exclusive with both Raf-1 and B-raf. These data suggest that rasGAP and neurofibromin are unable to downregulate Ras-GTP complexed to Raf-1 or B-raf.	CLEVELAND CLIN FDN,DEPT CELL BIOL,CLEVELAND,OH 44195; BRISTOL MYERS & SQUIBB RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; AGOURON PHARMACEUT,SAN DIEGO,CA 92191; SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033; UNIV COPENHAGEN,DEPT MOLEC CELL BIOL,DK-1353 COPENHAGEN,DENMARK	Cleveland Clinic Foundation; Bristol-Myers Squibb; Cleveland Clinic Foundation; Pfizer; Merck & Company; Schering Plough Corporation; University of Copenhagen			Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999	NIGMS NIH HHS [GM49652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049652, R01GM049652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAZENET CE, 1994, ONCOGENE, V9, P517; BUSS JE, 1989, BIOCHEM SOC T, V17, P867, DOI 10.1042/bst0170867; CATLING AD, 1994, J BIOL CHEM, V269, P30014; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DIBATTISTE D, 1993, ONCOGENE, V8, P637; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUTMANN DH, 1992, ANN NEUROL, V31, P555, DOI 10.1002/ana.410310515; HALL A, 1986, J BIOL CHEM, V261, P963; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1993, ONCOGENE, V8, P2583; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8693; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOODIE SA, 1994, MOL CELL BIOL, V14, P6944; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHIROUZU M, 1994, ONCOGENE, V9, P2153; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P206; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1989, GUANINE NUCLEOTIDE B, P165; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	58	65	65	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					447	454						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630628				2022-12-25	WOS:A1995RN53000004
J	JUSTICE, JM; MURTAGH, JJ; MOSS, J; VAUGHAN, M				JUSTICE, JM; MURTAGH, JJ; MOSS, J; VAUGHAN, M			HYDROPHOBICITY AND SUBUNIT INTERACTIONS OF ROD OUTER SEGMENT PROTEINS INVESTIGATED USING TRITON X-114 PHASE PARTITIONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCIN-ALPHA-SUBUNIT; CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; INTEGRAL MEMBRANE-PROTEINS; CGMP-PHOSPHODIESTERASE; ADP-RIBOSYLATION; PERTUSSIS TOXIN; GAMMA-SUBUNIT; BETA-GAMMA; TERMINAL DOMAIN	Triton X-114 phase partitioning, a procedure used for purifying integral membrane proteins, was used to study protein components of the mammalian visual transduction cascade. An integral membrane protein, rhodopsin, and two isoprenylated protein complexes, cyclic GMP phosphodiesterase and G(t beta gamma), partitioned into the detergent-rich phase. Arrestin, a soluble protein, accumulated in the aqueous phase. G(t alpha) distributed about equally between phases whether G;DP (G(t alpha). GDP) or GTP (G(t alpha). GTP) was bound. G(t beta gamma) increased recovery of G(t alpha). GDP but not G(t alpha). GTP in the detergent phase. Trypsin-treated G(t alpha), which lacks the fatty acylated amino-terminal 2-kDa region, accumulated to a greater extent in the aqueous phase than did intact G(t alpha). Trypsinized cGMP phosphodiesterase, which lacks the isoprenyl group, partitioned into the aqueous phase. A carboxyl-terminal truncated mutant (Val-331 stop) of G(t alpha) accumulated more in the aqueous phase then did recombinant full-length G(t alpha), supporting the role of the carboxyl terminus in increasing its hydrophobicity. N-Myristoylated recombinant G(o alpha) was more hydrophobic than recombinant G(o alpha) without myristate. ADP-ribosylation of G(t alpha) catalyzed by NAD:arginine ADP-ribosyltransferase, but not by pertussis toxin, increased hydrophilicity. Triton X-114 phase partitioning can thus semiquantify the hydrophobic nature of proteins and protein domains. It may aid in evaluating changes associated with post-translational protein modification and protein-protein interactions in a defined system.			JUSTICE, JM (corresponding author), NHLBI,PULM CRIT CARE MED BRANCH,10 CTR DR,MSC 1434,BLDG 10,RM 5N-307,BETHESDA,MD 20892, USA.							ANANT JS, 1992, J BIOL CHEM, V267, P687; AUDIGIER Y, 1990, J CELL BIOL, V111, P1427, DOI 10.1083/jcb.111.4.1427; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BIANCHI R, 1992, FEBS LETT, V296, P158, DOI 10.1016/0014-5793(92)80369-R; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CATTY P, 1992, J BIOL CHEM, V267, P19489; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; CLERC A, 1992, J BIOL CHEM, V267, P19948; CLERC A, 1992, J BIOL CHEM, V267, P6620; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DENTLER WL, 1988, J CELL BIOL, V107, P2679, DOI 10.1083/jcb.107.6.2679; DENTLER WL, 1992, J PROTOZOOL, V39, P368, DOI 10.1111/j.1550-7408.1992.tb01466.x; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; EDERCOLLI L, 1992, BRAIN RES, V573, P284, DOI 10.1016/0006-8993(92)90774-4; EIDE B, 1987, BIOCHEM BIOPH RES CO, V148, P1398, DOI 10.1016/S0006-291X(87)80287-5; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GRAF R, 1992, J BIOL CHEM, V267, P24307; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HONG JX, 1994, J BIOL CHEM, V269, P9743; HONG K, 1973, BIOCHEMISTRY-US, V12, P4517, DOI 10.1021/bi00746a033; HSIA JA, 1984, J BIOL CHEM, V259, P1086; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JOURNOT L, 1991, P NATL ACAD SCI USA, V88, P10054, DOI 10.1073/pnas.88.22.10054; JUSTICE JM, 1995, J BIOL CHEM, V270, P6436, DOI 10.1074/jbc.270.12.6436; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KRUEGER JG, 1983, CURR TOP MICROBIOL I, V107, P52; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MOSS J, 1980, J BIOL CHEM, V255, P5838; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NYSTROM S, 1991, BIOCHIM BIOPHYS ACTA, V1107, P39; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; REED SL, 1992, INFECT IMMUN, V60, P542, DOI 10.1128/IAI.60.2.542-549.1992; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SHINOZAWA T, 1980, P NATL ACAD SCI-BIOL, V77, P1408, DOI 10.1073/pnas.77.3.1408; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; TSAI SC, 1987, BIOCHEMISTRY-US, V26, P4728, DOI 10.1021/bi00389a020; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WEST RE, 1985, J BIOL CHEM, V260, P4428; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	68	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17970	17976		10.1074/jbc.270.30.17970	http://dx.doi.org/10.1074/jbc.270.30.17970			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629104	hybrid			2022-12-25	WOS:A1995RM26600054
J	WAKADE, AR; PRZYWARA, DA; PALMER, KC; KULKARNI, JS; WAKADE, TD				WAKADE, AR; PRZYWARA, DA; PALMER, KC; KULKARNI, JS; WAKADE, TD			DEOXYNUCLEOSIDE INDUCES NEURONAL APOPTOSIS INDEPENDENT OF NEUROTROPHIC FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ADENOSINE-DEAMINASE DEFICIENCY; SYMPATHETIC NEURONS; FACTOR DEPRIVATION; HUMAN-LYMPHOCYTES; CHICK-EMBRYO; CELL-DEATH; CYCLIC-AMP; DEOXYADENOSINE; TOXICITY	Postmitotic sympathetic neurons are known to undergo a programmed cell death (apoptosis) when they are deprived of nerve growth factor (NGF) or treated with arabinofuranosyl nucleoside antimetabolites. Here we report the existence of a biochemical mechanism for the induction of neuronal death by an endogenous nucleoside in the presence of NGF. In support of such a mechanism we show that 2-deoxyadenosine (dAdo) induces apoptosis in chick embryonic sympathetic neurons supported in culture by NGF, excess K+, phorbol 12,13-dibutyrate, or forskolin. Neuronal death was related to a dramatic increase in the dATP content of sympathetic neurons exposed to dAdo (34.96 +/- 5.98 versus 0.75 +/- 0.16 pmol/mu g protein in untreated controls, n = 9), implicating dATP in the toxicity. Supportive evidence for a central role of dATP was gained by inhibition of kinases necessary for phosphorylation of dAdo. 5'-Iodotubercidin in nanomolar concentrations completely and dose-dependently inhibited formation of dATP and also protected against toxicity of submillimolar lar concentrations of dAdo in sympathetic neurons. Although some of these actions of dAdo were remarkably similar to those reported for human lymphoid cells, several were uniquely different. For example, [H-3]dAdo was not transported into neurons by the nucleoside transporter, and therefore inhibition of the transporter (dilazep, nitrobenzylthioinosine) did not prevent neurotoxicity by dAdo. Precursors of pyrimidine synthesis (2'-deoxycytidine, uridine) or NAD(+) synthesis (nicotinamide) were ineffective in protecting sympathetic neurons against dAdo toxicity. Finally, inhibition of adenosine deaminase by deoxycoformycin or erythro-9-(2-hydroxy-3-nonyl) adenine did not potentiate the toxic effects of dAdo. Our results provide evidence for the first time that neuronal cells are as susceptible to nucleoside lethality as human lymphocytes are, and provide a new model to study the salvage pathway of deoxyribonucleosides in controlling neuronal populations through programmed cell death.	WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201	Wayne State University; Wayne State University								AGARWAL RP, 1982, PHARMACOL THERAPEUT, V17, P399, DOI 10.1016/0163-7258(82)90023-7; BAGNARA AS, 1982, P NATL ACAD SCI-BIOL, V79, P2673, DOI 10.1073/pnas.79.8.2673; BALT JA, 1993, ADV ENZYME REGUL, V33, P285; BHAVE SV, 1995, IN PRESS J NEUROCHEM; CARSON DA, 1977, P NATL ACAD SCI USA, V74, P5677, DOI 10.1073/pnas.74.12.5677; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; COLEMAN MS, 1978, J BIOL CHEM, V253, P1619; CRAWFORD CR, 1990, J BIOL CHEM, V265, P13730; DECKWERTH TL, 1994, DEV BIOL, V165, P63, DOI 10.1006/dbio.1994.1234; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; EDWARDS SN, 1994, J CELL BIOL, V124, P537, DOI 10.1083/jcb.124.4.537; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; GIBLETT ER, 1972, LANCET, V2, P1067; HENDERSON JF, 1980, PHARMACOL THERAPEUT, V8, P573; HERSHFIELD MS, 1979, J CLIN INVEST, V63, P807, DOI 10.1172/JCI109367; HIRSCHHORN R, 1980, NEW ENGL J MED, V303, P377, DOI 10.1056/NEJM198008143030706; HIRSCHHORN R, 1980, J CLIN INVEST, V65, P768, DOI 10.1172/JCI109725; HURLEY MC, 1988, ADV EXP MED BIOL, V195, P141; JOHNSTON JM, 1979, J IMMUNOL, V123, P97; KAUKEL E, 1972, BIOCHEM BIOPH RES CO, V48, P1516, DOI 10.1016/0006-291X(72)90886-8; KESLER JA, 1993, NEURON, V11, P1123; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN DP, 1990, J NEUROSCI, V10, P184; MITCHELL BS, 1978, P NATL ACAD SCI USA, V75, P5011, DOI 10.1073/pnas.75.10.5011; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PISONI RL, 1989, J BIOL CHEM, V264, P4850; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1022, P103, DOI 10.1016/0005-2736(90)90405-D; PLAGEMANN PGW, 1985, CANCER RES, V45, P6418; POLMAR SH, 1976, NEW ENGL J MED, V295, P13437; ROHER AE, 1991, BIOCHEM BIOPH RES CO, V174, P572, DOI 10.1016/0006-291X(91)91455-L; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; SNYDER FF, 1976, J CLIN INVEST, V58, P654, DOI 10.1172/JCI108512; SOLTER AW, 1969, BIOCHIM BIOPHYS ACTA, V174, P585, DOI 10.1016/0005-2787(69)90288-3; TATTERSALL MHN, 1975, BIOCHEM PHARMACOL, V24, P1495, DOI 10.1016/0006-2952(75)90025-8; TOMKINS CE, 1994, J CELL SCI, V107, P1499; ULLMAN B, 1976, CELL, V9, P205, DOI 10.1016/0092-8674(76)90111-2; ULLMAN B, 1978, CELL, V14, P365, DOI 10.1016/0092-8674(78)90122-8; WAKADE AR, 1990, J NEUROCHEM, V54, P1281, DOI 10.1111/j.1471-4159.1990.tb01960.x; WAKADE AR, 1983, EXP CELL RES, V144, P377, DOI 10.1016/0014-4827(83)90417-2; WAKADE AR, 1988, J NEUROCHEM, V57, P975; YU AL, 1981, CANCER RES, V41, P2677	42	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17986	17992		10.1074/jbc.270.30.17986	http://dx.doi.org/10.1074/jbc.270.30.17986			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629106	hybrid			2022-12-25	WOS:A1995RM26600056
J	YAMAUCHI, K; RIBON, V; SALTIEL, AR; PESSIN, JE				YAMAUCHI, K; RIBON, V; SALTIEL, AR; PESSIN, JE			IDENTIFICATION OF THE MAJOR SHPTP2-BINDING PROTEIN THAT IS TYROSINE-PHOSPHORYLATED IN RESPONSE TO INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; CELL ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; SH2 DOMAINS; DROSOPHILA; KINASE; TORSO; ACTIVATION; CORKSCREW; HOMOLOG	Immunoprecipitation of the cytosolic Src homology 2 domain-containing protein-tyrosine phosphatase, SHPTP2, from insulin-stimulated 3T3L1 adipocytes or Chinese hamster ovary cells expressing the human insulin receptor resulted in the coimmunoprecipitation of a diffuse tyrosine-phosphorylated band in the 115-kDa protein region on SDS-polyacrylamide gels. Although platelet-derived growth factor induced the tyrosine phosphorylation of the platelet-derived growth factor receptor and SHPTP2, there was no significant increase in the coimmunoprecipitation of tyrosine-phosphorylated pp115 with SHPTP2. SHPTP2 was also associated with tyrosine-phosphorylated insulin receptor substrate-1, but this only accounted for <2% of the total immunoreactive SHPTP2 protein. Similarly, only a small fraction of the total amount of tyrosine-phosphorylated insulin receptor substrate-1 (<4%) was associated with SHPTP2. Expression and immunoprecipitation of a Myc epitope-tagged wild-type SHPTP2 (Myc-WT-SHPTP2) and a catalytically inactive point mutant of SHPTP2 (Myc-C/S-SHPTP2) also demonstrated an insulin-dependent association of SHPTP2 with tyrosine-phosphorylated pp115. Furthermore, expression of the catalytically inactive SHPTP2 mutant resulted in a marked enhancement in the amount of coimmunoprecipitated tyrosine-phosphorylated pp115 compared with the expression of wild-type SHPTP2. These data indicate that the insulin-stimulated tyrosine-phosphorylated 115-kDa protein is the predominant in vivo SHPTP2-binding protein and that pp115 may function as a physiological substrate for the SHPTP2 protein-tyrosine phosphatase.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48104; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	University of Iowa; University of Michigan System; University of Michigan; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, P30DK025295, R37DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33823, DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1992, FEBS LETT, V314, P336; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BIFFEN M, 1994, EMBO J, V13, P1920, DOI 10.1002/j.1460-2075.1994.tb06461.x; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HIRAGA A, 1992, EUR J BIOCHEM, V209, P195, DOI 10.1111/j.1432-1033.1992.tb17277.x; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17716	17722		10.1074/jbc.270.30.17716	http://dx.doi.org/10.1074/jbc.270.30.17716			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629070	hybrid			2022-12-25	WOS:A1995RM26600016
J	DUGUAY, SJ; JIE, LZ; STEINER, DF				DUGUAY, SJ; JIE, LZ; STEINER, DF			MUTATIONAL ANALYSIS OF THE INSULIN-LIKE GROWTH-FACTOR-I PROHORMONE PROCESSING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS EXOTOXIN-A; MESSENGER-RNAS; MOUSE FURIN; CELLS; PRECURSOR; PC2; ENDOPROTEASE; RECEPTOR; CLEAVAGE; PROOPIOMELANOCORTIN	Insulin-like growth factor I (IGF-I) is a mitogenic peptide that is produced in most tissues and cell lines and plays an important role in embryonic development and postnatal growth. IGF-I is initially synthesized as a prohormone precursor that is converted to mature IGF-I by endoproteolytic removal of the carboxyl-terminal E-domain. Regulation of the conversion of proIGF-I to mature IGF-I is a potential mechanism by which the biological activity of this growth factor might be modulated. Endoproteolysis of the IGF-I prohormone occurs at the unique pentabasic motif Lys-X-X-Lys-X-X-Arg(71)-X-X-Arg-X-X-Arg. Recently, a family of enzymes which cleave prohormone precursors at sites containing multiple basic residues has been discovered. The goals of this study were 1) to determine which basic residues in the pentabasic proIGF-I processing site were necessary for proper cleavage and 2) to examine the role that subtilisin-related proprotein convertase 1 (SPC1/furin) might play in proIGF-I processing. We have shown that an expression vector coding for an epitope-tagged proIGF-I directs synthesis and secretion of mature IGF-I-(1-70), extended IGF-I-(1-76), proIGF-I, and N-glycosylated proIGF-I in human embryonic kidney 293 cells. Extended IGF-I-(1-76) is produced by cleavage at Arg(77) and requires both Arg(74) (P4) and Arg(77) (P1). Cleavage at Arg(77) does not occur in the SPC1-dedcient cell lines RPE.40 and LoVo, suggesting that processing at this site is mediated by SPC1. Mature IGF-I-(1-70) is produced by cleavage at Arg(71) and requires both Lys(68) (P4) and Arg(71) (P1). Lys(65) in the P7 position is important for efficient cleavage. SPC1 is not required for processing at Arg(71) since this cleavage occurs in RPE.40 and LoVo cells. These data suggest the existence of a processing enzyme which is specific for the Lys-X-X-Arg motif of proIGF-I.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago	DUGUAY, SJ (corresponding author), UNIV CHICAGO,HOWARD HUGHES MED INST,5841 S MARYLAND AVE,MC 1028,CHICAGO,IL 60637, USA.				NIDDK NIH HHS [DK13914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013914, R37DK013914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; CREEMERS JWM, 1993, FEBS LETT, V336, P65, DOI 10.1016/0014-5793(93)81610-C; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; GOTOH B, 1992, J VIROL, V66, P6391, DOI 10.1128/JVI.66.11.6391-6397.1992; HALBAN PA, 1994, BIOCHEM J, V299, P1; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; Higuchi R., 1990, PCR PROTOCOLS GUIDE; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MOEHRING JM, 1983, INFECT IMMUN, V41, P998, DOI 10.1128/IAI.41.3.998-1009.1983; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; OHUCHI R, 1991, J VIROL, V65, P3530, DOI 10.1128/JVI.65.7.3530-3537.1991; PIEROTTI AR, 1994, P NATL ACAD SCI USA, V91, P6078, DOI 10.1073/pnas.91.13.6078; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; ROTWEIN P, 1986, P NATL ACAD SCI USA, V83, P77, DOI 10.1073/pnas.83.1.77; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMMONS JG, 1993, GROWTH FACTORS, V9, P205, DOI 10.3109/08977199309010833; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEINER DF, 1990, HDB EXPT PHARM, V92, P67; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WALKER JA, 1994, J VIROL, V68, P1213, DOI 10.1128/JVI.68.2.1213-1218.1994; YANG YWH, 1985, J BIOL CHEM, V260, P2570; ZHOU A, 1993, J BIOL CHEM, V268, P1763	32	55	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17566	17574		10.1074/jbc.270.29.17566	http://dx.doi.org/10.1074/jbc.270.29.17566			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615562	hybrid			2022-12-25	WOS:A1995RK68900079
J	MAYER, B; SCHRAMMEL, A; KLATT, P; KOESLING, D; SCHMIDT, K				MAYER, B; SCHRAMMEL, A; KLATT, P; KOESLING, D; SCHMIDT, K			PEROXYNITRITE-INDUCED ACCUMULATION OF CYCLIC-GMP IN ENDOTHELIAL-CELLS AND STIMULATION OF PURIFIED SOLUBLE GUANYLYL CYCLASE - DEPENDENCE ON GLUTATHIONE AND POSSIBLE ROLE OF S-NITROSATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHESIS; RELAXING FACTOR; BOVINE LUNG; SUPEROXIDE; NO; OXIDATION; INVITRO; ACTIVATION; RELEASE; MEDIA	Peroxynitrite (ONOO-) is widely recognized as mediator of NO toxicity, but recent studies have indicated that this compound may also have physiological activity and induce vascular relaxation as well as inhibition of platelet aggregation. We found that ONOO- induced a pronounced increase in endothelial cyclic GMP levels, and that this effect was significantly attenuated by pretreatment of the cells with GSH depleting agents. In the presence of 2 mM GSH, ONOO- stimulated purified soluble guanylyl cyclase with a half maximally effective concentration of about 20 mu M. In contrast to the NO donor 2,2-Diethyl-1-nitroso-oxyhydrazine sodium salt (DEA/NO), ONOO- was completely inactive in the absence of GSH, indicating that thiol-mediated bioactivation of ONOO- is involved in enzyme stimulation. Studies on the reaction between ONOO- and GSH revealed that about 1% of ONOO- was non-enzymatically converted to S-nitrosoglutathione. The authentic nitrosothiol was found to be stable in solution, but slowly decomposed in the presence of GSH. GSH-induced decomposition of S-nitrosoglutathione was apparently catalyzed by trace metals and was accompanied by a sustained release of NO and a 40-100-fold increase in its potency to stimulate purified soluble guanylyl cyclase. Our data suggest that the biologic activity of ONOO- involves S-nitrosation of cellular thiols resulting in NO-mediated cyclic GMP accumulation.	FREE UNIV BERLIN,INST PHARMAKOL,D-14195 BERLIN,GERMANY	Free University of Berlin	MAYER, B (corresponding author), KARL FRANZENS UNIV GRAZ,INST PHARMAKOL & TOXIKOL,UNIV PL 2,A-8010 GRAZ,AUSTRIA.		Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				BAYDOUN AR, 1990, BIOCHEM BIOPH RES CO, V173, P940, DOI 10.1016/S0006-291X(05)80876-9; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CRAVEN PA, 1978, BIOCHIM BIOPHYS ACTA, V524, P231, DOI 10.1016/0005-2744(78)90121-3; CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; GARTHWAITE J, 1993, SEMIN NEUROSCI, V5, P171, DOI 10.1016/S1044-5765(05)80050-8; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; GHIGO D, 1993, AM J PHYSIOL, V265, pC728, DOI 10.1152/ajpcell.1993.265.3.C728; GORDGE MP, 1995, BRIT J PHARMACOL, V114, P1083, DOI 10.1111/j.1476-5381.1995.tb13317.x; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HECKER M, 1992, AM J PHYSIOL, V262, pH888, DOI 10.1152/ajpheart.1992.262.3.H888; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; LIU S, 1994, J PHARMACOL EXP THER, V268, P1114; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MAROZIN N, 1993, AM J PHYSIOL, V265, pL220; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; MAYER B, 1993, SEMIN NEUROSCI, V5, P197, DOI 10.1016/S1044-5765(05)80053-3; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; MURPHY ME, 1991, J BIOL CHEM, V266, P19378; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NIROOMAND F, 1991, BIOCHEM PHARMACOL, V41, P1777, DOI 10.1016/0006-2952(91)90185-8; PAPEE HM, 1964, NATURE, V204, P142, DOI 10.1038/204142a0; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; SCHMIDT K, 1994, BIOCHEM J, V301, P645, DOI 10.1042/bj3010645; SCHMIDT K, 1989, EUR J PHARMACOL, V170, P157, DOI 10.1016/0014-2999(89)90536-0; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P379; SPARROW CP, 1993, J LIPID RES, V34, P1219; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STONE JR, 1994, BIOCHEMISTRY-US, V83, P5636; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; WU MD, 1994, AM J PHYSIOL, V266, pH2108, DOI 10.1152/ajpheart.1994.266.5.H2108; YU AE, 1994, J AM CHEM SOC, V116, P4117, DOI 10.1021/ja00088a073	58	184	184	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17355	17360		10.1074/jbc.270.29.17355	http://dx.doi.org/10.1074/jbc.270.29.17355			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615539	hybrid			2022-12-25	WOS:A1995RK68900050
J	NAKAMURA, J; TAJIMA, G				NAKAMURA, J; TAJIMA, G			NEGATIVE OR POSITIVE COOPERATION IN CALCIUM-BINDING TO DETERGENT-SOLUBILIZED ATPASE OF THE SARCOPLASMIC-RETICULUM - ITS MODULATION BY A HIGH-CONCENTRATION OF ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; PUMP PROTEIN; CA-2+-ATPASE; CA2+-ATPASE; KINETICS; SITE; TRANSPORT; MEMBRANES; MUSCLE; STATE	Two different conformations of chemically equivalent Ca2+-ATPase molecules in the sarcoplasmic reticulum have been shown to non- and positive cooperatively bind two calcium ions, respectively (Nakamura, J. (1994) J. Biol. Chem. 269, 30822-30827). At pH 7.40, these ATPase molecules split into E(1) (high affinity state for calcium) and E(2) (low affinity state for calcium), respectively, before calcium binding. At this pH, calcium binding to the monomeric ATPase, solubilized with dodecyloctaethylenglycol monoether, was studied by examining Ca-45(2+) binding to the ATPase and calcium dependences of its phosphorylation, fluorescence intensity, ATP-hydrolysis at a low (5 mu M) concentration of ATP, and acetyl phosphate hydrolysis. The results suggest that the solubilized ATPase molecules predominantly preexist in E(2) and negative cooperatively (the Hill value (n(H)) = 0.5-0.6) bind 2 mol of calcium/mol of the ATPase with an apparent calcium affinity (K-0.5) of 3-5 mu M. The nonequivalences of calcium bindings at the membranous ATPase molecules seem to result from the intermolecular interaction of the molecules. A high concentration (5 mm) of ATP modulated the binding manner so that it became positively cooperative (n(H) similar to 2) and increased the K-0.5 to 0.1 mu M.			NAKAMURA, J (corresponding author), TOHOKU UNIV, FAC SCI, INST BIOL, AOBA KU, SENDAI, MIYAGI 98077, JAPAN.							ALBERS RW, 1968, MOL PHARMACOL, V4, P324; ANDERSEN JP, 1982, J BIOL CHEM, V257, P8300; ANDERSEN JP, 1981, BIOCHEMISTRY-US, V20, P4928, DOI 10.1021/bi00520a019; ANDERSEN JP, 1986, BIOCHEMISTRY-US, V25, P6439, DOI 10.1021/bi00369a015; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; BONTING SL, 1961, ARCH BIOCHEM BIOPHYS, V95, P416, DOI 10.1016/0003-9861(61)90170-9; De Meis L., 1982, MEMBRANE TRANSPORT C, P141; DEMEIS L, 1969, BIOCHIM BIOPHYS ACTA, V172, P343; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; LEMAIRE M, 1978, J BIOL CHEM, V253, P7051; LEMAIRE M, 1976, BIOCHEMISTRY-US, V15, P2336, DOI 10.1021/bi00656a014; LIPMANN F, 1945, J BIOL CHEM, V159, P21; MACINTOSH DB, 1988, J BIOL CHEM, V263, P12220; MAURER A, 1979, J BIOL CHEM, V254, P9209; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; MOLLER JV, 1988, METHOD ENZYMOL, V157, P261; MURPHY AJ, 1982, J BIOL CHEM, V257, P3551; NAKAMURA J, 1994, J BIOL CHEM, V269, P30818; NAKAMURA J, 1983, BIOCHIM BIOPHYS ACTA, V723, P182, DOI 10.1016/0005-2728(83)90118-4; NAKAMURA J, 1994, J BIOL CHEM, V269, P30822; NAKAMURA J, 1977, BIOCHIM BIOPHYS ACTA, V18, P108; PUCELL A, 1971, J BIOL CHEM, V246, P3389; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SILVA JL, 1983, BIOCHEMISTRY-US, V22, P707, DOI 10.1021/bi00272a028; SUZUKI H, 1990, BIOCHEMISTRY-US, V29, P7040, DOI 10.1021/bi00482a013; TADA M, 1978, PHYSIOL REV, V56, P1; TAYLOR JS, 1979, J BIOL CHEM, V254, P4402; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VANDERKOOI JM, 1977, BIOCHEMISTRY-US, V16, P1262, DOI 10.1021/bi00626a003; VERJOVSKIALMEIDA S, 1981, J BIOL CHEM, V256, P2940	38	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17350	17354		10.1074/jbc.270.29.17350	http://dx.doi.org/10.1074/jbc.270.29.17350			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615538	hybrid			2022-12-25	WOS:A1995RK68900049
J	SPANJAARD, RA; SUGAWARA, A; IKEDA, M; CHIN, WW				SPANJAARD, RA; SUGAWARA, A; IKEDA, M; CHIN, WW			EVIDENCE THAT RETINOID-X RECEPTORS MEDIATE RETINOID-DEPENDENT TRANSCRIPTIONAL ACTIVATION OF THE RETINOIC ACID RECEPTOR-BETA GENE IN S91 MELANOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; NUCLEAR RECEPTORS; RESPONSE ELEMENTS; DIFFERENTIAL PATTERN; AUXILIARY PROTEIN; BINDING-PROTEINS; DIRECT REPEATS; RXR-ALPHA; TRANSACTIVATION; EXPRESSION	S91 melanoma cells are growth arrested and differentiate when treated with retinoids. These processes correlate with expression of the retinoic acid receptor (RAR)beta gene, which is induced through a retinoic acid response element (beta RARE). We wished to determine which endogenous retinoid receptors (RARs and retinoid X receptors, RXRs) mediate induction of the RAR beta gene. We show that RXR alpha and RXR beta are constitutively expressed. Electrophoretic mobility shift assays with nuclear extracts show specific binding to the beta RARE (Complex I) in untreated cells, which can be supershifted by antibodies against RXRs but not by anti-RAR antibodies. After 48 h of treatment with retinoic acid, Complex I is replaced by a faster migrating Complex II, which can be supershifted by anti-RAR beta and anti-RXR alpha antibodies. This suggests that induction of the RAR beta gene is largely mediated by RXRs only. Accordingly, we also find that 9-cis RA, which activates both RAR and RXR, is a more potent inducer of the RAR beta gene than RA, which only activates RAR. After 48 h, all RXRs appear to be titrated by the newly synthesized RAR beta into an RAR beta . RXR heterodimer complex. Thus, it appears that the beta RARE is sequentially occupied by RXR dimers and RAR . RXR heterodimers.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	SPANJAARD, RA (corresponding author), BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,20 SHATTUCK ST,BOSTON,MA 02115, USA.			Sugawara, Akira/0000-0003-4511-8101				AMOS B, 1990, METHOD ENZYMOL, V189, P100; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BOYLAN JF, 1993, P NATL ACAD SCI USA, V9, P9601; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GOLDSTEIN AM, 1993, CURR OPIN ONCOL, V3, P358; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; HALL BL, 1993, P NATL ACAD SCI USA, V90, P6929, DOI 10.1073/pnas.90.15.6929; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; IKEDA M, 1995, ENDOCRINOLOGY, V135, P1628; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1978, J NATL CANCER I, V60, P1035, DOI 10.1093/jnci/60.5.1035; LOTAN R, 1981, J CELL PHYSIOL, V106, P179, DOI 10.1002/jcp.1041060203; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; REDFERN CPF, 1990, FEBS LETT, V273, P19, DOI 10.1016/0014-5793(90)81041-L; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Sambrook J, 1989, MOL CLONING LABORATO; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUGAWARA A, 1995, ENDOCRINOLOGY, V136, P1766, DOI 10.1210/en.136.4.1766; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	55	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17429	17436		10.1074/jbc.270.29.17429	http://dx.doi.org/10.1074/jbc.270.29.17429			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615548	hybrid			2022-12-25	WOS:A1995RK68900061
J	SNIJDER, EJ; WASSENAAR, ALM; SPAAN, WJM; GORBALENYA, AE				SNIJDER, EJ; WASSENAAR, ALM; SPAAN, WJM; GORBALENYA, AE			THE ARTERIVIRUS NSP2 PROTEASE - AN UNUSUAL CYSTEINE PROTEASE WITH PRIMARY STRUCTURE SIMILARITIES TO BOTH PAPAIN-LIKE AND CHYMOTRYPSIN-LIKE PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EQUINE ARTERITIS VIRUS; STRAND RNA VIRUSES; SERINE PROTEASES; SEQUENCE; PROTEINASE; SITE; FLAVIVIRUSES; PESTIVIRUSES; SUPERFAMILY; TRANSLATION	The replicase ORF1a polyprotein of equine arteritis virus, a positive stranded RNA virus, is proteolytically processed into (at least) six nonstructural proteins (Nsp). A papain-like Cys protease in Nsp1 and a chymotrypsin-like Ser protease in Nsp4 are involved in this process. In this paper we demonstrate that the Nsp2/3 junction is not cleaved by either of these previously described proteases. Comparative sequence analysis suggested that an additional Cys protease resided in the N-terminal Nsp2 domain. For equine arteritis virus, this domain was shown to induce Nsp2/3 cleavage in a trans-cleavage assay. Processing was abolished when the putative active site residues, Cys-270 and His-332, were replaced. Other Nsp2 domains and three other conserved Cys residues were also shown to be essential. The Nsp2 Cys protease displays sequence similarity with viral papain-like proteases. However, the presumed catalytic Cys-270 is followed by a conserved Gly rather than the characteristic Trp. Replacement of Gly-271 by Trp abolished the Nsp2/3 cleavage. Conservation of a Cys-Gly dipeptide is a hallmark of viral chymotrypsin-like Cys proteases. Thus, the arterivirus Nsp2 protease is an unusual Cys protease with amino acid sequence similarities to both papain-like and chymotrypsin-like proteases.	RUSSIAN ACAD MED SCI,INST POLIOMYELITIS & VIRAL ENCEPHALITIS,MOSCOW 142782,RUSSIA; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Russian Academy of Medical Sciences; Purdue University System; Purdue University; Purdue University West Lafayette Campus	SNIJDER, EJ (corresponding author), LEIDEN UNIV,FAC MED,INST MED MICROBIOL,DEPT VIROL,POSTBUS 320,2300 AH LEIDEN,NETHERLANDS.		Gorbalenya, Alexander E/J-4818-2012; Snijder, Eric J./E-6073-2018	Gorbalenya, Alexander E/0000-0002-4967-7341; Snijder, Eric J./0000-0003-3297-2309				ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BONIOTTI B, 1994, J VIROL, V68, P6487, DOI 10.1128/JVI.68.10.6487-6495.1994; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; Dayhoff M, 1978, ATLAS PROTEIN SEQ ST, P345; DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991; DENBOON JA, 1995, IN PRESS J VIROL, V69; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GARAVITO RM, 1977, BIOCHEMISTRY-US, V16, P5065, DOI 10.1021/bi00642a019; GODENY EK, 1993, VIROLOGY, V194, P585, DOI 10.1006/viro.1993.1298; Gorbalenya A.E., 1993, SOV SCI REV D, V11, P1; GORBALENYA AE, 1989, J MOL EVOL, V28, P256, DOI 10.1007/BF02102483; GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; GORBALENYA AE, 1986, FEBS LETT, V194, P253, DOI 10.1016/0014-5793(86)80095-3; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEONTOVICH AM, 1993, BIOSYSTEMS, V30, P57, DOI 10.1016/0303-2647(93)90062-H; LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; MEULENBERG JJM, 1993, VIROLOGY, V192, P62, DOI 10.1006/viro.1993.1008; PLAGEMANN PGW, 1991, ADV VIRUS RES, V41, P99; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; SNIJDER EJ, 1992, J VIROL, V66, P7040, DOI 10.1128/JVI.66.12.7040-7048.1992; SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Strauss JH, 1990, SEMIN VIROL, V1, P347; STRAUSS JH, 1990, SEMIN VIROL, V1, P307; STURROCK SS, 1993, MPSRCH VERSION 1 3; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; YU SYF, 1992, VIROLOGY, V186, P725, DOI 10.1016/0042-6822(92)90039-R	42	119	133	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16671	16676		10.1074/jbc.270.28.16671	http://dx.doi.org/10.1074/jbc.270.28.16671			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622476	hybrid			2022-12-25	WOS:A1995RJ34700035
J	BARRETT, JF; LEWIS, BC; HOANG, AT; ALVAREZ, RJ; DANG, CV				BARRETT, JF; LEWIS, BC; HOANG, AT; ALVAREZ, RJ; DANG, CV			CYCLIN-A LINKS C-MYC TO ADHESION-INDEPENDENT CELL-PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA-REPLICATION; TRANSFORMATION; PROGRESSION; FIBROBLASTS; EXPRESSION; ONCOGENES	Adhesion-independent growth is a neoplastic phenotype that is inducible in Rat 1a fibroblasts by enforced MYC expression. The c-Myc protein has been well characterized as a transcription factor, yet the molecular basis of c-Myc-induced neoplastic transformation has remained elusive, In this report, we demonstrate a link between ectopic MYC expression, deregulated cyclin A levels, and adhesion-independent growth.	JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	BARRETT, JF (corresponding author), JOHNS HOPKINS UNIV, SCH MED,DEPT MED,DIV HEMATOL,ROSS RES BLDG, RM 1025, 720 RUTLAND AVE, BALTIMORE, MD 21205 USA.		Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522	NCI NIH HHS [CA57341] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057341] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697	17	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					15923	15925		10.1074/jbc.270.27.15923	http://dx.doi.org/10.1074/jbc.270.27.15923			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608142	hybrid			2022-12-25	WOS:A1995RH22600003
J	BRANDA, SS; ISAYA, G				BRANDA, SS; ISAYA, G			PREDICTION AND IDENTIFICATION OF NEW NATURAL SUBSTRATES OF THE YEAST MITOCHONDRIAL INTERMEDIATE PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE FLAVOPROTEIN SUBUNIT; SACCHAROMYCES-CEREVISIAE GENE; CYTOCHROME-C-OXIDASE; IRON-SULFUR PROTEIN; NUCLEAR GENE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; MALATE-DEHYDROGENASE; RIBOSOMAL-PROTEIN	Most mitochondrial precursor proteins are processed to the mature form in one step by mitochondrial processing peptidase (MPP), while a subset of precursors destined for the matrix or the inner membrane are cleaved sequentially by MPP and mitochondrial intermediate peptidase (MIP), We showed previously that yeast MIP (YMIP) is required for mitochondrial function in Saccharomyces cerevisiae. To further define the role played by two-step processing in mitochondrial biogenesis, we have now characterized the natural substrates of YMIP, A total of 133 known yeast mitochondrial precursors were collected from the literature and analyzed for the presence of the motif RX(down arrow)(F/L/I)XX(T/S/G)XXXX(down arrow), typical of precursors cleaved by MPP and MIP. We found characteristic MIP cleavage sites in two distinct sets of proteins: respiratory components, including subunits of the electron transport chain and tricarboxylic acid cycle enzymes, and components of the mitochondrial genetic machinery, including ribosomal proteins, translation factors, and proteins required for mitochondrial DNA metabolism. Representative precursors from both sets were cleaved to predominantly mature form by mitochondrial matrix or intact mitochondria from wild-type yeast. In contrast, intermediate-size forms were accumulated upon incubation of the precursors with matrix from mip1 Delta yeast or intact mitochondria from mip1(ts) yeast, indicating that YMIP is necessary for maturation of these proteins. Consistent with the fact that some of these substrates are essential for the maintenance of mitochondrial protein synthesis and mitochondrial DNA replication, mip1 Delta yeast undergoes loss of functional mitochondrial genomes.	YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University				Branda, Steven/0000-0001-8763-1013	NIGMS NIH HHS [GM48076] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048076] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM PR, 1994, MOL GEN GENET, V242, P708, DOI 10.1007/BF00283426; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529; BECKMANN JD, 1989, J BIOL CHEM, V264, P3716; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; BRANDT U, 1993, J BIOL CHEM, V268, P8387; BROWNING KS, 1988, P NATL ACAD SCI USA, V85, P1831, DOI 10.1073/pnas.85.6.1831; DANG H, 1990, NUCLEIC ACIDS RES, V18, P6895, DOI 10.1093/nar/18.23.6895; DAUM G, 1982, J BIOL CHEM, V257, P3028; DAVIS ES, 1992, P NATL ACAD SCI USA, V89, P11169, DOI 10.1073/pnas.89.23.11169; DECOSTER E, 1993, J MOL BIOL, V232, P79, DOI 10.1006/jmbi.1993.1371; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; GANGLOFF SP, 1990, MOL CELL BIOL, V10, P3551, DOI 10.1128/MCB.10.7.3551; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; HAFTER P, 1990, GENETICS, V125, P495; HARRER R, 1993, CURR GENET, V24, P136, DOI 10.1007/BF00324677; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; ISAYA G, 1994, MOL CELL BIOL, V14, P5603, DOI 10.1128/MCB.14.8.5603; ISAYA G, 1995, GENOMICS, V28, P450, DOI 10.1006/geno.1995.1174; ISAYA G, 1992, J BIOL CHEM, V267, P7904; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; ISAYA G, 1994, SIGNAL PEPTIDASES, P87; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KITAKAWA M, 1990, NUCLEIC ACIDS RES, V18, P1521, DOI 10.1093/nar/18.6.1521; LABBEBOIS R, 1990, J BIOL CHEM, V267, P7278; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NAGATA S, 1983, P NATL ACAD SCI-BIOL, V80, P6192, DOI 10.1073/pnas.80.20.6192; OHMEN JD, 1990, MOL CELL BIOL, V10, P3027, DOI 10.1128/MCB.10.6.3027; PAPE LK, 1985, J BIOL CHEM, V260, P5362; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P6339, DOI 10.1093/nar/20.23.6339; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SANCAR GB, 1985, NUCLEIC ACIDS RES, V13, P8231, DOI 10.1093/nar/13.22.8231; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; STRICK CA, 1987, MOL CELL BIOL, V7, P2728, DOI 10.1128/MCB.7.8.2728; SZTUL ES, 1988, J BIOL CHEM, V263, P12085; SZTUL ES, 1987, J CELL BIOL, V105, P2631, DOI 10.1083/jcb.105.6.2631; THOMPSON LM, 1988, BIOCHEMISTRY-US, V27, P8393, DOI 10.1021/bi00422a015; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; UH M, 1990, J BIOL CHEM, V265, P19047; VAMBUTAS A, 1991, EUR J BIOCHEM, V201, P643, DOI 10.1111/j.1432-1033.1991.tb16325.x; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; VASSAROTTI A, 1987, J BIOL CHEM, V262, P411; WIESENBERGER G, 1992, J BIOL CHEM, V267, P6963; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	56	86	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27366	27373		10.1074/jbc.270.45.27366	http://dx.doi.org/10.1074/jbc.270.45.27366			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7593000	hybrid			2022-12-25	WOS:A1995TE58300100
J	BOIE, Y; SAWYER, N; SLIPETZ, DM; METTERS, KM; ABRAMOVITZ, M				BOIE, Y; SAWYER, N; SLIPETZ, DM; METTERS, KM; ABRAMOVITZ, M			MOLECULAR-CLONING AND CHARACTERIZATION OF THE HUMAN PROSTANOID DP RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; HIGH-AFFINITY; PROSTAGLANDIN-D2; EXPRESSION; CELLS; ANTAGONIST; SUBTYPE; PGD2; CDNA; STIMULATION	A cDNA encoding a functional human prostanoid DP (hDP) receptor has been constructed from a genomic clone and a fragment cloned by 3'-rapid amplification of cDNA ends-polymerase chain reaction. The hDP receptor consists of 359 amino acid residues with a predicted molecular mass of 40,276 and has the putative heptahelical transmembrane domains characteristic of G-protein-coupled receptors. The deduced amino acid sequence of the hDP receptor, when compared with ail other members of the prostanoid receptor family, shows the highest degree of identity with the hIP and hEP(2) receptors, followed by the hEP(4) receptor. Radioreceptor binding studies using membranes prepared from mammalian COS-M6 cells transiently transfected with an expression vector containing the DP receptor cDNA showed that the rank order of affinities for prostaglandins and prostaglandin analogs, in competition for [H-3]prostaglandin D-2 (PGD(2)) specific binding sites, was as predicted for the DP receptor, with PGD(2) >> PGE(2) > PGF(2 alpha) = iloprost > U46619. The signal transduction pathway of the cloned hDP receptor was studied by transfecting the hDP expression vector into HEK 293(EBNA) cells, Activation of the hDP receptor with PGD(2) resulted in an elevation of intracellular cAMP and in mobilization of Ca2+, but did not lead to generation of inositol 1,4,5-trisphosphate. Northern blot analysis of human tissues showed that the hDP receptor has a very discrete tissue distribution and was detectable only in retina and small intestine. In summary, we have cloned and expressed a functional cDNA for the hDP receptor.	MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA	Merck & Company								ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; ADAM M, 1994, FEBS LETT, V338, P170, DOI 10.1016/0014-5793(94)80358-7; AN SZ, 1994, BIOCHEMISTRY-US, V33, P14496, DOI 10.1021/bi00252a016; AN SZ, 1993, BIOCHEM BIOPH RES CO, V197, P263, DOI 10.1006/bbrc.1993.2470; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; BOIE Y, 1994, J BIOL CHEM, V269, P12173; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; COLEMAN RA, 1989, COMPREHENSIVE MED CH, V3, P643; DARIUS H, 1994, EUR J PHARMACOL, V258, P207, DOI 10.1016/0014-2999(94)90482-0; DAVIES P, 1992, INFLAMMATION BASIC P, P123; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; FUNK CD, 1993, J BIOL CHEM, V268, P26767; GILES H, 1989, BRIT J PHARMACOL, V96, P291, DOI 10.1111/j.1476-5381.1989.tb11816.x; HAMIDBLOOMFIELD S, 1990, BRIT J PHARMACOL, V100, P761, DOI 10.1111/j.1476-5381.1990.tb14089.x; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; ITO S, 1990, BRIT J PHARMACOL, V99, P13, DOI 10.1111/j.1476-5381.1990.tb14645.x; ITO S, 1989, PROSTAG LEUKOTR ESS, V37, P219, DOI 10.1016/0952-3278(89)90033-1; JOHNSTON SL, 1993, J ALLERGY CLIN IMMUN, V91, P903, DOI 10.1016/0091-6749(93)90348-J; KANTHA SS, 1994, PROSTAG LEUKOTR ESS, V51, P87, DOI 10.1016/0952-3278(94)90083-3; KATSUYAMA M, 1994, FEBS LETT, V344, P74, DOI 10.1016/0014-5793(94)00355-6; Kimura MA, 1985, NEUTRAL THEORY MOL E; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUNAPULI SP, 1994, BIOCHEM J, V298, P263, DOI 10.1042/bj2980263; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAKE S, 1994, FEBS LETT, V355, P317, DOI 10.1016/0014-5793(94)01198-2; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MATSUMURA H, 1994, P NATL ACAD SCI USA, V91, P11998, DOI 10.1073/pnas.91.25.11998; NAKAGAWA O, 1994, CIRCULATION, V90, P1643, DOI 10.1161/01.CIR.90.4.1643; NAKAJIMA M, 1991, GRAEF ARCH CLIN EXP, V229, P411, DOI 10.1007/BF00166301; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; NEY P, 1991, EICOSANOIDS, V4, P21; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OKUDAASHITAKA E, 1993, BIOCHIM BIOPHYS ACTA, V1176, P148, DOI 10.1016/0167-4889(93)90190-Z; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REGAN JW, 1994, BRIT J PHARMACOL, V112, P377, DOI 10.1111/j.1476-5381.1994.tb13082.x; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU T, 1982, J BIOL CHEM, V257, P13570; SUGAMA K, 1989, BIOCHIM BIOPHYS ACTA, V1011, P75, DOI 10.1016/0167-4889(89)90081-5; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; THIERAUCH KH, 1988, PROSTAGLANDINS, V35, P855, DOI 10.1016/0090-6980(88)90112-8; TOWN MH, 1983, PROSTAGLANDINS, V25, P13; VIRGOLINI I, 1992, J BIOL CHEM, V267, P12700; WATSON S, 1993, TRENDS PHARM SCI S, P31; WHEELDON A, 1993, BRIT J PHARMACOL, V108, P1051, DOI 10.1111/j.1476-5381.1993.tb13504.x; WOODWARD DF, 1993, EUR J PHARMACOL, V230, P327, DOI 10.1016/0014-2999(93)90569-4; YOSHIMURA S, 1989, BIOCHIM BIOPHYS ACTA, V981, P69, DOI 10.1016/0005-2736(89)90083-7	53	286	307	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18910	18916		10.1074/jbc.270.32.18910	http://dx.doi.org/10.1074/jbc.270.32.18910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642548	hybrid			2022-12-25	WOS:A1995RN95400035
J	KRAEMER, DM; STRAMBIODECASTILLIA, C; BLOBEL, G; ROUT, MP				KRAEMER, DM; STRAMBIODECASTILLIA, C; BLOBEL, G; ROUT, MP			THE ESSENTIAL YEAST NUCLEOPORIN NUP159 IS LOCATED ON THE CYTOPLASMIC SIDE OF THE NUCLEAR-PORE COMPLEX AND SERVES IN KARYOPHERIN-MEDIATED BINDING OF TRANSPORT SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 STEPS; PROTEIN; SACCHAROMYCES; TRANSLOCATION; ENVELOPE; IMPORT	We have identified a new yeast nucleoporin of 159 kDa that me term NUP159. Immunofluorescence microscopy with a monospecific monoclonal antibody against NUP159 gave the punctate nuclear rim staining characteristic of nucleoporins, Immunogold electron microscopy with isolated yeast NEs yielded decoration of only the cytoplasmic side of the nuclear pore complex, The gene encoding NUP159 is essential, and, like some other nucleoporins, NUP159 contains a coiled-coil domain as well as a domain of repeated motifs, Five segments of NUP159, covering its entire length, were expressed in Escherichia coli, The repeat motif-containing segment was found to bind a nuclear transport substrate in the presence of vertebrate cytosolic extract containing nuclear transport factors, This segment also bound S-35-labeled mammalian karyopherin beta, one such transport factor that mediates the docking of substrates to the nuclear pore complex, These data establish a direct biochemical link between the repeat motif domain of a yeast nucleoporin, transport factors, (specifically karyopherin beta), and nuclear transport substrates. Its cytoplasmic aspect implies a role for NUP159 in nuclear import.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University			Rout, Michael/Y-7090-2018	Rout, Michael/0000-0003-2010-706X; Strambio De Castillia, Caterina/0000-0002-1069-1816				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KILMARTIN JV, 1982, MICROTUBULES MICROOR, P157; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, IN PRESS P NATL ACAD; PEMBERTON LF, 1995, P NATL ACAD SCI USA, V92, P1187, DOI 10.1073/pnas.92.4.1187; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; SHERMAN F, 1991, METHODS YEAST GENETI; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WOZNIAK RW, 1994, J CELL BIOL, V125, P31, DOI 10.1083/jcb.125.1.31; WRAY BE, 1984, J HISTOCHEM CYTOCHEM, V32, P1117, DOI 10.1177/32.10.6481151; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209	35	124	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19017	19021		10.1074/jbc.270.32.19017	http://dx.doi.org/10.1074/jbc.270.32.19017			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642562	hybrid			2022-12-25	WOS:A1995RN95400050
J	APRELIKOVA, O; XIONG, Y; LIU, ET				APRELIKOVA, O; XIONG, Y; LIU, ET			BOTH P16 AND P21 FAMILIES OF CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS BLOCK THE PHOSPHORYLATION OF CYCLIN-DEPENDENT KINASES BY THE CDK-ACTIVATING KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE; CATALYTIC SUBUNIT; P34(CDC2); P40(MO15)	Phosphorylation of cyclin-dependent kinases (CDKs) by the CDK-activating kinase is required for the activation of CDK enzymes, Members of two families of CDK inhibitors, p16/p18 and p21/p27, become physically associated with and inhibit the activity of CDKs in response to a variety of growth-modulating signals, Here, we show that the representative members of both families of CDK inhibitors, p21(waf1,cip1), p27(kip1), and p18, can prevent the phosphorylation of their CDK partners, CDK2 and CDK6, by CDK-activating kinase. No direct interaction between CDK-activating kinase and the CDK inhibitors could be detected, suggesting that binding of these CDK inhibitors to CDK subunits renders CDK inaccessible to the CDK-activating kinase phosphorylation. These findings suggest that a general mechanism of CDK inhibitor function is to block the phosphorylation of CDK enzymes by CDK-activating kinase.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Liu, Edison/C-4141-2008		NCI NIH HHS [P50-CA-58223] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058223] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LI Y, 1994, ONCOGENE, V9, P2261; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	30	188	190	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18195	18197		10.1074/jbc.270.31.18195	http://dx.doi.org/10.1074/jbc.270.31.18195			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629134	hybrid, Green Published			2022-12-25	WOS:A1995RM64200006
J	CHESNOKOV, IN; SCHMID, CW				CHESNOKOV, IN; SCHMID, CW			SPECIFIC ALU BINDING-PROTEIN FROM HUMAN SPERM CHROMATIN PREVENTS DNA METHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; PURIFICATION; REPEATS; NUCLEI; CELLS	A protein from human sperm nuclei that specifically binds to Alu DNA repeats has been purified. The specific DNA binding site of this protein within the Alu sequence has been mapped by methylation interference and electrophoretic mobility shift assays. This sperm Alu binding protein selectively protects Alu elements from methylation in vitro and may be responsible for the unmethylated state of Alu sequences in the male germ line resulting in a parent-specific differential inheritance of Alu methylation.	UNIV CALIF DAVIS, MOLEC & CELLULAR BIOL PROGRAM, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, DEPT CHEM, DAVIS, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis				Chesnokov, Igor/0000-0002-6659-2913	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021346] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1994, CURRENT PORTOCOLS MO; BARLOW DP, 1994, TRENDS GENET, V10, P194, DOI 10.1016/0168-9525(94)90255-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; CHESNOKOV I, 1991, BIOCHEM BIOPH RES CO, V178, P613, DOI 10.1016/0006-291X(91)90152-W; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; GATEWOOD JM, 1990, J BIOL CHEM, V265, P20662; HELLMANNBLUMBERG U, 1993, MOL CELL BIOL, V13, P4523, DOI 10.1128/MCB.13.8.4523; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; KOCHANEK S, 1993, NUCLEIC ACIDS RES, V21, P2339, DOI 10.1093/nar/21.10.2339; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; LIU WM, 1993, NUCLEIC ACIDS RES, V21, P1351, DOI 10.1093/nar/21.6.1351; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; PERELYGINA LM, 1987, MOL BIOL REP, V12, P111, DOI 10.1007/BF00368878; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Razin A., 1993, Experientia Supplementum (Basel), V64, P343; RUBIN CM, 1994, NUCLEIC ACIDS RES, V22, P5121, DOI 10.1093/nar/22.23.5121; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; SCHMID CW, 1991, NUCLEIC ACIDS RES, V19, P5613, DOI 10.1093/nar/19.20.5613; SCHMID CW, 1985, MOL EVOLUTIONARY GEN, P323; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; SURANI MA, 1993, NATURE, V366, P302, DOI 10.1038/366302a0; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; ZALENSKY AO, 1993, MOL REPROD DEV, V36, P164, DOI 10.1002/mrd.1080360207	29	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18539	18542		10.1074/jbc.270.31.18539	http://dx.doi.org/10.1074/jbc.270.31.18539			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629183	hybrid			2022-12-25	WOS:A1995RM64200061
J	PESTELL, RG; ALBANESE, C; WATANABE, G; JOHNSON, J; EKLUND, N; LASTOWIECKI, P; JAMESON, JL				PESTELL, RG; ALBANESE, C; WATANABE, G; JOHNSON, J; EKLUND, N; LASTOWIECKI, P; JAMESON, JL			EPIDERMAL GROWTH-FACTOR AND C-JUN ACT VIA A COMMON DNA REGULATORY ELEMENT TO STIMULATE TRANSCRIPTION OF THE OVINE P-450 CHOLESTEROL SIDE-CHAIN CLEAVAGE (CYP11A1) PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MAP KINASES; RESPONSE ELEMENT; BINDING-PROTEIN; GENE PROMOTER; FOS PROTEINS; CYCLIC-AMP; V-JUN; AP-1	The P-450 side chain cleavage (CYP11A1) gene encodes the enzyme that catalyzes the initial step in steroid biosynthesis, resulting in the conversion of cholesterol to pregnenolone. Expression of the CYP11A1 gene is increased by hormones, such as adrenocorticotropin and luteinizing hormone, as well as by a number of growth factors, suggesting that its promoter may con tain regulatory elements that respond to multiple signal transduction pathways, Using transient expression assays of the ovine CYP11A1 promoter in JEG-3 placental cells, distinct regulatory elements were found to mediate transcriptional stimulation by cAMP and epidermal growth factor (EGF). The cAMP response was mediated through a CC-rich sequence localized between -117 and -92. In contrast, EGF induced CYP11A1 transcription through an adjacent but distinct sequence (-92 to -77 base pairs) that was shown previously to bind nuclear proteins in DNase I footprinting reactions, This EGF-responsive element (EGF-RE) resembles an activator protein-1 (AP-1) site and was also required for transactivation by co-transfected c-Jun, A point mutation within the EGF-RE impaired stimulation by both EGF and c-Jun, suggesting that these pathways converge on a common regulatory element, Transfer of single or multiple copies of the EGF-RE upstream of an heterologous promoter conferred EGF and c-Jun responses, providing further evidence that this element is sufficient for both responses, Transfection studies employing mutant c-Jun proteins confirmed a requirement for its DNA binding, leucine zipper and amino-terminal domains, each of which are required for activation of a classical AP-1 reporter, Gel shift studies demonstrated that protein binding to the CYP11A1 EGF-RE was competed specifically by a canonical AP-1 site, and the addition of an anti JUN antibody confirmed the presence of AP-1 proteins, Consistent with the possibility that EGF may act in part via c-Jun, EGF stimulated the activity of a chimeric GAL4 c-Jun protein, indicating that JUN can serve as a potential target of EGF in JEG-3 cells, EGF also induced mitogen-activated protein kinase activity, and a dominant negative mutant of mitogen-activated protein kinase partially blocked EGF stimulation of GAL4 c-Jun activity, We conclude that EGF stimulates the CYP11A1 promoter through an AP-1 like element and that c-Jun is one of the targets of EGF action.	NORTHWESTERN UNIV,SCH MED,DIV ENDOCRINOL METAB & MOLEC MED,CHICAGO,IL 60611	Northwestern University				Jameson, James/0000-0001-9538-4059	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023519] Funding Source: NIH RePORTER; NCI NIH HHS [KO8 CA 620008 01] Funding Source: Medline; NICHD NIH HHS [HD23519] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAIRD A, 1990, PEPTIDE GROWTH FACTO, V1, P369; BEGEOT M, 1993, J BIOL CHEM, V268, P17317; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DRUST DS, 1991, MOL ENDOCRINOL, V5, P1541, DOI 10.1210/mend-5-10-1541; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUIM DW, 1993, ENDOCRINOLOGY, V132, P546; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARIN M, 1989, TRENDS GENET, V5, P65, DOI 10.1016/0168-9525(89)90027-9; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PESTELL RG, 1993, J MOL ENDOCRINOL, V10, P297, DOI 10.1677/jme.0.0100297; PESTELL RG, 1994, MOL ENDOCRINOLOGY BA, P774; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RICE DA, 1990, J BIOL CHEM, V265, P11713; RYSECK RP, 1991, ONCOGENE, V6, P533; SAMBROOK T, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1992, J BIOL CHEM, V267, P24149; SETH A, 1992, J BIOL CHEM, V267, P24796; SMITH MJ, 1992, BLOOD, V79, P2107; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; URBAN RJ, 1994, J BIOL CHEM, V269, P25761; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD WM, 1989, J BIOL CHEM, V264, P14840	59	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18301	18308		10.1074/jbc.270.31.18301	http://dx.doi.org/10.1074/jbc.270.31.18301			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629150	hybrid			2022-12-25	WOS:A1995RM64200025
J	KURLANDSKY, SB; GAMBLE, MV; RAMAKRISHNAN, R; BLANER, WS				KURLANDSKY, SB; GAMBLE, MV; RAMAKRISHNAN, R; BLANER, WS			PLASMA DELIVERY OF RETINOIC ACID TO TISSUES IN THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; VITAMIN-A; LIQUID-CHROMATOGRAPHY; METABOLISM; TRANSPORT; CELLS; QUANTIFICATION; DISPOSITION; EXPRESSION; ADIPOCYTES	All-trans-retinoic acid (RA) activates Ligand-dependent transcription factors that regulate retinoid-responsive gene expression. It is assumed that all-trans-RA is formed within cells through in situ oxidation of retinol derived from the circulation. However, the circulation contains low level of all-trans-RA (approximately 0.2-0.7% of that of plasma retinol). Our studies investigated the extent to which plasma all-trans-RA contributes to tissue pools of this retinoid and explored factors responsible for regulating its uptake by tissues and cells. Rats were continuously infused, to steady state, with all-trans-[H-3]RA. From measures of specific activities of all-trans [H-3]RA at steady state, we determined that the preponderance of all-trans-RA in brain and liver was derived from the circulation. For six other tissues, approximately 10-30% of the retinoid was derived from the circulation, but pancreas and testis derived very little from the circulating pool. In other studies, we showed that retinoid nutritional status influences clearance of a bolus dose of all-trans-RA and that neither the rate of cellular all-trans-RA uptake nor its intracellular half-life is influenced by cellular lipid levels. Taken together, our data indicate that plasma all-trans-RA contributes to tissue pools of this retinoid and that specific and physiologically responsive cellular processes mediate its uptake.	COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT PEDIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV, INST HUMAN NUTR, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University					NIDDK NIH HHS [DK47389] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047389] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARUA AB, 1989, BIOCHEM J, V263, P403, DOI 10.1042/bj2630403; BLANER WS, 1990, METHOD ENZYMOL, V189, P270; BLANER WS, 1985, J NUTR, V115, P856, DOI 10.1093/jn/115.7.856; BLANER WS, 1994, J BIOL CHEM, V269, P16559; BLANER WS, 1994, RETINOIDS BIOL CHEM, P283; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; CASTER WO, 1956, P SOC EXP BIOL MED, V91, P122, DOI 10.3181/00379727-91-22186; CHIEN DS, 1992, DRUG METAB DISPOS, V20, P211; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; CULLUM ME, 1985, J BIOL CHEM, V260, P590; DELEENHEER AP, 1982, J LIPID RES, V23, P1362; ECKHOFF C, 1990, J LIPID RES, V31, P1445; GOLDBERG IJ, 1990, J CLIN INVEST, V86, P463, DOI 10.1172/JCI114732; GOODMAN DS, 1984, NEW ENGL J MED, V310, P1023, DOI 10.1056/NEJM198404193101605; GOODMAN DS, 1984, RETINOIDS, V2, P1; GREEN MH, 1987, J NUTR, V117, P694, DOI 10.1093/jn/117.4.694; Gudas Lorraine J., 1994, P443; KALIN JR, 1981, DRUG METAB DISPOS, V9, P196; KALUZNY MA, 1985, J LIPID RES, V26, P135; KATO M, 1985, J BIOL CHEM, V260, P4832; KIERSZENBAUM AL, 1986, BIOL REPROD, V35, P227, DOI 10.1095/biolreprod35.1.227; MAKOVER A, 1988, J BIOL CHEM, V263, P8598; Mangelsdorf David J., 1994, P319; MOORE T, 1957, VITAMIN A, P295; NAPOLI JL, 1986, METHOD ENZYMOL, V123, P112, DOI 10.1016/S0076-6879(86)23015-3; NAPOLI JL, 1985, J LIPID RES, V26, P387; NOY N, 1992, BIOCHIM BIOPHYS ACTA, V1106, P159, DOI 10.1016/0005-2736(92)90234-D; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; RIAZULHAQ, 1991, BIOCHEM BIOPH RES CO, V176, P1539, DOI 10.1016/0006-291X(91)90462-G; ROSS AC, 1993, FASEB J, V7, P317, DOI 10.1096/fasebj.7.2.8440409; SAARI JC, 1991, PROGR RETINAL RES, V9, P363; SMITH JE, 1973, BIOCHEM J, V132, P821, DOI 10.1042/bj1320821; Soprano Dianne Robert, 1994, P257; TANG GW, 1990, J LIPID RES, V31, P175; TANG GW, 1991, J NUTR BIOCHEM, V2, P210, DOI 10.1016/0955-2863(91)90018-Z; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; VANBENNEKUM AM, 1993, BIOCHEMISTRY-US, V32, P1727, DOI 10.1021/bi00058a005; VANPELT AMM, 1991, ENDOCRINOLOGY, V128, P697, DOI 10.1210/endo-128-2-697; WANG CC, 1980, DRUG METAB DISPOS, V8, P8; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; ZOVICH DC, 1992, J BIOL CHEM, V267, P13884	43	203	206	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17850	17857		10.1074/jbc.270.30.17850	http://dx.doi.org/10.1074/jbc.270.30.17850			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629087				2022-12-25	WOS:A1995RM26600035
J	LISTER, J; FORRESTER, WC; BARON, MH				LISTER, J; FORRESTER, WC; BARON, MH			INHIBITION OF AN ERYTHROID-DIFFERENTIATION SWITCH BY THE HELIX-LOOP-HELIX PROTEIN ID1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; ERYTHROLEUKEMIA CELL-DIFFERENTIATION; DNA-BINDING PROTEINS; C-MYC; TRANSCRIPTION FACTORS; MYOGENIC DIFFERENTIATION; TRANSIENT HETEROKARYONS; REGULATED EXPRESSION; CHROMATIN STRUCTURE; NEGATIVE REGULATOR	The Id proteins function as negative regulators of basic-helix-loop helix transcription factors, which play important roles in determination of cell lineage and in tissue-specific differentiation. Down-regulation of Id1 mRNA is associated with dimethyl sulfoxide-induced terminal differentiation of mouse erythroleukemia cells. To examine the significance of Id1 down-regulation in erythroid differentiation, we generated stable mouse erythroleukemia cell lines that constitutively express a ''marked'' form of the murine Id1 gene. Terminal erythroid differentiation was inhibited in these lines, as indicated by a block in activation of the erythroid-spe cific genes alpha-globin, beta-globin, and band 3 and continued proliferation in the presence of dimethyl sulfoxide. Interestingly, this block, occurred even in the presence of normal levels of the lineage-specific transcription factors GATA-1, NF-E2, and EKLF. Constitutive expression of Id1 did not interfere with DNase I hypersensitivity at site HS2 of the locus control region, expression of the erythropoietin receptor gene, or down-regulation of the endogenous Id1 or c-myc genes. The differentiation block is reversible in these lines and can be rescued by fusion with human erythroleukemia cells. These findings suggest that in vivo, Id1 functions as an antagonist of terminal erythroid differentiation.	HARVARD UNIV, BIOL LABS, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	Harvard University; University of California System; University of California San Francisco			Lister, James/A-9295-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042413] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 07620, R01 GM42413] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Baron MH, 1993, CURR OPIN CELL BIOL, V5, P1050, DOI 10.1016/0955-0674(93)90091-4; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BARON MH, 1991, MOL CELL BIOL, V11, P1239, DOI 10.1128/MCB.11.3.1239; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, ANN NY ACAD SCI, V599, P1, DOI 10.1111/j.1749-6632.1990.tb42359.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ENGEL JD, 1994, NATURE, V367, P516; FAIRMAN R, 1993, P NATL ACAD SCI USA, V90, P10429, DOI 10.1073/pnas.90.22.10429; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; HARA E, 1994, J BIOL CHEM, V269, P2139; HARLOW E, 1988, ANTIBODIES LABORATOR; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HOFER E, 1982, CELL, V29, P887, DOI 10.1016/0092-8674(82)90450-0; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1985, P NATL ACAD SCI USA, V82, P5323, DOI 10.1073/pnas.82.16.5323; MARKS PA, 1994, P NATL ACAD SCI USA, V91, P10251, DOI 10.1073/pnas.91.22.10251; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; ORKIN SH, 1992, BLOOD, V80, P575; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SHEFFERY M, 1982, P NATL ACAD SCI-BIOL, V79, P1180, DOI 10.1073/pnas.79.4.1180; SHEHEE WR, 1989, J MOL BIOL, V205, P41, DOI 10.1016/0022-2836(89)90363-X; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; VISVADER J, 1991, ONCOGENE, V6, P187; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	69	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17939	17946		10.1074/jbc.270.30.17939	http://dx.doi.org/10.1074/jbc.270.30.17939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629100				2022-12-25	WOS:A1995RM26600050
J	BERNASCONI, P; WOODWORTH, AR; ROSEN, BA; SUBRAMANIAN, MV; SIEHL, DL				BERNASCONI, P; WOODWORTH, AR; ROSEN, BA; SUBRAMANIAN, MV; SIEHL, DL			A NATURALLY-OCCURRING POINT MUTATION CONFERS BROAD RANGE TOLERANCE TO HERBICIDES THAT TARGET ACETOLACTATE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CROSS-RESISTANCE; MOLECULAR-BASIS; GENES; INHIBITORS; IMAZAQUIN; SEQUENCE; TOBACCO; SITE	Acetolactate synthase (ALS) inhibitors are among the most commonly used herbicides. They fall into four distinct families of compounds: sulfonylureas, imidazolinones, triazolopyrimidine sulfonanilides, and pyrimidinyl oxybenzoates. We have investigated the molecular basis of imidazolinone tolerance of two field isolates of cocklebur (Xanthium sp.) from Mississippi and Missouri. In both cases, tolerance was conferred by a form of ALS that was less sensitive to inhibitors than the wild type. The insensitivity pattern of the Mississippi isolate was similar to that of a commercial mutant of corn generated in the laboratory: ICI 8532 IT. Sequencing revealed that the same residue (Ala(57) --> Thr) was mutated in both Mississippi cocklebur and ICI 8532 IT corn. ALS from the Missouri isolate was highly insensitive to all the ALS herbicide families, similar in this respect to another commercial corn mutant: Pioneer 3180 IR corn, Sequencing of ALS from both plants revealed a common mutation that changed Trp(552) to Leu. The sensitive cocklebur ALS cDNA, fused with a glutathione S-transferase, was functionally expressed in Escherichia coli. The recombinant protein had enzymatic properties similar to those of the plant enzyme. All the possible point mutations affecting Trp(552) were investigated by site-directed mutagenesis. Only the Trp --> Leu mutation yielded an active enzyme. This mutation conferred a dramatically reduced sensitivity toward representatives of all four chemical families, demonstrating its role in herbicide tolerance. This study indicates that mutations conferring herbicide tolerance, obtained in an artificial environment, also occur in nature, where the selection pressure is much lower. Thus, this study validates the use of laboratory models to predict mutations that may develop in natural populations.			BERNASCONI, P (corresponding author), SANDOZ AGRO INC,DIV RES,975 CALIF AVE,PALO ALTO,CA 94304, USA.							Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BABCZINSKI P, 1991, PESTIC SCI, V31, P305, DOI 10.1002/ps.2780310306; BERNASCONI P, 1994, PLANT PHYSIOL, V106, P353, DOI 10.1104/pp.106.1.353; BRYAN JK, 1990, BIOCH PLANTS COMPREH, P161; DURNER J, 1991, PLANT PHYSIOL, V95, P1144, DOI 10.1104/pp.95.4.1144; FANG LY, 1992, PLANT MOL BIOL, V18, P1185, DOI 10.1007/BF00047723; GREAVES JA, 1993, 48TH P ANN CORN SORG, P104; GUTTIERI MJ, 1992, WEED SCI, V40, P670, DOI 10.1017/S0043174500058288; HAUGHN GW, 1988, MOL GEN GENET, V211, P266, DOI 10.1007/BF00330603; KENDIG JA, 1994, WEED SCI SOC AM; KLESCHICK WA, 1992, PESTIC SCI, V29, P341; LEE KY, 1988, EMBO J, V7, P1241, DOI 10.1002/j.1460-2075.1988.tb02937.x; LOS M, 1984, ACS SYM SER, V255, P29; MALLORYSMITH CA, 1990, WEED TECHNOL, V4, P163, DOI 10.1017/S0890037X00025173; MAZUR BJ, 1989, ANNU REV PLANT PHYS, V40, P441, DOI 10.1146/annurev.pp.40.060189.002301; MAZUR BJ, 1987, PLANT PHYSIOL, V85, P1110, DOI 10.1104/pp.85.4.1110; MIFLIN BJ, 1974, PLANT PHYSIOL, V54, P550, DOI 10.1104/pp.54.4.550; Saari L. L., 1994, P83; SATHASIVAN K, 1991, PLANT PHYSIOL, V97, P1044, DOI 10.1104/pp.97.3.1044; SAUERS RF, 1984, ACS SYM SER, V255, P21; SAXENA PK, 1988, PLANT PHYSIOL, V86, P863, DOI 10.1104/pp.86.3.863; SCHLOSS JV, 1988, NATURE, V331, P360, DOI 10.1038/331360a0; SCHMITZER PR, 1993, PLANT PHYSIOL, V103, P281, DOI 10.1104/pp.103.1.281; SIEHL DL, 1995, IN PRESS CROP SCI; SINGH B, 1992, PLANT PHYSIOL, V99, P812, DOI 10.1104/pp.99.3.812; SMITH JK, 1989, P NATL ACAD SCI USA, V86, P4179, DOI 10.1073/pnas.86.11.4179; SUBRAMANIAN MV, 1990, PLANT PHYSIOL, V94, P239, DOI 10.1104/pp.94.1.239; SUBRAMANIAN MV, 1991, PLANT PHYSIOL, V96, P310, DOI 10.1104/pp.96.1.310	28	195	223	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17381	17385		10.1074/jbc.270.29.17381	http://dx.doi.org/10.1074/jbc.270.29.17381			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615543	hybrid			2022-12-25	WOS:A1995RK68900054
J	CHEN, ZG; SPIES, A; HEIN, R; ZHOU, XL; THOMAS, BC; RICHTER, ML; GEGENHEIMER, P				CHEN, ZG; SPIES, A; HEIN, R; ZHOU, XL; THOMAS, BC; RICHTER, ML; GEGENHEIMER, P			A SUBUNIT INTERACTION IN CHLOROPLAST ATP SYNTHASE DETERMINED BY GENETIC COMPLEMENTATION BETWEEN CHLOROPLAST AND BACTERIAL ATP SYNTHASE GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; PROTON-TRANSLOCATING ATPASE; T7 RNA-POLYMERASE; BETA-SUBUNIT; ESCHERICHIA-COLI; ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE BINDING; EXPRESSION; SITES; RECONSTITUTION	F1F0-ATP synthases utilize protein conformational changes induced by a transmembrane proton gradient to synthesize ATP. The allosteric cooperativity of these multisubunit enzymes presumably requires numerous protein-protein interactions within the enzyme complex. To correlate known in vitro changes in subunit structure with in vivo allosteric interactions, we introduced the beta subunit of spinach chloroplast coupling factor 1 ATP into a bacterial F-1 ATP synthase. A cloned atpB gene, encoding the complete chloroplast beta subunit, complemented a chromosomal deletion of the cognate uncD gene in Escherichia coli and was incorporated into a functional hybrid F-1 ATP synthase. The cysteine residue at position 63 in chloroplast beta is known to be located at the interface between alpha and beta subunits and to be conformationally coupled, in vitro, to the nucleotide binding site >40 Angstrom away. Enlarging the side chain of chloroplast coupling factor 1 beta residue 63 from Cys to Trp blocked ATP synthesis in vivo without significantly impairing ATPase activity or ADP binding in vitro. The in vivo coupling of nucleotide binding at catalytic sites to transmembrane proton movement may thus involve an interaction, via conformational changes, between the amino-terminal domains of the alpha and beta subunits.	UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66045 USA; UNIV KANSAS, MOLEC GENET PROGRAM, LAWRENCE, KS 66045 USA; UNIV KANSAS, DEPT BOT, LAWRENCE, KS 66045 USA	University of Kansas; University of Kansas; University of Kansas			Gegenheimer, Peter Albert/E-2271-2013	Gegenheimer, Peter Albert/0000-0001-9863-1545				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AVNI A, 1992, SCIENCE, V257, P1245, DOI 10.1126/science.1387730; BALBAS P, 1988, VECTORS SURVEY MOL C, P5; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BURKOVSKI A, 1994, BBA-BIOENERGETICS, V1186, P243, DOI 10.1016/0005-2728(94)90184-8; CHEN ZG, 1992, FEBS LETT, V298, P69, DOI 10.1016/0014-5793(92)80024-B; COLVERT KK, 1992, BIOCHEMISTRY-US, V31, P3930, DOI 10.1021/bi00131a006; ENGELBRECHT S, 1986, EUR J BIOCHEM, V160, P635, DOI 10.1111/j.1432-1033.1986.tb10085.x; GATENBY AA, 1986, GENE, V41, P241, DOI 10.1016/0378-1119(86)90104-6; GIBSON F, 1977, BIOCHEM J, V164, P193, DOI 10.1042/bj1640193; GUNSALUS RP, 1982, P NATL ACAD SCI-BIOL, V79, P320, DOI 10.1073/pnas.79.2.320; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HAWTHORNE CA, 1986, J BIOL CHEM, V261, P5245; HU NM, 1993, J BIOL CHEM, V268, P8536; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; LILL H, 1993, BIOCHIM BIOPHYS ACTA, V1144, P278, DOI 10.1016/0005-2728(93)90112-S; MIKI J, 1994, ARCH BIOCHEM BIOPHYS, V312, P317, DOI 10.1006/abbi.1994.1315; MIKI J, 1994, J BIOL CHEM, V269, P4227; MILLS DA, 1991, J BIOL CHEM, V266, P7440; MILLS DA, 1995, BIOCHEMISTRY-US, V34, P6100, DOI 10.1021/bi00018a013; MUNN AL, 1991, BIOCHIM BIOPHYS ACTA, V1060, P82, DOI 10.1016/S0005-2728(05)80122-7; MUSIER KM, 1987, BIOCHEMISTRY-US, V26, P5982, DOI 10.1021/bi00393a006; NALIN CM, 1987, CURR TOP BIOENERG, V15, P273; NOUMI T, 1986, J BIOL CHEM, V261, P7070; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; REZNIKOFF WS, 1986, MAXIMIZING GENE EXPR, P1; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH PK, 1987, ANAL BIOCHEM, V163, P279; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2997, DOI 10.1093/nar/10.9.2997; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; ZURAWSKI G, 1982, P NATL ACAD SCI-BIOL, V79, P6260, DOI 10.1073/pnas.79.20.6260	41	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17124	17132		10.1074/jbc.270.29.17124	http://dx.doi.org/10.1074/jbc.270.29.17124			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615507	hybrid			2022-12-25	WOS:A1995RK68900014
J	KILSDONK, EPC; YANCEY, PG; STOUDT, GW; BANGERTER, FW; JOHNSON, WJ; PHILLIPS, MC; ROTHBLAT, GH				KILSDONK, EPC; YANCEY, PG; STOUDT, GW; BANGERTER, FW; JOHNSON, WJ; PHILLIPS, MC; ROTHBLAT, GH			CELLULAR CHOLESTEROL EFFLUX MEDIATED BY CYCLODEXTRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEIN; APOLIPOPROTEIN-A-I; LYSOSOMAL CHOLESTEROL; HUMAN-ERYTHROCYTES; KINETIC POOLS; CELLS; MEMBRANE; FIBROBLASTS; MACROPHAGES; STEROL	In this study, we compared cholesterol efflux mediated by either high density lipoproteins (HDL(3)) or beta-cyclodextrins, cyclic oligosaccharides that are able to dis solve lipids in their hydrophobic core. beta-Cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin, and methyl-beta-cyclodextrin at 10 mM induced the release of 50-90% of L-cell [H-3]cholesterol after 8 h of incubation, with a major portion of this cholesterol being released in the first 1-2 h of incubation. The cholesterol efflux kinetics are different if cells are incubated with HDL(3), which induces a relatively constant rate of release of cholesterol throughout an 8-h incubation. Cholesterol efflux to cyclodextrins was much greater than phospholipid release. To test the hypothesis that maximal efflux rate constants for a particular cell are independent of the type of acceptor, we estimated the maximal rate constants for efflux (V-max) of cellular cholesterol from L-cells, Fu5AH cells, and GM3468A fibroblasts. The rate constant for HDL(3)-mediated efflux varied among cell lines in the order Fu5AH > L-cells > fibroblasts. However, these differences were not evident when cyclodextrins were used as cholesterol accepters. The estimated V-max values for cyclodextrin-mediated efflux were 3.5-70-fold greater than for HDL(3) for the three cell lines. The very high efficiency of cyclodextrins in stimulating cell cholesterol efflux suggests that these compounds can be used in two general ways for studies of atherosclerosis: 1) as research tools to probe mechanisms of cholesterol transport and aspects of membrane structure or 2) as potential pharmacological agents that could modify in vivo cholesterol metabolism and influence the development of the atherosclerotic plaque.	MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129; HAHNEMANN UNIV,PHILADELPHIA,PA 19129; PFIZER INC,CENT RES,GROTON,CT 06340	Drexel University; Drexel University; Pfizer			Yancey, Patricia/ABB-5856-2021	Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, T32HL007443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633, HL07443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELLINI F, 1984, BIOCHIM BIOPHYS ACTA, V777, P209, DOI 10.1016/0005-2736(84)90422-X; BIELICKI JK, 1992, J LIPID RES, V33, P1699; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; DECAPRIO J, 1992, J LIPID RES, V33, P441; DELALLERAMOYA M, 1994, ARTERIOSCLER THROMB, V14, P1056, DOI 10.1161/01.ATV.14.7.1056; DIEDERICH F, 1994, ANGEW CHEM INT EDIT, V33, P1625; DUCHENE D, 1990, 5TH INT S CYCL; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRIJLINK HW, 1991, PHARMACEUT RES, V8, P9, DOI 10.1023/A:1015861719134; GLOMSET JA, 1968, J LIPID RES, V9, P155; Hatch F T, 1968, Adv Lipid Res, V6, P1; IRIE T, 1982, J PHARMACOBIO-DYNAM, V5, P741; IRIE T, 1992, J PHARM SCI, V81, P521, DOI 10.1002/jps.2600810609; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KILSDONK EPC, 1994, J LIPID RES, V36, P505; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MAHLBERG FH, 1990, ATHEROSCLEROSIS, V84, P95, DOI 10.1016/0021-9150(90)90078-W; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAZZONE T, 1992, J LIPID RES, V36, P544; MCCLOSKEY HM, 1987, BIOCHIM BIOPHYS ACTA, V921, P320, DOI 10.1016/0005-2760(87)90033-6; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; ORAM JF, 1983, ARTERIOSCLEROSIS, V3, P420, DOI 10.1161/01.ATV.3.5.420; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; REID VC, 1992, ATHEROSCLEROSIS, V92, P251, DOI 10.1016/0021-9150(92)90285-O; RIOTTOT M, 1993, LIPIDS, V28, P181, DOI 10.1007/BF02536637; Rothblat G H, 1986, Methods Enzymol, V129, P628; ROTHBLAT GH, 1970, SCIENCE, V169, P880, DOI 10.1126/science.169.3948.880; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; Segel IH, 1976, BIOCH CALCULATIONS; SHIRHATTI V, 1985, ANAL BIOCHEM, V147, P410, DOI 10.1016/0003-2697(85)90290-8; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; STECK TL, 1988, J BIOL CHEM, V263, P13023; Stern WC, 1989, DRUG NEWS PERSPECT, V2, P410; UEKAMA K, 1987, CRIT REV THER DRUG, V3, P1	40	697	709	0	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17250	17256		10.1074/jbc.270.29.17250	http://dx.doi.org/10.1074/jbc.270.29.17250			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615524	hybrid			2022-12-25	WOS:A1995RK68900032
J	KUBISESKI, TJ; FLYNN, TG				KUBISESKI, TJ; FLYNN, TG			STUDIES ON HUMAN ALDOSE REDUCTASE - PROBING THE ROLE OF ARGININE-268 BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KM ALDEHYDE REDUCTASE; HUMAN PSOAS MUSCLE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ACTIVE-SITE; PIG BRAIN; BINDING; EXPRESSION; COMPLICATIONS; SUPERFAMILY	Aldose reductase (ALR2) shows a strong specificity for its nucleotide coenzyme, binding NADPH much more tightly than NADH (K-D of <1 mu M versus 1.2 mM respectively). Interactions responsible for this specificity include salt linkages between the highly conserved residues Lys-262 and Arg-268, and the 2'-phosphate of NADP(H). Previous studies show that mutation of Lys-262 results in an increase in the K-m for both coenzyme and aldehyde substrate, as well as in the k(cat) of reduction. The present study shows that mutation of Arg-268 to methionine results in a 36-fold increase in K-m and 205-fold increase in K-D for NADPH, but little change in K-m for DL-glyceraldehyde or in the k(cat) of the reaction. Calculation of free energy changes show that the 2'-phosphate of NADPH contributes 4.7 kcal/mol of binding energy to its interaction with WT-hALR2. For the R268M mutant, the interaction of NADPH was destabilized by 3.2 kcal/mol, indicating that the mutation decreases the binding energy of NADPH by 65%. The effect of removing Arg-268 in the absence of the 2'-phosphate of NADPH was virtually identical to the destabilization of the activation energy in the absence of the 2'-phosphate itself (1.9 versus 2.0 kcal/mol, respectively). Therefore, while the 2'-phosphate of the coenzyme plays a role in both coenzyme binding and transition state stabilization during catalysis, the role of Arg-268 lies strictly in tighter coenzyme binding.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada				Kubiseski, Terrance/0000-0001-9388-8608				AMARA FM, 1994, J BIOL CHEM, V269, P6709; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOHREN KM, 1991, J BIOL CHEM, V266, P24031; BOHREN KM, 1994, BIOCHEMISTRY-US, V33, P2021, DOI 10.1021/bi00174a007; BOHREN KM, 1992, J BIOL CHEM, V267, P20965; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANLANT G, 1982, EUR J BIOCHEM, V129, P99, DOI 10.1111/j.1432-1033.1982.tb07026.x; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CROMLISH JA, 1983, J BIOL CHEM, V258, P3583; DAVIS GJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P307, DOI 10.1006/abbi.1994.1242; EHRIG T, 1994, BIOCHEMISTRY-US, V33, P7157, DOI 10.1021/bi00189a019; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; GABBAY KH, 1975, ANNU REV MED, V26, P521, DOI 10.1146/annurev.me.26.020175.002513; GRIMSHAW CE, 1992, BIOCHEMISTRY-US, V31, P10139, DOI 10.1021/bi00157a001; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; GRUNDMANN U, 1990, DNA CELL BIOL, V9, P149, DOI 10.1089/dna.1990.9.149; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; KUBISESKI TJ, 1994, J BIOL CHEM, V269, P2183; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU SQ, 1992, BIOCHEM PHARMACOL, V44, P2427, DOI 10.1016/0006-2952(92)90693-D; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MORJANA NA, 1989, J BIOL CHEM, V264, P2906; MORJANA NA, 1989, J BIOL CHEM, V264, P2912; NISHIMURA C, 1990, J BIOL CHEM, V265, P9788; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; QIN KN, 1994, BIOCHEMISTRY-US, V33, P3223, DOI 10.1021/bi00177a012; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; RYLE CM, 1985, BIOCHEM J, V227, P621, DOI 10.1042/bj2270621; Sambrook J, 1989, MOL CLONING LABORATO; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; TARLE I, 1993, J BIOL CHEM, V268, P25687; THOMPSON ST, 1975, P NATL ACAD SCI USA, V72, P669, DOI 10.1073/pnas.72.2.669; TOMLINSON DR, 1994, TRENDS PHARMACOL SCI, V15, P298; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; Turner A J, 1982, Prog Clin Biol Res, V114, P401; TURNER AJ, 1972, BIOCHEM J, V130, P765, DOI 10.1042/bj1300765; VEECH RL, 1987, PYRIDINE NUCLEOTIDE, V2, P79; WARD WHJ, 1993, ADV EXP MED BIOL, V328, P301; WELLS TNC, 1991, BIOCHEMISTRY-US, V30, P5151, DOI 10.1021/bi00235a006; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; WINEGRAD AI, 1972, HDB PHYSL, P456; YAMAOKA T, 1992, BIOCHEM BIOPH RES CO, V183, P327, DOI 10.1016/0006-291X(92)91647-9; YANAGIDA N, 1986, J BACTERIOL, V166, P937, DOI 10.1128/jb.166.3.937-944.1986; 1993, PROMEGA PROTEIN GUID	51	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16911	16917		10.1074/jbc.270.28.16911	http://dx.doi.org/10.1074/jbc.270.28.16911			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622508	hybrid			2022-12-25	WOS:A1995RJ34700069
J	KAWANO, T; KOYAMA, S; TAKEMATSU, H; KOZUTSUMI, Y; KAWASAKI, H; KAWASHIMA, S; KAWASAKI, T; SUZUKI, A				KAWANO, T; KOYAMA, S; TAKEMATSU, H; KOZUTSUMI, Y; KAWASAKI, H; KAWASHIMA, S; KAWASAKI, T; SUZUKI, A			MOLECULAR-CLONING OF CYTIDINE MONOPHOSPHO-N-ACETYLNEURAMINIC ACID HYDROXYLASE - REGULATION OF SPECIES-SPECIFIC AND TISSUE-SPECIFIC EXPRESSION OF N-GLYCOLYLNEURAMINIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANGANUTZIU-DEICHER ANTIGEN; MOUSE-LIVER CYTOSOL; GLYCOLOYLNEURAMINIC ACID; GLYCOLYNEURAMINIC ACID; GANGLIOSIDE EXPRESSION; MONOCLONAL-ANTIBODIES; SIALIC ACIDS; BIOSYNTHESIS; RAT; CHROMATOGRAPHY	Cytidine monophospho-N-acetylneuraminic acid (CMP-NeuAc) hydroxylase, which is the key enzyme for the synthesis of N-glycolylneuraminic acid (NeuGc), has been purified from the cytosolic fraction of mouse liver, as described in our previous paper. The amino acid sequences of the purified CMP-NeuAc hydroxylase, and peptides obtained by lysylendopeptidase digestion, were used to synthesize specific oligonucleotide primers. A mouse cDNA clone of the enzyme was obtained by a combination of the polymerase chain reaction and rapid amplification of cDNA ends. The sequence of the clone contained an open reading frame coding for a protein of 577 amino acids with a predicted molecular mass of 66 kDa. The deduced sequence included the amino acid sequences obtained for the purified enzyme and peptides, and a complete match was obtained for 159 residues. The enzyme has neither a signal peptide sequence nor a membrane spanning domain, which is consistent with localization of the enzyme in the cytosol. Transfection of a cDNA construct to COS-1 cells increased the enzyme activity and the amount of NeuGc. Comparison of the sequence with GenBank data indicated that no similar sequence has been reported so far. Northern blot analysis of various mouse tissues with the enzyme cDNA as a probe indicated that expression of NeuGc is related to the level of CMP-NeuAc hydroxylase mRNA. On Southern blot analysis with the same probe, cross-hybridizing bands were detected in the human and fish genomes.	TOKYO METROPOLITAN INST MED SCI,DEPT MEMBRANE BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAKYO KU,KYOTO 606,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Kyoto University			Kawano, Takehiro/A-3080-2016; Kawasaki, Hiroshi/C-3048-2011	Kawasaki, Hiroshi/0000-0002-2517-159X				BOUHOURS D, 1988, J BIOL CHEM, V263, P15540; BUSCHER HP, 1977, EUR J BIOCHEM, V77, P297, DOI 10.1111/j.1432-1033.1977.tb11668.x; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; FUKUNAGA R, 1984, P NATL ACAD SCI-BIOL, V81, P5086, DOI 10.1073/pnas.81.16.5086; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HIDARI K, 1991, J BIOCHEM-TOKYO, V110, P412, DOI 10.1093/oxfordjournals.jbchem.a123595; HIGASHI H, 1985, CANCER RES, V45, P3796; HIGASHI H, 1977, BIOCHEM BIOPH RES CO, V79, P388, DOI 10.1016/0006-291X(77)90169-3; HIGGA HH, 1985, J BIOL CHEM, V260, P8838; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P614; Innis MA, 1990, PCR PROTOCOLS GUIDE; IWAMORI M, 1978, BIOCHIM BIOPHYS ACTA, V528, P257; KAWAI T, 1991, CANCER RES, V51, P1242; KAWANO T, 1993, INT J CANCER, V53, P91, DOI 10.1002/ijc.2910530118; KAWANO T, 1993, GLYCOCONJUGATE J, V10, P109, DOI 10.1007/BF00731194; KAWANO T, 1994, J BIOL CHEM, V269, P9024; KAWASHIMA I, 1993, J BIOCHEM-TOKYO, V114, P186, DOI 10.1093/oxfordjournals.jbchem.a124153; KELM S, 1993, GLYCOCONJUGATE J, V10, P330, DOI 10.1007/BF01210145; KITAGAKIOGAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1033, P49, DOI 10.1016/0304-4165(90)90193-Z; KITAJIMA K, 1988, J BIOL CHEM, V263, P18269; KOTANI M, 1993, GLYCOBIOLOGY, V3, P137, DOI 10.1093/glycob/3.2.137; KOZUTSUMI Y, 1991, J BIOCHEM, V110, P429, DOI 10.1093/oxfordjournals.jbchem.a123598; KOZUTSUMI Y, 1990, J BIOCHEM, V108, P704, DOI 10.1093/oxfordjournals.jbchem.a123268; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LEPERS A, 1990, EUR J BIOCHEM, V193, P715, DOI 10.1111/j.1432-1033.1990.tb19391.x; LEPERS A, 1989, FEBS LETT, V250, P245, DOI 10.1016/0014-5793(89)80731-8; MIYAKE M, 1990, CANCER, V65, P499, DOI 10.1002/1097-0142(19900201)65:3<499::AID-CNCR2820650321>3.0.CO;2-P; MUCHMORE EA, 1989, J BIOL CHEM, V264, P20216; NAKAMURA K, 1983, J BIOCHEM-TOKYO, V94, P1359, DOI 10.1093/oxfordjournals.jbchem.a134482; NAKAMURA K, 1988, J BIOCHEM-TOKYO, V103, P201, DOI 10.1093/oxfordjournals.jbchem.a122232; NOBUSAWA E, 1991, VIROLOGY, V182, P475, DOI 10.1016/0042-6822(91)90588-3; ONO E, 1989, INFECT IMMUN, V57, P907, DOI 10.1128/IAI.57.3.907-911.1989; SAITO M, 1992, J NEUROCHEM, V58, P83, DOI 10.1111/j.1471-4159.1992.tb09280.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHAUER R, 1971, H-S Z PHYSIOL CHEM, V352, P1282, DOI 10.1515/bchm2.1971.352.2.1282; SCHAUER R, 1991, CARBOHYD RES, V213, P353, DOI 10.1016/S0008-6215(00)90623-2; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SHAW L, 1988, BIOL CHEM H-S, V369, P477, DOI 10.1515/bchm3.1988.369.1.477; SUZUKI Y, 1987, BIOCHIM BIOPHYS ACTA, V903, P417, DOI 10.1016/0005-2736(87)90048-4; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TAKEMATSU H, 1993, J BIOCH, V115, P381; TSUJI S, 1988, J BIOCHEM, V104, P498, DOI 10.1093/oxfordjournals.jbchem.a122498; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VASKOVSKY VE, 1970, COMP BIOCHEM PHYSIOL, V34, P163, DOI 10.1016/0010-406X(70)90064-2; WAKAMIYA N, 1991, BIOCHEM BIOPH RES CO, V181, P310, DOI 10.1016/S0006-291X(05)81419-6; WAKAMIYA N, 1991, BIOCHEM BIOPH RES CO, V181, P810	48	124	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16458	16463		10.1074/jbc.270.27.16458	http://dx.doi.org/10.1074/jbc.270.27.16458			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608218	hybrid			2022-12-25	WOS:A1995RH22600086
J	ZHANG, JN; WILKS, JE; BILLADELLO, JJ				ZHANG, JN; WILKS, JE; BILLADELLO, JJ			CHARACTERIZATION OF A NUCLEAR-PROTEIN THAT INTERACTS WITH REGULATORY ELEMENTS IN THE HUMAN B-CREATINE-KINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY OCCLUSION; CARDIAC-MUSCLE; DEVELOPMENTAL REGULATION; SKELETAL-MUSCLE; PROMOTER REGION; BINDING PROTEIN; MESSENGER-RNAS; POLYMERASE-III; EXPRESSION; TRANSCRIPTION	The B creatine kinase gene is regulated by an array of positive and negative cis-elements in the 5'-flanking DNA that function in both muscle and nonmuscle cells. In C2C12 myogenic cells M and B creatine kinase mRNAs are coordinately up-regulated in the early stages of myogenesis and then undergo distinct regulatory programs. The B creatine kinase gene is down-regulated in the late stages of myogenesis as M creatine kinase becomes the predominant species in mature myotubes, Sequences between -92 and +80 of the B creatine kinase gene confer a regulated pattern of expression to chimeric plasmids that closely resembles the time course of expression of the endogenous B creatine kinase gene in C2C12 cells undergoing differentiation. We show that sequences within the first exon of the B creatine kinase gene are important for the developmental regulation of the gene in C2C12 cells and that these sequences bind a nuclear protein that shows a similar tissue-specific distribution and developmentally regulated expression to that of the endogenous B creatine kinase gene.	WASHINGTON UNIV,SCH MED,DIV CARDIOVASC,ST LOUIS,MO 63110	Washington University (WUSTL)								AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; APPLE FS, 1985, J APPL PHYSIOL, V59, P149, DOI 10.1152/jappl.1985.59.1.149; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENFIELD PA, 1988, GENE, V63, P227, DOI 10.1016/0378-1119(88)90527-6; BERGSMA D, 1986, MOL BIOL MUSCLE DEV, P531; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHANDLER WL, 1984, CLIN CHEM, V30, P1804; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; CHNG JLC, 1994, J BIOL CHEM, V269, P2336; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; EPPENBERGER HM, 1964, DEV BIOL, V10, P1, DOI 10.1016/0012-1606(64)90002-8; FONTANET HL, 1991, CIRC RES, V68, P1007, DOI 10.1161/01.RES.68.4.1007; FRIEDMAN DL, 1989, EXP EYE RES, V49, P445, DOI 10.1016/0014-4835(89)90053-5; HAWKER KJ, 1993, BIOTECHNIQUES, V14, P764; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; HOBSON GM, 1988, NUCLEIC ACIDS RES, V16, P8925, DOI 10.1093/nar/16.18.8925; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INGWALL JS, 1993, CIRCULATION, V87, P58; INGWALL JS, 1979, HEART CREATINE KINAS, V1, P9; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KADDURAHDAOUK R, 1990, MOL CELL BIOL, V10, P1476, DOI 10.1128/MCB.10.4.1476; KAWAMOTO S, 1994, J BIOL CHEM, V269, P15101; KAYE FJ, 1987, J CLIN INVEST, V79, P1412, DOI 10.1172/JCI112969; KIM SJ, 1992, J BIOL CHEM, V267, P15140; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LOUGH J, 1977, DEV BIOL, V57, P330, DOI 10.1016/0012-1606(77)90219-6; MARIMAN E, 1991, GENE, V102, P205, DOI 10.1016/0378-1119(91)90079-Q; MARIMAN E C M, 1987, Genomics, V1, P126, DOI 10.1016/0888-7543(87)90004-8; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MITCHELL MT, 1992, J BIOL CHEM, V267, P1995; MITCHELL MT, 1990, J BIOL CHEM, V265, P8259; MITCHELL MT, 1993, J BIOL CHEM, V268, P1141; NAKAMURA S, 1993, J BIOL CHEM, V268, P11670; NIKOVITS W, 1990, MOL CELL BIOL, V10, P3468, DOI 10.1128/MCB.10.7.3468; PFEIFFER FE, 1984, ARCH NEUROL-CHICAGO, V41, P1175, DOI 10.1001/archneur.1984.04050220073017; REISS NA, 1981, J BIOL CHEM, V256, P5741; RITCHIE ME, 1991, NUCLEIC ACIDS RES, V19, P6231, DOI 10.1093/nar/19.22.6231; ROSENBERG UB, 1981, EUR J BIOCHEM, V116, P87, DOI 10.1111/j.1432-1033.1981.tb05304.x; SANDLER MA, 1994, J BIOL CHEM, V269, P21500; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; Seraydarian M W, 1986, Adv Exp Med Biol, V194, P41; SHAPIRO IM, 1992, J BONE MINER RES, V7, P493; SHARKEY SW, 1989, AM J PHYSIOL, V256, pH508, DOI 10.1152/ajpheart.1989.256.2.H508; SHARKEY SW, 1991, CIRCULATION, V84, P333, DOI 10.1161/01.CIR.84.1.333; SOMJEN D, 1984, BIOCHEM J, V219, P1037; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; TRASK RV, 1992, NUCLEIC ACIDS RES, V20, P2313, DOI 10.1093/nar/20.9.2313; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	57	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16134	16139		10.1074/jbc.270.27.16134	http://dx.doi.org/10.1074/jbc.270.27.16134			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608177	hybrid			2022-12-25	WOS:A1995RH22600040
J	KLOTH, S; EBENBECK, C; KUBITZA, M; SCHMIDBAUER, A; ROCKL, W; MINUTH, WW				KLOTH, S; EBENBECK, C; KUBITZA, M; SCHMIDBAUER, A; ROCKL, W; MINUTH, WW			STIMULATION OF RENAL MICROVASCULAR DEVELOPMENT UNDER ORGANOTYPIC CULTURE CONDITIONS	FASEB JOURNAL			English	Article						KIDNEY; VASCULAR DEVELOPMENT; PERFUSION CELL CULTURE; ENDOTHELIUM; GROWTH FACTORS	ENDOTHELIAL GROWTH-FACTOR; DEVELOPING KIDNEY; RABBIT KIDNEY; CELLS; DIFFERENTIATION; ANGIOGENESIS; RECEPTORS; NEPHRON; SPECIFICITY; EXPRESSION	The development of the renal vascular system requires the coordinated action of soluble morphogenic factors and specific extracellular matrix components, Despite intensive research it remains unknown whether the humoral or the environmental component is more important in the development of renal microvessels, The prolonged serum-free culture of embryonic kidney cortex explants was achieved by means of a newly developed perfusion culture system, This system made the investigation of renal vascular development under defined organotypic conditions possible, Thus, growth factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and hormones (aldosterone, vitamin D-3) could be applied without the interference with serum components. Medium supplementation with VEGF or aldosterone in combination with vitamin D-3 resulted in the coordinated proliferation of endothelial cells in the explant, A well-developed collecting duct epithelium and numerous tubular structures were always observed, In contrast, only a uniform cell layer was found between fibrous organ capsule and the collecting duct epithelium after bFGF application, but neither tubular structures nor endothelial cells. Thus, the experiments indicate that bFGF alone has no stimulating effect on the growth of the renal microvasculature under perfusion culture conditions.	GESELL BIOTECHNOL FORSCH MBH,DEPT GENEXPRESS,D-38124 BRAUNSCHWEIG,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH	KLOTH, S (corresponding author), UNIV REGENSBURG,INST ANAT,UNIV STR 31,D-93053 REGENSBURG,GERMANY.							ABRAHAMSON DR, 1991, SEMIN NEPHROL, V11, P375; AUFDERHEIDE E, 1987, J CELL BIOL, V105, P599, DOI 10.1083/jcb.105.1.599; BARD JBL, 1991, DEVELOPMENT, V113, P193; BREIER G, 1992, DEVELOPMENT, V114, P521; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; EMURA M, 1972, DEV GROWTH DIFFER, V14, P237; FARMAN N, 1992, SEMIN NEPHROL, V12, P12; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; IIJIMA K, 1993, KIDNEY INT, V44, P959, DOI 10.1038/ki.1993.337; KAZIMIERCZAK J, 1971, ACTA PATHOL MICROB A, V218, P9; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KLOTH S, 1992, DIFFERENTIATION, V52, P79, DOI 10.1111/j.1432-0436.1992.tb00502.x; KLOTH S, 1994, CELL TISSUE RES, V277, P247, DOI 10.1007/s004410050152; KLOTH S, 1993, EUR J CELL BIOL, V63, P84; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; KUMAR R, 1994, AM J PHYSIOL, V266, pF477, DOI 10.1152/ajprenal.1994.266.3.F477; Ledoux D, 1991, Growth Factors, V5, P221, DOI 10.3109/08977199109000286; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINUTH WW, 1987, DIFFERENTIATION, V36, P12, DOI 10.1111/j.1432-0436.1987.tb00177.x; MINUTH WW, 1992, EUR J CELL BIOL, V57, P132; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; POTTER EL, 1965, ARCH PATHOL, V80, P241; RAJI L, 1991, J AM SOC NEPHROL, V2, pS2; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SARIOLA H, 1983, DEV BIOL, V96, P427, DOI 10.1016/0012-1606(83)90180-X; SHI DL, 1994, DEV BIOL, V164, P173, DOI 10.1006/dbio.1994.1189; SIMON M, 1995, AM J PHYSIOL-RENAL, V268, pF240, DOI 10.1152/ajprenal.1995.268.2.F240; UCHIDA K, 1994, AM J PHYSIOL, V266, pF81, DOI 10.1152/ajprenal.1994.266.1.F81; VAISMAN N, 1990, J BIOL CHEM, V265, P19461	35	30	30	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					963	967		10.1096/fasebj.9.10.7615165	http://dx.doi.org/10.1096/fasebj.9.10.7615165			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615165				2022-12-25	WOS:A1995RK89900019
J	ABEL, S; NGUYEN, MD; CHOW, W; THEOLOGIS, A				ABEL, S; NGUYEN, MD; CHOW, W; THEOLOGIS, A			ASC4, A PRIMARY INDOLEACETIC ACID-RESPONSIVE GENE ENCODING 1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE IN ARABIDOPSIS-THALIANA - STRUCTURAL CHARACTERIZATION, EXPRESSION IN ESCHERICHIA-COLI, AND EXPRESSION CHARACTERISTICS IN RESPONSE TO AUXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEA PISUM-SATIVUM; ETHYLENE BIOSYNTHESIS; MULTIGENE FAMILY; RAPID INDUCTION; MESSENGER-RNA; TOMATO; TRANSCRIPTION; TISSUE; FRUIT; IDENTIFICATION	1-Aminocyclopropane-1-carboxylic acid (ACC) synthase is the key regulatory enzyme in the biosynthetic pathway of the plant hormone ethylene. The enzyme is encoded by a divergent multigene family in Arabidopsis thaliana, comprising at least five genes, ACS1-5 (Liang, X., Abel, S., Keller, J. A., Shen, N. F., and Theologis, A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11046-11050), In etiolated seedlings, ACS4 is specifically induced by indoleacetic acid (IAA), The response to IAA is rapid (within 25 min) and insensitive to protein synthesis inhibition, suggesting that the ACS4 gene expression is a primary response to IAA, The ACS4 mRNA accumulation displays a biphasic dose-response curve which is optimal at 10 mu M of IAA. However, IAA concentrations as low as 100 nM are sufficient to enhance the basal level of ACS4 mRNA. The expression of ACS4 is defective in the Arabidopsis auxin-resistant mutant lines axr1-12, axr2-1, and aux1-7, ACS4 mRNA levels are severely reduced in axr1-12 and axr2-1 but are only 1.5-fold lower in aux1-7, IAA inducibility is abolished in axr2-1. The ACS4 gene was isolated and structurally characterized. The promoter contains four sequence motifs reminiscent of functionally defined auxin-responsive cis-elements in the early auxin-inducible genes PS-IAA4/5 from pea and GH3 from soybean, Conceptual translation of the coding region predicts a protein with a molecular mass of 53,795 Da and a theoretical isoelectric point of 8.2, The ACS4 polypeptide contains the 11 invariant amino acid residues conserved between aminotransferases and ACC synthases from various plant species. An ACS4 cDNA was generated by reverse transcriptase-polymerase chain reaction, and the authenticity was confirmed by expression of ACC synthase activity in Escherichia coli.	CTR PLANT GENE EXPRESS, ALBANY, CA 94710 USA									Abeles F.B., 1992, PLANT BIOL ETHYL, P1, DOI [DOI 10.1016/B978-0-08-091628-6.50001-1, 10.1016/b978-0-08-091628-6.50001-1, DOI 10.1016/C2009-0-03226-7]; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BALLAS N, 1995, P NATL ACAD SCI USA, V92, P3483, DOI 10.1073/pnas.92.8.3483; BALLAS N, 1993, J MOL BIOL, V233, P580, DOI 10.1006/jmbi.1993.1537; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLATT MR, 1994, PLANT J, V5, P55, DOI 10.1046/j.1365-313X.1994.5010055.x; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BOTELLA JR, 1993, GENE, V123, P249, DOI 10.1016/0378-1119(93)90132-M; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; ECKER JR, 1987, P NATL ACAD SCI USA, V84, P5202, DOI 10.1073/pnas.84.15.5202; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; HAGEN G, 1985, MOL CELL BIOL, V5, P1197, DOI 10.1128/MCB.5.6.1197; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HICKS GR, 1989, SCIENCE, V245, P52, DOI 10.1126/science.245.4913.52; HOBBIE L, 1994, PLANT CELL ENVIRON, V17, P525, DOI 10.1111/j.1365-3040.1994.tb00147.x; HUANG PL, 1991, P NATL ACAD SCI USA, V88, P7021, DOI 10.1073/pnas.88.16.7021; JONES MD, 1993, METHOD ENZYMOL, V218, P413; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIM WT, 1992, PLANT PHYSIOL, V100, P1126, DOI 10.1104/pp.100.3.1126; LI Y, 1991, PLANT CELL, V3, P1167, DOI 10.1105/tpc.3.11.1167; LIANG XW, 1992, P NATL ACAD SCI USA, V89, P11046, DOI 10.1073/pnas.89.22.11046; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; LINCOLN JE, 1993, J BIOL CHEM, V268, P19422; LIU ZB, 1994, PLANT CELL, V6, P645, DOI 10.1105/tpc.6.5.645; MEYEROWITZ EM, 1989, CELL, V56, P263, DOI 10.1016/0092-8674(89)90900-8; NAKAGAWA N, 1991, PLANT CELL PHYSIOL, V32, P1153; NAKAJIMA N, 1990, PLANT CELL PHYSIOL, V31, P1021; OELLER PW, 1993, J MOL BIOL, V233, P789, DOI 10.1006/jmbi.1993.1555; PICKETT FB, 1990, PLANT PHYSIOL, V94, P1462, DOI 10.1104/pp.94.3.1462; ROTTMANN WH, 1991, J MOL BIOL, V222, P937, DOI 10.1016/0022-2836(91)90587-V; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; TIMPTE C, 1994, GENETICS, V138, P1239; VAN DER STRAETEN D, 1992, P NATL ACAD SCI USA, V89, P9969, DOI 10.1073/pnas.89.20.9969; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YIP WK, 1990, P NATL ACAD SCI USA, V87, P7930, DOI 10.1073/pnas.87.20.7930; ZAREMBINSKI TI, 1994, PLANT MOL BIOL, V26, P1579, DOI 10.1007/BF00016491; ZAREMBINSKI TI, 1993, MOL BIOL CELL, V4, P363, DOI 10.1091/mbc.4.4.363	44	189	202	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19093	19099		10.1074/jbc.270.32.19093	http://dx.doi.org/10.1074/jbc.270.32.19093			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642574	hybrid			2022-12-25	WOS:A1995RN95400062
J	ERIKSSON, S; XU, BJ; CLAYTON, DA				ERIKSSON, S; XU, BJ; CLAYTON, DA			EFFICIENT INCORPORATION OF ANTI-HIV DEOXYNUCLEOTIDES BY RECOMBINANT YEAST MITOCHONDRIAL-DNA POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; HUMAN THYMIDINE KINASE-1; SUBSTRATE-SPECIFICITY; NUCLEOSIDE ANALOGS; 3'->5' EXONUCLEASE; INSERTION FIDELITY; CATALYTIC SUBUNIT; XENOPUS-LAEVIS; GAMMA; PURIFICATION	Saccharomyces cerevisiae mtDNA polymerase, isolated as a single 135-kDa recombinant polypeptide, showed high processivity and a capacity to use poly(dA). oligo(dT), poly(rA). oligo(dT), or primed bacteriophage M13 DNA as a template, In a primer extension assay, the enzyme exhibited an intrinsic 3'-5'-exonuclease activity, By optimizing the polymerization reaction conditions, apparent K-m and V-max values could be determined for the incorporation of dTTP, 2'-3'-dideoxy-TTP (ddTTP), 3'-azido-TTP (AZTTP), 3'-fluoro-TTP, dCTP, 2'-3'-dideoxy-CTP, and didehydro(d4)CTP, The yeast mtDNA polymerase used ddTTP, 3'-fluoro-TTP, and ddCTP almost as efficiently as natural deoxynucleoside triphosphates. Both 3'-AZTTP and d4CTP were each significantly less efficient as substrates. Overall, the kinetic data with mtDNA polymerase were very similar to those of the recombinant human immunodeficiency virus reverse transcriptase control, Terminally incorporated AZTTP or ddTTP was not removed by the 3'-5' exonuclease activity of mtDNA polymerase. This may explain the inhibition of mtDNA replication observed in anti-human immunodeficiency virus treatment with dideoxynucleoside analogs and suggests that screening of antiviral nucleosides for their effects on mtDNA polymerase could be of value in future rational drug design.	STANFORD UNIV,SCH MED,BECKMAN CTR MOLEC & GENET MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033088, R37GM033088] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33088-23] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; BABA M, 1987, BIOCHEM BIOPH RES CO, V142, P128, DOI 10.1016/0006-291X(87)90460-8; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHEN CH, 1991, MOL PHARMACOL, V39, P625; CHENG YC, 1987, J BIOL CHEM, V262, P2187; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DALUGE SM, 1994, ANTIMICROB AGENTS CH, V38, P1590, DOI 10.1128/AAC.38.7.1590; DUBANSKY RM, 1989, MUSCLE NERVE, V12, P856; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; FARAJ A, 1994, ANTIMICROB AGENTS CH, V28, P924; FICHL MA, 1987, NEW ENGL J MED, V317, P185; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FOURY F, 1989, J BIOL CHEM, V264, P20552; GRAY H, 1992, J BIOL CHEM, V267, P5835; HERNIGA J, 1994, EVOLUTIONARY BIOL VI, P87; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; IZUTA S, 1991, BIOCHEM BIOPH RES CO, V179, P776, DOI 10.1016/0006-291X(91)91884-F; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS LD, 1992, ANTIMICROB AGENTS CH, V36, P2061, DOI 10.1128/AAC.36.9.2061; LEWIS W, 1994, CIRC RES, V74, P344, DOI 10.1161/01.RES.74.2.344; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; LUNDGREN B, 1991, J ACQ IMMUN DEF SYND, V4, P489; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MOSBAUGH DW, 1988, NUCLEIC ACIDS RES, V16, P5645, DOI 10.1093/nar/16.12.5645; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; OLSON MW, 1992, J BIOL CHEM, V267, P23136; SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; UNGE T, 1990, AIDS RES HUM RETROV, V6, P1297, DOI 10.1089/aid.1990.6.1297; WANG LY, 1993, J BIOL CHEM, V268, P22847; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855; WINTERSBERGER U, 1970, EUR J BIOCHEM, V13, P20, DOI 10.1111/j.1432-1033.1970.tb00894.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XU BJ, 1992, NUCLEIC ACIDS RES, V20, P1053, DOI 10.1093/nar/20.5.1053; ZIMMERMANN W, 1980, J BIOL CHEM, V255, P1847	44	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18929	18934		10.1074/jbc.270.32.18929	http://dx.doi.org/10.1074/jbc.270.32.18929			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642550	hybrid			2022-12-25	WOS:A1995RN95400038
J	GAMETT, DC; GREENE, T; WAGREICH, AR; KIM, HH; KOLAND, JG; CERIONE, RA				GAMETT, DC; GREENE, T; WAGREICH, AR; KIM, HH; KOLAND, JG; CERIONE, RA			HEREGULIN-STIMULATED SIGNALING IN RAT PHEOCHROMOCYTOMA CELLS - EVIDENCE FOR ERBB3 INTERACTIONS WITH NEU/ERBB2 AND P85	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU ONCOGENE; LIGAND	We have reported that overexpression of Neu leads to heregulin-stimulated neurite outgrowth and the tyrosine-phosphorylation of Neu and other cellular proteins in PC12 cells, Considering that Neu/ErbB2 alone is not able to functionally couple to heregulin, we looked for the possible involvement of ErbB3 in these neurite out-growth and tyrosine phosphorylation responses, We found that heregulin stimulates the tyrosine phosphorylation of endogenous ErbB3 protein in PC12 cells and that this phosphorylation, like that of Neu, is greatly enhanced in cells that overexpress Neu, Furthermore, overexpression of ErbB3 in PC12 cells led to heregulin-stimulated neurite extension, In addition to becoming tyrosine-phosphorylated, Neu/ErbB2 and ErbB3 associate with each other, and each associates with the 85-kDa regulatory subunit (p85) of phosphatidylinositol 3-kinase in a heregulin dependent manner, Thus, Neu/ErbB2 and ErbB3 appear to cooperate to mediate the heregulin signal in PC12 cells, Like heregulin, epidermal growth factor (EGF) also stimulates the tyrosine phosphorylation of both Neu and ErbB3, However, there are clear differences between the EGF- and heregulin-stimulated phosphorylations of ErbB3, In the heregulin response, two tyrosine phosphorylated forms of ErbB3 are detected, Of these, only the more quickly migrating form (on SDS-polyacrylamide gel electrophoresis) is found to be associated with Neu, whereas the other, more slowly migrating form is uniquely capable of forming stable complexes with p85, In the EGF response, at least two tyrosine-phosphorylated forms of ErbB3 are detected, but these phosphoproteins have distinctly fewer apparent molecular weights compared with the heregulin-stimulated ErbB3 phosphoproteins and do not complex with p85, Thus the formation of a stable ErbB3-p85 complex in PC12 cells is a unique outcome of heregulin signaling that correlates with the differences in cell morphology induced by the activated EGF receptor and the Neu tyrosine kinase.	CORNELL UNIV, DEPT PHARMACOL, ITHACA, NY 14853 USA; UNIV IOWA, COLL MED, DEPT PHARMACOL, IOWA CITY, IA 52242 USA	Cornell University; University of Iowa				Koland, John/0000-0002-5028-4297	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GAMETT DC, 1994, FEBS LETT, V351, P335, DOI 10.1016/0014-5793(94)00855-8; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KIM HH, 1994, J BIOL CHEM, V269, P24747; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	20	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19022	19027		10.1074/jbc.270.32.19022	http://dx.doi.org/10.1074/jbc.270.32.19022			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642563	hybrid			2022-12-25	WOS:A1995RN95400051
J	TSENG, MJ; DETJEN, K; STRUK, V; LOGSDON, CD				TSENG, MJ; DETJEN, K; STRUK, V; LOGSDON, CD			CARBOXYL-TERMINAL DOMAINS DETERMINE INTERNALIZATION AND RECYCLING CHARACTERISTICS OF BOMBESIN RECEPTOR CHIMERAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTORS; HUMAN BETA-2-ADRENERGIC RECEPTOR; MEDIATED ENDOCYTOSIS; MOLECULAR-CLONING; PEPTIDE RECEPTOR; DOWN-REGULATION; MEMBRANE FORM; GROWTH-FACTOR; AGONIST	To investigate the role of the carboxyl terminus in the regulation of the bombesin (BN) receptor, we constructed two chimeric receptors with carboxyl termini transferred from either m3 muscarinic cholinergic (m3 ACh) (BMC) or cholecystokinin A (CCKA) (BCC) receptors and expressed them in Chinese hamster ovary cells, Previous studies showed that agonist treatment caused rapid internalization of CCKA but not m3 ACh receptors in these cells, In the current study we conducted separate analyses of ligand and receptor internalization and analyzed receptor recycling. Ligand internalization was assessed using acid washing. BN and CCKA receptors internalized ligand with 80 +/- 3 and 85 +/- 7% in an acid-resistant compartment at equilibrium, Ligand internalization of chimeric receptors generally assumed the properties of the donor receptors. Thus, BCC receptors internalized ligand to a similar extent as wild-type CCKA receptors (75 +/- 3%), whereas, BMC receptors showed reduced ligand internalization (38 +/- 1%), Receptor internalization was more directly assessed by determining agonist-induced loss of surface binding. BN and CCKA receptors were largely internalized (56 +/- 8 and 50 +/- 7%, respectively). BCC receptors were also extensively internalized (82 +/- 3%). In contrast, BMC receptors were minimally internalized (22 +/- 8%), Receptor recycling was assessed as recovery from agonist induced loss of binding, BN, CCKA, and BMC receptors showed rapid recycling, In contrast, BCC receptors did not recycle, These data indicate that carboxyl-terminal structures determine both internalization of ligand-receptor complexes and subsequent receptor recycling.	UNIV MICHIGAN, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R01DK041225] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41225, DK34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENYA RV, 1994, MOL PHARMACOL, V46, P495; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOULAY G, 1994, ENDOCRINOLOGY, V135, P2130, DOI 10.1210/en.135.5.2130; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CARPENTIER JL, 1992, PROG HISTOCHEM CYTOC, V26, P77, DOI 10.1016/S0079-6336(11)80081-1; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAMEH J, 1992, J BIOL CHEM, V267, P13406; MORO O, 1994, J BIOL CHEM, V269, P6651; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; WALDO GL, 1983, J BIOL CHEM, V258, P3900; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; YANG J, 1993, MOL PHARMACOL, V44, P1158; YULE DI, 1993, AM J PHYSIOL, V265, pG999, DOI 10.1152/ajpgi.1993.265.5.G999; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x; ZHU WY, 1991, AM J PHYSIOL, V261, pG57, DOI 10.1152/ajpgi.1991.261.1.G57	48	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18858	18864		10.1074/jbc.270.32.18858	http://dx.doi.org/10.1074/jbc.270.32.18858			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642540	hybrid			2022-12-25	WOS:A1995RN95400027
J	BOYD, RS; DUGGAN, MJ; SHONE, CC; FOSTER, KA				BOYD, RS; DUGGAN, MJ; SHONE, CC; FOSTER, KA			THE EFFECT OF BOTULINUM NEUROTOXINS ON THE RELEASE OF INSULIN FROM THE INSULINOMA CELL-LINES HIT-15 AND RINM5F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TETANUS-TOXIN; MEMBRANE-PROTEIN; NEUROTRANSMITTER RELEASE; PROTEOLYTIC CLEAVAGE; NERVE-TERMINALS; PC12 CELLS; SYNAPTOBREVIN; FUSION; NORADRENALINE; PURIFICATION	Western blotting of the insulin-secreting beta-cell lines HIT-15 and RINm5F with anti SNAP-25 (synaptosomal associated protein of 25 kDa), anti-synaptobrevin, and anti-syntaxin 1 antibodies revealed the presence of proteins with the same electrophoretic mobility as found in neural tissue. Permeabilization of both of these insulinoma cell lines to botulinum neurotoxin A by electroporation resulted, after 3 days of culture, in the loss of similar to 90% of SNAP-25 immunoreactivity. A similar permeabilization of these cells with botulinum neurotoxin B resulted in the cleavage of similar to 90% of the synaptobrevin-like immunoreactivities. Botulinum neurotoxin F also cleaved similar to 90% of the synaptobrevin-like immunoreactivity in RINm5F cells. The permeabilization of both insulinoma cells to neurotoxin A resulted in a >90% inhibition of potassium-stimulated, calcium-dependent insulin release. By contrast, permeabilization of the insulinoma cell lines to neurotoxin B resulted in only a similar to 60% inhibition of potassium-stimulated insulin release in HIT-15 cells, and neither neurotoxin B nor F caused inhibition in RINm5F cells. Thus HIT-15 and RINm5F cells contain the components of the putative exocytotic docking complex described in cells derived from the neural crest. In HIT-15 cells both SNAP-25 and synaptobrevin appear to be involved in calcium-dependent insulin secretion, whereas in RINm5F cells SNAP-25 but not synaptobrevin is involved.	PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,DIV BIOL,SALISBURY SP4 0JG,WILTS,ENGLAND		BOYD, RS (corresponding author), SPEYWOOD PHARMACEUT LTD,PORTON HOUSE,1 BATH RD,MAIDENHEAD SL4 4UH,BERKS,ENGLAND.							BARTELS F, 1992, INFECT IMMUN, V60, P302, DOI 10.1128/IAI.60.1.302-307.1992; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BLACK JD, 1986, J CELL BIOL, V103, P521, DOI 10.1083/jcb.103.2.521; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BORDIER C, 1981, J BIOL CHEM, V256, P1604; DAGMAR R, 1994, FEBS LETT, V351, P207; DOLLY JO, 1990, J PHYSIOL-PARIS, V84, P237; DOLLY JO, 1984, NATURE, V307, P457, DOI 10.1038/307457a0; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FORAN P, 1995, BIOCHEMISTRY-US, V34, P5544; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; KOMATSU M, 1993, J BIOL CHEM, V268, P23927; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MCINNES C, 1990, FEBS LETT, V261, P323, DOI 10.1016/0014-5793(90)80582-4; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PENNER R, 1986, NATURE, V324, P76, DOI 10.1038/324076a0; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SHONE CC, 1993, EUR J BIOCHEM, V217, P965, DOI 10.1111/j.1432-1033.1993.tb18327.x; SHONE CC, 1992, EUR J BIOCHEM, V207, P1009, DOI 10.1111/j.1432-1033.1992.tb17137.x; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOLLNER T, 1993, NATURE, V364, P318; WADSWORTH JDF, 1990, BIOCHEM J, V268, P123, DOI 10.1042/bj2680123; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	30	49	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18216	18218		10.1074/jbc.270.31.18216	http://dx.doi.org/10.1074/jbc.270.31.18216			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629139	hybrid			2022-12-25	WOS:A1995RM64200012
J	GEMS, D; FERGUSON, CJ; ROBERTSON, BD; NIEVES, R; PAGE, AP; BLAXTER, ML; MAIZELS, RM				GEMS, D; FERGUSON, CJ; ROBERTSON, BD; NIEVES, R; PAGE, AP; BLAXTER, ML; MAIZELS, RM			AN ABUNDANT, TRANS-SPLICED MESSENGER-RNA FROM TOXOCARA-CANIS INFECTIVE LARVAE ENCODES A 26-KDA PROTEIN WITH HOMOLOGY TO PHOSPHATIDYLETHANOLAMINE-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCRETORY-SECRETORY ANTIGENS; CDNA LIBRARY CONSTRUCTION; LIPID TRANSFER PROTEIN; BOVINE BRAIN CYTOSOL; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; 23-KDA PROTEIN; SURFACE; PURIFICATION; RNA	A full-length mRNA encoding a secreted 26-kDa antigen of infective larvae of the ascarid nematode parasite Toxocara canis has been identified. This was characterized as a 1,082-base pair clone highly abundant (0.8-1.9%) in cDNA prepared from infective stage larvae but absent from cDNA from adult male worms. Sequence analysis revealed an open reading frame corresponding to a hydrophilic 263-amino acid residue polypeptide with a 20-residue N-terminal signal peptide, indicating that it is secreted. The 5' end of the cDNA was isolated by polymerase chain reaction using a primer containing the nematode spliced leader sequence, SL1, showing that the mRNA is trans-spliced. The molecular mass of the putative protein with the signal peptide removed is 26.01 kDa, and antibody to the recombinant protein expressed in bacterial vectors reacts with a similarly sized protein in T. canis excretory/secretory (TES) products. An identical sequence was obtained from a genomic clone isolated by expression screening with mouse antibody to TES. The 72 amino acid residues adjacent to the signal peptide form two homologous 36 residue motifs containing 6 cysteine residues; this motif is found also in the T. canis-secreted glycoprotein TES-120 and in genes of Caenorhabditis elegans. Sequence data base searches revealed significant similarity to 7 other sequences in a newly recognized gene family of phosphatidylethanolamine binding proteins that includes yeast, Drosophila, rat, bovine, simian, and human genes and a representative from the filarial nematode Onchocerca volvulus. Assays with the T. canis recombinant 26-kDa protein expressed as a fusion with maltose-binding protein have confirmed phosphatidylethanolamine-binding specificity for this novel product.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, WELLCOME RES CTR PARASIT INFECT, DEPT BIOL, LONDON SW7 2BB, ENGLAND	Imperial College London			Blaxter, Mark/O-2535-2019; Blaxter, Mark L/B-4113-2010	Blaxter, Mark L/0000-0003-2861-949X; Robertson, Brian D./0000-0001-5785-5307; Gems, David/0000-0002-6653-4676	FIC NIH HHS [T37-TW00046] Funding Source: Medline; Wellcome Trust Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [T37TW000046] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Wellcome Trust(Wellcome TrustEuropean Commission); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AKEROYD R, 1981, EUR J BIOCHEM, V114, P385, DOI 10.1111/j.1432-1033.1981.tb05158.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BADLEY JE, 1987, J PARASITOL, V73, P593, DOI 10.2307/3282142; BAXA CA, 1989, BIOCHEMISTRY-US, V28, P8683, DOI 10.1021/bi00448a003; BEAVER PAUL C., 1962, BULL SOC PATHOL EXOT, V55, P555; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BERNIER I, 1986, BIOCHIM BIOPHYS ACTA, V871, P19, DOI 10.1016/0167-4838(86)90128-7; BERNIER I, 1984, BIOCHIM BIOPHYS ACTA, V790, P174, DOI 10.1016/0167-4838(84)90221-8; BLAXTER ML, 1992, PARASITOL TODAY, V8, P243, DOI 10.1016/0169-4758(92)90126-M; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Savigny D.H., 1975, Journal Parasit, V61, P781, DOI 10.2307/3279492; DOMEC C, 1990, ANAL BIOCHEM, V188, P422, DOI 10.1016/0003-2697(90)90630-R; GILLESPIE SH, 1988, PARASITOL TODAY, V4, P180, DOI 10.1016/0169-4758(88)90156-1; Glickman L.T., 1986, P201; GLICKMAN LT, 1981, EPIDEMIOL REV, V3, P230, DOI 10.1093/oxfordjournals.epirev.a036235; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; HORI N, 1994, GENE, V140, P293; JONES R, 1991, BIOCHIM BIOPHYS ACTA, V1080, P78, DOI 10.1016/0167-4838(91)90114-F; KENNEDY MW, 1987, MOL BIOCHEM PARASIT, V22, P233, DOI 10.1016/0166-6851(87)90054-5; KENNEDY MW, 1993, TOXOCARA AND TOXOCARIASIS, P151; LINNESTAD C, 1991, PLANT PHYSIOL, V97, P841, DOI 10.1104/pp.97.2.841; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOBOS E, 1991, SCIENCE, V251, P1603, DOI 10.1126/science.2011741; LOBOS E, 1990, MOL BIOCHEM PARASIT, V39, P135, DOI 10.1016/0166-6851(90)90016-F; MAIZELS RM, 1993, EXP PARASITOL, V77, P380, DOI 10.1006/expr.1993.1096; MAIZELS RM, 1984, PARASITE IMMUNOL, V6, P23, DOI 10.1111/j.1365-3024.1984.tb00779.x; MAIZELS RM, 1990, ACTA TROP, V47, P355, DOI 10.1016/0001-706X(90)90036-Y; MAIZELS RM, 1993, TOXOCARA AND TOXOCARIASIS, P141; MEGHJI M, 1986, MOL BIOCHEM PARASIT, V18, P155, DOI 10.1016/0166-6851(86)90035-6; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; MOSER D, 1991, J BIOL CHEM, V266, P8447; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; PAGE AP, 1992, EXP PARASITOL, V75, P56, DOI 10.1016/0014-4894(92)90122-Q; PAGE AP, 1992, PARASITOLOGY, V105, P297, DOI 10.1017/S0031182000074229; PAGE AP, 1992, EXP PARASITOL, V75, P72, DOI 10.1016/0014-4894(92)90123-R; PAGE AP, 1991, PARASITOLOGY, V103, P451, DOI 10.1017/S0031182000059977; PERRY ACF, 1994, BIOCHEM J, V301, P235, DOI 10.1042/bj3010235; PIKIELNY CW, 1994, NEURON, V12, P35, DOI 10.1016/0896-6273(94)90150-3; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; RODRIGUEZPEREZ J, 1992, EXP PARASITOL, V74, P400, DOI 10.1016/0014-4894(92)90202-L; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; Sambrook J, 1989, MOL CLONING LABORATO; SCHANTZ P M, 1989, American Journal of Tropical Medicine and Hygiene, V41, P21; SCHOENTGEN F, 1987, EUR J BIOCHEM, V166, P333, DOI 10.1111/j.1432-1033.1987.tb13519.x; SPRENT JFA, 1958, PARASITOLOGY, V48, P184, DOI 10.1017/S0031182000021168; SUGANE K, 1983, IMMUNOLOGY, V50, P113; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	47	80	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18517	18522		10.1074/jbc.270.31.18517	http://dx.doi.org/10.1074/jbc.270.31.18517			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629180	hybrid			2022-12-25	WOS:A1995RM64200058
J	LIN, TA; KONG, XM; SALTIEL, AR; BLACKSHEAR, PJ; LAWRENCE, JC				LIN, TA; KONG, XM; SALTIEL, AR; BLACKSHEAR, PJ; LAWRENCE, JC			CONTROL OF PHAS-I BY INSULIN IN 3T3-L1 ADIPOCYTES - SYNTHESIS, DEGRADATION, AND PHOSPHORYLATION BY A RAPAMYCIN-SENSITIVE AND MITOGEN-ACTIVATED PROTEIN KINASE-INDEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; GLUCOSE-TRANSPORT; CELLS; INITIATION; GROWTH; ACID; FACTOR-EIF-4E; STIMULATION; TRANSLATION; P70(S6K)	PHAS-I levels increased 8-fold as 3T3-L1 fibroblasts differentiated into adipocytes and acquired sensitivity to insulin. Insulin increased PHAS-I protein (3.3 fold after 2 days), the rate of PHAS-I synthesis (3-fold after 1 h), and the half-life of the protein (from 1.5 to 2.5 days). Insulin also increased the phosphorylation of PHAS-I and promoted dissociation of the PHAS-I eukaryotic initiation factor-4E (eIF-4E) complex, effects that were maximal within 10 min. With recombinant [H-6]PHAS-I as substrate, mitogen-activated protein (MAP) kinase was the only insulin-stimulated PHAS-I kinase detected after fractionation of extracts by Mono Q chromatography; however, MAP kinase did not readily phosphorylate [H-6]PHAS-I when the [H-6]PHAS-I . eIF-4E complex was the substrate. Thus, while MAP kinase may phosphorylate free PHAS-I, it is not sufficient to dissociate the complex. Moreover, rapamycin attenuated the stimulation of PHAS-I phosphorylation by insulin and markedly inhibited dissociation of PHAS-I . eIF-4E, without decreasing MAP kinase activity. Rapamycin abolished the effects of insulin on increasing phosphorylation of ribosomal protein S6 and on activating p70(S6K). The MAP kinase kinase inhibitor, PD 098059, markedly decreased MAP kinase activation by insulin, but it did not change PHAS-I phosphorylation or the association of PHAS-I with eIF-4E. In summary, insulin increases the expression of PHAS-I and promotes phosphorylation of multiple sites in the protein via multiple transduction pathways, one of which is rapamycin-sensitive and independent of MAP kinase. Rapamycin may inhibit translation initiation by increasing PHAS-I binding to eIF-4E.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; DUKE UNIV,MED CTR,DEPT MED,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710	Washington University (WUSTL); Pfizer; Duke University; Duke University			Blackshear, Perry J./C-6206-2019; Saltiel, Alan/L-3632-2019	Blackshear, Perry J./0000-0002-9561-8529; Saltiel, Alan/0000-0002-9726-9828	NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DENTON RM, 1981, DIABETOLOGIA, V21, P347; DEPHILIP RM, 1980, BIOCHEMISTRY-US, V19, P1662, DOI 10.1021/bi00549a022; DIGGLE TA, 1991, BIOCHEM J, V279, P545, DOI 10.1042/bj2790545; DIGGLE TA, 1995, BIOCHEM J, V306, P135, DOI 10.1042/bj3060135; DUDLEY DT, 1995, IN PRESS P NAT ACAD; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FREDERICKSON RM, 1992, CELL BIOL, V3, P107; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; HAMMOND ML, 1988, J BIOL CHEM, V263, P17785; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HEI YJ, 1993, J BIOL CHEM, V268, P13203; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; KONG XM, 1994, J BIOL CHEM, V269, P12963; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1995, IN PRESS EXCERPTA ME; LAZARISKARATZAS A, 1990, NATURE, V235, P544; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHATKIN AJ, 1987, BIOESSAYS, V7, P275, DOI 10.1002/bies.950070611; SMITH CJ, 1979, P NATL ACAD SCI USA, V76, P2725, DOI 10.1073/pnas.76.6.2725; SMITH M R, 1990, New Biologist, V2, P648; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sonenberg Nahum, 1993, Gene Expression, V3, P317; STERN BD, 1993, PROTEIN EXPRES PURIF, V4, P320, DOI 10.1006/prep.1993.1041; STJOHN TP, 1990, CURRENT PROTOCOLS MO; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WHITE MF, 1994, J BIOL CHEM, V269, P1	57	225	227	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18531	18538		10.1074/jbc.270.31.18531	http://dx.doi.org/10.1074/jbc.270.31.18531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629182	hybrid			2022-12-25	WOS:A1995RM64200060
J	MA, L; CONRAD, PJ; WEBB, DL; BLUE, ML				MA, L; CONRAD, PJ; WEBB, DL; BLUE, ML			ASPARTATE-698 WITHIN A NOVEL CATION-BINDING MOTIF IN ALPHA(4) INTEGRIN IS REQUIRED FOR CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; VLA-4 INTEGRIN; LYMPHOCYTES-T; FIBRONECTIN; SITE; DISTINCT; SUBUNIT; RECEPTOR; DOMAIN; VCAM-1	The interactions of alpha(4) beta(1) integrin with vascular cell adhesion molecule (VCAM) and fibronectin play important roles in many physiological and pathological processes, To understand the mechanism of alpha(1) beta(1) integrin-mediated cell adhesion, we made mutant alpha(4) constructs, Three aspartic acid (Asp) residues in alpha(4), Asp 489, Asp-698, and Asp-811, were replaced with glutamic acids (Glu), The wild-type and mutant alpha(4) constructs were transfected into K562 cells, and stable transfectants with similar levels of alpha(4) surface expression were established, The Asp --> Glu substitutions did not affect alpha(4) beta(1) association or heterodimer formation as demonstrated by immunoprecipitation analysis. However, the glutamate substitutions at Asp-489 and Asp-698 severely impaired cell adhesion to VCAM and fibronectin, whereas the substitution at Asp-811 had no detectable effect on cell adhesion. In contrast to these results, isolated alpha(4) beta(1), containing the D489E or D698E substitution, was able to bind to VCAM, suggesting that these two residues are not critical for ligand recognition. In searching for a mechanism to explain inhibition of adhesion by Asp-489 and Asp 698 mutations, we found that the sequences flanking Asp 698 resemble the DxxxxxD-S-Sx divalent cation/ligand binding motif in beta integrins and the I-domains of alpha integrins. This suggests that Asp-698 in the alpha(4) integrin, which does not possess an I-domain, may also be involved in cation binding and may be part of a sequence functionally similar to that found in the I-domains of other alpha integrins.	BAYER RES CTR,INST BONE & JOINT DISORDERS & CANC,W HAVEN,CT 06516	Bayer AG			Ma, Lan/B-9295-2009	Ma, Lan/0000-0001-9034-5472				ABRAHAM WM, 1994, J CLIN INVEST, V93, P776, DOI 10.1172/JCI117032; AMIOT M, 1986, SCAND J IMMUNOL, V23, P109, DOI 10.1111/j.1365-3083.1986.tb01948.x; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BAO L, 1993, DIFFERENTIATION, V52, P239, DOI 10.1111/j.1432-0436.1993.tb00636.x; BLUE ML, 1993, IMMUNOLOGY, V78, P80; BURKLY LC, 1994, DIABETES, V43, P529, DOI 10.2337/diabetes.43.4.529; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; EDWARDS JG, 1988, J CELL SCI, V89, P507; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUANG X, 1994, MOL BIOL CELL, V4, pA283; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; MARKAREM R, 1994, J BIOL CHEM, V269, P4005; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; PULIDO R, 1991, J BIOL CHEM, V266, P10241; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WEBB DL, 1993, BIOCHEM BIOPH RES CO, V197, P674, DOI 10.1006/bbrc.1993.2532; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	38	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18401	18407		10.1074/jbc.270.31.18401	http://dx.doi.org/10.1074/jbc.270.31.18401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629165	hybrid			2022-12-25	WOS:A1995RM64200041
J	MILLER, VP; GOODIN, DB; FRIEDMAN, AE; HARTMANN, C; DEMONTELLANO, PRO				MILLER, VP; GOODIN, DB; FRIEDMAN, AE; HARTMANN, C; DEMONTELLANO, PRO			HORSERADISH-PEROXIDASE PHE(172)-]TYR MUTANT - SEQUENTIAL FORMATION OF COMPOUND-I WITH A PORPHYRIN RADICAL-CATION AND A PROTEIN RADICAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; SPERM WHALE MYOGLOBIN; LACTOPEROXIDASE-H2O2 COMPOUNDS; RIBONUCLEOTIDE REDUCTASE; LIGNIN PEROXIDASE; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; ACID; SITE; PH	A gene coding for the F172Y mutant of horseradish peroxidase isozyme C (HRP) has been constructed and expressed in both Spodoptera frugiperda (SF-9) and Trichoplusia ni egg cell homogenate (HighFive(R)) cells. Homology modeling with respect to three peroxidases for which crystal structures are available places Phe(172) on the proximal side of the heme in the vicinity of porphyrin pyrrole ring C. The pH optimum and spectroscopic properties of the F172Y mutant are essentially identical to those of wild type HRP. V-max values show that the mutant protein retains most of the guaiacol oxidizing activity. Stopped flow studies indicate that Compound I is formed with H2O2 at the same rate (k(1) = 1.6 x 10(7) M(-1) s(-1)) at both pH 6.0 and 8.0 as it is with the wild type enzyme. This Compound I species decays rapidly at a rate k(2) = 1.01 s(-1), pH 7.0, to a second two-electron oxidized species that retains the ferryl (Fe-IV = O) absorption. EPR studies establish that a ferryl porphyrin radical cation is present in the initial Compound I, but electron transfer from the protein results in formation of a second Compound I species with an unpaired electron on the protein (presumably on Tyr(172)). The presence or absence of oxidizable amino acids adjacent to the heme is thus a key determinant of whether the second oxidation equivalent in Compound I is found as a porphyrin or protein radical cation.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; JOHNSON & JOHNSON CLIN DIAGNOST, RES LABS, ROCHESTER, NY 14650 USA	University of California System; University of California San Francisco; Scripps Research Institute; Johnson & Johnson			Friedman, Alan/Q-4858-2018	Friedman, Alan/0000-0002-4764-8168	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488, R37GM041049, R01GM041049, R29GM041049] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41049, GM32488, R01 GM041049] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUNSGAARD L, 1993, EUR J BIOCHEM, V213, P605, DOI 10.1111/j.1432-1033.1993.tb17800.x; BELFORD RL, 1979, 2UST EPR S ROCK MOUN; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BOSSHARD HR, 1991, PEROXIDASES CHEM BIO, V2, P51; CHEN ZG, 1994, J AM CHEM SOC, V116, P8772, DOI 10.1021/ja00098a040; COURTIN F, 1984, BIOCHEM BIOPH RES CO, V121, P463, DOI 10.1016/0006-291X(84)90205-5; COURTIN F, 1982, EUR J BIOCHEM, V124, P603; DAVIES DM, 1976, BIOCHEM J, V157, P247, DOI 10.1042/bj1570247; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DEPILLIS GD, 1991, J BIOL CHEM, V266, P19334; DETTY MR, 1994, ORGANOMETALLICS, V13, P3338, DOI 10.1021/om00020a053; DOLMAN D, 1975, CAN J BIOCHEM CELL B, V53, P495, DOI 10.1139/o75-069; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; Everse J., 1991, PEROXIDASES CHEM BIO, V2; Everse J.E.K.E., 1991, PEROXIDASES CHEM BIO, VI; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FITZGERALD MM, 1994, BIOCHEMISTRY-US, V33, P3807, DOI 10.1021/bi00179a004; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; HARTMANN C, 1992, ARCH BIOCHEM BIOPHYS, V297, P61, DOI 10.1016/0003-9861(92)90641-9; HASCHKE RH, 1978, BIOCHEM BIOPH RES CO, V80, P1039, DOI 10.1016/0006-291X(78)91350-5; HENDERSON WR, 1991, PEROXIDASES CHEM BIO, V1, P106; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; HURST JK, 1991, PEROXIDASES CHEM BIO, V1, P37; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; MAGNUSSON RP, 1991, PEROXIDASES CHEM BIO, V1, P200; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; OZAKI S, 1995, IN PRESS J AM CHEM S; OZAKI SI, 1994, J AM CHEM SOC, V116, P4487, DOI 10.1021/ja00089a052; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1993, J BIOL CHEM, V268, P4429; SCHONBAUM GR, 1972, J BIOL CHEM, V247, P3353; SHIRO Y, 1986, J BIOL CHEM, V261, P9382; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; STILLMAN JS, 1975, BIOCHEMISTRY-US, V14, P3183, DOI 10.1021/bi00685a023; STOLL VS, 1990, METHOD ENZYMOL, V182, P24; TEW D, 1988, J BIOL CHEM, V263, P17880; THANABAL V, 1988, J AM CHEM SOC, V110, P3027, DOI 10.1021/ja00218a005; THANABAL V, 1987, J AM CHEM SOC, V109, P7516, DOI 10.1021/ja00258a043; VEITCH NC, 1990, EUR J BIOCHEM, V189, P351, DOI 10.1111/j.1432-1033.1990.tb15496.x; VIRION A, 1985, ARCH BIOCHEM BIOPHYS, V242, P41, DOI 10.1016/0003-9861(85)90477-1; WARNCKE K, 1994, J AM CHEM SOC, V116, P7332, DOI 10.1021/ja00095a042; WELINDER KG, 1985, EUR J BIOCHEM, V151, P497, DOI 10.1111/j.1432-1033.1985.tb09129.x; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; WILKS A, 1992, J BIOL CHEM, V267, P8827	49	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18413	18419		10.1074/jbc.270.31.18413	http://dx.doi.org/10.1074/jbc.270.31.18413			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629167	hybrid			2022-12-25	WOS:A1995RM64200043
J	OSTANIN, K; POKALSKY, C; WANG, S; VANETTEN, RL				OSTANIN, K; POKALSKY, C; WANG, S; VANETTEN, RL			CLONING AND CHARACTERIZATION OF A SACCHAROMYCES-CEREVISIAE GENE ENCODING THE LOW-MOLECULAR-WEIGHT PROTEIN-TYROSINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-PHOSPHATASE; BOVINE HEART; CATALYTIC MECHANISM; CDC25 PROTEIN; FISSION YEAST; PURIFICATION; LIVER; GROWTH; DEPHOSPHORYLATION; EXPRESSION	The low molecular weight protein tyrosine phosphatase (low M(r) PTPase) is an 18-kDa cytoplasmic enzyme of unknown function that has been previously found in several vertebrates, Using an oligonucleotide probe derived from the active site sequence of the mammalian low M(r) PTPases, a Saccharomyces cerevisiae gene that encodes a homolog of this enzyme was cloned by low stringency hybridization, This gene, LTP1, together with a neighboring gene, TKL1, is shown to be located on the right arm of chromosome XVI. The deduced amino acid sequence of its 161-amino acid residue product shows a 39% average identity with that of the mammalian enzymes. The yeast Ltp1 protein was expressed in Escherichia coli, purified to homogeneity, and shown to possess PTPase activity. The recombinant Ltp1 efficiently hydrolyzes phosphotyrosine and a phosphotyrosine-containing peptide, Tyr(531)-fyn, but it shows low activity toward phosphoserine and phosphothreonine. The catalytic activity of Ltp1 toward a number of substrates was approximately 30-fold lower than the corresponding values measured for the bovine low M(r) PTPase. However, the yeast enzyme was markedly activated by adenine and some purine nucleosides and nucleotides, including cAMP and cGMP. In the case of adenine, the activity of Ltp1 was increased by approximately 30-fold. The high degree of evolutionary conservation of the low M(r) PTPases implies a significant role for this enzyme. However, neither the disruption of the LTP1 gene nor an approximately 10-fold overexpression of its product in S. cerevisiae caused any apparent phenotypic changes under the conditions tested. No proteins related to Ltp1 could be detected in extracts of the ltp1 null mutant, either by immunoblotting or by gelfiltration analysis accompanied by extended kinetic assays, consistent with the conclusion that LTP1 is the only low M(r) PTPase-encoding gene in S. cerevisiae.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Wang, Shuishu/0000-0002-0865-4522	NIGMS NIH HHS [GM 27003] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BAXTER JH, 1985, ARCH BIOCHEM BIOPHYS, V239, P29, DOI 10.1016/0003-9861(85)90808-2; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; BOIVIN P, 1987, INT J BIOCHEM, V19, P613, DOI 10.1016/0020-711X(87)90227-8; Brady-Kalnay Susann, 1994, Trends in Cell Biology, V4, P73, DOI 10.1016/0962-8924(94)90172-4; CASELLI A, 1994, J PROTEIN CHEM, V13, P107, DOI 10.1007/BF01891998; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; DAVIS JP, 1994, J BIOL CHEM, V269, P8734; DAVIS JP, 1994, BIOCHEMISTRY-US, V33, P1278, DOI 10.1021/bi00171a031; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; DIPIETRO DL, 1967, J BIOL CHEM, V242, P3391; DISSING J, 1992, BIOCHIM BIOPHYS ACTA, V1121, P261, DOI 10.1016/0167-4838(92)90155-7; DISSING J, 1993, BIOCHIM BIOPHYS ACTA, V1162, P275, DOI 10.1016/0167-4838(93)90291-X; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FISHER EH, 1991, SCIENCE, V253, P401; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1992, J BIOL CHEM, V267, P10024; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANNIG G, 1993, YEAST, V9, P1039, DOI 10.1002/yea.320091002; HEINRIKSON RL, 1969, J BIOL CHEM, V244, P299; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAMES P, 1992, GENE, V122, P101, DOI 10.1016/0378-1119(92)90037-P; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAZARUK KDA, 1993, BIOCHEM BIOPH RES CO, V196, P440, DOI 10.1006/bbrc.1993.2269; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANAO G, 1992, J PROTEIN CHEM, V11, P333, DOI 10.1007/BF01024871; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MONDESERT O, 1994, J BIOL CHEM, V269, P27996; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OAKADA M, 1986, BIOCHEM J, V239, P155; OTA IM, 1992, P NATL ACAD SCI USA, V89, P2355, DOI 10.1073/pnas.89.6.2355; PANARA F, 1991, INT J BIOCHEM, V23, P1115, DOI 10.1016/0020-711X(91)90152-D; PANARA F, 1985, INT J BIOCHEM, V17, P1213, DOI 10.1016/0020-711X(85)90011-4; PANARA F, 1989, COMP BIOCHEM PHYS B, V92, P751, DOI 10.1016/0305-0491(89)90262-9; POKALSKY C, 1995, J BIOL CHEM, V270, P3809, DOI 10.1074/jbc.270.8.3809; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; RILES L, 1993, GENETICS, V134, P81; Rose MD., 1990, METHODS YEAST GENETI; RUGGIERO M, 1993, FEBS LETT, V326, P294, DOI 10.1016/0014-5793(93)81811-D; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; Sambrook J, 1989, MOL CLONING LABORATO; SPURR NK, 1994, KCYTOGENET CELL GENE, V67, P215; STEFANI M, 1993, FEBS LETT, V326, P131, DOI 10.1016/0014-5793(93)81776-V; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; SUNDSTROM M, 1993, J BIOL CHEM, V268, P24346; TABOR S, 1990, CURRENT PROTOCOL S11, V2; TAGA EM, 1982, ARCH BIOCHEM BIOPHYS, V214, P505, DOI 10.1016/0003-9861(82)90054-6; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WAHEED A, 1988, BIOCHEMISTRY-US, V27, P4265, DOI 10.1021/bi00412a010; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; WO YYP, 1992, J BIOL CHEM, V267, P10856; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C; ZHANG ZY, 1990, MECHANISTIC KINETIC	67	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18491	18499		10.1074/jbc.270.31.18491	http://dx.doi.org/10.1074/jbc.270.31.18491			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629177	hybrid			2022-12-25	WOS:A1995RM64200054
J	TAIRIS, N; GABRIEL, JL; SOPRANO, KJ; SOPRANO, DR				TAIRIS, N; GABRIEL, JL; SOPRANO, KJ; SOPRANO, DR			ALTERATION IN THE RETINOID SPECIFICITY OF RETINOIC ACID RECEPTOR-BETA BY SITE-DIRECTED MUTAGENESIS OF ARG(269) AND LYS(220)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; DIFFERENTIAL PATTERN; GAMMA; MOUSE; IDENTIFICATION; LIGAND; ALPHA; EXPRESSION; ISOFORMS; TRANSCRIPTION	Retinoic acid receptor-beta (RAR-beta) specifically binds retinoic acid (RA) and functions as a RA-inducible transcriptional regulatory factor. Simultaneous mutation of Arg(269) and Lys(220) of RAR-beta to Ala results in a dramatic reduction in both transactivation and affinity for RA along with creating a RA concentration-dependent dominant negative mutant. In this report, we found that mutation of these two amino acid residues singly and simultaneously to Gin results in mutant RAR-beta s, each displaying a more dramatic reduction in transactivation and affinity for RA than their corresponding Ala mutant, with the R269Q more profoundly affected than K220Q. Furthermore, we examined both the Ala and Gin mutants for their ability to transactivate and bind two other retinoids with different functional end groups (all-trans-retinol and all-trans-retinal). Mutation of Lys(220) to either an Ala or a Gin favors transactivation and binding of retinal, while mutation of either Lys(220) or Arg(269) to Gin favors retinol transactivation and binding. Taken together, these results suggest that Arg(269) and Lys(220) lie within the ligand binding pocket of RAR-beta and that these two amino acid residues play an important role in determining retinoid specificity most likely by directly interacting with the carboxylate group of RA.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Tairis, Nikolaos/W-9326-2019		NCI NIH HHS [CA64945] Funding Source: Medline; NICHD NIH HHS [HD01076] Funding Source: Medline; NIDDK NIH HHS [DK44517] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044517] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BENBROOK D, 1988, NATURE, V333, P444; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHENG L, 1991, J BIOL CHEM, V266, P24404; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GUDAS L, 1993, RETINOIDS, P443; HASHIMOTO Y, 1991, CELL STRUCT FUNCT, V16, P113, DOI 10.1247/csf.16.113; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; JETTEN AM, 1990, METHOD ENZYMOL, V189, P248; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KNEGTEL RMA, 1993, BIOCHEM BIOPH RES CO, V192, P492, DOI 10.1006/bbrc.1993.1442; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; MANGELSDORF DJ, 1993, RETINOIDS, P319; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NEWCOMER ME, 1993, P NATL ACAD SCI USA, V90, P9223, DOI 10.1073/pnas.90.19.9223; ONG DE, 1987, J BIOL CHEM, V262, P2729; ONG DE, 1978, J BIOL CHEM, V253, P4551; ONG DE, 1993, RETINOIDS, P283; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCATCHARD G, 1946, ANN NY ACAD SCI, V51, P660; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOPRANO DR, 1993, TOXICOL APPL PHARM, V122, P159, DOI 10.1006/taap.1993.1183; STUMP DG, 1991, J BIOL CHEM, V266, P4622; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	45	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18380	18387		10.1074/jbc.270.31.18380	http://dx.doi.org/10.1074/jbc.270.31.18380			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629162	hybrid			2022-12-25	WOS:A1995RM64200038
J	BALSALOBRE, A; JOLICOEUR, P				BALSALOBRE, A; JOLICOEUR, P			FOS PROTEINS CAN ACT AS NEGATIVE REGULATORS OF CELL-GROWTH INDEPENDENTLY OF THE FOS TRANSFORMING PATHWAY	ONCOGENE			English	Article						FOS; CELL CYCLE; CELL GROWTH	D-TYPE CYCLINS; RETINOBLASTOMA GENE-PRODUCT; C-FOS; DIFFERENTIAL EXPRESSION; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; ANTISENSE RNA; V-FOS; PHOSPHORYLATION; JUN	The proto-oncogene c-fos is known to be an important positive regulator of cell growth and notably of the G0/G1 transition. However, we observed that v-fos or c-fos-transformed rat-1 fibroblasts paradoxically had a low growth rate as compared to control untransformed rat-1 cells. We determined that this slow growth mainly reflects an increase of the G1 phase of the cell cycle (up to fourfold). In addition, the G0-->S progression of serum-starved fos-expressing rat-1 cells refed with serum was found to be also delayed as compared to rat-1 cells. The delayed G0-->S progression in fos-expressing cells was accompanied by the inappropriate levels or kinetics of expression of several cell cycle-regulated genes (cyclin D1, cdc2, cdk2, cdk4 and rb). Furthermore, a clear uncoupling of the pRb hyperphosphorylation with the entry into S phase was found in these fos-expressing rat-1 cells. Interestingly, the effect of the Fos proteins on the cell cycle was independent of the fos transforming pathway, indicating that the effector genes for Fos proteins are likely to be different for each process. In conclusion, our results indicate that Fos proteins may act as negative regulators of cell growth in some cell types, independently of the fos transforming pathway.	CLIN RES INST MONTREAL,MOLEC BIOL LAB,MONTREAL,PQ H2W 1R7,CANADA; UNIV MONTREAL,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3C 3J7,CANADA; MCGILL UNIV,DEPT EXPTL MED,MONTREAL,PQ H3G 1A4,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILED SJ, 1992, P NATL ACAD SCI USA, V89, P9306; FISHER C, 1991, DEVELOPMENT, V111, P253; GARRIDO C, 1993, ONCOGENE, V8, P2713; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holt J, 1992, Cancer Treat Res, V63, P301; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IBA H, 1988, ONCOGENE RES, V2, P121; JIANG X, 1994, MAMM GENOME, V5, P142, DOI 10.1007/BF00352344; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOLICOEUR P, 1992, J VIROL, V66, P3904, DOI 10.1128/JVI.66.6.3904-3908.1992; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER AD, 1984, CELL, V36, P51; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; MULLER R, 1983, EMBO J, V2, P679, DOI 10.1002/j.1460-2075.1983.tb01484.x; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OGRYZKO VV, 1994, J VIROL, V68, P3724, DOI 10.1128/JVI.68.6.3724-3732.1994; PARDEE A B, 1992, Current Opinion in Cell Biology, V4, P186, DOI 10.1016/0955-0674(92)90031-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEAR WS, 1993, P NATL ACAD SCI USA, V98, P8392; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; VANBEVEREN C, 1983, CELL, V32, P124; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	57	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					455	465						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630629				2022-12-25	WOS:A1995RN53000005
J	HENNIG, G; BEHRENS, J; TRUSS, M; FRISCH, S; REICHMANN, E; BIRCHMEIER, W				HENNIG, G; BEHRENS, J; TRUSS, M; FRISCH, S; REICHMANN, E; BIRCHMEIER, W			PROGRESSION OF CARCINOMA-CELLS IS ASSOCIATED WITH ALTERATIONS IN CHROMATIN STRUCTURE AND FACTOR-BINDING AT THE E-CADHERIN PROMOTER IN-VIVO	ONCOGENE			English	Article						E-CADHERIN PROMOTER; CARCINOMA PROGRESSION; IN VIVO FOOTPRINTING; GENE REGULATION; CHROMATIN STRUCTURE; DNA METHYLATION	LIGATION MEDIATED PCR; GENE-EXPRESSION; HYPERSENSITIVE SITES; ADHESION MOLECULE; DNA INTERACTIONS; INVIVO PROTEIN; METHYLATION; ACTIVATION; ENHANCER; IDENTIFICATION	E-cadherin has been identified as a tumor (invasion) suppressor gene, which is mutated in 50% of diffuse-type human gastric carcinomas. In other carcinomas, the expression of E-cadherin is down-regulated in the poorly differentiated cells such as from breast, bladder, lung and colon. We have here examined the in vivo properties of the genomic E-cadherin promoter in well and poorly differentiated carcinoma cell lines in order to gain insights into the mechanisms of E-cadherin downregulation in tumors. In vivo footprinting analysis revealed that positive regulatory elements of the E-cadherin promoter (a GC-rich region, the CCAAT-box and a palindromic element) are specifically bound by transcription factors in E-cadherin-expressing but not in non-expressing cells. The tested cell systems include more than a dozen carcinomas cell lines as well as mammary epithelial cells where E-cadherin expression can be switched off by activation of a Fos-estrogen receptor fusion protein and rhabdomyosarcoma cells where E-cadherin expression was induced by transfection with E1A. Mapping of DNase I hypersensitive sites showed that the chromatin structure in the promoter region is loosened in expressing but condensed in nonexpressing cells. Furthermore, the endogenous E-cadherin promoter is specifically methylated at CpG sites in the undifferentiated cells. We also show that the in vivo properties of the promoter in E-cadherin-negative carcinoma cells are similar as in mesenchymal cells, i.e. fibroblasts or sarcoma cells. These data suggest that silencing of the E-cadherin promoter during epithelial-mensenchymal transition and tumor progression is due to a loss of factor binding in vivo and to chromatin rearrangement in the regulatory region.	MAX DELBRUCK CENTRUM MOLEK MED,D-13125 BERLIN,GERMANY; INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Sanford Burnham Prebys Medical Discovery Institute; Swiss Institute Experimental Cancer Research								BECKER KF, 1994, CANCER RES, V54, P3845; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bienz Mariann, 1992, Current Opinion in Cell Biology, V4, P955, DOI 10.1016/0955-0674(92)90124-U; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BRABANT G, 1994, CANCER RES, V53, P4987; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DORUDI S, 1993, AM J PATHOL, V142, P981; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; LACRONIQUE V, 1992, NUCLEIC ACIDS RES, V20, P5669, DOI 10.1093/nar/20.21.5669; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; SALUZ HP, 1987, LABORATORY GUIDE GEN; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SORKIN BC, 1993, P NATL ACAD SCI USA, V90, P11356, DOI 10.1073/pnas.90.23.11356; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1994, CURR OPIN CELL BIOL, V5, P806; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VALLES AM, 1991, CELL MOTILITY FACTOR, P17; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WU C, 1978, J CELL BIOL, V79, P113	54	137	141	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					475	484						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630631				2022-12-25	WOS:A1995RN53000007
J	FAN, JQ; TAKEGAWA, K; IWAHARA, S; KONDO, A; KATO, I; ABEYGUNAWARDANA, C; LEE, YC				FAN, JQ; TAKEGAWA, K; IWAHARA, S; KONDO, A; KATO, I; ABEYGUNAWARDANA, C; LEE, YC			ENHANCED TRANSGLYCOSYLATION ACTIVITY OF ARTHROBACTER-PROTOPHORMIAE ENDO-BETA-N-ACETYLGLUCOSAMINIDASE IN MEDIA CONTAINING ORGANIC-SOLVENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC-SYNTHESIS; D-GALACTOSIDASE; SIMPLE STRATEGY; SUGAR CHAINS; PURIFICATION; GLYCOPROTEINS; SPECTROSCOPY; OLIGOSACCHARIDES; REGIOSELECTIVITY; DISACCHARIDES	The transglycosylation activity of endo beta-N-acetylglucosaminidase hom Arthrobacter protophormiae (endo-A) was enhanced by inclusion of organic solvents in the reaction mixture. In aqueous solution, the transglycosylation yield relative to starting substrate was 32% using Man(9)GlcNAc(2)Asn as donor and 0.5 M GlcNAc as acceptor. However, in the media containing 30% (v/v) acetone, dioxane, N,N-dimethylformamide, or dimethyl sulfoxide with 0.5 M GlcNAc as acceptor, the transglycosylation attained yields of 89, 13, 28, and 75% respectively, as analyzed by high performance anion exchange chromatography. The enzyme was stable in media containing up to 30% acetone, 30% dimethyl sulfoxide, or 20% N,N-dimethylformamide at 37 degrees C for at least 30 min. The acceptor (GlcNAc) concentration must be greater than 0.2 M for efficient transglycosylation. Electrospray mass spectrometry analysis of the transglycosylation product obtained in 30% acetone with Man(5)GlcNAc(2)Asn as donor and methyl alpha-2-acetamido-2-deoxy-D-glucopyranoside as acceptor showed a mass ion of m/z 1249.4, consistent with the expected molecular weight. Analysis by H-1 NMR of the product revealed that transglycosylation occurred at the C-4 of GlcNAc and the linkage was of the beta-configuration. In the acetone-containing me dium, Glc, Man, a deoxy-Glc, and methyl alpha-D-GlcNAc can serve as a good acceptor as GlcNAc. Less favorable accepters are xylose, fructose, 6-deoxy-Glc, and 3-O-methyl-D-glucose. On the other hand, GalNAc, Gal, allose, and 3-deoxy-Glc could not serve as accepters of the enzyme transglycosylation.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; KAGAWA UNIV, FAC AGR, DEPT BIORESOURCE SCI, KAGAWA, JAPAN; TAKARA SHUZO CO LTD, BIOTECHNOL RES LAB, OTSU, SHIGA 52021, JAPAN; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University; Kagawa University; Takara Holdings Inc.; Johns Hopkins University								ABEYGUNAWARDANA C, 1991, BIOCHEMISTRY-US, V30, P8568, DOI 10.1021/bi00099a012; AJISAKA K, 1989, CARBOHYD RES, V185, P139, DOI 10.1016/0008-6215(89)84029-7; ASHIDA H, 1993, ARCH BIOCHEM BIOPHYS, V305, P559, DOI 10.1006/abbi.1993.1461; BARDALES RM, 1989, J BIOL CHEM, V264, P19893; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; COHENANISFELD ST, 1993, J AM CHEM SOC, V115, P10531, DOI 10.1021/ja00076a010; DELMOTTE F, 1976, CR ACAD SCI D NAT, V283, P1121; FAN JQ, 1994, ANAL BIOCHEM, V219, P224, DOI 10.1006/abio.1994.1261; FAN JQ, 1995, J BIOL CHEM, V270, P17730, DOI 10.1074/jbc.270.30.17730; HEDBYS L, 1989, CARBOHYD RES, V186, P217, DOI 10.1016/0008-6215(89)84036-4; HITOMI J, 1985, J BIOCHEM-TOKYO, V98, P527, DOI 10.1093/oxfordjournals.jbchem.a135307; ICHIKAWA Y, 1992, ANAL BIOCHEM, V202, P215, DOI 10.1016/0003-2697(92)90099-S; INADA Y, 1986, TRENDS BIOTECHNOL, V4, P190, DOI 10.1016/0167-7799(86)90244-1; ITO K, 1993, J BIOL CHEM, V268, P16074; KADOWAKI S, 1991, J BIOCHEM-TOKYO, V110, P17, DOI 10.1093/oxfordjournals.jbchem.a123536; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V96, P1156, DOI 10.1016/0006-291X(80)90073-X; Lee Y. C., 1994, P3; LI YT, 1991, J BIOL CHEM, V266, P10723; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MATSUI I, 1994, BIOCHEMISTRY-US, V33, P451, DOI 10.1021/bi00168a009; MOREAU A, 1994, EUR J BIOCHEM, V219, P261, DOI 10.1111/j.1432-1033.1994.tb19937.x; MURAMATS.T, 1971, J BIOL CHEM, V246, P5534; NAKAMURA A, 1994, FEBS LETT, V337, P66, DOI 10.1016/0014-5793(94)80631-4; NILSSON K, 1984, BIOTECHNOL BIOENG, V26, P1146, DOI 10.1002/bit.260261003; Nilsson K. G. I., 1987, In 'Biocatalysis in organic media', edited by Laane, C. et al. Amsterdam, Netherlands; Elsevier Science Publishers BV. ISBN 0-444-42785-6 [see FSTA (1989) 21 8B67]., P369; NILSSON KGI, 1988, CARBOHYD RES, V180, P53, DOI 10.1016/0008-6215(88)80063-6; NILSSON KGI, 1987, CARBOHYD RES, V167, P95, DOI 10.1016/0008-6215(87)80271-9; NISHIGAK.M, 1974, BIOCHEM BIOPH RES CO, V59, P638, DOI 10.1016/S0006-291X(74)80027-6; OGATAARAKAWA M, 1977, J BIOCHEM-TOKYO, V82, P611; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SAKAI K, 1992, J CARBOHYD CHEM, V11, P553, DOI 10.1080/07328309208016148; SHINOYAMA H, 1988, AGR BIOL CHEM TOKYO, V52, P2375; SHINOYAMA H, 1988, AGR BIOL CHEM TOKYO, V52, P2197; TACHIBANA Y, 1982, ARCH BIOCHEM BIOPHYS, V214, P199, DOI 10.1016/0003-9861(82)90023-6; TAKEGAWA K, 1991, BIOCHEM INT, V24, P849; TAKEGAWA K, 1989, APPL ENVIRON MICROB, V55, P3107, DOI 10.1128/AEM.55.12.3107-3112.1989; TAKEGAWA K, 1995, J BIOL CHEM, V270, P3094, DOI 10.1074/jbc.270.7.3094; TAKEGAWA K, 1991, BIOCHEM INT, V25, P829; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TOONE EJ, 1989, TETRAHEDRON, V45, P5365, DOI 10.1016/S0040-4020(01)89487-4; TRIMBLE RB, 1986, J BIOL CHEM, V261, P2000; USUI T, 1993, CARBOHYD RES, V244, P315, DOI 10.1016/0008-6215(83)85010-1; USUI T, 1993, CARBOHYD RES, V250, P57, DOI 10.1016/0008-6215(93)84154-X; USUI T, 1988, J BIOCHEM-TOKYO, V103, P969, DOI 10.1093/oxfordjournals.jbchem.a122395; VANHALBEEK H, 1980, FEBS LETT, V121, P65; YAMAMOTO K, 1986, AGR BIOL CHEM TOKYO, V50, P421, DOI 10.1080/00021369.1986.10867399; YET MG, 1988, J BIOL CHEM, V263, P118	48	83	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17723	17729		10.1074/jbc.270.30.17723	http://dx.doi.org/10.1074/jbc.270.30.17723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629071	hybrid			2022-12-25	WOS:A1995RM26600017
J	GARCIARAMIREZ, M; ROCCHINI, C; AUSIO, J				GARCIARAMIREZ, M; ROCCHINI, C; AUSIO, J			MODULATION OF CHROMATIN FOLDING BY HISTONE ACETYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; TRANSCRIPTIONALLY ACTIVE CHROMATIN; HYPERACETYLATION; DNA; OLIGONUCLEOSOMES; DYNAMICS; PROTEINS; NUCLEI; TAILS	A homogeneous oligonucleosome complex was prepared by reconstitution of highly hyperacetylated histone octamers onto a linear DNA template consisting of 12 tandemly arranged 208-base pair fragments of the 5 S rRNA gene from the sea urchin Lytechinus variegatus. The ionic strength-dependent folding of this oligonucleosome assembly was monitored by sedimentation velocity and electron microscopy. Both types of analysis indicate that under ionic conditions resembling those found in the physiological range and in the absence of histone H1, the acetylated oligonucleosome complexes remain in an extended conformation in contrast to their nonacetylated counterparts. The implications of this finding in the context of a multistate model of chromatin folding (Hansen, J. C., and Ausio, J. (1992) TIBS 197, 187-191) as well as its biological relevance are discussed.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA,BC V8W 3P6,CANADA; HOSP DURAN REYNALS,INST RECERCA ONCOL,GEN CATALUNYA,E-08907 BARCELONA,SPAIN	University of Victoria; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals				Garcia-Ramirez, Marta/0000-0003-4249-7177				ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; AUSIO J, 1992, J CELL SCI, V102, P1; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; BAUER WR, 1994, J MOL BIOL, V236, P685, DOI 10.1006/jmbi.1994.1180; BERTRAND E, 1984, ARCH BIOCHEM BIOPHYS, V229, P395, DOI 10.1016/0003-9861(84)90167-X; BODE J, 1983, EUR J BIOCHEM, V130, P437, DOI 10.1111/j.1432-1033.1983.tb07170.x; BODE J, 1980, EUR J BIOCHEM, V110, P143, DOI 10.1111/j.1432-1033.1980.tb04849.x; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Cavalier- Smith T, 1981, SOC GEN MICROBIOL S, V32, P33; CAVALIERSMITH T, 1988, BIOESSAYS, V9, P72, DOI 10.1002/bies.950090209; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; DIMITROV S, 1986, FEBS LETT, V197, P217, DOI 10.1016/0014-5793(86)80329-5; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GRIGORYEV SA, 1990, NUCLEIC ACIDS RES, V18, P7397, DOI 10.1093/nar/18.24.7397; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HANSEN JC, 1992, TRENDS BIOCHEM SCI, V17, P187, DOI 10.1016/0968-0004(92)90264-A; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; IMAI BS, 1986, J BIOL CHEM, V261, P8784; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; LABHART P, 1981, EUR J CELL BIOL, V24, P309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; LIBERTINI LJ, 1988, BIOPHYS J, V53, P477, DOI 10.1016/S0006-3495(88)83126-6; LUTTER LC, 1992, MOL CELL BIOL, V12, P5004, DOI 10.1128/MCB.12.11.5004; Maniatis T., 1982, MOL CLONING; MCGHEE JD, 1983, NUCLEIC ACIDS RES, V11, P4065, DOI 10.1093/nar/11.12.4065; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PERRY CA, 1991, EXP CELL RES, V196, P337, DOI 10.1016/0014-4827(91)90269-Z; POGO BGT, 1966, P NATL ACAD SCI USA, V55, P805, DOI 10.1073/pnas.55.4.805; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; SIMPSON RT, 1978, CELL, V13, P691, DOI 10.1016/0092-8674(78)90219-2; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1979, J BIOL CHEM, V254, P123; TURNER BM, 1991, J CELL SCI, V99, P13; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; WEISCHET WO, 1978, NUCLEIC ACIDS RES, V5, P139, DOI 10.1093/nar/5.1.139; WOLFFE AP, 1992, FASEB J, V6, P3354, DOI 10.1096/fasebj.6.15.1464369; YAO J, 1990, P NATL ACAD SCI USA, V87, P7603, DOI 10.1073/pnas.87.19.7603; ZLANATOVA J, 1992, J CELL SCI, V103, P889	48	274	278	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17923	17928		10.1074/jbc.270.30.17923	http://dx.doi.org/10.1074/jbc.270.30.17923			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629098	hybrid			2022-12-25	WOS:A1995RM26600047
J	REIKERSTORFER, A; HOLZ, H; STUNNENBERG, HG; BUSSLINGER, M				REIKERSTORFER, A; HOLZ, H; STUNNENBERG, HG; BUSSLINGER, M			LOW-AFFINITY BINDING OF INTERLEUKIN-1-BETA AND INTRACELLULAR SIGNALING VIA NF-KAPPA-B IDENTIFY FIT-1 AS A DISTANT MEMBER OF THE INTERLEUKIN-1 RECEPTOR FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IL-1 RECEPTOR; SOLUBLE RECEPTOR; VACCINIA VIRUS; PROTEIN; GENE; EXPRESSION; DROSOPHILA; IDENTIFICATION; TRANSFORMATION; PURIFICATION	The fit-1 gene gives rise to two different mRNA isoforms, which code for soluble (Fit-1S) and membrane-bound (Fit-1M) proteins related to the type I interleukin (IL)-1 receptor. To investigate IL-1 binding, we have synthesized and purified histidine-tagged polypeptides corresponding to Fit-1S and the extracellular domain of the type I IL-1 receptor using a vaccinia expression system. Fit-1S is shown to interact with IL-1 beta, but not with IL-1 alpha. However, Fit-1S binds IL-1 beta only with low affinity in contrast to the IL-1 receptor, suggesting that IL-1 beta is not a physiological ligand of Fit-1S. Moreover, expression of the membrane-bound protein Fit-1M in transiently transfected Jurkat cells did not result in activation of the transcription factor NF-kappa B following IL-1 beta treatment. However, a chimeric protein consisting of the extracellular domain of the type I IL-1 receptor and of the transmembrane and intracellular regions of Fit-1M stimulated NF-kappa B-dependent transcription as efficiently as the full-length type I IL-1 receptor. These data indicate that Fit-1M is a signaling molecule belonging to the IL-1 receptor family.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); European Molecular Biology Laboratory (EMBL)			Stunnenberg, Hendrik G./D-6875-2012; Busslinger, Meinrad J./J-1249-2016	Stunnenberg, Hendrik G./0000-0002-0066-1576; Busslinger, Meinrad J./0000-0002-9111-9351				ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; BERGERS G, 1994, EMBO J, V13, P176; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BRADFORD M, 1906, ANAL BIOCHEM, V72, P248; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DINARELLO CA, 1991, CYTOKINE HDB, P47; DOWER SK, 1989, J IMMUNOL, V142, P4314; EASTGATE JA, 1990, FEBS LETT, V260, P213, DOI 10.1016/0014-5793(90)80106-S; FRESHNEY NWW, 1994, CELL, V78, P103; GIRI JG, 1990, J BIOL CHEM, V265, P17416; HART RP, 1993, J NEUROIMMUNOL, V44, P49, DOI 10.1016/0165-5728(93)90267-3; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KUNO K, 1993, J BIOL CHEM, V268, P13510; LEUNG KY, 1994, J BIOL CHEM, V269, P1579; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; NISHIDA T, 1988, P73; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLACK J, 1993, J BIOL CHEM, V268, P2513; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; SYMONS J A, 1990, Cytokine, V2, P190, DOI 10.1016/1043-4666(90)90015-L; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	33	24	28	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17645	17648		10.1074/jbc.270.30.17645	http://dx.doi.org/10.1074/jbc.270.30.17645			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629057	hybrid, Green Accepted			2022-12-25	WOS:A1995RM26600002
J	VIDAL, M; HOEKSTRA, D				VIDAL, M; HOEKSTRA, D			IN-VITRO FUSION OF RETICULOCYTE ENDOCYTIC VESICLES WITH LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOSOME-ENDOSOME FUSION; MEMBRANE-FUSION; TRANSFERRIN RECEPTOR; VESICULAR TRANSPORT; SENDAI VIRUS; PROTEIN; REQUIRES; INVITRO; INHIBITORS; EXOCYTOSIS	Since reticulocytes have a high demand for iron, which is required for heme biosynthesis, these cells are highly specialized in the endocytosis of the iron carrier transferrin (Tf). From the resulting endocytic vesicles (EVs), iron is released and the vesicles rapidly return to the cell membrane where they fuse, causing the release of the apotransferrin. Due to a lack of other intracellular compartments, the endocytic vesicles can be readily isolated. In this study, we have investigated the fusogenic properties of EVs, using liposomes as target membranes. Membrane fusion was monitored by a lipid mixing assay based on the relief of fluorescence self-quenching, using octadecylrhodamine B-chloride (R18). Application of this procedure was verified and solidified by analysis of the fusion event by an independent lipid mixing assay, after in situ labeling of EVs, and by determination of the mixing of aqueous contents. We demonstrate that the endocytic vesicles are particularly prone to fuse with target membranes that contain dioleoylphosphatidylethanolamine (DOPE). Relative to DOPE, bilayers composed of phosphatidylserine or phosphatidylcholine show a reduced fusion activity with EV. The specific and strong inhibition of fusion by cyclosporin A and a peptide known to interfere with the propensity of DOPE to adopt the hexagonal HII phase suggests that the mechanism of fusion involves the ability of this lipid to readily adopt non-bilayer phases. ATP, GTP, and/or cytosol are not necessary to obtain fusion. However, trypsin treatment of the endocytic vesicles inhibits fusion, indicating the involvement of (a) protein(s) in the fusion event.	UNIV GRONINGEN,PHYSIOL CHEM LAB,9712 KZ GRONINGEN,NETHERLANDS	University of Groningen	VIDAL, M (corresponding author), UNIV MONTPELLIER 2,CNRS,URA 1856,PL E BATAILLON,CC 107,F-34095 MONTPELLIER,FRANCE.							ADAM M, 1986, J CELL PHYSIOL, V127, P8, DOI 10.1002/jcp.1041270103; ARTS EGJM, 1993, EUR J BIOCHEM, V217, P1001, DOI 10.1111/j.1432-1033.1993.tb18331.x; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BECK KA, 1992, J CELL BIOL, V119, P787, DOI 10.1083/jcb.119.4.787; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BETTEBOBILLO P, 1995, EUR J BIOCHEM, V228, P199, DOI 10.1111/j.1432-1033.1995.0199o.x; COLOMBO MI, 1991, J BIOL CHEM, V266, P23438; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EPAND RM, 1993, BIOCHIM BIOPHYS ACTA, V1152, P128, DOI 10.1016/0005-2736(93)90239-V; EPAND RM, 1987, J BIOL CHEM, V262, P1526; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GRASSO JA, 1990, BIOCHEM J, V266, P261, DOI 10.1042/bj2660261; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HOEKSTRA D, 1982, BIOCHEMISTRY-US, V21, P6097, DOI 10.1021/bi00267a011; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; KAGIWADA S, 1993, J BIOL CHEM, V268, P1430; KELSEY DR, 1990, J BIOL CHEM, V265, P12178; KLAPPE K, 1986, BIOCHEMISTRY-US, V25, P8252, DOI 10.1021/bi00373a019; KOK JW, 1990, EUR J CELL BIOL, V53, P173; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LENHARD JM, 1994, ARCH BIOCHEM BIOPHYS, V312, P474, DOI 10.1006/abbi.1994.1334; MARTIN I, 1992, ADV MEMBRANE FLUIDIT, V6, P365; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MULLOCK BM, 1994, J CELL BIOL, V126, P1173, DOI 10.1083/jcb.126.5.1173; PITT A, 1991, EUR J CELL BIOL, V55, P328; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; RAPOPORT SM, 1991, BLOOD CELL BIOCH ERY, P151; RUTLEDGE EA, 1991, J BIOL CHEM, V266, P21125; SCHEULE RK, 1986, BIOCHEMISTRY-US, V25, P4223, DOI 10.1021/bi00363a009; SIEGEL DP, 1986, BIOPHYS J, V49, P1171, DOI 10.1016/S0006-3495(86)83745-6; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STECK TL, 1973, J SUPRAMOL STRUCT, V1, P221; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STROUS GJ, 1988, J BIOL CHEM, V263, P18197; Sztul Elizabeth S., 1992, Trends in Cell Biology, V2, P381, DOI 10.1016/0962-8924(92)90051-N; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TOURNOIS H, 1987, BIOCHEMISTRY-US, V26, P6613, DOI 10.1021/bi00395a008; VIDAL MJ, 1993, EUR J CELL BIOL, V60, P261; VOGEL SS, 1992, J BIOL CHEM, V267, P25640; WASCHULEWSKI IH, 1993, BRIT J PHARMACOL, V108, P892, DOI 10.1111/j.1476-5381.1993.tb13483.x; YEAGLE PL, 1992, BIOCHEMISTRY-US, V31, P3177, DOI 10.1021/bi00127a019; ZAAL KJM, 1994, EUR J CELL BIOL, V63, P10	44	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17823	17829		10.1074/jbc.270.30.17823	http://dx.doi.org/10.1074/jbc.270.30.17823			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629083	hybrid			2022-12-25	WOS:A1995RM26600031
J	WANG, YL; KENT, C				WANG, YL; KENT, C			EFFECTS OF ALTERED PHOSPHORYLATION SITES ON THE PROPERTIES OF CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHOLIPASE-C TREATMENT; MEMBRANE-ASSOCIATED CTP; HEP G2 CELLS; FATTY-ACIDS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; HELA-CELLS; MAMMALIAN-CELLS; RAT-LIVER	To investigate the role of phosphorylation and dephosphorylation in modulating the activity and location of CTP:phosphocholine cytidylyltransferase, we used site-directed mutagenesis to construct four mutant forms of cytidylyltransferase. These forms were 5SP --> AP, in which five of the seven Ser-Pro sequences were converted to Ala-Pro; 7SP --> AP, in which all of the seven Ser-Pro sequences converted to Ala-Pro; 16S --> A, in which all sixteen Ser residues that can be phosphorylated in wild type cytidylyltransferase were converted to Ala; and 16S --> E, in which all sixteen Ser residues were converted to Glu. The mutant enzymes were expressed in the strain 58 Chinese hamster ovary cell line, which is temperature-sensitive for growth and cytidylyltransferase activity. All mutant enzyme forms were enzymatically as active as the wild type when assayed under optimal conditions. In untreated cells, more of the Ser --> Ala mutants were membrane-associated than in cells expressing wild type enzyme, consistent with the phosphorylation state of the enzyme affecting its affinity for membranes. About half of the 16S --> A mutant remained soluble, however, indicating that dephosphorylation alone does not trigger membrane association. Although the amount of membrane-associated enzyme in the 16S --> A mutant was about 10-fold greater than that of wild type, phosphatidylcholine synthesis was increased by only about 75%, suggesting that membrane association does not necessarily cause full activation. Ah mutant forms, including the 16S --> E mutant, translocated to the particulate fraction upon oleate treatment, indicating that a high negative charge in the phosphorylation region does not preclude association of cytidylyltransferase with membranes. Ah mutant enzymes were able to support growth of strain 58 at 40 degrees C, and the rate of phosphatidylcholine synthesis was not greatly altered in the cell lines expressing mutant cytidylyltransferase forms, These results are consistent with a role for phosphorylation in the equilibrium distribution of cytidylyltransferase but suggest that changes in enzyme activity and location are not triggered exclusively by changes in the phosphorylation state.	UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA064159] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCI NIH HHS [CA64159] Funding Source: Medline; NCRR NIH HHS [M01RR00042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAIG L, 1994, J BIOL CHEM, V269, P3311; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FELDMAN DA, 1980, BIOCHIM BIOPHYS ACTA, V620, P603, DOI 10.1016/0005-2760(80)90152-6; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MORAND JN, 1989, J BIOL CHEM, V264, P13785; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1983, J BIOL CHEM, V258, P6782; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; WEINHOLD PA, 1994, BBA-LIPID LIPID MET, V1210, P335, DOI 10.1016/0005-2760(94)90238-0; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; WHITLON DS, 1985, BIOCHIM BIOPHYS ACTA, V835, P369, DOI 10.1016/0005-2760(85)90293-0	32	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17843	17849		10.1074/jbc.270.30.17843	http://dx.doi.org/10.1074/jbc.270.30.17843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629086	hybrid			2022-12-25	WOS:A1995RM26600034
J	AGNEW, BJ; MINAMIDE, LS; BAMBURG, JR				AGNEW, BJ; MINAMIDE, LS; BAMBURG, JR			REACTIVATION OF PHOSPHORYLATED ACTIN DEPOLYMERIZING FACTOR AND IDENTIFICATION OF THE REGULATORY SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; NUCLEAR TRANSPORT; CULTURED-CELLS; PORCINE BRAIN; CHICK BRAIN; COFILIN; PROTEINS; SEQUENCE; MUSCLE; CDNA	Actin depolymerizing factor (ADF) occurs naturally in two forms, one of which contains a phosphorylated Ser and does not bind G-actin or depolymerize F-actin. Removal of this phosphate in vitro by alkaline phosphatase restores full F-actin depolymerizing activity. To identify the phosphorylation site, [P-32]pADF was purified and digested with endoproteinase Lys-C. The digest contained only one P-32-labeled peptide. Further digestion with endoproteinase Asp-N and mass spectrometric analysis showed that this peptide came from the N terminus of ADF. Alkaline phosphatase treatment of one Asp-N peptide (mass 753) converted it to a peptide of mass 673, demonstrating that this peptide contains the phosphate group. Tandem mass spectrometric sequence analysis of this peptide identified the phosphorylated Ser as the encoded Ser(3) (Ser(2) in the processed protein). HeLa cells, transfected with either chick wild-type ADF cDNA or a cDNA mutated to code for Ala in place of Ser(24) or Thr(25), express and phosphorylate the exogenous ADF. Cells also expressed high levels of mutant ADF when Ser(3) was deleted or converted to either Ala or Glu. However, none of these mutants was phosphorylated, confirming that Ser(3) in the encoded ADF is the single in vivo regulatory site.	COLORADO STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, FT COLLINS, CO 80523 USA; COLORADO STATE UNIV, PROGRAM NEURONAL GROWTH & DEV, FT COLLINS, CO 80523 USA	Colorado State University; Colorado State University					FIC NIH HHS [TW01856] Funding Source: Medline; NCRR NIH HHS [RR06217] Funding Source: Medline; NIGMS NIH HHS [GM35126, R01 GM035126] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW001856] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035126] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; BAMBURG JR, 1991, METHOD ENZYMOL, V196, P125; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; GIULIANO KA, 1988, BIOCHEMISTRY-US, V27, P8931, DOI 10.1021/bi00425a009; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARRIS HE, 1982, ANAL BIOCHEM, V119, P102, DOI 10.1016/0003-2697(82)90672-8; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIM SR, 1993, PLANT MOL BIOL, V21, P39, DOI 10.1007/BF00039616; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; MORIYAMA K, 1990, J BIOL CHEM, V265, P5771; NELLES LP, 1976, ANAL BIOCHEM, V73, P522, DOI 10.1016/0003-2697(76)90202-5; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OHTA Y, 1989, J BIOL CHEM, V264, P16143; ONO S, 1993, J MUSCLE RES CELL M, V14, P195, DOI 10.1007/BF00115454; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; QUIRK S, 1993, BIOCHEMISTRY-US, V32, P8525, DOI 10.1021/bi00084a019; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; Sambrook J, 1989, MOL CLONING LABORATO; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; SWIDERIK KM, 1995, IN PRESS METHODS ENZ; TAKAGI T, 1988, J BIOL CHEM, V263, P3097; WALSH DA, 1991, PHYSIOL REV, V71, P285, DOI 10.1152/physrev.1991.71.1.285; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410	51	308	315	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17582	17587		10.1074/jbc.270.29.17582	http://dx.doi.org/10.1074/jbc.270.29.17582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615564	hybrid			2022-12-25	WOS:A1995RK68900081
J	KANTOROW, M; HORWITZ, J; VANBOEKEL, MAM; DEJONG, WW; PIATIGORSKY, J				KANTOROW, M; HORWITZ, J; VANBOEKEL, MAM; DEJONG, WW; PIATIGORSKY, J			CONVERSION FROM OLIGOMERS TO TETRAMERS ENHANCES AUTOPHOSPHORYLATION BY LENS ALPHA-A-CRYSTALLIN - SPECIFICITY BETWEEN ALPHA-A AND ALPHA-B-CRYSTALLIN SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CREUTZFELDT-JAKOB DISEASE; NONLENTICULAR TISSUES; PHOSPHORYLATION SITES; BOVINE LENS; EXPRESSION; UBIQUITIN; GENE; CHAPERONES; EVOLUTION	Previously we showed that cu crystallins are autophosphorylated (Kantorow, M., and Piatigorsky, J. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 3112-3116), Here we report that addition of 1% deoxycholate converted alpha A-crystallin aggregates into 80-kDa tetramers which were 16-fold more active for autophosphorylation, Circular dichroism (CD) spectra of alpha-crystallin revealed little or no change in secondary and tertiary structures in 1% deoxycholate, alpha A2D, a truncated form of bovine alpha A that exists as a tetramer, was as active for autophosphorylation in the absence of deoxycholate as intact alpha A was in the presence of deoxycholate, At least one serine between amino acids 131 and 145 of bovine alpha A was auto phosphorylated in peptide mapping experiments, Chicken alpha A-crystallin, which lacks the Ser-122 cAMP-dependent kinase site of bovine alpha A, was also autophosphorylated in the presence of deoxycholate, In contrast to alpha A crystallin, autophosphorylation by alpha B-crystallin was not activated by deoxycholate despite its conversion to a tetrameric form, and alpha B was also more efficiently phosphorylated by cAMP-dependent kinase than alpha A, These data suggest metabolic differences between the alpha-crystallin subunits that may be related to specific expression of alpha A in the lens and ubiquitous expression of alpha B in numerous normal and diseased tissues.	NEI, MOLEC & DEV BIOL LAB, BETHESDA, MD 20892 USA; UNIV CALIF LOS ANGELES, SCH MED, JULES STEIN EYE INST, LOS ANGELES, CA 90024 USA; UNIV NIJMEGEN, DEPT BIOCHEM, 6525 EK NIJMEGEN, NETHERLANDS	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Radboud University Nijmegen					NATIONAL EYE INSTITUTE [R01EY009683] Funding Source: NIH RePORTER; NEI NIH HHS [EY03879, EYO9683] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AUGUSTEYN RC, 1992, EXP EYE RES, V54, P219, DOI 10.1016/S0014-4835(05)80211-8; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BLOEMENDAL H, 1991, PROG NUCLEIC ACID RE, V41, P259; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; CHIESA R, 1988, EXP EYE RES, V46, P199, DOI 10.1016/S0014-4835(88)80077-0; CHIESA R, 1987, J BIOL CHEM, V262, P1438; CHIESA R, 1990, FEBS LETT, V268, P222, DOI 10.1016/0014-5793(90)81013-E; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1991, KIDNEY INT, V40, P52, DOI 10.1038/ki.1991.178; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; IWAKI T, 1991, AM J PATHOL, V139, P1303; IWAKI T, 1991, CANCER, V68, P2230, DOI 10.1002/1097-0142(19911115)68:10<2230::AID-CNCR2820681023>3.0.CO;2-7; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KATO K, 1992, J BIOL CHEM, V267, P7718; KATO S, 1992, ACTA NEUROPATHOL, V84, P443; KLEIMAN NJ, 1988, J BIOL CHEM, V263, P14978; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LANDRY J, 1992, J BIOL CHEM, V267, P794; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; MULDERS JWM, 1985, EUR J BIOCHEM, V152, P721, DOI 10.1111/j.1432-1033.1985.tb09253.x; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; PALMISANO DV, 1995, BBA-PROTEIN STRUCT M, V1246, P91, DOI 10.1016/0167-4838(94)00176-H; REDDY MC, 1992, BIOCHEM BIOPH RES CO, V189, P1578, DOI 10.1016/0006-291X(92)90256-K; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAX CM, 1993, ADV ENZYMOL RAMB, V69, P155; SCOTTING P, 1991, FEBS LETT, V285, P75, DOI 10.1016/0014-5793(91)80728-L; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; SREDY J, 1984, EXP EYE RES, V39, P653, DOI 10.1016/0014-4835(84)90064-2; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STOKOE D, 1992, FEBS LETT, V309, P111; TAWA P, 1994, BIOCHEMISTRY-US, V33, P7917, DOI 10.1021/bi00191a019; TOMOKANE N, 1991, AM J PATHOL, V138, P875; VANHAERINGEN B, 1993, EUR J BIOCHEM, V217, P143; VOORTER CEM, 1989, FEBS LETT, V259, P50; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	60	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17215	17220		10.1074/jbc.270.29.17215	http://dx.doi.org/10.1074/jbc.270.29.17215			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615520	hybrid			2022-12-25	WOS:A1995RK68900027
J	MIRZA, UA; CHAIT, BT; LANDER, HM				MIRZA, UA; CHAIT, BT; LANDER, HM			MONITORING REACTIONS OF NITRIC-OXIDE WITH PEPTIDES AND PROTEINS BY ELECTROSPRAY-IONIZATION MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; ACTIVATION; CELLS	Recent studies have demonstrated the biological importance of the interaction of nitric oxide (NO) with proteins, Protein-associated targets of NO include heme, Cys, and Tyr. Electrospray ionization-mass spectrometry was used to monitor the results of exposure of model peptides and an enzyme to NO under different conditions and thus addressed aspects of NO-protein interactions, The molecular mass of a decapeptide containing a single Cys residue increased by 29 Da upon treatment with NO under aerobic and acidic conditions, consistent with the substitution of one NO moiety, The mass of reduced somatostatin, a peptide containing two Cys residues, increased by 58 Da, consistent with the substitution of two NO moieties, These substitutions were prevented by pretreatment of the peptides with N-ethylmaleimide. The strength of the nitrosothiol bond was examined by varying the amount of energy applied to the peptide ions and indicated a labile species, Cys residues were very rapidly nitrosated, while other reactions were observed to occur at much slower rates, These include the further oxidation of nitrosothiol to sulfonic acid and nitration of Tyr, Peptides treated with NO at physiological pH were observed to undergo dimerization as well as nitrosation. These studies were extended to the enzyme p21(ras), whose activity has been postulated to be modulated by nitrosothiol formation, and revealed the formation of a single nitrosothiol on p21(ras) upon NO treatment, These data suggest that electrospray ionization-mass spectrometry allows for quantitation and characterization of nitrosothiol bonds in peptides and proteins.	CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021	Cornell University; Rockefeller University					NCRR NIH HHS [RR00862] Funding Source: Medline; NIAID NIH HHS [AI37637] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037637] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHOWDHURY SK, 1990, RAPID COMMUN MASS SP, V4, P81, DOI 10.1002/rcm.1290040305; DERUBERTIS FR, 1976, SCIENCE, V193, P897, DOI 10.1126/science.7837; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; HAJJAR DP, 1995, J AM CHEM SOC, V17, P3340; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OAE S, 1978, J CHEM SOC PERK T 1, P913, DOI 10.1039/p19780000913; PARTIS MD, 1983, J PROTEIN CHEM, V2, P263, DOI 10.1007/BF01025358; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0	20	100	101	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17185	17188		10.1074/jbc.270.29.17185	http://dx.doi.org/10.1074/jbc.270.29.17185			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615515	hybrid			2022-12-25	WOS:A1995RK68900022
J	MULLINS, C; LU, YQ; CAMPBELL, A; FANG, H; GREEN, N				MULLINS, C; LU, YQ; CAMPBELL, A; FANG, H; GREEN, N			A MUTATION AFFECTING SIGNAL PEPTIDASE INHIBITS DEGRADATION OF AN ABNORMAL MEMBRANE-PROTEIN IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-SEQUENCE; SEC11 PROTEIN; TRANSLOCATION; TRANSPORT; COMPLEX; GENE; PURIFICATION; INSERTION	Signal peptidase removes amino terminal signal peptides from precursor proteins during or immediately following their translocation to the lumen of the endoplasmic reticulum (ER) and may participate in ER degradation, a poorly defined process whereby abnormal proteins are rapidly degraded early in the secretory pathway. Here, the involvement of signal peptidase in ER degradation is examined through the use of two chimeric membrane proteins that lack amino-terminal signal peptides: A18BinvHD, which contains sequences derived from arginine permease and histidinol dehydrogenase, and AHDK2, containing the ER-resident protein Kar2p fused to the carboxyl terminus of A189invHD, Degradation of approximately 95% of A189invHD is observed in yeast cells expressing enzymatically active signal peptidase, whereas only 60% undergoes rapid degradation in a sec11 mutant bearing a temperature-sensitive mutation in the gene encoding the 18-kDa subunit (Sec11p) of the signal peptidase complex, AHDR2 is proteolyzed in a reaction yielding at least two fragments in wild-type cells and in the sec11 mutant containing a plasmid bearing the SEC11 gene, The proteolytic reaction is catalyzed in a temperature-dependent manner in the sec11 mutant, with AHDK2 remaining stable at the nonpermissive temperature, Using conditional mutants defective in protein translocation into and out of the ER and in vitro protease protection studies, the site of degradation for AHDK2 is localized to the ER lumen, The data therefore indicate (i) A189invHD is degraded through both signal peptidase-dependent and independent processes; (ii) signal peptidase, specifically the Sec11p subunit, is required for the proteolysis of AHDK2; and (iii) the Kar2 fragment at the carboxyl terminus of AHDK2 permits detection of proteolytic intermediates.			MULLINS, C (corresponding author), VANDERBILT UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, NASHVILLE, TN 37232 USA.				NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NCI NIH HHS [2 T32 CA09385-11] Funding Source: Medline; NCRR NIH HHS [RR-05424] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; DONAHUE TF, 1982, GENE, V18, P47, DOI 10.1016/0378-1119(82)90055-5; DUNN B, 1994, CURRENT PROTOCOLS MO; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FANG H, 1994, MOL BIOL CELL, V5, P933, DOI 10.1091/mbc.5.9.933; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GREEN GN, 1989, J CELL SCI, P109; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LILJESTROM P, 1991, J VIROL, V65, P147; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; STRAUSS AW, 1979, P NATL ACAD SCI USA, V76, P4225, DOI 10.1073/pnas.76.9.4225; TAUSSIG R, 1983, NUCLEIC ACIDS RES, V11, P1943, DOI 10.1093/nar/11.6.1943; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735	37	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17139	17147		10.1074/jbc.270.29.17139	http://dx.doi.org/10.1074/jbc.270.29.17139			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615509	hybrid			2022-12-25	WOS:A1995RK68900016
J	SCHAPER, S; MESSER, W				SCHAPER, S; MESSER, W			INTERACTION OF THE INITIATOR PROTEIN DNAA OF ESCHERICHIA-COLI WITH ITS DNA TARGET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION ORIGIN; GEL RETARDATION; AUTO-REGULATION; CHROMOSOME; INVITRO; SEQUENCE; BINDING; SITES; GENE; COMPLEXES	Equilibrium and kinetic rate constants were determined for the binding of the initiator protein DnaA of Escherichia coli to its binding site, the non-palindromic 9-bp DnaA box, using gel retardation techniques. The dissociation constant for specific binding was between 1 and 50 nM for individual DnaA boxes on 21-bp double-stranded oligonucleotides. Only DnaA boxes of the sequence TT(A/T)TNCACA resulted in specific fragment retention. Both the 9-bp consensus sequence and flanking sequences determined the binding efficiency. One DnaA monomer was found to bind to a DnaA box and to induce a bend of about 40 degrees.	MAX PLANCK INST MOLEC GENET,D-14195 BERLIN,GERMANY	Max Planck Society								ATLUNG T, 1985, MOL GEN GENET, V200, P442, DOI 10.1007/BF00425729; BARCELO F, 1991, BIOCHEMISTRY-US, V30, P4863, DOI 10.1021/bi00234a005; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P82; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; BUHK HJ, 1983, GENE, V24, P265, DOI 10.1016/0378-1119(83)90087-2; CARAS IW, 1980, J BIOL CHEM, V255, P3575; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; CROOKE E, 1992, J BIOL CHEM, V267, P16779; DIEDERICH L, 1994, BIOTECHNIQUES, V16, P916; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HANSEN FG, 1991, J BACTERIOL, V173, P5194, DOI 10.1128/jb.173.16.5194-5199.1991; HOLZ A, 1992, MOL GEN GENET, V233, P81, DOI 10.1007/BF00587564; KIM J, 1988, GENE AMST, V85, P15; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; Kornberg A., 1992, DNA REPLICATION; KUBISTA M, 1987, BIOCHEMISTRY-US, V26, P4545, DOI 10.1021/bi00388a057; KUCHERER C, 1986, MOL GEN GENET, V205, P115, DOI 10.1007/BF02428040; LANGER U, 1994, FEMS MICROBIOL LETT, V119, P123; MANZINI G, 1983, NUCLEIC ACIDS RES, V11, P8861, DOI 10.1093/nar/11.24.8861; MASAI H, 1990, J BIOL CHEM, V265, P15134; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; MESSER W, 1995, ESCHERICHIA COLI SAL; PARADA CA, 1991, J BIOL CHEM, V266, P18895; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; Sambrook J, 1989, MOL CLONING LABORATO; SAMITT CE, 1989, EMBO J, V8, P989, DOI 10.1002/j.1460-2075.1989.tb03462.x; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; SEUFERT W, 1987, CELL, V48, P73, DOI 10.1016/0092-8674(87)90357-6; SEUFERT W, 1986, EMBO J, V5, P3401, DOI 10.1002/j.1460-2075.1986.tb04656.x; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; WANG QP, 1987, MOL GEN GENET, V209, P518, DOI 10.1007/BF00331158; WOELKER B, 1993, NUCLEIC ACIDS RES, V21, P5025, DOI 10.1093/nar/21.22.5025; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0	43	206	208	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17622	17626		10.1074/jbc.270.29.17622	http://dx.doi.org/10.1074/jbc.270.29.17622			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615570	hybrid			2022-12-25	WOS:A1995RK68900087
J	DEBINSKI, W; OBIRI, NI; PASTAN, I; PURI, RK				DEBINSKI, W; OBIRI, NI; PASTAN, I; PURI, RK			A NOVEL CHIMERIC PROTEIN COMPOSED OF INTERLEUKIN-13 AND PSEUDOMONAS EXOTOXIN IS HIGHLY CYTOTOXIC TO HUMAN CARCINOMA-CELLS EXPRESSING RECEPTORS FOR INTERLEUKIN-13 AND INTERLEUKIN-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CHAIN; FUNCTIONAL COMPONENT; SIGNAL-TRANSDUCTION; INVITRO; DOMAIN	Chimeric proteins provide a unique opportunity to target therapeutic bacterial toxins to a subset of specific cells. We have generated a new recombinant chimeric toxin composed of human interleukin 13 (hIL13) and a Pseudomonas exotoxin A (PE) mutant, PE38QQR. The hIL13-PE38QQR chimera is highly cytotoxic to cell lines derived from several human epithelial carcinomas such as adenocarcinoma of stomach, colon, and skin. The cytotoxic action of hIL13-PE38QQR, which can only occur upon internalization of ligand-receptor complex, is blocked by an excess of hIL13 but not of hIL2. This action is not solely hIL13-specific because an excess of hIL4 also blocks the cytotoxicity of hIL13 toxin. Conversely, hIL13 blocks the cytotoxicity of a hIL4-PE38QQR chimera. Binding studies showed that hIL13 displaces competitively I-126-labeled hIL4-PE38QQR on carcinoma cells. These results indicate that IL4 and IL13 compete for a common binding site on the studied human cell lines. Despite this competition, hIL4 but not hIL13 decreased protein synthesis in malignant cells susceptible to the cytotoxicity of both hIL13- and hIL4-PE38QQR. Our results suggest that a spectrum of human carcinomas express binding sites for IL13. Furthermore, hIL13 and hIL4 compete reciprocally for a form of the receptor that is internalized upon binding a ligand. Thus, cancer cells represent an interesting model fbr studying receptors for these two growth factors. Finally, hIL13-PE38QQR may be a useful agent in the treatment of several malignancies.	PENN STATE UNIV,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033; US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,MOLEC TUMOR BIOL LAB,BETHESDA,MD 20892; NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BETHESDA,MD 20892	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	DEBINSKI, W (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT SURG,DIV NEUROSURG,HERSHEY,PA 17033, USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DEBINSKI W, 1993, J BIOL CHEM, V268, P14065; DEBINSKI W, 1992, J CLIN INVEST, V90, P405, DOI 10.1172/JCI115875; DEBINSKI W, 1994, INT J CANCER, V58, P744, DOI 10.1002/ijc.2910580520; DEBINSKI W, 1994, BIOCONJUGATE CHEM, V5, P40, DOI 10.1021/bc00025a006; DEBINSKI W, 1995, IN PRESS CLIN CANCER; HARADA N, 1992, J BIOL CHEM, V267, P22752; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; JACOBSEN SEW, 1994, J EXP MED, V180, P75, DOI 10.1084/jem.180.1.75; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MORRISON BW, 1992, J BIOL CHEM, V267, P11957; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; PASTAN L, 1992, ANNU REV BIOCHEM, V61, P331; PUNNONEN J, 1994, J EXP MED, V179, P135; PURI RK, 1994, CELL IMMUNOL, V154, P369, DOI 10.1006/cimm.1994.1084; RAMANATHAN L, 1993, BIOCHEMISTRY-US, V32, P3549, DOI 10.1021/bi00065a005; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SIEGALL CB, 1992, FASEB J, V3, P2647; SIRONI M, 1994, BLOOD, V84, P1913; WALDMANN TA, 1992, ANN INTERN MED, V116, P148, DOI 10.7326/0003-4819-116-2-148; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	25	154	173	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16775	16780		10.1074/jbc.270.28.16775	http://dx.doi.org/10.1074/jbc.270.28.16775			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622490	hybrid			2022-12-25	WOS:A1995RJ34700050
J	JOSEPH, M; NAGARAJ, R				JOSEPH, M; NAGARAJ, R			INTERACTION OF PEPTIDES CORRESPONDING TO FATTY ACYLATION SITES IN PROTEINS WITH MODEL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-MYRISTOYLTRANSFERASE; INTRACELLULAR RELEASE; PHOSPHOLIPID-VESICLES; MYRISTOYL-COA; BINDING; FLUORESCENCE; TRYPTOPHAN; SEQUENCE; P60SRC; IDENTIFICATION	In recent years, a large number of proteins having covalently linked myristic and palmitic acids have been discovered. It is assumed that fatty acid acylation serves to anchor proteins to membranes. However, it is not clear whether fatty acids modulate orientation of peptide chain in membranes or help in associating hydrophilic segments of peptides with membranes. We have examined the aggregation properties and membrane association of peptides corresponding to myristoylation and palmitoylation regions of proteins by fluorescence spectroscopy. Both acylated and non-acylated peptides were used for investigation. Binding of the peptides to lipid vesicles was assessed by monitoring the fluorescence of tryptophan as well as the quenching of its fluorescence in the presence of quenchers like I- and acrylamide. Our results indicate that in the peptide corresponding to a transmembrane segment, palmitoylation results in a change in the orientation of the peptide chain in the lipid bilayer. In the case of peptides that do not have a hydrophobic segment, acylation with palmitic or myristic acid does not appear to result in increased binding to lipid bilayer, Our results suggest that (i) the primary role of myristoylation may not be an anchor for membrane attachment as assumed, (ii) palmitoylation in the case of proteins having transmembrane segments may serve to realign the transmembrane segment from the normal orientation perpendicular to the bilayer surface, (iii) in the case of proteins where there is no hydrophobic segment, palmitoylation may not serve as a membrane anchor and could be involved in interaction with other membrane bound proteins.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)								ATHERTON E, 1989, SOLID PHASE PEPTIDE, P75; BERGER M, 1986, J BIOL CHEM, V261, P4912; BLUMENTHAL R, 1977, P NATL ACAD SCI USA, V74, P5603, DOI 10.1073/pnas.74.12.5603; CHEN RF, 1965, SCIENCE, V147, P729, DOI 10.1126/science.147.3659.729; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CREED D, 1984, PHOTOCHEM PHOTOBIOL, V39, P537; DEKROON AIP, 1990, BIOCHEMISTRY-US, V29, P8229, DOI 10.1021/bi00488a006; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DEYOUNG LR, 1993, ACCOUNTS CHEM RES, V26, P614, DOI 10.1021/ar00036a002; EFTINK MR, 1976, J PHYS CHEM-US, V80, P486, DOI 10.1021/j100546a014; GLOVER CJ, 1988, BIOCHEM J, V250, P485, DOI 10.1042/bj2500485; GODDARD C, 1989, J BIOL CHEM, V264, P15173; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOSEPH M, 1993, BIOORG MED CHEM LETT, V3, P1025, DOI 10.1016/S0960-894X(00)80280-2; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; Lakowicz J.R., 1983, PRINC FLUORESC SPECT, P341, DOI [10.1007/978-1-4615-7658-7_11, DOI 10.1007/978-1-4615-7658-7_11]; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MATHEW MK, 1982, J BIOL CHEM, V257, P2170; MATSUZAKI K, 1994, BIOCHEMISTRY-US, V33, P3342, DOI 10.1021/bi00177a027; MCKNIGHT CJ, 1991, BIOCHEMISTRY-US, V30, P6241, DOI 10.1021/bi00239a023; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RENIL M, 1994, TETRAHEDRON, V50, P6681, DOI 10.1016/S0040-4020(01)89696-4; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SABERWAL G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P43, DOI 10.1016/0005-2736(93)90069-C; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHOLTZ JM, 1992, ANNU REV BIOPH BIOM, V21, P95, DOI 10.1146/annurev.bb.21.060192.000523; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; SITARAM N, 1993, BIOCHEMISTRY-US, V32, P3124, DOI 10.1021/bi00063a026; SUREWICZ WK, 1984, BIOCHEMISTRY-US, V23, P6072, DOI 10.1021/bi00320a026; TAPPIN MJ, 1988, BIOCHEMISTRY-US, V27, P1643, DOI 10.1021/bi00405a038; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WEINSTEIN JN, 1977, SCIENCE, V195, P489, DOI 10.1126/science.835007; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WOLD F, 1981, ANNU REV BIOCHEM, V50, P783, DOI 10.1146/annurev.bi.50.070181.004031; ZAGORSKI MG, 1991, BIOCHEMISTRY-US, V30, P8009, DOI 10.1021/bi00246a019	45	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16749	16755		10.1074/jbc.270.28.16749	http://dx.doi.org/10.1074/jbc.270.28.16749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622487	hybrid			2022-12-25	WOS:A1995RJ34700047
J	LOMAS, DA; ELLIOTT, PR; SIDHAR, SK; FOREMAN, RC; FINCH, JT; COX, DW; WHISSTOCK, JC; CARRELL, RW				LOMAS, DA; ELLIOTT, PR; SIDHAR, SK; FOREMAN, RC; FINCH, JT; COX, DW; WHISSTOCK, JC; CARRELL, RW			ALPHA(1)-ANTITRYPSIN MMALTON (PHE(52)-DELETED) FORMS LOOP-SHEET POLYMERS IN-VIVO - EVIDENCE FOR THE C-SHEET MECHANISM OF POLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; CRYSTAL-STRUCTURE; ALPHA-1-ANTITRYPSIN DEFICIENCY; PROTEINASE-INHIBITORS; PLASMINOGEN-ACTIVATOR; ANTITHROMBIN-III; MOLECULAR-BASIS; REACTIVE SITE; LUNG-DISEASE; RESOLUTION	The Z (Glu(342) --> Lys) and Siiyama (Ser(53) --> Phe) deficiency variants of alpha(1)-antitrypsin result in the retention of protein in the endoplasmic reticulum of the hepatocyte by loop-sheet polymerization in which the reactive center loop of one molecule is inserted into a beta-pleated sheet of a second. We show here that antitrypsin Mmal-ton (Phe(52)-deleted), which is associated with the same liver inclusions, is also retained at an endoglycosidase H-sensitive stage of processing in the Xenopus oocyte and spontaneously forms polymers in vivo. These polymers, obtained from the plasma of an Mmalton/QO (null) bolton heterozygote, were much shorter than other antitrypsin polymers and contained a reactive center loop-cleaved species. Monomeric mutant antitrypsin was also isolated from the plasma. The monomeric component had a normal unfolding transition on transverse urea gradient gel electrophoresis and formed polymers in vitro more readily than M, but less readily than Z, antitrypsin, The A beta-sheet accommodated a reactive center loop peptide much less readily than Z antitrypsin, which in turn was less receptive than native M antitrypsin. The nonreceptive conformation of the A sheet in antitrypsin Mmalton had little effect on kinetic parameters, the formation of SDS-stable complexes, the S to R transition, and the formation of the latent conformation. Comparison of the results with similar findings of short chain polymers associated with the antithrombin variant Rouen VI (Bruce, D., Perry, D., Borg, J.-Y., Carrell, R. W., and Wardell, M. R. (1994) J. Clin. Invest. 94, 2265-2274) suggests that polymerization is more complicated than the mechanism proposed earlier. The Z, Siiyama, and Mmalton mutations favor a conformational change in the antitrypsin molecule to an intermediate between the native and latent forms. This would involve a partial overinsertion of the reactive loop into the A sheet with displacement of strand 1C and consequent loop-C sheet polymerization.	MRC CTR, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND; UNIV SOUTHAMPTON, DEPT PHYSIOL & PHARMACOL, SOUTHAMPTON SO9 3TU, HANTS, ENGLAND; HOSP SICK CHILDREN, DEPT PEDIAT, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT GENET, TORONTO, ON M5G 1X8, CANADA	MRC Laboratory Molecular Biology; University of Southampton; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	LOMAS, DA (corresponding author), UNIV CAMBRIDGE, DEPT HEMATOL, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.			Whisstock, James/0000-0003-4200-5611	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AULAK KS, 1993, J BIOL CHEM, V268, P18088; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; CHANG WSW, 1994, BLOOD, V84, pA391; COX DW, 1986, FEBS LETT, V205, P255, DOI 10.1016/0014-5793(86)80908-5; COX DW, 1975, PROTIDES BIOL FLUIDS, V23, P375; CURIEL DT, 1989, J BIOL CHEM, V264, P13938; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; FABER JP, 1993, J HEPATOL, V18, P313, DOI 10.1016/S0168-8278(05)80275-2; FRAIZER GC, 1989, AM J HUM GENET, V44, P894; FRAIZER GC, 1989, HUM GENET, V83, P377, DOI 10.1007/BF00291385; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GRAHAM A, 1989, HUM GENET, V84, P55, DOI 10.1007/BF00210671; GUZDEK A, 1990, FEBS LETT, V272, P125, DOI 10.1016/0014-5793(90)80464-T; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1993, J BIOL CHEM, V268, P516; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MATSUNAGA E, 1990, AM J HUM GENET, V46, P602; MIKUS P, 1993, EUR J BIOCHEM, V218, P1071, DOI 10.1111/j.1432-1033.1993.tb18467.x; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; OGUSHI F, 1987, J CLIN INVEST, V80, P1366, DOI 10.1172/JCI113214; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; ROBERTS EA, 1984, AM J CLIN PATHOL, V82, P424, DOI 10.1093/ajcp/82.4.424; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SERGI C, 1994, LAB INVEST, V70, P130; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; SIDHAR SK, 1995, J BIOL CHEM, V270, P8393, DOI 10.1074/jbc.270.15.8393; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVIS J, 1981, METHOD ENZYMOL, V80, P754; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251	51	141	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16864	16870		10.1074/jbc.270.28.16864	http://dx.doi.org/10.1074/jbc.270.28.16864			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622502	hybrid			2022-12-25	WOS:A1995RJ34700063
J	SEALFON, SC; CHI, L; EBERSOLE, BJ; RODIC, V; ZHANG, D; BALLESTEROS, JA; WEINSTEIN, H				SEALFON, SC; CHI, L; EBERSOLE, BJ; RODIC, V; ZHANG, D; BALLESTEROS, JA; WEINSTEIN, H			RELATED CONTRIBUTION OF SPECIFIC HELIX-2 AND HELIX-7 RESIDUES TO CONFORMATIONAL ACTIVATION OF THE SEROTONIN 5-HT2A RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC RECEPTORS; 2ND TRANSMEMBRANE DOMAIN; LIGAND-BINDING; CONSERVED ASPARTATE; AGONIST BINDING; AMINO-ACIDS; IDENTIFICATION; MUTATION; AFFINITY	A conserved helix 2 Asp is required for the proper function of many G-protein-coupled receptors. To reveal the structural basis for the role of this residue, the additive effects of mutations at this locus and at a conserved helix 7 locus were investigated in the 5-HT2A receptor. All mutant receptors studied retained high affinity agonist and antagonist binding. Whereas an Asp --> Asn mutation in helix 2 eliminated coupling, interchanging the residues at the two positions by a second mutation of Asn --> Asp in helix 7 restored receptor function. These data suggest that these residues are adjacent in space and interact. The loss of function observed with Ala at either position is consistent with each side chain forming hydrogen bonds. Molecular dynamics simulations were performed on three-dimensional computational models of agonist-receptor complexes of both the wild-type receptor and the Asp --> Asn mutant receptor. Consonant with the lack of coupling observed for the mutant construct, introducing the mutation into the computational model produced a conformational change in a direction opposite to that seen from computational simulations of activation of the wild-type receptor model. These results implicate both loci in a common hydrogen-bonding network underlying receptor activation by agonist.	CUNY MT SINAI SCH MED, DEPT NEUROL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT ANESTHESIOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT PHARMACOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	SEALFON, SC (corresponding author), CUNY MT SINAI SCH MED, FISHBERG RES CTR NEUROBIOL, BOX 1065, 1 GUSTAVE LEVY PL, NEW YORK, NY 10029 USA.		WEINSTEIN, HAREL/O-8245-2019	WEINSTEIN, HAREL/0000-0003-3473-9818; SEALFON, Stuart/0000-0001-5791-1217	NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000060, R01DA009083, R01DA009088] Funding Source: NIH RePORTER; NIDA NIH HHS [DA09083, DA09088, KO5 DA00060] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BERG KA, 1994, MOL PHARMACOL, V45, P826; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHANDA PK, 1993, MOL PHARMACOL, V43, P516; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; DONNELLY D, 1994, CURR OPIN STRUC BIOL, V4, P582, DOI 10.1016/S0959-440X(94)90221-6; FRASER CM, 1989, J BIOL CHEM, V264, P9266; FRASER CM, 1989, MOL PHARMACOL, V36, P840; HO BY, 1992, FEBS LETT, V312, P259, DOI 10.1016/0014-5793(92)80948-G; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; JI IH, 1991, J BIOL CHEM, V266, P14953; KONG HY, 1993, J BIOL CHEM, V268, P23055; KONG HY, 1993, MOL PHARMACOL, V44, P380; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO XC, 1994, PROTEIN ENG, V7, P1441, DOI 10.1093/protein/7.12.1441; NEVE KA, 1991, MOL PHARMACOL, V39, P733; NEVE KA, 1991, MOL PHARMACOL, V39, P570; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; QUINTANA J, 1993, MOL ENDOCRINOL, V7, P767, DOI 10.1210/me.7.6.767; SALTZMAN AG, 1991, BIOCHEM BIOPH RES CO, V181, P1469, DOI 10.1016/0006-291X(91)92105-S; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; WANG CD, 1993, MOL PHARMACOL, V43, P931; WANG CD, 1991, MOL PHARMACOL, V40, P168; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; ZHANG DQ, 1994, FEBS LETT, V337, P207, DOI 10.1016/0014-5793(94)80274-2; ZHANG DQ, 1993, J MED CHEM, V36, P934, DOI 10.1021/jm00059a021; ZHANG DQ, 1993, MED CHEM RES, V3, P357; ZHOU W, 1994, MOL PHARMACOL, V45, P165	35	191	193	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16683	16688		10.1074/jbc.270.28.16683	http://dx.doi.org/10.1074/jbc.270.28.16683			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622478	hybrid			2022-12-25	WOS:A1995RJ34700037
J	TETI, A; PANICCIA, R; GOLDRING, SR				TETI, A; PANICCIA, R; GOLDRING, SR			CALCITONIN INCREASES CYTOSOLIC-FREE CALCIUM-CONCENTRATION VIA CAPACITATIVE CALCIUM INFLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; INOSITOL PHOSPHATE; EXTRACELLULAR CALCIUM; RECEPTOR; ENTRY; CA2+; CLONING; OSTEOCLASTS; EXPRESSION; ACTIVATION	The calcitonin receptor has been proposed to function as an extracellular Ca2+ concentration ([Ca2+](o)) sensor (Stroop, S. D., Thompson, D. L., Kuestner, R. E., and Moore, E. E. (1993) J, Biol. Chem, 268, 19927-19930). To test this hypothesis we studied the LLC-PK1 renal tubular cells and the PC, cells, a cell line stably transfected with the cloned porcine calcitonin receptor. [Ca2+](i) was measured by fura-a single cell microfluorometry. Addition to the cells equilibrated in 1.25 mM Ca2+-containing media of 1-10 mM extracellular Ca2+ did not result in a significant increase of [Ca2+](i). Treatment with 10(-7) M salmon calcitonin (sCT) elicited a rapid, persistent elevation of [Ca2+](i). Addition of 1-10 mM extracellular Ca2+ in the presence of sCT induced a significant [Ca2+](i) elevation, about 10-fold that observed in the absence of the hormone. Ca2+ influx was inhibited by lanthanum. The rise of [Ca2+](i) at elevated [Ca2+](o) was not due to a Ca2+ sensing mechanism with release of Ca2+ from intracellular stores, since it was prolonged, and was not abolished by prior depletion of Ca2+ stores with 10(-6) M thapsigargin. On the contrary, this agent potentiated Ca2+ influx after addition of 1-10 mM Ca2+ by 13-fold versus control. Prior stimulation of [Ca2+](i) with 10(-7) M arginine-vasopressin had similar effects, enhancing the subsequent Ca2+ influx. Enhancement of Ca2+ influx by sCT was confirmed by increased Mn2+ quenching of fura-2 fluorescence. In conclusion, arginine-vasopressin or calcitonin enhance Ca2+ influx in LLC-PK1 cells via a Ca2+ release-activated conductance, probably dependent upon capacitative Ca2+ entry. Thus, these effects are not unique to the calcitonin receptor and argue against the receptor functioning as a [Ca2+](o) sensor.	IST DERMOPAT IMMACOLATA,I-00167 ROME,ITALY; UNIV ROMA LA SAPIENZA,INST HISTOL & GEN EMBRYOL,I-00161 ROME,ITALY; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA 02129; HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,BOSTON,MA 02129; HARVARD UNIV,BAPTIST MEM HOSP,SCH MED,BOSTON,MA 02129	IRCCS Istituto Dermopatico dell'Immacolata (IDI); Sapienza University Rome; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	TETI, A (corresponding author), UNIV LAQUILA,SCH MED,DEPT EXPTL MED,VIA VETOIO,COPPITO 2,I-67100 LAQUILA,ITALY.			Teti, Anna Maria/0000-0002-5887-4419	NIAMS NIH HHS [AR-03564] Funding Source: Medline; NIDDK NIH HHS [DK-46773] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR003564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046773] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azria M, 1989, CALCITONINS; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHAMBERS TJ, 1986, ENDOCRINOLOGY, V116, P234; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; GOLDRING SR, 1978, BIOCHEM BIOPH RES CO, V83, P434, DOI 10.1016/0006-291X(78)91009-4; GOLTZMAN D, 1985, SCIENCE, V227, P1343, DOI 10.1126/science.2983422; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P2440; HALLAM TJ, 1989, BIOCHEM J, V259, P125, DOI 10.1042/bj2590125; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1992, SCIENCE, V254, P1024; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; MENE P, 1994, KIDNEY INT, V46, P122, DOI 10.1038/ki.1994.251; MONTERO M, 1994, J BIOL CHEM, V269, P29451; MURAD F, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P446, DOI 10.1073/pnas.65.2.446; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SEXTON PM, 1987, KIDNEY INT, V32, P862, DOI 10.1038/ki.1987.287; STROOP SD, 1993, J BIOL CHEM, V268, P19927; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V163, P1461, DOI 10.1016/0006-291X(89)91143-1	35	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16666	16670		10.1074/jbc.270.28.16666	http://dx.doi.org/10.1074/jbc.270.28.16666			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622475	hybrid			2022-12-25	WOS:A1995RJ34700034
J	VASU, SK; ROME, LH				VASU, SK; ROME, LH			DICTYOSTELIUM VAULTS - DISRUPTION OF THE MAJOR PROTEINS REVEALS GROWTH AND MORPHOLOGICAL DEFECTS AND UNCOVERS A NEW ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOPROTEIN-PARTICLES; SMALL RNA; CONTAIN	Vaults are large cytoplasmic ribonucleoprotein particles that are highly conserved in both morphology and protein composition. Protein components of vaults isolated from Dictyostelium discoideum migrate on SDS-polyacrylamide gels as two bands, one at 94 kDa (MvpA) and the other at 92 kDa (MvpB). An MvpB cDNA clone was isolated from a Dictyostelium expression library. MvpB shares 60% identity with MvpA at the amino acid level. This cDNA has been used to disrupt the single mvpB gene in both wild-type and mvpA(-) genetic backgrounds. Although the mvp(-) mutant lines are viable, they show that loss of MvpA and/or MvpB interferes with vault function sufficiently to impede growth under conditions of nutritional stress. The resulting mutant cell lines reach stationary phase in suspension culture at one-third of the density of wild-type cells. Ovoid structures isolated from mvp(-) single mutant lines represent what remains of vaults in these cells. Similar ovoid structures isolated from the mvpA(-) mvpB(-) line copurify with a newly identified protein of 92 kDa (MvpC), which lacks cross-reactivity with currently available anti-vault antibodies. Our results indicate that the major vault proteins are necessary for optimal cell growth in Dictyostelium and reveal an unanticipated complexity in vault composition.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,MENTAL RETARDAT RES CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Rome, Leonard H/E-8786-2016	Rome, Leonard H/0000-0002-1236-2063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038097] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38097] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHUGANI DC, 1993, J CELL SCI, V106, P23; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COCUCCI SM, 1970, J CELL BIOL, V45, P399, DOI 10.1083/jcb.45.2.399; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1990, MOL BIOL REP, V14, P121, DOI 10.1007/BF00360441; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1994, GENE, V151, P257, DOI 10.1016/0378-1119(94)90667-X; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPUDICH JA, 1987, METHOD CELL BIOL, V28, P3; SUSSMAN M, 1961, J GEN MICROBIOL, V25, P375, DOI 10.1099/00221287-25-3-375; VASU SK, 1993, J BIOL CHEM, V268, P15356	15	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16588	16594		10.1074/jbc.270.28.16588	http://dx.doi.org/10.1074/jbc.270.28.16588			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622465	hybrid			2022-12-25	WOS:A1995RJ34700022
J	WU, CL; WHITEWAY, M; THOMAS, DY; LEBERER, E				WU, CL; WHITEWAY, M; THOMAS, DY; LEBERER, E			MOLECULAR CHARACTERIZATION OF STE20P, A POTENTIAL MITOGEN-ACTIVATED PROTEIN OR EXTRACELLULAR SIGNAL-REGULATED KINASE KINASE (MEK) KINASE KINASE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; MAP KINASE; CONSERVED FEATURES; GAMMA-SUBUNITS; CELL-CYCLE; YEAST; PHOSPHORYLATION; GENE; IDENTIFICATION; TRANSDUCTION	The Ste20p protein kinase was immunopurified from yeast cells and analyzed in an in vitro assay system, Ste20p immune complexes exhibited autophosphorylating activity at serine and threonine residues and specifically phosphorylated a bacterially expressed glutathione S-transferase (GST) fusion of Ste11p (a mitogen-activated protein or extracellular signal-regulated kinase kinase (MEK) kinase homologue) at serine and threonine residues. In contrast, GST fusions either of Ste7p (a MEK homologue) or the beta-subunit of the mating response G-protein and immunoprecipitated Ste5p were not phosphorylated by the Ste20p immune complexes. Myelin basic protein was identified as an excellent in. vitro substrate, whereas histone H1 was only poorly phosphorylated. Evidence was obtained that autophosphorylation might play a regulatory role for the in vitro kinase activity. The in vitro activity was found to be Ca2+-independent. Both the in vivo and in vitro activities were abolished by mutational changes of either the conserved lysine residue 649 within the ATP binding site or threonine 777 between the catalytic subdomains VII and VIII. Wild-type Ste20p and the catalytically inactive T777A mutant were identified as phosphoproteins in vivo. The phosphorylation occurred at serine and threonine residues independent of pheromone stimulation. Based on the genetically determined significance of Ste20p in pheromone signal transduction and on our in vitro studies, we propose the model that Ste20p represents a yeast MEK kinase kinase whose function is to link G-protein-coupled receptors through G(beta gamma) to a mitogen-activated protein kinase module.	NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, EUKARYOT GENET GRP, MONTREAL, PQ H4P 2R2, CANADA	National Research Council Canada			Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHOI KY, 1994, CELL, V78, P499; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FINEGOLD AA, 1990, SCIENCE, V249, P165, DOI 10.1126/science.1695391; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Maniatis T., 1982, MOL CLONING; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; PRINTEN JA, 1994, GENETICS, V138, P609; RAD MR, 1992, MOL GEN GENET, V236, P145; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; Rose MD., 1990, METHODS YEAST GENETI; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	60	153	159	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					15984	15992		10.1074/jbc.270.27.15984	http://dx.doi.org/10.1074/jbc.270.27.15984			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608157	hybrid			2022-12-25	WOS:A1995RH22600018
J	WU, ZN; JOHNSON, KW; CHOI, Y; CIARDELLI, TL				WU, ZN; JOHNSON, KW; CHOI, Y; CIARDELLI, TL			LIGAND-BINDING ANALYSIS OF SOLUBLE INTERLEUKIN-2 RECEPTOR COMPLEXES BY SURFACE-PLASMON RESONANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANALOGS	Knowledge of the kinetic binding characteristics is often critical to the development of ligand/receptor structure-activity relationships, To better understand the contribution of each of the subunits to ligand binding in the multimeric interleukin-2 receptor system, we have previously prepared stable solution complexes of the alpha- and beta subunits. In this study, we have employed surface plasmon resonance biosensor methodology (BLAcore(TM)) to evaluate both the kinetic and equilibrium binding constants for these complexes, The structural nature of the complexes facilitated immobilization on the sensor surfaces in a manner that minimized interference with ligand interactions. The interleukin-2 receptor complex surfaces displayed excellent binding capacity and stability toward regeneration. In all eases where the binding constants were measurable, the values determined for interleukin-2 were in good agreement with those previously determined by other methods, When interleukin-2 analogs with receptor subunit specific mutations were employed, the binding parameters were consistent with the nature of the mutations. The combination of coiled-coil-mediated solution assembly and surface plasmon resonance analysis of ligand binding provides a powerful approach to the study of multimeric cytokine receptor systems.	DARTMOUTH COLL,SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755; VET ADM MED CTR,WHITE RIVER JCT,VT 05009; CHIRON CORP,EMERYVILLE,CA 94608	Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA); Novartis					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034331] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34331] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNDT WG, 1994, BIOCHEMISTRY-US, V33, P6571, DOI 10.1021/bi00187a026; CHANG DZ, 1995, MOL PHARMACOL, V47, P206; COLLINS L, 1988, P NATL ACAD SCI USA, V85, P7709, DOI 10.1073/pnas.85.20.7709; Fisher Robert J., 1994, Current Opinion in Biotechnology, V5, P389, DOI 10.1016/0958-1669(94)90047-7; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; LANDGRAF BE, 1991, PROTEINS, V9, P207, DOI 10.1002/prot.340090306; LANDGRAF BE, 1992, J BIOL CHEM, V267, P18511; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; MATSUOKA M, 1993, EUR J IMMUNOL, V23, P2472, DOI 10.1002/eji.1830231014; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; Morton Thomas A., 1994, Journal of Molecular Recognition, V7, P47, DOI 10.1002/jmr.300070107; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; O'Shannessy D J, 1994, Curr Opin Biotechnol, V5, P65, DOI 10.1016/S0958-1669(05)80072-2; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; QU Z, 1995, J BIOL CHEM, V270, P16039; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WU ZN, 1994, PROTEIN ENG, V7, P1137, DOI 10.1093/protein/7.9.1137	18	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16045	16051		10.1074/jbc.270.27.16045	http://dx.doi.org/10.1074/jbc.270.27.16045			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608166	hybrid			2022-12-25	WOS:A1995RH22600027
J	YUAN, CS; BORCHARDT, RT				YUAN, CS; BORCHARDT, RT			PHOTOAFFINITY-LABELING OF HUMAN PLACENTAL S-ADENOSYLHOMOCYSTEINE HYDROLASE WITH [2-H-3]8-AZIDO-ADENOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-HOMOCYSTEINE HYDROLASE; AMINO-ACID SEQUENCE; RAT-LIVER; CHEMICAL MODIFICATION; COENZYME BINDING; CDNA SEQUENCE; ACTIVE-SITE; INACTIVATION; MECHANISM; RESIDUES	The potential photoaffinity probe 8-azido-adenosine (8-N-3-Ado) was shown to serve as a substrate for the 3'-oxidative activity of human S-adenosylhomocysteine (AdoHcy) hydrolase (Aiyar, V. N., and Hershfield, M.S. (1985) Biochem. J. 232, 643-650). In this study, we have determined the equilibrium binding properties of 8-N-3-Ado with AdoHcy hydrolase (NAD(+) form) and identified the specific amino acid residues that are covalently modified. After irradiation of the reaction mixture of [2-H-3]8-N-3-Ado and AdoHcy hydrolase (NAD(+) form) and followed by tryptic digestion, peptides specifically photolabeled by [2-H-3]3'-keto-8-N-3-Ado were effectively separated from peptides nonspecifically labeled with [2-H-3]8-N-3-Ado using boronate affinity chromatography. After purification by reverse phase high performance liquid chromatography, two photolabeled peptides were isolated and identified as Val(175)-Lys(186) and Val(319)-Arg(327), in which Ala(177) and Ile(321) were associated with radioactivity, The specificity of the photoaffinity labeling with [2-H-3]3'-keto-8-N-3-Ado was demonstrated by the observation that these photolabeled peptides were not isolated when [2-H-3]8-N-3-Ado was incubated with apo AdoHcy hydrolase and irradiated, The two photolabeled peptides are assumed to be parts of the adenine-binding domain for substrates, They are both within well conserved regions of AdoHcy hydrolases. The peptide Val(175)-Lys(186) is located very close to Cys(195) and Glu(197) Ser(198), both of which were indicated to be located in the active site of the enzyme by chemical modification and limited proteolysis methods. The peptide Val(319)-Arg(327) is adjacent to Leu(330), which is proposed by a computer graphics model to interact with the C-6-NH2 group of Ado.	UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66045 USA	University of Kansas					NIGMS NIH HHS [GM-29332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR VN, 1985, BIOCHEM J, V232, P643, DOI 10.1042/bj2320643; AKSAMIT RR, 1994, J BIOL CHEM, V269, P4084; AULTRICHE DB, 1994, J BIOL CHEM, V269, P31472; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; DELAHABA G, 1959, J BIOL CHEM, V234, P603; GOMI T, 1986, J BIOL CHEM, V261, P3422; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; GOMI T, 1982, BIOCHEMISTRY-US, V21, P4171, DOI 10.1021/bi00260a039; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; GOMI T, 1990, J BIOL CHEM, V265, P16102; GUPTA RA, 1995, ARCH BIOCHEM BIOPHYS, V319, P365, DOI 10.1006/abbi.1995.1306; HENDERSON DM, 1992, MOL BIOCHEM PARASIT, V53, P169, DOI 10.1016/0166-6851(92)90019-G; KASIR J, 1988, BIOCHEM BIOPH RES CO, V153, P359, DOI 10.1016/S0006-291X(88)81231-2; KAWALLECK P, 1992, P NATL ACAD SCI USA, V89, P4713, DOI 10.1073/pnas.89.10.4713; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; PALMER JL, 1979, J BIOL CHEM, V254, P1217; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; PRASAD SS, 1993, GENOME, V36, P57, DOI 10.1139/g93-008; RICHARDS KD, 1993, EMBL L11872 GENB ACC; SCHOTT H, 1973, BIOCHEMISTRY-US, V12, P932, DOI 10.1021/bi00729a022; SCHROEDER G, 1993, EMBL Z26881 GENB ACC; SGANGA MW, 1992, P NATL ACAD SCI USA, V89, P6328, DOI 10.1073/pnas.89.14.6328; TAKATA Y, 1983, J BIOL CHEM, V258, P7374; TAKATA Y, 1985, ARCH BIOCHEM BIOPHYS, V240, P827, DOI 10.1016/0003-9861(85)90092-X; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YEH JC, 1991, J COMPUT AID MOL DES, V5, P213, DOI 10.1007/BF00124340; YUAN CS, 1993, J BIOL CHEM, V268, P17030; YUAN CS, 1993, BIOCHEMISTRY-US, V32, P10414, DOI 10.1021/bi00090a017; YUAN CS, 1994, BIOCHEMISTRY-US, V33, P12305, DOI 10.1021/bi00206a038	33	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16140	16146		10.1074/jbc.270.27.16140	http://dx.doi.org/10.1074/jbc.270.27.16140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608178	hybrid			2022-12-25	WOS:A1995RH22600041
J	HSU, B; MARIN, MC; ELNAGGAR, AK; STEPHENS, LC; BRISBAY, S; MCDONNELL, TJ				HSU, B; MARIN, MC; ELNAGGAR, AK; STEPHENS, LC; BRISBAY, S; MCDONNELL, TJ			EVIDENCE THAT C-MYC MEDIATED APOPTOSIS DOES NOT REQUIRE WILD-TYPE P53 DURING LYMPHOMAGENESIS	ONCOGENE			English	Article						APOPTOSIS; ONCOGENE; C-MYC; P53; LYMPHOMA	CELL-CYCLE ARREST; BURKITT-LYMPHOMA; PROTEIN; GENE; DEATH; MICE; FIBROBLASTS; EXPRESSION; INDUCTION; LINE	Deregulation of c-myc, frequently implicated in oncogenesis, is associated with increased cell proliferation and also cell death. Similarly, the p53 tumor suppressor gene commonly mutated in human tumors, is known to induce apoptosis or cell cycle arrest in its wild-type conformation. Genetically altered mice simultaneously overexpressing c-myc and possessing a disrupted p53 gene were used to investigate whether c-myc mediated apoptosis requires wild-type p53, The accelerated development of malignant lymphomas in these mice was found to be a consequence of enhanced proliferation and not reduced apoptosis resulting from the synergistic effect of c-myc overexpression and p53 inactivation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT VET MED & SURG,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marín Vieira, María del Carmen/B-8108-2015; Marin, Maria C/G-1040-2010	Marín Vieira, María del Carmen/0000-0002-7149-287X; Marin, Maria C/0000-0002-7149-287X	NCI NIH HHS [CA09255, CA16672, CA62597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062597, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELDIERY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P4279; KASTAN MB, 1991, CANCER RES, V53, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; MILNER AE, 1993, ONCOGENE, V8, P3385; OCONNOR PM, 1993, CANCER RES, V53, P4776; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; WAFIK S, 1994, CANCER RES, V54, P1169; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WATERS CM, 1991, ONCOGENE, V6, P797; XIONG Y, 1993, NATURE, V336, P701; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	32	96	100	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					175	179						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624125				2022-12-25	WOS:A1995RJ29500020
J	YAMATO, K; YAMAMOTO, M; HIRANO, Y; TSUCHIDA, N				YAMATO, K; YAMAMOTO, M; HIRANO, Y; TSUCHIDA, N			A HUMAN TEMPERATURE-SENSITIVE P53 MUTANT P53(VAL-138) - MODULATION OF THE CELL-CYCLE, VIABILITY AND EXPRESSION OF P53-RESPONSIVE GENES	ONCOGENE			English	Article						HUMAN TS P53 MUTANT; G1 ARREST; G2 ARREST; APOPTOSIS	WILD-TYPE P53; MAMMALIAN-CELLS; BINDING-SITE; IN-VIVO; PROTEIN; DNA; INHIBITION; APOPTOSIS; SEQUENCE; POTENT	A human p53 mutant, p53(Val-138) (amino acid 138, Alanine-->Valine), generated by in vitro mutagenesis was introduced into Saos-2 human osteosarcoma and Jurkat acute T-lymphoblastic leukemia cell lines, both lacking p53 protein expression. p53(Val-138) caused growth arrest in Saos-2 cell line and apoptosis in Jurkat cell line at 32.5 degrees C while it allowed both cell lines to grow continuously at 37.5 degrees C. p53(Val-138) activated expression of p53-responsive genes including MDM2, GADD45 and WAF1/CIP1/SDI1 in Saos-2 cell line upon the temperature shift-down from 37.5 degrees C to 32.5 degrees C. Thus, p53(Val-138) acted as a temperature-sensitive p53 mutant. Taking advantage of these human cell systems, we demonstrated that p53-mediated cell cycle arrest occurred in G1 and G2/M phases of Saos-2 cell line but not in Jurkat cell line. The induced level of WAF1/CIP1/SDI1 mRNA by p53 was extremely lower in Jurkat cell line than that of Saos-2 cell line. However, MDM2 mRNA accumulated to the similar levels in these two cell lines. These results suggest that a factor(s) other than p53 may be involved in differential expression of WAF1/CIP1/SDI1 and MDM2 mRNA	TOKYO MED & DENT UNIV,FAC DENT,DEPT MOLEC CELLULAR ONCOL & MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT PERIODONTOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1995, GENE DEV, V8, P2939; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; HIRANO Y, ONCOGENE, V10, P1879; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KWON HJ, 1992, CANCER RES, V52, P6926; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SEHGAL PB, 1993, ONCOGENE, V8, P3417; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	57	60	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					1	6						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624116				2022-12-25	WOS:A1995RJ29500001
J	BHAT, GJ; THEKKUMKARA, TJ; THOMAS, WG; CONRAD, KM; BAKER, KM				BHAT, GJ; THEKKUMKARA, TJ; THOMAS, WG; CONRAD, KM; BAKER, KM			ACTIVATION OF THE STAT PATHWAY BY ANGIOTENSIN-II IN T3CHO/AT(1A) CELLS - CROSS-TALK BETWEEN ANGIOTENSIN-II AND INTERLEUKIN-6 NUCLEAR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; CARDIAC FIBROBLASTS; PROTEIN-SYNTHESIS; INTERFERON-GAMMA; GENE-EXPRESSION; RECEPTOR; BINDING; KINASE	We recently reported that angiotensin II (AII), acting through the STAT (Signal Transducers and Activators of Transcription) pathway, stimulated a delayed SIF (sis-inducing factor)-like DNA binding activity (maximal at 2-3 h) (Bhat, G. J., Thekkumkara, T. J., Thomas, W. G., Conrad, K. M., and Baker, K. M. (1994) J. Biol. Chem. 269, 31443-31449). Using a cell line transfected with the AT(1A) receptor (T3CHO/AT(1A)), we further characterized the AII-induced SIF response and explored the possible rea sons for the delay in stimulated SIF activity, In cells transfected with a chloramphenicol acetyltransferase reporter plasmid, under the control of a SIE (sis-inducing element), AII markedly stimulated chloramphenicol acetyltransferase activity. The delayed SIF activation by AII was not due to a requirement for the release of other SIF inducing factors into the medium and contrasts with the rapid (5 min) induction elicited by the cytokine, interleukin-6 (IL-6), Interestingly, both agents stimulated tyrosine phosphorylation of Stat92 and predominantly the formation of SIF complex A. We tested the hypothesis that AII initially activated an inhibitory pathway, which was responsible for delaying the maximal SIF stimulation until 2 h, Pretreatment of cells for 15 min with AII resulted in significant inhibition of the IL-6-induced nuclear SIF response (10 min) and Stat92 tyrosine phosphorylation, which was blocked by EXP3174, an AT(1) receptor antagonist. This inhibition was transient with return of the IL-6-induced SIF response at 2 h, suggesting that the delayed maximal activation of SIF by AII occurs following an initial transient inhibitory phase, Pretreatment of cells with phorbol 12-myristate 13-acetate for 15 min, to activate protein kinase C, resulted in inhibition of the IL-6-induced SIF response (10 min). However, down-regulation of protein kinase C activity prevented phorbol 12-myristate 13-acetate, but not AII mediated inhibition of the IL-6-induced SIF response. Although the mechanism is not clear, the results presented in this paper raise the interesting possibility that the activation of SIF/Stat92 by AII is characterized by an initial inhibitory phase, followed by the induction process. The observation that AII and IL-6 utilize similar components of the STAT pathway and that AII can cross-talk with IL-6 signaling through inhibition of IL-6-induced SIF/Stat92, implies a modulatory role for AII in cellular responses to cytokines.			BHAT, GJ (corresponding author), GEISINGER MED CLIN, WEIS CTR RES, 100 N ACAD AVE, DANVILLE, PA 17822 USA.		Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952	NHLBI NIH HHS [HL-44883] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044883] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACETO JF, 1990, AM J PHYSIOL, V258, pH806, DOI 10.1152/ajpheart.1990.258.3.H806; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRABB DW, 1989, METHOD ENZYMOL, V168, P690; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; CRAWFORD DC, 1994, CIRC RES, V74, P727, DOI 10.1161/01.RES.74.4.727; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOSTAL DE, 1993, TRENDS CARDIOVAS MED, V3, P67, DOI 10.1016/1050-1738(93)90039-9; DOSTAL DE, 1991, HORIZONS ENDOCRINOLO, P265; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; JOHNSON MC, 1992, ENDOCRINOLOGY, V131, P2404, DOI 10.1210/en.131.5.2404; KAI H, 1994, HYPERTENSION, V24, P523, DOI 10.1161/01.HYP.24.4.523; LANDPAINTER K, 1994, CARDIAC RENIN ANGIOT; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; RAINEY WE, 1991, MOL CELL ENDOCRINOL, V81, P33, DOI 10.1016/0303-7207(91)90202-4; Raizada M.K., 1993, CELLULAR MOL BIOL RE; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SCORB W, 1995, J MOL CELL CARDIOL, V27, P1151; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THEKKUMKARA TJ, 1995, MOL CELL BIOCHEM, V146, P79, DOI 10.1007/BF00926885; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186	47	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19059	19065		10.1074/jbc.270.32.19059	http://dx.doi.org/10.1074/jbc.270.32.19059			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642569	hybrid			2022-12-25	WOS:A1995RN95400057
J	KUMAGAI, H; CHUN, KT; SIMONI, RD				KUMAGAI, H; CHUN, KT; SIMONI, RD			MOLECULAR DISSECTION OF THE ROLE OF THE MEMBRANE DOMAIN IN THE REGULATED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL-ENHANCED DEGRADATION; HMG-COA REDUCTASE; A REDUCTASE; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-SEQUENCE; ARABIDOPSIS-THALIANA; BOUND DOMAIN; ENZYME; CDNA; EXPRESSION	We have previously shown that the membrane domain of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase from hamster contains all of the sequences required for both localization to the endoplasmic reticulum and regulated degradation of the enzyme, It has been reported that the enzymatic activity and mRNA levels of HMG-CoA reductase from sea urchin embryos cultured in the presence of regulators were unchanged compared to levels in control embryos (Woodward, H. D., Alien, M. C., and Lennarz, W. J. (1988) J. Biol. Chem. 263, 18411-18418), This observation led us to investigate the possibility that the sea urchin enzyme is not subject to regulated protein turnover, Interestingly, the sea urchin enzyme shares 62% amino acid sequence identity with the hamster enzyme in the membrane domain and shares similar predicted topological features, In the current studies we have compared the degradation phenotypes of the sea urchin HMG-CoA reductase and the hamster HMG-CoA reductase in Chinese hamster ovary cells to further elucidate the role of the membrane domain in enzyme degradation in response to physiological regulators, To accomplish this, we constructed sea urchin HMGal (uHMGal), the structural equivalent of hamster HMGal (httMGal), which has the sea urchin HMG-CoA reductase membrane domain fused to Escherichia coli beta-galactosidase. The uHMGal was stably expressed in CHO cells, and we found that the degradation of uHMGal is not accelerated by sterols, and even in the absence of sterols, it is less stable than hHMGal. We also constructed chimeric hamster/sea urchin HMGal molecules to investigate which amino acid sequences from the hamster enzyme are sufficient to confer sterol-regulated degradation upon the sea urchin enzyme. Our results identify the second membrane-spanning domain of hamster enzyme as important for the regulated degradation of HMG-CoA reductase.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26502] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; CAELLES C, 1989, PLANT MOL BIOL, V13, P627, DOI 10.1007/BF00016018; CHEN HJ, 1990, J BIOL CHEM, V265, P4622; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; INOUE S, 1991, J BIOL CHEM, V266, P13311; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; LEARNED RM, 1989, P NATL ACAD SCI USA, V86, P2779, DOI 10.1073/pnas.86.8.2779; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSKEY KL, 1985, J BIOL CHEM, V263, P8929; MARTINEZGONZALEZ J, 1993, EUR J BIOCHEM, V213, P233, DOI 10.1111/j.1432-1033.1993.tb17753.x; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SKALNIK DG, 1985, DNA-J MOLEC CELL BIO, V4, P439, DOI 10.1089/dna.1985.4.439; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WOODWARD HD, 1988, J BIOL CHEM, V263, P18411	26	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19107	19113		10.1074/jbc.270.32.19107	http://dx.doi.org/10.1074/jbc.270.32.19107			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642576	hybrid			2022-12-25	WOS:A1995RN95400064
J	MCDONOUGH, VM; BUXEDA, RJ; BRUNO, MEC; OZIERKALOGEROPOULOS, O; ADELINE, MT; MCMASTER, CR; BELL, RM; CARMAN, GM				MCDONOUGH, VM; BUXEDA, RJ; BRUNO, MEC; OZIERKALOGEROPOULOS, O; ADELINE, MT; MCMASTER, CR; BELL, RM; CARMAN, GM			REGULATION OF PHOSPHOLIPID BIOSYNTHESIS IN SACCHAROMYCES-CEREVISIAE BY CTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE METHYLATION PATHWAY; ENZYME PHOSPHATIDYLSERINE SYNTHASE; CDP-DIACYLGLYCEROL SYNTHASE; COORDINATE REGULATION; ESCHERICHIA-COLI; PHOSPHATIDYLINOSITOL SYNTHASE; INOSITOL SYNTHESIS; SHUTTLE VECTORS; MESSENGER-RNA; YEAST MUTANT	In the yeast Saccharomyces cerevisiae, the major membrane phospholipid phosphatidylcholine is synthesized by the CDP-diacylglycerol and CDP-choline pathways. We examined the regulation of phosphatidylcholine synthesis by CTP. The cellular concentration of CTP was elevated (2.4-fold) by overexpressing CTP synthetase, the enzyme responsible for the synthesis of CTP. The overexpression of CTP synthetase resulted in a a-fold increase in the utilization of the CDP-choline pathway for phosphatidylcholine synthesis. The increase in CDP-choline pathway usage was not due to an increase in the expression of any of the enzymes in this pathway. CDP-choline, the product of the phosphocholine cytidylyltransferase reaction, was the limiting intermediate in the CDP-choline pathway. The apparent K-m of CTP (1.4 mM) for phosphocholine cytidylyltransferase was 2-fold higher than the cellular concentration of CTP (0.7 mM) in control cells. This provided an explanation of why the overexpression of CTP synthetase caused an increase in the cellular concentration of CDP-choline, Phosphatidylserine synthase activity was reduced in cells overexpressing CTP synthetase. This was not due to a transcriptional repression mechanism, Instead, the decrease in phosphatidylserine synthase activity was due, at least in part, to a direct inhibition of activity by CTP. These results show that CTP plays a role in the regulation of the pathways by which phosphatidylcholine is synthesized. This regulation includes the supply of CTP for the phosphocholine cytidylyltransferase reaction in the CDP-choline pathway and the inhibition of the phosphatidylserine synthase reaction in the CDP-diacylglycerol pathway.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA; UNIV PARIS 06, CNRS, CTR GENET MOLEC, LAB PROPRE, F-91198 GIF SUR YVETTE, FRANCE; INST CHIM SUBST NAT, F-91198 GIF SUR YVETTE, FRANCE; DUKE UNIV, MED CTR, DEPT MOLEC CANC BIOL, DURHAM, NC 27710 USA	Rutgers State University New Brunswick; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Duke University				McMaster, Christopher/0000-0003-0822-5776	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-20015, GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BAELEE MS, 1984, J BIOL CHEM, V259, P857; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CARSON MA, 1984, J BIOL CHEM, V259, P6267; CARSON MA, 1982, J BIOL CHEM, V257, P8115; CARTER JR, 1966, J LIPID RES, V7, P678; CHRISTIANSEN K, 1979, BIOCHIM BIOPHYS ACTA, V574, P448, DOI 10.1016/0005-2760(79)90241-8; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; COVIELLA ILG, 1992, J NEUROCHEM, V59, P338, DOI 10.1111/j.1471-4159.1992.tb08909.x; CULBERTSON MR, 1975, GENETICS, V80, P23; DOWHAN W, 1992, METHOD ENZYMOL, V209, P348; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; HAID A, 1983, METHOD ENZYMOL, V96, P192; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1994, J BIOL CHEM, V269, P20995; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1980, J BACTERIOL, V143, P176, DOI 10.1128/JB.143.1.176-181.1980; JUND R, 1970, J BACTERIOL, V102, P607, DOI 10.1128/JB.102.3.607-615.1970; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KODAKI T, 1989, EUR J BIOCHEM, V185, P243, DOI 10.1111/j.1432-1033.1989.tb15109.x; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; NIKAWA J, 1983, EUR J BIOCHEM, V131, P223, DOI 10.1111/j.1432-1033.1983.tb07253.x; OVERMEYER JH, 1991, ARCH BIOCHEM BIOPHYS, V290, P511, DOI 10.1016/0003-9861(91)90574-3; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SPERKAGOTTLIEB C, 1990, YEAST, V6, P331, DOI 10.1002/yea.320060406; STORER AC, 1976, BIOCHEM J, V159, P1; SUMMERS EF, 1988, GENETICS, V120, P909; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; VANCE DE, 1980, J BIOL CHEM, V255, P1064; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; WAECHTER CJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P401, DOI 10.1016/0003-9861(73)90637-1; WU WI, 1994, J BIOL CHEM, V269, P29495; YAMASHITA S, 1980, EUR J BIOCHEM, V104, P611, DOI 10.1111/j.1432-1033.1980.tb04465.x; YAMASHITA S, 1982, EUR J BIOCHEM, V128, P589; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028	79	56	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18774	18780		10.1074/jbc.270.32.18774	http://dx.doi.org/10.1074/jbc.270.32.18774			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642527				2022-12-25	WOS:A1995RN95400014
J	ROZANOWSKA, M; JARVISEVANS, J; KORYTOWSKI, W; BOULTON, ME; BURKE, JM; SARNA, T				ROZANOWSKA, M; JARVISEVANS, J; KORYTOWSKI, W; BOULTON, ME; BURKE, JM; SARNA, T			BLUE LIGHT-INDUCED REACTIVITY OF RETINAL AGE PIGMENT - IN-VITRO GENERATION OF OXYGEN-REACTIVE SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACULAR DEGENERATION; HYDROPEROXIDES; LIPOFUSCIN; MELANINS; RADICALS; EYE	Exposure of the eye to intense light, particularly blue light, can cause irreversible, oxygen-dependent damage to the retina, However, no key chromophores that trigger such photooxidative processes have been identified yet, We have found that illumination of human retinal pigment epithelium (RPE) cells with light induces significant uptake of oxygen that is both wavelength- and age-dependent, Analysis of photoreactivity of RPE cells and their age pigment lipofuscin indicates that the observed photoreactivity in RPE cells is primarily due to the presence of lipofuscin, which, under aerobic conditions, generates several oxygen-reactive species including singlet oxygen, superoxide anion, and hydrogen peroxide, We have also found that lipofuscin-photosensitized aerobic reactions lead to enhanced lipid peroxidation as measured by accumulation of lipid hydroperoxides and malondialdehyde in illuminated pigment granules, Hydrogen peroxide is only a minor product of aerobic photoexcitation of lipofuscin, We postulate that lipofuscin is a potential photosensitizer that may increase the risk of retinal photodamage and contribute to the development of age related maculopathy.	JAGIELLONIAN UNIV, JAN ZURZYCKI INST MOLEC BIOL, DEPT BIOPHYS, PL-31120 KRAKOW, POLAND; UNIV MANCHESTER, DEPT OPHTHALMOL, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV MANCHESTER, SCH BIOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND; MED COLL WISCONSIN, DEPT OPHTHALMOL & CELLULAR BIOL, MILWAUKEE, WI 53226 USA	Jagiellonian University; University of Manchester; University of Manchester; Medical College of Wisconsin			Rozanowska, Malgorzata B/B-7860-2014; Rozanowska, Malgorzata/AAD-4806-2021	Rozanowska, Malgorzata B/0000-0003-2913-8954; Rozanowska, Malgorzata/0000-0003-2913-8954	NCRR NIH HHS [RR01008] Funding Source: Medline; NEI NIH HHS [P30EY01931, R01EY06664] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY001931, R01EY006664] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIELSKI BHJ, 1991, INT J RADIAT BIOL, V59, P291, DOI 10.1080/09553009114550301; BIELSKI BHJ, 1983, J BIOL CHEM, V258, P4759; BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4; BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BURKE JM, 1988, INVEST OPHTH VIS SCI, V29, P1784; DRAPER HH, 1993, FREE RADICAL BIO MED, V15, P353, DOI 10.1016/0891-5849(93)90035-S; ENOCHS WS, 1993, PIGM CELL RES, V6, P91, DOI 10.1111/j.1600-0749.1993.tb00587.x; FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195; FEENEYBURNS L, 1980, CURRENT TOPICS EYE R, P119; FOOTE CS, 1984, PORPHYRIN LOCALIZATI, P3; Fridovich, 1976, FREE RADICALS BIOLOG, V1, P239; GIROTTI AW, 1990, PHOTOCHEM PHOTOBIOL, V51, P497, DOI 10.1111/j.1751-1097.1990.tb01744.x; GREEN WR, 1985, OPHTHALMOLOGY, V92, P615; Gutteridge J M, 1983, J Appl Biochem, V5, P293; Halliwell B., 1989, FREE RADICAL BIO MED, V2nd; HALPERN HJ, 1990, J MAGN RESON, V90, P40, DOI 10.1016/0022-2364(90)90364-F; JAFFE GJ, 1988, OPHTHALMOLOGY, V95, P1130; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; KORYTOWSKI W, 1987, PHOTOCHEM PHOTOBIOL, V45, P185, DOI 10.1111/j.1751-1097.1987.tb05362.x; KORYTOWSKI W, 1993, ANAL BIOCHEM, V213, P111, DOI 10.1006/abio.1993.1393; LERMAN S, 1989, PHOTOMEDICINE, V1, P79; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PRYOR WA, 1984, METHOD ENZYMOL, V105, P293; Rosen G.M., 1985, ADV FREE RADIC BIOL, V1, P345, DOI [10.1016/8755-9668(85)90012-2, DOI 10.1016/8755-9668(85)90012-2]; SARNA T, 1994, NATO ADV SCI INST SE, V272, P125; SARNA T, 1980, ARCH BIOCHEM BIOPHYS, V200, P140, DOI 10.1016/0003-9861(80)90340-9; SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R; Sarna T., 1993, ATMOSPHERIC OXIDATIO, VIII, P129; TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035; VINDING T, 1992, ACTA OPHTHALMOL, V70, P66; WEITER J, 1987, CLIN LIGHT DAMAGE EY, P79; WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145; Yannuzzi L A, 1987, Trans Am Ophthalmol Soc, V85, P120; YOUNG RW, 1988, SURV OPHTHALMOL, V32, P265	35	346	350	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18825	18830		10.1074/jbc.270.32.18825	http://dx.doi.org/10.1074/jbc.270.32.18825			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642534	hybrid			2022-12-25	WOS:A1995RN95400021
J	WOO, SK; LEE, JI; PARK, IK; YOO, YJ; CHO, CM; KANG, MS; HA, DB; TANAKA, K; CHUNG, CH				WOO, SK; LEE, JI; PARK, IK; YOO, YJ; CHO, CM; KANG, MS; HA, DB; TANAKA, K; CHUNG, CH			MULTIPLE UBIQUITIN C-TERMINAL HYDROLASES FROM CHICK SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; PROTEIN-DEGRADATION; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; CELL CYCLE; HEAT-SHOCK; GENE; EXPRESSION; CLONING; ENZYME	A new method for assaying ubiquitin C-terminal hydrolases was developed using a I-125-labeled ubiquitin-alpha NH-MHISPPEPESEEEEEHYC as substrate, Since the peptide portion was almost exclusively radiolabeled, the enzymes could be assayed directly by simple measurement of the radioactivity released into acid-soluble products, Using this assay protocol, we identified at least 10 ubiquitin C-terminal hydrolase activities from the extract of chick skeletal muscle, which were tentatively named UCHs 1 through 10, Of these, UCH-B was purified to apparent homogeneity, Purified UCH-6 behaved as a dimer of 27-kDa subunits, The apparent molecular masses of the other partially purified UCHs ranged hom 35 to 810 kDa as determined under a nondenaturing condition, Muscle UCHs, except UCH-1, were activated dramatically by poly-L-Lys but with an unknown mechanism. Ah of the UCHs were sensitive to inhibition by sulfhydryl-blocking agents such as iodoacetamide. In addition, all of the UCHs were capable of releasing free ubiquitin from a ubiquitin-alpha NH-carboxyl extension protein of 80 amino acids and from ubiquitin-alpha NH-dihydrofolate reductase, Five of the enzymes, UCHs 1 through 5, were also capable of generating free ubiquitin from poly-His-tagged diubiquitin. In addition, UCH-1 and UCH-7 could remove ubiquitin that had been ligated covalently by an isopeptide linkage to a ubiquitin(RGA)-alpha NH-peptide, the peptide portion of which consists of the 20 amino acids of the calmodulin binding domain of myosin light chain kinase, These results suggest that the 10 UCH activities isolated from chick skeletal muscle appear to be distinct from each other at least in their chromatographic behavior, size, and substrate specificity.	SEOUL NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,SRC CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA; LUCKY BIOTECH LTD,TAEJON 305,SOUTH KOREA; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN	Seoul National University (SNU); Tokushima University			Yoo, Yung Joon/AAH-5002-2020					BAKER RT, 1992, J BIOL CHEM, V267, P23364; BOND U, 1986, MOL CELL BIOL, V6, P4602, DOI 10.1128/MCB.6.12.4602; CARLSON N, 1987, J CELL BIOL, V104, P537, DOI 10.1083/jcb.104.3.537; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1988, UBIQUITIN, P173; HADARI T, 1992, J BIOL CHEM, V267, P719; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JOSLIN G, 1991, J IMMUNOL, V147, P1614; KIM YM, 1994, PLANT PHYSIOL, V106, P791, DOI 10.1104/pp.106.2.791; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DH, 1993, BIOCHEM MOL BIOL INT, V30, P121; LUND PK, 1985, J BIOL CHEM, V260, P7609; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; MONIA BP, 1989, J BIOL CHEM, V264, P4093; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PICKART CM, 1988, UBIQUITIN, P77; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEOL JH, 1989, FEBS LETT, V247, P197, DOI 10.1016/0014-5793(89)81333-X; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; YOO Y, 1989, J BIOL CHEM, V264, P17078	41	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18766	18773		10.1074/jbc.270.32.18766	http://dx.doi.org/10.1074/jbc.270.32.18766			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642526	hybrid			2022-12-25	WOS:A1995RN95400013
J	PETERSON, BZ; CATTERALL, WA				PETERSON, BZ; CATTERALL, WA			CALCIUM-BINDING IN THE PORE OF L-TYPE CALCIUM CHANNELS MODULATES HIGH-AFFINITY DIHYDROPYRIDINE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SKELETAL-MUSCLE; ALPHA-1 SUBUNIT; CA2+ CHANNELS; ION SELECTIVITY; BRAIN; IDENTIFICATION; DETERMINANTS; LOCALIZATION; PERMEATION; EXPRESSION	The pore forming alpha(1) subunit of L-type voltage-gated Ca2+ channels contains a Ca2+-binding site that is allosterically coupled to the receptor site for dihydropyridine (DHP) Ca2+ antagonists. Site-directed mutations of conserved Phe and Glu residues in the pore-lining SS1/SS2 segments greatly reduced Ca2+ enhancement of DHP binding. Substitution of Phe-1O13 in the alpha(1) subunit from rabbit skeletal muscle (alpha(1S)) with Gly (F1013G) as in DHP-insensitive Ca2+ channels caused a 4-fold decrease in sensitivity to Ca2+. Mutation of the Ca2+-binding residues Glu-1014 in domain III and Glu-1323 in domain IV to Gln (E1014Q and E1323Q) caused 11- and 35-fold decreases in sensitivity to Ca2+, respectively, as well as decreases in the maximal DHP binding affinities attained at optimal concentrations of Ca2+, DHP binding to the charge-reversal mutation, E1014K, had no sensitivity to Ca2+. Our results demonstrate that high affinity Ca2+ binding to the Glu residues in the SS1/SS2 segments of domains III and TV of alpha(1S) stabilizes the DHP receptor site in its high affinity state. We propose a three-state model in which the affinity for DHPs is dependent on the presence of 0, 1, or 2 bound Ca2+ ions at sites in the pore.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312, P01HL044948] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 44948, T32 HL07312] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P565, DOI 10.1113/jphysiol.1984.sp015351; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FOSSET M, 1983, J BIOL CHEM, V258, P6086; GLOSSMANN H, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1917; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; Hille B., 1992, IONIC CHANNELS EXCIT; KALASZ H, 1993, FEBS LETT, V331, P177, DOI 10.1016/0014-5793(93)80321-K; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KOSTYUK PG, 1983, J MEMBRANE BIOL, V76, P83, DOI 10.1007/BF01871455; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Sather William A., 1994, Current Opinion in Neurobiology, V4, P313, DOI 10.1016/0959-4388(94)90091-4; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0; Smith RM, 1974, CRITICAL STABILITY C, V1-6; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V87, P5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	28	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18201	18204		10.1074/jbc.270.31.18201	http://dx.doi.org/10.1074/jbc.270.31.18201			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629136	hybrid			2022-12-25	WOS:A1995RM64200008
J	QUIROS, LM; SALAS, JA				QUIROS, LM; SALAS, JA			BIOSYNTHESIS OF THE MACROLIDE OLEANDOMYCIN BY STREPTOMYCES-ANTIBIOTICUS - PURIFICATION AND KINETIC CHARACTERIZATION OF AN OLEANDOMYCIN GLUCOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							23S RIBOSOMAL-RNA; RESISTANCE DETERMINANT; PRODUCER ORGANISM; METHYLATION; INHIBITORS; POLYMERASE; MECHANISM; FRADIAE; CLONING; GENE	The oleandomycin (OM) producer, Streptomyces antibioticus, possesses a mechanism involving two enzymes for the intracellular inactivation and extracellular reactivation of the antibiotic, Inactivation takes place by transfer of a glucose molecule from a donor (UDP-glucose) to OM, a process catalyzed by an intracellular glucosyltransferase, Glucosyltransferase activity is detectable in cell-free extracts concurrent with biosynthesis of OM, The enzyme has been purified 1,097-fold as a monomer, with a molecular mass of 57.1 kDa by a four-step procedure using three chromatographic columns, The reaction operates via a compulsory-order mechanism, This has been shown by steady state kinetic studies using either ORI or an alternative substrate (rosaramycin) and dead-end inhibitors, and isotopic exchange reactions at equilibrium, OM binds first to the enzyme, followed by UDP-glucose, A ternary complex is thus formed prior to transfer of glucose. UDP is then released, followed by the glycosylated oleandomycin (GS OM).	UNIV OVIEDO,DEPT BIOL FUNC,E-33006 OVIEDO,SPAIN; UNIV OVIEDO,INST UNIV BIOTECNOL ASTURIAS,E-33006 OVIEDO,SPAIN	University of Oviedo; University of Oviedo			Quirós, Luis/T-3822-2017	Quirós, Luis/0000-0003-3505-3762				ARCA P, 1988, ANTIMICROB AGENTS CH, V32, P1552, DOI 10.1128/AAC.32.10.1552; BLANCO MG, 1984, J GEN MICROBIOL, V130, P2883; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; DAZIEL K, 1957, ACTA CHEM SCAND, V11, P1706; GLOCKNER C, 1984, FEMS MICROBIOL LETT, V25, P121, DOI 10.1016/0378-1097(84)90058-2; Hopwood D. A., 1985, GENETIC MANIPULATION; KAWAGUCHI A, 1979, ARCH BIOCHEM BIOPHYS, V197, P30, DOI 10.1016/0003-9861(79)90214-5; LAEMMLI UK, 1971, NATURE, V227, P680; OLANO C, 1995, MOL MICROBIOL, V16, P333, DOI 10.1111/j.1365-2958.1995.tb02305.x; PIENDL W, 1982, ANTIMICROB AGENTS CH, V22, P231, DOI 10.1128/AAC.22.2.231; QUIROS LM, 1994, EUR J BIOCHEM, V222, P129, DOI 10.1111/j.1432-1033.1994.tb18850.x; RODRIGUEZ AM, 1992, MOL MICROBIOL, V8, P571; ROZA J, 1986, J ANTIBIOT, V39, P609, DOI 10.7164/antibiotics.39.609; SKINNER RH, 1982, J GEN MICROBIOL, V128, P2411; THIARA AS, 1988, EMBO J, V7, P2255, DOI 10.1002/j.1460-2075.1988.tb03065.x; VARA J, 1985, BIOCHEMISTRY-US, V24, P8074, DOI 10.1021/bi00348a036; VILCHES C, 1992, J BACTERIOL, V174, P161, DOI 10.1128/jb.174.1.161-165.1992; VILCHES C, 1990, J GEN MICROBIOL, V136, P1447, DOI 10.1099/00221287-136-8-1447; WATANABE S, 1976, BIOCHEM BIOPH RES CO, V72, P522, DOI 10.1016/S0006-291X(76)80072-1; YAMAMOTO H, 1981, BIOCHEM BIOPH RES CO, V100, P1396, DOI 10.1016/0006-291X(81)91979-3; ZALACAIN M, 1989, J BACTERIOL, V171, P4254, DOI 10.1128/JB.171.8.4254-4260.1989; ZALACAIN M, 1990, EUR J BIOCHEM, V189, P67, DOI 10.1111/j.1432-1033.1990.tb15460.x; ZALACAIN M, 1991, GENE, V97, P137, DOI 10.1016/0378-1119(91)90021-3	25	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18234	18239		10.1074/jbc.270.31.18234	http://dx.doi.org/10.1074/jbc.270.31.18234			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629141	hybrid			2022-12-25	WOS:A1995RM64200015
J	HUPP, TR; LANE, DP				HUPP, TR; LANE, DP			2 DISTINCT SIGNALING PATHWAYS ACTIVATE THE LATENT DNA-BINDING FUNCTION OF P53 IN A CASEIN KINASE-II-INDEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; SERUM RESPONSE FACTOR; GROWTH ARREST; PHOSPHORYLATION SITE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MUTANT P53; CELLS; FORMS	Post-translational modification of a carboxyl-terminal negative regulatory domain in vitro by either casein kinase II or protein kinase C allosterically activates the latent sequence-specific DNA binding function of p53. Reported here is a biochemical approach to determine the types of signaling pathways and enzymes that are involved in p53 activation in cells. Using a novel chromatographic method, we have been able to separate three distinct biochemical forms of p53 that have been synthesized in vivo; two are in an activated state, and one is in a latent state for sequence specific DNA binding. The two activated forms of p53 appear to be controlled individually by either a constitutive or a UV-inducible signaling pathway. p53 lacking the COOH-terminal casein kinase II site (p53 Delta 4) was characterized biochemically and used to determine the affects of deletion of the casein kinase II motif on the production of the two activated forms of p53 in vivo. As observed with full-length p53, the production of two distinct chromatographic forms of activated p53 Delta 4 occurs in vivo, indicating that p53 activation can occur through a casein kinase II-independent pathway and suggesting that two other factors are involved in activation of p53 in vivo.	UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADDISON C, 1990, ONCOGENE, V5, P423; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1991, ONCOGENE, V6, P1699; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOUSSET K, 1993, ONCOGENE, V8, P3211; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAYAMAKIN M, 1994, CANCER RES, V15, P2262; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCELLA M, 1993, ONCOGENE, V8, P1519; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P4469; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALL PA, 1993, ONCOGENE, V8, P203; HALL PA, 1994, J PATHOL, V1172, P1; HARLOW E, 1988, ANTIBODIES LABORATOR; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOLMAN JL, 1993, P NATL ACAD SCI USA, V90, P10115, DOI 10.1073/pnas.90.21.10115; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MERRITT AJ, 1994, CANCER RES, V54, P614; MESTRES P, 1994, ACTA ANAT, V149, P13; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIDGLEY CA, 1993, J CELL SCI, V101, P183; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SKOUV J, 1994, CELL GROWTH DIFFER, V5, P329; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOUSSI T, 1990, ONCOGENE, V5, P945; STIGARE J, 1983, MOL CELL BIOCHEM, V129, P77; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TURMAN MA, 1993, BIOCHEM MED METAB B, V50, P210, DOI 10.1006/bmmb.1993.1063; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VANDELFT S, 1993, BIOCHEM BIOPH RES CO, V197, P542, DOI 10.1006/bbrc.1993.2513; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1995, ONCOGENE, V10, P389; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105; YONISH RE, 1991, NATURE, V353, P345; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	96	123	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18165	18174		10.1074/jbc.270.30.18165	http://dx.doi.org/10.1074/jbc.270.30.18165			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629129	hybrid			2022-12-25	WOS:A1995RM26600081
J	KHOO, KH; SARDA, S; XU, XF; CAULFIELD, JP; MCNEIL, MR; HOMANS, SW; MORRIS, HR; DELL, A				KHOO, KH; SARDA, S; XU, XF; CAULFIELD, JP; MCNEIL, MR; HOMANS, SW; MORRIS, HR; DELL, A			A UNIQUE MULTIFUCOSYLATED -3GALNAC-BETA-1-]4GLCNAC-BETA-1-]3GAL-ALPHA-1- MOTIF CONSTITUTES THE REPEATING UNIT OF THE COMPLEX O-GLYCANS DERIVED FROM THE CERCARIAL GLYCOCALYX OF SCHISTOSOMA-MANSONI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; N-ACETYLGALACTOSAMINE; HIGH-RESOLUTION; GLYCOPROTEINS; CARBOHYDRATE; ULTRASTRUCTURE; SYNTHESIZES; ANTIBODIES; ANTIGENS; EPITOPES	The entire surface of the cercarial stage of the human blood fluke Schistosoma mansoni is covered by a 1-mu m thick, highly immunogenic, fucose-rich glycocalyx (GCX). Using strategies based on enzymatic, chemical, and mass spectrometric analysis, we have defined the structures of the major glycans released by reductive elimination from GCX. They comprise a heterogeneous population of multifucosylated complex oligosaccharides with the following nonreducing terminal sequences: +/- Fuc alpha 1 --> 2Fuc alpha 1 --> 3GalNAc beta 1 --> 4GlcNAc beta 1 --> 3Gal alpha 1 --> 3 (up arrow) +/- Fuc alpha 1 --> 2Fuc alpha 1 --> 2Fuc alpha 1 STRUCTURE 1 Our structural data suggest that these tri- to pentafucosylated epitopes are carried on type 1, R-->Gal beta-1-->3GalNAc, and type 2, R-->Gal beta 1-->3(R-->GlcNAc beta-1-->6)GalNAc, core structures via repeat units of (3GalNAc beta 1-->4(Fuc alpha 1-->2Fuc alpha 1-->2Fuc alpha 1--3_GlcNAc beta-1-->3Gal alpha-->)(n)), where it is mainly 0 and 1, and all sugars are in the pyranose form, The proposed structure represents the first instance where an alpha-galactosylated beta-GalNAc(1-->4)-beta-GlcNAc sequence occurs as a repeating unit in a glycoprotein. It is also unique in being substituted with oligofucosyl appendages. The unusual oligosaccharide structures described here, particularly the potentially immunodominant oligofucosyl moieties, are most likely responsible for the known potency of GCX in modulating various immune responses including complement activation, B cell mitogenesis, and delayed type hypersensitivity in schistosomiasis.	UNIV LONDON IMPERIAL COLL SCI & TECHNOL, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND; SYNTEX INC, DISCOVERY RES, PALO ALTO, CA 94304 USA; COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA; UNIV ST ANDREWS, INSTV BIOMOLEC SCI, ST ANDREWS KY16 9ST, FIFE, SCOTLAND	Imperial College London; Syntex Corporation; Colorado State University; University of St Andrews			McNeil, Michael/G-3325-2019; Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023083, R22AI023083] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23083] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; CAULFIELD JP, 1987, J PARASITOL, V73, P514, DOI 10.2307/3282129; COUTO AS, 1990, MOL BIOCHEM PARASIT, V39, P100; DALTON JP, 1987, EXP PARASITOL, V63, P215, DOI 10.1016/0014-4894(87)90164-0; DELL A, 1994, METHOD ENZYMOL, V230, P108; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; DELL A, 1993, CURR OPIN STRUC BIOL, V3, P687, DOI 10.1016/0959-440X(93)90051-L; DUNNE DW, 1990, PARASITOL TODAY, V6, P45, DOI 10.1016/0169-4758(90)90068-F; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GOWDA DC, 1994, J BIOL CHEM, V269, P20031; GRZYCH JM, 1982, J IMMUNOL, V129, P2739; HARN DA, 1984, J EXP MED, V159, P1371, DOI 10.1084/jem.159.5.1371; KANG S, 1993, J PARASITOL, V79, P815, DOI 10.2307/3283717; KEMP WM, 1970, J PARASITOL, V56, P713, DOI 10.2307/3277718; KO AI, 1990, P NATL ACAD SCI USA, V87, P4159, DOI 10.1073/pnas.87.11.4159; KOSTER B, 1994, PARASITOLOGY, V108, P433, DOI 10.1017/S0031182000075995; LEVERY SB, 1992, J BIOL CHEM, V267, P5542; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MULDER H, 1995, EUR J BIOCHEM, V227, P175, DOI 10.1111/j.1432-1033.1995.tb20374.x; NANDURI J, 1991, J BIOL CHEM, V266, P1341; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; NYAME K, 1989, J BIOL CHEM, V264, P3235; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; REASON AJ, 1994, GLYCOBIOLOGY, V4, P593, DOI 10.1093/glycob/4.5.593; SAMUELSON JC, 1985, J CELL BIOL, V100, P1423, DOI 10.1083/jcb.100.5.1423; SEKO A, 1989, J BIOL CHEM, V264, P15922; SIMPSON AJG, 1990, PARASITOL TODAY, V6, P40, DOI 10.1016/0169-4758(90)90067-E; SRIVATSAN J, 1994, J PARASITOL, V80, P884, DOI 10.2307/3283435; SRIVATSAN J, 1992, GLYCOBIOLOGY, V2, P445, DOI 10.1093/glycob/2.5.445; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; STANDEN O. D., 1952, JOUR HELMINTHOL, V26, P25, DOI 10.1017/S0022149X00032570; STRECKER G, 1995, GLYCOBIOLOGY, V5, P137, DOI 10.1093/glycob/5.1.137; STRECKER G, 1992, EUR J BIOCHEM, V207, P995, DOI 10.1111/j.1432-1033.1992.tb17135.x; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; VANDAM GJ, 1994, EUR J BIOCHEM, V225, P467, DOI 10.1111/j.1432-1033.1994.00467.x; VANKUIK JA, 1987, EUR J BIOCHEM, V169, P399; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WEISS JB, 1986, J IMMUNOL, V136, P4275; WEISS JB, 1985, J IMMUNOL, V135, P1421; Xu X. F., 1993, Molecular Biology of the Cell, V4, p455A; XU XF, 1994, EXP PARASITOL, V79, P399, DOI 10.1006/expr.1994.1102; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244	44	108	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17114	17123		10.1074/jbc.270.29.17114	http://dx.doi.org/10.1074/jbc.270.29.17114			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615506	hybrid			2022-12-25	WOS:A1995RK68900013
J	QUAN, H; FAN, GB; WANG, CC				QUAN, H; FAN, GB; WANG, CC			INDEPENDENCE OF THE CHAPERONE ACTIVITY OF PROTEIN DISULFIDE-ISOMERASE FROM ITS THIOREDOXIN-LIKE ACTIVE-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PEPTIDE BINDING	Protein disulfide isomerase (PDI) alkylated at thiols of the thioredoxin-like -CHC- active sites is devoid of isomerase activity, but its chaperone-like activity to increase the reactivation yield and prevent the aggregation of guanidine hydrochloride-denatured D-glyceraldehyde-3-phospate dehydrogenase upon dilution is unimpaired. A peptide of 28 amino acids markedly inhibits both the enzyme and the chaperone activities of PDI. The above results indicate that the -CGHC- active site is necessary for the isomerase activity but not required for the chaperone activity of PDI, whereas the peptide binding site is essential for both activities.	ACAD SINICA,INST BIOPHYS,NATL LAB BIOMACROMOLECULES,BEIJING 100101,PEOPLES R CHINA	Chinese Academy of Sciences; Institute of Biophysics, CAS								CAI H, 1994, J BIOL CHEM, V269, P24550; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; KATZEN HM, 1966, J BIOL CHEM, V241, P1006; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LILIE H, 1994, J BIOL CHEM, V269, P14290; MARANGOS PJ, 1974, BIOCHEMISTRY-US, V13, P904, DOI 10.1021/bi00702a012; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1991, J BIOL CHEM, V266, P19645; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; OTSU M, 1994, J BIOL CHEM, V269, P6874; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; SHORTLE D, 1986, J CELL BIOCHEM, V30, P281, DOI 10.1002/jcb.240300402; VUORI K, 1992, J BIOL CHEM, V267, P7211; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263	24	116	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17078	17080		10.1074/jbc.270.29.17078	http://dx.doi.org/10.1074/jbc.270.29.17078			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615500	hybrid			2022-12-25	WOS:A1995RK68900007
J	VANDERKLEI, IJ; HILBRANDS, RE; SWAVING, GJ; WATERHAM, HR; VRIELING, EG; TITORENKO, VI; CREGG, JM; HARDER, W; VEENHUIS, M				VANDERKLEI, IJ; HILBRANDS, RE; SWAVING, GJ; WATERHAM, HR; VRIELING, EG; TITORENKO, VI; CREGG, JM; HARDER, W; VEENHUIS, M			THE HANSENULA-POLYMORPHA PER3 GENE IS ESSENTIAL FOR THE IMPORT OF PTS1 PROTEINS INTO THE PEROXISOMAL MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOL METABOLISM; TARGETING SIGNAL; DEFICIENT MUTANT; YEAST; BIOGENESIS; MEMBRANE; MICROBODIES; REPLICATION; SYNTHASE; LOCATION	PER genes are essential for the assembly of peroxisomes in Hansenula polymorpha. Here we describe the PER3 gene which was cloned by functional complementation of a H. polymorpha per3 mutant. The complementing PER3 gene encodes a protein of 569 amino acids (Per3p) with a calculated mass of 63.9 kDa; Per3p belongs to the tetratricopeptide repeat protein family and is located in both the cytosol and the peroxisomal matrix. Remarkably, Per3p does not contain a known targeting signal (PTS1 or PTS2). The PER3 gene product shows similarity to the Saccharomyces cerevisiae Pas10p (40% identity) and the Pichia pastoris Pas8p (55% identity). However, their function apparently cannot be interchanged since the P. pastoris PAS8 gene failed to functionally complement a H. polymorpha per3 disruption mutant, The per3 disruption mutant contained normal but small peroxisomes in which PTS2 proteins (both homologous and heterologous) were imported. Other matrix proteins (in particular PTS1 proteins) resided in the cytosol where they were normally assembled and active. We argue that Per3p is a component of the peroxisomal import machinery and most probably shuttles matrix proteins from the cytosol to the organellar matrix.	OREGON GRAD INST SCI & TECHNOL,PORTLAND,OR 97291		VANDERKLEI, IJ (corresponding author), UNIV GRONINGEN,CTR BIOL,GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST,DEPT MICROBIOL,KERKLAAN 30,9751 NN HAREN,NETHERLANDS.		van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679	NIDDK NIH HHS [DK-43698] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043698] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAFLE A, 1990, PEDIATR RES, V27, P304; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; BRUINENBERG PG, 1990, YEAST, V6, P245, DOI 10.1002/yea.320060309; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; DOUMA AC, 1990, YEAST, V6, P99, DOI 10.1002/yea.320060203; DOUMA AC, 1985, ARCH MICROBIOL, V143, P237, DOI 10.1007/BF00411242; EVERS ME, 1995, IN PRESS FEBS LETT; FABER KN, 1995, FEBS LETT, V357, P115, DOI 10.1016/0014-5793(94)01317-T; FABER KN, 1992, J GEN MICROBIOL, V138, P2405, DOI 10.1099/00221287-138-11-2405; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; FABER KN, 1994, P NATL ACAD SCI USA, V91, P12985, DOI 10.1073/pnas.91.26.12985; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P315; KEIZER I, 1992, FEMS MICROBIOL LETT, V93, P7, DOI 10.1016/0378-1097(92)90481-3; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; ROGGENKAMP R, 1986, MOL GEN GENET, V202, P302, DOI 10.1007/BF00331655; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; SUBRAMANI S, 1992, J MEMBRANE BIOL, V125, P99; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SULTER GJ, 1993, EMBO J, V12, P2205, DOI 10.1002/j.1460-2075.1993.tb05868.x; TITORENKO VI, 1993, P NATL ACAD SCI USA, V90, P7470, DOI 10.1073/pnas.90.16.7470; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDERKLEI IJ, 1991, YEAST, V7, P15, DOI 10.1002/yea.320070103; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; VEENHUIS M, 1992, CELL BIOCHEM FUNCT, V10, P175, DOI 10.1002/cbf.290100307; VEENHUIS M, 1989, ARCH MICROBIOL, V151, P105, DOI 10.1007/BF00414422; VEENHUIS M, 1990, YEAST, V6, P511, DOI 10.1002/yea.320060608; VEENHUIS M, 1990, METHOD ENZYMOL, V188, P411; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531; WATERHAM HR, 1992, YEAST, V8, P961, DOI 10.1002/yea.320081106; WATERHAM HR, 1994, J CELL BIOL, V137, P737; ZWART KB, 1983, A VAN LEEUW J MICROB, V49, P369	46	117	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17229	17236		10.1074/jbc.270.29.17229	http://dx.doi.org/10.1074/jbc.270.29.17229			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615522	hybrid			2022-12-25	WOS:A1995RK68900029
J	BEAUMONT, A; ODONOHUE, MJ; PAREDES, N; ROUSSELET, N; ASSICOT, M; BOHUON, C; FOURNIEZALUSKI, MC; ROQUES, BP				BEAUMONT, A; ODONOHUE, MJ; PAREDES, N; ROUSSELET, N; ASSICOT, M; BOHUON, C; FOURNIEZALUSKI, MC; ROQUES, BP			THE ROLE OF HISTIDINE-231 IN THERMOLYSIN-LIKE ENZYMES - A SITE-DIRECTED MUTAGENESIS STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL ENDOPEPTIDASE 24.11; TRANSITION-STATE ANALOGS; CRYSTALLINE THERMOLYSIN; ZINC PEPTIDASES; RETRO-THIORPHAN; ACTIVE-SITE; COS-1 CELLS; PROTEASE; INHIBITORS; BINDING	In the zinc metallopeptidases produced by the genus Bacillus, an active site histidine has been proposed to either stabilize the transition state in catalysis by donating a hydrogen bond to the hydrated peptide (Matthews, B. W. (1988) Acc. Chem. Res. 21, 333-340) or to polarize a water molecule, which subsequently attacks the peptidyl bond (Mock, W. L., and Aksamawati, M. (1994) Biochem, J. 302, 57-68). Site-directed mutagenesis techniques have been used to change this residue in the zinc endopeptidase from Bacillus stearothermophillus to either phenylalanine or alanine. At pH 7.0, the k(cat)/K-m values of the substrate leucine enkephalin for the phenylalanine and alanine mutants were reduced by factors of 430- and 500-fold, respectively, as compared with the wild-type enzyme, mostly due to changes in k(cat). In addition, the enzymatic activities of the mutant enzymes showed little pH dependence in the alkaline range, unlike the wild-type enzyme. The mutations did not greatly alter the binding affinities of inhibitors containing sulfydryl groups to chelate the active site zinc, while those of inhibitors containing hydroxamate or carboxylate zinc-chelating groups were increased between 80- and 250-fold. The largest change in the binding affinity of an inhibitor (>5 orders of magnitude) was found with the proposed transition state mimic, phosphoramidon. The results are generally in agreement with x-ray crystallography studies and favor the involvement of the active site histidine in transition state binding.	UNIV PARIS 05,FAC PHARM,DEPT PHARMACOCHIM MOLEC & STRUCT,UFR SCI PHARMACEUT & BIOL,CNRS,F-75270 PARIS 06,FRANCE; INST GUSTAVE ROUSSY,DEPT BIOL CLIN,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy			O'Donohue, Michael J/E-9183-2013; O'Donohue, Michael/ABD-9239-2021	O'Donohue, Michael J/0000-0003-4246-3938; O'Donohue, Michael/0000-0003-4246-3938				BATEMAN RC, 1990, J BIOL CHEM, V265, P8365; BENCHETRIT T, 1987, BIOCHEM BIOPH RES CO, V147, P1034, DOI 10.1016/S0006-291X(87)80174-2; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BOUBOUTOU R, 1984, LIFE SCI, V35, P1023, DOI 10.1016/0024-3205(84)90669-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRON S, 1990, MOL BIOL METHODS BAC, P142; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CORBEIL D, 1993, FEBS LETT, V335, P361, DOI 10.1016/0014-5793(93)80420-Y; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; DION N, 1993, FEBS LETT, V318, P301, DOI 10.1016/0014-5793(93)80533-Z; EIJSINK VGH, 1990, PROTEIN ENG, V4, P99, DOI 10.1093/protein/4.1.99; FEDER J, 1974, BIOCHEMISTRY-US, V9, P2784; FOURNIEZALUSKI MC, 1992, P NATL ACAD SCI USA, V89, P6388, DOI 10.1073/pnas.89.14.6388; GOMEZRUTH FX, 1994, J MOL BIOL, V239, P513; GOMEZRUTH FX, 1993, J MOL BIOL, V229, P945; GOOLEY PR, 1994, NAT STRUCT BIOL, V1, P111, DOI 10.1038/nsb0294-111; HAUSRATH AC, 1994, J BIOL CHEM, V269, P18839; HOLMES MA, 1981, BIOCHEMISTRY-US, V20, P6912, DOI 10.1021/bi00527a026; KITAGISHI K, 1984, J BIOCHEM-TOKYO, V95, P529, DOI 10.1093/oxfordjournals.jbchem.a134635; KUBO M, 1992, APPL ENVIRON MICROB, V58, P3779, DOI 10.1128/AEM.58.11.3779-3783.1992; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; LOVEJOY B, 1994, SCIENCE, V236, P375; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MOEK WL, 1994, BIOCHEM J, V302, P57; MONZINGO AF, 1982, BIOCHEMISTRY-US, V21, P3390, DOI 10.1021/bi00257a022; MONZINGO AF, 1984, BIOCHEMISTRY-US, V23, P5724, DOI 10.1021/bi00319a010; NICOLETTI VG, 1993, BIOTECHNIQUES, V14, P536; ODONOHUE MJ, 1994, BIOCHEM J, V300, P599, DOI 10.1042/bj3000599; PAUPTIT RA, 1988, J MOL BIOL, V199, P525, DOI 10.1016/0022-2836(88)90623-7; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; RODERICK SL, 1989, BIOCHEMISTRY-US, V28, P1493, DOI 10.1021/bi00430a011; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; ROQUES BP, 1993, PHARMACOL REV, V45, P87; ROQUES BP, 1983, P NATL ACAD SCI-BIOL, V80, P3178, DOI 10.1073/pnas.80.11.3178; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIGNOR G, 1990, EUR J BIOCHEM, V189, P221, DOI 10.1111/j.1432-1033.1990.tb15480.x; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; Thorsett E. D., 1987, NEUROPEPTIDES THEIR, P229; TOMA S, 1989, PROTEIN ENG, V2, P359, DOI 10.1093/protein/2.5.359; TRONRUD DE, 1986, EUR J BIOCHEM, V157, P261, DOI 10.1111/j.1432-1033.1986.tb09664.x; TSURU D, 1993, J BIOCHEM-TOKYO, V113, P101, DOI 10.1093/oxfordjournals.jbchem.a123991; VOGEL Z, 1977, FEBS LETT, V80, P332, DOI 10.1016/0014-5793(77)80469-9; VRIEND G, 1993, J COMPUT AID MOL DES, V7, P367, DOI 10.1007/BF02337558	46	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16803	16808		10.1074/jbc.270.28.16803	http://dx.doi.org/10.1074/jbc.270.28.16803			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622493	Green Submitted, hybrid			2022-12-25	WOS:A1995RJ34700054
J	ITOH, Y; NAGASE, H				ITOH, Y; NAGASE, H			PREFERENTIAL INACTIVATION OF TISSUE INHIBITOR OF METALLOPROTEINASES-1 THAT IS BOUND TO THE PRECURSOR OF MATRIX METALLOPROTEINASE-9 (PROGELATINASE-B) BY HUMAN NEUTROPHIL ELASTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IV COLLAGENASE; ALPHA-1-PROTEINASE INHIBITOR; GELATINASE-B; ALVEOLAR MACROPHAGES; FIBROSARCOMA CELLS; V COLLAGEN; STROMELYSIN; EXPRESSION; PURIFICATION; ACTIVATION	The precursor of matrix metalloproteinase 9 (pro-MMP-9) forms a complex with the tissue inhibitor of metalloproteinases (TIMP)-1 through the C-terminal domain of each molecule, and the N-terminal domain of TIMP-1 in the complex interacts and inhibits active MMPs. We have reported that a catalytic amount of MMP-3 (stromelysin 1) activates pro-MMP-9 (Ogata, Y., Enghild, J. J., and Nagase, H. (1992) J. Biol. Chem. 267, 3581-3584). To activate pro-MMP-9 in the complex, however, an excess molar amount of MMP-3 is required to saturate the TIMP-1 in the complex. The aim of this study was to test the hypothesis that the requirement for excess MMP-3 can be circumvented by specific destruction of TIMP-1 by non-target proteinases. We have tested trypsin, plasmin, cathepsin G, neutrophil elastase, and chymotrypsin as possible inactivators of TIMP-1 and found that neutrophil elastase inactivates TIMP-1 in the complex without significant destruction of pro-MMP-9. Once TIMP-1 is inactivated, pro MMP-9 can be readily activated by a catalytic amount of MMP-3. These results suggest that neutrophil elastase may participate in connective tissue destruction at the inflammatory sites not only by its direct action on matrix macromolecules but also by rendering pro-MMP-9 in the pro-MMP-9 . TIMP-1 complex activable by MMP-3 as well as activating pro MMP-3.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center				Itoh, Yoshifumi/0000-0002-2128-2823	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994, R01AR039189] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 39189, AR 40994] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; JOHNSON DA, 1986, J BIOL CHEM, V261, P4748; LEFEBVRE V, 1991, BIOCHIM BIOPHYS ACTA, V1094, P8, DOI 10.1016/0167-4889(91)90020-X; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; MAINARDI CL, 1984, COLLAGEN REL RES, V4, P479; MAST AE, 1991, J BIOL CHEM, V266, P15810; MOHTAI M, 1993, J CLIN INVEST, V92, P179, DOI 10.1172/JCI116547; MONTGOMERY AMP, 1993, BIOCHIM BIOPHYS ACTA, V1176, P265, DOI 10.1016/0167-4889(93)90054-S; MORIHARA K, 1984, J BIOCHEM, V95, P795, DOI 10.1093/oxfordjournals.jbchem.a134671; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; MURPHY G, 1989, J CELL SCI, V92, P487; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; NGUYEN Q, 1993, BIOCHEM J, V295, P595, DOI 10.1042/bj2950595; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OGATA Y, 1992, EXP CELL RES, V201, P254; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1989, FEBS LETT, V229, P157; POTEMPA J, 1986, J BIOL CHEM, V261, P14330; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SIRES UI, 1993, J BIOL CHEM, V268, P2069; SOPATA I, 1974, BIOCHIM BIOPHYS ACTA, V370, P510, DOI 10.1016/0005-2744(74)90112-0; STETLERSTEVENSO.WG, 1993, ANNU REV CELL BIOL, V9, P541; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TETLOW LC, 1993, RHEUMATOL INT, V13, P53, DOI 10.1007/BF00307734; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZHOU H, 1993, BIOCHIM BIOPHYS ACTA, V1177, P174, DOI 10.1016/0167-4889(93)90037-P	39	145	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16518	16521		10.1074/jbc.270.28.16518	http://dx.doi.org/10.1074/jbc.270.28.16518			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622455	hybrid			2022-12-25	WOS:A1995RJ34700010
J	LEE, SJ; LEE, SD; PARK, JG; KIM, CM; RYU, SH; SUH, PG				LEE, SJ; LEE, SD; PARK, JG; KIM, CM; RYU, SH; SUH, PG			OVEREXPRESSION OF PHOSPHOLIPASE C-GAMMA-1 IN COLORECTAL CARCINOMAS IS ASSOCIATED WITH OVEREXPRESSION OF FACTORS THAT BIND ITS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; C ISOZYMES; EGF RECEPTOR; BETA-GAMMA; TRANSCRIPTION; PROTEINS; GENE; SP1; EXPRESSION; REGION	The 5'-upstream sequence of the phospholipase C-gamma 1 (PLC-gamma 1) gene contains several transcriptional regulatory regions. We have studied one of the regions (-551 to -480, named GPE1) which exhibits a strong positive regulatory activity, GPE1 stimulated the transcription when fused to heterologous TATA element in an orientation-dependent manner. The region between -536 and -470 was identified as the protein binding site in GPE1 by the DNase I footprinting method, Electrophoretic mobility shift assays with several competitors revealed three protein binding sites in this region, designated as GES1, GES2, and GES3. The binding sites were -535 GGAGGGGGCG -524, -512 TGTCACTCA -504, and -491 CAATCCA -485, respectively. Mutational analyses suggested that GPE1 binding proteins cooperate with each other to activate the transcription of the PLC-gamma 1 gene. Additionally, immunoblot analyses revealed that the level of PLC-gamma 1 expression was considerably higher in 9 of 11 colorectal carcinomas than in adjacent normal colorectal tissues. In 7 of 9 cases of colorectal carcinomas which express higher level of PLC-gamma 1, the DNA binding activities to GES1, GES2, and GES3 sites also increased when compared with normal tissues. These results suggest that the GPE1 binding proteins might be attributed to the elevated expression of PLC-gamma 1 in colorectal carcinomas and may play important roles in proliferation of colorectal carcinoma cells.	POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,POHANG 790784,SOUTH KOREA; POHANG UNIV SCI & TECHNOL,BASIC SCI RES CTR,POHANG 790784,SOUTH KOREA; SEOUL NATL UNIV,CANC RES INST,CELL BIOL LAB,SEOUL 110799,SOUTH KOREA; KOREA CANC CTR HOSP,DEPT INTERNAL MED,SEOUL 139240,SOUTH KOREA	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Seoul National University (SNU); National Cancer Center - Korea (NCC)			Park, Jae-Gahb/J-5494-2012; Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIM SJ, 1989, J BIOL CHEM, V264, P402; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KITADAI Y, 1992, BIOCHEM BIOPH RES CO, V189, P1342, DOI 10.1016/0006-291X(92)90221-6; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SJ, 1993, BIOCHEM BIOPH RES CO, V194, P294, DOI 10.1006/bbrc.1993.1818; LEE SJ, 1995, BIOCHEM BIOPH RES CO, V206, P194, DOI 10.1006/bbrc.1995.1027; LEE YH, 1993, CANCER LETT, V68, P237, DOI 10.1016/0304-3835(93)90152-Y; LEE YH, 1995, FEBS LETT, V358, P105, DOI 10.1016/0014-5793(94)01404-O; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MITCHELL PJ, 1988, SCIENCE, V245, P371; NANNEY LB, 1992, CELL GROWTH DIFFER, V3, P233; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; PARK JG, 1994, CANCER RES, V54, P2240; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROESLER WT, 1989, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, J BIOL CHEM, V263, P14497; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; YAMADA M, 1991, DEV BRAIN RES, V59, P7, DOI 10.1016/0165-3806(91)90023-C	39	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16378	16384		10.1074/jbc.270.27.16378	http://dx.doi.org/10.1074/jbc.270.27.16378			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608208	hybrid			2022-12-25	WOS:A1995RH22600075
J	SAITO, K; YOKOYAMA, H; NOJI, M; MURAKOSHI, I				SAITO, K; YOKOYAMA, H; NOJI, M; MURAKOSHI, I			MOLECULAR-CLONING AND CHARACTERIZATION OF A PLANT SERINE ACETYLTRANSFERASE PLAYING A REGULATORY ROLE IN CYSTEINE BIOSYNTHESIS FROM WATERMELON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CDNA CLONING; SPINACIA-OLERACEA; O-ACETYLSERINE; GENE; SYNTHASE; EXPRESSION; METABOLISM; CYSE	Serine acetyltransferase (SATase; EC 2.3.1.30), which catalyzes the reaction connecting serine and cysteine/methionine metabolism, plays a regulatory role in cysteine biosynthesis in plants. We have isolated a cDNA clone encoding SATase by direct genetic complementation of a Cys(-) mutation in Escherichia coli using an expression library of Citrullus vulgaris (watermelon) cDNA. The cDNA encodes a polypeptide of 294 amino acids (31,536 Da) exhibiting 51% homology with that of E. coli SATase. RNA-blot analysis indicated the presence of a single copy of the SATase gene (sat) in watermelon. RNA hybridization analysis suggested the relatively ubiquitous and preferential expression in the hypocotyls of etiolated seedlings. Immunoblot analysis indicated the accumulation of SATase predominantly in etiolated plants. L-Cysteine, an end product of the cysteine biosynthetic pathway, inhibited the SATase in an allosteric manner, indicating the regulatory function of SATase in this metabolic pathway, whereas beta-(pyrazole-1-yl)-L-alanine, a secondary metabolite formed partly through the cysteine biosynthetic pathway, showed no inhibitory effect. A multi-enzyme complex was formed from recombinant proteins of SATase and cysteine synthase (O-acetylserine(thiol)-lyase) from watermelon, suggesting efficient metabolic channeling from serine to cysteine, preventing the diffusion of intermediary O-acetyl-L-serine.			SAITO, K (corresponding author), CHIBA UNIV,FAC PHARMACEUT SCI,MED RESOURCES RES CTR,MOLEC BIOL & BIOTECHNOL LAB,INAGE KU,CHIBA 263,JAPAN.		Saito, Kazuki/D-2670-2009	Saito, Kazuki/0000-0001-6310-5342				ALLIGNET J, 1993, GENE, V130, P91, DOI 10.1016/0378-1119(93)90350-C; Anderson JW, 1991, MOL ACTIVITIES PLANT; BAECKER PA, 1980, ANAL BIOCHEM, V102, P16, DOI 10.1016/0003-2697(80)90310-3; BAEV N, 1992, PLANT MOL BIOL, V18, P843, DOI 10.1007/BF00020033; BROWN EG, 1990, PHYTOCHEMISTRY, V29, P469, DOI 10.1016/0031-9422(90)85099-2; BROWN HG, 1982, PHYTOCHEMISTRY, V21, P863; BRUNOLD C, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P13; BRUNOLD C, 1982, PLANTA, V155, P321, DOI 10.1007/BF00429459; COOK PF, 1977, ARCH BIOCHEM BIOPHYS, V178, P293, DOI 10.1016/0003-9861(77)90194-1; DENK D, 1987, J GEN MICROBIOL, V133, P515; DUNNILL PM, 1963, BIOCHEM J, V86, P388, DOI 10.1042/bj0860388; EVANS DJ, 1991, J BACTERIOL, V173, P5457, DOI 10.1128/jb.173.17.5457-5469.1991; FOWDEN L, 1964, ANNU REV BIOCHEM, V33, P173, DOI 10.1146/annurev.bi.33.070164.001133; GIOVANELLI J, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P33; HEDIGER MA, 1985, P NATL ACAD SCI USA, V82, P6414, DOI 10.1073/pnas.82.19.6414; IKEGAMI F, 1988, PHYTOCHEMISTRY, V27, P697, DOI 10.1016/0031-9422(88)84078-0; IKEGAMI F, 1994, BIOL PHARM BULL, V18, P360; KLONUS D, 1994, PLANT J, V6, P105, DOI 10.1046/j.1365-313X.1994.6010105.x; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; KREDICH NM, 1987, ESCHERICHIA COLI SAL, V1, P419; LAI CY, 1992, GENE, V119, P113, DOI 10.1016/0378-1119(92)90074-Y; LEUSTEK T, 1994, PLANT PHYSIOL, V105, P897, DOI 10.1104/pp.105.3.897; Luckner M., 1990, SECONDARY METABOLISM; NAKAMURA K, 1988, PLANT CELL PHYSIOL, V29, P689; NAKAMURA K, 1987, PLANT CELL PHYSIOL, V28, P885, DOI 10.1093/oxfordjournals.pcp.a077370; NAKAMURA K, 1990, AGR BIOL CHEM TOKYO, V54, P649, DOI 10.1080/00021369.1990.10870005; NEUENSCHWANDER U, 1991, PLANT PHYSIOL, V97, P253, DOI 10.1104/pp.97.1.253; NOE FF, 1960, BIOCHEM J, V77, P543, DOI 10.1042/bj0770543; NOJI M, 1993, BIOCHEM BIOPH RES CO, V197, P1111, DOI 10.1006/bbrc.1993.2592; NOJI M, 1994, MOL GEN GENET, V244, P57, DOI 10.1007/BF00280187; PARENT R, 1992, J BACTERIOL, V174, P2891, DOI 10.1128/JB.174.9.2891-2897.1992; RENNENBERG H, 1982, PHYTOCHEMISTRY, V21, P2771, DOI 10.1016/0031-9422(80)85045-X; RENNENBERG H, 1983, PLANT PHYSIOL, V73, P560, DOI 10.1104/pp.73.3.560; ROLLAND N, 1993, ARCH BIOCHEM BIOPHYS, V300, P213, DOI 10.1006/abbi.1993.1030; ROMER S, 1992, J BIOL CHEM, V267, P17966; RUFFET ML, 1994, PLANT PHYSIOL, V104, P597, DOI 10.1104/pp.104.2.597; SAITO K, 1993, FEBS LETT, V324, P247, DOI 10.1016/0014-5793(93)80127-G; SAITO K, 1994, PLANT PHYSIOL, V106, P887, DOI 10.1104/pp.106.3.887; SAITO K, 1992, P NATL ACAD SCI USA, V89, P8078, DOI 10.1073/pnas.89.17.8078; SAITO K, 1994, J BIOL CHEM, V269, P28187; Sambrook J, 1989, MOL CLONING LABORATO; Schmidt A., 1986, Progress in Botany, V48, P133; SCHMIDT A, 1992, ANNU REV PLANT PHYS, V43, P325, DOI 10.1146/annurev.pp.43.060192.001545; SIMOENS CR, 1988, GENE, V67, P1, DOI 10.1016/0378-1119(88)90002-9; SIVAPRASAD AV, 1991, EMBL X59594 DAT BANK; SMITH IK, 1971, BIOCHIM BIOPHYS ACTA, V227, P288, DOI 10.1016/0005-2744(71)90061-1; SMITH IK, 1972, PLANT PHYSIOL, V50, P477, DOI 10.1104/pp.50.4.477; STODIER FW, 1990, METHOD ENZYMOL, V185, P60; SURIN BP, 1988, MOL MICROBIOL, V2, P173, DOI 10.1111/j.1365-2958.1988.tb00019.x; TEI H, 1990, BIOCHEM BIOPH RES CO, V167, P948, DOI 10.1016/0006-291X(90)90615-T; TENNIGKEIT J, 1991, GENE, V98, P113, DOI 10.1016/0378-1119(91)90112-O; YOUSSEFIAN S, 1993, PLANT J, V4, P759, DOI 10.1046/j.1365-313X.1993.04050759.x	52	102	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16321	16326		10.1074/jbc.270.27.16321	http://dx.doi.org/10.1074/jbc.270.27.16321			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608200	hybrid			2022-12-25	WOS:A1995RH22600067
J	MURRELL, AM; BOCKAMP, EO; GOTTGENS, B; CHAN, YS; CROSS, MA; HEYWORTH, CM; GREEN, AR				MURRELL, AM; BOCKAMP, EO; GOTTGENS, B; CHAN, YS; CROSS, MA; HEYWORTH, CM; GREEN, AR			DISCORDANT REGULATION OF SCL/TAL-1 MESSENGER-RNA AND PROTEIN DURING ERYTHROID-DIFFERENTIATION	ONCOGENE			English	Article						SCL/TAL-1; ERYTHROID DIFFERENTIATION	SCL GENE-PRODUCT; LOOP-HELIX GENE; T-CELL LEUKEMIA; SELF-RENEWAL; TRANSLOCATION; EXPRESSION; HEMATOPOIESIS; ENCODES; TAL-1; LINES	SCL/TAL1 gene was originally identified by virtue of its rearrangement and transcriptional activation in patients with T cell acute lymphoblastic leukaemia, It encodes a helix-loop-helix transcription factor, is not normally expressed in T cells, but is expressed in erythroid, mast, megakaryocytic and progenitor cells, Over-expression of sense and antisense constructs have implicated SCL as a positive regulator of erythroid differentiation, In addition we have previously shown that SCL mRNA levels undergo biphasic modulation during induced erythroid differentiation of murine erythroleukaemia (MEL) cells with a transient early fall followed by a late rise, In this paper we have studied expression of the SCL protein during erythroid differentiation and also the molecular basis for the raised SCL mRNA levels that accompany erythroid differentiation, We have generated an anti-SCL antiserum and used it to demonstrate that an early transient fall in SCL protein does not occur during induced differentiation of MEL cells, Furthermore SCL protein levels underwent a late fall in three different models of erythroid differentiation and in two models of myeloid differentiation, The fall in SCL protein levels during induced erythroid differentiation contrasted with the concomitant marked rise in SCL mRNA levels. These observations have significant implications for the mechanism by which SCL may regulate erythropoiesis. In addition we have demonstrated that the stability of SCL mRNA was only marginally enhanced during erythroid differentiation of MEL cells, whereas the activity of a luciferase reporter construct driven by the SCL promoter was increased 11- to 17-fold, Up-regulation of transcription therefore accounted for most of the increase in SCL mRNA levels during erythroid differentiation.	UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND; CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC,DEPT EXPTL HAEMATOL,MANCHESTER M20 9BX,LANCS,ENGLAND	University of Cambridge; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research				Cross, Michael/0000-0002-8815-7621; Gottgens, Berthold/0000-0001-6302-5705; Bockamp, Ernesto/0000-0002-6181-1734; Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; CROSS MA, 1994, ONCOGENE, V9, P3013; ELWOOD NJ, 1994, LEUKEMIA, V8, P106; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GOLDFARB AN, 1992, BLOOD, V80, P2858; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GREEN AR, 1993, EXP HEMATOL, V21, P525; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; KAIHO SI, 1985, ANAL BIOCHEM, V149, P117, DOI 10.1016/0003-2697(85)90483-X; KAN O, 1993, HAEMOPOIEISIS PRACTI; KIM KJ, 1979, J IMMUNOL, V122, P549; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; MITSUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322; MOUTHON MA, 1993, BLOOD, V81, P647; MURRELL AM, 1995, ONCOGENE, V10, P631; PROUD CG, 1994, NATURE, V371, P747, DOI 10.1038/371747a0; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P195; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x	41	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					131	139						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624120				2022-12-25	WOS:A1995RJ29500016
J	JAMES, NL; HARRISON, DG; NEREM, RM				JAMES, NL; HARRISON, DG; NEREM, RM			EFFECTS OF SHEAR ON ENDOTHELIAL-CELL CALCIUM IN THE PRESENCE AND ABSENCE OF ATP	FASEB JOURNAL			English	Article						CALCIUM; ENDOTHELIAL CELLS; FLOW; CONFOCAL; FLUO-3	PROSTACYCLIN PRODUCTION; STRESS; FLOW; SECRETION; CA2+	The purpose of this study was to characterize the effect of various shear conditions on endothelial cell intracellular calcium ([Ca2+](i)). Bovine aortic endothelial cells (BAEC) were loaded with Fluo-3 and exposed to flow in a paralled plate flow chamber designed for confocal microscopy. The flow medium was medium 199 (M-199), which was prepared with and without adenosine triphosphate (ATP). In the presence of ATP, initiation of flow at a shear stress of 2.5 dyn/cm(2) evoked a strong, sustained elevation of [Ca2+](i) that gradually returned to baseline levels over 10 to 15 min. By contrast, in the absence of ATP, initiation of flow at 2.5 dyn/cm(2) produced only transient increases in [Ca2+](i) in a small proportion of the cells, As shear rate was increased from 2.5 to 15 dyn/cm(2) in this medium, both the relative fluorescence of the monolayer and the proportion of cells across the monolayer that displayed calcium transients increased in a dose-dependent fashion, In conclusion, the response of an endothelial cell monolayer to increasing levels of shear is not only to increase [Ca2+](i) within individual cells, but to increase the duration of response and the number of cells responding at the onset of shear, This recruitment of larger numbers of cells at higher levels of shear may represent a novel signaling mechanism within the endothelium.	EMORY UNIV,VET ADM MED CTR,SCH MED,DEPT INTERNAL MED,ATLANTA,GA; GEORGIA INST TECHNOL,SCH MECH ENGN,ATLANTA,GA 30322	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; University System of Georgia; Georgia Institute of Technology					NHLBI NIH HHS [HL32717, HL39006] Funding Source: Medline; NIDDK NIH HHS [DK 45215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032717, R01HL039006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO J, 1993, BIOCHEM BIOPH RES CO, V190, P716, DOI 10.1006/bbrc.1993.1108; ANDO J, 1988, IN VITRO CELL DEV B, V24, P871; BARBEE KA, 1994, CIRC RES, V74, P163, DOI 10.1161/01.RES.74.1.163; DEWEY CF, 1981, J BIOMECH ENG-T ASME, V103, P177, DOI 10.1115/1.3138276; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; DULL RO, 1991, AM J PHYSIOL, V261, pH149, DOI 10.1152/ajpheart.1991.261.1.H149; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; HADJIAGAPIOU C, 1986, BIOCHIM BIOPHYS ACTA, V875, P369, DOI 10.1016/0005-2760(86)90188-8; HELMLINGER G, 1994, THESIS GEORGIA I TEC; LEVESQUE MJ, 1985, J BIOMECH ENG-T ASME, V107, P341, DOI 10.1115/1.3138567; LEVESQUE MJ, 1989, BIOTECHNOL PROGR, V5, P1, DOI 10.1002/btpr.5420050105; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; PRZYWARA DA, 1991, FASEB J, V5, P217, DOI 10.1096/fasebj.5.2.2004666; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Savino J. M., 1964, INT J HEAT MASS TRAN, V7, P733; SCHILLING WP, 1992, EXP CELL RES, V198, P31, DOI 10.1016/0014-4827(92)90145-X; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; SHEN J, 1993, BIOPHYS J, V64, P1323, DOI 10.1016/S0006-3495(93)81498-X; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1	21	51	52	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					968	973		10.1096/fasebj.9.10.7615166	http://dx.doi.org/10.1096/fasebj.9.10.7615166			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615166				2022-12-25	WOS:A1995RK89900020
J	PALLANCK, L; ORDWAY, RW; RAMASWAMI, M; CHI, WY; KRISHNAN, KS; GANETZKY, B				PALLANCK, L; ORDWAY, RW; RAMASWAMI, M; CHI, WY; KRISHNAN, KS; GANETZKY, B			DISTINCT ROLES FOR N-ETHYLMALEIMIDE-SENSITIVE FUSION PROTEIN (NSF) SUGGESTED BY THE IDENTIFICATION OF A 2ND DROSOPHILA NSF HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								The N-ethylmaleimide-sensitive fusion protein (NSF) is a cytoplasmic protein implicated in the fusion of intracellular transport vesicles with their target membranes, NSF is thought to function in the fusion of essentially all types of vesicles, including endoplasmic reticulum, Golgi, and endocytic vesicles, as well as secretory vesicles undergoing regulated fusion (for review see Rothman, J. E. (1994) Nature 372, 55-63), However, little experimental evidence exists to address the possibility that organisms might have multiple NSF proteins serving distinct functions in the same or different cells, We previously cloned a neurally expressed Drosophila homolog, dNSF-1 (Ordway, R. W., Pallanck, L., and Ganetzky, B. (1994) Proc. Natl. Acad. Sci, U.S.A. 91, 5715-5719), and have subsequently identified mutations in this gene that confer an apparent failure of synaptic transmission at elevated temperature (Pallanck, L., Ordway, R. W., and Ganetzky, B. (1995) Nature, 376, 25; Siddiqi, O., and Benzer, S. (1976) Proc. Natl. Acad. Sci. U.S.A. 73, 3253-3257), Here we report that 1) Drosophila contains a second NSF homolog, termed dNSF-2, that exhibits 84% amino acid identity to dNSF-1, 2) dNSF-1 and dNSF-2 display overlapping but different temporal expression, and 3) multiple transcripts are derived from the dNSF-2 gene. These findings raise the possibility that different NSF gene products serve distinct or overlapping functions within the organism.	UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; TATA INST FUNDAMENTAL RES,MOLEC BIOL UNIT,BOMBAY 400005,MAHARASHTRA,INDIA	University of Arizona; University of California System; University of California San Francisco; Tata Institute of Fundamental Research (TIFR)	PALLANCK, L (corresponding author), UNIV WISCONSIN,GENET LAB,MADISON,WI 53706, USA.			Ramaswami, Mani/0000-0001-7631-0468	NINDS NIH HHS [NS15390, NS09364, NS5927] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009364, R01NS015390] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; ORDWAY RW, 1994, P NATL ACAD SCI USA, V91, P5715, DOI 10.1073/pnas.91.12.5715; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; RAMASWAMI M, 1989, P NATL ACAD SCI USA, V86, P2079, DOI 10.1073/pnas.86.6.2079; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SIDDIQI O, 1976, P NATL ACAD SCI USA, V73, P3253, DOI 10.1073/pnas.73.9.3253	7	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18742	18744		10.1074/jbc.270.32.18742	http://dx.doi.org/10.1074/jbc.270.32.18742			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642522	hybrid			2022-12-25	WOS:A1995RN95400009
J	MOCK, WL; LIU, YY				MOCK, WL; LIU, YY			HYDROLYSIS OF PICOLINYLPROLINES BY PROLIDASE - A GENERAL MECHANISM FOR THE DUAL-METAL ION CONTAINING AMINOPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS LEUCINE AMINOPEPTIDASE; HUMAN-ERYTHROCYTE PROLIDASE; CARBOXYPEPTIDASE-A; BOVINE LENS; PROLINE DIPEPTIDASE; PURIFICATION; INHIBITION; SUBSTITUTION; DEFICIENCY; BESTATIN	The velocity of enzymic cleavage of 4-substituted picolinylprolines by swine kidney prolidase approaches that of physiological; dipeptides, but depends substantially upon the nature of the pyridine-ring substituent. The pH dependence of k(cat)/K-m for picolinylproline is sigmoidal, with optimum activity on the acidic limb and a delimiting enzymic pK(alpha) of 6.6, unlike glycylproline (bell-shaped pH profile, maximum at pH 7.7). Productive chelation to an active site metal ion by the N terminus of substrates is indicated, with a water molecule ligated to that hyper(Lewis)acidic center prior to substrate binding supplying the pK(alpha) of 6.6. The rate-governing catalytic step differs according to the 4-substituent on the picolinyl residue; productive binding is slow in the case of electron-withdrawing groups, but subsequent nucleophilic addition to the metal ion-activated scissile linkage becomes controlling with more basic pyridine rings, Rate constants yield a Bronsted-type correlation with substrate pK(alpha), providing a gauge of active-site Lewis acidity. A mechanism is suggested involving the cooperative participation of two especially acidic metal ions positioned adjacently within the active site (situated as in an homologous and structurally characterized aminopeptidase), with both serving to stabilize a bridging carboxamide-hydrate intermediate.			MOCK, WL (corresponding author), UNIV ILLINOIS,DEPT CHEM,CHICAGO,IL 60607, USA.							ALLEN MP, 1983, BIOCHEMISTRY-US, V22, P3778, DOI 10.1021/bi00285a010; AULD DS, 1970, BIOCHEMISTRY-US, V9, P602, DOI 10.1021/bi00805a022; BIZZOZERO SA, 1975, FEBS LETT, V59, P105, DOI 10.1016/0014-5793(75)80351-6; BLACKBURN GM, 1968, J AM CHEM SOC, V90, P2638, DOI 10.1021/ja01012a031; BROWNE P, 1983, J BIOL CHEM, V258, P6147; BURLEY SK, 1990, P NATL ACAD SCI USA, V87, P6878, DOI 10.1073/pnas.87.17.6878; BURLEY SK, 1992, J MOL BIOL, V224, P113, DOI 10.1016/0022-2836(92)90580-D; BURLEY SK, 1991, P NATL ACAD SCI USA, V88, P6916, DOI 10.1073/pnas.88.16.6916; BZAN JF, 1994, P NATL ACAD SCI USA, V91, P2473; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; Clemo GR, 1938, J CHEM SOC, P478, DOI 10.1039/jr9380000478; DAVIS NC, 1957, J BIOL CHEM, V224, P261; DEADY LW, 1971, AUST J CHEM, V24, P385, DOI 10.1071/CH9710385; DENSLOW ND, 1994, BIOCHEM BIOPH RES CO, V205, P1790, DOI 10.1006/bbrc.1994.2877; ENDO F, 1989, J BIOL CHEM, V264, P4476; ENDO F, 1982, PEDIATR RES, V16, P227, DOI 10.1203/00006450-198203000-00013; ENDO M, 1960, YAKUGAKU ZASSHI, V80, P875; FABRE JL, 1985, TETRAHEDRON LETT, V26, P5447, DOI 10.1016/S0040-4039(00)98232-7; HEINISCH G, 1985, ANGEW CHEM INT EDIT, V24, P692, DOI 10.1002/anie.198506921; KIM H, 1993, BIOCHEMISTRY-US, V32, P8465, DOI 10.1021/bi00084a011; KIM HD, 1993, P NATL ACAD SCI USA, V90, P5006, DOI 10.1073/pnas.90.11.5006; KING GF, 1986, BIOCHEMISTRY-US, V25, P1054, DOI 10.1021/bi00353a016; KING SW, 1983, BIOCHEMISTRY-US, V22, P3603, DOI 10.1021/bi00284a010; KUZNETSOVA EA, 1989, KHIM FARM ZH+, V23, P1425; LEUSSING DL, 1968, ANAL CHEM, V40, P575, DOI 10.1021/ac60259a019; LIN LN, 1979, BIOCHEMISTRY-US, V18, P43, DOI 10.1021/bi00568a007; MANAO G, 1972, PHYSIOL CHEM PHYS M, V4, P75; MOCK WL, 1991, J BIOL CHEM, V266, P6393; MOCK WL, 1990, J BIOL CHEM, V265, P19606; MOCK WL, 1993, BIOCHEM J, V289, P185, DOI 10.1042/bj2890185; MOCK WL, 1994, BIOCHEM J, V302, P57, DOI 10.1042/bj3020057; MOCK WL, 1992, BIOORG CHEM, V20, P377, DOI 10.1016/0045-2068(92)90047-7; MOCK WL, 1994, BIOORG CHEM, V22, P373, DOI 10.1006/bioo.1994.1031; MOCK WL, 1991, BIOCHEM BIOPH RES CO, V180, P401, DOI 10.1016/S0006-291X(05)81307-5; MOCK WL, 1990, J BIOL CHEM, V265, P19600; MOSHER HS, 1955, J ORG CHEM, V20, P283, DOI 10.1021/jo01121a002; MYARA I, 1994, INT J BIOCHEM, V26, P207, DOI 10.1016/0020-711X(94)90147-3; POSTMUS C, 1966, INORG CHEM, V5, P1154, DOI 10.1021/ic50041a017; RICHTER AM, 1989, BIOCHEM CELL BIOL, V67, P34, DOI 10.1139/o89-005; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; Samvelyan V. M., 1992, Eksperimental'naya i Klinicheskaya Farmakologiya, V55, P11; SJOSTROM H, 1974, BIOCHIM BIOPHYS ACTA, V359, P177, DOI 10.1016/0005-2795(74)90141-X; TANOUE A, 1990, J BIOL CHEM, V265, P11306; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; THOMPSON GA, 1976, J BIOL CHEM, V251, P53; THOMPSON GA, 1976, J BIOL CHEM, V251, P1618; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572; YOSHIMOTO T, 1983, J BIOCHEM, V94, P1889, DOI 10.1093/oxfordjournals.jbchem.a134542	48	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18437	18446		10.1074/jbc.270.31.18437	http://dx.doi.org/10.1074/jbc.270.31.18437			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629169	hybrid			2022-12-25	WOS:A1995RM64200046
J	WONG, JM; SHI, YB				WONG, JM; SHI, YB			COORDINATED REGULATION OF AND TRANSCRIPTIONAL ACTIVATION BY XENOPUS THYROID-HORMONE AND RETINOID-X RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; AMPHIBIAN METAMORPHOSIS; RESPONSE ELEMENTS; ACID RECEPTORS; BETA GENES; LAEVIS	Thyroid hormone (T-3) plays a causative role in amphibian metamorphosis, This regulation is thought to be mediated by heterodimers of T-3 receptors (TRs) and retinoid X receptors (RXRs). We report here that Xenopus TRs can indeed form strong heterodimers with Xenopus RXRs on the T-3 response element (TRE) present in Xenopus TRP beta genes. Using a T-3-responsive in vivo tran scription system established by introducing TRs and RXRs into Xenopus oocytes, we demonstrated that TR-RXR heterodimers repressed TR beta gene promoter in the absence of T-3 and activated the promoter in the presence of the hormone. Furthermore, by analyzing the expression of TR and RXR genes, we showed that TR and RXR genes were coordinately regulated in different tissues during metamorphosis. Thus high levels of their mRNAs are present in the limb during early stages of limb development when morphogenesis occurs and in the tail toward the end of metamorphosis when it is being resorbed. Such correlations coupled with our TRE-binding and in vivo transcriptional activation experiments provide strong evidence that TRs and RXRs function together to mediate the effects of T-3 during metamorphosis, These results further suggest a possible molecular basis for the temporal regulation of tissue-specific metamorphosis.	NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Wong, Jiemin/0000-0002-5311-842X; Shi, Yun-Bo/0000-0002-6330-0639				ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; Dodd M.H.I., 1976, P467; ELICEIRI BP, 1994, J BIOL CHEM, V269, P24459; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gilbert L, 1981, METAMORPHOSIS PROBLE; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HELBING C, 1992, DEV GENET, V13, P289, DOI 10.1002/dvg.1020130406; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; MACHUCA I, 1995, MOL ENDOCRINOL, V9, P96, DOI 10.1210/me.9.1.96; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER MJ, 1991, MOL ENDOCRINOL, V5, P201, DOI 10.1210/mend-5-2-201; SHEPEL L A, 1988, Biofactors, V1, P71; SHI YB, 1994, FEBS LETT, V355, P61, DOI 10.1016/0014-5793(94)01173-7; SHI YB, 1992, J BIOL CHEM, V267, P733; SHI YB, 1993, J BIOL CHEM, V268, P20312; SHI YB, 1994, BBA-GENE STRUCT EXPR, V1217, P227, DOI 10.1016/0167-4781(94)90042-6; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P7767, DOI 10.1073/pnas.91.16.7767; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG Z, 1993, J BIOL CHEM, V268, P16270; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YEN PM, 1994, TRENDS ENDOCRIN MET, V5, P65, DOI 10.1016/1043-2760(94)90004-3	32	137	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18479	18483		10.1074/jbc.270.31.18479	http://dx.doi.org/10.1074/jbc.270.31.18479			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629175	hybrid			2022-12-25	WOS:A1995RM64200052
J	KIM, SY; CHUNG, SI; STEINERT, PM				KIM, SY; CHUNG, SI; STEINERT, PM			HIGHLY-ACTIVE SOLUBLE PROCESSED FORMS OF THE TRANSGLUTAMINASE-1 ENZYME IN EPIDERMAL-KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FACTOR-XIII; GUINEA-PIG; PROTRANSGLUTAMINASE-E; MEMBRANE ANCHORAGE; SUBUNIT DEFICIENCY; RETINYL ACETATE; HAIR FOLLICLE; CDNA CLONES; EXPRESSION	The transglutaminase 1 (TGase 1) enzyme is required for the formation of a cornified cell envelope in epidermal keratinocytes. We show here that in addition to its membrane-anchored form, soluble forms of it are also important in keratinocytes. Proliferating cells contain soluble full-length enzyme of 106 kDa, but terminally differentiating cells contain a soluble 67-kDa form often complexed with a 33-kDa protein as well. The amino terminus of the 67 kDa form is residue 93 of the TGase 1 protein, corresponding to the site of proteolytic activation of the factor XIIIa TGase. The amino terminus of the 33-kDa protein is residue 573, corresponding to the site of a second proteolytic cleavage site of factor XIIIa, and of the site for proteolytic activation of the TGase 3 enzyme. The specific activity of the 67/33-kDa soluble complex is twice that of the soluble 67-kDa form and 10 times that of full-length TGase 1. The half-lives of the 67/33- and 106-kDa forms are about 7 or 20 h, respectively. Thus the TGase 1 enzyme is complex, since it exists in keratinocytes as multiple soluble forms, either intact or proteolytically processed at conserved sites, and which have varying specific activities and likely functions.	NIAMS, SKIN BIOL BRANCH, BETHESDA, MD 20892 USA; NIDR, CELLULAR DEV & ONCOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ANDO Y, 1988, ARCH DERMATOL RES, V280, P380, DOI 10.1007/BF00426618; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; BOARD P, 1992, BLOOD, V80, P937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CHANG SK, 1986, J BIOL CHEM, V261, P8112; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; CHUNG SI, 1988, ADV POSTTRANSLATIONA, P1; CHUNG SI, 1992, J DENT RES, V71, P466; CLINE PR, 1983, CANCER RES, V43, P3203; CONNELLAN JM, 1971, J BIOL CHEM, V246, P1093; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3257, DOI 10.1021/bi00713a012; DUVIC M, 1994, J INVEST DERMATOL, V102, P462, DOI 10.1111/1523-1747.ep12373021; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1973, ADV ENZYMOL RAMB, V38, P109; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; JETTEN AM, 1986, J BIOL CHEM, V261, P5097; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; KAMURA T, 1992, J CLIN INVEST, V90, P315, DOI 10.1172/JCI115864; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM IG, 1992, J BIOL CHEM, V267, P7710; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; LAZARUS GS, 1991, PHYSL BIOCH MOL BIOL, P464; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; MIKKOLA H, 1994, BLOOD, V84, P517; MUELLEREBERHARD HJ, 1992, INFLAMMATION BASIC P, P63; MULLERTZ S, 1984, SEMIN THROMB HEMOST, V10, P1, DOI 10.1055/s-2007-1004402; NEGI M, 1985, J INVEST DERMATOL, V85, P75, DOI 10.1111/1523-1747.ep12275357; OGAWA H, 1976, J BIOL CHEM, V251, P7281; PARK SC, 1988, J CELL BIOL, V107, P139; PETERSON LL, 1984, MOL CELL BIOCHEM, V58, P99, DOI 10.1007/BF00240609; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; PISANO JJ, 1975, PROTEASES BIOL CONTR, P199; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; SCHMIDT R, 1988, J INVEST DERMATOL, V90, P475, DOI 10.1111/1523-1747.ep12460936; SCHROEDER WT, 1992, J INVEST DERMATOL, V99, P27, DOI 10.1111/1523-1747.ep12611394; STANDEN GR, 1993, BRIT J HAEMATOL, V85, P769, DOI 10.1111/j.1365-2141.1993.tb03221.x; STEINERT P, 1976, J INVEST DERMATOL, V66, P276; STEINERT PM, 1994, CHONNAM J MED SCI, V6, P78; TAKAGI T, 1974, BIOCHEMISTRY-US, V13, P750, DOI 10.1021/bi00701a018; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	56	103	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18026	18035		10.1074/jbc.270.30.18026	http://dx.doi.org/10.1074/jbc.270.30.18026			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629111	hybrid			2022-12-25	WOS:A1995RM26600062
J	IRRGANG, KD; SHI, LX; FUNK, C; SCHRODER, WP				IRRGANG, KD; SHI, LX; FUNK, C; SCHRODER, WP			A NUCLEAR-ENCODED SUBUNIT OF THE PHOTOSYSTEM-II REACTION-CENTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MASS PROTEINS; REACTION CENTER COMPLEX; THYLAKOID MEMBRANE-PROTEIN; SPINACH-CHLOROPLASTS; POLYACRYLAMIDE GELS; ELECTRON-TRANSPORT; OXYGEN EVOLUTION; SYNECHOCYSTIS SP; CORE COMPLEX; GENE-PRODUCT	A nuclear encoded polypeptide of 6.1 kDa was identified in isolated photosystem II (PSII) reaction center from Spinacia oleracea. The hydrophobic membrane protein easily escapes staining procedures such as Coomassie R-250 or silver staining, but it is clearly detected by immunodecoration with peptide-directed IgG. This additional subunit was found to be present in PSII reaction centers previously known to contain only the D1/D2/cytb(559) proteins and the psbI gene product. Furthermore, cross-linking experiments using 1-(3-dimethylaminopropyl-)3-ethylcarbodiimide showed that the nearest neighbors were the D1 and D2 proteins and the cytb(559). The 6.1-kDa protein was purified by immune affinity chromatography. N-terminal sequence analysis of the isolated protein confirmed the identity of the 6.1-kDa protein and enabled finding of strong similarities with a randomly obtained cDNA from Arabidopsis thaliana. Using enzyme-linked immunosorbent assay in combination with thylakoid membrane preparations of different orientation, the N terminus off the protein, predicted to span the membrane once, is suggested to be exposed at the lumen side of the membrane. Consequently the 6.1-kDa protein seems to be the only subunit in the PSII reaction center that is nuclear encoded and has its N terminus on the lumen side of the membrane. These findings open for new interesting suggestions concerning the properties of photosystem II reaction center with respect to the photosynthetic activity, regulation and assembly in higher plants.	UNIV STOCKHOLM, ARRHENIUS LABS NAT SCI, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN	Stockholm University			Schröder, Wolfgang/A-8799-2008; Funk, Christiane/AAO-6041-2021	Funk, Christiane/0000-0002-7897-4038; Schroder, Wolfgang/0000-0001-9831-1533				AKERLUND HE, 1976, BIOCHIM BIOPHYS ACTA, V449, P525, DOI 10.1016/0005-2728(76)90161-4; ANDERSSON B, 1976, BIOCHIM BIOPHYS ACTA, V423, P122, DOI 10.1016/0005-2728(76)90106-7; ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; ANDERSSON B, 1992, MOL MECHANISMS BIOEN, P121; BARBER J, 1987, FEBS LETT, V220, P67, DOI 10.1016/0014-5793(87)80877-3; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOZA MVT, 1993, 41ST HARD C PHOT PHO; BURKE JJ, 1978, ARCH BIOCHEM BIOPHYS, V187, P252, DOI 10.1016/0003-9861(78)90031-0; CRAMER WA, 1977, ANNU REV PLANT PHYS, V28, P133, DOI 10.1146/annurev.pp.28.060177.001025; DEBOER D, 1993, PIGMENT PROTEIN COMP, P311; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; GHANOTAKIS DF, 1989, BIOCHIM BIOPHYS ACTA, V974, P44, DOI 10.1016/S0005-2728(89)80164-1; GHANOTAKIS DF, 1986, FEBS LETT, V197, P244, DOI 10.1016/0014-5793(86)80335-0; HAAG E, 1990, EUR J BIOCHEM, V189, P47, DOI 10.1111/j.1432-1033.1990.tb15458.x; HANSSON O, 1990, PHOTOSYNTH RES, V23, P131, DOI 10.1007/BF00035006; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; IKEUCHI M, 1988, FEBS LETT, V241, P99, DOI 10.1016/0014-5793(88)81039-1; IKEUCHI M, 1991, J BIOL CHEM, V266, P11111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND LK, 1993, J BIOL CHEM, V268, P1575; LJUNGBERG U, 1986, BIOCHIM BIOPHYS ACTA, V849, P112, DOI 10.1016/0005-2728(86)90102-7; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MICHEL H, 1986, ENCY PLANT PHYSL PHO, V19, P371; NAGATSUKA T, 1991, BIOCHIM BIOPHYS ACTA, V1057, P223, DOI 10.1016/S0005-2728(05)80105-7; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; RENGER G, 1993, PHOTOSYNTH RES, V38, P229, DOI 10.1007/BF00046749; ROCHAIX JD, 1984, PLANT MOL BIOL, V3, P363, DOI 10.1007/BF00033383; SAYRE RT, 1986, CELL, V47, P601, DOI 10.1016/0092-8674(86)90624-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRODER WP, 1988, FEBS LETT, V235, P289, DOI 10.1016/0014-5793(88)81281-X; SEIBERT M, 1988, PLANT PHYSIOL, V87, P303, DOI 10.1104/pp.87.2.303; TAE GS, 1994, BIOCHEMISTRY-US, V33, P10060, DOI 10.1021/bi00199a033; TAE GS, 1988, BIOCHEMISTRY-US, V27, P9075, DOI 10.1021/bi00426a002; TANG XS, 1990, FEBS LETT, V273, P257, DOI 10.1016/0014-5793(90)81098-9; TOMO T, 1993, FEBS LETT, V323, P15, DOI 10.1016/0014-5793(93)81438-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WEBBER AN, 1989, FEBS LETT, V242, P259, DOI 10.1016/0014-5793(89)80481-8	46	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17588	17593		10.1074/jbc.270.29.17588	http://dx.doi.org/10.1074/jbc.270.29.17588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615565	hybrid			2022-12-25	WOS:A1995RK68900082
J	BUCHBERGER, A; THEYSSEN, H; SCHRODER, H; MCCARTY, JS; VIRGALLITA, G; MILKEREIT, P; REINSTEIN, J; BUKAU, B				BUCHBERGER, A; THEYSSEN, H; SCHRODER, H; MCCARTY, JS; VIRGALLITA, G; MILKEREIT, P; REINSTEIN, J; BUKAU, B			NUCLEOTIDE-INDUCED CONFORMATIONAL-CHANGES IN THE ATPASE AND SUBSTRATE-BINDING DOMAINS OF THE DNAK CHAPERONE PROVIDE EVIDENCE FOR INTERDOMAIN COMMUNICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI DNAJ; UNCOATING PROTEIN; PEPTIDE BINDING; GRPE; DISSOCIATION; HYDROLYSIS; FRAGMENT; GENE	Interactions of the DnaK (Hsp70) chaperone from Escherichia coli with substrates are controlled by ATP. Nucleotide-induced changes in DnaK conformation were investigated by monitoring changes in tryptic digestion pattern and tryptophan fluorescence. Using nucleotide-free DnaK preparations, not only the known ATP-induced major changes in kinetics and pattern of proteolysis but also minor ADP-induced changes were detected. Similar ATP-induced conformational changes occurred in the DnaK-T199A mutant protein defective in ATPase activity, demonstrating that they result from binding, not hydrolysis, of ATP. N-terminal sequencing and immunological mapping of tryptic fragments of DnaK identified cleavage sites that, upon ATP addition, appeared within the proposed C-terminal substrate binding region and disappeared in the N-terminal ATPase domain. They hence reflect structural alterations in DnaK correlated to substrate release and indicate ATP-dependent domain interactions. Domain interactions are a prerequisite for efficient tryptic degradation as fragments of DnaK comprising the ATPase and C-terminal domains were highly protease-resistant. Fluorescence analysis of the N-terminally located single tryptophan residue of DnaK revealed that the known ATP-induced alteration of the emission spectrum, proposed to result directly from conformational changes in the ATPase domain, requires the presence of the C-terminal domain and therefore mainly results from altered domain interaction. Analyses of the C-terminally truncated DnaK163 mutant protein revealed that nucleotide-dependent interdomain communication requires a 15-kDa segment assumed to constitute the substrate binding site.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,D-69120 HEIDELBERG,GERMANY; MAX PLANCK INST MOLEK PHYSIOL,PHYS BIOCHEM ABT,D-44139 DORTMUND,GERMANY; HOFFMANN LA ROCHE AG,CH-4002 BASEL,SWITZERLAND	Ruprecht Karls University Heidelberg; Max Planck Society; Roche Holding			Buchberger, Alexander/AAF-4728-2019; Buchberger, Alexander/J-4070-2019	Buchberger, Alexander/0000-0002-2836-0820; Buchberger, Alexander/0000-0002-2836-0820; Bukau, Bernd/0000-0003-0521-7199				BANECKI B, 1992, J BIOL CHEM, V267, P25051; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; BURKHOLDER WF, 1994, J MOL BIOL, V242, P364, DOI 10.1006/jmbi.1994.1587; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DEMACARIO EC, 1994, J MOL BIOL, V240, P65; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; HOLTZMAN DA, 1994, J CELL BIOL, V126, P423, DOI 10.1083/jcb.126.2.423; HONTS JE, 1994, J CELL BIOL, V126, P413, DOI 10.1083/jcb.126.2.413; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MCGOUGH A, 1994, J CELL BIOL, V126, P433, DOI 10.1083/jcb.126.2.433; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MONTGOMERY D, 1993, J MOL BIOL, V232, P680, DOI 10.1006/jmbi.1993.1418; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; NARBERHAUS F, 1992, J BACTERIOL, V174, P3290, DOI 10.1128/jb.174.10.3290-3299.1992; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; WANG TF, 1993, J BIOL CHEM, V268, P26049; WETZSTEIN M, 1992, J BACTERIOL, V174, P3300, DOI 10.1128/jb.174.10.3300-3310.1992; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	49	215	217	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16903	16910		10.1074/jbc.270.28.16903	http://dx.doi.org/10.1074/jbc.270.28.16903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622507	hybrid			2022-12-25	WOS:A1995RJ34700068
J	THINAKARAN, G; SLUNT, HH; SISODIA, SS				THINAKARAN, G; SLUNT, HH; SISODIA, SS			NOVEL REGULATION OF CHONDROITIN SULFATE GLYCOSAMINOGLYCAN MODIFICATION OF AMYLOID PRECURSOR PROTEIN AND ITS HOMOLOG, APLP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; MESSENGER-RNA; PROTEOGLYCAN FORM; NEXIN-II; IDENTIFICATION; DOMAIN; CDNA	Alzheimer's disease is characterized by the presence of parenchymal and cerebrovascular deposits of beta-amyloid (A beta). A beta is derived from larger amyloid precursor proteins (APP), a member of a family of related polypeptides that includes amyloid precursor-like proteins, APLP1 and APLP2, APP and APLP2 isoforms are encoded by several alternatively spliced APP and APLP2 transcripts, respectively, We previously reported that the APLP2-751 isoform is modified by the addition of chondroitin sulfate glycosminoglycan (CS GAG) at Ser-614, In this report, we demonstrate that the APLP2-763 isoform, which contains an insertion of 12 amino acids immediately N-terminal to Ser-614, is not modified by CS GAG, Finally, we demonstrate that like APLP2-751, APP isoforms that lack sequences encoded by exon 15 (L-APP) are also modified by CS GAG, whereas APP forms containing exon 15 are not, We suggest that CS GAG modification of a subset of APP and APLP2 isoforms represents a means of generating functional diversity for these polypeptides.	JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS020471, P50NS020471] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 20471, NS AG 05146] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; CHEN C, 1987, MOL CELL BIOL, V7, P2746; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; OHGAMI T, 1993, J NEUROCHEM, V61, P1553, DOI 10.1111/j.1471-4159.1993.tb13655.x; OHGAMI T, 1993, MOL BRAIN RES, V20, P240, DOI 10.1016/0169-328X(93)90046-R; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PETERSEN LC, 1994, FEBS LETT, V338, P53, DOI 10.1016/0014-5793(94)80115-0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SANDBRINK R, 1994, J BIOL CHEM, V269, P14227; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SHIOI J, 1993, NEUROSCI LETT, V154, P121, DOI 10.1016/0304-3940(93)90186-O; SHIOI J, 1992, J BIOL CHEM, V267, P13819; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; THINAKARAN G, 1994, J BIOL CHEM, V269, P22099; VANNOSTRAND WE, 1994, BBA-PROTEIN STRUCT M, V1209, P165, DOI 10.1016/0167-4838(94)90180-5; VANNOSTRAND WE, 1989, NATURE, V341, P546; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	30	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16522	16525		10.1074/jbc.270.28.16522	http://dx.doi.org/10.1074/jbc.270.28.16522			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622456	hybrid			2022-12-25	WOS:A1995RJ34700011
J	TSIANG, M; JAIN, AK; DUNN, KE; ROJAS, ME; LEUNG, LLK; GIBBS, CS				TSIANG, M; JAIN, AK; DUNN, KE; ROJAS, ME; LEUNG, LLK; GIBBS, CS			FUNCTIONAL MAPPING OF THE SURFACE RESIDUES OF HUMAN THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; THROMBOMODULIN-BINDING SITE; PRO-ARG CHLOROMETHYLKETONE; AMINO-ACID SUBSTITUTIONS; STRANDED-DNA APTAMER; BLOOD-COAGULATION; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; PROTEIN-C; KUNITZ INHIBITORS	Utilizing site directed mutagenesis, 77 charged and polar residues that are highly exposed on the surface of human thrombin were systematically substituted with alanine. Functional assays using thrombin mutants identified residues that were required for the recognition and cleavage of the procoagulant substrate fibrinogen (Lys(21), Trp(50), Lys(52), Asn(53)+Thr(55), Lys(65), His(66), Arg(68), Tyr(71), Arg(73), Lys(77), Lys(106)+Lys(107), Asp(193)+Lys(196), Glu(202), Glu(229), Arg(233), Asp(234)) and the anticoagulant substrate protein C (Lys(21), Trp(50), Lys(65), His(66), Arg(68), Tyr(71), Arg(73), Lys(77), Lys(106)+Lys(107), Glu(229), Arg(233)), interactions with the cofactor thrombomodulin (Gln(24), Arg(70)) and inhibition by the thrombin aptamer, an oligonucleotide-based thrombin inhibitor (Lys(65) , His(66), Arg(7)0, Tyr(71) Arg(73)). Although there is considerable overlap between the functional epitopes, distinct and specific residues with unique functions were identified. When the functional residues were mapped on the surface of thrombin, they were located on a single hemisphere of thrombin that included both the active site cleft and the highly basic exosite 1. No functional residues were located on the opposite face of thrombin. Residues with procoagulant or anticoagulant functions were not spatially separated but interdigitated with residues of opposite or shared function. Thus thrombin utilizes the same general surface for substrate recognition regardless of substrate function although the critical contact residues may vary.			TSIANG, M (corresponding author), GILEAD SCI INC,353 LAKESIDE DR,FOSTER CITY,CA 94404, USA.							ADAMS GA, 1985, MOL CELL BIOL, V5, P1442, DOI 10.1128/MCB.5.6.1442; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BINNIE CG, 1993, BLOOD, V81, P3186; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1993, SEMIN THROMB HEMOST, V19, P321, DOI 10.1055/s-2007-993283; BODE W, 1992, PROTEIN SCI, V1, P426; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; FURIE B, 1982, J BIOL CHEM, V257, P3875; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gibbs C.S., 1991, METHODS COMPANION ME, V3, P165; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HEDNER U, 1989, METABOLIC BASIS INHE, P2107; HORNE MK, 1983, BLOOD, V63, P188; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KLAPPER MH, 1977, BIOCHEM BIOPH RES CO, V78, P1018, DOI 10.1016/0006-291X(77)90523-X; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIU LW, 1994, J BIOL CHEM, V269, P11807; LORAND L, 1992, THROMBIN STRUCTURE F, P257; Mann K.G.R., 1987, HEMOSTASIS THROMBOSI, P148; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; NOE G, 1988, J BIOL CHEM, V263, P11729; PABORSKY LR, 1993, J BIOL CHEM, V268, P20808; PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; ROSENBERG RD, 1987, MOL BASIS BLOOD DISE, P534; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STUBBS MT, 1993, SEMIN THROMB HEMOST, V19, P344, DOI 10.1055/s-2007-993285; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; SUZUKI K, 1990, J BIOL CHEM, V265, P13263; SUZUKI K, 1991, J BIOL CHEM, V266, P18498; TSIANG M, 1992, J BIOL CHEM, V267, P6164; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; WU QY, 1992, J BIOL CHEM, V267, P24408; YE J, 1994, J BIOL CHEM, V269, P17965	49	166	174	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16854	16863		10.1074/jbc.270.28.16854	http://dx.doi.org/10.1074/jbc.270.28.16854			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622501	hybrid			2022-12-25	WOS:A1995RJ34700062
J	LEVINGER, L; VASISHT, V; GREENE, V; BOURNE, R; BIRK, A; KOLLA, S				LEVINGER, L; VASISHT, V; GREENE, V; BOURNE, R; BIRK, A; KOLLA, S			SEQUENCE AND STRUCTURE REQUIREMENTS FOR DROSOPHILA TRANSFER-RNA 5'-END AND 3'-END PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; XENOPUS-LAEVIS; ENDONUCLEOLYTIC CLEAVAGE; RIBONUCLEASE-P; RIBOSOMAL-RNA; 3' END; COMPONENT; TRANSCRIPTION; POLYMERASE; SELECTION	Eukaryotic tRNAs are processed at their 5'- and 3'-ends by the endonucleases RNase P and 3'-tRNase, respectively, We have prepared substrates for both enzymes, separated the activities from a Drosophila extract, and designed variant tRNAs to assess the effects of sequence and structure on processing. Mutations affect these reactions in similar ways; thus, RNase P and 3'-tRNase probably require similar substrate structures to maintain the catalytic fit. RNase P is more sensitive to substrate substitutions than 3'-tRNase. In three of the four stems, one substitution prevents both processing reactions while the opposite one has less effect; anticodon stem substitutions hardly affect processing, and double substitutions intended to restore base pairing also restore processing to the wild type rate. Structure probing suggests that tRNA misfolding sometimes coincides with reduced processing. In other cases, processing inhibition probably results from specific unfavorable stem appositions leading to local helix deformation. A single T loop substitution disrupts the tertiary D-T loop interaction and reduces processing. We have thus begun mapping tRNA processing determinants on the global, local, and tertiary structure levels.			LEVINGER, L (corresponding author), CUNY YORK COLL,DEPT NAT SCI BIOL,JAMAICA,NY 11451, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T34GM008498, S06GM008153] Funding Source: NIH RePORTER; NIGMS NIH HHS [R15 GM04603, S06 GM08153, T34 GM08498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman Sidney, 1995, P67; BAER M, 1990, NUCLEIC ACIDS RES, V18, P97, DOI 10.1093/nar/18.1.97; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; Bjork Glenn R., 1995, P165; BRUNEL C, 1990, J MOL BIOL, V215, P103, DOI 10.1016/S0022-2836(05)80099-3; CARRARA G, 1989, CELL, V58, P37, DOI 10.1016/0092-8674(89)90400-5; CASTANO JG, 1985, J BIOL CHEM, V260, P9002; CIESIOLKA J, 1994, EUR J BIOCHEM, V219, P49, DOI 10.1111/j.1432-1033.1994.tb19913.x; COOLEY L, 1982, P NATL ACAD SCI-BIOL, V79, P6475, DOI 10.1073/pnas.79.21.6475; Deutscher Murray P., 1995, P51; DICHTL B, 1993, NUCLEIC ACIDS RES, V21, P531, DOI 10.1093/nar/21.3.531; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3908; Dirheimer G., 1995, P93; DORIA M, 1991, NUCLEIC ACIDS RES, V19, P2315, DOI 10.1093/nar/19.9.2315; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; FURTER R, 1992, BIOCHEMISTRY-US, V31, P10817, DOI 10.1021/bi00159a024; GUERRIERTAKADA C, 1984, CELL, V38, P219, DOI 10.1016/0092-8674(84)90543-9; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HARDT WD, 1993, BIOCHEMISTRY-US, V32, P13046, DOI 10.1021/bi00211a014; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; KRUPP G, 1991, J MOL BIOL, V217, P637, DOI 10.1016/0022-2836(91)90522-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE JY, 1989, MOL CELL BIOL, V9, P2536, DOI 10.1128/MCB.9.6.2536; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; McClain William H., 1995, P335; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PREISER PR, 1991, J BIOL CHEM, V266, P7509; PRICE DH, 1987, J BIOL CHEM, V262, P3244; Westaway Shawn K., 1995, P79; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848; ZENNARO E, 1989, NUCLEIC ACIDS RES, V17, P5741	33	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18903	18909		10.1074/jbc.270.32.18903	http://dx.doi.org/10.1074/jbc.270.32.18903			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642547	hybrid			2022-12-25	WOS:A1995RN95400034
J	YAN, BF; YANG, DF; BULLOCK, P; PARKINSON, A				YAN, BF; YANG, DF; BULLOCK, P; PARKINSON, A			RAT SERUM CARBOXYLESTERASE - CLONING, EXPRESSION, REGULATION, AND EVIDENCE OF SECRETION FROM LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MICROSOMAL CYTOCHROME-P-450; NUCLEOTIDE-SEQUENCE; BETA-GLUCURONIDASE; RETENTION SIGNAL; HDEL RECEPTOR; PROTEIN; CDNA; MOUSE; CELLS	Multiple forms of carboxylesterase have been identified in rat liver, and five carboxylesterases (designated hydrolases A, B, C, S, and egasyn) have been cloned, Hydrolases A, B, C and egasyn all have a C-terminal consensus sequence (HXEL) for retaining proteins in the endoplasmic reticulum, and these carboxylesterases are found in rat liver microsomes, In contrast, hydrolase S lacks this C-terminal consensus sequence and is presumed to be secreted. In order to test this hypothesis, a polyclonal antibody was raised against recombinant hydrolase S from cDNA-directed expression in Escherichia coli. In addition to hydrolases A, B, and C (57-59 kDa), this antibody recognized a 67-kDa protein in rat liver microsomes and a 71-kDa protein in rat serum, The 71-kDa protein detected in rat serum was also detected in the extracellular medium from primary cultures of rat hepatocytes. Non-denaturing gel electrophoresis with staining for esterase activity showed that a serum carboxylesterase comigrated with the 71-kDa protein. Immunoprecipitation of the 71-kDa enzyme from rat serum decreased esterase activity toward 1-naphthylacetate and para-nitrophenylacetate. The 71-kDa protein immunoprecipitated from rat serum had an N-terminal amino acid sequence identical to that predicted from the cDNA encoding hydrolase S, providing further evidence that hydrolase S is synthesized in and secreted by the liver. The levels of the 67-kDa protein in rat liver microsomes and the levels of the 71-kDa protein in rat serum were co-regulated. Deglycosylation of microsomes and serum converted the 67- and 71-kDa proteins to a 58-kDa peptide, which matches the molecular mass calculated from the cDNA for hydrolase S. These results suggest that the 67-kDa protein in liver microsomes is a precursor form of hydrolase S that undergoes further glycosylation before being secreted into serum. In rats, liver appears to be the only source of hydrolase S because no mRNA encoding hydrolase S could be detected in several extrahepatic tissues. Serum carboxylesterases have been found to play an important role in lipid metabolism and detoxication of organophosphates, therefore, the secretion of hydrolase S and the modulation of its expression by xenobiotics may have physiological as well as toxicological significance.	UNIV KANSAS, MED CTR, CTR ENVIRONM & OCCUPAT HLTH, DEPT PHARMACOL TOXICOL & THERAPEUT, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center					NIEHS NIH HHS [ES 04996] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004996] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALEXANDER S, 1989, METHOD ENZYMOL, V179, P505; ALEXSON SEH, 1994, J BIOL CHEM, V269, P17118; ARLOTTO MP, 1987, BIOCHEM PHARMACOL, V36, P3859, DOI 10.1016/0006-2952(87)90450-3; BERNAL DL, 1992, INT J VITAM NUTR RES, V62, P186; BOYER CS, 1992, J PHARMACOL EXP THER, V260, P939; HALBAN PA, 1994, BIOCHEM J, V299, P1; HARDWICK KG, 1992, EMBO J, V11, P4187, DOI 10.1002/j.1460-2075.1992.tb05512.x; KADNER SS, 1992, ARCH BIOCHEM BIOPHYS, V296, P435, DOI 10.1016/0003-9861(92)90594-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINWEBER FJ, 1987, DRUG METAB REV, V18, P379, DOI 10.3109/03602538708994129; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LONG RM, 1988, BIOCHEM BIOPH RES CO, V156, P866, DOI 10.1016/S0006-291X(88)80924-0; LU AYH, 1972, BIOCHEM BIOPH RES CO, V46, P1334, DOI 10.1016/S0006-291X(72)80121-9; MACINTYRE S, 1994, J BIOL CHEM, V269, P24496; MEDDA S, 1986, BIOCHEM GENET, V24, P229, DOI 10.1007/BF00502791; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MENTLEIN R, 1980, ARCH BIOCHEM BIOPHYS, V200, P547, DOI 10.1016/0003-9861(80)90386-0; MENTLEIN R, 1986, J BIOL CHEM, V261, P7816; MORGAN EW, 1994, ARCH BIOCHEM BIOPHYS, V315, P495, DOI 10.1006/abbi.1994.1531; MORGAN EW, 1994, ARCH BIOCHEM BIOPHYS, V315, P513, DOI 10.1006/abbi.1994.1532; MURAKAMI K, 1993, J BIOCHEM-TOKYO, V113, P61, DOI 10.1093/oxfordjournals.jbchem.a124004; NAKAMURA M, 1993, OPHTHALMIC RES, V25, P46, DOI 10.1159/000267220; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; ROBBI M, 1987, BIOCHEM J, V248, P545, DOI 10.1042/bj2480545; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1992, BIOCHEM BIOPH RES CO, V183, P836, DOI 10.1016/0006-291X(92)90559-4; ROBBI M, 1994, BIOCHEM BIOPH RES CO, V203, P1404, DOI 10.1006/bbrc.1994.2341; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; SEGLEN PO, 1983, METHOD CELL BIOL, V29, P1767; SIDHU JS, 1993, ARCH BIOCHEM BIOPHYS, V301, P103, DOI 10.1006/abbi.1993.1121; SONDERFAN AJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P208, DOI 10.1016/0003-9861(88)90386-4; SULTATOS LG, 1986, TOXICOL APPL PHARM, V86, P105, DOI 10.1016/0041-008X(86)90403-5; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TAKEMOTO H, 1992, ARCH BIOCHEM BIOPHYS, V296, P129, DOI 10.1016/0003-9861(92)90554-A; TARENTINO AL, 1989, METHOD CELL BIOL, V32, P111; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TSUJITA T, 1990, PROG CLIN BIOL RES, V334, P915; VERONESI B, 1993, TOXICOL APPL PHARM, V120, P240, DOI 10.1006/taap.1993.1108; WATSON AM, 1994, TOXICOL LETT, V71, P217, DOI 10.1016/0378-4274(94)90108-2; WAXMAN DJ, 1990, BIOCHEM J, V271, P113, DOI 10.1042/bj2710113; WILSON DW, 1993, J BIOL CHEM, V268, P7465; YAN BF, 1995, ARCH BIOCHEM BIOPHYS, V317, P222, DOI 10.1006/abbi.1995.1157; YAN BF, 1995, ARCH BIOCHEM BIOPHYS, V316, P899, DOI 10.1006/abbi.1995.1121; YAN BF, 1994, J BIOL CHEM, V269, P29688; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	49	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19128	19134		10.1074/jbc.270.32.19128	http://dx.doi.org/10.1074/jbc.270.32.19128			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642579	hybrid			2022-12-25	WOS:A1995RN95400067
J	LU, XY; XU, L; MEISSNER, G				LU, XY; XU, L; MEISSNER, G			PHOSPHORYLATION OF DIHYDROPYRIDINE RECEPTOR II-III LOOP PEPTIDE REGULATES SKELETAL-MUSCLE CALCIUM-RELEASE CHANNEL FUNCTION - EVIDENCE FOR AN ESSENTIAL ROLE OF THE BETA-OH GROUP OF SER(687)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SARCOPLASMIC-RETICULUM; ADENINE-NUCLEOTIDE; BLOCKERS; CA-2+; ACTIVATION; CALMODULIN; SUBUNITS; MG-2+; SITE	In vertebrate skeletal muscle, excitation-contraction coupling may occur by a mechanical coupling mechanism involving protein-protein interactions between the dihydropyridine receptor (DHPR) of the transverse tubule membrane and the ryanodine receptor (RYR)/Ca2+ release channel of the sarcoplasmic reticulum membrane. We have previously shown that the cytoplasmic II-III loop peptides of the skeletal and cardiac muscle DHPR alpha 1 subunits (SDCL and CDCL, respectively) activate the skeletal muscle RYR. We now report that cyclic AMP dependent protein kinase mediated phosphorylation of Ser(687) of SDCL yields a peptide that fails to activate the RYR, as determined in [H-3]ryanodine binding and single channel measurements. The phosphorylated SDCL bound to the skeletal muscle but not cardiac muscle RYR, and the binding could be displaced by the unphosphorylated SDCL. A mutant SDCL with a Ser687 --> Ala substitution failed to activate the RYR, but was still able to bind. Similarly, a Ser(813) --> Ala substitution in CDCL yielded a peptide that failed to activate the skeletal RYR. Use of three smaller overlapping peptides within the SDCL region identified an amino acid region from 666 to 726 including Ser687, which bound to and activated the skeletal muscle RYR. These results suggest that cyclic AMP-dependent protein kinase-mediated phosphorylation of the DHPR cu, subunit may play a role in the functional interaction of the DHPR and RYR in skeletal muscle.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27430] Funding Source: Medline; NIAMS NIH HHS [AR18687] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON K, 1994, AM J PHYSIOL, V266, pC462, DOI 10.1152/ajpcell.1994.266.2.C462; BRANDT NR, 1992, FEBS LETT, V299, P57, DOI 10.1016/0014-5793(92)80100-U; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHANG CF, 1991, J BIOL CHEM, V266, P16395; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; FRANZINIARMSTRO.C, 1994, ANNU REV PHYSIOL, V56, P509; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; LAI Y, 1990, J BIOL CHEM, V265, P20839; LEE HB, 1994, J BIOL CHEM, V269, P13305; LU XY, 1994, J BIOL CHEM, V269, P6511; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MUNDINAWEILENMA.C, 1991, BIOPHYS J, V60, P902; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; WIER WG, 1990, ANNU REV PHYSIOL, V52, P467	25	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18459	18464		10.1074/jbc.270.31.18459	http://dx.doi.org/10.1074/jbc.270.31.18459			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629172	hybrid			2022-12-25	WOS:A1995RM64200049
J	CERNI, C; BOUSSET, K; SEELOS, C; BURKHARDT, H; HENRIKSSON, M; LUSCHER, B				CERNI, C; BOUSSET, K; SEELOS, C; BURKHARDT, H; HENRIKSSON, M; LUSCHER, B			DIFFERENTIAL-EFFECTS BY MAD AND MAX ON TRANSFORMATION BY CELLULAR AND VIRAL ONCOPROTEINS	ONCOGENE			English	Article						RAS; C-MYC; ELA; P53; HPV16	C-MYC; DNA-BINDING; PHOSPHORYLATION SITES; RAS COTRANSFORMATION; EMBRYONIC LETHALITY; NEOPLASTIC-CELLS; PROTEIN; ONCOGENES; GROWTH; GENES	c-Myc is an essential component of the regulatory mechanisms controlling cell growth. Max is the obligatory partner of c-Myc for all its biological functions analysed to date. Recently two Max interacting proteins, Mad and Mxi1, have been identified. It has been suggested that these two proteins modulate c-Myc function, in the simplest model by competing with c-Myc for the interaction with Max. We have analysed different aspects of Mad function in comparison to Max, Native Mad/Max heterodimers bound specifically to a c-Myc/Max consensus DNA binding site. Furthermore Mad inhibited efficiently c-Myc, mutant p53, adenovirus Ela, or human papilloma virus type 16 transformation of rat embryo cells in cooperation with activated Ha-Ras, Myc transformed clones showed an increased cell cycle time and a reduced immortalization frequency after cotransfection with either mad or max. In contrast to Mad, Max did not inhibit E1a/Ha-Ras cotransformation but repressed c-Myc/Ha-Ras transformation efficiently. Mad Delta N, an N-terminal deletion mutant of Mad, was as efficient in repressing c-Myc/Ha-Ras cotransformation as full length Mad but showed little inhibitory activity when assayed on E1a/Ha-Ras. Unlike wt Mad, Mad Delta N had little effect on cell growth. Our data suggest that Mad affects cell growth at least in part by a c-Myc independent mechanism.	HANNOVER MED SCH, INST MOLEK BIOL, D-30623 HANNOVER, GERMANY; UNIV VIENNA, INST TUMORBIOL, A-1090 VIENNA, AUSTRIA	Hannover Medical School; University of Vienna			Henriksson, Marie Arsenian/F-5010-2015; Luscher, Bernhard/A-7330-2011	Arsenian Henriksson, Marie/0000-0001-6376-7792; Luscher, Bernhard/0000-0002-9622-8709				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BOUSSET K, 1993, ONCOGENE, V8, P3211; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGLIATI T, 1993, ONCOGENE, V8, P1263; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; EDELHOFF S, 1994, ONCOGENE, V9, P665; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALAZONETIS TD, 1992, SCIENCE, V255, P464, DOI 10.1126/science.1734524; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	57	64	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					587	596						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630643				2022-12-25	WOS:A1995RN53000020
J	PRESS, RD; WISNER, TW; EWERT, DL				PRESS, RD; WISNER, TW; EWERT, DL			INDUCTION OF B-CELL LYMPHOMAS BY OVEREXPRESSION OF A MYB ONCOGENE TRUNCATED AT EITHER TERMINUS	ONCOGENE			English	Article						LYMPHOMA; MYB; ONCOGENE; B CELL	AVIAN-LEUKOSIS VIRUS; C-MYB; DNA-BINDING; MONOCLONAL-ANTIBODIES; V-MYB; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; RAPID INDUCTION; CHICKEN; DIFFERENTIATION	The c-myb oncogene encodes a nuclear transcriptional transactivator that is often terminally truncated in hematopoietic tumors. To directly assess the tumorigenic activity of full length and terminally-truncated variants of c-myb, we have overexpressed several structurally-altered forms of myb within an avian retroviral vector and have shown that overexpression of truncated (but not full length) myb transforms both myeloid cells in vitro and mesenchymal cells in vivo. In vivo infection with these truncated myb viruses is now shown to induce metastatic B cell lymphomas in a significant minority of animals. Evaluation of the lymphomas revealed two distinct mechanisms of myb-induced tumorigenesis. In most of the lymphomas, proviral DNA inserted into the endogenous chicken c-myb gene and promoted the expression of a 5'-truncated myb transcript encoding an amino terminal truncated protein. In comparison, some animals infected with a virus encoding a carboxyl (C) terminal truncated myb (T-myb) developed non-insertional B cell lymphomas that directly expressed the provirally-encoded T-myb gene. The lymphomagenic T-myb protein lacks 214 C terminal amino acids including all of the myb transcription inhibition domain, This novel lymphomagenic activity for a C terminal truncated myb suggests that a loss of regulatory sequences at either end of c-myb is sufficient to create a B cell-specific transforming gene.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute	PRESS, RD (corresponding author), OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201, USA.			Press, Richard/0000-0002-2103-5144	NATIONAL CANCER INSTITUTE [R01CA057516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001551] Funding Source: NIH RePORTER; NCI NIH HHS [CA-57516] Funding Source: Medline; NINDS NIH HHS [NS-01551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABA TW, 1985, P NATL ACAD SCI USA, V82, P213, DOI 10.1073/pnas.82.1.213; CHEN CLH, 1982, J IMMUNOL, V129, P2580; CHEN CLH, 1986, J EXP MED, V164, P375, DOI 10.1084/jem.164.1.375; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V210, P249; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HU YL, 1991, ONCOGENE, V6, P1549; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; OLSON WC, 1990, HYBRIDOMA, V9, P331, DOI 10.1089/hyb.1990.9.331; ONG GLS, 1984, SCIENCE, V226, P1077; PINK JR, 1983, HYBRIDOMA, V2, P287, DOI 10.1089/hyb.1983.2.287; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; PRESS RD, 1992, J VIROL, V66, P5373, DOI 10.1128/JVI.66.9.5373-5383.1992; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1991, ONCOGENE, V6, P1875; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; VELLARD M, 1991, ONCOGENE, V6, P505; VEROMAA T, 1988, HYBRIDOMA, V7, P41, DOI 10.1089/hyb.1988.7.41; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010	37	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					525	535						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630637				2022-12-25	WOS:A1995RN53000013
J	CHOI, SG; ODONNELL, SE; SARKEN, KD; HARDMAN, JK				CHOI, SG; ODONNELL, SE; SARKEN, KD; HARDMAN, JK			TRYPTOPHAN-CONTAINING ALPHA-SUBUNITS OF THE ESCHERICHIA-COLI TRYPTOPHAN SYNTHASE - ENZYMATIC AND UREA STABILITY PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANIDINE-HYDROCHLORIDE; DENATURATION; INTERMEDIATE	Early studies suggested that the Escherichia coli tryptophan synthase alpha-subunit unfolded in a two-step process in which there was a stable intermediate composed of a native alpha-1 folding unit (residues 1-188) and a completely unfolded alpha-2 folding unit (residues 189-268). More recent evidence has indicated that such a structure for the intermediate seems unlikely. In this report, single Trp residues (absent in the wild-type alpha-subunit) are substituted separately for Phe residues at positions 139 (in alpha-1) and 258 (in alpha-2) to produce the F139W, F258W, and F139W/F258W mutant alpha-subunits. The UV absorbance and fluorescence properties of the F139W/F258W double mutant are identical with those of equimolar mixtures of the single mutants, suggesting that the Trp residue at each position can independently report the behavior of its respective folding unit. Each mutant alpha-subunit is wild-type enzymatically, and when UV absorbance is monitored, the urea induced unfolding of the three tryptophan-containing alpha-subunits is virtually identical to the wild-type protein. These wild-type properties make these proteins attractive candidates for a fluorescence examination of the behavior of the individual folding units and the structure of potential intermediate(s) and as host proteins for the insertion of our existing destabilizing and/or stabilizing mutational alterations.	UNIV ALABAMA,DEPT BIOL SCI,CELL & DEV SECT,TUSCALOOSA,AL 35487; UNIV MONTEVALLO,DEPT BIOL & CHEM,MONTEVALLO,AL 35115	University of Alabama System; University of Alabama Tuscaloosa								BEASTY AM, 1986, BIOCHEMISTRY-US, V25, P2965, DOI 10.1021/bi00358a035; BEASTY AM, 1985, BIOCHEMISTRY-US, V24, P3547, DOI 10.1021/bi00335a024; CHEN XW, 1994, BIOCHEMISTRY-US, V33, P6356, DOI 10.1021/bi00186a040; CHRUNYK BA, 1990, BIOCHEMISTRY-US, V29, P2149, DOI 10.1021/bi00460a027; CRISANTI MM, 1981, BIOCHEMISTRY-US, V20, P2700, DOI 10.1021/bi00512a052; CUPO JF, 1983, BIOCHEMISTRY-US, V22, P2654, DOI 10.1021/bi00280a010; FABER GK, 1980, TRENDS BIOCHEM SCI, V15, P228; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; HURLE MR, 1987, BIOCHIM BIOPHYS ACTA, V913, P179, DOI 10.1016/0167-4838(87)90328-1; HURLE MR, 1987, PROTEINS, V2, P54, DOI 10.1002/prot.340020107; HYDE CC, 1988, J BIOL CHEM, V263, P17857; IWAHASHI H, 1983, BIOCHIM BIOPHYS ACTA, V744, P189, DOI 10.1016/0167-4838(83)90089-4; LEGGETTBAILEY J, 1962, TECHNIQUES PROTEIN C, P249; LIM WK, 1991, J BIOL CHEM, V266, P20205; LIM WK, 1992, ARCH BIOCHEM BIOPHYS, V292, P34, DOI 10.1016/0003-9861(92)90047-Z; MATTHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784, DOI 10.1021/bi00507a021; MILES EW, 1982, BIOCHEMISTRY-US, V21, P2586, DOI 10.1021/bi00540a002; MILES EW, 1978, J BIOL CHEM, V253, P6266; MILTON DL, 1986, J BIOL CHEM, V261, P6604; OGASAHARA K, 1994, J MOL BIOL, V236, P1227, DOI 10.1016/0022-2836(94)90023-X; OGASAHARA K, 1993, J MOL BIOL, V234, P1197, DOI 10.1006/jmbi.1993.1670; Pace C N, 1986, Methods Enzymol, V131, P266; PRESS WH, 1986, NUMERICAL RECIPES AR; SAABRINCON G, 1993, BIOCHEMISTRY-US, V32, P13981, DOI 10.1021/bi00213a031; SARKER KD, 1995, PROTEINS, V21, P130, DOI 10.1002/prot.340210207; TSUJI T, 1993, BIOCHEMISTRY-US, V32, P5566, DOI 10.1021/bi00072a011; YUTANI K, 1979, J BIOCHEM-TOKYO, V85, P915, DOI 10.1093/oxfordjournals.jbchem.a132423	27	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17712	17715		10.1074/jbc.270.30.17712	http://dx.doi.org/10.1074/jbc.270.30.17712			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629069	hybrid			2022-12-25	WOS:A1995RM26600015
J	VOLIOVITCH, H; SCHINDLER, DG; HADARI, YR; TAYLOR, SI; ACCILI, D; ZICK, Y				VOLIOVITCH, H; SCHINDLER, DG; HADARI, YR; TAYLOR, SI; ACCILI, D; ZICK, Y			TYROSINE PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1 IN-VIVO DEPENDS UPON THE PRESENCE OF ITS PLECKSTRIN HOMOLOGY REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNAL TRANSDUCTION; PROTEIN-KINASE; PH DOMAIN; IRS-1; CELLS; ASSOCIATION; ACTIVATION; ANTIBODIES; EXPRESSION	To characterize the structural basis for the interactions between the insulin receptor (IR) and its major substrate, insulin receptor substrate-1 (IRS-1), a segment of the NH2-terminal region of IRS-1 (Pro(5)-Pro(65)) was deleted. This region contains the first four conserved boxes of a pleckstrin homology (PH) domain, located at the NH2-terminal part of IRS-1. COS-7 cells were then cotransfected with the genes coding for IR and a wild-type (WT) or a mutated form of IRS-1. IRS-1(Delta PH) underwent significantly reduced insulin-dependent tyrosine phosphorylation compared with WT IRS-1. The reduced in. vivo tyrosine phosphorylation of IRS-1(Delta PH) was accompanied by reduced association between IRS-1(Delta PH) and its downstream effector p85 regulatory subunit of phosphatidylinositol-3 kinase. In contrast, both WT IRS-1 and IRS-1(Delta PH) underwent comparable in insulin-dependent tyrosine phosphorylation in vitro when incubated with partially purified insulin receptor ki nase. These findings suggest that the overall structure of IRS-1 is not altered by deletion of its PH domain and that the PR domain is not the main site for protein-protein interactions between the insulin receptor and IRS-1, at least in vitro. In conclusion, the PH region might facilitate in vivo binding of IRS-1 to membrane phospholipids or other cellular constituents in close proximity to the IR, whereas the actual interactions with the IR are presumably mediated through other domains of the IRS-1 molecule. This could account for the fact that partial deletion of the PH domain selectively impairs the in vivo interactions between the insulin receptor and IRS-1, whereas their in vitro interactions remain unaffected.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; NIH, DIABET BRANCH, BETHESDA, MD 20982 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA			Zick, Yehiel/K-1479-2012					ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HADARI YR, 1993, MOL CELL ENDOCRINOL, V97, P9, DOI 10.1016/0303-7207(93)90206-Y; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HEFFETZ D, 1991, METHOD ENZYMOL, V201, P44; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TAYLOR SI, 1991, INSULIN LIKE GROWTH, P221; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZICK Y, 1983, J BIOL CHEM, V258, P75; ZICK Y, 1989, CRIT REV BIOCHEM MOL, V24, P217, DOI 10.3109/10409238909082554; ZICK Y, 1983, J BIOL CHEM, V258, P3431	44	87	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18083	18087		10.1074/jbc.270.30.18083	http://dx.doi.org/10.1074/jbc.270.30.18083			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629118	hybrid			2022-12-25	WOS:A1995RM26600069
J	WANG, CC; MORIYAMA, R; LOMBARDO, CR; LOW, PS				WANG, CC; MORIYAMA, R; LOMBARDO, CR; LOW, PS			PARTIAL CHARACTERIZATION OF THE CYTOPLASMIC DOMAIN OF HUMAN KIDNEY BAND-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; ANION-TRANSPORT PROTEIN; ANKYRIN-BINDING SITE; RED-CELL MEMBRANE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; INTERCALATED CELLS; COLLECTING DUCT; RAT-KIDNEY; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE	The major anion exchanger in type A intercalated cells of the cortical and medullary collecting ducts of the human kidney is a truncated isoform of erythrocyte band 3 (AE1) that lacks the N-terminal 65 residues. Because this missing sequence has been implicated in the binding of ankyrin, protein 4.1, several glycolytic enzymes, hemoglobin, and hemichromes in erythrocytes, we have undertaken examination of the structure and peripheral protein interactions of this kidney isoform. The cytoplasmic domain of kidney band 3, kidney CDB3, was expressed in Escherichia coli and purified to homogeneity. The kidney isoform exhibited a circular dichroism spectrum and Stokes radius similar to its larger erythrocyte counterpart. Kidney CDB3 was also observed to engage in the same conformational equilibrium characteristic of erythrocyte CDB3. In contrast, the tryptophan and cysteine clusters of kidney CDB3 behaved very differently from erythrocyte CDB3 in response to pH changes and oxidizing conditions. Furthermore, kidney CDB3 did not bind ankyrin, protein 4.1, or aldolase, and expression of erythrocyte CDB3 was toxic to its bacterial host, whereas expression of kidney CDB3 was not. Taken together, these data suggest that the absence of the N-terminal 65 amino acids in kidney CDB3 eliminates the major function currently ascribed to CDB3 in erythrocytes, i.e. that of peripheral protein binding. The primary function of residues 66-379 found in kidney CDB3 thus remains to be elucidated.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024417, R37GM024417] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24417] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; APPELL KC, 1981, J BIOL CHEM, V256, P1104; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CASEY JR, 1991, J BIOL CHEM, V266, P15726; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DING Y, 1995, J BIOL CHEM, V269, P32201; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; ERCOLANI L, 1992, AM J PHYSIOL, V262, pF892, DOI 10.1152/ajprenal.1992.262.5.F892; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; IDEGUCHI H, 1992, BRIT J HAEMATOL, V82, P122, DOI 10.1111/j.1365-2141.1992.tb04603.x; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; KOLLERTJONS A, 1993, AM J PHYSIOL, V265, pF813, DOI 10.1152/ajprenal.1993.265.6.F813; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149, DOI 10.1073/pnas.84.20.7149; KORSGREN C, 1986, J BIOL CHEM, V261, P5536; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOW PS, 1987, J BIOL CHEM, V262, P4592; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1984, J BIOL CHEM, V259, P3070; LOW PS, 1991, BLOOD, V77, P1581; LOW PS, 1993, J BIOL CHEM, V268, P14627; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MADSEN KM, 1992, AM J PHYSIOL, V262, pF1015, DOI 10.1152/ajprenal.1992.262.6.F1015; MURONETZ VI, 1994, ARCH BIOCHEM BIOPHYS, V313, P253, DOI 10.1006/abbi.1994.1385; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; MURTHY SNP, 1984, H-S Z PHYSIOL CHEM, V365, P9, DOI 10.1515/bchm2.1984.365.1.9; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; OSTEDGAARD LS, 1991, P NATL ACAD SCI USA, V88, P981, DOI 10.1073/pnas.88.3.981; REITHMEIER RAF, 1979, J BIOL CHEM, V254, P3054; REITHMEIER RAF, 1979, J BIOL CHEM, V254, P6151; ROGALSKI AA, 1989, J BIOL CHEM, V264, P6438; RYBICKI AC, 1993, BLOOD, V81, P2155; SCHOFIELD AE, 1994, BLOOD, V84, P2000; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; THEVENIN BJM, 1989, J BIOL CHEM, V264, P15886; TSAI IH, 1982, J BIOL CHEM, V257, P1438; VERLANDER JW, 1988, AM J PHYSIOL, V255, pF115, DOI 10.1152/ajprenal.1988.255.1.F115; WAGNER S, 1987, AM J PHYSIOL, V253, pF213, DOI 10.1152/ajprenal.1987.253.2.F213; WALDER JA, 1984, J BIOL CHEM, V259, P238; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	57	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17892	17897		10.1074/jbc.270.30.17892	http://dx.doi.org/10.1074/jbc.270.30.17892			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629093	hybrid			2022-12-25	WOS:A1995RM26600041
J	ADAM, D; KESSLER, U; KRONKE, M				ADAM, D; KESSLER, U; KRONKE, M			CROSS-LINKING OF THE P55 TUMOR-NECROSIS-FACTOR RECEPTOR CYTOPLASMIC DOMAIN BY A DIMERIC LIGAND INDUCES NUCLEAR FACTOR-KAPPA-B AND MEDIATES CELL-DEATH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR TNF RECEPTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; FACTOR-BINDING; FACTOR-ALPHA; EXPRESSION; ACTIVATION; FORM; INTERLEUKIN-2	We have fused the cytoplasmic domain of the p55 tumor necrosis factor (TNF) receptor to the extracellular and transmembrane domain of the mouse platelet-derived growth factor (PDGF) receptor. Mouse mammary gland epithelial (NMuMG;) cells were stably transfected with the PDGFR-TR55 chimeric receptor. These cells lack endogenous PDGF receptor expression and do not respond to PDGF. In the PDGFR-TR55 transfectants, PDGF elicited a cytotoxic response, which is indistinguishable from that induced by the wild type p55 TNF receptor. In addition, PDGF-induced activation of the PDGFR-TR55 chimeric receptor resulted in nuclear translocation of NF-kappa B. The data presented suggest that cross-linking of the p55 TNF receptor cytoplasmic domain by a dimeric ligand such as PDGF is sufficient to generate cellular responses that do not differ from those observed with the trimeric ligand TNF.	TECH UNIV MUNICH,INST MED MIKROBIOL & HYG,TROGERSTR 32,D-81675 MUNICH,GERMANY	Technical University of Munich	ADAM, D (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,INST IMMUNOL,BRUNSWIKER STR 4,D-24105 KIEL,GERMANY.		Adam, Dieter/E-9763-2010	Adam, Dieter/0000-0002-5668-5032				ADAM D, 1993, J BIOL CHEM, V268, P19882; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BELKA K, 1995, EMBO J, V14, P1156; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOLDIN MP, 1994, J BIOL CHEM, V2700, P387; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; PERKINS ND, 1991, P NATL ACAD SCI USA, V89, P1529; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH RA, 1987, J BIOL CHEM, V262, P6951; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287	40	23	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17482	17487						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615552				2022-12-25	WOS:A1995RK68900067
J	ALMLOF, T; WRIGHT, APH; GUSTAFSSON, JA				ALMLOF, T; WRIGHT, APH; GUSTAFSSON, JA			ROLE OF ACIDIC AND PHOSPHORYLATED RESIDUES IN GENE ACTIVATION BY THE GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; YEAST; PROTEINS; SUPERFAMILY; EXPRESSION; BINDING; CELLS; SITES; GAL4	To investigate the role of acidic and phosphorylated amino acids in the function of the major transactivation domain (tau(1)) of the glucocorticoid receptor, we have performed a mutagenesis study. Aspartic and glutamic acid residues were neutralized in clusters of 2 to 4 amino acids throughout the tau(1) domain. The activity of the mutant proteins was determined using transactivation as says in yeast and mammalian cells. Some acidic residues in the core region of tau(1) appear to play a minor role in tau(1) activity, but, generally, individual acidic residues are not critical for activity. Mutagenesis of five serine residues that are phosphorylated in the mouse glucocorticoid receptor and which are conserved in the human receptor did not affect the transactivation activity of the tau(1) domain in yeast. As in mouse cells, these serine residues are the predominant sites of phosphorylation for ectopically expressed receptor in yeast, since the mutant protein lacking all five sites had a severely reduced phosphorylation level. Mutant proteins in which larger numbers of acidic residues are neutralized show a progressive decrease in activity indicating that acidity in general is important for tau(1) function. However, our results are not consistent with the ''acid blob'' theory of transactivator function that has been suggested for some other activator proteins. Other putative roles for the acidity of tau(1) are discussed.	KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet			Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969				ANDERSSON S, 1988, J BIOL CHEM, V264, P8222; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; ECKSTEIN F, 1988, NUCLEIC ACIDS RES, V16, P791; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GEISSELSODER MC, 1989, BIOTECHNIQUES, V7, P282; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; JENSEN EV, 1991, NUCLEAR HORMONE RECE, P1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MASON SA, 1993, J BIOL CHEM, V268, P21501; MCEWAN IJ, 1994, J BIOL CHEM, V269, P25629; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORTI E, 1989, J STEROID BIOCHEM, V34, P85, DOI 10.1016/0022-4731(89)90069-1; POLETTI A, 1993, BIOCHEMISTRY-US, V32, P9563, DOI 10.1021/bi00088a007; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; WRIGHT APH, 1991, MOL ENDOCRINOL, V5, P1366, DOI 10.1210/mend-5-10-1366; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	42	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17535	17540		10.1074/jbc.270.29.17535	http://dx.doi.org/10.1074/jbc.270.29.17535			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615559	hybrid			2022-12-25	WOS:A1995RK68900075
J	GANGULI, S; WANG, H; MATSUMURA, P; VOLZ, K				GANGULI, S; WANG, H; MATSUMURA, P; VOLZ, K			UNCOUPLED PHOSPHORYLATION AND ACTIVATION IN BACTERIAL CHEMOTAXIS - THE 2.1-ANGSTROM STRUCTURE OF A THREONINE TO ISOLEUCINE MUTANT AT POSITION-87 OF CHEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOSIGNALING PROTEIN CHEY; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; FLAGELLAR SWITCH; CONSERVED ASPARTATE; RESPONSE REGULATOR; F-19 NMR; BINDING; MUTATIONS	Position 87 of the chemotaxis regulatory protein CheY is a highly conserved threonine/serirle residue in the response regulator superfamily. A threonine 87 to isoleucine mutant in CheY, identified by its in vivo non-chemotactic phenotype, was also found to be phosphorylatable in vitro. These properties indicate that this mutant does not undergo activation upon phosphorylation. The x-ray crystallographic structure of the threonine to isoleucine CheY mutant has been solved and refined at 2.1-Angstrom resolution, to an R factor of 15.6%. Comparison with the wild-type, Mg2+-free CheY structure shows that the active site structure is retained, but there are significant localized differences in the backbone conformation distal from the substitution. The presence of the isoleucine side chain also restricts the rotational conformation of another conserved residue in the molecule. tyrosine at position 106. These results provide further evidence for a signaling surface remote from the phosphorylation site of the CheY molecule and implicate threonine 87 and other residues in the post-phosphorylation signaling events.	UNIV ILLINOIS,DEPT MICROBIOL & IMMUNOL,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047522] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18985] Funding Source: Medline; NIGMS NIH HHS [GM47522] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BARAK R, 1992, BIOCHEMISTRY-US, V31, P10099, DOI 10.1021/bi00156a033; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; BERG HC, 1988, COLD SPRING HARB SYM, V53, P1, DOI 10.1101/SQB.1988.053.01.003; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1993, J BIOL CHEM, V268, P13089; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISSETTE RE, 1991, J BACTERIOL, V173, P3749, DOI 10.1128/JB.173.12.3749-3755.1991; BUCKLE AM, 1993, J MOL BIOL, V234, P847, DOI 10.1006/jmbi.1993.1630; CLEGG DO, 1984, P NATL ACAD SCI-BIOL, V81, P5056, DOI 10.1073/pnas.81.16.5056; DAILEY FE, 1993, J BACTERIOL, V175, P3236, DOI 10.1128/JB.175.10.3236-3239.1993; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; HALL SR, 1988, XTAL 2 4 USERS MANUA; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KANAMARU K, 1992, J BIOCHEM-TOKYO, V111, P425, DOI 10.1093/oxfordjournals.jbchem.a123773; KAR L, 1992, BIOCHEM J, V287, P521, DOI 10.1042/bj2870521; KAR L, 1992, BIOCHEM J, V287, P533, DOI 10.1042/bj2870533; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MARTINEZOYANEDEL J, 1991, J MOL BIOL, V222, P335, DOI 10.1016/0022-2836(91)90215-R; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; OHLENDORF DH, 1994, ACTA CRYSTALLOGR D, V50, P808, DOI 10.1107/S0907444994002659; OLMEDO G, 1990, J MOL BIOL, V215, P359, DOI 10.1016/S0022-2836(05)80357-2; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; RAVID S, 1986, P NATL ACAD SCI USA, V83, P7157, DOI 10.1073/pnas.83.19.7157; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; Rossmann M. G., 1972, MOL REPLACEMENT METH; RUSSO FD, 1993, J MOL BIOL, V231, P261, DOI 10.1006/jmbi.1993.1281; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SMITH JL, 1986, BIOCHEMISTRY-US, V25, P5018, DOI 10.1021/bi00366a008; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; VOLZ K, 1991, J BIOL CHEM, V266, P15511; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WEINSTEIN M, 1992, MOL MICROBIOL, V6, P2041, DOI 10.1111/j.1365-2958.1992.tb01377.x; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8757; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6	52	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17386	17393		10.1074/jbc.270.29.17386	http://dx.doi.org/10.1074/jbc.270.29.17386			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615544	hybrid			2022-12-25	WOS:A1995RK68900055
J	HAWES, BE; VANBIESEN, T; KOCH, WJ; LUTTRELL, LM; LEFKOWITZ, RJ				HAWES, BE; VANBIESEN, T; KOCH, WJ; LUTTRELL, LM; LEFKOWITZ, RJ			DISTINCT PATHWAYS OF G(I)-MEDIATED AND G(Q)-MEDIATED MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; SIGNAL-TRANSDUCTION; ADENYLYL CYCLASE; TYROSINE KINASES; ALPHA-SUBUNIT; MAP KINASE; SF9 CELLS; RECEPTOR; EXPRESSION	Receptors that couple to the heterotrimeric G proteins, G(1) or G(q), can stimulate phosphoinositide (PI) hydrolysis and mitogen-activated protein kinase (MAPK) activation. PI hydrolysis produces inositol 1,4,5-trisphosphate and diacylglycerol, leading to activation of protein kinase C (PKC), which can stimulate increased MAPK activity. However, the relationship between PI hydrolysis and MAPK activation in G(i) and G(q) signaling has not been clearly defined and is the subject study. The effects of several signaling inhibitors assessed including expression of a peptide derived from the carboxyl terminus of the beta adrenergic receptor kinase 1 (beta ARKct), which specifically blocks signaling mediated by the beta gamma subunits of G proteins (G beta gamma), expression of dominant negative mutants of p21(ras) (RasN17) and p74(raf-1) (N Delta Raf), protein-tyrosine kinase (PTK) inhibitors and cellular depletion of PRC. The G(1)-coupled alpha 2A adrenergic receptor (AR) stimulates MAPK activation which is blocked by expression of beta ARKct, RasN17, or N Delta Raf, or by PTK inhibitors, but unaffected by cellular depletion of PKC. In contrast, MAPK activation stimulated by the G(q) coupled, alpha 1B AR or M1 muscarinic cholinergic receptor is unaffected by expression of beta ARKct or RasN17 expression or by PTK inhibitors, but is blocked by expression of N Delta Raf or by PKC depletion. These data demonstrate that G(i)- and G(q)-coupled receptors stimulate MAPK activation via distinct signaling pathways. G beta gamma is responsible for mediating G(i)-coupled receptor-stimulated MAPK activation through a mechanism utilizing p21ras and p74raf independent of PKC. In contrast, G alpha mediates G(q)-coupled receptor-stimulated MAPK activation using a p21(ras)-independent mechanism employing PKC and p74(raf). To define the role of G beta gamma in G(i)-coupled receptor mediated PI hydrolysis and MAPK activation, direct stimulation with G beta gamma was used. Expression of G beta gamma resulted in MAPK activation that was sensitive to inhibition by expression of beta ARKct, RasN17, or N Delta Raf or by PTK inhibitors, but insensitive to PKC deletion. By comparison, G beta gamma-mediated PI hydrolysis not affected by beta ARKct, RasN17, or N Delta Raf expression or by PTK inhibitors. Together, these results demonstrate that G beta gamma mediates MAPK activation and PI hydrolysis via independent signaling pathways.	DUKE UNIV, MED CTR, DEPT MED CARDIOL, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITS AMM, 1992, NATURE, V357, P602; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; UEDA N, 1994, J BIOL CHEM, V269, P4388; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297	50	419	425	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17148	17153		10.1074/jbc.270.29.17148	http://dx.doi.org/10.1074/jbc.270.29.17148			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615510	hybrid			2022-12-25	WOS:A1995RK68900017
J	MA, JF; SHINADA, T; MATSUDA, C; NOMOTO, K				MA, JF; SHINADA, T; MATSUDA, C; NOMOTO, K			BIOSYNTHESIS OF PHYTOSIDEROPHORES, MUGINEIC ACIDS, ASSOCIATED WITH METHIONINE CYCLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2'-DEOXYMUGINEIC ACID; HIGHER-PLANTS	The biosynthesis of 2'-deoxymugineic acid, a key phytosiderophore, was examined in association with the putative methionine recycling pathway in the roots of wheat using labeling experiments and structural analysis, Feeding with D-[1-C-13]ribose did not result in C-13 enrichment of 2'-deoxymugineic acid, while D-[2-C-13]ribose resulted in C-13 enrichment at the C-4'', -1, -4' positions, and D-[5-C-13]ribose did in C-1', -4, and -1'' positions of 2'-deoxymugineic acid, respectively. Furthermore, two isotope-labeled intermediates of the methionine recycling pathway, 5-[5-H-2(2)]methylthioribose and 2-[1-C-13]keto-4-methylthiobutyric acid, were synthesized, and their incorporation into 2'-deoxymugineic acids was investigated. Six deuterium atoms at the C-4, -1', and -1'' positions of 2'-deoxymugineic acid were observed after feeding with 5-[5-H-2(2)]methylthioribose. Feeding with 2-[1-C-13]keto-4-methylthiobutyric acid yielded 2'-deoxymugineic acid enriched with C-13 at the C-4', -1, and -4'' positions. These results demonstrated for the first time that the biosynthesis of 2'-deoxymugineic acid is associated with the methionine recycling pathway. This association system functions to recycle methionine required for continued synthesis of mugineic acids in the roots of gramineous plants.	SUNTORY INST BIOORGAN RES,SHIMAMOTO 618,OSAKA,JAPAN	Suntory Holdings Ltd			Feng, Jian/C-7213-2009; Ma, Jianfeng/GZB-0110-2022	Feng, Jian/0000-0003-3411-827X; 				DEVOSS JJ, 1994, J ORG CHEM, V59, P2715, DOI 10.1021/jo00089a013; GIOVANELLI J, 1974, PLANT PHYSIOL, V54, P725, DOI 10.1104/pp.54.5.725; KAWAI S, 1988, TETRAHEDRON LETT, V29, P1053, DOI 10.1016/0040-4039(88)85333-4; MA JF, 1992, CHEM PHARM BULL, V40, P2888, DOI 10.1248/cpb.40.2888; MA JF, 1994, SOIL SCI PLANT NUTR, V40, P311, DOI 10.1080/00380768.1994.10413305; MA JF, 1994, PLANT PHYSIOL, V105, P607, DOI 10.1104/pp.105.2.607; MA JF, 1993, PLANT PHYSIOL, V102, P373, DOI 10.1104/pp.102.2.373; MA JF, 1993, PHYTOCHEMISTRY, V34, P599, DOI 10.1016/0031-9422(93)85323-J; MEISTER A, 1952, J BIOL CHEM, V197, P309; MORI S, 1987, PLANT CELL PHYSIOL, V28, P1081; Nomoto K, 1987, IRON TRANSPORT MICRO; ROMHELD V, 1987, PHYSIOL PLANTARUM, V70, P231, DOI 10.1111/j.1399-3054.1987.tb06137.x; SHOJIMA S, 1990, PLANT PHYSIOL, V93, P1497, DOI 10.1104/pp.93.4.1497; TAKAGI S, 1984, J PLANT NUTR, V7, P469, DOI 10.1080/01904168409363213; TAKAGI SI, 1976, SOIL SCI PLANT NUTR, V22, P423, DOI 10.1080/00380768.1976.10433004; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103	16	103	110	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16549	16554		10.1074/jbc.270.28.16549	http://dx.doi.org/10.1074/jbc.270.28.16549			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622460	hybrid			2022-12-25	WOS:A1995RJ34700016
J	PALMER, CNA; HSU, MH; GRIFFIN, KJ; JOHNSON, EF				PALMER, CNA; HSU, MH; GRIFFIN, KJ; JOHNSON, EF			NOVEL SEQUENCE DETERMINANTS IN PEROXISOME PROLIFERATOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; COA OXIDASE GENE; RESPONSE ELEMENT; RETINOIC ACID; NUCLEAR RECEPTOR; ORPHAN RECEPTORS; BINDING-PROTEIN; DIRECT REPEAT; FATTY-ACIDS; DNA-BINDING	The gene encoding cytochrome P-450 4A6 (CYP4A6) is transcriptionally activated by peroxisome proliferators, This response is dependent on a strong enhancer element (Z) and weaker elements (X and -27), The peroxisome proliferator response is mediated by the binding of heterodimers containing the peroxisome proliferator-activated receptor cu (PPAR alpha) and the retinoid X receptor alpha (RXR alpha) to these elements, These peroxisome proliferator response elements (PPREs) contain imperfect direct repeats of the nuclear receptor consensus recognition sequence with a spacing of one nucleotide (DR1) (AGGTCA N AGGTCA). This DR1 motif is seen in the binding sites for other nuclear receptor complexes, such as ARP-1, HNF-4, and RXR alpha homodimers. Mutational analysis of the Z element reveals that the DR1 motif is required for the transcriptional activation of the CYP4A6 gene by peroxisome proliferators; however, deletion of sequences immediately upstream of this motif also abolishes this response. Oligonucleotides corresponding to truncated and mutated Z elements were assayed by gel retardation for binding to RXR alpha, PPAR alpha, and ARP-1. Deletions or mutations within six nucleotides 5' of the DR1 motif dramatically diminish PPAR alpha . RXR alpha binding without reducing the binding of either RXR alpha or ARP-1 homodimers, whereas mutation or deletion of the core DR1 sequences abolishes the binding of PPAR alpha . RXR alpha heterodimers and of RXR alpha or ARP-1 homodimers, Thus, the DR1 motif in the Z element is not sufficient to constitute a PPRE. Moreover, the binding of PPAR alpha . RXR alpha to the Z element requires sequences immediately 5' of the DR1, These sequences are conserved in natural PPREs and promote binding of PPAR alpha . RXR alpha heterodimers in preference to potential competitors such as ARP-1 and RXR alpha.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute			Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD004445] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NICHD NIH HHS [HD04445] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BARDOT O, 1995, FEBS LETT, V360, P183, DOI 10.1016/0014-5793(95)00097-S; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FORMAN B M, 1990, New Biologist, V2, P587; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MOODY DE, 1991, FUND APPL TOXICOL, V16, P233, DOI 10.1016/0272-0590(91)90108-G; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RAO MS, 1987, CARCINOGENESIS, V8, P631; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	38	242	249	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16114	16121		10.1074/jbc.270.27.16114	http://dx.doi.org/10.1074/jbc.270.27.16114			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608174	hybrid			2022-12-25	WOS:A1995RH22600037
J	WIENECKE, R; KONIG, A; DECLUE, JE				WIENECKE, R; KONIG, A; DECLUE, JE			IDENTIFICATION OF TUBERIN, THE TUBEROUS SCLEROSIS-2 PRODUCT - TUBERIN POSSESSES SPECIFIC RAP1GAP ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 NEUROFIBROMATOSIS; RAS SUPERFAMILY; PROTEINS; GENE; GTPASE; CELLS; RAP1/KREV-1; ACTIVATION; REGION; DOMAIN	Tuberous sclerosis (TSC) is a human genetic syndrome characterized by the development of benign tumors in a variety of tissues, as well as rare malignancies. Two different genetic loci have been implicated in TSC; one of these loci, the tuberous sclerosis-2 gene (TSC2), encodes an open reading frame with a putative protein product of 1784 amino acids. The putative TSC2 product (tuberin) contains a region of limited homology to the catalytic domain of Rap1GAP. We have generated antisera against the N-terminal and C-terminal portions of tuberin, and these antisera specifically recognize a 180-kDa protein in immunoprecipitation and immunoblotting analyses. A wide variety of human cell lines express the 180-kDa tuberin protein, and subcellular fractionation revealed that most tuberin is found in a membrane/particulate (100,000 x g) fraction. Immunoprecipitates of native tuberin contain an activity that specifically stimulates the intrinsic GTPase activity of Rap1a. These results were confirmed in assays with a C-terminal fragment of tuberin, expressed in bacteria or Sf9 cells. Tuberin did not stimulate the GTPase activity of Rap2, Ha-Ras, Rac, or Rho. These results suggest that the loss of tuberin leads to constitutive activation of Rap1 in tumors of patients with tuberous sclerosis.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; European Chromosome 16 Tuberous Sclerosis C., 1993, CELL, V75, P1305; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTORI M, 1995, MOL CELL BIOL, V15, P552, DOI 10.1128/MCB.15.1.552; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KIM H, IN PRESS ONCOGENE; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUBBERT M, 1991, BLOOD, V77, P909; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; PIZON V, 1994, J CELL SCI, V107, P1661; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; TUNG JS, 1989, PCR TECHNOLOGY PRINC, P99; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	37	317	320	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16409	16414		10.1074/jbc.270.27.16409	http://dx.doi.org/10.1074/jbc.270.27.16409			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608212	hybrid			2022-12-25	WOS:A1995RH22600079
J	DUCKETT, CS; PERKINS, ND; LEUNG, K; AGRANOFF, AB; NABEL, GJ				DUCKETT, CS; PERKINS, ND; LEUNG, K; AGRANOFF, AB; NABEL, GJ			CYTOKINE INDUCTION OF NUCLEAR FACTOR KAPPA-B IN CYCLING AND GROWTH-ARRESTED CELLS - EVIDENCE FOR CELL CYCLE-INDEPENDENT ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; HUMAN IMMUNODEFICIENCY VIRUS; RECEPTOR-ALPHA-GENE; TRANSCRIPTIONAL ACTIVATION; C-MYC; MOUSE FIBROBLASTS; G0/G1 TRANSITION; 3T3 CELLS; PROTEIN-KINASE	Nuclear factor kappa B (NF-kappa B) is a pleiotropic transcription factor which regulates the expression of a large number of cellular and viral genes. Induction of NF-kappa B has been shown previously to occur during cell cycle transition from G(0) to G(1), but the relationship of cytokine induction of this transcription factor to cell cycling has not been directly addressed. Here we examine the induction of NF-kappa B in serum-deprived and cycling cells in response to tumor necrosis factor-alpha (TNF-alpha). In 3T3 fibroblasts deprived of serum, and in the temperature-sensitive G(2) phase mutant carcinoma line FT210, we find that NF-kappa B DNA binding activity is rapidly induced upon addition of TNF-alpha. In addition, NF-kappa B induction in cycling cells occurs without a significant change in cell cycle distribution. These data reveal that NF-kappa B is rapidly induced by TNF-alpha in both proliferating and arrested cells and suggest that distinct activation pathways can lead to cell cycle-dependent or -independent induction of NF-kappa B.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Duckett, Colin/0000-0001-9413-2263	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029179] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29179] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Naeve GS, 1991, CURR OPIN CELL BIOL, V3, P261, DOI 10.1016/0955-0674(91)90150-W; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN M, 1992, ONCOGENE, V7, P2095; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAMBROOK JJ, 1994, LABORATORY MANUAL; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; VOLLAND S, 1994, INT J CANCER, V56, P696; Zetterberg A, 1990, CURR OPIN CELL BIOL, V2, P296, DOI 10.1016/0955-0674(90)90022-7; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	62	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18836	18840		10.1074/jbc.270.32.18836	http://dx.doi.org/10.1074/jbc.270.32.18836			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642536	hybrid			2022-12-25	WOS:A1995RN95400023
J	FURMAN, I; COOK, O; KASIR, J; LOW, W; RAHAMIMOFF, H				FURMAN, I; COOK, O; KASIR, J; LOW, W; RAHAMIMOFF, H			THE PUTATIVE AMINO-TERMINAL SIGNAL PEPTIDE OF THE CLONED RAT-BRAIN NA+-CA2+ EXCHANGER GENE (RBE-1) IS NOT MANDATORY FOR FUNCTIONAL EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; CLONING; SEQUENCE; CLEAVAGE; CELLS	The rat brain Na+-Ca2+ exchanger (RBE) gene, as well as other isoforms of this protein family, can be organized into 12 transmembrane alpha helices, the first of which was proposed by Durkin et al. (14) to constitute a cleavable signal peptide. We have prepared three amino-terminal mutants, in which 21, 26, and 31 amino acids beyond the initiating methionine were deleted. The deletions include the hydrophobic core of the putative signal peptide (N21), the entire putative signal peptide and parts of the putative signal peptidase cleavage site (N26), and the entire putative signal peptide and putative signal peptidase cleavage site (N31). Ah three mutant clones were transiently expressed in HeLa cells. The average Na+ gradient-dependent Ca2+ transport activity of the mutant exchangers was 108% (N21), 37.2% (N26), and 60.06% (N31) of the wild-type clone. Mutation of the putative cleavage site by an exchange of Ala-32 --> Asp, resulted in a decrease in Na+-Ca2+ exchange activity to 7.7%, relative to the wild-type exchanger. Functional reconstitution of the proteins that were expressed in the transfected cells, resulted in transport activities of: 60.1% (N21), 26.75% (N26), 85.36% (N31), and 31% (Ala-32 --> Asp) relative to the wild-type exchanger. Western blot analysis of the protein profile of RBE-I, N21, N26, N31 and Ala-32 --> Asp-transfected HeLa cells was carried out by using an antipeptide antibody directed against a pentadecapeptide segment derived from the large putative cytoplasmic loop of the cloned rat exchanger gene. In the total cell extract and in the plasma membrane-enriched fraction, in addition to a major protein band of about 125 kDa, which corresponds to the molecular mass of the mature fully processed Na+-Ca2+ exchanger, an additional protein of about 135 kDa is revealed in the profile of N21- and N26-transfected cells. This band is not detected in the protein profile of RBE-1, N31, or Ala-32 --> Asp. The amino-terminal truncated mutants of the cloned Na+-Ca2+ exchanger could be expressed and processed also in a reticulocyte lysate supplemented with dog microsomes. Our results suggest that the putative signal peptide of the cloned Na+-Ca2+ exchanger gene does not play a mandatory role in functional expression of the protein in HeLa cells.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; ALLEN TJA, 1989, SODIUM CALCIUM EXCHA; ANDREWS D, 1987, PROMEGA NOTES, V11, P3; BARZILAI A, 1987, BIOCHEMISTRY-US, V26, P6113, DOI 10.1021/bi00393a025; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HARLOW E, 1988, ANTIBODIES LABORATOR, P490; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; JAIN RG, 1994, J BIOL CHEM, V269, P16305; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1992, J BIOL CHEM, V267, P7828; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOW W, 1992, FEBS LETT, V316, P63; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, DECONTAMINATION DILU; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; REILLY RF, 1992, AM J PHYSIOL, V262, pF1105, DOI 10.1152/ajprenal.1992.262.6.F1105; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAM LY, 1994, J BIOL CHEM, V269, P32542; von Heijne G, 1994, Subcell Biochem, V22, P1; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635	31	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19120	19127		10.1074/jbc.270.32.19120	http://dx.doi.org/10.1074/jbc.270.32.19120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642578	hybrid			2022-12-25	WOS:A1995RN95400066
J	LI, XR; ADAM, G; CUI, HM; SANDSTEDT, B; OHLSSON, R; EKSTROM, TJ				LI, XR; ADAM, G; CUI, HM; SANDSTEDT, B; OHLSSON, R; EKSTROM, TJ			EXPRESSION, PROMOTER USAGE AND PARENTAL IMPRINTING STATUS OF INSULIN-LIKE GROWTH-FACTOR-II (IGF2) IN HUMAN HEPATOBLASTOMA - UNCOUPLING OF IGF2 AND H19 IMPRINTING	ONCOGENE			English	Article						IGF2; H19; HEPATOBLASTOMA; PARENTAL IMPRINTING; PROMOTER; METHYLATION	BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; GENE; RELAXATION; ALLELE; RNA	We have studied the promoter utilization and parental imprinting status of human IGF2 in three genetically informative hepatoblastomas from patients ranging in age from 9 months to 3 years, In all three cases, there is a downregulation of promoter P1 in the tumor tissues while the P2 and P3 promoters are upregulated compared to the normal liver, One of the three patients displayed loss of imprinting (LOI) of IGF2 in the tumor tissue, We also investigated the expression of the H19 gene in all three cases and the methylation pattern in H19 from the patient with LOI of IGF2. The expression of H19 was greatly reduced in all tumors. Monoallelic H19 expression however, was retained even in the case which showed LOI of IGF2. Unlike the situation in Wilms' tumor, no differences in the methylation pattern between the normal liver and tumor tissues were observed in the H19 promoter or 3' region, using HpaII analysis. We show here, that in contrast to the situation in Wilms' tumor, H19 expression is not a prerequisite for maintaining a monoallelic IGF2 expression.	KAROLINSKA HOSP,DEPT CLIN NEUROSCI,EXPTL ALCOHOL & DRUG ADDICT RES SECT,S-17176 STOCKHOLM,SWEDEN; UNIV UPPSALA,DEPT ANIM DEV & GENET,S-75236 UPPSALA,SWEDEN; KAROLINSKA HOSP,DEPT PATHOL,DIV PEDIAT,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Uppsala University; Karolinska Institutet; Karolinska University Hospital			Cui, Hengmi/A-2598-2008; Ekström, Tomas/B-7764-2013					BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRICE AL, 1989, DEVELOPMENT, V106, P543; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAVIES SM, 1993, CANCER RES, V53, P4781; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RECHLER MM, 1990, INSULIN LIKE GROWTH, P263; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; SCHNEID H, 1993, ENDOCRINOLOGY, V132, P1145, DOI 10.1210/en.132.3.1145; SHAFFORD EA, 1994, EUR J CANCER, V30A, P1050, DOI 10.1016/0959-8049(94)90453-7; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SUSSENBACH JS, 1993, ADV EXP MED BIOL, V343, P63; SUSSENBACH JS, 1991, ADV EXP MED BIOL, V293, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WALSH C, 1995, CANCER RES, V55, P1111; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; YUN K, 1992, LAB INVEST, V67, P653; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	37	91	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					221	229						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624139				2022-12-25	WOS:A1995RK95700002
J	SMITH, JB; HERSCHMAN, HR				SMITH, JB; HERSCHMAN, HR			GLUCOCORTICOID-ATTENUATED RESPONSE GENES ENCODE INTERCELLULAR MEDIATORS, INCLUDING A NEW C-X-C CHEMOKINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; NITRIC-OXIDE SYNTHASE; IMMEDIATE-EARLY GENE; GROWTH-FACTOR-BETA; SWISS 3T3 CELLS; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; IDENTIFICATION; INTERFERON; INDUCTION	A major part of the anti-inflammatory effect of glucocorticoids is attributable to their attenuation of the induction of genes whose products mediate intercellular interactions, e.g. cytokines and the inducible forms of prostaglandin synthase and nitric oxide synthase. We hypothesized that (i) there exists a class of immediate-early/primary response genes whose induction by inflammatory agents, mitogens, and other stimuli is attenuated by glucocorticoids, and (ii) the products of these glucocorticoid-attenuated response genes (GARGs) function predominantly in paracrine cell processes. We constructed a lambda cDNA library from transforming growth factor beta 1-pretreated murine Swiss 3T3 cells stimulated with lipopolysaccharide (LPS) or serum in the presence of cycloheximide, screened 15,000 plaques by differential hybridization, and cloned 12 LPS-induced, dexamethasone-attenuated cDNAs. Seven were previously known. Six of these encode intercellular mediators (thrombospondin-1, MCSF, JE/MCP-1, MARC/fic/MCP-3, crg2/IP-10, and cyr61); one encodes a protein of unknown function (IRG2). Thus, a large majority of these GARG cDNAs encode intercellular mediators, as hypothesized. Of the five GARG cDNAs not previously known, one encodes a novel member of the CXC chemokine family, designated LM (LPS-induced CXC chemokine). The predicted LM protein has a 40-amino acid signal sequence and a 92-amino acid mature peptide with a distinctive COOH-terminal region. Surprisingly, segments of the 3'-untranslated regions of LIX and two other CXC chemokines have substantially greater nucleotide sequence homology than do their coding regions. These segments may perform an unknown regulatory function. The LM message is strongly induced by LPS in fibroblasts, but not in macrophages, suggesting that LM may participate in the recruitment of inflammatory cells by injured or infected tissue.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV NEONATOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMANO Y, 1993, MOL PHARMACOL, V43, P176; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DELAMARTER JF, 1987, NUCLEIC ACIDS RES, V15, P2389, DOI 10.1093/nar/15.5.2389; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; DENG ZW, 1994, BIOCHEM BIOPH RES CO, V203, P1809, DOI 10.1006/bbrc.1994.2397; DEWAAL RMW, 1994, MOL BIOL REP, V19, P81, DOI 10.1007/BF00997151; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; FENG L, 1994, AM J PHYSIOL, V266, pF713, DOI 10.1152/ajprenal.1994.266.5.F713; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; GILBERT RS, 1993, J CELL PHYSIOL, V157, P128, DOI 10.1002/jcp.1041570117; GILBERT RS, 1993, BIOCHEM BIOPH RES CO, V195, P380, DOI 10.1006/bbrc.1993.2054; GILBERT RS, 1994, J CELL PHYSIOL, V159, P67, DOI 10.1002/jcp.1041590110; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GODAMBE SA, 1994, J IMMUNOL, V153, P143; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOODMAN RB, 1992, BIOCHEMISTRY-US, V31, P10483, DOI 10.1021/bi00158a011; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HEINRICH JN, 1993, MOL CELL BIOL, V13, P2020, DOI 10.1128/MCB.13.4.2020; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSCHMAN HR, 1993, J LIPID MEDIATOR, V6, P89; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; JONAT G, 1990, CELL, V62, P1189; KAWAHARA RS, 1991, J BIOL CHEM, V266, P13261; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KULMBURG PA, 1992, J EXP MED, V176, P1773, DOI 10.1084/jem.176.6.1773; LEE CGL, 1994, J IMMUNOL, V152, P5758; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; LIM RW, 1987, ONCOGENE, V1, P263; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; MANSFIELD PJ, 1994, J IMMUNOL, V153, P4219; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V168, P1261, DOI 10.1016/0006-291X(90)91164-N; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PROOST P, 1993, BIOCHEMISTRY-US, V32, P10170, DOI 10.1021/bi00089a037; RAMEH LE, 1992, MOL CELL BIOL, V12, P4612, DOI 10.1128/MCB.12.10.4612; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; THIRION S, 1994, BIOCHEM BIOPH RES CO, V201, P493, DOI 10.1006/bbrc.1994.1729; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; VANGURI P, 1990, J BIOL CHEM, V265, P15049; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	64	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16756	16765		10.1074/jbc.270.28.16756	http://dx.doi.org/10.1074/jbc.270.28.16756			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622488	hybrid			2022-12-25	WOS:A1995RJ34700048
J	TOUHARA, K; KOCH, WJ; HAWES, BE; LEFKOWITZ, RJ				TOUHARA, K; KOCH, WJ; HAWES, BE; LEFKOWITZ, RJ			MUTATIONAL ANALYSIS OF THE PLECKSTRIN HOMOLOGY DOMAIN OF THE BETA-ADRENERGIC-RECEPTOR KINASE - DIFFERENTIAL-EFFECTS ON G(BETA-GAMMA) AND PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; G-PROTEINS; GAMMA-SUBUNITS; DEPENDENT PHOSPHORYLATION; SIGNALING PROTEINS; PH DOMAIN; ACTIVATION	The beta gamma subunits of heterotrimeric G proteins (G(beta gamma)) play a variety of roles in cellular signaling, one of which is membrane targeting of the beta-adrenergic receptor kinase (beta ARK). This is accomplished via a physical interaction of G(beta gamma) and a domain within the carboxyl terminus of beta ARK which overlaps with a pleckstrin homology (PH) domain. The PH domain of beta ARK not only binds G(beta gamma) but also interacts with phosphatidylinositol 4,5-bisphosphate (PIP2). Based on previous mapping of the G(beta gamma) binding region of beta ARK, and conserved residues within the PH domain, we have constructed a series of mutants in the carboxyl terminus of beta ARK in order to determine important residues involved in G(beta gamma) and PIP2 binding. To examine the effects of mutations on G(beta gamma) binding, we employed three different methodologies: direct G(beta gamma) binding to GST fusion proteins; the ability of GST fusion proteins to inhibit G(beta gamma)-mediated beta ARK translocation to rhodopsin-enriched rod outer segments; and the ability of mutant peptides expressed in cells to inhibit G(beta gamma)-mediated inositol phosphate accumulation. Direct PIP2 binding was also assessed on mutant GST fusion proteins. Ala residue insertion following Trp(643) completely abolished the ability of beta ARK to bind G(beta gamma), suggesting that a proper alpha-helical conformation is necessary for the G(beta gamma).beta ARK interaction. In contrast, this insertional mutation had no effect on PIP2 binding. Both G(beta gamma) binding and PIP2 binding were abolished following Ala replacement of Trp(643), suggesting that this conserved residue within the last subdomain of the PH domain is crucial for both interactions. Other mutations also produced differential effects on the physical interactions of the beta ARK carboxyl terminus with G(beta gamma) and PIP2. These results suggest that the last PH subdomain and its neighboring sequences within the carboxyl terminus of beta ARK, including Trp(643), Leu(647), and residues Lys(663)-Arg(669), are critical for G(beta gamma) binding while Trp(643) and residues Asp(635)-Glu(639) are important for the PH domain to form the correct structure for binding to PIP2.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; CASSILL JA, 1993, P NATL ACAD SCI USA, V88, P11067; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; DAYHOFF MO, 1978, ATLAS PROTEIN SEQ S3, V2; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P310; HAWES BE, 1994, J BIOL CHEM, V269, P29825; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PARRUTI G, 1993, BIOCHEM BIOPH RES CO, V190, P475, DOI 10.1006/bbrc.1993.1072; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SIMONDS WF, 1993, TRENDS BIOCHEM SCI, V18, P315; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0	39	111	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					17000	17005		10.1074/jbc.270.28.17000	http://dx.doi.org/10.1074/jbc.270.28.17000			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622521	hybrid			2022-12-25	WOS:A1995RJ34700082
J	HAYSLETT, JP; MACALA, LJ; SMALLWOOD, JI; KALGHATGI, L; GASSALAHERRAIZ, J; ISALES, C				HAYSLETT, JP; MACALA, LJ; SMALLWOOD, JI; KALGHATGI, L; GASSALAHERRAIZ, J; ISALES, C			VASOPRESSIN-STIMULATED ELECTROGENIC SODIUM-TRANSPORT IN A6 CELLS IS LINKED TO A CA2+-MOBILIZING SIGNAL MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CORTICAL COLLECTING TUBULE; ADENYLATE-CYCLASE; CYCLIC-AMP; INTRACELLULAR CALCIUM; NA-TRANSPORT; FORSKOLIN; CAMP; ADENOSINE; DUCT	Vasopressin is known to activate two types of cell surface receptors; V-2, coupled to adenylate cyclase, and V-1, linked to a Ca2+-dependent transduction system. We investigated whether arginine vasopressin (AVP) stimulation of electrogenic sodium transport in A6 cells, derived from Xenopus laevis, is mediated by activation of either one or both types of AVP-specific receptors. AVP caused a rapid increase in electrogenic sodium transport, reflected by the transepithelial potential difference (V-T) and equivalent short circuit current (I-eq) measurements. AVP also rapidly increased intracellular Ca2+ (Ca-i(2+)) and total inositol trisphosphate. The increase in I-eq was dependent on the rise in (Ca-i(2+)), because 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) dose-dependently inhibited the I-eq response. There was no evidence, however, that activation of adenylate cyclase mediated AVP-stimulated I-eq; transport was not inhibited after AVP-induced activation of adenylate cyclase was abolished by 2',5'-dideoxyadenosine or when cAMP-dependent protein kinase (PKA) activity was abolished by the specific PKA inhibitor IP20. Further studies showed that although both forskolin and 8-(4-chlorophenylthio)-cAMP stimulated I-eq, this occurred by mechanisms independent of PKA activation. These results indicate that AVP-stimulated Na+ transport is mediated by a V-1 receptor and a Ca2+-dependent mechanism.	MED COLL GEORGIA,INST MOLEC MED,AUGUSTA,GA 30912	University System of Georgia; Augusta University	HAYSLETT, JP (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,333 CEDAR ST,LMP 2076,NEW HAVEN,CT 06510, USA.		Isales, Carlos/J-9902-2013	Isales, Carlos/0000-0002-4480-3484	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019813, R37DK019813, R01DK018061] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19813, DK 18061] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFTAB DT, 1991, MOL PHARMACOL, V40, P798; ANDO Y, 1988, NEWS PHYSIOL SCI, V3, P235; BREYER MD, 1991, AM J PHYSIOL, V260, pF1, DOI 10.1152/ajprenal.1991.260.1.F1; BREYER MD, 1991, J CLIN INVEST, V88, P1502, DOI 10.1172/JCI115460; BURNATOWSKAHLED.MA, 1989, J CLIN INVEST, V83, P84; BURNATOWSKAHLED.MA, 1991, AM J PHYSIOL, V260, pC143; CHENG HC, 1986, J BIOL CHEM, V261, P989; DEWIT RJW, 1982, EUR J BIOCHEM, V122, P95; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DILLINGHAM MA, 1985, J MEMBRANE BIOL, V88, P277, DOI 10.1007/BF01871091; FELDER CC, 1990, AM J PHYSIOL, V259, pF297, DOI 10.1152/ajprenal.1990.259.2.F297; FLORES JA, 1992, ENDOCRINOLOGY, V130, P1862, DOI 10.1210/en.130.4.1862; HAYS RM, 1987, KIDNEY INT, V31, P530, DOI 10.1038/ki.1987.32; HAYSLETT JP, 1995, KIDNEY INT, V47, P1576, DOI 10.1038/ki.1995.221; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; JARD S, 1985, FRONTIERS HORMONE RE, V13, P89; JOOST HG, 1988, MOL PHARMACOL, V33, P449; KEMP BE, 1977, J BIOL CHEM, V252, P4888; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; ORLOFF J, 1962, J CLIN INVEST, V41, P702, DOI 10.1172/JCI104528; PETZEL D, 1992, J CLIN INVEST, V89, P150, DOI 10.1172/JCI115555; RISS TL, 1980, J LIQ CHROMATOGR, V3, P133, DOI 10.1080/01483918008060160; RODRIGUEZCOMMES J, 1994, KIDNEY INT, V46, P666, DOI 10.1038/ki.1994.319; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SATOH T, 1992, J CLIN INVEST, V89, P1496, DOI 10.1172/JCI115740; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SEAMON KB, 1984, P NATL ACAD SCI-BIOL, V81, P5081, DOI 10.1073/pnas.81.16.5081; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V677, P512, DOI 10.1016/0304-4165(81)90267-1; SORBERA LA, 1991, SCIENCE, V253, P1286, DOI 10.1126/science.1653970; TORPHY TJ, 1982, J BIOL CHEM, V257, P1609; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507; WHITE MM, 1988, MOL PHARMACOL, V34, P427; WINDHAGER EE, 1983, ANNU REV PHYSIOL, V45, P519, DOI 10.1146/annurev.ph.45.030183.002511; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; WONG SME, 1988, AM J PHYSIOL, V255, pF1015	37	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16082	16088		10.1074/jbc.270.27.16082	http://dx.doi.org/10.1074/jbc.270.27.16082			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608170	hybrid			2022-12-25	WOS:A1995RH22600033
J	WILLIAMS, AC; MILLER, JC; COLLARD, TJ; BRACEY, TS; COSULICH, S; PARASKEVA, C				WILLIAMS, AC; MILLER, JC; COLLARD, TJ; BRACEY, TS; COSULICH, S; PARASKEVA, C			MUTANT P53 IS NOT FULLY DOMINANT OVER ENDOGENOUS WILD-TYPE P53 IN A COLORECTAL ADENOMA CELL-LINE AS DEMONSTRATED BY INDUCTION OF MDM2 PROTEIN AND RETENTION OF A P53 DEPENDENT G1 ARREST AFTER GAMMA-IRRADIATION	ONCOGENE			English	Article						P53; COLON; ADENOMA; MDM2; G1 ARREST; GAMMA IRRADIATION; TGF-BETA	AUTOREGULATORY FEEDBACK LOOP; TUMOR-SUPPRESSOR GENE; BINDING-SITE; CANCER CELLS; MUTATIONS; GROWTH; DNA; TRANSFORMATION; EXPRESSION; APOPTOSIS	To determine whether a single mutational event in one p53 gene is sufficient to confer a significant growth advantage on a colonic epithelial cell, the 143(Ala) p53 mutation was previously expressed in the human colonic adenoma derived cell line AA/C1 (which is wild type for p53) and shown to have no effect on it's in vitro or in vivo growth characteristics. In this investigation, by expressing the 175(His), 248(Trp) or 273(His) mutations in the same AA/C1 cell line, we have shown that this failure to affect the growth of the cells was not mutant specific. We have also demonstrated, using induction of MDM2 protein and the ability of the cells to undergo a p53 dependent G1 arrest, that the 143(Ala), 175(His) or 248(Trp) transfected cells retain functional endogenous wild type p53 activity, and suggest that these p53 mutations would not have a fully dominant negative mode of action in vivo. In contrast, one of the two AA/C1 cell lines transfected with the 273(His) mutation did fail to cell cycle arrest after gamma irradiation, indicating that this mutation can act as a dominant negative. However even loss of wild type p53 function in this fell line was insufficient to directly effect the growth rate of the AA/C1 cells, suggesting that acquisition of the 273(His) mutation may contribute to malignant progression through genomic instability (by inhibiting the G1 arrest) and that other mutations are required before outgrowth of the cell population containing the p53 mutation.	UNIV YORK,DEPT BIOL,JACK BIRCH UNIT ENVIRONM CARCINOGENESIS,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	WILLIAMS, AC (corresponding author), UNIV BRISTOL,DEPT PATHOL & MICROBIOL,CRC,COLORECTAL TUMOUR BIOL RES GRP,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND.			Williams, Ann/0000-0002-6009-7137				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BOND JA, 1994, ONCOGENE, V9, P281; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FREBOURG T, 1994, CANCER RES, V54, P878; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISAACS WB, 1991, CANCER RES, V51, P4716; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1992, NEW ENGL J MED, V326, P1350, DOI 10.1056/NEJM199205143262008; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI Y, 1994, ONCOGENE, V9, P2261; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAITY A, 1994, ONCOL, V31, P1; MANNING AM, 1991, ONCOGENE, V6, P1471; MATOZAKI T, 1992, CANCER RES, V52, P4335; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARK DJ, 1994, ONCOGENE, V9, P1899; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; WILLIAMS AC, 1994, ONCOGENE, V9, P1479; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	61	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					141	149						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624121				2022-12-25	WOS:A1995RJ29500017
J	HOLLIDAY, LS; DEAN, AD; GREENWALD, JE; GLUCK, SL				HOLLIDAY, LS; DEAN, AD; GREENWALD, JE; GLUCK, SL			C-TYPE NATRIURETIC PEPTIDE INCREASES BONE-RESORPTION IN 1,25-DIHYDROXYVITAMIN D-3 STIMULATED MOUSE BONE-MARROW CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; MICROBIAL ORIGIN; CELL-LINE; RAT; INHIBITION; DIFFERENTIATION; RECEPTORS; CNP; OSTEOCLASTS; EXPRESSION	Most agents that regulate osteoclast bone resorption exert their effects indirectly, through the osteoblast, Nitric oxide, which stimulates soluble guanylyl cyclase, has been reported to inhibit osteoclast bone resorption directly, by a cGMP-independent mechanism (1). In this report, we demonstrate that C-type natriuretic peptide (CNP), an activator of membrane-bound guanylyl cyclase, stimulates bone resorption by osteoclast-containing 1,25-dihydroxyvitamin D-3 (1,2 5-(OH)(2)D-3)-stimulated mouse bone marrow cultures. Quantitative reverse transcription polymerase chain reaction assays and anti-CNP immunocytochemistry were used to demonstrate that CNP is expressed in mouse marrow cells cultured in the presence, but not the absence, of 1,25-(OH)(2)D-3. mRNA for guanylyl cyclase type B, the receptor for CNP, was expressed in cultures independent of 1,25-(OH)(2)D-3, CNP (1 and 10 mu M) elevated cGMP production in marrow cultures to 350 and 870%, respectively, of control values, 10 mu M CNP increased osteoclast bone resorptive activity, measured by the resorption area on whale dentine wafers, or by the NH4Cl-inhibitable release of [H-3]proline from radiolabeled bone chips, to 214 and 557% of control, respectively, without affecting osteoclast formation, Bone resorption by the marrow cultures was inhibited by 7F9.1, a monoclonal antibody raised against CNP, but not by control antibodies. These results indicate that CNP is a potent activator of osteoclast activity and may be a novel local regulator of bone remodeling.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV RENAL, ST LOUIS, MO 63108 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63108 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63108 USA; WASHINGTON UNIV, SCH MED, GEORGE M OBRIEN KIDNEY & UROL DIS CTR, ST LOUIS, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Holliday, Lexie/GYQ-4972-2022	Holliday, Lexie/0000-0002-0844-1965	NIAMS NIH HHS [AR32087] Funding Source: Medline; NIDDK NIH HHS [DK09976, DK38848] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK009976, R01DK038848] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUI T, 1992, ENDOCRINOLOGY, V130, P2487, DOI 10.1210/en.130.5.2487; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BOYDE A, 1985, SCANNING ELECTRON MI, V3, P1259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DEAN AD, 1994, AM J PHYSIOL, V266, pF491, DOI 10.1152/ajprenal.1994.266.3.F491; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P670; FLETCHER AE, 1986, FEBS LETT, V208, P263, DOI 10.1016/0014-5793(86)81029-8; FUKUSHIMA O, 1991, J HISTOCHEM CYTOCHEM, V39, P529, DOI 10.1177/39.4.1672318; GARBERS DL, 1993, ADV SEC MESS PHOSPH, V28, P91; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GESEK FA, 1992, J CLIN INVEST, V90, P429, DOI 10.1172/JCI115878; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; Humphreys G K, 1981, J Immunoassay, V2, P137, DOI 10.1080/15321818108056973; IMURA R, 1992, MOL PHARMACOL, V42, P982; ISHIZAKA Y, 1992, BIOCHEM BIOPH RES CO, V189, P697, DOI 10.1016/0006-291X(92)92257-X; KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; LOWIK CWGM, 1994, J CLIN INVEST, V93, P1465, DOI 10.1172/JCI117124; MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936; MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312; MARTIN TJ, 1993, OSTEOPOROSIS INT, V3, pS121, DOI 10.1007/BF01621884; MINAMINO N, 1993, BIOCHEM BIOPH RES CO, V197, P326, DOI 10.1006/bbrc.1993.2479; MUNDY GR, 1993, J CELL BIOCHEM, V53, P296, DOI 10.1002/jcb.240530405; MUNDY GR, 1993, J BONE MINER RES, V8, pS505, DOI 10.1002/jbmr.5650081315; MUNDY GR, 1993, OSTEOPOROSIS INT, V3, pS126; MUNDY GR, 1992, INT J CELL CLONING, V10, P215, DOI 10.1002/stem.5530100404; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V183, P743, DOI 10.1016/0006-291X(92)90546-W; OHYAMA Y, 1993, LIFE SCI, V52, pPL153, DOI 10.1016/0024-3205(93)90071-A; RODAN GA, 1975, SCIENCE, V189, P467, DOI 10.1126/science.168639; SANO T, 1992, J PHARMACOL EXP THER, V260, P825; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; STERN PH, 1992, RES COMMUN CHEM PATH, V75, P19; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUDA T, 1989, P SOC EXP BIOL MED, V191, P214; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUGA S, 1993, ENDOCRINOLOGY, V133, P3038, DOI 10.1210/en.133.6.3038; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VARGAS SJ, 1989, ENDOCRINOLOGY, V125, P2527, DOI 10.1210/endo-125-5-2527; WANG ZQ, 1992, AM J PHYSIOL, V263, pF277, DOI 10.1152/ajprenal.1992.263.2.F277; WILKINS MR, 1990, J CLIN INVEST, V85, P1274, DOI 10.1172/JCI114564	47	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18983	18989		10.1074/jbc.270.32.18983	http://dx.doi.org/10.1074/jbc.270.32.18983			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642558				2022-12-25	WOS:A1995RN95400046
J	CRATER, DL; VANDERIJN, I				CRATER, DL; VANDERIJN, I			HYALURONIC-ACID SYNTHESIS OPERON (HAS) EXPRESSION IN GROUP-A STREPTOCOCCI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; TYPE-12 M-PROTEIN; MOLECULAR CHARACTERIZATION; ESCHERICHIA-COLI; MESSENGER-RNA; GENE; PYOGENES; VIRULENCE; LOCUS; IDENTIFICATION	The has operon is composed of three genes, hasA, hasB, and hasC that encode hyaluronate synthase. UDP-glucose dehydrogenase, and presumptively UDP-glucose pyrophosphorylase, respectively. Expression of the has operon was shown to be required for the synthesis of the hyaluronic acid capsule in group A streptococci. Previous studies indicated that some group A and group C streptococcal strains produce the hyaluronic acid capsule, while others do not. In addition, it was observed that encapsulated strains cultured in stationary phase of growth lose the hyaluronic acid capsule. Therefore, the molecular mechanisms controlling the expression of the hyaluronic acid capsule in group A streptococci was investigated. In this study, it was determined that all encapsulated and unencapsulated strains of group A streptococci as well as encapsulated group C streptococci analyzed possess the has operon locus. The acapsular phenotype was accounted for by the absence of hyaluronate synthase activity in the membrane and not the production of extracellular hyaluronidase. A has operon mRNA transcript was not expressed by unencap sulated strains of group A streptococci, whereas encapsulated strains of group A streptococci grown to mid to late exponential phase produced the hyaluronate capsule, as well as has operon mRNA. However, as the streptococci entered the stationary phase of growth, they became acapsular and this was concomitant with the loss of has operon mRNA transcript. These results were confirmed by primer extension analyses of RNA isolated from encapsulated and unencapsulated strains of group A streptococci as well as RNA prepared from encapsulated strains cultured in exponential and stationary phases of growth. Thus, the loss of has operon mRNA in unencapsulated group A streptococci, as well as growth phase regulation occurs at the previously mapped has operon promoter. These data suggested that the synthesis of the hyaluronic acid capsule for group A streptococci may be controlled by transcriptional mechanisms.	WAKE FOREST UNIV, MED CTR, WINSTON SALEM, NC 27157 USA	Wake Forest University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401, R01AI037320] Funding Source: NIH RePORTER; NCI NIH HHS [CA12107] Funding Source: Medline; NIAID NIH HHS [T32-AI-07401, AI37320] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BOULNOIS GJ, 1990, CURR TOP MICROBIOL, V150, P1; BOYLE MDP, 1994, INFECT IMMUN, V62, P1336, DOI 10.1128/IAI.62.4.1336-1347.1994; CAPARON MG, 1992, J BACTERIOL, V174, P5693, DOI 10.1128/JB.174.17.5693-5701.1992; CAPARON MG, 1987, P NATL ACAD SCI USA, V84, P8677, DOI 10.1073/pnas.84.23.8677; CHITNIS CE, 1993, MOL MICROBIOL, V8, P583, DOI 10.1111/j.1365-2958.1993.tb01602.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DERETIC V, 1994, J BACTERIOL, V176, P2773, DOI 10.1128/JB.176.10.2773-2780.1994; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; GEORGELLIS D, 1992, J BACTERIOL, V174, P5382, DOI 10.1128/JB.174.16.5382-5390.1992; GOTTESMAN S, 1991, MOL MICROBIOL, V5, P1599, DOI 10.1111/j.1365-2958.1991.tb01906.x; HOTEZ PJ, 1992, INFECT IMMUN, V60, P1018, DOI 10.1128/IAI.60.3.1018-1023.1992; HYNES WL, 1989, INFECT IMMUN, V57, P533, DOI 10.1128/IAI.57.2.533-539.1989; KELLY T, 1994, INFECT IMMUN, V62, P1813, DOI 10.1128/IAI.62.5.1813-1819.1994; Krause RM, 1972, STREPTOCOCCI STREPTO, P3; KROLL JS, 1992, J INFECT DIS, V165, pS93, DOI 10.1093/infdis/165-Supplement_1-S93; LEE CY, 1992, MOL MICROBIOL, V6, P1515, DOI 10.1111/j.1365-2958.1992.tb00872.x; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; MELIN L, 1990, MOL MICROBIOL, V4, P1881, DOI 10.1111/j.1365-2958.1990.tb02037.x; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; PODBIELSKI A, 1993, MOL GEN GENET, V237, P287, DOI 10.1007/BF00282810; ROBBINS JC, 1987, J BACTERIOL, V169, P5633, DOI 10.1128/jb.169.12.5633-5640.1987; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMPSON WJ, 1990, J BACTERIOL, V172, P696, DOI 10.1128/jb.172.2.696-700.1990; VANDERIJN I, 1983, J BACTERIOL, V156, P1059, DOI 10.1128/JB.156.3.1059-1065.1983; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994	34	101	113	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18452	18458		10.1074/jbc.270.31.18452	http://dx.doi.org/10.1074/jbc.270.31.18452			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629171	hybrid			2022-12-25	WOS:A1995RM64200048
J	GILBERT, GE; ARENA, AA				GILBERT, GE; ARENA, AA			PHOSPHATIDYLETHANOLAMINE INDUCES HIGH-AFFINITY BINDING-SITES FOR FACTOR-VIII ON MEMBRANES CONTAINING PHOSPHATIDYL-L-SERINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTHROMBIN-CONVERTING ACTIVITY; COAGULATION FACTOR-V; PHOSPHOLIPID-VESICLES; ENZYMATIC-SYNTHESIS; HUMAN-PLATELETS; C2 DOMAIN; SURFACE; SEQUENCES; PROTEINS; RELEASE	Synthetic membranes of phosphatidylcholine require inclusion of at least 5% phosphatidylserine (Ptd-L-Ser) to form binding sites for factor VIII. The relatively high requirement for Ptd-L-Ser suggests that stimulated platelets may contain another membrane constituent that enhances expression of factor VIII-binding sites. We report that phosphatidylethanolamine (PE), which is exposed in concert with Ptd-L-Ser in the course of platelet stimulation, induces high affinity binding sites for factor VIII on synthetic membranes containing 1-15% Ptd-L-Ser. The affinity of factor VIII for binding sites on membranes of Ptd-L-Ser/PE/phosphatidylcholine in a 4:20:76 ratio was 10.2 +/- 3.5 nM with 180 +/- 33 phospholipid molecules/site. PE did not induce binding sites on membranes of 4% Ptd-D-Ser, indicating that the induced binding sites require the correct stereochemistry of Ptd-L-Ser as well as PE. Egg PE and dimyristoyl-PE were equivalent for inducing factor VIII-binding sites, indicating that hexagonal phase-inducing properties of PE are not important. We conclude that PE induces high affinity factor VIII-binding sites on membranes with physiologic mole fractions of Ptd-L-Ser, possibly including those of stimulated platelets.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	GILBERT, GE (corresponding author), BROCKTON W ROXBURY VET AFFAIRS MED CTR, DEPT MED, 1400 VFW PKWY, BOSTON, MA 02132 USA.							BARDELLE C, 1993, J BIOL CHEM, V268, P8815; BARTLES JR, 1982, BIOCHIM BIOPHYS ACTA, V687, P129, DOI 10.1016/0005-2736(82)90538-7; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; CHANG CP, 1993, J BIOL CHEM, V268, P7171; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; COMFURIUS P, 1990, J LIPID RES, V31, P1719; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; Cullis P, 1983, CONCEPTS MEMBRANE ST, P39; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FOSTER PA, 1990, BLOOD, V75, P1999; GAESTEL M, 1983, BIOCHIM BIOPHYS ACTA, V732, P405, DOI 10.1016/0005-2736(83)90057-3; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; GILBERT GE, 1995, BIOCHEMISTRY-US, V34, P3022, DOI 10.1021/bi00009a033; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; GILBERT GE, 1993, BLOOD, V82, pA60; GILBERT GE, 1994, THROMBOSIS HEMORRHAG, P37; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; HINDERLITER AK, 1994, BIOPHYS J, V67, P1906, DOI 10.1016/S0006-3495(94)80673-3; KANE WH, 1988, BLOOD, V71, P539; LUBIN B, 1981, J CLIN INVEST, V67, P1643, DOI 10.1172/JCI110200; MANN KG, 1990, BLOOD, V76, P1; MARCUS AJ, 1969, J LIPID RES, V10, P108; MARINETTI GV, 1977, BIOCHIM BIOPHYS ACTA, V465, P198, DOI 10.1016/0005-2736(77)90074-8; MONCELLI MR, 1994, BIOPHYS J, V66, P1969, DOI 10.1016/S0006-3495(94)80990-7; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; PUSSEY ML, 1984, BIOCHEMISTRY-US, V23, P6202; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SCHICK PK, 1976, J CLIN INVEST, V57, P1221, DOI 10.1172/JCI108390; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; SIMS PJ, 1986, BLOOD, V68, P556; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019; WOLF P, 1967, BRIT J HAEMATOL, V13, P269, DOI 10.1111/j.1365-2141.1967.tb08741.x	39	56	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18500	18505		10.1074/jbc.270.31.18500	http://dx.doi.org/10.1074/jbc.270.31.18500			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629178	hybrid			2022-12-25	WOS:A1995RM64200055
J	TOLIAS, KF; CANTLEY, LC; CARPENTER, CL				TOLIAS, KF; CANTLEY, LC; CARPENTER, CL			RHO-FAMILY GTPASES BIND TO PHOSPHOINOSITIDE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; CELL POLARITY; PURIFICATION; CDC42	Rho family GTPases appear to play an important role in the regulation of the actin cytoskeleton, but the mechanism of regulation is unknown. Since phosphoinositide 3-kinase and phosphatidylinositol 4,5-bisphosphate have also been implicated in actin reorganization, we investigated the possibility that Rho family members interact with phosphoinositide kinases. We found that both GTP- and GDP-bound Rac1 associate with phosphatidylinositol-4-phosphate 5-kinase in vitro and in vivo. Phosphoinositide 3-kinase also bound to Rac1 and Cdc42Hs, and these interactions were GTP-dependent. Stimulation of Swiss 3T3 cells with platelet-derived growth factor induced the association of PI 3-kinase with Rac in immunoprecipitates. PI 3-kinase activity was also detected in Cdc42 immunoprecipitates from COS7 cells. These results suggest that phosphoinositide kinases are involved in Rho family signal transduction pathways and raise the possibility that the effects of Rho family members on the actin cytoskeleton are mediated in part by phosphoinositide kinases.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BETH ISRAEL HOSP,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Tolias, Kimberley/0000-0002-2092-920X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36624] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BAZENET CE, 1990, J BIOL CHEM, V265, P10812; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DIVECHA N, 1992, BIOCHEM J, V288, P637, DOI 10.1042/bj2880637; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LING LE, 1989, J BIOL CHEM, V264, P5080; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P386; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	25	407	409	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17656	17659		10.1074/jbc.270.30.17656	http://dx.doi.org/10.1074/jbc.270.30.17656			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629060	hybrid			2022-12-25	WOS:A1995RM26600005
J	VIGNERON, L; RUYSSCHAERT, JM; GOORMAGHTIGH, E				VIGNERON, L; RUYSSCHAERT, JM; GOORMAGHTIGH, E			FOURIER-TRANSFORM INFRARED-SPECTROSCOPY STUDY OF THE SECONDARY STRUCTURE OF THE RECONSTITUTED NEUROSPORA-CRASSA PLASMA-MEMBRANE H+-ATPASE AND OF ITS MEMBRANE-ASSOCIATED PROTEOLYTIC PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; HYDROGEN-DEUTERIUM EXCHANGE; NEGATIVELY STAINED CRYSTALS; LOW-DENSITY-LIPOPROTEIN; SARCOPLASMIC-RETICULUM; PURPLE MEMBRANE; PROTEIN BACTERIORHODOPSIN; CYTOPLASMIC LOCATION; RESOLUTION; AMINO	We reconstituted purified plasma membrane H+-ATPase from Neurospora crassa into soybean phospholipid vesicles (lipid/ATPase ratio of 5:1 w/w), The proteo-liposomes contained an active ATPase, oriented inside-out. They were subjected to proteolysis by using Pronase, proteinase K, trypsin, and carboxypeptidase Y. Fourier transform infrared attenuated total reflection spectroscopy indicates that the amount of protein remaining after hydrolysis and elimination of the extramembrane domain of ATPase represents about 43% of the intact protein. The secondary structure of intact ATPase and of the membrane-associated domain of ATPase was determined by infrared spectroscopy. The membrane domain shows a typical alpha-helix and beta-sheet absorption. Polarized infrared spectroscopy reveals that the orientation of the helices is about perpendicular to the membrane. Amide hydrogen/deuterium exchange kinetics performed for the intact H+-ATPase and for the membrane-associated domain demonstrate that this part of ATPase shows less accessibility to the solvent than the entire protein but remains much more accessible to the solvent than bacteriorhodopsin membrane segments.			VIGNERON, L (corresponding author), FREE UNIV BRUSSELS,CHIM PHYS MACROMOLEC INTERFACES LAB,CP206-2,CAMPUS PLAINE,B-1050 BRUSSELS,BELGIUM.			Goormaghtigh, Erik/0000-0002-2071-2262				ADDISON R, 1986, J BIOL CHEM, V261, P4896; ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; CHIRGADZE YN, 1974, BIOPOLYMERS, V13, P1701, DOI 10.1002/bip.1974.360130902; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORBALANGARCIA S, 1994, BIOCHEMISTRY-US, V33, P8247, DOI 10.1021/bi00193a011; COWAN SW, 1994, SCIENCE, V264, P914, DOI 10.1126/science.8178151; DOWNER NW, 1986, J BIOL CHEM, V261, P3640; DRAHEIM JE, 1991, BIOPHYS J, V60, P89, DOI 10.1016/S0006-3495(91)82033-1; DUMONT ME, 1985, J MEMBRANE BIOL, V88, P233, DOI 10.1007/BF01871088; EARNEST TN, 1990, BIOPHYS J, V58, P1539, DOI 10.1016/S0006-3495(90)82498-X; FIMMEL S, 1989, BIOCHIM BIOPHYS ACTA, V978, P231, DOI 10.1016/0005-2736(89)90120-X; FISCHBARG J, 1993, P NATL ACAD SCI USA, V90, P11658, DOI 10.1073/pnas.90.24.11658; FRINGELI UP, 1981, MEMBRANE SPECTROSCOP, P270; GOORMAGHTIGH E, 1986, ANAL BIOCHEM, V159, P122, DOI 10.1016/0003-2697(86)90316-7; GOORMAGHTIGH E, 1993, BIOCHEMISTRY-US, V32, P6104, DOI 10.1021/bi00074a023; GOORMAGHTIGH E, 1994, SPECTROCHIM ACTA A, V50, P2137; Goormaghtigh E, 1994, Subcell Biochem, V23, P363; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1986, J BIOL CHEM, V261, P7466; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1989, BIOCHIM BIOPHYS ACTA, V1006, P147, DOI 10.1016/0005-2760(89)90338-X; GOORMAGHTIGH E, 1991, EUR J BIOCHEM, V195, P421, DOI 10.1111/j.1432-1033.1991.tb15721.x; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; GORNETSCHELNOKO.U, 1994, EMBO J, V13, P338; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HARIS PI, 1989, BIOCHIM BIOPHYS ACTA, V995, P160, DOI 10.1016/0167-4838(89)90075-7; Harrick N.J., 1967, INTERNAL REFLECTION; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENNESSEY JP, 1989, ANAL BIOCHEM, V176, P284, DOI 10.1016/0003-2697(89)90310-2; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; HENNESSEY JP, 1988, J BIOL CHEM, V263, P3123; HEYN MP, 1981, BIOCHEMISTRY-US, V20, P840, DOI 10.1021/bi00507a029; HUCHO F, 1994, TRENDS BIOCHEM SCI, V19, P383, DOI 10.1016/0968-0004(94)90116-3; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P8829, DOI 10.1021/bi00152a020; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KAUPPINEN JK, 1981, APPL OPTICS, V20, P1866, DOI 10.1364/AO.20.001866; LIN J, 1994, J BIOL CHEM, V269, P3887; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; NABEDRYK E, 1988, BIOPHYS J, V53, P671, DOI 10.1016/S0006-3495(88)83148-5; NIELSEN BL, 1984, ANAL BIOCHEM, V141, P311, DOI 10.1016/0003-2697(84)90047-2; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; RAO US, 1990, J BIOL CHEM, V265, P7227; RAO US, 1991, J BIOL CHEM, V266, P14740; RAO US, 1992, BIOCHIM BIOPHYS ACTA, V1108, P153, DOI 10.1016/0005-2736(92)90020-M; RATH P, 1991, BIOPHYS J, V59, P516, DOI 10.1016/S0006-3495(91)82268-8; ROTHSCHILD KJ, 1984, BIOCHEMISTRY-US, V23, P6103, DOI 10.1021/bi00320a031; ROTHSCHILD KJ, 1979, SCIENCE, V204, P311, DOI 10.1126/science.432645; SAMI M, 1988, FEBS LETT, V240, P211, DOI 10.1016/0014-5793(88)80370-3; SCARBOROUGH GA, 1976, P NATL ACAD SCI USA, V73, P1485, DOI 10.1073/pnas.73.5.1485; SCARBOROUGH GA, 1984, J BIOL CHEM, V259, P9109; SCARBOROUGH GA, 1990, J BIOL CHEM, V265, P16145; SMITH R, 1984, ANAL BIOCHEM, V138, P156, DOI 10.1016/0003-2697(84)90784-X; SONVEAUX N, 1994, J BIOL CHEM, V269, P25637; STOKES DL, 1990, BIOCHEM SOC T, V18, P841, DOI 10.1042/bst0180841; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VENYAMINOV SY, 1991, BIOPOLYMERS, V30, P1259; VIGNERON L, 1995, BBA-BIOMEMBRANES, V1236, P95, DOI 10.1016/0005-2736(95)00028-2; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WILSON CM, 1979, ANAL BIOCHEM, V96, P263, DOI 10.1016/0003-2697(79)90581-5	73	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17685	17696		10.1074/jbc.270.30.17685	http://dx.doi.org/10.1074/jbc.270.30.17685			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629067	hybrid			2022-12-25	WOS:A1995RM26600012
J	CAMACHO, M; GODESSART, N; ANTON, R; GARCIA, M; VILA, L				CAMACHO, M; GODESSART, N; ANTON, R; GARCIA, M; VILA, L			INTERLEUKIN-1 ENHANCES THE ABILITY OF CULTURED HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS TO OXIDIZE LINOLEIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; ARACHIDONIC-ACID; 13-HYDROXYOCTADECADIENOIC ACID; 15-HYDROXYEICOSATETRAENOIC ACID; 9-HYDROXYOCTADECADIENOIC ACID; POLYMORPHONUCLEAR LEUKOCYTES; FIBROBLAST CYCLOOXYGENASE; LIPOXYGENASE PATHWAY; OMEGA-6 LIPOXYGENASE; SURFACE EXPRESSION	Human umbilical vein endothelial cells (HUVEC) were treated with recombinant interleukin (IL)-1 beta, and the metabolism of exogenous linoleic acid was studied. High performance liquid chromatography, gas chromatography-mass spectrometry, and chiral analysis revealed that HUVEC enzymatically convert linoleic acid mainly into 13-(S)hydroxy-9(Z),11(E)-octadecadienoic (13-HODE) and 9-(R)hydroxy-10(E),12(Z)-octadecadienoic acids, which may isomerize toward all-trans compounds. IL-1 beta increased the formation of all octadecanoids in a time and dose-dependent manner with similar EC(50) (approximately 1 unit/ml). The apparent K-m values of linoleic acid were 15.59 +/- 8.39 and 152.9 +/- 84 mu M (P < 0.05) in IL-1 beta-treated cells and controls, respectively, indicating a higher substrate affinity in cells stimulated with IL-1 beta. Ratios of S/R enantiomers for the hydroxyoctadecanoids produced by untreated and IL-1 beta-treated cells were similar to those from isolated cyclooxygenases (COXs), whereas isolated 15-lipoxygenase yielded 13-HODE with a strict S configuration. The formation of octadecanoids was inhibited in a dose dependent manner by several COX inhibitors in both controls and IL-1 beta-treated cells, COX2 selective inhibitors being more effective on IL-1 beta-treated cells than on controls. COX1 and COX2 protein levels increased less than 2-fold and 8-fold, respectively, after IL-1 beta treatment. The specificity of COX inhibitors was proven since they did not inhibit 13-HODE formation by human polymorphonuclear leukocytes. Overall, these results indicate that COXs are responsible for the oxidative metabolism of linoleic acid in HUVEC, and IL-1 beta increases it by inducing the expression of new enzyme, mainly COX2.	HOSP SANTA CRUZ & SAN PABLO,INFLAMMAT MEDIATOR LAB,E-08025 BARCELONA,SPAIN				Antón, Rosa/AAO-1350-2021	Antón, Rosa/0000-0003-4261-4150; Camacho, Mercedes/0000-0001-5970-3294; Godessart, Nuria/0000-0003-3546-4924				AGARWAL R, 1991, DRUG METAB DISPOS, V19, P620; ANDERSON KM, 1992, CLIN BIOCHEM, V25, P1, DOI 10.1016/0009-9120(92)80038-I; BAER AN, 1991, BIOCHIM BIOPHYS ACTA, V1085, P45, DOI 10.1016/0005-2760(91)90230-F; BAER AN, 1991, J LIPID RES, V32, P341; BALCONI G, 1986, MED BIOL, V64, P231; BASTIDA E, 1990, J LIPID MEDIATOR, V2, P281; BERTOMEU MC, 1993, CLIN EXP METASTAS, V11, P243, DOI 10.1007/BF00121167; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIDER MA, 1993, J AM VET MED ASSOC, V203, P300; BUCHANAN MR, 1993, BLOOD, V81, P3303; BUCHANAN MR, 1985, THROMB HAEMOSTASIS, V53, P306; BUCHANAN MR, 1985, J BIOL CHEM, V260, P6056; CLAEYS M, 1985, BIOCHIM BIOPHYS ACTA, V837, P35, DOI 10.1016/0005-2760(85)90083-9; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; COWLEN MS, 1993, BIOCHIM BIOPHYS ACTA, V1174, P234, DOI 10.1016/0167-4781(93)90192-G; DARET D, 1989, PROSTAGLANDINS, V38, P203, DOI 10.1016/0090-6980(89)90083-X; DeWitt D L, 1993, Am J Med, V95, p40S, DOI 10.1016/0002-9343(93)90396-7; DINARELLO CA, 1991, BLOOD, V77, P1627; FOLCIK VA, 1994, J LIPID RES, V35, P1570; FUNK CD, 1985, J BIOL CHEM, V260, P7481; FUNK CD, 1983, BIOCHIM BIOPHYS ACTA, V754, P57; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GODESSART N, 1994, J INVEST DERMATOL, V102, P98, DOI 10.1111/1523-1747.ep12371740; HAAS TA, 1990, BIOCHIM BIOPHYS ACTA, V1051, P174, DOI 10.1016/0167-4889(90)90190-O; HAMBERG M, 1980, BIOCHIM BIOPHYS ACTA, V617, P545, DOI 10.1016/0005-2760(80)90022-3; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HECKER M, 1987, EUR J BIOCHEM, V169, P113, DOI 10.1111/j.1432-1033.1987.tb13587.x; HLA T, 1993, ANN NY ACAD SCI, V696, P197; HOPKINS NK, 1984, J BIOL CHEM, V259, P4048; INGRAM CD, 1988, LIPIDS, V23, P340, DOI 10.1007/BF02537345; IVERSEN L, 1991, AGENTS ACTIONS, V33, P286, DOI 10.1007/BF01986575; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JONES DA, 1993, J BIOL CHEM, V268, P9049; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KORN JH, 1989, CLIN IMMUNOL IMMUNOP, V50, P196, DOI 10.1016/0090-1229(89)90128-1; KU G, 1992, J BIOL CHEM, V267, P14183; KUHN H, 1985, PROSTA LEUKOTR MED, V17, P291, DOI 10.1016/0262-1746(85)90118-0; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; KUNN H, 1992, EICOSANOIDS, V5, P17; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG MW, 1992, EXP HEMATOL, V20, P288; LOPEZ S, 1993, BIOCHIM BIOPHYS ACTA, V1170, P17, DOI 10.1016/0005-2760(93)90170-E; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MANTOVANI A, 1989, IMMUNOL TODAY, V10, P370, DOI 10.1016/0167-5699(89)90270-3; MATTHEW JA, 1977, LIPIDS, V12, P324, DOI 10.1007/BF02533358; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MONTESANO R, 1985, J CELL PHYSL, V122, P422; MORITA E, 1990, SCAND J IMMUNOL, V32, P497, DOI 10.1111/j.1365-3083.1990.tb03190.x; NUGTEREN DH, 1987, BIOCHIM BIOPHYS ACTA, V921, P135, DOI 10.1016/0005-2760(87)90179-2; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; RAZ A, 1988, J BIOL CHEM, V263, P3022; REINAUD O, 1989, BIOCHEM BIOPH RES CO, V161, P883, DOI 10.1016/0006-291X(89)92682-X; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; SETTY BNY, 1987, BIOCHEM BIOPH RES CO, V148, P528, DOI 10.1016/0006-291X(87)90908-9; SETTY BNY, 1986, J CLIN INVEST, V77, P202, DOI 10.1172/JCI112277; SETTY BNY, 1987, BIOCHEM BIOPH RES CO, V146, P502, DOI 10.1016/0006-291X(87)90557-2; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SIGAL E, 1988, J BIOL CHEM, V263, P5328; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SOBERMAN RJ, 1985, J BIOL CHEM, V260, P4508; SOLA J, 1991, ARCH DERMATOL RES, V283, P77, DOI 10.1007/BF00371612; TAKAYAMA H, 1987, THROMB RES, V45, P803, DOI 10.1016/0049-3848(87)90090-9; TANG DG, 1993, INT J CANCER, V54, P102, DOI 10.1002/ijc.2910540117; TLOTI MA, 1991, THROMB RES, V62, P305, DOI 10.1016/0049-3848(91)90151-L; TOBIAS LD, 1979, LIPIDS, V14, P181, DOI 10.1007/BF02533870	68	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17279	17286		10.1074/jbc.270.29.17279	http://dx.doi.org/10.1074/jbc.270.29.17279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615528	hybrid			2022-12-25	WOS:A1995RK68900037
J	CURNOW, AW; GARCIA, GA				CURNOW, AW; GARCIA, GA			TRANSFER-RNA-GUANINE TRANSGLYCOSYLASE FROM ESCHERICHIA-COLI - MINIMAL TRANSFER-RNA STRUCTURE AND SEQUENCE REQUIREMENTS FOR RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ASPARTIC-ACID; TRANSFER-RNA; PURIFICATION; REFINEMENT; STABILITY; LOOP	Previously, we have demonstrated that the tRNA-guanine transglycosylase (TGT) from Escherichia coli is capable of utilizing an in vitro generated minihelix consisting of the anticodon stem and loop sequence of E. coli tRNA(Tyr) (Curnow, A. W., Kung, F. L., Koch, K. A., and Garcia, G. A. (1993) Biochemistry 32, 5239-5246). This suggests that the tRNA structural motifs necessary for recognition comprise a loop at the end of a short helix. To gain further insight into the structural requirements for TGT recognition, we have investigated the conformation of this minimal substrate. Thermal denaturation studies and kinetic analyses at 20 and 37 degrees C indicate that this minihelix is predominantly melted at 37 degrees C and that the melted conformation is not a substrate for TGT. This is confirmed by the determination that a non-helical analogue of the minihelix is not a substrate for TGT at either temperature. Two additional minihelices designed to be stable at 37 degrees C, ECYMH (a 4-base pair extension of the previous minihelix) and SCDMH (a yeast tRNA(Asp) analogue of ECYMH), were generated and char acterized. Finally, several sequence mutants of SCDMH, focusing on the G(30)U(40) base pair and U(33)G(34)U(35) loop sequence, have been produced, and kinetic parameter determinations have been performed at 37 degrees C. Our results are consistent with a recent report (Nakanishi, S., Ueda, T., Hori, H., Yamazaki, N., Okada, N., and Watanabe, K. (1994) J. Biol. Chem. 269, 32221-32225) indicating that a UGU sequence in a 7-base loop is the minimal requirement for TGT recognition.	UNIV MICHIGAN, COLL PHARM, INTERDEPT PROGRAM MED CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767, R29GM045968, R55GM045968] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07767, GM45968] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHONG SR, 1994, BIOTECHNIQUES, V17, P686; CURNOW AW, 1994, BIOCHIMIE, V76, P1183, DOI 10.1016/0300-9084(94)90048-5; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; CURNOW AW, 1994, FASEB J, V8, pA1348; DERRICK WB, 1993, NUCLEIC ACIDS RES, V21, P4948, DOI 10.1093/nar/21.21.4948; DUMAS P, 1985, BIOCHIMIE, V67, P597, DOI 10.1016/S0300-9084(85)80199-1; GARCIA GA, 1993, J MOL BIOL, V231, P489, DOI 10.1006/jmbi.1993.1296; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GROEBE DR, 1989, BIOCHEMISTRY-US, V28, P742, DOI 10.1021/bi00428a049; GROEBE DR, 1988, NUCLEIC ACIDS RES, V16, P11725, DOI 10.1093/nar/16.24.11725; GU XG, 1991, BIOCHEMISTRY-US, V30, P2999, DOI 10.1021/bi00226a003; HARADA F, 1972, BIOCHEMISTRY-US, V11, P301, DOI 10.1021/bi00752a024; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; OKADA N, 1979, J BIOL CHEM, V254, P3061; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; TSANG TH, 1983, BIOCHIM BIOPHYS ACTA, V741, P180, DOI 10.1016/0167-4781(83)90058-1; WESTHOF E, 1988, ACTA CRYSTALLOGR A, V44, P112, DOI 10.1107/S010876738700446X; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8	19	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17264	17267		10.1074/jbc.270.29.17264	http://dx.doi.org/10.1074/jbc.270.29.17264			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615526	hybrid			2022-12-25	WOS:A1995RK68900034
J	SAKATSUME, M; IGARASHI, K; WINESTOCK, KD; GAROTTA, G; LARNER, AC; FINBLOOM, DS				SAKATSUME, M; IGARASHI, K; WINESTOCK, KD; GAROTTA, G; LARNER, AC; FINBLOOM, DS			THE JAK KINASES DIFFERENTIALLY ASSOCIATE WITH THE ALPHA AND BETA (ACCESSORY FACTOR) CHAINS OF THE INTERFERON-GAMMA RECEPTOR TO FORM A FUNCTIONAL RECEPTOR UNIT CAPABLE OF ACTIVATING STAT TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCER; HUMAN-MONOCYTES; DOMAIN; PROMOTER; BINDING; REGION; GENE	Interferon gamma (IFN gamma) induces the expression of early response genes by tyrosine phosphorylation of Jak kinases and transcription factors referred to as STAT proteins. The topology of the IFN gamma receptor is partially understood and the relationship between the alpha chain that binds the ligand and the beta chain that is required for signal transduction is undefined. In a cell line which expresses only the human alpha chain, we show that these cells did not activate Jak kinases or STAT proteins with human IFN gamma, even though Jak1 co-immunoprecipitated with the alpha chain. In cells unexposed to IFN gamma, Jak1 preferentially associated with the alpha chain, while Jak2 associated with the beta chain. There was evidence for Jak1 kinase activity in untreated cells. For Jak2, kinase activity was IFN gamma-dependent. Although the alpha chain was tyrosine-phosphorylated in response to ligand, we found no evidence for tyrosine phosphorylation of the beta chain. These data are consistent with a model of the IFN gamma receptor in which Jak1 associates with the a chain, whereas Jak2 associates with the beta chain, IFN gamma clusters at least two receptor units which results in the tyrosine phosphorylation of Jak1 and Jak2, the activation of Jak2 kinase activity, and the recruitment of STAT1 alpha resulting in its activation by tyrosine phosphorylation.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892; F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES,NEW TECHNOL,CH-4002 BASEL,SWITZERLAND	US Food & Drug Administration (FDA); Roche Holding								AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FINBLOOM DS, 1991, J BIOL CHEM, V266, P22545; FINBLOOM DS, 1985, J IMMUNOL, V135, P300; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; JUNG V, 1987, P NATL ACAD SCI USA, V84, P6934; LARNER AC, 1995, IN PRESS BIOCH BIOPH; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SLATE DL, 1978, J VIROL, V25, P319, DOI 10.1128/JVI.25.1.319-325.1978; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAN YH, 1973, J EXP MED, V137, P317, DOI 10.1084/jem.137.2.317; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964	31	120	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17528	17534		10.1074/jbc.270.29.17528	http://dx.doi.org/10.1074/jbc.270.29.17528			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615558	hybrid			2022-12-25	WOS:A1995RK68900074
J	DEGOMEZPUYOU, MT; SANDOVAL, F; GOMEZPUYOU, A				DEGOMEZPUYOU, MT; SANDOVAL, F; GOMEZPUYOU, A			SYNTHESIS OF MEDIUM PYROPHOSPHATE BY SOLUBLE MITOCHONDRIAL F1 THROUGH DIMETHYL SULFOXIDE-WATER TRANSITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; ENZYME-BOUND ATP; BEEF-HEART; ADENOSINE-TRIPHOSPHATASE; CATALYTIC PROPERTIES; DIMETHYLSULFOXIDE; SYNTHASE; BINDING; ENERGY; SITES	Soluble F-1 from heart mitochondria incubated in mixtures that have Mg2+, inorganic phosphate, and dimethyl sulfoxide (40% (v/v)) catalyzes the spontaneous synthesis of ATP and pyrophosphate (Tuena de Gomez-Puyou, M., Garcia, J. J,, and Gomez-Puyou, A. (1993) Biochemistry 32, 2213-2218). By filtration techniques, it was determined that synthesized ATP and pyrophosphate are enzyme bound, albeit the affinity for pyrophosphate was lower than that of ATP. After ATP and pyrophosphate were formed in dimethyl sulfoxide mixtures, dilution with aqueous buffer to a dimethyl sulfoxide concentration of 6.0% brought about the partition of pyrophosphate into the media. This was evidenced by filtration experiments as well as by the accessibility of synthesized pyrophosphate to soluble inorganic pyrophosphatase. Release of pyrophosphate induced by dilution occurred in less than 15 s. Under conditions that produce release of pyrophosphate, no release of ATP was observed; instead, ATP underwent hydrolysis. Studies on the effect of arsenate on the synthesis and hydrolysis of ATP and PPi in F-1 showed that hydrolysis of synthesized PPi at its site of synthesis was slower than that of ATP. Thus, the question of whether differences in the rates of hydrolysis accounted for the dilution-induced release of PPi but not of ATP was addressed, Synthesis and hydrolysis of ATP and pyrophosphate were examined in preparations of soluble F-1 in complex with its inhibitor protein; the complex had an ATPase activity about 100 times lower than that of free F-1. In mixtures that contained dimethyl sulfoxide, the complex synthesized ATP and pyrophosphate at nearly the same rates; upon dilution, hydrolysis of both compounds occurred also at similar rates, yet only pyrophosphate was released. The same phenomenon was observed in F-1 that had been depleted of adenine nucleotides. Hence, dilution-induced release of PPi was independent of the overall catalytic properties of the enzyme or its content of adenine nucleotides. Since synthesis of ATP occurs at the expense of the ADP that remains after depletion of adenine nucleotides, it is likely that the failure of ATP to be released is due to the high affinity that F-1 exhibits for the synthesized ATP. Nevertheless, the results illustrate that a complete catalytic cycle that starts with medium P-i and ends with medium pyrophosphate may be reproduced in soluble mitochondrial F-1.			DEGOMEZPUYOU, MT (corresponding author), UNIV NACL AUTONOMA MEXICO, INST FISIOL CELULAR, APARTADO POSTAL 70600, MEXICO CITY 04510, DF, MEXICO.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P886, DOI 10.1021/bi00118a034; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; BALTSCHEFFSKY H, 1966, SCIENCE, V153, P1120, DOI 10.1126/science.153.3740.1120; BEHARRY S, 1992, BIOCHEM BIOPH RES CO, V182, P697, DOI 10.1016/0006-291X(92)91788-R; BEHARRY S, 1991, FEBS LETT, V291, P282, DOI 10.1016/0014-5793(91)81302-O; BEHARRY S, 1991, BIOCHEM CELL BIOL, V69, P291, DOI 10.1139/o91-044; BELTRAN C, 1984, EUR J BIOCHEM, V144, P151, DOI 10.1111/j.1432-1033.1984.tb08443.x; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; CRANE RK, 1953, J BIOL CHEM, V201, P235; DEGOMEZPUYOU MT, 1993, BIOCHEMISTRY-US, V32, P2213, DOI 10.1021/bi00060a012; DEGOMEZPUYOU MT, 1977, ARCH BIOCHEM BIOPHYS, V90, P147; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1984, J BIOL CHEM, V259, P6090; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; ISSARTEL JP, 1987, J BIOL CHEM, V262, P13538; KANDPAL RP, 1987, BIOCHEMISTRY-US, V31, P2088; KASAHARA M, 1978, J BIOL CHEM, V253, P4180; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PEINNEQUIN A, 1992, BIOCHEMISTRY-US, V31, P2088, DOI 10.1021/bi00122a028; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; PENEFSKY HS, 1985, J BIOL CHEM, V260, P3728; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; PUYOU AG, 1986, EUR J BIOCHEM, V159, P133, DOI 10.1111/j.1432-1033.1986.tb09843.x; SAKAMOTO J, 1983, J BIOCHEM, V93, P1601, DOI 10.1093/oxfordjournals.jbchem.a134299; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; WOOD JM, 1987, J BIOL CHEM, V262, P2180; YOSHIDA M, 1983, BIOCHEM BIOPH RES CO, V114, P907, DOI 10.1016/0006-291X(83)90646-0	35	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16820	16825		10.1074/jbc.270.28.16820	http://dx.doi.org/10.1074/jbc.270.28.16820			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622496	hybrid			2022-12-25	WOS:A1995RJ34700057
J	GUNTHER, MR; KELMAN, DJ; CORBETT, JT; MASON, RP				GUNTHER, MR; KELMAN, DJ; CORBETT, JT; MASON, RP			SELF-PEROXIDATION OF METMYOGLOBIN RESULTS IN FORMATION OF AN OXYGEN-REACTIVE TRYPTOPHAN-CENTERED RADICAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; SPERM WHALE MYOGLOBIN; CYTOCHROME-C PEROXIDASE; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; PHOTOLYSIS; TYROSINE; TYR-151; DAMAGE; AGENTS	In the reaction between hydrogen peroxide and metmyoglobin, the heme iron is oxidized to its ferryl-oxo form and the globin to protein radicals, at least one of which reacts with dioxygen to form a peroxyl radical. To identify the residue(s) that forms the oxygen-reactive radical, we utilized electron spin resonance (ESR) spectroscopy and the spin traps 2-methyl-2-nitrosopropane and 3,5-dibromo-4-nitrosobenzenesulfonic acid (DBNBS), Metmyoglobin radical adducts had spectra typical of immobilized nitroxides that provided little structural information, but subsequent nonspecific protease treatment resulted in the detection of isotropic three-line spectra, indicative of a radical adduct centered on a tertiary carbon with no bonds to nitrogen or hydrogen. Similar isotropic three-line ESR spectra were obtained by spin trapping the oxidation product of tryptophan reacting with catalytic metmyoglobin and hydrogen peroxide. High resolution ESR spectra of DBNBS/(.)trp and of the protease-treated DBNBS/(.)metMb were simulated using superhyperfine coupling to a nitrogen and three non equivalent hydrogens, consistent with a radical adduct formed at C-3 of the indole ring. Oxidation of tryptophan by catalytic metMb and hydrogen peroxide resulted in spin trap-inhibitable oxygen consumption, consistent with formation of a peroxyl radical. The above results support self-peroxidation of a tryptophan residue in the reaction between metMb and hydrogen peroxide.			GUNTHER, MR (corresponding author), NIEHS, MOLEC TOXICOL LAB, RES TRIANGLE PK, NC 27709 USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				ANTON M, 1991, P INT C MEAT SCI TEC, V37, P320; ARDUINI A, 1992, FREE RADICAL BIO MED, V13, P449, DOI 10.1016/0891-5849(92)90185-J; ARNHEIM N, 1992, MUTAT RES, V275, P157, DOI 10.1016/0921-8734(92)90020-P; BUTLER J, 1982, BIOCHIM BIOPHYS ACTA, V705, P150, DOI 10.1016/0167-4838(82)90173-X; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CHOE YS, 1994, ARCH BIOCHEM BIOPHYS, V314, P126, DOI 10.1006/abbi.1994.1420; DAVIES MJ, 1991, FREE RADICAL RES COM, V15, P111, DOI 10.3109/10715769109049131; DAVIES MJ, 1990, FREE RADICAL RES COM, V10, P361, DOI 10.3109/10715769009149905; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; DEFELIPPIS MR, 1989, BIOCHEMISTRY-US, V28, P4847, DOI 10.1021/bi00437a049; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; EVANS SV, 1990, J MOL BIOL, V213, P885, DOI 10.1016/S0022-2836(05)80270-0; FERRARI R, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90291-5; GEORGE P, 1955, BIOCHEM J, V60, P596, DOI 10.1042/bj0600596; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; HARADA K, 1987, J BIOCHEM, V101, P283, DOI 10.1093/oxfordjournals.jbchem.a121903; HAREL S, 1988, FREE RADICAL RES COM, V5, P21, DOI 10.3109/10715768809068555; HIRAMOTO K, 1994, FREE RADICAL RES, V21, P341, DOI 10.3109/10715769409056586; HOFFMAN BM, 1981, J BIOL CHEM, V256, P6556; HONG S-J, 1989, Korean Biochemical Journal, V22, P196; JANSSEN YMW, 1993, LAB INVEST, V69, P261; JOVANOVIC SV, 1985, FREE RADICAL BIO MED, V1, P125; KANNER J, 1985, ARCH BIOCHEM BIOPHYS, V237, P314, DOI 10.1016/0003-9861(85)90282-6; KAUR H, 1981, J CHEM SOC CHEM COMM, P142, DOI 10.1039/c39810000142; KELMAN DJ, 1992, FREE RADICAL RES COM, V16, P27, DOI 10.3109/10715769209049156; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; KNECHT KT, 1992, MOL PHARMACOL, V41, P943; LION Y, 1982, PHOTOCHEM PHOTOBIOL, V35, P53, DOI 10.1111/j.1751-1097.1982.tb03810.x; LION Y, 1982, PHOTOCHEM PHOTOBIOL, V35, P43, DOI 10.1111/j.1751-1097.1982.tb03809.x; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; MURAKAMI J, 1989, PHOTOCHEM PHOTOBIOL, V49, P465, DOI 10.1111/j.1751-1097.1989.tb09196.x; NEWMAN ESR, 1991, BIOCHEM BIOPH RES CO, V179, P1414, DOI 10.1016/0006-291X(91)91730-Z; PAILTHORPE MT, 1971, PHOTOCHEM PHOTOBIOL, V14, P135, DOI 10.1111/j.1751-1097.1971.tb06158.x; PUPPO A, 1988, FREE RADICAL RES COM, V4, P415, DOI 10.3109/10715768809066910; RAO SI, 1993, J BIOL CHEM, V268, P803; ROMERO FJ, 1992, J BIOL CHEM, V267, P1680; SAHLIN M, 1994, J BIOL CHEM, V269, P11699; SHIGA T, 1973, ARCH BIOCHEM BIOPHYS, V154, P540, DOI 10.1016/0003-9861(73)90006-4; SZAJDZINSKAPIETEK E, 1993, J PHOTOCH PHOTOBIO A, V75, P131, DOI 10.1016/1010-6030(93)80194-E; TAJIMA G, 1993, INT J BIOCHEM, V25, P101, DOI 10.1016/0020-711X(93)90495-Z; TASSIN JD, 1980, PHOTOCHEM PHOTOBIOL, V32, P577, DOI 10.1111/j.1751-1097.1980.tb04025.x; TEW D, 1988, J BIOL CHEM, V263, P17880; TURNER JJO, 1991, BIOCHEM J, V277, P833, DOI 10.1042/bj2770833; WILKS A, 1992, J BIOL CHEM, V267, P8827; WOGAN GN, 1989, ENVIRON HEALTH PERSP, V81, P9, DOI 10.2307/3430797; XU Y, 1990, J AGR FOOD CHEM, V38, P1494, DOI 10.1021/jf00097a014	51	103	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16075	16081		10.1074/jbc.270.27.16075	http://dx.doi.org/10.1074/jbc.270.27.16075			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608169	hybrid			2022-12-25	WOS:A1995RH22600032
J	BEUG, H; DAHL, R; STEINLEIN, P; MEYER, S; DEINER, EM; HAYMAN, MJ				BEUG, H; DAHL, R; STEINLEIN, P; MEYER, S; DEINER, EM; HAYMAN, MJ			IN-VITRO GROWTH OF FACTOR-DEPENDENT MULTIPOTENTIAL HEMATOPOIETIC-CELLS IS INDUCED BY THE NUCLEAR ONCOPROTEIN V-SKI	ONCOGENE			English	Article						SKI; C-KIT; MULTIPOTENT PROGENITORS; HEMATOPOIESIS; CYTOKINES; STEROID HORMONES	AVIAN ERYTHROBLASTOSIS VIRUS; CHICKEN-EMBRYO FIBROBLASTS; PROGENITOR CELLS; STEM-CELLS; MONOCLONAL-ANTIBODIES; SELF-RENEWAL; ERYTHROID-DIFFERENTIATION; ONCOGENE; INVITRO; TRANSFORMATION	Understanding how self renewal, commitment and differentiation are regulated in normal, multipotent hematopoietic progenitors is important for our understanding of underlying mechanisms involved in leukemogenesis, In addition, knowledge of progenitor cell biology is critical if these cells are to be used far gene therapy, In this communication, we demonstrate that the oncogenic transcription factor v-Ski, together with the ligand activated receptor tyrosine kinase c-Kit, induces the continuous in vitro self renewal of primary avian multipotent progenitors, These cells have an in vitro life span of >100 generations, In addition they spontaneously differentiate into cells of the erythroid, monocytic and granulocytic lineages, If clonal strains of these multipotent progenitors are exposed to specific mixtures of growth factors and hormones, they develop into committed cells of either the erythroid or myeloid Lineages, These committed cells underwent efficient terminal differentiation when they were treated with the relevant lineage-specific growth/differentiation factors, but underwent apoptosis when exposed to the incorrect factors for the respective lineage, While the committed tells coexpress marker proteins from different lineages, expression of the 'wrong' lineage marker is repressed during terminal differentiation, Our results indicate that a combination of v-Ski and activated c-Kit induces long-term self renewal in primary multipotent progenitors, which can be induced to commit and differentiate along specific lineages under different, defined conditions, Our data also suggest that growth factors and steroid hormones control terminal differentiation by a combined induction of commitment, growth and apoptosis, a process likely to be affected in stem cell leukemias.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Dahl, Richard/0000-0002-6341-5604				BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1977, EXP CELL RES, V107, P417, DOI 10.1016/0014-4827(77)90363-9; BEUG H, 1994, IN PRESS METHODS ENZ; BROXMEYER HE, 1991, BLOOD, V77, P2142; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DALYOT N, 1993, NUCLEIC ACIDS RES, V21, P4031, DOI 10.1093/nar/21.17.4031; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1982, J CELL BIOCHEM, V18, P351, DOI 10.1002/jcb.1982.240180308; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; KAMPS MP, 1988, ONCOGENE, V2, P305; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; LARSEN J, 1992, ONCOGENE, V7, P1903; LARSEN J, 1993, ONCOGENE, V8, P3221; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; NAMCIU S, 1994, ONCOGENE, V9, P1407; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	40	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					59	72						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624132				2022-12-25	WOS:A1995RJ29500008
J	MENON, SD; GUY, GR; TAN, YH				MENON, SD; GUY, GR; TAN, YH			INVOLVEMENT OF A PUTATIVE PROTEIN-TYROSINE-PHOSPHATASE AND I-KAPPA-B-ALPHA SERINE PHOSPHORYLATION IN NUCLEAR FACTOR KAPPA-B ACTIVATION BY TUMOR-NECROSIS-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CELLS; KINASE; INTERLEUKIN-1; INHIBITOR; RECEPTORS; VANADATE; ADIPOCYTES	Inhibitors of phosphotyrosyl protein phosphatases, pervanadate and phenylarsine oxide, abrogate tumor necrosis factor (TNF)-induced nuclear factor kappa B (NF-kappa B) nuclear translocation in transformed cell lines (U-937 and Jurkat) and primary fibroblasts (MRC-5 and REF). The inhibitors also abrogate NF-kappa B activation by the phosphoseryl/threonyl protein phosphatase inhibitor okadaic acid in U-937 cells, Inhibition of NF-kappa B activation is not due to a general inhibitory effect since neither pervanadate nor phenylarsine oxide treatment affected the constitutive DNA-binding activity of the transcription factors octamer-1 and cAMP response element-binding protein in U-937 cells, nor did these compounds inhibit the TNF-induced phosphorylation of proteins, viz, hsp 27, eukaryotic initiation factor 4e, and pp19, in MRC-5 fibroblasts, Overexpression of the protein-tyrosine phosphatase HPTP alpha resulted in a constitutive nuclear NF-kappa B-like DNA-binding activity in REF cells, Conversely, treatment of human protein-tyrosine phosphatase alpha-overexpressing cells with phenylarsine oxide led to a loss of the constitutive NF-kappa B activity, The presence of a tyrosine phosphorylation site on the inhibitor of NF-kappa B (I kappa B-alpha) suggested that it could be a target for TNF/okadaic acid-induced tyrosine dephosphorylation. However, no tyrosine phosphorylation was detected on I kappa B-alpha from unstimulated cells, while TNF/okadaic acid-treated cells showed increased phosphorylation of I kappa B-alpha exclusively at serine residue(s), Treatment of cells with pervanadate inhibited TNF-induced I kappa B-alpha phosphorylation and degradation, whereas the serine protease inhibitors tosylphenylalanyl chloro methyl ketone and N-alpha-p-tosyl-L-lysine chloromethyl ketone prevented TNF-induced I kappa B-alpha degradation and NF-kappa B nuclear translocation, but not the TNF-induced phosphorylation of I kappa B-alpha. The data suggest that TNF and okadaic acid induce the activation of a putative protein-tyrosine phosphatase(s), leading to IKB-alpha serine phosphorylation and degradation and NF-kappa B nuclear translocation.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								AL ZW, 1993, BIOCHEM J, V296, P675, DOI 10.1042/bj2960675; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BAUR A, 1994, J IMMUNOL, V152, P976; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOLEN JB, 1993, ONCOGENE, V8, P2025; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROXMEYER HE, 1991, J EXP MED, V174, P447, DOI 10.1084/jem.174.2.447; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GRILLI M, 1993, INT REV CYTOL, V143, P1; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOONG AC, 1994, CANCER RES, V54, P1425; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MENON SD, 1993, J BIOL CHEM, V268, P26805; Pallen Catherine J., 1992, Current Opinion in Cell Biology, V4, P1000, DOI 10.1016/0955-0674(92)90132-V; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PORTER AG, 1991, TRENDS BIOTECHNOL, V9, P158, DOI 10.1016/0167-7799(91)90053-K; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TAN YH, 1993, SCIENCE, V262, P376, DOI 10.1126/science.7692598; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANLINT J, 1992, J BIOL CHEM, V267, P25916; ZHENG XM, 1994, J BIOL CHEM, V269, P23302; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	52	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18881	18887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642544				2022-12-25	WOS:A1995RN95400031
J	TEODORO, JG; SHORE, GC; BRANTON, PE				TEODORO, JG; SHORE, GC; BRANTON, PE			ADENOVIRUS E1A PROTEINS INDUCE APOPTOSIS BY BOTH P53-DEPENDENT AND P53-INDEPENDENT MECHANISMS	ONCOGENE			English	Article						APOPTOSIS; P53; ADENOVIRUS; E1A; E1B	E2F TRANSCRIPTION FACTOR; REGION 1A PROTEINS; RAT-KIDNEY CELLS; CELLULAR PROTEINS; 19-KILODALTON PROTEIN; FUNCTIONAL DOMAINS; TUMOR-ANTIGENS; INFECTED-CELLS; GENE-PRODUCT; DNA-BINDING	E1A of human adenovirus type 5 (Ad5) encodes proteins of 289 and 243 residues (289R and 243R) which differ only by the 46 amino acid CR3 region known to activate expression of certain cellular and early viral genes. E1A proteins also induce DNA synthesis and cell transformation, but as well can stimulate apoptosis. Two adenovirus E1B products act to protect cells from E1A-induced cell death, including a 19 kDa protein which is functionally similar to the cellular Bcl-2 suppressor of apoptosis, and a 55 kDa species which binds to and inhibits p53. Previous studies suggested that E1A-induced cell death occurs via a p53-dependent mechanism requiring regions of E1A proteins linked to induction of DNA synthesis and cell transformation. We report here that the 289R E1A protein induces apoptosis in cell lines lacking p53, whereas the 243R product was dependent upon p53. We also show that this p53-independent process involves the expression of one or more additional viral proteins which are presumably synthesized in response to transactivation by 289R. Thus E1A proteins induce cell death by both p53-dependent and p53-independent mechanisms involving separate E1A functions.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA	McGill University			Teodoro, Joe/AFT-2440-2022	Teodoro, Joe/0000-0002-3713-6839				Akusjarvi G, 1993, Trends Microbiol, V1, P163, DOI 10.1016/0966-842X(93)90085-6; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BACCHETTI S, 1993, INT J ONCOL, V3, P781; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BARBEAU D, 1994, ONCOGENE, V9, P359; BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMONT DJ, 1989, J VIROL, V63, P987, DOI 10.1128/JVI.63.2.987-991.1989; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EZOE H, 1981, J VIROL, V40, P20, DOI 10.1128/JVI.40.1.20-27.1981; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOROWITZ MS, 1990, VIROLOGY, P1679; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; ROWE DT, 1983, VIROLOGY, V129, P456, DOI 10.1016/0042-6822(83)90183-6; SEARLE J, 1975, J PATHOL, V116, P129, DOI 10.1002/path.1711160302; SHENK T, 1991, ADV CANCER RES, V57, P47; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; TREMBLAY ML, 1989, VIROLOGY, V169, P397, DOI 10.1016/0042-6822(89)90165-7; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZHANG S, 1992, J VIROL, V66, P2302, DOI 10.1128/JVI.66.4.2302-2309.1992	80	138	145	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					467	474						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630630				2022-12-25	WOS:A1995RN53000006
J	BERDITCHEVSKI, F; BAZZONI, G; HEMLER, ME				BERDITCHEVSKI, F; BAZZONI, G; HEMLER, ME			SPECIFIC ASSOCIATION OF CD63 WITH THE VLA-3 AND VLA-6 INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION RECEPTORS; CYTOPLASMIC DOMAIN; MONOCLONAL-ANTIBODIES; ALPHA-SUBUNIT; ONCOGENIC TRANSFORMATION; MEMBRANE GLYCOPROTEIN; EXTRACELLULAR-MATRIX; FIBRONECTIN RECEPTOR; MOLECULAR-CLONING; ENDOTHELIAL-CELLS	We screened monoclonal antibodies to cell surface proteins and selected an antibody, called 6H1, that recognizes a putative integrin-associated protein. The 6H1 monoclonal antibody (mAb) indirectly coprecipitated alpha(3) beta(1) and/or alpha(6) beta(1) but not alpha(2) beta(1), or alpha(5) beta(1) from Brij 96 detergent lysates of multiple cell lines. Large scale purification using the 6H1 mAb yielded a single protein of 45-60 kDa with an amino-terminal sequence that exactly matched CD63. Confirming that the 6H1 mAb recognized the CD63 protein, 6H1 and a known anti-CD63 mAb yielded identical coprecipitation results and identical colocalization into lysosomal granules containing cathepsin D. Furthermore, we used an established anti-CD63 mAb to detect this protein in an alpha(3) beta(1) immunoprecipitate, and also we observed VLA-3 and CD63 colocalization in cellular ''footprints.'' Notably, the cytoplasmic domain of alpha(3) was neither required nor sufficient for CD63 association, suggesting that it occurred elsewhere within the alpha(3) beta(1) complex. Knowledge of these specific CD63-alpha(3) beta(1), and CD63-alpha(6) beta(1) biochemical associations should lead to critical insights into the specialized functions of alpha(3) beta(1), alpha(6) beta(1) and CD63.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NIGMS NIH HHS [GM46526] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046526] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BEAULIEU JF, 1992, J CELL SCI, V102, P427; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHOY MY, 1990, J PATHOL, V160, P35, DOI 10.1002/path.1711600109; DAMJANOVICH L, 1992, AM J RESP CELL MOL, V6, P197, DOI 10.1165/ajrcmb/6.2.197; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; GEHLSEN KR, 1988, SCIENCE, V24, P1228; GIUNTA M, 1991, J EXP MED, V173, P1537, DOI 10.1084/jem.173.6.1537; HEMLER ME, 1983, J IMMUNOL, V131, P334; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HOTTA H, 1994, CANCER RES, V48, P2955; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KIM JP, 1992, J INVEST DERMATOL, V98, P764, DOI 10.1111/1523-1747.ep12499947; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LOBB RR, 1994, J CLIN INVEST, V1269, P8348; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; MIYAMOTO H, 1994, BBA-GENE STRUCT EXPR, V1217, P312, DOI 10.1016/0167-4781(94)90291-7; NAGIRA M, 1994, CELL IMMUNOL, V157, P144, DOI 10.1006/cimm.1994.1212; NIEUWENHUIS HK, 1987, BLOOD, V70, P838; NISHIBORI M, 1993, J CLIN INVEST, V91, P1775, DOI 10.1172/JCI116388; NISHIKATA H, 1992, J IMMUNOL, V149, P862; OREN R, 1994, MOL CELL BIOL, V10, P4007; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1993, J CELL SCI, V105, P101; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SHAW LM, 1993, J BIOL CHEM, V268, P11401; SHAW LM, 1994, MOL BIOL CELL, V5, P679, DOI 10.1091/mbc.5.6.679; SIKORA LKJ, 1987, INT J CANCER, V39, P138, DOI 10.1002/ijc.2910390203; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; SONNENBERG A, 1988, NATURE, V360, P487; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TOOTHILL VJ, 1990, J IMMUNOL, V145, P283; TSUJI T, 1991, J BIOCHEM-TOKYO, V109, P659, DOI 10.1093/oxfordjournals.jbchem.a123436; VISCHER UM, 1993, BLOOD, V82, P1184, DOI 10.1182/blood.V82.4.1184.1184; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4	72	143	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17784	17790		10.1074/jbc.270.30.17784	http://dx.doi.org/10.1074/jbc.270.30.17784			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629079	hybrid			2022-12-25	WOS:A1995RM26600026
J	DECOTTIGNIES, A; LAMBERT, L; CATTY, P; DEGAND, H; EPPING, EA; MOYEROWLEY, WS; BALZI, E; GOFFEAU, A				DECOTTIGNIES, A; LAMBERT, L; CATTY, P; DEGAND, H; EPPING, EA; MOYEROWLEY, WS; BALZI, E; GOFFEAU, A			IDENTIFICATION AND CHARACTERIZATION OF SNQ2, A NEW MULTIDRUG ATP BINDING CASSETTE TRANSPORTER OF THE YEAST PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ADENYLATE KINASE; DRUG-RESISTANCE; P-GLYCOPROTEIN; GENE; CELLS; DNA; EXPRESSION; PROTEINS; MUTATION	The SNQ2 gene of Saccharomyces cerevisiae, which encodes an ATP binding cassette protein responsible for resistance to the mutagen 4-nitroquinoline oxide, is regulated by the DNA-binding proteins PDR1 and PDR3. In a plasma membrane-enriched fraction from a pdr1 mutant, the SNQ2 protein is found in the 160-kDa over-expressed band, together with PDR5. The SNQ2 protein was solubilized with n-dodecyl beta-D-maltoside from the plasma membranes of a PDR5-deleted strain and separated from the PMA1 H+-ATPase by sucrose gradient centrifugation. The enzyme shows a nucleoside triphosphatase activity that differs biochemically from that of PDR5 (Decottignies, A., Kolaczkowski, M., Balzi, E., and Goffeau, A. (1994) J. Biol. Chem. 269, 12797-12803) and is sensitive to vanadate, erythrosine B, and Triton X-100 but not to oligomycin, which inhibits the PDR5 activity only. Disruption of both PDR5 and SNQ2 in a pdr1 mutant decreases the cell growth rate and reveals the presence of at least two other ATP binding cassette proteins in the 160-kDa overexpressed band that have been identified by amino-terminal microsequencing.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Universite Catholique Louvain; University of Iowa			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120; Epping, Eric/0000-0001-7193-3041	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1994, BIOCHIM BIOPHYS ACTA, V1187, P151; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BORSTPAUWELS GWFH, 1977, BIOCHIM BIOPHYS ACTA, V466, P488, DOI 10.1016/0005-2736(77)90341-8; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DELAHODDE A, 1995, IN PRESS MOL CELL BI; DELAVEAU T, 1992, YEAST, V8, P761, DOI 10.1002/yea.320080909; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DEXTER D, 1994, GENETICS, V136, P505; DUFOUR JP, 1980, EUR J BIOCHEM, V105, P145, DOI 10.1111/j.1432-1033.1980.tb04484.x; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUERINEAU M, 1974, BIOCHEM BIOPH RES CO, V61, P462, DOI 10.1016/0006-291X(74)90979-6; HAASE E, 1992, CURR GENET, V21, P319, DOI 10.1007/BF00351689; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KUO CL, 1983, MOL CELL BIOL, V3, P1730, DOI 10.1128/MCB.3.10.1730; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; LEPPERT G, 1990, GENETICS, V125, P13; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Miller J.H., 1972, EXPT MOL GENETICS; MOOS M, 1988, J BIOL CHEM, V263, P6005; NASS G, 1976, MOL GEN GENET, V147, P39, DOI 10.1007/BF00337933; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101; RANK GH, 1976, MOL GEN GENET, V144, P281, DOI 10.1007/BF00341726; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Sambrook J, 1989, MOL CLONING LABORATO; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; THOMAS PJ, 1993, J BIOENERG BIOMEMBR, V25, P11, DOI 10.1007/BF00768063; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; ULAWZEWSKI S, 1987, MOL GEN GENET, V207, P38	46	139	144	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18150	18157		10.1074/jbc.270.30.18150	http://dx.doi.org/10.1074/jbc.270.30.18150			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629127	hybrid			2022-12-25	WOS:A1995RM26600079
J	DOPPLER, W; WELTE, T; PHILIPP, S				DOPPLER, W; WELTE, T; PHILIPP, S			CCAAT/ENHANCER-BINDING PROTEIN ISOFORM-BETA AND ISOFORM-DELTA ARE EXPRESSED IN MAMMARY EPITHELIAL-CELLS AND BIND TO MULTIPLE SITES IN THE BETA-CASEIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ACID GLYCOPROTEIN GENE; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; C/EBP FAMILY; GLUCOCORTICOID RECEPTOR; EXTRACELLULAR-MATRIX; MYELOMONOCYTIC CELLS; SIGNAL TRANSDUCTION; HORMONAL INDUCTION; RESPONSE ELEMENTS	Lactogenic hormone-dependent expression of the rat beta-casein gene in mammary epithelial cells is controlled via a complex regulatory region in the promoter. The sequence between -176 and -82 is the minimal region to confer the response to glucocorticoid hormone and prolactin on a heterologous promoter. The response is further enhanced by the region between -282 and -176. DNase I footprinting experiments and electromobility shift assays revealed the presence of four binding sites for CCAAT/enhancer-binding protein (C/EBP) isoforms in the hormone response region between -220 and -132. In nuclear extracts from mammary epithelial cells, the prevalent C/EBP isoform binding to these sites is beta (C/EBP-beta). C/EBP-delta is also present in mammary epithelial cells, whereas C/EBP-alpha is not detectable. The C/EBP sites are located in close proximity to the previously characterized binding sites for the prolactin-inducible mammary gland factor/signal transducer and activator of transcription-5, the nuclear factor YY1, and the glucocorticoid receptor. The importance of the two proximal C/EBP binding sites at the 5' border of the minimal region was tested by mutational analysis. Mutations of each site were found to inhibit strongly both the basal and the lactogenic hormone-induced transcription of a beta-casein gene promoter chloramphenicol acetyltransferase construct. The results implicate C/EBPs as important regulators of beta-casein gene expression in the mammary epithelium.			DOPPLER, W (corresponding author), UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, FRITZ PREGL STR 3, A-6020 INNSBRUCK, AUSTRIA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALAM T, 1993, J BIOL CHEM, V268, P15681; ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; ALTIOK S, 1994, MOL CELL BIOL, V14, P6004, DOI 10.1128/MCB.14.9.6004; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN HM, 1993, J BIOL CHEM, V268, P25311; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; DOPPLER W, 1991, MOL ENDOCRINOL, V5, P1624, DOI 10.1210/mend-5-11-1624; DOPPLER W, 1990, MOL ENDOCRINOL, V4, P912, DOI 10.1210/mend-4-6-912; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; GOTOH T, 1994, J BIOCHEM-TOKYO, V115, P778, DOI 10.1093/oxfordjournals.jbchem.a124409; GROENEN MAM, 1992, NUCLEIC ACIDS RES, V20, P4311, DOI 10.1093/nar/20.16.4311; INGRASSIA R, 1994, DNA CELL BIOL, V13, P615, DOI 10.1089/dna.1994.13.615; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KANAI A, 1993, GENE, V126, P195, DOI 10.1016/0378-1119(93)90006-O; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LECAM A, 1994, J BIOL CHEM, V269, P21532; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEE CS, 1992, ENDOCRINOLOGY, V131, P2257, DOI 10.1210/en.131.5.2257; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LI S, 1994, J BIOL CHEM, V269, P14235; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PIERRE S, 1994, MOL ENDOCRINOL, V8, P1720, DOI 10.1210/me.8.12.1720; PIONTKEWITZ Y, 1993, ENDOCRINOLOGY, V133, P2327, DOI 10.1210/en.133.5.2327; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RAY BK, 1994, GENE, V147, P253, DOI 10.1016/0378-1119(94)90076-0; RAY BK, 1994, EUR J BIOCHEM, V222, P891, DOI 10.1111/j.1432-1033.1994.tb18937.x; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SCOTT LM, 1992, BLOOD, V80, P1725; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; THEISEN M, 1993, MOL CELL BIOL, V13, P7666, DOI 10.1128/MCB.13.12.7666; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WELTE T, 1993, J STEROID BIOCHEM, V47, P75, DOI 10.1016/0960-0760(93)90059-6; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; YOSHIMURA M, 1990, P NATL ACAD SCI USA, V87, P3670, DOI 10.1073/pnas.87.10.3670	66	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17962	17969		10.1074/jbc.270.30.17962	http://dx.doi.org/10.1074/jbc.270.30.17962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629103	hybrid			2022-12-25	WOS:A1995RM26600053
J	GOPALAKRISHNAN, L; SCARPULLA, RC				GOPALAKRISHNAN, L; SCARPULLA, RC			STRUCTURE, EXPRESSION, AND CHROMOSOMAL ASSIGNMENT OF THE HUMAN GENE ENCODING NUCLEAR RESPIRATORY FACTOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-GENE; SUBUNIT-IV GENE; MITOCHONDRIAL-DNA; RAT; IDENTIFICATION; TRANSCRIPTION; ACTIVATOR; SEQUENCES; FAMILY; NRF-1	Nuclear respiratory factor 1 (NRF-1) is a transcription factor that acts on nuclear genes encoding respiratory subunits and components of the mitochondrial transcription and replication machinery. Here we describe the isolation and characterization of the human gene encoding NRF-1. The human genomic sequences detected with NRF-1 cDNA probes at high stringency are all contained within seven overlapping recombinant lambda clones. The NRF-1 gene encompassed by these recombinants spans similar to 65 kilobases (kb) and has 11 exons and 10 introns that range in size from 0.8 to 15 kb. A rapid amplification of cDNA ends-polymerase chain reaction product containing the 5'-terminus of the NRF-1 cDNA has two exons from the 5'-untranslated region and terminates at a major transcription initiation site identified by S1 nuclease mapping. A genomic fragment containing a portion of the 5'-terminal exon and an additional 1 kb upstream had a functional promoter that was active in transfected COS cells, HeLa cells, and L6 myoblasts. The transcription initiation site utilized by the transfected promoter corresponded to that used by the endogenous gene in vivo. NRF-1 mRNA was expressed at very low levels in rat tissues compared with cytochrome c and, unlike cytochrome c, was most abundantly expressed in lung and testis. The NRF-1 gene was localized to human chromosome 7 by analysis of DNA from a panel of human-hamster cell hybrids with human-specific NRF-1 polymerase chain reaction primers. This assignment was further refined to 7q31 by cohybridization of NRF-1- and chromosome 7-specific probes to human metaphase chromosomes. These analyses should be useful in evaluating the potential role of NRF-1 in mitochondrial diseases resulting from defects in the nuclear control of mitochondrial function.			GOPALAKRISHNAN, L (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MOLEC & CELL BIOL,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032525, R56GM032525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32525-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; BURKE JF, 1984, GENE, V30, P63, DOI 10.1016/0378-1119(84)90105-7; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CLAYTON DA, 1992, INT REV CYTOL, V141, P317; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; KASLOW DC, 1986, NUCLEIC ACIDS RES, V14, P6767, DOI 10.1093/nar/14.16.6767; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MORAES CT, 1991, AM J HUM GENET, V48, P492; PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951; POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARPULLA RC, 1981, J BIOL CHEM, V256, P6480; SCARPULLA RC, 1983, CELL, V32, P473, DOI 10.1016/0092-8674(83)90467-1; SCARPULLA RC, 1982, P NATL ACAD SCI-BIOL, V79, P739, DOI 10.1073/pnas.79.3.739; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; TOMINAGA K, 1993, BIOCHEM BIOPH RES CO, V194, P544, DOI 10.1006/bbrc.1993.1854; TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; VIRBASIUS JV, 1990, NUCLEIC ACIDS RES, V18, P6581, DOI 10.1093/nar/18.22.6581; VIRBASIUS JV, 1988, J BIOL CHEM, V263, P6791; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523	33	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18019	18025		10.1074/jbc.270.30.18019	http://dx.doi.org/10.1074/jbc.270.30.18019			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629110	hybrid			2022-12-25	WOS:A1995RM26600061
J	HEWITT, SM; FRAIZER, GC; SAUNDERS, GF				HEWITT, SM; FRAIZER, GC; SAUNDERS, GF			TRANSCRIPTIONAL SILENCER OF THE WILMS-TUMOR GENE WT1 CONTAINS AN ALU REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; NEGATIVE REGULATION; REPEATED SEQUENCES; NUCLEAR PROTEINS; KERATIN-18 GENE; TRANSGENIC MICE; PROMOTER REGION; EXPRESSION; BINDING; ENHANCER	Expression of the Wilms' tumor gene WT1 is tightly regulated throughout development. In constrast, the WT1 promoter is promiscuous, functioning in all cell lines tested, We have cloned a transcriptional silencer that is involved in regulation of the WT1 gene. The transcriptional silencer is located in the third intron of the WT1 gene, approximately 12 kilobases from the promoter, and functions to repress transcription from the WT1 promoter in cell lines of non-renal origin. The 460-base pair silencer region is unusual in that it contains a full-length Alu repeat. We have also cloned an enhancer like-element located 1.3 kilobases upstream of the WT1 promoter.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center				Hewitt, Stephen/0000-0001-8283-1788	NCI NIH HHS [CA34936, CA 16672, T32 CA09299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936, T32CA009299, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGEREAU P, 1986, EMBO J, V5, P1791, DOI 10.1002/j.1460-2075.1986.tb04428.x; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BRINI AT, 1993, J BIOL CHEM, V268, P1355; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1994, ONCOGENE, V9, P583; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HOUCK CM, 1979, J MOL BIOL, V132, P289, DOI 10.1016/0022-2836(79)90261-4; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KIM JH, 1989, NUCLEIC ACIDS RES, V17, P5687, DOI 10.1093/nar/17.14.5687; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOCKER J, 1990, J DNA SEQUENCING MAP, V1, P3; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAOUCHE L, 1994, NUCLEIC ACIDS RES, V22, P338, DOI 10.1093/nar/22.3.338; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; MIWA H, 1992, LEUKEMIA, V6, P405; MIYAGI T, 1993, LEUKEMIA, V7, P970; NEZNANOV N, 1993, MOL CELL BIOL, V13, P2214, DOI 10.1128/MCB.13.4.2214; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; OKA T, 1991, ONCOGENE, V6, P2077; PARK JH, 1988, MOL CELL BIOL, V8, P2536, DOI 10.1128/MCB.8.6.2536; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERELYGINA LM, 1987, MOL BIOL REP, V12, P111, DOI 10.1007/BF00368878; RICCARDI VM, 1978, PEDIATRICS, V61, P604; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHEN MR, 1991, J MOL EVOL, V33, P311; TADOKORO K, 1992, JPN J CANCER RES, V83, P1198, DOI 10.1111/j.1349-7006.1992.tb02745.x; VANWIJNEN AJ, 1988, NUCLEIC ACIDS RES, V16, P571, DOI 10.1093/nar/16.2.571; WALKER C, 1992, CANCER RES, V52, P301; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WALSH K, 1987, J BIOL CHEM, V262, P9429; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1994, J BIOL CHEM, V269, P12577; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7	55	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17908	17912		10.1074/jbc.270.30.17908	http://dx.doi.org/10.1074/jbc.270.30.17908			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629096	hybrid			2022-12-25	WOS:A1995RM26600044
J	JAKUBOWSKI, H				JAKUBOWSKI, H			PROOFREADING IN-VIVO - EDITING OF HOMOCYSTEINE BY AMINOACYL-TRANSFER-RNA SYNTHETASES IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSFER-RNA-SYNTHETASE; ASPARAGINYL-TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; PROTEIN-SYNTHESIS; HYDROXY ANALOGS; SEQUENCE; CLONING; GENE; INVIVO; ACIDS	Editing reactions are an essential part of biological information transfer processes that require high accuracy, such as replication, transcription, and translation. The editing in amino acid selection for protein synthesis by an aminoacyl-tRNA synthetase, the first proofreading process discovered in the flow of genetic information, prevents attachment of incorrect amino acids to tRNA. Of numerous editing reactions studied in vitro, only one, editing of homocysteine by methionyl-tRNA synthetase, has also been demonstrated in vivo. It is therefore unclear to what extent editing of errors is physiologically relevant. Here we show that isoleucyl-and leucyl-tRNA synthetases also edit homocysteine by cyclizing it to homocysteine thiolactone in the bacterium Escherichia coli. These and other data also suggest that metabolite compartmentation or channeling governs which synthetase participates in editing in bacterial cells.			JAKUBOWSKI, H (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103, USA.		Jakubowski, Hieronim/AAA-6834-2019; Jakubowski, Hieronim/A-2510-2017	Jakubowski, Hieronim/0000-0001-5845-4409				ANSELME J, 1989, GENE, V84, P481, DOI 10.1016/0378-1119(89)90524-6; BREVET A, 1989, P NATL ACAD SCI USA, V86, P8275, DOI 10.1073/pnas.86.21.8275; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; ENGLISCHPETERS S, 1990, BIOCHEMISTRY-US, V29, P7953, DOI 10.1021/bi00486a025; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1989, NUCLEIC ACIDS RES, V17, P5725, DOI 10.1093/nar/17.14.5725; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, NUCLEIC ACIDS RES, V19, P265, DOI 10.1093/nar/19.2.265; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1250, DOI 10.1021/bi00574a021; FERSHT AR, 1986, ACCURACY MOL PROCESS, P67; GAO WW, 1994, BIOCHEMISTRY-US, V33, P11528, DOI 10.1021/bi00204a015; HARTLEIN M, 1987, NUCLEIC ACIDS RES, V15, P1005, DOI 10.1093/nar/15.3.1005; HARTLEIN M, 1987, NUCLEIC ACIDS RES, V15, P10199, DOI 10.1093/nar/15.24.10199; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1990, P NATL ACAD SCI USA, V87, P4504, DOI 10.1073/pnas.87.12.4504; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; JAKUBOWSKI H, 1994, ANN NY ACAD SCI, V745, P4; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	21	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17672	17673		10.1074/jbc.270.30.17672	http://dx.doi.org/10.1074/jbc.270.30.17672			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629064	hybrid			2022-12-25	WOS:A1995RM26600009
J	POTAPOV, AP; TRIANAALONSO, FJ; NIERHAUS, KH				POTAPOV, AP; TRIANAALONSO, FJ; NIERHAUS, KH			RIBOSOMAL DECODING PROCESSES AT CODONS IN THE A-SITE OR P-SITE DEPEND DIFFERENTLY ON 2'-OH GROUPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA BINDING; ESCHERICHIA-COLI RIBOSOMES; SUGAR-PHOSPHATE BACKBONE; ALLOSTERIC 3-SITE MODEL; ANTICODON INTERACTION; ELONGATION CYCLE; MESSENGER-RNA; TRANSLATION; EFFICIENCY; ACCURACY	The importance of 2'-OH groups of codons for binding of cognate tRNAs to ribosomal P and A sites was analyzed applying the following strategy. An mRNA of 41 nucleotides was synthesized with the structure C-16-GAA-UUG-GUC-C-16 coding for glutamic acid (E), phenylalanine (F) and valine (V), respectively, in the middle (EFV-mRNA). A second template, the E(dF)V-mRNA, was identical except that it carried a deoxyribo-codon-dUdUdC- for phenylalanine. tRNA binding to the P site is totally insensitive to the presence or absence of the 2'-OH group of the P-site codon, and tRNA binding to the P site is also not affected if the A-site codon lacks the 2'-OH groups. However, binding is impaired if the deoxy-codon is present at the E site. In sharp contrast, the A-site binding of Ac-aminoacyl-tRNA was severely reduced in the presence of the deoxy-codon at the A-site as well as at the P site. The results demonstrate that the correctness of base pairing is also ''sensed'' via a correct sugar structure of the codon, e.g. positioning of the sugar pucker (2'-OH), during the decoding process at the A site (elongation) but not during the decoding at the P site (initiation).	MAX PLANCK INST MOLEC GENET, AG RIBSOMEN, D-14195 BERLIN, GERMANY	Max Planck Society								BEYER D, 1994, J BIOL CHEM, V269, P30713; BILGIN N, 1992, J MOL BIOL, V224, P1011, DOI 10.1016/0022-2836(92)90466-W; BOUADLOUN F, 1983, EMBO J, V2, P1351, DOI 10.1002/j.1460-2075.1983.tb01591.x; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; GROSJEAN HJ, 1978, P NATL ACAD SCI USA, V75, P610, DOI 10.1073/pnas.75.2.610; HALL KB, 1993, CURR OPIN STRUC BIOL, V3, P336, DOI 10.1016/S0959-440X(05)80103-4; HARTZ D, 1990, RIBOSOME, P275; HOPFIELD JJ, 1980, RIBOSOMES STRUCTURE, P585; KANG C, 1985, J MOL BIOL, V181, P241, DOI 10.1016/0022-2836(85)90088-9; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; KURLAND CG, 1987, TRENDS BIOCHEM SCI, V12, P126, DOI 10.1016/0968-0004(87)90060-0; LIBBY RT, 1989, EMBO J, V8, P3153, DOI 10.1002/j.1460-2075.1989.tb08469.x; LUHRMANN R, 1979, NATURE, V280, P423, DOI 10.1038/280423a0; MCCARTHY BJ, 1965, P NATL ACAD SCI USA, V54, P880, DOI 10.1073/pnas.54.3.880; MORGAN AR, 1967, J MOL BIOL, V26, P447; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; POTAPOV AP, 1992, BIOCHIMIE, V74, P435, DOI 10.1016/0300-9084(92)90083-Q; POTAPOV AP, 1990, BIOCHIMIE, V72, P345, DOI 10.1016/0300-9084(90)90030-K; POTAPOV AP, 1988, J MOL BIOL, V203, P885, DOI 10.1016/0022-2836(88)90114-3; POTAPOV AP, 1982, FEBS LETT, V146, P5, DOI 10.1016/0014-5793(82)80693-5; POTAPOV AP, 1991, 14TH INT TRNA WORKSH, P202; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; RICKER RD, 1991, NUCLEIC ACIDS RES, V19, P6573, DOI 10.1093/nar/19.23.6573; RUUSALA T, 1982, EMBO J, V1, P741, DOI 10.1002/j.1460-2075.1982.tb01240.x; SALAS J, 1968, J BIOL CHEM, V243, P1012; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4693; SOLDATKIN KO, 1992, BIOCHIM BIOPHYS ACTA, V1130, P38, DOI 10.1016/0167-4781(92)90458-C; THOMPSON RC, 1977, P NATL ACAD SCI USA, V74, P198, DOI 10.1073/pnas.74.1.198; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WURMBACH P, 1979, P NATL ACAD SCI USA, V76, P2143, DOI 10.1073/pnas.76.5.2143; WURMBACH P, 1983, EUR J BIOCHEM, V130, P9	35	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17680	17684		10.1074/jbc.270.30.17680	http://dx.doi.org/10.1074/jbc.270.30.17680			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629066	hybrid			2022-12-25	WOS:A1995RM26600011
J	SCHONEBERG, T; LIU, J; WESS, J				SCHONEBERG, T; LIU, J; WESS, J			PLASMA-MEMBRANE LOCALIZATION AND FUNCTIONAL RESCUE OF TRUNCATED FORMS OF A G-PROTEIN-COUPLED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTORS; BINDING; BACTERIORHODOPSIN; LIGAND; COEXPRESSION; FRAGMENTS; GENES	To test the hypothesis that G protein-coupled receptors consist of multiple autonomous folding domains, the rat m3 muscarinic acetylcholine receptor was ''split'' in all three intracellular (i1-i3) and all three extracellular loops (o2-o4). The six resulting polypeptide pairs (N-i1. C-i1, N-o2. C-o2, etc.) were coexpressed in COS-7 cells and studied for their ability to bind muscarinic ligands and to activate G proteins. In addition, immunocytochemical and ELISA studies were carried out to study the expression and subcellular localization of the individual receptor fragments. Interestingly, all N- and C-terminal receptor fragments studied (except N-i1, which contained only the first transmembrane domain) were found to be localized to the plasma membrane, even when expressed alone. Coexpression of three of the six polypeptide pairs, generated by splitting the m3 muscarinic receptor in the i2, o3, or i3 loop, resulted in receptor complexes (N-i2. C-i2, N-o3. C-o3, and N-i3. C-i3, respectively), which were able to bind muscarinic agonists and antagonists with high affinity. The N-o3. C-o3 and N-i3. C-i3 polypeptide combinations, but not the N-i2. C-i2 complex, were also able to stimulate carbachol-dependent phosphatidyl inositol hydrolysis to a similar maximum extent as the wild type m3 muscarinic receptor. These findings strongly suggest that G protein-coupled receptors are composed of several independent folding units and may shed light on the molecular mechanisms governing receptor assembly and membrane insertion.	NIDDKD, BIOORGAN CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Higuchi R., 1989, PCR TECHNOLOGY, P61; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIAO MJ, 1983, J BIOL CHEM, V258, P9949; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; MORO O, 1993, J BIOL CHEM, V268, P22273; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RAYMOND JR, 1994, AM J PHYSIOL, V266, pF163, DOI 10.1152/ajprenal.1994.266.2.F163; ROSENFELD PJ, 1992, NAT GENET, V1, P85; SAVARESE TM, 1992, BIOCHEM J, V283, P1; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WONG SKF, 1990, J BIOL CHEM, V265, P6219	26	141	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18000	18006						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629108				2022-12-25	WOS:A1995RM26600058
J	ZIMMER, G; KLENK, HD; HERRLER, G				ZIMMER, G; KLENK, HD; HERRLER, G			IDENTIFICATION OF A 40-KDA CELL-SURFACE SIALOGLYCOPROTEIN WITH THE CHARACTERISTICS OF A MAJOR INFLUENZA-C VIRUS RECEPTOR IN A MADIN-DARBY CANINE KIDNEY-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-CONTAINING RECEPTORS; DE-ORTHO-ACETYLATION; HUMAN-MELANOMA CELLS; SIALIC ACIDS; DESTROYING ENZYME; N-ACETYL-9-O-ACETYLNEURAMINIC ACID; LINKED OLIGOSACCHARIDES; POLYACRYLAMIDE GELS; BOVINE CORONAVIRUS; ENDOCYTIC PATHWAY	Infection of cells by influenza C virus is known to be initiated by virus attachment to cell surface glycoconjugates containing N-acetyl-9-O-acetylneuraminic acid. Using an in vitro virus binding assay, we have detected this carbohydrate on several glycoproteins of Madin-Darby canine kidney cells (type I), a polarized epithelial cell line permissive for infection with influenza C virus. Among these proteins, only one was found to be present to a significant extent on the cell surface. This protein, gp40, was characterized as an O-glycosylated (mucin-type) integral membrane protein of 40 kDa, which was predominantly localized on the apical plasma membrane of filter-grown cells. It is a major cell surface sialoglycoprotein in this cell line and was shown to be subject to constitutive and rapid endocytosis. Thus, this glycoprotein can mediate not only the binding of influenza C virus to the cell surface, but also its delivery to endosomes, where penetration occurs by membrane fusion. Other highly sialylated cell surface glycoproteins were also detected but did not mediate influenza C virus binding to a significant extent, indicating that only gp40 contains 9-O-acetylated sialic acids.	UNIV MARBURG, INST VIROL, D-35037 MARBURG, GERMANY	Philipps University Marburg				Zimmer, Gert/0000-0002-2708-2507				BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; CARRAWAY KL, 1992, J CELL SCI, V103, P299; DEH ME, 1985, ANAL BIOCHEM, V150, P166, DOI 10.1016/0003-2697(85)90456-7; DIAZ S, 1989, J BIOL CHEM, V264, P19416; FORMANOWSKI F, 1990, J GEN VIROL, V71, P1181, DOI 10.1099/0022-1317-71-5-1181; GALLAGHER JT, 1985, BIOCHEM J, V231, P115, DOI 10.1042/bj2310115; GOTTSCHALK A, 1949, NATURE, V164, P232, DOI 10.1038/164232a0; Gottschalk A, 1959, VIRUSES, V3, P51; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HERRLER G, 1987, VIROLOGY, V159, P102, DOI 10.1016/0042-6822(87)90352-7; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HERRLER G, 1988, J GEN VIROL, V69, P839, DOI 10.1099/0022-1317-69-4-839; HERRLER G, 1991, ADV VIRUS RES, V40, P213; HERRLER G, 1981, VIROLOGY, V113, P439, DOI 10.1016/0042-6822(81)90173-2; HERRLER G, 1992, J BIOL CHEM, V267, P12501; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HIGA HH, 1985, VIROLOGY, V144, P279, DOI 10.1016/0042-6822(85)90325-3; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KITAME F, 1982, ARCH VIROL, V73, P357, DOI 10.1007/BF01318090; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENTZ TL, 1990, J GEN VIROL, V71, P751, DOI 10.1099/0022-1317-71-4-751; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MERRIL CR, 1979, P NATL ACAD SCI USA, V76, P4335, DOI 10.1073/pnas.76.9.4335; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; OHUCHI M, 1982, J VIROL, V42, P1076, DOI 10.1128/JVI.42.3.1076-1079.1982; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; ROGERS GN, 1983, VIROLOGY, V127, P361, DOI 10.1016/0042-6822(83)90150-2; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SCHAUER R, 1988, BIOL CHEM H-S, V369, P1121, DOI 10.1515/bchm3.1988.369.2.1121; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SCHULTZE B, 1992, J GEN VIROL, V73, P901, DOI 10.1099/0022-1317-73-4-901; SCHULTZE B, 1990, VIRUS RES, V16, P185, DOI 10.1016/0168-1702(90)90022-4; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; STROBL B, 1993, VIROLOGY, V192, P679, DOI 10.1006/viro.1993.1087; SUEYOSHI S, 1988, CARBOHYD RES, V178, P213, DOI 10.1016/0008-6215(88)80113-7; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; SZEPANSKI S, 1992, VIROLOGY, V188, P85, DOI 10.1016/0042-6822(92)90737-A; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526; WANG WC, 1988, J BIOL CHEM, V263, P4576; WILLOUGHBY RE, 1993, GLYCOBIOLOGY, V3, P437, DOI 10.1093/glycob/3.5.437	57	53	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17815	17822		10.1074/jbc.270.30.17815	http://dx.doi.org/10.1074/jbc.270.30.17815			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629082	hybrid			2022-12-25	WOS:A1995RM26600030
J	BEAUDET, L; GROS, P				BEAUDET, L; GROS, P			FUNCTIONAL DISSECTION OF P-GLYCOPROTEIN NUCLEOTIDE-BINDING DOMAINS IN CHIMERIC AND MUTANT PROTEINS - MODULATION OF DRUG-RESISTANCE PROFILES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; BACTERIAL TRANSPORT PROTEINS; CONFER MULTIDRUG RESISTANCE; CYSTIC-FIBROSIS MUTATIONS; ASCITES TUMOR-CELLS; MDR GENE FAMILY; CLASS-II REGION; ESCHERICHIA-COLI; MOUSE MDR1; SUBSTRATE-SPECIFICITY	We wished to determine if the two nucleotide-binding domains (NBD) of P-glycoprotein are functionally equivalent and interchangeable, and if not, which segments and amino acids are important for proper function of each NBD within the context of the C- or N-terminal P-glycoprotein halves, For this, we constructed and tested the biological activity in yeast and mammalian cells of a series of chimeric mdr3 cDNAs in which discrete domains of the N-terminal NBD (NBD1) were replaced by the homologous segments of the C-terminal NBD (NBD2). Although most NBD1 segments could be replaced without loss of P-glycoprotein function, exchange of small segments near the Walker B motif caused a dramatic reduction in Adriamycin, actinomycin D, and colchicine resistance in LR73 cells, as well as in FK506 resistance and STE6 complementation in yeast, Site-directed mutagenesis identified amino acid positions 522-525 (ERGA --> DKGT) and 578 (Thr --> Cys) as essential for proper function of NBD1 in the context of the N-terminal half P-glycoprotein, In addition, the observed phenotype of the mutants (altered drug resistance profile) suggests that these residues may participate directly or indirectly in substrate interactions and are possibly implicated in signal transduction from NBDs to transmembrane domains, the primary sites of drug binding in P-glycoprotein.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA	McGill University								AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CHAN HSL, 1994, HEMATOL ONCOL CLIN N, V8, P383, DOI 10.1016/S0889-8588(18)30178-3; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; DANO K, 1973, BIOCHIM BIOPHYS ACTA, V323, P466, DOI 10.1016/0005-2736(73)90191-0; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1993, BIOCHEMISTRY-US, V32, P9492, DOI 10.1021/bi00087a030; DUDLER R, 1992, J BIOL CHEM, V267, P5882; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GIBBS TW, 1992, MOL GEN GENET, V234, P121, DOI 10.1007/BF00272353; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Gros P, 1993, Int Rev Cytol, V137C, P169; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; HIGGINS FC, 1992, ANN REV CELL BIOL, V8, P67; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; HOOF T, 1994, J BIOL CHEM, V269, P20575; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Innis MA, 1990, PCR PROTOCOLS GUIDE; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINCKE CR, 1991, J BIOL CHEM, V266, P5303; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1993, J BIOL CHEM, V268, P19965; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RAYMOND M, 1994, MOL CELL BIOL, V14, P277, DOI 10.1128/MCB.14.1.277; RIORDAN JR, 1989, SCIENCE, V245, P1066; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SAFA AR, 1992, CANCER INVEST, V10, P295, DOI 10.3109/07357909209032754; SCHURR E, 1989, CANCER RES, V49, P2729; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; Sherman F., 1982, METHODS YEAST GENETI; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SIMON SM, 1994, P NATL ACAD SCI USA, V91, P3497, DOI 10.1073/pnas.91.9.3497; SKOVSGAARD T, 1978, CANCER RES, V38, P4722; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; TANGWAI DF, 1993, BIOCHEMISTRY-US, V32, P6470, DOI 10.1021/bi00076a022; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WU CT, 1991, MOL CELL BIOL, V11, P3940, DOI 10.1128/MCB.11.8.3940	76	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17159	17170		10.1074/jbc.270.29.17159	http://dx.doi.org/10.1074/jbc.270.29.17159			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615512	hybrid			2022-12-25	WOS:A1995RK68900019
J	LEROY, D; SCHMID, N; BEHR, JP; FILHOL, O; PARES, S; GARIN, J; BOURGARIT, JJ; CHAMBAZ, EM; COCHET, C				LEROY, D; SCHMID, N; BEHR, JP; FILHOL, O; PARES, S; GARIN, J; BOURGARIT, JJ; CHAMBAZ, EM; COCHET, C			DIRECT IDENTIFICATION OF A POLYAMINE BINDING DOMAIN ON THE REGULATORY SUBUNIT OF THE PROTEIN-KINASE CASEIN KINASE-2 BY PHOTOAFFINITY-LABELING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR PROTEIN; EPIDERMAL GROWTH-FACTOR; LARGE T-ANTIGEN; BETA-SUBUNIT; II ACTIVITY; POLYAMINOBENZENEDIAZONIUM SALTS; CELL-GROWTH; PHOSPHORYLATION; DNA; ACTIVATION	Phosphorylation of many protein substrates by the protein kinase casein kinase 2 (CK2) is stimulated severalfold in the presence of polyamines such as spermine. Previous experiments have shown that CK2 is a polyamine binding protein and that the regulatory beta subunit is required for this binding activity. To delineate the spermine binding site of CK2, we have applied a photoaffinity labeling method using a tritiated photoactivable analog of spermine, [H-3]sperminediazonium. The photoaffinity labeled beta subunit was cleaved with cyanogen bromide, and two labeled peptides were separated by high performance liquid chromatography. The major one was the peptide T(72)EQAAEM(78) and the minor one was a 22-amino acid peptide comprising residues Ile(98) to Met(119). Thr(72) and His(108) were identified as the labeled amino acids of the Thr(72)-Met(78) and Ile(98) Met(119) peptides, respectively. In the same manner, we succeeded in determining the residue Leu(220) as an alpha subunit residue covalently bound to the probe. The photoaffinity labeling method described here enabled the first elucidation, by direct microsequencing, of a polyamine binding site on CK2 for which we propose a provisional structural model. These observations suggest a possible mechanism for CK2 activation by polyamines at the molecular level.	CEN GRENOBLE, DEPT BIOL MOLEC & STRUCT, CEA, INSERM, U244, F-38054 GRENOBLE 9, FRANCE; FAC PHARM ILLKIRCH, CNRS, UNIT 1386, F-67401 ILLKIRCH GRAFFENSTADEN, FRANCE; INST BIOL STRUCT, CRISTALLOG MACROMOLEC LAB, F-38027 GRENOBLE 1, FRANCE	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)			Filhol-Cochet, Odile/I-3962-2016	Cochet, Claude/0000-0002-1772-4270; Filhol, Odile/0000-0003-1964-7958				ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ALLEN JC, 1983, CELL BIOCHEM FUNCT, V1, P131, DOI 10.1002/cbf.290010302; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BEHR JP, 1989, J CHEM SOC CHEM COMM, P101, DOI 10.1039/c39890000101; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOLDYREFF B, 1994, J BIOL CHEM, V269, P4827; BOLDYREFF B, 1990, ADV MOL GENET, V3, P91; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, X PLOR VERSION 3 1; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; COCHET C, 1983, J BIOL CHEM, V258, P1403; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; FIRZLAFF J M, 1989, New Biologist, V1, P44; GARCIA A, 1990, NUCLEIC ACIDS RES, V18, P89, DOI 10.1093/nar/18.1.89; GOYNS MH, 1982, J THEOR BIOL, V97, P577, DOI 10.1016/0022-5193(82)90359-9; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; HOPKINS D, 1982, S AFR J SCI, V78, P25; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOTZYBAHIBERT F, 1995, ANGEW CHEM INT ED; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MELLGREN RL, 1990, BIOCHIM BIOPHYS ACTA, V1040, P28, DOI 10.1016/0167-4838(90)90142-3; MORENO FJ, 1993, BIOCHEM J, V289, P631, DOI 10.1042/bj2890631; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; POMERANTZ AH, 1975, BIOCHEMISTRY-US, V14, P3858, DOI 10.1021/bi00688a019; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; SCALABRINO G, 1991, MOL CELL ENDOCRINOL, V77, P1, DOI 10.1016/0303-7207(91)90056-X; SCALABRINO G, 1981, ADV CANCER RES, V35, P151, DOI 10.1016/S0065-230X(08)60911-2; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMID N, 1991, BIOCHEMISTRY-US, V30, P4357, DOI 10.1021/bi00231a035; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SRIVENUGOPAL KS, 1985, BIOCHEMISTRY-US, V24, P4766, DOI 10.1021/bi00339a009; TABET M, 1993, J AM CHEM SOC, V115, P3866, DOI 10.1021/ja00063a002; TRAUGH JA, 1990, ADV SEC MESS PHOSPH, V24, P224; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; TUNG HYL, 1985, EUR J BIOCHEM, V149, P305, DOI 10.1111/j.1432-1033.1985.tb08927.x; VOGEL S, 1986, EUR J BIOCHEM, V154, P253, DOI 10.1111/j.1432-1033.1986.tb09390.x; WOLFF J, 1975, J BIOL CHEM, V250, P6897	52	42	44	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17400	17406		10.1074/jbc.270.29.17400	http://dx.doi.org/10.1074/jbc.270.29.17400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615545	hybrid			2022-12-25	WOS:A1995RK68900057
J	RODRIGUEZ, H; DROUIN, R; HOLMQUIST, GP; OCONNOR, TR; BOITEUX, S; LAVAL, J; DOROSHOW, JH; AKMAN, SA				RODRIGUEZ, H; DROUIN, R; HOLMQUIST, GP; OCONNOR, TR; BOITEUX, S; LAVAL, J; DOROSHOW, JH; AKMAN, SA			MAPPING OF COPPER HYDROGEN PEROXIDE-INDUCED DNA-DAMAGE AT NUCLEOTIDE RESOLUTION IN HUMAN GENOMIC DNA BY LIGATION-MEDIATED POLYMERASE CHAIN-REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ENDONUCLEASE-III; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; OXIDATIVE DAMAGE; MAMMALIAN CHROMATIN; OXYGEN RADICALS; ION; 8-HYDROXYGUANINE	The ligation-mediated polymerase chain reaction was used to map the frequency of reactive oxygen species-induced DNA damage at nucleotide resolution in genomic DNA purified from cultured human male fibroblasts, Damaged pyrimidine and purine bases were recognized and cleaved by the Nth and Fpg proteins from Escherichia coli, respectively. Strand breaks and modified bases were induced in vitro by copper ion-mediated reduction of hydrogen peroxide in the presence of ascorbate; reactant concentrations were adjusted to induce lesions at a frequency of 1 per 2-3 kilobases in purified genomic DNA. Glyoxal gel analysis demonstrated that the ratio of induced strand breaks to induced base damage was 0.8/2.7 in DNA dialyzed extensively to remove adventitious transition metal ions. Ligation-mediated polymerase chain reaction analysis of the damage frequency in the promoter region of the transcriptionally active phosphoglycerate kinase (PGK 1) gene revealed that Cu(II)/ascorbate/H2O2 caused DNA base damage by a sequence-dependent mechanism, with the 5' bases of d(pG(n)) and d(pC(n)) being damage hot spots, as were the most internal guanines of d(pGGGCCC) and d(pCCCGGG). Since base damage occurs after formation of a DNA-Cu(I)-H2O2 complex, these data suggest that the local DNA sequence affects formation of DNA-Cu(I)-H2O2 complexes and/or the efficiency of base oxidation during resolution of this complex.	CITY HOPE NATL MED CTR, DEPT MED ONCOL & THERAPEUT RES, DUARTE, CA 91010 USA; CITY HOPE NATL MED CTR, BECKMAN RES INST, DIV BIOL, DUARTE, CA 91010 USA; INST GUSTAVE ROUSSY, CNRS, URA 147, F-94805 VILLEJUIF, FRANCE	City of Hope; City of Hope; Beckman Research Institute of City of Hope; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy				O'Connor, Timothy/0000-0001-5848-3592	NCI NIH HHS [CA-53115] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKMAN SA, 1991, MUTAT RES, V261, P123, DOI 10.1016/0165-1218(91)90058-T; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; ARUOMA OI, 1991, BIOCHEM J, V273, P601, DOI 10.1042/bj2730601; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BRYAN SE, 1976, BIOCHEMISTRY-US, V15, P1667, DOI 10.1021/bi00653a013; CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7; DIZDAROGLU M, 1991, ARCH BIOCHEM BIOPHYS, V285, P317, DOI 10.1016/0003-9861(91)90366-Q; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; DIZDAROGLU M, 1991, ARCH BIOCHEM BIOPHYS, V285, P388, DOI 10.1016/0003-9861(91)90378-V; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; DROUIN R, 1993, CHROMOSOMAL ABERRATI, P10; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; FLOYD RA, 1986, BIOCHEM BIOPH RES CO, V137, P841, DOI 10.1016/0006-291X(86)91156-3; FLOYD RA, 1988, ARCH BIOCHEM BIOPHYS, V262, P266, DOI 10.1016/0003-9861(88)90188-9; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GEIERSTANGER BH, 1991, J BIOL CHEM, V266, P20185; GOLDSTEIN S, 1986, Journal of Free Radicals in Biology and Medicine, V2, P3, DOI 10.1016/0748-5514(86)90117-0; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; IZATT RM, 1971, CHEM REV, V71, P439, DOI 10.1021/cr60273a002; JOHN DCA, 1989, BIOCHEM BIOPH RES CO, V165, P1235, DOI 10.1016/0006-291X(89)92734-4; JOHNSON GRA, 1988, J CHEM SOC FARAD T 1, V84, P501, DOI 10.1039/f19888400501; KAGAWA TF, 1991, J BIOL CHEM, V266, P20175; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KAZAKOV SA, 1988, NATURE, V335, P186, DOI 10.1038/335186a0; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LOEB LA, 1988, P NATL ACAD SCI USA, V85, P3918, DOI 10.1073/pnas.85.11.3918; MACCABEE M, 1994, J MOL BIOL, V236, P514, DOI 10.1006/jmbi.1994.1162; MALINS DC, 1993, CANCER-AM CANCER SOC, V71, P3036, DOI 10.1002/1097-0142(19930515)71:10<3036::AID-CNCR2820711025>3.0.CO;2-P; MASARWA M, 1988, J AM CHEM SOC, V110, P4293, DOI 10.1021/ja00221a031; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; MILNE L, 1993, ARCH BIOCHEM BIOPHYS, V304, P102, DOI 10.1006/abbi.1993.1327; MINCHENKOVA LE, 1967, BIOPOLYMERS, V5, P615, DOI 10.1002/bip.1967.360050703; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; PEZZANO H, 1980, CHEM REV, V80, P366; Pfeifer G P, 1993, Methods Mol Biol, V23, P169; PFEIFER GP, 1993, MUTAT RES, V288, P39, DOI 10.1016/0027-5107(93)90206-U; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PRUTZ WA, 1990, INT J RADIAT BIOL, V58, P215, DOI 10.1080/09553009014551581; SAGRIPANTI JL, 1989, J BIOL CHEM, V264, P1729; SCHNEIDER JE, 1990, NUCLEIC ACIDS RES, V18, P631, DOI 10.1093/nar/18.3.631; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; STOEWE R, 1987, FREE RADICAL BIO MED, V3, P97, DOI 10.1016/S0891-5849(87)80003-5; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TKESHELASHVILI LK, 1991, J BIOL CHEM, V266, P6401; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; WEITZMAN SA, 1990, BLOOD, V76, P655; Willis C E, 1988, Appl Theor Electrophor, V1, P11; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YAMAMOTO K, 1989, J BIOL CHEM, V264, P15435; YAMAMOTO K, 1992, CHEM RES TOXICOL, V5, P440, DOI 10.1021/tx00027a019	63	88	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17633	17640		10.1074/jbc.270.29.17633	http://dx.doi.org/10.1074/jbc.270.29.17633			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615572	hybrid			2022-12-25	WOS:A1995RK68900089
J	LABRECQUE, S; MATLASHEWSKI, GJ				LABRECQUE, S; MATLASHEWSKI, GJ			VIABILITY OF WILD-TYPE P53-CONTAINING AND P53-DEFICIENT TUMOR-CELLS FOLLOWING ANTICANCER TREATMENT - THE USE OF HUMAN PAPILLOMAVIRUS E6 TO TARGET P53	ONCOGENE			English	Note						P53; CELL VIABILITY; ANTICANCER TREATMENT	TRANSFORMED-CELLS; ACTIVATED RAS; EARLY GENES; CANCER; IDENTIFICATION; TRANSCRIPTION; PROTEINS	One of the mechanisms in which anticancer therapies function is to induce cell death by apoptosis. In this regard, the biological activity of p53 may be critical since the presence of p53 appears to play a role in apoptosis following genotoxic stress. In experimental systems using in vitro transformed primary cells, there is a direct correlation between the presence of p53 and apoptosis. For example, E1A/ras-transformed primary mouse fibroblasts are less viable and undergo apoptosis following genotoxic stress if these cells contain a wild type p53. In comparison, similarly transformed cells which are p53-deficient are more viable and will not undergo apoptosis under these conditions. Although these are important observations, it remains to be established whether there exists a similar relationship between the presence of wild type p53 and loss of cell viability following therapy in human tumour cells. One way to address this question is to target wild type p53 in human tumour cells using human papillomavirus E6 which mediates the degradation of wild type p53 through the ubiquitin pathway. In this manner, E6 engineered p53-deficient and parental p53-containing human tumour cells provides an appropriate experimental system in which to determine whether wild type p53 in tumour cells has influence on cell viability following genotoxic anticancer treatments, In the present study, the wild type p53 protein in human fibrosarcoma HT1080 cells were targeted with HPV-18 E6 and the viability of these cells in response to treatment with adriamycin, u.v.-irradiation and gamma-irradiation was examined. Data is presented which shows that p53-containing and p53-deficient cells were equally sensitive to these treatments, These data argue that the wild type p53 in these tumour cells does not cause these cells to be less viable when treated with anticancer agents or u.v.-irradiation, Therefore, the status of p53 alone in tumour cells may not be an indicator of response to anticancer treatments.	MCGILL UNIV, INST PARASITOL, ST ANNE DE BELLEVUE, PQ H9X 3V9, CANADA; MCGILL CANC CTR, MONTREAL, PQ, CANADA	McGill University; McGill University								CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GU ZM, 1994, ONCOGENE, V9, P629; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARX J, 1993, SCIENCE, V262, P1645, DOI 10.1126/science.8259507; MATLASHEWSKI G, 1989, ANTICANCER RES, V9, P1447; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIYASHITA T, 1995, CELL, V80, P293; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1994, ONCOGENE, V9, P1869; RON D, 1994, P NATL ACAD SCI USA, V91, P1985, DOI 10.1073/pnas.91.6.1985; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SHARMA S, 1993, CELL GROWTH DIFFER, V4, P861; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STOREY A, 1994, KERATINOCYTE HDB, P439; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	30	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					387	392						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624152				2022-12-25	WOS:A1995RK95700019
J	GUO, B; BROWN, FM; PHILLIPS, JD; YU, Y; LEIBOLD, EA				GUO, B; BROWN, FM; PHILLIPS, JD; YU, Y; LEIBOLD, EA			CHARACTERIZATION AND EXPRESSION OF IRON REGULATORY PROTEIN-2 (IRP2) - PRESENCE OF MULTIPLE IRP2, TRANSCRIPTS REGULATED BY INTRACELLULAR IRON LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR EXPRESSION; RESPONSIVE ELEMENT; SULFUR CLUSTER; UNTRANSLATED REGION; CYTOSOLIC ACONITASE; PROCESSING FACTOR; PURIFICATION; CLONING	Iron regulatory proteins (IRP1 and IRP2) are RNA-binding proteins that bind to stem-loop structures, termed iron-responsive elements (IREs), present in either the 5'- or 3'-untranslated regions of specific mRNAs. The binding of IRPs to 5'-IREs inhibits translation of mRNA, whereas the binding of IRPs to 3'-IREs stabilizes mRNA. To study the structure and regulation of IRP2, we isolated cDNAs for rat and human IRP2. The derived amino acid sequence of rat IPR2 is 93% identical with that of human IRP2 and is present in lower eukaryotes, indicating that IRP2 is highly conserved, IRP1 and IRP2 share 61% overall amino acid identity, IRP2 is ubiquitously expressed in rat tissues, the highest amounts present in skeletal muscle and heart, IRP2 is encoded by multiple mRNAs of 6.4, 4.0, and 3.7 kilobases, The 3'-untranslated region of rat IRP2 contains multiple polyadenylation signals, two of which could account for the 4.0 kb and 3.7-kb mRNAs, The 3.7-kb mRNA is increased in iron-depleted cells and occurs with a reciprocal decrease in the 6.4-kb transcript, These data suggest that the 3.7-kb mRNA is produced by alternative poly(A) site utilization in iron-depleted cells.	UNIV UTAH,DEPT MED,SALT LAKE CITY,UT 84112; UNIV UTAH,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NCI NIH HHS [CA4201] Funding Source: Medline; NIGMS NIH HHS [GM45201] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BHASKER CR, 1993, J BIOL CHEM, V268, P12699; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CAIRO G, 1994, J BIOL CHEM, V270, P700; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX LA, 1993, BIOCHEMISTRY-US, V32, P4738, DOI 10.1021/bi00069a007; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GUO B, 1994, J BIOL CHEM, V269, P24252; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENDERSON BR, 1994, J BIOL CHEM, V268, P27327; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; MANN KP, 1993, MOL CELL BIOL, V13, P2411, DOI 10.1128/MCB.13.4.2411; MCLAUCHLAN J, 1989, CELL, V59, P1093, DOI 10.1016/0092-8674(89)90765-4; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; PATINO MM, 1992, J BIOL CHEM, V267, P19011; PETERSON ML, 1994, MOL CELL BIOL, V14, P7891, DOI 10.1128/MCB.14.12.7891; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; TANG CK, 1992, J BIOL CHEM, V267, P24466; THEIL EC, 1993, BIOFACTORS, V4, P87; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YU Y, 1992, J BIOL CHEM, V267, P19005; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7; ZHENG LM, 1990, J BIOL CHEM, V265, P2814	43	111	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16529	16535		10.1074/jbc.270.28.16529	http://dx.doi.org/10.1074/jbc.270.28.16529			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622457	hybrid			2022-12-25	WOS:A1995RJ34700013
J	SUQUET, C; MITCHELL, DL; SMERDON, MJ				SUQUET, C; MITCHELL, DL; SMERDON, MJ			REPAIR OF UV-INDUCED (6-4) PHOTOPRODUCTS IN NUCLEOSOME CORE DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-CELLS; PYRIMIDINE(6-4)PYRIMIDONE PHOTOPRODUCTS; CYCLOBUTANE DIMERS; PYRIMIDINE DIMERS; ESCHERICHIA-COLI; HUMAN CHROMATIN; ULTRAVIOLET; DAMAGE; (6-4)PHOTOPRODUCTS; BINDING	Using radioimmunoassays, we examined rates of removal of UV-induced pyrimidine-pyrimidone (6-4) photoproducts ((6-4)PDs) and cyclobutane pyrimidine dimers (CPDs) from 146-base pair nucleosome core DNA (and 166-base pair chromatosome DNA) of confluent human diploid fibroblasts. Dose-response experiments indicate that the yield of (6-4)PDs in core DNA is about 30% that of CPDs in the UV dose range of 0-200 J/m(2). Repair experiments indicate that, at 40 J/m(2), (6-4)PDs are removed much faster (similar to 75% in 2 h) from nucleosome core (and chromatosome) DNA than CPDs (10-15% in 2 h). A slow rate of removal of CPDs is also observed when the UV dose is reduced to 10 J/m(2) (i.e. even when the level of CPDs is less than that of (6-4)PDs at 40 J/m(2)). These results indicate that (a) the accessibility of repair proteins to (6-4)PDs in nucleosomes is markedly different than their accessibility to CPDs and/or (b) repair enzymes are much more efficient at incising and removing (6-4)PDs than CPDs in human chromatin.	UNIV TEXAS,MD ANDERSON CANC CTR,SMITHVILLE,TX 78957	University of Texas System; UTMD Anderson Cancer Center	SUQUET, C (corresponding author), WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164, USA.				NIEHS NIH HHS [ES05914, ES02614] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002614, R01ES002614] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMSTRONG JD, 1992, MUTAT RES, V268, P83, DOI 10.1016/0027-5107(92)90086-H; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; CADET J, 1992, J PHOTOCH PHOTOBIO B, V15, P277, DOI 10.1016/1011-1344(92)85135-H; FRIEDBERG EC, 1994, MUTAT RES, V307, P5, DOI 10.1016/0027-5107(94)90272-0; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GALE JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P411, DOI 10.1111/j.1751-1097.1990.tb01732.x; GALE JM, 1988, J MOL BIOL, V204, P949, DOI 10.1016/0022-2836(88)90054-X; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; Harm W, 1980, BIOL EFFECTS ULTRAVI; HOLBROOK SR, 1988, REV CHEM INTERMED, V10, P71, DOI 10.1007/BF03158339; JENSEN KA, 1990, BIOCHEMISTRY-US, V29, P4773, DOI 10.1021/bi00472a005; LAN SY, 1985, BIOCHEMISTRY-US, V24, P7771, DOI 10.1021/bi00347a041; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MITCHELL DL, 1990, J INVEST DERMATOL, V95, P55, DOI 10.1111/1523-1747.ep12873312; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; MITCHELL DL, 1981, BIOCHIM BIOPHYS ACTA, V655, P54, DOI 10.1016/0005-2787(81)90066-6; MITCHELL DL, 1990, J BIOL CHEM, V265, P5353; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MULLENDERS LHF, 1993, MUTAT RES, V299, P271, DOI 10.1016/0165-1218(93)90103-K; NIGGLI HJ, 1982, BIOCHEM BIOPH RES CO, V105, P1215, DOI 10.1016/0006-291X(82)91098-1; PEHRSON JR, 1992, NUCLEIC ACIDS RES, V20, P1321, DOI 10.1093/nar/20.6.1321; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; REARDON JT, 1993, J BIOL CHEM, V268, P21301; SIDIK K, 1990, CANCER RES, V50, P1613; SMERDON MJ, 1978, BIOCHEMISTRY-US, V17, P2377, DOI 10.1021/bi00605a020; SMERDON MJ, 1982, J BIOL CHEM, V257, P13441; SMERDON MJ, 1989, DNA REPAIR MECHANISM, V182, P271; SUQUET C, 1993, J BIOL CHEM, V268, P23755; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; TAYLOR JS, 1988, BIOCHEMISTRY-US, V27, P7206, DOI 10.1021/bi00419a007; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276	34	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16507	16509		10.1074/jbc.270.28.16507	http://dx.doi.org/10.1074/jbc.270.28.16507			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622452	hybrid			2022-12-25	WOS:A1995RJ34700007
J	MCCOLLAM, L; BONFINI, L; KARLOVICH, CA; CONWAY, BR; KOZMA, LM; BANERJEE, U; CZECH, MP				MCCOLLAM, L; BONFINI, L; KARLOVICH, CA; CONWAY, BR; KOZMA, LM; BANERJEE, U; CZECH, MP			FUNCTIONAL ROLES FOR THE PLECKSTRIN AND DBL HOMOLOGY REGIONS IN THE RAS EXCHANGE FACTOR SON-OF-SEVENLESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR TYROSINE KINASES; GENE-PRODUCT; SH3 DOMAINS; GRB2; PROTEIN; BINDING; P21(RAS); SOS1	Activation of p21(ras) by receptor tyrosine kinases is thought to result from recruitment of guanine nucleotide exchange factors such as Son-of-sevenless (Sos) to plasma membrane receptor substrates via adaptor proteins such as Grb2. This hypothesis was tested in the present studies by evaluating the ability of truncation and deletion mutants of Drosophila (d)Sos to enhance [P-32]GTP loading of p21(ras) when expressed in P-32-labeled COS or 293 cells, The dSos catalytic domain (residues 758-1125), expressed without the dSos NH2-terminal (residues 1-757) or adaptor-binding, COOH-terminal (residues 1126-1596) regions, exhibits intrinsic exchange activity as evidenced by its rescue of mutant Saccharomyces cerevisiae deficient in endogenous GTP/GDP exchange activity, Here we show that this dSos catalytic domain fails to affect GTP.p21(ras) levels when expressed in cultured mammalian cells unless the NH2-terminal domain is also present, Surprisingly, the COOH-terminal, adaptor binding domain of dSos was not sufficient to confer p21(ras) exchange activity to the Sos catalytic domain in these cells in the absence of the NH2-terminal domain. This function of promoting catalytic domain activity could be localized by mutational analysis to the pleckstrin and Dbl homology sequences located just NH2-terminal to the catalytic domain, The results demonstrate a functional role for these pleckstrin and Dbl domains within the dsos protein, and suggest the presence of unidentified cellular elements that interact with these domains and participate in the regulation of p21(ras).	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	MCCOLLAM, L (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NIDDK NIH HHS [P30DK32520, DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520, R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIU BX, 1993, ONCOGENE, V8, P3081; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WANG W, 1995, IN PRESS NATURE GENE; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	34	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					15954	15957		10.1074/jbc.270.27.15954	http://dx.doi.org/10.1074/jbc.270.27.15954			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608150	hybrid			2022-12-25	WOS:A1995RH22600011
J	WILSON, DM; TAKESHITA, M; GROLLMAN, AP; DEMPLE, B				WILSON, DM; TAKESHITA, M; GROLLMAN, AP; DEMPLE, B			INCISION ACTIVITY OF HUMAN APURINIC ENDONUCLEASE (APE) AT ABASIC SITE ANALOGS IN DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; APYRIMIDINIC ENDONUCLEASE; EXONUCLEASE-III; REPAIR ENZYME; IV; PURIFICATION; EXPRESSION; MECHANISM; CLEAVAGE; APN1	The major apurinic/apyrimidinic (AP) endonuclease of human cells, the Ape protein, incises DNA adjacent to abasic sites to initiate DNA repair and counteract the cytotoxic and mutagenic effects of AP sites. Here we address the determinants of Ape AP endonuclease activity using duplex DNA substrates that contain synthetic analogs of AP sites: tetrahydrofuranyl (F), propanediol (P), ethanediol (E), or 2-(aminobutyl)-1,3-propanediol (Q). The last of these, a branched abasic structure, was a poor substrate for which Ape had k(cat) > 1000-fold lower than for F. In contrast, the specificity constant (k(cat)/K-m) for E or P of Ape purified from HeLa cells was only 5-8-fold lower than for F, Positioning a phosphorothioate ester immediately 5' to F inhibited Ape incision activity 20-fold (Rp isomer) or > 10,000-fold (Sp isomer). Although Ape did not have detectable endonuclease activity toward single-stranded substrates or unmodified double-stranded DNA, the enzyme displayed a low level of 3'-exonuclease activity for duplex DNA (<0.03% of its AP endonuclease activity), which was influenced by the reaction conditions. The base positioned opposite F did not dramatically affect the cleavage efficiency of Ape, but an F:F arrangement was cleaved at approximately one-third of the efficiency of F:C. A 3'-mismatch diminished P and E cleavage only slightly and F not at all. A 5'-mismatch reduced the Ape cleavage rate 4-10-fold for F and similar to 100-fold for P and E. A series of substrates with F at different positions along the oligonucleotide showed that Ape requires greater than or equal to 4 base pairs 5' to the abasic site and greater than or equal to 3 base pairs on the 3'-side. The implications of these results for substrate recognition by Ape are discussed.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,BOSTON,MA 02115; SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	Harvard University; Harvard T.H. Chan School of Public Health; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Wilson, David M/AAK-5409-2021	Wilson, David M/0000-0002-8945-0395	NATIONAL CANCER INSTITUTE [R37CA017395, R01CA017395, P01CA047995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER; NCI NIH HHS [CA47995, CA17395] Funding Source: Medline; NIGMS NIH HHS [GM40000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; GILONI L, 1981, J BIOL CHEM, V256, P8608; HARING M, 1994, NUCLEIC ACIDS RES, V22, P2010, DOI 10.1093/nar/22.11.2010; HENNER WD, 1983, J BIOL CHEM, V258, P5198; KANE CM, 1981, J BIOL CHEM, V256, P3405; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; LEVIN JD, 1991, J BIOL CHEM, V266, P22893; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; LINDAHL T, 1993, NATURE, V363, P709; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; NES IF, 1980, EUR J BIOCHEM, V112, P161, DOI 10.1111/j.1432-1033.1980.tb04997.x; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1037; Sambrook J, 1989, MOL CLONING LABORATO; SANDER M, 1993, J BIOL CHEM, V268, P2075; SANDERSON BJS, 1989, BIOCHEMISTRY-US, V28, P3894, DOI 10.1021/bi00435a040; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; SEKI S, 1993, INT J BIOCHEM, V25, P53; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; STEIGHNER RJ, 1990, P NATL ACAD SCI USA, V87, P8350, DOI 10.1073/pnas.87.21.8350; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TAKEUCHI M, 1994, J BIOL CHEM, V269, P21907; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WEISS B, 1976, J BIOL CHEM, V251, P1896; WINTERS TA, 1994, NUCLEIC ACIDS RES, V22, P1866, DOI 10.1093/nar/22.10.1866; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P2573, DOI 10.1093/nar/20.10.2573; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	37	240	248	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16002	16007		10.1074/jbc.270.27.16002	http://dx.doi.org/10.1074/jbc.270.27.16002			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608159	hybrid			2022-12-25	WOS:A1995RH22600020
J	GUSTAFSSON, CM; FALKENBERG, M; SIMONSSON, S; VALADI, H; ELIAS, P				GUSTAFSSON, CM; FALKENBERG, M; SIMONSSON, S; VALADI, H; ELIAS, P			THE DNA LIGANDS INFLUENCE THE INTERACTIONS BETWEEN THE HERPES-SIMPLEX VIRUS-1 ORIGIN-BINDING PROTEIN AND THE SINGLE-STRAND DNA-BINDING PROTEIN, ICP-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL INTERACTION; UL42 PROTEIN; C-TERMINUS; TYPE-1; POLYMERASE; REPLICATION; HELICASE; DOMAIN; PURIFICATION; UL9	The herpes simplex virus type 1 (HSV-1) origin binding protein, OBP, is a DNA helicase specifically stimulated by the viral single strand DNA-binding protein, ICP-8. The stimulation is dependent on direct protein-protein interactions between the C-terminal domain of OBP,Delta OBP, and ICP 8 (Boehmer, P, E,, Craigie, M, C,, Stow, N, D,, and Lehman, I.R. (1994) J. Biol. Chem, 269, 29329-29334). We have now observed that this interaction is dramatically influenced by the nature of the DNA ligand, Stable complexes between Delta OBP, ICP 8, and double stranded DNA,presented either as a specific duplex oligonucleotide or a restriction fragment containing the HSV-1 origin of replication, oriS, can be detected by gel chromatography and gel electrophoresis, In contrast, a single-stranded oligonucleotide, oligo(dT)(65), will completely disrupt the complex between Delta OBP and ICP 8, We therefore suggest that the interaction between Delta OBP and ICP 8 serves to position the single strand DNA-binding protein with high precision onto single-stranded DNA at a replication fork or at an origin of DNA replication.	GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg			Valadi, Hadi/ABH-9766-2020; Simonsson, Stina/R-2699-2016	Valadi, Hadi/0000-0003-3482-2451; Simonsson, Stina/0000-0001-9020-3714; Gustafsson, Claes/0000-0003-3531-8468				ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; BURKE RL, 1985, J BIOL CHEM, V260, P1711; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DIGARD P, 1990, J BIOL CHEM, V265, P17393; DIGARD P, 1993, J VIROL, V67, P398, DOI 10.1128/JVI.67.1.398-406.1993; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTCH RE, 1993, J VIROL, V67, P6945, DOI 10.1128/JVI.67.12.6945-6949.1993; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1992, J BIOL CHEM, V267, P17424; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; ELIAS P, 1990, J BIOL CHEM, V267, P17424; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; FIERER DS, 1995, J BIOL CHEM, V270, P7330, DOI 10.1074/jbc.270.13.7330; GAO M, 1988, VIROLOGY, V163, P319, DOI 10.1016/0042-6822(88)90272-3; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GUPTE SS, 1991, J BIOL CHEM, V266, P11413; GUSTAFSSON CM, 1994, P NATL ACAD SCI USA, V91, P4629, DOI 10.1073/pnas.91.11.4629; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; HAZUDA DJ, 1992, J BIOL CHEM, V267, P17424; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; Kornberg A., 1992, DNA REPLICATION; LEINBACH SS, 1989, BIOCHIM BIOPHYS ACTA, V1008, P281, DOI 10.1016/0167-4781(89)90017-1; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MARTIN DW, 1994, VIROLOGY, V198, P71, DOI 10.1006/viro.1994.1009; MARTINEZ R, 1993, PROTEIN EXPRES PURIF, V4, P32, DOI 10.1006/prep.1993.1005; MCLEAN GW, 1994, J GEN VIROL, V75, P2699, DOI 10.1099/0022-1317-75-10-2699; MONAHAN SJ, 1993, J VIROL, V67, P5922, DOI 10.1128/JVI.67.10.5922-5931.1993; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; RUYCHEAN WT, 1983, J VIROL, V46, P661; RUYCHEAN WT, 1992, J VIROL, V66, P6273; SKALITER R, 1994, P NATL ACAD SCI USA, V91, P10665, DOI 10.1073/pnas.91.22.10665; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STOW ND, 1993, NUCLEIC ACIDS RES, V21, P87, DOI 10.1093/nar/21.1.87; TENNEY DJ, 1993, J VIROL, V67, P534; WANG YS, 1990, J VIROL, V64, P2082, DOI 10.1128/JVI.64.5.2082-2089.1990	42	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19028	19034		10.1074/jbc.270.32.19028	http://dx.doi.org/10.1074/jbc.270.32.19028			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642564	hybrid			2022-12-25	WOS:A1995RN95400052
J	HIROTA, J; MICHIKAWA, T; MIYAWAKI, A; FURUICHI, T; OKURA, I; MIKOSHIBA, K				HIROTA, J; MICHIKAWA, T; MIYAWAKI, A; FURUICHI, T; OKURA, I; MIKOSHIBA, K			KINETICS OF CALCIUM-RELEASE BY IMMUNOAFFINITY-PURIFIED INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN RECONSTITUTED LIPID VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; FUNCTIONAL-CHARACTERIZATION; PERMEABILIZED HEPATOCYTES; ADENINE-NUCLEOTIDES; MOUSE CEREBELLUM; RAT HEPATOCYTES; INSP3 RECEPTOR; SMOOTH-MUSCLE; PURKINJE-CELL; TRISPHOSPHATE	The kinetics of inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release of the immunoaffinity-purified IP3 receptor (IP(3)R), reconstituted into lipid vesicles, was investigated using the fluorescent Ca2+ indicator fluo-3. IP(3)R was purified from mouse cerebellar microsomal fraction by using an immunoaffinity column conjugated with an anti-IP(3)R type 1 (IP(3)R1) antibody. The immunoblotting analysis using monoclonal antibodies against each IP(3)R type showed that the purified IP(3)R is almost homogeneous, composed of IP(3)R1. Ca2+ efflux from the proteoliposomes was monitored as fluorescence changes of 10 mu M fluo-3, whose concentration was high enough to buffer released Ca2+ and to keep deviations of extravesicular free Ca2+ concentration within 30 nM, excluding the possibility of Ca2+-mediated regulation of IP3-induced Ca2+ release. We also examined IP3-induced Ca2+ release using 1 mu M fluo-3, where the deviations of free Ca2+ concentration were within 300 nM. At both fluo-3 concentrations, IP3-induced Ca2+ release showed similar kinetic properties, i.e. little Ca2+ regulation of Ca2+ release was observed in this system. IP3-induced Ca2+ release of the purified IP(3)R exhibited positive cooperativity; the Hill coefficient was 1.8 +/- 0.1. The half-maximal initial rate for Ca2+ release occurred at 100 nM IP3. At the submaximal concentrations of IP3, the purified IP(3)R showed quantal Ca2+ release, indicating that a single type of IP(3)R is capable of producing the phenomenon of quantal Ca2+ release. The profiles of the IP3-induced Ca2+ release of the purified IP(3)R were found to be biexponential with the fast and slow rate constants (k(fast) = 0.3 similar to 0.7 s(-1), k(slow) = 0.03 similar to 0.07 s(-1)), indicating that IP(3)R has two states to release Ca2+. The amount of released Ca2+ by the slow phase was constant over the range of 10-5000 nM IP3 concentrations, whereas that by the fast phase increased in proportion to added IP3. This provides evidence to support the view that the fast phase of Ca2+ release is mediated by the low affinity state and the slow phase by the high affinity state of the IP(3)R. This also suggests that the fast component of Ca2+ release is responsible for the process of quantal Ca2+ release.	TOKYO INST TECHNOL, DEPT BIOENGN, MIDORI KU, YOKOHAMA, KANAGAWA 226, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC NEUROBIOL LAB, TSUKUBA, IBARAKI 305, JAPAN	Tokyo Institute of Technology; RIKEN	HIROTA, J (corresponding author), UNIV TOKYO, INST MED SCI, DEPT MOLEC NEUROBIOL, MINATO KU, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.		Hirota, Junji/O-9315-2019; Hirota, Junji/G-1357-2019; Furuichi, Teiichi/B-5086-2014; Mikoshiba, Katsuhiko/N-7943-2015; Miyawaki, Atsushi/K-3569-2014	Hirota, Junji/0000-0002-5741-0655; Hirota, Junji/0000-0002-5741-0655; Furuichi, Teiichi/0000-0002-9676-1888; Miyawaki, Atsushi/0000-0002-2329-3235				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; COMBETTES L, 1994, SCIENCE, V265, P813, DOI 10.1126/science.8047889; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HIROSE K, 1994, NATURE, V372, P791; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1994, BIOCHEM J, V300, P81, DOI 10.1042/bj3000081; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; PIETRI F, 1990, GASTROEN CLIN BIOL, V14, P710; PIETRI F, 1990, J BIOL CHEM, V265, P17478; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; RICHARDSON A, 1993, J BIOL CHEM, V268, P11528; SOMLYO AV, 1992, J BIOL CHEM, V267, P22316; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1994, FEBS LETT, V349, P191, DOI 10.1016/0014-5793(94)00662-8; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WATRAS J, 1991, J NEUROSCI, V11, P3239; YAMAMOTOHINO M, 1995, NEUROREPORT, V6, P273, DOI 10.1097/00001756-199501000-00012	41	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19046	19051		10.1074/jbc.270.32.19046	http://dx.doi.org/10.1074/jbc.270.32.19046			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642567				2022-12-25	WOS:A1995RN95400055
J	CHEN, CK; INGLESE, J; LEFKOWITZ, RJ; HURLEY, JB				CHEN, CK; INGLESE, J; LEFKOWITZ, RJ; HURLEY, JB			CA2+-DEPENDENT INTERACTION OF RECOVERIN WITH RHODOPSIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; ROD OUTER SEGMENTS; CYCLIC-GMP PHOSPHODIESTERASE; GUANYLATE-CYCLASE; NERVOUS-SYSTEM; RETINAL RODS; FATTY-ACIDS; S-MODULIN; CELLS; PHOSPHORYLATION	Recoverin (Rv) is a myristoylated Ca2+-binding protein present primarily in bovine photoreceptors. It represents a newly identified family of neuronal specific Ca2+-binding proteins that includes neurocalcin, hippocalcin, and guanylyl cyclase-activating protein. To investigate the function of Rv in photoreceptors, we identified proteins that bind immobilized Rv in a Ca2+-dependent manner. Rhodopsin kinase (RK), interphotoreceptor retinoid-binding protein, and tubulin interact with Rv in the presence of Ca2+. The importance of the Rv/RK interaction was further characterized. RK, purified using immobilized Rv as an affinity matrix, catalyzed the light-dependent and Ca2+-independent incorporation of phosphates into rhodopsin when reconstituted with urea-stripped rod outer segment membranes. When only a small fraction (0.04%) of rhodopsin was photolyzed, as many as 700 phosphates were incorporated per photolyzed rhodopsin, a phenomenon known as ''high gain'' phosphorylation. When recoverin was added, the activity of RK became sensitive to free Ca2+, with EC(50) = 3 mu M. The N-terminal myristoyl residue of Rv enhances the inhibitory effect of Rv and introduces cooperativity to the Ca2+-dependent inhibition of rhodopsin phosphorylation. Rv neither interacts with other members of the G-protein-coupled receptor kinase family such as beta-adrenergic receptor kinase 1 nor inhibits beta-adrenergic receptor kinase 1 activity. The specific and Ca2+-dependent Rv/RK interaction is necessary for the inhibitory effect of Rv on rhodopsin phosphorylation and may play an important role in photoreceptor light adaptation.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED & BIOCHEM,DURHAM,NC 27710	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NEI NIH HHS [R01 EY006641, EYO6641] Funding Source: Medline; NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006641] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; BENOVIC JL, 1986, NATURE, V322, P869; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703; CHEN CK, 1994, INVEST OPHTH VIS SCI, V35, P1485; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GORODOVIKOVA EN, 1993, FEBS LETT, V335, P277, DOI 10.1016/0014-5793(93)80746-H; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; GRAYKELLER MP, 1994, NEURON, V13, P1; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KLENCHIN VA, 1994, BIOPHYS J, V66, pA48; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; MILAM AH, 1993, VISUAL NEUROSCI, V10, P1, DOI 10.1017/S0952523800003175; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; SHICHI H, 1978, J BIOL CHEM, V253, P7040; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; YAMAGATA K, 1990, NEURON, V4, P469, DOI 10.1016/0896-6273(90)90059-O; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	44	252	255	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18060	18066		10.1074/jbc.270.30.18060	http://dx.doi.org/10.1074/jbc.270.30.18060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629115	hybrid			2022-12-25	WOS:A1995RM26600066
J	ROSCHE, B; TSHISUAKA, B; FETZNER, S; LINGENS, F				ROSCHE, B; TSHISUAKA, B; FETZNER, S; LINGENS, F			2-OXO-1,2-DIHYDROQUINOLINE 8-MONOOXYGENASE, A 2-COMPONENT ENZYME-SYSTEM FROM PSEUDOMONAS-PUTIDA-86	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-METHOXYBENZOATE O-DEMETHYLASE; BENZOATE 1,2-DIOXYGENASE SYSTEM; COMAMONAS-TESTOSTERONI T-2; IRON SULFUR PROTEINS; RHODOCOCCUS-SPEC B1; SP STRAIN NCIB-9816; MICROBIAL-METABOLISM; OXYGENASE COMPONENT; QUINOLINE OXIDOREDUCTASE; NAPHTHALENE DIOXYGENASE	2-Oxo-1,2-dihydroquinoline 8-monooxygenase, which catalyzes the NADH-dependent oxygenation of 2-oxo-1,2-dihydroquinoline to 8-hydroxy-2-oxo-1,2-dihydroquinoline, is the second enzyme in the quinoline degradation pathway of Pseudomonas putida 86. This enzyme system consists of two inducible protein components, which were purified, characterized, and identified as reductase and oxygenase. The yellow reductase is a monomeric iron-sulfur flavoprotein (M(r), 38,000), containing flavin adenine dinucleotide and plant-type ferredoxin [2Fe-2S]. It transferred electrons from NADH to the oxygenase or to some artificial electron accepters. The red-brown oxygenase (M(r), 330,000) consists of six identical subunits (M(r), 55,000) and was identified as an iron-sulfur protein, possessing about six Rieske-type [2Fe-2S] clusters and additional iron. It was reduced by NADH plus catalytic amounts of reductase. For monooxygenase activity, reductase, oxygenase, NADH, molecular oxygen, and substrate were required. The activity was considerably enhanced by the addition of polyethylene glycol and Fe2+. 2-Oxo-1,2-dihydroquinoline 8-monooxygenase revealed a high substrate specificity toward 2-oxo-1,2-dihydroquinoline, since none of 25 other tested compounds was converted. Based on its physical, chemical, and catalytic properties, we presume 2-oxo-1,2-dihydroquinoline 8-monooxygenase to belong to the class IB multicomponent non-heme iron oxygenases.	UNIV HOHENHEIM,INST MIKROBIOL,D-70593 STUTTGART,GERMANY	University Hohenheim				Fetzner, Susanne/0000-0002-7228-1871				ADRIAN W, 1980, H-S Z PHYSIOL CHEM, V361, P211; ARMSTRONG JM, 1964, BIOCHIM BIOPHYS ACTA, V86, P194; ATKINSON A, 1973, J APPL CHEM BIOTECHN, V23, P517; AXCELL BC, 1975, BIOCHEM J, V146, P173, DOI 10.1042/bj1460173; BABSON AL, 1973, CLIN CHEM, V19, P766; BATIE CJ, 1987, J BIOL CHEM, V262, P1510; BATIE CJ, 1991, CHEM BIOCH FLAVOENZY, P543; BAUDER R, 1990, BIOL CHEM H-S, V371, P1137, DOI 10.1515/bchm3.1990.371.2.1137; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BERGMEYER HU, 1975, Z KLIN CHEM KLIN BIO, V13, P507; BERNHARD.FH, 1973, EUR J BIOCHEM, V35, P126, DOI 10.1111/j.1432-1033.1973.tb02818.x; BERNHARDT FH, 1978, EUR J BIOCHEM, V92, P209, DOI 10.1111/j.1432-1033.1978.tb12739.x; BERNHARDT FH, 1975, EUR J BIOCHEM, V57, P241, DOI 10.1111/j.1432-1033.1975.tb02296.x; BILL E, 1981, EUR J BIOCHEM, V121, P39, DOI 10.1111/j.1432-1033.1981.tb06426.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNEL F, 1988, J BACTERIOL, V170, P4924, DOI 10.1128/jb.170.10.4924-4930.1988; BUNZ PV, 1993, J BACTERIOL, V175, P6467; Cann J R, 1979, Methods Enzymol, V61, P142; ENSLEY BD, 1983, J BACTERIOL, V155, P505, DOI 10.1128/JB.155.2.505-511.1983; ERICKSON BD, 1992, J BACTERIOL, V174, P2903, DOI 10.1128/JB.174.9.2903-2912.1992; FETZNER S, 1993, FEMS MICROBIOL LETT, V112, P151, DOI 10.1111/j.1574-6968.1993.tb06441.x; FETZNER S, 1992, J BACTERIOL, V174, P279, DOI 10.1128/jb.174.1.279-290.1992; FRATER R, 1970, J CHROMATOGR, V50, P469, DOI 10.1016/S0021-9673(00)97974-3; GEARY PJ, 1984, BIOCHEM J, V217, P667, DOI 10.1042/bj2170667; HAAK B, 1995, J BACTERIOL, V177, P667, DOI 10.1128/jb.177.3.667-675.1995; HAIGLER BE, 1990, J BACTERIOL, V172, P457, DOI 10.1128/JB.172.1.457-464.1990; HAIGLER BE, 1990, J BACTERIOL, V172, P465, DOI 10.1128/JB.172.1.465-468.1990; HARAYAMA S, 1986, MOL GEN GENET, V202, P226, DOI 10.1007/BF00331641; HETTRICH D, 1991, BIOL CHEM H-S, V372, P513, DOI 10.1515/bchm3.1991.372.2.513; HOLLAND HL, 1992, ORGANIC SYNTHESIS OX; LOCHER HH, 1991, BIOCHEM J, V274, P833, DOI 10.1042/bj2740833; LOCHER HH, 1991, J BACTERIOL, V173, P3741, DOI 10.1128/JB.173.12.3741-3748.1991; MARKUS A, 1986, J BIOL CHEM, V261, P2883; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; NIELSEN P, 1986, METHOD ENZYMOL, V122, P209, DOI 10.1016/0076-6879(86)22172-2; PESCHKE B, 1991, BIOL CHEM H-S, V372, P1081, DOI 10.1515/bchm3.1991.372.2.1081; POWLOWSKI J, 1990, J BACTERIOL, V172, P6834, DOI 10.1128/jb.172.12.6834-6840.1990; RIBBONS DW, 1970, FEBS LETT, V12, P105, DOI 10.1016/0014-5793(70)80574-9; SARIASLANI FS, 1989, CRIT REV BIOTECHNOL, V9, P170; SAUBER K, 1977, EUR J BIOCHEM, V74, P89, DOI 10.1111/j.1432-1033.1977.tb11370.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHELLENBERG KA, 1958, J BIOL CHEM, V231, P547; SCHICKLE H, SDRE01 PHARM B; SCHWARZ G, 1988, SYST APPL MICROBIOL, V10, P185, DOI 10.1016/S0723-2020(88)80035-3; SCHWARZ G, 1989, BIOL CHEM H-S, V370, P1183, DOI 10.1515/bchm3.1989.370.2.1183; SCHWEIZER D, 1987, J BIOL CHEM, V262, P9340; SHAW JP, 1992, EUR J BIOCHEM, V209, P51, DOI 10.1111/j.1432-1033.1992.tb17260.x; SHUKLA OP, 1986, APPL ENVIRON MICROB, V51, P1332, DOI 10.1128/AEM.51.6.1332-1342.1986; Siegel L M, 1978, Methods Enzymol, V53, P419; SUBRAMANIAN V, 1981, J BIOL CHEM, V256, P2723; SUBRAMANIAN V, 1979, BIOCHEM BIOPH RES CO, V91, P1131, DOI 10.1016/0006-291X(79)91998-3; SUBRAMANIAN V, 1985, J BIOL CHEM, V260, P2355; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; TAKIZAWA N, 1994, J BACTERIOL, V176, P2444, DOI 10.1128/JB.176.8.2444-2449.1994; TSHISUAKA B, 1993, BIOCHEMISTRY-US, V32, P12928, DOI 10.1021/bi00210a047; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; WHITED GM, 1991, J BACTERIOL, V173, P3010, DOI 10.1128/JB.173.9.3010-3016.1991; WHITESTEVENS RH, 1972, J BIOL CHEM, V247, P2358; YAMAGUCHI M, 1980, J BIOL CHEM, V255, P5058; YAMAGUCHI M, 1978, J BIOL CHEM, V253, P8848; YAMAGUCHI M, 1982, J BIOL CHEM, V257, P2497	62	31	33	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17836	17842		10.1074/jbc.270.30.17836	http://dx.doi.org/10.1074/jbc.270.30.17836			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629085	hybrid			2022-12-25	WOS:A1995RM26600033
J	DAVIDSON, WS; RODRIGUEZA, WV; LUNDKATZ, S; JOHNSON, WJ; ROTHBLAT, GH; PHILLIPS, MC				DAVIDSON, WS; RODRIGUEZA, WV; LUNDKATZ, S; JOHNSON, WJ; ROTHBLAT, GH; PHILLIPS, MC			EFFECTS OF ACCEPTOR PARTICLE-SIZE ON THE EFFLUX OF CELLULAR FREE-CHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; LARGE UNILAMELLAR VESICLES; ENDOTHELIAL SURFACE; PERIPHERAL LYMPH; LPA-I; MEMBRANE; CHROMATOGRAPHY; PERMEABILITY; FIBROBLASTS	Several subspecies of human high density lipoprotein (HDL) have been shown to exist, and particle size is one parameter that can be used to distinguish them, Recently, a small HDL subspecies has been described that may be a particularly efficient acceptor of peripheral cell unesterified (free) cholesterol (FC), To address the effects of particle size on the ability of HDL to remove FC from cells, homogeneous, well defined HDL particles were reconstituted (rHDL) that varied in particle diameter within the size range of human HDL particles (7-13 nm), The abilities of each of these particles to remove cellular FC from mouse L-cells and rat Fu5AH hepatoma cells were compared on the basis of their phospholipid (PL) content as well as on a per particle basis, The effect of particle size was also examined using small unilamellar vesicles (SUV) of 25 nm in diameter and large unilamellar vesicles (LUVs) of 70-180 nn in diameter, The SUV were prepared by sonication, and the LUVs were prepared by extrusion techniques, The FC efflux efficiency of these particles (in order of decreasing efficiency) was: rHDL > SUV > LUV when compared on the basis of acceptor PL content across a range of concentrations (i.e. at a given PL concentration for these three acceptor classes, smaller particles were more efficient), The FC efflux differences between the rHDL and the vesicles were not due to the absence of apolipoprotein in the vesicles, No difference was detected among the rHDL of varying size, nor was a difference detected among the LUVs of varying size when compared on the basis of PL content, When the FC efflux data for rHDL and LUVs were normalized on the basis of the number of acceptor particles present at a given PL concentration, a correlation was found between acceptor particle radius and the ability to accept cellular FC with larger particles being the most efficient, However, the dependence of the rate of FC efflux on acceptor particle size was not quantitatively the same within the rHDL and LUV classes of acceptor particles, The dependence of FC efflux on acceptor particle size may reflect differing abilities of the variously sized acceptor particles to access the region very close to the cell plasma membrane where most of the FC removal is expected to occur.	MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129; HAHNEMANN UNIV,PHILADELPHIA,PA 19129	Drexel University; Drexel University				Davidson, William/0000-0003-2756-2989; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, T32HL007443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633, HL07443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGNANI G, 1993, BIOCHEMISTRY-US, V32, P2643, DOI 10.1021/bi00061a024; BARBEE KA, 1994, CIRC RES, V74, P163, DOI 10.1161/01.RES.74.1.163; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARENHOLZ Y, 1984, PHYSL MEMBRANE FLUID, V1, P134; BARRY PH, 1984, PHYSIOL REV, V64, P763, DOI 10.1152/physrev.1984.64.3.763; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHRISTENSEN HN, 1974, ENZYME KINETICS, P50; CLOUGH G, 1991, PROG BIOPHYS MOL BIO, V55, P47, DOI 10.1016/0079-6107(91)90011-G; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; FRANCONE OL, 1990, EUR HEART J, V11, P218, DOI 10.1093/eurheartj/11.suppl_E.218; GERRITY RG, 1977, PROG BIOCHEM PHARM, V14, P134; GOROG P, 1982, BRIT J EXP PATHOL, V63, P447; HALDENBY KA, 1994, J VASC RES, V31, P2, DOI 10.1159/000159025; HAVEL RJ, 1955, J CLIN INVEST, V34, P476; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; HUANG YD, 1993, ARTERIOSCLER THROMB, V13, P445, DOI 10.1161/01.ATV.13.3.445; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1994, J LIPID RES, V35, P860; LEFEVRE M, 1988, J LIPID RES, V29, P1139; LETIZIA JY, 1991, BIOCHEMISTRY-US, V30, P866, DOI 10.1021/bi00217a041; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; MARCEL YL, 1984, EUR J BIOCHEM, V143, P467, DOI 10.1111/j.1432-1033.1984.tb08394.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCLEAN LR, 1984, BIOCHIM BIOPHYS ACTA, V776, P21, DOI 10.1016/0005-2736(84)90246-3; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; RADER DJ, 1991, J LIPID RES, V32, P1849; REICHL D, 1990, EUR HEART J, V11, P230, DOI 10.1093/eurheartj/11.suppl_E.230; RODRIGUEZA WV, 1995, BIOCHEMISTRY-US, V34, P6208, DOI 10.1021/bi00018a025; RODRIGUEZA WV, 1993, BIOCHIM BIOPHYS ACTA, V1153, P9, DOI 10.1016/0005-2736(93)90270-A; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; RYAN US, 1986, FASEB J, V45, P101; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SCHROEDER F, 1991, P SOC EXP BIOL MED, V195, P235; SKIPSKI VP, 1972, BLOOD LIPIDS LIPOPRO, P471; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; THOMAS PD, 1988, BIOCHEM J, V254, P155, DOI 10.1042/bj2540155; WEAST RC, 1983, HDB CHEM PHYSICS, pF40; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; WESTERGAARD H, 1974, J CLIN INVEST, V54, P718, DOI 10.1172/JCI107810; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333	50	115	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17106	17113		10.1074/jbc.270.29.17106	http://dx.doi.org/10.1074/jbc.270.29.17106			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615505	hybrid			2022-12-25	WOS:A1995RK68900012
J	GRUNEWALD, M; KANNER, B				GRUNEWALD, M; KANNER, B			CONFORMATIONAL-CHANGES MONITORED ON THE GLUTAMATE TRANSPORTER GLT-1 INDICATE THE EXISTENCE OF 2 NEUROTRANSMITTER-BOUND STATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ANTIGENIC DETERMINANTS; RAT-BRAIN; MEMBRANE-VESICLES; ACID TRANSPORTER; SYNAPTIC CLEFT; HIGH-AFFINITY; AMINO-ACIDS; RECONSTITUTION; EXPRESSION; ASPARTATE	Membrane vesicles from rat brain have been subjected to trypsin treatment in the absence and presence of substrates of the (Na+ + K+)-coupled L-glutamate transporter GLT-1. The fragments of this transporter have been detected upon immunoblotting employing several antibodies raised against sequences from this transporter. At the amino terminus, initially a fragment of an apparent molecular mass of 30 kDa is generated. This fragment is subsequently cleaved to one of 16 kDa. The generation of these bands is greatly inhibited in the presence of lithium. Moreover, lithium abolishes the positive cooperative activation of the transporter by sodium. The generation of the 30- and 16-kDa fragments is accelerated in the presence of L-glutamate and other transportable analogues, provided sodium is present as well. The 30-kDa fragment also contains an epitope from the loop connecting the putative membrane-spanning alpha-helices 3 and 4. This epitope, in contrast with the amino-terminal one, is destroyed with time. The carboxyl-terminal epitope is predominantly located on a 43-kDa fragment which is slowly converted to one of 35 kDa. This conversion is not inhibited by lithium. It is, however, stimulated by L-glutamate and other transportable analogues, but only in sodium-containing media. Potassium also stimulates this conversion regardless of the presence of L-glutamate. The stimulation of generation of amino- and carboxyl-terminal fragments by L-glutamate is not mimicked by the nontransportable analogue dihydrokainate. However, the analogue blocks the stimulation exerted by L-glutamate. In addition to new experimental information on the trans porters topology, our observations provide novel information on the function of the GLT-1 transporter. Although lithium by itself does not sustain transport, it may occupy one of the sodium sites and be transported. Furthermore, the transporter-glutamate complex appears to exist in at least two states. After the initial binding (suggested to be important for the decay of synaptic glutamate), it undergoes a conformational change which represents, or is tightly associated with, the transport step.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BALCAR VJ, 1972, J NEUROBIOL, V3, P295, DOI 10.1002/neu.480030403; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BOUVIER M, 1992, NATURE, V335, P433; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; FOLCH J, 1957, J BIOL CHEM, V226, P497; HOPP TP, 1983, MOL IMMUNOL, V20, P483, DOI 10.1016/0161-5890(83)90029-9; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P1287; JIANG J, 1989, J BACTERIOL, V171, P5244, DOI 10.1128/jb.171.10.5244-5253.1989; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1993, FEBS LETT, V325, P9599; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; LIAO MJ, 1984, J BIOL CHEM, V259, P4200; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; POCOCK JM, 1988, J NEUROCHEM, V50, P745, DOI 10.1111/j.1471-4159.1988.tb02977.x; RADIAN R, 1985, J BIOL CHEM, V260, P1859; Reimerdes E H, 1976, Methods Enzymol, V45, P26, DOI 10.1016/S0076-6879(76)45005-X; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; SHAFQAT S, 1993, J BIOL CHEM, V268, P14351; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TAGAKI T, 1991, ADV ELECTROPHORESIS, V4, P391; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	40	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					17017	17024		10.1074/jbc.270.28.17017	http://dx.doi.org/10.1074/jbc.270.28.17017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622523	hybrid			2022-12-25	WOS:A1995RJ34700085
J	PALMER, TM; GETTYS, TW; STILES, GL				PALMER, TM; GETTYS, TW; STILES, GL			DIFFERENTIAL INTERACTION WITH AND REGULATION OF MULTIPLE G-PROTEINS BY THE RAT A(3) ADENOSINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITORY G-PROTEIN; DOWN-REGULATION; MOLECULAR-CLONING; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; ACETYLCHOLINE-RECEPTOR; RBL-2H3 CELLS; CHO CELLS; ACTIVATION; DEGRADATION	Interaction of the rat A(3) adenosine receptor (A(3)AR) with G-proteins has been assessed using a stably transfected Chinese hamster ovary cell system. The non-selective AR agonist 5'-N-ethylcarboxamidoadenosine (NECA) increased the labeling of a 41-kDa membrane protein by 4-azidoanilido-[alpha-P-32] guanosine 5'-triphosphate (AA-[P-32]GTP), a photolabile GTP analogue. Subsequent immunoprecipitation of G(i) alpha-subunits indicated that NECA stimulated incorporation of label into both G(i) alpha-2 and G(i) alpha-3. Additional experiments revealed an A(3)AR stimulation of label into G(q) and/or G(11) alpha-subunits, albeit to a lesser degree than that elicited by endogenous P-2U purinergic receptors. No interaction with G(s) could be detected. Sustained cellular exposure to NECA induced A(3)AR desensitization and specific down-regulation of G(i) alpha-3 and G-protein beta-subunits without changing levels of G(i) alpha-2, G(s) alpha, or G(q+11) alpha-subunits. Therefore the A(3)AR can interact with G(i) alpha-2, G(i) alpha-3, and, to some extent, G(q)-like proteins, but sustained agonist exposure downregulates only one of the G-proteins with which it interacts. This is the first description of the differing specificities of A(3)AR/G-protein coupling versus downregulation in situ and provides a potential mechanism by which the A(3)AR could elicit the heterologous desensitization of signaling events mediated by G(i)3.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; MED UNIV S CAROLINA, DEPT MED, CHARLESTON, SC 29425 USA	Duke University; Medical University of South Carolina	PALMER, TM (corresponding author), DUKE UNIV, MED CTR, DEPT MED, BOX 3444, DURHAM, NC 27710 USA.		Palmer, Timothy/E-7290-2013; Palmer, Timothy/C-4975-2009; Gettys, Thomas W/N-1964-2017	Palmer, Timothy/0000-0002-9803-7164; Gettys, Thomas W/0000-0001-7125-7995	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017670, R01HL035134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042486] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL35134, P50HL17670] Funding Source: Medline; NIDDK NIH HHS [DK42486] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADIE EJ, 1994, BIOCHEM J, V300, P709, DOI 10.1042/bj3000709; ALI H, 1990, J BIOL CHEM, V265, P745; CHANG FH, 1989, J BIOL CHEM, V264, P5352; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; EASON MG, 1994, MOL PHARMACOL, V45, P696; FIELDS TA, 1994, BIOCHEMISTRY-US, V33, P6877, DOI 10.1021/bi00188a017; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; GETTYS TW, 1994, ANAL BIOCHEM, V220, P82, DOI 10.1006/abio.1994.1302; GREEN A, 1992, J BIOL CHEM, V267, P3223; GREEN A, 1990, J BIOL CHEM, V265, P5206; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HIDE M, 1991, MOL PHARMACOL, V40, P473; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; KIM GD, 1994, J BIOL CHEM, V269, P19933; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LINDEN J, 1993, MOL PHARMACOL, V44, P524; LONGABAUGH JP, 1989, MOL PHARMACOL, V36, P681; MCKENZIE FR, 1990, J BIOL CHEM, V265, P17084; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; MILLIGAN G, 1989, BIOCHEM J, V262, P643, DOI 10.1042/bj2620643; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; MULLANEY I, 1993, FEBS LETT, V324, P241, DOI 10.1016/0014-5793(93)81401-K; MULLANEY I, 1992, BIOCHEM J, V289, P125; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; OLAH ME, 1994, MOL PHARMACOL, V45, P978; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; Palmer T M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P83; PALMER TM, 1994, MOL PHARMACOL, V45, P1082; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; RAMKUMAR V, 1994, REGULATION CELLULAR, P217; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; SHAH BH, 1994, MOL PHARMACOL, V46, P1; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	40	106	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16895	16902		10.1074/jbc.270.28.16895	http://dx.doi.org/10.1074/jbc.270.28.16895			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622506	hybrid			2022-12-25	WOS:A1995RJ34700067
J	SWEITZER, SM; CALVO, S; KRAUS, MH; FINBLOOM, DS; LARNER, AC				SWEITZER, SM; CALVO, S; KRAUS, MH; FINBLOOM, DS; LARNER, AC			CHARACTERIZATION OF A STAT-LIKE DNA-BINDING ACTIVITY IN DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR-TYROSINE KINASES; TRANSCRIPTION FACTOR; INTERFERON-ALPHA; PHOSPHORYLATION; ACTIVATION; PROTEIN; GAMMA; ISGF3	The cytokine signaling pathways that activate the Janus family of tyrosine kinases (Jaks) and the ''signal transducers and activators of transcription'' (Stats) have been well characterized in mammalian systems. Work shown here provides evidence that an analogous signaling pathway exists in Drosophila melanogaster. Because many of the ligand-receptor pairs in Drosophila have not been fully characterized, it was necessary to bypass the receptor stimulation event that normally triggers intracellular Jak/Stat activation, This was done by treating Drosophila Schneider 2 cells with vanadate/peroxide, which has been shown to closely mimic some signaling events triggered by interferon gamma, including the activation of Jak1, Jak2, and the Stat1 alpha protein. Evidence presented here demonstrates that vanadate/peroxide can induce a gamma response region binding complex in Drosophila Schneider 2 cells, This complex contains two phosphoproteins of 100 and 150 kDa, respectively, and shares many features with the vanadate/peroxide-stimulated binding complex in the mammalian system, Southern blot analysis of genomic DNA using the src homology domain 2 (SH2) of Stat1 alpha confirms the presence of a related gene in the Drosophila genome.	US FDA, DIV CYTOKINE BIOL, BETHESDA, MD 20892 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; RAZ E, 1991, GENETICS, V129, P191; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHILO BZ, 1992, FASEB J, V6, P2915, DOI 10.1096/fasebj.6.11.1322852; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	22	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16510	16513		10.1074/jbc.270.28.16510	http://dx.doi.org/10.1074/jbc.270.28.16510			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622453	hybrid			2022-12-25	WOS:A1995RJ34700008
J	PRICE, BD; HUGHESDAVIES, L; PARK, SJ				PRICE, BD; HUGHESDAVIES, L; PARK, SJ			CDK2 KINASE PHOSPHORYLATES SERINE-315 OF HUMAN P53 IN-VITRO	ONCOGENE			English	Article						P53; CDK2; PHOSPHORYLATION; DNA DAMAGE; TRANSCRIPTION	CELL-CYCLE CONTROL; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; MAMMALIAN-CELLS; GENE; INHIBITION; P34CDC2	DNA damage increases p53 protein levels and activates transcription of the p21 gene. The p21 protein binds to and inhibits cdk2 kinase, causing G1 arrest. Here, we have investigated if a p53 fusion protein is a substrate for cdk2 kinase in vitro. Cdk2 kinase was immunoprecipitated from NIH3T3 cells and allowed to phosphorylate a human p53-GST (glutathione-s-transferase) fusion protein. Cdk2 and cyclin E-cdk2 efficiently phosphorylated both wild-type (wt) and mutant p53-GST. Cdk2 immunoprecipitated from cells in Go and early G1 exhibited minimal p53 kinase activity, whereas cells in S-phase displayed high levels of p53 kinase activity. If NIH3T3 cells were X-ray irradiated to induce DNA damage, cdk2 p53 kinase activity was rapidly inhibited within 1 h, but had recovered by 4 h post irradiation. Mutation of serine 315 of p53 to alanine (p53-S315A) abolished phosphorylation by cdk2 kinase. However, wtp53 and p53-S315A were equally effective at activating transcription when cotransfected with a p53 reporter construct. The results demonstrate that ser 315 of p53 is phosphorylated by cdk2 in vitro. However, ser 315 of wtp53 is not required for transcriptional activity in vivo, suggesting that cdk2 phosphorylation of p53 may be involved in regulating other cellular functions of wtp53.			PRICE, BD (corresponding author), DANA FARBER CANC INST,JOINT CTR RADIAT THERAPY,STRESS PROT GRP,44 BINNEY ST,BOSTON,MA 02115, USA.				NCI NIH HHS [CA64585] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BADER SB, 1992, J CELL PHYSIOL, V151, P56, DOI 10.1002/jcp.1041510110; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHO Y, 1994, NATURE, V265, P346; CROOK T, 1994, EMBO J, V79, P817; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUERBITZ SJ, 1991, SCIENCE, V252, P1708; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIN X, 1993, MOL CELL BIOL, V13, P3291; LOCK RB, 1990, CANCER RES, V50, P3761; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRICE BD, 1994, CANCER RES, V54, P896; PRICE BD, 1993, ONCOGENE, V8, P3055; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEVENSON MA, 1994, CANCER RES, V54, P12; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TARUNINA M, 1993, ONCOGENE, V8, P3165; TISHLER RB, 1993, CANCER RES, V53, P2212; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG W, 1994, CELL GROWTH DIFFER, V5, P705	55	53	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					73	80						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624134				2022-12-25	WOS:A1995RJ29500009
J	FORGE, V; MINTZ, E; CANET, D; GUILLAIN, F				FORGE, V; MINTZ, E; CANET, D; GUILLAIN, F			LUMENAL CA2+ DISSOCIATION FROM THE PHOSPHORYLATED CA2+-ATPASE OF THE SARCOPLASMIC-RETICULUM IS SEQUENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING SITES; ADENOSINE-TRIPHOSPHATASE; BOUND CALCIUM; ATPASE; MECHANISM; AFFINITY; PUMP; CA-2+-ATPASE; FLUORESCENCE; TEMPERATURE	Once two radioactive Ca2+ coming from the cytoplasm are bound to the transport sites of the nonphosphorylated ATPase, excess EGTA induces rapid dissociation of both ions, whereas excess nonradioactive Ca2+ only reaches one of the two bound Ca2+. This difference has been explained assuming that the two Ca2+ sites are in a single file channel in which the superficial Ca2+ is freely exchangeable from the cytoplasm, whereas the deeper Ca2+ is exchangeable only when the superficial site is vacant, The same experiment was done using phosphorylated ATPase to determine whether Ca2+ dissociation toward the lumen is sequential as well, Under conditions that allow ADP-sensitive phosphoenzyme to accumulate (leaky vesicles, 5 degrees C, pH 8, 300 mM KCl), we found the same two pools of Ca2+. Excess EGTA induced dissociation of both ions together with dephosphorylation, Excess nonradioactive Ca2+ induced the exchange of half the radioactive Ca2+ without any effect on the phosphoenzyme level, Our results show a close similarity between the transport sites of the nonphosphorylated and the phosphorylated enzymes, although the orientation, affinities, and dissociation rate constants are different.	CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,BIOPHYS PROT & MEMBRANES SECT,CNRS,UNITE RECH 1290,F-91191 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	FORGE, V (corresponding author), CTR ETUD SACLAY,CEA,F-91191 GIF SUR YVETTE,FRANCE.							ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CUENDA A, 1991, FEBS LETT, V283, P273, DOI 10.1016/0014-5793(91)80606-4; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; FORGE V, 1993, J BIOL CHEM, V268, P10953; FORGE V, 1993, J BIOL CHEM, V268, P10961; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; GUIMARAESMOTTA H, 1980, ARCH BIOCHEM BIOPHYS, V203, P395, DOI 10.1016/0003-9861(80)90192-7; HANEL AM, 1991, BIOCHEMISTRY-US, V30, P11320, DOI 10.1021/bi00111a019; IKEMOTO N, 1974, J BIOL CHEM, V249, P649; INESI G, 1994, BIOPHYS J, V66, P554, DOI 10.1016/S0006-3495(94)80872-0; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PRAGER R, 1979, EUR J BIOCHEM, V97, P239, DOI 10.1111/j.1432-1033.1979.tb13108.x; SHIGEKAWA M, 1979, J BIOL CHEM, V254, P4726; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; VERJOVSKIALMEID.S, 1977, BIOCHEMISTRY-US, V16, P329; VILSEN B, 1992, J BIOL CHEM, V267, P25739; YAMADA S, 1980, J BIOL CHEM, V255, P3108	28	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18271	18276		10.1074/jbc.270.31.18271	http://dx.doi.org/10.1074/jbc.270.31.18271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629146	hybrid			2022-12-25	WOS:A1995RM64200021
J	YANO, T; YAGI, T; SLED, VD; OHNISHI, T				YANO, T; YAGI, T; SLED, VD; OHNISHI, T			EXPRESSION AND CHARACTERIZATION OF THE 66-KILODALTON (NQO3) IRON-SULFUR SUBUNIT OF THE PROTON-TRANSLOCATING NADH-QUINONE OXIDOREDUCTASE OF PARACOCCUS-DENITRIFICANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; ATP SYNTHASE COMPLEX; UBIQUINONE OXIDOREDUCTASE; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; CROSS-LINKING; F0 SUBUNITS; CLUSTERS; DEHYDROGENASE; PROTEIN	The proton translocating NADH-quinone oxidoreductase (NDH-1) of Paracoccus denitrificans is composed of at least 14 dissimilar subunits which are designated NQO1-14 and contains one noncovalently bound FMN and at least five EPR-visible iron-sulfur clusters (N1a, N1b, N2, N3, and N4) as prosthetic groups. Comparison of the deduced primary structures of the subunits with consensus sequences for the cofactor binding sites has predicted that NQO1, NQO2, NQO3, NQO9, and probably NQO6 subunits are cofactor binding subunits. Previously, we have reported that the NQO2 (25 kDa) subunit was overexpressed as a water-soluble protein in Escherichia coli and was found to ligate a single [2Fe-2S] cluster with rhombic symmetry (g(x,y,z) = 1.92, 1.95, and 2.00) (Yano, T., Sled', V. D., Ohnishi, T., and Yagi, T. (1994) Biochemistry 33, 494-499). In the present study, the NQO3 (66 kDa) subunit, which is equivalent to the 75-kDa subunit of bovine heart Complex I, was overexpressed in E. coli. The expressed NQO3 subunit was found predominantly in the cytoplasmic phase and was purified by ammonium sulfate fractionation and anion-exchange chromatography. The chemical analyses and W-visible and EPR spectroscopic studies showed that the expressed NQO3 subunit contains at least two distinct iron-sulfur clusters: a [2Fe-2S] cluster with axial EPR signals (g(perpendicular to,parallel to) = 1.934 and 2.026, and L(perpendicular to,parallel to) = 1.8 and 3.0 millitesla) and a [4Fe-4S] cluster with rhombic symmetry (g(x,y,z) = 1.892, 1.928, and 2.063, and L(x,y,z) = 2.40, 1.55, and 1.75 millitesla). The midpoint redox potentials of [2Fe-2S] and [4Fe-4S] clusters at pH 8.6 are -472 and -391 mV, respectively. The tetranuclear cluster in the isolated NQO3 subunit is sensitive toward oxidants and converts into [3Fe-4S] form. The assignment of these iron-sulfur clusters to those identified in the P. denitrificans NDH-1 enzyme complex and the possible functional role of the NQO3 subunit is discussed.	UNIV PENN, SCH MED, JOHNSON RES FDN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	YANO, T (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA.				NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIGMS NIH HHS [R01GM33712, R01GM30376] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033712, R01GM030376] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BELL SH, 1982, FEBS LETT, V142, P143, DOI 10.1016/0014-5793(82)80238-X; BLUM H, 1980, BIOCHIM BIOPHYS ACTA, V621, P9, DOI 10.1016/0005-2795(80)90057-4; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CROUSE BR, 1994, J BIOL CHEM, V269, P21030; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOEG KA, 1962, ARCH BIOCHEM BIOPHYS, V97, P37, DOI 10.1016/0003-9861(62)90041-3; Dutton P L, 1978, Methods Enzymol, V54, P411; FECKE W, 1994, EUR J BIOCHEM, V220, P551, DOI 10.1111/j.1432-1033.1994.tb18655.x; FORGO JK, 1949, ANAL BIOCHEM, V21, P732; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRAY KA, 1995, IN PRESS ANOXYGENIC; GUIGLIARELLI B, 1985, BIOCHIM BIOPHYS ACTA, V810, P319, DOI 10.1016/0005-2728(85)90216-6; HAN AL, 1988, ARCH BIOCHEM BIOPHYS, V267, P490, DOI 10.1016/0003-9861(88)90055-0; HAN AL, 1989, ARCH BIOCHEM BIOPHYS, V275, P166, DOI 10.1016/0003-9861(89)90360-3; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HEKMAN C, 1991, ARCH BIOCHEM BIOPHYS, V284, P90, DOI 10.1016/0003-9861(91)90268-N; JAWOROWSKI A, 1981, BIOCHEMISTRY-US, V20, P2041, DOI 10.1021/bi00510a047; JOHNSON MK, 1994, ENCY INORGANIC CHEM, P1896; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIF H, 1995, IN PRESS EUR J BIOCH; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASUI R, 1991, J BIOCHEM-TOKYO, V109, P534, DOI 10.1093/oxfordjournals.jbchem.a123416; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEINHARDT SW, 1987, J BIOL CHEM, V262, P9147; MORGAN TV, 1984, FEBS LETT, V167, P137, DOI 10.1016/0014-5793(84)80848-0; OHNISHI T, 1985, J BIOL CHEM, V260, P2782; OHNISHI T, 1981, J BIOL CHEM, V256, P9216; PATEL SD, 1988, BIOCHEM J, V256, P529, DOI 10.1042/bj2560529; PATEL SD, 1988, BIOCHEM J, V256, P521, DOI 10.1042/bj2560521; PRICE MG, 1989, CELL MOTIL CYTOSKEL, V13, P274, DOI 10.1002/cm.970130406; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER K, 1984, EUR J BIOCHEM, V142, P75, DOI 10.1111/j.1432-1033.1984.tb08252.x; SLED VD, 1994, BIOCHEMISTRY-US, V33, P10069, DOI 10.1021/bi00199a034; THOMSON AJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P423, DOI 10.1016/0005-2728(81)90047-5; TRANBETCKE A, 1990, J BACTERIOL, V172, P2920, DOI 10.1128/jb.172.6.2920-2929.1990; UNEMOTO T, 1993, J BIOENERG BIOMEMBR, V25, P385, DOI 10.1007/BF00762464; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; XU XM, 1992, BIOCHEMISTRY-US, V31, P6925, DOI 10.1021/bi00145a009; XU XM, 1992, ARCH BIOCHEM BIOPHYS, V296, P40, DOI 10.1016/0003-9861(92)90542-5; XU XM, 1993, BIOCHEMISTRY-US, V32, P968, DOI 10.1021/bi00054a030; XU XM, 1991, BIOCHEMISTRY-US, V30, P8678, DOI 10.1021/bi00099a027; XU XM, 1991, BIOCHEMISTRY-US, V30, P6422, DOI 10.1021/bi00240a012; YAGI T, 1990, BIOCHEMISTRY-US, V29, P5515, DOI 10.1021/bi00475a015; YAGI T, 1993, J BIOENERG BIOMEMBR, V25, P339, DOI 10.1007/BF00762459; YAGI T, 1986, ARCH BIOCHEM BIOPHYS, V250, P302, DOI 10.1016/0003-9861(86)90731-9; YAGI T, 1992, BIOCHIM BIOPHYS ACTA, V1101, P181, DOI 10.1016/S0005-2728(05)80014-3; YAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P1, DOI 10.1016/0005-2728(93)90182-F; YAMAGUCHI M, 1993, BIOCHEMISTRY-US, V32, P1935, DOI 10.1021/bi00059a008; YANO T, 1994, FEBS LETT, V354, P160, DOI 10.1016/0014-5793(94)01107-9; YANO T, 1994, BIOCHEMISTRY-US, V33, P494, DOI 10.1021/bi00168a014	58	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18264	18270		10.1074/jbc.270.31.18264	http://dx.doi.org/10.1074/jbc.270.31.18264			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629145	hybrid			2022-12-25	WOS:A1995RM64200020
J	BELLIS, SL; MILLER, JT; TURNER, CE				BELLIS, SL; MILLER, JT; TURNER, CE			CHARACTERIZATION OF TYROSINE PHOSPHORYLATION OF PAXILLIN IN-VITRO BY FOCAL ADHESION KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-TRANSFORMED CELLS; SWISS 3T3 CELLS; EXTRACELLULAR-MATRIX; SH3 DOMAINS; PROTEIN; IDENTIFICATION; FIBRONECTIN; VASOPRESSIN; PP125FAK; BOMBESIN	The concomitant tyrosine phosphorylation of the focal adhesion protein, paxillin, and the tyrosine kinase, focal adhesion kinase (FAK), in response to multiple stimuli including integrin-mediated cell adhesion suggests that paxillin phosphorylation is closely coupled to FAK activity. In the present study, we have identified a specific tyrosine residue within paxillin, tyrosine 118 (Tyr-118), that represents the principle site of phospho rylation by FAK in vitro. The identification of this site as a target for FAK phosphorylation was accomplished by immunoprecipitating FAK and performing in vitro kinase assays, using as substrate either glutathione S-transferase (GST)-paxillin fusion proteins containing truncations in paxillin sequence or fusion proteins with phenylalanine substitutions for tyrosine residues. GST-paxillin containing a phenylalanine substitution at Tyr-118 (Y118F) was not phosphorylated by FAK immunoprecipitates; however, this mutant was shown to bind FAK equally as well as the wild type fusion protein. As a first step toward assessing the function of paxillin phosphorylation on Tyr-118, a Y118F paxillin cDNA construct was transiently transfected into NIH 3T3 cells. Similar to wild type paxillin, mutated paxillin localized to focal adhesions, indicating that the phosphorylation of paxillin on Tyr-118 is not essential for the recruitment of paxillin to sites of cell adhesion.	SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R29GM047607] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047607, GM47607] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER CE, 1995, J CELL SCI, V108, P333; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	297	298	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17437	17441		10.1074/jbc.270.29.17437	http://dx.doi.org/10.1074/jbc.270.29.17437			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615549	hybrid			2022-12-25	WOS:A1995RK68900062
J	CALLAHAN, SM; CORNELL, NW; DUNLAP, PV				CALLAHAN, SM; CORNELL, NW; DUNLAP, PV			PURIFICATION AND PROPERTIES OF PERIPLASMIC 3'/5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE - A NOVEL ZINC-CONTAINING ENZYME FROM THE MARINE SYMBIOTIC BACTERIUM VIBRIO-FISCHERI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; DICTYOSTELIUM-DISCOIDEUM; PROTEINS; BINDING; RELEASE	The 3':5'-cyclic nucleotide phosphodiesterase (CNP) of Vibrio fischeri, due to its unusual location in the periplasm, allows this symbiotic bacterium to utilize extracellular 3':5'-cyclic nucleotides (e.g. cAMP) as sole sources of carbon and energy, nitrogen, and phosphorus for growth. The enzyme was purified to apparent homogeneity by a four-step procedure: chloroform shock, ammonium sulfate precipitation, and chromotography on DEAE-Sephacel and Cibacron Blue 3GA-agarose. The active enzyme consists of a single polypeptide with a mass of 34 kDa. At 25 degrees C, it has a pH optimum of 8.25, a K-m for cAMP of 73 mu m, and a V-max of 3700 mu mol of cAMP hydrolyzed/min/mg protein (turnover number of 1.24 x 10(5)/min). The specific activity of the V. fischeri enzyme is approximately 20-fold greater than that of any previously characterized CNP when comparisons of activity are made at the same assay temperature. Activity increases with temperature up to 60 degrees C. The CNP contains 2 atoms of zinc/monomer, and zinc, copper, magnesium, and calcium can restore activity of the apoenzyme 60 varying degrees. The exceptional specific activity of the enzyme and its unusual location in the periplasm support proposals that the enzyme enables the bacterium to scavenge 3':5'-cyclic nucleotides in seawater and that the enzyme plays a role in cAMP-mediated host-symbiont interactions.	WOODS HOLE OCEANOG INST,REDFIELD LAB,DEPT BIOL,WOODS HOLE,MA 02543; MARINE BIOL LAB,WOODS HOLE,MA 02543	Woods Hole Oceanographic Institution; Marine Biological Laboratory - Woods Hole								AMES GF, 1984, J BACTERIOL, V160, P1181, DOI 10.1128/JB.160.3.1181-1183.1984; AMMERMAN JW, 1981, MAR ECOL PROG SER, V5, P85, DOI 10.3354/meps005085; Beavo J., 1990, CYCLIC NUCLEOTIDE PH, P3; Bertini I., 1986, ZINC ENZYMES, P27; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTCHER RW, 1962, J BIOL CHEM, V237, P1244; CHASIN M, 1972, METHODS CYCLIC NUCLE, P169; CORNELL NW, 1972, ANAL BIOCHEM, V47, P203, DOI 10.1016/0003-2697(72)90293-X; Dunlap P.V., 1991, MICROBIAL CELL CELL, P219; DUNLAP PV, 1993, J BACTERIOL, V175, P4615, DOI 10.1128/JB.175.15.4615-4624.1993; DUNLAP PV, 1992, J GEN MICROBIOL, V138, P115, DOI 10.1099/00221287-138-1-115; DVORAK HF, 1968, J BIOL CHEM, V243, P2647; FERSHT A, 1984, ENZYME STRUCTURE MEC, P156; FERSHT A, 1984, ENZYME STRUCTURE MEC, P152; FRANCKO DA, 1989, J PHYCOL, V25, P300, DOI 10.1111/j.1529-8817.1989.tb00126.x; HANSEN RS, 1982, P NATL ACAD SCI-BIOL, V79, P2788, DOI 10.1073/pnas.79.9.2788; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; HORECKER BL, 1948, J BIOL CHEM, V175, P385; Jaffe E. K., 1993, COMMENTS INORG CHEM, V15, P67; KESSIN RH, 1979, P NATL ACAD SCI USA, V76, P5450, DOI 10.1073/pnas.76.11.5450; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIODA L, 1991, BIOCHEMISTRY-US, V30, P2823, DOI 10.1021/bi00225a013; LONDESBOROUGH J, 1983, J BIOL CHEM, V258, P2966; MANNERVIK B, 1986, ZINC ENZYMES, P517; MATIN A, 1982, J BACTERIOL, V149, P801, DOI 10.1128/JB.149.3.801-807.1982; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; OKABAYASHI T, 1970, BIOCHIM BIOPHYS ACTA, V220, P116, DOI 10.1016/0005-2744(70)90235-4; ORLOW SJ, 1981, J BIOL CHEM, V256, P7620; PLOCKE DJ, 1962, BIOCHEMISTRY-US, V1, P373, DOI 10.1021/bi00909a001; REICH KA, 1994, J BACTERIOL, V176, P3085, DOI 10.1128/JB.176.10.3085-3088.1994; RUBY EG, 1992, J BACTERIOL, V174, P4865, DOI 10.1128/JB.174.15.4865-4870.1992; RUBY EG, 1976, BIOL BULL, V151, P574, DOI 10.2307/1540507; SCHAAP P, 1991, MICROBIAL CELL CELL, P147; Sharp GWG, 1971, NATURE, V229, P266, DOI 10.1038/229266a0; ULLMANN A, 1983, ADV CYCL NUCL RES<D>, V15, P1	36	47	49	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17627	17632		10.1074/jbc.270.29.17627	http://dx.doi.org/10.1074/jbc.270.29.17627			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615571	hybrid			2022-12-25	WOS:A1995RK68900088
J	XING, LP; GOPAL, VK; QUINN, PG				XING, LP; GOPAL, VK; QUINN, PG			CAMP RESPONSE ELEMENT-BINDING PROTEIN (CREB) INTERACTS WITH TRANSCRIPTION FACTOR-IIB AND FACTOR-IID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; CYCLIC-AMP; FACTOR-TFIIB; PREINITIATION COMPLEX; ACCURATE INITIATION; ACTIVATION DOMAIN; NUCLEAR-PROTEIN; MINIMAL SET; FACTOR ATF; BASAL	cAMP response element-binding protein (CREB) participates in both constitutive and cAMP-induced transcription of cAMP-responsive genes. CREB-mediated constitutive transcription requires only CREB-binding sites and a minimal promoter region (containing the TATA through start sequences), indicating that CREB interacts directly with components of the general transcription machinery. In this study, a coimmunoprecipitation assay was used to test for interaction of CREB with the general transcription factors (TF) TFIIB and TFIID and the core component of TFIID, TATA-binding protein (TBP). Human TFIIB and TBP, tagged with distinct epitopes (eTFIIB and eTBP), were expressed in and purified from Escherichia coli, and holo-eTFIID, containing eTBP, was obtained from the HeLa cell line LTR alpha 3. S-35-Labeled CREB, synthesized in vitro and incubated with eTFIIB, was coimmunoprecipitated with antibody recognizing eTFIIB, indicating that CREB spe cifically binds to TFIIB. S-35-CREB was coimmunoprecipitated with antibody against eTBP, but only when incubated with the holo eTFIID complex, not with eTBP alone. TFIIB interacted with TBP, but CREB was not coprecipitated with the eTBP antibody when incubated with eTBP plus TFIIB, so CREB did not form a stable ternary complex with TFIIB and TBP. Conversely, depletion of TFIIB from the holo-TFIID preparation did not diminish the level of interaction between CBEB and TFIID. Thus, CREB interacts independently with TFIIB and TFIID, but not directly with TBP. A protein kinase A phosphorylation site mutant of CREB and wild-type CREB exhibited equivalent interaction with TFIIB, indicating that this phosphorylation is not required. Consistent with the role of CREB in promoting constitutive or basal transcription, the constitutive activation domain of CREB was sufficient for interaction with both TFIIB and TFIID.	PENN STATE UNIV, COLL MED, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA; PENN STATE UNIV, COLL MED, PROGRAM CELL & MOLEC BIOL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043871] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43871] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FIRE A, 1984, J BIOL CHEM, V259, P2509; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; ING NH, 1992, J BIOL CHEM, V267, P17617; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RAPOPORT SM, 1986, RETICULOCYTE; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; RUPPERT S, 1993, NATURE, V362, P15; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SMITH CA, 1993, J VIROL, V67, P4676, DOI 10.1128/JVI.67.8.4676-4687.1993; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; XING LP, 1994, J BIOL CHEM, V269, P28732; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	48	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17488	17493		10.1074/jbc.270.29.17488	http://dx.doi.org/10.1074/jbc.270.29.17488			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615553	hybrid			2022-12-25	WOS:A1995RK68900068
J	ZAKUT, R; GIVOL, D				ZAKUT, R; GIVOL, D			THE TUMOR SUPPRESSION FUNCTION OF P21(WAF) IS CONTAINED IN ITS N-TERMINAL HALF (HALF-WAF)	ONCOGENE			English	Note						WAF-1; P53; TUMOR SUPPRESSOR; N-TERMINAL HALF; GENE THERAPY	CYCLIN-DEPENDENT KINASES; P53; GENE	The Waf-1 encoded protein, p21, mediates p53 suppression of tumor cell growth. Overexpression of p21 in the H1299 tumor cell line suppresses colony formation similar to that resulted;from p53 overexpression. In an effort to localize the tumor suppression function within the structure of p21 we utilized vectors constructed with systematic truncations of p21 and tested their efficiency in suppressing tumor cell growth. We demonstrate that the N-terminal half of the p21 molecule (residues 1-80 and 1-89) shows better tumor cell growth suppression than the entire p21 molecule whereas the C-terminal half of p21 does not show this effect, These results may have implications for gene therapy of cancer.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BODNER SM, 1992, ONCOGENE, V7, P743; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY SW, 1994, CANCER RES, V154, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HALEVY O, 1995, SCIENCE, V267, P1024; HARPER JW, 1993, CELL, V75, P805; JIANG HP, 1994, ONCOGENE, V9, P3397; MICHIELI P, 1994, CANCER RES, V54, P3391; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PARKER SB, 1995, SCIENCE, V267, P1018; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SCOTT WL, 1994, SCIENCE, V266, P807; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TOYOSHIMA H, 1994, CELL, V79, P67; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V36, P701	21	41	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					393	395						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624153				2022-12-25	WOS:A1995RK95700020
J	EMILSSON, V; NILSSON, L				EMILSSON, V; NILSSON, L			FACTOR FOR INVERSION STIMULATION-DEPENDENT GROWTH-RATE REGULATION OF SERINE AND THREONINE TRANSFER-RNA SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA SYNTHESIS; COLI FIS PROTEIN; ESCHERICHIA-COLI; GUANOSINE TETRAPHOSPHATE; FEEDBACK-REGULATION; STRINGENT CONTROL; OPERONS; EXPRESSION; TRANSCRIPTION; ACTIVATION	We have previously shown that the accumulation of 20 tRNA species in Escherichia coli is individually regulated as a function of cellular growth rate. We have also reported that the growth rate regulation of some but not all tRNA species is dependent on the activity of the factor for inversion stimulation (FIS). In present work, we studied the growth rate regulation of the serine- and threonine-accepting tRNA families. We show that the levels of tRNA(3)(Thr), tRNA(3)(Ser), tRNA(2)(Thr), tRNA(3)(Thr), and tRNA(4)(Thr) are reduced in fis cells as the growth rate increases. The accumulation of these tRNA species is reduced 2-5-fold at the fastest bacterial growth rate. The strongest effect is observed for the two minor tRNA species; tRNA(2)(Ser) and tRNA(2)(Thr). In contrast, we find that the accumulation of tRNA(1)(Ser), tRNA(5)(Ser), and tRNA(1)(Ser) is similar in wild type and fis bacteria, The data presented provide further evidence for the suggestion that FIS is a stimulating factor that is involved, directly or indirectly, in the high expression level of some tRNA genes at fast bacterial growth rates.	UPPSALA UNIV, BIOMED CTR, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN	Uppsala University				Emilsson, Valur/0000-0001-9982-0524				BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; BARTLETT MS, 1994, J BACTERIOL, V176, P5560, DOI 10.1128/JB.176.17.5560-5564.1994; BOSCH L, 1990, BIOCHIM BIOPHYS ACTA, V1050, P293, DOI 10.1016/0167-4781(90)90184-4; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; CONDON C, 1992, EMBO J, V11, P4175, DOI 10.1002/j.1460-2075.1992.tb05511.x; EMILSSON V, 1990, EMBO J, V9, P4359, DOI 10.1002/j.1460-2075.1990.tb07885.x; EMILSSON V, 1993, J MOL BIOL, V230, P483, DOI 10.1006/jmbi.1993.1165; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; GOURSE RL, 1984, J BACTERIOL, V160, P1022, DOI 10.1128/JB.160.3.1022-1026.1984; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; HERNANDEZ VJ, 1993, J BIOL CHEM, V268, P10851; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; HIASA H, 1994, J BIOL CHEM, V269, P24999; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; KOMINE Y, 1990, J MOL BIOL, V96, P69; LAZARUS LR, 1993, EMBO J, V12, P2483, DOI 10.1002/j.1460-2075.1993.tb05903.x; LECLERC G, 1989, J BACTERIOL, V171, P2090, DOI 10.1128/jb.171.4.2090-2095.1989; Maniatis T., 1982, MOL CLONING; MIZUSHIMASUGANO J, 1985, EMBO J, V4, P1053, DOI 10.1002/j.1460-2075.1985.tb03738.x; MULLIN DA, 1984, CELL, V37, P669, DOI 10.1016/0092-8674(84)90399-4; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NILSSON L, 1990, EMBO J, V9, P727, DOI 10.1002/j.1460-2075.1990.tb08166.x; NILSSON L, 1994, J BIOL CHEM, V269, P9460; NILSSON L, 1992, J BACTERIOL, V174, P921, DOI 10.1128/jb.174.3.921-929.1992; NINNEMANN O, 1992, EMBO J, V11, P1075, DOI 10.1002/j.1460-2075.1992.tb05146.x; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SARUBBI E, 1988, MOL GEN GENET, V213, P214, DOI 10.1007/BF00339584; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; VIND J, 1993, J MOL BIOL, V231, P678, DOI 10.1006/jmbi.1993.1319; ZACHARIAS M, 1990, NUCLEIC ACIDS RES, V18, P6271, DOI 10.1093/nar/18.21.6271	39	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16610	16614		10.1074/jbc.270.28.16610	http://dx.doi.org/10.1074/jbc.270.28.16610			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622468	hybrid			2022-12-25	WOS:A1995RJ34700025
J	SERVETNICK, DA; BRASAEMLE, DL; GRUIAGRAY, J; KIMMEL, AR; WOLFF, J; LONDOS, C				SERVETNICK, DA; BRASAEMLE, DL; GRUIAGRAY, J; KIMMEL, AR; WOLFF, J; LONDOS, C			PERILIPINS ARE ASSOCIATED WITH CHOLESTERYL ESTER DROPLETS IN STEROIDOGENIC ADRENAL-CORTICAL AND LEYDIG-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; ADIPOSE-TISSUE; TUMOR-CELLS; RECEPTORS; ENZYME	Steroidogenic cells store cholesteryl esters, precursors for steroid hormone synthesis, in intracellular lipid droplets. Cholesteryl ester hydrolysis is activated by protein kinase A and catalyzed by cholesteryl esterase. The esterase is similar, if not identical, to hormone-sensitive lipase in adipocytes where an analogous lipolytic mechanism occurs. Perilipins, proteins located exclusively at lipid droplet surfaces in adipocytes, are polyphosphorylated by protein kinase A in response to lipolytic stimuli, suggesting a role for these proteins in mediating lipid metabolism. The present study reveals that perilipins are associated with cholesteryl ester droplets in two steroidogenic cell lines: Y-1 adrenal cortical cells and MA-10 Leydig cells. The relative abundance of perilipin mRNAs and protein is much less in steroidogenic cells than in adipocytes. Like adipocytes, steroidogenic cells express perilipin A; additionally, the latter cells contain relatively abundant amounts of perilipin C, a protein that is not detectable in adipocytes by Western analysis. The data suggest a strong link between perilipins and lipid hydrolysis that is mediated by the hormone sensitive lipase/cholesteryl esterase class of enzymes.	NIDDK,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892; NIDDK,MEMBRANE REGULAT SECT,BETHESDA,MD 20892; NIDDK,MOLEC MECHANISMS DEV SECT,BETHESDA,MD 20892; NIDDK,ENDOCRINE BIOCHEM SECT,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Brasaemle, Dawn/0000-0002-8553-8285				ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BUONASSISI V, 1962, P NATL ACAD SCI USA, V48, P1184, DOI 10.1073/pnas.48.7.1184; COOK KG, 1982, EUR J BIOCHEM, V125, P245, DOI 10.1111/j.1432-1033.1982.tb06675.x; DIXON JL, 1993, J LIPID RES, V34, P167; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; LI WH, 1988, J LIPID RES, V29, P245; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SACKETT DL, 1986, BIOCHIM BIOPHYS ACTA, V888, P163, DOI 10.1016/0167-4889(86)90017-0; STRALFORS P, 1987, ENZYMES B, V18, P147; TEMPLE R, 1973, J BIOL CHEM, V248, P261; YEAMAN SJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P128, DOI 10.1016/0167-4889(90)90067-N	13	159	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16970	16973		10.1074/jbc.270.28.16970	http://dx.doi.org/10.1074/jbc.270.28.16970			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622516	hybrid			2022-12-25	WOS:A1995RJ34700077
J	DESNOS, C; LARAN, MP; LANGLEY, K; AUNIS, D; HENRY, JP				DESNOS, C; LARAN, MP; LANGLEY, K; AUNIS, D; HENRY, JP			LONG-TERM STIMULATION CHANGES THE VESICULAR MONOAMINE TRANSPORTER CONTENT OF CHROMAFFIN GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE BETA-HYDROXYLASE; RAT ADRENAL-MEDULLA; IMMATURE SECRETORY GRANULE; AMINE TRANSPORTER; MESSENGER-RNA; TYROSINE-HYDROXYLASE; SECRETOGRANIN-II; CELLS; MEMBRANE; CATECHOLAMINES	Bovine chromaffin cells cultured for 5 days in the presence of depolarizing concentrations of K+ ions show a decreased number of secretory (chromaffin) granules per cell. These cells were still capable of exocytosis, Their contents in catecholamine and chromogranin A, components of the granule matrix, and cytochrome b(561), a major protein of the granule membrane, were decreased to 35, 30, and 50% of control cells, respectively, However, in the same cells, the number of [H-3]dihydrotetrabenazine binding sites, a specific ligand of the vesicular monoamine transporter, was increased to 180% of controls. In situ uptake of noradrenaline in permeabilized cells indicated that [H-3]dihydrotetrabenazinc binding sites were associated with a functional vesicular monoamine transporter, When analyzed by isopycnic centrifugation, these sites cosedimented with catecholamine, chromogranin A, and cytochrome b(561), in a peak with a density lighter than that from controls, The composition of this peak suggests that it contains incompletely matured secretory granules, with a 3-5-fold increase in the vesicular monoamine transporter content of this membrane, This increase might indicate that an adaptative process occurs which allows a faster filling of the granules in continuously secreting cells.	INST BIOL PHYSICOCHIM,SERV NEUROBIOL PHYSICOCHIM,CNRS,UNITE ASSOCIEE 1112,F-75005 PARIS,FRANCE; CTR NEUROCHIM,INSERM,U338,UNITE BIOL COMMUN CELLULAIRE,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Dominique, Aunis/W-1419-2019; Langley, Keith/M-7516-2014					AHNERTHILGER G, 1993, METHOD ENZYMOL, V221, P139, DOI 10.1016/0076-6879(93)21013-X; ANNAERT WG, 1993, J NEUROCHEM, V60, P1746, DOI 10.1111/j.1471-4159.1993.tb13399.x; ANOUAR Y, 1991, J NEUROENDOCRINOL, V3, P233, DOI 10.1111/j.1365-2826.1991.tb00269.x; BADER MF, 1986, J BIOL CHEM, V261, P5777; BANNON MJ, 1992, P NATL ACAD SCI USA, V89, P7095, DOI 10.1073/pnas.89.15.7095; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; CLIFTOGRADY L, 1990, J CELL BIOL, V10, P1693; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DESNOS C, 1992, J NEUROCHEM, V59, P2105; EIDEN LE, 1984, NATURE, V312, P661, DOI 10.1038/312661a0; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; GAGNON C, 1977, J NEUROCHEM, V28, P853, DOI 10.1111/j.1471-4159.1977.tb10638.x; GASNIER B, 1994, FEBS LETT, V342, P225, DOI 10.1016/0014-5793(94)80506-7; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; HENRY JP, 1989, BIOCHEM PHARMACOL, V38, P2395, DOI 10.1016/0006-2952(89)90082-8; HOPWOOD D, 1971, PROGR HISTOCHEM CYTO, V3, P1; HOWELL M, 1994, FEBS LETT, V338, P16, DOI 10.1016/0014-5793(94)80108-8; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KACSER H, 1974, CONTROL FLUX, P65; KANAMATSU T, 1986, P NATL ACAD SCI USA, V83, P9245, DOI 10.1073/pnas.83.23.9245; KLEY N, 1986, EMBO J, V5, P967, DOI 10.1002/j.1460-2075.1986.tb04310.x; KREJCI E, 1993, FEBS LETT, V335, P27, DOI 10.1016/0014-5793(93)80432-T; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MAHATA SK, 1993, MOL BRAIN RES, V19, P83, DOI 10.1016/0169-328X(93)90152-F; MAHATA SK, 1993, NEUROSCI LETT, V156, P70, DOI 10.1016/0304-3940(93)90442-N; MORO MA, 1991, J NEUROCHEM, V57, P363, DOI 10.1111/j.1471-4159.1991.tb03761.x; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; PATRICK RL, 1971, MOL PHARMACOL, V7, P87; PEYRIN L, 1973, ANAL BIOCHEM, V56, P515, DOI 10.1016/0003-2697(73)90218-2; PHILLIPS JH, 1982, NEUROSCIENCE, V7, P1595, DOI 10.1016/0306-4522(82)90017-3; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SCHERMAN D, 1983, BIOCHEMISTRY-US, V22, P2805, DOI 10.1021/bi00281a006; SCHERMAN D, 1983, P NATL ACAD SCI-BIOL, V80, P584, DOI 10.1073/pnas.80.2.584; SIETZEN M, 1987, NEUROSCIENCE, V22, P131, DOI 10.1016/0306-4522(87)90203-X; STACHOWIAK MK, 1990, BRAIN RES, V510, P277, DOI 10.1016/0006-8993(90)91378-T; THOENEN H, 1974, LIFE SCI, V14, P223, DOI 10.1016/0024-3205(74)90052-6; THOENEN H, 1969, J PHARMACOL EXP THER, V160, P249; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; UNSICKER K, 1983, DEV BRAIN RES, V9, P369, DOI 10.1016/0165-3806(83)90034-2; VONEULER US, 1961, ACTA PHYSL SCAND, V51, P343; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7	43	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16030	16038		10.1074/jbc.270.27.16030	http://dx.doi.org/10.1074/jbc.270.27.16030			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608164	hybrid			2022-12-25	WOS:A1995RH22600025
J	ELSON, A; DENG, CX; CAMPOSTORRES, J; DONEHOWER, LA; LEDER, P				ELSON, A; DENG, CX; CAMPOSTORRES, J; DONEHOWER, LA; LEDER, P			THE MMTV/C-MYC TRANSGENE AND P53 NULL ALLELES COLLABORATE TO INDUCE T-CELL LYMPHOMAS, BUT NOT MAMMARY CARCINOMAS IN TRANSGENIC MICE	ONCOGENE			English	Article						C-MYC; P53; COLLABORATION; T-CELL LYMPHOMA; MAMMARY CARCINOMA	C-MYC; P53-DEFICIENT MICE; BREAST-CANCER; GROWTH-FACTOR; N-MYC; TUMORS; GENE; ONCOGENE; MUTATION; CARCINOGENESIS	A number of properties of the cancer-related genes c-myc and p53 suggest that they might collaborate to induce tumorigenesis, To test this notion, we produced doubly heterozygotic mice bearing disrupted p53 alleles and a fusion transgene consisting of the mouse mammary tumor virus (MMTV) I;TR and the oncogene c-myc. Mice bearing both the MMTV/c-myc transgene and a single p53(-) allele develop very aggressive pre-T- and T-cell lymphomas with a significantly shorter latency than mice carrying either the p53- allele or the c-myc transgene alone, Moreover, every lymphoma occurring in these animals has lost or suffers an inactivation of its wild type p53 allele indicating that loss of p53 activity is necessary for this c-myc-accelerated lymphomagenesis. Nonetheless, p53 inactivation and expression of the MMTV/c-myc transgene are not sufficient for lymphoid transformation, Tumors that arise in homozygous p53(-) mice carrying the c-myc transgene are monoclonal, suggesting that at least one additional event is necessary for their transformation, Moreover, since mice bearing only the MMTV/c-myc transgene predominantly develop mammary carcinomas, it was surprising that the p53(-) allele failed to accelerate the incidence of mammary carcinomas, Further, in contrast to the lymphomas, only one in four mammary tumors that arose in the double heterozygotic mice had lost its wild type p53 allele, Apparently cell context influences the ability of c-myc and p53(-) to cooperate in inducing oncogenesis.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Baylor College of Medicine				Elson, Ari/0000-0001-9808-9135				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; EELES RA, 1993, CANCER SURV, V18, P57; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HARPER JW, 1993, CELL, V75, P805; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU B, 1995, ONCOGENE, V11, P175; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMAMURA J, 1993, CANCER RES, V53, P4053; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KREIPE H, 1993, CANCER RES, V53, P1956; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, BRIT J CANCER, V69, P409; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MOROY T, 1991, ONCOGENE, V6, P1941; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PURDIE CA, 1994, ONCOGENE, V9, P603; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOLZENBERG MC, 1994, ONCOGENE, V9, P2799; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRANGE R, 1992, DEVELOPMENT, V115, P49; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUBURA A, 1988, CANCER RES, V48, P6555; VARLEY JM, 1991, ONCOGENE, V6, P413; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	48	76	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					181	190						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624126				2022-12-25	WOS:A1995RJ29500021
J	MIYASHIRO, I; SENDA, T; MATSUMINE, A; BAEG, GH; KURODA, T; SHIMANO, T; MIURA, S; NODA, T; KOBAYASHI, S; MONDEN, M; TOYOSHIMA, K; AKIYAMA, T				MIYASHIRO, I; SENDA, T; MATSUMINE, A; BAEG, GH; KURODA, T; SHIMANO, T; MIURA, S; NODA, T; KOBAYASHI, S; MONDEN, M; TOYOSHIMA, K; AKIYAMA, T			SUBCELLULAR-LOCALIZATION OF THE APC PROTEIN - IMMUNOELECTRON MICROSCOPIC STUDY OF THE ASSOCIATION OF THE APC PROTEIN WITH CATENIN	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; APC; FAP; CATENIN; COLORECTAL TUMOR	FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; CANCER CELL-LINE; GENE-PRODUCT; MUTATIONS; CHROMOSOME-5Q21; IDENTIFICATION; EXPRESSION; FAP	Mutations in the APC gene are linked to the development of sporadic colorectal tumors as well as to familial adenomatous polyposis, Recently, the APC protein was reported to associate with catenins, proteins that bind to the cell adhesion molecule E-cadherin, In the present study, we examined the distribution and localization of the APC protein and alpha-catenin in the normal mouse intestine by light and immunoelectron microscopy using specific antibodies, The APC protein was found to be localized in microvilli and in the apical and lateral cytoplasm of the epithelial cells, whereas alpha-catenin was detected only in the lateral cytoplasm. Double-labeling immunoelectron microscopy showed colocalization of the APC protein with alpha-catenin in the lateral cytoplasm, especially along the lateral plasma membrane, although a certain portion of the APC protein in this region was distributed independently of alpha-catenin. These results suggest that a portion of the APC protein localized in the lateral cytoplasm of intestinal epithelial cells functions in cooperation with catenins, whereas the APC protein in microvilli and in the apical cytoplasm has other functions independent of catenins.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENSE RES,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 2,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,SCH MED,DEPT ANAT 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN; UNIV TOKYO,INST MED SCI,DEPT PATHOL,MINATO KU,TOKYO 108,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT CELL BIOL,TOSHIMA KU,TOKYO 170,JAPAN	Osaka University; Osaka University; Nagoya University; University of Tokyo; Japanese Foundation for Cancer Research			Baeg, Gyeong-Hun/A-2951-2008; Noda, Tetsuo/B-1667-2016	Kuroda, Toshihiko/0000-0001-6660-8930				BHAT RV, 1994, J NEUROSCI, V14, P3059; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; GARDNER EJ, 1953, AM J HUM GENET, V5, P139; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1994, CANCER RES, V54, P3676; NAGAFUCHI A, 1994, DEV GROWTH DIFFER, V36, P59; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897, DOI 10.1006/bbrc.1993.1710; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SENDA T, 1991, HISTOCHEMISTRY, V96, P25, DOI 10.1007/BF00266757; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1993, CANCER RES, V53, P2728; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z	30	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					89	96						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624136				2022-12-25	WOS:A1995RJ29500011
J	TAKAISHI, K; SASAKI, T; KAMEYAMA, T; TSUKITA, S; TSUKITA, S; TAKAI, Y				TAKAISHI, K; SASAKI, T; KAMEYAMA, T; TSUKITA, S; TSUKITA, S; TAKAI, Y			TRANSLOCATION OF ACTIVATED RHO FROM THE CYTOPLASM TO MEMBRANE RUFFLING AREA, CELL-CELL ADHESION SITES AND CLEAVAGE FURROWS	ONCOGENE			English	Article						SMALL GTP-BINDING PROTEIN; RHOA; ERM FAMILY; CD44; MEMBRANE RUFFLING; CELL-CELL ADHESION; CYTOKINESIS	GTP-BINDING-PROTEIN; BOTULINUM ADP-RIBOSYLTRANSFERASE; SWISS 3T3 CELLS; GENE-PRODUCT; CLOSTRIDIUM-BOTULINUM; FOCAL ADHESIONS; BRAIN CYTOSOL; RIBOSYLATION; PURIFICATION; GDI	Rho small GTP-binding protein regulates various cell functions, such as formation of stress fibers and focal adhesions, cell motility, membrane ruffling, cytokinesis and smooth muscle contraction in mammalian cells and bud formation in the yeast Saccharomyces cerevisiae. As to the functioning sites of Rho in Saccharomyces cerevisiae, we have recently shown that RHO1 protein, a homologue of mammalian RhoA, is concentrated to the growth region of the cells where cortical actin patches are clustered. However, in mammalian cells, the functioning sites of Rho have not yet been studied. In the present study, MDCK cell lines stably expressing myc-tagged RhoA (myc-RhoA) were prepared and localization of myc-RhoA was first immunohistochemically examined using an anti-myc antibody. In the resting cells, almost all of myc-RhoA was observed in the cytosol. When the cells were stimulated with phorbol ester or hepatocyte growth factor, membrane rufflings were induced and myc-RhoA was translocated to the membrane ruffling area. Moreover, myc-RhoA was translocated from the cytosol to the cell-cell adhesion sites when the cells were transferred from a low to normal Ca2+ medium. RhoA was also concentrated to the cleavage furrows during cytokinesis in Swiss 3T3 cells. Translocation of myc-RhoA to the membrane ruffling area was inhibited by prior microinjection into the cells of Rho GDI, a negative regulator of Rho which inhibits activation of Rho, or of C3, an exoenzyme of Clostridium botulinum which ADP-ribosylates Rho and inhibits its functions, indicating that both activation and functioning of Rho are essential for the translocation of Rho. The ERM (Ezrin, Radixin, Moesin) family members were colocalized with RhoA at all of these sites. However, RhoA was not apparently observed at the focal adhesion plaque where vinculin was localized. These results suggest that at least one of the functioning sites of Rho is the ERM family-controlled actin filament/plasma membrane association sites.	OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN; KYOTO UNIV,COLL MED TECHNOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT CELL BIOL,KYOTO 606,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; Kyoto University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)								ABERCROMBIE M, 1970, EXP CELL RES, V60, P437, DOI 10.1016/0014-4827(70)90537-9; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DIPASQUALE A, 1975, EXP CELL RES, V94, P191, DOI 10.1016/0014-4827(75)90545-5; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HIRATA K, 1992, J BIOL CHEM, V267, P8719; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LANG P, 1992, J BIOL CHEM, V267, P11677; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MIURA Y, 1993, J BIOL CHEM, V268, P510; MORII N, 1992, J BIOL CHEM, V267, P20921; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; PAKKANEN R, 1987, J HISTOCHEM CYTOCHEM, V135, P809; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SATO N, 1992, J CELL SCI, V103, P131; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1993, ONCOGENE, V8, P655; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHANG J, 1993, J BIOL CHEM, V268, P22251	50	193	196	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					39	48						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624130				2022-12-25	WOS:A1995RJ29500006
J	CHANG, ZF; HUANG, DY; LAI, TC				CHANG, ZF; HUANG, DY; LAI, TC			DIFFERENT REGULATION OF THE HUMAN THYMIDINE KINASE PROMOTER IN NORMAL HUMAN-DIPLOID IMR-90 FIBROBLASTS AND HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CYCLIN-A; S-PHASE; CANDIDATE ONCOGENE; PROTEIN-BINDING; GENE PROMOTER; IDENTIFICATION; AMPLIFICATION; OVEREXPRESSION; TRANSCRIPTION	Transcriptional activation of the human thymidine kinase (hTK) promoter plays an important role in the cell cycle control of thymidine kinase expression, Using the luciferase reporter cotransfection assay, we found that the activity of the hTK promoter in IMR-90 normal human diploid fibroblasts was increased by the constitutively: over-expressed cyclin A or cyclin E but not by cyclin D, suggesting that the former two cyclins may act as positive regulators for the hTK promoter. The sequence responsible for the transcriptional activation by cyclin E was identified to be located between -133 and -92 of the hTK promoter, Regulation of the hTK promoter in HeLa cells appeared to be different from that in IMR-90 fibroblasts. Firstly, the hTK promoter in HeLa was already highly activated and could not be further activated by ectopically expressed cyclin A or E, Secondly, the -133 to -92 region of the hTK promoter was important for the promoter strength in HeLa cells but not in IMR-90 cells. The steady-state levels of cyclins A and E were readily detected in HeLa cells but not in normal IMR-90 fibroblasts. Based on these results, we propose. that the cellular environment of the HeLa cell allows the hTK promoter to stay fully activated for transcription regardless of ectopically expressed cyclin A or E and that transcriptional activation of thymidine kinase gene is deregulated in these tumor cells.			CHANG, ZF (corresponding author), CHANG GUNG COLL MED & TECHNOL,DEPT BIOCHEM,259 WEN HWA 1 RD,TAYUAN,TAIWAN.							ARCOT SS, 1989, J BIOL CHEM, V264, P2343; BELLO LJ, 1974, EXP CELL RES, V89, P263, DOI 10.1016/0014-4827(74)90790-3; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHANG ZF, 1988, J BIOL CHEM, V263, P11431; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHANG ZF, 1993, CANCER RES, V53, P3253; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; GUDAS JM, 1990, MOL CELL BIOL, V10, P5591, DOI 10.1128/MCB.10.10.5591; HALLEK M, 1992, ANN HEMATOL, V65, P1, DOI 10.1007/BF01715117; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; ITO M, 1990, J BIOL CHEM, V265, P6954; JIANG W, 1992, CANCER RES, V52, P2980; JOHNSON LF, 1982, EXP CELL RES, V138, P79, DOI 10.1016/0014-4827(82)90093-3; KEYOMARSI K, 1994, CANCER RES, V54, P380; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KIM YK, 1992, J BIOL CHEM, V267, P2723; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEACH FS, 1993, CANCER RES, V53, P1986; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Maxam A M, 1980, Methods Enzymol, V65, P499; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0	47	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	1995	270	45					27374	27379		10.1074/jbc.270.45.27374	http://dx.doi.org/10.1074/jbc.270.45.27374			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE583	7593001	hybrid			2022-12-25	WOS:A1995TE58300101
J	HUANG, CC; SPRINGER, TA				HUANG, CC; SPRINGER, TA			A BINDING INTERFACE ON THE I-DOMAIN OF LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 (LFA-1) REQUIRED FOR SPECIFIC INTERACTION WITH INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; BETA-SUBUNIT; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; MEDIATED CYTOLYSIS; COUNTER-RECEPTOR; DISTINCT; INTEGRIN; CLONING; EXPRESSION	Previous studies have shown that lymphocyte function-associated antigen-1 (LFA-1) molecules containing the human alpha (CD11a) and human beta (CD18) subunits but not the murine a and human beta subunits can bind to human intercellular adhesion molecule 1 (ICAM-1). Using human/mouse LFA-1 alpha subunit chimeras, we mapped regions required for binding to ICAM-1 N-terminal to amino acid (aa) residue 359. Ligand binding sites were mapped in greater detail by scanning this region with murine sequences from 56 down to 17 aa in length and finally by introducing single or few murine aa residue replacements into the human sequence. Replacement of two non-contiguous regions of aa residues 119-153 and 218-248 in the I domain with the corresponding mouse sequences abolished most binding to human ICAM-1, without affecting alpha beta subunit association or expression on the surface of transfected COS cells. Specific residues within the I domain found to be important were Met-140, Glu-146, Thr-243, and Ser-245. Using the recently solved structure of the Mac-1 (CD11b) I domain as a model (Lee, J.-O., Rieu, P., Aznaout, M. A., and Liddington, R. (1995) Cell 80, 631-638), these residues are shown to be located on the surface of the I domain surrounding the site to which Mg2+ is chelated, and define a ligand binding interface. Mapping of the epitopes of a panel of mouse anti-human and rat anti-mouse monoclonal antibodies gave concordant results. Epitopes were mapped to two different regions in the N-terminal domain, four regions within the I domain, and two regions between the I domain and the EF handlike repeats. Monoclonal antibodies to epitopes within the mid- to C-terminal portion of the I domain and the N-terminal portion of the region between the I domain and the EF hand-like repeats gave good inhibition of LFA-1-dependent homotypic aggregation with cells that express either ICAM-1 or ICAM-3 as the major LFA-1 ligand.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BILSLAND CAG, 1994, J LEUKOCYTE BIOL, V55, P501, DOI 10.1002/jlb.55.4.501; Casasnovas Jose M., 1994, Methods (Orlando), V6, P157, DOI 10.1006/meth.1994.1018; CHAMPE M, 1995, J BIOL CHEM, V270, P1388, DOI 10.1074/jbc.270.3.1388; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; FISCHER A, 1986, LANCET, V2, P1058; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAUFMANN Y, 1991, J IMMUNOL, V147, P369; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KERN A, 1994, J BIOL CHEM, V269, P22811; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MORIMOTO C, 1987, NATURE, V330, P479, DOI 10.1038/330479a0; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; NAKAMURA Y, 1989, P NATL ACAD SCI USA, V86, P1318, DOI 10.1073/pnas.86.4.1318; OHASHI Y, 1992, TOHOKU J EXP MED, V167, P297, DOI 10.1620/tjem.167.297; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANCHEZMADRID F, 1982, CELL IMMUNOL, V73, P1, DOI 10.1016/0008-8749(82)90431-2; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WARE CF, 1983, J IMMUNOL, V131, P1182; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	53	156	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19008	19016		10.1074/jbc.270.32.19008	http://dx.doi.org/10.1074/jbc.270.32.19008			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642561	hybrid			2022-12-25	WOS:A1995RN95400049
J	KAPOOR, M; ZHANG, LW; RAMACHANDRA, M; KUSUKAWA, J; EBNER, KE; PADMANABHAN, R				KAPOOR, M; ZHANG, LW; RAMACHANDRA, M; KUSUKAWA, J; EBNER, KE; PADMANABHAN, R			ASSOCIATION BETWEEN NS3 AND NS5 PROTEINS OF DENGUE VIRUS TYPE-2 IN THE PUTATIVE RNA REPLICASE IS LINKED TO DIFFERENTIAL PHOSPHORYLATION OF NS5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER VIRUS; ADENOVIRUS DNA-POLYMERASE; SV40 T-ANTIGEN; NF-KAPPA-B; STRUCTURAL PROTEINS; NONSTRUCTURAL PROTEIN; POLYPROTEIN PRECURSOR; VIRAL POLYPROTEIN; NUCLEAR TRANSPORT; INVITRO SYNTHESIS	Dengue virus type 2, a member of the family Flaviviridae, encodes a single polyprotein precursor consisting of 3391 amino acid residues that is processed to at least 10 mature proteins by host and viral proteases. The NS3 protein contains a domain commonly found in cellular serine proteinases that in cooperation with NS2B is involved in polyprotein processing. In addition, NS3 and NS5 proteins contain conserved motifs found in several RNA helicases and RNA-dependent RNA polymerases, respectively. Both enzymatic activities have been suggested to be involved in viral RNA replication. In this report, we demonstrate that the NS3 and NS5 proteins interact in vivo in dengue virus type 2-infected monkey kidney (CV-1) cells and in HeLa cells coinfected with recombinant vaccinia viruses encoding these proteins as shown by coimmunoprecipitations and immunoblotting methods. We also show by immunofluorescence, metabolic labeling, and two-dimensional peptide mapping that NS5 is a nuclear phosphoprotein and that phosphorylation occurs on serine residues at multiple sites. Furthermore, NS5 exists in differentially phosphorylated states in the nuclear and the cytoplasmic fractions, and only the cytoplasmic form of NS5 is found to coimmunoprecipitate with NS3, suggesting that differential phosphorylation may control the interaction between these proteins and its function in the viral RNA replicase.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center				Ramachandra, Murali/0000-0003-4039-1491	NIAID NIH HHS [AI 32078] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032078, R21AI032078] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTHOLOMEUSZ AI, 1993, ARCH VIROL, V128, P111, DOI 10.1007/BF01309792; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUCKLEY A, 1992, J GEN VIROL, V73, P1125, DOI 10.1099/0022-1317-73-5-1125; CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992; CHAMBERS TJ, 1991, J VIROL, V65, P6042, DOI 10.1128/JVI.65.11.6042-6050.1991; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHU PWG, 1987, VIROLOGY, V157, P330, DOI 10.1016/0042-6822(87)90275-3; CHU PWG, 1985, VIROLOGY, V140, P68, DOI 10.1016/0042-6822(85)90446-5; CHU PWG, 1992, J VIROL METHODS, V37, P219, DOI 10.1016/0166-0934(92)90049-J; Earl P, 1991, CURRENT PROTOCOLS MO; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; GRUN JB, 1987, J VIROL, V61, P3641, DOI 10.1128/JVI.61.11.3641-3644.1987; GRUN JB, 1986, J VIROL, V60, P1113, DOI 10.1128/JVI.60.3.1113-1124.1986; IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KNUSUKAWA J, 1994, J BIOL CHEM, V269, P2189; KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBINIEC.AS, 1974, P SOC EXP BIOL MED, V145, P1165; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MARKOFF L, 1989, J VIROL, V63, P3345, DOI 10.1128/JVI.63.8.3345-3352.1989; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NEVINS JR, 1992, SCIENCE, V258, P424; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; RAMACHANDRA M, 1993, J BIOL CHEM, V268, P442; RANSONE LJ, 1989, J VIROL, V63, P4563, DOI 10.1128/JVI.63.11.4563-4568.1989; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; Rice CM., 1986, TOGAVIRIDAE FLAVIVIR, P279, DOI 10.1007/978-1-4757-0785-4_10; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RUIZLINARES A, 1989, J VIROL, V63, P4199, DOI 10.1128/JVI.63.10.4199-4209.1989; SASAGURI Y, 1987, VIROLOGY, V160, P389, DOI 10.1016/0042-6822(87)90010-9; Schlesinger, 1986, TOGAVIRIDAE FLAVIVIR, P327; STOLLAR V, 1967, VIROLOGY, V33, P650, DOI 10.1016/0042-6822(67)90065-7; SVITKIN YV, 1984, VIROLOGY, V135, P536, DOI 10.1016/0042-6822(84)90207-1; TAKEGAMI T, 1989, VIRUS RES, V13, P337; TRENT DW, 1969, J VIROL, V3, P385, DOI 10.1128/JVI.3.4.385-394.1969; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M; WENGLER G, 1978, VIROLOGY, V89, P423, DOI 10.1016/0042-6822(78)90185-X; WESTAWAY EG, 1987, ADV VIRUS RES, V33, P45, DOI 10.1016/S0065-3527(08)60316-4; WESTAWAY EG, 1985, INTERVIROLOGY, V24, P183, DOI 10.1159/000149642; ZHANG L, 1993, GENE, V129, P197, DOI 10.1016/0378-1119(93)90269-9; ZHANG LW, 1992, J VIROL, V66, P7549, DOI 10.1128/JVI.66.12.7549-7554.1992; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	58	267	276	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19100	19106		10.1074/jbc.270.32.19100	http://dx.doi.org/10.1074/jbc.270.32.19100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642575	hybrid			2022-12-25	WOS:A1995RN95400063
J	KHARBANDA, S; SALEEM, A; SHAFMAN, T; EMOTO, Y; TANEJA, N; RUBIN, E; WEICHSELBAUM, R; WOODGETT, J; AVRUCH, J; KYRIAKIS, J; KUFE, D				KHARBANDA, S; SALEEM, A; SHAFMAN, T; EMOTO, Y; TANEJA, N; RUBIN, E; WEICHSELBAUM, R; WOODGETT, J; AVRUCH, J; KYRIAKIS, J; KUFE, D			IONIZING-RADIATION STIMULATES A GRB2-MEDIATED ASSOCIATION OF THE STRESS-ACTIVATED PROTEIN-KINASE WITH PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; MYELOID-LEUKEMIA CELLS; C-JUN GENE; SH3 DOMAINS; GRB2; BINDS; PHOSPHORYLATION; EXPRESSION	The stress-activated protein (SAP) kinases are induced by tumor necrosis factor, oncoproteins, and UV light. The present studies demonstrate that ionizing radiation (IR) activates p54 SAP kinase. IR-induced activation of SAP kinase is associated with binding to the SH2/SH3-containing adaptor protein Grb2, This interaction is mediated by the SH3 domains of Grb2 and the proline-rich sequence PPPKIP in the carboxyl terminal region of SAP kinase, We also demonstrate that SAP kinase and the p85 alpha-subunit of phosphatidylinositol (PI) 3-kinase form a complex in irradiated cells, The results indicate that this complex involves binding of the p85 alpha subunit of PI 3-kinase to the SH2 domain of Grb2. The functional role of linking SAP kinase to PI 3-kinase is further supported by the finding that wortmannin, an inhibitor of PI 3-kinase, stimulates SAP kinase activity. These results suggest that the cellular response to IR may include regulation of SAP kinase by a PI 3-kinase-dependent signaling pathway.	HARVARD UNIV,DANA FARBER CANC INST,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP EAST,DIABET RES LAB,MED SRV,BOSTON,MA 02129; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637; UNIV TORONTO,ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; University of Chicago; University of Toronto; University Toronto Affiliates; University Health Network Toronto	KHARBANDA, S (corresponding author), HARVARD UNIV,DANA FARBER CANC INST,DIV CANC PHARMACOL,44 BINNEY ST,BOSTON,MA 02115, USA.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797	NCI NIH HHS [CA55241] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P128; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KHARBANDA SM, 1990, J CLIN INVEST, V86, P1517, DOI 10.1172/JCI114870; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAM K, 1994, J BIOL CHEM, V269, P20648; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUBIN E, 1991, MOL PHARMACOL, V39, P697; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SALEEM A, 1995, J BIOL CHEM, V270, P10380, DOI 10.1074/jbc.270.18.10380; SALEEM A, 1995, J IMMUNOL, V154, P4150; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Wymann M. P., 1993, BIOCHEM J, V296, P297; YAN MH, 1994, NATURE, V372, P798; YANO H, 1993, J BIOL CHEM, V268, P25846	33	74	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18871	18874		10.1074/jbc.270.32.18871	http://dx.doi.org/10.1074/jbc.270.32.18871			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642542	Green Submitted, hybrid			2022-12-25	WOS:A1995RN95400029
J	XIA, Y; ZWEIER, JL				XIA, Y; ZWEIER, JL			SUBSTRATE CONTROL OF FREE-RADICAL GENERATION FROM XANTHINE-OXIDASE IN THE POSTISCHEMIC HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPERFUSION INJURY; MYOCARDIAL ISCHEMIA; INFARCT SIZE; ALLOPURINOL; MECHANISM; TISSUES; DAMAGE; ENZYME	While the free radical-generating enzyme xanthine oxidase is a central mechanism of injury in postischemic tissues, questions remain regarding how xanthine oxidase-mediated radical generation is triggered during ischemia and reperfusion. There is controversy regarding whether radical generation is caused by enzyme formation or that of its substrates xanthine and hypo xanthine. Therefore, studies were performed in isolated rat hearts correlating the magnitude and time course of radical generation with alterations in xanthine oxidase and its substrates. Radical generation was measured by electron paramagnetic resonance spectroscopy and correlated with spectrophotometric assays of tissue xanthine oxidase activity and chromatographic measurement of tissue and effluent concentrations of xanthine oxidase substrates and products. Xanthine oxidase was present in preischemic hearts and slightly increased during 30-min global ischemia. Hypoxanthine and xanthine were not present prior to ischemia but accumulated greatly during ischemia due to ATP degradation. These substrate concentrations rapidly declined over the first 5 min of reperfusion matching the observed time course of radical generation, whereas xanthine oxidase activity was largely unchanged. Both substrates were also observed in the coronary effluent during the first 5 min of reflow along with the product uric acid. Thus, the burst of xanthine oxidase-mediated free radical generation upon reperfusion is triggered and its time course controlled by a large increase in substrate formation that occurs secondary to the degradation of ATP during ischemia.	JOHNS HOPKINS MED INST, JOHNS HOPKINS BAYVIEW MED CTR, JOHNS HOPKINS ASTHMA & ALLERGY CTR, BALTIMORE, MD 21224 USA; JOHNS HOPKINS MED INST, JOHNS HOPKINS BAYVIEW MED CTR, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [HL-38324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038324, R01HL038324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELFATTAH AS, 1988, CIRCULATION, V78, P224; ABDELFATTAH AS, 1990, CIRCULATION, V82, P341; ABDELFATTAH AS, 1987, CARDIOVASC DRUG THER, V1, P210; ACKERMAN E, 1962, BIOCHIM BIOPHYS ACTA, V56, P397, DOI 10.1016/0006-3002(62)90591-7; ADKISON D, 1986, ACTA PHYSIOL SCAND, V126, P101; AMBROSIO G, 1986, CIRCULATION, V74, P1424, DOI 10.1161/01.CIR.74.6.1424; ARROYO CM, 1987, FEBS LETT, V221, P101, DOI 10.1016/0014-5793(87)80360-5; CERUTTI PA, 1988, OXYRADICALS MOL BIOL, P1; CHAMBERS DE, 1985, J MOL CELL CARDIOL, V17, P145, DOI 10.1016/S0022-2828(85)80017-1; CHAMBERS DJ, 1987, ANN THORAC SURG, V44, P291, DOI 10.1016/S0003-4975(10)62076-0; COUDRAY C, 1992, BASIC RES CARDIOL, V87, P478; EDDY LJ, 1987, AM J PHYSIOL, V253, pH709, DOI 10.1152/ajpheart.1987.253.3.H709; ENGERSON TD, 1989, FASEB J, V3, P628; FREDERIKS WM, 1993, INT J EXP PATHOL, V74, P21; HULLRYDE EA, 1986, J CHROMATOGR, V377, P165, DOI 10.1016/S0378-4347(00)80771-9; JENNINGS RB, 1985, ANNU REV PHYSIOL, V47, P727, DOI 10.1146/annurev.ph.47.030185.003455; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; KUPPUSAMY P, 1989, J BIOL CHEM, V264, P9880; LAZZARINO G, 1994, CIRCULATION, V90, P291, DOI 10.1161/01.CIR.90.1.291; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MOUSSON B, 1983, ENZYME, V29, P32, DOI 10.1159/000469601; ONTYD J, 1984, J CHROMATOGR, V307, P404, DOI 10.1016/S0378-4347(00)84113-4; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; PISARENKO OI, 1994, BIOCHEM MED METAB B, V51, P16, DOI 10.1006/bmmb.1994.1002; REIMER KA, 1985, CIRCULATION, V71, P1069, DOI 10.1161/01.CIR.71.5.1069; Roy R.S., 1983, CELLULAR MED ASPECTS, VII, P145; SIMPSON PJ, 1987, J LAB CLIN MED, V110, P13; STIRPE F, 1969, J BIOL CHEM, V244, P3855; TAYLOR AE, 1986, PHYSL OXYGEN RADICAL, P1; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	37	134	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18797	18803		10.1074/jbc.270.32.18797	http://dx.doi.org/10.1074/jbc.270.32.18797			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642530	hybrid			2022-12-25	WOS:A1995RN95400017
J	CHEN, XR; RAAB, G; DEUTSCH, U; ZHANG, JC; EZZELL, RM; KLAGSBRUN, M				CHEN, XR; RAAB, G; DEUTSCH, U; ZHANG, JC; EZZELL, RM; KLAGSBRUN, M			INDUCTION OF HEPARIN-BINDING EGF-LIKE GROWTH-FACTOR EXPRESSION DURING MYOGENESIS - ACTIVATION OF THE GENE BY MYOD AND LOCALIZATION OF THE TRANSMEMBRANE FORM OF THE PROTEIN ON THE MYOTUBE SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; DIPHTHERIA-TOXIN RECEPTOR; DNA-BINDING; FIBROBLAST GROWTH; SKELETAL-MUSCLE; MESSENGER-RNA; MYC HOMOLOGY; DIFFERENTIATION; SULFATE; MEMBER	Heparin binding epidermal growth factor-like growth factor (HB-EGF) gene expression and protein localization were analyzed during the process of myogenic differentiation, The mouse HB-EGF gene was isolated, and a 1.8-kilobase genomic fragment flanking the 5' end of the cDNA was cloned, This fragment contains two sequences which match the consensus CANNTG sequence for E-boxes, binding sites for the MyoD family of DNA-binding transcription factors that regulate myogenesis. Accordingly, HB-EGF synthesis was analyzed in 10T1/2 cells and C2C12 cells which are used commonly for the study of myogenesis, HB-EGF gene expression was upregulated in both cell types during myogenesis. In 10T1/2 cells, direct activation of HB-EGF gene expression by MyoD was shown in that: i) transient transfection of these cells with a plasmid expressing MyoD resulted in a 10-20-fold increase in endogenous HB-EGF mRNA levels; ii) co-transfection of MyoD and an HE EGF promoter-reporter plasmid resulted in a 5-10-fold increase in reporter activity, an increase that was abrogated by deletion of a putative HB-EGF proximal E-box sequence; and iii) incubation of MyoD protein with a 25-base pair double stranded oligonucleotide corresponding to the HB-EGF proximal E-box sequence resulted in retarded electrophoretic mobility of the oligonucleotide. In C2C12 cells, differentiation of myoblasts into myotubes resulted in a 40-50 fold increase in HB-EGF promoter activity, In addition, immunostaining and laser confocal microscopy detected HB-EGF protein in C2C12 myotubes but not in myoblasts, The HB-EGF produced was in its transmembrane form and localized to the myotube surface, Taken together, it was concluded that during skeletal muscle cell differentiation, MyoD plays a direct role in activating HB-EGF gene expression and that HB-EGF protein is expressed preferentially in myotubes and in its membrane-anchored form.	CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,SURG RES LAB,BOSTON,MA 02129	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Deutsch, Urban/0000-0003-4265-6262	NATIONAL CANCER INSTITUTE [R01CA037392, R56CA037392, R37CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER; NCI NIH HHS [CA37392] Funding Source: Medline; NIGMS NIH HHS [GM47397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V161, P156; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COVAULT J, 1986, J CELL BIOL, V102, P716, DOI 10.1083/jcb.102.3.716; DAS SK, 1994, DEVELOPMENT, V120, P1071; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLORKIEWICZ RZ, 1991, ANN NY ACAD SCI, V638, P109, DOI 10.1111/j.1749-6632.1991.tb49022.x; FOX JC, 1994, MOL CELL BIOL, V14, P4244, DOI 10.1128/MCB.14.6.4244; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KINGSTON RE, 1992, CURRENT PROTOCOLS MO, P481; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MESRI EA, 1994, J CELL SCI, V107, P2559; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NAKANO T, 1993, J BIOL CHEM, V268, P22941; NAKANO T, 1994, P NATL ACAD SCI USA, V268, P22941; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; ONO M, 1994, J BIOL CHEM, V269, P31315; POWELL PP, 1993, AM J PATHOL, V147, P784; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; ZUK A, 1989, J CELL BIOL, V108, P903, DOI 10.1083/jcb.108.3.903	53	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18285	18294		10.1074/jbc.270.31.18285	http://dx.doi.org/10.1074/jbc.270.31.18285			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629148	hybrid			2022-12-25	WOS:A1995RM64200023
J	KOIKETAKESHITA, A; KOYAMA, T; OBATA, S; OGURA, K				KOIKETAKESHITA, A; KOYAMA, T; OBATA, S; OGURA, K			MOLECULAR-CLONING AND NUCLEOTIDE-SEQUENCES OF THE GENES FOR 2 ESSENTIAL PROTEINS CONSTITUTING A NOVEL ENZYME-SYSTEM FOR HEPTAPRENYL DIPHOSPHATE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXAPRENYL PYROPHOSPHATE SYNTHETASE; MICROCOCCUS-LUTEUS B-P-26; 2 ESSENTIAL COMPONENTS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SYNTHASE; PRENYLTRANSFERASE; PURIFICATION; FARNESYLTRANSFERASE; SEPARATION	The genes encoding two dissociable components essential for Bacillus stearothermophilus heptaprenyl diphosphate synthase (all-trans-hexaprenyl-diphosphate:isopentenyl-diphosphate hexaprenyl-trans-transferase, EC 2.5.1.30) were cloned, and their nucleotide sequences were determined. Sequence analyses revealed the presence of three open reading frames within 2,350 base pairs, designated as ORF-1, ORF-2, and ORF-3 in order of nucleotide sequence, which encode proteins of 220, 234, and 323 amino acids, respectively. Deletion experiments have shown that expression of the enzymatic activity requires the presence of ORF-1 and ORF-3, but ORF-2 is not essential. As a result, this enzyme was proved genetically to consist of two different protein components with molecular masses of 25 kDa (Component I) and 36 kDa (Component II), encoded by two of the three tandem genes. The protein encoded by ORF-1 has no similarity to any protein so far registered. However, the protein encoded by ORF-3 shows a 32% similarity to the farnesyl diphosphate synthase of the same bacterium and has seven highly conserved regions that have been shown typical in prenyltransferases (Koyama, T., Obata, S., Osabe, M., Takeshita, A., Yokoyama, K., Uchida, M., Nishino, T., and Ogura, K. (1993) J. Biochem. (Tokyo) 113, 355-363).	TOYOTA MOTOR CO LTD,BIORES LAB,TOYOTA,AICHI 47171,JAPAN; TOHOKU UNIV,INST CHEM REACT SCI,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Toyota Motor Corporation; Tohoku University								ADAIR WL, 1984, J BIOL CHEM, V259, P4441; ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; ASHBY MN, 1990, MOL BIOL ATHEROSCLER, P27; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; EBERHARDT NL, 1975, J BIOL CHEM, V250, P863; FUJII H, 1983, FEBS LETT, V161, P257, DOI 10.1016/0014-5793(83)81020-5; FUJII H, 1982, J BIOL CHEM, V257, P4610; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; HESS A, 1979, J GEN MICROBIOL, V115, P247, DOI 10.1099/00221287-115-1-247; ISHII K, 1986, BIOCHEM J, V233, P733; KOYAMA T, 1994, BIOCHEMISTRY-US, V33, P12644, DOI 10.1021/bi00208a015; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KOYAMA T, 1985, METHOD ENZYMOL, V110, P153; MUTH JD, 1984, ARCH BIOCHEM BIOPHYS, V230, P49, DOI 10.1016/0003-9861(84)90085-7; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; POULTER CD, 1982, BIOSYNTHESIS ISOPREN, V1, P161; REISS Y, 1991, J BIOL CHEM, V266, P10672; SAGAMI H, 1994, J BIOL CHEM, V269, P20561; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TAKAHASHI I, 1980, J BIOL CHEM, V255, P4539; TORAYA T, 1974, BIOCHEMISTRY-US, V13, P3895, DOI 10.1021/bi00716a012; YOSHIDA I, 1987, BIOCHEMISTRY-US, V26, P6840, DOI 10.1021/bi00395a038; YOSHIDA I, 1989, BIOCHEM BIOPH RES CO, V160, P448, DOI 10.1016/0006-291X(89)92453-4	32	54	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18396	18400		10.1074/jbc.270.31.18396	http://dx.doi.org/10.1074/jbc.270.31.18396			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629164	hybrid			2022-12-25	WOS:A1995RM64200040
J	STURCHLERPIERRAT, C; HUBERT, N; TOTSUKA, T; MIZUTANI, T; CARBON, P; KROL, A				STURCHLERPIERRAT, C; HUBERT, N; TOTSUKA, T; MIZUTANI, T; CARBON, P; KROL, A			SELENOCYSTEYLATION IN EUKARYOTES NECESSITATES THE UNIQUELY LONG AMINOACYL ACCEPTOR STEM OF SELENOCYSTEINE TRNA(SEC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; TRANSFER RNA(SEC); ESCHERICHIA-COLI; SERINE; GENE	Selenocysteine synthesis is achieved on a specific tRNA, tRNA(Sec), which is first charged with serine to yield seryl-tRNA(Sec). Eukaryotic tRNA(Sec) exhibits an aminoacyl acceptor stem with a unique length of 9 base pairs. Within this stem, two base pairs, G5a.U67b and U6.U67, drew our attention, whose non-Watson-Crick status is maintained in the course of evolution either through U6.U67 base conservation or base covariation at G5a.U67b. Single or double point mutations were performed, which modified the identity of either or both of the base pairs. Serylation by seryl-tRNA synthetase was unaffected by substitutions at either G5a.U67b or U6.U67. Instead, and quite surprisingly, changing G5a.U67b and U6.U67 to G5a-C67b/U6.G67 or G5a-C67b/C6-G67 gave rise to a tRNA(Sec) mutant exhibiting a gain of function in serylation. This finding sheds light on the negative influence born by a few base pairs in the acceptor stem of tRNA(Sec) on its serylation abilities. The tRNA(Sec) capacities to support selenocysteylation were next examined with regard to a possible role played by the two non-Watson-crick base pairs and the unique length of the acceptor stem. It first emerges from our study that tRNA(Sec) transcribed in vitro is able to support selenocysteylation. Second, none of the point mutations engineered at G5a.U67b and/or U6.U67 significantly modified the selenocysteylation level. In contrast, reduction of the acceptor stem length to 8 base pairs led tRNA(Sec) to lose its ability to efficiently support selenocysteylation. Thus, our study provides strong evidence that the length of the acceptor stem is of prime importance for the serine to selenocysteine conversion step.	INST BIOL MOLEC & CELLULAIRE,CNRS,UPR 9002,F-67084 STRASBOURG,FRANCE; AICHI PREFECTURAL COLONY HANDICAPPED,INST DEV RES,KASUGAI,AICHI 48003,JAPAN; NAGOYA CITY UNIV,FAC PHARMACEUT SCI,NAGOYA,AICHI 467,JAPAN	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Nagoya City University								AMBERG R, 1993, NUCLEIC ACIDS RES, V21, P5583, DOI 10.1093/nar/21.24.5583; BARON C, 1991, J BIOL CHEM, V266, P20375; BARON C, 1993, J MOL BIOL, V231, P274, DOI 10.1006/jmbi.1993.1282; BARON C, 1995, TRNA STRUCTURE BIOSY, P524; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; DIETRICH A, 1976, EUR J BIOCHEM, V70, P147, DOI 10.1111/j.1432-1033.1976.tb10965.x; GAUTHERET D, 1994, J MOL BIOL, V242, P1, DOI 10.1006/jmbi.1994.1552; GELPI C, 1992, P NATL ACAD SCI USA, V89, P9739, DOI 10.1073/pnas.89.20.9739; JUNG JE, 1994, J BIOL CHEM, V269, P29739; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; MIZUTANI T, 1989, FEBS LETT, V250, P142, DOI 10.1016/0014-5793(89)80707-0; MIZUTANI T, 1984, EUR J BIOCHEM, V143, P9, DOI 10.1111/j.1432-1033.1984.tb08331.x; MIZUTANI T, 1992, BIOCHEM J, V284, P827, DOI 10.1042/bj2840827; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; OHAMA T, 1994, ARCH BIOCHEM BIOPHYS, V315, P293, DOI 10.1006/abbi.1994.1503; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; STURCHLER C, 1993, NUCLEIC ACIDS RES, V21, P1073, DOI 10.1093/nar/21.5.1073; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589; YAMADA K, 1994, FEBS LETT, V347, P137, DOI 10.1016/0014-5793(94)00523-0; ZADOWSKI V, 1991, NUCLEIC ACIDS RES, V19, P1948	24	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18570	18574		10.1074/jbc.270.31.18570	http://dx.doi.org/10.1074/jbc.270.31.18570			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629188	hybrid			2022-12-25	WOS:A1995RM64200066
J	BLIN, N; YUN, J; WESS, J				BLIN, N; YUN, J; WESS, J			MAPPING OF SINGLE AMINO-ACID-RESIDUES REQUIRED FOR SELECTIVE ACTIVATION OF G(Q/11) BY THE M3 MUSCARINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTORS; PHOSPHATIDYLINOSITOL HYDROLYSIS; CYTOPLASMIC DOMAINS; LIGAND-BINDING; SUBTYPES; REGIONS; GENES	Each G protein coupled receptor can interact only with a limited number of the many structurally similar G proteins expressed within a cell. This study was undertaken to identify single amino acids required for selectively coupling the m3 muscarinic acetylcholine receptor to G proteins of the G(q/11) family. To this goal, distinct intracellular segments/amino acids of the m3 receptor were systematically substituted into the structurally closely related m2 muscarinic receptor, which couples to G(i/o) proteins, not G(q/11) proteins. The resultant mutant receptors were expressed in COS-7 cells and studied for their ability to induce agonist-dependent stimulation of phosphatidylinositol hydrolysis, a response known to be mediated by G proteins of the G(q/11) class. Using this approach, we were able to identify four amino acids in the second intracellular loop and four amino acids at the C terminus of the third intracellular loop of the m3 muscarinic receptor that are essential for efficient G(q/11) activation. We could demonstrate that these amino acids, together with a short segment at the N terminus of the third intracellular loop, fully account for the G protein coupling preference of the m3 muscarinic receptor. Taken together, our data strongly suggest that only a limited number of amino acids, located on different intracellular regions, are required to determine the functional profile of a given G protein-coupled receptor.	NIDDK,BIOORGAN CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLUML K, 1994, J BIOL CHEM, V269, P402; BLUML K, 1994, P NATL ACAD SCI USA, V91, P7980, DOI 10.1073/pnas.91.17.7980; BLUML K, 1994, J BIOL CHEM, V269, P11537; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; FRASER CM, 1989, MOL PHARMACOL, V36, P840; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOGGER P, 1995, J BIOL CHEM, V270, P7405; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MORO O, 1993, J BIOL CHEM, V268, P6862; MORO O, 1993, J BIOL CHEM, V268, P22273; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PARKER EM, 1991, J BIOL CHEM, V266, P519; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; WATSON S, 1994, G PROTEIN LINKED REC, P1; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1990, MOL PHARMACOL, V38, P872; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WONG SKF, 1990, J BIOL CHEM, V265, P6219; ZHU SZ, 1994, MOL PHARMACOL, V45, P517	48	105	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17741	17748		10.1074/jbc.270.30.17741	http://dx.doi.org/10.1074/jbc.270.30.17741			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629074	hybrid			2022-12-25	WOS:A1995RM26600020
J	BROWNAUGSBURGER, P; TISDALE, C; BROEKELMANN, T; SLOAN, C; MECHAM, RP				BROWNAUGSBURGER, P; TISDALE, C; BROEKELMANN, T; SLOAN, C; MECHAM, RP			IDENTIFICATION OF AN ELASTIN CROSS-LINKING DOMAIN THAT JOINS 3 PEPTIDE CHAINS - POSSIBLE ROLE IN NUCLEATED ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL	The alignment of elastin molecules in the mature elastic fiber was investigated by purifying and sequencing crosslink-containing peptides generated by proteolytic digestion of incompletely cross-linked insoluble elastin. Peptides of interest were purified by reverse phase and size exclusion high performance liquid chromatography and characterized by amino acid analysis and protein sequencing. One peptide, consisting of the cross-linking domain encoded by exon 10, contained a modified lysine residue that had not condensed to form a polyfunctional cross link. Although this domain contains the characteristic paired lysine residues found in other cross-linking domains of elastin, protein sequence analysis indicated that the first but not the second lysine had been oxidized by lysyl oxidase. This finding suggests that lysine residues in an individual cross-linking domain may not have equal susceptibility to oxidation by lysyl oxidase. In a second peptide, we found that a major cross-linking site in elastin is formed through the association of sequences encoded by exons 10, 19, and 25 and that the three chains are joined together by one desmosine and two lysinonor-leucine cross-links. Past structural studies and computer modeling predict that domains 19 and 25 are linked by a desmosine cross-link, while domain 10 bridges domains 19 and 25 through lysinonorleucine cross-links. These findings, together with the high degree of sequence conservation for these three domains, suggest an important function for these regions of the molecule, possibly nucleating the aggregation and polymerization of tropoelastin monomers in the developing elastic fiber.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026499, R37HL053325, R01HL053325] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26499, HL-53325] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAIG KM, 1980, BIOCHEM J, V185, P611, DOI 10.1042/bj1850611; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; FOSTER JA, 1976, BIOPOLYMERS, V15, P833, DOI 10.1002/bip.1976.360150503; FOSTER JA, 1974, J BIOL CHEM, V249, P6191; GALLOP PM, 1972, ANNU REV BIOCHEM, V41, P617, DOI 10.1146/annurev.bi.41.070172.003153; GERBER GE, 1975, BIOCHEM J, V149, P685, DOI 10.1042/bj1490685; GERBER GE, 1974, J BIOL CHEM, V249, P5200; Gray W R, 1977, Adv Exp Med Biol, V79, P285; GRAY WR, 1973, NATURE, V246, P461, DOI 10.1038/246461a0; GRAY WR, 1968, NATURE, V220, P1300, DOI 10.1038/2201300a0; INDIK Z, 1990, GENES EXTRACELLULAR, P221; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; MECHAM RP, 1978, BIOCHEM J, V173, P617, DOI 10.1042/bj1730617; MECHAM RP, 1979, BIOCHIM BIOPHYS ACTA, V577, P147, DOI 10.1016/0005-2795(79)90017-5; PARTRIDGE SM, 1964, BIOCHEM J, V93, pC30; PARTRIDGE SM, 1955, BIOCHEM J, V61, P11, DOI 10.1042/bj0610011; PIERCE RA, 1990, BIOCHEMISTRY-US, V29, P9677, DOI 10.1021/bi00493a024; RAJU K, 1987, J BIOL CHEM, V262, P5755; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; Sandberg LB., 1984, PEPTIDES PROTEIN REV, V3, P169	21	122	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17778	17783		10.1074/jbc.270.30.17778	http://dx.doi.org/10.1074/jbc.270.30.17778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629078	hybrid			2022-12-25	WOS:A1995RM26600025
J	BRYANT, SS; BRIGGS, S; SMITHGALL, TE; MARTIN, GA; MCCORMICK, F; CHANG, JH; PARSONS, SJ; JOVE, R				BRYANT, SS; BRIGGS, S; SMITHGALL, TE; MARTIN, GA; MCCORMICK, F; CHANG, JH; PARSONS, SJ; JOVE, R			2 SH2 DOMAINS OF P120 RAS GTPASE-ACTIVATING PROTEIN BIND SYNERGISTICALLY TO TYROSINE-PHOSPHORYLATED P190 RHO-GTPASE-ACTIVATING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; GAP-ASSOCIATED PROTEINS; SRC-TRANSFORMED-CELLS; C-TERMINAL DOMAIN; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; P21 GTPASE; KINASES; P62	p120 GTPase-activating protein (GAP) is a negative regulator of Pas that functions at a key relay point in signal transduction pathways that control cell proliferation. Among other proteins, p120 GAP associates with p190, a GAP for the Pas-related protein, Rho. To characterize the p120 . p190 interaction further, we used bacterially expressed glutathione S-transferase fusion polypeptides to map the regions of p120 necessary for its interactions with p190. Our results show that both the N-terminal and the C-terminal SH2 domains of p120 are individually capable of binding p190 expressed in a baculovirus/insect cell system. Moreover, the two SH2 domains together on one polypeptide bind synergistically to p190, and this interaction is dependent on tyrosine phosphorylation of p190. In addition, mutation of the highly conserved Arg residues in the critical FLVR sequences of both SH2 domains of full-length p120 reduces binding to tyrosine-phosphorylated p190. The dependence on p190 phosphorylation for complex formation with p120 . SH2 domains observed in vitro is consistent with analysis of the native p120 . p190 complexes formed in vivo. These findings suggest that SH2-phosphotyrosine interaction is one mechanism by which the cell regulates p120 p190 association and thus may be a means for coordinating the Ras- and Rho-mediated signaling pathways.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,MOLEC & CELLULAR BIOL PROGRAM,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC,OMAHA,NE 68198; ONYX PHARMACEUT,RICHMOND,CA 94806; UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Nebraska System; University of Nebraska Medical Center; University of Virginia				Briggs, Scott D/0000-0003-2852-3594	NCI NIH HHS [CA58667, CA39438, CA55652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058667, R01CA055652, R01CA039438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CHANG JH, 1995, METHOD ENZYMOL, V254, P430; CHANG JH, 1993, ONCOGENE, V8, P959; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KUNG HF, 1986, EXP CELL RES, V162, P363, DOI 10.1016/0014-4827(86)90341-1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PARK S, 1992, J BIOL CHEM, V267, P11612; PARK S, 1992, J BIOL CHEM, V267, P17194; PARK S, 1993, J BIOL CHEM, V268, P25728; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	47	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17947	17952		10.1074/jbc.270.30.17947	http://dx.doi.org/10.1074/jbc.270.30.17947			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629101	hybrid			2022-12-25	WOS:A1995RM26600051
J	ZHU, ZX; BAO, ZH; LI, JX				ZHU, ZX; BAO, ZH; LI, JX			MACMARCKS MUTATION BLOCKS MACROPHAGE PHAGOCYTOSIS OF ZYMOSAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-C; RECEPTOR-MEDIATED PHAGOCYTOSIS; PLASMA-MEMBRANE; HUMAN-MONOCYTES; MARCKS FAMILY; ACTIVATION; CALMODULIN; SUBSTRATE; PHOSPHORYLATION; ERYTHROCYTES	A major protein kinase C substrate, MacMARCKS (F52, MPR), was examined for its role in phagocytosis. In macrophage-phagocytosing zymosan particles, MacMARCKS was concentrated around nascent phagosomes as detected by immunofluorescent microscopy. The effector domain of MacMARCKS contains the phosphorylation sites, a calmodulin binding site, as well as a putative actin binding site. Stable J774 macrophage cell lines constitutively expressing effector domain deletion mutants of MacMARCKS were generated. When given zymosan particles, these transfectants showed approximately a 90% reduction in their phagocytic capacity. The receptor-mediated endocytosis of acetylated low density lipoproteins, however, was not affected by the mutant. These results strongly suggest the involvement of MacMARCKS in macrophage phagocytosis.	UNIV TENNESSEE,COLL MED,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; ALPUCHEARANDA CM, 1994, J EXP MED, V179, P601, DOI 10.1084/jem.179.2.601; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; COSTA TE, 1992, J EXP MED, V175, P1669, DOI 10.1084/jem.175.6.1669; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; GEORGE DJ, 1989, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GREENBERG S, 1988, Journal of Cell Biology, V107, p453A; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; GREENBERG S, 1991, J IMMUNOL METHODS, V139, P115, DOI 10.1016/0022-1759(91)90358-M; GRESHAM HD, 1990, J BIOL CHEM, V265, P7819; GRIFFIN FM, 1975, J EXP MED, V142, P1263, DOI 10.1084/jem.142.5.1263; GRIFFIN FM, 1976, J EXP MED, V144, P788, DOI 10.1084/jem.144.3.788; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LIAO GJ, 1994, BLOOD, V83, P2294; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MITCHELL MA, 1994, BLOOD, V84, P1753; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROSS GD, 1985, J IMMUNOL, V134, P3307; SAWAI T, 1993, J BIOL CHEM, V268, P1995; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; SPEERT DP, 1985, J LEUKOCYTE BIOL, V38, P665; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; SUZUKI K, 1990, BIOCHIM BIOPHYS ACTA, V1042, P210, DOI 10.1016/0005-2760(90)90010-U; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042; ZIGMOND SH, 1972, EXP CELL RES, V73, P383, DOI 10.1016/0014-4827(72)90062-6	38	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17652	17655		10.1074/jbc.270.30.17652	http://dx.doi.org/10.1074/jbc.270.30.17652			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629059	hybrid			2022-12-25	WOS:A1995RM26600004
J	KRUEGER, JK; PADRE, RC; STULL, JT				KRUEGER, JK; PADRE, RC; STULL, JT			INTRASTERIC REGULATION OF MYOSIN LIGHT-CHAIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACHEAL SMOOTH-MUSCLE; BASIC RESIDUES; CALMODULIN BINDING; PROTEIN-KINASE; PHOSPHORYLATION; AUTOINHIBITION; RECOGNITION; ACTIVATION; SEQUENCE; LOCATION	Ca2+/calmodulin activates myosin light chain kinase by reversal of an autoinhibited state. The effects of substitution mutations on calmodulin activation properties implicate 4 of the 8 basic residues between the catalytic core and the calmodulin-binding domain in maintaining autoinhibition. These residues are further amino-terminal to the basic residues comprising the previously proposed pseudosubstrate sequence and suggest involvement of the connecting region in intrasteric autoinhibition. The pseudosubstrate model for autoinhibition proposes that basic residues within the autoinhibitory region mimic basic residues in the substrate and bind to defined acidic residues within the catalytic core, Charge reversal mutations of these specific acidic residues, however, had little or no effect on the K-m value for regulatory light chain. From a total of 20 acidic residues on the surface of the substrate binding lobe of the catalytic core, 7 are implicated in binding directly or indirectly to the autoinhibitory domain but not to the light chain. Only 2 acidic residues near the catalytic site may bind to the autoinhibitory domain and the arginine at P-3 in the light chain. Exposure of these 2 residues upon calmodulin binding may be necessary and sufficient for light chain phosphorylation.			KRUEGER, JK (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Krueger, Joanna/A-3110-2011		NHLBI NIH HHS [HL26043, T32-HL07360, F32 HL08874] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043, R01HL026043, T32HL007360, F32HL008874] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; FAUX MC, 1993, MOL CELL BIOCHEM, V128, P81, DOI 10.1007/BF01076759; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HERRING BP, 1992, J BIOL CHEM, V267, P25945; HERRING BP, 1990, J BIOL CHEM, V265, P16588; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; IKEBE M, 1989, J BIOL CHEM, V264, P6967; IKEBE M, 1987, J BIOL CHEM, V262, P13828; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILLER JR, 1983, MOL PHARMACOL, V24, P235; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; POTTER JD, 1975, J BIOL CHEM, V250, P4628; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; STULL JT, 1990, J BIOL CHEM, V265, P16683; STULL JT, 1995, IN PRESS 1995 INT S; WALSH MP, 1982, BIOCHEMISTRY-US, V21, P1919, DOI 10.1021/bi00537a034; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; ZHI G, 1994, J BIOL CHEM, V40, P24723	35	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16848	16853		10.1074/jbc.270.28.16848	http://dx.doi.org/10.1074/jbc.270.28.16848			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622500	hybrid			2022-12-25	WOS:A1995RJ34700061
J	PALLARD, C; GOUILLEUX, F; CHARON, M; GRONER, B; GISSELBRECHT, S; DUSANTERFOURT, I				PALLARD, C; GOUILLEUX, F; CHARON, M; GRONER, B; GISSELBRECHT, S; DUSANTERFOURT, I			INTERLEUKIN-3, ERYTHROPOIETIN, AND PROLACTIN ACTIVATE A STAT5-LIKE FACTOR IN LYMPHOID-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLONY-STIMULATING FACTOR; REGULATORY FACTOR-I; TYROSINE PHOSPHORYLATION; GROWTH-HORMONE; RECEPTOR; LINE; KINASE	Interleukin-3 (IL-3)-, erythropoietin (EPO)-, and prolactin (PRL)-induced signal transduction via the JAK/STAT pathway was studied in the IL-3-dependent BAF-3 lymphoid cell Line. Transfected cells expressing either the long form of the PRL receptor or the EPO receptor were used. We demonstrated that IL-3, EPO, and PRL activated a transcription factor related to the mammary transcription factor STATS but not to STAT1, -2, -3, or -4 as opposed to interferon gamma (IFN gamma) which activated STAT1 in the same cells. Similarly, PRL and EPO activated a STAT5-like factor (STAT5-L) in the rat Nb2 and the human UT7 cells expressing endogenous PRL and EPO receptors, respectively. The hematopoietic STAT5-L activated by IL-3, EPO, or PRL was identified as a 97-kDa tyrosine-phosphorylated protein. These results confer to STAT5 a much broader role than previously suggested.	HOP COCHIN,INST COCHIN GENET MOLEC,INSERM,U363,F-75014 PARIS,FRANCE; TUMOR BIOL CTR,INST EXPTL CANC RES,D-79106 FREIBURG,GERMANY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Dusanter-Fourt, Isabelle/P-4558-2017	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Gouilleux, Fabrice/0000-0001-6047-1718				ALI S, 1991, J BIOL CHEM, V266, P20110; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZANJF, 1989, P NATL ACAD SCI USA, V87, P6934; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FUH G, 1993, J BIOL CHEM, V268, P5376; GALA RR, 1991, P SOC EXP BIOL MED, V198, P513; GILMOUR KC, 1994, P NATL ACAD SCI USA, V91, P6850, DOI 10.1073/pnas.91.15.6850; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HERMINE O, 1992, BLOOD, V80, P3060; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KOMATSU N, 1991, CANCER RES, V51, P341; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; ONEAL KD, 1994, J BIOL CHEM, V269, P26076; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUI H, 1992, J BIOL CHEM, V267, P24076; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	33	113	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					15942	15945		10.1074/jbc.270.27.15942	http://dx.doi.org/10.1074/jbc.270.27.15942			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608147	hybrid, Green Published			2022-12-25	WOS:A1995RH22600008
J	RIFKIN, MR; STROBOS, CAM; FAIRLAMB, AH				RIFKIN, MR; STROBOS, CAM; FAIRLAMB, AH			SPECIFICITY OF ETHANOLAMINE TRANSPORT AND ITS FURTHER METABOLISM IN TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINE TRANSPORT; RAT-LIVER; GLUCOSE-TRANSPORT; PHOSPHATIDYLETHANOLAMINE; BIOSYNTHESIS; CELLS; MEMBRANES; PHOSPHATIDYLCHOLINE; KINASE; GENE	Ethanolamine is found in trypanosomes as an integral component of the variant surface glycoprotein (VSG) and the membrane phospholipid phosphatidylethano-lamine (PE). Steps in the utilization of ethanolamine could represent novel targets for the development of chemotherapeutic drugs and were therefore investigated in detail. Transport of [H-3]ethanolamine was studied using structural analogs of ethanolamine. Compounds with substitutions in the amino group or of one of the methylene hydrogens of ethanolamine were the most effective inhibitors, Those analogs studied in detail with respect to their kinetic properties were all found to be competitive inhibitors of ethanolamine transport. Following uptake, ethanolamine is rapidly phosphorylated by an ethanolamine-specific kinase to form phosphoethanolamine. Other acid-soluble intermediates identified by thin layer chromatography were CDP-ethanolamine, dCDP-ethanolamine, and glycero-phosphorylethanolamine. The relative amounts of these metabolites varied between slender (dividing) and stumpy (non-dividing) trypanosomes and may reflect special biosynthetic needs of the different morphological forms, Pulse-chase experiments indicated that the acid-soluble metabolites served as precursors for chloroform/methanol-soluble Lipids. Radioactive lipids included PE, mono-methyl and dimethyl PE, and lysoPE. Further methylation of dimethylPE to phosphatidylcholine was not observed under the experimental conditions described. These results are consistent with the conclusion that trypanosomes are able to synthesize phospholipids via the Kennedy pathway.	ROCKEFELLER UNIV,MED BIOCHEM LAB,NEW YORK,NY 10021	Rockefeller University			Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020324, R01AI021429] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20324, AI-21429] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA S, 1984, CLIN CHIM ACTA, V136, P49, DOI 10.1016/0009-8981(84)90246-8; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXON H, 1970, COMP BIOCHEM PHYSIOL, V33, P111, DOI 10.1016/0010-406X(70)90487-1; DODIA C, 1992, AM J RESP CELL MOL, V6, P426, DOI 10.1165/ajrcmb/6.4.426; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FOLCH J, 1957, J BIOL CHEM, V226, P497; HIRATA F, 1980, SCIENCE, V209, P1082, DOI 10.1126/science.6157192; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; INFANTE JP, 1984, FEBS LETT, V170, P1, DOI 10.1016/0014-5793(84)81358-7; JENNINGS FW, 1979, INT J PARASITOL, V9, P381, DOI 10.1016/0020-7519(79)90089-4; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; KANOSUEOKA T, 1983, J CELL PHYSIOL, V117, P109, DOI 10.1002/jcp.1041170115; KANOSUEOKA T, 1993, CELL GROWTH DIFFER, V4, P533; KENNEDY EP, 1959, J BIOL CHEM, V234, P1998; KRUSE T, 1985, J NEUROL SCI, V70, P129, DOI 10.1016/0022-510X(85)90082-6; LEVINE RF, 1981, INFECT IMMUN, V34, P513, DOI 10.1128/IAI.34.2.513-518.1981; LIPTON BA, 1988, J CELL PHYSIOL, V137, P571, DOI 10.1002/jcp.1041370325; MCGEE R, 1980, J NEUROCHEM, V35, P829, DOI 10.1111/j.1471-4159.1980.tb07079.x; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MILLS GORDON C., 1960, TEXAS REPTS BIOL AND MED, V18, P43; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; NIKAWA JI, 1986, J BACTERIOL, V166, P328, DOI 10.1128/jb.166.1.328-330.1986; OPPERDOES FR, 1984, FEBS LETT, V169, P35, DOI 10.1016/0014-5793(84)80284-7; PIERINGER RA, 1983, ENZYMES, V16, P255; PILCH PF, 1980, P NATL ACAD SCI-BIOL, V77, P915, DOI 10.1073/pnas.77.2.915; PLAGEMANN PG, 1969, BIOCHEMISTRY-US, V8, P4782, DOI 10.1021/bi00840a020; PORTER RK, 1992, J BIOL CHEM, V267, P14637; POTTER RL, 1958, J BIOL CHEM, V233, P462; POTTER RL, 1957, J BIOL CHEM, V226, P381; PU GAW, 1984, J NEUROCHEM, V42, P185, DOI 10.1111/j.1471-4159.1984.tb09715.x; RIDGWAY ND, 1988, J BIOL CHEM, V263, P16864; RIFKIN MR, 1985, MOL BIOCHEM PARASIT, V15, P245, DOI 10.1016/0166-6851(85)90088-X; SCHNEIDER WC, 1966, ANAL BIOCHEM, V14, P121, DOI 10.1016/0003-2697(66)90064-9; SCHNEIDER WC, 1958, J BIOL CHEM, V233, P948; SUNDLER R, 1973, BIOCHIM BIOPHYS ACTA, V306, P218, DOI 10.1016/0005-2760(73)90227-0; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TURNER JD, 1970, ANAL BIOCHEM, V38, P423, DOI 10.1016/0003-2697(70)90467-7; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; WEINHOLD PA, 1972, BIOCHIM BIOPHYS ACTA, V276, P143, DOI 10.1016/0005-2744(72)90015-0; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5135, DOI 10.1021/bi00722a013; WEISS SB, 1958, J BIOL CHEM, V231, P53; YOREK MA, 1986, J LIPID RES, V27, P1205; YULI I, 1981, BIOCHEMISTRY-US, V20, P4250, DOI 10.1021/bi00518a003	48	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16160	16166		10.1074/jbc.270.27.16160	http://dx.doi.org/10.1074/jbc.270.27.16160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608181	hybrid			2022-12-25	WOS:A1995RH22600044
J	ZHAO, Y; NICHOLS, JE; BULUN, SE; MENDELSON, CR; SIMPSON, ER				ZHAO, Y; NICHOLS, JE; BULUN, SE; MENDELSON, CR; SIMPSON, ER			AROMATASE P450 GENE-EXPRESSION IN HUMAN ADIPOSE-TISSUE - ROLE OF A JAK/STAT PATHWAY IN REGULATION OF THE ADIPOSE-SPECIFIC PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; POLYMERASE CHAIN-REACTION; BREAST-CANCER CELLS; PLASMA ANDROSTENEDIONE; ESTROGEN BIOSYNTHESIS; MOLECULAR-CLONING; MONOLAYER-CULTURE; SKIN FIBROBLASTS; MENSTRUAL-CYCLE; ALTERNATIVE USE	In the present report we describe a heretofore unrecognized role for a Jak/STAT signaling pathway, namely the stimulation of expression of the aromatase P450 (CYP19) gene, and hence of estrogen biosynthesis, in human adipose tissue. Expression of this gene in adipose tissue as well as in adipose stromal cells maintained in the presence of serum and glucocorticoids is regulated by a distal TATA-less promoter, I.4, which contains a glucocorticoid response element, an Sp1 binding site, and an interferon-gamma activation site (GAS) element, The stimulatory action of serum (in the presence of dexamethasone) can be replaced by interleukin (IL)-11, leukemia inhibitory factor, and oncostatin-M, as web as by IL-6, providing the IL-6 soluble receptor is also present. Stimulation of the cells by these factors led to rapid phosphorylation of Jak1, but not Jak2 or Jab3, on tyrosine residues. STAT3 but not STAT1 was also phosphorylated and bound to the GAS element in the I.4 promoter region. When regions of this promoter were fused upstream of the chloramphenicol acetyltransferase reporter gene and transfected into the cells, mutagenesis or deletion of the GAS element led to complete loss of reporter gene expression. Since adipose tissue is the major site of estrogen biosynthesis in men and in postmenopausal women, this pathway involving a Jak/STAT signaling mechanism acting together with glucocorticoids and Sp1 appears to be the principal means whereby estrogen biosynthesis is regulated in the elderly.	UNIV TEXAS, SW MED CTR, CECIL H & IDA GREEN CTR REPROD BIOL SCI, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OBSTET GYNECOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Mendelson, Carole Ruth/0000-0003-1696-9791	NIA NIH HHS [5-R37-AG08174] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG008174] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACKERMAN GE, 1981, J CLIN ENDOCR METAB, V53, P412, DOI 10.1210/jcem-53-2-412; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BERKOVITZ GD, 1989, J STEROID BIOCHEM, V33, P341, DOI 10.1016/0022-4731(89)90322-1; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; BULUN SE, 1994, TRENDS ENDOCRIN MET, V5, P113, DOI 10.1016/1043-2760(94)90092-2; BULUN SE, 1994, J CLIN ENDOCR METAB, V78, P428, DOI 10.1210/jc.78.2.428; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOODY KJ, 1990, J CLIN ENDOCR METAB, V70, P1041, DOI 10.1210/jcem-70-4-1041; EDMAN CD, 1975, GASTROENTEROLOGY, V69, P819; EDMAN CD, 1978, AM J OBSTET GYNECOL, V130, P456, DOI 10.1016/0002-9378(78)90288-0; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; GORDON GG, 1975, J CLIN ENDOCR METAB, V40, P1018, DOI 10.1210/jcem-40-6-1018; GRODIN JM, 1973, J CLIN ENDOCR METAB, V36, P207, DOI 10.1210/jcem-36-2-207; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMSELL DL, 1974, J CLIN ENDOCR METAB, V38, P476, DOI 10.1210/jcem-38-3-476; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HONDA S, 1994, BIOCHEM BIOPH RES CO, V198, P1153, DOI 10.1006/bbrc.1994.1163; JENKINS C, 1993, MOL CELL ENDOCRINOL, V97, pR1, DOI 10.1016/0303-7207(93)90227-B; KELLER DC, 1993, BLOOD, V82, P1428; KELLIS JT, 1987, J BIOL CHEM, V262, P4413; KILGORE MW, 1992, MOL CELL ENDOCRINOL, V83, pR9, DOI 10.1016/0303-7207(92)90202-H; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LANOUX MJ, 1985, ENDOCRINOLOGY, V117, P361, DOI 10.1210/endo-117-1-361; MACDONALD PC, 1979, J CLIN ENDOCR METAB, V49, P905, DOI 10.1210/jcem-49-6-905; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; MCNATTY KP, 1976, J ENDOCRINOL, V71, P77, DOI 10.1677/joe.0.0710077; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MENDELSON CR, 1985, ARCH BIOCHEM BIOPHYS, V243, P480, DOI 10.1016/0003-9861(85)90525-9; Naftolin F, 1975, Recent Prog Horm Res, V31, P295; NAKAJIN S, 1986, BIOCHEM BIOPH RES CO, V134, P704, DOI 10.1016/S0006-291X(86)80477-6; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; ONEILL JS, 1988, BRIT MED J, V296, P741, DOI 10.1136/bmj.296.6624.741; PRICE T, 1992, J CLIN ENDOCR METAB, V74, P1247, DOI 10.1210/jc.74.6.1247; PRICE T, 1992, P SOC GYNECOL INVEST, V39, P179; REED MJ, 1993, J STEROID BIOCHEM, V44, P589, DOI 10.1016/0960-0760(93)90264-W; REED MJ, 1992, J ENDOCRINOL, V132, pR5, DOI 10.1677/joe.0.132R005; ROSELLI CE, 1985, ENDOCRINOLOGY, V117, P2471, DOI 10.1210/endo-117-6-2471; SASANO H, 1994, HUM PATHOL, V25, P530, DOI 10.1016/0046-8177(94)90127-9; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHMIDT M, 1994, EUR J CELL BIOL, V63, P96; SIMPSON ER, 1981, P NATL ACAD SCI-BIOL, V78, P5690, DOI 10.1073/pnas.78.9.5690; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; THOMPSON EA, 1974, J BIOL CHEM, V249, P5373; TODA K, 1994, MOL ENDOCRINOL, V8, P210, DOI 10.1210/me.8.2.210; TODA K, 1993, EUR J BIOCHEM, V213, P383, DOI 10.1111/j.1432-1033.1993.tb17772.x; TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x; TSAIMORRIS CH, 1985, ENDOCRINOLOGY, V116, P31, DOI 10.1210/endo-116-1-31; ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	64	209	214	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16449	16457		10.1074/jbc.270.27.16449	http://dx.doi.org/10.1074/jbc.270.27.16449			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608217	hybrid			2022-12-25	WOS:A1995RH22600085
J	XIAO, GH; JIN, F; YEUNG, RS				XIAO, GH; JIN, F; YEUNG, RS			GERM-LINE TSC2 MUTATION IN A DOMINANTLY INHERITED CANCER MODEL DEFINES A NOVEL FAMILY OF RAT INTRACISTERNAL-A PARTICLE ELEMENTS	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; ANIMAL MODEL; IAP ELEMENT; TUBEROUS SCLEROSIS; EKER RAT	LONG TERMINAL REPEATS; RENAL-CELL CARCINOMA; EKER RAT; SUSCEPTIBILITY GENE; DNA REARRANGEMENT; SEQUENCE; PROMOTER; INSERTION; CHROMOSOME-10; GENOME	A spontaneous hereditary cancer syndrome in the Eker rat serves as a useful model for studying tissue-specific tumorigenesis. The genetic basis of this germline mutation was found to involve the tuberous sclerosis 2 (Tsc2) gene. In this study, we have identified and characterized a full-length rat intracisternal A-particle (IAP) element that has undergone an intronic transposition as the mechanism of inactivating the Tsc2 gene. The insertion of this 6253 basepair element disrupted the transcription of the gene to give rise to multiple abnormal mRNA. Genomic organization of this novel IAP element is similar to a typical retroviral structure including the gag, pol and env domains with flanking LTRs. This Eker rat associated CERA) IAP sequence was found to contain multiple termination codons rendering it non-functional with respect to its endogenous genes. The element is conserved among different rat strains and the distribution of the estimated similar to 580 copies throughout the rat genome would support their random integration. The net effect of the mutation causes the expression of abnormal predicted proteins devoid of the rap1GAP-like catalytic domain that lies 3' to the insertion. These results provide evidence that cancer predisposition can be the direct consequence of germ-like insertional mutation by retrotransposition targeting a tumor suppressor gene.	FOX CHASE CANC CTR,DIV MED SCI,PHILADELPHIA,PA 19111	Fox Chase Cancer Center								BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; EKER R, 1954, ACTA PATHOL MIC SC, V34, P554; EKER R, 1981, DIAGN HISTOPATHOL, V4, P99; FURTER CS, 1989, J BIOL CHEM, V264, P18276; FURTER CS, 1992, BIOCHIM BIOPHYS ACTA, V1130, P213, DOI 10.1016/0167-4781(92)90531-4; GOFF SP, 1990, CANCER CELL-MON REV, V2, P172; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HINO O, 1993, JPN J CANCER RES, V84, P1106, DOI 10.1111/j.1349-7006.1993.tb02808.x; KAZAZIAN HH, 1988, NATURE, V322, P164; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LUEDERS KK, 1983, NUCLEIC ACIDS RES, V11, P4391, DOI 10.1093/nar/11.13.4391; LUEDERS KK, 1984, MOL CELL BIOL, V4, P2128, DOI 10.1128/MCB.4.10.2128; MIETZ JA, 1987, J VIROL, V61, P3020, DOI 10.1128/JVI.61.10.3020-3029.1987; MIKI Y, 1992, CANCER RES, V52, P643; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SONG CS, 1990, BIOCHEMISTRY-US, V29, P542, DOI 10.1021/bi00454a031; WALKER C, 1992, SCIENCE, V255, P1693, DOI 10.1126/science.1553556; YEUNG RS, 1993, P NATL ACAD SCI USA, V90, P8038, DOI 10.1073/pnas.90.17.8038; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YEUNG RS, 1993, CYTOGENET CELL GENET, V62, P149, DOI 10.1159/000133459; YEUNG RS, 1995, IN PRESS MOL CARCINO; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	31	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					81	87						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624135				2022-12-25	WOS:A1995RJ29500010
J	FUKUCHI, JI; KASHIWAGI, K; YAMAGISHI, M; ISHIHAMA, A; IGARASHI, K				FUKUCHI, JI; KASHIWAGI, K; YAMAGISHI, M; ISHIHAMA, A; IGARASHI, K			DECREASE IN CELL VIABILITY DUE TO THE ACCUMULATION OF SPERMIDINE IN SPERMIDINE ACETYLTRANSFERASE-DEFICIENT MUTANT OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYAMINE-REQUIRING MUTANTS; RIBOSOME MODULATION FACTOR; ORNITHINE DECARBOXYLASE; PROTEIN-SYNTHESIS; MESSENGER-RNA; GROWTH; STIMULATION; INHIBITION; ABSENCE; GENE	Physiological functions of spermidine acetyltransferase in Escherichia coli have been studied using the spermidine acetyltransferase (speG) gene deficient mutant CAG2242 and the cloned speG gene, The growth of E. coli CAG2242 in the defined M9 medium was normal in the presence and absence of 0.5 mM spermidine. How ever, cell viability of E. coli CAG2242 at 48 h after the onset of growth decreased greatly by the addition of 0.5 mM spermidine. The amount of spermidine accumulated in the cells was approximately 3-fold that in the cells grown in the absence of spermidine. Transformation of the cloned speG gene to E. coli CAG2242 recovered the cell viability, Decrease in cell viability of E. coli CAG2242 was observed even when 0.5 mM spermidine was added at 24 h after the onset of growth. The results indicate that accumulated spermidine functions at the late stationary phase of growth. The accumulation of spermidine caused a decrease in protein synthesis but not in DNA and RNA synthesis at 28 h after the onset of growth, The synthesis of several kinds of proteins was particularly inhibited, They included ribosome modulation factor and OmpC protein, Since the ribosome modulation factor is essential for cell viability at the stationary phase of growth (Yamagishi, M., Matsushima, H., Wada, A., Sakagami, Ri,, Fujita, N., and Ishihama, A. (1993) EMBO J. 12, 625-630), the decrease in the protein was thought to be one of the reasons for the decrease in cell viability, The decrease in the ribosome modulation factor mainly occurred at the translational level.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN	Chiba University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan				Igarashi, Kazuei/0000-0003-3751-3187				CARPER SW, 1991, J BIOL CHEM, V266, P12439; CASERO RA, 1993, FASEB J, V656, P653; DUBIN DT, 1960, J BIOL CHEM, V235, P776; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; FUKUCHI J, 1994, J BIOL CHEM, V269, P22581; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; HE Y, 1994, EUR J BIOCHEM, V221, P391, DOI 10.1111/j.1432-1033.1994.tb18751.x; HE Y, 1993, EUR J BIOCHEM, V217, P89, DOI 10.1111/j.1432-1033.1993.tb18222.x; HERSHEY JWB, 1977, ARCH BIOCHEM BIOPHYS, V182, P626, DOI 10.1016/0003-9861(77)90543-4; IGARASHI K, 1981, EUR J BIOCHEM, V114, P127; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; ITO K, 1990, J BIOL CHEM, V265, P13036; KASHIWAGI K, 1987, BIOCHIM BIOPHYS ACTA, V911, P180, DOI 10.1016/0167-4838(87)90007-0; KASHIWAGI K, 1989, ARCH BIOCHEM BIOPHYS, V268, P379, DOI 10.1016/0003-9861(89)90598-5; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1982, MOL CLONING LABORATO, P440; MCCANN MP, 1991, J BACTERIOL, V173, P4188, DOI 10.1128/jb.173.13.4188-4194.1991; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; NEILSEN PJ, 1982, J BIOL CHEM, V257, P12316; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEGG AE, 1988, CANCER RES, V48, P759; PERSSON L, 1984, J BIOL CHEM, V259, P2364; POULIN R, 1993, J BIOL CHEM, V268, P4690; SATO T, 1981, J BACTERIOL, V145, P88, DOI 10.1128/JB.145.1.88-96.1981; TABOR CW, 1970, J BIOL CHEM, V245, P2086; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; WADA A, 1987, J BIOCHEM, V101, P817, DOI 10.1093/jb/101.3.817; WADA A, 1990, P NATL ACAD SCI USA, V87, P2657, DOI 10.1073/pnas.87.7.2657; WATANABE S, 1991, J BIOL CHEM, V266, P20803; YAMAGISHI M, 1993, EMBO J, V12, P625, DOI 10.1002/j.1460-2075.1993.tb05695.x; YAMAGUCHI K, 1985, MOL GEN GENET, V200, P362, DOI 10.1007/BF00425718	35	62	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18831	18835		10.1074/jbc.270.32.18831	http://dx.doi.org/10.1074/jbc.270.32.18831			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642535				2022-12-25	WOS:A1995RN95400022
J	WEINER, KXB; CIESLA, J; JAFFE, AB; KETRING, R; MALEY, F; MALEY, GF				WEINER, KXB; CIESLA, J; JAFFE, AB; KETRING, R; MALEY, F; MALEY, GF			CHROMOSOMAL LOCATION AND STRUCTURAL ORGANIZATION OF THE HUMAN DEOXYCYTIDYLATE DEAMINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DCMP DEAMINASE; TRIPHOSPHATE POOL; HAMSTER-CELLS; DNA; THYMIDYLATE; IMBALANCES	Deoxycytidylate deaminase is an allosteric enzyme whose impairment can lead to deoxynucleotide imbalances that affect the fidelity of DNA synthesis, A DNA fragment encompassing the gene for deoxycytidylate deaminase has been isolated from a human lung fibroblast genomic library and sequenced in both directions through 26,764 base pairs, The previously isolated cDNA, which was used to establish the amino acid sequence for this enzyme (Weiner, K. X. B., Weiner, R. S., Maley, F., and Maley, G. F. (1993) J. Biol. Chem. 268, 12983-12989) was instrumental in isolating this gene. The gene consists of five exons of about 100 base pairs each, separated by four introns, The most striking feature of the genomic structure is that the second and third exons are separated by an intron of about 20 kilobases, The chromosomal location of the deaminase gene was determined by fluorescence in situ hybridization as 4q35, which is the extreme end of this chromosome, The position of this gene on chromosome 4, in addition to the role of its product in limiting potentially detrimental mutations, suggests that the normal operation of both the gene and its product is important to the well being of the organism.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center			Cieśla, Joanna/F-8445-2011; Cieśla, Joanna/D-7918-2015	Cieśla, Joanna/0000-0002-0115-5595	NATIONAL CANCER INSTITUTE [R35CA044355] Funding Source: NIH RePORTER; NCI NIH HHS [CA44355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DESAINTVINCENT BR, 1980, J BIOL CHEM, V255, P162; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; KOHALMI SE, 1991, J MOL BIOL, V220, P933, DOI 10.1016/0022-2836(91)90364-C; MALEY F, 1960, J BIOL CHEM, V235, P2968; Maley F, 1990, Prog Nucleic Acid Res Mol Biol, V39, P49, DOI 10.1016/S0079-6603(08)60623-6; MALEY F, 1972, CURR TOP CELL REGUL, V5, P177; MALEY GF, 1959, J BIOL CHEM, V234, P2975; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT RG, 1987, J BIOL CHEM, V262, P5546; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WEINER KXB, 1990, MOL ENDOCRINOL, V4, P1249, DOI 10.1210/mend-4-8-1249; WEINER KXB, 1993, J BIOL CHEM, V268, P12983; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7	20	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18727	18729		10.1074/jbc.270.32.18727	http://dx.doi.org/10.1074/jbc.270.32.18727			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642519	hybrid			2022-12-25	WOS:A1995RN95400005
J	CASCIO, M; KUMAR, NM; SAFARIK, R; GILULA, NB				CASCIO, M; KUMAR, NM; SAFARIK, R; GILULA, NB			PHYSICAL CHARACTERIZATION OF GAP JUNCTION MEMBRANE CONNEXONS (HEMI-CHANNELS) ISOLATED FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; CIRCULAR-DICHROISM; SECONDARY STRUCTURE; MOLECULAR-WEIGHT; PROTEIN; DIFFRACTION; DETERGENT; SIZE; CELLS; CHROMATOGRAPHY	Enriched subcellular fractions of double membrane gap junctions (plaques) from rat livers were treated under reducing conditions with high salt and non-ionic detergent concentrations at high pH to obtain a preparation of structural 80-90 Angstrom complexes of oligomers (connexons). The isolated oligomers were chromatographically purified, and subsequently characterized immunologically, morphologically by electron microscopy, hydrodynamically by gel filtration and ultracentrifugation, spectroscopically by circular dichroism, and chemically via cross-linking studies. The physical characteristics of these isolated gap junction complexes were compared to those of native membrane-bound gap junctions in rat liver. These analyses indicate that the isolated complex (connexon) principally contains a hexameric arrangement of gap junction protein to form a single membrane hemi channel.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15261 USA	Scripps Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037904, R01GM041449, R37GM037904] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06884] Funding Source: Medline; NIGMS NIH HHS [GM 37904, GM 41449] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1967, J BIOL CHEM, V242, P3237; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CASCIO M, 1990, J BIOL CHEM, V265, P2358; CASCIO M, 1988, PROTEINS, V4, P89, DOI 10.1002/prot.340040203; CASCIO M, 1995, ANAL BIOCHEM, V227, P90, DOI 10.1006/abio.1995.1257; CASCIO M, 1994, PROTEIN PEPTIDE LETT, V1, P136; CASPAR DLD, 1977, J CELL BIOL, V74, P605, DOI 10.1083/jcb.74.2.605; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CLARKE S, 1975, J BIOL CHEM, V250, P5459; CLARKE S, 1989, METHOD ENZYMOL, V172, P696; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GOODENOUGH DA, 1972, J CELL BIOL, V54, P646, DOI 10.1083/jcb.54.3.646; GORDON DJ, 1971, ARCH BIOCHEM BIOPHYS, V142, P481, DOI 10.1016/0003-9861(71)90511-X; HERTZBERG EL, 1979, J BIOL CHEM, V254, P2138; HERTZBERG EL, 1988, J BIOL CHEM, V263, P19105; HERTZBERG EL, 1984, J BIOL CHEM, V259, P9936; Kumar N M, 1992, Semin Cell Biol, V3, P3; KUMAR NM, 1986, J CELL BIOL, V103, P767, DOI 10.1083/jcb.103.3.767; LAEMMLI UK, 1970, NATURE, V224, P149; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; LEMAIRE M, 1989, J BIOCHEM-TOKYO, V106, P814, DOI 10.1093/oxfordjournals.jbchem.a122936; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LOEWENSTEIN WR, 1987, CELL, V48, P725, DOI 10.1016/0092-8674(87)90067-5; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MAKOWSKI L, 1984, J MOL BIOL, V174, P449, DOI 10.1016/0022-2836(84)90331-0; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MAO D, 1982, BIOCHEMISTRY-US, V21, P4960, DOI 10.1021/bi00263a020; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; NICHOLSON B, 1987, NATURE, V329, P732, DOI 10.1038/329732a0; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; REYNOLDS JA, 1985, METHOD ENZYMOL, V117, P41; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHNEIDER AS, 1976, BIOCHEMISTRY-US, V15, P4158, DOI 10.1021/bi00664a004; SMITH AP, 1978, BIOCHEMISTRY-US, V17, P1761, DOI 10.1021/bi00602a029; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; TIBBITTS TT, 1990, BIOPHYS J, V57, P1025, DOI 10.1016/S0006-3495(90)82621-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; WALLACE BA, 1984, P NATL ACAD SCI-BIOL, V81, P1406, DOI 10.1073/pnas.81.5.1406; Warner A., 1992, Seminars in Cell Biology, V3, P81; YOUNG JDE, 1987, CELL, V48, P733, DOI 10.1016/0092-8674(87)90071-7; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; ZIMMER DB, 1987, J BIOL CHEM, V262, P7751	48	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18643	18648		10.1074/jbc.270.31.18643	http://dx.doi.org/10.1074/jbc.270.31.18643			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629194	hybrid			2022-12-25	WOS:A1995RM64200076
J	JIANG, XC; BRUCE, C				JIANG, XC; BRUCE, C			REGULATION OF MURINE PLASMA PHOSPHOLIPID TRANSFER PROTEIN-ACTIVITY AND MESSENGER-RNA LEVELS BY LIPOPOLYSACCHARIDE AND HIGH CHOLESTEROL DIET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; ESTER TRANSFER PROTEIN; LIPID TRANSFER PROTEINS; ENDOTOXIN; RNA; ACYLTRANSFERASE; CONVERSION; EXCHANGE; LECITHIN; MOUSE	Plasma phospholipid transfer protein mediates the net movement of phospholipids between lipoproteins and between lipid bilayers and high density lipoprotein, In this study, the mouse phospholipid transfer protein cDNA was cloned by reverse transcription polymerase chain reactions based on the cDNA sequence of human phospholipid transfer protein, The predicted amino acid sequence of mouse phospholipid transfer protein shows the protein to be 476 amino acids long and to have a sequence identity of 83% with that of human phospholipid transfer protein, Mouse plasma phospholipid transfer protein activity is 1.5-2 times that of human plasma phospholipid transfer protein activity, As in humans, mouse peripheral tissues displayed a higher abundance of phospholipid transfer protein mRNA than observed in central organs, The order of phospholipid transfer protein mRNA expression was as follows: lung > adipose tissue, placenta, testis > brain > muscle, heart, liver, We examined the regulation of phospholipid transfer protein expression by dietary cholesterol and by bacterial lipopolysaccharide, A high fat, high cholesterol diet caused a significant increase (35%) in plasma phospholipid transfer protein activity and a significant increase (18%) in high density lipoprotein phospholipids. This increased activity was accompanied by similar to 100% increase in phospholipid transfer protein mRNA in lung, After lipopolysaccharide injection, plasma phospholipid transfer protein activity was decreased by similar to 66%, This decrease in activity was associated with a similar decrease in phospholipid transfer protein mRNA in lung, adipose tissue, and liver, The decrease in plasma phospholipid transfer protein activity was also associated with a significant increase (17%) in high density lipoprotein phospholipid concentration, The opposite changes in phospholipids levels with lipopolysaccharide treat ment and dietary cholesterol despite similarly increased high density lipoprotein phospholipids levels indicate that high density lipoprotein phospholipids levels are likely determined both by phospholipid transfer protein levels and by gradients of phospholipids concentration between high density lipoprotein and other phospholipids sources.			JIANG, XC (corresponding author), COLUMBIA UNIV,DEPT MED,DIV MOLEC MED,630 W 168TH ST,NEW YORK,NY 10032, USA.			Bruce, Can/0000-0002-3101-1250	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591, R01HL043165] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54591, HL43165] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAGBY GJ, 1980, AM J PHYSIOL, V239, pH325; Brown ML, 1990, CURR OPIN LIPIDOL, V1, P122; DAY JR, 1994, J BIOL CHEM, V269, P9388; DULLAART RPF, 1994, ARTERIOSCLER THROMB, V14, P1581, DOI 10.1161/01.ATV.14.10.1581; DULLAART RPF, 1994, EUR J CLIN INVEST, V24, P188, DOI 10.1111/j.1365-2362.1994.tb00987.x; ETTINGER WH, 1992, BIOCHIM BIOPHYS ACTA, V1128, P186, DOI 10.1016/0005-2760(92)90306-G; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS, P335; HOFFMAN JS, 1982, J BIOL CHEM, V257, P510; JANSEN H, 1992, BIOCHIM BIOPHYS ACTA, V1128, P181, DOI 10.1016/0005-2760(92)90305-F; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; JIANG XC, 1991, J BIOL CHEM, V266, P4631; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; MARRA MN, 1990, J IMMUNOL, V144, P662; MASUCCIMAGOULAS L, 1995, J CLIN INVEST, V95, P1587, DOI 10.1172/JCI117832; MEIJER GW, 1993, BIOCHEM J, V293, P729, DOI 10.1042/bj2930729; POWNALL HJ, 1991, J LIPID RES, V32, P793; QUINET EM, 1990, J CLIN INVEST, V85, P3357; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; SU GL, 1994, J IMMUNOL, V153, P743; TALL AR, 1983, J BIOL CHEM, V258, P2174; TALL AR, 1985, J LIPID RES, V26, P842; TALL AR, 1986, J LIPID RES, V27, P361; TALL AR, 1993, J LIPID RES, V34, P1255; TALL AR, 1983, J LIPID RES, V24, P277; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOBIAS PS, 1986, J EXP MED, V164, P7777; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TU AY, 1993, J BIOL CHEM, V268, P23098; TU AY, 1995, BIOCHEM BIOPH RES CO, V207, P552, DOI 10.1006/bbrc.1995.1223; ULEVITCH RJ, 1978, J CLIN INVEST, V62, P1313, DOI 10.1172/JCI109252; VOYNOYASENETSKA.TA, 1993, P NATL ACAD SCI USA, V90, P4256	34	97	101	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17133	17138		10.1074/jbc.270.29.17133	http://dx.doi.org/10.1074/jbc.270.29.17133			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615508	hybrid			2022-12-25	WOS:A1995RK68900015
J	JOHNSON, ES; MA, PCM; OTA, IM; VARSHAVSKY, A				JOHNSON, ES; MA, PCM; OTA, IM; VARSHAVSKY, A			A PROTEOLYTIC PATHWAY THAT RECOGNIZES UBIQUITIN AS A DEGRADATION SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; SHORT-LIVED PROTEIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MULTIUBIQUITIN CHAIN; BETA-GALACTOSIDASE; BINDING-PROTEINS; SHUTTLE VECTORS; E6 ONCOPROTEIN; GENE ENCODES	Previous work has shown that a fusion protein bearing a ''nonremovable'' N-terminal ubiquitin (Uh) moiety is short-lived in vivo, the fusion's Ub functioning as a degradation signal. The proteolytic system involved, termed the UFD pathway (Ub fusion degradation), was dissected in the yeast Saccharomyces cerevisiae by analyzing mutations that perturb the pathway. Two of the five genes thus identified, UFD1 and UFD5, function at post ubiquitination steps in the UFD pathway. UFD3 plays a role in controlling the concentration of Ub in a cell: ufd3 mutants have greatly reduced levels of free Ub, and the degradation of Ub fusions in these mutants can be restored by overexpressing Ub. UFD2 and UFD4 appear to influence the formation and topology of a multi-Ub chain linked to the fusion's Ub moiety. UFD1, UFD2, and UFD4 encode previously undescribed proteins of 40, 110, and 170 kDa, respectively. The sequence of the last similar to 280 residues of Ufd4p is similar to that of E6AP, a human protein that binds to both the E6 protein of oncogenic papilloma viruses and the tumor suppressor protein p53, whose Ub-dependent degradation involves E6AP. UFD5 is identical to the previously identified SON1, isolated as an extragenic suppressor of sec63 alleles that impair the transport of proteins into the nucleus. UFD5 is essential for activity of both the UFD and N-end rule pathways (the latter system degrades proteins that bear certain N-terminal residues). We also show that a Lys --> Arg conversion at either position 29 or position 48 in the fusion's Ub moiety greatly reduces ubliquitination and degradation of Ub fusions to beta-galactosidase. By contrast, the ubiquitination and degradation of Ub fusions to dihydrofolate reductase are inhibited by the Ub(R29) but not by the Ub(R48) moiety. ufd4 mutants are unable to ubiquitinate the fusion's Ub moiety at Lys(29), whereas ufd2 mutants are impaired in the ubiquitination at Lys(48). These and related findings suggest that Ub-Ub isopeptide bonds in substrate-linked multi-Ub chains involve not only the previously identified Lys(48) but also Lys(29) of Ub, and that structurally different multi-Ub chains have distinct functions in Ub-dependent protein degradation.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology					NIDDK NIH HHS [DK39520] Funding Source: Medline; NIGMS NIH HHS [GM31530] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039520, R37DK039520, R56DK039520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARCHAMBAULT J, 1992, J BIOL CHEM, V267, P3282; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER R, 1991, NUCLEIC ACIDS RES, V19, P1945, DOI 10.1093/nar/19.8.1945; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BUTT TR, 1988, J BIOL CHEM, V263, P16364; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COVITZ PA, 1991, GENE DEV, V5, P1982, DOI 10.1101/gad.5.11.1982; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GREGORI L, 1990, J BIOL CHEM, V265, P8354; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1992, THESIS MIT CAMBRIDGE; JOHNSSON N, 1994, P NATL ACAD SCI USA, V91, P10340, DOI 10.1073/pnas.91.22.10340; LINNEN JM, 1993, GENE, V128, P181, DOI 10.1016/0378-1119(93)90561-G; MADURA K, 1993, J BIOL CHEM, V268, P12046; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; MULLER D, 1992, NUCLEIC ACIDS RES, V20, P1471, DOI 10.1093/nar/20.7.1471; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NELSON MK, 1993, GENETICS, V134, P159; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P119; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PARKHURST SM, 1988, GENE DEV, V2, P1205, DOI 10.1101/gad.2.10.1205; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PASCOLO S, 1992, YEAST, V8, P987, DOI 10.1002/yea.320081109; PICKART CM, 1988, UBIQUITIN, P77; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; ROSE M, 1981, P NATL ACAD SCI-BIOL, V78, P2460, DOI 10.1073/pnas.78.4.2460; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH SA, 1992, MOL GEN GENET, V235, P285, DOI 10.1007/BF00279372; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WOYCHIK NA, 1992, P NATL ACAD SCI USA, V89, P3999, DOI 10.1073/pnas.89.9.3999; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	94	659	679	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17442	17456		10.1074/jbc.270.29.17442	http://dx.doi.org/10.1074/jbc.270.29.17442			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615550	hybrid			2022-12-25	WOS:A1995RK68900063
J	BURRITT, JB; QUINN, MT; JUTILA, MA; BOND, CW; JESAITIS, AJ				BURRITT, JB; QUINN, MT; JUTILA, MA; BOND, CW; JESAITIS, AJ			TOPOLOGICAL MAPPING OF NEUTROPHIL CYTOCHROME-B EPITOPES WITH PHAGE-DISPLAY LIBRARIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE-GENERATING OXIDASE; NADPH-BINDING-COMPONENT; CELL-FREE SYSTEM; HUMAN-GRANULOCYTES; PEPTIDE LIBRARIES; PLASMA-MEMBRANE; NUCLEOTIDE; ACTIVATION; PROTEIN	Cytochrome b of human neutrophils is the central component of the microbicidal NADPH-oxidase system. However, the folding topology of this integral membrane protein remains undetermined. Two random-sequence bacteriophage peptide libraries were used to map structural features of cytochrome b by determining the epitopes of monoclonal antibodies (mAbs) 44.1 and 54.1, specific for the p22(phox) and gp91(phox) cytochrome b chains, respectively. The unique peptides of phage selected by mAb affinity purification were deduced from the phage DNA sequences. Phage selected by mAb 44.1 displayed the consensus peptide sequence GGPQVXPI, which is nearly identical to (181)GGPQVNPI(188) of p22(phox). Phage selected by mAb 54.1 displayed the consensus sequence PKXAVDGP, which resembles (382)pKIAVDGP(389) of gp91(phox). Western blotting demonstrated specific binding of each mAb to the respective cytochrome b subunit and selected phage peptides. In flow cytometric analysis, mAb 44.1 bound only permeabilized neutrophils, while 54.1 did not bind intact or permeabilized cells. However, mAb 54.1 immunosedimented detergent-solubilized cytochrome b in sucrose gradients. These results suggest the (181)GGPQVNPI(188) segment of p22(phox) is accessible on its intracellular surface, but the (382)PKIAVDGP(389) region on gp91(phox) is not accessible to antibody, and probably not on the protein surface.	MONTANA STATE UNIV,DEPT MICROBIOL,BOZEMAN,MT 59717; MONTANA STATE UNIV,DEPT VET MOLEC BIOL,BOZEMAN,MT 59717	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman				Jesaitis, Algirdas/0000-0001-9001-5617; Quinn, Mark/0000-0001-8114-5073	NIAID NIH HHS [5RO1 AI 26711] Funding Source: Medline; NIAMS NIH HHS [AR 20929] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026711] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BERENDES H, 1957, Minn Med, V40, P309; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P5720; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; Burritt J. B., 1994, Molecular Biology of the Cell, V5, p121A; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2, DOI 10.1006/clin.1993.1078; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; De Leo F. R., 1994, Molecular Biology of the Cell, V5, p121A; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; EBRIGHT R, 1992, GENE, V114, P81, DOI 10.1016/0378-1119(92)90710-7; FELICI F, 1993, GENE, V128, P21, DOI 10.1016/0378-1119(93)90148-V; GINSEL LA, 1990, BLOOD, V76, P2105; GOLDSMITH ME, 1977, BIOCHEMISTRY-US, V16, P2686, DOI 10.1021/bi00631a016; GUILLET V, 1993, STRUCTURE, V1, P165, DOI 10.1016/0969-2126(93)90018-C; HACKETT PB, 1988, INTRO RECOMBINANT DN; HENRY TJ, 1969, P NATL ACAD SCI USA, V62, P800, DOI 10.1073/pnas.62.3.800; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; JAZWINSKI SM, 1973, P NATL ACAD SCI USA, V70, P205, DOI 10.1073/pnas.70.1.205; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; LANDING BH, 1957, PEDIATRICS, V20, P431; MICELI RM, 1994, J IMMUNOL METHODS, V167, P279, DOI 10.1016/0022-1759(94)90097-3; Miller J.H., 1972, EXPT MOL GENETICS; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, BIOCHIM BIOPHYS ACTA, V932, P71, DOI 10.1016/0005-2728(88)90140-5; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PARKOS CA, 1992, MOL BASIS OXIDATIVE; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SMITH RM, 1991, BLOOD, V77, P673; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; TZAGOLOFF H, 1964, VIROLOGY, V24, P372, DOI 10.1016/0042-6822(64)90174-6; UMEI T, 1987, BIOCHEM J, V243, P467, DOI 10.1042/bj2430467; UMEI T, 1991, J BIOL CHEM, V266, P6019; UMEI T, 1986, J BIOL CHEM, V261, P5229; WOOLFORD JL, 1977, BIOCHEMISTRY-US, V12, P2694	49	155	160	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16974	16980		10.1074/jbc.270.28.16974	http://dx.doi.org/10.1074/jbc.270.28.16974			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622517	Green Submitted, hybrid			2022-12-25	WOS:A1995RJ34700078
J	CANDEIAS, LP; HARVEY, PJ				CANDEIAS, LP; HARVEY, PJ			LIFETIME AND REACTIVITY OF THE VERATRYL ALCOHOL RADICAL-CATION - IMPLICATIONS FOR LIGNIN PEROXIDASE CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULSE-RADIOLYSIS; OXIDATION; BIODEGRADATION; CHRYSOSPORIUM; HORSERADISH; ACID	The formation and decay of veratryl alcohol radical cation upon oxidation of veratryl alcohol by thallium (II) ions was studied by pulse radiolysis with spectrophotometric and conductometric detection. In aqueous solution at pH 3 the radical cation decays by a first order process, assigned to the deprotonation from the ru-carbon. On the basis of its Lifetime (59 +/- 8 ms) and of its ability to oxidize a polymeric dye (Poly R-478) we estimate that the radical cation can diffuse about 7 mu m in an aqueous environment to act as a mediator of oxidations over long distances. However, 4-methoxymandelic acid is not oxidized by the veratryl alcohol radical cation in homogeneous solution, and the comparison with previous studies on lignin peroxidase catalysis suggests a second role for veratryl alcohol radical cation in the enzyme action: it may exist as an enzyme-bound species that has either a longer lifetime or a higher reduction potential than the free radical cation in bulk solution.	UNIV GREENWICH,SCH BIOL & CHEM SCI,LONDON SE18 6PF,ENGLAND	University of Greenwich	CANDEIAS, LP (corresponding author), MT VERNON HOSP,GRAY LAB,POB 100,NORTHWOOD HA6 2JR,MIDDX,ENGLAND.		Harvey, Patricia/D-4577-2012	Harvey, Patricia/0000-0001-7193-4570				BANCI L, 1993, BIOCHEMISTRY-US, V32, P5825, DOI 10.1021/bi00073a015; BARR DP, 1994, ARCH BIOCHEM BIOPHYS, V312, P511, DOI 10.1006/abbi.1994.1339; BIELSKI BHJ, 1993, RADIAT PHYS CHEM, V41, P527, DOI 10.1016/0969-806X(93)90015-M; CANDEIAS LP, 1993, FREE RADICAL BIO MED, V15, P385, DOI 10.1016/0891-5849(93)90038-V; CERCEK B, 1966, J CHEM SOC A, P612, DOI 10.1039/j19660000612; DEJONG E, 1994, FEMS MICROBIOL REV, V13, P153, DOI 10.1016/0168-6445(94)90078-7; GILARDI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P129, DOI 10.1016/0167-4838(90)90055-K; HAMMEL KE, 1991, ENZYME MICROB TECH, V13, P15, DOI 10.1016/0141-0229(91)90182-A; HARVEY PJ, 1986, FEBS LETT, V195, P242, DOI 10.1016/0014-5793(86)80168-5; KERSTEN PJ, 1990, BIOCHEM J, V268, P475, DOI 10.1042/bj2680475; KODURI RS, 1994, BIOCHEMISTRY-US, V33, P4225, DOI 10.1021/bi00180a016; ONEILL P, 1975, J PHYS CHEM-US, V79, P2773, DOI 10.1021/j100592a013; PASCZYNSKI A, 1991, BIOCHEM BIOPH RES CO, V178, P1056; REDDY CA, 1994, FEMS MICROBIOL REV, V13, P137, DOI 10.1016/0168-6445(94)90077-9; SCHOEMAKER HE, 1994, FEMS MICROBIOL REV, V13, P321, DOI 10.1111/j.1574-6976.1994.tb00052.x; SCOTT SL, 1993, J PHYS CHEM-US, V97, P6710, DOI 10.1021/j100127a022; TABATA Y, 1991, HDB RAD CHEM, P79; Tabata Y., 1990, PULSE RADIOLYSIS; TIEN M, 1986, J BIOL CHEM, V261, P1687; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; VALLI K, 1990, BIOCHEMISTRY-US, V29, P8535, DOI 10.1021/bi00489a005; WELLINDER KG, 1995, BIOCHEM SOC T, V23, P257	22	63	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16745	16748		10.1074/jbc.270.28.16745	http://dx.doi.org/10.1074/jbc.270.28.16745			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622486	hybrid			2022-12-25	WOS:A1995RJ34700046
J	CORNILLE, F; DELOYE, F; FOURNIEZALUSKI, MC; ROQUES, BP; POULAIN, B				CORNILLE, F; DELOYE, F; FOURNIEZALUSKI, MC; ROQUES, BP; POULAIN, B			INHIBITION OF NEUROTRANSMITTER RELEASE BY SYNTHETIC PROLINE-RICH PEPTIDES SHOWS THAT THE N-TERMINAL DOMAIN OF VESICLE-ASSOCIATED MEMBRANE PROTEIN/SYNAPTOBREVIN IS CRITICAL FOR NEURO-EXOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETANUS TOXIN; ACETYLCHOLINE-RELEASE; PROTEIN; GENES; SYNAPTOBREVIN; NEUROTOXINS; IDENTIFICATION; SYNAPTOTAGMIN; DROSOPHILA; APLYSIA	Tetanus toxin and clostridial neurotoxins type B, D, F, and G inhibit intracellular Ca2+ dependent neurotransmitter release via the specific proteolytic cleavage of vesicle-associated membrane protein (VAMP)/synaptobrevin, a highly conserved 19-kDa integral protein of the small synaptic vesicle membrane. This results in the release of the larger part of the cytosolic domain of this synaptic protein into the cytoplasm. Microinjection of synthetic peptides corresponding to this fragment into identified presynaptic neurons of Aplysia californica led to a potent, long lasting, and dose-dependent inhibition (similar to 50% at 10 mu M) of acetylcholine release, probably by hindering endogenous VAMP/synaptobrevin from interacting with synaptic proteins involved in exocytosis. Structure activity studies showed that this effect is confined to the N-terminal domain of VAMP/synaptobrevin isoform II and is related to the presence of a proline-rich motif (PGGPXGX(3)PP or PAAPXGX(3)PP). At higher concentrations, the inhibitory effect was lower and only transient, suggesting that the N-terminal proline-rich domain of VAMP/synaptobrevin plays opposing roles in neurotransmitter release very likely by interacting with different synaptic proteins. This probably occurs by disruption of the recently reported in vitro VAMP-synaptophysin interaction that involves the N-terminal domain of VAMP II and was proposed to hinder synaptophysin-related formation of a fusion pore. The observed recovery of neurotransmitter release following injection of high concentration of N-terminal fragments of VAMP II brings a strong in vivo support to this hypothesis. The minimum active peptide GPGGPQGGMQPPREQS could be used for rationally designing potent synthetic blockers of neurotransmission.	UNIV PARIS 05,FAC PHARM,FAC SCI PHARMACEUT & BIOL,DEPT PHARMACOCHIM MOLEC & BIOL,CNRS,F-75270 PARIS 06,FRANCE; CNRS,NEUROBIOL CELLULAIRE & MOLEC LAB,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BARK IC, 1994, P NATL ACAD SCI USA, V91, P4621, DOI 10.1073/pnas.91.11.4621; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CORNILLE F, 1994, EUR J BIOCHEM, V222, P173, DOI 10.1111/j.1432-1033.1994.tb18855.x; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DIANTONIO A, 1993, J NEUROSCI, V13, P4924; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GARDNER D, 1971, SCIENCE, V173, P550, DOI 10.1126/science.173.3996.550; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HORIKAWA HPM, 1993, FEBS LETT, V2, P236; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; JOHN R, 1994, ANNU REV NEUROSCI, V17, P219; LLINAS R, 1994, J PHYSIOL-LONDON, V477, P129, DOI 10.1113/jphysiol.1994.sp020177; MACMAHON HT, 1993, NATURE, V364, P346; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOCHIDA S, 1989, FEBS LETT, V253, P47, DOI 10.1016/0014-5793(89)80926-3; MOLGO J, 1990, J PHYSIOLOGY PARIS, V84, P152; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; POULAIN B, 1991, J BIOL CHEM, V266, P9580; POULAIN B, 1993, J NEUROCHEM, V61, P1175, DOI 10.1111/j.1471-4159.1993.tb03640.x; POULAIN B, 1995, IN PRESS CURR TOP IM, V195; POULAIN B, 1988, P NATL ACAD SCI USA, V85, P1090; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHANTZ EJ, 1992, MICROBIOL REV, V56, P80, DOI 10.1128/MMBR.56.1.80-99.1992; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOLLNER T, 1994, TRENDS NEUROSCI, V17, P3; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4238; WASHBOURNE P, 1995, BIOCHEM J, V305, P721, DOI 10.1042/bj3050721; YAMASAKI S, 1994, BIOCHEM BIOPH RES CO, V200, P829, DOI 10.1006/bbrc.1994.1526; YAMASAKI S, 1994, P NATL ACAD SCI USA, V981, P4688; [No title captured]	43	47	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16826	16832		10.1074/jbc.270.28.16826	http://dx.doi.org/10.1074/jbc.270.28.16826			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622497	hybrid			2022-12-25	WOS:A1995RJ34700058
J	DILWORTH, FJ; SCOTT, I; GREEN, A; STRUGNELL, S; GUO, YD; ROBERTS, EA; KREMER, R; CALVERLEY, MJ; MAKIN, HLJ; JONES, G				DILWORTH, FJ; SCOTT, I; GREEN, A; STRUGNELL, S; GUO, YD; ROBERTS, EA; KREMER, R; CALVERLEY, MJ; MAKIN, HLJ; JONES, G			DIFFERENT MECHANISMS OF HYDROXYLATION SITE SELECTION BY LIVER AND KIDNEY CYTOCHROME-P450 SPECIES (CYP27 AND CYP24) INVOLVED IN VITAMIN-D METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN; CELL-DIFFERENTIATION; KERATINOCYTE MODEL; MOLECULAR-CLONING; TUMOR PROGRESSION; D ANALOG; 1,25-DIHYDROXYVITAMIN-D3; 25-HYDROXYVITAMIN-D3; MITOCHONDRIA; EXPRESSION	A series of homologated 1 alpha-hydroxyvitamin D-3 and 1,25-dihydroxyvitamin D-3 molecules with one to three extra carbons in the side chain were used to examine the substrate preferences and hydroxylation site selection mechanisms of the liver vitamin D-3-25-hydroxylase (CYP27) and the target cell 25-hydroxyvitamin D-3-24-hydroxylase (CYP24). Cultured and transfected cell models, used as sources of these hydroxylases, gave 23-, 24-, 25-, and 27-hydroxylated metabolites which were identified by their high performance liquid chromatography and GC-MS characteristics. Lengthening the side chain is tolerated by each cytochrome P450 isoform such that 25-hydroxylation or 24-hydroxylation continues to occur at the same rate as in the native side chain, while the site of hydroxylation remains the same for the liver enzyme in that CYP27 continues to hydroxylate at C-25 and C-27 (minor) despite the two-carbon-atom extension. Somewhat surprising is the finding that C-24 and C-23 (minor) hydroxylations also do not change as the side chain is extended by as much as three carbons. We conclude that CYP24 must be directed to its hydroxylation site(s) by the distance of carbon 24 from the vitamin D ring structure and not as in CYP27 by the distance of the hydroxylation site from the end of the side chain.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON M5G 1X8,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3A 1A1,CANADA; LEO PHARMACEUT PROD,DEPT CHEM RES,DK-2750 BALLERUP,DENMARK; UNIV LONDON LONDON HOSP,COLL MED,DEPT CHEM PATHOL,LONDON E1 2AD,ENGLAND	Queens University - Canada; University of Toronto; McGill University; University of London; University College London				Dilworth, F. Jeffrey/0000-0002-6265-8102; Kremer, Richard/0000-0002-7053-2139; Scott, Ian/0000-0001-6665-1410				AKIYOSHISHIBATA M, 1994, EUR J BIOCHEM, V224, P335, DOI 10.1111/j.1432-1033.1994.00335.x; AMARNEH B, 1993, MOL ENDOCRINOL, V7, P1617, DOI 10.1210/me.7.12.1617; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BRETTING C, 1991, VITAMIN D, P159; BROWN AJ, 1992, BIOCHEM BIOPH RES CO, V189, P759, DOI 10.1016/0006-291X(92)92266-Z; Calverley M. J., 1992, ANTITUMOR STEROIDS, P193; DILWORTH FJ, 1994, BIOCHEM PHARMACOL, V47, P987; DILWORTH FJ, 1994, VITAMIN D, P131; GUO YD, 1993, P NATL ACAD SCI USA, V90, P8668, DOI 10.1073/pnas.90.18.8668; HENDERSON J, 1991, CANCER RES, V51, P6521; IKEKAWA N, 1993, BIOORG MED CHEM LETT, V3, P1789, DOI 10.1016/S0960-894X(00)80106-7; JONES G, 1993, TRENDS ENDOCRIN MET, V4, P297, DOI 10.1016/1043-2760(93)90049-K; JONES G, 1986, METHOD ENZYMOL, V123, P141; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; MASUDA S, 1994, J BIOL CHEM, V269, P4794; OFTEBRO H, 1981, J LIPID RES, V22, P1254; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OHYAMA Y, 1991, J BIOL CHEM, V266, P8690; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; OSTREM VK, 1987, P NATL ACAD SCI USA, V84, P2610, DOI 10.1073/pnas.84.9.2610; OSTREM VK, 1987, J BIOL CHEM, V262, P14164; PAULSON SK, 1990, J BONE MINER RES, V5, P201, DOI 10.1002/jbmr.5650050214; PERLMAN K, 1990, BIOCHEMISTRY-US, V29, P190, DOI 10.1021/bi00453a026; QAW F, 1993, J BIOL CHEM, V268, P282; REDDY GS, 1993, BIOORG MED CHEM LETT, V3, P1879, DOI 10.1016/S0960-894X(00)80124-9; ROBERTS EA, 1993, DRUG METAB DISPOS, V21, P56; SAMBROOK J, 1985, MOL CLONING LABORATO; SEBAG M, 1992, J BIOL CHEM, V267, P12162; SORENSEN H, 1990, BIOCHEM PHARMACOL, V39, P391, DOI 10.1016/0006-2952(90)90039-N; STRUGNELL S, 1990, BIOCHEM PHARMACOL, V40, P333, DOI 10.1016/0006-2952(90)90696-I; SUDA T, 1990, ANNU REV NUTR, V10, P195, DOI 10.1146/annurev.nu.10.070190.001211; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; USUI E, 1990, FEBS LETT, V274, P175, DOI 10.1016/0014-5793(90)81357-T	33	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16766	16774		10.1074/jbc.270.28.16766	http://dx.doi.org/10.1074/jbc.270.28.16766			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622489	hybrid			2022-12-25	WOS:A1995RJ34700049
J	PENG, HB; RAJAVASHISTH, TB; LIBBY, P; LIAO, JK				PENG, HB; RAJAVASHISTH, TB; LIBBY, P; LIAO, JK			NITRIC-OXIDE INHIBITS MACROPHAGE-COLONY-STIMULATING FACTOR GENE-TRANSCRIPTION IN VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; LOW-DENSITY LIPOPROTEINS; ATHEROSCLEROTIC LESIONS; MESSENGER-RNA; EXPRESSION; ADHESION; INVITRO; ACTIVATION; INDUCTION	Macrophage-colony stimulating factor (M-CSF) contributes to atherogenesis by regulating macrophage-derived foam cells in atherosclerotic lesions. Here we report that nitric oxide (NO) inhibits the expression of M-CSF in human vascular endothelial cells independent of guanylyl cyclase activation. The induction of M-CSF mRNA expression by either oxidized low density lipoprotein (ox-LDL) or tumor necrosis factor-alpha (TNF alpha) was attenuated by NO donors, S-nitrosoglutathione (GSNO), sodium nitroprusside (SNP), and 3-morpholinosydnonimine, but not by cGMP analogues, glutathione, or nitrite. Inhibition of endogenous NO production by N-monomethyl-L-arginine (L-NMA) also increased M-CSF expression in control and TNF alpha-stimulated cells. Nuclear run-on assays and transfection studies using M-CSF promoter constructs linked to chloramphenicol acetyltransferase reporter gene indicated that NO repressed M-CSF gene transcription through nuclear factor-kappa B (NF-kappa B). Electrophoretic mobility shift assays demonstrated that activation of NF-kappa B by L-NMA, ox-LDL, and TNF alpha was attenuated by GSNO and SNP, but not by glutathione or cGMP analogues. Since the induction of M-CSF expression depends upon NF-kappa B activation, the ability of NO to inhibit NF-kappa B activation and M-CSF expression may contribute to some of NO's antiatherogenic properties.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Libby, Peter/AAY-6404-2021; Rajavashisth, Tripathi/ABB-6379-2020	Libby, Peter/0000-0002-1502-502X; 	NHLBI NIH HHS [HL34636, HL02508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034636, R01HL034636] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOSSALER C, 1987, J CLIN INVEST, V79, P174; CLINTON SK, 1992, AM J PATHOL, V140, P301; COLLINS T, 1993, LAB INVEST, V68, P499; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUNSCH C, 1994, J IMMUNOL, V153, P153; KURUSE L, 1993, CIRC RES, V73, P164; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LIAO JK, 1994, J BIOL CHEM, V269, P12987; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MUNN DH, 1993, CANCER RES, V53, P2603; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RASBAND W, 1993, NIH IMAGE PROGRAM; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; Sambrook J, 1989, MOL CLONING LABORATO; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; STANLEY ER, 1978, NATURE, V274, P168, DOI 10.1038/274168a0; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; TIPPING PG, 1993, AM J PATHOL, V142, P1721; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1; YAMADA H, 1991, BLOOD, V78, P1988; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	44	156	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					17050	17055		10.1074/jbc.270.28.17050	http://dx.doi.org/10.1074/jbc.270.28.17050			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622526	hybrid			2022-12-25	WOS:A1995RJ34700089
J	CREUWELS, LAJM; BOER, EH; DEMEL, RA; VANGOLDE, LMG; HAAGSMAN, HP				CREUWELS, LAJM; BOER, EH; DEMEL, RA; VANGOLDE, LMG; HAAGSMAN, HP			NEUTRALIZATION OF THE POSITIVE CHARGES OF SURFACTANT PROTEIN-C - EFFECTS ON STRUCTURE AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; LUNG SURFACTANT; SP-B; MONOMOLECULAR LAYERS; ORIENTATION; LIPOPEPTIDE; MEMBRANES; RESIDUES; BILAYER; BOVINE	Pulmonary surfactant protein C (SP-C) is a small, extremely hydrophobic peptide with a highly conservative primary structure. The protein is characterized by two adjacent palmitoylated cysteine residues, two positively charged residues (one arginine residue and one lysine residue) in the N-terminal region, and a long hydrophobic stretch. SP-C enhances the adsorption of phospho lipids into an air-water interface. To determine the importance of the positively charged residues, we carried out experiments with natural porcine SP-C and modified porcine SP-C (SP-C-m) in which the positive charges had been blocked by phenylglyoxal. Circular dichroism experiments showed that SP-C-m had an increased content of alpha-helix. Natural SP-C, but not SP-C-m, catalyzed insertion of phospholipids into a monolayer at the air-water interface. This reduced insertion was due to a strong reduction of binding of phospholipid vesicles to the monolayer. The insertion catalyzed by the natural porcine SP-C was decreased by an increased pH of the subphase. In contrast to natural SP-C, SP-C-m induced lipid mixing between phospholipid vesicles. The extent of lipid mixing was a function of the SP-C content. We conclude that the positively charged residues of SP-C are important for the binding of phospholipid vesicles to the monolayer, a process that precedes the insertion of phospholipids into the monolayer.	UNIV UTRECHT,VET BIOCHEM LAB,3508 TD UTRECHT,NETHERLANDS; UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,3508 TD UTRECHT,NETHERLANDS	Utrecht University; Utrecht University			Haagsman, Henk P/F-8919-2010					BAATZ JE, 1992, CHEM PHYS LIPIDS, V63, P91, DOI 10.1016/0009-3084(92)90026-L; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; CHUNG J, 1989, BIOCHIM BIOPHYS ACTA, V1002, P348, DOI 10.1016/0005-2760(89)90349-4; CRENWELS LAJ, 1993, J BIOL CHEM, V268, P26752; CREUWELS LAJM, 1995, BBA-LIPID LIPID MET, V1254, P326, DOI 10.1016/0005-2760(94)00195-5; CURSTEDT T, 1990, P NATL ACAD SCI USA, V87, P2985, DOI 10.1073/pnas.87.8.2985; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAAGSMAN HP, 1991, ANNU REV PHYSIOL, V53, P441, DOI 10.1146/annurev.ph.53.030191.002301; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; JOHANSSON J, 1991, FEBS LETT, V281, P119, DOI 10.1016/0014-5793(91)80373-B; KELLER A, 1991, BIOCHEM J, V277, P493, DOI 10.1042/bj2770493; KEOUGH KMW, 1992, PULMONARY SURFACTANT, P110; LIS LJ, 1982, BIOPHYS J, V37, P657; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; OOSTERLAKENDIJK.MA, 1991, BIOCHEMISTRY-US, V30, P8276; OOSTERLAKENDIJK.MA, 1992, BIOCHIM BIOPHYS ACTA, V1110, P45; OOSTERLAKENDIJK.MA, 1991, BIOCHEMISTRY-US, V30, P10965; PASTRANA B, 1991, BIOCHEMISTRY-US, V30, P10058, DOI 10.1021/bi00105a033; PEREZGIL J, 1992, BIOPHYS J, V63, P197, DOI 10.1016/S0006-3495(92)81582-5; PHIZACKERLEY PJR, 1979, BIOCHEM J, V183, P731, DOI 10.1042/bj1830731; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; ROBERTSON B, 1991, PEDIATR RES, V30, P239, DOI 10.1203/00006450-199109000-00007; SASAKI T, 1985, BIOCHEMISTRY-US, V24, P1079, DOI 10.1021/bi00326a002; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIFFER K, 1993, BIOCHEMISTRY-US, V32, P590, DOI 10.1021/bi00053a026; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; TAKAHASHI A, 1986, BIOCHEM BIOPH RES CO, V135, P527, DOI 10.1016/0006-291X(86)90026-4; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAKAHASHI K, 1977, J BIOCHEM-TOKYO, V81, P395, DOI 10.1093/oxfordjournals.jbchem.a131471; VANDENBUSSCHE G, 1992, EUR J BIOCHEM, V203, P201, DOI 10.1111/j.1432-1033.1992.tb19848.x; WARR RG, 1987, P NATL ACAD SCI USA, V84, P7915, DOI 10.1073/pnas.84.22.7915	33	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16225	16229		10.1074/jbc.270.27.16225	http://dx.doi.org/10.1074/jbc.270.27.16225			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608188	hybrid			2022-12-25	WOS:A1995RH22600053
J	LI, CQ; DONG, JF; LANZA, F; SANAN, DA; SAETUNG, G; LOPEZ, JA				LI, CQ; DONG, JF; LANZA, F; SANAN, DA; SAETUNG, G; LOPEZ, JA			EXPRESSION OF PLATELET GLYCOPROTEIN (GP)-V IN HETEROLOGOUS CELLS AND EVIDENCE FOR ITS ASSOCIATION WITH GP IB-ALPHA IN FORMING A GP IB-IX-V COMPLEX ON THE CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH GLYCOPROTEINS; MEMBRANE; GENE	The glycoprotein (GP) Ib-IX-V complex comprises four polypeptides: the subunits of the GP Ib-IX complex (GP Ib alpha, GP Ib beta, GP IX) and GP V, To determine the requirements for cell-surface expression of GP V, we transiently expressed the recombinant polypeptide in wild-type Chinese hamster ovary (CHO) cells by cotransfection with plasmids for the subunits of the GP Ib-IX complex and in CHO cells that stably express different combinations of the GP Ib IX complex subunits. Glycoprotein V expressed alone was detectable on the cell surface, and the level was not augmented by cotransfection with any one of the subunits of the GP Ib-IX complex, However, when GP V was expressed in cells that stably express combinations of GP Ib-IX complex subunits, its expression on the cell surface was greater in an the cell lines that contained GP Ib alpha than in wild-type CHO cells, That GP V associates with GP Ib alpha was also suggested by confocal microscopy studies: GP V colocalized with GP Ib alpha in CHO alpha beta IX (cells that express GP Ib alpha, GP Ib beta, and GP IX), CHO alpha beta, and CHO alpha IX cells, but did not colocalize with GP Ib beta in CHO PIX cells, Similarly, immunoprecipitation of GP V from cells expressing GP Ib alpha led to coprecipitation of the latter polypeptide; neither GP Ib beta nor GP IX coprecipitated with GP V from CHO beta IX cells. Taken together, these data indicate that G;P V associates with the GP Ib-IX complex through a direct interaction with GP Ib alpha and establish the topology of the GP Ib-IX-V subunits on the cell surface.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94110; CTR REG TRANSFUS SANGUINE,INSERM,F-67085 STRASBOURG,FRANCE	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Lanza, Francois/H-9252-2016	Lanza, Francois/0000-0002-5802-4748	NHLBI NIH HHS [HL46416, HL02463] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002463, R29HL046416] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CLEMETSON JM, 1994, BLOOD, V84, P1124; DELASALLE C, 1995, BRIT J HAEMATOL, V89, P501; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; GEORGE JN, 1994, HEMOSTASIS THROMBOSI, P726; HICKEY MJ, 1993, P NATL ACAD SCI USA, V90, P8327, DOI 10.1073/pnas.90.18.8327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZA F, 1993, J BIOL CHEM, V268, P20801; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P479; LOPEZ JA, 1994, J BIOL CHEM, V269, P23716; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MCMICHAEL AJ, 1981, BRIT J HAEMATOL, V49, P501, DOI 10.1111/j.1365-2141.1981.tb07258.x; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; ROTH GJ, 1991, BLOOD, V77, P5; WRIGHT SD, 1993, BLOOD, V81, P2339	16	67	67	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16302	16307		10.1074/jbc.270.27.16302	http://dx.doi.org/10.1074/jbc.270.27.16302			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608197	hybrid			2022-12-25	WOS:A1995RH22600064
J	UDDIN, S; YENUSH, L; SUN, XJ; SWEET, ME; WHITE, MF; PLATANIAS, LC				UDDIN, S; YENUSH, L; SUN, XJ; SWEET, ME; WHITE, MF; PLATANIAS, LC			INTERFERON-ALPHA ENGAGES THE INSULIN-RECEPTOR SUBSTRATE-1 TO ASSOCIATE WITH THE PHOSPHATIDYLINOSITOL 3'-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; SH3 DOMAINS; PHOSPHORYLATION; IRS-1; STIMULATION; EXPRESSION; JAK	Interferon-alpha (IFN alpha) induces rapid tyrosine phosphorylation of the insulin receptor substrate-1 (IRS-1), a docking protein with multiple tyrosine phosphorylation sites that bind to the Src homology 2 (SH2) domains of various signaling proteins. During IFN alpha stimulation, the p85 regulatory subunit of the phosphatidylinositol 3'-kinase binds via its SH2 domains to tyrosine-phosphorylated IRS-1, and phosphatidylinositol 3'-kinase activity is detected in association with IRS-1. Thus, IFN alpha responses occur by activation of the IRS signaling system, which it shares with insulin, insulin-like growth factor-1, and interleukin-4.	EDWARD HINES VET ADM MED CTR,HINES,IL 60141; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	UDDIN, S (corresponding author), LOYOLA UNIV,DIV HEMATOL ONCOL,BLDG 112,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.		Yenush, Lynne/J-8815-2014	Yenush, Lynne/0000-0001-8589-7002; Uddin, Shahab/0000-0003-1886-6710	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038712, R01DK043808, R01DK038712, R55DK038712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38712, DK43808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUTCH MJ, 1992, P NATL ACAD SCI USA, V8, P11411; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LARNER AC, 1993, J IMMUNOL, V150, P1944; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; UDDIN S, 1995, J BIOL CHEM, V270, P7712, DOI 10.1074/jbc.270.13.7712; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032	30	185	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					15938	15941		10.1074/jbc.270.27.15938	http://dx.doi.org/10.1074/jbc.270.27.15938			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608146	hybrid			2022-12-25	WOS:A1995RH22600007
J	WHITE, TK; ZHU, QA; TANZER, ML				WHITE, TK; ZHU, QA; TANZER, ML			CELL-SURFACE CALRETICULIN IS A PUTATIVE MANNOSIDE LECTIN WHICH TRIGGERS MOUSE MELANOMA CELL SPREADING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING PROTEIN; LAMININ; PURIFICATION; EXPRESSION; HOMOLOGY; DOMAINS; ANTIGEN; CHAINS	B16 mouse melanoma cells adhere to and spread on laminin. We have previously shown that cell spreading is uncoupled from adhesion when unglycosylated laminin is used as a substratum; spreading was restored by a Pronase digest of laminin which became inactive when it was specifically depleted of its mannoside peptides; spreading was also specifically restored by mannosides such as mannan, Man9, and Man6, but not Man3. The effector mannosides bind to a cell surface receptor, previously shown by direct and indirect methods, We have now identified the receptor as cell surface calreticulin by isolating it via mannan affinity chromatography and showing its sequence identity with mouse calreticulin, Anti-calreticulin antibodies confirm this identity, decorate the B16 cell surface, and block cell spreading, Purified B16 cell calreticulin from whole cell lysates successfully competes with cell surface calreticulin and prevents cell spreading. The composite data implicate cell surface calreticulin as a putative lectin that must be occupied to initiate spreading of laminin-adherent B16 cells.	UNIV CONNECTICUT, CTR HLTH, SCH DENT MED, DEPT BIOSTRUCT & FUNCT, FARMINGTON, CT 06030 USA	University of Connecticut					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007340, R01AR017220] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR17220, T32 AR07340] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKITA EM, 1992, J FOOD SCI, V57, P629, DOI 10.1111/j.1365-2621.1992.tb08058.x; ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; Burns K, 1994, Trends Cell Biol, V4, P152; CHANDRASEKARAN S, 1994, J BIOL CHEM, V269, P3367; CHANDRASEKARAN S, 1994, J BIOL CHEM, V269, P3356; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEAN JW, 1990, J BIOL CHEM, V265, P12553; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; GERSTEN DM, 1990, BIOCHIM BIOPHYS ACTA, V1096, P20, DOI 10.1016/0925-4439(90)90007-C; GERSTEN DM, 1992, BIOCHIM BIOPHYS ACTA, V1138, P109, DOI 10.1016/0925-4439(92)90049-S; GINGELL D, 1993, SYM SOC EXP BIOL, V47, P1; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; HURLEY WL, 1990, METHOD ENZYMOL, V184, P429; KAWANO T, 1993, INT J CANCER, V53, P91, DOI 10.1002/ijc.2910530118; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; KRAMER RH, 1991, CANCER METAST REV, V10, P49, DOI 10.1007/BF00046843; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Malhotra R, 1993, Behring Inst Mitt, P254; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; Schweighoffer Tamas, 1992, Current Opinion in Cell Biology, V4, P824, DOI 10.1016/0955-0674(92)90106-M; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697	33	146	147	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					15926	15929		10.1074/jbc.270.27.15926	http://dx.doi.org/10.1074/jbc.270.27.15926			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608143	hybrid			2022-12-25	WOS:A1995RH22600004
J	ZHANG, HL; YUNIANTA; MARTIN, ML				ZHANG, HL; YUNIANTA; MARTIN, ML			SITE-SPECIFIC ISOTOPE FRACTIONATION IN THE CHARACTERIZATION OF BIOCHEMICAL-MECHANISMS - THE GLYCOLYTIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOGLUCOISOMERASE-CATALYZED INTERCONVERSION; NATURAL ABUNDANCE LEVEL; HEXOSE PHOSPHATES; DEUTERIUM; DISCRIMINATION; HYDROGEN; SUGAR; NMR	For a given biochemical transformation, such as the fermentation reaction, the redistribution coefficients, which relate the natural site specific isotope contents in end products to those of their precursors, are a source of mechanistic information, These coefficients characterize the traceability of specific hydrogens in the products (ethanol and water) to their parent hydrogens in the starting materials (glucose and water). In conditions of complete transformation, they also enable intermolecular exchanges with the water medium to be estimated. Thus it is directly confirmed that hydrogens 1, 2, 6, and 6' of glucose are strongly connected to the methyl site I of ethanol obtained by fermentation by Saccharomyces cerevisiae, However, whereas hydrogens 6 and 6' are transferred to a great extent, transfer is only partial for hydrogen 2, and it is even less for hydrogen 1. Because the two moieties of glucose corresponding to carbons 1-2-3 and 4-5-6 are scrambled by the aldolase and triosephosphate isomerase reactions, additional exchange of hydrogens at positions 1 and 2 must have occurred before these steps. The value of the coefficient that relates site 2 of glucose to site I of ethanol in particular can be used to quantify the contribution of intermolecular exchange occurring in the course of the transfer from site 2 of glucose 6-phosphate to site I of fructose 6-phosphate mediated by phosphoglucoisomerase. The average hydrogen isotope effects associated with the transfer of hydrogen from the water pool to the methyl or methylene site of ethanol are estimated. In contrast to conventional experiments carried out in strongly deuterium-enriched media where metabolic switching may occur, the NMR investigation of site-specific natural isotope fractionation, which operates at tracer isotopic abundance, faithfully describes the unperturbed metabolic pathways.			ZHANG, HL (corresponding author), UNIV NANTES,RESONANCE MAGNET NUCL & REACTIV CHIM LAB,CNRS,URA 472,2 RUE HOUSSINIERE,F-44072 NANTES 03,FRANCE.							COOK PF, 1980, BIOCHEMISTRY-US, V19, P4853, DOI 10.1021/bi00562a023; DENHOLLANDER JA, 1979, P NATL ACAD SCI USA, V76, P6096; DUNBAR J, 1983, VITIS, V22, P375; GUNTHER H, 1973, Z NATURFORSCH C, VC 28, P241; KOZIET J, 1993, ANAL CHIM ACTA, V271, P31, DOI 10.1016/0003-2670(93)80548-Y; LOEWUS FA, 1953, J AM CHEM SOC, V75, P5018, DOI 10.1021/ja01116a039; London R.E., 1992, BIOL MAGN RESON, V11, P277; MAHLER HR, 1957, J AM CHEM SOC, V79, P1159, DOI 10.1021/ja01562a035; MALAISSE WJ, 1990, MOL CELL BIOCHEM, V93, P153; MARTENS L, 1990, MOD AUSTRIAN LIT, V23, P1; MARTIN GJ, 1986, J AM CHEM SOC, V108, P5116, DOI 10.1021/ja00277a013; MARTIN GJ, 1981, TETRAHEDRON LETT, V22, P3525, DOI 10.1016/S0040-4039(01)81948-1; MARTIN GJ, 1991, J SCI FOOD AGR, V56, P419, DOI 10.1002/jsfa.2740560403; MARTIN YL, 1994, J MAGN RESON SER A, V111, P1, DOI 10.1006/jmra.1994.1218; MOUSSA I, 1990, J PHYS CHEM-US, V94, P8303, DOI 10.1021/j100384a056; RABILLER C, 1990, CHIRALITY, V2, P85, DOI 10.1002/chir.530020205; RIEDER SV, 1959, J BIOL CHEM, V234, P1007; ROSE IA, 1961, J BIOL CHEM, V236, P3086; ROSE IA, 1991, BIOCHEMISTRY-US, V30, P722, DOI 10.1021/bi00217a021; SAUR WK, 1968, BIOCHEMISTRY-US, V7, P3529, DOI 10.1021/bi00850a030; SCHMIDT K, 1968, Z NATURFORSCH PT B, VB 23, P64; SIMON H, 1968, Z NATURFORSCH PT B, VB 23, P59, DOI 10.1515/znb-1968-0112; WILLEM R, 1990, BIOCHEM J, V265, P519, DOI 10.1042/bj2650519; ZHANG BL, 1994, PHYTOCHEM ANALYSIS, V5, P105, DOI 10.1002/pca.2800050304	24	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16023	16029		10.1074/jbc.270.27.16023	http://dx.doi.org/10.1074/jbc.270.27.16023			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608163				2022-12-25	WOS:A1995RH22600024
J	FUJITA, M; SHIKU, H				FUJITA, M; SHIKU, H			DIFFERENCES IN SENSITIVITY TO INDUCTION OF APOPTOSIS AMONG RAT FIBROBLAST CELLS TRANSFORMED BY HTLV-I TAX GENE OR CELLULAR NUCLEAR ONCOGENES	ONCOGENE			English	Article						HTLV-I; TAX; C-MYC; C-FOS; APOPTOSIS; RAT-1	VIRUS TYPE-I; LONG TERMINAL REPEAT; NF-KAPPA-B; LEUKEMIA-VIRUS; C-FOS; TRANSCRIPTIONAL ACTIVATOR; NEOPLASTIC TRANSFORMATION; EXPRESSION; PROTEIN; MYC	The tax gene of human T lymphotropic virus type I has been implicated in the genesis of adult T cell leukemia (ATL), It has been reported that expression of tax induces neoplastic transformation in the rat fibroblast cell line Rat-1, and that co-expression with the ras gene can transform rat embryo fibroblasts. Possible activation of cellular oncogenes including c-myc and c-fos by tax has been implicated in these tax functions, In this study, comparative analysis of biological properties of tax and cellular nuclear oncogenes c-myc and c-fos was performed in Rat-1 cells, While all three oncogenes could transform Rat-1 cells, significant differences in the sensitivity to induction of apoptosis were observed between cells transformed with each oncogene, Induction of apoptosis by serum starvation was observed in tax-transfected Rat-1 cells but to a lesser extent than that in those transfected with c-myc or c-fos, In contrast, exposure to a DNA-damaging agent, etoposide, resulted in enhanced apoptotic death only in c-myc-transfected Rat-1 cells, Our findings indicate that the pathways for apoptosis induction may not be identical among these three oncogenes, and that the relatively low apoptosis-inducing activity and sufficient transforming capacity of tax might be associated with transformation of T cells and the low susceptibility of the transformed T cells (ATL cells) to chemotherapeutic agents.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN	Nagasaki University				Fujita, Masatoshi/0000-0001-6617-2452				BHALLA K, 1993, BLOOD, V82, P3133; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJITA M, 1994, BLOOD, V84, P2591, DOI 10.1182/blood.V84.8.2591.bloodjournal8482591; FUJITA M, 1993, FEBS LETT, V322, P15, DOI 10.1016/0014-5793(93)81101-5; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MILLER AD, 1984, CELL, V36, P51; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKAMURA M, 1989, J BIOL CHEM, V264, P20189; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SAKURAI M, 1992, INT J CANCER, V52, P323, DOI 10.1002/ijc.2910520228; Sambrook J., 1989, MOL CLONING; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TSUDA H, 1993, JPN J CANCER RES, V84, P431, DOI 10.1111/j.1349-7006.1993.tb00154.x; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; 1991, LEUKEMIA RES, V15, P81	45	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					15	20						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624122				2022-12-25	WOS:A1995RJ29500003
J	HAAPAJARVI, T; KIVINEN, L; PITKANEN, K; LAIHO, M				HAAPAJARVI, T; KIVINEN, L; PITKANEN, K; LAIHO, M			CELL-CYCLE DEPENDENT EFFECTS OF UV-RADIATION ON P53 EXPRESSION AND RETINOBLASTOMA PROTEIN-PHOSPHORYLATION	ONCOGENE			English	Article						P53; PRB; GROWTH ARREST; CELL CYCLE; UV RADIATION	WILD-TYPE P53; SUSCEPTIBILITY GENE-PRODUCT; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGING AGENTS; IONIZING-RADIATION; APOPTOSIS; INDUCTION; PROLIFERATION; CHECKPOINT; GROWTH	Control of fate of cells encountered with DNA damaging agents is pivotal for normal cellular homeostasis. DNA damage leads in many cases to growth arrest of the cells ensuring sufficient time for damage repair. Growth arrest can be mediated by p53 tumor suppressor protein and loss pf its function leads to inability of the cells to both growth arrest and undergo apoptosis. We show here that followed by genotoxic stress, the retinoblastoma gene product, pRB, is associated with growth arrest of cells in a p53 independent manner. In u.v.-treated human and mouse fibroblasts, pRB is rapidly dephosphorylated. pRB dephosphorylation occurs concomitant with growth arrest of cells including cells with p53 mutations (SW 480 colon carcinoma cells), cells expressing SV40 T antigen and rat-transformed cells (T-24 bladder carcinoma cells) unresponsive in regard to p53 stimulation. Furthermore, how cytometry analysis of u.v.-radiated synchronized G1 cells indicates that the cells transiently arrest in G1 for 10-12 h with pRB dominating in its underphosphorylated form, whereas p53 accumulation occurs only after the cells have entered into S-phase. In addition, u.v.-radiation of late S- and G2/M-phase cells leads to p53 accumulation and cell cycle arrest. The results indicate that p53 accumulation upon u.v.-radiation occurs during DNA replication and is thus not involved in G1 arrest. We suggest that the events that lead to pRB dephosphorylation upon u.v.-radiation provide the cell an efficient G1 arrest which occurs prior and independently of p53.	HELSINKI UNIV,DEPT VIROL,SF-00014 HELSINKI,FINLAND	University of Helsinki								BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRITSCHE M, 1993, ONCOGENE, V8, P307; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL PA, 1993, ONCOGENE, V8, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVINS JR, 1992, SCIENCE, V258, P424; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RON D, 1994, P NATL ACAD SCI USA, V91, P1985, DOI 10.1073/pnas.91.6.1985; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	49	43	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					151	159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624123				2022-12-25	WOS:A1995RJ29500018
J	PUGLIELLI, L; RIGOTTI, A; GRECO, AV; SANTOS, MJ; NERVI, F				PUGLIELLI, L; RIGOTTI, A; GRECO, AV; SANTOS, MJ; NERVI, F			STEROL CARRIER PROTEIN-2 IS INVOLVED IN CHOLESTEROL TRANSFER FROM THE ENDOPLASMIC-RETICULUM TO THE PLASMA-MEMBRANE IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTRACELLULAR-TRANSPORT; GOLGI-APPARATUS; EXPRESSION	The cellular mechanism of cholesterol transport from the endoplasmic reticulum to the plasma membrane is currently unknown. To assess the possibility that sterol carrier protein-2 (SCP-2) is involved in this transport, we studied the time course of newly synthesized cholesterol incorporation in the plasma membrane of normal and SCP-2 deficient (Zellweger syndrome) human fibroblasts. Cholesterol transfer was rapid, cytoskeleton-independent, and Golgi independent in normal cells, but it was slower, cytoskeleton dependent, and Golgi-dependent in SCP-2-deficient cells. After SCP-2 antisense oligonucleotides treatment of normal fibroblasts, the rapid transport was reduced by 81% with a simultaneous increase of the slower one. These results suggest that in normal fibroblasts the major fraction of newly synthesized cholesterol is trans ported to the plasma membrane by a SCP-2-dependent mechanism. In contrast, in SCP-2-deficient cells, newly synthesized cholesterol leaves the endoplasmic reticulum by a cytoskeleton/Golgi-dependent mechanism.	PONTIFICIA UNIV CATOLICA CHILE, FAC MED, DEPT GASTROENTEROL, SANTIAGO, CHILE; PONTIFICIA UNIV CATOLICA CHILE, FAC MED, CTR PARA PREVENT & TRATAMIENTO CANC DIGEST, SANTIAGO, CHILE; PONTIFICIA UNIV CATOLICA CHILE, FAC CIENCIAS BIOL, DEPT BIOL CELULAR & MOLEC, SANTIAGO, CHILE; UNIV CATTOLICA SACRO CUORE, FAC MED & CHIRURG, IST MED INTERNA, I-00198 ROME, ITALY	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli				Nervi, Flavio/0000-0002-6642-7985				BAUM CL, 1993, J LIPID RES, V34, P729; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN MS, 1974, J BIOL CHEM, V249, P7306; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FREEMAN DA, 1987, J BIOL CHEM, V262, P13061; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LANGE Y, 1991, J BIOL CHEM, V266, P2439; LISCUM L, 1992, J LIPID RES, V33, P1239; Liscum Laura, 1994, Current Opinion in Lipidology, V5, P221, DOI 10.1097/00041433-199405030-00010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; OSSENDORP BC, 1994, CURR TOP MEMBR, V40, P217, DOI 10.1016/S0070-2161(08)60983-1; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; ROSCHLAU P, 1974, Z KLIN CHEM KLIN BIO, V12, P403; SALMON ED, 1984, J CELL BIOL, V99, P1066, DOI 10.1083/jcb.99.3.1066; SCHRODER F, 1991, P SOC EXP BIOL MED, V193, P235; SLOTTE JP, 1994, CURR TOP MEMBR, V40, P483, DOI 10.1016/S0070-2161(08)60993-4; URBANI L, 1990, J BIOL CHEM, V265, P1919; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	26	106	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18723	18726		10.1074/jbc.270.32.18723	http://dx.doi.org/10.1074/jbc.270.32.18723			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642518	hybrid			2022-12-25	WOS:A1995RN95400004
J	WANG, Y; KENT, C				WANG, Y; KENT, C			IDENTIFICATION OF AN INHIBITORY DOMAIN OF CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHOLIPASE-C TREATMENT; MEMBRANE-ASSOCIATED CTP; HEP G2 CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; MAMMALIAN-CELLS; FATTY-ACIDS; HELA-CELLS; BACILLUS-SUBTILIS	The function of the putative amphipathic helices between residues 236 and 314 of CTP:phosphocholine cytidylyltransferase was examined by constructing two truncation mutants; CT314 was missing the entire phosphorylation segment, whereas CT236 was missing both the region with the putative amphipathic helices and the phosphorylation segment. Stable cells lines expressing these truncation mutants in Chinese hamster ovary 58 cells were isolated and characterized. CT314 was predominantly soluble in control cells but became membrane-associated in cells treated with oleate, which also causes translocation of wild type cytidylyltransferase. CT236 was found to be soluble both in control cells and in cells treated to cause translocation. These results strongly suggest that the membrane-binding site is located within residues 237-314. When assayed for activity in vitro, the mutant forms were catalytically active in the presence of exogenous lipids, CT236, moreover, was as active in the absence of lipids as in their presence, whereas CT314 required lipids for activity. The rate of phosphatidylcholine synthesis in cells expressing CT236 was considerably higher than in wild-type cells, consist ent with the enzyme being constitutively active in the cells. These results indicate that residues 237-314 constitute an inhibitory segment; when this segment is removed from the catalytic domain by truncation or by binding to membranes, an inhibitory constraint is removed and cytidylyltransferase is activated.	UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA064159] Funding Source: NIH RePORTER; NCI NIH HHS [CA64159] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CRAIG L, 1994, J BIOL CHEM, V269, P3311; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FELDMAN DA, 1980, BIOCHIM BIOPHYS ACTA, V620, P603, DOI 10.1016/0005-2760(80)90152-6; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; KALMAR GB, 1994, BBA-GENE STRUCT EXPR, V1219, P328, DOI 10.1016/0167-4781(94)90056-6; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KRUG EL, 1984, ARCH BIOCHEM BIOPHYS, V231, P400, DOI 10.1016/0003-9861(84)90403-X; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; MORAND JN, 1989, J BIOL CHEM, V264, P13785; PARK YS, 1993, J BIOL CHEM, V268, P16648; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; POOLE HM, 1991, J GEN MICROBIOL, V137, P921, DOI 10.1099/00221287-137-4-921; RUTHERFORD MS, 1993, GENOMICS, V18, P698, DOI 10.1016/S0888-7543(05)80377-5; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SLEIGHT R, 1983, J BIOL CHEM, V258, P824; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; WEINHOLD PA, 1994, BBA-LIPID LIPID MET, V1210, P335, DOI 10.1016/0005-2760(94)90238-0; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9	40	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18948	18952		10.1074/jbc.270.32.18948	http://dx.doi.org/10.1074/jbc.270.32.18948			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642553	hybrid			2022-12-25	WOS:A1995RN95400041
J	MCQUENEY, MS; MARKHAM, GD				MCQUENEY, MS; MARKHAM, GD			INVESTIGATION OF MONOVALENT CATION ACTIVATION OF S-ADENOSYLMETHIONINE SYNTHETASE USING MUTAGENESIS AND URANYL INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL ASPECTS; ESCHERICHIA-COLI; ION SPECIFICITY; BINDING-SITES; ACTIVE-SITE; METAL; SALTS; COMPLEXES; ENZYMES; DNA	S-Adenosylmethionine (AdoMet) synthetase catalyzes the formation of AdoMet from ATP and L-methionine with subsequent hydrolysis of the bound tripolyphosphate intermediate. Maximal activity requires the presence of two divalent and one monovalent cation per active site, Recently, the x-ray structure of the Escherichia coli AdoMet synthetase was solved, and the positions of the two Mg2+ binding sites were identified, Based on additional spherical electron density, the K+ binding site was postulated to be a nearby site where the uranyl heavy atom derivative also bound in the crystal, The side chain of glutamate 42 is within ligation distance of the metals. Mutagenesis of glutamate 42 to glutamine (E42QMetK) abolished monovalent cation activation and produced an enzyme that has kinetic properties virtually identical to those of K+-free wild type AdoMet synthetase in both the overall AdoMet synthetase reaction and in the hydrolysis of tripolyphosphate, Thus, there is a similar to 100-fold decrease in the V-max for AdoMet synthesis and large increases in the K-m values for both substrates. In contrast there is only a a-fold decrease in V-max for tripolyphosphate hydrolysis. The uranyl ion, UO22+, is a competitive inhibitor with respect to K+ (K-i = 350 nM) and is the first ion to bind at this site and inhibit the enzyme, The UO22+ inhibition is reversible and tight-binding, and results from UO22+ and not UO22+. ATP. Analogous to K+ activation, UO22+ predominantly inhibits AdoMet formation rather than tripolyphosphate hydrolysis, The kinetic results indicate that UO22+ inhibition is likely to result from interference with productive ATP binding, UO22+ remains a tight-binding inhibitor of the E42Q mutant, which suggests that K+ and UO22+ have different ligation preferences when bound in the monovalent cation binding pocket, The results support the model that glutamate 42 provides ligands to the K+ and has a major role in monovalent cation binding.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [GM-31186, GM-15790] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015790, R01GM031186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balzani V., 1978, TOP CURR CHEM, P1, DOI [10.1007/BFb0048835, DOI 10.1007/BFB0048835]; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BELL JT, 1965, J MOL SPECTROSC, V18, P247, DOI 10.1016/0022-2852(65)90140-2; BLUNDELL TL, 1976, PROTEIN CRYSTALLOGRA, P201; BOYLE SM, 1984, GENE, V30, P129, DOI 10.1016/0378-1119(84)90113-6; BUCHACHENKO AL, 1991, ACCOUNTS CHEM RES, V24, P177, DOI 10.1021/ar00006a004; Bucholtz A., 1805, ANN CHIM PHYS, V56, P142; BURROWS HD, 1974, CHEM SOC REV, V3, P139, DOI 10.1039/cs9740300139; BURROWS HD, 1989, MEM ACAD CIENCIAS LI, V30, P33; CARRELL CJ, 1988, J AM CHEM SOC, V110, P8651, DOI 10.1021/ja00234a011; Cleland W W, 1979, Methods Enzymol, V63, P103; COHN M, 1954, NATURE, V173, P1090, DOI 10.1038/1731090b0; FALKE JJ, 1991, BIOCHEMISTRY-US, V30, P8690, DOI 10.1021/bi00099a029; FELDMAN I, 1967, J AM CHEM SOC, V89, P49, DOI 10.1021/ja00977a010; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; GREENWOOD NN, 1986, CHEM ELEMENTS, P1478; HAMPTON A, 1969, BIOCHEMISTRY-US, V8, P2303, DOI 10.1021/bi00834a011; HUHEEY JE, 1983, INORG CHEM; JENKINS J, 1992, BIOCHEMISTRY-US, V31, P5449, DOI 10.1021/bi00139a005; JUNG WS, 1987, J CHEM SOC CHEM COMM, P372, DOI 10.1039/c39870000372; KE HYD, 1992, APPL SPECTROSC, V46, P1168, DOI 10.1366/0003702924124178; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MARKHAM GD, 1987, J BIOL CHEM, V262, P5609; MARKHAM GD, 1981, J BIOL CHEM, V256, P1903; MARKHAM GD, 1987, J AM CHEM SOC, V109, P599, DOI 10.1021/ja00236a057; MARKHAM GD, 1986, J BIOL CHEM, V261, P1507; Martell A.E., 1976, CRITICAL STABILITY C, V4; MATHEWS FS, 1971, COLD SPRING HARB SYM, V36, P387, DOI 10.1101/SQB.1972.036.01.050; NEEDHAM JV, 1993, BIOCHEMISTRY-US, V32, P3363, DOI 10.1021/bi00064a020; NIELSEN PE, 1988, FEBS LETT, V235, P122, DOI 10.1016/0014-5793(88)81245-6; NIELSEN PE, 1992, J AM CHEM SOC, V114, P4967, DOI 10.1021/ja00039a003; O'Sullivan W J, 1979, Methods Enzymol, V63, P294; Rabinowitch E., 1964, SPECTROSCOPY PHOTOCH; SCHLOSS JV, 1988, ACCOUNTS CHEM RES, V21, P348, DOI 10.1021/ar00153a005; SHANNON RD, 1969, ACTA CRYSTALL B-STRU, VB 25, P925, DOI 10.1107/S0567740869003220; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TANSWELL P, 1974, FEBS LETT, V48, P60, DOI 10.1016/0014-5793(74)81062-8; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; TOTH LM, 1981, J PHYS CHEM-US, V85, P547, DOI 10.1021/j150605a018; Williams J W, 1979, Methods Enzymol, V63, P437	41	37	39	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18277	18284		10.1074/jbc.270.31.18277	http://dx.doi.org/10.1074/jbc.270.31.18277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629147	hybrid			2022-12-25	WOS:A1995RM64200022
J	TOLLEFSBOL, TO; HUTCHISON, CA				TOLLEFSBOL, TO; HUTCHISON, CA			MAMMALIAN DNA (CYTOSINE-5-)-METHYLTRANSFERASE EXPRESSED IN ESCHERICHIA-COLI, PURIFIED AND CHARACTERIZED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; FRAGILE-X-SYNDROME; CPG DINUCLEOTIDE; METHYLATION PATTERNS; SEQUENCE SPECIFICITY; DENOVO METHYLATION; MISMATCH REPAIR; METHYLTRANSFERASE; GENE; 5-METHYLCYTOSINE	Besides modulating specific DNA-protein interactions, methylated cytosine, frequently referred to as the fifth base of the genome, also influences DNA structure, recombination, transposition, repair, transcription, imprinting, and mutagenesis, DNA (cytosine-5-)-methyl transferase catalyzes cytosine methylation in eukaryotes. We have cloned and expressed this enzyme in Escherichia coli, purified it to apparent homogeneity, characterized its properties, and we have shown that it hemimethylates DNA. The cDNA for murine maintenance methyltransferase was reconstructed and cloned for direct expression in native form. Immunoblotting revealed a unique protein (M(r) = 190,000) not present in control cells. The mostly soluble overexpressed protein was purified by DEAE, Sephadex, and DNA cellulose chromatography. Peak methylating activity correlated with methyltransferase immunoblots. The purified enzyme preferentially transferred radioactive methyl moieties to hemimethylated DNA in assays and on autoradiograms. All of the examined properties of the purified recombinant DNA methyltransferase are consistent with the enzyme purified from mammalian cells. Further characterization revealed enhanced in vitro methylation of premethylated oligodeoxynucleotides. The cloning of hemimethyltransferase in E. coli should allow facilitated structure-function mutational analysis of this enzyme, studies of its biological effects in prokaryotes, and potential large scale methyltransferase production for crystallography, and it may have broad applications in maintaining the native methylated state of cloned DNA.			TOLLEFSBOL, TO (corresponding author), UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CB 7290, 804 FLOB, CHAPEL HILL, NC 27599 USA.			Tollefsbol, Trygve/0000-0002-0284-1511	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021313] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR08998] Funding Source: Medline; NIGMS NIH HHS [GM21313] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEY NB, 1994, P NATL ACAD SCI USA, V91, P1569, DOI 10.1073/pnas.91.4.1569; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BARLETTA J, 1992, ANTIVIR RES, V18, P1, DOI 10.1016/0166-3542(92)90002-M; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOLDEN A, 1984, J BIOL CHEM, V259, P2437; BOLDEN AH, 1986, MOL CELL BIOL, V6, P1135, DOI 10.1128/MCB.6.4.1135; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; CZANK A, 1991, GENE, V109, P259, DOI 10.1016/0378-1119(91)90618-L; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DOERFLER W, 1990, FEBS LETT, V268, P329, DOI 10.1016/0014-5793(90)81280-2; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FEDOROFF NV, 1989, CELL, V56, P181, DOI 10.1016/0092-8674(89)90891-X; FEIL R, 1994, NUCLEIC ACIDS RES, V22, P695, DOI 10.1093/nar/22.4.695; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PEDRALINOY G, 1986, J BIOL CHEM, V261, P7600; PFEIFER GP, 1983, BIOCHIM BIOPHYS ACTA, V740, P323, DOI 10.1016/0167-4781(83)90141-0; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RALEIGH EA, 1986, P NATL ACAD SCI USA, V83, P9070, DOI 10.1073/pnas.83.23.9070; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; RIGGS AD, 1990, PHILOS T R SOC B, V326, P285, DOI 10.1098/rstb.1990.0012; Sambrook J, 1989, MOL CLONING LABORATO; SANO H, 1983, EUR J BIOCHEM, V135, P181, DOI 10.1111/j.1432-1033.1983.tb07635.x; SCHEIDT G, 1994, NUCLEIC ACIDS RES, V22, P953, DOI 10.1093/nar/22.6.953; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SELKER EU, 1993, SCIENCE, V262, P1724, DOI 10.1126/science.8259516; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SMITH SS, 1987, NUCLEIC ACIDS RES, V15, P6899, DOI 10.1093/nar/15.17.6899; SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A; SMITH SS, 1992, BIOCHEMISTRY-US, V31, P850, DOI 10.1021/bi00118a030; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5636, DOI 10.1128/MCB.14.9.5636; TOLLEFSBOL TO, 1993, MED HYPOTHESES, V41, P83, DOI 10.1016/0306-9877(93)90040-W; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; TURKER MS, 1990, SOMAT CELL MOLEC GEN, V16, P331, DOI 10.1007/BF01232461; WOODCOCK DM, 1987, BIOCHEM BIOPH RES CO, V145, P888, DOI 10.1016/0006-291X(87)91048-5; ZUCKER KE, 1985, J CELL BIOCHEM, V29, P337, DOI 10.1002/jcb.240290407	60	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18543	18550		10.1074/jbc.270.31.18543	http://dx.doi.org/10.1074/jbc.270.31.18543			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629184	hybrid, Green Published			2022-12-25	WOS:A1995RM64200062
J	FAN, JQ; QUESENBERRY, MS; TAKEGAWA, K; IWAHARA, S; KONDO, A; KATO, I; LEE, YC				FAN, JQ; QUESENBERRY, MS; TAKEGAWA, K; IWAHARA, S; KONDO, A; KATO, I; LEE, YC			SYNTHESIS OF NEOGLYCOCONJUGATES BY TRANSGLYCOSYLATION WITH ARTHROBACTER PROTOPHORMIAE ENDO-BETA-N-ACETYLGLUCOSAMINIDASE - DEMONSTRATION OF A MACRO-CLUSTER EFFECT FOR MANNOSE-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC-SYNTHESIS; ANIMAL LECTINS; ALPHA; OLIGOSACCHARIDES; RECOGNITION; GLYCOSIDES; XYLOSIDASE; LIGANDS; SERUM	The transglycosylation activity of endo-beta-N-acetylglucosaminidase from Arthrobacter protophormiae (endo-A) can be enhanced dramatically by inclusion of organic solvent in the reaction mixture (see accompanying article; Fan, J.-Q., Takegawa, K., Iwahara, S., Kondo, A., Kato, I., Abeygunawardana, C., and Lee, Y. C. (1995) J. Biol. Chem. 270, 17723-17729). This finding was extended to synthesis of important intermediates for preparation of neoglycoconjugates. When 0.2 M GlcNAc-O-(CH2)(6)NH2, GlcNAc-O-CH2CH=CH2, GlcNAc-O-(CH2)(3)CH=CH2, GlcNAc-O-(CH2)(3)NHCOCH=CH2, GlcNAc-SCH2CN, GlcNAc-S-(CH2)(3)CH3, or GlcNAc-S-CH2CONHCH2CH(OMe)(2) were used as accepters in 30% acetone-containing media, the transglycosylation was accomplished with about 80% yield. The transglycosylation yields to benzyl beta-GlcNAc (67%), 4-methyl-umbelliferyl beta-GlcNAc (66%), p-nitrophenyl beta-GlcNAc (33%), and (GlcNAc-beta-S-CH2CH2CH2)(2) (43%) were lower, because their poor solubilities allowed only 0.05 M or lower concentrations in the reaction mixture. A micromole-scale synthesis of Man(9)GlcNAc(2)-O-(CH2)NHCOCH=CH2 (Man(9)GlcNAc(2)-NAP) was accomplished with 90% yield, and the structure of the transglycosylation product was confirmed by H-1 NMR. Man(9)GlcNAc(2)NAP was co-polymerized with acrylamide. The ratio of sugar side chain to acrylamide in this glycopolymer was 1:44 and the molecular weight of glycopolymer was estimated to be between 1,500,000 and 2,000,000 by high performance gel filtration chromatography. The glycopolymer was shown to be a much more efficient inhibitor of binding by recombinant rat mannose binding pro tein-carbohydrate recognition domains (MBP-CRD) from serum (I-50 = 3.5 mu M Man(9)GlcNAc(2) sugar chain) and liver (I-50 = 74.5 mu M) than soybean agglutinin.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; KAGAWA UNIV,FAC AGR,DEPT BIORESOURCE SCI,KAGAWA,JAPAN; TAKARA SHUZO CO LTD,BIOTECHNOL RES LAB,OTSU,SHIGA 52021,JAPAN	Johns Hopkins University; Kagawa University; Takara Holdings Inc.								BARDALES RM, 1989, J BIOL CHEM, V264, P19893; CANTACUZENE D, 1991, BIOMED BIOCHIM ACTA, V50, pS231; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FAN JQ, 1994, ANAL BIOCHEM, V219, P224, DOI 10.1006/abio.1994.1261; FAN JQ, 1995, J BIOL CHEM, V270, P17723, DOI 10.1074/jbc.270.30.17723; FUKASE K, 1994, J CARBOHYD CHEM, V13, P715, DOI 10.1080/07328309408011676; GLICK GD, 1991, J BIOL CHEM, V266, P23660; KOBAYASHI K, 1994, J CARBOHYD CHEM, V13, P753, DOI 10.1080/07328309408011678; KOCHETKOV NK, 1984, PURE APPL CHEM, V56, P923, DOI 10.1351/pac198456070923; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; Lee Reiko T., 1994, P23; LEE RT, 1992, ARCH BIOCHEM BIOPHYS, V299, P129, DOI 10.1016/0003-9861(92)90254-T; LEE RT, 1987, METHOD ENZYMOL, V138, P424; Lee Y. C., 1994, P3; Lee Y C, 1988, Adv Exp Med Biol, V228, P105; LEE YC, 1993, BIOCHEM SOC T, V21, P460, DOI 10.1042/bst0210460; LEE YC, 1991, PURE APPL CHEM, V63, P499, DOI 10.1351/pac199163040499; LEE YC, 1992, GLYCOCONJUGATES, P121; MCKELVY JF, 1969, ARCH BIOCHEM BIOPHYS, V132, P99, DOI 10.1016/0003-9861(69)90341-5; NILSSON KGI, 1989, CARBOHYD RES, V188, P9, DOI 10.1016/0008-6215(89)84053-4; NILSSON KGI, 1987, CARBOHYD RES, V167, P95, DOI 10.1016/0008-6215(87)80271-9; NISHIMURA SI, 1994, MACROMOLECULES, V27, P157, DOI 10.1021/ma00079a023; NISHIMURA SI, 1994, MACROMOLECULES, V27, P4876, DOI 10.1021/ma00096a004; NISHIMURA SI, 1991, MACROMOLECULES, V24, P4236, DOI 10.1021/ma00015a002; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; SAKAI K, 1992, J CARBOHYD CHEM, V11, P553, DOI 10.1080/07328309208016148; SHINOYAMA H, 1988, AGR BIOL CHEM TOKYO, V52, P2375; SHINOYAMA H, 1988, AGR BIOL CHEM TOKYO, V52, P2197; TAKEGAWA K, 1991, BIOCHEM INT, V24, P849; TAKEGAWA K, 1989, APPL ENVIRON MICROB, V55, P3107, DOI 10.1128/AEM.55.12.3107-3112.1989; TAKEGAWA K, 1991, BIOCHEM INT, V25, P829; TOOGOOD PL, 1991, J MED CHEM, V34, P3140; TRIMBLE RB, 1986, J BIOL CHEM, V261, P2000; USUI T, 1994, GLYCOCONJUGATE J, V11, P105, DOI 10.1007/BF00731150; USUI T, 1988, J BIOCHEM-TOKYO, V103, P969, DOI 10.1093/oxfordjournals.jbchem.a122395; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WASSARMAN PM, 1991, DEVELOPMENT, V108, P1	38	54	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17730	17735		10.1074/jbc.270.30.17730	http://dx.doi.org/10.1074/jbc.270.30.17730			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629072				2022-12-25	WOS:A1995RM26600018
J	HASHIMOTO, R; FUJIWARA, H; HIGASHIHASHI, N; KIMURA, TE; TERASAWA, H; FUJITAYAMAGUCHI, Y; INAGAKI, F; PERDUE, JF; SAKANO, KI				HASHIMOTO, R; FUJIWARA, H; HIGASHIHASHI, N; KIMURA, TE; TERASAWA, H; FUJITAYAMAGUCHI, Y; INAGAKI, F; PERDUE, JF; SAKANO, KI			N-TERMINAL DELETION MUTANTS OF INSULIN-LIKE GROWTH FACTOR-II (IGF-II) SHOW THR(7) AND LEU(8) IMPORTANT FOR BINDING TO INSULIN AND IGF-I RECEPTORS AND LEU(8) CRITICAL FOR ALL IGF-II FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; BIOLOGICAL-ACTIVITIES; IDENTIFICATION; PURIFICATION; EXPRESSION; POTENCY; PROTEIN; BRAIN; FORM	To define the role of the N-terminal region of insulinlike growth factor-II (IGF-II) in its binding to insulin and IGF receptors, deletion mutants des-(1-5)-, des-(1-7)-, and des-(1-8)-recombinant (r) IGF-II, and the Gly(8) for Leu substitution mutant of rIGF-II were prepared by site-directed mutagenesis, expressed in Escherichia coli, and purified. The binding affinity and mitogenic activity of these rIGF-II mutants as well as commercially available des-(1-6)-rIGF-II were analyzed. While the relative affinity of des-(1-5)- and des-(1-6)-rIGF-II for purified human insulin and IGF-I receptors remained at greater than or equal to 50% levels of that of rIGF-II, the affinity of des-(1-7)-rIGF-II decreased to similar to 10% and similar to 3%, respectively, of that of rIGF-II. When the octapeptide including Leu(8) was removed prior to the Cys(9)-Cys(47) intrachain bond, the relative affinity of this deletion mutant, des(1-8)-rIGF-II, for these receptors dramatically decreased to <1% of that of rIGF-II. Substituting Gly(8) for Leu in rIGF-II decreased the affinity of this mutant for the IGF-I and insulin receptors to about the same extent. These results suggest that the side chains of Thr(7) and Leu(8) may play an important role in retaining all of the IGF-II functions. Decreases in the relative affinity for binding of the mutants to these receptors paralleled the decreases in their mitogenic potency for cultured Balb/c 3T3 cells. Although the relative affinity of des-(1-8)- or [Gly(8)]rIGF-II for rat IGF-II/CIM6-P (cation-independent mannose 6-phosphate) receptors was also <1% of that of rIGF-II, the relative affinities of des-(1-5)-, des-(1-6)-, and des-(1-7)-rIGF-II for these receptors was significantly greater than that of rIGF-II. These results clearly demonstrate that Thr(7) and Leu(8) are important for binding to insulin and IGF-I receptors and Leu(8) is critical for expression of all IGF-II functions.	TOKYO METROPOLITAN INST MED SCI, BUNKYO KU, TOKYO 113, JAPAN; CITY HOPE NATL MED CTR, BECKMAN RES INST, DEPT MOLEC GENET, DUARTE, CA 91010 USA; AMER RED CROSS, JEROME H HOLLAND LAB, MOLEC BIOL LAB, ROCKVILLE, MD 20855 USA	Tokyo Metropolitan Institute of Medical Science; City of Hope; Beckman Research Institute of City of Hope; American Red Cross	HASHIMOTO, R (corresponding author), DAIICHI PHARMACEUT CO LTD, MOLEC BIOL RES LAB, EDOGAWA KU, 16-13 KITAKASAI 1-CHOME, TOKYO 134, JAPAN.				NCI NIH HHS [CA47150] Funding Source: Medline; NIDDK NIH HHS [DK34427] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034427] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH LA, 1993, J BIOL CHEM, V268, P9246; BAGLEY CJ, 1989, BIOCHEM J, V259, P665, DOI 10.1042/bj2590665; BAYNE ML, 1990, J BIOL CHEM, V265, P15648; CARLSSONSKWIRUT C, 1986, FEBS LETT, V201, P46, DOI 10.1016/0014-5793(86)80568-3; CASCIERI MA, 1989, J CELL PHYSIOL, V139, P181, DOI 10.1002/jcp.1041390125; CASELLA SJ, 1986, J BIOL CHEM, V261, P9268; FRANCIS GL, 1988, BIOCHEM J, V251, P95, DOI 10.1042/bj2510095; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IWAI M, 1989, J BIOCHEM-TOKYO, V106, P949, DOI 10.1093/oxfordjournals.jbchem.a122978; LEBON TR, 1986, J BIOL CHEM, V261, P7685; LUTHI C, 1992, EUR J BIOCHEM, V205, P483, DOI 10.1111/j.1432-1033.1992.tb16804.x; MARUMOTO Y, 1987, J GEN VIROL, V68, P2599, DOI 10.1099/0022-1317-68-10-2599; NAKAGAWA SH, 1991, J BIOL CHEM, V266, P11502; OGASAWARA M, 1989, BIOCHEMISTRY-US, V28, P2710, DOI 10.1021/bi00432a052; PERDUE JF, 1994, INT CONGR SER, V1056, P67; PERDUE JF, 1983, J BIOL CHEM, V258, P7800; ROSS M, 1989, BIOCHEM J, V258, P267, DOI 10.1042/bj2580267; SAHAGIAN GG, 1982, METHOD ENZYMOL, V83, P392; SAITO Y, 1987, J BIOCHEM-TOKYO, V101, P123, DOI 10.1093/oxfordjournals.jbchem.a121883; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARA VR, 1986, P NATL ACAD SCI USA, V83, P4904, DOI 10.1073/pnas.83.13.4904; SMITH MC, 1989, J BIOL CHEM, V264, P9314; TERASAWA H, 1994, EMBO J, V13, P5590, DOI 10.1002/j.1460-2075.1994.tb06896.x	25	10	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18013	18018		10.1074/jbc.270.30.18013	http://dx.doi.org/10.1074/jbc.270.30.18013			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629109	hybrid			2022-12-25	WOS:A1995RM26600060
J	ZULIANELLO, L; VANULSEN, P; VANDEPUTTE, P; GOOSEN, N				ZULIANELLO, L; VANULSEN, P; VANDEPUTTE, P; GOOSEN, N			PARTICIPATION OF THE FLANK REGIONS OF THE INTEGRATION HOST FACTOR PROTEIN IN THE SPECIFICITY AND STABILITY OF DNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-LIKE PROTEINS; ESCHERICHIA-COLI; FACTOR IHF; SITES; GENE; REPLICATION; EXPRESSION; RESOLUTION; COMPLEXES; MUTANTS	The heterodimeric integration host factor (IHF) protein is a site-specific DNA-binding protein from Escherichia coli that strongly bends the DNA. It has been proposed (Yang, C., and Nash, H. A. (1989) Cell 57, 869-880; Granston, A. E., and Nash, H. A. (1993) J. Mol. Biol 234, 45-59; Lee, E. C., Hales, L. M., Gumport, R. I., and Gardner, J. F. (1992) EMBO J. 11, 305313) that the wrapping of the DNA around the protein is stabilized through interactions between the flanks of the protein and the DNA. In order to elucidate which domains of the IHF protein are involved in these interactions, we have constructed mutant proteins in which the C-terminal part of one of the subunits has been deleted. We observed that the C-terminal alpha 3 helix of HimD is involved in the stability of DNA binding, but not in the specificity. In contrast the corresponding alpha 3 helix of HimA is essential for the sequence specificity, since an IHF mutant lacking this domain only binds to the DNA in a nonspecific way. The possible role of the two C-terminal alpha-helical structures in complex formation will be discussed. We also examined the properties of an IHF mutant that has an amino acid substitution between beta sheets beta 1 and beta 2 of the HimD subunit (R46H). The occupancy of the ihf site by the mutant and wild type proteins differ in the 3' part of the ihf site and as a result the bend introduced in the DNA by the mutant protein is less pronounced. We propose that the arginine 46 in the HimD subunit is in vicinity of the TTR region of the consensus and that through contacts within the minor groove the DNA bend introduced by IHF is stabilized.	LEIDEN UNIV,GORLAEUS LABS,LEIDEN INST CHEM,GENET MOLEC LAB,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC				van Ulsen, Peter/0000-0002-2164-1611				BONNEFOY E, 1991, EMBO J, V10, P687, DOI 10.1002/j.1460-2075.1991.tb07998.x; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FLAMM EL, 1985, J MOL BIOL, V183, P117, DOI 10.1016/0022-2836(85)90206-2; FREUNDLICH M, 1992, MOL MICROBIOL, V6, P2557, DOI 10.1111/j.1365-2958.1992.tb01432.x; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GAMAS P, 1987, J MOL BIOL, V195, P261, DOI 10.1016/0022-2836(87)90648-6; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; GOLDENBERG D, 1994, BIOCHIMIE, V76, P941, DOI 10.1016/0300-9084(94)90019-1; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GOOSEN N, 1995, MOL MICROBIOL, V16, P1, DOI 10.1111/j.1365-2958.1995.tb02386.x; GRANSTON AE, 1993, J MOL BIOL, V234, P45, DOI 10.1006/jmbi.1993.1562; HALES LM, 1994, J BACTERIOL, V176, P2999, DOI 10.1128/JB.176.10.2999-3006.1994; JIA X, 1994, BIOCHEMISTRY-US, V33, P8842, DOI 10.1021/bi00195a028; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEE EC, 1992, EMBO J, V11, P305, DOI 10.1002/j.1460-2075.1992.tb05053.x; MENGERITSKY G, 1993, J MOL BIOL, V231, P646, DOI 10.1006/jmbi.1993.1316; MILLER HI, 1984, COLD SPRING HARB SYM, V49, P691, DOI 10.1101/SQB.1984.049.01.078; MILLER HI, 1977, DNA INSERTION ELEMEN, P349; Miller J. H., 1972, EXPT MOL GENETICS, P431; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; SAYRE MH, 1988, J VIROL, V62, P3455, DOI 10.1128/JVI.62.9.3455-3462.1988; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANRIJN PA, 1989, NUCLEIC ACIDS RES, V17, P10203, DOI 10.1093/nar/17.24.10203; WERNER MH, 1994, CURR BIOL, V4, P477, DOI 10.1016/S0960-9822(00)00108-1; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; Williams JGK, 1977, DNA INSERTION ELEMEN, P357; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; YANG SW, 1994, P NATL ACAD SCI USA, V91, P12183, DOI 10.1073/pnas.91.25.12183; ZULIANELLO L, 1994, EMBO J, V13, P1534, DOI 10.1002/j.1460-2075.1994.tb06415.x	36	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17902	17907		10.1074/jbc.270.30.17902	http://dx.doi.org/10.1074/jbc.270.30.17902			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629095	hybrid			2022-12-25	WOS:A1995RM26600043
J	RUVINOV, SB; AHMED, SA; MCPHIE, P; MILES, EW				RUVINOV, SB; AHMED, SA; MCPHIE, P; MILES, EW			MONOVALENT CATIONS PARTIALLY REPAIR A CONFORMATIONAL DEFECT IN A MUTANT TRYPTOPHAN SYNTHASE ALPHA(2)BETA(2) COMPLEX (BETA-E109A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHENOL-LYASE; AMINO-ACID SWITCH; ESCHERICHIA-COLI; BETA-SUBUNIT; SALMONELLA-TYPHIMURIUM; BIENZYME COMPLEX; ALPHA-SUBUNIT; ALLOSTERIC INTERACTIONS; 3-DIMENSIONAL STRUCTURE; ALPHA-2-BETA-2 COMPLEX	We are using the tryptophan synthase alpha(2) beta(2) complex as a model system to investigate how ligands, protein-protein interaction, and mutations regulate enzyme activity, reaction specificity, and substrate specificity. The rate of conversion of L-serine and indole to L-tryptophan by the beta(2) subunit alone is quite low, but is activated by certain monovalent cations or by association with alpha subunit to form an alpha(2) beta(2) complex. Since monovalent cations and a subunit appear to stabilize an active conformation of the beta(2) subunit, we have investigated the effects of monovalent cations on the activities and spectroscopic properties of a mutant form of alpha(2) beta(2) complex having beta(2) subunit glutamic acid 109 replaced by alanine (E109A). The E109A alpha(2) beta(2) complex is inactive in reactions with L-serine but active in reactions with beta-chloro-L-alanine. Parallel experiments show effects of monovalent cations on the properties of wild type beta(2) subunit and alpha(2) beta(2) complex. We find that CsCl stimulates the activity of the E109A alpha(2) beta(2) complex and of wild type beta(2) subunit with L-serine and indole and alters the equilibrium distribution of L-serine reaction intermediates. The results indicate that CsCl partially repairs the deleterious effects of the E109A mutation on the activity of the alpha(2) beta(2) complex by stabilizing a conformation with catalytic properties more similar to those of the wild type alpha(2) beta(2) complex. This conclusion is consistent with observations that monovalent cations alter the catalytic and spectroscopic properties of several pyridoxal phosphate dependent enzymes by stabilizing alternative conformations.	NIDDK, BIOCHEM PHARMACOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AASLESTAD HG, 1968, PYRIDOXAL CATALYSIS, P479; AHMED SA, 1991, J BIOL CHEM, V266, P21548; AHMED SA, 1994, J BIOL CHEM, V269, P16486; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; ANTSON AA, 1993, BIOCHEMISTRY-US, V32, P4195, DOI 10.1021/bi00067a006; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; CRAWFORD IP, 1963, GENETICS, V48, P725; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; DEMIDKINA TV, 1989, BIOCHIMIE, V71, P565, DOI 10.1016/0300-9084(89)90188-0; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1987, INDIAN J BIOCHEM BIO, V24, P44; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; DUNN MF, 1994, ADV LIF SCI-SERIES, P119; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; HATANAKA M, 1962, ARCH BIOCHEM BIOPHYS, V97, P596, DOI 10.1016/0003-9861(62)90129-7; HOHENESTER E, 1994, BIOCHEMISTRY-US, V33, P13561, DOI 10.1021/bi00250a008; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1988, J BIOL CHEM, V263, P17857; ISUPOV M, 1994, ADV LIF SCI-SERIES, P183; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KAYASTHA AM, 1991, INDIAN J BIOCHEM BIO, V28, P352; KAYASTHA AM, 1991, INT UNION B, V199, P265; KAYASTHA AM, 1990, FASEB J, V4, pA2118; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; KUMAGAI H, 1971, BIOCHEM BIOPH RES CO, V44, P1271, DOI 10.1016/S0006-291X(71)80223-1; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; Miles Edith Wilson, 1994, P127, DOI 10.1002/9783527615971.ch7; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1974, J BIOL CHEM, V249, P2852; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1991, J BIOL CHEM, V266, P10715; MORINO Y, 1967, J BIOL CHEM, V242, P2800; MOZZARELLI A, 1991, INT UNION B, V199, P273; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; PERACCHI A, 1994, ADV LIF SCI-SERIES, P125; SUELTER CH, 1977, J BIOL CHEM, V252, P1852; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; TONEY MD, 1995, J MOL BIOL, V245, P151, DOI 10.1006/jmbi.1994.0014; TORAYA T, 1976, EUR J BIOCHEM, V69, P411, DOI 10.1111/j.1432-1033.1976.tb10925.x; WOEHL EU, 1995, IN PRESS BIOCHEMISTR; WOEHL EU, 1995, IN PRESS COORDINATIO; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANOFSKY C, 1972, ENZYMES, V7, P1; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029; ZHAO GP, 1993, J BIOL CHEM, V268, P14921; ZHAO GP, 1992, J BIOL CHEM, V267, P526	53	34	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17333	17338		10.1074/jbc.270.29.17333	http://dx.doi.org/10.1074/jbc.270.29.17333			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615535	hybrid			2022-12-25	WOS:A1995RK68900046
J	AMFO, K; NEYNS, B; TEUGELS, E; LISSENS, W; BOURGAIN, C; DESUTTER, P; VANDAMME, B; VAMOS, E; DEGREVE, J				AMFO, K; NEYNS, B; TEUGELS, E; LISSENS, W; BOURGAIN, C; DESUTTER, P; VANDAMME, B; VAMOS, E; DEGREVE, J			FREQUENT DELETION OF CHROMOSOME-19 AND A RARE REARRANGEMENT OF 19P13.3 INVOLVING THE INSULIN-RECEPTOR GENE IN HUMAN OVARIAN-CANCER	ONCOGENE			English	Article						OVARIAN CANCER; LOSS OF HETEROZYGOSITY; REARRANGEMENT; INSULIN RECEPTOR; CHROMOSOME 19	RIBONUCLEIC-ACID; P53 GENE; C-JUN; DNA; HETEROZYGOSITY; CARCINOMAS; LOSSES; POLYMORPHISM; ABERRATIONS; ALLELOTYPE	Human ovarian cancer cells usually have multiple specific chromosomal deletions which can be detected by cytogenetic analysis or molecular techniques. Tumour suppressor genes might be located in these deleted chromosomal segments. The importance of these different loci is usually estimated from the frequency with which they are deleted. Here we report a 59% loss of heterozygosity for chromosome 19 in the DNA of human invasive epithelial ovarian cancer from a series of 37 patients. In all cases informative on both chromosomal arms a subchromosomal loss is observed, Analysis of the same tumours for chromosome 17p and 11p loss suggests that loss of chromosome 19p/q is less important than 17p loss, but more important than lip loss. The deletion of chromosome 19q seems to be associated with distant, hematogeneous metastasis (stage TV), In two patients with high grade tumours, the deletion involves a rearrangement of the insulin receptor locus (19p13.3), This suggests that some of the previously described frequent cytogenetic 19p(+) markers and 19p13.3 breaks observed in high grade ovarian cancers, might actually occur in the insulin receptor gene.	FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,MED ONCOL LAB,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,DEPT MED ONCOL & HEMATOL,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,EXPTL PATHOL LAB,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,DEPT GYNAECOL ONCOL,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,CYTOGENET LAB,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,MED GENET LAB,B-1090 JETTE,BELGIUM	Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel			Neyns, Bart/ABG-3145-2021; De Greve, Jacques/J-4939-2012; Lissens, Willy/B-2892-2013; Neyns, Bart/AAA-8267-2021	Neyns, Bart/0000-0003-0658-5903; De Greve, Jacques/0000-0002-2389-0742; Lissens, Willy/0000-0003-3875-9955; Teugels, Erik/0000-0002-7828-4555; De Sutter, Philippe/0000-0002-3064-3344				AMAN P, 1994, INT J ONCOL, V5, P177; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BARKER D, 1987, CYTOGENET CELL GENET, V46, P576; Battey, 1986, BASIC METHODS MOL BI; BELLO MJ, 1990, INT J CANCER, V45, P50, DOI 10.1002/ijc.2910450111; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P674; BOYD P, 1986, HUM GENET, V73, P171, DOI 10.1007/BF00291609; BRYSCH W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P401; CHEVENIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLIBY W, 1993, CANCER RES, V53, P2393; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; ELLEIN SC, 1986, P NATL ACAD SCI USA, V83, P5223; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FROSSARD PM, 1987, GENE, V51, P103, DOI 10.1016/0378-1119(87)90480-X; GOLDSTEIN BJ, 1987, MOL ENDOCRINOL, V1, P759, DOI 10.1210/mend-1-11-759; HOPPENER JWM, 1988, FEBS LETT, V233, P57, DOI 10.1016/0014-5793(88)81355-3; JENKINS RB, 1993, CANCER GENET CYTOGEN, V71, P76, DOI 10.1016/0165-4608(93)90205-Z; KORNELUK RG, 1991, NUCLEIC ACIDS RES, V19, P1157, DOI 10.1093/nar/19.5.1157; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEE JH, 1990, CANCER RES, V50, P2724; MAEDA N, 1983, P NATL ACAD SCI-BIOL, V80, P5012, DOI 10.1073/pnas.80.16.5012; MARKS JR, 1991, CANCER RES, V51, P2979; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK CH, 1992, CANCER RES, V52, P5119; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; OKAMOTO A, 1991, CANCER RES, V51, P5171; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SNDBERG AA, 1990, CHROMOSOMES HUMAN CA, P839; SOUTHERN EM, 1975, J MOL BIOL, V938, P503; TAVASSOLI M, 1993, GENE CHROMOSOME CANC, V8, P195, DOI 10.1002/gcc.2870080310; TSAO SW, 1991, ANTICANCER RES, V11, P1975; VANDAMME B, 1992, CANCER RES, V52, P6646; VONDEIMLING A, 1992, CANCER RES, V52, P4277; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; Young R.C., 1993, CANC PRINCIPLES PRAC, P1226; ZHENG JP, 1991, CANCER RES, V51, P4045	45	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					351	358						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624149				2022-12-25	WOS:A1995RK95700015
J	NISHINO, H; KNOLL, A; BUETTNER, VL; FRISK, CS; MARUTA, Y; HAAVIK, J; SOMMER, SS				NISHINO, H; KNOLL, A; BUETTNER, VL; FRISK, CS; MARUTA, Y; HAAVIK, J; SOMMER, SS			P53 WILD-TYPE AND P53 NULLIZYGOUS BIG-BLUE TRANSGENIC MICE HAVE SIMILAR FREQUENCIES AND PATTERNS OF OBSERVED MUTATION IN LIVER, SPLEEN AND BRAIN	ONCOGENE			English	Article						P53; LACI TRANSGENIC MICE; MUTATION FREQUENCY	P53-DEFICIENT MICE; IONIZING-RADIATION; GENE AMPLIFICATION; SOMATIC MUTATION; MAMMALIAN-CELLS; SHUTTLE VECTOR; SKIN TUMORS; MOUSE MODEL; LACI GENE; HA-RAS	Transgenic mouse mutation detection systems offer a powerful tool for analysis of spontaneous and induced mutations in vivo. Mice doubly transgenic for a null mutation of the p53 tumor suppressor gene and a lambda shuttle vector harboring the lacI gene were utilized to examine the rate and pattern of spontaneous somatic mutation of the lad transgene in vivo. Three somatic tissues were examined: liver, spleen and brain, At 6 weeks of age, three p53 wild type (+/+) and three p53 nullizygous (-/-), lad (+/-) male mice were analysed, The mutation frequencies in the two genotypes were similar. The mutant frequencies for wild type (+/+) and nullizygous (-/-) p53 genotypes were, respectively, 4.2x10(-5) and 3.6x10(-5) in the liver, 4.3x10(-5) and 3.4 x 10(-5) in the spleen and 2.8 x 10(-5) and 3.0 x 10(-5) in the brain. When the data from the three tissues were combined, the mutant frequency was 3.7x10(-5) for the (+/+) genotype and 3.3 x 10(5) for the (-/-) genotype. By sequencing both strands in the DNA-binding region of the lad gene, 91 mutations were found. When recurrent mutations in the same mouse were excluded, a total of 67 definitely independent mutations were found. No statistically significant differences were found in the mutational spectra between the two genotypes when the three tissues were analysed individually or combined (P = 0.58). These findings suggest a need to reconsider the general form of hypothesis that the p53 gene serves as the 'guardian of the genome'.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT VET MED,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic				Haavik, Jan/0000-0001-7865-2808; Knoll, Antje/0000-0002-1294-6923				BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; CALLAHAN JD, 1995, MUTAT RES-FUND MOL M, V327, P201, DOI 10.1016/0027-5107(94)00191-7; CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cooper D. N., 1993, HUMAN GENE MUTATION; DAMARUN KM, 1994, SCIENCE, V265, P1582; DIX D, 1989, J GERONTOL, V4, P10; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower Lawrence A., 1994, Cancer Bulletin (Houston), V46, P161; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULDS L, 1958, J Chronic Dis, V8, P2, DOI 10.1016/0021-9681(58)90039-0; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GOSSEN J, 1993, TRENDS GENET, V9, P27, DOI 10.1016/0168-9525(93)90069-T; GOSSEN JA, 1991, MUTAT RES, V250, P423, DOI 10.1016/0027-5107(91)90198-W; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HENDERSON BE, 1988, CANCER RES, V48, P246; HUTCHINSON F, 1993, SEMIN CANCER BIOL, V4, P85; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KEYSE SM, 1988, MOL CELL BIOL, V8, P5425, DOI 10.1128/MCB.8.12.5425; KNOLL A, 1994, MUTAT RES-FUND MOL M, V311, P57, DOI 10.1016/0027-5107(94)90073-6; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KOHLER SW, 1990, NUCLEIC ACIDS RES, V18, P3007, DOI 10.1093/nar/18.10.3007; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE AT, 1994, FASEB J, V8, P545, DOI 10.1096/fasebj.8.8.8181674; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1989, CANCER RES, V49, P5489; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, ANNU REV GENET, V28, P433; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEHTA CR, 1993, J AM STAT ASSOC, V78, P427; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONROE TJ, 1993, CANCER RES, V53, P5690; MYHR BC, 1991, ENVIRON MOL MUTAGEN, V18, P308, DOI 10.1002/em.2850180420; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; PETO R, 1975, BRIT J CANCER, V32, P411, DOI 10.1038/bjc.1975.242; PIEGORSCH WW, 1994, ENVIRON MOL MUTAGEN, V23, P17, DOI 10.1002/em.2850230105; PINES J, 1994, NATURE, V369, P520, DOI 10.1038/369520a0; PROVOST GS, 1994, P NATL ACAD SCI USA, V91, P6564, DOI 10.1073/pnas.91.14.6564; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAPER RM, 1991, GENETICS, V129, P317; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SISK SC, 1994, CARCINOGENESIS, V15, P471, DOI 10.1093/carcin/15.3.471; SOMMER SS, 1994, MUTAT RES, V307, P517; SOMMER SS, 1992, FASEB J, V6, P2767, DOI 10.1096/fasebj.6.10.1634040; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAO KS, 1993, P NATL ACAD SCI USA, V90, P10681, DOI 10.1073/pnas.90.22.10681; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	65	75	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					263	270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624143				2022-12-25	WOS:A1995RK95700007
J	RAYGALLET, D; MAO, C; TAVITIAN, A; MOREAUGACHELIN, F				RAYGALLET, D; MAO, C; TAVITIAN, A; MOREAUGACHELIN, F			DNA-BINDING SPECIFICITIES OF SPI-1/PU.1 AND SPI-B TRANSCRIPTION FACTORS AND IDENTIFICATION OF A SPI-1/SPI-B BINDING-SITE IN THE C-FES/C-FPS PROMOTER	ONCOGENE			English	Article						SPI-1/PU.1 AND SPI-B; DNA BINDING SITE SELECTION; C-FES/C-FPS	PU.1 REGULATES EXPRESSION; ETS-DOMAIN; PUTATIVE ONCOGENE; ESCHERICHIA-COLI; GENE; PROTEIN; PROTOONCOGENE; ACTIVATION; FAMILY; CELLS	Spi-1/PU.1 and Spi-B encode hematopoietic-specific transcription factors that are the most distantly related members of the Ets family. The Ets proteins share a conserved 85 amino acids DNA binding domain, the Ets domain and recognize various DNA target sites around a common core 5'-GGAA/T-3'. The DNA binding specificities of Spi-1 and Spi-B were investigated by using the method of polymerase chain reaction (PCR)-mediated random site selection. The deduced Spi-1 and Spi-B consensus binding sites are very similar suggesting that the functional activities of Spi-1 and Spi-B cannot be distinguished on the basis of their DNA binding specificities. We identified a putative Spi-1/Spi-B binding site in the promoter region of the c-fes/c-fps protooncogene which encodes a tyrosine kinase expressed predominantly in myeloid cells. In vitro translated Spi-1 and Spi-B proteins were capable to bind this site similarly and to activate the c-fes promoter in HeLa transfected cells. We showed that Spi-1 binds the Spi-1/Spi-B binding site of c-fes in HL-60 cells suggesting that Spi-1 may be involved in the regulation of c-fes transcription in myeloid cells. Intriguingly, we detected only Spi-l binding to this site in the Raji cell line which express both Spi-1 and Spi-B proteins. This suggests that Spi-1 and Spi-B exhibit different DNA binding activities in vivo although they share similar DNA binding specificities in vitro.	FAC MED LARIBOISIERE, INSERM, U248, 10 AVE VERDUN, F-75010 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Ray-Gallet, Dominique/A-9224-2019					ALCALAY M, 1990, ONCOGENE, V5, P267; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DELGADO MD, 1994, ONCOGENE, V9, P1723; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GORMAN CM, 1982, VIROLOGY, V52, P456; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JUCKER M, 1992, ONCOGENE, V7, P943; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MAO XH, 1994, J BIOL CHEM, V269, P18216; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PFAFF SL, 1985, VIROLOGY, V146, P307, DOI 10.1016/0042-6822(85)90014-5; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAY D, 1990, ONCOGENE, V5, P663; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROEBROEK AJM, 1987, J VIROL, V61, P2009, DOI 10.1128/JVI.61.6.2009-2016.1987; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; YU G, 1989, J BIOL CHEM, V264, P10276; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	61	105	105	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					303	313						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624145				2022-12-25	WOS:A1995RK95700011
J	CHUEH, SH; SONG, SL; LIU, TY				CHUEH, SH; SONG, SL; LIU, TY			HETEROLOGOUS DESENSITIZATION OF OPIOID-STIMULATED CA2+ INCREASE BY BRADYKININ OR ATP IN NG108-15 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIOMA HYBRID NG108-15; NG 108-15 CELLS; INTRACELLULAR CA-2+; ADENYLATE-CYCLASE; CALCIUM CHANNELS; EXTRACELLULAR ATP; RECEPTORS; INHIBITION; MOBILIZATION; ENKEPHALIN	Leucine-enkephalin (Leu-EK) dose-dependently elicited an increase in cytosolic Ca2+ concentration ([Ca2+](i)) with an EC(50) of 1.2 mu M via the phosphoinositide cascade in NG108-15 cells. Chronic treatment of cells with [D-Ala(2),D-Leu(5)]enkephalin caused time-dependent homologous desensitization. In the presence of extracellular Ca2+, ATP as well as bradykinin stimulated significantly higher increases in inositol 1,4,5-trisphosphate (IF3) generation than did Leu-EK; however, the magnitude of intracellular Ca2+ pools increased after ATP stimulation, whereas bradykinin depleted intracellular pools. Hence, cells lost their [Ca2+](i) response to Leu-EK if bradykinin was first added to induce a [Ca2+](i) increase, whereas the response was unchanged if Leu-EK was added after addition of ATP. When Leu-EK was added simultaneously with bradykinin or ATP, an additive response was observed in IF3 generation; however, the rise in [Ca2+](i) reached the same level as that induced by bradykinin or ATP alone. In the absence of extracellular Ca2+ in which the replenishment of intracellular pools was not possible, ATP displayed an inhibitory effect similar to that of bradykinin on the Leu-EK-induced [Ca2+](i) increase. Prior treatment of cells with Leu-EK slightly heterologously desensitized the action of bradykinin, but had no effect on the ATP response. Our results suggest that a shared intracellular Ca2+ pool is sensitive to the opioid, bradykinin and P-2-purinoceptor agonists; however, a defined pool of phosphatidylinositol 4,5-bisphosphate or a specific phospholipase C is responsible for each receptor.	NATL DEF MED CTR,GRAD INST LIFE SCI,TAIPEI 10764,TAIWAN	National Defense Medical Center	CHUEH, SH (corresponding author), NATL DEF MED CTR,DEPT BIOCHEM,TAIPEI 10764,TAIWAN.							BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BORIN ML, 1994, AM J PHYSIOL, V266, pC311, DOI 10.1152/ajpcell.1994.266.1.C311; CARRITHERS MD, 1990, BIOCHEM BIOPH RES CO, V170, P1096, DOI 10.1016/0006-291X(90)90505-H; CHAN J, 1991, J PHARMACOL EXP THER, V258, P524; CHUEH SH, 1994, BRAIN RES, V660, P81, DOI 10.1016/0006-8993(94)90841-9; CHUEH SH, 1994, MOL PHARMACOL, V45, P532; CHUEH SH, 1993, J NEUROCHEM, V61, P1782, DOI 10.1111/j.1471-4159.1993.tb09816.x; CHUEH SH, 1994, AM J PHYSIOL, V266, pC1008; EBERHARD DA, 1988, TRENDS NEUROSCI, V11, P517, DOI 10.1016/0166-2236(88)90174-9; EHRLICH YH, 1988, J NEUROCHEM, V50, P295, DOI 10.1111/j.1471-4159.1988.tb13263.x; GREEN DA, 1982, J NEUROCHEM, V39, P1125, DOI 10.1111/j.1471-4159.1982.tb11505.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; JIN WZ, 1992, MOL PHARMACOL, V42, P1083; JIN WZ, 1994, J NEUROSCI, V14, P1920; JIN WZ, 1993, BRAIN RES, V607, P17, DOI 10.1016/0006-8993(93)91484-A; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; KOSKI G, 1981, P NATL ACAD SCI-BIOL, V78, P4185, DOI 10.1073/pnas.78.7.4185; LAW PY, 1991, J PHARMACOL EXP THER, V256, P710; LOW PY, 1983, MOL PHARMACOL, V23, P26; MIWA N, 1988, J NEUROCHEM, V50, P1418, DOI 10.1111/j.1471-4159.1988.tb03025.x; MONTERO M, 1990, BIOCHEM J, V271, P535, DOI 10.1042/bj2710535; OKAJIMA F, 1993, BIOCHEM J, V290, P241, DOI 10.1042/bj2900241; OKAJIMA F, 1992, FEBS LETT, V301, P223, DOI 10.1016/0014-5793(92)81252-H; PRATHER PL, 1994, MOL PHARMACOL, V45, P997; SABOL SL, 1979, J BIOL CHEM, V254, P1913; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHIMAHARA T, 1990, BRAIN RES, V524, P219, DOI 10.1016/0006-8993(90)90694-7; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSUNOO A, 1986, P NATL ACAD SCI USA, V83, P9832, DOI 10.1073/pnas.83.24.9832; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; YANO K, 1984, J BIOL CHEM, V259, P201	33	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16630	16637		10.1074/jbc.270.28.16630	http://dx.doi.org/10.1074/jbc.270.28.16630			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622472	hybrid			2022-12-25	WOS:A1995RJ34700029
J	CROSTON, GE; CAO, ZD; GOEDDEL, DV				CROSTON, GE; CAO, ZD; GOEDDEL, DV			NF-KAPPA-B ACTIVATION BY INTERLEUKIN-1 (IL-1) REQUIRES AN IL-1 RECEPTOR-ASSOCIATED PROTEIN-KINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; ELAM-1 GENE-TRANSCRIPTION; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; EXPRESSION; CELLS; DROSOPHILA; DISEASE; CLONING; DORSAL	An important function of interleukin-1 (IL-1) is activation of the transcription factor NF-kappa B, which is signaled via the type I IL-1 receptor (IL-1RI), By receptor mutagenesis studies, we have identified a region of the cytoplasmic domain of IL-1RI that is required for both IL-1-mediated NF-kappa B activation and IL-1-dependent activation of a receptor-associated protein kinase activity we term IRAK. No IL-1RI mutants were found that can activate NF-kappa B in the absence of IRAK activity, Therefore, we propose that IRAK activation is a necessary step in the activation of NF-kappa B by IL-1.	TULARIK INC,S SAN FRANCISCO,CA 94080									Ausubel FM, 1994, CURRENT PROTOCOLS MO; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; COLLINS T, 1993, TRENDS CARDIOVAS MED, V3, P92, DOI 10.1016/1050-1738(93)90030-A; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DINARELLO CA, 1993, IMMUNOL TODAY, V14, P260, DOI 10.1016/0167-5699(93)90042-J; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEGUY A, 1992, J BIOL CHEM, V267, P2605; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; KUNO K, 1993, J BIOL CHEM, V268, P13510; LEUNG KY, 1994, J BIOL CHEM, V269, P1579; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PITTI RM, 1994, MOL IMMUNOL, V17, P1345; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645	27	146	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16514	16517		10.1074/jbc.270.28.16514	http://dx.doi.org/10.1074/jbc.270.28.16514			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622454	hybrid			2022-12-25	WOS:A1995RJ34700009
J	DOMIGAN, NM; CHARLTON, TS; DUNCAN, MW; WINTERBOURN, CC; KETTLE, AJ				DOMIGAN, NM; CHARLTON, TS; DUNCAN, MW; WINTERBOURN, CC; KETTLE, AJ			CHLORINATION OF TYROSYL RESIDUES IN PEPTIDES BY MYELOPEROXIDASE AND HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOCHLOROUS ACID PRODUCTION; HYDROGEN PEROXIDE; OXIDANTS; SUPEROXIDE; CYTOTOXICITY; CHLORAMINES; GENERATION; LEUKOCYTE; MECHANISM; OXIDATION	Hypochlorous acid is the major strong oxidant generated by human neutrophils, and it has the potential to cause much of the tissue damage that these inflammatory cells promote, It is produced from hydrogen peroxide and chloride by the heme enzyme myeloperoxidase. To unequivocally establish that hypochlorous acid contributes to inflammation, a stable and unique marker for its reaction with biomolecules needs to be identified, In this investigation we have found that reagent hypochlorous acid reacts with tyrosyl residues in small peptides and converts them to chlorotyrosine. Purified myeloperoxidase in combination with hydrogen peroxide and chloride, as well as stimulated human neutrophils, chlorinated tyrosine in the peptide Gly-Gly-Tyr-Arg. Rather than reacting directly with the aromatic ring of tyrosine, hypochlorous acid initially reacted with an amine group of the peptide to form a chloramine. The chloramine then underwent an intramolecular reaction with the tyrosyl residue to convert it to chlorotyrosine. This indicates that tyrosyl residues in proteins that are close to amine groups will be susceptible to chlorination. Peroxidases are the only enzymes capable of chlorinating an aromatic ring. Furthermore, myeloperoxidase isthe only human enzyme that produces hypochlorous acid under physiological conditions. Therefore, chlorotyrosine will be a specific marker for the production of hypochlorous acid in vivo and for the involvement of myeloperoxidase in inflammatory tissue damage.	CHRISTCHURCH SCH MED,FREE RADICAL RES GRP,CHRISTCHURCH,NEW ZEALAND; UNIV NEW S WALES,BIOMED MASS SPECT UNIT,SYDNEY,NSW 2052,AUSTRALIA	University of Otago; University of New South Wales Sydney			Kettle, Anthony J/A-8520-2008	Kettle, Anthony J/0000-0002-8218-7766; Duncan, Mark/0000-0001-9256-8274				ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BEAN MF, 1991, ANAL CHEM, V63, P1473, DOI 10.1021/ac00014a024; BEERS RF, 1952, J BIOL CHEM, V195, P133; BERNOFSKY C, 1991, FASEB J, V5, P295, DOI 10.1096/fasebj.5.3.1848195; Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77; COHEN SA, 1988, ANAL BIOCHEM, V174, P1, DOI 10.1016/0003-2697(88)90512-X; DELAMARE PBD, 1959, AROMATIC SUBSTITUTIO; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; GRISHAM MB, 1994, LANCET, V344, P859, DOI 10.1016/S0140-6736(94)92831-2; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; HAGER LP, 1966, J BIOL CHEM, V241, P1769; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HEINECKE JW, 1994, CORONARY ARTERY DIS, V5, P205, DOI 10.1097/00019501-199403000-00004; JOHNSON RA, 1975, J ORG CHEM, V40, P2186, DOI 10.1021/jo00903a011; KETTLE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P379, DOI 10.1016/0167-4889(90)90146-5; KETTLE AJ, 1994, J BIOL CHEM, V269, P17146; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V957, P185, DOI 10.1016/0167-4838(88)90271-3; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; KETTLE AJ, 1993, BIOCHEM PHARMACOL, V45, P2003, DOI 10.1016/0006-2952(93)90010-T; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; LAMPERT MB, 1983, BLOOD, V62, P645; Magnussen RP, 1991, PEROXIDASES CHEM BIO, P199; MITCHELL E D JR, 1981, Proceedings of the Oklahoma Academy of Science, V61, P43; MORRISON M, 1976, ANNU REV BIOCHEM, V45, P861, DOI 10.1146/annurev.bi.45.070176.004241; Neidleman S.L., 1986, BIOHALOGENATION PRIN; ODAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V206, P71, DOI 10.1016/0005-2744(70)90083-5; PEREIRA WE, 1973, BIOCHIM BIOPHYS ACTA, V313, P170, DOI 10.1016/0304-4165(73)90198-0; RUDIE NG, 1980, J BIOL CHEM, V255, P498; SAYO H, 1990, XENOBIOTICA, V20, P957, DOI 10.3109/00498259009046911; SELVARAJ RJ, 1974, INFECT IMMUN, V9, P255, DOI 10.1128/IAI.9.2.255-260.1974; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; TAUROG A, 1991, ARCH BIOCHEM BIOPHYS, V287, P288, DOI 10.1016/0003-9861(91)90481-W; TEST ST, 1984, J CLIN INVEST, V74, P1341, DOI 10.1172/JCI111544; Thomas E L, 1986, Methods Enzymol, V132, P569; UETRECHT JP, 1991, CHEM RES TOXICOL, V4, P218, DOI 10.1021/tx00020a015; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P53, DOI 10.1016/0003-9861(91)90327-F; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEITZMAN SA, 1990, BLOOD, V76, P655; Winterbourn C.C., 1990, OXYGEN RADICALS SYST, P31; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5	45	277	281	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16542	16548		10.1074/jbc.270.28.16542	http://dx.doi.org/10.1074/jbc.270.28.16542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622459	hybrid			2022-12-25	WOS:A1995RJ34700015
J	MATHUPALA, SP; REMPEL, A; PEDERSEN, PL				MATHUPALA, SP; REMPEL, A; PEDERSEN, PL			GLUCOSE CATABOLISM IN CANCER-CELLS - ISOLATION, SEQUENCE, AND ACTIVITY OF THE PROMOTER FOR TYPE-II HEXOKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BOUND HEXOKINASE; NOVIKOFF ASCITES TUMOR; RAT HEPATOMA; AEROBIC GLYCOLYSIS; ENERGY-METABOLISM; GLUCOKINASE GENE; BINDABLE FORM; BINDING-SITES; EXPRESSION; PHOSPHORYLATION	One of the most characteristic phenotypes of rapidly growing cancer cells is their propensity to catabolize glucose at high rates. Type II hexokinase, which is expressed at high levels in such cells and bound to the outer mitochondrial membrane, has been implicated as a major player in this aberrant metabolism. Here we report the isolation and sequence of a 4.3-kilobase pair proximal promoter region of the Type II hexokinase gene from a rapidly growing, highly glycolytic hepatoma cell line (AS-30D). Analysis of the sequence enabled the identification of putative promoter elements, including a TATA box, a CAAT element, several Sp-1 sites, and response elements for glucose, insulin, cAMP, Ap-1, and a number of other factors. Transfection experiments with AS-30D cells showed that promoter activity was enhanced 3.4-, 3.3-, 2.4-, 2.1-, and 1.3-fold, respectively, by glucose, phorbol 12-myristate 13-acetate (a phorbol ester), insulin, cAMP, and glucagon. In transfected hepatocytes, these same agents produced little or no effect. The results emphasize normal versus tumor cell differences in the regulation of Type II hexokinase and indicate that transcription of the Type II tumor gene may occur independent of metabolic state, thus, providing the cancer cell with a selective advantage over its cell of origin.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,MOLEC & CELLULAR BIOENERGET LAB,BALTIMORE,MD 21205	Johns Hopkins University					NCI NIH HHS [CA 32742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aisenberg A.C., 1961, GLYCOLYSIS RESPIRATI; ARORA KK, 1990, J BIOL CHEM, V265, P6481; ARORA KK, 1988, J BIOL CHEM, V263, P17422; ARORA KK, 1993, ARCH BIOCHEM BIOPHYS, V304, P515, DOI 10.1006/abbi.1993.1384; BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; BERRY MN, 1991, LAB TECH BIOCH MOL B, V21, P56; BERRY MN, 1991, LAB TECH BIOCH MOL B, V21, P24; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLORIDI A, 1981, J NATL CANCER I, V66, P497; FLORIDI A, 1981, CANCER RES, V41, P4661; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P264; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GUMAA KA, 1969, BIOCHEM BIOPH RES CO, V36, P771, DOI 10.1016/0006-291X(69)90676-7; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAMMOND KD, 1978, CANCER RES, V38, P1323; HERZFELD A, 1972, CANCER RES, V32, P1826; INUI M, 1979, J BIOCHEM, V85, P1151; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JOHANSSON T, 1985, BIOCHEM BIOPH RES CO, V133, P608, DOI 10.1016/0006-291X(85)90948-9; KIKUCHI Y, 1972, CANCER, V30, P444, DOI 10.1002/1097-0142(197208)30:2<444::AID-CNCR2820300222>3.0.CO;2-9; KUROKAWA M, 1981, BIOCHEM INT, V2, P645; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15986; NAKASHIMA RA, 1984, CANCER RES, V44, P5702; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; NAKASHIMA RA, 1988, CANCER RES, V48, P913; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PAGGI MG, 1991, BIOCHEM BIOPH RES CO, V178, P648, DOI 10.1016/0006-291X(91)90157-3; PARRY DM, 1983, J BIOL CHEM, V258, P904; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; REMPEL A, 1994, BBA-GENE STRUCT EXPR, V1219, P660, DOI 10.1016/0167-4781(94)90225-9; ROSE IA, 1982, ARCH BIOCHEM BIOPHYS, V213, P625, DOI 10.1016/0003-9861(82)90592-6; ROSE IA, 1967, J BIOL CHEM, V242, P1635; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO S, 1972, GANN MONOGR CANCER R, V13, P279; SHINOHARA Y, 1991, FEBS LETT, V291, P55, DOI 10.1016/0014-5793(91)81102-E; SHOWE MK, 1992, NUCLEIC ACIDS RES, V20, P3153, DOI 10.1093/nar/20.12.3153; SINGH M, 1978, J CELL PHYSIOL, V97, P285, DOI 10.1002/jcp.1040970303; TANIZAWA Y, 1992, MOL ENDOCRINOL, V6, P1070, DOI 10.1210/me.6.7.1070; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WARBURG O, 1980, METABOLISM TUMORS; WEINHOUSE SIDNEY, 1966, GANN MONOGR, V1., P99; [No title captured]; 1991, PROMEGA PROTOCOLS AP	56	136	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16918	16925		10.1074/jbc.270.28.16918	http://dx.doi.org/10.1074/jbc.270.28.16918			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622509	hybrid			2022-12-25	WOS:A1995RJ34700070
J	ZHOU, JZ; BAI, YL; WEINER, H				ZHOU, JZ; BAI, YL; WEINER, H			PROTEOLYSIS PREVENTS IN-VIVO CHIMERIC FUSION PROTEIN IMPORT INTO YEAST MITOCHONDRIA - CYTOSOLIC CLEAVAGE AND SUBCELLULAR-DISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1-ATPASE BETA-SUBUNIT; LIVER ALDEHYDE DEHYDROGENASE; ESCHERICHIA-COLI; SIGNAL PEPTIDE; GENE FUSIONS; RAT; PRESEQUENCE; PURIFICATION; SEQUENCES; PRECURSOR	The in vivo import of liver mitochondrial aldehyde dehydrogenase was investigated in yeast by constructing fusion proteins between its leader sequence and beta-galactosidase. Only 7% of the protein was imported. If 21 or 71 amino acids from the mature portion of aldehyde dehydrogenase were included in the construct, 40% was imported. The protein remaining in cytosol was sequenced. When the leader was fused directly to beta-galactosidase, the first 7 residues of the leader were missing. When 21 residues of mature aldehyde dehydrogenase were included, the entire leader plus 6 residues of the mature portion were missing; if 71 residues of mature aldehyde dehydrogenase were included, the first residue found corresponds to the 66th residue of the mature portion. When the leader was fused directly to beta-galactosidase, no processing of the imported protein occurred, and the N-terminal amino acid was blocked, presumably by acetylation. If the 21-amino acid insert was included, processing occurred. A modified leader sequence lacking the three-amino acid linker (RGP) was imported but not processed, just as we found in vitro (Thornton, K., Wang, Y., Weiner, H., and Gorenstein, D.G. (1993) J. Biol. Chem. 268, 19906-19914). The less than 100% import of pre-aldehyde dehydrogenase was due to the action of a post-translational protease attack which prevented import by destroying the leader peptide segment.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIAAA NIH HHS [AA00028, AA05812] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA005812, R37AA005812] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BADARACCO G, 1983, J BIOL CHEM, V258, P2022; BELTZER JP, 1988, J BIOL CHEM, V263, P368; Bergmeyer HU, 1974, METHOD ENZYMAT AN, P452; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; BRUCH MD, 1992, BIOCHIM BIOPHYS ACTA, V1159, P81, DOI 10.1016/0167-4838(92)90078-R; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; DAUM G, 1982, J BIOL CHEM, V257, P3028; DOUGLAS MG, 1984, P NATL ACAD SCI-BIOL, V81, P3983, DOI 10.1073/pnas.81.13.3983; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; EPAND RM, 1986, J BIOL CHEM, V261, P17; FARRES J, 1989, EUR J BIOCHEM, V180, P67, DOI 10.1111/j.1432-1033.1989.tb14616.x; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GERMINO J, 1983, P NATL ACAD SCI-BIOL, V80, P6848, DOI 10.1073/pnas.80.22.6848; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; Guthrie C, 1991, GUIDE YEAST GENETICS; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HEMPEL J, 1985, EUR J BIOCHEM, V153, P13, DOI 10.1111/j.1432-1033.1985.tb09260.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENG JJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P214, DOI 10.1016/0003-9861(91)90464-T; JUST WW, 1987, PEROXISOMES BIOL MED, P402; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LOHR GW, 1974, METHOD ENZYMAT AN, P636; MAGDOLEN V, 1992, FEBS LETT, V299, P267, DOI 10.1016/0014-5793(92)80129-5; Maniatis T., 1982, MOL CLONING; Miller J.H., 1972, EXPT MOL GENETICS; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VERNER K, 1992, MOL MICROBIOL, V6, P1723, DOI 10.1111/j.1365-2958.1992.tb01344.x; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG TTY, 1991, ALCOHOL CLIN EXP RES, V15, P286, DOI 10.1111/j.1530-0277.1991.tb01870.x; WANG Y, 1993, J BIOL CHEM, V268, P4759; WEINER H, 1991, ADV LIF SCI, P161; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	40	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16689	16693		10.1074/jbc.270.28.16689	http://dx.doi.org/10.1074/jbc.270.28.16689			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622479	hybrid			2022-12-25	WOS:A1995RJ34700038
J	OGASAWARA, Y; VOELKER, DR				OGASAWARA, Y; VOELKER, DR			THE ROLE OF THE AMINO-TERMINAL DOMAIN AND THE COLLAGENOUS REGION IN THE STRUCTURE AND THE FUNCTION OF RAT SURFACTANT PROTEIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; LUNG; PHOSPHATIDYLINOSITOL; PURIFICATION; CONGLUTININ; SPECIFICITY; CP4	Surfactant protein D (SP-D) is a member of the C-type lectin superfamily with four distinct structural domains: an amino terminus involved in forming intermolecular disulfides, a collagen-like domain, a neck region, and a carbohydrate recognition domain, A collagen domain deletion mutant (CDM) of SP-D was created by site-directed mutagenesis, A second variant lacking both the amino-terminal region and the collagen-like domain was generated by collagenase treatment and purification of the collagenase-resistant fragment (CRF), The CDM expressed in CHO-K1 cells formed the covalent trimers, but not the noncovalent dodecamers, typical of native SP-D, The CRF derived from recombinant SP-D formed only monomers. The CDM bound mannose-Sepharose and phosphatidylinositol (PI) as well as SP-D, but the binding to mannosyl bovine serum albumin and glucosylceramide was diminished by approximately 60%. The CRF displayed weak binding to mannose-Sepharose and PI and essentially no binding to mannosyl bovine serum albumin and glucosylceramide. Both SP-D and CDM altered the self-aggregation of PI-containing liposomes. SP-D reduced the density and the light scattering properties of PI aggregates. These results demonstrate that the collagen-like domain is required for dodecamer but not covalent trimer formation of SP-D and plays an important, but not essential, role in the interaction of SP-D with PI and GlcCer. Removal of the amino-terminal domain of SP-D along with the collagen-like domain diminishes PI binding and effectively eliminates GlcCer binding.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,LORD & TAYLOR LAB LUNG BIOCHEM,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,ANNA PERAHIA ADATTO CLIN RES CTR,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80262	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029891, R01HL045286, R37HL029891] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29891, HL45286] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSBEL FM, 1992, CURRENT PROTOCOLS MO; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1994, J BIOL CHEM, V269, P15808; FISHER JH, 1995, AM J RESP CELL MOL, V12, P13, DOI 10.1165/ajrcmb.12.1.7811466; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUAN SF, 1994, AM J RESP CELL MOL, V10, P430, DOI 10.1165/ajrcmb.10.4.8136158; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1992, ARCH BIOCHEM BIOPHYS, V299, P129, DOI 10.1016/0003-9861(92)90254-T; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1995, J BIOL CHEM, V270, P14725, DOI 10.1074/jbc.270.24.14725; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; ROSS GF, 1986, J BIOL CHEM, V261, P14283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEINLE JE, 1993, J BIOL CHEM, V268, P364; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853	27	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19052	19058		10.1074/jbc.270.32.19052	http://dx.doi.org/10.1074/jbc.270.32.19052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642568	hybrid			2022-12-25	WOS:A1995RN95400056
J	ROEBUCK, KA; RAHMAN, A; LAKSHMINARAYANAN, V; JANAKIDEVI, K; MALIK, AB				ROEBUCK, KA; RAHMAN, A; LAKSHMINARAYANAN, V; JANAKIDEVI, K; MALIK, AB			H2O2 AND TUMOR-NECROSIS-FACTOR-ALPHA ACTIVATE INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1) GENE-TRANSCRIPTION THROUGH DISTINCT CIS-REGULATORY ELEMENTS WITHIN THE ICAM-1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSIVE ELEMENT; PEROXIDE-INDUCED INCREASE; YA SUBUNIT GENE; NF-KAPPA-B; HYDROGEN-PEROXIDE; BINDING-ACTIVITY; INTACT-CELLS; NEUTROPHILS; INDUCTION; INVITRO	We investigated the mechanisms by which H2O2 increases intercellular adhesion molecule 1 (ICAM-1; CD54) expression in endothelial cells. The H2O2-induced increase in ICAM-1 mRNA was inhibited by actinomycin D, by the antioxidant N-acetylcysteine, and by 3-aminobenzamide (which blocks oxidant-induced AP-1 activity), but not by pyrrolidine dithiocarbamate (which blocks oxidant-induced NF-kappa B activity). Nuclear run-on and transient transfections of ICAM-1 promoter constructs indicated that H2O2 stimulated ICAM-1 gene transcription by activation of a distinct region of the ICAM-1 promoter. The H2O2-responsive element was localized to sequences between -981 and -769 (relative to the start codon). Located within this region are two 16-base pair repeats, each containing binding sites for the transcription factors AP-1 and Ets. A similar composite AP-1/Ets element isolated from the macrophage scavenger receptor gene conferred H2O2 responsiveness to a minimal promoter. Mutation of the 16-base pair repeats within the ICAM-1 promoter prevented H2O2-induced DNA binding activity, and their deletion abrogated the H2O2-induced transcriptional activity. In contrast, TNF alpha induced ICAM-1 transcription via activation of promoter sequences between -393 and -176, a region with C/EBP and NF-kappa B binding sites. The results indicate that H2O2 activates ICAM-1 transcription through AP-1/Ets elements within the ICAM-1 promoter, which are distinct from NF-kappa B-mediated ICAM-1 expression induced by TNF alpha.	RUSH MED COLL,RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT IMMUNOL MICROBIOL,CHICAGO,IL 60612; ALBANY MED COLL,DEPT PHYSIOL & CELL BIOL,ALBANY,NY 12208	Rush University; Albany Medical College	ROEBUCK, KA (corresponding author), RUSH MED COLL,RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PHARMACOL,1750 W HARRISON ST,CHICAGO,IL 60612, USA.			Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL45638, HL46350, HL27016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046350, R37HL027016, R01HL045638, R01HL027016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMSTAD PA, 1992, CANCER RES, V52, P3952; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; BERGELSON S, 1994, CANCER RES, V54, P36; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON DF, 1983, MOL CELL BIOL, V3, P1552, DOI 10.1128/MCB.3.9.1552; DUSTIN ML, 1988, J IMMUNOL, V137, P245; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; IKEDA M, 1994, J INVEST DERMATOL, V103, P791, DOI 10.1111/1523-1747.ep12413176; KUKIELKA GL, 1993, J CLIN INVEST, V92, P1504, DOI 10.1172/JCI116729; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LI WC, 1994, EXP EYE RES, V59, P179, DOI 10.1006/exer.1994.1096; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; LO SK, 1993, AM J PHYSIOL, V264, pL406; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LOOK DC, 1994, J BIOL CHEM, V269, P8952; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MYERS CL, 1992, AM J PHYSIOL, V262, pC365, DOI 10.1152/ajpcell.1992.262.2.C365; NAKAMURA K, 1993, ONCOGENE, V6, P3133; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; NOURSHARGH S, 1990, ENDOTHELIUM INTRO CU, P171; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; ROEBUCK KA, 1993, J CLIN INVEST, V92, P1336, DOI 10.1172/JCI116707; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SELLAK H, 1994, BLOOD, V83, P2669; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIFLINGERBIRNBO.A, 1992, LAB INVEST, V67, P24; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WANG B, 1994, BBA-GENE STRUCT EXPR, V1219, P645, DOI 10.1016/0167-4781(94)90223-2; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12020; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P60330; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	45	237	241	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18966	18974		10.1074/jbc.270.32.18966	http://dx.doi.org/10.1074/jbc.270.32.18966			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642556	hybrid			2022-12-25	WOS:A1995RN95400044
J	SMITH, ER; MERRILL, AH				SMITH, ER; MERRILL, AH			DIFFERENTIAL ROLES OF DE-NOVO SPHINGOLIPID BIOSYNTHESIS AND TURNOVER IN THE BURST OF FREE SPHINGOSINE AND SPHINGANINE, AND THEIR 1-PHOSPHATES AND N-ACYL-DERIVATIVES, THAT OCCURS UPON CHANGING THE MEDIUM OF CELLS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HAMSTER OVARY CELLS; LONG-CHAIN BASES; SERINE PALMITOYLTRANSFERASE; PHOSPHOLIPASE-D; RAT-LIVER; HUMAN-NEUTROPHILS; PHOSPHATIDATE PHOSPHOHYDROLASE; STEREOSELECTIVE SYNTHESIS; SUBCELLULAR-LOCALIZATION	Long-chain (sphingoid) bases are highly bioactive intermediates of sphingolipid metabolism, yet relatively little is known about how the amounts of these compounds are regulated, This study used J774A.1 cells to characterize the ''burst'' of sphinganine and sphingosine, or the transient increase of up to 10-fold in long-chain base mass, that occurs when cells in culture are changed to fresh medium, The increase in sphinganine was attributable to de novo sphingolipid biosynthesis because: 1) there is increased incorporation of [H-3]serine and [H-3]palmitate into sphinganine; 2) the incorporation of [H-3]serine was equivalent to the increase in sphinganine mass; 3) beta-F-alanine, an inhibitor of serine palmitoyltransferase, blocked the sphinganine burst; 4) the magnitude of the burst depended on the concentration of serine in the medium, which is known to affect long chain base biosynthesis; and 5) the appearance of sphinganine was relatively unaffected by lyso-osmotrophic agents (NH4Cl and chloroquine) that blocked sphingolipid hydrolysis in these cells, In contrast, the sphingosine burst arose mainly from turnover of complex sphingolipids because no incorporation of [H-3]serine or [H-3]palmitate into sphingosine was detected; sphingosine mass was not affected by beta-F-alanine or the serine concentration; and, the burst could be followed by the release of sphingosine and ceramide from complex sphingolipids (especially sphingomyelin) in a process that was inhibited by NH4Cl and chloroquine, Additionally, the fate of these long-chain bases differed: sphinganine was mostly (80-85%) acylated and incorporated into dihydroceramide and complex sphingolipids, whereas most of the sphingosine (70%) was phosphorylated and degraded, with incorporation of the resulting ethanolamine phosphate into phosphatidylethanolamine. Sphinganine, however, could be diverted toward degradation by adding an inhibitor of N-acylation (fumonisin B-1), In accounting for the elevation in sphingosine and sphinganine after cells are changed to new medium, these studies have provided fundamental information about long-chain base metabolism. The existence of differential changes in sphinganine and sphingosine, as well as their 1-phosphates and N-acyl-derivatives, should be considered when evaluating the roles of sphingolipid metabolites in cell regulation,	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University				Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM46368, GM08367, GM33369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367, R01GM033369, R01GM046368] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN CM, 1967, J BIOL CHEM, V242, P1895; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARIDORPITERMAN O, 1992, EUR J BIOCHEM, V204, P561, DOI 10.1111/j.1432-1033.1992.tb16668.x; BRAUN PE, 1970, J BIOL CHEM, V245, P335; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CHAO R, 1992, J BIOL CHEM, V267, P23459; COOKE JWB, 1993, TETRAHEDRON, V49, P7955, DOI 10.1016/S0040-4020(01)88019-4; DECKER L, 1972, WORTHINGTON ENZYME M; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DIMARI SJ, 1971, ARCH BIOCHEM BIOPHYS, V143, P553, DOI 10.1016/0003-9861(71)90240-2; FUTERMAN AH, 1994, CURR TOP MEMBR, V40, P93, DOI 10.1016/S0070-2161(08)60978-8; GAVER RC, 1965, J AM OIL CHEM SOC, V42, P295; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GOLDIN E, 1992, BIOCHIM BIOPHYS ACTA, V1127, P301; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HIRSCHBERG CB, 1970, J BIOL CHEM, V245, P3084; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KISS Z, 1991, EUR J BIOCHEM, V197, P785, DOI 10.1111/j.1432-1033.1991.tb15972.x; KISS Z, 1992, BIOCHEM J, V288, P853, DOI 10.1042/bj2880853; KISS Z, 1991, LIPIDS, V26, P321, DOI 10.1007/BF02537144; KOBAYASHI T, 1988, EUR J BIOCHEM, V171, P747; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1994, BBA-MOL CELL RES, V1220, P323, DOI 10.1016/0167-4889(94)90156-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MEDLOCK KA, 1988, BIOCHEM BIOPH RES CO, V157, P232, DOI 10.1016/S0006-291X(88)80037-8; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1993, ADV LIPID RES, V26, P215; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1988, BIOCHEMISTRY-US, V27, P340, DOI 10.1021/bi00401a051; MERRILL AH, 1994, CURR TOP MEMBR, V40, P361, DOI 10.1016/S0070-2161(08)60988-0; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MERRILL AH, 1992, POLYUNSATURATED FATT, V28, P41; MESSMER TO, 1989, J NUTR, V119, P534, DOI 10.1093/jn/119.4.534; MORRELL P, 1970, J BIOL CHEM, V245, P342; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OISHI K, 1990, J BIOL CHEM, V265, P70; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; ONG DE, 1973, J BIOL CHEM, V248, P3884; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SARMIENTOS F, 1985, EUR J BIOCHEM, V146, P59, DOI 10.1111/j.1432-1033.1985.tb08619.x; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SMITH ER, 1993, FASEB J, V7, pA173; SMITH ER, 1992, FASEB J, V6, pA968; SMITH ER, 1994, THESIS EMORY U ATLAN; SMITH ER, 1991, FASEB J, V5, pA1836; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1041, DOI 10.1515/bchm2.1970.351.2.1041; SU Y, 1994, J BIOL CHEM, V269, P16512; SWEELEY CC, 1991, BIOCH LIPIDS LIPOPRO, P327; Thudichum J.L.W., 1884, TREATISE CHEM CONSTI; VANDENEIJNDEN DH, 1971, Z PHYSIOL CHEM, V352, P1601; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VANVELDHOVEN PP, 1993, ADV LIPID RES, V26, P69; WANG E, 1991, J BIOL CHEM, V266, P14486; WARDEN LA, 1990, FASEB J, V4, pA1910; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; WILSON E, 1988, J BIOL CHEM, V263, P9304; WILSON E, 1986, J BIOL CHEM, V261, P2616; WU WI, 1993, J BIOL CHEM, V268, P13830; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	76	132	135	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18749	18758		10.1074/jbc.270.32.18749	http://dx.doi.org/10.1074/jbc.270.32.18749			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642524	hybrid			2022-12-25	WOS:A1995RN95400011
J	BUTKERAIT, P; ZHENG, YJ; HALLAK, H; GRAHAM, TE; MILLER, HA; BURRIS, KD; MOLINOFF, PB; MANNINGS, DR				BUTKERAIT, P; ZHENG, YJ; HALLAK, H; GRAHAM, TE; MILLER, HA; BURRIS, KD; MOLINOFF, PB; MANNINGS, DR			EXPRESSION OF THE HUMAN 5-HYDROXYTRYPTAMINE(1A) RECEPTOR IN SF9 CELLS - RECONSTITUTION OF A COUPLED PHENOTYPE BY COEXPRESSION OF MAMMALIAN G-PROTEIN SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; INFECTED INSECT CELLS; TERNARY COMPLEX MODEL; GTP-BINDING PROTEINS; ALPHA-SUBUNITS; ADENYLATE-CYCLASE; PERTUSSIS TOXIN; 5-HT1A RECEPTOR; GAMMA-SUBUNITS; FUNCTIONAL EXPRESSION	The possibility that Spodoptera frugiperda (Sf9) cells can provide an intact cell setting for reconstitution of the human 5-hydroxytryptamine(1A) (5-HT1A) receptor with mammalian G protein subunits was explored. The 5-HT1A receptor was found to assume an uncoupled phenotype when expressed alone in Sf9 cells at relatively high levels (5-34 pmol of receptor/mg of membrane protein), i.e. agonist-binding to the receptor was characterized by a relatively high K-d and an insensitivity to GTP, Go-expression of the receptor with members of the alpha(i) ''family'' together with various combinations of beta(1) and gamma subunits increased the affinity for agonists to that ob served for the coupled form of receptor in mammalian cells, concomitant with conferrance of guanosine 5'-(beta,gamma-imino)triphosphate sensitivity. The agonists employed were [H-3]8-hydroxy-N,N-dipropyl-2-aminotetralin ([H-3] 8-OH-DPAT) and [I-125]R(+)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin ([I-125]8-OH-PI-PAT), The binding of an antagonist, [I-125]4-(2'-methoxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-iodobenzamido]ethyl] piperazine ([I-125]p-MPPI), was unaffected by co-expression of G protein subunits. Both alpha and beta gamma subunits were required for optimal coupling. No differences were evident among alpha(i1), alpha(i2), alpha(i3), alpha(o), and alpha(z) when expressed with beta(1) gamma(2) in this regard, nor among most permutations of beta(1) gamma subunits when expressed with alpha(i1), (beta(1) gamma(2) approximate to beta(1) gamma(3) approximate to beta(1) gamma(5) > beta(1) gamma(2)). alpha(s) and alpha(q) expressed with beta(1) gamma(2) did not participate in coupling, These data support the conclusion that normal interactions between a mammalian receptor and a select array of G proteins can be established in intact Sf9 cells, and extend previous observations of 5-HT1A receptor coupling to G(o) and the pertussis toxin-insensitive G protein G(z).	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH048125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009245] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51196] Funding Source: Medline; NIMH NIH HHS [MH48125] Funding Source: Medline; NINDS NIH HHS [NS09245] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERT PR, 1990, J BIOL CHEM, V265, P5825; ANDRADE R, 1986, SCIENCE, V234, P1261, DOI 10.1126/science.2430334; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BOUNDY VA, 1993, J PHARMACOL EXP THER, V264, P1002; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHAMBERLAIN J, 1993, J PHARMACOL EXP THER, V266, P618; COLINO A, 1987, NATURE, V328, P73, DOI 10.1038/328073a0; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DEMONTIGNY C, 1984, NEUROPHARMACOLOGY, V23, P1511, DOI 10.1016/0028-3908(84)90095-9; DEVIVO M, 1986, J PHARMACOL EXP THER, V238, P248; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GRABER SG, 1992, J BIOL CHEM, V267, P1271; HALL MD, 1985, J NEUROCHEM, V44, P1685, DOI 10.1111/j.1471-4159.1985.tb07155.x; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HINTON DR, 1990, J NEUROSCI, V10, P2763; HUMPHREY PPA, 1993, TRENDS PHARMACOL SCI, V14, P233, DOI 10.1016/0165-6147(93)90016-D; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; INNIS RB, 1987, EUR J PHARMACOL, V143, P195, DOI 10.1016/0014-2999(87)90533-4; INNIS RB, 1988, BRAIN RES, V459, P27, DOI 10.1016/0006-8993(88)90282-X; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KARSCHIN A, 1991, P NATL ACAD SCI USA, V88, P5694, DOI 10.1073/pnas.88.13.5694; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KUNG HF, 1994, LIFE SCI, V55, P1459, DOI 10.1016/0024-3205(94)00686-5; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAW SF, 1991, J BIOL CHEM, V266, P17885; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU YF, 1991, J BIOL CHEM, V266, P23689; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MILLS A, 1993, FEBS LETT, V320, P130, DOI 10.1016/0014-5793(93)80077-8; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NENONENE EK, 1994, J NEUROCHEM, V62, P1822; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PARKER EM, 1991, J BIOL CHEM, V266, P519; PARKER EM, 1994, EUR J PHARM-MOLEC PH, V268, P43, DOI 10.1016/0922-4106(94)90118-X; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; RAYMOND JR, 1992, N-S ARCH PHARMACOL, V346, P127, DOI 10.1007/BF00165293; RAYMOND JR, 1994, BIOCHEMISTRY-US, V32, P11064; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLEGEL JR, 1986, BIOCHEM PHARMACOL, V35, P1943, DOI 10.1016/0006-2952(86)90725-2; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SINGER WD, 1994, J BIOL CHEM, V269, P19796; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; UEDA N, 1994, J BIOL CHEM, V269, P4388; WILLIAMS AG, 1990, BLOOD, V76, P721; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WOOLKALIS MJ, 1986, J BIOL CHEM, V261, P3408; WREGGETT KA, 1984, MOL PHARMACOL, V26, P214; YOCCA FD, 1994, ANN NY ACAD SCI, V600, P212; ZGOMBICK JM, 1989, MOL PHARMACOL, V35, P484; ZHUANG ZP, 1994, J MED CHEM, V37, P1406, DOI 10.1021/jm00036a003; ZHUANG ZP, 1993, J MED CHEM, V36, P3161, DOI 10.1021/jm00073a016	66	147	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18691	18699		10.1074/jbc.270.31.18691	http://dx.doi.org/10.1074/jbc.270.31.18691			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629202	hybrid			2022-12-25	WOS:A1995RM64200084
J	HARTLEY, D; MEISNER, H; CORVERA, S				HARTLEY, D; MEISNER, H; CORVERA, S			SPECIFIC ASSOCIATION OF THE BETA-ISOFORM OF THE P85 SUBUNIT OF PHOSPHATIDYLINOSITOL-3 KINASE WITH THE PROTOONCOGENE C-CBL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; SH2 DOMAINS; T-CELLS; 3-KINASE; RECEPTOR; BINDING; PI3-KINASE; ACTIVATION; PROTEINS	Phosphatidylinositol-3 kinase (PI-3 kinase) has been implicated in cellular events such as mitogenic signaling, actin organization, and receptor sorting, The p85 subunit of PI-3 kinase contains multiple domains capable of protein-protein interactions that may contribute to mediate the multiple physiological functions of this enzyme, Here, we demonstrate that antibodies raised against the p85 subunit of PI-3 kinase immunoprecipitate a single tyrosine-phosphorylated protein of 120 kDa (pp120) from lysates of activated Jurkat T cells and A20 B cells, This protein is the only significant phosphotyrosine-containing protein in p85 immunoprecipitates from these cells, and it cannot be detected in immunoprecipitates of other signaling proteins such as PLC gamma. Furthermore, antibodies specific for the beta isoform of p85 but not antibodies specific for the alpha isoform immunoprecipitate this tyrosine-phosphorylated protein. pp120 completely comigrates with the proto-oncogene c-cbl, which is a 120 kDa protein product abundant in lymphoid cells, Furthermore, immunoblots of p85 immunoprecipitates using antibodies raised against c-cbl detect a band at exactly the position of pp120, In addition, p85 can be detected in immunoblots of c-cbl immunoprecipitates, Thus, pp120 appears to correspond to c-cbl, A direct association between c-cbl and p85 can be observed in vitro using a fusion protein comprising the Src homology 2 (SH2) domains of p85, and this binding is abolished by phenyl phosphate, suggesting that the interaction is mediated through phosphotyrosine-SH2 domain interactions, Thus, these results show important functional differences between the alpha and beta isoforms of p85 in vivo and point to c-cbl as a potentially important mediator of some of the functions of PI-3 kinase in intact cells.	UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040330] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40330] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; BLAKE TJ, 1991, ONCOGENE, V6, P653; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; REIF K, 1993, J BIOL CHEM, V268, P10780; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; WARD SG, 1992, J BIOL CHEM, V267, P23862	21	92	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18260	18263		10.1074/jbc.270.31.18260	http://dx.doi.org/10.1074/jbc.270.31.18260			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629144	hybrid			2022-12-25	WOS:A1995RM64200019
J	OGATA, Y; ITOH, Y; NAGASE, H				OGATA, Y; ITOH, Y; NAGASE, H			STEPS INVOLVED IN ACTIVATION OF THE PRO-MATRIX METALLOPROTEINASE-9 (PROGELATINASE-B)-TISSUE INHIBITOR OF METALLOPROTEINASES-1 COMPLEX BY 4-AMINOPHENYLMERCURIC ACETATE AND PROTEINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 72-KDA GELATINASE; 72 KDA PROGELATINASE; C-TERMINAL DOMAIN; TISSUE INHIBITOR; IV COLLAGENASE; INTERSTITIAL COLLAGENASE; ENZYMATIC-PROPERTIES; FIBROSARCOMA CELLS; CYSTEINE SWITCH; TIMP-2	The precursor of matrix metalloproteinase 9 (pro-MMP-9, progelatinase B) noncovalently binds to tissue inhibitor of metalloproteinases (TIMP)-1 through the C-terminal domain of each molecule. We have isolated the proMMP-9 . TIMP-1 complex from the medium of human fibrosarcoma HT-1080 cells and investigated the activation processes of the complex by 4-aminophenylmercuric acetate, trypsin, and matrix metalloproteinase 3 (MMP-3, stromelysin 1). The treatment of the proMMP-9 . TIMP-1 complex with 4-aminophenylmercuric acetate or trypsin converts proMMP-9 to lower molecular weight species corresponding to active forms, but no gelatinolytic activity is detected. The lack of enzymic activity results from binding of TIMP-1 to the activated MMP-9. The treatment of the proMMP-9 . TIMP-1 complex with a possible physiological proMMP-9 activator, MMP-3, does not reveal any gelatinolytic activity unless the molar ratio of MMP-3 to the complex exceeds 1. This is due to the inhibition of MMP-3 by TIMP-1 forming a ternary proMMP-9 . TIMP-1 . MMP-3 complex. The formation of the ternary complex weakens the interaction between proMMP-9 and TIMP-1, resulting in partial dissociation of the complex into proMMP-9 and the TIMP-1 . MMP-3 complex. When MMP-3 is in excess, the propeptide is completely processed, and the full activity of MMP-9 is detected. Similarly, the proMMP-9 . TIMP-1 complex inhibits MMP-1 (interstitial collagenase) and in turn renders the proMMP-9 activable by a catalytic amount of MMP-3. These results suggest that formation of the proMMP-9 . TIMP-1 complex regulates extracellular matrix breakdown in tissue by switching the predominant MMP activity from one type to another.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center				Itoh, Yoshifumi/0000-0002-2128-2823	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994, R01AR039189] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994, AR39189] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BROWN PD, 1990, CANCER RES, V50, P6184; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CURRY VA, 1992, BIOCHEM J, V285, P143, DOI 10.1042/bj2850143; DAVIS GE, 1991, ARCH BIOCHEM BIOPHYS, V286, P551, DOI 10.1016/0003-9861(91)90078-W; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; KOLKENBROCK H, 1994, BIOL CHEM H-S, V375, P589; KOLKENBROCK H, 1991, EUR J BIOCHEM, V198, P775, DOI 10.1111/j.1432-1033.1991.tb16080.x; MOLL UM, 1990, CANCER RES, V50, P6162; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1993, J BIOL CHEM, V268, P15453; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PEI DQ, 1994, J BIOL CHEM, V269, P25849; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSO.WG, 1993, ANNU REV CELL BIOL, V9, P541; STETLERSTEVENSO.WG, 1993, FASEB J, V7, P14334; STETLERSTEVENSO.WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	50	169	170	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18506	18511		10.1074/jbc.270.31.18506	http://dx.doi.org/10.1074/jbc.270.31.18506			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629179	hybrid			2022-12-25	WOS:A1995RM64200056
J	CHALLETON, C; BOUNACER, A; DUVILLARD, JA; CAILLOU, B; DEVATHAIRE, F; MONIER, R; SCHLUMBERGER, M; SUAREZ, HG				CHALLETON, C; BOUNACER, A; DUVILLARD, JA; CAILLOU, B; DEVATHAIRE, F; MONIER, R; SCHLUMBERGER, M; SUAREZ, HG			PATTERN OF RAS AND GSP ONCOGENE MUTATIONS IN RADIATION-ASSOCIATED HUMAN THYROID-TUMORS	ONCOGENE			English	Note						RADIATION-ASSOCIATED TUMORS; ONCOGENES; RAS; GSP; ACTIVATION	ACTIVATION; CANCER	The preferential activation of the Ki-ras oncogene in follicular radiation-associated human thyroid carcinomas, has been suggested by Wright et al. (1991). However, only 12 thyroid tumors were analysed in this study. In order to confirm if radiation favours, in human thyroid tumorigenesis, the appearance of a particular molecular lesion, we studied 33 benign and malignant human radiation-associated thyroid tumors. We used polymerase chain reaction (PCR) amplification and allele-specific hybridization with mutant-specific probes for the three ras genes and the gsp oncogene. Compared to 85 'spontaneous' human thyroid tumors, the radiation-associated cases: (1) show a similar overall frequency of uas and gsp mutations (about 30% and 6% respectively); (2) present a similar frequency of mutation of the three ras genes without any predominance in adenomas and papillary carcinomas and (3) all Ki-ras mutations were found in papillary carcinomas (4/15). ras and gsp genes were never found mutated simultaneously, suggesting an alternative role for both oncogenes in the thyroid tumorigenic radiation-associated process.	IFC HO1,MOLEC GENET GRP,F-94801 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT HISTOPATHOL,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT NUCL MED,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy			de Vathaire, Florent/L-2983-2016	de Vathaire, Florent/0000-0002-8374-9281				BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; DEVRIES MV, 1986, GENE, V50, P313; DUFFY BJ, 1950, CANCER, V3, P1018, DOI 10.1002/1097-0142(1950)3:6<1018::AID-CNCR2820030611>3.0.CO;2-H; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KOSAZA T, 1988, P NATL ACAD SCI USA, V85, P2081; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, ONCOGENE, V3, P541; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; SUAREZ HG, 1989, ANTICANCER RES, V9, P1331; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; WOOD JW, 1969, AM J EPIDEMIOL, V89, P4, DOI 10.1093/oxfordjournals.aje.a120914; WRIGHT PA, 1991, ONCOGENE, V6, P471; YASHIMOTO K, 1993, CANCER, V72, P1386	17	56	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					601	603						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630645				2022-12-25	WOS:A1995RN53000022
J	KAMBEROV, ES; ATKINSON, MR; NINFA, AJ				KAMBEROV, ES; ATKINSON, MR; NINFA, AJ			THE ESCHERICHIA-COLI PII SIGNAL-TRANSDUCTION PROTEIN IS ACTIVATED UPON BINDING 2-KETOGLUTARATE AND ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE-SYNTHETASE ADENYLYLATION; URIDYLYL-REMOVING ENZYME; REGULATOR-II NR(II); ALLOSTERIC REGULATION; NITROGEN-METABOLISM; ENTERIC BACTERIA; CASCADE CONTROL; GLNALG OPERON; URIDYLYLTRANSFERASE; PHOSPHORYLATION	Nitrogen regulation of transcription in Escherichia coli requires sensation of the intracellular nitrogen status and control of the dephosphorylation of the transcriptional activator NRI similar to P. This dephosphorylation is catalyzed by the bifunctional kinase/phosphatase NRII in the presence of the dissociable PII protein. The ability of PII to stimulate the phosphatase activity of NRII is regulated by a signal transducing uridylyltransferase/uridylyl-removing enzyme (UTase/UR), which converts PII to PB-UMP under conditions of nitrogen starvation; this modification prevents PII from stimulating the dephosphorylation of NRI similar to P. We used purified components to examine the binding of small molecules to PII, the effect of small molecules on the stimulation of the NRII phosphatase activity by PII, the retention of PII on immobilized NRII, and the regulation of the uridylylation of PII by the UTase/UR enzyme. Our results indicate that PII is activated upon binding ATP and either 2-ketoglutarate or glutamate, and that the liganded form of PII binds much better to immobilized NRII. We also demonstrate that the concentration of glutamine required to inhibit the uridylyltransferase activity is independent of the concentration of 2-ketoglutarate present. We hypothesize that nitrogen sensation in E. coli involves the separate measurement of glutamine by the UTase/UR protein and 2-ketoglutarate by the PII protein.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM47460] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047460] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER SP, 1975, J BIOL CHEM, V250, P6264; ATKINSON MR, 1992, J BACTERIOL, V174, P4538, DOI 10.1128/JB.174.14.4538-4548.1992; ATKINSON MR, 1994, J BIOL CHEM, V269, P28288; ATKINSON MR, 1993, J BACTERIOL, V175, P7016, DOI 10.1128/jb.175.21.7016-7023.1993; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1971, P NATL ACAD SCI USA, V68, P2949, DOI 10.1073/pnas.68.12.2949; BUENO R, 1985, J BACTERIOL, V164, P816, DOI 10.1128/JB.164.2.816-822.1985; CONTRERAS A, 1991, J BACTERIOL, V173, P7741, DOI 10.1128/jb.173.24.7741-7749.1991; ENGLEMAN EG, 1978, ARCH BIOCHEM BIOPHYS, V191, P602, DOI 10.1016/0003-9861(78)90398-3; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; FRANCIS SH, 1978, ARCH BIOCHEM BIOPHYS, V191, P590, DOI 10.1016/0003-9861(78)90397-1; FREIFELDER D, 1982, PHYSICAL BIOCH APPLI, P654; GARCIA E, 1983, J BIOL CHEM, V258, P2246; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; KAMBEROV ES, 1994, CELL MOL BIOL RES, V40, P175; KAMBEROV ES, 1994, J BIOL CHEM, V269, P28294; KAMBEROV ES, 1994, CELLULAR MOL BIOL PH, P302; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KEENER J, 1987, RNA POLYM REGULATION, P159; LIU J, 1995, J BACTERIOL, V177, P926, DOI 10.1128/jb.177.4.926-931.1995; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNEIL T, 1982, MOL GEN GENET, V188, P325, DOI 10.1007/BF00332696; MACNEIL T, 1982, J BACTERIOL, V150, P1302, DOI 10.1128/JB.150.3.1302-1313.1982; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; MAGASANIK B, 1987, ESCHERICHIA COLI SAL, P1318; MANGUM JH, 1973, ARCH BIOCHEM BIOPHYS, V158, P514, DOI 10.1016/0003-9861(73)90543-2; MURA U, 1981, J BIOL CHEM, V256, P3022; MURA U, 1981, J BIOL CHEM, V256, P3014; NINFA AJ, 1991, J BIOL CHEM, V266, P6888; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; PAHEL G, 1978, J BACTERIOL, V133, P139, DOI 10.1128/JB.133.1.139-148.1978; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; RHEE SG, 1985, CURR TOP CELL REGUL, V27, P221; RHEE SG, 1978, P NATL ACAD SCI USA, V75, P3138, DOI 10.1073/pnas.75.7.3138; SENIOR PJ, 1975, J BACTERIOL, V123, P407, DOI 10.1128/JB.123.2.407-418.1975; Stadtman ER, 1980, GLUTAMINE METABOLISM, P41; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	39	148	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17797	17807		10.1074/jbc.270.30.17797	http://dx.doi.org/10.1074/jbc.270.30.17797			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629080	hybrid			2022-12-25	WOS:A1995RM26600028
J	PU, RT; XU, G; WU, LP; VIERULA, J; ODONNELL, K; YE, XS; OSMANI, SA				PU, RT; XU, G; WU, LP; VIERULA, J; ODONNELL, K; YE, XS; OSMANI, SA			ISOLATION OF A FUNCTIONAL HOMOLOG OF THE CELL CYCLE-SPECIFIC NIMA PROTEIN-KINASE OF ASPERGILLUS-NIDULANS AND FUNCTIONAL-ANALYSIS OF CONSERVED RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CATALYTIC DOMAINS; NEUROSPORA-CRASSA; CONTROL GENE; ACTIVATION; MUTATION; CLONING; FAMILY; DNA; PHOSPHORYLATION	To investigate the degree of conservation of the cell cycle-specific NIMA protein kinase of Aspergillus nidulans, and to help direct its functional analysis, we cloned a homolog (designated nim-1) from Neurospora crassa. Over the catalytic domain NIM-1 is 75% identical to NIMA, but overall the identity drops to 52%. nim-1 was able to functionally complement nimA5 in A. nidulans. Mutational analysis of potential activating phosphorylation sites found in NIMA, NIM-1, and related protein kinases was performed on NIMA. Mutation of threonine 199 (conserved in all NIMA-related kinases) inhibited NIMA beta-casein kinase activity and abolished its in vivo function. This site conforms to a minimal consensus phosphorylation site for NIMA (FXXT) and is analogous to the autophosphorylation site of cyclic-AMP-dependent protein kinases. However, mutation of a unique cysteine residue found only in the catalytic site of NIMA and NIM-1 had no effect on NIMA kinase activity or function. Three temperature-sensitive alleles of nimA that cause arrest in G(2) were sequenced and shown to generate three different amino acid substitutions. None of the mutations prevented accumulation of NIMA protein during G(2) arrest, but all prevented the p34(cdc2)/cyclin B-dependent phosphorylation of NIMA normally seen during mitotic initiation even though p34(cdc2)/cyclin B H1 kinase activity was fully activated.	WEIS CTR RES,GEISINGER CLIN,DANVILLE,PA 17822; CARLETON UNIV,DEPT BIOL,OTTAWA,ON K1S 5B6,CANADA; USDA,NATL CTR AGR UTILIZAT RES,PEORIA,IL 61604	Carleton University; United States Department of Agriculture (USDA)			Osmani, Stephen A./AAS-3904-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042564] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42564] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON AB, 1992, GENE, V117, P137, DOI 10.1016/0378-1119(92)90502-G; BERGEN LG, 1984, J BACTERIOL, V159, P114, DOI 10.1128/JB.159.1.114-119.1984; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOONAN JH, 1991, J BIOL CHEM, V266, P18889; DOONAN JH, 1982, J CELL SCI, V103, P599; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; GALE M, 1993, MOL BIOCHEM PARASIT, V59, P111, DOI 10.1016/0166-6851(93)90012-M; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JONES DGL, 1990, GENE, V90, P87, DOI 10.1016/0378-1119(90)90442-T; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; LU KP, 1994, J BIOL CHEM, V269, P6603; LU KP, 1994, CELL, V13, P2103; MORRIS NR, 1975, GENET RES, V26, P237, DOI 10.1017/S0016672300016049; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OAKLEY BR, 1987, GENE, V61, P385, DOI 10.1016/0378-1119(87)90201-0; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; ORBACH MJ, 1990, J BIOL CHEM, V265, P10981; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1994, J CELL SCI, V107, P1519; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P1; SCHWEITZER B, 1992, MOL GEN GENET, V234, P164, DOI 10.1007/BF00272358; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	43	51	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18110	18116		10.1074/jbc.270.30.18110	http://dx.doi.org/10.1074/jbc.270.30.18110			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629122	hybrid			2022-12-25	WOS:A1995RM26600073
J	CROSS, AR; RAE, J; CURNUTTE, JT				CROSS, AR; RAE, J; CURNUTTE, JT			CYTOCHROME-B(-245) OF THE NEUTROPHIL SUPEROXIDE-GENERATING SYSTEM CONTAINS 2 NONIDENTICAL HEMES - POTENTIOMETRIC STUDIES OF A MUTANT FORM OF GP91(PHOX)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHAGOCYTE NADPH OXIDASE; RESPIRATORY BURST; PLASMA-MEMBRANE; PURIFICATION; COMPONENT	Analysis of potentiometric titrations of the cytochrome b(-245) from a X(+) chronic granulomatous disease patient with an Arg(54) --> Ser mutation in gp91(phox) indicates that the mutant form of the cytochrome contains two nonidentical hemes with midpoint potentials of E(m7) = -220 and E(m7) = -300 mV. In the light of this information, reanalysis of redox titrations of wild type cytochrome b(-245) implies that it probably also contains two separate heme centers with midpoint potentials of E(m7) = -225 and E(m7) = -265 mV. The effect of the Arg(54) --> Ser substitution is to reduce the midpoint potential of one of the heme centers by approximately 35 mV and suggests possible interaction between Arg(54) and heme propionate side chain.	GENENTECH INC, DEPT IMMUNOL, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech	CROSS, AR (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED CAL1, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELLAVITE P, 1983, BIOCHIM BIOPHYS ACTA, V746, P40, DOI 10.1016/0167-4838(83)90008-0; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1995, J BIOL CHEM, V270, P8194, DOI 10.1074/jbc.270.14.8194; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; CUTLER RL, 1989, BIOCHEMISTRY-US, V28, P3188, DOI 10.1021/bi00434a012; DOUSSIERE J, 1995, BIOCHEMISTRY-US, V34, P1760, DOI 10.1021/bi00005a033; HARPER AM, 1984, BIOCHEM J, V219, P519, DOI 10.1042/bj2190519; HURST JK, 1991, J BIOL CHEM, V266, P1627; IIZUKA T, 1985, J BIOL CHEM, V260, P2049; ISOGAI Y, 1993, J BIOL CHEM, V268, P4025; KNIGHT M, 1979, ANAL BIOCHEM, V95, P19, DOI 10.1016/0003-2697(79)90179-9; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; MIKI T, 1992, J BIOL CHEM, V267, P19673; PALMER G, 1994, BIOCHEMISTRY-US, V33, P176, DOI 10.1021/bi00167a023; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; YAMAGUCHI T, 1989, J BIOL CHEM, V264, P112; YOSHIDA LS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P245	23	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17075	17077		10.1074/jbc.270.29.17075	http://dx.doi.org/10.1074/jbc.270.29.17075			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615499	hybrid			2022-12-25	WOS:A1995RK68900006
J	EBERT, SN; WONG, DL				EBERT, SN; WONG, DL			DIFFERENTIAL ACTIVATION OF THE RAT PHENYLETHANOLAMINE N-METHYLTRANSFERASE GENE BY SP1 AND EGR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; MESSENGER-RNA; TRANSCRIPTION FACTORS; INSITU HYBRIDIZATION; GROWTH-FACTORS; LESS PROMOTER; BINDING-SITE; EXPRESSION; DNA; ZIF268	The rat phenylethanolamine N-methyltransferase (PNMT) gene contains overlapping consensus elements for the Sp1 and Egr-1 transcription factors located at -45 bp and -165 bp in the PNMT promoter. In the present study, we show that Sp1 and Egr-1 can specifically bind to these overlapping elements, that this binding appears to be mutually exclusive, and that binding site occupancy is dependent upon the concentration of each factor and its binding affinity for each site. Egr-1 binds to the -165 bp site with relatively high affinity (IC50 = 14 nM) and to the -45 bp site with relatively low affinity (IC50 = 1360 nM), whereas Sp1 binds to both sites with intermediate affinities (IC50 = 210 and 140 nM, respectively). Consistent with the DNA-binding data, Egr-1 stimulates PNMT promoter activity primarily through interaction with the -165 bp site, while Sp1 stimulates PNMT promoter activity by interacting with both the -45 bp and the -165 bp sites. These results show that Sp1 and Egr-1 are capable of differentially activating PNMT gene expression, thereby suggesting that different stimuli may control the activity of the PNMT gene by selectively regulating Sp1 and/or Egr-1.	STANFORD UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,NANCY PRITZKER LAB DEV & MOLEC NEUROBIOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH010350] Funding Source: NIH RePORTER; NIMH NIH HHS [MH10350] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; BHAT RV, 1992, J PHARMACOL EXP THER, V263, P343; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CIARANELLO RD, 1980, CATECHOLAMINES STRES, P317; CIARANELLO RD, 1971, SCIENCE, V175, P789; EBERT SN, 1994, J BIOL CHEM, V269, P20885; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KATAYAMA N, 1993, J NEUROCHEM, V60, P902, DOI 10.1111/j.1471-4159.1993.tb03235.x; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; KVETANSK.R, 1971, AM J PHYSIOL, V220, P928, DOI 10.1152/ajplegacy.1971.220.4.928; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LI Y, 1993, J BIOL CHEM, V268, P3563; LIM RW, 1987, ONCOGENE, V1, P263; MAILLEUX P, 1992, NEUROSCI LETT, V147, P182, DOI 10.1016/0304-3940(92)90590-4; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MORITA K, 1995, J BIOL CHEM, V270, P11161, DOI 10.1074/jbc.270.19.11161; MULLER MT, 1987, J VIROL, V61, P858, DOI 10.1128/JVI.61.3.858-865.1987; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J, 1989, MOL CLONING LABORATO; VISKUPIC E, 1994, J NEUROCHEM, V63, P808; WEISBERG EP, 1989, MOL BRAIN RES, V6, P159, DOI 10.1016/0169-328X(89)90050-8; WONG DL, 1992, FASEB J, V6, P3310, DOI 10.1096/fasebj.6.14.1426768; WONG DL, 1993, MOL BRAIN RES, V18, P107, DOI 10.1016/0169-328X(93)90178-R	36	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17299	17305		10.1074/jbc.270.29.17299	http://dx.doi.org/10.1074/jbc.270.29.17299			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615530	hybrid			2022-12-25	WOS:A1995RK68900040
J	JANS, DA; MOLL, T; NASMYTH, K; JANS, P				JANS, DA; MOLL, T; NASMYTH, K; JANS, P			CYCLIN-DEPENDENT KINASE SITE-REGULATED SIGNAL-DEPENDENT NUCLEAR-LOCALIZATION OF THE SWI5 YEAST TRANSCRIPTION FACTOR IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RETINOBLASTOMA GENE-PRODUCT; RENAL EPITHELIAL-CELLS; SV40 T-ANTIGEN; NF-KAPPA-B; PROTEIN-KINASE; VASOPRESSIN V2-RECEPTOR; LATERAL MOBILITY; PHOSPHORYLATION; TRANSLOCATION; TRANSPORT	Control over the nuclear transport of transcription factors (TFs) represents a level of gene regulation integral to cellular processes such as differentiation, transformation and signal transduction. The Saccharomyces cerevisiae TF SW15 is excluded from the nucleus in a cell cycle-dependent fashion, mediated by phosphorylation by the cyclin-dependent kinase (cdk) CDC28. Nuclear entry occurs in G(1). beta-galactosidase fusion proteins carrying SWI5 amino acids 633-682, including the nuclear localization sequence (NLS: Lys-Lys-Tyr-Glu-Asn-Val-Val-Ile-Lys-Arg-Ser-Pro-Arg-Lys-Arg-Gly-Arg-Pro-Arg-Lys(655)) were analyzed for subcellular localization in appropriate temperature-sensitive yeast strains blocked in G(1) or G(2)/M using indirect immunofluorescence, and for nuclear import kinetics in living rat hepatoma or Vero African green monkey kidney cells microinjected with fluorescently labeled bacterially expressed protein and quantitative confocal laser micros copy, Cell cycle dependent nuclear localization in yeast was both NLS and cdk site-dependent, whereby mutation of the cdk site serines (Ser(646) and Ser(664)) to alanine resulted in constitutive nuclear localization, In mammalian cells, the SWI5 fusion proteins were similarly transported to the nucleus in an NLS dependent fashion, while the mutation to Ala of the cdk site serines increased the maximal level of nuclear accumulation from about 1- to over 8-fold, We suggest that phosphorylation at the cdk sites inhibits nuclear transport of SWI5, consistent with our previous observations for the inhibition of SV40 large tumor antigen nuclear transport by phosphorylation by the cdk cdc2. The results indicate for the first time that a yeast NLS and, fascinatingly, its regulatory mechanisms are functional in higher eukaryotes, implying the universal nature of regulatory signals for protein transport to the nucleus.	MAX PLANCK INST BIOPHYS, W-6000 FRANKFURT, GERMANY; VIENNA INT RES COOPERAT CTR, VIENNA, AUSTRIA; INST MOLEK PATHOL, VIENNA, AUSTRIA	Max Planck Society; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	JANS, DA (corresponding author), AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOLEC BIOL, NUCL SIGNALLING LAB, CANBERRA, ACT 2601, AUSTRALIA.			Nasmyth, Kim/0000-0001-7030-4403				CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; JANS DA, 1989, EMBO J, V8, P2481, DOI 10.1002/j.1460-2075.1989.tb08384.x; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; JANS DA, 1991, J CELL BIOL, V114, P53, DOI 10.1083/jcb.114.1.53; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JANS DA, 1992, BIOCHIM BIOPHYS ACTA, V1113, P271, DOI 10.1016/0304-4157(92)90001-Q; JANS DA, 1995, IN PRESS BIOCH J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OHTA Y, 1989, J BIOL CHEM, V264, P16143; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; TINLAND B, 1992, P NATL ACAD SCI USA, V89, P7442, DOI 10.1073/pnas.89.16.7442; VANCUROVA I, 1995, J CELL SCI, V108, P779; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588	41	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17064	17067		10.1074/jbc.270.29.17064	http://dx.doi.org/10.1074/jbc.270.29.17064			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615496	hybrid			2022-12-25	WOS:A1995RK68900003
J	RYAN, TC; CRUIKSHANK, WW; KORNFELD, H; COLLINS, TL; CENTER, DM				RYAN, TC; CRUIKSHANK, WW; KORNFELD, H; COLLINS, TL; CENTER, DM			THE CD4-ASSOCIATED TYROSINE KINASE P56(LCK) IS REQUIRED FOR LYMPHOCYTE CHEMOATTRACTANT FACTOR-INDUCED T-LYMPHOCYTE MIGRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEARING MONONUCLEAR-CELLS; PROTEIN-KINASE; SIGNAL TRANSDUCTION; CD4 RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; FUNCTIONAL-CHARACTERISTICS; SURFACE-ANTIGENS; HERBIMYCIN-A; MYOSIN-I; ACTIVATION	Lymphocyte chemoattractant factor (LCF) is a polypeptide cytokine which induces both cell motility and activation of T lymphocytes. These LCF-induced events demonstrate an absolute requirement for the cell surface expression of CD4, Because many CD4-mediated T lymphocyte activation events have been demonstrated to require the association of the src-related tyrosine kinase p56(lck) with the cytoplasmic domain of CD4, we examined the role of p56(lck) in LCF-induced lymphocyte migration in a murine T cell hybridoma line expressing transfected human CD4. LCF induces the catalytic activity of CD4 associated p56(lck) at chemoattractant concentrations of cytokine, Hybridoma cells that express CD4 with cytoplasmic point mutations which uncouple the CD4-lck association lack both lck enzymatic activity and chemotactic responses to LCF. The enzymatic activity of lck however does not appear to be required for CD4-mediated migratory signal, First, the protein tyrosine kinase inhibitor herbimycin A blocked LCF-induced p56(lck) activation but had no effect on the LCF-induced motile response. Second, T cell hybridomas expressing a chimeric receptor combining the extracellular domain of human CD4 and murine p56(lck) which lacked the kinase domain had a normal LCF-induced motile response, We conclude from these observations that CD4-lck coupling is essential for LCF-induced T lymphocyte migration but the motile response is independent of the enzymatic activity of CD4-associated p56(lck).	BOSTON UNIV, SCH MED, CTR PULM, BOSTON, MA 02118 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA	Boston University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Kornfeld, Hardy/AAS-2903-2021	Center, David/0000-0002-5879-7978	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032802] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32802] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BERMAN JS, 1990, AM REV RESPIR DIS, V142, P238, DOI 10.1164/ajrccm/142.1.238; BERMAN JS, 1984, J IMMUNOL, V133, P1495; BERMAN JS, 1985, CELL IMMUNOL, V95, P105, DOI 10.1016/0008-8749(85)90299-0; BRAMSON HN, 1991, J BIOL CHEM, V266, P16219; CENTER DM, 1983, J IMMUNOL, V131, P1854; CENTER DM, 1993, CHEST, V103, pS88; COLLINS TL, 1992, J IMMUNOL, V148, P2159; COLLINS TL, 1993, P NATL ACAD SCI USA, V90, P11885, DOI 10.1073/pnas.90.24.11885; CRUIKSHANK WW, 1991, J IMMUNOL, V146, P2928; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; GOLDMAN F, 1994, J IMMUNOL, V153, P2905; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; METZGER H, 1992, J IMMUNOL, V149, P1477; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; ROITT IM, 1991, ESSENTIAL IMMUNOLOGY; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SHELANSKI ML, 1989, ANN NY ACAD SCI, V568, P121; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SLECKMAN BP, 1992, P NATL ACAD SCI USA, V89, P7566, DOI 10.1073/pnas.89.16.7566; TEFLER JC, 1991, SCIENCE, V254, P439; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; THORP KM, 1994, IMMUNOLOGY, V81, P546; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WENG ZG, 1993, J BIOL CHEM, V268, P14956; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	41	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17081	17086		10.1074/jbc.270.29.17081	http://dx.doi.org/10.1074/jbc.270.29.17081			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615501	hybrid			2022-12-25	WOS:A1995RK68900008
J	TROUSSARD, AA; KHALLOU, J; MANN, CJ; ANDRE, P; STRICKLAND, DK; BIHAIN, BE; YEN, FT				TROUSSARD, AA; KHALLOU, J; MANN, CJ; ANDRE, P; STRICKLAND, DK; BIHAIN, BE; YEN, FT			INHIBITORY EFFECT ON THE LIPOLYSIS-STIMULATED RECEPTOR OF THE 39-KDA RECEPTOR-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LOW-DENSITY-LIPOPROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; HIGH-AFFINITY; MULTIFUNCTIONAL RECEPTOR; BINDING; LIVER	Adenovirus vector-mediated transfer of the receptor-associated protein (RAP) gene into low density lipoprotein (LDL) receptor deficient mice was shown to achieve plasma concentrations ranging between 20 and 200 mu g/ml and to result in the accumulation of remnant lipoproteins (Willnow, T. E., Sheng, Z., Ishibashi, S., and Herz, J. (1994) Science 264, 1471-1474). Both this finding and the observation that in addition to various other members of the LDL receptor gene family, RAP binds to a yet unidentified protein of apparent molecular mass of 105 kDa prompted us to examine the effect of high concentrations of RAP on the lipolysis-stimulated receptor (LSR). LSR is a receptor distinct from the LDL receptor and the LDL receptor-related protein and is capable of binding apoB and apoE when activated by free fatty acids. Data reported here show that in fibroblasts isolated from a subject homozygous for familial hypercholesterolemia, RAP fusion protein inhibited LSR-mediated binding of I-125-LDL and the subsequent internalization and degradation of the particles. Studies on the interaction of RAP with LSR in isolated rat liver membranes revealed that at concentrations greater than or equal to 10 mu g/ml, RAP inhibited in a dose-dependent manner the binding of LDL to LSR; half-maximum inhibition was obtained with 20 mu g/ml RAP. Ligand blotting studies revealed that RAP bound directly to two rat liver membrane proteins of apparent molecular masses identical to those that bind I-125-LDL after preincubation with oleate. However, unlike LDL, binding of I-125-RAP to LSR did not require preincubation with oleate. Preincubation of nitrocellulose membranes with an excess of unlabeled RAP fusion protein decreased oleate-induced binding of I-125-LDL to LSR candidate proteins, whereas preincubation with excess unlabeled LDL was unable to prevent the subsequent binding of I-125-RAP to the LSR proteins. Both the latter data and analysis of the mechanism of inhibition were consistent with the RAP inhibitory effect on LSR being achieved by interference with a site distinct from the oleate induced LDL binding site. In conclusion, this study shows that at concentrations reported to delay chylomicron remnant removal in LDL receptor-deficient mice, RAP exerted a significant inhibitory effect on LSR.	UNIV RENNES 1,FAC SCI PHARMACEUT & BIOL,INSERM,U391,F-35043 RENNES,FRANCE; AMER RED CROSS,ROCKVILLE,MD 20855	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; American Red Cross			André, Patrice/M-8139-2014; Yen, Frances T/G-9175-2014	André, Patrice/0000-0002-5834-7395; Yen, Frances T/0000-0001-8740-4304; Laschet, Jamila/0000-0002-5090-4417				ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BIHAIN BE, 1992, BIOCHEMISTRY-US, V31, P4628, DOI 10.1021/bi00134a013; BIHAIN BE, 1995, ATHEROSCLEROSIS, V10, P465; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; FARQUHAR MG, 1994, ANN NY ACAD SCI, V737, P96, DOI 10.1111/j.1749-6632.1994.tb44304.x; GAFVELS ME, 1994, ENDOCRINOLOGY, V1135, P387; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1977, INT CELL BIOL 1976 1, P639; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V787, P114; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Markwell M A, 1981, Methods Enzymol, V72, P296; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; SOUTAR AK, 1989, NATURE, V341, P106, DOI 10.1038/341106a0; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Van Berkel Theo J. C., 1994, Current Opinion in Lipidology, V5, P331, DOI 10.1097/00041433-199410000-00004; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; YEN FT, 1994, BIOCHEMISTRY-US, V33, P1172, DOI 10.1021/bi00171a017	31	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17068	17071		10.1074/jbc.270.29.17068	http://dx.doi.org/10.1074/jbc.270.29.17068			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615497	hybrid			2022-12-25	WOS:A1995RK68900004
J	PELLEGATA, NS; CAJOT, JF; STANBRIDGE, EJ				PELLEGATA, NS; CAJOT, JF; STANBRIDGE, EJ			THE BASIC CARBOXY-TERMINAL DOMAIN OF HUMAN P53 IS DISPENSABLE FOR BOTH TRANSCRIPTIONAL REGULATION AND INHIBITION OF TUMOR-CELL GROWTH	ONCOGENE			English	Article						P53; C-TERMINAL DOMAINS	WILD-TYPE P53; DNA-BINDING; PROTEIN COMPLEXES; OLIGOMERIZATION; SUPPRESSION; MUTATIONS; TRANSFORMATION; WILD-TYPE-P53; LOCALIZATION; DETERMINANT	To investigate the relevance of the C-terminal domains of the human p53 tumor suppressor gene to its growth suppressive and transcriptional regulatory properties deletion mutants were generated which eliminated 30 (53 Delta 363), 60 (p53 Delta 333) and 87 (p53 Delta 306) amino acids from the C-terminus of the p53 protein. p53 Delta 363 has lost the highly basic tail of the protein (residues 360-386). p53 Delta 333 and p53 Delta 306 lack the oligomerization domain (residues 320-360); p53 Delta 306 has also lost the major nuclear localization signal of p53 (NLSI, residues 316-325). These mutants were assayed for transactivation from two p53 consensus binding sites and for transcriptional repression of two promoter systems in Calu6 lung cancer cells (p53 null). Moreover, their ability to inhibit cell growth in tumor cell lines with a defined p53 status was analysed. Deletion of the oligomerization domain correlated with significant loss of: (a) transactivation from a genomic sequence; (b) transcriptional repression; (c) the ability to inhibit colony formation. An intact NLSI was not a prerequisite for transactivation. p53 Delta 363 behaved similarly to wt p53 in all the assays. We established an inducible expression system for p53 Delta 363 in a human fibrosarcoma cell line known to be growth-suppressed by wt p53. The induction of p53 Delta 363 expression also inhibited cell proliferation albeit to a lesser extent than wt p53. However, p53 Delta 363 could upregulate WAF1/CIP1, GADD45 and MDM2 genes. Thus, the basis tail of p53 appears not to be required for the biological functions of the protein assayed.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine			Pellegata, Natalia S/I-1256-2012	Pellegata, Natalia S/0000-0002-8000-7784	NATIONAL CANCER INSTITUTE [P30CA062203, R01CA019401, R37CA019401] Funding Source: NIH RePORTER; NCI NIH HHS [CA-62203, CA 19401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAJOT JF, 1992, CANCER RES, V52, P6956; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DONEHOWER LA, 1992, NATURE, V56, P215; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V252, P49; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1707; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEHMAN TA, 1991, CANCER RES, V51, P4090; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	48	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					337	349						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624148				2022-12-25	WOS:A1995RK95700014
J	GALISTEO, ML; GORDON, CL; KING, J				GALISTEO, ML; GORDON, CL; KING, J			STABILITY OF WILD-TYPE AND TEMPERATURE-SENSITIVE PROTEIN SUBUNITS OF THE PHAGE-P22 CAPSID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY FORMATION; TURNIP CRINKLE VIRUS; ESCHERICHIA-COLI; FOLDING MUTANTS; COAT PROTEIN; CONFORMATIONAL-CHANGES; SCANNING CALORIMETRY; SCAFFOLDING SUBUNITS; BACTERIOPHAGE P22; HEAD	Temperature-sensitive folding (tsf) mutants of the phage P22 coat protein prevent newly synthesized polypeptide chains from reaching the conformation competent for capsid assembly in cells, and can be rescued by the GroEL chaperone (Gordon, C., Sather, S., Casjens, S., and King, J. (1994) J. Biol. Chem. 269, 27941-27951). Here we investigate the stabilities of wild-type and four tsf mutant unpolymerized subunits. Wild-type coat protein subunits denatured at 40 degrees C, with a calorimetric enthalpy of approximately 600 kJ/mol. Comparison with coat protein denaturation within the shell lattice (T-m = 87 degrees C, Delta H similar to 1700 kJ/mol) (Galisteo, M. L., and King, J. (1993) Biophys, J. 65, 227-235) indicates that protein-protein interactions within the capsid provide enormous stabilization. The melting temperatures of the subunits carrying tsf substitutions were similar to wildtype. At low temperatures, the tsf mutants, but not the wild-type, formed non-covalent dimers, which were dissociated at temperatures above 30 degrees C. Spectroscopic and calorimetric studies indicated that the mutant proteins have reduced amounts of ordered structure at low temperature, as compared to the wild-type protein. Although complex, the in vitro phenotypes are consistent with the in vivo finding that the mutants are defective in folding, rather than subunit stability. These results suggest a role for incompletely folded subunits as precursors in viral capsid assembly, providing a mechanism of reaching multiple conformations in the polymerized form.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV GRANADA,FAC CIENCIAS,DEPT QUIM FIS,E-18071 GRANADA,SPAIN	Massachusetts Institute of Technology (MIT); University of Granada					NIGMS NIH HHS [GM17980] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017980, R01GM017980] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTAZZON A, 1989, BIOCHEMISTRY-US, V28, P9784, DOI 10.1021/bi00451a036; BERTAZZON A, 1990, BIOCHEMISTRY-US, V29, P6447, DOI 10.1021/bi00479a016; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CASPAR DLD, 1980, BIOPHYS J, V32, P103, DOI 10.1016/S0006-3495(80)84929-0; CEPKO CL, 1982, CELL, V31, P407, DOI 10.1016/0092-8674(82)90134-9; CHRUNYK BA, 1993, J BIOL CHEM, V268, P18053; COPPO A, 1973, J MOL BIOL, V76, P61, DOI 10.1016/0022-2836(73)90081-8; EARNSHAW W, 1976, J MOL BIOL, V104, P387, DOI 10.1016/0022-2836(76)90278-3; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EPPLER K, 1991, VIROLOGY, V183, P519, DOI 10.1016/0042-6822(91)90981-G; FOGUEL D, 1995, BIOCHEMISTRY-US, V34, P1120, DOI 10.1021/bi00004a003; FULLER MT, 1981, VIROLOGY, V112, P529, DOI 10.1016/0042-6822(81)90300-7; FULLER MT, 1982, J MOL BIOL, V156, P633, DOI 10.1016/0022-2836(82)90270-4; GALISTEO ML, 1991, BIOCHEMISTRY-US, V30, P2061, DOI 10.1021/bi00222a009; GALISTEO ML, 1993, BIOPHYS J, V65, P227, DOI 10.1016/S0006-3495(93)81073-7; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLDENBERG D, 1991, J MOL BIOL, V145, P633; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GORDON CL, 1993, J BIOL CHEM, V268, P9358; GORDON CL, 1994, GENETICS, V136, P427; GREENE B, 1994, VIROLOGY, V205, P188, DOI 10.1006/viro.1994.1634; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARRISON SC, 1984, TRENDS BIOCHEM SCI, V9, P345, DOI 10.1016/0968-0004(84)90057-4; HENDRIX RW, 1985, VIRUS STRUCTURE ASSE, P169; HORWITZ M S, 1991, P771; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KING J, 1974, NATURE, V251, P112, DOI 10.1038/251112a0; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LARSON SB, 1993, J MOL BIOL, V231, P375, DOI 10.1006/jmbi.1993.1289; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NEWCOMB WW, 1991, J VIROL, V65, P613, DOI 10.1128/JVI.65.2.613-620.1991; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; PREVELIGE PE, 1993, BIOPHYS J, V64, P824, DOI 10.1016/S0006-3495(93)81443-7; PREVELIGE PE, 1994, BIOPHYS J, V66, P1631, DOI 10.1016/S0006-3495(94)80955-5; Privalov P L, 1986, Methods Enzymol, V131, P4; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; ROSS PD, 1985, J MOL BIOL, V183, P353, DOI 10.1016/0022-2836(85)90006-3; RUECKERT R R, 1991, P409; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SORGER PK, 1986, J MOL BIOL, V191, P639, DOI 10.1016/0022-2836(86)90451-1; STEVEN AC, 1992, J MOL BIOL, V228, P870, DOI 10.1016/0022-2836(92)90871-G; STOCKLEY PG, 1986, J MOL BIOL, V191, P721, DOI 10.1016/0022-2836(86)90456-0; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; TESCHKE CM, 1995, IN PRESS BIOCHEMISTR; THOMAS D, 1991, VIROLOGY, V182, P673, DOI 10.1016/0042-6822(91)90608-E; TRUONG HTN, 1991, BIOCHEMISTRY-US, V30, P10722; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979	59	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16595	16601		10.1074/jbc.270.28.16595	http://dx.doi.org/10.1074/jbc.270.28.16595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622466	hybrid			2022-12-25	WOS:A1995RJ34700023
J	KANE, PM				KANE, PM			DISASSEMBLY AND REASSEMBLY OF THE YEAST VACUOLAR H+-ATPASE IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; SUBUNIT; MUTANTS; TRANSPORT; PATHWAY	The vacuolar H+-ATPase of the yeast Saccharomyces cerevisiae is composed of a complex of peripheral subunits (the V-1 sector) attached to an integral membrane complex (the V-0 sector). In the experiments described here, attachment of the V-1 to the V-0 sector was assessed in wild-type cells under a variety of growth conditions. Depriving the yeast cells of glucose, even for as little as 5 min, caused dissociation of approximately 70% of the assembled enzyme complexes into separate V-1 and V-0 subcomplexes. Restoration of glucose induced rapid and efficient reassembly of the enzyme from the previously synthesized subcomplexes. Indirect immunofluorescence microscopy and subcellular fractionation revealed detachment of the peripheral subunits from the vacuolar membrane in the absence of glucose, followed by reattachment in the presence of glucose. Rapid dissociation of vacuolar H+-ATPases could also be triggered by shifting cells into a variety of other carbon sources, and reassembly could be generated by addition of glucose. Disassembly and reassembly of vacuolar H+-ATPases in vivo may be a means of regulating organelle acidification in response to extracellular conditions, or a mechanism for assembling alternate complexes of vacuolar H+-ATPases in different intracellular compartments.			KANE, PM (corresponding author), SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA.				NIGMS NIH HHS [R01-GM50322, R01 GM050322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; JOHNSTON M, 1991, MOL CELL BIOL YEAST, V2, P193; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; LAI S, 1991, J BIOL CHEM, V266, P16078; LILL H, 1986, EUR J BIOCHEM, V160, P627, DOI 10.1111/j.1432-1033.1986.tb10084.x; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PENEFSKY HS, 1991, ADV ENZYMOL, V64, P173; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SERRANO R, 1991, MOL CELLULAR BIOL YE, V1, P523; SHERMAN F, 1982, METHODS YEAST GENETI, P177; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; THEVELEIN JM, 1992, ANTON LEEUW INT J G, V62, P109, DOI 10.1007/BF00584466; THEVELEIN JM, 1995, TRENDS BIOCHEM SCI, V20, P3, DOI 10.1016/S0968-0004(00)88938-0; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WARD JM, 1992, PLANT PHYSIOL, V99, P170, DOI 10.1104/pp.99.1.170; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	38	381	384	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					17025	17032						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622524				2022-12-25	WOS:A1995RJ34700086
J	SRIVASTAVA, SP; DAVIES, MV; KAUFMAN, RJ				SRIVASTAVA, SP; DAVIES, MV; KAUFMAN, RJ			CALCIUM DEPLETION FROM THE ENDOPLASMIC-RETICULUM ACTIVATES THE DOUBLE-STRANDED RNA-DEPENDENT PROTEIN-KINASE (PKR) TO INHIBIT PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; MAMMALIAN-CELLS; TRANSLATIONAL INITIATION; SECRETORY PROTEINS; HELA-CELLS; INTERFERON; PHOSPHORYLATION; VIRUS; EXPRESSION; MECHANISM	Calcium depletion from the endoplasmic reticulum inhibits protein synthesis and correlates with increased phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eLF-2 alpha) by a mechanism that does not require ongoing protein synthesis, To elucidate whether protein synthesis inhibition requires eIF-2 alpha phosphorylation and whether eIF-2 alpha phosphorylation is mediated by the double-stranded RNA-dependent protein kinase (PKR), we studied protein synthesis in response to calcium depletion mediated by calcium ionophore A23187 in cell lines overexpressing wild-type eIF-2 alpha, a mutant eLF-2 alpha (S51A) that is resistant to phosphorylation, or a dominant negative mutant PKR (K296P in catalytic subdomain II), Expression of either mutant eIF-2 alpha or mutant PKR partially protected NIH3T3 cells from inhibition of protein synthesis upon A23187 treatment. In contrast, overexpression of wild-type PKR increased sensitivity to protein synthesis inhibition mediated by A23187 treatment. In a COS-1 monkey cell transient transfection system, increased eLF-2 alpha phosphorylation in response to A23187 treatment was inhibited by expression of the dominant negative PKR mutant. Overexpression of the PKR regulatory RNA binding domain, independent of the PKR catalytic do main, was sufficient to inhibit increased phosphorylation of eIF-2 alpha upon A23187 treatment. In addition, over expression of the HIV TAR RNA binding protein also inhibited eIF-2 alpha phosphorylation upon A23187 treatment. Taken together, our data show that calcium depletion activates PKR to phosphorylate eIF-2 alpha, and this activation is likely mediated through the PKR RNA binding domain.	UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48105; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48105; GENET INST INC,CAMBRIDGE,MA 02140	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan					NHLBI NIH HHS [HL5777, HL5273] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMESZ H, 1979, EUR J BIOCHEM, V98, P513, DOI 10.1111/j.1432-1033.1979.tb13212.x; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSTROM CO, 1989, J BIOL CHEM, V264, P1644; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; CHENG TC, 1994, BIOCHEM J, V301, P563, DOI 10.1042/bj3010563; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DAVIES MV, 1989, P NATL ACAD SCI USA, V86, P9163, DOI 10.1073/pnas.86.23.9163; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HERSHEY JWB, 1993, SEMIN VIROL, V4, P201, DOI 10.1006/smvy.1993.1016; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; HOVANESSIAN AG, 1982, EUR J BIOCHEM, V167, P467; JACKSON RJ, 1990, TRANSLATION EUKARYOT, P193; JUDWARE R, 1992, J BIOL CHEM, V267, P21685; KATZE MG, 1993, SEMIN VIROL, V4, P259, DOI 10.1006/smvy.1993.1022; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; LODISH HF, 1990, J BIOL CHEM, V265, P10893; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MATHEWS MB, 1993, SEMIN VIROL, V4, P247, DOI 10.1006/smvy.1993.1021; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU L, 1992, J BIOL CHEM, V267, P21685; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; PRESTON SF, 1992, CELL CALCIUM, V13, P303, DOI 10.1016/0143-4160(92)90065-Z; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; Singh V K, 1985, Prog Clin Biol Res, V202, P351; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; WEISSMANN G, 1980, P NATL ACAD SCI-BIOL, V77, P1506, DOI 10.1073/pnas.77.3.1506; WHITAKER M, 1990, DEVELOPMENT, V108, P525	52	114	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16619	16624		10.1074/jbc.270.28.16619	http://dx.doi.org/10.1074/jbc.270.28.16619			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622470	hybrid			2022-12-25	WOS:A1995RJ34700027
J	YAMAGUCHI, M; HATEFI, Y				YAMAGUCHI, M; HATEFI, Y			PROTON-TRANSLOCATING NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE OF ESCHERICHIA-COLI - INVOLVEMENT OF ASPARTATE-213 IN THE MEMBRANE-INTERCALATING DOMAIN OF THE BETA-SUBUNIT IN ENERGY TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-ENERGY; SEQUENCE; PROTEIN; ENZYME; GENE; N,N'-DICYCLOHEXYLCARBODIIMIDE; TRANSPORT; FRAGMENTS; CLEAVAGE; SITES	Mutations in the beta subunit of Escherichia coli proton-translocating nicotinamide nucleotide transhydrogenase of the conserved residue beta Asp-213 to Asn (beta D213N) and He (beta D213I) resulted in the loss, respectively, of about 70% and 90% NADPH --> 3-acetylpyridine adenine dinucleotide (AcPyAD) transhydrogenation and coupled proton translocation activities. However, the cyclic NADP(H)-dependent NADH --> AcPyAD transhydrogenase activities of the mutants were only similar to 35% inhibited. The latter transhydrogenation, which is not coupled to proton translocation, occurs apparently via NADP under conditions that enzyme-NADP(H) complex is stabilized. Mutations beta D213N and beta D213I also resulted in decreases in apparent K-m(NADPH) for the NADPH --> AcPyAD and S-0.5(NADPH) (NADPH concentration needed for half-maximal activity) for the cyclic NADH --> AcPyAD transhydrogenation reactions, and in K-d(NADPH), as determined by equilibrium binding studies on the purified wild-type and the beta D213I mutant enzymes. These results point to a structural role of beta Asp-213 in energy transduction and are discussed in relation to our previous suggestion that proton translocation coupled to NADPH --> NAD (or AcPyAD) transhydrogenation is driven mainly by the difference in the binding energies of NADPH and NADP.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NCRR NIH HHS [M01 RR0033] Funding Source: Medline; NIGMS NIH HHS [GM24887] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024887] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1992, EUR J BIOCHEM, V207, P733, DOI 10.1111/j.1432-1033.1992.tb17103.x; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CLARKE DM, 1985, J BACTERIOL, V162, P367, DOI 10.1128/JB.162.1.367-373.1985; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FISHER R. R., 1982, PYRIDINE NUCLEOTIDE, P279; GLAVAS NA, 1994, THESIS U BRIT COLUMB; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HATEFI Y, 1980, J BIOL CHEM, V255, P9526; HATEFI Y, 1992, MOL MECHANISMS BIOEN, P265; HOLMBERG E, 1994, BIOCHEMISTRY-US, V33, P7691, DOI 10.1021/bi00190a024; HOU C, 1990, BIOCHIM BIOPHYS ACTA, V1018, P61, DOI 10.1016/0005-2728(90)90110-P; HOWLETT GJ, 1978, ARCH BIOCHEM BIOPHYS, V190, P809, DOI 10.1016/0003-9861(78)90341-7; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JENCKS WP, 1989, METHOD ENZYMOL, V171, P145; KRAMER RA, 1993, MOL BIOCHEM PARASIT, V60, P327, DOI 10.1016/0166-6851(93)90144-M; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CP, 1989, BIOCHIM BIOPHYS ACTA, V1000, P371, DOI 10.1016/S0006-3002(89)80032-0; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P6340, DOI 10.1021/bi00321a008; PHELPS DC, 1985, BIOCHEMISTRY-US, V24, P3503, DOI 10.1021/bi00335a017; PHELPS DC, 1980, J BIOL CHEM, V255, P9647; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; Rydstrom J., 1987, PYRIDINE NUCLEOTIDE, P433; Sambrook J, 1989, MOL CLONING LABORATO; SEGEL IH, 1975, ENZYME KINETICS BEHA, P218; SONAR S, 1994, J BIOL CHEM, V269, P28851; SONE N, 1977, J BIOCHEM-TOKYO, V81, P519, DOI 10.1093/oxfordjournals.jbchem.a131485; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VERMEULEN AN, 1993, FEMS MICROBIOL LETT, V110, P223, DOI 10.1111/j.1574-6968.1993.tb06324.x; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P915; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P667; WANG TP, 1954, J BIOL CHEM, V211, P465; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; WU LNY, 1981, J BIOL CHEM, V256, P7401; YAMAGUCHI M, 1993, J BIOL CHEM, V268, P17871; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P5728; YAMAGUCHI M, 1994, J BIOENERG BIOMEMBR, V26, P435, DOI 10.1007/BF00762784; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; YAMAGUCHI M, 1989, BIOCHEMISTRY-US, V28, P6050, DOI 10.1021/bi00440a049; YU Y, 1994, MOL BIOCHEM PARASIT, V68, P323, DOI 10.1016/0166-6851(94)90178-3	45	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16653	16659		10.1074/jbc.270.28.16653	http://dx.doi.org/10.1074/jbc.270.28.16653			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622474	hybrid			2022-12-25	WOS:A1995RJ34700032
J	HUTCHINSON, LE; MCCLOSKEY, MA				HUTCHINSON, LE; MCCLOSKEY, MA			FC-EPSILON-RI-MEDIATED INDUCTION OF NUCLEAR FACTOR OF ACTIVATED T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYCLOSPORINE-A; MAST-CELLS; ANTIGEN RECEPTOR; TRANSCRIPTION; CALCINEURIN; LYMPHOCYTE; FOS; EXPRESSION; SIGNALS	Nuclear factor of activated T-cells (NFAT) is a transcriptional activator that binds to the interleukin-2 promoter and is believed to be responsible for T-cell-specific interleukin-2 gene expression. Here we demonstrate using electrophoretic mobility shift assays that nuclear NFAT can be induced in the rat basophilic leukemia (RBL 2H3) mast cell line and rat bone marrow-derived mast cells upon cross-linkage of the high affinity receptor (Fc epsilon RI) for immunoglobulin E (IgE). Receptor-dependent activation of NFAT was mimicked by the combination of the protein kinase C activator phorbol myristate acetate and the calcium ionophore ionomycin. The induced binding activity was specific for the NFAT recognition motif because competition with nonradioactive NFAT oligonucleotide abolished the DNA binding activity, whereas nonradioactive oligonucleotides recognized by the transcription factors NF kappa B, glucocorticoid receptors, and TFIID did not, An oligonucleotide representing the AP-1 recognition sequence also blocked the NFAT DNA binding activity, as did a combination of anti-Fos and anti-Jun antibodies. Using electrophoretic mobility shift assays, AP-1-binding proteins were found to be induced in RBL-2H3 cells under the same conditions as was the NFAT binding activity. Together these data suggest that the NFAT complex in mast cells contains Fos and dun proteins as does NFAT in T-cells, The appearance of nuclear NFAT binding activity was dependent in part upon calcium mobilization, as buffering the antigen-induced calcium rise with intracellular BAPTA strongly inhibited NFAT activation. Prevention of calcium influx with external EGTA also inhibited NFAT activation, indicating that release of calcium from internal stores was insufficient for sustained activation of mast cell NFAT. Cyclosporin A, a potent inhibitor of the calmodulin-dependent phosphatase calcineurin, blocked the induction of NFAT-DNA binding activity, implicating calcineurin as a key signaling enzyme in this pathway, These results suggest that NFAT is present in the mast cell line RBL-2H3 and in primary bone marrow-derived mast cells, is similar in subunit composition to the T-cell NFAT, and may play a role in calcium-dependent signal transduction in mast cells.	IOWA STATE UNIV SCI & TECHNOL,SIGNAL TRANSDUCT TRAINING GRP,AMES,IA 50011	Iowa State University	HUTCHINSON, LE (corresponding author), IOWA STATE UNIV SCI & TECHNOL,DEPT ZOOL & GENET,AMES,IA 50011, USA.				NIGMS NIH HHS [GM48144] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048144] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARANES D, 1991, BLOOD, V78, P2354; BARSUMIAN EL, 1984, EUR J IMMUNOL, V11, P317; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; LEWIN I, 1993, BLOOD, V82, P3745; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RUDOLPH AK, 1981, EUR J IMMUNOL, V11, P527, DOI 10.1002/eji.1830110617; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; YASEEN NR, 1993, J BIOL CHEM, V268, P14285	31	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16333	16338		10.1074/jbc.270.27.16333	http://dx.doi.org/10.1074/jbc.270.27.16333			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608202	hybrid			2022-12-25	WOS:A1995RH22600069
J	SHAPIRO, AB; LING, V				SHAPIRO, AB; LING, V			RECONSTITUTION OF DRUG TRANSPORT BY PURIFIED P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSING DIFFERENT LEVELS; MULTIDRUG-RESISTANCE; ADENOSINE-TRIPHOSPHATASE; ATPASE ACTIVITY; CELL-LINES; BINDING; SERIES; PROBE; GENE	P-glycoprotein confers multidrug resistance upon cells in which it is highly expressed, reducing the effectiveness of numerous cytotoxic drugs, including many of those used for chemotherapy of cancer. Although P-glycoprotein is widely believed to function as an ATP-dependent drug efflux pump, the unusually broad substrate specificity of P-glycoprotein has engendered the proposal of other, less direct mechanisms. None of the hypothetical mechanisms has been definitively tested, however, in a purified system where other cellular components and processes are absent. We have used a fluorescent substrate of P-glycoprotein, Hoechst 33342, to measure transport activity in real-time of highly purified P-glycoprotein in a reconstituted liposome system in which the P-glycoprotein has a uniformly inside-out orientation. Using this system, we demonstrated MgATP-dependent, chemosensitizer-inhibitable transport of Hoechst 33342. Transport was prevented by omission of Mg2+, by substitution of nonhydrolyzable adenylyl-beta,gamma-imidodiphosphate for ATP, by inhibition of the ATPase activity of P-glycoprotein with vanadate and N-ethylmaleimide, and by the chemosensitizers verapamil and amiodarone, Measurements of intraliposomal pH during Hoechst 33342 transport detected no large pH changes in P-glycoprotein-containing liposomes. These results are inconsistent with a mechanism in which P-glycoprotein affects drug accumulation by directly altering intracellular pH. The Hoechst 33342 transport assay re suits are consistent with mechanisms in which P-glycoprotein alone is sufficient to transport drugs out of the membrane bilayer.	ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto					NCI NIH HHS [CA 37130] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; ALTENBERG GA, 1993, P NATL ACAD SCI USA, V90, P9735, DOI 10.1073/pnas.90.20.9735; ALTENBERG GA, 1994, P NATL ACAD SCI USA, V91, P4654, DOI 10.1073/pnas.91.11.4654; CHEN AY, 1993, CANCER RES, V53, P1332; Childs S, 1994, Important Adv Oncol, P21; CHIN KV, 1993, ADV CANCER RES, V60, P157; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FREZARD F, 1991, EUR J BIOCHEM, V196, P483, DOI 10.1111/j.1432-1033.1991.tb15840.x; Gatmaitan Z C, 1993, Adv Pharmacol, V24, P77, DOI 10.1016/S1054-3589(08)60934-5; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; LALANDE ME, 1981, P NATL ACAD SCI-BIOL, V78, P363, DOI 10.1073/pnas.78.1.363; NIELSEN D, 1992, BIOCHIM BIOPHYS ACTA, V1139, P169, DOI 10.1016/0925-4439(92)90131-6; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014; ROEPE PD, 1992, BIOCHEMISTRY-US, V31, P12555, DOI 10.1021/bi00165a003; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SCHLEMMER SR, 1994, J BIOL CHEM, V269, P31059; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; STEIN WD, 1994, MOL PHARMACOL, V45, P763; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WEST IC, 1990, TRENDS BIOCHEM SCI, V15, P42, DOI 10.1016/0968-0004(90)90171-7; YOUNG XK, 1992, THESIS CORNELL U	35	186	189	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16167	16175		10.1074/jbc.270.27.16167	http://dx.doi.org/10.1074/jbc.270.27.16167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608182	hybrid			2022-12-25	WOS:A1995RH22600045
J	WRUTNIAK, C; CASSARMALEK, I; MARCHAL, S; RASCLE, A; HEUSSER, S; KELLER, JM; FLECHON, J; DAUCA, M; SAMARUT, J; GHYSDAEL, J; CABELLO, G				WRUTNIAK, C; CASSARMALEK, I; MARCHAL, S; RASCLE, A; HEUSSER, S; KELLER, JM; FLECHON, J; DAUCA, M; SAMARUT, J; GHYSDAEL, J; CABELLO, G			A 43-KDA PROTEIN RELATED TO C-ERB-A-ALPHA-1 IS LOCATED IN THE MITOCHONDRIAL MATRIX OF RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ADENINE-NUCLEOTIDE TRANSLOCASE; TRANSCRIPTIONAL ACTIVITY; TRIIODOTHYRONINE T3; LIVING CELLS; LOCALIZATION; BINDING; ACID; PHOSPHORYLATION; ACTIVATION	In order to characterize Sterling's triiodothyronine (T-3) mitochondrial receptor using photoaffinity labeling, we observed two specific T-3-binding proteins in the inner membrane (28 kDa) and in the matrix (43 kDa) of rat liver mitochondria. Western blots and immunoprecipitation using antibodies raised against the T-3-binding domain of the T-3 nuclear receptor c-Erb A alpha 1 indicated that at least the 43-kDa protein was c-Erb A alpha 1-related. In addition, gel mobility shift assays demonstrated the occurrence of a c-Erb A alpha 1-related mitochondrial protein that specifically binds to a natural or a palindromic thyroid-responsive element. Moreover, this protein specifically binds to a direct repeat 2 sequence located in the D-loop of the mitochondrial genome. Furthermore, electron microscopy studies allowed the direct observation of a c-Erb A-related protein in mitochondria. Lastly, the relative amounts of the 43-kDa protein related to c-Erb A alpha 1 were in good correlation with the known mitochondrial mass in three typical tissues. Interestingly, expression of a truncated form of the c-Erb A alpha 1 nuclear receptor in CV1 cells was associated with a mitochondrial localization and a stimulation of mitochondrial activity. These results supply evidence of the localization of a member of the nuclear receptor superfamily in the mitochondrial matrix involved in the regulation of mitochondrial activity that could act as a mitochondrial T-3-dependent transcription factor.	INRA,DIFFERENCIAT CELLULAIRE & CROISSANCE LAB,UNITE ENDOCRINOL CELLULAIRE,F-34060 MONTPELLIER 1,FRANCE; ECOLE NORMALE SUPER LYON,INRA,BIOL CELLULAIRE & MOLEC LAB,CNRS,UMR 40,F-69364 LYON 07,FRANCE; UNIV NANCY 1,BIOL CELLULAIRE DEV LAB,F-54506 VANDOEUVRE NANCY,FRANCE; INRA,BIOL CELLULAIRE & MOLEC LAB,F-78352 JOUY EN JOSAS,FRANCE; INST CURIE,ONCOGENESE VIRALE & CELLULAIRE LAB,URA D1443,F-91405 ORSAY,FRANCE	INRAE; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE; Universite de Lorraine; INRAE; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Samarut, Jacques/AAD-2587-2019; , Cassar-Malek/AAW-6386-2020; Rascle, Anne/AAC-1904-2019; GHYSDAEL, Jacques/F-3377-2013	, Cassar-Malek/0000-0001-7407-1408; Rascle, Anne/0000-0001-7464-8545; 				BIGLER J, 1992, MOL CELL BIOL, V12, P2406, DOI 10.1128/MCB.12.5.2406; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; DELEO T, 1976, PFLUG ARCH EUR J PHY, V366, P73, DOI 10.1007/BF02486563; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; Fleischer S, 1974, Methods Enzymol, V31, P6; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GOGLIA F, 1981, PFLUG ARCH EUR J PHY, V390, P120, DOI 10.1007/BF00590193; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; Greenawalt J W, 1974, Methods Enzymol, V31, P310; GUSTAFSS.R, 1965, J CELL BIOL, V26, P555, DOI 10.1083/jcb.26.2.555; HAFNER RP, 1990, BIOCHEM J, V265, P731, DOI 10.1042/bj2650731; HASHIZUME K, 1982, BIOCHEM BIOPH RES CO, V106, P920, DOI 10.1016/0006-291X(82)91798-3; HOGER TH, 1991, EUR J CELL BIOL, V54, P150; HOROWITZ ZD, 1988, AFFINITY LABELING CL, P79; JAKOVCIC S, 1978, J CELL BIOL, V77, P887, DOI 10.1083/jcb.77.3.887; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KADENBACH B, 1986, REGULATION METABOLIC, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; MARTINO G, 1986, MOL BIOL REP, V11, P205, DOI 10.1007/BF00419598; MORRE DJ, 1971, METHOD ENZYMOL, V22, P130; MUTVEI A, 1989, EUR J BIOCHEM, V180, P235, DOI 10.1111/j.1432-1033.1989.tb14638.x; MUTVEI A, 1989, ACTA ENDOCRINOL-COP, V121, P223, DOI 10.1530/acta.0.1210223; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; RASMUSSEN UB, 1989, FEBS LETT, V255, P385, DOI 10.1016/0014-5793(89)81128-7; RODD C, 1992, ENDOCRINOLOGY, V131, P2559, DOI 10.1210/en.131.6.2559; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; SOBOLL S, 1992, BIOCHEM J, V281, P171, DOI 10.1042/bj2810171; STERLING K, 1975, P NATL ACAD SCI USA, V72, P3225, DOI 10.1073/pnas.72.8.3225; STERLING K, 1986, ENDOCRINOLOGY, V119, P292, DOI 10.1210/endo-119-1-292; STERLING K, 1977, SCIENCE, V197, P996, DOI 10.1126/science.196334; STERLING K, 1984, CELL TISSUE RES, V236, P321; STERLING K, 1984, ACTA ENDOCRINOL-COP, V105, P391, DOI 10.1530/acta.0.1050391; STERLING K, 1980, SCIENCE, V210, P340, DOI 10.1126/science.7423197; STERLING K, 1978, SCIENCE, V201, P1126, DOI 10.1126/science.210507; SZCZESNAKACZMAR.A, 1990, INT J BIOCHEM, V22, P617; VANITALLIE CM, 1990, ENDOCRINOLOGY, V127, P55, DOI 10.1210/endo-127-1-55; Wharton DC., 1967, METHOD ENZYMOL, P245; [No title captured]	44	172	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16347	16354		10.1074/jbc.270.27.16347	http://dx.doi.org/10.1074/jbc.270.27.16347			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608204	Green Submitted, hybrid			2022-12-25	WOS:A1995RH22600071
J	KUPRASH, DV; UDALOVA, IA; TURETSKAYA, RL; RICE, NR; NEDOSPASOV, SA				KUPRASH, DV; UDALOVA, IA; TURETSKAYA, RL; RICE, NR; NEDOSPASOV, SA			CONSERVED KAPPA-B ELEMENT LOCATED DOWNSTREAM OF THE TUMOR-NECROSIS-FACTOR-ALPHA GENE - DISTINCT NF-KAPPA-B BINDING PATTERN AND ENHANCER ACTIVITY IN LPS ACTIVATED MURINE MACROPHAGES	ONCOGENE			English	Article						NF-KAPPA-B; TUMOR NECROSIS FACTOR; TRANSCRIPTION	C-REL; NUCLEAR FACTOR; DNA-BINDING; V-REL; TRANSCRIPTIONAL ACTIVATION; P65 SUBUNIT; TNF LOCUS; PREFERENTIALLY INTERACTS; PROTEIN; MOTIFS	Transcriptional activation of various genes by lipopolysaccharide (LPS) is known to be mediated, at least in part, by the NF-kappa B/Rel family of transcription factors. We have identified a novel kappa B element located immediately downstream of the TNF-alpha gene that is conserved together with its flanking sequences across species lines and can act as an LPS-responsive enhancer for reporter gene constructs driven by the minimal TNF promoter. In extracts from activated murine macrophages and macrophage cell lines this element binds several non-canonical NF-kappa B/Rel complexes, in addition to p50 (NFKB1) homodimer and p50-p65 (NKFB1-RelA) heterodimer. Combination of high-resolution electrophoretic mobility shift assays (EMSA) with monospecific antibodies and u.v.-cross-linking indicates that the prominent slow migrating complex III contain p65 homodimer and c-Rel. The appearance of complex III in EMSA parallels the translocation of p65 and c-Rel into the nucleus and occurs shortly after LPS induction. Transfection experiments with reporter constructs driven by this kappa B element indicate strong inducibility by LPS and p65, moderate inducibility by c-Rel and repression by p50. Functional activity of sandwich TNF-CAT-TNF constructs further suggests that LPS-inducible transcriptional activation of the TNF gene in murine macrophages may be partly mediated by a downstream enhancer.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702; RUSSIAN ACAD SCI,VA ENGELHARDT MOLEC BIOL INST,CYTOKINE MOLEC BIOL LAB,MOSCOW,RUSSIA; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Nedospasov, Sergei/J-5936-2013; Nedospasov, Sergei/C-3043-2018; Nedospasov, Sergei/L-1990-2015; Kuprash, Dmitry/O-4899-2015; Nedospasov, Sergei/Q-7319-2016	Kuprash, Dmitry/0000-0002-1488-4148; Udalova, Irina/0000-0002-6716-2528	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEUTLER B, 1992, TUMOR NECROSIS FACTO, P561; BIRAGYN A, 1995, IN PRESS J IMMUNOL, V155; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; DROUET C, 1991, J IMMUNOL, V147, P1694; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FRANZOSO G, 1994, J EXP MED, V180, P1445, DOI 10.1084/jem.180.4.1445; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GIROIR BP, 1992, P NATL ACAD SCI USA, V89, P4864, DOI 10.1073/pnas.89.11.4864; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAN J, 1991, J IMMUNOL, V146, P1843; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JONGENEEL CV, 1989, EUR J IMMUNOL, V19, P549; JONGENEEL CV, 1992, TUMOR NECROSIS FACTO, P561; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KOCHEL T, 1992, ONCOGENE, V7, P567; KUHNERT P, 1991, GENE, V102, P171, DOI 10.1016/0378-1119(91)90075-M; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUPRASH D, 1993, TUMOR NECROSIS FACTOR : MOLECULAR AND CELLULAR BIOLOGY AND CLINICAL RELEVANCE, P19; KUPRASH DV, 1994, P ACAD SCI USSR DOKL, V337, P658; LATTION AL, 1992, MOL CELL BIOL, V12, P5217, DOI 10.1128/MCB.12.11.5217; LAWTON P, 1995, J IMMUNOL, V154, P239; LAYBOURN PJ, 1994, SCIENCE, V257, P1682; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611, DOI 10.1101/SQB.1986.051.01.073; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEMON D, 1987, NUCLEIC ACIDS RES, V15, P9083, DOI 10.1093/nar/15.21.9083; SHAKHOV AN, 1990, GENE, V95, P215, DOI 10.1016/0378-1119(90)90364-W; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TURETSKAYA RL, 1992, TUMOR NECROSIS FACTO, P35; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x	67	111	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					97	106						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624137				2022-12-25	WOS:A1995RJ29500012
J	EDGINGTON, TS				EDGINGTON, TS			VASCULAR BIOLOGY - INTEGRATIVE MOLECULAR CELL BIOLOGY	FASEB JOURNAL			English	Article									Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	EDGINGTON, TS (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.								0	7	7	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1995	9	10					841	842		10.1096/fasebj.9.10.7615153	http://dx.doi.org/10.1096/fasebj.9.10.7615153			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RK899	7615153				2022-12-25	WOS:A1995RK89900003
J	BJORBAEK, C; ZHAO, Y; MOLLER, DE				BJORBAEK, C; ZHAO, Y; MOLLER, DE			DIVERGENT FUNCTIONAL ROLES FOR P90(RSK) KINASE DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RIBOSOMAL S6 KINASE; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; SKELETAL-MUSCLE; PHORBOL ESTER; XENOPUS EGGS; INSULIN; PHOSPHORYLATION; CELLS	A unique and highly conserved structural feature of approximate to 90-kDa ribosomal S6 kinase (p90(rsk) or RSK) is the presence of two non-identical kinase domains. To explore the mechanism of RSK activation, a cloned human RSK cDNA (RSK3) was used to generate and characterize several site directed RSK mutants: K91A (N-Lys, NH2-terminal ATP-binding mutant), K444A (C-Lys, COOH-terminal ATP-binding mutant), N/C-Lys (double ATP-binding mutant), T570A (C-Thr, mutant of the putative MAPK phosphorylation site in subdomain MI of the C-domain), S218A (N-Ser, mutant of the corresponding NH2-terminal residue). Epitope-tagged RSKs were expressed in transfected COS cells followed by immunoprecipitation with or without prior in vivo epidermal growth factor stimulation. Kinase activity (S6 peptide) of N/C-Lys and N-Lys was ablated (and partially impaired with N-Ser). In contrast, both C-Lys and C-Thr retained high levels of kinase activity and were capable of responding to stimulation, C-Lys also retained partial kinase activity toward other substrates (c-Fos, S40 ribosomes, protein phosphatase 1 G-subunit, histones, and Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide)) whereas N-Lys did not. The isolated NH2- and COOH-terminal domains were also expressed; the C-domain was inactive, whereas the N-domain retained partial activity. Relative to wild-type, both N-Lys and C-Lys (as well as N-Ser and C-Thr) underwent partial in vitro autophosphorylation that was further stimulated by EGF protein tyrosine phosphatase. We conclude that 1) the NB-terminal RSK kinase domain mediates substrate Phosphorylation; 2) both domains contribute to autophosphorylation; 3) the putative MAPK phosphorylation site is not required for growth factor-stimulated autophosphorylation or kinase activation.	BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Bjorbaek, Christian/S-4727-2019		PHS HHS [R01 45874-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BJORBAEK C, 1995, DIABETES, V44, P90, DOI 10.2337/diabetes.44.1.90; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CALVO V, 1992, EUR J IMMUNOL, V22, P457, DOI 10.1002/eji.1830220225; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1993, BIOCHEM SOC T, V21, P895, DOI 10.1042/bst0210895; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; ERIKSON E, 1988, SEC MESS PHOSPHOPROT, V12, P135; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; ERIKSON RL, 1988, 1ST P INT C GEN REG, P13; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1986, ENZYMES ENZYME CONTR, P191; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1993, FRONTIERS MOL BIOL; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THOMAS G, 1993, BIOCHEM SOC T, V21, P901, DOI 10.1042/bst0210901; ZHAO Y, 1995, IN PRESS MOL CELL BI; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	55	95	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18848	18852		10.1074/jbc.270.32.18848	http://dx.doi.org/10.1074/jbc.270.32.18848			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642538	hybrid			2022-12-25	WOS:A1995RN95400025
J	HARENDZA, S; POLLOCK, AS; MERTENS, PR; LOVETT, DH				HARENDZA, S; POLLOCK, AS; MERTENS, PR; LOVETT, DH			TISSUE-SPECIFIC ENHANCER-PROMOTER INTERACTIONS REGULATE HIGH-LEVEL CONSTITUTIVE EXPRESSION OF MATRIX METALLOPROTEINASE-2 BY GLOMERULAR MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; RNA POLYMERASE-II; IV COLLAGENASE; TRANSGENIC MICE; Z-DNA; GENE; SECRETE; INHIBITORS; EFFICIENT; SEQUENCES	The 72-kDa gelatinase A (MMP-2) is a central mediator of the response of the intrinsic glomerular mesangial cell to inflammatory stimuli and is regulated in a unique, cell-specific manner, We isolated a 6-kilobase pair genomic fragment of the rat MMP-2 gene and sequenced and characterized 1686-base pair of the 5'-flanking region, Using a series of 5' deletion constructs of the proximal 5'-flanking region, a strong MMP-2 enhancer element was identified, Gel shift and mutational analyses suggest that the enhancer region represents the binding site for a complex transcription factor demonstrating separable DNA-binding and transcriptional activating domains. The presence and activity of the enhancer element was evaluated in several cell types with varying capabilities to synthesize MMP-2 including mesangial cells, glomerular epithelial cells, and the monocytic U937 cell. Although binding activity was present in all cell types studied, enhancer activity was demonstrated only in mesangial and glomerular epithelial cells, Additional transcriptional control resided in a tissue-specific promoter, which supported transcription only in mesangial cells. These results indicate that the final control of mesangial cell specific synthesis of MMP-2 derives from an interaction between the strong enhancer element and the tissue-specific MMP-2 promoter.	DEPT VET AFFAIRS MED CTR,DEPT MED,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Mertens, Peter/AAI-7310-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK039776, R01DK039776, R01DK031398] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39776, DK 31398] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERWAER M, 1994, MOL ENDOCRINOL, V8, P635, DOI 10.1210/me.8.5.635; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BURDON TG, 1994, FEBS LETT, V350, P177, DOI 10.1016/0014-5793(94)00757-8; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRISCH SM, 1990, MOL CELL BIOL, V10, P6514; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GARBISA S, 1986, J BIOL CHEM, V261, P2369; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; HANSEN PK, 1993, J MOL BIOL, V233, P191, DOI 10.1006/jmbi.1993.1499; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; JOHNSON R, 1992, J AM SOC NEPHROL, V2, P1388; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LOVETT DH, 1992, AM J PATHOL, V141, P85; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; MARTIN J, 1989, KIDNEY INT, V36, P790, DOI 10.1038/ki.1989.264; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; NITCH D, 1993, MOL CELL BIOL, V13, P4494; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; REPONEN P, 1992, J BIOL CHEM, V267, P7856; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SATO H, 1992, ONCOGENE, V7, P77; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; TRYGGVASON K, 1990, CELL DIFFER DEV, V32, P307, DOI 10.1016/0922-3371(90)90044-W; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	41	82	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18786	18796		10.1074/jbc.270.32.18786	http://dx.doi.org/10.1074/jbc.270.32.18786			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642529				2022-12-25	WOS:A1995RN95400016
J	OBARA, K; NIKCEVIC, G; PESTIC, L; NOWAK, G; LORIMER, DD; GUERRIERO, V; ELSON, EL; PAUL, RJ; DELANEROLLE, P				OBARA, K; NIKCEVIC, G; PESTIC, L; NOWAK, G; LORIMER, DD; GUERRIERO, V; ELSON, EL; PAUL, RJ; DELANEROLLE, P			FIBROBLAST CONTRACTILITY WITHOUT AN INCREASE IN BASAL MYOSIN LIGHT-CHAIN PHOSPHORYLATION IN WILD-TYPE CELLS AND CELLS EXPRESSING THE CATALYTIC DOMAIN OF MYOSIN LIGHT-CHAIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE MYOSIN; ISOMETRIC CONTRACTION; PURIFICATION	We investigated the role of myosin light chain (MLC(20)) phosphorylation (MLC-P) in non-muscle contractility by comparing MLC-P and the contractile properties of wild type 3T3 fibroblasts and 3T3 fibroblasts expressing the catalytic domain of myosin light chain kinase (tMK), MLC-P is 0.96 mol of PO4/mol of MLC(20) in cells expressing tMK compared to 0.20 mol of PO4/mol of MLC(20) in control cells, Expressing tMK also results in a 2-fold increase in cortical stiffness compared to control cells. Contractile properties were quantified by growing wild type and transfected fibroblasts in collagen and attaching the ensuing fibers to an apparatus for performing mechanical measurements, Serum stimulation resulted in a dose-dependent increase in force with maximal force generated in the presence of 30% (v/v) serum. Surprisingly, MLC-P did not increase in wild type cells following stimulation with 30% serum, and tMK expression did not affect the contractile properties of fibers made from these cells. Moreover, the dose responses to serum, maximal force, force-Velocity relationships, and dynamic stiffness were similar in the wild type cells and fibroblasts expressing tMK. These data demonstrate that non-muscle cells can generate force without an increase in MLC-P, and that an increase in MLC-P does not affect the contractile properties of fibroblast fibers.	UNIV CINCINNATI,COLL MED,DEPT PHYSIOL & BIOPHYS,CINCINNATI,OH 45221; UNIV ILLINOIS,COLL MED,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612; UNIV ARIZONA,DEPT ANIM SCI,TUCSON,AZ 85721; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	University System of Ohio; University of Cincinnati; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Arizona; Washington University (WUSTL)					NHLBI NIH HHS [HL 23240, HL 43651] Funding Source: Medline; NIGMS NIH HHS [GM 38838] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043651, R01HL023240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038838] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; DANIEL JL, 1992, METHOD ENZYMOL, V215, P78; DELANEROLLE P, 1988, J BIOL CHEM, V263, P9071; DELANEROLLE P, 1993, J BIOL CHEM, V268, P16883; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; GIULIANO KA, 1992, MOL BIOL CELL, V3, P1037, DOI 10.1091/mbc.3.9.1037; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; KOPP SJ, 1979, J BIOL CHEM, V254, P2007; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OBARA K, 1994, BIOPHYS J, V66, pA412; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; WALSH MP, 1982, BIOCHEMISTRY-US, V21, P1919, DOI 10.1021/bi00537a034; WILSON AK, 1992, CANCER METAST REV, V11, P79, DOI 10.1007/BF00047605; WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255	19	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18734	18737		10.1074/jbc.270.32.18734	http://dx.doi.org/10.1074/jbc.270.32.18734			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642521	hybrid			2022-12-25	WOS:A1995RN95400007
J	SEUBERT, P; MAWALDEWAN, M; BARBOUR, R; JAKES, R; GOEDERT, M; JOHNSON, GVW; LITERSKY, JM; SCHENK, D; LIEBERBURG, I; TROJANOWSKI, JQ; LEE, VMY				SEUBERT, P; MAWALDEWAN, M; BARBOUR, R; JAKES, R; GOEDERT, M; JOHNSON, GVW; LITERSKY, JM; SCHENK, D; LIEBERBURG, I; TROJANOWSKI, JQ; LEE, VMY			DETECTION OF PHOSPHORYLATED SER(262) IN FETAL TAU, ADULT TAU, AND PAIRED HELICAL FILAMENT TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; ALZHEIMER-LIKE STATE; MICROTUBULE-BINDING; NEUROFIBRILLARY PATHOLOGY; ABNORMAL PHOSPHORYLATION; DISEASE; BRAIN; ISOFORMS; SITES	Paired helical filaments (PHFs) are the major structural elements of Alzheimer's disease neurofibrillary lesions, and these filaments are formed from hyperphosphorylated brain tau known as PHF-tau, Recent studies showed that many previously identified phosphorylated residues in PHF-tau also are phosphate acceptor sites in fetal and rapidly processed adult brain tau, However, Ser(262) has been suggested to be uniquely phosphorylated in PHF-tau and a key regulator of the binding of tau to microtubules. For these reasons, we generated a monoclonal antibody (12E8) specific for phosphorylated Se-262 and showed that 12E8 binds to PHF-tau, rat and human fetal brain tau, as well as to rapidly processed adult rat and biopsy-derived human brain tau, Further, phosphorylation at Ser(262) was developmentally regulated, and endogenous brain phosphatases rapidly dephosphorylated Ser(262) in biopsy-derived brain tau isolates. Finally, the phosphorylation of Ser(262) did not eliminate the binding of tau to microtubules. Thus, we speculate that the binding of tau to microtubules is regulated by phosphorylation at multiple sites and that the generation of PHF-tau in Alzheimer's disease results from the reduced efficiency of phosphatases leading to the incremental accumulation of hyperphosphorylated tau.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,DIV ANAT PATHOL,PHILADELPHIA,PA 19104; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV ALABAMA,DEPT PSYCHIAT,BIRMINGHAM,AL 35294	University of Pennsylvania; MRC Laboratory Molecular Biology; University of Alabama System; University of Alabama Birmingham			Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404				BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRAMBLETT GT, 1992, LAB INVEST, V66, P212; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; CORREAS I, 1992, J BIOL CHEM, V267, P15721; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; ISHIGURO K, 1993, FEBS LETT, V336, P417; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MORISHIMAKAWASHIMA, 1995, J BIOL CHEM, V270, P823; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TROJANOWSKI JQ, 1993, BRAIN PATHOL, V3, P45, DOI 10.1111/j.1750-3639.1993.tb00725.x; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	46	318	329	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18917	18922		10.1074/jbc.270.32.18917	http://dx.doi.org/10.1074/jbc.270.32.18917			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642549	hybrid			2022-12-25	WOS:A1995RN95400036
J	ZHOU, W; RODIC, V; KITANOVIC, S; FLANAGAN, CA; CHI, L; WEINSTEIN, H; MAAYANI, S; MILLAR, RP; SEALFON, SC				ZHOU, W; RODIC, V; KITANOVIC, S; FLANAGAN, CA; CHI, L; WEINSTEIN, H; MAAYANI, S; MILLAR, RP; SEALFON, SC			A LOCUS OF THE GONADOTROPIN-RELEASING-HORMONE RECEPTOR THAT DIFFERENTIATES AGONIST AND ANTAGONIST BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; GNRH RECEPTOR; MOLECULAR-CLONING; RAT PITUITARY; FUNCTIONAL-CHARACTERIZATION; EXPRESSION	The decapeptide gonadotropin-releasing hormone controls reproductive function via interaction with a heptahelical G protein-coupled receptor, Because a molecular model of the receptor predicts that Lys(121) in the third transmembrane helix contributes to the binding pocket, the function of this side chain was studied by site-directed mutagenesis, Substitution of Arg at this position preserved high affinity agonist binding, whereas Gln at this position reduced binding below the limits of detection, Leu and Asp at this locus abolished both binding and detectable signal transduction, The EC(50) of concentration-response curves for coupling to phosphatidyl inositol hydrolysis obtained with the Gln(121) receptor was more than 3 orders of magnitude higher than that obtained for the wild-type receptor, In order to determine whether the increased EC(50) obtained with this mutant reflects an altered receptor affinity, the effect of decreases in wild-type receptor density on concentration-response curves was determined by irreversible antagonism, Progressively decreasing the concentration of the wild-type receptor increased the EC(50) values obtained to a maximal level of 2.4 +/- 0.2 nM. Comparison of this value with the EC(50) of 282 +/- 52 nM observed with the Gln(121) receptor mutant indicates that the agonist affinity for this mutant is reduced more than 100-fold. In contrast, antagonist had comparable high affinities for the wild-type, Arg(121), and Gln(121) mutants, The results indicate that a charge-strengthened hydro gen bond donor is required at this locus for high affinity agonist binding but not for high affinity antagonist binding.	MT SINAI SCH MED,FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029; MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; MT SINAI SCH MED,DEPT ANESTHESIOL,NEW YORK,NY 10029; MT SINAI SCH MED,DEPT NEUROL,NEW YORK,NY 10029; UNIV CAPE TOWN,SCH MED,DEPT CHEM PATHOL,CAPE TOWN 7925,SOUTH AFRICA; UNIV CAPE TOWN,SCH MED,DEPT MED,MRC REGULATORY PEPTIDES RES UNIT,CAPE TOWN 7925,SOUTH AFRICA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Cape Town; University of Cape Town			WEINSTEIN, HAREL/O-8245-2019; Flanagan, Colleen/ABG-2109-2020	WEINSTEIN, HAREL/0000-0003-3473-9818; SEALFON, Stuart/0000-0001-5791-1217; Millar, Robert P/0000-0003-3606-2708; Flanagan, Colleen A./0000-0003-2803-8986	NIDA NIH HHS [KO5 DA00060] Funding Source: Medline; NIDDK NIH HHS [R01 DK46943] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000060] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADHAM N, 1993, MOL PHARMACOL, V43, P427; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; CHI L, 1993, MOL CELL ENDOCRINOL, V91, pR1, DOI 10.1016/0303-7207(93)90278-R; EIDNE KA, 1992, MOL CELL ENDOCRINOL, V90, pR5, DOI 10.1016/0303-7207(92)90116-N; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; FLANAGAN CA, 1994, J BIOL CHEM, V269, P22636; FONG TM, 1993, NATURE, V362, P350; FRASER CM, 1989, J BIOL CHEM, V264, P9266; FURCHGOTT RF, 1966, ADV DRUG RES, P21; HAYNES R, 1967, BIOCHEMISTRY-US, V6, P541, DOI 10.1021/bi00854a023; ILLING N, 1993, BIOCHEM BIOPH RES CO, V196, P745, DOI 10.1006/bbrc.1993.2312; JANOVICK JA, 1993, ENDOCRINOLOGY, V133, P942, DOI 10.1210/en.133.2.942; Jeffrey G.A., 2012, HYDROGEN BONDING BIO; KAISER UB, 1992, BIOCHEM BIOPH RES CO, V189, P1645, DOI 10.1016/0006-291X(92)90266-N; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V189, P289, DOI 10.1016/0006-291X(92)91556-6; KAKAR SS, 1993, DOMEST ANIM ENDOCRIN, V10, P335, DOI 10.1016/0739-7240(93)90037-C; KARTEN MJ, 1986, ENDOCR REV, V7, P44, DOI 10.1210/edrv-7-1-44; Kenakin TP, 1993, PHARM ANAL DRUG RECE, P39; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LAWS SC, 1990, ENDOCRINOLOGY, V127, P373, DOI 10.1210/endo-127-1-373; MEI L, 1989, J PHARMACOL EXP THER, V251, P90; MILLAR RP, 1989, J BIOL CHEM, V264, P21007; MUNSON PJ, 1980, ANAL BIOCHEM, V58, P220; PERRIN MH, 1993, BIOCHEM BIOPH RES CO, V191, P1139, DOI 10.1006/bbrc.1993.1335; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REINHART J, 1992, J BIOL CHEM, V267, P21281; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P16470; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; VANDERSPUY ZM, 1987, EARLY CLIN STUDIES L, P293; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; ZHOU W, 1994, MOL PHARMACOL, V45, P165	34	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18853	18857		10.1074/jbc.270.32.18853	http://dx.doi.org/10.1074/jbc.270.32.18853			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642539	hybrid			2022-12-25	WOS:A1995RN95400026
J	GUPTABANSAL, R; FREDERICKSON, RCA; BRUNDEN, KR				GUPTABANSAL, R; FREDERICKSON, RCA; BRUNDEN, KR			PROTEOGLYCAN-MEDIATED INHIBITION OF A-BETA PROTEOLYSIS - A POTENTIAL CAUSE OF SENILE PLAQUE ACCUMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; HEPARAN-SULFATE PROTEOGLYCAN; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; DERMATAN SULFATE; PEPTIDES; DEPOSITS; MUTATION; INVITRO; CDNA	Senile plaques of Alzheimer's disease brain contain, in addition to beta amyloid peptide (A beta), multiple proteoglycans. glycans, Systemic amyloidotic deposits also routinely contain proteoglycan, suggesting that these glycoconjugates are generally involved in amyloid plaque formation and/or persistence. We demonstrate that heparan sulfate proteoglycan (HSPG) and chondroitin sulfate proteoglycan (CSPG) inhibit the proteolytic degradation of fibrillar, but not non-fibrillar, A beta at physiological pH. In accordance with the proteolysis studies, high affinity binding of proteoglycans to fibrillar A beta(1-40) and A beta(1-42) is observed from pH 4 to 9, whereas appreciable binding of HSPG or CSPG to non-fibrillar peptide is only seen at pH < 6, This differing pH dependence of binding suggests that a lysine residue is involved in proteoglycan association with fibrillar A beta, whereas a protonated histidine appears to be needed for binding of the glycoconjugates to non-fibrillar peptide, Scatchard analysis of fibrillar A beta association with proteoglycans indicates a single affinity interaction, and the binding of both HSPG and CSPG to fibrillar A beta is completely inhibited by free glycosaminoglycan chains. This implies that these sulfated carbohydrate moieties are primarily responsible for proteoglycan . A beta interaction, The ability of proteoglycans to bind fibrillar A beta and inhibit its proteolytic degradation suggests a possible mechanism of senile plaque accumulation and persistence in Alzheimer's disease.			GUPTABANSAL, R (corresponding author), GLIATECH INC,DISCOVERY RES GRP,23420 COMMERCE PK RD,CLEVELAND,OH 44122, USA.		Brunden, Kurt/D-1994-2009					BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; BUEE L, 1993, BRAIN RES, V627, P199, DOI 10.1016/0006-8993(93)90321-D; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CANNING DR, 1993, EXP NEUROL, V124, P289, DOI 10.1006/exnr.1993.1199; CARRINO DA, 1991, BIOCHEM INT, V24, P485; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; FRANSSON LA, 1990, BIOCHEM J, V269, P381, DOI 10.1042/bj2690381; FREDERICKSON RCA, 1994, ALZ DIS ASSOC DIS, V8, P159, DOI 10.1097/00002093-199408030-00002; FREDERICKSON RCA, 1991, NEUROBIOL AGING, V13, P239; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOLLIN PA, 1992, NEUROREPORT, V3, P201, DOI 10.1097/00001756-199202000-00020; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; Hertz L., 1989, DISSECTION TISSUE CU, P105; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIVILEVSKY R, 1994, MOL NEUROBIOL, V8, P65; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; PERLMUTTER L S, 1992, Neurobiology of Aging, V13, pS89; PERLMUTTER LS, 1990, NEUROSCI LETT, V119, P32, DOI 10.1016/0304-3940(90)90748-X; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1992, NEUROREPORT, V3, P769, DOI 10.1097/00001756-199209000-00012; REBECK GW, 1993, NEURON, V11, P575; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEN CL, 1993, BIOPHYS J, V65, P2383, DOI 10.1016/S0006-3495(93)81312-2; SNOW A D, 1991, Society for Neuroscience Abstracts, V17, P1106; SNOW AD, 1994, AM J PATHOL, V144, P337; SNOW AD, 1992, J HISTOCHEM CYTOCHEM, V40, P105, DOI 10.1177/40.1.1370306; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; SNOW AD, 1988, AM J PATHOL, V133, P456; SNOW AD, 1985, LAB INVEST, V53, P37; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STENSTAD T, 1994, BIOCHEM J, V303, P663, DOI 10.1042/bj3030663; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367	47	156	159	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18666	18671		10.1074/jbc.270.31.18666	http://dx.doi.org/10.1074/jbc.270.31.18666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629198	hybrid			2022-12-25	WOS:A1995RM64200080
J	SUN, SC; MAGGIRWAR, SB; HARHAJ, E				SUN, SC; MAGGIRWAR, SB; HARHAJ, E			ACTIVATION OF NF-KAPPA-B BY PHOSPHATASE INHIBITORS INVOLVES THE PHOSPHORYLATION OF I-KAPPA-B-ALPHA AT PHOSPHATASE 2A-SENSITIVE SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; DNA-BINDING SUBUNIT; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; PHORBOL ESTER; MESSENGER-RNA; 65-KD SUBUNIT; REL ONCOGENE; PROTEIN; GENE	Activation of NF-kappa B by various cellular stimuli involves the phosphorylation and subsequent degradation of its inhibitor, I kappa B alpha, although the underlying mechanism remains unclear. In the present study, the role of serine/threonine phosphatases in the regulation of I kappa B alpha phosphorylation was investigated. Our studies demonstrate that incubation of human T cells with low concentrations (similar to 1-5 nM) of calyculin A or okadaic acid, potent inhibitors of protein phosphatase type 1 (PP-1) and type 2A (PP-2A), induces the phosphorylation of I kappa B alpha even in the absence of any cellular stimulus. This action of the phosphatase inhibitors, which is associated with the activation of the RelA . p50 NF-kappa B heterodimer, is not affected by agents that block the induction of I kappa B alpha phosphorylation by tumor necrosis factor alpha (TNF-alpha). Furthermore, the phosphorylated I kappa B alpha from calyculin A-treated cells, but not that from TNF-alpha-stimulated cells, is sensitive to PP-BA in vitro, suggesting the existence of fundamental differences in the phosphorylation of I kappa B alpha induced by the two different NF-kappa B inducers. However, induction of I kappa B alpha phosphorylation by both TNF-alpha and the phosphatase inhibitors is associated with the subse quent degradation of I kappa B alpha. We further demonstrate that TNF-alpha- and calyculin A-induced I kappa B alpha degradation exhibits similar but not identical sensitivities to a proteasome inhibitor, Together, these results suggest that phosphorylation of I kappa B alpha, mediated through both the TMF-alpha-inducible and the PP-2A-opposing kinases, may serve to target I kappa B alpha for proteasome-mediated degradation.			SUN, SC (corresponding author), PENN STATE UNIV,COLL MED,MILTON S HERSHEY MED CTR,DEPT MICROBIOL & IMMUNOL,POB 850,HERSHEY,PA 17033, USA.							ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, MOL ASPECTS CELLULAR, P409; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MENON SD, 1993, J BIOL CHEM, V268, P26805; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; THEVENIN C, 1991, NEW BIOL, V2, P793; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	49	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18347	18351		10.1074/jbc.270.31.18347	http://dx.doi.org/10.1074/jbc.270.31.18347			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629157	hybrid			2022-12-25	WOS:A1995RM64200033
J	TANG, L; GOUNARIS, K; GRIFFITHS, CM; SELKIRK, ME				TANG, L; GOUNARIS, K; GRIFFITHS, CM; SELKIRK, ME			HETEROLOGOUS EXPRESSION AND ENZYMATIC-PROPERTIES OF A SELENIUM-INDEPENDENT GLUTATHIONE-PEROXIDASE FROM THE PARASITIC NEMATODE BRUGIA-PAHANGI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE CUTICULAR GLYCOPROTEIN; I IODOTHYRONINE DEIODINASE; LYMPHATIC FILARIAE; CDNA SEQUENCE; LINOLEIC-ACID; HUMAN-PLASMA; SELENOENZYME; PURIFICATION; HYDROPEROXIDES; IDENTIFICATION	A full-length cDNA from the parasitic nematode Brugia pahangi encoding a secreted homolog of glutathione peroxidase in which the codon for the active site selenocysteine is substituted naturally by a cysteine codon has been expressed in Spodoptera frugiperda (insect) cells via Autographa californica nuclear polyhedrosis virus (baculovirus). The recombinant protein was glycosylated and secreted from the cells in tetrameric form, The purified protein showed glutathione peroxidase activity with a range of organic hydroperoxides, including L-alpha-phosphatidylcholine hydroperoxide, but no significant activity against hydrogen peroxide, Glutathione was the only thiol tested that served as a substrate for the enzyme, which showed no activity with the thioredoxin system (thioredoxin, thioredoxin reductase, and NADPH), No glutathione-conjugating activity was detected against a range of electrophilic compounds that are common substrates for glutathione S-transferases. The apparent (pseudo) K-m for glutathione was determined as 4.9 mM at a fixed concentration of linolenic acid hydroperoxide (3 mu M). The enzyme showed low affinity for hydroperoxide substrates (apparent K-m for linolenic acid hydroperoxide and L-alpha-phosphatidylcholine hydroperoxide of 3.8 and 9.7 mM, respectively at a fixed glutathione concentration of 3 mM).	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND; WELLCOME CTR PARASIT INFECT,BECKENHAM,KENT,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	Imperial College London; GlaxoSmithKline; GlaxoSmithKline; Wellcome Research Laboratories				Selkirk, Murray/0000-0002-6274-6014	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON ME, 1980, J BIOL CHEM, V255, P9530; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; CHAUDIERE J, 1984, J BIOL CHEM, V259, P1043; CHU FF, 1993, J BIOL CHEM, V268, P2571; COOKSON E, 1992, P NATL ACAD SCI USA, V89, P5837, DOI 10.1073/pnas.89.13.5837; COOKSON E, 1993, MOL BIOCHEM PARASIT, V58, P155, DOI 10.1016/0166-6851(93)90099-J; CRIQUI MC, 1992, PLANT MOL BIOL, V18, P623, DOI 10.1007/BF00040684; DEAR TN, 1991, BIOCHEMISTRY-US, V30, P10376, DOI 10.1021/bi00107a003; Devaney E., 1991, P46; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; ESWORTHY RS, 1993, ARCH BIOCHEM BIOPHYS, V307, P29, DOI 10.1006/abbi.1993.1555; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Flohe L., 1974, GLUTATHIONE, P132; FRIEDRICH MJ, 1986, J BACTERIOL, V167, P928, DOI 10.1128/jb.167.3.928-934.1986; FUNK CD, 1987, BIOCHIM BIOPHYS ACTA, V921, P213, DOI 10.1016/0005-2760(87)90021-X; GANTHER HE, 1984, METHOD ENZYMOL, V107, P593; GARSSEN GJ, 1971, BIOCHEM J, V122, P327, DOI 10.1042/bj1220327; GHYSELINCK NB, 1990, NUCLEIC ACIDS RES, V18, P7144, DOI 10.1093/nar/18.23.7144; GODEAS C, 1994, BBA-BIOMEMBRANES, V1191, P147, DOI 10.1016/0005-2736(94)90242-9; GROSSMANN A, 1983, EUR J BIOCHEM, V135, P549, DOI 10.1111/j.1432-1033.1983.tb07687.x; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HOLLAND D, 1993, PLANT MOL BIOL, V21, P923, DOI 10.1007/BF00027124; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HUBER RE, 1967, ARCH BIOCHEM BIOPHYS, V122, P164, DOI 10.1016/0003-9861(67)90136-1; KRAUS RJ, 1980, BIOCHIM BIOPHYS ACTA, V615, P19, DOI 10.1016/0005-2744(80)90004-2; LADENSTEIN R, 1979, J MOL BIOL, V134, P199, DOI 10.1016/0022-2836(79)90032-9; MADDIPATI KR, 1987, J BIOL CHEM, V262, P17398; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MAIZELS RM, 1989, MOL BIOCHEM PARASIT, V32, P213, DOI 10.1016/0166-6851(89)90072-8; MANNERVIK B, 1985, METHOD ENZYMOL, V113, P490; MARTIN H, 1991, BIOCHEM BIOPH RES CO, V175, P123, DOI 10.1016/S0006-291X(05)81209-4; OVERBAUGH JM, 1985, PLANT PHYSIOL, V77, P437, DOI 10.1104/pp.77.2.437; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PERRY ACF, 1992, BIOCHEM J, V285, P863, DOI 10.1042/bj2850863; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; ROVERI A, 1992, J BIOL CHEM, V267, P6142; SCHALLREUTER KU, 1988, BIOCHIM BIOPHYS ACTA, V967, P103, DOI 10.1016/0304-4165(88)90194-8; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SELKIRK ME, 1990, MOL BIOCHEM PARASIT, V42, P31, DOI 10.1016/0166-6851(90)90110-8; SELKIRK ME, 1989, MOL BIOCHEM PARASIT, V32, P229, DOI 10.1016/0166-6851(89)90073-X; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; URSINI F, 1995, IN PRESS METHODS ENZ; YAMAMOTO Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P541, DOI 10.1006/abbi.1993.1458; ZVELEBIL MJJM, 1993, MOL BIOCHEM PARASIT, V58, P145, DOI 10.1016/0166-6851(93)90098-I	51	43	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18313	18318		10.1074/jbc.270.31.18313	http://dx.doi.org/10.1074/jbc.270.31.18313			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629152	hybrid			2022-12-25	WOS:A1995RM64200027
J	CHEN, XS; NAUMANN, TA; KURRE, U; JENKINS, NA; COPELAND, NG; FUNK, CD				CHEN, XS; NAUMANN, TA; KURRE, U; JENKINS, NA; COPELAND, NG; FUNK, CD			CDNA CLONING, EXPRESSION, MUTAGENESIS, INTRACELLULAR-LOCALIZATION, AND GENE CHROMOSOMAL ASSIGNMENT OF MOUSE 5-LIPOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT CELL SYSTEM; MAST-CELLS; ARACHIDONIC-ACID; MEMBRANE TRANSLOCATION; LEUKOTRIENE SYNTHESIS; HUMAN-LEUKOCYTES; BONE-MARROW; PROTEIN; ENZYME; BIOSYNTHESIS	5-Lipoxygenase of mouse macrophages and bone marrow derived mast cells (BMMC) was investigated. Indirect immunocytofluorescence combined with confocal microscopy provided evidence for distinct intracellular expression patterns and trafficking of 5-lipoxygenase upon cellular activation. In resting BMMC, 5-lipoxygenase was found within the nucleus co-localizing with the nuclear stain Yo-Pro-1. When BMMC were IgE/antigen-activated the 5-lipoxygenase immunofluorescence pattern was changed from nuclear to perinuclear. The absence of divalent cations in the incubation medium, or calcium ionophore A23187 challenge, altered the predominantly nuclear expression pattern to new sites both cytosolic and intranuclear. The cDNA for murine macrophage 5-lipoxygenase was cloned by the polymerase chain reaction and would predict a 674 amino acid protein. Using control cells obtained from 5-lipoxygenase-deficient mice it was determined that a single isoform accounts for both soluble and membrane bound and nuclear and cytosolic-localized enzyme in macrophages and BMMC. A mutation at amino acid 672 (Val --> Met) introduced serendipitously during the cloning process was found to completely abolish 5-lipoxygenase enzyme activity when the enzyme was expressed in human embryonic kidney 293 cells. This subtle change is proposed to affect the ability of the COOH-terminal isoleucine to coordinate the essential non-heme iron atom. In macrophages and BMMC obtained from 5-lipoxygenase-deficient mice, compensatory changes in expression of genes involved in the biosynthesis of leukotriene B-4 were investigated. 5-Lipoxygenase-activating protein expression was reduced by 50%, while leukotriene A(4) hydrolase expression was unaltered. The 5-lipoxygenase gene was mapped to the central region of mouse chromosome 6 in a region that shares homology with human chromosome 10 by interspecific backcross analysis. These studies provide a global picture of the murine 5-lipoxygenase system and raise questions about the role of 5-lipoxygenase and leukotrienes within the nucleus.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-46000] Funding Source: Medline; NHLBI NIH HHS [HL02710] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BOADO RJ, 1992, P NATL ACAD SCI USA, V89, P9044, DOI 10.1073/pnas.89.19.9044; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY M, 1992, J BIOL CHEM, V267, P570; COHN ZA, 1965, J EXP MED, V121, P153, DOI 10.1084/jem.121.1.153; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FUNK CD, 1991, J BIOL CHEM, V266, P12508; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2592, DOI 10.1073/pnas.86.8.2592; FUNK CD, 1994, ANN NY ACAD SCI, V714, P253, DOI 10.1111/j.1749-6632.1994.tb12051.x; FUNK CD, 1995, ADV PROSTAG THROMB L, V23, P145; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Green EL, 1981, GENETICS PROBABILITY, P77; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOGAN A, 1991, DEVELOPMENT, V113, P363; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KENNEDY BP, 1991, J BIOL CHEM, V266, P8511; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1990, J BIOL CHEM, V265, P13438; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P3406; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1982, J EXP MED, V155, P720, DOI 10.1084/jem.155.3.720; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; WONG A, 1992, BIOCHEMISTRY-US, V31, P4046, DOI 10.1021/bi00131a021; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485; ZHENG YL, 1991, EXP CELL RES, V194, P301, DOI 10.1016/0014-4827(91)90369-6	46	82	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17993	17999		10.1074/jbc.270.30.17993	http://dx.doi.org/10.1074/jbc.270.30.17993			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629107	hybrid			2022-12-25	WOS:A1995RM26600057
J	HAUSNER, W; THOMM, M				HAUSNER, W; THOMM, M			THE TRANSLATION PRODUCT OF THE PRESUMPTIVE THERMOCOCCUS-CELER TATA-BINDING PROTEIN-SEQUENCE IS A TRANSCRIPTION FACTOR-RELATED IN STRUCTURE AND FUNCTION TO METHANOCOCCUS TRANSCRIPTION FACTOR-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA-POLYMERASE; THERMOLITHOTROPHICUS; EXPRESSION; VANNIELII; SYSTEM; TFIIB; GENES; BOX	A gene for a putative homolog of TATA-binding protein (TBP) from Thermococcus celer has been expressed in Escherichia coli, and the function of the purified recombinant protein was studied in a Methanococcus-derived cell-free transcription system. Thermococcus TBP can replace archaeal transcription factor B (aTFB) in cell-free transcription reactions. This transcriptional activation is TATA box-dependent and occurs both on tRNA(Val) and protein-encoding genes as templates indicating that Thermococcus TBP is a general transcription factor. Antibodies raised against Thermococcus TBP bind to Methanococcus aTFB and inhibit aTFB activity. These findings demonstrate that Thermococcus TBP (like eucaryal TBPs) can direct specific transcription from TATA boxes.	CHRISTIAN ALBRECHTS UNIV KIEL,INST ALLGEMEINE MIKROBIOL,D-24118 KIEL,GERMANY	University of Kiel								CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CRETI R, 1993, NUCLEIC ACIDS RES, V21, P2942, DOI 10.1093/nar/21.12.2942; FREY G, 1990, NUCLEIC ACIDS RES, V18, P1361, DOI 10.1093/nar/18.6.1361; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; HAUSNER W, 1993, J BIOL CHEM, V268, P24047; HUBER H, 1982, ARCH MICROBIOL, V132, P47, DOI 10.1007/BF00690816; MARSH TL, 1994, P NATL ACAD SCI USA, V91, P5788; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMM M, 1994, SYST APPL MICROBIOL, V16, P648; THOMM M, 1993, J BACTERIOL, V174, P3508; WETTACH J, 1995, P NATL ACAD SCI USA, V92, P472, DOI 10.1073/pnas.92.2.472; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	17	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17649	17651		10.1074/jbc.270.30.17649	http://dx.doi.org/10.1074/jbc.270.30.17649			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629058	hybrid			2022-12-25	WOS:A1995RM26600003
J	KOWALAK, JA; BRUENGER, E; MCCLOSKEY, JA				KOWALAK, JA; BRUENGER, E; MCCLOSKEY, JA			POSTTRANSCRIPTIONAL MODIFICATION OF THE CENTRAL LOOP OF DOMAIN-V IN ESCHERICHIA-COLI 23-S RIBOSOMAL-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; PEPTIDYL TRANSFERASE; SECONDARY STRUCTURE; MAGNETIC-RESONANCE; NUCLEOTIDES; NUCLEOSIDES; PROTEIN; SITES	Knowledge of the sites, structures, and functional roles of posttranscriptional modification in rRNAs is limited, despite steadily accumulating evidence that rRNA plays a direct role in the peptidyl transferase reaction and that modified nucleotides are concentrated at the functional center of the ribosome. Using methods based on mass spectrometry, modifications have been mapped in Escherichia coli 23 S rRNA in the central loop of domain V, a region of established interaction between 23 S RNA and tRNA. Two segments of RNA were isolated following protection with oligodeoxynucleotides and nuclease digestion: residues 2423-2473 (51-mer) and 2481-2519 (39-mer). Dihydrouridine was located at position 2449, within the RNase T-1 hydrolysis product 2448-ADAACAGp-2454, as evidenced by a molecular mass 2 daltons higher than the gene sequence-predicted mass. This nucleoside, which is nearly ubiquitous in tRNA (where it is involved in maintenance of loop structure), is two bases from A-2551, a previously determined site of interaction between 23 S RNA and the CCA-aminoacyl terminus of tRNA at the ribosomal P-site. The oligonucleotide 2496-CACmCUCGp-2502 was isolated and accurately mass measured, and its nucleoside constituents were characterized by high performance liquid chromatography-mass spectrometry; there was no evidence of modification at position 2501 as implied by earlier work. Using similar techniques, the modified adenosine at position 2503 was unambiguously determined to be 2-methyladenosine in the fragment 2503-m(2)A Psi Gp-2505.	UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT MED CHEM,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NCI NIH HHS [5P30CA42014] Funding Source: Medline; NIGMS NIH HHS [GM29812] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P4303, DOI 10.1093/nar/9.17.4303; BRANLANT C, 1977, J MOL BIOL, V111, P215, DOI 10.1016/S0022-2836(77)80050-8; BRANLANT C, 1975, BIOCHIMIE, V57, P175, DOI 10.1016/S0300-9084(75)80168-4; BRIMACOMBE R, 1993, FASEB J, V7, P161, DOI 10.1096/fasebj.7.1.8422963; BROSIUS J, 1980, P NATL ACAD SCI-BIOL, V77, P201, DOI 10.1073/pnas.77.1.201; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; CRAIN PF, 1994, BIOLOGICAL MASS SPECTROMETRY: PRESENT AND FUTURE, P509; CUNDLIFFE E, 1990, RIBOSOME, P479; DESLAURIERS R, 1971, CAN J BIOCHEM CELL B, V49, P1279, DOI 10.1139/o71-185; EDMONDS CG, 1985, NUCLEIC ACIDS RES, V13, P8197, DOI 10.1093/nar/13.22.8197; EMERSON J, 1980, ACTA CRYSTALLOGR B, V36, P537, DOI 10.1107/S0567740880003780; FELLNER P, 1969, EUR J BIOCHEM, V11, P12, DOI 10.1111/j.1432-1033.1969.tb00733.x; GEHRKE CW, 1989, J CHROMATOGR, V471, P3, DOI 10.1016/S0021-9673(00)94152-9; GUTELL RR, 1993, NUCL ACIDS RES S, V20, P2095; JACK A, 1976, J MOL BIOL, V108, P619, DOI 10.1016/S0022-2836(76)80109-X; JOHNSON JD, 1971, BIOCHIM BIOPHYS ACTA, V247, P262, DOI 10.1016/0005-2787(71)90675-7; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; KOWALAK JA, 1993, NUCLEIC ACIDS RES, V21, P4577, DOI 10.1093/nar/21.19.4577; KOWALAK JA, 1993, TRANSLATIONAL APPARATUS, P79; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1980, NATURE, V288, P293, DOI 10.1038/288293a0; MOAZED D, 1986, J MOL BIOL, V191, P483, DOI 10.1016/0022-2836(86)90143-9; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; NICHOLS JL, 1967, J MOL BIOL, V30, P477, DOI 10.1016/0022-2836(67)90363-4; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1981, NUCLEIC ACIDS RES, V9, P6167, DOI 10.1093/nar/9.22.6167; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; NOLLER HF, 1993, J BACTERIOL, V175, P5297, DOI 10.1128/JB.175.17.5297-5300.1993; POMERANTZ SC, 1993, J AM SOC MASS SPECTR, V4, P204, DOI 10.1016/1044-0305(93)85082-9; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; QUIGLEY GJ, 1976, SCIENCE, V194, P794; SMITH JE, 1992, BIOCHEMISTRY-US, V31, P10825, DOI 10.1021/bi00159a025; STAHL DA, 1978, THESIS U ILLINOIS UR; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; SUCK D, 1980, ACTA CRYSTALLOGR, V28, P596; SUNDARALINGAM M, 1971, SCIENCE, V172, P725, DOI 10.1126/science.172.3984.725; SUNDARALINGAM M, 1982, CONFORMATION BIOL, P191; TAKEDA N, 1991, J CHROMATOGR-BIOMED, V562, P225, DOI 10.1016/0378-4347(91)80580-6; WOESE CR, 1980, RIBOSOMES STRUCTURE, P3; YOKOYAMA S, 1981, BIOCHEMISTRY-US, V20, P2981, DOI 10.1021/bi00513a041	48	77	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17758	17764		10.1074/jbc.270.30.17758	http://dx.doi.org/10.1074/jbc.270.30.17758			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629075				2022-12-25	WOS:A1995RM26600022
J	LESCAR, J; PELLEGRINI, M; SOUCHON, H; TELLO, D; POLJAK, RJ; PETERSON, N; GREENE, M; ALZARI, PM				LESCAR, J; PELLEGRINI, M; SOUCHON, H; TELLO, D; POLJAK, RJ; PETERSON, N; GREENE, M; ALZARI, PM			CRYSTAL-STRUCTURE OF A CROSS-REACTION COMPLEX BETWEEN FAB F9.13.7 AND GUINEA-FOWL LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ANTIBODY-ANTIGEN COMPLEX; 3-DIMENSIONAL STRUCTURE; HYPERVARIABLE REGIONS; BINDING SPECIFICITY; RECOGNITION; RESOLUTION; MIMICRY; REFINEMENT; GENERATION	The crystal structure of the complex between the cross-reacting antigen Guinea fowl lysozyme and the Fab from monoclonal antibody F9.13.7, raised against hen egg lysozyme, has been determined by x-ray diffraction to 3-Angstrom resolution. The antibody interacts with exposed residues of an alpha-helix and surrounding loops adjacent to the lysozyme active site cleft. The epitope of lysozyme bound by antibody F9.13.7 overlaps almost completely with that bound by antibody HyHEL10; the same 12 residues of the antigen interact with the two antibodies. The antibodies, however, have different combining sites with no sequence homology at any of their complementarity-determining regions and show a dissimilar pattern of cross-reactivity with heterologous antigens. Side chain mobility of epitope residues contributes to confer steric and electrostatic complementarity to differently shaped combining sites, allowing functional mimicry to occur. The capacity of two antibodies that have different fine specificities to bind the same area of the antigen emphasizes the operational character of the definition of an antigenic determinant. This example demonstrates that degenerate binding of the same structural motif does not require the existence of sequence homology or other chemical similarities between the different binding sites.	INST PASTEUR,DEPT IMMUNOL,UNITE IMMUNOL STRUCT,F-75724 PARIS 15,FRANCE; INST PASTEUR,CNRS,URA 359,F-75724 PARIS 15,FRANCE; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Pennsylvania				Alzari, Pedro/0000-0002-4233-1903				AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRADEN BC, 1994, J MOL BIOL, V243, P767, DOI 10.1016/0022-2836(94)90046-9; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIES D R, 1992, Current Biology, V2, P254, DOI 10.1016/0960-9822(92)90369-L; DAVIS SJ, 1992, NATURE, V358, P76, DOI 10.1038/358076a0; DEVEREUX J, 1991, GCG SEQUENCE ANAL SO; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; HARPER M, 1987, MOL IMMUNOL, V24, P97, DOI 10.1016/0161-5890(87)90081-2; HOUDUSSE AA, 1992, THESIS U PARIS SUD F; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABAT EA, 1991, NIH913242 PUBL; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; LASCOMBE MB, 1992, P NATL ACAD SCI USA, V89, P9429, DOI 10.1073/pnas.89.20.9429; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LESCAR J, 1994, PROTEIN SCI, V3, P788; LESCAR J, 1993, PROTEINS, V15, P209, DOI 10.1002/prot.340150211; LESLIE A, 1990, CRYSTALLOGRAPHIC COM, P110; MALBY RL, 1994, STRUCTURE, V2, P733, DOI 10.1016/S0969-2126(00)00074-5; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PELLEGRINI M, 1993, PROTEINS, V15, P436, DOI 10.1002/prot.340150410; SANZ I, 1987, P NATL ACAD SCI USA, V84, P1085, DOI 10.1073/pnas.84.4.1085; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SIEKEVITZ M, 1983, EUR J IMMUNOL, V13, P123, DOI 10.1002/eji.1830130207; SMITHGILL SJ, 1984, J IMMUNOL, P384; TAUB R, 1992, BIOCHEMISTRY-US, V31, P7431, DOI 10.1021/bi00148a001; TELLO D, 1993, BIOCHEM SOC T, V21, P943, DOI 10.1042/bst0210943; TELLO D, 1990, BIOCHIMIE, V72, P507, DOI 10.1016/0300-9084(90)90114-V; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANREGENMORTEL MHV, 1989, IMMUNOL TODAY, V10, P266, DOI 10.1016/0167-5699(89)90140-0; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; 1986, SERC4 DAR LAB COLL C	45	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18067	18076		10.1074/jbc.270.30.18067	http://dx.doi.org/10.1074/jbc.270.30.18067			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629116	Green Published, hybrid			2022-12-25	WOS:A1995RM26600067
J	OU, WJ; BERGERON, JJM; LI, Y; KANG, CY; THOMAS, DY				OU, WJ; BERGERON, JJM; LI, Y; KANG, CY; THOMAS, DY			CONFORMATIONAL-CHANGES INDUCED IN THE ENDOPLASMIC-RETICULUM LUMINAL DOMAIN OF CALNEXIN BY MG-ATP AND CA2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; MOLECULAR CHAPERONE; BINDING-PROTEIN; BIP; MEMBRANE; IDENTIFICATION; RELEASE; LIVER; ALPHA; SITE	The type I membrane protein calnexin functions as a molecular chaperone for secretory glycoproteins in the endoplasmic reticulum with ATP and Ca2+ as two of the cofactors involved in substrate binding. Protease protection experiments with intact canine rough microsomes showed that amino acid residues 1-462 of calnexin are located within the lumen of the endoplasmic reticulum. Expression using the baculovirus Sf9 insect cell system of a recombinant truncated calnexin corresponding to residues 1-462 (calnexin Delta TMC) revealed an association in vivo with a coexpressed secretory glycoprotein substrate, human immunodeficiency virus type I gp120. For the in vitro characterization of calnexin Delta TMC, we purified this secreted form to homogeneity from the medium of Sf9 cells. We demonstrate that the properties of the purified calnexin Delta TMC correspond to those of full-length calnexin in canine microsomes with at least one intramolecular disulfide bond and binding to Ca-45(2+). Calnexin Delta TMC underwent a marked and reversible conformational change following Ca2+ binding as measured by its resistance to proteinase K digestion of a 60-kDa fragment and also by the change from an oligomeric form of calnexin Delta TMC to a monomeric form. We also found that calnexin bound Mg-ATP leading to a conformational change from a monomeric to an oligomeric form that coincided as with markedly increased proteinase sensitivity. Our results identify the luminal domain of calnexin as responsible for binding substrates, Ca2+, and Mg-ATP. Because Ca2+ and ATP are required in vivo for the maintenance of calnexin-substrate interactions, conformational changes in the luminal domain of calnexin induced by Ca2+ and Mg-ATP are relevant to the in vivo function of calnexin as a molecular chaperone.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,EUKARYOT GENET GRP,MONTREAL,PQ H4P 2R2,CANADA; MCGILL UNIV,DEPT ANAT & CELL BIOL,MONTREAL,PQ H3A 2B2,CANADA; MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA; UNIV WESTERN ONTARIO,FAC MED,DEPT ZOOL,LONDON,ON N6A 5B7,CANADA; UNIV WESTERN ONTARIO,FAC MED,DEPT MICROBIOL & IMMUNOL,LONDON,ON N6A 5B7,CANADA	National Research Council Canada; McGill University; McGill University; Western University (University of Western Ontario); Western University (University of Western Ontario)			Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROT N, 1994, P NATL ACAD SCI USA, V91, P12120, DOI 10.1073/pnas.91.25.12120; CALA SE, 1993, J BIOL CHEM, V268, P2969; CAPPS GG, 1994, J BIOL CHEM, V269, P11634; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DAVID V, 1993, J BIOL CHEM, V268, P9585; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE AQ, 1994, J BIOL CHEM, V269, P7514; LI Y, 1994, VIROLOGY, V204, P266, DOI 10.1006/viro.1994.1531; LOO TW, 1994, J BIOL CHEM, V269, P28683; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OU WJ, UNPUB; OU WJ, 1993, NATURE, V364, P671; PARODI AJ, 1984, J BIOL CHEM, V259, P6351; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; SIMON WL, 1981, NATURE, V291, P201; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9	35	102	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18051	18059		10.1074/jbc.270.30.18051	http://dx.doi.org/10.1074/jbc.270.30.18051			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629114	hybrid			2022-12-25	WOS:A1995RM26600065
J	DURRER, P; GAUDIN, Y; RUIGROK, RWH; GRAF, R; BRUNNER, J				DURRER, P; GAUDIN, Y; RUIGROK, RWH; GRAF, R; BRUNNER, J			PHOTOLABELING IDENTIFIES A PUTATIVE FUSION DOMAIN IN THE ENVELOPE GLYCOPROTEIN OF RABIES AND VESICULAR STOMATITIS VIRUSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; INFLUENZA-VIRUS; LOW-PH; CONFORMATIONAL-CHANGES; PROTEINS; PEPTIDE; MECHANISM; CELLS	Vesicular stomatitis and rabies viruses enter cells through receptor-mediated endocytosis, followed by fusion of the viral with the endosomal membrane. The latter step is catalyzed by the viral envelope glycoprotein, which, in the low pH environment of the endosome, undergoes a conformational transition to a fusion com petent state. To investigate whether fusion competence involves the low pH exposure of a hydrophobic fusion region(s), we have applied hydrophobic photolabeling using the recently developed phospholipid analogue 1-O-hexadecanoyl-2-O-[9-[[[2-[I-125]iodo-4-(trifluoro-methyl-3H-diazirin-3-yl)benzyl]oxy]carbonyl]nonanoyl]-sn-glycero-3-phosphocholine ([I-125]TID-PC/16) (Weber, T., and Brunner, J. (1995) J. Am. Chem. Soc. 117, 3084-3095). Rosettes of rabies virus glycoprotein, whole rabies virus, or vesicular stomatitis virus were incubated with large unilamellar vesicles containing [I-125]TID-PC/16. Following reagent activation, the labeled glycoprotein was isolated and analyzed. In all cases, labeling of the glycoprotein strongly increased as the pH was lowered from 7.0 to 6.0, suggesting the exposure at acidic pH of a domain capable of interacting with membranes. To identify the labeled region(s), CNBr fragments were generated and analyzed by SDS-polyacrylamide followed by autoradiography. In rabies glycoprotein, the labeled segment was found to be contained within fragment RCr5 (residues 103-179). Glycoprotein from vesicular stomatitis virus was labeled within fragment VCr1 (residues 59-221). These results demonstrate that rhabdovirus glycoprotein contains a domain that at low pH is capable of interacting with a target membrane in a hydrophobic manner. This domain may play a role similar to that of the fusion peptide found in many other viral fusion proteins.	ETH ZENTRUM, BIOCHEM LAB 2, CH-8092 ZURICH, SWITZERLAND; CNRS, GENET VIRUS LAB, F-91198 GIF SUR YVETTE, FRANCE; INST MAX VON LAUE PAUL LANGEVIN, EMBL, GRENOBLE OUTSTN, F-38042 GRENOBLE 9, FRANCE	Swiss Federal Institutes of Technology Domain; ETH Zurich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL)				Gaudin, Yves/0000-0002-0122-2954				BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BARGE A, 1993, J VIROL, V67, P7246, DOI 10.1128/JVI.67.12.7246-7253.1993; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; CLAGUE MJ, 1990, BIOCHEMISTRY-US, V29, P1303, DOI 10.1021/bi00457a028; CRIMMINS DL, 1983, BIOCHEMISTRY-US, V22, P5790, DOI 10.1021/bi00294a017; DIETZSCHOLD B, 1982, J VIROL, V44, P595, DOI 10.1128/JVI.44.2.595-602.1982; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; FREDERICKSEN BL, 1995, J VIROL, V69, P1435, DOI 10.1128/JVI.69.3.1435-1443.1995; GALLIONE CJ, 1983, J VIROL, V46, P162, DOI 10.1128/JVI.46.1.162-169.1983; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; GAUDIN Y, 1991, J VIROL, V65, P4853, DOI 10.1128/JVI.65.9.4853-4859.1991; GAUDIN Y, 1992, VIROLOGY, V187, P627, DOI 10.1016/0042-6822(92)90465-2; GAUDIN Y, 1993, J VIROL, V67, P1365, DOI 10.1128/JVI.67.3.1365-1372.1993; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; HARTER C, 1989, J BIOL CHEM, V264, P6459; KAMP HH, 1974, METHOD ENZYMOL, V22, P140; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIERE M, 1993, ANAL BIOCHEM, V212, P206, DOI 10.1006/abio.1993.1313; LI Y, 1993, J VIROL, V67, P4070, DOI 10.1128/JVI.67.7.4070-4077.1993; MASTERS PS, 1989, VIROLOGY, V171, P285, DOI 10.1016/0042-6822(89)90540-0; MATLIN KS, 1982, J MOL BIOL, V156, P609, DOI 10.1016/0022-2836(82)90269-8; MORIMOTO K, 1992, VIROLOGY, V189, P203, DOI 10.1016/0042-6822(92)90696-M; MUGA A, 1994, BIOCHEMISTRY-US, V33, P4444, DOI 10.1021/bi00181a002; Ohnishi Shun-Ichi, 1988, Curr Top Membr Transp, V32, P257, DOI 10.1016/S0070-2161(08)60137-9; PURI A, 1988, J BIOL CHEM, V263, P4749; RAMALHOSANTOS J, 1993, BIOCHEMISTRY-US, V32, P2771, DOI 10.1021/bi00062a006; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; ROSE JK, 1982, J VIROL, V43, P361, DOI 10.1128/JVI.43.1.361-364.1982; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLEGEL R, 1984, J BIOL CHEM, V259, P4691; SCHLEGEL R, 1985, J VIROL, V53, P319, DOI 10.1128/JVI.53.1.319-323.1985; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; SUPERTI F, 1984, J GEN VIROL, V65, P781, DOI 10.1099/0022-1317-65-4-781; TORDO N, 1993, VIROLOGY, V194, P59, DOI 10.1006/viro.1993.1235; TORDO N, 1986, P NATL ACAD SCI USA, V83, P3914, DOI 10.1073/pnas.83.11.3914; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WEBER T, 1994, J BIOL CHEM, V269, P18353; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITT MA, 1990, J VIROL, V64, P4907, DOI 10.1128/JVI.64.10.4907-4913.1990; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; ZHANG L, 1994, J VIROL, V68, P2186, DOI 10.1128/JVI.68.4.2186-2193.1994; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	51	133	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17575	17581		10.1074/jbc.270.29.17575	http://dx.doi.org/10.1074/jbc.270.29.17575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615563	hybrid			2022-12-25	WOS:A1995RK68900080
J	KUDO, N; BARR, AJ; BARR, RL; DESAI, S; LOPASCHUK, GD				KUDO, N; BARR, AJ; BARR, RL; DESAI, S; LOPASCHUK, GD			HIGH-RATES OF FATTY-ACID OXIDATION DURING REPERFUSION OF ISCHEMIC HEARTS ARE ASSOCIATED WITH A DECREASE IN MALONYL-COA LEVELS DUE TO AN INCREASE IN 5'-AMP-ACTIVATED PROTEIN-KINASE INHIBITION OF ACETYL-COA CARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL TRIGLYCERIDE TURNOVER; CARNITINE PALMITOYLTRANSFERASE; LIVER-MITOCHONDRIA; GLOBAL-ISCHEMIA; WORKING HEART; COENZYME-A; METABOLISM; GLUCOSE; PHOSPHORYLATION; IDENTIFICATION	We determined whether high fatty acid oxidation rates during aerobic reperfusion of ischemic hearts could be explained by a decrease in malonyl-CoA levels, which would relieve inhibition of carnitine palmitoyltransferase 1, the rate limiting enzyme involved in mitochondrial uptake of fatty acids. Isolated working rat hearts perfused with 1.2 mM palmitate were subjected to 30 min of global ischemia, followed by 60 min of aerobic reperfusion. Fatty acid oxidation rates during reperfusion were 136% higher than rates seen in aerobically perfused control hearts, despite the fact that cardiac work recovered to only 16% of pre-ischemic values. Neither the activity of carnitine palmitoyltransferase 1, or the IC50 value of malonyl-CoA for carnitine palmitoyl transferase 1 were altered in mitochondria isolated from aerobic, ischemic, or reperfused ischemic hearts. Levels of malonyl-CoA were extremely low at the end of reperfusion compared to levels seen in aerobic controls, as was the activity of acetyl-CoA carboxylase, the enzyme which produces malonyl-CoA. The activity of 5'-AMP activated protein kinase, which has been shown to phosphorylate and inactivate acetyl CoA carboxylase in other tissues, was significantly increased at the end of ischemia, and remained elevated throughout reperfusion. These results suggest that accumulation of 5'-AMP during ischemia results in an activation of AMP-activated protein kinase, which phosphorylates and inactivates ACC during reperfusion. The subsequent decrease in malonyl-CoA levels will result in accelerated fatty acid oxidation rates during reperfusion of ischemic hearts.	UNIV ALBERTA, FAC MED,DEPT PEDIAT & PHARMACOL, LIPID & LIPOPROT RES GRP,CARDIOVASC DIS RES GRP, EDMONTON, AB T6G 2S2, CANADA	University of Alberta								AQUAN K, 1994, GENE, V149, P345; AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BENZI RH, 1992, CIRC RES, V71, P567, DOI 10.1161/01.RES.71.3.567; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; BING RJ, 1965, PHYSIOL REV, V45, P171, DOI 10.1152/physrev.1965.45.2.171; BREMER J, 1981, BIOCHIM BIOPHYS ACTA, V665, P628, DOI 10.1016/0005-2760(81)90282-4; BRODERICK TL, 1993, CIRCULATION, V87, P972, DOI 10.1161/01.CIR.87.3.972; BUNGER R, 1989, EUR J BIOCHEM, V180, P221, DOI 10.1111/j.1432-1033.1989.tb14637.x; CARLING D, 1989, J BIOCH, V29, P129; CHALLONE.DR, 1966, AM J PHYSIOL, V210, P280, DOI 10.1152/ajplegacy.1966.210.2.280; CONSTANTINTEODOSIU D, 1991, ANAL BIOCHEM, V198, P347, DOI 10.1016/0003-2697(91)90437-X; COOK GA, 1992, MOL CELL BIOCHEM, V116, P39, DOI 10.1007/BF01270567; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; GORGE G, 1991, CIRC RES, V68, P1681, DOI 10.1161/01.RES.68.6.1681; HA J, 1994, J BIOL CHEM, V269, P22162; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HERBIN C, 1987, EUR J BIOCHEM, V165, P201, DOI 10.1111/j.1432-1033.1987.tb11212.x; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KIM YS, 1978, ARCH BIOCHEM BIOPHYS, V190, P234, DOI 10.1016/0003-9861(78)90273-4; KING MT, 1988, METHOD ENZYMOL, V166, P70; LIEDTKE AJ, 1988, CIRC RES, V62, P535, DOI 10.1161/01.RES.62.3.535; LOPASCHUK GD, 1992, AM J PHYSIOL, V263, pE1046; LOPASCHUK GD, 1988, CIRC RES, V63, P1036, DOI 10.1161/01.RES.63.6.1036; LOPASCHUK GD, 1994, AM HEART J, V128, P61, DOI 10.1016/0002-8703(94)90010-8; LOPASCHUK GD, 1990, CIRC RES, V66, P546, DOI 10.1161/01.RES.66.2.546; LOPASCHUK GD, 1993, J PHARMACOL EXP THER, V264, P135; LOPASCHUK GD, 1994, BBA-LIPID LIPID MET, V1213, P263, DOI 10.1016/0005-2760(94)00082-4; LOPASCHUK GD, 1994, J BIOL CHEM, V269, P25871; LOPASCHUK GD, 1994, CAN J PHYSIOL PHARM, V72, P1101, DOI 10.1139/y94-156; LOPASCHUK GD, 1991, AM J PHYSIOL, V261, pH1698, DOI 10.1152/ajpheart.1991.261.6.H1698; MALLET RT, 1990, EUR J BIOCHEM, V188, P481, DOI 10.1111/j.1432-1033.1990.tb15426.x; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCVEIGH JJ, 1990, AM J PHYSIOL, V259, pH1079, DOI 10.1152/ajpheart.1990.259.4.H1079; MUELLER HS, 1978, AM J CARDIOL, V42, P363, DOI 10.1016/0002-9149(78)90929-3; NEELY JR, 1976, CIRC RES, V38, P22; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; OHGOSHI Y, 1991, CIRC RES, V69, P975, DOI 10.1161/01.RES.69.4.975; OLIVER MF, 1968, LANCET, V1, P710; OPIE LH, 1975, AM J CARDIOL, V36, P938, DOI 10.1016/0002-9149(75)90086-7; PAULY DF, 1991, CIRC RES, V68, P1085, DOI 10.1161/01.RES.68.4.1085; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; RENSTROM B, 1989, CIRC RES, V65, P1094, DOI 10.1161/01.RES.65.4.1094; SADDIK M, 1992, J BIOL CHEM, V267, P3825; SADDIK M, 1991, J BIOL CHEM, V266, P8162; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SCHULZ H, 1994, J NUTR, V124, P165, DOI 10.1093/jn/124.2.165; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SVENSSON S, 1990, J THORAC CARDIOV SUR, V99, P1063; SVORONOS S, 1988, COMP BIOCHEM PHYS B, V90, P179, DOI 10.1016/0305-0491(88)90058-2; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WINZ R, 1994, J BIOL CHEM, V269, P14438; WITTERS LA, 1992, J BIOL CHEM, V267, P2864	58	490	513	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17513	17520		10.1074/jbc.270.29.17513	http://dx.doi.org/10.1074/jbc.270.29.17513			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615556	hybrid			2022-12-25	WOS:A1995RK68900072
J	LAI, F; DRAKAS, R; NISHIKURA, K				LAI, F; DRAKAS, R; NISHIKURA, K			MUTAGENIC ANALYSIS OF DOUBLE-STRANDED-RNA ADENOSINE-DEAMINASE, A CANDIDATE ENZYME FOR RNA EDITING OF GLUTAMATE-GATED ION-CHANNEL TRANSCRIPTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CHANNELS; ESCHERICHIA-COLI; CYTIDINE DEAMINASE; UNWINDING ACTIVITY; MODIFYING ACTIVITY; CA2+ PERMEABILITY; MAMMALIAN-CELLS; PROTEIN-KINASE; BINDING DOMAIN; IDENTIFICATION	Mutagenic analysis of the substrate binding and catalytic domains of double-stranded RNA (dsRNA) adenosine deaminase (DRADA) was carried out. This nuclear enzyme is likely to be involved in the RNA editing of glutamate-gated ion channels that are essential for fast excitatory neurotransmission in mammalian brain. The deletion of the first or the third of the three dsRNA binding motifs within the substrate binding domain dramatically decreases enzyme activity, whereas the second motif seems to be dispensable. The results indicate that the three motifs are not functionally equivalent in the catalytic action of DRADA. Mutation of the putative zinc coordinating residues, His(910), Cys(966), and Cys(1036), abolished the DRADA activity. Similarly, the Glu(912) residue, predicted to be involved in the proton transfer functions of the enzyme, was found to be indispensable. Our results reinforce the previous proposal that the hydrolytic deamination mechanism of DRADA may be more similar to that of the cytidine deaminases than of adenosine deaminases.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute					NCI NIH HHS [CA09171, CA10815] Funding Source: Medline; NIGMS NIH HHS [GM40536] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009171, P30CA010815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BASILIO C, 1962, P NATL ACAD SCI USA, V48, P613, DOI 10.1073/pnas.48.4.613; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1993, RNA WORLD, P383; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BURK RR, 1983, METHOD ENZYMOL, V91, P247; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHANG HW, 1993, VIROLOGY, V194, P537, DOI 10.1006/viro.1993.1292; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGERBJERG J, 1994, P NATL ACAD SCI USA, V91, P10270; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11157; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAMBROOK S, 1989, MOL CLONING LABORATO; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SILVERKLANG M, 1979, METHOD ENZYMOL, V91, P247; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STEITZ TA, 1993, RNA WORLD, P219; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WEINER KXB, 1993, J BIOL CHEM, V268, P12983; WILSON DK, 1991, SCIENCE, V250, P1278; WILSON R, 1994, NATURE, V68, P32; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YANG C, 1992, BIOCHEMISTRY-US, V31, P4168, DOI 10.1021/bi00132a003; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	52	135	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17098	17105		10.1074/jbc.270.29.17098	http://dx.doi.org/10.1074/jbc.270.29.17098			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615504	hybrid			2022-12-25	WOS:A1995RK68900011
J	YANAGAWA, Y; CHEN, JC; HSU, LC; YOSHIDA, A				YANAGAWA, Y; CHEN, JC; HSU, LC; YOSHIDA, A			THE TRANSCRIPTIONAL REGULATION OF HUMAN ALDEHYDE DEHYDROGENASE-I GENE - THE STRUCTURAL AND FUNCTIONAL-ANALYSIS OF THE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; ALBUMIN PROMOTER; BINDING-PROTEIN; EXPRESSION; CLONING; CELLS; MOUSE; CDNA; EXTRACTION; RECEPTORS	Human cytosolic aldehyde dehydrogenase 1 (ALDH1) plays a role in the biosynthesis of retinoic acid that is a modulator for gene expression and cell differentiation. Northern blot analysis showed that liver tissue, pancreas tissue, hepatoma cells, and genital skin fibroblast cells expressed high levels of ALDH1. Sequence analysis showed that the 5'-flanking region contains a number of putative regulatory elements, such as NF-IL6, HNF-5, GATA binding sites, and putative response elements for interleukin-6, phenobarbital and androgen, in addition to a noncanonical TATA box (ATAAA) and a CCAAT box. Functional characterization of the 5'-regulatory region of the human ALDH1 gene was carried out by a fusion to the chloramphenicol acetyltransferase gene. A construct containing 2.6 kilobase pairs of the 5'-flanking region was efficiently expressed in hepatoma Hep3B cells, but not in erythroleukemic K562 cells or in fibroblast LTK(-) cells, which do not express ALDH1. Within this region, we define a minimal promoter (-91 to +53) that contains positive regulatory elements. The study using site directed mutagenesis demonstrated that the CCAAT box region is the major cis-acting element involved in basal ALDH1 promoter activity in Hep3B cells. Gel mobility shift assays showed that NF-Y and other octamer factors bound CCAAT box and an octamer motif sequence, but not GATA site existing in the minimal promoter region. Two additional DNA binding activities associated with the minimal promoter were found in the nuclear extract from Hep3B cells, but not from K562 cells. These results offer the possible molecular mechanism of the cell type-specific expression of ALDH1 gene.			YANAGAWA, Y (corresponding author), CITY HOPE NATL MED CTR, BECKMAN RES INST, DEPT BIOCHEM GENET, DUARTE, CA 91010 USA.				NHLBI NIH HHS [HL-29515] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029515, R37HL029515] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIEL V, 1988, NUCLEIC ACIDS RES, V16, P351, DOI 10.1093/nar/16.1.351; DE LUCA LM, 1991, FASEB J, V5, P2924; DENT CL, 1991, MOL CELL BIOL, V11, P3925, DOI 10.1128/MCB.11.8.3925; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FALANY CN, 1987, J BIOL CHEM, V262, P5924; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GODBOUT R, 1992, EXP EYE RES, V54, P297, DOI 10.1016/S0014-4835(05)80219-2; HARADA S, 1980, LIFE SCI, V26, P1773, DOI 10.1016/0024-3205(80)90577-9; HE JS, 1991, J BIOL CHEM, V266, P7864; HERBOMEL P, 1989, MOL CELL BIOL, V9, P4750, DOI 10.1128/MCB.9.11.4750; HSU LC, 1989, GENOMICS, V5, P857, DOI 10.1016/0888-7543(89)90127-4; HSU LC, 1985, P NATL ACAD SCI USA, V82, P3771, DOI 10.1073/pnas.82.11.3771; HSU LC, 1986, AM J HUM GENET, V38, P641; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; KOVACS WJ, 1989, ENDOCRINOLOGY, V124, P1270, DOI 10.1210/endo-124-3-1270; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MANIATIS T, 1989, GENE CLONING LABORAT; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MARSELOS M, 1987, CHEM-BIOL INTERACT, V62, P75, DOI 10.1016/0009-2797(87)90080-9; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PEREIRA F, 1991, BIOCHEM BIOPH RES CO, V175, P831, DOI 10.1016/0006-291X(91)91640-X; RADIN AI, 1991, BIOCHEM PHARMACOL, V42, P1933, DOI 10.1016/0006-2952(91)90592-S; RAGHUNATHAN L, 1988, Genomics, V2, P267, DOI 10.1016/0888-7543(88)90012-2; RONGNOPARUT P, 1991, GENE, V101, P261, DOI 10.1016/0378-1119(91)90421-7; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHERMAN PA, 1989, MOL CELL BIOL, V9, P50, DOI 10.1128/MCB.9.1.50; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; URANO Y, 1986, J BIOL CHEM, V261, P3244; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; YOSHIDA A, 1993, ADV EXP MED BIOL, V328, P63; YOSHIDA A, 1990, EXPERIENTIA, V46, P747, DOI 10.1007/BF01939955; YOSHIDA A, 1993, ADV EXP MED BIOL, V328, P37; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794; YOSHIDA A, 1991, PROG NUCLEIC ACID RE, V40, P255; ZHAO J, 1990, DNA CELL BIOL, V9, P37, DOI 10.1089/dna.1990.9.37	50	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17521	17527		10.1074/jbc.270.29.17521	http://dx.doi.org/10.1074/jbc.270.29.17521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615557	hybrid			2022-12-25	WOS:A1995RK68900073
J	CONWAY, EM; LIU, LL; NOWAKOWSKI, B; STEINERMOSONYI, M; RIBEIRO, SP; MICHALAK, M				CONWAY, EM; LIU, LL; NOWAKOWSKI, B; STEINERMOSONYI, M; RIBEIRO, SP; MICHALAK, M			HEAT SHOCK-SENSITIVE EXPRESSION OF CALRETICULIN - IN-VITRO AND IN-VIVO UP-REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MUSCLE SARCOPLASMIC-RETICULUM; RO/SS-A AUTOANTIGEN; MOLECULAR-CLONING; CELLS; IDENTIFICATION; ANTIGEN; GENES; THROMBOMODULIN; ACTIVATION	Calreticulin (CRT) is an ubiquitous, highly conserved, Ca2+-binding protein of the sarcoplasmic and endoplasmic reticulum. The precise function(s) of CRT is unknown. However, based on sequence analyses and observations that it may bind to steroid receptors and integrins and store Ca2+ within the cell, it has been postulated to play a ''housekeeping'' role. To determine whether the level of expression of CRT is affected by stress, we examined the heat shock response of CRT from a variety of cultured cells, including vascular endothelial, lung epithelial, and lung fibroblasts. Following exposure of the cells to 42 degrees C, CRT mRNA transiently accumulated 2.5-4.2-fold at 1-6 h. Nuclear run-on studies and mRNA stability experiments confirmed that the predominant mechanism of augmentation was transcriptional. Chloramphenieol acetyltransferase assays further indicated that the promoter region, containing a putative heat shock element between -172 and -158 of the human CRT gene, is heat shock-sensitive. Finally, we demonstrated the in vivo significance of these findings by exposing rats to hyperthermia. This resulted in accumulation of CRT mRNA and an augmentation of CRT protein in lung tissue. We hypothesize that this stress-induced up-regulation of CRT contributes to the mechanism(s) by which the vascular endothelium and lung tissue, and possibly other organ systems, maintain homeostasis when exposed to a variety of pathophysiological conditions.	UNIV TORONTO, TORONTO HOSP, DEPT MED, TORONTO, ON M5G 2C4, CANADA; UNIV ALBERTA, DEPT BIOCHEM, CARDIOVASC DIS RES GRP, EDMONTON, AB T6G 2S2, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Alberta	CONWAY, EM (corresponding author), UNIV TORONTO, TORONTO HOSP, DIV HEMATOL ONCOL, 586 UNIV AVE, MULOCK LARKIN BLDG 2-031A, TORONTO, ON M5G 2C4, CANADA.			Conway, Edward/0000-0003-0081-0305				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BURNS K, 1992, J BIOL CHEM, V267, P19039; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; BURNS K, 1993, FEBS LETT, V318, P181, DOI 10.1016/0014-5793(93)80017-O; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONWAY EM, 1994, J BIOL CHEM, V269, P22804; CONWAY EM, 1992, J CELL PHYSIOL, V151, P604, DOI 10.1002/jcp.1041510321; CONWAY EM, 1993, BLOOD, V81, P726; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GERSTEN DM, 1990, BIOCHIM BIOPHYS ACTA, V1096, P20, DOI 10.1016/0925-4439(90)90007-C; GUAN SH, 1991, BIOCHEMISTRY-US, V30, P9892, DOI 10.1021/bi00105a012; HAWN TR, 1993, J BIOL CHEM, V268, P7692; HOOPER WC, 1994, BLOOD, V84, P483, DOI 10.1182/blood.V84.2.483.bloodjournal842483; HOTCHKISS R, 1993, AM J PHYSIOL, V265, pR1447, DOI 10.1152/ajpregu.1993.265.6.R1447; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JETHMALANI SM, 1994, J BIOL CHEM, V269, P23603; KENNEDY TE, 1992, NEURON, V9, P1013, DOI 10.1016/0896-6273(92)90062-I; KETIS NV, 1988, J CELL BIOL, V106, P893, DOI 10.1083/jcb.106.3.893; KHANNA NC, 1986, J BIOL CHEM, V261, P8883; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIU N, 1993, BIOCHIM BIOPHYS ACTA, V1202, P70, DOI 10.1016/0167-4838(93)90064-X; MACLENNAN DH, 1973, COLD SPRING HARB SYM, V37, P469, DOI 10.1101/SQB.1973.037.01.058; MCCAULIFFE DP, 1990, J CLIN INVEST, V86, P332, DOI 10.1172/JCI114704; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MIRAULT ME, 1982, EMBO J, V1, P1279, DOI 10.1002/j.1460-2075.1982.tb00025.x; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NAKAMURA M, 1992, BIOCHEM BIOPH RES CO, V186, P984, DOI 10.1016/0006-291X(92)90843-A; OBANION MK, 1993, J VIROL, V67, P3427, DOI 10.1128/JVI.67.6.3427-3434.1993; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RIBEIRO SP, 1994, CRIT CARE MED, V22, P922, DOI 10.1097/00003246-199406000-00008; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; ROKEACH LA, 1991, J IMMUNOL, V147, P3031; Sambrook J, 1989, MOL CLONING LABORATO; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; TREVES S, 1992, BIOCHEM J, V287, P579, DOI 10.1042/bj2870579; UDELSMAN R, 1993, J CLIN INVEST, V91, P465, DOI 10.1172/JCI116224; VILLAR J, 1994, CRIT CARE MED, V22, P914; WELCH WJ, 1993, PHILOS T ROY SOC B, V339, P327, DOI 10.1098/rstb.1993.0031; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q	51	71	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					17011	17016		10.1074/jbc.270.28.17011	http://dx.doi.org/10.1074/jbc.270.28.17011			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622522	hybrid			2022-12-25	WOS:A1995RJ34700084
J	HANSON, PI; OTTO, H; BARTON, N; JAHN, R				HANSON, PI; OTTO, H; BARTON, N; JAHN, R			THE N-ETHYLMALEIMIDE-SENSITIVE FUSION PROTEIN AND ALPHA-SNAP INDUCE A CONFORMATIONAL CHANGE IN SYNTAXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; NEUROTRANSMITTER RELEASE; SYNAPTIC VESICLES; MEMBRANE-PROTEIN; ESCHERICHIA-COLI; GOLGI MEMBRANES; SYNAPTOBREVIN; PURIFICATION; CLEAVAGE; BINDING	The N-ethylmaleimide-sensitive fusion protein (NSF) plays an essential role in intracellular membrane fusion events and has been implicated in the exocytosis of synaptic vesicles. NSF binds through soluble NSF attachment proteins (SNAPs) to a complex of neuronal membrane proteins comprised of synaptobrevin, syntaxin, and SNAP-25. Disassembly of this complex by NSF is thought to be a critical step in the molecular events which lead to vesicle fusion with the plasma membrane. Here we have studied the interaction of alpha-SNAP and NSF with individual components of this complex and have identified syntaxin as a primary substrate for NSF/alpha-SNAP. We find that alpha-SNAP binds directly to syntaxin 1A as well as weakly to SNAP-25, while it does not bind to synaptobrevin II. NSF binds to syntaxin through alpha-SNAP and in the presence of ATP catalyzes a conformational rearrangement which abolishes binding of itself and alpha-SNAP. This reaction leads to the previously described disassembly of the fusion complex, since synaptobrevin binding to syntaxin is also reduced, alpha-SNAP binds to a carboxyl-terminal syntaxin fragment (residues 194-288) that also binds synaptobrevin and SNAP-25. However, NSF action on this syntaxin fragment has no effect on the binding of alpha-SNAP or synaptobrevin. This suggests that the conformational change normally induced by NSF in syntaxin depends on an interaction between carboxyl- and amino-terminal do mains of syntaxin.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University	HANSON, PI (corresponding author), YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,RM 247,NEW HAVEN,CT 06510, USA.		Hanson, Phyllis/E-9420-2012	Jahn, Reinhard/0000-0003-1542-3498				BARK IC, 1993, J MOL BIOL, V233, P67, DOI 10.1006/jmbi.1993.1485; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; INOUE A, 1992, J BIOL CHEM, V267, P10613; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MORGAN A, 1994, J BIOL CHEM, V269, P29347; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, METHOD ENZYMOL, V219, P309; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	54	195	197	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16955	16961		10.1074/jbc.270.28.16955	http://dx.doi.org/10.1074/jbc.270.28.16955			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622514	hybrid			2022-12-25	WOS:A1995RJ34700075
J	MONK, PN; BARKER, MD; PARTRIDGE, LJ; PEASE, JE				MONK, PN; BARKER, MD; PARTRIDGE, LJ; PEASE, JE			MUTATION OF GLUTAMATE-199 OF THE HUMAN C5A RECEPTOR DEFINES A BINDING-SITE FOR LIGAND DISTINCT FROM THE RECEPTOR N-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHYLATOXIN; IDENTIFICATION; EXPRESSION; ANTIBODIES; CLONING	C5a, a potent chemoattractant for monocytes, neutrophils, and other leukocytes, binds to a cell surface receptor of the seven-transmembrane superfamily. Here we report the effects of substituting Gin for Glu(199) of the human C5a receptor (hC5aR) expressed in a model cell system for chemoattractant receptor signaling, the rat basophilic leukemia cell line RBL-2H3. Both the binding affinity for hC5a and the EC(50) for subsequent cellular signals are reduced 5-10-fold by this substitution. A peptide mimic of the C terminus of C5a also binds to, and activates, hC5aR. The response to this peptide is reduced in cells bearing mutated hC5aR, indicating that the mutation affects interactions with the C terminus of hC5a. The C-terminal peptide contains only two basic residues, a Lys and an Arg (assumed to be analogous to Lys(68) and Arg(74) of hC5a), which could act as counter-ions for Glu(199) of the receptor. If the counter-ion on hC5a was Arg(74), then it would be expected that intact hC5a and hC5a des-Arg(74) would have identical affinities and potencies when interacting with mutant hC5aR. It was found, however, that the binding affinity and potency (for receptor signaling events) of hC5a des-Arg(74) was always lower than for intact hC5a. Furthermore, the equivalent C-terminal peptide to hC5a des-Arg(74) (i.e. lacking the C-terminal Arg) could partially activate the wild type but not the mutant receptor, whereas the converse peptide, containing Arg but containing Met instead of Lys, had equal potencies for both wild type and mutant receptors. Taken together these data indicate that Glu(199) of hC5aR is not involved in an interaction with Arg(74) Of hC5a, but may interact with Lys(68) of hC5a. Mutation of Glu(199) defines a second ligand binding site on hC5aR, distinct from the previously characterized site on the receptor N terminus. Unlike the N-terminal binding site, this second site is associated not just with the interaction with hC5a, but also with receptor activation.			MONK, PN (corresponding author), UNIV SHEFFIELD,KREBS INST BIOMOLEC RES,DEPT MOLEC BIOL & BIOTECHNOL,POB 594,SHEFFIELD S10 2UH,S YORKSHIRE,ENGLAND.		Monk, Peter/C-6155-2008; Pease, James/X-4521-2018	Monk, Peter/0000-0003-4637-3059; Pease, James/0000-0003-3749-0341; Partridge, Linda/0000-0001-9615-0094				ALI H, 1993, J BIOL CHEM, V268, P24247; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; CHENOWETH DE, 1980, MOL IMMUNOL, V17, P151, DOI 10.1016/0161-5890(80)90067-X; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Gallin JI., 1992, INFLAMMATION BASIC P; GERARD C, 1981, P NATL ACAD SCI-BIOL, V78, P1833, DOI 10.1073/pnas.78.3.1833; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GROTZINGER J, 1991, PROTEIN ENG, V4, P767, DOI 10.1093/protein/4.7.767; KAWAI M, 1992, J MED CHEM, V35, P223; KONTEATIS ZD, 1994, J IMMUNOL, V153, P4200; MERY L, 1994, J BIOL CHEM, V269, P3457; MOLLISON KW, 1989, P NATL ACAD SCI USA, V86, P292, DOI 10.1073/pnas.86.1.292; MONK PN, 1994, EUR J IMMUNOL, V24, P2922, DOI 10.1002/eji.1830241152; MONK PN, 1994, BIOCHEM MOL BIOL INT, V32, P13; MORGAN EL, 1993, J IMMUNOL, V151, P377; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; PEASE JE, 1994, EUR J IMMUNOL, V24, P211, DOI 10.1002/eji.1830240133; PEASE JE, 1993, BIOCHEM MOL BIOL INT, V31, P719; PEASE JE, 1993, BIOCHEM MOL BIOL INT, V29, P339; PEASE JE, 1994, MOL IMMUNOL, V31, P733, DOI 10.1016/0161-5890(94)90147-3; PERRET JJ, 1992, BIOCHEM J, V288, P911, DOI 10.1042/bj2880911; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214	22	35	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16625	16629		10.1074/jbc.270.28.16625	http://dx.doi.org/10.1074/jbc.270.28.16625			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622471	hybrid			2022-12-25	WOS:A1995RJ34700028
J	KLENCHIN, VA; CALVERT, PD; BOWNDS, MD				KLENCHIN, VA; CALVERT, PD; BOWNDS, MD			INHIBITION OF RHODOPSIN KINASE BY RECOVERIN - FURTHER EVIDENCE FOR A NEGATIVE FEEDBACK-SYSTEM IN PHOTOTRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; CYCLIC-GMP PHOSPHODIESTERASE; RETINAL RODS; CALCIUM SENSOR; AUTOPHOSPHORYLATION; PHOTORECEPTORS; TERMINUS; PROTEIN; VISION; CELLS	Recoverin is a 23-kDa Ca2+-binding protein found predominantly in vertebrate photoreceptor cells. Recent electrophysiological and biochemical studies suggest that recoverin may regulate the photoresponse by inhibiting rhodopsin phosphorylation. We find in both cell homogenates and reconstituted systems that the inhibition of rhodopsin phosphorylation by recoverin occurs over a significantly higher free Ca2+ range than previously reported, Half-maximal inhibition occurs at 1.5-3 mu M free Ca2+ and is cooperative with a Hill coefficient of similar to 2. Measurements of transducin activation demonstrate that this inhibition prolongs the lifetime of catalytically active rhodopsin. Ca2+-recoverin directly inhibits rhodopsin kinase activity, and Ca2+-dependent binding of recoverin to rod outer segment membranes is not required for its action, Extrapolation of the in vitro data to in vivo conditions based on simple mass action calculations places the Ca2+-recoverin regulation within the physiological free Ca2+ range in intact rod outer segment. The data are consistent with a model in which the fall in free Ca2+ that accompanies rod excitation exerts negative feedback by relieving inhibition of rhodopsin phosphorylation.	UNIV WISCONSIN,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706; UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	KLENCHIN, VA (corresponding author), UNIV WISCONSIN,MOLEC BIOL LAB 327,1525 LINDEN DR,MADISON,WI 53706, USA.				NEI NIH HHS [EY 00463] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; BIERNBAUM MS, 1985, J GEN PHYSIOL, V85, P83, DOI 10.1085/jgp.85.1.83; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CHEN CK, 1994, INVEST OPHTH VIS SCI, V35, P1485; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DODD RL, 1995, INVEST OPHTH VIS SCI, V36, pS641; DUMKE CL, 1994, J GEN PHYSIOL, V103, P1071, DOI 10.1085/jgp.103.6.1071; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GORODOVIKOVA EN, 1994, FEBS LETT, V353, P171, DOI 10.1016/0014-5793(94)01030-7; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KLENCHIN VA, 1994, BIOPHYS J, V66, pA48; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KORENBROT JI, 1989, VISION RES, V29, P939, DOI 10.1016/0042-6989(89)90108-9; LAGNADO L, 1992, J PHYSIOL-LONDON, V455, P111, DOI 10.1113/jphysiol.1992.sp019293; LAGNADO L, 1994, NATURE, V367, P273, DOI 10.1038/367273a0; Liebman P.A., 1972, PHOTOCHEMISTRY VISIO, P481; MCCARTHY ST, 1994, BIOPHYS J, V67, P2076, DOI 10.1016/S0006-3495(94)80691-5; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; MCGUIGAN JAS, 1990, CAN J PHYSL PHARM, V69, P1733; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; MILAM AH, 1993, VISUAL NEUROSCI, V10, P1, DOI 10.1017/S0952523800003175; MILLER DJ, 1984, AM J PHYSIOL, V246, pC160, DOI 10.1152/ajpcell.1984.246.1.C160; Miller James L., 1994, Current Opinion in Neurobiology, V4, P488, DOI 10.1016/0959-4388(94)90048-5; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; POLANS AS, 1993, METH NEUROSCI, V15, P248; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569; [No title captured]	37	181	181	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16147	16152		10.1074/jbc.270.27.16147	http://dx.doi.org/10.1074/jbc.270.27.16147			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608179	hybrid			2022-12-25	WOS:A1995RH22600042
J	KUNTZWEILER, TA; WALLICK, ET; JOHNSON, CL; LINGREL, JB				KUNTZWEILER, TA; WALLICK, ET; JOHNSON, CL; LINGREL, JB			AMINO-ACID REPLACEMENT OF ASP(369) IN THE SHEEP ALPHA-1 ISOFORM ELIMINATES ATP AND PHOSPHATE STIMULATION OF [H-3] OUABAIN BINDING TO THE NA+,K+-ATPASE WITHOUT ALTERING THE CATION-BINDING PROPERTIES OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; (NA+ + K+)-ATPASE; TRANSPORT ADENOSINE-TRIPHOSPHATASE; CARDIAC GLYCOSIDE INTERACTIONS; G-STROPHANTHIN; OX BRAIN; PHOSPHORYLATION; NA,K-ATPASE; OUABAIN; SUBUNIT	Modification of aspartic acid 369 in the sheep alpha 1 Na+,K+-ATPase to asparagine results in a membrane-associated form of Na+,K+-ATPase that can bind [H-3]ouabain with high affinity in the presence of Mg2+ alone (K-D = 20.4 +/- 2.6 nM). Ouabain binding to the D369N mutant is not stimulated by inorganic phosphate, confirming that Asp(369) is both the catalytic phosphorylation site and the only P-i interaction site which stimulates ouabain binding. Cation inhibition of Mg2+-stimulated ouabain binding to the D369N mutant demonstrated that three Na+ and two K+ ions inhibit [H-3]ouabain binding and suggests that this inhibition must occur via a cation-sensitive conformational change which does not directly involve dephosphorylation of the enzyme. In the presence of 10 mM Mg2+, ATP stimulates ouabain binding to the wild type protein, (AC(50) = 21.4 +/- 2.7 mu M) but inhibits the binding to the D369N mutant (IC50 = 2.52 +/- 0.17 mu M) indicating that the mutation does not destroy the high affinity site for MgATP but does change the nature of the protein conformation normally induced by a nucleotide-Na+,K+-ATPase interaction. Increasing the Mg2+ from 1 to 10 mM did not alter the AC(50) or IC50 values for ATP and reveals that the Mg2+ inter-action which stimulates ouabain binding in the absence of nucleotide involves a distinct divalent cation site not associated with the binding of the magnesium-nucleotide complex. Thus, altering the catalytic phosphorylation site of Na+,K+-ATPase does not affect the expression of the ouabain-sensitive protein in the membrane fraction of NIH 3T3 cells and does not disrupt the binding of Na+, K+, Mg2+, ouabain, or ATP to the enzyme. However, the D369N substitution does inhibit the formation of a nucleotide-protein complex with high affinity for ouabain.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267	University of Cincinnati; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008612, R01HL050613, R01HL028573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 50613, HL 28573, HL 08612-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS RW, 1968, MOL PHARMACOL, V4, P324; ASKARI A, 1988, J BIOL CHEM, V263, P235; BALL WJ, 1982, BIOCHIM BIOPHYS ACTA, V719, P413, DOI 10.1016/0304-4165(82)90228-8; BALL WJ, 1988, METHOD ENZYMOL, V156, P87; CAVIERES JD, 1977, MEMBRANE TRANSPORT R, P1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; ERDMANN E, 1973, BIOCHIM BIOPHYS ACTA, V330, P302, DOI 10.1016/0005-2736(73)90235-6; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; GRISHAM CM, 1974, J BIOL CHEM, V249, P3187; HANSEN O, 1973, BIOCHIM BIOPHYS ACTA, V311, P51, DOI 10.1016/0005-2736(73)90254-X; HANSEN O, 1984, PHARMACOL REV, V36, P143; JOHNSON CL, 1995, ARCH BIOCHEM BIOPHYS, V317, P133, DOI 10.1006/abbi.1995.1145; JOHNSON CL, 1995, IN PRESS BIOCH J, V308; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; LANE LK, 1973, J BIOL CHEM, V248, P7197; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MATSUI H, 1968, BIOCHIM BIOPHYS ACTA, V151, P655, DOI 10.1016/0005-2744(68)90013-2; OHTSUBO M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P157, DOI 10.1016/0005-2736(90)90028-M; PLESNER IW, 1981, BIOCHIM BIOPHYS ACTA, V643, P483, DOI 10.1016/0005-2736(81)90090-0; POST RL, 1975, J BIOL CHEM, V250, P691; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; RAO R, 1993, J BIOL CHEM, V268, P6708; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHWARTZ A, 1968, SCIENCE, V160, P323, DOI 10.1126/science.160.3825.323; SIEGEL GJ, 1969, J BIOL CHEM, V244, P3264; SKOU JC, 1971, BIOCHIM BIOPHYS ACTA, V241, P443, DOI 10.1016/0005-2736(71)90044-7; SKOU JC, 1960, BIOCHIM BIOPHYS ACTA, V255, P9852; STEKHOVEN FMA, 1980, BIOCHIM BIOPHYS ACTA, V597, P100; SWANN AC, 1978, BIOCHIM BIOPHYS ACTA, V523, P215, DOI 10.1016/0005-2744(78)90024-4; TOBIN T, 1970, BIOCHIM BIOPHYS ACTA, V198, P120, DOI 10.1016/0005-2744(70)90040-9; WALDERHAUG MO, 1985, J BIOL CHEM, V260, P3852; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; WALLICK ET, 1980, ARCH BIOCHEM BIOPHYS, V202, P442, DOI 10.1016/0003-9861(80)90448-8; YODA A, 1982, MOL PHARMACOL, V22, P700	37	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16206	16212		10.1074/jbc.270.27.16206	http://dx.doi.org/10.1074/jbc.270.27.16206			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608186	hybrid			2022-12-25	WOS:A1995RH22600050
J	BENNICELLI, JL; FREDERICKS, WJ; WILSON, RB; RAUSCHER, FJ; BARR, FG				BENNICELLI, JL; FREDERICKS, WJ; WILSON, RB; RAUSCHER, FJ; BARR, FG			WILD-TYPE PAX3 PROTEIN AND THE PAX3-FKHR FUSION PROTEIN OF ALVEOLAR RHABDOMYOSARCOMA CONTAIN POTENT, STRUCTURALLY DISTINCT TRANSCRIPTIONAL ACTIVATION DOMAINS	ONCOGENE			English	Article						PAX3; FKHR; FUSION PROTEIN; TRANSCRIPTION FACTOR; CHROMOSOMAL TRANSLOCATION	DNA-BINDING DOMAIN; MAMMALIAN-CELLS; GENE-EXPRESSION; EWINGS-SARCOMA; PRE-B; TRANSLOCATION; VIRUS; RNA; LIPOSARCOMA; E2A-PBX1	Alveolar rhabdomyosarcoma (ARMS) is characterized cytogenetically by a t(2;13)(q35;q14) chromosomal translocation involving two transcription factor genes: PAX3 and FKHR. ARMS cells express a PAX3-FKHR fusion protein containing the complete N-terminal, DNA-binding domain of PAX3 and the C-terminus of FKHR. Recently we demonstrated that PAX3-FKHR is a more potent transcriptional activator than PAX3 despite impaired binding to canonical PAX3 binding sites. Therefore, we propose that the gene fusion results in snitching of PAX3 and FKHR transactivation domains with distinct structure, potency or function. To compare the PAX3 and putative PAX3-FKHR transactivation domains, we fused C-terminal test fragments to the heterologous GAL4 DNA-binding domain and tested activation of a reporter gene co-transfected into four cell types. GAL4-PAX3 and GAL4-PAX3-FKHR were found to be potent activators exhibiting different concentration-dependent transactivation profiles and distinct structural motifs. Deletion mapping demonstrated essential acidic and/or serine/threonine-rich domains in the extreme 3' ends of their respective coding regions and positive modifying elements in adjacent 5' sequences. These data demonstrate that PAX3 and PAX3-FKHR contain structurally distinct transcriptional activation domains and suggest that a consequent difference in function is important for oncogenesis.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; The Wistar Institute					NATIONAL CANCER INSTITUTE [P01CA047983, R01CA064202] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002871] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64202, CA 47983] Funding Source: Medline; NHLBI NIH HHS [K08 HL02871] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DAVIS RJ, 1994, CANCER RES, V54, P2869; DENECKE B, 1993, J BIOL CHEM, V268, P18076; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Manet Evelyne, 1993, Gene Expression, V3, P49; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OHNO T, 1993, CANCER RES, V53, P5859; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; TASSABEHJI M, 1994, HUM MOL GENET, V3, P1069, DOI 10.1093/hmg/3.7.1069; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; VANDIJK MA, 1989, P NATL ACAD SCI USA, V90, P6061; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	39	77	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					119	130						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624119				2022-12-25	WOS:A1995RJ29500015
J	CALIFANO, D; MONACO, C; DEVITA, G; DALESSIO, A; DATHAN, NA; POSSENTI, R; VECCHIO, G; FUSCO, A; SANTORO, M; DEFRANCISCIS, V				CALIFANO, D; MONACO, C; DEVITA, G; DALESSIO, A; DATHAN, NA; POSSENTI, R; VECCHIO, G; FUSCO, A; SANTORO, M; DEFRANCISCIS, V			ACTIVATED RET/PTC ONCOGENE ELICITS IMMEDIATE-EARLY AND DELAYED-RESPONSE GENES IN PC12 CELLS	ONCOGENE			English	Article						RET; PHEOCHROMOCYTOMA; TYROSINE KINASE; ONCOGENE; PC12	NERVE GROWTH-FACTOR; NEURON-SPECIFIC ENOLASE; RET PROTO-ONCOGENE; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; TYROSINE KINASE; VGF GENE; EXPRESSION; RAS	The expression of the receptor-like tyrosine kinase RET is associated with tumors, tissues or cell lines of neural crest origin, In addition RET products (Ret) are involved in determining cell fate during the differentiation of the enteric nervous system and during renal organogenesis. However, as yet, no direct evidence exists to indicate that the Ret kinase activity might interfere in a specific way with cellular differentiation, or proliferation, of a neural crest derived cell line. By using two constitutively activated forms of RET (RET/PTC1 and RET/PTC3) in transient transfection experiments, we have obtained evidence that active RET could reprogramme the gene expression pattern in the rat pheochromocytoma PC12 cell line. Transcription driven by gene promoters, such as NGFI-A and vgf, which belong, respectively, to primary and delayed response genes to nerve growth factor (NGF), and by the neuron-specific enolase (NSE) promoter, is rapidly induced by the expression of activated RET oncogenes. This induction is not elicited in other non neural derived cell types tested. We also demonstrate that endogenous vas activity is required for RET induction of these neural markers. Finally, in the RET/PTC transfected PC12 cells, NGF is unable to induce further their transcription. This suggests that RET/PTC could share an intracellular signalling pathway with the NGF-receptor.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; FDN G PASCALE,IST STUDIO & CURA TUMORI,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; CNR,INST NEUROBIOL,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Fondazione Pascale; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR)			Califano, Daniela/Y-6313-2018; De Vita, Gabriella/H-4422-2011	Califano, Daniela/0000-0001-6945-3209; De Vita, Gabriella/0000-0002-7302-1174; Fusco, Alfredo/0000-0003-3332-5197				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ANTORO M, 1994, ONCOGENE, V9, P509; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P1; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BAYBIS M, 1992, FEBS LETT, V308, P202, DOI 10.1016/0014-5793(92)81274-P; BONGARZONE I, 1994, CANCER RES, V54, P2979; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DAHMER MK, 1988, ENDOCRINOLOGY, V122, P2109, DOI 10.1210/endo-122-5-2109; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; HAWLEY RJ, 1992, J NEUROSCI, V12, P2573; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUJUBU DA, 1987, ONCOGENE, V1, P257; LANZI C, 1992, ONCOGENE, V7, P2189; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEVI A, 1980, SCIENCE, V229, P3469; LUKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490; MILLBRANDT J, 1987, SCIENCE, V238, P797; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SCHMECHEL D, 1983, CURRENT METHODS CELL, V1, P1; SCHMECHEL DE, 1980, BRAIN RES, V190, P195, DOI 10.1016/0006-8993(80)91169-5; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOGARI A, 1985, J NEUROSCI, V5, P307; VANDENPOL AN, 1989, J NEUROSCI, V9, P4122; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P133, DOI 10.1016/0304-419X(93)90002-T; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	55	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					107	112						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624117				2022-12-25	WOS:A1995RJ29500013
J	HOFER, AM; SCHLUE, WR; CURCI, S; MACHEN, TE				HOFER, AM; SCHLUE, WR; CURCI, S; MACHEN, TE			SPATIAL-DISTRIBUTION AND QUANTITATION OF FREE LUMINAL [CA] WITHIN THE INSP(3)-SENSITIVE INTERNAL STORE OF INDIVIDUAL BHK-21-CELLS - ION DEPENDENCE OF INSP(3)-INDUCED CA RELEASE AND RELOADING	FASEB JOURNAL			English	Article						RATIO IMAGING; THAPSIGARGIN; CA IONOPHORES	CYTOSOLIC FREE MAGNESIUM; INDUCED CALCIUM RELEASE; ENDOPLASMIC-RETICULUM; INOSITOL TRISPHOSPHATE; PERMEABILIZED HEPATOCYTES; GOLGI-APPARATUS; FLUORESCENT INDICATOR; CHANNEL BLOCKERS; CA-2+ RELEASE; PC12 CELLS	Free [Ga] within organelles of permeabilized BHK-21 cells was measured using ratio imaging of compartmentalized mag-fura-2. In BHK-21 cells, this dye monitors free [Ca] in principally one type of ATP-dependent Ca-sequestering organelle in which intrastore Ca was released uniformly and entirely by 100 nM thapsigargin or removal of ATP or Ca from the bath, and was reduced by 85% upon treatment with a supramaximal dose of InsP(3) (6 mu M). Examination of the spatial distribution of InsP(3)-sensitive Ca stores showed that InsP(3) released Ca throughout all regions of the cell, although we often noted a perinuclear region (which we speculate may correspond to the Golgi apparatus) with reduced responsiveness to InsP(3). InsP(3)-induced changes of intraluminal Mg could not be detected. Cyclic ADP-ribose, ryanodine, caffeine, mitochondrial inhibitors, and GTP, agents known to influence intraorganellar Ca sequestration in other cell types, were all without effect on the mag-fura-2 ratio. In situ calibration of the mag-fura-2 ratio with Ca ionophores revealed that the average free intraorganellar [Ca] was initially 188 +/- 21 mu M in the presence of 170 nM free Ca and 3 mM ATP, and was reduced to 25 +/- 5 mu M upon stimulation with 6 mu M InsP(3). The ionic dependence of the release and reloading process was also investigated. The presence of either K, Na, or Cl could consistently support both InsP(3)-induced release and the refilling of stores with Ca, but physiological concentrations of HCO3 were effective in sustaining the response in only 24% of cells examined.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV CELL & DEV BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019520] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19520] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHANDRA S, 1991, J CELL SCI, V100, P747; CHANDRA S, 1994, J BIOL CHEM, V269, P15186; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GOEGER DE, 1989, BIOCHEM PHARMACOL, V38, P3995, DOI 10.1016/0006-2952(89)90679-5; GUILLEMETTE G, 1991, CELL CALCIUM, V12, P51, DOI 10.1016/0143-4160(91)90084-R; GUNTER TE, 1993, AM J PHYSIOL, V258, pC755; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HODSON S, 1978, J CELL SCI, V30, P117; HOFER AM, 1994, AM J PHYSIOL, V267, pG442, DOI 10.1152/ajpgi.1994.267.3.G442; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; JOSEPH SK, 1986, J BIOL CHEM, V261, P4658; KEMMER TP, 1987, J BIOL CHEM, V262, P13758; KOCH GLE, 1987, J CELL SCI, V87, P491; LONDON RE, 1991, ANNU REV PHYSIOL, V53, P241, DOI 10.1146/annurev.physiol.53.1.241; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1985, P NATL ACAD SCI USA, V82, P4433, DOI 10.1073/pnas.82.13.4433; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; OROURKE F, 1994, BIOCHEM J, V300, P673, DOI 10.1042/bj3000673; OZAWA M, 1993, J BIOL CHEM, V268, P699; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PALADE P, 1989, MOL PHARMACOL, V36, P664; QUAMME GA, 1990, BIOCHEM BIOPH RES CO, V167, P1406, DOI 10.1016/0006-291X(90)90679-H; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; SHAH J, 1988, BIOCHEM J, V250, P617, DOI 10.1042/bj2500617; SHAH J, 1987, BRAIN RES, V419, P1, DOI 10.1016/0006-8993(87)90562-2; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VILLA A, 1991, J CELL BIOL, V113, P779, DOI 10.1083/jcb.113.4.779; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152; ZHANG GH, 1990, CELL CALCIUM, V11, P397, DOI 10.1016/0143-4160(90)90051-U	49	51	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1995	9	9					788	798		10.1096/fasebj.9.9.7601343	http://dx.doi.org/10.1096/fasebj.9.9.7601343			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601343				2022-12-25	WOS:A1995RH98200012
J	HUGHES, CA; BENNETT, V				HUGHES, CA; BENNETT, V			ADDUCIN - A PHYSICAL MODEL WITH IMPLICATIONS FOR FUNCTION IN ASSEMBLY OF SPECTRIN-ACTIN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ERYTHROCYTE ADDUCIN; MEMBRANE SKELETON; ALPHA-ADDUCIN; BETA-ADDUCIN; CALMODULIN; BINDING; PURIFICATION; CLONING; DOMAIN	Adducin binds to spectrin-actin complexes, promotes association of spectrin with actin, and is subject to regulation by calmodulin as well as protein kinases A and C. Adducin is a heteromer comprised of homologous alpha- and beta-subunits with an NH2-terminal protease-resistant head domain, connected by a neck region to a COOH-terminal hydrophilic, protease-sensitive region, This study provides evidence that adducin in solution is a mixture of heterodimers and tetramers. CD spectroscopy of COOH-terminal domains of alpha- and beta-adducin bacterial recombinants provides direct evidence for an unstructured random coil configuration, Cross-linking, proteolysis, and blot binding experiments suggest a model for the adducin tetramer in which four head domains contact one another to form a globular core with extended interacting alpha- and beta-adducin tails. The site for binding to spectrin-actin complexes on adducin was identified as the COOH-terminal tail of both the alpha- and beta-adducin subunits. The capacity of native adducin to recruit spectrin to actin filaments is similar to that of adducin tail domains. Thus, adducin tail domains alone are sufficient to interact with F-actin and a single spectrin and to recruit additional spectrin molecules to the ternary complex.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University	HUGHES, CA (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.							BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1988, J BIOL CHEM, V263, P5860; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GARDNER K, 1986, J BIOL CHEM, V261, P1339; GARDNER K, 1988, P293; GILLIGAN DM, 1991, J CELL BIOL, V115, P42; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; JOSHI R, 1990, J BIOL CHEM, V265, P13130; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; LING E, 1986, J BIOL CHEM, V261, P13875; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MISCHE SM, 1987, J CELL BIOL, V105, P2837, DOI 10.1083/jcb.105.6.2837; NEHLS V, 1991, BLOOD, V78, P1692; NOZAKI Y, 1976, BIOCHEMISTRY-US, V15, P3884, DOI 10.1021/bi00662a036; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; SCARAMUZZINO DA, 1993, P NATL ACAD SCI USA, V90, P3398, DOI 10.1073/pnas.90.8.3398; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SINARD JH, 1994, MOL BIOL CELL, V5, P421; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tanford C, 1961, PHYS CHEM MACROMOLEC, P364; TAYLOR KA, 1993, J MOL BIOL, V230, P196, DOI 10.1006/jmbi.1993.1136; TAYLOR SAM, 1992, NAT GENET, V2, P223, DOI 10.1038/ng1192-223; TRIPODI G, 1991, BIOCHEM BIOPH RES CO, V177, P939, DOI 10.1016/0006-291X(91)90629-L; WASEEM A, 1988, FASEB J, V2, pA349; WASEEM A, 1988, EUR J BIOCHEM, V178, P563, DOI 10.1111/j.1432-1033.1988.tb14483.x; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308; YUE L, 1992, GENE DEV, V6, P2443, DOI 10.1101/gad.6.12b.2443	41	142	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18990	18996		10.1074/jbc.270.32.18990	http://dx.doi.org/10.1074/jbc.270.32.18990			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642559	hybrid			2022-12-25	WOS:A1995RN95400047
J	LIU, JQ; KURIHARA, T; MIYAGI, M; ESAKI, N; SODA, K				LIU, JQ; KURIHARA, T; MIYAGI, M; ESAKI, N; SODA, K			REACTION-MECHANISM OF L-2-HALOACID DEHALOGENASE OF PSEUDOMONAS SP. YL - IDENTIFICATION OF ASP(10) AS THE ACTIVE-SITE NUCLEOPHILE BY O-18 INCORPORATION EXPERIMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-HALOALKANOIC ACID DEHALOGENASE; 2-HALOACID HALIDOHYDROLASE IVA; SP STRAIN CBS3; CEPACIA MBA4; PURIFICATION; GENE; MUTAGENESIS; PROTEIN; PUTIDA	L-2-Haloacid dehalogenase (EC 3.8.1.2) catalyzes the hydrolytic dehalogenation of L-2-haloacids to produce the corresponding D-2-hydroxy acids, We have analyzed the reaction mechanism of the enzyme from Pseudomonas sp, YL and found that Asp(10) is the active site nucleophile, When the multiple turnover enzyme reaction was carried out in (H2O)-O-18 with L-2-chloropropionate as a substrate, lactate produced was labeled with O-18. However, when the single turnover enzyme reaction was carried out by use of a large excess of the enzyme, the product was not labeled, This suggests that an oxygen atom of the solvent water is first incorporated into the enzyme and then transferred to the product, After the multiple turnover reaction in (H2O)-O-18, the enzyme was digested with lysyl endopeptidase, and the molecular masses of the peptide fragments formed were measured by an ionspray mass spectrometer, Two O-18 atoms were shown to be incorporated into a hexapeptide, Gly(6)-Lys(11). Tandem mass spectrometric analysis of this peptide revealed that Asp(10) was labeled with two O-18 atoms, Our previous site-directed mutagenesis experiment showed that the replacement of Asp(10) led to a significant loss in the enzyme activity. These results indicate that Asp(10) acts as a nucleophile on the alpha-carbon of the substrate leading to the formation of an ester intermediate, which is hydrolyzed by nucleophilic attack of a water molecule on the carbonyl carbon atom.	TAKARA SHUZO CO LTD, BIOTECHNOL RES LABS, OTSU, SHIGA 52021, JAPAN; KYOTO UNIV, INST CHEM RES, MICROBIAL BIOCHEM LAB, UJI, KYOTO 611, JAPAN	Takara Holdings Inc.; Kyoto University								ASMARA W, 1993, BIOCHEM J, V292, P69, DOI 10.1042/bj2920069; GOLDMAN P, 1968, J BIOL CHEM, V243, P428; HASAN AKMQ, 1994, BIOSCI BIOTECH BIOCH, V58, P1599, DOI 10.1271/bbb.58.1599; IWASAKI I, 1956, B CHEM SOC JPN, V29, P860, DOI 10.1246/bcsj.29.860; JONES DHA, 1992, J GEN MICROBIOL, V138, P675, DOI 10.1099/00221287-138-4-675; KAWASAKI H, 1992, J GEN MICROBIOL, V138, P1317, DOI 10.1099/00221287-138-7-1317; KAWASAKI H, 1994, BIOSCI BIOTECH BIOCH, V58, P160, DOI 10.1271/bbb.58.160; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115; LITTLE M, 1971, EUR J BIOCHEM, V21, P99, DOI 10.1111/j.1432-1033.1971.tb01445.x; LIU JQ, 1994, APPL ENVIRON MICROB, V60, P2389, DOI 10.1128/AEM.60.7.2389-2393.1994; LIU JQ, 1994, J BIOCHEM-TOKYO, V116, P248, DOI 10.1093/oxfordjournals.jbchem.a124514; LIU JQ, 1995, IN PRESS BIODEGRADAT; MOTOSUGI K, 1982, AGR BIOL CHEM TOKYO, V46, P837, DOI 10.1080/00021369.1982.10865158; MURDIYATMO U, 1992, BIOCHEM J, V284, P87, DOI 10.1042/bj2840087; NARDIDEI V, 1994, APPL ENVIRON MICROB, V60, P3375, DOI 10.1128/AEM.60.9.3375-3380.1994; PRIES F, 1994, BIOCHEMISTRY-US, V33, P1242, DOI 10.1021/bi00171a026; SCHNEIDER B, 1993, BIOL CHEM H-S, V374, P489, DOI 10.1515/bchm3.1993.374.7-12.489; SCHNEIDER B, 1991, J BACTERIOL, V173, P1530, DOI 10.1128/jb.173.4.1530-1535.1991; TSANG JSH, 1988, ARCH MICROBIOL, V150, P441, DOI 10.1007/BF00422284; VANDERPLOEG J, 1991, J BACTERIOL, V173, P7925, DOI 10.1128/jb.173.24.7925-7933.1991; YANG G, 1994, BIOCHEMISTRY-US, V33, P8527, DOI 10.1021/bi00194a018	24	79	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18309	18312		10.1074/jbc.270.31.18309	http://dx.doi.org/10.1074/jbc.270.31.18309			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629151	hybrid			2022-12-25	WOS:A1995RM64200026
J	SUBLETT, JE; JEON, IS; SHAPIRO, DN				SUBLETT, JE; JEON, IS; SHAPIRO, DN			THE ALVEOLAR RHABDOMYOSARCOMA PAX3/FKHR FUSION PROTEIN IS A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Article						RHABDOMYOSARCOMA; TRANSCRIPTION FACTORS; DNA BINDING; PAIRED BOX; HOMEOBOX	DNA-BINDING-DOMAIN; FORK HEAD DOMAIN; PAIRED BOX; MAMMALIAN-CELLS; GENE FUSION; PAX3; DROSOPHILA; FAMILY; IDENTIFICATION; TRANSLOCATION	Chimeric transcription factors, created by gene fusions as the result of chromosomal translocations, have been implicated in the pathogenesis of several pathologically disparate solid tumors. The PAX3/FKHR fusion gene, formed by a t(2;13)(q35;q14) in alveolar rhabdomyosarcoma, encodes a hybrid protein that contains both PAX3 DNA binding domains, the paired box and homeodomain, linked to the bisected DNA binding domain of FKHR, a member of the forkhead family of transcription factors: Here we report that PAX3 and PAX3/FKHR display similar, but not identical transactivation activities when tested with model Pax recognition sequences. No functional role could be ascribed solely to the residual FKHR binding domain present in the fusion protein, but FKHR was found to contribute a strong carboxyl terminal activation domain replacing the one located in the unrearranged PAX3 gene. We show that the native PAX3/FKHR protein present in tumor cells with this translocation has transcriptional characteristics similar to the in vitro expressed protein. The ability of the PAX3/FKHR hybrid protein to bind DNA in a sequence specific manner and to transactivate the expression of artificial reporter genes suggests that its aberrant expression could subvert the transcriptional programs that normally control the growth, differentiation, and survival of primitive myogenic precursors in vivo.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NCI NIH HHS [CA-23099, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUERSPERG N, 1969, JNCI-J NATL CANCER I, V43, P151; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DAVIS RJ, 1994, CANCER RES, V54, P2869; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HOTH CF, 1993, AM J HUM GENET, V52, P455; KASTURY K, 1994, P NATL ACAD SCI USA, V91, P3616, DOI 10.1073/pnas.91.9.3616; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LI C, 1993, P NATL ACAD SCI USA, V90, P11583, DOI 10.1073/pnas.90.24.11583; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	44	65	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					545	552						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630639				2022-12-25	WOS:A1995RN53000015
J	DOHMEN, RJ; STAPPEN, R; MCGRATH, JP; FORROVA, H; KOLAROV, J; GOFFEAU, A; VARSHAVSKY, A				DOHMEN, RJ; STAPPEN, R; MCGRATH, JP; FORROVA, H; KOLAROV, J; GOFFEAU, A; VARSHAVSKY, A			AN ESSENTIAL YEAST GENE ENCODING A HOMOLOG OF UBIQUITIN-ACTIVATING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE Y-CHROMOSOME; N-END RULE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROTEIN-DEGRADATION; CONJUGATING ENZYME; TAGGED UBIQUITIN; EXPRESSION; PURIFICATION; CLONING	Ubiquitin (Ub) activation by the Ub-activating (E1) enzyme is the initial and essential step common to all of the known processes that involve post-translational conjugation of Ub to itself or other proteins. The ''activated'' Ub, linked via a thioester bond to a specific cysteine residue of E1 enzyme, can be transferred to a cysteine residue in one of several Ub-conjugating (E2) enzymes, which catalyze the formation of isopeptide bonds between the C-terminal glycine of Ub and lysine residues of acceptor proteins. In the yeast Saccharomyces cerevisiae, a 114-kDa E1 enzyme is encoded by an essential gene termed UBA1 (McGrath, J. P., Jentsch, S., and Varshavsky, A. (1991) EMBO J. 10, 227-236). We describe the isolation and analysis of another essential gene, termed UBA2, that encodes a 71-kDa protein with extensive sequence similarities to both the UBA1-encoded yeast E1 and E1 enzymes of other organisms. The regions of similarities between Uba1p and Uba2p encompass a putative ATP-binding site as well as a sequence that is highly conserved between the known E1 enzymes and contains the active-site cysteine of E1. This cysteine is shown to be required for an essential function of Uba2p, suggesting that Uba2p-catalyzed reactions involve a transient thioester bond between Uba2p and either Ub or another protein. Uba2p is located largely in the nucleus. The putative nuclear localization signal of Uba2p is near its C terminus. The Uba1p (E1 enzyme) and Uba2p cannot complement each others essential functions even if their subcellular localization is altered by mutagenesis. Uba2p appears to interact with itself and several other S. cerevisiae proteins with apparent molecular masses of 52, 63, 87, and 120 kDa. Uba2p is multiubiquitinated in vivo, suggesting that at least a fraction of Uba2p is metabolically unstable. Uba2p is likely to be a component of the Ub system that functions as either an E2 or E1/E2 enzyme.	ALKERMES INC,CAMBRIDGE,MA 02139; COMENIUS UNIV BRATISLAVA,DEPT BIOCHEM,BRATISLAVA 84215,SLOVAKIA; UNIV CATHOLIQUE LOUVAIN,UNITE BIOCHEM PHYSIOL,B-1348 LOUVAIN,BELGIUM; CALTECH,DIV BIOL,PASADENA,CA 91125; UNIV DUSSELDORF,INST MIKROBIOL,D-40225 DUSSELDORF,GERMANY	Alkermes; Comenius University Bratislava; Universite Catholique Louvain; California Institute of Technology; Heinrich Heine University Dusseldorf			Dohmen, R. Jürgen/AAD-6649-2022; kolarov, jordan/R-5382-2019; Kolarov, Jordan/O-3768-2014	Dohmen, R. Jürgen/0000-0002-5756-6780; 	NIGMS NIH HHS [GM31530] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; AYSAWA D, 1992, CELL STRUCT FUNCT, V17, P113; BEERS EP, 1993, J BIOL CHEM, V268, P21645; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CIECHANOVER A, 1984, CELL, V37, P43; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; DUNN TM, 1990, MOL CELL BIOL, V10, P2308, DOI 10.1128/MCB.10.5.2308; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1983, BIOCHEMISTRY-US, V22, P4388, DOI 10.1021/bi00288a007; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HERSKOWITZ I, 1986, METHOD ENZYMOL, V194, P132; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; IMAI N, 1992, GENE, V118, P279, DOI 10.1016/0378-1119(92)90200-9; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KULKA RG, 1988, J BIOL CHEM, V263, P15726; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MADURA K, 1993, J BIOL CHEM, V268, P12046; MCGRATH JP, 1991, EMBO J, V10, P27; MENDENHALL MD, 1988, NUCLEIC ACIDS RES, V16, P8713, DOI 10.1093/nar/16.17.8713; MINVIELLESEBAST.L, 1994, SCIENCE, V266, P1702; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; NISHITANI H, 1992, BIOCHEM BIOPH RES CO, V184, P1015, DOI 10.1016/0006-291X(92)90692-E; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PICKART CM, 1994, J BIOL CHEM, V269, P7115; PICKART CM, 1988, UBIQUITIN, P77; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; ROTHSTEIN R, 1993, METHOD ENZYMOL, V194, P281; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1986, GENETICS, V122, P19; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; VARSHAVSKY A, 1991, CELL, V69, P725; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WINSTON F, 1986, NUCLEIC ACIDS RES, V14, P6885, DOI 10.1093/nar/14.17.6885; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	63	165	169	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18099	18109		10.1074/jbc.270.30.18099	http://dx.doi.org/10.1074/jbc.270.30.18099			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629121	hybrid, Green Accepted			2022-12-25	WOS:A1995RM26600072
J	WITCHER, DR; DEWAARD, M; LIU, HY; PRAGNELL, M; CAMPBELL, KP				WITCHER, DR; DEWAARD, M; LIU, HY; PRAGNELL, M; CAMPBELL, KP			ASSOCIATION OF NATIVE CA2+ CHANNEL BETA-SUBUNITS WITH THE ALPHA(1) SUBUNIT INTERACTION DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK SENSORY NEURONS; CALCIUM-CHANNEL; SKELETAL-MUSCLE; 1,4-DIHYDROPYRIDINE RECEPTOR; BRAIN; EXPRESSION; CLONING; IDENTIFICATION; RELEASE; BINDING	beta Subunits of voltage-dependent Ca2+ channels play an important role in regulating Ca2+ channel function. The sites of alpha(1)-beta subunit interaction have been localized recently to cytoplasmic domains of both subunits. The alpha(1) subunit interaction domain (AID) is an 18-amino-acid conserved motif located between repeats I and II on all alpha(1) subunits which is essential for the binding of beta subunits. In order to further study the interaction of beta subunits with AID, we have expressed a 50-amino-acid glutathione S-transferase (GST) fusion protein from the alpha(1A) subunit that contains the AID. Mutant GST fusion proteins that contain a single amino acid change (Y392S, Y392F, and Y392W) in the AID(A) along with control GST were coupled to glutathione-Sepharose beads to form affinity beads. Binding assays using these affinity beads with in vitro synthesized S-35-labeled beta(2) and beta(3) subunits demonstrate that the hydroxyl group on tyrosine 392 of AID(A) is critical for binding to beta subunits. The affinity bead assay was also used to identify and characterize native beta subunits from detergent extracts of different tissues. The AID(A) affinity beads, but not the control or Y392S beads, specifically bind beta subunits from detergent extracts of skeletal muscle, cardiac muscle, and brain. Immunoblot analyses demonstrate the presence of beta(1a) in skeletal muscle, beta(2) and beta(3) in cardiac muscle, and beta(1b), beta(3), and beta(4) in brain. The assays also demonstrate the AID(A) beads bind to beta subunits from tissue homogenates extracted with low salt and no detergent suggesting the existence of a pool of beta subunits which is not always associated with alpha(1) subunits. Also, beta subunits from solubilized skeletal muscle triads can be affinity-purified using AID(A) CNBr-Sepharose. Our data demonstrate that the AID binds to native beta subunits from detergent and non-detergent tissue extracts illustrating that this domain on the alpha(1) subunit is the major anchoring site for the beta subunit.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,PROGRAM NEUROSCI,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa			De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Campbell, Kevin/0000-0003-2066-5889	NIAID NIH HHS [T32-AI07343] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007343] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRNBAUMER L, 1994, NEURON, V13, P503; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; De Waard M., 1995, Biophysical Journal, V68, pA13; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; FOX AP, 1987, J PHYSIOL-LONDON, V394, P173, DOI 10.1113/jphysiol.1987.sp016865; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; POWERS PA, 1992, J BIOL CHEM, V267, P22967; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SHARP AH, 1989, J BIOL CHEM, V264, P2816; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WITCHER DR, 1994, J BIOL CHEM, V269, P13076; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1993, NEUROPHARMACOLOGY, V32, P1127, DOI 10.1016/0028-3908(93)90007-P	34	78	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18088	18093		10.1074/jbc.270.30.18088	http://dx.doi.org/10.1074/jbc.270.30.18088			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629119	hybrid			2022-12-25	WOS:A1995RM26600070
J	KISHIGAMI, S; KANAYA, E; KIKUCHI, M; ITO, K				KISHIGAMI, S; KANAYA, E; KIKUCHI, M; ITO, K			DSBA-DSBB INTERACTION THROUGH THEIR ACTIVE-SITE CYSTEINES - EVIDENCE FROM AN ODD CYSTEINE MUTANT OF DSBA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DISULFIDE BOND FORMATION; FORMATION INVIVO; ALKALINE-PHOSPHATASE; PERIPLASMIC ENZYME; IN-VIVO; IDENTIFICATION; PRODUCT; INVITRO	Formation of disulfide bonds in Escherichia coli envelope proteins is facilitated by the Dsb system, which is thought to consist of at least two components, a periplasmic soluble enzyme (DsbA) and a membrane-bound factor (DsbB), Although it is believed that DsbA directly oxidizes substrate cysteines and DsbB reoxidizes DsbA to allow multiple rounds of reactions, direct evidence for the DsbA-DsbB interaction has been lacking, We examined intracellular activities of mutant forms of DsbA, DsbA30S and DsbA33S, in which one of its active site cysteines (Cys(30) or Cys(33), respectively) has been replaced by serine, The DsbA33S protein was found to dominantly interfere with the disulfide bond formation and to form intermolecular disulfide bonds with numerous other proteins when cells were grown in media containing low molecular weight disulfides such as GSSG. In the absence of added GSSG, DsbA33S protein remained specifically disulfide-bonded with DsbB, These in vivo results not only confirm the previous findings that Cys(30) of DsbA is hyper-reactive in vitro but provide evidence that DsbA indeed interacts selectively with DsbB. We propose that the Cys(30)-mediated DsbA-DsbB complex represents an intermediate state of DsbA-DsbB recycling reaction that has been fixed because of the absence of Cys(33) on DsbA.	KYOTO UNIV,INST VIRUS RES,DEPT CELL BIOL,SAKYO KU,KYOTO 60601,JAPAN; PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN	Kyoto University				Kishigami, Satoshi/0000-0001-9447-5100				AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; ITO K, 1993, CELL, V32, P789; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KANAYA E, 1994, J BIOL CHEM, V269, P4273; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; YU J, 1993, J BIOL CHEM, V268, P4326; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P1907, DOI 10.1021/bi00173a038	21	99	101	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17072	17074		10.1074/jbc.270.29.17072	http://dx.doi.org/10.1074/jbc.270.29.17072			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615498	hybrid			2022-12-25	WOS:A1995RK68900005
J	MCGWIRE, GB; SKIDGEL, RA				MCGWIRE, GB; SKIDGEL, RA			EXTRACELLULAR CONVERSION OF EPIDERMAL GROWTH-FACTOR (EGF) TO DES-ARG(53)-EGF BY CARBOXYPEPTIDASE-M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND CARBOXYPEPTIDASE; CANINE KIDNEY-CELLS; UROGASTRONE; PURIFICATION; TRANSCYTOSIS; ENDOSOMES; TRANSPORT; NERVE	Epidermal growth factor (EGF) is a 53-amino-acid mitogenic polypeptide present in a variety of tissues and fluids including kidney, urine, and amniotic fluid, An EGF isoform, des-Arg(53)-EGF, has been identified in urine and is the earliest metabolite generated in target cells upon EGF binding, In this study, purified carboxypeptidase M efficiently released the COOH-terminal arginine residue from EGF with a K-m = 56 mu M, k(cat) = 388 min(-1), and k(cat)/K-m = 6.9 mu M(-1) min(-1), When EGF was incubated with urine or amniotic fluid, des-Arg(53)-EGF was the only metabolite detected, This conversion was blocked by immunoprecipitation with specific antiserum to carboxypeptidase M or by 10 mu M DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid (a carboxypeptidase M inhibitor), indicating that the major EGF metabolizing enzyme in these fluids is carboxypeptidase M. When incubated on a confluent monolayer of Madin-Darby canine kidney (MDCK) cells, EGF was readily converted to a single metabolite, des-Arg(53)-EGF, by carboxypeptidase M, To investigate one possible functional consequence of this conversion, mitogenic activities of EGF and des-Arg(53)-EGF were tested, Both peptides were equipotent in stimulating [H-3]thymidine incorporation in MDCK cells at all doses tested, In addition, inhibition of the conversion of EGF to des-Arg(53)-EGF by the carboxypeptidase M inhibitor did not affect the mitogenic potency of EGF. These data indicate that carboxypeptidase M, present in a variety of cells and biological fluids, can convert EGF to des-Arg(53)-EGF, However, in contrast to many other peptide hormones whose activity depends on a final carboxypeptidase processing step, removal of Arg(53) of EGF is not required for its mitogenic activity.	UNIV ILLINOIS, COLL MED, DEPT PHARMACOL MC 868, CHICAGO, IL 60612 USA; UNIV ILLINOIS, COLL MED, DEPT ANESTHESIOL, PEPTIDE RES LAB, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			McGwire, Gerd/E-3638-2011		NIDDK NIH HHS [DK41431] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041431, R01DK041431, R56DK041431] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRANDLI AW, 1991, J BIOL CHEM, V266, P8560; BURGESS AW, 1988, BIOCHEMISTRY-US, V27, P4977, DOI 10.1021/bi00414a005; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; DEDDISH PA, 1990, J BIOL CHEM, V265, P15083; FAHNESTOCK M, 1991, CURR TOP MICROBIOL, V165, P1; FISHER DA, 1989, ANNU REV PHYSIOL, V51, P67, DOI 10.1146/annurev.physiol.51.1.67; GOODYER PR, 1988, AM J PHYSIOL, V255, pF1191, DOI 10.1152/ajprenal.1988.255.6.F1191; GREGORY H, 1988, REGUL PEPTIDES, V22, P217, DOI 10.1016/0167-0115(88)90034-1; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HAUGUELDEMOUZON S, 1992, J CELL PHYSIOL, V150, P180, DOI 10.1002/jcp.1041500124; HOLLENBERG MD, 1980, MOL PHARMACOL, V17, P314; JAHNKE GD, 1994, ENDOCRINOLOGY, V135, P2022, DOI 10.1210/en.135.5.2022; JORGENSEN PE, 1994, GROWTH FACTORS, V11, P113, DOI 10.3109/08977199409001053; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; MCGWIRE GB, 1995, FASEB J, V9, pA692; NAGAE A, 1993, AM J RESP CELL MOL, V9, P221, DOI 10.1165/ajrcmb/9.2.221; NAGAE A, 1992, J NEUROCHEM, V59, P2201; NICHOLS RA, 1985, DEV NEUROSCI-BASEL, V7, P216, DOI 10.1159/000112290; OLSEN PS, 1984, REGUL PEPTIDES, V10, P37, DOI 10.1016/0167-0115(84)90051-X; PLANCK SR, 1984, J BIOL CHEM, V259, P3053; RAO RK, 1990, PEPTIDES, V11, P1093, DOI 10.1016/0196-9781(90)90136-S; RENFREW CA, 1991, J BIOL CHEM, V266, P4348; SCHAUDIES RP, 1986, ENDOCRINOLOGY, V118, P875, DOI 10.1210/endo-118-2-875; SCHAUDIES RP, 1987, BIOCHEM BIOPH RES CO, V143, P710, DOI 10.1016/0006-291X(87)91412-4; SERVER AC, 1976, J BIOL CHEM, V251, P1188; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SKIDGEL RA, 1984, ANAL BIOCHEM, V140, P520, DOI 10.1016/0003-2697(84)90203-3; SKIDGEL RA, 1984, BIOCHEM PHARMACOL, V33, P3471, DOI 10.1016/0006-2952(84)90122-9; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAN F, 1995, IN PRESS METHODS ENZ, V248; TAN FL, 1989, J BIOL CHEM, V264, P13165; VEHASKARI VM, 1991, AM J PHYSIOL, V261, pF896, DOI 10.1152/ajprenal.1991.261.5.F896; WARDEN DH, 1993, AM J PHYSIOL, V264, pF670, DOI 10.1152/ajprenal.1993.264.4.F670	34	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17154	17158		10.1074/jbc.270.29.17154	http://dx.doi.org/10.1074/jbc.270.29.17154			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615511	hybrid			2022-12-25	WOS:A1995RK68900018
J	VALENZANO, KJ; REMMLER, J; LOBEL, P				VALENZANO, KJ; REMMLER, J; LOBEL, P			SOLUBLE INSULIN-LIKE GROWTH-FACTOR-II MANNOSE 6-PHOSPHATE RECEPTOR CARRIES MULTIPLE HIGH-MOLECULAR-WEIGHT FORMS OF INSULIN-LIKE GROWTH-FACTOR II IN FETAL BOVINE SERUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-II; POLYACRYLAMIDE GELS; BINDING-PROTEINS; RAT; PURIFICATION; ARGININE; RESIDUES; SEQUENCE; VARIANT	We have characterized a soluble form of the insulinlike growth factor II/mannose 6-phosphate receptor (sIGF-II/MPR) and bound ligands from bovine serum. Fetal serum contained 2-8 mg/liter sIGF-II/MPR. Affinity-purified receptor isolated by adsorption to phosphomannan-agarose and elution with mannose 6-phosphate contained nearly stoichiometric amounts of bound 7.5-kDa IGF-II. In addition, at least 12 distinct 12-20-kDa proteins immunologically related to IGF-II also copurified with receptor. Receptor was separated from its associated ligands by acidification and gel filtration chromatography. Sequence analysis revealed that the 12-20-kDa proteins have the same amino termini as mature 7.5-kDa IGF-II. Protease and glycosidase treatments revealed that the different high molecular weight IGF-II species contain an identical COOH-terminal extension that is differentially glycosylated with O-linked sugars. Radiolabeled tracer experiments demonstrated that the sIGF-II/MPR carries similar to 1/4 of the IGF-II in fetal bovine serum. These results support a significant role for sIGF-II/MPR in the transport of circulating IGF-II isoforms during development.	CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,DEPT PHARMACOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NIGMS NIH HHS [GM08339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008339] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNER P, 1989, DIABETOLOGIA, V32, P753, DOI 10.1007/BF00274537; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BANKER GA, 1972, J BIOL CHEM, V247, P5856; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAUSIN C, 1988, BIOCHEM J, V252, P795, DOI 10.1042/bj2520795; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CLEMMONS DR, 1993, MOL REPROD DEV, V35, P368, DOI 10.1002/mrd.1080350409; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DAUGHADAY WH, 1993, P NATL ACAD SCI USA, V90, P5823, DOI 10.1073/pnas.90.12.5823; DAUGHADAY WH, 1987, METHOD ENZYMOL, V146, P248; DEIBLER GE, 1975, J BIOL CHEM, V250, P7931; FIELDER K, 1994, CELL, V77, P625; FILSON AJ, 1993, DEVELOPMENT, V118, P761; FROST AA, 1953, KINETICS MECHANISM, P178; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; GELATO MC, 1989, ENDOCRINOLOGY, V124, P2935, DOI 10.1210/endo-124-6-2935; GELATO MC, 1988, J CLIN ENDOCR METAB, V67, P669, DOI 10.1210/jcem-67-4-669; HAMPTON B, 1989, J BIOL CHEM, V264, P19155; HOFLACK B, 1993, ADV CELL MOL BIOL M, V1, P51; HONEGGER A, 1986, J BIOL CHEM, V261, P569; HUDGINS WR, 1992, J BIOL CHEM, V267, P8153; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KIESS W, 1987, J BIOL CHEM, V262, P12745; KIESS W, 1987, P NATL ACAD SCI USA, V84, P7720, DOI 10.1073/pnas.84.21.7720; KIESS W, 1989, J BIOL CHEM, V264, P4710; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamson G, 1991, Growth Factors, V5, P19, DOI 10.3109/08977199109000268; Lentner C, 1984, GEIGY SCI TABLES, V3, P78; LI M, 1991, Glycobiology, V1, P511, DOI 10.1093/glycob/1.5.511; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MCCUMBER LJ, 1976, BIOCHIM BIOPHYS ACTA, V446, P536, DOI 10.1016/0005-2795(76)90020-9; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NISHIMOTO I, 1991, MODERN CONCEPTS INSU, P517; OKA Y, 1985, J BIOL CHEM, V260, P9435; RECHLER MM, 1991, INSULIN LIKE GROWTH, P87; SAHAGIAN GG, 1982, METHOD ENZYMOL, V83, P392; SAIRAM MR, 1989, FASEB J, V3, P1915, DOI 10.1096/fasebj.3.8.2542111; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; WHITE RM, 1982, J CLIN INVEST, V69, P1239, DOI 10.1172/JCI110563; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANG YWH, 1991, ENDOCRINOLOGY, V128, P1177, DOI 10.1210/endo-128-2-1177; ZUMSTEIN PP, 1985, P NATL ACAD SCI USA, V82, P3169, DOI 10.1073/pnas.82.10.3169	47	48	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16441	16448		10.1074/jbc.270.27.16441	http://dx.doi.org/10.1074/jbc.270.27.16441			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608216	hybrid			2022-12-25	WOS:A1995RH22600084
J	DERGUINI, F; NAKANISHI, K; HAMMERLING, U; CHUA, R; EPPINGER, T; LEVI, E; BUCK, J				DERGUINI, F; NAKANISHI, K; HAMMERLING, U; CHUA, R; EPPINGER, T; LEVI, E; BUCK, J			13,14-DIHYDROXY-RETINOL, A NEW BIOACTIVE RETINOL METABOLITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALL-TRANS-RETINOL; NUCLEAR RECEPTOR; BINDING PROTEIN; ACID; GROWTH; CELLS; DIFFERENTIATION; IDENTIFICATION; ANHYDRORETINOL; FIBROBLASTS	Deprivation of vitamin A (retinol) leads to reduced potential of B cell proliferation and nearly complete block of T cell activation in vitro. Retinol, which is thought to function as a pro-hormone, is enzymatically converted into intracellular messenger molecules. Thus, 14-hydroxy-retro-retinol (14-HRR) is an intracellular messenger molecule linked to activation and growth regulation of lymphocytes; whereas, anhydroretinol, another natural retro-retinoid, is an antagonist of 14-HRR effects. In this article, we describe the isolation, structure determination, synthesis, and biological properties of a new intracellular retinol derivative, 13,14-dihydroxy-retinol (DHR), which also supports the viability of retinol-deprived lymphocytes. DHR is found in numerous cell lines representing a large cross-section of tissues and animals hom insects to mammals. In T lymphocytes the production of DHR and 14-HRR is up-regulated by phorbol ester. DHR is converted to 14-HRR by mild acid treatment, but not by cells; therefore DHR is not a biosynthetic intermediate in the conversion of retinol to 14-HRR. DHR is a distinct end point of retinol metabolism. Although it is linked to cell proliferation, its biological role remains to be determined.	COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027; CORNELL UNIV,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM IMMUNOL,NEW YORK,NY 10021	Columbia University; Cornell University; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA038351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036564] Funding Source: NIH RePORTER; NCI NIH HHS [CA-38351] Funding Source: Medline; NIGMS NIH HHS [GM-36564] Funding Source: Medline; PHS HHS [JM-47599] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baer E, 1939, J BIOL CHEM, V128, P463; BHAT PV, 1979, J LIPID RES, V20, P357; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BREITMAN TR, 1984, METHODS SERUM FREE C, P215; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; BUCK J, 1991, J CELL BIOL, V115, P851, DOI 10.1083/jcb.115.3.851; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DAVIS CY, 1983, J NUTR, V113, P1914, DOI 10.1093/jn/113.10.1914; DENNERT G, 1984, RETINOIDS, V2, P373; DERGUINI F, 1994, BIOCHEMISTRY-US, V33, P623, DOI 10.1021/bi00169a001; DERGUINI F, 1994, ANGEW CHEM INT EDIT, V33, P1837, DOI 10.1002/anie.199418371; Edisbury JR, 1932, BIOCHEM J, V26, P1164, DOI 10.1042/bj0261164; Embree ND, 1939, J BIOL CHEM, V128, P187; EPPINGER TM, 1993, J EXP MED, V178, P1995, DOI 10.1084/jem.178.6.1995; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GONELLA NC, 1982, J AM CHEM SOC, V104, P3775; Harada N., 1983, CIRCULAR DICHROIC SP; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; NOACK K, 1979, HELV CHIM ACTA, V62, P1902, DOI 10.1002/hlca.19790620620; Olive J L, 1969, Bull Soc Chim Fr, V9, P3247; PALMER HJ, 1989, IN VITRO CELL DEV B, V25, P1009; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; VARMA TNR, 1965, J PHARM PHARMACOL, V17, P474, DOI 10.1111/j.2042-7158.1965.tb07707.x; WIESLER WT, 1986, J AM CHEM SOC, V108, P6811, DOI 10.1021/ja00281a063; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239	34	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18875	18880		10.1074/jbc.270.32.18875	http://dx.doi.org/10.1074/jbc.270.32.18875			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642543				2022-12-25	WOS:A1995RN95400030
J	HORTSCH, M; WANG, YME; MARIKAR, Y; BIEBER, AJ				HORTSCH, M; WANG, YME; MARIKAR, Y; BIEBER, AJ			THE CYTOPLASMIC DOMAIN OF THE DROSOPHILA CELL-ADHESION MOLECULE NEUROGLIAN IS NOT ESSENTIAL FOR ITS HOMOPHILIC ADHESIVE PROPERTIES IN S2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; FASCICLIN-I; IMMUNOGLOBULIN SUPERFAMILY; NEURITE OUTGROWTH; NG-CAM; BINDING; EXPRESSION; RNA; COMPONENT; L1	Drosophila neuroglian is a transmembrane glycoprotein that has strong structural and sequence homology to the vertebrate L1 gene family of cell adhesion molecules (Bieber, A J., Snow, P. M., Hortsch, M., Patel, N. H., Jacobs, J. R., Traquina, Z. R., Schilling, J., and Goodman, C. S. (1989) Cell 59, 447-460). Two different neuroglian protein forms that are generated by a differential splicing process are expressed in a tissue-specific fashion by embryonic and larval cells (Hortsch, M., Bieber, A. J., Patel, N. H., and Goodman, C. S. (1990) Neuron 4, 697-709). The two neuroglian polypeptides differ only in their cytoplasmic domains. Both of these neuroglian species, when transfected into and expressed in Drosophila S2 cells, induce the calcium-independent, homophilic aggregation of transformed cells. A third artificial neuroglian protein form was constructed by substituting the neuroglian transmembrane segment and cytoplasmic domains with the glycosyl phosphatidylinositol attachment signal of the Drosophila fasciclin I protein. This cDNA construct generates a glycosyl phosphatidylinositol-anchored form of neuroglian, which retains the ability to induce homophilic cell aggregation when expressed in S2 cells, and was able to interact with both of the two naturally occurring neuroglian polypeptides. These results demonstrate that neuroglian mediates a calcium-independent, homophilic cell adhesion activity and that neither cytoplasmic neuroglian domains nor a direct interaction with cytoskeletal elements is essential for this property.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	HORTSCH, M (corresponding author), UNIV MICHIGAN, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA.			Hortsch, Michael/0000-0002-3750-737X	NICHD NIH HHS [HD29388] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029388, R29HD029388] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BIEBER AJ, 1994, DROSOPHILA MELANOGAS, V44, P683; BRUMMENDORF T, 1993, NEURON, V10, P711; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DOHERTY P, 1992, J NEUROCHEM, V58, P2338, DOI 10.1111/j.1471-4159.1992.tb10984.x; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1992, J NEUROSCI RES, V31, P1, DOI 10.1002/jnr.490310102; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HORTSCH M, 1985, J BIOL CHEM, V260, P9137; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; HORTSCH M, 1990, J BIOL CHEM, V265, P15104; HORTSCH M, 1991, TRENDS BIOCHEM SCI, V16, P283, DOI 10.1016/0968-0004(91)90116-D; HORTSCH M, 1994, DROSOPHILA MELANOGAS, V44, P289; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; LANDMESSER L, 1988, DEV BIOL, V130, P645, DOI 10.1016/0012-1606(88)90358-2; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MIURA M, 1992, J BIOL CHEM, V267, P10752; MORALES G, 1993, NEURON, V11, P1113, DOI 10.1016/0896-6273(93)90224-F; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; RATHJEN FG, 1984, EMBO J, V3, P1; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; REID RA, 1992, J MOL NEUROSCI, V3, P127, DOI 10.1007/BF02919404; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SANTONI MJ, 1987, NUCLEIC ACIDS RES, V15, P8621, DOI 10.1093/nar/15.21.8621; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; WONG MH, 1994, J CELL BIOL, V126, P1089, DOI 10.1083/jcb.126.4.1089; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	48	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18809	18817		10.1074/jbc.270.32.18809	http://dx.doi.org/10.1074/jbc.270.32.18809			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642532	hybrid			2022-12-25	WOS:A1995RN95400019
J	KAGEYAMA, T; ICHINOSE, M; YONEZAWA, S				KAGEYAMA, T; ICHINOSE, M; YONEZAWA, S			PROCESSING OF THE PRECURSORS TO NEUROTENSIN AND OTHER BIOACTIVE PEPTIDES BY CATHEPSIN-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROMEDIN-N-PRECURSOR; ASPARTIC PROTEINASES; CONVERTING ENZYME; NUCLEOTIDE-SEQUENCE; SECRETORY VESICLES; PROCATHEPSIN-E; B-CHAIN; PURIFICATION; SPECIFICITY; CLEAVAGE	Cathepsin E (EC 3.4.23.34), an intracellular aspartic proteinase, was purified from monkey intestine by simple procedures that included affinity chromatography and fast protein liquid chromatography, Cathepsin E was very active at weakly acidic pH in the processing of chemically synthesized precursors such as the precursor to neurotensin/neuromedin, proopiomelanocortin, the precursor to xenopsin, and angiotensinogen. The processing sites were adjacent to a dibasic motif in the former two precursors and at hydrophobic recognition sites in the latter two, The common structural features that specified the processing sites were found in the carboxyl-terminal sequences of the active peptide moieties of these precursors; namely, the sequence Pro-Xaa-X'aa-hydrophobic amino acid was found at positions P4 through P1. Pro at the P4 position is thought to be important for directing the processing sites of the various precursor molecules to the active site of cathepsin E, Although the positions of Xaa and X'aa were occupied by various amino acids, including hydrophobic and aromatic amino acids, some of these had a negative effect, as typically observed when Glu/Arg and Pro were present at the P3 and P2 positions, respectively, Cathepsin D was much less active or was almost inactive in the processing of the precursors to neurotensin and related peptides as a result of the inability of the Pro-directed conformation of the precursor molecules to gain access to the active site of cathepsin D. Thus, the consensus sequence of precursors, Pro-Xaa-X'aa-hydrophobic amino acid, might not only generate the best conformation for cleavage by cathepsin E but might be responsible for the difference in specificities between cathepsins E and D.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 1, BUNKYO KU, TOKYO 113, JAPAN; AICHI HUMAN SERV CTR, INST DEV RES, KASUGAI, AICHI 48003, JAPAN	University of Tokyo	KAGEYAMA, T (corresponding author), KYOTO UNIV, PRIMATE RES INST, DEPT MOLEC & CELLULAR BIOL, INUYAMA, AICHI 484, JAPAN.		Ichinose, Masao/HAB-1645-2022					ATHAUDA SBP, 1991, FEBS LETT, V292, P53, DOI 10.1016/0014-5793(91)80832-N; AZUMA T, 1989, J BIOL CHEM, V264, P16748; Barrett A, 1977, PROTEINASES MAMMALIA, P209; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; CARRAWAY RE, 1987, J BIOL CHEM, V262, P5968; CARRAWAY RE, 1985, J BIOL CHEM, V260, P921; CARRAWAY RE, 1990, PEPTIDES, V11, P747, DOI 10.1016/0196-9781(90)90190-G; CARRAWAY RE, 1987, ENDOCRINOLOGY, V120, P2101, DOI 10.1210/endo-120-5-2101; CARRAWAY RE, 1992, ANN NY ACAD SCI, V668, P1, DOI 10.1111/j.1749-6632.1992.tb27335.x; CARRAWAY RE, 1992, PEPTIDES, V13, P319, DOI 10.1016/0196-9781(92)90115-J; CARRAWAY RE, 1977, ANN NY ACAD SCI, P209; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DOBNER PR, 1987, P NATL ACAD SCI USA, V84, P3516, DOI 10.1073/pnas.84.10.3516; DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899; FINLEY EM, 1994, J BIOL CHEM, V269, P31259; FRIEDMAN TC, 1994, ENDOCRINOLOGY, V135, P854, DOI 10.1210/en.135.3.854; FRUTON JS, 1970, ADV ENZYMOL REL S BI, V33, P401; GALEN FX, 1978, BIOCHIM BIOPHYS ACTA, V523, P485, DOI 10.1016/0005-2744(78)90051-7; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; INAGAMI T, 1977, J BIOL CHEM, V252, P2978; KAGEYAMA T, 1986, J BIOL CHEM, V261, P4395; KAGEYAMA T, 1995, METHOD ENZYMOL, V248, P120; KAGEYAMA T, 1992, J BIOL CHEM, V267, P16450; KAGEYAMA T, 1993, EUR J BIOCHEM, V216, P717, DOI 10.1111/j.1432-1033.1993.tb18191.x; KAY J, 1992, SCAND J CLIN LAB INV, V52, P23, DOI 10.3109/00365519209104651; KISLAUSKIS E, 1988, J BIOL CHEM, V263, P4963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapresle C, 1971, TISSUE PROTEINASES, P135; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; LOH YP, 1985, J BIOL CHEM, V260, P7194; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MATSUZAKI O, 1988, BIOMED RES-TOKYO, V9, P515; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; OKAMURA T, 1981, P NATL ACAD SCI-BIOL, V78, P6940, DOI 10.1073/pnas.78.11.6940; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; POWERS JC, 1977, ACID PROTEASES STRUC, P141, DOI DOI 10.1007/978-1-4757-0719-9_9; RAO C, 1991, ADV EXP MED BIOL, V306, P143; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; SAKU T, 1991, J BIOCHEM-TOKYO, V110, P956, DOI 10.1093/oxfordjournals.jbchem.a123696; SCARBOROUGH PE, 1993, PROTEIN SCI, V2, P264; SCHWARTZ TW, 1986, FEBS LETT, V200, P1, DOI 10.1016/0014-5793(86)80500-2; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; SLATER EE, 1981, METHOD ENZYMOL, V80, P427; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; STEINER DF, 1992, J BIOL CHEM, V267, P23435; SZECSI PB, 1992, SCAND J CLIN LAB INV, V52, P5, DOI 10.3109/00365519209104650; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TANJI M, 1991, BIOMED RES-TOKYO, V12, P339, DOI 10.2220/biomedres.12.339; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; YONEZAWA S, 1988, ARCH BIOCHEM BIOPHYS, V267, P176, DOI 10.1016/0003-9861(88)90021-5; YONEZAWA S, 1987, ARCH BIOCHEM BIOPHYS, V256, P499, DOI 10.1016/0003-9861(87)90607-2	55	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19135	19140		10.1074/jbc.270.32.19135	http://dx.doi.org/10.1074/jbc.270.32.19135			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642580	hybrid			2022-12-25	WOS:A1995RN95400068
J	PFALLER, R; NEWPORT, JW				PFALLER, R; NEWPORT, JW			ASSEMBLY DISASSEMBLY OF THE NUCLEAR-ENVELOPE MEMBRANE - CHARACTERIZATION OF THE MEMBRANE-CHROMATIN INTERACTION USING PARTIALLY PURIFIED REGULATORY ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CHROMOSOME CONDENSATION; FORMATION INVITRO; PROTEIN-KINASE; XENOPUS EGGS; COMPONENTS; INDUCTION; EXTRACTS; VESICLES; BINDING	Assembly and disassembly of the nucleus at mitosis in eukaryotes involves the reversible interaction of chromatin with the nuclear membrane. previously we have shown that this interaction is regulated by the antagonistic activities of a kinase and a phosphatase. The kinase promotes membrane release while the phosphatase stimulates binding. In this report we describe four steps in the purification of the kinase needed for release of membranes from chromatin. We also show that the release kinase and the mitotic initiation kinase, cdcs, are distinct and are separated from each other during the second purification step. Reconstitution experiments using these two kinases demonstrate that the release kinase and cdc2 kinase work in concert to cause membrane release from chromatin. In phosphorylation experiments, protein targets that are substrates for the regulatory release kinase are identified on the membranes. These phosphorylated proteins are candidates for regulated proteins mediating membrane-chromatin interaction. Finally, we find that membrane release activity can also be extracted from membranes by high salt treatment, indicating a possible dual localization of this activity.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; LABBE JC, 1989, EMBO J, V8, P3050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1	18	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19066	19072		10.1074/jbc.270.32.19066	http://dx.doi.org/10.1074/jbc.270.32.19066			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642570				2022-12-25	WOS:A1995RN95400058
J	WU, JJ; EYRE, DR				WU, JJ; EYRE, DR			STRUCTURAL-ANALYSIS OF CROSS-LINKING DOMAINS IN CARTILAGE TYPE-XI COLLAGEN - INSIGHTS ON POLYMERIC ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; AMINO-TERMINAL PROPEPTIDE; IX COLLAGEN; II COLLAGEN; PRO-ALPHA-1(XI) COLLAGEN; NH2-TERMINAL DOMAIN; MOLECULAR-CLONING; CHAIN; IDENTIFICATION; EXPRESSION	The collagen framework of hyaline cartilage is based on copolymers of types II, IX, and XI collagens, Previous studies have established specific covalent interactions between types II and IX collagens, The present study examined cross-linking sites in type XI collagen to define better the full heteropolymeric assembly, Pepsin-solubilized type XI collagen was purified from fetal bovine cartilage, The cross-linking amino acids in the preparation were primarily divalent, borohydride-reducible structures; pyridinoline residues were essentially absent. Individual alpha 1(XI), alpha 2(XI), and alpha 3(XI) chains were resolved by high performance liquid chromatography, Telopeptides still attached by cross-links to helical sites were released by periodate oxidation and identified by microsequencing, Analysis of cross-linked peptides isolated from trypsin digests of each alpha-chain identified the attachment helical sites for the telopeptides. A high degree of interchain specificity was evident in the cross-linking between type XI collagen molecules, The dominant cross-links were between N-telopeptides and the COOH terminus of the triple-helix, consistent with a head-to tail interaction of molecules staggered by 4D (D = 67 nm) periods. In addition, alpha 1(II) C-telopeptide was linked to the amino terminal site of the alpha 1(XI) triple helix. In summary, the results show that type XI collagen molecules are primarily cross-linked to each other in cartilage, implying that a homopolymer is initially formed. Links to type II collagen are also indicated, consistent with an eventual cofibrillar assembly. Analysis of cartilage extracts showed that all three chains, alpha 1(XI), alpha 2(XI), and alpha 3(XI), had at least in part retained their N-propeptides in cartilage matrix and that the alpha 3(XI) chain was the IIB splicing variant product of the COL2A1 gene. Of particular note was the finding that the N-telopeptide cross-linking site in both alpha 1(XI) and alpha 2(XI) is located amino-terminal to the putative N-propeptidase cleavage site, This structural feature provides a potential mechanism for the proteolytic depolymerization of type XI collagen by proteases that can cleave between the cross-link and the triple helix (e.g. stromelysin).			WU, JJ (corresponding author), UNIV WASHINGTON,DEPT ORTHOPAED,ORTHOPAED RES LABS,BOX 356500,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036794, R37AR037318, R37AR036794] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR036794, R37 AR037318, AR36794] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BROWN KE, 1991, J BIOL CHEM, V266, P23268; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; DIAB M, 1994, AM J MED GENET, V49, P402, DOI 10.1002/ajmg.1320490411; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE, P132; Eyre D, 1987, STRUCTURE FUNCTION C, P261; EYRE D R, 1990, P188; EYRE DR, 1984, BIOCHEM BIOPH RES CO, V118, P724, DOI 10.1016/0006-291X(84)91454-2; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; EYRE DR, 1980, SCIENCE, V207, P1315, DOI 10.1126/science.7355290; EYRE DR, 1987, J RHEUMATOL, V14, P25; EYRE DR, 1973, BIOCHEM J, V135, P393, DOI 10.1042/bj1350393; EYRE DR, 1980, BIOCHEM BIOPH RES CO, V92, P403, DOI 10.1016/0006-291X(80)90347-2; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; KIMURA T, 1989, J BIOL CHEM, V264, P13910; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MILLER EJ, 1987, METHOD ENZYMOL, V144, P3; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; NIYIBIZI C, 1994, EUR J BIOCHEM, V224, P943, DOI 10.1111/j.1432-1033.1994.00943.x; OKADA Y, 1992, LAB INVEST, V66, P680; PETIT B, 1993, HISTOCHEMISTRY, V100, P231, DOI 10.1007/BF00269096; PODELL DN, 1978, BIOCHEM BIOPH RES CO, V81, P176, DOI 10.1016/0006-291X(78)91646-7; ROBINS SP, 1983, BIOCHEM J, V215, P175, DOI 10.1042/bj2150175; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SMITH GN, 1987, COLLAGEN REL RES, V7, P17; SMITH GN, 1985, J BIOL CHEM, V260, P761; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; THOM JR, 1991, J BIOL CHEM, V266, P7262; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; WATT SL, 1992, J BIOL CHEM, V267, P20093; WU JJ, 1989, CONNECT TISSUE RES, V20, P241, DOI 10.3109/03008208909023893; WU JJ, 1984, BIOCHEMISTRY-US, V23, P1850, DOI 10.1021/bi00303a041; WU JJ, 1992, J BIOL CHEM, V267, P23007; WU JJ, 1991, J BIOL CHEM, V266, P5625; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5; WU JJ, 1985, ANN NY ACAD SCI, V460, P520, DOI 10.1111/j.1749-6632.1985.tb51228.x; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M	44	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18865	18870		10.1074/jbc.270.32.18865	http://dx.doi.org/10.1074/jbc.270.32.18865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642541	hybrid			2022-12-25	WOS:A1995RN95400028
J	CHEN, YG; DANOFF, A; SHIELDS, D				CHEN, YG; DANOFF, A; SHIELDS, D			THE PROPEPTIDE OF ANGLERFISH PREPROSOMATOSTATIN-I RESCUES PROSOMATOSTATIN-II FROM INTRACELLULAR DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; SECRETORY PATHWAY; PRO-REGION; PROHORMONE CONVERTASES; ASPARTYL PROTEASE; YEAST; EXPRESSION; SOMATOSTATIN; CELLS; PRECURSOR	Polypeptide hormones and neuropeptides are initially synthesized as precursors possessing one or several domains that constitute the propeptide. Previous work from our laboratory demonstrated that expression of anglerfish prosomatostatin-I (proSRIF-I) in rat anterior pituitary GH(3) cells resulted in efficient and accurate cleavage of the prohormone to generate the mature 14-amino acid peptide, SRIF-I. We also implicated the propeptide in mediating intracellular sorting to the trans Golgi network where proteolytic processing is initiated. In contrast, expression of a second form of the precursor, proSRIF-II in GH(3) cells resulted in its intracellular degradation in an acidic, post-trans Golgi network compartment, most probably lysosomes. To further investigate the positive sorting signal present in proSRIF-I, we constructed a chimera comprising the signal peptide and proregion of SRIF-I fused to proSRIF-II and expressed the cDNA in GH(3) cells. Here we demonstrate that the propeptide of SRIF-I rescued proSRIF-II from intracellular degradation quantitatively and diverted it to secretory vesicles. Furthermore, the chimera was processed to SRIF-28, an amino-terminally extended form of the hormone that is the physiological cleavage product of proSRIF-II processing in vivo. Most significantly, the SRIF-I propeptide functioned only in cis as part of the fusion protein and not in trans when expressed as a separate polypeptide. These data suggest that the SRIF-I propeptide may possess a sorting signal for sequestration into the secretory pathway rather than functioning as an intramolecular chaperone to promote protein folding.	ALBERT EINSTEIN COLL MED,DEPT DEV & MOLEC BIOL,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT MED,DIV ENDOCRINOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK21860, DK 18994] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021860, R01DK021860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BOURBONNAIS Y, 1993, EMBO J, V12, P285, DOI 10.1002/j.1460-2075.1993.tb05655.x; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURKE B, 1984, CELL, V36, P847, DOI 10.1016/0092-8674(84)90034-5; CAWLEY NX, 1993, FEBS LETT, V332, P273, DOI 10.1016/0014-5793(93)80648-E; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; DANOFF A, 1991, J BIOL CHEM, V266, P10004; ELGORT A, 1994, J BIOL CHEM, V269, P30668; FABRE E, 1992, J BIOL CHEM, V267, P15049; FISHER JM, 1988, J BIOL CHEM, V263, P16515; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; HOBART P, 1980, NATURE, V288, P137, DOI 10.1038/288137a0; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MAINS RE, 1988, J BIOL CHEM, V263, P7887; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MCCRACKEN AA, 1989, J BIOL CHEM, V264, P20843; MCDONALD JK, 1987, J HISTOCHEM CYTOCHEM, V35, P155, DOI 10.1177/35.2.2878951; NOE BD, 1983, J BIOL CHEM, V258, P1121; NOE BD, 1987, SOMATOSTATIN BASIC C, P59; SEETHALER G, 1991, J CELL BIOL, V114, P1125, DOI 10.1083/jcb.114.6.1125; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SEVARINO KA, 1991, J BIOL CHEM, V266, P18507; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; XU HX, 1994, J BIOL CHEM, V269, P22875; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	39	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18598	18605		10.1074/jbc.270.31.18598	http://dx.doi.org/10.1074/jbc.270.31.18598			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629190	hybrid			2022-12-25	WOS:A1995RM64200070
J	YETTER, A; UDDIN, S; KROLEWSKI, JJ; JIAO, HY; YI, TL; PLATANIAS, LC				YETTER, A; UDDIN, S; KROLEWSKI, JJ; JIAO, HY; YI, TL; PLATANIAS, LC			ASSOCIATION OF THE INTERFERON-DEPENDENT TYROSINE KINASE TYK-2 WITH THE HEMATOPOIETIC-CELL PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOTH-EATEN MICE; TRANSCRIPTION FACTOR; SH2 DOMAIN; PHOSPHORYLATION; ALPHA; EXPRESSION; MUTATIONS; RECEPTOR; GENE; JAK	The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation. We report that Tyk-2 forms stable complexes with the SH2-containing hematopoietic cell phosphatase (HCP) in several hematopoietic cell lines in vivo, and that the IFN alpha-induced tyrosine-phosphorylated form of Tyk-2 is a substrate for the phosphatase activity of HCP in in vitro assays. Furthermore, treatment of cells with the phosphatase inhibitor sodium orthovanadate induces tyrosine phosphorylation of Tyk-2 and an associated 115-kDa protein. Altogether, these data suggest that HCP regulates tyrosine phosphorylation of the Tyk-2 kinase, and thus its function may be important in the transmission of signals generated at the Type I IFN receptor level.	LOYOLA UNIV,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; EDWARD HINES VET ADM MED CTR,HINES,IL 60141; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Columbia University; Columbia University; Cleveland Clinic Foundation				Uddin, Shahab/0000-0003-1886-6710	NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUTCH MJ, 1992, P NATL ACAD SCI USA, V8, P11411; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UDDIN S, 1995, J BIOL CHEM, V270, P7712, DOI 10.1074/jbc.270.13.7712; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	31	96	105	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18179	18182		10.1074/jbc.270.31.18179	http://dx.doi.org/10.1074/jbc.270.31.18179			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629131	hybrid			2022-12-25	WOS:A1995RM64200002
J	LI, YJ; HOANGXUAN, K; DELATTRE, JY; POISSON, M; THOMAS, G; HAMELIN, R				LI, YJ; HOANGXUAN, K; DELATTRE, JY; POISSON, M; THOMAS, G; HAMELIN, R			FREQUENT LOSS OF HETEROZYGOSITY ON CHROMOSOME-9, AND LOW INCIDENCE OF MUTATIONS OF CYCLIN-DEPENDENT KINASE INHIBITORS P15 (MTS2) AND P16 (MTS1) GENES IN GLIOMAS	ONCOGENE			English	Note						GLIOMAS; CKIS; P16 GENE; P15 GENE	DELETIONS; P21	Four cyclin-dependent kinase inhibitors called p15, p16, p21 and p27 have been identified in mammals. Because these proteins participate in the control of cell cycle, they are potential targets for somatic mutations during carcinogenesis. In order to document the prevalence of p15 and p16 alterations in gliomas, we looked for loss of heterozygosity of chromosome 9p where these genes are localized. Allelic losses were observed in 31 of 44 investigated cases. In all cases they involved the p15/ p16 locus. We then looked for mutations in the p16 and p15 genes in 46 gliomas. A total of three DNA variants were observed which were all present in the matched constitutional DNA. They may be unrelated to tumor development. A single somatic mutation was detected. It involved a C to G substitution in codon 93 of p16 and is predicted to change a threonine into an arginine. Taken together, these data indicate that inactivation by point mutation of these two cyclin-dependent kinase inhibitors is uncommon in glial tumor carcinogenesis, but that there may be a tumor suppressor gene on 9p in the vicinity of pld and p15 genes.	INST CURIE,INSERM,U434,F-75231 PARIS 05,FRANCE; HOP LA PITIE SALPETRIERE,NEUROL CLIN,F-75013 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite			Hoang-Xuan, Khe/O-7527-2017					CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENG JQ, 1994, CANCER RES, V54, P5547; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIANI C, 1994, CANCER RES, V54, P6338; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HOANGXUAN K, 1994, INT J CANCER, V60, P478; HUGOT JP, 1994, AM J MED GENET, V52, P207, DOI 10.1002/ajmg.1320520216; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JAMES CD, 1993, CANCER RES, V53, P3674; JEGO N, 1993, ONCOGENE, V8, P209; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLOPADE OI, 1992, CANCER RES, V52, P2523; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SCHMIDT EE, 1994, CANCER RES, V54, P321; SERRANO M, 1994, NATURE, V366, P704; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU L, 1994, CANCER RES, V54, P5262; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737	35	66	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					597	600						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630644				2022-12-25	WOS:A1995RN53000021
J	CAO, YW; CRAWFORD, NM; SCHROEDER, JI				CAO, YW; CRAWFORD, NM; SCHROEDER, JI			AMINO-TERMINUS AND THE FIRST 4 MEMBRANE-SPANNING SEGMENTS OF THE ARABIDOPSIS K+ CHANNEL KAT1 CONFER INWARD-RECTIFICATION PROPERTY OF PLANT-ANIMAL CHIMERIC CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; DROSOPHILA; GENE; CLONING; PROTEIN; FAMILY; MOUSE	The Arabidopsis hyperpolarization-activated (inward-rectifying) K+ channel KAT1 is structurally more similar to animal depolarization-activated (outward-rectifying) K+ channels than to animal hyperpolarization-activated K+ channels. To gain insight into the structural basis for the opposite voltage dependences of plant inward-rectifying and animal outward-rectifying K+ channels, we constructed recombinant chimeric channels between the hyperpolarization-activated K+ channel KAT1 and a Xenopus depolarization-activated K+ channel. We report here that two of the chimeric constructs, which contain the first third of the KAT1 sequence, including the first four membrane-spanning segments (S1-S4) and the linker sequence between the fourth and fifth membrane-spanning segments, express functional channels that retain activation by hyperpolarization, but not depolarization. These two chimeric channels are no longer selective for K+. The chimeras are selective for cations over anions and are permeable to Ca2+. Therefore, unlike animal hyperpolarization-activated K+ channels, in which the carboxyl terminus is important for inward rectification induced by Mg2+ and polyamine block, the plant KAT1 channel has its major determinants for inward rectification in the amino-terminal region, which ends at the end of the S4-S5 linker.	UNIV CALIF SAN DIEGO, DEPT BIOL 0116, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040672, R01GM040672] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40672] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BEZANILLA F, 1994, ANNU REV BIOPH BIOM, V23, P819, DOI 10.1146/annurev.bb.23.060194.004131; BROWN AM, 1993, ANNU REV BIOPH BIOM, V22, P173, DOI 10.1146/annurev.bb.22.060193.001133; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; CAO Y, 1995, IN PRESS PLANT PHYSL; CAO YW, 1992, PLANT CELL, V4, P961, DOI 10.1105/tpc.4.8.961; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MATSUDA H, 1991, ANNU REV PHYSIOL, V53, P289, DOI 10.1146/annurev.ph.53.030191.001445; RIBERA AB, 1990, NEURON, V5, P691, DOI 10.1016/0896-6273(90)90223-3; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SCHROEDER JI, 1987, P NATL ACAD SCI USA, V84, P4108, DOI 10.1073/pnas.84.12.4108; SCHROEDER JI, 1995, FEBS LETT, V363, P157, DOI 10.1016/0014-5793(95)00306-T; Schroeder Julian I., 1994, Methods (Orlando), V6, P70, DOI 10.1006/meth.1994.1009; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; SOREQ H, 1992, METHOD ENZYMOL, V207, P225; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; VANDONGEN AM, 1990, NEURON, V5, P691; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	32	43	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17697	17701		10.1074/jbc.270.30.17697	http://dx.doi.org/10.1074/jbc.270.30.17697			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629068	hybrid			2022-12-25	WOS:A1995RM26600013
J	TSENG, MJ; COON, S; STUENKEL, E; STRUK, V; LOGSDON, CD				TSENG, MJ; COON, S; STUENKEL, E; STRUK, V; LOGSDON, CD			INFLUENCE OF 2ND AND 3RD CYTOPLASMIC LOOPS ON BINDING, INTERNALIZATION, AND COUPLING OF CHIMERIC BOMBESIN/M3 MUSCARINIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; SWISS 3T3 CELLS; SIGNAL TRANSDUCTION; DOWN-REGULATION; LIGAND-BINDING; CARBOXYL-TERMINUS; PEPTIDE RECEPTOR; AGONIST BINDING; G-PROTEINS	In order to investigate the molecular basis for differences in the characteristics of bombesin (Bn) and m3 muscarinic cholinergic (m3 ACh) receptors, chimeric Bn receptors possessing cytoplasmic domains from the m3 ACh receptor were produced. The receptors were expressed in CHO-KI cells and binding, structural, and signal transduction characteristics were analyzed. Cell lines bearing chimeric Bn receptors possessing m3 ACh receptor domains in place of either the second cytoplasmic loop (BM2L), the third cytoplasmic loop (BM3L), or both loops (BM23L) each bound I-125-bombesin with a single affinity that was approximately the same as that of the Bn receptor (5-10 nM). However, Bn receptors possessing the m3 ACh third cytoplasmic loop were severely affected in other respects, Internalization of ligand in Bn and BM2L cells was rapid and extensive (>80% of bound I-125-bombesin was acid-resistant). In contrast, internalization was dramatically reduced in BM3L and BM23L cells (similar to 20% of bound I-125-bombesin was acid-resistant). In Bn or BM2L cells 10 nM bombesin stimulated similar to 10-fold increases in phosphatidylinositol hydrolysis. Activation of Bn receptors also induced an increase in arachidonic acid release (478 +/- 32% of control, n = 3) and large increases in intracellular Ca2+. In contrast, in BM3L or BM23L cells, bombesin had no significant effect on phosphatidylinositol hydrolysis. Furthermore, BM3L receptor activation did not increase arachidonic acid release. However, BM3L and BM23L cells showed a small increase in intracellular Ca2+ at high concentrations of bombesin. These data indicate that the third cytoplasmic loop alone, or together with the second cytoplasmic loop, was not sufficient to transfer the characteristics of G protein interaction between m3 ACh and bombesin receptors. Furthermore, for the Bn receptor, ligand internalization does, whereas formation of the high affinity binding state does not, appear to require activation of G proteins.	UNIV MICHIGAN,DEPT PHYSIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan				Stuenkel, Edward/0000-0001-8225-5725	NIDDK NIH HHS [DK41350] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041350] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENYA RV, 1994, MOL PHARMACOL, V46, P495; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BLUML K, 1994, J BIOL CHEM, V269, P402; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; CURRIE S, 1992, J BIOL CHEM, V267, P6056; DUZIC E, 1992, J BIOL CHEM, V267, P9844; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Gardner Jerry D., 1993, P151; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HERTEL C, 1990, J BIOL CHEM, V265, P17988; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; MANTEY S, 1993, MOL PHARMACOL, V43, P762; MORO O, 1994, J BIOL CHEM, V269, P6651; MORO O, 1993, J BIOL CHEM, V268, P6862; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; WESS J, 1990, MOL PHARMACOL, V38, P872; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YANG J, 1993, MOL PHARMACOL, V44, P1158; YULE DI, 1993, AM J PHYSIOL, V265, pG999, DOI 10.1152/ajpgi.1993.265.5.G999; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	43	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17884	17891		10.1074/jbc.270.30.17884	http://dx.doi.org/10.1074/jbc.270.30.17884			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629092	hybrid			2022-12-25	WOS:A1995RM26600040
J	ALTMANN, F; SCHWIHLA, H; STAUDACHER, E; GLOSSL, J; MARZ, L				ALTMANN, F; SCHWIHLA, H; STAUDACHER, E; GLOSSL, J; MARZ, L			INSECT CELLS CONTAIN AN UNUSUAL, MEMBRANE-BOUND BETA-N-ACETYLGLUCOSAMINIDASE PROBABLY INVOLVED IN THE PROCESSING OF PROTEIN N-GLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; ENZYME; LIVER	The beta-N-acetylglucosaminidase activity in the lepidopteran insect cell line Sf21 has been studied using pyridylaminated oligosaccharides and chromogenic synthetic glycosides as substrates. Ultracentrifugation experiments indicated that the insect cell beta-N-acetylglucosaminidase exists in a soluble and a membrane-bound form. This latter form accounted for two-thirds of the total activity and was associated with vesicles of the same density as those containing GlcNAc transferase I. Partial membrane association of the enzyme was observed with all substrates tested, i.e. 4-nitrophenyl beta-N-acetylglucosaminide, tri-N-acetylchitotriose, and an N-linked biantennary agalactooligosaccharide. Inhibition studies indicated a single enzyme to be responsible for the hydrolysis of all these substrates. With the biantennary substrate, the beta-N-acetylglucosaminidase exclusively removed beta-N-acetylglucosamine from the alpha 1,3-antenna. GlcNAcMan(5)GlcNAc(2), the primary product of GlcNAc-transferase I, was not perceptibly hydrolyzed. beta-N-Acetylglucosaminidases with the same branch specificity were also found in the lepidopteran cell lines Bm-N and Mb-0503. In contrast, beta-N-acetylglucosaminidase activities from rat or frog (Xenopus laevis) liver and from mung bean seedlings were not membrane-bound, and they did not exhibit a strict branch specificity. An involvement of this unusual beta-N-acetylglucosaminidase in the processing of asparagine-linked oligosaccharides in insects is suggested.	UNIV BODENKULTUR WIEN,ZENTRUM ANGEW GENET,A-1180 VIENNA,AUSTRIA	University of Natural Resources & Life Sciences, Vienna	ALTMANN, F (corresponding author), UNIV BODENKULTUR WIEN,INST CHEM,GREGOR MENDELSTR 33,A-1180 VIENNA,AUSTRIA.		Glössl, Josef/H-8208-2013	Glössl, Josef/0000-0002-5042-8828; Altmann, Friedrich/0000-0002-0112-7877; Staudacher, Erika/0000-0001-8282-1424				ALTMANN F, 1992, ANAL BIOCHEM, V204, P215, DOI 10.1016/0003-2697(92)90164-3; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P150, DOI 10.1007/BF00731359; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; IWAMOTO T, 1993, BIOSCI BIOTECH BIOCH, V57, P841, DOI 10.1271/bbb.57.841; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; LONGMORE GD, 1982, CARBOHYD RES, V100, P365, DOI 10.1016/S0008-6215(00)81049-6; MARZ L, 1995, IN PRESS PROTEIN GLY; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; STAUDACHER E, 1992, EUR J BIOCHEM, V207, P987, DOI 10.1111/j.1432-1033.1992.tb17134.x; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; VELARDO MA, 1993, J BIOL CHEM, V268, P17902; VITALE A, 1984, J CELL BIOL, V99, P133, DOI 10.1083/jcb.99.1.133	16	177	181	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17344	17349		10.1074/jbc.270.29.17344	http://dx.doi.org/10.1074/jbc.270.29.17344			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615537	hybrid			2022-12-25	WOS:A1995RK68900048
J	BARBER, GN; JAGUS, R; MEURS, EF; HOVANESSIAN, AG; KATZE, MG				BARBER, GN; JAGUS, R; MEURS, EF; HOVANESSIAN, AG; KATZE, MG			MOLECULAR MECHANISMS RESPONSIBLE FOR MALIGNANT TRANSFORMATION BY REGULATORY AND CATALYTIC DOMAIN VARIANTS OF THE INTERFERON-INDUCED ENZYME RNA-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; INITIATION FACTOR-2-ALPHA; FUNCTIONAL EXPRESSION; P68 KINASE; PHOSPHORYLATION; YEAST; GCN2; AUTOPHOSPHORYLATION; TRANSLATION; HOMOLOGY	Double-stranded RNA-dependent protein kinase (PKR) is suggested to play an important role in both the antiviral and antiproliferative arms of the interferon response. To gain insights into the molecular mechanisms underlying PKR's growth regulatory properties, we examined the biological and biochemical properties of PKR variants containing either a mutation in catalytic domain II (PKR-M1) or a deletion of RNA binding domain I (PKR-M7) in both reticulocyte translation extracts and in vitro kinase assays with purified reagents and compared these results with those using the same mutants stably expressed in vivo. While wild-type PKR (PKR-WT) efficiently inhibited mRNA translation in a reticulocyte extract, the inactive PKR-M1 had no effect. The PKR-M7 mutant was modestly inhibitory in this assay. The PKR-M1 variant was able to reverse the translational inhibitory effects and increased eukaryotic initiation factor (eLF)-2 alpha phosphorylation levels caused by addition of double stranded RNA to reticulocyte extract, whereas PKR-M7 could not. Both PKR-M1 and PKR-M7 functioned as transdominant inhibitors of PKR-WT in our in vitro kinase assays. While the inhibition by PKR-M1 required a vast excess of mutant to shut down PKR function, PKR-M7 inhibited PKR-WT at approximately stoichiometric levels. To complement these experiments, we compared growth rates and alpha phosphorylation levels in transformed cell lines overexpressing either PKR-M1 or PKR-M7. Levels of endogenous eIF-2 alpha phosphorylation were significantly more diminished in PKR-M7 overexpressing cells compared with PKR-M1. These paradoxical data will be discussed in terms of the potential molecular mechanisms underlying malignant transformation caused by the PKR variants.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV MARYLAND,INST BIOTECHNOL,CTR MARINE BIOTECHNOL,BALTIMORE,MD 21202; INST PASTEUR,VIROL & CELLULAR IMMUNOL UNIT,F-75724 PARIS,FRANCE	University of Washington; University of Washington Seattle; University System of Maryland; University of Maryland Baltimore; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris					NCRR NIH HHS [RR 00166] Funding Source: Medline; NIAID NIH HHS [AI-22646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P466; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GALABRU J, 1987, J BIOL CHEM, V262, P15538; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; JAGUS R, 1987, METHOD ENZYMOL, V152, P267; KATZE MG, 1993, SEMIN VIROL, V4, P259, DOI 10.1006/smvy.1993.1022; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LANGLAND JO, 1994, J VIROL, V68, P3821, DOI 10.1128/JVI.68.6.3821-3829.1994; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SHARP TV, 1993, EUR J BIOCHEM, V214, P945, DOI 10.1111/j.1432-1033.1993.tb17998.x; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993	36	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17423	17428		10.1074/jbc.270.29.17423	http://dx.doi.org/10.1074/jbc.270.29.17423			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615547	hybrid			2022-12-25	WOS:A1995RK68900060
J	MERLE, PL; FEIGE, JJ; VERDETTI, J				MERLE, PL; FEIGE, JJ; VERDETTI, J			BASIC FIBROBLAST GROWTH-FACTOR ACTIVATES CALCIUM CHANNELS IN NEONATAL RAT CARDIOMYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR RECEPTOR; SIGNAL TRANSDUCTION; ENDOTHELIAL-CELLS; HEART MYOCYTES; DNA-SYNTHESIS; LOCALIZATION; STIMULATION; BINDING; IDENTIFICATION	Basic fibroblast growth factor (bFGF) is a potent mitogen for many cell lineages including fetal cardiomyocytes. Furthermore, bFGF has been shown to modify gene expression, in vitro, in adult nonproliferative ventricular myocytes. This effect is suspected to be partly responsible for the genetic modifications that occur in vivo under pathophysiological conditions such as ischemia or pressure overload and that lead to myocardial hypertrophy. However, little is known about the first steps of the molecular mechanisms that take place soon after cell activation by bFGF. In this study, using bio chemical and electrophysiological approaches, we have established, on cardiomyocytes cultured from neonatal rat ventricles, that (i) differentiated beating cells express at least two classes of bFGF-receptors having high and low affinity (K-d = 10 +/- 2 pM and 1 +/- 0.5 nM); (ii) the stimulation of these bFGF receptors promotes an increase in the beating frequencies of cultured cardiomyocytes (40 +/- 10%); (iii) bFGF provokes the activation of poorly specific and voltage-independent calcium channels (12pS); (iv) inositol 1,4,5-trisphosphate enhances similar bFGF-induced Ca2+ currents and is therefore suspected to be a second messenger triggering this activation. These results support the presence, in cultured cardiomyocytes, of new calcium channels whose activation after bFGF binding may be partly responsible for the cell response to this growth factor.	CEN, DEPT BIOL MOLEC & STRUCT, INSERM, U244, CEA, F-38054 GRENOBLE 9, FRANCE	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	MERLE, PL (corresponding author), UNIV GRENOBLE 1, CTR PHYSIOL & PHYSIOPHATHOL, ELECTROPHYSIOL MOLEC GRP, BP 53X, F-38041 GRENOBLE, FRANCE.		Feige, Jean-Jacques/M-8905-2017	Feige, Jean-Jacques/0000-0002-1354-7692				ATGHIAS P, 1979, PATHOL BIOL, V27, P13; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERRIDGE MJ, NATURE, V341, P197; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BURGESS W, 1988, ANNR EV BIOCH, V58, P575; CASSCELLS W, 1990, J CLIN INVEST, V85, P433, DOI 10.1172/JCI114456; CHAPRON Y, 1989, BIOCHEM BIOPH RES CO, V158, P527, DOI 10.1016/S0006-291X(89)80081-6; COHEN NM, 1987, J PHYSIOL-LONDON, V391, P169, DOI 10.1113/jphysiol.1987.sp016732; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CUMMINS P, 1993, CARDIOVASC RES, V27, P1150, DOI 10.1093/cvr/27.7.1150; ESTACION M, 1993, CELL CALCIUM, V14, P439, DOI 10.1016/0143-4160(93)90003-O; FEIGE JJ, 1988, J BIOL CHEM, V263, P14023; FERHAT L, 1993, J NEUROCHEM, V61, P1105, DOI 10.1111/j.1471-4159.1993.tb03626.x; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JIN Y, 1994, J MOL CELL CARDIOL, V26, P1449, DOI 10.1006/jmcc.1994.1164; KAN M, 1991, METHOD ENZYMOL, V198, P158; KARDAMI E, 1989, J CELL BIOL, V109, P1865, DOI 10.1083/jcb.109.4.1865; KATZBERG AA, 1977, AM J ANAT, V149, P489, DOI 10.1002/aja.1001490406; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; MOGAMI H, 1993, BIOCHEM BIOPH RES CO, V196, P650, DOI 10.1006/bbrc.1993.2299; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOOLENAAR WH, 1986, J EXP BIOL, V124, P359; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1988, J CELL PHYSIOL, V136, P537, DOI 10.1002/jcp.1041360321; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PINSON A, 1973, BIOCHIMIE, V55, P1261; RABKIN SW, 1987, BIOCHEM BIOPH RES CO, V146, P889, DOI 10.1016/0006-291X(87)90614-0; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Savona C, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000291; SAWYER ST, 1981, BIOCHEMISTRY-US, V20, P6280, DOI 10.1021/bi00524a057; SCHANNE OF, 1990, J APPL PHYSIOL, V29, P892; SCHNEIDER MD, 1992, BASIC RES CARDIOL, V87, P33; SOLTOFF SP, 1988, ANNU REV PHYSIOL, V50, P207; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; SPIRITO P, 1991, CIRCULATION, V84, P322, DOI 10.1161/01.CIR.84.1.322; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VETTER U, 1988, BASIC RES CARDIOL, V83, P647, DOI 10.1007/BF01906959; WALICKE PA, 1989, J BIOL CHEM, V264, P4120	42	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17361	17367		10.1074/jbc.270.29.17361	http://dx.doi.org/10.1074/jbc.270.29.17361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615540	hybrid			2022-12-25	WOS:A1995RK68900051
J	RAMAMOORTHY, JD; RAMAMOORTHY, S; PAPAPETROPOULOS, A; CATRAVAS, JD; LEIBACH, FH; GANAPATHY, V				RAMAMOORTHY, JD; RAMAMOORTHY, S; PAPAPETROPOULOS, A; CATRAVAS, JD; LEIBACH, FH; GANAPATHY, V			CYCLIC AMP-INDEPENDENT UP-REGULATION OF THE HUMAN SEROTONIN TRANSPORTER BY STAUROSPORINE IN CHORIOCARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INDUCED NEURITE OUTGROWTH; HIGH-AFFINITY BINDING; NOREPINEPHRINE TRANSPORTER; HUMAN PLATELETS; RAT-BRAIN; EXPRESSION; INHIBITION; STIMULATION; DOPAMINE	Treatment of confluent cultures of JAR human placental choriocarcinoma cells with staurosporine caused a marked stimulation of serotonin transport activity in these cells, The stimulatory effect was noticeable at nanomolar concentrations of staurosporine, and a treatment time of >4 h was required for staurosporine to elicit the effect, At 40 nM and with a treatment time of 16 h, the stimulation of the transport activity was 3.5-6.0-fold, None of the several other protein kinase inhibitors tested had similar effect except KT 5720, a protein kinase A inhibitor, which showed a small but significant (similar to 1.4-fold) stimulatory effect at a concentration of 5 mu M. Blockade of RNA synthesis and protein synthesis in the cells prevented completely the stimulation of the trans port activity induced by staurosporine. The stimulation was observed not only in intact cells but also in plasma membrane vesicles prepared from staurosporine-treated cells, The stimulation was accompanied by a 5-7-fold increase in the steady state levels of the trans porter specific mRNAs, by a 7-fold increase in the maximal velocity of the transport process, and by a 6-fold increase in the transporter density in the plasma membrane, Even though both staurosporine and cholera toxin had similar effects on the serotonin transport activity in these cells, the effect was not additive when the cells were treated with both reagents together. While treatment of the cells with cholera toxin markedly elevated intracellular levels of cAMP, staurosporine did not have any effect on the cellular levels of this cyclic nucleotide. It is concluded that staurosporine up-regulates the serotonin transport activity in JAR cells by increasing the steady state levels of the serotonin transporter mRNA and by the consequent increase in the transporter density in the plasma membrane and that the process involves a cAMP-independent signaling pathway.	MED COLL GEORGIA,DEPT BIOCHEM & MOLEC BIOL,AUGUSTA,GA 30912; MED COLL GEORGIA,DEPT PHARMACOL & TOXICOL,AUGUSTA,GA 30912	University System of Georgia; Augusta University; University System of Georgia; Augusta University			Andreas, Papapetropoulos/AAJ-3089-2020	Papapetropoulos, Andreas/0000-0002-4253-5930	NICHD NIH HHS [HD 27487] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027487] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; BOJA JW, 1992, SYNAPSE, V12, P27, DOI 10.1002/syn.890120104; BOSIN TR, 1990, BIOCHEM PHARMACOL, V40, P723, DOI 10.1016/0006-2952(90)90307-7; BRANDSCH M, 1994, BBA-BIOMEMBRANES, V1192, P177, DOI 10.1016/0005-2736(94)90116-3; COOL DR, 1991, J BIOL CHEM, V266, P15750; COOL DR, 1990, BIOCHEMISTRY-US, V29, P1818, DOI 10.1021/bi00459a022; FOGUET M, 1993, EMBO J, V12, P903, DOI 10.1002/j.1460-2075.1993.tb05731.x; GANAPATHY V, 1994, PLACENTA, V15, P785, DOI 10.1016/S0143-4004(05)80181-X; GANAPATHY V, 1995, PLACENTAL TOXICOLOGY, P161; GANAPATHY V, 1993, TROPHOBLAST RES, V7, P35; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HASHIMOTO S, 1989, EXP CELL RES, V184, P351, DOI 10.1016/0014-4827(89)90334-0; JAYANTHI LD, 1993, BIOCHEMISTRY-US, V32, P12178, DOI 10.1021/bi00096a030; JAYYANATHI LD, 1994, J BIOL CHEM, V269, P14424; KULANTHAIVEL P, 1991, BIOCHEM J, V277, P53, DOI 10.1042/bj2770053; LAUNAY JM, 1994, AM J PHYSIOL, V266, pR526, DOI 10.1152/ajpregu.1994.266.2.R526; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; LESCH KP, 1994, J NEURAL TRANSM-GEN, V95, P157, DOI 10.1007/BF01276434; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; LESCH KP, 1993, J NEURAL TRANSM-GEN, V91, P67, DOI 10.1007/BF01244919; MARCZIN N, 1992, CIRC RES, V70, P326, DOI 10.1161/01.RES.70.2.326; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; MYERS CL, 1989, AM J PHYSIOL, V257, pL253, DOI 10.1152/ajplung.1989.257.4.L253; NISHIO H, 1995, EUR J PHARM-MOLEC PH, V288, P149, DOI 10.1016/0922-4106(95)90189-2; PRASAD PD, 1994, PLACENTA, V15, P267, DOI 10.1016/0143-4004(94)90018-3; RAFFIONI S, 1995, J BIOL CHEM, V270, P7568, DOI 10.1074/jbc.270.13.7568; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; RAMAMOORTHY S, 1992, AM J PHYSIOL, V262, pC1119; RASOULY D, 1992, MOL PHARMACOL, V42, P35; TISCHLER AS, 1990, J NEUROCHEM, V55, P1159, DOI 10.1111/j.1471-4159.1990.tb03120.x; WALL SC, 1993, MOL PHARMACOL, V43, P264; ZHANG L, 1994, J BIOL CHEM, V269, P10270	35	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17189	17195		10.1074/jbc.270.29.17189	http://dx.doi.org/10.1074/jbc.270.29.17189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615516	hybrid			2022-12-25	WOS:A1995RK68900023
J	SANCHEZ, MA; ZEOLI, D; KLAMO, EM; KAVANAUGH, MP; LANDFEAR, SM				SANCHEZ, MA; ZEOLI, D; KLAMO, EM; KAVANAUGH, MP; LANDFEAR, SM			A FAMILY OF PUTATIVE RECEPTOR-ADENYLATE CYCLASES FROM LEISHMANIA-DONOVANI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; GUANYLATE-CYCLASE; CYCLIC-AMP; EXPRESSION; GENE; DIFFERENTIATION; ACID; IDENTIFICATION; CRUZI; PROMASTIGOTES	Leishmania parasites are exposed to pronounced changes in their environment during their life cycle as they migrate from the sandfly midgut to the insect proboscis and then into the phagolysosomes of the vertebrate macrophages. The developmental transformations that produce each life cycle stage of the parasite may be signaled in part by binding of environmental ligands to receptors which mediate transduction of extracellular signals. We have identified a family of five clustered genes in Leishmania donovani which may encode signal transduction receptors. The coding regions of two of these genes, designated rac-A and rac-B, have been sequenced and shown to code for proteins with an NH2-terminal hydrophilic domain, an intervening putative transmembrane segment, and a COOH-terminal domain that has high sequence identity to the catalytic domain from adenylate cyclases in other eukaryotes. We have expressed the receptor-adenylate cyclase protein (RAC)-A protein in Xenopus oocytes and demonstrated that it functions as an adenylate cyclase. Although RAC-B exhibits no catalytic activity when expressed in oocytes, co-expression of RAC-A and RAC-B negatively regulates the adenylate cyclase activity of RAC-A, suggesting that these two proteins interact in the membrane. Furthermore, a truncated version of RAC-A functions as a dominant negative mutant that inhibits the catalytic activity of the wild type receptor. The rac-A and rac-B genes encode developmentally regulated mRNAs which are expressed in the insect stage but not in the mammalian host stage of the parasite life cycle.	OREGON HLTH SCI UNIV,DEPT MOLEC MICROBIOL & IMMUNOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University				Landfear, Scott/0000-0002-1643-6664	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048709] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25920, AI01162] Funding Source: Medline; NIGMS NIH HHS [GM48709] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; CAIRNS BR, 1989, P NATL ACAD SCI USA, V85, P2130; Chang K.-P., 1990, P79; CHANG KP, 1980, SCIENCE, V209, P1240, DOI 10.1126/science.7403880; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1987, SCIENCE, V234, P1582; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; COMEAU AM, 1986, MOL BIOCHEM PARASIT, V21, P161, DOI 10.1016/0166-6851(86)90019-8; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRAIDENRAICH D, 1993, P NATL ACAD SCI USA, V90, P10140, DOI 10.1073/pnas.90.21.10140; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GONZALESPERDOMO M, 1988, EXP PARASITOL, V66, P205, DOI 10.1016/0014-4894(88)90092-6; GOY MF, 1987, J NEUROCHEM, V48, P954, DOI 10.1111/j.1471-4159.1987.tb05610.x; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; LANGFORD CK, 1994, J BIOL CHEM, V269, P17939; LANGFORD CK, 1992, EXP PARASITOL, V74, P360, DOI 10.1016/0014-4894(92)90161-3; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MANCINI PE, 1981, MOL BIOCHEM PARASIT, V3, P19, DOI 10.1016/0166-6851(81)90074-8; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PAVLOFF MS, 1990, J NEUROCHEM, V55, P788, DOI 10.1111/j.1471-4159.1990.tb04561.x; RANGELALDAO R, 1987, MOL BIOCHEM PARASIT, V22, P39, DOI 10.1016/0166-6851(87)90067-3; REED SL, 1985, INFECT IMMUN, V49, P844, DOI 10.1128/IAI.49.3.844-847.1985; ROSS DT, 1991, EMBO J, V10, P2047, DOI 10.1002/j.1460-2075.1991.tb07735.x; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1987, P NATL ACAD SCI USA, V74, P5463; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TILLY BC, 1992, J BIOL CHEM, V267, P9470; VIERA J, 1987, METHOD ENZYMOL, V153, P3; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTER RD, 1982, MOL BIOCHEM PARASIT, V6, P287, DOI 10.1016/0166-6851(82)90061-5; WALTER RD, 1981, BIOCH PARASITES, P152	44	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17551	17558		10.1074/jbc.270.29.17551	http://dx.doi.org/10.1074/jbc.270.29.17551			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615561	Green Published, hybrid			2022-12-25	WOS:A1995RK68900077
J	DECESARE, D; VALLONE, D; CARACCIOLO, A; SASSONECORSI, P; NERLOV, C; VERDE, P				DECESARE, D; VALLONE, D; CARACCIOLO, A; SASSONECORSI, P; NERLOV, C; VERDE, P			HETERODIMERIZATION OF C-JUN WITH ATF-2 AND C-FOS IS REQUIRED FOR POSITIVE AND NEGATIVE REGULATION OF THE HUMAN UROKINASE ENHANCER	ONCOGENE			English	Article						C-JUN; ATF-2; HETERODIMERIZATION UROKINASE; ENHANCER	ELEMENT-BINDING PROTEIN; RESPONSE ELEMENT; PLASMINOGEN-ACTIVATOR; TRANSCRIPTION FACTORS; STROMELYSIN PROMOTER; LEUCINE ZIPPER; CYCLIC-AMP; AP-1; PHOSPHORYLATION; CRE-BP1	Dimerization plays a pivotal role in modulating the activity of the c-Jun proto-oncogene product. Heterodimerization with activating transcription factor-2 (ATF-2) alters the DNA-binding specificity of c-Jun, allowing its targeting to several cAMP responsive element (CRE)related sequences, which control a subset of AP-1-responsive genes, Here me show that a c-Jun/ATF-2 heterodimer binds to the AP-1 site (nPA 5'-TRE) essential for the activity of the human urokinase enhancer, conferring on this element several distinctive regulatory properties. The c-Jun/ATF-2 heterodimer was identified by binding competition assays, u.v. cross linking, and monospecific antibodies, In vitro binding studies revealed that the uPA 5'-TRE sequence is recognized by the cyclic AMP-unresponsive ATF-2 factor, but not by the cyclic AMP-inducible CREB, In addition, in vivo studies suggest that ATF-2 can mediate, at the same time, the activation of the c-Jun/ATF-2 site and the repression of the canonical. collagenase AP-1 site. We report that heterodimerization with c-Fos does not increase the binding of c-Jun to the uPA 5'-TRE, in contrast to the increased binding at a consensus AP-1 site. Our data further suggest that c-Fos can act as a repressor of the c-Jun/ATF-2 binding site, revealing an important functional difference, with respect to canonical AP-I elements.	INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; CU STRASBOURG,IGBMC,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV COPENHAGEN,DEPT MOLEC CELL BIOL,DK-1353 COPENHAGEN K,DENMARK	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Copenhagen								ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BENBROOK DM, 1990, ONCOGENE, V5, P295; Blasi F, 1990, Semin Cancer Biol, V1, P117; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOEFFLER JP, 1992, J INVEST DERMATOL, V98, pS21, DOI 10.1111/1523-1747.ep12462126; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE JS, 1994, J BIOL CHEM, V4, P2887; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR PF, 1990, ONCOGENE, V5, P451; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NOMURA N, 1993, J BIOL CHEM, V268, P4259; PESCINI R, 1994, J BIOL CHEM, V269, P1159; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYSECK RP, 1991, ONCOGENE, V6, P533; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STACEY KJ, 1991, NUCLEIC ACIDS RES, V19, P6839; TAKEDA J, 1991, ONCOGENE, V6, P1009; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	47	110	110	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					365	376						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624151				2022-12-25	WOS:A1995RK95700017
J	HUNYADY, L; BOR, M; BAUKAL, AJ; BALLA, T; CATT, KJ				HUNYADY, L; BOR, M; BAUKAL, AJ; BALLA, T; CATT, KJ			A CONSERVED NPLFY SEQUENCE CONTRIBUTES TO AGONIST BINDING AND SIGNAL-TRANSDUCTION BUT IS NOT AN INTERNALIZATION SIGNAL FOR THE TYPE-1 ANGIOTENSIN-II RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ADRENAL GLOMERULOSA CELLS; POTENTIAL MECHANISM; CARBOXYL-TERMINUS; LIGAND-BINDING; MUTAGENESIS; SEQUESTRATION; GENERATION; RESIDUES	A conserved NPX(2-3)Y sequence that is located in the seventh transmembrane helix of many G protein-coupled receptors has been predicted to participate in receptor signaling and endocytosis, The role of this sequence (NPLFY) in angiotensin II receptor function was studied in mutant and wild-type rat type la angiotensin II receptors transiently expressed in COS-7 cells. The ability of the receptor to interact with G proteins and to stimulate inositol phosphate responses was markedly impaired by alanine replacement of Asn(298) and was reduced by replacement of Pro(299) or Tyr(302). The F301A mutant receptor exhibited normal G protein coupling and inositol phosphate responses, and the binding of the peptide antagonist, [Sar(1),Ile(8)]angiotensin II, was only slightly affected, However, its affinity for angiotensin II and the nonpeptide antagonist losartan was reduced by an order of a magnitude, suggesting that angiotensin II and losartan share an intramembrane binding site, possibly through their aromatic moieties. None of the agonist-occupied mutant receptors, including Y302A and triple alanine replacements of Phe(301), Tyr(302), and Phe(304), showed substantial changes in their internalization kinetics, These findings demonstrate that the NPLFY sequence of the type 1a angiotensin II receptor is not an important determinant of agonist-induced internalization, However, the Phe(301) residue contributes significantly to agonist binding, and Asn(298) is required for normal receptor activation and signal transduction.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Balla, Tamas/0000-0002-9077-3335				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BALLA T, 1991, J BIOL CHEM, V266, P24719; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERNSTEIN KE, 1993, AM J KIDNEY DIS, V22, P745, DOI 10.1016/S0272-6386(12)80441-0; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BUMPUS FM, 1977, FED PROC, V36, P2128; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CATT KJ, 1991, J BIOENERG BIOMEMBR, V23, P7; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; FINDLAY JBC, 1993, BIOCHEM SOC T, V21, P869, DOI 10.1042/bst0210869; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; JI H, 1994, J BIOL CHEM, V269, P16583; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARIE J, 1994, J BIOL CHEM, V269, P20815; MORO O, 1993, J BIOL CHEM, V268, P6862; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SALTMAN S, 1975, ENDOCRINOLOGY, V97, P275, DOI 10.1210/endo-97-2-275; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHULTZ G, 1993, ARZNEIMITTELFORSCUNG, V42, P229; SLICE LW, 1994, J BIOL CHEM, V269, P21755; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; YU SS, 1993, J BIOL CHEM, V268, P337; ZHOU W, 1994, MOL PHARMACOL, V45, P165	40	106	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16602	16609		10.1074/jbc.270.28.16602	http://dx.doi.org/10.1074/jbc.270.28.16602			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622467	hybrid			2022-12-25	WOS:A1995RJ34700024
J	KIS, K; BACHER, A				KIS, K; BACHER, A			SUBSTRATE CHANNELING IN THE LUMAZINE SYNTHASE RIBOFLAVIN SYNTHASE COMPLEX OF BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOGLYCERATE KINASE; TRYPTOPHAN SYNTHASE; MECHANISM; PURIFICATION; SYNTHETASE; SUBUNIT	The lumazine synthase/riboflavin synthase complex of Bacillus subtilis consists of an icosahedral capsid of 60 beta subunits surrounding a core of three alpha subunits. The beta subunits catalyze the condensation of 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione (PYR) with 3,4-dihydroxy-2-butanone 4-phosphate (DHB) yielding 6,7-dimethyl-8-ribityllumazine. This intermediate is converted to riboflavin by the alpha subunits via an unusual dismutation. The second product of this reaction is PYR, which is also a substrate of the beta subunits and can be recycled in the catalytic process. Sigmoidal kinetics would be expected for the formation of riboflavin from PYR and DHB and are indeed observed with mixtures of artifactual beta(60) capsids and alpha subunit trimers. In contrast, the formation of riboflavin from PYR and DHB by the native alpha(3) beta(60) is characterized by a finite initial rate, which is similar to the rate of lumazine formation. Most notably, the rate of riboflavin formation has its maximum value at t = 0 and decreases dramatically after the consumption of PYR and DHB despite the presence of transiently formed lumazine. These data suggest that a significant fraction of DHB is converted to riboflavin by substrate channeling, which is conducive to an improved overall catalytic rate of riboflavin formation at low substrate concentrations. The channel is leaky, and the intermediate lumazine is therefore transiently accumulated in the bulk solution. The partitioning factor relating the direct formation of riboflavin via substrate channeling and the formation of transient 6,7-dimethyl-8-ribityllumazine increases at low concentrations of the substrates PYR and DHB and has a maximum value at pH 7.5. Channeling appears to result from the compartmentalization of the alpha subunits inside the icosahedral beta subunit capsid whose catalytic sites are located close to the inner capsid surface.			KIS, K (corresponding author), TECH UNIV MUNICH,DEPT ORGAN CHEM & BIOCHEM,LICHTENBERGSTR 4,D-85747 GARCHING,GERMANY.							ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BACHER A, 1986, METHOD ENZYMOL, V122, P192; BACHER A, 1980, J BIOL CHEM, V255, P632; BACHER A, 1986, J MOL BIOL, V187, P75, DOI 10.1016/0022-2836(86)90407-9; BACHER A, 1978, J BACTERIOL, V134, P476, DOI 10.1128/JB.134.2.476-482.1978; BACHER A, 1990, CHEM BIOCH FLAVOENZY, V1, P215; BRESLER SE, 1976, GENETIKA+, V12, P83; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; CRESSWELL RM, 1960, J CHEM SOC, P4776, DOI 10.1039/jr9600004776; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; HARVEY RA, 1966, J BIOL CHEM, V241, P2120; KIS K, 1995, BIOCHEMISTRY-US, V34, P2883, DOI 10.1021/bi00009a019; KVASSMAN J, 1989, EUR J BIOCHEM, V186, P261, DOI 10.1111/j.1432-1033.1989.tb15204.x; KVASSMAN J, 1989, EUR J BIOCHEM, V186, P265, DOI 10.1111/j.1432-1033.1989.tb15205.x; LADENSTEIN R, 1994, EUR J BIOCHEM, V223, P1007, DOI 10.1111/j.1432-1033.1994.tb19079.x; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LADENSTEIN R, 1986, J MOL BIOL, V187, P87, DOI 10.1016/0022-2836(86)90408-0; NEUBERGER G, 1986, BIOCHEM BIOPH RES CO, V127, P175; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; Plaut G. W., 1975, CHEM BIOL PTERIDINES, P101; PLAUT GWE, 1970, BIOCHEMISTRY-US, V9, P771, DOI 10.1021/bi00806a010; Plaut GWE, 1971, METHODS ENZYMOL B, V18, P515; RITSERT K, 1995, IN PRESS J MOL BIOL; SCHOTT K, 1990, J BIOL CHEM, V265, P4204; SCHOTT K, 1990, J BIOL CHEM, V265, P12686; SEDLMAIER H, 1987, Z NATURFORSCH C, V42, P425; VOLK R, 1990, J BIOL CHEM, V265, P19479	27	77	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16788	16795		10.1074/jbc.270.28.16788	http://dx.doi.org/10.1074/jbc.270.28.16788			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622491	hybrid			2022-12-25	WOS:A1995RJ34700052
J	SEPPLORENZINO, L; MA, ZP; LEBWOHL, DE; VINITSKY, A; ROSEN, N				SEPPLORENZINO, L; MA, ZP; LEBWOHL, DE; VINITSKY, A; ROSEN, N			HERBIMYCIN-A INDUCES THE 20S PROTEASOME-DEPENDENT AND UBIQUITIN-DEPENDENT DEGRADATION OF RECEPTOR TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; ROUS-SARCOMA VIRUS; MULTICATALYTIC PROTEINASE COMPLEX; RAT-KIDNEY CELLS; TRANSFORMING ACTIVITY; CONSERVED FEATURES; INSULIN-RECEPTOR; INHIBITION; GROWTH; IDENTIFICATION	Herbimycin A is an ansamycin antibiotic isolated as an agent that reverses morphological transformation induced by v-src. Although herbimycin A is widely used as a tool for inhibiting multiple tyrosine protein kinases and tyrosine kinase-activated signal transduction, its mechanism of action is not well defined and includes a decrease in both tyrosine kinase protein levels and activity (Uehara, Y., Murakami, Y., Sugimoto, Y., and Mizuno, S, (1989) Cancer Res. 49, 780-785). We now show that herbimycin A induces a profound decrease in the total cellular activity of transmembrane tyrosine kinase receptors, such as insulin-like growth factor, insulin, and epidermal growth factor receptors. A substantial proportion of the in vivo inhibition could be explained by an increase in the rate of degradation, The enhanced degradation of insulin-like growth factor-insulin receptor was prevented by inhibitors of the 20S proteasome, whereas neither lysosomotropic agents nor general serine- and cysteine-protease inhibitors were active in preventing receptor degradation induced by herbimycin A. Moreover, in a temperature-sensitive mutant cell line defective in the E1-catalyzed activation of ubiquitin, herbimycin A treatment at the restrictive temperature did not result in the degradation of insulin receptor, These results suggest that herbimycin A represents a novel class of drug that targets the degradation of tyrosine kinases by the 20S proteasome. The ubiquitin dependence of this process indicates that this degradation of tyrosine kinases might involve the 20S proteasome as the proteolytic core of the ubiquitin-dependent 26S protease.	MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, NEW YORK, NY 10021 USA; CUNY MT SINAI SCH MED, DEPT PHARMACOL, NEW YORK, NY 10029 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Rosen, Neal/ABF-2677-2020		NCI NIH HHS [CA 58706-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058706] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; BOLEN JB, 1993, ONCOGENE, V8, P2025; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DICKSON RB, 1986, CANCER RES, V46, P1707; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FUKAZAWA H, 1990, BIOCHEM BIOPH RES CO, V173, P276, DOI 10.1016/S0006-291X(05)81053-8; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Knop M, 1993, CURR OPIN CELL BIOL, V5, P990, DOI 10.1016/0955-0674(93)90082-2; KULKA RG, 1988, J BIOL CHEM, V263, P15726; MILLER P, 1994, CANCER RES, V54, P2724; MURAKAMI Y, 1994, BIOCHEM J, V301, P63, DOI 10.1042/bj3010063; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PAPA V, 1993, CANCER RES, V53, P3736; PFITZNER KE, 1965, J AM CHEM SOC, V87, P5661, DOI 10.1021/ja00952a026; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SEPPLORENZINO L, 1994, CELL GROWTH DIFFER, V5, P1077; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WILK S, 1983, J NEUROCHEM, V41, P69, DOI 10.1111/j.1471-4159.1983.tb11815.x; WILKS AF, 1993, ADV CANCER RES, V60, P43	39	177	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16580	16587		10.1074/jbc.270.28.16580	http://dx.doi.org/10.1074/jbc.270.28.16580			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622464	hybrid			2022-12-25	WOS:A1995RJ34700021
J	FORNE, T; ROSSI, F; LABOURIER, E; ANTOINE, E; CATHALA, G; BRUNEL, C; TAZI, J				FORNE, T; ROSSI, F; LABOURIER, E; ANTOINE, E; CATHALA, G; BRUNEL, C; TAZI, J			DISRUPTION OF BASE-PAIRED U4-CENTER-DOT-U6 SMALL NUCLEAR RNAS INDUCED BY MAMMALIAN HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-C PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							U6 SNRNA; 3' END; ACTIVE-SITE; SPLICEOSOME; BINDING; U2; PURIFICATION; PARTICLES; U5; U4	Due to 3' end modifications, mammalian U6 small nuclear RNA (snRNA) is heterogeneous in size. The major form terminates with five U residues and a 2',3'-cyclic phosphate, but multiple RNAs containing up to 12 U residues have a 3'-OH end. They are labeled in the presence of [alpha-P-32]UTP by the terminal uridylyl transferase activity present in HeLa cell nuclear extracts. That these forms all enter the U6 snRNA-containing particles, U4 . U6, U4 . U5 . U6, and the spliceosome, has been demonstrated previously. Here, we report an interaction between the heterogeneous nuclear ribonucleoprotein (hnRNP) C protein, an abundant nuclear pre-mRNA binding protein, and the U6 snRNAs that have the longest uridylate stretches. This U6 snRNA subset is free of any one of the other snRNPs, since anti-Sm antibodies failed to immunoprecipitate hnRNP C protein. Furthermore, isolated U4 . U6 snRNPs containing U6 snRNAs with long oligouridylate stretches are disrupted upon binding of hnRNP C protein either purified from HeLa cells or produced as recombinant protein from Escherichia coli. In view of these data and our previous proposal that the U6 snRNA active in splicing has 3'-OH end, we discuss a model where the hnRNP C protein has a decisive function in the catalytic activation of the spliceosome by allowing the release of U4 snRNP.	UNIV MONTPELLIER 1,INST GENET MOLEC,CNRS,UMR 9942,F-34033 MONTPELLIER 1,FRANCE; UNIV MONTPELLIER 2,CNRS,F-34033 MONTPELLIER 1,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Forne, Thierry/D-3718-2013	Forne, Thierry/0000-0002-9179-1551; Labourier, Emmanuel/0000-0001-8010-0674; Tazi, Jamal/0000-0002-1949-8748				BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAUGERON MC, 1992, NUCLEIC ACIDS RES, V14, P3625; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GRABOWSKI PJ, 1986, SCIENCE, V223, P1294; HINTERBERGER M, 1983, J BIOL CHEM, V258, P2604; HIRAI H, 1988, J BIOCHEM-TOKYO, V104, P991, DOI 10.1093/oxfordjournals.jbchem.a122597; HUANG M, 1994, MOL CELL BIOL, V14, P518, DOI 10.1128/MCB.14.1.518; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KHELLIL S, 1991, NUCLEIC ACIDS RES, V19, P877, DOI 10.1093/nar/19.4.877; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LELAYTAHA MN, 1986, J MOL BIOL, V189, P519, DOI 10.1016/0022-2836(86)90321-9; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; Moore M., 1993, RNA WORLD, P303; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; REDDY R, 1987, J BIOL CHEM, V262, P75; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEPHANO JE, 1984, CELL, V36, P145; STRAUSS EJ, 1991, GENE DEV, V5, P773; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAZI J, 1993, MOL CELL BIOL, V13, P1641, DOI 10.1128/MCB.13.3.1641; TERNS MP, 1992, MOL CELL BIOL, V12, P3032, DOI 10.1128/MCB.12.7.3032; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WASSARMAN DA, 1991, NATURE, V249, P463; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WILUSZ J, 1988, MOL CELL BIOL, V8, P4477, DOI 10.1128/MCB.8.10.4477; WISE JA, 1993, SCIENCE, V262, P1978, DOI 10.1126/science.8266091; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	42	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16476	16481		10.1074/jbc.270.27.16476	http://dx.doi.org/10.1074/jbc.270.27.16476			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608220	Green Published, hybrid			2022-12-25	WOS:A1995RH22600089
J	ROTMAN, EI; MURPHY, BJ; CATTERALL, WA				ROTMAN, EI; MURPHY, BJ; CATTERALL, WA			SITES OF SELECTIVE CAMP-DEPENDENT PHOSPHORYLATION OF THE L-TYPE CALCIUM-CHANNEL ALPHA-1 SUBUNIT FROM INTACT RABBIT SKELETAL-MUSCLE MYOTUBES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 SIZE FORMS; PROTEIN-KINASE; DIHYDROPYRIDINE RECEPTOR; CYCLIC-AMP; 1,4-DIHYDROPYRIDINE RECEPTOR; ANTAGONIST RECEPTOR; BINDING POLYPEPTIDE; CA-2+ CHANNEL; IDENTIFICATION; ALPHA-1-SUBUNIT	The principal (alpha 1) subunit of purified skeletal muscle dihydropyridine-sensitive (L-type) calcium channels is present in full-length (212 kDa) and COOH-terminal truncated (190 kDa) forms, which are both phosphorylated by cAMP-dependent protein kinase (cA-PK) in vitro. Immunoprecipitation of the calcium channel from rabbit muscle myotubes in primary cell culture followed by phosphorylation with cA-PK, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and two-dimensional phosphopeptide mapping revealed comparable phosphorylation of three COOH-terminal phosphopeptides found in the purified full-length alpha 1 subunit. Stimulation of muscle myotubes with a permeant cAMP analogue, 8-(4-chlorophenylthio) adenosine 3',5'-cyclic monophosphate, prior to immunoprecipitation of alpha 1 results in a 60-80% reduction of cA-PK catalyzed ''back'' phosphorylation of each of these sites in vitro in calcium channels purified from the cells, indicating that these sites are phosphorylated in vivo in response to increased intracellular cAMP. Serine 687, the most rapidly phosphorylated site in the truncated 190-kDa alpha 1 subunit, was observed as a minor phosphopeptide whose level of phosphorylation was not significantly affected by stimulation of endogenous cA-PK in the myotubes. The COOH-terminal sites, designated tryptic phosphopeptides 4, 5, and 6, were identified as serine 1757 (phosphopeptides 4 and 6) and 1854 (phosphopeptide 5) by a combination of protease cleavage, phosphorylation of synthetic peptides and fusion proteins, specific immunoprecipitation, and phosphopeptide mapping. Phosphorylation of serines 1757 and 1854 in the COOH-terminal region of the 212-kDa alpha 1 subunit in intact skeletal muscle cells may play a pivotal role in the regulation of calcium channel function by cA-PK.			ROTMAN, EI (corresponding author), UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA.				NINDS NIH HHS [NS22625] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022625] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BORSOTTO M, 1985, J BIOL CHEM, V260, P4255; CURTIS BM, 1984, BIOCHEMISTRY-US, V23, P2113, DOI 10.1021/bi00305a001; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; FLUCHER BE, 1990, NEURON, V5, P339, DOI 10.1016/0896-6273(90)90170-K; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P4290, DOI 10.1073/pnas.85.12.4290; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1990, J BIOL CHEM, V265, P20839; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; OCALLAHAN CM, 1988, BIOCHEMISTRY-US, V27, P6071, DOI 10.1021/bi00416a036; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; SCHAFFNER AE, 1982, J NEUROSCI, V2, P623; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID A, 1985, J BIOL CHEM, V260, P3041; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SHARP AH, 1987, J BIOL CHEM, V262, P12309; STRIESSNIG J, 1990, J BIOL CHEM, V265, P363; STRIESSNIG J, 1987, FEBS LETT, V212, P247, DOI 10.1016/0014-5793(87)81354-6; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; TSIEN RW, 1983, ANNU REV PHYSIOL, V45, P341, DOI 10.1146/annurev.ph.45.030183.002013; VAGHY PL, 1987, J BIOL CHEM, V262, P14337	46	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16371	16377		10.1074/jbc.270.27.16371	http://dx.doi.org/10.1074/jbc.270.27.16371			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608207	hybrid			2022-12-25	WOS:A1995RH22600074
J	DURO, D; BERNARD, O; DELLAVALLE, V; BERGER, R; LARSEN, CJ				DURO, D; BERNARD, O; DELLAVALLE, V; BERGER, R; LARSEN, CJ			A NEW-TYPE OF P16(INK4)/MTS1 GENE TRANSCRIPT EXPRESSED IN B-CELL MALIGNANCIES	ONCOGENE			English	Article						P(16INK4)/MTS1 GENE EXPRESSION; LYMPHOID PROLIFERATIONS; CYTOGENETICS	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; SHORT ARM; NONRANDOM ABNORMALITIES; LYMPHOMATOUS FEATURES; HOMOZYGOUS DELETIONS; CHROMOSOME-9; INTERFERON; TRANSLOCATION; ASSOCIATION	Chromosome band 9p21-22 is frequently altered by nonrandom abnormalities, mainly deletions, in hemopoietic malignancies of the lymphoid lineage. We have analysed a translocation t(9;14)(p21-p22;q11) in a B-cell type acute lymphoblastic leukemia. Location of the 14q11 breakpoint within the TCR-alpha/delta locus allowed the isolation of a fusion transcript composed of a 3' segment containing part of the constant region of the TCR-alpha gene and a 5' segment from chromosome 9, designated 0.18. This 0.18 segment was also part of cDNAs isolated from two tumoral B-cell lines (RPMI-8226, Raji). In both cases, 0.18 was juxtaposed 5' to a sequence corresponding to exons 2 and 3 of the p16(INK4)/MTS1 gene which is located on band 9p21-22. Unexpectedly, none of the two ATG codons found in 0.18 was in phase with that of the exons 2 and 3 of p16(INK4)/MTS1. Furthermore, in vitro translation product of a RPMI-8226 cDNA clone generated a product that was not immunoprecipitated by antibodies specific of the C-terminal end of the p16(INK4)/MTS1 protein. Evidence for similar transcripts in non tumoral lymphoid B cells (unstimulated peripheral blood lymphocytes (PBL) and lymphoblastoid cell lines) were obtained by using amplimers representative of the 0.18 segment and the p16(INK4)/MTS1 exon 2. Altogether, these data are consistent with the existence of a new type of p16(INK4)/MTS1 transcript whose significance is discussed.	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; CNRS,SDI 16954,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)			Bernard, Olivier A./E-5721-2016	Bernard, Olivier/0000-0002-0463-9747				BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1992, J EXP MED, V176, P915; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CARROLL AJ, 1987, BLOOD, V70, P1962; CARROLL AJ, 1987, BLOOD, V69, P735; CHENG JQ, 1994, CANCER RES, V54, P5547; CHILCOTE RR, 1985, NEW ENGL J MED, V313, P286, DOI 10.1056/NEJM198508013130503; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN A, 1994, CANCER RES, V54, P344; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DURO D, 1994, CR ACAD SCI III-VIE, V317, P913; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HEYMAN M, 1993, INT J CANCER, V54, P748, DOI 10.1002/ijc.2910540507; HUANG DP, 1994, CANCER RES, V54, P4003; ISSHIKI K, 1994, ONCOGENE, V9, P1649; JAMES CD, 1993, CANCER RES, V53, P3674; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEEN AJ, 1994, ONCOGENE, V9, P2083; KOWALCZYK J, 1983, CANCER GENET CYTOGEN, V9, P383, DOI 10.1016/0165-4608(83)90086-9; LAABI Y, 1992, EMBO J, V11, P3897, DOI 10.1002/j.1460-2075.1992.tb05482.x; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MATHIEUMAHUL D, 1986, J EXP MED, V163, P1308, DOI 10.1084/jem.163.5.1308; MATHIEUMAHUL D, 1985, EMBO J, V4, P3427, DOI 10.1002/j.1460-2075.1985.tb04100.x; MITELMAN F, 1991, CATALOG CHROMOSOME A; MORI T, 1994, CANCER RES, V54, P3396; MURPHY SB, 1989, BLOOD, V74, P409; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1992, CANCER RES, V52, P2523; ORLOW I, 1994, CANCER RES, V54, P2848; ROMANROMAN S, 1991, EUR J IMMUNOL, V21, P2848; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SOULARD M, 1991, EXP CELL RES, V193, P59, DOI 10.1016/0014-4827(91)90538-6; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TSAI YC, 1990, CANCER RES, V50, P44	44	154	166	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					21	29						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624129				2022-12-25	WOS:A1995RJ29500004
J	ZHAO, JF; NAKANO, H; SHARMA, S				ZHAO, JF; NAKANO, H; SHARMA, S			SUPPRESSION OF RAS AND MOS TRANSFORMATION BY RADICICOL	ONCOGENE			English	Article						RADICICOL; RAS; MOS; SUPPRESSION; ERKS; GAP-P62	GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; TYROSINE KINASES; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; XENOPUS OOCYTES; MAP KINASE; IN-VITRO; PHOSPHORYLATION; RECEPTOR	Activated versions of ras and mos oncogenes subvert the signal transduction pathway by mimicking transducers at the plasma membrane and cytosol respectively. Radicicol (UCS1006), an antifungal antibiotic, had the ability to suppress transformation by ras and mos oncogenes in a rapid, reversible and dose-dependent manner. UCS1006 inhibited MAP kinase activity (both ERK1 and ERK2) in untransformed as well as uas and mos transformed cells. However, ERK2 but not ERK1 activity was constitutively elevated in ras and mos transformed cells used in this study. In addition, a 62 kDa (kilodalton) phosphoprotein was identified whose tyrosine phosphorylation was inhibited by UCS1006, in both ras and mos transformed cells. This 62 kDa phosphoprotein, which was found to be heavily phosphorylated on tyrosine residues only in the ras and mos transformed cells but not in untransformed NIH3T3 cells, was identical to the previously described GAP-associated tyrosine phosphoprotein, p62, that is the major target for phosphorylation in cells transformed by tyrosine kinase oncogenes. These results suggest that agents such as radicicol can suppress transformation by diverse oncogenes such as src, ras and mos at least in part by inhibiting the function of key signal transduction intermediates such as MAP kinase and GAP-associated p62.	UNIV TENNESSEE,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,TOKYO 194,JAPAN	University of Tennessee System; University of Tennessee Health Science Center; Kyowa Kirin Ltd					NCI NIH HHS [CA 55983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOS JL, 1989, CANCER RES, V49, P4682; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DELMOTTE P, 1953, NATURE, V171, P344, DOI 10.1038/171344a0; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; McCAPRA FRANK, 1964, TETRAHEDRON LETT, V15/16, P869; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OIKAWA T, 1993, EUR J PHARMACOL, V241, P221, DOI 10.1016/0014-2999(93)90206-W; PARK S, 1993, J BIOL CHEM, V268, P25728; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHARMA SV, 1993, ONCOGENE, V8, P939; SHARMA SV, 1992, ONCOGENE, V7, P193; SINGH B, 1992, MOL CARCINOGEN, V6, P182, DOI 10.1002/mc.2940060303; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOPOL LZ, 1995, CELL GROWTH DIFFER, V6, P27; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANDEWOUDE GF, 1990, ORIGINS HUMAN CANCER; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEINBERG RA, 1991, ORIGINS HUMAN CANCER; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P45; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; ZHENG XF, 1993, NATURE, V364, P308	65	56	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					161	173						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624124				2022-12-25	WOS:A1995RJ29500019
J	BUKHTIYAROV, YE; OMER, CA; ALLEN, CM				BUKHTIYAROV, YE; OMER, CA; ALLEN, CM			PHOTOREACTIVE ANALOGS OF PRENYL DIPHOSPHATES AS INHIBITORS AND PROBES OF HUMAN PROTEIN FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE TYPE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; METHYL-ESTER; TRANSFERASE; BINDING; CLONING; BRAIN	Photoreactive analogues of prenyl diphosphates have been useful in studying prenyltransferases. The effectiveness of analogues with different chain lengths as probes of recombinant human protein prenyltransferases is established here. A putative geranylgeranyl diphosphate analogue, 2-diazo-3,3,3-trifluoropropionyloxy-farnesyl diphosphate (DATFP-FPP), was the best inhibitor of both protein farnesyltransferase (PFT) and protein geranylgeranyltransferase-I (PGGT-I), Shorter photoreactive isoprenyl diphosphate analogues with geranyl and dimethylallyl moieties and the DATFP-derivative of farnesyl monophosphate were much poorer inhibitors. DATFP-FPP was a competitive inhibitor of both PFT and PGGT-I with K-i values of 100 and 18 nM, respectively, [P-32]DATFP-FPP specifically photoradiolabeled the beta-subunits of both PFT and PGGT-I. Photoradiolabeling of PGGT-I was inhibited more effectively by geranylgeranyl diphosphate than farnesyl diphosphate, whereas photoradiolabeling of PFT was inhibited better by farnesyl diphosphate than geranylgeranyl diphosphate. These results lead to the conclusions that DATFP-FPP is an effective probe of the prenyl diphosphate binding domains of PFT and PGGT-I. Furthermore, the beta-subunits of protein prenyltransferases must contribute significantly to the recognition and binding of the isoprenoid substrate.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610; MERCK SHARP & DOHME LTD,RES LABS,DEPT CANC RES,W POINT,PA 19486	State University System of Florida; University of Florida; Merck & Company				Bukhtiyarov, Yuri/0000-0003-3370-5413				ALLEN CM, 1985, METHOD ENZYMOL, V111, P281; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; BABA T, 1985, J BIOL CHEM, V260, P467; BABA T, 1983, BIOCHEMISTRY-US, V23, P1312; BHALERAO UT, 1971, J AM CHEM SOC, V93, P4835; BREMS DN, 1979, BIOCHEMISTRY-US, V18, P860, DOI 10.1021/bi00572a019; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHAN KC, 1968, J ORG CHEM, V33, P3382, DOI 10.1021/jo01273a004; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAS NP, 1991, BIOCHEM BIOPH RES CO, V81, P729; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; DOGDO O, 1987, BIOCHIM BIOPHYS ACTA, V920, P140; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FINEGOLD AA, 1990, SCIENCE, V249, P165, DOI 10.1126/science.1695391; GRAHAM SL, 1994, J MED CHEM, V37, P725, DOI 10.1021/jm00032a004; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1993, CURR BIOL, V3, P770, DOI 10.1016/0960-9822(93)90027-L; HOLLOWAY PW, 1967, BIOCHEM J, V104, P57, DOI 10.1042/bj1040057; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOLY A, 1991, J BIOL CHEM, V266, P13495; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MARSHALL J A, 1986, Journal of Organic Chemistry, V51, P4316, DOI 10.1021/jo00372a048; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REISS Y, 1991, J BIOL CHEM, V266, P10672; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; UMBREIT M, 1977, JA M CHEM SOC, V94, P5526; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YING WL, 1994, J BIOL CHEM, V269, P470; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; [No title captured]	44	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19035	19040		10.1074/jbc.270.32.19035	http://dx.doi.org/10.1074/jbc.270.32.19035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642565	hybrid			2022-12-25	WOS:A1995RN95400053
J	HUTCHISON, KA; STANCATO, LF; OWENSGRILLO, JK; JOHNSON, JL; KRISHNA, P; TOFT, DO; PRATT, WB				HUTCHISON, KA; STANCATO, LF; OWENSGRILLO, JK; JOHNSON, JL; KRISHNA, P; TOFT, DO; PRATT, WB			THE 23-KDA ACIDIC PROTEIN IN RETICULOCYTE LYSATE IS THE WEAKLY-BOUND COMPONENT OF THE HSP FOLDOSOME THAT IS REQUIRED FOR ASSEMBLY OF THE GLUCOCORTICOID RECEPTOR INTO A FUNCTIONAL HETEROCOMPLEX WITH HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; PROGESTERONE-RECEPTOR; RECONSTITUTION; COMPLEX; BINDING	The heat shock proteins hsp90 and hsp70 have been immunopurified from rabbit reticulocyte lysate in a multiprotein complex that acts as a self-sufficient protein folding machine. This immunopurified ''foldosome'' directs the assembly of the glucocorticoid receptor-hsp90 complex and refolds the receptor to the steroid binding state (Hutchison, K. A., Dittmar, K. D., and Pratt, W. B. (1994) J. Biol, Chem. 269, 27894-27899). Extensive washing of the immunoadsorbed foldosome eliminates a weakly bound component required for receptor heterocomplex assembly and folding. This protein factor is contained in a Centricon C-100 filtrate of lysate which reconstitutes the receptor activating activity of the washed foldosome. This hsp90-associated protein folding system is present in both animal and plant cells, and the Centricon C-100 fraction of rabbit reticulocyte ly sate potentiates receptor folding directed by wheat germ lysate. We have used this ability to stimulate wheat germ lysate-directed folding of the glucocorticoid receptor as a rapid assay for the factor. We demonstrate that the activity segregates with the 23-kDa acidic protein component of the hsp90 foldosome when rabbit reticulocyte lysate is fractionated by ammonium sulfate precipitation and ion exchange chromatography, Immunoadsorption of the Centricon C-100 filtrate with a monoclonal antibody against p23 eliminates its ability to stimulate the wheat germ heterocomplex assembly/receptor folding system, and the activity is replaced by purified, bacterially expressed p23. Immunodepletion of p23 also eliminates the ability of the Centricon C-100 filtrate to reconstitute receptor activating activity of the washed foldosome and addition of purified, bacterially expressed p23 restores its activity, confirming that p23 is the weakly bound component of the foldosome complex required for refolding of the receptor to the steroid binding conformation.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; MAYO GRAD SCH,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; UNIV WESTERN ONTARIO,DEPT PLANT SCI,LONDON,ON N6A 5B7,CANADA	University of Michigan System; University of Michigan; Mayo Clinic; Western University (University of Western Ontario)				Krishna, Priti/0000-0001-6394-3012	NICHD NIH HHS [HDO9140] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; ERHART JC, 1988, ONCOGENE, V3, P595; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; NAKAO K, 1985, CAN J BIOCHEM CELL B, V63, P33, DOI 10.1139/o85-005; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; WHITELAW ML, 1991, J BIOL CHEM, V266, P6708	20	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18841	18847		10.1074/jbc.270.32.18841	http://dx.doi.org/10.1074/jbc.270.32.18841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642537				2022-12-25	WOS:A1995RN95400024
J	NEL, AE; GUPTA, S; LEE, L; LEDBETTER, JA; KANNER, SB				NEL, AE; GUPTA, S; LEE, L; LEDBETTER, JA; KANNER, SB			LIGATION OF THE T-CELL ANTIGEN RECEPTOR (TCR) INDUCES ASSOCIATION OF HSOS1, ZAP-70, PHOSPHOLIPASE C-GAMMA-1, AND OTHER PHOSPHOPROTEINS WITH GRB2 AND THE ZETA-CHAIN OF THE TCR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; LYMPHOCYTE-T; ACTIVATION; PHOSPHORYLATION; STIMULATION; RAS; P21RAS; SH2	Signaling by the T-cell antigen receptor (TCR) involves both phospholipase C (PLC)-gamma 1 and p21(ras) activation. While failing to induce Shc/Grb2 association, ligation of the TCR/CDS receptor in Jurkat T-cells induced hSos1-Grb2 complexes. In addition to hSos1, Grb2 participates in the formation of a tyrosine phosphoprotein complex that includes 145-, 95-, 70-, 54-, and 36-38 kDa proteins. p145 was identified as PLC-gamma 1 and p70 as the protein tyrosine kinase, ZAP-70. Although of the same molecular weight, p95 was not recognized by an antiserum to p95 Vav. The SH2 domains of Grb2 and PLC-gamma 2 were required for the formation of this protein complex. In anti-CD3-treated cells, Grb2 redistributed from the cytosol to a particulate cell compartment along with p36/p38, ZAP-70, and PLC-gamma 1. Part of the Grb2 complex associated with the particulate compartment could be extracted with Nonidet P-40, while the rest was Nonidet P-40 insoluble. In both the detergent-soluble and -insoluble fractions, Grb2 coimmunoprecipitated with the zeta chain of the TCR. Taken together, these results indicate that anti-CDS induces Grb2-hSos1-PLC-gamma 1-p36/p38-ZAP70 complexes, which localize in the vicinity of TCR-zeta.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb	NEL, AE (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,10833 LE CONTE AVE,LOS ANGELES,CA 90024, USA.		Nel, Andre E/J-2808-2012		NIGMS NIH HHS [GM41576] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLIPSTONE NA, 1992, NATURE, V357, P659; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GEPEPRT TD, 1991, J IMMUNOL, V46, P3298; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GOLDSCHMIDTCLER.PJ, 1991, SCIENCE, V251, P1231; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GUPTA S, 1994, J BIOL CHEM, V269, P17349; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KUBO RT, 1989, J IMMUNOL, V142, P2736; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTH JD, 1989, J IMMUNOL, V142, P2430; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NEL AE, 1990, J IMMUNOL, V144, P2683; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; REIF K, 1994, J BIOL CHEM, V269, P14081; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMUELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358; SANCHO J, 1993, J IMMUNOL, V150, P3230; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1989, SCIENCE, V239, P1018; YANG LJ, 1994, J BIOL CHEM, V269, P7156	48	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18428	18436		10.1074/jbc.270.31.18428	http://dx.doi.org/10.1074/jbc.270.31.18428			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629168	hybrid			2022-12-25	WOS:A1995RM64200045
J	YU, W; SCHUSTER, W				YU, W; SCHUSTER, W			EVIDENCE FOR A SITE-SPECIFIC CYTIDINE DEAMINATION REACTION INVOLVED IN C TO U RNA EDITING OF PLANT-MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MOLECULES; INSERTION; ENZYME	Transcripts of higher plant mitochondria are modified post-transcriptionally by RNA editing. To distinguish between the mechanisms by which the cytidine to uridine transition could occur a combined transcription/RNA editing assay and an in vitro RNA editing system were investigated. Mitochondria isolated from etiolated pea seedlings and potato tubers were supplied with [alpha-P-32]CTP to radiolabel the mitochondrial run-on transcripts. High molecular weight run-on transcripts were isolated and hydrolyzed, and nucleotide identities were analyzed by one- and two dimensional thin layer chromatography. The amount of label comigrating with UMP nucleotides increases with extended incubation times. Analogous products were obtained by incubation of [alpha-P-32]CTP or, [5-H-3]CTP radiolabeled in vitro transcripts with a mitochondrial lysate from pea mitochondria. 5-H-3 label of the cytosine base was detected in the UMP spot after incubation of in vitro transcripts with mitochondrial lysate. These results are consistent with a deamination reaction involved in this post-transcriptional C to U modification process. To prove that cytidines are deaminated specifically in vitro transcripts were reisolated after incubation and analyzed by reverse transcription-polymerase chain reaction. Sequence analysis clearly shows that only cytidines at editing sites are edited while residual cytidines are not modified and suggests that site specific factors are involved in RNA editing of plant mitochondria.	INST GENBIOL FORSCH BERLIN GMBH,D-14195 BERLIN,GERMANY									ARAYA A, 1992, P NATL ACAD SCI USA, V89, P1040, DOI 10.1073/pnas.89.3.1040; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BENNE R, 1986, CELL, V46, P519; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; COVELLO PS, 1990, FEBS LETT, V268, P5, DOI 10.1016/0014-5793(90)80958-L; COVELLO PS, 1990, NUCLEIC ACIDS RES, V18, P5189, DOI 10.1093/nar/18.17.5189; ELLIOTT MS, 1984, J BIOL CHEM, V259, P2407; FINNEGAN PM, 1987, PLANT PHYSIOL, V85, P304, DOI 10.1104/pp.85.1.304; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HODGES PE, 1991, NUCLEIC ACIDS RES, V19, P1197, DOI 10.1093/nar/19.6.1197; MULLIGAN RM, 1991, MOL CELL BIOL, V11, P533, DOI 10.1128/MCB.11.1.533; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; Nishimura S, 1972, Prog Nucleic Acid Res Mol Biol, V12, P49; OKADA N, 1979, J BIOL CHEM, V254, P3061; RAJASEKHAR VK, 1993, PLANT CELL, V5, P1843, DOI 10.2307/3869699; SCHUSTER W, 1994, PLANT MOL BIOL, V25, P33, DOI 10.1007/BF00024196; SCHUSTER W, 1990, MOL CELL BIOL, V10, P2428, DOI 10.1128/MCB.10.5.2428; SCHUSTER W, 1991, CURR GENET, V20, P397, DOI 10.1007/BF00317068; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J	24	97	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18227	18233		10.1074/jbc.270.31.18227	http://dx.doi.org/10.1074/jbc.270.31.18227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629140	hybrid			2022-12-25	WOS:A1995RM64200014
J	BUSCH, S; WIELAND, T; ESCHE, H; JAKOBS, KH; SIFFERT, W				BUSCH, S; WIELAND, T; ESCHE, H; JAKOBS, KH; SIFFERT, W			G-PROTEIN REGULATION OF THE NA+/H+ ANTIPORTER IN XENOPUS-LAEVIS OOCYTES - INVOLVEMENT OF PROTEIN-KINASE-A AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; CYCLIC-AMP; ACTIVATION; INHIBITOR; EXCHANGE; RECEPTOR; CLONING; CELLS	We have characterized the regulation of the endogenous Na+/H+ exchanger in Xenopus laevis oocytes by G proteins and protein kinases by measuring the ethylisopropylamiloride-sensitive Li+ uptake. Injection of oocytes with the stable GTP analog GTP gamma S stimulated Li+ uptake up to almost 4-fold, an effect blocked by coinjection with the GDP analog guanyl-5'-yl thiophosphate. Injection into oocytes of beta gamma subunits of the heterotrimeric G protein transducin enhanced Li+ uptake by about 3-fold. This stimulation was blocked by transducin alpha subunits, which by themselves did not influence Li+ uptake. Using various activators and inhibitors of protein kinases, it is demonstrated that the X. laevis oocyte Na+/H+ antiporter can be stimulated by activation of both protein kinase A and C. Stimulation of Na+/H+ exchanger activity by GTP gamma S but not that induced by transducin beta gamma subunits was blocked by the protein kinase A inhibitor H-89. On the other hand, transducin beta gamma subunit-stimulated activity was prevented by the protein kinase C inhibitor, calphostin C. The non-selective protein kinase inhibitor H-7 blocked both GTP gamma S- and transducin beta gamma subunit-stimulated Na+/H+ exchanger activity. The results suggest that the Na+/H+ exchanger of X. laevis oocytes can be activated by G proteins and that this activation is not direct but mediated by protein kinase A- and/or protein kinase C-dependent pathways.	UNIV ESSEN GESAMTHSCH, INST PHARMAKOL, D-45122 ESSEN, GERMANY; UNIV ESSEN GESAMTHSCH, INST MOLEK BIOL, D-45122 ESSEN, GERMANY	University of Duisburg Essen; University of Duisburg Essen			Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; BORGESE F, 1994, P NATL ACAD SCI USA, V91, P5431, DOI 10.1073/pnas.91.12.5431; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P78, DOI 10.1007/BF00378644; BUSCH S, 1995, PFLUG ARCH EUR J PHY, V429, P859, DOI 10.1007/BF00374811; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COUNILLON L, 1993, SOC GEN PHY, V48, P169; COUNILLON L, 1992, Cellular Physiology and Biochemistry, V2, P138, DOI 10.1159/000154636; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; GREEN J, 1992, AM J PHYSIOL, V262, pC111, DOI 10.1152/ajpcell.1992.262.1.C111; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GUIZOUARN H, 1993, J BIOL CHEM, V268, P8632; GUPTA A, 1994, AM J PHYSIOL, V266, pC1083, DOI 10.1152/ajpcell.1994.266.4.C1083; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MA HW, 1993, J BIOL CHEM, V268, P19915; PARK DG, 1993, J BIOL CHEM, V268, P4573; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SAKUTA H, 1991, EUR J PHARM-MOLEC PH, V208, P31, DOI 10.1016/0922-4106(91)90048-M; TOWLE DW, 1991, J EXP BIOL, V159, P359; TSE M, 1994, J AM SOC NEPHROL, V4, P969; VANWEZENBEEK LACM, 1988, EUR J PHARMACOL, V151, P497, DOI 10.1016/0014-2999(88)90551-1; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x	30	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17898	17901		10.1074/jbc.270.30.17898	http://dx.doi.org/10.1074/jbc.270.30.17898			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629094	hybrid			2022-12-25	WOS:A1995RM26600042
J	PAYNE, JA; XU, JC; HAAS, M; LYTLE, CY; WARD, D; FORBUSH, B				PAYNE, JA; XU, JC; HAAS, M; LYTLE, CY; WARD, D; FORBUSH, B			PRIMARY STRUCTURE, FUNCTIONAL EXPRESSION, AND CHROMOSOMAL LOCALIZATION OF THE BUMETANIDE-SENSITIVE NA-K-CL COTRANSPORTER IN HUMAN COLON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; CO-TRANSPORT SYSTEM; CELL LINE; NA+/K+/CL COTRANSPORT; SQUALUS-ACANTHIAS; DOG KIDNEY; PROTEIN; GENES; PHOSPHORYLATION; IDENTIFICATION	By moving chloride into epithelial cells, the Na-K-CI cotransporter aids transcellular movement of chloride across both secretory and absorptive epithelia. Using cDNA probes from the recently identified elasmobranch secretory Na-K-Cl cotransporter (sNKCC1) (Xu, J. C., Lytle, C. Zhu, T. T., Payne, J. A., Bent, E., and Forbush, B., III (1994) Proc. Natl. Acad. Sci. 91, 2201-2205), we have identified the human homologue. By screening cDNA libraries of a human colonic carcinoma line, T84 cell, we identified a sequence of 4115 bases from overlapping clones. The deduced protein is 1212 amino acids in length, and analysis of the primary structure indicates 12 transmembrane segments. The primary structure is 74% identical to sNKCC1, 91% identical to a mouse Na-K-Cl cotransporter (mNKCC1), 58% identical to rabbit and rat renal Na-K-Cl cotransporters (NKCC2), and 43% identical to the thiazide-sensitive Na-Cl cotransporters from flounder urinary bladder and rat kidney. Similar to sNKCC1 and mNKCC1, the 5'-end of the human colonic cotransporter is rich in G+C content. Interestingly, a triple repeat (GCG)(7) occurs within the 5'-coding region and contributes to a large alanine repeat (Ala(15)). Two sites for N-linked glycosylation are predicted on an extracellular loop between putative transmembrane segments 7 and 8. A single potential site for phosphorylation by protein kinase A is present in the predicted cytoplasmic C-terminal domain. Northern blot analysis revealed a 7.4-7.5-kilobase transcript in T84 cells and shark rectal gland and a similar to 7.2-kilobase transcript in mammalian colon, kidney, lung, and stomach. Metaphase spreads from lymphocytes were probed with biotin-labeled cDNA and avidin fluorescein (the cotransporter gene was localized to human chromosome 5 at position 5q23.3). Human embryonic kidney cells stably transfected with the full-length cDNA expressed a similar to 170-kDa protein recognized by anti-cotransporter antibodies. Following treatment with N-glycosidase F, the molecular mass of the expressed protein was similar to that predicted for the core protein from the cDNA sequence (132-kDa) and identical to that of deglycosylated T84 cotransporter (similar to 135-kDa). The stably transfected cells exhibited a similar to 15-fold greater bumetanide-sensitive Rb-86 influx than control cells, and this flux required external sodium and chloride. Flux kinetics were consistent with an electroneutral cotransport of 1Na:1K:2Cl. Preincubation in chloride-free media was necessary to activate fully the expressed cotransporter, suggesting a [Cl]-dependent regulatory mechanism.	YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Yale University; Yale University			Lytle, Christian/X-2836-2019	Lytle, Christian/0000-0001-5442-1546	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047661, P01DK017433] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK17433, DK47661] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARNOLD N, 1993, TECHNIQUES METHODS M, P324; BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; CANTRELL A, 1987, PLANT MOL BIOL, V9, P453, DOI 10.1007/BF00015877; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DHARMSATHAPHORN K, 1985, J CLIN INVEST, V75, P462, DOI 10.1172/JCI111721; FONG P, 1991, AM J PHYSIOL, V261, pL290, DOI 10.1152/ajplung.1991.261.4.L290; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; FORBUSH B, 1983, J BIOL CHEM, V258, P1787; FORBUSH B, 1989, BIOPHYS J, V55, P422; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; GREGER R, 1981, PFLUG ARCH EUR J PHY, V392, P92, DOI 10.1007/BF00584588; HAAS M, 1994, AM J PHYSIOL, V266, pC1440, DOI 10.1152/ajpcell.1994.266.5.C1440; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HAAS M, 1993, MAMM GENOME, V4, P711, DOI 10.1007/BF00357794; HAAS M, 1991, AM J PHYSIOL, V260, pC791, DOI 10.1152/ajpcell.1991.260.4.C791; HAAS M, 1988, BIOCHIM BIOPHYS ACTA, V939, P131, DOI 10.1016/0005-2736(88)90054-5; HAAS M, 1987, AM J PHYSIOL, V253, pC243, DOI 10.1152/ajpcell.1987.253.2.C243; HALM DR, 1990, TXB SECRETORY DIARRH, P47; HANNAFIN J, 1983, J MEMBRANE BIOL, V75, P73, DOI 10.1007/BF01870801; KIM HD, 1988, BIOCHIM BIOPHYS ACTA, V946, P397, DOI 10.1016/0005-2736(88)90415-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LTLE C, 1992, AM J PHYSIOL, V262, pC1009; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; LYTLE C, 1992, J GEN PHYSIOL, V100, P39; MCROBERTS JA, 1982, J BIOL CHEM, V257, P2260; MORELL V, 1993, SCIENCE, V260, P1422, DOI 10.1126/science.8502986; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; QUAGGIN SE, 1995, IN PRESS MAMM GENOME; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1995, IN PRESS PROTEIN SCI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVA P, 1986, AM J PHYSIOL, V250, pF516, DOI 10.1152/ajprenal.1986.250.3.F516; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TORCHIA J, 1992, J BIOL CHEM, V267, P25444; TURNER RJ, 1986, J MEMBRANE BIOL, V94, P143, DOI 10.1007/BF01871194; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	47	224	237	0	84	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17977	17985		10.1074/jbc.270.30.17977	http://dx.doi.org/10.1074/jbc.270.30.17977			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629105	hybrid			2022-12-25	WOS:A1995RM26600055
J	WISE, A; LEE, TW; MACEWAN, DJ; MILLIGAN, G				WISE, A; LEE, TW; MACEWAN, DJ; MILLIGAN, G			DEGRADATION OF G(11)ALPHA/G(Q)ALPHA IS ACCELERATED BY AGONIST OCCUPANCY OF ALPHA(1A/D), ALPHA(1B), AND ALPHA(1C) ADRENERGIC-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; ALPHA-1-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; DOWN-REGULATION; FUNCTIONAL IMPLICATIONS; ACETYLCHOLINE-RECEPTOR; MEDIATED PATHWAYS; ADENYLYL CYCLASE; CROSS-REGULATION; RAT-BRAIN	Cells of clones of rat 1 fibroblasts transfected to express the molecularly defined alpha(1A/D), alpha(1B), or alpha(1C) adrenoreceptors and prelabeled with myo-[H-3]inositol were each shown to generate high levels of inositol phosphates when exposed to the alpha(1) adrenoreceptor agonist phenylephrine, Maintained exposure of each of these cells to phenylephrine resulted in a large down-regulation of the receptors and also a marked down-regulation of cellular levels of both of the phosphoinositidase C-linked G-proteins G(q) alpha and G(11)alpha. To examine the mechanism of phenylephrine-induced down-regulation of G(q) alpha and G(11)alpha, pulse-chase S-35-amino acid labeling experiments were performed with each of the alpha(1A/D), alpha(1B), and alpha(1C) adrenoreceptor-expressing cell lines. The rate of degradation of G(11)alpha/G(q) alpha, which was adequately modeled by a monoexponential with half-life between 33 and 40 h in each of the cell lines in the absence of agonist, was accelerated substantially (some 4 fold) in the presence of phenylephrine. By contrast, the rate of degradation of the G-protein G(i)2 alpha, which would not be anticipated to be activated by members of the alpha(1) adrenoreceptor family, was unaltered by the presence of phenylephrine, Levels of mRNA encoding G(q) alpha and G(11)alpha were not substantially altered by exposure of the cells to phenylephrine in any of the cell lines studied.	UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV BIOCHEM & MOLEC BIOL,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Glasgow			Milligan, Graeme/F-9426-2011; MacEwan, David/F-7044-2011	Milligan, Graeme/0000-0002-6946-3519; MacEwan, David/0000-0002-2879-0935				ADIE EJ, 1994, BIOCHEM J, V300, P709, DOI 10.1042/bj3000709; ADIE EJ, 1992, BIOCHEM J, V285, P529, DOI 10.1042/bj2850529; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; EASON MG, 1992, J BIOL CHEM, V267, P25473; EASON MG, 1991, P NATL ACAD SCI USA, V91, P11178; FINAN PM, 1994, PLANT MOL BIOL, V25, P59, DOI 10.1007/BF00024198; FORD APDW, 1994, TRENDS PHARMACOL SCI, V15, P167, DOI 10.1016/0165-6147(94)90136-8; GREEN A, 1990, J BIOL CHEM, V265, P5206; HADCOCK JR, 1991, J BIOL CHEM, V266, P11915; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KIM GD, 1994, J BIOL CHEM, V269, P19933; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MCKENZIE FR, 1990, J BIOL CHEM, V265, P17084; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1994, BIOCHEM PHARMACOL, V48, P1059; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; MITCHELL FM, 1991, FEBS LETT, V287, P171, DOI 10.1016/0014-5793(91)80043-3; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; MORROW AL, 1985, EUR J PHARMACOL, V109, P285, DOI 10.1016/0014-2999(85)90432-7; MORROW AL, 1986, MOL PHARMACOL, V29, P321; MULLANEY I, 1993, FEBS LETT, V324, P241, DOI 10.1016/0014-5793(93)81401-K; MULLANEY I, 1994, FEBS LETT, V353, P231, DOI 10.1016/0014-5793(94)01043-9; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PLEVIN R, 1990, BIOCHEM J, V268, P605, DOI 10.1042/bj2680605; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SHAH BH, 1994, MOL PHARMACOL, V46, P1; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STEEL MC, 1993, MOL PHARMACOL, V43, P694; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SVOBODA P, 1994, EUR J BIOCHEM, V224, P455, DOI 10.1111/j.1432-1033.1994.00455.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WU DQ, 1992, J BIOL CHEM, V267, P25798	38	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17196	17203		10.1074/jbc.270.29.17196	http://dx.doi.org/10.1074/jbc.270.29.17196			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615517	hybrid			2022-12-25	WOS:A1995RK68900024
J	FUKUDA, M; GOTOH, Y; TACHIBANA, T; DELL, K; HATTORI, S; YONEDA, Y; NISHIDA, E				FUKUDA, M; GOTOH, Y; TACHIBANA, T; DELL, K; HATTORI, S; YONEDA, Y; NISHIDA, E			INDUCTION OF NEURITE OUTGROWTH BY MAP KINASE IN PC12 CELLS	ONCOGENE			English	Article						PC12 CELL DIFFERENTIATION; THIOPHOSPHORYLATED MAP KINASE; CL100	NERVE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; XENOPUS-OOCYTES; PHOSPHORYLATION; CASCADE; ACTIVATION; INVITRO; PATHWAY	Treatment of PC12 cells with nerve growth factor (NGF) results in neural differentiation of the cells, inducing neurite outgrowth. Ras protein has been shown to play an essential role in this process. To examine whether or not the MAP kinase (MAPK) cascade mediates the NGF- and Pas-induced neural differentiation process, we injected PC12 cells with constitutive active forms of each components of the MAPK cascade. When a moderately active mutant of Xenopus MAPK kinase (S222E-MAPKK) in which Ser 222 was changed into glutamic acid was injected, the neurite outgrowth of PC12 cells occurred to some extent. Injection of an N-terminal truncated STE11 protein (Delta N-STE11), a constitutively active form of STE11 which is a yeast MAPKK kinase, induced neurite outgrowth in PC12 cells. Furthermore, injection of thiophosphorylated MAPK, but not purified active MAPK, into PC12 cells resulted in neurite outgrowth. Thiophosphorylated MAPK was resistant to protein phosphatase 2A treatment, while purified active MAPK was inactivated by this treatment. All these results have suggested that sustained activation of MAPK is sufficient for PC12 cell differentiation. In accord with this, the Delta N-STE11- or S222E- MAPKK-induced neurite outgrowth was inhibited by coinjection of CL-100 protein, a dual-specificity phosphatase that is capable of inactivating MAPK.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,DEPT ANAT & CELL BIOL,SUITA,OSAKA 565,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA 187,TOKYO,JAPAN	Kyoto University; University of Tokyo; Osaka University; National Center for Neurology & Psychiatry - Japan			Fukuda, Makoto/C-9745-2009	Fukuda, Makoto/0000-0003-0112-9925				AHN NG, 1991, J BIOL CHEM, V266, P4220; ALLESSI DR, 1993, ONCOGENE, V8, P2015; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MUROYA K, 1992, ONCOGENE, V7, P277; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEBREDA AR, 1994, TRENDS BIOCHEM SCI, V19, P1, DOI 10.1016/0968-0004(94)90163-5; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SAMMUELS ML, 1993, MOL CELL BIOL, V13, P6241; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; ZHENG CF, 1993, J BIOL CHEM, V268, P644	53	141	143	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					239	244						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624141				2022-12-25	WOS:A1995RK95700004
J	GANJU, P; WALLS, E; BRENNAN, J; REITH, AD				GANJU, P; WALLS, E; BRENNAN, J; REITH, AD			CLONING AND DEVELOPMENTAL EXPRESSION OF NSK2, A NOVEL RECEPTOR TYROSINE KINASE IMPLICATED IN SKELETAL MYOGENESIS	ONCOGENE			English	Article						NSK2; RECEPTOR TYROSINE KINASE; MYOGENESIS; EPITHELIA; MOUSE CHROMOSOME 13; DEVELOPMENT	HEPATOCYTE GROWTH-FACTOR; GENE-EXPRESSION; PROTEIN; DIFFERENTIATION; MUSCLE; CELLS; IDENTIFICATION; PROTEASES; MODULES; FAMILY	The protein superfamily of transmembrane receptor tyrosine kinases (RTKs) are essential components of intercellular signalling pathways necessary for normal cellular regulation, We report the cloning and developmental expression pattern of NskZ, a novel, structurally distinct mammalian RTK characterised by a putative extracellular region bearing four immunoglobulin-like domains. The Nsk2 locus was mapped to the distal region of mouse chromosome 13 and was found to be expressed preferentially in skeletal muscle amongst adult mouse tissues. Moreover, increased steady-state levels of Nsk2 transcripts were apparent on terminal differentiation of committed skeletal myoblast cell lines in vitro and multiple isoforms of the NskZ RTK were identified in skeletal myotube cultures. RNA in situ hybridisation studies of mouse embryos confirmed skeletal myogenesis to be a major site of Nsk2 expression during normal embryogenesis, and identified other likely sites of Nsk2 function in ganglia of the developing peripheral nervous system and various embryonic epithelia, including those of kidney, lung and gut, during fetal development. Taken together, our data suggest normal functions for Nsk2 RTKs in distinctive aspects of skeletal muscle development, neurogenesis and mesenchymal-epithelial interactions during organ formation.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research				Brennan, Jane/0000-0003-3222-5485				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARBACID M, 1993, ONCOGENE, V8, P2033; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BIRCHMEIER C, 1993, BIOESSAYS, V15, P185, DOI 10.1002/bies.950150307; BIRKENMEIER EH, 1992, MAMM GENOME, V3, P537, DOI 10.1007/BF00350618; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; ELLIOTT RW, 1991, MAMM GENOME, V1, P118, DOI 10.1007/BF02443788; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FRANKEL WN, 1989, J VIROL, V63, P3810, DOI 10.1128/JVI.63.9.3810-3821.1989; GANJU P, 1994, ONCOGENE, V9, P1613; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KARP SL, 1994, P NATL ACAD SCI USA, V91, P5286, DOI 10.1073/pnas.91.12.5286; LEUDERS KK, 1993, MAMM GENOME, V4, P69; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MINOO P, 1994, ANNU REV PHYSIOL, V56, P13; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; OLSEN EN, 1992, DEV BIOL, V154, P261; OLSEN EN, 1994, GENE DEV, V8, P1; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; QU Z, 1990, NEURON, V2, P367; REITH AD, 1985, IN PRESS MAMM GENOME; REITH AD, 1991, GENOME ANAL, V3, P105; SAXEN L, 1992, CIBA F SYMP, V165, P183; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SZEBENYI G, 1991, J BIOL CHEM, V266, P5534; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	47	54	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					281	290						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624144				2022-12-25	WOS:A1995RK95700009
J	GUDAS, J; NGUYEN, H; LI, T; HILL, D; COWAN, KH				GUDAS, J; NGUYEN, H; LI, T; HILL, D; COWAN, KH			EFFECTS OF CELL-CYCLE, WILD-TYPE P53 AND DNA-DAMAGE ON P21(CIP1/WAF1) EXPRESSION IN HUMAN BREAST EPITHELIAL-CELLS	ONCOGENE			English	Article						P21(CIP1/WAF1); POST TRANSCRIPTIONAL REGULATING; WILD-TYPE P53; RADIATION EFFECTS; CELL CYCLE	HUMAN PAPILLOMAVIRUS TYPE-16; SYNTHASE MESSENGER-RNA; E6 ONCOPROTEIN; PROTEIN; CANCER; GROWTH; LINE; CDNA; TRANSFORMATION; TRANSCRIPTION	In this study we examine the relationship between p21(CIP1/Waf1) (CIP1), a 21 kDa protein that binds to and modulates the activity of several cyclin dependent kinases and expression of wild-type (WT) p53 in human breast epithelial cells. Basal CTP1 protein, but not CIP1 mRNA levels correlated well with expression of WT p53 in human breast epithelial cells. To obtain more direct evidence that WT p53 regulated the level of CTP1 protein, the Human Papilloma Virus (HPV) E6 protein was introduced into immortalized 184B5 breast cells, Residual WT p53 levels correlated well with CIP1 protein but not CIP1 mRNA levels in isolated clones of transfected cells. CIP1 protein mas increased at early times after growth factor arrested cells were stimulated to proliferate. The rise in CLP1 protein was due to a concomitant increase in CIP1 mRNA levels in MCF10, but not in normal mammary epithelial cells. DNA damage induced by ionizing radiation resulted in a transient increase in WT p53 levels but a prolonged induction of CIP1 protein. The sustained increase in CIP1 protein 24 h after radiation could not be attributed to a concomitant increase in CIP1 mRNA levels, Although the half-life of the CIP1 protein was not altered following irradiation, a fourfold increase in the amount of radioactivity incorporated into CIP1 protein was detected. When considered together these data suggest that wild-type p53 affects CIP1 protein accumulation at a posttranscriptional level in human breast epithelial cells under different physiologic and stress conditions.	ONCOGENE SCI, CAMBRIDGE, MA 02142 USA		GUDAS, J (corresponding author), NCI, MED BRANCH,DIV CANC TREATMENT, MED BREAST CANC SECT,BLDG 10, ROOM 12N226, BETHESDA, MD 20892 USA.							ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARNES DM, 1993, HUM PATHOL, V24, P469, DOI 10.1016/0046-8177(93)90158-D; BARTEK J, 1990, ONCOGENE, V5, P893; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; Dulcic V, 1994, CELL, V76, P1013; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GRAHAM KA, 1986, BREAST CANCER RES TR, V8, P29, DOI 10.1007/BF01805922; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; GUDAS JM, 1994, CELL GROWTH DIFFER, V5, P295; GUDAS JM, 1993, CELL GROWTH DIFFER, V4, P421; HALDAR S, 1994, CANCER RES, V54, P2095; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASTAN MB, 1991, CANCER RES, V51, P6304; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LI Y, 1994, ONCOGENE, V9, P2261; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MICHIELI P, 1994, CANCER RES, V54, P3391; MUNGER K, 1989, J VIROL, V63, P4417; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1990, CANCER RES, V50, P6075; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	55	67	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					253	261						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624142				2022-12-25	WOS:A1995RK95700006
J	ENENKEL, C; BLOBEL, G; REXACH, M				ENENKEL, C; BLOBEL, G; REXACH, M			IDENTIFICATION OF A YEAST KARYOPHERIN HETERODIMER THAT TARGETS IMPORT SUBSTRATE TO MAMMALIAN NUCLEAR-PORE COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; KARYOPHILIC PROTEINS; TRANSLOCATION; TRANSPORT; ENVELOPE; INVITRO	Targeting of import substrate to nuclear pore complexes of permeabilized vertebrate cells was previously shown to require a protein complex composed of two subunits, termed karyopherin. Yeast contain a homologue of karyopherin alpha named Srp1p, which was initially identified as a genetic Suppressor of mutations in a subunit of RNA polymerase I. To determine whether yeast contain a karyopherin complex that includes Srp1p as the karyopherin alpha homologue, we genetically replaced Srp1p with a Srp1-Protein A chimera, Cytosol from this strain contained a complex, composed of the chimera and a protein of 95 kDa, that was purified using affinity chromatography on IgG Sepharose, Microsequence analysis showed that the 95-kDa protein was identical with a yeast protein encoded by gene L8300.15 on chromosome XII. Sequence comparison revealed that the L8300.15 gene product is the closest structural homologue of vertebrate karyopherin beta. The yeast alpha and beta karyopherin subunits were expressed in Escherichia coli and were purified, When combined, they formed a heterodimeric complex and were active in targeting import substrate to nuclear envelopes of mammalian cells. We propose that all karyopherins function as alpha/beta heterodimers.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University								ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; [Anonymous], 1991, Methods Enzymol, V194, P1; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KALINICH JF, 1989, J BIOL CHEM, V264, P17979; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, IN PRESS P NATL ACAD; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SIKORSKI RS, 1989, GENETICS, V122, P19; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	30	194	196	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16499	16502		10.1074/jbc.270.28.16499	http://dx.doi.org/10.1074/jbc.270.28.16499			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622450	hybrid			2022-12-25	WOS:A1995RJ34700005
J	ROWLINSON, SW; BARNARD, R; BASTIRAS, S; ROBINS, AJ; BRINKWORTH, R; WATERS, MJ				ROWLINSON, SW; BARNARD, R; BASTIRAS, S; ROBINS, AJ; BRINKWORTH, R; WATERS, MJ			A GROWTH-HORMONE AGONIST PRODUCED BY TARGETED MUTAGENESIS AT BINDING-SITE-1 - EVIDENCE THAT SITE-1 REGULATES BIOACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; SCANNING MUTAGENESIS; RABBIT LIVER; RECEPTOR; PURIFICATION; PROTEIN; SERUM	Growth hormone (GH) is believed to signal by dimerizing its receptor through two binding sites on the hormone, Previous attempts to increase the biopotency of GH by increasing its site 1 affinity have been unsuccessful, which has led to a bias toward engineering site 2 interactions in the quest for creation of super agonists, Here we report that increasing site 1 affinity can markedly increase proliferative bioactivity in FDC-P1 cells expressing full-length GHR, In contrast, we find three site 1 mutants with affinities for site one similar to or greater than wild type GH, which have markedly decreased bioactivity. Through crystal structure analysis of the receptor interactive regions of these GH analogues, we are able to suggest why previous mutagenesis on human GH failed to improve biopotency, and thus provide a new avenue for GH and cytokine agonist design.	UNIV QUEENSLAND,CTR MOLEC BIOL & BIOTECHNOL,BRISBANE,QLD 4072,AUSTRALIA; BRESATEC LTD,ADELAIDE,SA 5001,AUSTRALIA; UNIV QUEENSLAND,CTR DRUG DESIGN & DEV,BRISBANE,QLD 4072,AUSTRALIA	University of Queensland; University of Queensland	ROWLINSON, SW (corresponding author), UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA.		waters, michael j/C-9582-2014; Barnard, Ross/AAR-9852-2020	Barnard, Ross/0000-0002-5685-4828				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BARNARD R, 1988, BIOCHEM J, V250, P533, DOI 10.1042/bj2500533; BARNARD R, 1986, BIOCHEM J, V237, P885, DOI 10.1042/bj2370885; BASTIRAS S, 1992, BIOCHEMISTRY-US, V31, P9304, DOI 10.1021/bi00153a025; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BELLEAU B, 1964, J MED CHEM, V7, P776, DOI 10.1021/jm00336a022; CAMPBELL RG, 1988, J ANIM SCI, V66, P1643; CLARK AJ, 1937, HDB EXPERIMENTELLEN, V4, P4; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GOBIUS KS, 1992, J MOL ENDOCRINOL, V9, P213, DOI 10.1677/jme.0.0090213; HAPEL AJ, 1984, BLOOD, V64, P786; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; ROWLINSON SW, 1994, BIOCHEMISTRY-US, V33, P11724, DOI 10.1021/bi00205a008; SEELY JE, 1992, 74TH ANN M END SOC S; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; WATERS MJ, 1979, J BIOL CHEM, V254, P6815; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253; [No title captured]	29	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16833	16839		10.1074/jbc.270.28.16833	http://dx.doi.org/10.1074/jbc.270.28.16833			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622498	hybrid			2022-12-25	WOS:A1995RJ34700059
J	TIPPING, AJ; MCPHERSON, MJ				TIPPING, AJ; MCPHERSON, MJ			CLONING AND MOLECULAR ANALYSIS OF THE PEA SEEDLING COPPER AMINE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-METHYLPUTRESCINE OXIDASE; DIAMINE-OXIDASE; FUNCTIONAL EXPRESSION; PEROXIDASE-ACTIVITIES; STRUCTURAL GENE; TOBACCO ROOTS; TOPA QUINONE; ACTIVE-SITE; SEQUENCE; PURIFICATION	A pea seedling amine oxidase cDNA has been isolated and sequenced. A single long open reading frame has amino acid sequences corresponding to those determined from active site peptide (Janes, S. M., Palcic, M. M., Scaman, C. H., Smith, A. J., Brown, D. E., Dooley, D. M., Mure, M., and Klinman, J.P. (1992) Biochemistry 31, 12147-12154) and N-terminal sequencing experiments, The latter reveals the protein to have a 25-amino acid leader sequence with characteristics of a secretion signal peptide, as expected for this extracellular enzyme. Comparisons of the amino acid sequence of the mature pea enzyme (649 amino acids) with that of the mature lentil enzyme (569 amino acids; Rossi, A., Petruzzelli, R., and Finazzi-Agro, A. (1992) FEBS Lett. 301, 253-257) reveal important and unexpected differences particularly with regard to protein length. Sequencing of part of the lentil gene identified several frameshift differences within the coding region resulting in a mature lentil protein of exactly the same length, 649 amino acids, as the pea enzyme. Multiple alignments of 10 copper amine oxidase sequences reveal 33 completely conserved residues of which 10 are found within 41 aligned residues at the C-terminal tails, the region missing from the original lentil sequence. One of only four conserved histidines is found in this region and may represent the third ligand to the copper, The pea enzyme contains around 3-4% carbohydrate as judged by deglycosylation experiments. We have also demonstrated by hybridization analysis that copper amine oxidase genes are present in a range of mono- and dicotyledonous plants.	UNIV LEEDS, DEPT BIOCHEM & MOLEC BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; UNIV LEEDS, CTR PLANT BIOCHEM & BIOTECHNOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds; University of Leeds				McPherson, Michael/0000-0002-0719-6427				ANGELINI R, 1993, J PLANT PHYSIOL, V142, P704, DOI 10.1016/S0176-1617(11)80906-5; ANGELINI R, 1990, PLANTA, V182, P89, DOI 10.1007/BF00239989; ANGELINI R, 1989, J PLANT PHYSIOL, V135, P212, DOI 10.1016/S0176-1617(89)80179-8; ANGELINI R, 1985, BIOCH STUDIES NATURA, P183; AZAKAMI H, 1994, J FERMENT BIOENG, V77, P315, DOI 10.1016/0922-338X(94)90241-0; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BARKER GJ, 1986, BIOCHEM J, V237, P609; BRUINENBERG PG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P157, DOI 10.1016/0167-4781(80)90003-2; CAI DY, 1994, J BIOL CHEM, V269, P32039; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; CHOI YH, 1995, J BIOL CHEM, V270, P4712, DOI 10.1074/jbc.270.9.4712; COOPER RA, 1992, BIOCHEM J, V288, P337, DOI 10.1042/bj2880337; DAVIES HM, 1989, PHYTOCHEMISTRY, V28, P1573, DOI 10.1016/S0031-9422(00)97802-6; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; FARNUM M, 1986, BIOCHEMISTRY-US, V25, P1898, DOI 10.1021/bi00356a010; FEDERICO R, 1988, PLANTA, V173, P317, DOI 10.1007/BF00401018; FEDERICO R, 1985, CELL MOL BIOL, V31, P171; FEDERICO R, 1986, PLANTA, V167, P300, DOI 10.1007/BF00391430; FEDERICO R, 1988, PLASMA MEMBRANE OXID, P333; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FETH F, 1986, PLANTA, V168, P402, DOI 10.1007/BF00392368; GURR SJ, 1992, MOL PLANT PATHOL, V1, P109; HAINES BD, 1981, GEL ELECTROPHORESIS, P1; HASHIMOTO T, 1990, PLANT PHYSIOL, V93, P216, DOI 10.1104/pp.93.1.216; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOOPES BC, 1981, NUCLEIC ACIDS RES, V9, P5493, DOI 10.1093/nar/9.20.5493; HUNT AG, 1994, ANNU REV PLANT PHYS, V45, P47, DOI 10.1146/annurev.pp.45.060194.000403; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; KNOWLES PF, 1994, MET IONS BIOL SYST, V30, P361; Large P. J., 1986, YEAST, V2, P1; LINGUEGLIA E, 1993, EUR J BIOCHEM, V216, P679, DOI 10.1111/j.1432-1033.1993.tb18188.x; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MCCRACKEN J, 1987, J AM CHEM SOC, V109, P4064, DOI 10.1021/ja00247a037; MCGOWAN RE, 1971, PLANT PHYSIOL, V47, P644, DOI 10.1104/pp.47.5.644; MCGUIRL MA, 1994, PLANT PHYSIOL, V106, P1205, DOI 10.1104/pp.106.3.1205; McIntire W. S., 1993, COPPER CONTAINING AM, P97; MIZUSAKI S, 1972, PHYTOCHEMISTRY, V11, P2757, DOI 10.1016/S0031-9422(00)86509-7; MU D, 1994, J BIOL CHEM, V269, P9926; MU D, 1992, J BIOL CHEM, V267, P7979; PARRYSMITH DJ, 1991, COMPUT APPL BIOSCI, V7, P233; PEDERSEN JZ, 1992, BIOCHEMISTRY-US, V31, P8, DOI 10.1021/bi00116a002; PERCIVAL FW, 1974, PLANT PHYSIOL, V54, P601, DOI 10.1104/pp.54.4.601; RINALDI A, 1982, EUR J BIOCHEM, V127, P417, DOI 10.1111/j.1432-1033.1982.tb06888.x; ROB JH, 1994, J MOL BIOL, V238, P635, DOI 10.1006/jmbi.1994.1321; ROSSI A, 1992, FEBS LETT, V301, P253, DOI 10.1016/0014-5793(92)80251-B; Sambrook J, 1989, MOL CLONING LABORATO; SCALET M, 1991, J PLANT PHYSIOL, V137, P571, DOI 10.1016/S0176-1617(11)80701-7; SCOTT RA, 1985, J AM CHEM SOC, V107, P4348, DOI 10.1021/ja00300a055; SLOCUM RD, 1991, PLANTA, V183, P443; SMITH TA, 1985, BIOCHEM SOC T, V13, P319, DOI 10.1042/bst0130319; SRIVASTAVA SK, 1977, PHYTOCHEMISTRY, V16, P185, DOI 10.1016/S0031-9422(00)86781-3; STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217; SUGINO H, 1992, J BACTERIOL, V174, P2485, DOI 10.1128/jb.174.8.2485-2492.1992; SUZUKI Y, 1993, PHYTOCHEMISTRY, V33, P995, DOI 10.1016/0031-9422(93)85010-O; TANIZAWA K, 1994, BIOCHEM BIOPH RES CO, V199, P1096, DOI 10.1006/bbrc.1994.1343; TORRIGIANI P, 1989, PLANT PHYSIOL, V89, P69, DOI 10.1104/pp.89.1.69; TSUSHIDA T, 1985, AGR BIOL CHEM TOKYO, V49, P319, DOI 10.1080/00021369.1985.10866725; VIGNEVICH V, 1993, J MOL BIOL, V229, P243, DOI 10.1006/jmbi.1993.1022; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZHANG XP, 1993, J BACTERIOL, V175, P5617, DOI 10.1128/JB.175.17.5617-5627.1993	63	109	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16939	16946		10.1074/jbc.270.28.16939	http://dx.doi.org/10.1074/jbc.270.28.16939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622512	hybrid			2022-12-25	WOS:A1995RJ34700073
J	VALDIZAN, EM; LOUKIANOV, EV; OLSNES, S				VALDIZAN, EM; LOUKIANOV, EV; OLSNES, S			INDUCTION OF TOXIN SENSITIVITY IN INSECT CELLS BY INFECTION WITH BACULOVIRUS ENCODING DIPHTHERIA-TOXIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERO CELLS; LOW PH; GROWTH-FACTOR; MOUSE CELLS; CD9 ANTIGEN; MEMBRANE; EXPRESSION; BINDING; PROTEIN; ENTRY	The diphtheria toxin receptor (DTR) has been identified as the precursor of heparin-binding epidermal growth factor-like growth factor, which may interact with other membrane proteins to form the functional receptor. To test if mammalian DTR is able to confer toxin sensitivity onto phylogenetically distant cells, we expressed monkey DTR in the baculovirus system and tested infected insect cells for toxin sensitivity. cDNA encoding an epitope-tagged heparin-binding epidermal growth factor-like growth factor precursor (DTR(B3)) was inserted into the virus genome by allelic replacement to construct the recombinant virus VAc-DTR(B3). SF9 cells infected with vAc-DTR(B3), expressed functional DTR, which could be precipitated from the solubilized membrane fraction of infected cells with Sepharose-immobilized diphtheria toxin. The highest level of expression (about 5 x 10(6) receptors/cell) was observed 48 h after infection, at which time the infected cells were highly sensitive to diphtheria toxin. Uninfected SF9 cells and cells infected with the wild type virus were resistant to the toxin. The presence of heparin increased both the binding and the toxin sensitivity of vAc-DTR(B3)-infected SF9 cells. Translocation of toxin A fragment was induced when cells with surface bound toxin were exposed to low pH, and the translocation was optimal at pH less than or equal to 5.5. It was similar to 100 times more efficient at 24 degrees C than at 4 degrees C. The data indicate that monkey DTR is fully functional when expressed in insect cells.	NORWEGIAN RADIUM HOSP,CANC RES INST,DEPT BIOCHEM,N-0310 OSLO,NORWAY	University of Oslo				Valdizan, Elsa/0000-0001-8898-8217				BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BROWN JG, 1993, P NATL ACAD SCI USA, V90, P8184, DOI 10.1073/pnas.90.17.8184; CHRISTOPHE S, 1993, BIOCHEM BIOPH RES CO, V196, P402, DOI 10.1006/bbrc.1993.2263; CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; KOHNO K, 1987, EXP CELL RES, V172, P54, DOI 10.1016/0014-4827(87)90092-9; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; MEKADA E, 1982, BIOCHEM BIOPH RES CO, V109, P792, DOI 10.1016/0006-291X(82)92009-5; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P147; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NAGLICH JG, 1992, P NATL ACAD SCI USA, V89, P2170, DOI 10.1073/pnas.89.6.2170; ONO M, 1994, J BIOL CHEM, V269, P31315; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P216; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PARKER EM, 1991, J BIOL CHEM, V266, P519; REILANDER H, 1991, FEBS LETT, V282, P441, DOI 10.1016/0014-5793(91)80532-8; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH GE, 1993, J VIROL, V46, P584; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555	37	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16879	16885		10.1074/jbc.270.28.16879	http://dx.doi.org/10.1074/jbc.270.28.16879			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622504	hybrid			2022-12-25	WOS:A1995RJ34700065
J	LEONE, TC; CRESCI, S; CARTER, ME; ZHANG, ZF; LALA, DS; STRAUSS, AW; KELLY, DP				LEONE, TC; CRESCI, S; CARTER, ME; ZHANG, ZF; LALA, DS; STRAUSS, AW; KELLY, DP			THE HUMAN MEDIUM-CHAIN ACYL-COA DEHYDROGENASE GENE PROMOTER CONSISTS OF A COMPLEX ARRANGEMENT OF NUCLEAR RECEPTOR RESPONSE ELEMENTS AND SP1 BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR; ALPHA-SUBUNIT; MOUSE; PROTEINS; CLONING; HORMONE; FAMILY; SUPERFAMILY; DEFICIENCY	Expression of the gene encoding the mitochondrial fatty acid beta-oxidation enzyme, medium-chain acyl-CoA dehydrogenase (MCAD), is regulated among tissues during development and in response to alterations in substrate availability. To identify and characterize cis-acting MCAD gene promoter regulatory elements and corresponding transcription factors, DNA-protein binding studies and mammalian cell transfection analyses were performed with human MCAD gene promoter fragments, DNA:protein binding studies with nuclear protein extracts prepared from hepatoma G2 cells, 3T3 fibroblasts, or Y-1 adrenal tumor cells identified three sequences (nuclear receptor response element 1 or NRRE-1, NRRE-2, and NRRE-3) that bind orphan mem members of the steroid/thyroid nuclear receptor superfamily including chicken ovalbumin upstream promoter transcription factor and steroidogenic factor 1, Sp1 binding sites (A-C) were identified in close proximity to each of the NRREs. NRRE-3 conferred cell line-specific transcriptional repression by interacting with chicken ovalbumin upstream promoter transcription factor or activation via steroidogenic factor 1. In contrast, the Sp1 binding site A behaved as a transcriptional activator in all cell lines examined, Ne propose that multiple nuclear receptor transcription factors interact with MCAD gene promoter elements to differentially regulate transcription among a variety of cell types.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV CARDIOVASC,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Duke University			Kelly, Daniel/ABG-2056-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045416, R29DK045416] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45416-03] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; BEINERT H, 1963, ENZYMES, P447; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BROWN CJ, 1992, GENE, V121, P313, DOI 10.1016/0378-1119(92)90136-D; CARTER ME, 1993, J BIOL CHEM, V268, P13805; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CHAN CA, 1992, J BIOL CHEM, V267, P6999; DESAIYAJNIK V, 1993, MOL CELL BIOL, V13, P5057, DOI 10.1128/MCB.13.8.5057; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DURAN M, 1986, PEDIATRICS, V78, P1052; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KELLY DP, 1989, J BIOL CHEM, V264, P18921; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NAGAO M, 1993, J BIOL CHEM, V268, P24114; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; STANLEY CA, 1983, PEDIATR RES, V17, P877, DOI 10.1203/00006450-198311000-00008; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SYLVESTER I, 1994, NUCLEIC ACIDS RES, V22, P901, DOI 10.1093/nar/22.6.901; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; TENG CT, 1992, MOL ENDOCRINOL, V6, P1969, DOI 10.1210/me.6.11.1969; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEHRENBERG U, 1994, P NATL ACAD SCI USA, V91, P1440, DOI 10.1073/pnas.91.4.1440; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; XU J, 1993, J BIOL CHEM, V268, P16065; ZHANG ZF, 1992, BIOCHEMISTRY-US, V31, P81, DOI 10.1021/bi00116a013	42	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16308	16314		10.1074/jbc.270.27.16308	http://dx.doi.org/10.1074/jbc.270.27.16308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608198	hybrid			2022-12-25	WOS:A1995RH22600065
J	NISIMOTO, Y; OTSUKAMURAKAMI, H; LAMBETH, DJ				NISIMOTO, Y; OTSUKAMURAKAMI, H; LAMBETH, DJ			RECONSTITUTION OF FLAVIN-DEPLETED NEUTROPHIL FLAVOCYTOCHROME B(558) WITH 8-MERCAPTO-FAD AND CHARACTERIZATION OF THE FLAVIN-RECONSTITUTED ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CHRONIC GRANULOMATOUS-DISEASE; PHAGOCYTE NADPH-OXIDASE; ACTIVE-SITE PROBES; CELL-FREE SYSTEM; FLAVOPROTEIN COMPONENT; SUPEROXIDE GENERATION; CYTOSOLIC COMPONENT; PORCINE NEUTROPHILS	Cytochrome b(558) isolated from human neutrophils was inactive and contained no detectable FAD, However, high NADPH oxidase activity was seen upon reconstitution of the cytochrome with either native FAD or 8-mercapto-FAD in the presence of phospholipids (phosphatidylcholine/phosphatidylethanolamine/phosphatidylinositol/sphingomyelin/cholesterol, 4:2:1:3:3 (w/w)). Their cell-free superoxide-generating activities were 40.5 and 35.5 mol/s/mol of heme, respectively, which corresponded to 70 and 61% of the original activity of the plasma membranes, Both flavins co-eluted with heme and protein on gel exclusion chromatography. The respective specific flavin content was 6.45 and 7.93 nmol/mg of protein and corresponded to a flavin:heme molar ratio of 0.41 and 0.51 consistent with a 2:1 ratio of heme to flavin. Mixing of 8-mercapto-FAD with flavin-depleted cytochrome b(558) caused a red-shift of the flavin absorption maximum from 520 nm to around 560 nn, as has been seen when a variety of other apoflavoprotein dehydrogenases bind this analog. The 8-mercapto-FAD reconstituted into the cytochrome reacted readily with either iodoacetamide (k = 38.8 M(-1). min(-1)) or iodoacetic acid (k = 12.1 M(-1). min(-1)) to give a fluorescence spectrum characteristic of a 8-mercaptoflavin derivative, 8-SCH2CONH2 FAD or 8-SCH2COOH FAD. These results indicate that position 8 of FAD bound to the protein is freely accessible to solvent. These studies support the idea that cytochrome b(558) is a flavocytochrome.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University	NISIMOTO, Y (corresponding author), AICHI MED UNIV,DEPT BIOCHEM,NAGAKUTE,AICHI 48011,JAPAN.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22809] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1977, BLOOD, V50, P517; BORREGAARD N, 1984, J BIOL CHEM, V259, P47; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CROSS AR, 1982, BIOCHEM J, V208, P759, DOI 10.1042/bj2080759; GABIG TG, 1983, J BIOL CHEM, V258, P6352; HALEY EE, 1954, J AM CHEM SOC, V76, P5093, DOI 10.1021/ja01649a025; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; KAKINUMA K, 1986, J BIOL CHEM, V261, P9426; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIGHT DR, 1981, BIOCHEMISTRY-US, V20, P1468, DOI 10.1021/bi00509a010; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTER R, 1985, J BIOL CHEM, V260, P2237; MANSTEIN DJ, 1986, J BIOL CHEM, V261, P6169; MARKERT M, 1985, P NATL ACAD SCI USA, V82, P3144, DOI 10.1073/pnas.82.10.3144; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MIKI T, 1992, J BIOL CHEM, V267, P18695; MOORE EG, 1978, J BIOL CHEM, V254, P8173; NAKAMURA M, 1988, BLOOD, V72, P1550; NISIMOTO Y, 1994, BIOCHEM J, V297, P585, DOI 10.1042/bj2970585; NISIMOTO Y, 1993, ARCH BIOCHEM BIOPHYS, V302, P215; NISIMOTO Y, 1990, BIOCHIM BIOPHYS ACTA, V1010, P260; PARKINSON JF, 1988, J BIOENERG BIOMEMBR, V20, P653, DOI 10.1007/BF00762547; PARKINSON JF, 1988, J BIOL CHEM, V263, P8859; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEMBER SO, 1983, BLOOD, V61, P1105; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; Rudolph S A, 1979, Adv Cyclic Nucleotide Res, V10, P107; SCHOPFER LM, 1981, J BIOL CHEM, V256, P7329; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1989, J CLIN INVEST, V326, P88; SMITH RM, 1989, J BIOL CHEM, V264, P1958; SWAIN CG, 1968, J AM CHEM SOC, V90, P4328, DOI 10.1021/ja01018a024; TAKASUGI S, 1989, J BIOCHEM-TOKYO, V105, P155, DOI 10.1093/oxfordjournals.jbchem.a122630; TANAKA T, 1990, J BIOL CHEM, V265, P18717; TAUBER AI, 1979, BIOCHEMISTRY-US, V18, P5576, DOI 10.1021/bi00592a009; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEI T, 1991, J BIOL CHEM, V266, P6019; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195	49	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16428	16434		10.1074/jbc.270.27.16428	http://dx.doi.org/10.1074/jbc.270.27.16428			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608214	hybrid			2022-12-25	WOS:A1995RH22600082
J	FAGO, A; CARRATORE, V; DIPRISCO, G; FEUERLEIN, RJ; SOTTRUPJENSEN, L; WEBER, RE				FAGO, A; CARRATORE, V; DIPRISCO, G; FEUERLEIN, RJ; SOTTRUPJENSEN, L; WEBER, RE			THE CATHODIC HEMOGLOBIN OF ANGUILLA-ANGUILLA - AMINO-ACID-SEQUENCE AND OXYGEN EQUILIBRIA OF A REVERSE BOHR EFFECT HEMOGLOBIN WITH HIGH OXYGEN-AFFINITY AND HIGH PHOSPHATE SENSITIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROUT SALMO-IRIDEUS; LIGAND-BINDING; ALPHA-CHAIN; NUCLEOSIDE TRIPHOSPHATES; FUNCTIONAL-PROPERTIES; ALLOSTERIC MECHANISM; MULTIPLE HEMOGLOBINS; RANA-CATESBEIANA; FISH HEMOGLOBINS; CYPRINUS-CARPIO	As in other fish, the cathodic hemoglobin of the eel Anguilla anguilla is considered to play an important role in oxygen transport under hypoxic and acidotic conditions. In the absence of phosphates this hemoglobin shows a reverse Bohr effect and high oxygen affinity, which is strongly modulated over a wide pH range by GTP (whose concentration in the red blood cells varies with ambient oxygen availability), GTP obliterates the reverse Bohr effect in the cathodic hemoglobin. The molecular basis for the reverse Bohr effect in fish hemoglobins has remained obscure due to the lack of structural data. We have determined the complete amino acid sequence of the alpha and beta chains of the cathodic hemoglobin of A. anguilla and relate it to the oxygen equilibrium characteristics. Several substitutions in crucial positions are observed compared with other hemoglobins, such as the replacement of the C-terminal His of the beta chain by Phe (that suppresses the alkaline Bohr effect) and of residues at the switch region between alpha and beta subunits (that may alter the allosteric equilibrium, thus causing the high intrinsic oxygen affinity and low cooperativity). The residues binding organic phosphate in the beta cleft of fish hemoglobins are conserved, which explains the strong effect of GTP on oxygen affinity and suggests that these residues contribute to the reverse Bohr effect in the absence of alkaline Bohr groups. Moreover, His(beta 14S) that is considered to be responsible for the reverse Bohr effect in human and tadpole Hbs is replaced by Lys.	AARHUS UNIV,INST BIOL SCI,DEPT ZOOPHYSIOL,DK-8000 AARHUS C,DENMARK; CNR,INST PROT BIOCHEM & ENZYMOL,I-80125 NAPLES,ITALY; AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS C,DENMARK	Aarhus University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Aarhus University			Fago, Angela/J-5946-2013	Fago, Angela/0000-0001-7315-2628				ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; ATHA DH, 1979, J BIOL CHEM, V254, P3393; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BARRA D, 1983, BIOCHIM BIOPHYS ACTA, V742, P72, DOI 10.1016/0167-4838(83)90360-6; BINOTTI I, 1971, ARCH BIOCHEM BIOPHYS, V142, P274, DOI 10.1016/0003-9861(71)90284-0; BONAVENTURA C, 1977, NATURE, V265, P474, DOI 10.1038/265474a0; BONAVENTURA C, 1978, BIOCH CLIN ASPECTS H, P641; BOSSA F, 1978, BIOCHIM BIOPHYS ACTA, V536, P298, DOI 10.1016/0005-2795(78)90077-6; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; BRUNORI M, 1979, COMP BIOCHEM PHYS A, V62, P173, DOI 10.1016/0300-9629(79)90751-5; CARUSO C, 1991, BIOCHIM BIOPHYS ACTA, V1078, P273, DOI 10.1016/0167-4838(91)90569-L; CONDO SG, 1981, EUR J BIOCHEM, V120, P323, DOI 10.1111/j.1432-1033.1981.tb05707.x; DAVINO R, 1989, EUR J BIOCHEM, V179, P707, DOI 10.1111/j.1432-1033.1989.tb14604.x; DAVINO R, 1992, POLAR BIOL, V12, P135, DOI 10.1007/BF00239974; di Prisco G., 1991, BIOL ANTARCTIC FISH; FAGO A, 1992, EUR J BIOCHEM, V210, P963, DOI 10.1111/j.1432-1033.1992.tb17501.x; FAGO A, 1993, EUR J BIOCHEM, V218, P829, DOI 10.1111/j.1432-1033.1993.tb18438.x; FANELLI AR, 1958, BIOCHIM BIOPHYS ACTA, V30, P608, DOI 10.1016/0006-3002(58)90108-2; FERMI G, 1981, ATLAS MOL STRUCTURES, V2; FEUERLEIN RJ, 1993, J EXP BIOL, V189, P273; FRONTICELLI C, 1994, J BIOL CHEM, V269, P23965; GARLICK RL, 1979, COMP BIOCHEM PHYS A, V62, P219, DOI 10.1016/0300-9629(79)90759-X; GILLEN RG, 1972, J BIOL CHEM, V247, P6039; GILLEN RG, 1973, J BIOL CHEM, V248, P1961; GRONENBORN AM, 1984, J MOL BIOL, V178, P731, DOI 10.1016/0022-2836(84)90249-3; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; GRUJICINJAC B, 1980, H-S Z PHYSIOL CHEM, V361, P1629, DOI 10.1515/bchm2.1980.361.2.1629; HYDE DA, 1987, J COMP PHYSIOL B, V157, P635, DOI 10.1007/BF00700984; KILMARTIN JV, 1970, NATURE, V228, P766, DOI 10.1038/228766a0; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; LESK AM, 1985, J MOL BIOL, V183, P267, DOI 10.1016/0022-2836(85)90219-0; LICATA VJ, 1993, PROTEINS, V17, P279, DOI 10.1002/prot.340170306; MARTIN JP, 1979, COMP BIOCHEM PHYS A, V62, P155, DOI 10.1016/0300-9629(79)90748-5; MARUYAMA T, 1980, J BIOL CHEM, V255, P3285; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MORPURGO G, 1970, NATURE, V225, P76, DOI 10.1038/225076a0; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1985, J MOL BIOL, V183, P491, DOI 10.1016/0022-2836(85)90016-6; PERUTZ MF, 1982, NATURE, V299, P421, DOI 10.1038/299421a0; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; PETRUZZELLI R, 1989, BIOCHIM BIOPHYS ACTA, V995, P255, DOI 10.1016/0167-4838(89)90043-5; POWERS DA, 1972, J BIOL CHEM, V247, P6686; RIGGS AF, 1988, ANNU REV PHYSIOL, V50, P181, DOI 10.1146/annurev.ph.50.030188.001145; RODEWALD K, 1984, H-S Z PHYSIOL CHEM, V365, P95, DOI 10.1515/bchm2.1984.365.1.95; RODEWALD K, 1987, BIOL CHEM H-S, V368, P795, DOI 10.1515/bchm3.1987.368.2.795; SHIH DTB, 1993, J MOL BIOL, V230, P1291; SHIH TB, 1984, J BIOL CHEM, V259, P967; TAME J, 1991, J MOL BIOL, V218, P761, DOI 10.1016/0022-2836(91)90264-7; WATT KWK, 1980, J BIOL CHEM, V255, P3294; WEBER RE, 1987, J COMP PHYSIOL B, V157, P145, DOI 10.1007/BF00692358; WEBER RE, 1979, COMP BIOCHEM PHYS A, V62, P179, DOI 10.1016/0300-9629(79)90752-7; WEBER RE, 1990, COMP PHYSIOL, V6, P58; WEBER RE, 1976, J EXP BIOL, V65, P333; WEBER RE, 1981, NATURE, V292, P386, DOI 10.1038/292386a0; WEBER RE, 1976, J EXP BIOL, V64, P75; WEBER RE, 1992, J APPL PHYSIOL, V72, P1611, DOI 10.1152/jappl.1992.72.4.1611; WOOD SC, 1972, NATURE-NEW BIOL, V237, P278, DOI 10.1038/newbio237278a0; WOOD SC, 1973, AM J PHYSIOL, V225, P849, DOI 10.1152/ajplegacy.1973.225.4.849	62	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18897	18902		10.1074/jbc.270.32.18897	http://dx.doi.org/10.1074/jbc.270.32.18897			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642546	hybrid			2022-12-25	WOS:A1995RN95400033
J	KIEHLBAUCH, CC; LAM, YF; RINGER, DP				KIEHLBAUCH, CC; LAM, YF; RINGER, DP			HOMODIMERIC AND HETERODIMERIC ARYL SULFOTRANSFERASES CATALYZE THE SULFURIC-ACID ESTERIFICATION OF N-HYDROXY-2-ACETYLAMINOFLUORENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; GLUTATHIONE TRANSFERASES; N-HYDROXYARYLAMINE; GROWTH-HORMONE; IV; HEPATOCARCINOGENESIS; EXPRESSION; CDNA; DNA; IDENTIFICATION	Three aryl sulfotransferases (ASTs) isolated from rat liver catalyze the sulfuric acid esterification of the carcinogen N-hydroxy-2-acetylaminofluorene (N-OH-2AAF), These three ASTs were separated by high resolution anion exchange chromatography and were designated Q1, Q2, and Q3. Q1 and Q2 had high N-OH-2AAF sulfonation activity, whereas Q3 showed low activity, Reversed phase high performance liquid chromatography/mass spectrometry analysis showed Q1 Q3 to be comprised of 33,945- and 35,675-Da protein subunits, Q1 contained only the 35,675-Da protein subunit, Q2 contained equal quantities of 33,945- and 35,675-Da subunits, and Q3 contained only the 33,945-Da subunit. The subunit compositions of Q1-Q3 were confirmed by immunochemical analysis, Size exclusion high performance Liquid chromatography confirmed that the active quaternary structure of the three isoenzymes was dimeric, Analysis of liver cytosols for the relative contributions of Q1-Q3 to total cytosolic N-OH-2AAF sulfotransferase activity indicated that Q1, Q2, and Q3 accounted for 44, 46, and 10% of the activity, respectively, These results demonstrate the existence of both homodimeric and heterodimeric aryl sulfotransferases and show that two ASTs, a homodimer of 35,675-Da subunits and a heterodimer of a 33,945- and a 35,675-Da subunit, are primarily responsible for hepatic N-OH-2AAF sulfotransferase activity.	OKLAHOMA MED RES FDN, NOBLE CTR BIOMED RES, OKLAHOMA CITY, OK 73104 USA	Oklahoma Medical Research Foundation								BLANCK A, 1991, CARCINOGENESIS, V12, P1259, DOI 10.1093/carcin/12.7.1259; CHEN X, 1992, PROTEIN EXPRES PURIF, V3, P421, DOI 10.1016/S1046-5928(05)80045-2; Cleland W W, 1979, Methods Enzymol, V63, P103; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; DEBAUN JR, 1970, CANCER RES, V30, P577; DUFFEL MW, 1991, MOL PHARMACOL, V40, P36; FARBER E, 1984, CANCER RES, V44, P5463; GONG DW, 1991, J BIOCHEM-TOKYO, V110, P226, DOI 10.1093/oxfordjournals.jbchem.a123561; HAYES JD, 1994, J BIOL CHEM, V269, P20707; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIRSHEY SJ, 1992, MOL PHARMACOL, V42, P257; JACOBY W, 1981, METHOD ENZYMOL, V77, P197; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P199; KATO R, 1994, DRUG METAB REV, V26, P413, DOI 10.3109/03602539409029806; KHAN AS, 1993, GENE, V137, P321, DOI 10.1016/0378-1119(93)90028-2; LAI CC, 1985, CARCINOGENESIS, V6, P1037, DOI 10.1093/carcin/6.7.1037; MANGOLD BLK, 1990, CARCINOGENESIS, V11, P1563, DOI 10.1093/carcin/11.9.1563; MEERMAN JHN, 1981, CARCINOGENESIS, V2, P413, DOI 10.1093/carcin/2.5.413; Miller E C, 1985, Carcinog Compr Surv, V10, P93; MILLER EC, 1981, CANCER-AM CANCER SOC, V47, P2327, DOI 10.1002/1097-0142(19810515)47:10<2327::AID-CNCR2820471003>3.0.CO;2-Z; Mulder G.J., 1990, CONJUGATION REACTION, P107; NAGATA K, 1993, J BIOL CHEM, V268, P24720; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OZAWA S, 1990, NUCLEIC ACIDS RES, V18, P4001, DOI 10.1093/nar/18.13.4001; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; RINGER DP, 1994, MOL CARCINOGEN, V9, P2, DOI 10.1002/mc.2940090103; RINGER DP, 1988, CANCER LETT, V40, P247, DOI 10.1016/0304-3835(88)90083-3; RINGER DP, 1990, CANCER RES, V50, P5301; RINGER DP, 1994, CHEM-BIOL INTERACT, V92, P1; ROBERTSON IGC, 1986, CARCINOGENESIS, V7, P295; SATO K, 1989, ADV CANCER RES, V52, P205; SCOPES RK, 1987, PROTEIN PURIFICATION, P278; SEKURA RD, 1981, ARCH BIOCHEM BIOPHYS, V211, P352, DOI 10.1016/0003-9861(81)90464-1; WEBB EC, 1992, ENZYME NOMENCLATURE, P299; WESTRA JG, 1976, CHEM-BIOL INTERACT, V15, P149, DOI 10.1016/0009-2797(76)90160-5; YAMAZOE Y, 1987, MOL PHARMACOL, V32, P536; YEROKUN T, 1992, CANCER RES, V52, P4779	37	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18941	18947		10.1074/jbc.270.32.18941	http://dx.doi.org/10.1074/jbc.270.32.18941			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642552	hybrid			2022-12-25	WOS:A1995RN95400040
J	LEE, JH; LEE, JS; JAYARAM, M				LEE, JH; LEE, JS; JAYARAM, M			JUNCTION MOBILITY AND RESOLUTION OF HOLLIDAY STRUCTURES BY FLP SITE-SPECIFIC RECOMBINASE - TESTING PARTNER COMPATIBILITY DURING RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-LAMBDA; STRAND TRANSFER; HALF-SITE; PROTEIN; HOMOLOGY; RECOGNITION; PLASMID; MUTANTS; BINDING	Absolute homology between partner substrates within the strand exchange region (spacer) is an essential requirement for recombination mediated by the yeast site-specific recombinase Flp. Recent experiments suggest that 3-base pair homology adjacent to the points of exchange at each end of the spacer is utilized in a base complementarity-dependent strand joining reaction. Homology of the central 2 base pairs of the spacer is also critical, but how homology is tested at these two positions is unknown, We have addressed the role of homology-dependent branch migration in Flp recombination by assaying strand cleavage and resolution in a set of synthetic Holliday junctions in which the branch point is freely or partially mobile through the spacer, or is immobilized at each position within the spacer or immediately nanking it A strong bias in the direction of Holliday resolution is observed only when the branch point is located just outside the spacer (at the junction of the Flp, binding element and the spacer). A significantly smaller bias is noticed when the branch point is frozen immediately adjacent to this position within the spacer. Resolution in these cases is most often mediated by exchange of the scissile phosphodiesters at the branch point or proximal to it, and rarely by exchange of the scissile phosphodiesters distal to it. In light of these and previous results, we discuss possible checkpoints for testing partner compatibility during Flp recombination.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin			Lee, Jehee/AAS-3229-2021	Lee, Jehee/0000-0001-9144-3648				ANDREWS BJ, 1986, MOL CELL BIOL, V6, P2482, DOI 10.1128/MCB.6.7.2482; ARCISZEWSKA LK, 1995, IN PRESS EMBO J; BAUER CE, 1985, J MOL BIOL, V181, P187, DOI 10.1016/0022-2836(85)90084-1; BAUER CE, 1984, COLD SPRING HARB SYM, V49, P699, DOI 10.1101/SQB.1984.049.01.079; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BROACH JR, 1991, MOL BIOL YEAST SACCH, P297; CHEN JW, 1992, GENE, V119, P37; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P627; COWART M, 1991, J MOL BIOL, V220, P621, DOI 10.1016/0022-2836(91)90105-F; COX MM, 1988, MOBILE DNA, P661; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DIXON JE, 1994, J MOL BIOL, V243, P199, DOI 10.1006/jmbi.1994.1647; DIXON JE, 1993, J MOL BIOL, V234, P522, DOI 10.1006/jmbi.1993.1608; HSU PL, 1984, NATURE, V311, P721, DOI 10.1038/311721a0; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; KHO SH, 1994, EMBO J, V13, P2714, DOI 10.1002/j.1460-2075.1994.tb06562.x; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEE J, 1995, J BIOL CHEM, V270, P4042, DOI 10.1074/jbc.270.8.4042; Maniatis T., 1982, MOL CLONING; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; QIAN XH, 1990, J BIOL CHEM, V265, P21779; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SENECOFF JF, 1986, J BIOL CHEM, V261, P7380; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7; WEISBERG RA, 1983, J MOL BIOL, V170, P319, DOI 10.1016/S0022-2836(83)80151-X; YANG SH, 1994, J BIOL CHEM, V269, P12789	33	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19086	19092		10.1074/jbc.270.32.19086	http://dx.doi.org/10.1074/jbc.270.32.19086			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642573	hybrid			2022-12-25	WOS:A1995RN95400061
J	BOURGUIGNON, LYW; CHU, A; JIN, H; BRANDT, NR				BOURGUIGNON, LYW; CHU, A; JIN, H; BRANDT, NR			RYANODINE RECEPTOR-ANKYRIN INTERACTION REGULATES INTERNAL CA2+ RELEASE IN MOUSE T-LYMPHOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; CALCIUM RELEASE; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; TRANSMEMBRANE GLYCOPROTEIN; INOSITOL TRISPHOSPHATE; BINDING-SITES; CHANNEL; CHARGE; PURIFICATION	In this study, we have identified and partially characterized a mouse T-lymphoma ryanodine receptor on a unique type of internal vesicle which bands at the relatively light density of 1.07 g/ml. Analysis of the binding of [H-3]ryanodine to these internal vesicles reveals the presence of a single, low affinity binding site with a dissociation constant (K-d) of 200 nM. The second messenger, cyclic ADP-ribose, was found to increase the binding affinity of [H-3]ryanodine to its vesicle receptor at least 5-fold (K-d approximate to 40 nM). In addition, cADP-ribose appears to be a potent activator of internal Ca2+ release in T-lymphoma cells and is capable of overriding ryanodine-mediated inhibition of internal Ca2+ release. Immunoblot analyses using a monoclonal mouse anti-ryanodine receptor antibody indicate that mouse T-lymphoma cells contain a 500-kDa polypeptide similar to the ryanodine receptor found in skeletal muscle, cardiac muscle, and brain tissues. Double immunofluorescence staining and laser confocal microscopic analysis show that the ryanodine receptor is preferentially accumulated underneath surface receptor-capped structures. T-lymphoma ryanodine receptor was isolated (with an apparent sedimentation coefficient of 30 S) by extraction of the light density vesicles with 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS) in 1 M NaCl followed by sucrose gradient centrifugation. Further analysis indicates that specific, high affinity binding occurs between ankyrin and this 30 S lymphoma ryanodine receptor (K-d = 0.075 nM). Most importantly, the binding of ankyrin to the light density vesicles significantly blocks ryanodine binding and ryanodine-mediated inhibition of internal Ca2+ release. These findings suggest that the cytoskeleton plays a pivotal role in the regulation of ryanodine receptor-mediated internal Ca2+ release during lymphocyte activation.	UNIV MIAMI,SCH MED,DEPT MOLEC PHARMACOL,MIAMI,FL 33101	University of Miami	BOURGUIGNON, LYW (corresponding author), UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,1600 NW 10TH AVE,MIAMI,FL 33101, USA.				NATIONAL CANCER INSTITUTE [R01CA066163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66163] Funding Source: Medline; NIGMS NIH HHS [GM 36353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT V, 1980, J BIOL CHEM, V255, P2540; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOURGUIGNON GJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P109, DOI 10.1016/0005-2736(81)90277-7; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BOURGUIGNON LYW, 1986, J CELL PHYSIOL, V127, P146, DOI 10.1002/jcp.1041270118; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; BOURGUIGNON LYW, 1988, J CELL BIOCHEM, V37, P131, DOI 10.1002/jcb.240370202; BOURGUIGNON LYW, 1992, ENCY IMMUNOLOGY, P1044; CARROLL S, 1991, ARCH BIOCHEM BIOPHYS, V290, P239, DOI 10.1016/0003-9861(91)90615-P; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; FABIATO A, 1989, MOL CELL BIOCHEM, V89, P135; Fleischer S., 1967, METHOD ENZYMOL, V10, P406; FRUEN BR, 1994, FEBS LETT, V352, P123, DOI 10.1016/0014-5793(94)00931-7; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MONNERON A, 1978, J CELL BIOL, V27, P211; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OTSU K, 1990, J BIOL CHEM, V265, P13472; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROSSIER MF, 1989, J BIOL CHEM, V264, P14078; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; WANG JP, 1993, J BIOL CHEM, V268, P20974	44	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17917	17922		10.1074/jbc.270.30.17917	http://dx.doi.org/10.1074/jbc.270.30.17917			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629097	hybrid			2022-12-25	WOS:A1995RM26600046
J	CHELSTOWSKA, A; BUTOW, RA				CHELSTOWSKA, A; BUTOW, RA			RTG GENES IS YEAST THAT FUNCTION IN COMMUNICATION BETWEEN MITOCHONDRIA AND THE NUCLEUS ARE ALSO REQUIRED FOR EXPRESSION OF GENES ENCODING PEROXISOMAL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVE SELECTION PROCEDURE; SACCHAROMYCES-CEREVISIAE; CITRATE SYNTHASE; TRANSCRIPTIONAL CONTROL; MALATE-DEHYDROGENASE; ASSEMBLY MUTANTS; BETA-OXIDATION; FATTY-ACIDS; CATALASE-A; PROLIFERATION	In Saccharomyces cerevisiae cells with dysfunctional mitochondria, such as in petites, the CIT2 gene encoding the peroxisomal glyoxylate cycle enzyme, citrate synthase 2 (CS2), is transcriptionally activated by as much as 30-fold, a phenomenon we call retrograde regulation. Two genes, RTG1 and RTG2, are required for both basal and elevated expression of CIT2 (Liao, X, and Butow, R. A. (1993) Cell 72, 61-71). Different blocks in the tricarboxylic acid cycle also elicit an increase in CIT2 expression, but not to the extent observed in petites. We have examined whether other genes of the glyoxylate cycle exhibit retrograde regulation and the role of RTG1 and RTG2 in their expression. Of the glyoxylate cycle genes tested, CIT2 is the only one that shows retrograde regulation, suggesting that CS2 may be an important control point for metabolic cross-feeding from the glyoxylate cycle to mitochondria. Surprisingly, RTG1 and RTG2 are required for efficient growth of cells on medium containing oleic acid, a condition which induces peroxisome biogenesis; these genes are also required together for oleic acid induction of three peroxisomal protein genes tested, POX1 and CTA1 involved beta-oxidation of long chain fatty acids and PMP27, which encodes the most abundant protein of peroxisomal membranes. These data indicate that, in addition to their role in retrograde regulation of CIT2, the RTG genes are important for expression of genes encoding peroxisomal proteins and are thus key components in a novel, three-way path of communication between mitochondria, the nucleus, and peroxisomes.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Chelstowska, Anna/0000-0002-2431-7921	PHS HHS [22525] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ATOMI H, 1993, FEMS MICROBIOL LETT, V112, P31, DOI 10.1016/0378-1097(93)90533-8; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; COHEN G, 1988, EUR J BIOCHEM, V176, P159; CONRADWEBB H, 1995, MOL CELL BIOL, V15, P2420; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; ELGERSMA Y, 1993, GENETICS, V135, P731; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FEARON K, 1988, MOL CELL BIOL, V8, P3636, DOI 10.1128/MCB.8.9.3636; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNANDEZ E, 1992, EUR J BIOCHEM, V204, P983, DOI 10.1111/j.1432-1033.1992.tb16720.x; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; HARTIG A, 1992, NUCLEIC ACIDS RES, V20, P5677, DOI 10.1093/nar/20.21.5677; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KOONIN EV, 1994, TRENDS BIOCHEM SCI, V19, P156, DOI 10.1016/0968-0004(94)90275-5; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; Mayfield SP, 1990, CURR OPIN CELL BIOL, V2, P509, DOI 10.1016/0955-0674(90)90135-2; MCCAMMON MT, 1990, J BACTERIOL, V172, P5816, DOI 10.1128/jb.172.10.5816-5827.1990; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; ROSE MD, 1988, METHODS YEAST GENETI; ROSENKRANTZ M, 1986, MOL CELL BIOL, V6, P4509, DOI 10.1128/MCB.6.12.4509; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHYJAN AW, 1993, CURR BIOL, V3, P398, DOI 10.1016/0960-9822(93)90212-7; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; SMALL WC, 1995, BIOCHEMISTRY-US, V34, P5569, DOI 10.1021/bi00016a031; SRERE P, 1994, TRENDS BIOCHEM SCI, V19, P519, DOI 10.1016/0968-0004(94)90048-5; STEFFAN JS, 1992, J BIOL CHEM, V267, P24708; SUISSA M, 1984, EMBO J, V3, P1773, DOI 10.1002/j.1460-2075.1984.tb02045.x; SUSEK RE, 1992, AUST J PLANT PHYSIOL, V19, P387, DOI 10.1071/PP9920387; SUSEK RE, 1993, CELL, V74, P787, DOI 10.1016/0092-8674(93)90459-4; THOMPSON LM, 1988, BIOCHEMISTRY-US, V27, P8393, DOI 10.1021/bi00422a015; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204	42	102	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18141	18146		10.1074/jbc.270.30.18141	http://dx.doi.org/10.1074/jbc.270.30.18141			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629125	hybrid			2022-12-25	WOS:A1995RM26600077
J	SCHNEIKERT, J; HERSCOVICS, A				SCHNEIKERT, J; HERSCOVICS, A			2 NATURALLY-OCCURRING MOUSE ALPHA-1,2-MANNOSIDASE IB CDNA CLONES DIFFER IN 3 POINT MUTATIONS - MUTATION OF PHE(592) TO SER(592) IS SUFFICIENT TO ABOLISH ENZYME-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; LIVER GOLGI MEMBRANES; GLYCOPROTEIN-BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; ALPHA-MANNOSIDASE; PURIFICATION; GENE; IA	In mammalian cells, alpha-1,2-mannosidases play an essential role in the early steps of N-linked oligosaccharide maturation. We previously reported (Herscovics, A., Schneikert, J., Athanassiadis, A., and Moremen, K. W. (1994) J. Biol. Chem. 269, 9864-9871) the isolation of mouse cy-mannosidase IB cDNA clones from a Balb/c 3T3 cDNA library. Clone 4 encodes a type II membrane protein of 641 amino acids with a cytoplasmic tail of 35 amino acids, followed by a transmembrane domain and a large C-terminal catalytic domain, whereas clone 16 encodes only the last 471 amino acids. Their overlapping sequences (from amino acid 152) are identical, except for three point mutations that result in three amino acid differences in the catalytic domain of the enzyme (Thr(411), Leu(468), and Ser(592) in clone 4 to Met(411), Phe(468), and Phe(592) in clone 16, respectively). Both sequences could be amplified by polymerase chain reaction using templates of cDNAs derived from colon and brain of CD1 mice and from L cells derived from the C3H/An mouse, indicating that both are natural isoforms found in two inbred and one outbred mouse strains. When expressed in COS7 cells as a secreted protein A fusion protein, the catalytic domain of clone 16 displays alpha-1,2-mannosidase activity using [H-3]mannose-labeled Man(9)GlcNAc as substrate, but the corresponding region of clone 4 is poorly secreted under identical conditions. The contribution of each point mutation to this differential secretion and enzyme activity of the two fusion proteins was assessed by testing the six recombinants corresponding to all the possible sequence permutations. Mutation of Phe(592) to Ser(592), as found in clone 4, is sufficient to abolish alpha-1,2-mannosidase activity, whereas mutation of Met(411) to Thr(411) or of Phe(468) to Leu(468) affects secretion with relatively little effect on enzyme activity. Phe(592) is part of a highly conserved region that seems important for enzyme activity of class 1 alpha-1,2-mannosidases.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA	McGill University								BANERJEE P, 1994, J BIOL CHEM, V269, P4819; BAUSE E, 1993, EUR J BIOCHEM, V217, P535, DOI 10.1111/j.1432-1033.1993.tb18274.x; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; FORSEE WT, 1989, J BIOL CHEM, V264, P3869; HERSCOVICS A, 1987, ANAL BIOCHEM, V166, P85, DOI 10.1016/0003-2697(87)90550-1; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; JELINEKKELLY S, 1988, J BIOL CHEM, V263, P14757; JELINEKKELLY S, 1985, J BIOL CHEM, V260, P2253; KERSCHER S, 1995, DEV BIOL, V168, P613, DOI 10.1006/dbio.1995.1106; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAL A, 1994, J BIOL CHEM, V269, P9872; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; PONDER BAJ, 1985, J EMBRYOL EXP MORPH, V87, P229; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIKERT J, 1994, GLYCOBIOLOGY, V4, P445, DOI 10.1093/glycob/4.4.445; SCHWEDEN J, 1986, EUR J BIOCHEM, V157, P563, DOI 10.1111/j.1432-1033.1986.tb09703.x; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YANG MH, 1992, BIOCHEM BIOPH RES CO, V189, P1063, DOI 10.1016/0006-291X(92)92312-L; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605	23	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17736	17740		10.1074/jbc.270.30.17736	http://dx.doi.org/10.1074/jbc.270.30.17736			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629073	hybrid			2022-12-25	WOS:A1995RM26600019
J	HARRISON, KA; MURPHY, RC				HARRISON, KA; MURPHY, RC			ISOLEUKOTRIENES ARE BIOLOGICALLY-ACTIVE FREE-RADICAL PRODUCTS OF LIPID-PEROXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; LEUKOTRIENE-B4 RECEPTORS; ACTIVATION; MECHANISM; ANALOGS; BINDING; ACID; 8-EPI-PROSTAGLANDIN-F2-ALPHA; PHOSPHOLIPIDS; STIMULATION	The free radical oxidation of arachidonic acid esterified to glycerophospholipids is known to generate complex metabolites, termed isoprostanes, that share structural features of prostaglandins derived from prostaglandin H-2 synthase. Furthermore, certain isoprostanes have been found to exert biological activity through endogenous receptors on cell surfaces. Using mass spectrometry and ancillary techniques, the free radical oxidation of 1-hexadecanoyl-2-arachidonoyl-glycerophosphocholine was studied in the search for products of arachidonic acid isomeric to the leukotrienes that are derived from 5-lipoxygenase-catalyzed metabolism of arachidonic acid. Several conjugated triene metabolites were chromatographically separated from known 5-lipoxygenase products and structures characterized as 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid esterified to the glycerophosphocholine backbone. We have termed these products as B-4-isoleukotrienes. Following saponification some, but not all, B-4-isoleukotrienes were found to exert biological activity in elevating intracellular calcium in Indo-1-loaded human polymorphonuclear leukocytes. This activity could be blocked by a leukotriene B-4 receptor antagonist. An EC(50) of approximately 30 nM was determined for one unique B-4-isoleukotriene with a relative retention index of 2.54. We have shown that free radical processes can lead to the formation of biologically active isoleukotrienes in glycerophosphocholine liposomes, and we propose that B-4-isoleukotrienes may also be formed in membrane glycerophospholipids as a result of lipid peroxidation during tissue injury. Such B-4-isoleukotrienes could then mediate events of tissue damage through activation of leukotriene B-4 receptors on target cells.	NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206	National Jewish Health			Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU AK, 1984, CARCINOGENESIS LOND, V4, P331; BOMALASKI JS, 1987, PROSTAGLANDINS, V33, P855, DOI 10.1016/0090-6980(87)90114-6; BRITTON RS, 1994, HEPATO-GASTROENTEROL, V41, P343; DAHINDEN CA, 1984, J IMMUNOL, V133, P1477; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; GOLDMAN DW, 1985, J IMMUNOL, V135, P525; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Halliwell B., 1989, FREE RADICAL BIO MED, V2nd; Halliwell B, 1989, FREE RADICAL BIO MED, P416; JACKSON WT, 1992, J PHARMACOL EXP THER, V263, P1009; JAESCHKE H, 1991, CHEM-BIOL INTERACT, V79, P115, DOI 10.1016/0009-2797(91)90077-K; KANG KH, 1993, J APPL PHYSIOL, V74, P460, DOI 10.1152/jappl.1993.74.1.460; KAYGANICHHARRIS.KA, 1993, J LIPID RES, V34, P1229; KERWIN JL, 1994, J LIPID RES, V35, P1102; KNEEPKENS CMF, 1994, FREE RADICAL BIO MED, V17, P127; KOBAYASHI Y, 1994, BBA-LIPID LIPID MET, V1215, P280, DOI 10.1016/0005-2760(94)90054-X; LAZZARI KG, 1986, J BIOL CHEM, V261, P9710; LEBLANC Y, 1987, PROSTAGLANDINS, V33, P617, DOI 10.1016/0090-6980(87)90029-3; LEE TH, 1984, J BIOL CHEM, V259, P2383; LEWIS RA, 1981, J EXP MED, V154, P1243, DOI 10.1084/jem.154.4.1243; MCLEAN LR, 1993, LIPIDS, V28, P505, DOI 10.1007/BF02536081; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; MURPHY RC, 1993, HDB LIPID RES MASS S, P106; OMANN GM, 1987, J IMMUNOL, V138, P2626; PALMBLAD J, 1981, BLOOD, V58, P658; POWELL WS, 1993, J BIOL CHEM, V268, P9280; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; SEYA A, 1988, FATTY ACIDS, V34, P37; SHIMIZU T, 1981, ARCH BIOCHEM BIOPHYS, V206, P271, DOI 10.1016/0003-9861(81)90091-6; SOYOMBO O, 1993, EUR J BIOCHEM, V218, P59, DOI 10.1111/j.1432-1033.1993.tb18351.x; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; TARR M, 1993, OXYGEN FREE RADICAL; WHEELAN P, 1995, J AM SOC MASS SPECTR, V6, P40, DOI 10.1016/1044-0305(94)00090-M; WHITE JR, 1983, BIOCHEM BIOPH RES CO, V113, P44, DOI 10.1016/0006-291X(83)90429-1	38	86	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17273	17278		10.1074/jbc.270.29.17273	http://dx.doi.org/10.1074/jbc.270.29.17273			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615527	hybrid			2022-12-25	WOS:A1995RK68900036
J	LEE, HJ; MASUDA, ES; ARAI, N; ARAI, K; YOKOTA, T				LEE, HJ; MASUDA, ES; ARAI, N; ARAI, K; YOKOTA, T			DEFINITION OF CIS-REGULATORY ELEMENTS OF THE MOUSE INTERLEUKIN-5 GENE PROMOTER - INVOLVEMENT OF NUCLEAR FACTOR OF ACTIVATED T-CELL-RELATED FACTORS IN INTERLEUKIN-5 EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; MEDIATES INDUCTION; LYMPHOKINE GENES; CYCLOSPORINE-A; GM-CSF; IL-5; RECEPTOR; CAMP	We have previously reported that the promoter region of the mouse interleukin-5 (IL-5) gene, extending from a nucleotide position about -1,200 to +33 relative to the transcription initiation site, can mediate transcriptional stimulation by phorbol 12-myristate 13-acetate and dibutyryl cAMP (Bt(2)cAMP) in mouse thymoma EL-4 cells. Here, we describe identification of four cis-regulatory elements necessary for full activity of the IL-5 promoter, using deletion and mutation analyses. We designated these elements as IL-5A (-948 similar to -933), IL-5P (-117 similar to -92), IL-5C (-74 similar to -56), and IL-5CLEO (-55 similar to -38). We found that IL-5P bears homology to the binding site for the nuclear factor of activated T cells (NF-AT) and interacted with protein factors in nuclear extracts prepared from EL-4 cells stimulated with phorbol 12-myristate 13-acetate and Bt(2)cAMP (designated NFIL-5P). NFIL-5P complex was inhibited in the presence of an excess NF-AT and AP1 oligonucleotides and supershifted by antisera raised against NF-ATp, c-Fos, and c-Jun. It thus seems likely that an NF-AT-related factor is involved in the regulation of IL-5 gene transcription.	UNIV TOKYO, INST MED SCI, DEPT MOLEC & DEV BIOL, MINATO KU, TOKYO 108, JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC, DEPT CELL SIGNALING, PALO ALTO, CA 94304 USA	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Yokota, Takashi/J-8483-2015	Masuda, Esteban/0000-0002-3175-2868				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ARAI N, 1992, PHARMACOL THERAPEUT, V55, P303, DOI 10.1016/0163-7258(92)90054-4; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BETZ M, 1991, J IMMUNOL, V146, P108; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUHN KW, 1993, P NATL ACAD SCI USA, V90, P9707, DOI 10.1073/pnas.90.20.9707; CAMPBELL HD, 1988, EUR J BIOCHEM, V174, P345, DOI 10.1111/j.1432-1033.1988.tb14104.x; CHANG TC, 1990, J BIOL CHEM, V265, P8176; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, J IMMUNOL, V151, P837; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KRUSEMEIER M, 1988, J IMMUNOL, V140, P367; LEE HJ, 1993, J IMMUNOL, V151, P6135; LEE JS, 1989, SOMAT CELL MOLEC GEN, V15, P143, DOI 10.1007/BF01535075; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; LI TK, 1993, J IMMUNOL, V150, P1680; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MASUDA ES, 1993, IMMUNOLOGIST, V1, P198; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; Mizuta TR, 1988, GROWTH FACTORS, V1, P51, DOI 10.3109/08977198809000246; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MORI A, 1994, INT ARCH ALLERGY IMM, V104, P32, DOI 10.1159/000236745; MOSMANN TR, 1991, IMMUNOL RES, V10, P183, DOI 10.1007/BF02919690; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; NAORA H, 1994, J IMMUNOL, V153, P3466; NAORA H, 1994, BLOOD, V83, P3620; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; ORKIN SH, 1992, BLOOD, V80, P575; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHMIDT J, 1994, EUR J PHARMACOL, V260, P247, DOI 10.1016/0014-2999(94)90345-X; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TAKATSU K, 1988, IMMUNOL REV, V102, P107, DOI 10.1111/j.1600-065X.1988.tb00743.x; TANABE T, 1987, J BIOL CHEM, V262, P16580; TSURUTA L, 1995, J IMMUNOL, V154, P5255; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YOKOTA T, 1987, P NATL ACAD SCI USA, V84, P7388, DOI 10.1073/pnas.84.21.7388	62	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17541	17550		10.1074/jbc.270.29.17541	http://dx.doi.org/10.1074/jbc.270.29.17541			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615560	hybrid			2022-12-25	WOS:A1995RK68900076
J	ROBERTS, JR; NARASIMHAN, C; MIZIORKO, HM				ROBERTS, JR; NARASIMHAN, C; MIZIORKO, HM			EVALUATION OF CYSTEINE-266 OF HUMAN 3-HYDROXY-3-METHYLGLUTARYL-COA LYASE AS A CATALYTIC RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A LYASE; PSEUDOMONAS-MEVALONII; ESCHERICHIA-COLI; ENZYME; SYNTHASE; LIVER; PROTEIN; ISOZYME; BINDING; SITE	The role of cysteine 266 in human 3-hydroxy-3-methylglutaryl-CoA (HMG CoA) lyase, a residue that is homologous to a cysteine mapped to the active site of prokaryotic HMG-CoA lyase by protein chemistry approaches, has been investigated by site-directed mutagenesis. Both the wild-type human enzyme and a C323S variant, in which a regulatory sulfhydryl has been eliminated without any negative effect on catalytic activity (Roberts, J. R., Narasimhan, C., Hruz, P. W., Mitchell, G. A. and Miziorko, H. M. (1994) J. Biol. Chem. 269, 17841-17846), were used as models. Mutant enzymes C266A, C266A/C323S, C266S, and C266S/C323S were overexpressed in Escherichia coli and purified to homo geneity. In all cases, kinetic characterization indicated that the K-m value for HMG-CoA was not substantially different from the value measured using wild-type human lyase, suggesting that no serious structural perturbation occurs upon replacing Cys-266. A dissociable divalent cation (Mn2+ or Mg2+), which is required for activity in both native and C323S enzymes, is also an essential component for activity in each of the Cys-266 mutants. The structural integrity of the human mutants was further indicated by Mn2+ binding studies, which demonstrate similarities not only in the activator cation binding stoichiometries, but also in the K-D values for Mn2+ as determined for wild-type and mutant C266A or C266S proteins. Purified C266A and C266A/C323S mutants both displayed approximate to 1.3 x 10(4)-fold diminution in specific activity, while the k(cat) value was diminished in both C266S and C266S/C323S by approximate to 9.9 x 10(2) fold. This large diminution in catalytic efficiency in enzyme variants that display no substantial structural perturbations is in accord with an active site assignment to Cys-266 and qualifies its sulfhydryl group for consideration as a component of the catalytic apparatus.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin					NCRR NIH HHS [RR-01008] Funding Source: Medline; NIDDK NIH HHS [DK21491, DK09018] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, F32DK009018, R01DK021491] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DH, 1989, J BACTERIOL, V171, P6468, DOI 10.1128/jb.171.12.6468-6472.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; Coon M. J., 1955, S AMINO ACID METABOL, P431; DIXON M, 1958, ENZYMES, P456; GIBSON KM, 1988, EUR J PEDIATR, V148, P180, DOI 10.1007/BF00441397; GOLDFARB S, 1971, J LIPID RES, V12, P512; HANSON KR, 1975, ACCOUNTS CHEM RES, V8, P1, DOI 10.1021/ar50085a001; HRUZ PW, 1993, BIOCHIM BIOPHYS ACTA, V1162, P149, DOI 10.1016/0167-4838(93)90141-D; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; HRUZ PW, 1992, PROTEIN SCI, V1, P1144, DOI 10.1002/pro.5560010908; KRAMER PR, 1980, J BIOL CHEM, V255, P1023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marquardt D. W., 1963, J SOC IND APPL MATH, V2, P431; MILDVAN AS, 1965, J BIOL CHEM, V240, P238; MISRA I, 1993, J BIOL CHEM, V268, P12129; MITCHELL GA, 1993, J BIOL CHEM, V368, P4376; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; NARASIMHAN C, 1994, ARCH BIOCHEM BIOPHYS, V312, P467, DOI 10.1006/abbi.1994.1333; NARASIMHAN C, 1992, BIOCHEMISTRY-US, V31, P11224, DOI 10.1021/bi00160a037; OZAND PT, 1992, J CHILD NEUROL S, V7, pS4; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; ROBERTS JR, 1994, J BIOL CHEM, V269, P17841; ROBINSON AM, 1980, PHYSIOL REV, V60, P143, DOI 10.1152/physrev.1980.60.1.143; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHER DS, 1989, BIOCHIM BIOPHYS ACTA, V1003, P321, DOI 10.1016/0005-2760(89)90239-7; SIMON EJ, 1953, J AM CHEM SOC, V75, P2520, DOI 10.1021/ja01106a522; STEGINK LD, 1968, J BIOL CHEM, V243, P5272; STEPHENS CM, 1992, J BIOL CHEM, V267, P5762; WANG SP, 1993, MAMM GENOME, V4, P382, DOI 10.1007/BF00360589; WEIDMAN SW, 1973, BIOCHEMISTRY-US, V12, P1874, DOI 10.1021/bi00734a006	31	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17311	17316		10.1074/jbc.270.29.17311	http://dx.doi.org/10.1074/jbc.270.29.17311			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615532	hybrid			2022-12-25	WOS:A1995RK68900042
J	ZAIDI, SHE; MALTER, JS				ZAIDI, SHE; MALTER, JS			NUCLEOLIN AND HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-C PROTEINS SPECIFICALLY INTERACT WITH THE 3'-UNTRANSLATED REGION OF AMYLOID PROTEIN-PRECURSOR MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; BINDING-PROTEINS; ALZHEIMERS-DISEASE; SEQUENCE; CELLS; CDNA; IDENTIFICATION; ACTIVATION; CYTOPLASM; RECEPTOR	The central nervous system deposition by neurons and glia of beta A4 amyloid protein is an important contributing factor to the development of Alzheimer's disease. Amyloidogenic cells overexpress amyloid precursor protein (APP) mRNAs suggesting a transcriptional or posttranscriptional defect may contribute to this process. We have previously shown that APP mRNAs display regulated stability which is dependent on a 29-base element within the 3'-untranslated region (UTR). This domain specifically interacted with several cytoplasmic RNA-binding proteins. We have purified these APP RNA-binding proteins from a human T-cell leukemia and demonstrate that five cytoplasmic proteins of 70, 48, 47, 39, and 38 kDa form the previously observed APP RNA protein complexes. Amino acid sequence analyses showed that the 70-, 48-, and 47-kDa proteins were fragments of nucleolin and that the 39- and 38-kDa proteins were heterogeneous nuclear ribonucleoprotein (hnRNP) C protein. Northwestern and Western blot analyses of purified material further confirmed these data. Nucleolin protein is known to shuttle between the nucleus and cytoplasm but hnRNP C has not been reported within the cytoplasm. This report of sequence specific, mRNA binding by nucleolin Emd hnRNP C suggests that these proteins participate in the post-transcriptional regulation of APP mRNA through 3'-UTR, site-specific interactions.	UNIV WISCONSIN, SCH MED, DEPT PATHOL & LAB MED, MADISON, WI 53792 USA; UNIV WISCONSIN, SCH MED, NEUROSCI PROGRAM, MADISON, WI 53792 USA; UNIV WISCONSIN, SCH MED, INST AGING, MADISON, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIA NIH HHS [R01-AG 10675] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010675] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BARNETT SF, 1990, METHOD ENZYMOL, V181, P293; BARRIJAL S, 1992, NUCLEIC ACIDS RES, V20, P5053, DOI 10.1093/nar/20.19.5053; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BUGLER B, 1987, J BIOL CHEM, V262, P10922; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CHEN CM, 1991, J BIOL CHEM, V266, P7754; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; HENSON J, 1992, ANN NEUROL, V32, P72, DOI 10.1002/ana.410320112; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PINOLROMA S, 1990, METHOD ENZYMOL, V181, P317; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; ROYER HD, 1991, NUCLEIC ACIDS RES, V19, P2363, DOI 10.1093/nar/19.9.2363; SAPP M, 1989, EUR J BIOCHEM, V179, P541, DOI 10.1111/j.1432-1033.1989.tb14581.x; SELKOE DJ, 1991, SCI AM, V11, P68; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH C, 1994, NEUROPATH APPL NEURO, V20, P322, DOI 10.1111/j.1365-2990.1994.tb00977.x; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TREJO J, 1994, J BIOL CHEM, V269, P21682; VOELKERDING KV, 1995, ONCOGENE, V10, P515; WILUSZ J, 1988, MOL CELL BIOL, V8, P4477, DOI 10.1128/MCB.8.10.4477; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007	41	97	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17292	17298		10.1074/jbc.270.29.17292	http://dx.doi.org/10.1074/jbc.270.29.17292			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615529	hybrid			2022-12-25	WOS:A1995RK68900039
J	CHOI, H; TANG, CK; TU, SC				CHOI, H; TANG, CK; TU, SC			CATALYTICALLY ACTIVE FORMS OF THE INDIVIDUAL SUBUNITS OF VIBRIO-HARVEYI LUCIFERASE AND THEIR KINETIC AND BINDING-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL BIOLUMINESCENT REACTION; SITE-DIRECTED MUTATION; ALPHA-SUBUNIT; BETA-SUBUNIT; ALDEHYDE	Contradictory findings have recently been reported regarding the (in)abilities of individual subunits of the Vibrio harveyi alpha beta dimeric luciferase to catalyze bioluminescence. We have produced individual alpha and beta subunits separately in Escherichia coli JM109 cells by recombinant DNA techniques. Both subunits were purified to more than 90% homogeneity and found to be catalytically active, with their general catalytic properties and the specific activities similar to those reported earlier (Sinclair, J. F., Waddle, J. J., Waddill, E. F., and Baldwin, T. O. (1993) Biochemistry 32, 5038-5044). Individual subunits were significantly distinct from the native luciferase with respect to inactivations by trypsin and N-ethylmaleimide, and the stability of the flavin 4a-hydroperoxide intermediate. The active species in isolated alpha and beta samples were each the predominant protein species, corresponding to a 42,000 M(r) alpha monomer and a 67,000 M(r) beta dimer, respectively. These findings clearly indicate that the activities of the individual subunits are not due to trace contaminations of the respective counter subunits. The much reduced specific activities of the individual subunits are, in part, a consequence of diminished abilities to oxidize the aldehyde substrate. Kinetic and equilibrium measurements indicate that alpha and beta(2) each contained a reduced flavin site, an aldehyde substrate site, and an aldehyde inhib itor site. The on and off rates of the decanal inhibitor binding were substantially slower than the bindings of decanal and reduced riboflavin 5'-phosphate substrates. These findings are consistent with a scheme that the aldehyde inhibitor blocks the binding of the reduced flavin substrate.	UNIV HOUSTON,DEPT BIOCHEM & BIOPHYS SCI,HOUSTON,TX 77204; UNIV HOUSTON,DEPT CHEM,HOUSTON,TX 77204	University of Houston System; University of Houston; University of Houston System; University of Houston					NIGMS NIH HHS [GM25953] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025953] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN TO, 1978, J BIOL CHEM, V253, P5551; BECVAR JE, 1975, P NATL ACAD SCI USA, V72, P3374, DOI 10.1073/pnas.72.9.3374; CLINE TW, 1972, BIOCHEMISTRY-US, V11, P3359, DOI 10.1021/bi00768a008; DUNN DK, 1973, BIOCHEMISTRY-US, V12, P4911, DOI 10.1021/bi00748a016; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; FRIEDLAND J, 1967, P NATL ACAD SCI USA, V58, P2336, DOI 10.1073/pnas.58.6.2336; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GUNSALUSMIGUEL A, 1972, J BIOL CHEM, V247, P398; HASTINGS JW, 1969, BIOCHEMISTRY-US, V8, P4681, DOI 10.1021/bi00840a004; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P532; Job P, 1928, ANN CHIM FRANCE, V9, P113; LEI BF, 1991, PHOTOCHEM PHOTOBIOL, V54, P473, DOI 10.1111/j.1751-1097.1991.tb02043.x; LEI BF, 1993, J BIOL CHEM, V269, P5612; LI Z, 1993, BIOCHIM BIOPHYS ACTA, V1158, P137, DOI 10.1016/0304-4165(93)90007-U; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIGHEN EA, 1971, J BIOL CHEM, V246, P7666; MEIGHEN EA, 1973, BIOCHEMISTRY-US, V12, P1482, DOI 10.1021/bi00732a003; MEIGHEN EA, 1971, BIOCHEMISTRY-US, V10, P4069, DOI 10.1021/bi00798a009; MEIGHEN EA, 1980, J BIOL CHEM, V255, P1181; NICOLI MZ, 1974, J BIOL CHEM, V249, P2385; SINCLAIR JF, 1993, BIOCHEMISTRY-US, V32, P5036, DOI 10.1021/bi00070a010; TU S, 1975, BIOCHEMISTRY-US, V14, P4310, DOI 10.1021/bi00690a027; TU SC, 1983, BIOCHEMISTRY-US, V22, P519, DOI 10.1021/bi00271a040; WADDLE J, 1991, BIOCHEM BIOPH RES CO, V178, P1188, DOI 10.1016/0006-291X(91)91018-8; WATANABE H, 1982, ARCH BIOCHEM BIOPHYS, V215, P405, DOI 10.1016/0003-9861(82)90100-X; XI L, 1990, J BIOL CHEM, V265, P4200; XIN X, 1994, BIOCHEMISTRY-US, V33, P12194, DOI 10.1021/bi00206a023; XIN X, 1991, BIOCHEMISTRY-US, V30, P11255, DOI 10.1021/bi00111a010	28	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16813	16819		10.1074/jbc.270.28.16813	http://dx.doi.org/10.1074/jbc.270.28.16813			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622495	hybrid			2022-12-25	WOS:A1995RJ34700056
J	LIN, KT; XUE, JY; NOMEN, M; SPUR, B; WONG, PYK				LIN, KT; XUE, JY; NOMEN, M; SPUR, B; WONG, PYK			PEROXYNITRITE-INDUCED APOPTOSIS IN HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NITRIC-OXIDE; DNA FRAGMENTATION; L-ARGININE; SUPEROXIDE; OXIDATION	Peroxynitrite (ONOO-), an anion and a potent oxidant, generated by the interaction of nitric oxide (NO) and superoxide is able to induce apoptosis in HL-60 human leukemia cells in a time- and concentration-dependent manner. Characteristic morphology of apoptosis can be observed 3 h after HL-60 cells are exposed to 10 mu M ONOO-. Treatment of HL-60 cells with increasing concentrations of ONOO- from 1 to 100 mu M confirms the concentration dependence of apoptosis as evidenced by: 1) degradation of nuclear DNA of these cells into integer multiples of approximately 200 base pairs; 2) colorimetric DNA fragmentation assay; and 3) evidence of condensation of chromatin and nuclear fragmentation shown by propidium iodide staining, Under the same conditions, peroxynitrite causes apoptosis in another transformed cell line, U-937 cells, but is ineffective at inducing apoptosis in normal endothelial cells derived from human umbilical cord and normal human peripheral blood mononuclear cells, This direct evidence of peroxynitrite inducing apoptosis implicated a new function of this potent oxidant.	UNIV MED & DENT NEW JERSEY, SCH OSTEOPATH MED, DEPT CELL BIOL, STRATFORD, NJ 08084 USA	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center				Spur, Bernd/0000-0002-7581-4741	PHS HHS [P01-43203, 41747, R01-25316-15] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBINA JE, 1993, J IMMUNOL, V150, P5080; ALLAN DJ, 1992, J PATHOL, V167, P25, DOI 10.1002/path.1711670106; BECKER H, 1977, ORGANICUM, P657; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CUI SJ, 1994, CANCER RES, V54, P2462; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HADDAD IY, 1994, AM J PHYSIOL, V267, pL242, DOI 10.1152/ajplung.1994.267.3.L242; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1991, RES IMMUNOL, V142, P565, DOI 10.1016/0923-2494(91)90103-P; IGNARRO LJ, 1993, THROMB HAEMOSTASIS, V70, P148; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KERR KM, 1984, J PATHOL, V107, P41; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; LEIS JR, 1993, J CHEM SOC CHEM COMM, P1298, DOI 10.1039/c39930001298; MARTIN BL, 1990, J BIOL CHEM, V265, P7108; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; RACHMILEWITZ D, 1993, GASTROENTEROLOGY, V105, P1681, DOI 10.1016/0016-5085(93)91063-N; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SEAGO ND, 1995, MEDIAT INFLAMM, V4, P19, DOI 10.1155/S0962935195000044; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SKAPER SD, 1995, J NEUROCHEM, V64, P266; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WIZEMANN TM, 1994, J LEUKOCYTE BIOL, V56, P759, DOI 10.1002/jlb.56.6.759; WONG YPK, 1993, ATHEROSCLER REV, V25, P101; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	33	289	299	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16487	16490		10.1074/jbc.270.28.16487	http://dx.doi.org/10.1074/jbc.270.28.16487			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622447	hybrid			2022-12-25	WOS:A1995RJ34700002
J	MCINTOSH, JM; HASSON, A; SPIRA, ME; GRAY, WR; LI, WQ; MARSH, M; HILLYARD, DR; OLIVERA, BM				MCINTOSH, JM; HASSON, A; SPIRA, ME; GRAY, WR; LI, WQ; MARSH, M; HILLYARD, DR; OLIVERA, BM			A NEW FAMILY OF CONOTOXINS THAT BLOCKS VOLTAGE-GATED SODIUM-CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONUS-GEOGRAPHUS; OMEGA-CONOTOXIN; PEPTIDE LIGAND; VENOM; SNAIL; NEUROTOXINS; SUBTYPES; TOXINS; CELLS	Conus peptides, including omega-conotoxins and alpha-conotoxins (targeting calcium channels and nicotinic acetylcholine receptors, respectively) have been useful ligands in neuroscience. In this report, we describe a new family of sodium channel ligands, the mu O-conotoxins. The two peptides characterized, mu O-conotoxins MrVIA and MrVIB from Conus marmoreus potently block the sodium conductance in Aplysia neurons. This is in marked contrast to standard sodium channel blockers that are relatively ineffective in this system. The sequences of the peptides are as follows. mu O-conotoxin MrVIA: ACRKKWEYCIVPIIGFIYCCPGLICGPFVCV mu O-conotoxin MrVIB: ACSKKWEYCIVPILGFVYCCPGLICGPFVCV mu O-conotoxin MrVIA was chemically synthesized and proved indistinguishable from the natural product. Surprisingly, the mu O-conotoxins show no sequence similarity to the mu-conotoxins. However, ananalysis of cDNA clones encoding the mu O-conotoxin MrVIB demonstrated striking sequence similarity to omega- and delta-conotoxin pre cursors. Together, the omega-, delta-, and mu O-conotoxins define the O-superfamily of Conus peptides. The probable bio logical role and evolutionary affinities of these peptides are discussed.	UNIV UTAH,DEPT PATHOL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT PSYCHIAT,SALT LAKE CITY,UT 84112; HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT NEUROBIOL,IL-91904 JERUSALEM,ISRAEL; INTERUNIV INST MARINE SCI,IL-88103 ELAT,ISRAEL	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Hebrew University of Jerusalem	MCINTOSH, JM (corresponding author), UNIV UTAH,DEPT BIOL,201 SO BIOL,SALT LAKE CITY,UT 84112, USA.		Spira, Micha/B-6470-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH000929] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM28677] Funding Source: Medline; NIMH NIH HHS [K20 MH 00929] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BENBASSAT D, 1993, EXP NEUROL, V122, P295, DOI 10.1006/exnr.1993.1129; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CLARK C, 1981, TOXICON, V19, P691, DOI 10.1016/0041-0101(81)90106-9; COLLEDGE CJ, 1992, TOXICON, V30, P1111, DOI 10.1016/0041-0101(92)90056-B; CRUZ LJ, 1989, BIOCHEMISTRY-US, V28, P3437, DOI 10.1021/bi00434a043; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; FAINZILBER M, 1995, IN PRESS J NAT TOXIN; Fox AP, 1987, J PHYSIOL-LONDON, V394, P49; GEDULDIG D, 1968, J PHYSIOL-LONDON, V199, P347, DOI 10.1113/jphysiol.1968.sp008657; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASSON A, 1995, J NEUROPHYSIOL, V73, P1295, DOI 10.1152/jn.1995.73.3.1295; HASSON A, 1993, EUR J NEUROSCI, V5, P56, DOI 10.1111/j.1460-9568.1993.tb00205.x; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MCINTOSH JM, 1993, TOXICON, V32, P1561; MONJE VD, 1993, NEUROPHARMACOLOGY, V32, P1141, DOI 10.1016/0028-3908(93)90008-Q; OHIZUMI Y, 1986, J PHARMACOL EXP THER, V239, P243; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; SPIRA ME, 1993, J NEUROBIOL, V24, P300, DOI 10.1002/neu.480240304; SPIRA ME, 1993, ISRAEL J MED SCI, V29, P530; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; Walls J.G., 1979, CONE SHELLS SYNOPSIS; WOODWARD SR, 1990, EMBO J, V1, P1015; ZIV NE, 1993, EUR J NEUROSCI, V5, P657, DOI 10.1111/j.1460-9568.1993.tb00531.x	29	139	147	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16796	16802		10.1074/jbc.270.28.16796	http://dx.doi.org/10.1074/jbc.270.28.16796			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622492	hybrid			2022-12-25	WOS:A1995RJ34700053
J	NELSON, CC; HENDY, SC; ROMANIUK, PJ				NELSON, CC; HENDY, SC; ROMANIUK, PJ			RELATIONSHIP BETWEEN P-BOX AMINO-ACID-SEQUENCE AND DNA-BINDING SPECIFICITY OF THE THYROID-HORMONE RECEPTOR - THE EFFECTS OF HALF-SITE SEQUENCE IN EVERTED REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER DOMAIN; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; RESPONSE ELEMENTS; NUCLEAR RECEPTORS; RETINOIC ACID; WILD-TYPE; DETERMINANTS; HETERODIMERS; SUPERFAMILY	The three P-box amino acids in the DNA recognition alpha-helix of steroid/thyroid hormone receptors participate in the discrimination of the central base pairs of the hexameric half-sites of receptor response elements in DNA. A series of 57 variants of the beta isoform of the human thyroid hormone receptor were constructed in which the 19 possible amino acid substitutions were incorporated at each of the three P-box positions. The effects of these substitutions on the sequence specificity of the DNA binding activity of the receptor were analyzed using 16 everted repeat elements which differed in sequence in the two central base pairs of the hexameric half-sites. Only receptors with glutamate or aspartate as the first P-box amino acid had detectable DNA binding affinity on everted repeats with AGGNCA half-sites. Only those receptors with alanine, glycine, serine, or proline in the second P-box position were able to bind to this same group of everted repeat elements. In contrast, many of the variant receptors with substitutions at the third P-box position were capable of binding to the AGGNCA group of repeat elements. The actual substitutions at the third P-box position that were compatible with binding depended upon the identity of the fourth base pair of the AGGNCA half-sites. Of the remaining 12 everted repeat sequences, only those with AGTTCA or AGTCCA half-sites were able to bind any of the receptors. In addition to wild type receptor, several variant receptors with amino acid substitutions in either the first or third P-box position were able to bind to the everted repeat with AGTTCA half-sites. The everted repeat with AGTCCA half-sites was bound by receptors with a DGG, NGG, or EGQ P-box sequence, but not the wild type receptor which has an EGG P-box sequence. These data demonstrate that all three P-box positions of the thyroid hormone receptor function to discriminate between half sites that differ in sequence at the third and fourth base pairs.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA,BC V8W 3P6,CANADA	University of Victoria				Romaniuk, Paul/0000-0002-5931-8879				CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LANDET V, 1992, EMBO J, V11, P1003; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NELSON CC, 1995, J BIOL CHEM, V270, P16988, DOI 10.1074/jbc.270.28.16988; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; NISHIKAWA J, 1993, J BIOL CHEM, V268, P19739; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; ZILLIACUS J, 1994, P NATL ACAD SCI USA, V91, P4175, DOI 10.1073/pnas.91.10.4175; ZILLIACUS J, 1992, J BIOL CHEM, V267, P24941	29	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16981	16987		10.1074/jbc.270.28.16981	http://dx.doi.org/10.1074/jbc.270.28.16981			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622518	hybrid			2022-12-25	WOS:A1995RJ34700079
J	WOLFF, J; KNIPLING, L				WOLFF, J; KNIPLING, L			COLCHICINE BINDING BY THE ISOLATED BETA-MONOMER OF TUBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ANISOTROPY; DIMER DISSOCIATION; BRAIN TUBULIN; LACTOPEROXIDASE; KINETICS; IDENTIFICATION; PURIFICATION	At mole ratios of lactoperoxidase to tubulin monomers of 3-4, bovine lactoperoxidase forms 1:1 adducts with both alpha- and beta-tubulin from rat brain, thereby separating the tubulin heterodimer into its monomers. This mixture binds colchicine normally, and we show here by direct photoaffinity labeling that the bulk of the [H-3]colchicine becomes attached to beta-tubulin under these conditions. When the alpha-tubulin has been displaced by lactoperoxidase, the ratio of label in beta-tubulin to alpha-tubulin is increased. The amount of label in alpha-tubulin decreases with a corresponding appearance of label in lactoperoxidase. The rate of labeling of beta-tubulin remains slow. We conclude that alpha-tubulin is not necessary for colchicine binding and propose a model wherein the A and C rings of colchicine bind to beta-tubulin, while the B ring faces alpha-tubulin in the dimer.			WOLFF, J (corresponding author), NIDDK,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892, USA.			Knipling, Leslie/0000-0002-2636-6460				ANDREU JM, 1982, BIOCHEMISTRY-US, V21, P534, DOI 10.1021/bi00532a019; BANE S, 1984, J BIOL CHEM, V259, P7391; BHATTACHARYYA B, 1986, P NATL ACAD SCI USA, V83, P2052, DOI 10.1073/pnas.83.7.2052; DETRICH HW, 1982, BIOCHEMISTRY-US, V21, P2392, DOI 10.1021/bi00539a018; DUMONTET C, 1983, J BIOL CHEM, V258, P4166; ENGELBORGHS Y, 1987, J BIOL CHEM, V262, P5204; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; HASTIE SB, 1991, PHARMACOL THERAPEUT, V51, P377, DOI 10.1016/0163-7258(91)90067-V; HESSE J, 1987, J BIOL CHEM, V262, P15472; JAYARAM B, 1994, J BIOL CHEM, V269, P3233; MEJILLANO MR, 1989, BIOCHEMISTRY-US, V28, P6518, DOI 10.1021/bi00441a053; PANDA D, 1992, BIOCHEMISTRY-US, V31, P9709, DOI 10.1021/bi00155a026; RIGHETTI PG, 1976, J CHROMATOGR, V127, P1, DOI 10.1016/S0021-9673(00)98537-6; ROUSSET B, 1980, J BIOL CHEM, V255, P2514; ROUSSET B, 1980, J BIOL CHEM, V255, P1677; ROUSSET B, 1980, FEBS LETT, V115, P235, DOI 10.1016/0014-5793(80)81176-8; SACKETT DL, 1991, BIOCHEMISTRY-US, V30, P3511, DOI 10.1021/bi00228a023; SACKETT DL, 1994, BIOCHEMISTRY-US, V33, P12868, DOI 10.1021/bi00209a019; SHEARWIN KE, 1994, BIOCHEMISTRY-US, V33, P894, DOI 10.1021/bi00170a007; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; SUZUKI T, 1984, BIOCHEM MED METAB B, V31, P211, DOI 10.1016/0006-2944(84)90025-5; UPPULURI S, 1993, P NATL ACAD SCI USA, V890, P11598; WOLFF J, 1992, BIOCHEMISTRY-US, V31, P3935, DOI 10.1021/bi00131a007; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820	24	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16809	16812		10.1074/jbc.270.28.16809	http://dx.doi.org/10.1074/jbc.270.28.16809			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622494	hybrid			2022-12-25	WOS:A1995RJ34700055
J	WRAGG, S; HAGEN, FK; TABAK, LA				WRAGG, S; HAGEN, FK; TABAK, LA			KINETIC-ANALYSIS OF A RECOMBINANT UDP-N-ACETYL-D-GALACTOSAMINE - POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-GLYCOSYLATION; PURIFICATION; PROTEINS; GALNAC; TRANSFERASE; INVITRO	A mammalian expression vector was designed to express a secreted soluble form of the UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase (polypeptide GalNAc transferase) with a metal binding site (HHWHHH) at the NH2 terminus. The recombinant enzyme was purified to homogeneity from COS-7 cell media by sequential chromatography on columns of NiCl2-chelating Sepharose, Affi-Gel blue, and Sephacryl S-100. Kinetic parameters of recombinant and native polypeptide GalNAc transferase were comparable for the donor UDP-GalNAc and for the peptide accepters Ac (T) under bar PPP, EPO-T (PPDAA (T) under bar AAPLR), and HVF (PHMAQV (T) under bar VGPGL). Initial velocity and product inhibition studies were carried out with purified recombinant polypeptide GalNAc transferase and the substrates UDP-GalNAc and peptide EPO-T. Initial velocity data was consistent with a sequential type mechanism in which binding of both substrates precedes product release. Product inhibition analysis using UDP showed competitive inhibition against UDP-GalNAc and a noncompetitive inhibition against peptide EPO-T. The dead end peptide analogue EPO-G (PPDAAGAAPLR) was a noncompetitive inhibitor of UDP-GalNAc and a competitive inhibitor of peptide EPO-T. Collectively, the results suggest that the most probable kinetic mechanism for the enzyme is one in which both substrates must bind in a random order prior to catalysis. Interestingly, the K-m for EPO-T is similar to the K-i for EPO-G, suggesting that peptide interaction with the polypeptide GalNAc transferase does not require a hydroxyamino acid.	UNIV ROCHESTER, SCH MED & DENT, DEPT DENT RES, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008108, R01DE008108] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08108] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		[Anonymous], 1989, SAS STAT USERS GUIDE, V2; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HSUEH EC, 1986, J BIOL CHEM, V261, P4940; KASHER MS, 1993, BIOTECHNIQUES, V14, P630; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; MCGUIRE EJ, 1967, J BIOL CHEM, V242, P3745; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; OCONNELL BC, 1993, J DENT RES, V72, P1554, DOI 10.1177/00220345930720120401; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Segel I.H., 1975, ENZYME KINETICS; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; TABAK LA, 1985, ARCH BIOCHEM BIOPHYS, V242, P383, DOI 10.1016/0003-9861(85)90222-X; WANG YC, 1992, J BIOL CHEM, V267, P2728	21	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16947	16954		10.1074/jbc.270.28.16947	http://dx.doi.org/10.1074/jbc.270.28.16947			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622513	hybrid			2022-12-25	WOS:A1995RJ34700074
J	XU, Q; HOPPE, D; CHITNIS, VP; ODOM, WR; GUIKEMA, JA; CHITNIS, PR				XU, Q; HOPPE, D; CHITNIS, VP; ODOM, WR; GUIKEMA, JA; CHITNIS, PR			MUTATIONAL ANALYSIS OF PHOTOSYSTEM-I POLYPEPTIDES IN THE CYANOBACTERIUM SYNECHOCYSTIS SP, PCC-6803 - TARGETED INACTIVATION OF PSAI REVEALS THE FUNCTION OF PSAI IN THE STRUCTURAL ORGANIZATION OF PSAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANABAENA-VARIABILIS ATCC-29413; CHEMICAL CROSS-LINKING; ENCODING SUBUNIT-II; SP PCC-6803; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CHLOROPLAST GENOME; MOLECULAR-CLONING; GENE ORGANIZATION; SYNECHOCOCCUS-SP	We cloned, characterized, and inactivated the psaI gene encoding a 4-kDa hydrophobic subunit of photosystem I from the cyanobacterium Synechocystis sp. PCC 6803, The peal gene is located 90 base pairs downstream from psaL, and is transcribed on 0,94- and 0,SB-kilobase transcripts, To identify the function of psaI, we generated a cyanobacterial strain in which psaI has been interrupted by a gene for chloramphenicol resistance. The wild-type and the mutant cells showed comparable rates of photoautotrophic growth at 25 degrees C, However, the mutant cells grew slower and contained less chlorophyll than the wild-type cells, when grown at 40 degrees C. The PsaI-less membranes from cells grown at either temperature showed a small decrease in NADP(+) photoreduction rate when compared to the wild-type membranes. Inactivation of psaI led to an 80% decrease in the PsaL level in the photosynthetic membranes and to a complete loss of PsaL in the purified photosystem I preparations, but had little effect on the accumulation of other photosystem I subunits, Upon solubilization with nonionic detergents, photosystem I trimers could be obtained from the wild-type, but not from the PsaI-less membranes, The PsaI-less photosystem I monomers did not contain detectable levels of PsaL. Therefore, a structural interaction between PsaL and PsaI may stabilize the association of PsaL with the photosystem I core. PsaL in the mild-type and PsaI-less membranes showed equal resistance to removal by chaotropic agents. However, PsaL in the PsaI-less strain exhibited an increased susceptibility to proteolysis. From these data, we conclude that PsaI has a crucial role in aiding normal structural organization of PsaL within the photosystem I complex and the absence of PsaI alters PsaL organization, leading to a small, but physiologically significant, defect in photosystem I function.	KANSAS STATE UNIV AGR & APPL SCI, DIV BIOL, MANHATTAN, KS 66506 USA	Kansas State University								ANDERSON SL, 1991, PLANT MOL BIOL, V16, P487, DOI 10.1007/BF00023416; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BRYANT DA, 1992, PHOTOSYSTEMS STRUCTU, P501; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; CHITNIS PR, 1992, PLANT PHYSIOL, V99, P239, DOI 10.1104/pp.99.1.239; CHITNIS PR, 1991, PHOTOSYNTHETIC APPAR, P178; CHITNIS PR, 1995, IN PRESS PHOTOSYNTH; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; COOPER CE, 1991, BIOCHEM CELL BIOL, V69, P586, DOI 10.1139/o91-089; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HENRY RL, 1992, PLANT PHYSIOL BIOCH, V30, P357; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; IKEUCHI M, 1992, PLANT CELL PHYSIOL, V33, P1057; IKEUCHI M, 1991, FEBS LETT, V287, P5, DOI 10.1016/0014-5793(91)80003-L; Kok B., 1980, METHODS ENZYMOLOGY C, V69, P280; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MENGINLECREULX D, 1990, NUCLEIC ACIDS RES, V18, P2810, DOI 10.1093/nar/18.9.2810; MENGINLECREULX D, 1991, J BACTERIOL, V173, P4625, DOI 10.1128/jb.173.15.4625-4636.1991; MUHLENHOFF U, 1993, GENE, V127, P71, DOI 10.1016/0378-1119(93)90618-D; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; REILLY P, 1988, J BIOL CHEM, V263, P17658; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLER HV, 1989, J BIOL CHEM, V264, P18402; SHEN GZ, 1994, BIOCHEMISTRY-US, V33, P7379, DOI 10.1021/bi00189a044; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SMART LB, 1991, PLANT MOL BIOL, V17, P959, DOI 10.1007/BF00037136; SONOIKE K, 1992, PLANT MOL BIOL, V20, P987, DOI 10.1007/BF00027168; STEINMULLER K, 1992, PLANT MOL BIOL, V20, P997, DOI 10.1007/BF00027170; VERMAAS WFJ, 1991, PHOTOSYNTHETIC APPAR, P26; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WEBER N, 1993, BIOCHIM BIOPHYS ACTA, V1143, P204, DOI 10.1016/0005-2728(93)90144-5; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; XU Q, 1994, PLANT PHYSIOL, V106, P1057, DOI 10.1104/pp.106.3.1057; XU Q, 1994, PLANT MOL BIOL, V26, P291, DOI 10.1007/BF00039540; XU Q, 1994, J BIOL CHEM, V269, P21512; XU QA, 1994, J BIOL CHEM, V269, P3205; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	56	74	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16243	16250		10.1074/jbc.270.27.16243	http://dx.doi.org/10.1074/jbc.270.27.16243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608190	hybrid			2022-12-25	WOS:A1995RH22600056
J	CHOU, TY; HART, GW; DANG, CV				CHOU, TY; HART, GW; DANG, CV			C-MYC IS GLYCOSYLATED AT THREONINE-58, A KNOWN PHOSPHORYLATION SITE AND A MUTATIONAL HOT-SPOT IN LYMPHOMAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BURKITT-LYMPHOMA; TERMINAL DOMAIN; POINT MUTATIONS; PROTEIN; CELLS; GENE; TRANSFORMATION; IDENTIFICATION; LOCALIZATION; ONCOPROTEINS	c-Myc is a helix-loop-helix leucine zipper phosphoprotein that heterodimerizes with Max and regulates gene transcription in cell proliferation, cell differentiation, and programmed cell death, Previously, we demonstrated that c-Myc is modified by O-linked N-acetylglucosamine (O-GlcNAc) within or nearby the N-terminal transcriptional activation domain (Chou, T.-Y., Dang, C. V., and Hart, G. W. (1995) Proc, Natl, Acad, Sci, U.S.A. 92, 4417-4421), In this paper, we identified the O-GlcNAc attachment site(s) on c-Myc, c-Myc purified from sf9 insect cells was trypsinized, and its GlcNAc moieties were enzymically labeled with [H-3]galactose, The [H-3]galactose-labeled glycopeptides were isolated by reverse phase high performance liquid chromatography and then subjected to gas-phase sequencing, manual Edman degradation, and laser desorption/ionization mass spectrometry. These analyses show that threonine 58, an in vivo phosphorylation site in the transactivation domain, is the major O-GlcNAc glycosylation site of c-Myc. Mutation of threonine 58, frequently found in retroviral v-Myc proteins and in human Burkitt and AIDS-related lymphomas, is associated with enhanced transforming activity and tumorigenicity. The reciprocal glycosylation and phosphorylation at this biologically significant amino acid residue may play an important role in the regulation of the functions of c-Myc.	UNIV ALABAMA,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; JOHNS HOPKINS UNIV,SCH MED,BIOCHEM CELLULAR & MOLEC BIOL TRAINING PROGRAM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV HEMATOL,BALTIMORE,MD 21205	University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins University			Dang, Chi/Y-3375-2019	Hart, Gerald/0000-0001-7812-4351; Dang, Chi/0000-0002-4031-2522	NCI NIH HHS [CA57341, CA42486] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042486, R01CA057341] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT T, 1994, ONCOGENE, V9, P759; BHATIA K, 1994, BLOOD, V84, P883; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWELL TK, 1990, SCIENCE, V251, P1149; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHEVRIER MR, 1991, RAPID COMMUN MASS SP, V5, P611, DOI 10.1002/rcm.1290051209; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CLARK HM, 1994, CANCER RES, V54, P3383; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAULKNER P, 1992, J VIROL, P3324; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; FRYKBERG L, 1987, ONCOGENE, V1, P415; GREIS KD, 1994, J VIROL, V68, P8339, DOI 10.1128/JVI.68.12.8339-8349.1994; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HART GW, 1993, 44TH C MOSB GLYC CEL, P91; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOLT GD, 1986, J BIOL CHEM, V261, P8049; IBERG N, 1986, J BIOL CHEM, V261, P3542; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1989, MOL CELL BIOL, V10, P5914; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KU NO, 1994, EXP CELL RES, V211, P24, DOI 10.1006/excr.1994.1054; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MEEK JL, 1981, J CHROMATOGR, V211, P15, DOI 10.1016/S0021-9673(00)81169-3; MIYAMOTO C, 1985, MOL CELL BIOL, V5, P2860, DOI 10.1128/MCB.5.10.2860; MOORE JP, 1987, ONCOGENE RES, V2, P65; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Raffeld M, 1995, Curr Top Microbiol Immunol, V194, P265; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SETH A, 1991, J BIOL CHEM, V226, P23521; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; Summers MD, 1987, MANUAL METHODS BACUL; SYMONDS G, 1989, ONCOGENE, V4, P285; YANO T, 1993, ONCOGENE, V8, P2741	41	336	366	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18961	18965		10.1074/jbc.270.32.18961	http://dx.doi.org/10.1074/jbc.270.32.18961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642555	hybrid			2022-12-25	WOS:A1995RN95400043
J	FUTER, O; DECENZO, MT; ALDAPE, RA; LIVINGSTON, DJ				FUTER, O; DECENZO, MT; ALDAPE, RA; LIVINGSTON, DJ			FK506 BINDING-PROTEIN MUTATIONAL ANALYSIS - DEFINING THE SURFACE RESIDUE CONTRIBUTIONS TO STABILITY OF THE CALCINEURIN CO-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; SITE-SPECIFIC MUTAGENESIS; ENDOPLASMIC-RETICULUM; FK506-BINDING PROTEIN; PHENOTYPIC SELECTION; IMMUNOPHILIN LIGAND; CYCLOSPORINE-A; RAPAMYCIN; EFFICIENT; FKBP-13	The 12 and 13-kDa FK506 binding proteins (FKBP12 and FKBP13) are cis-trans peptidyl-prolyl isomerases that bind the macrolides FK506 (Tacrolimus) and rapamycin (Sirolimus). The FKBP12 . FK506 complex is immunosuppressive, acting as an inhibitor of the protein phosphatase calcineurin, We have examined the role of the key surface residues of FKBP12 and FKBP13 in calcineurin interactions by generating substitutions at these residues by site-directed mutagenesis. All mutants are active catalysts of the prolyl isomerase reaction, and bind FK506 or rapamycin with high affinity, Mutations at FKBP12 residues Asp-37, Arg-42, His-87, and Ile-90 decrease calcineurin affinity of the mutant FKBP12 FK506 complex by as much as 2600-fold in the case of I90K, Replacement of three FKBP13 surface residues (Gln-50, Ala-95, and Lys-98) with the corresponding homologous FKBP12 residues (Arg-42, His-87, and Ile-90) generates an FKBP13 variant that is equivalent to FKBP12 in its affinity for FK506, rapamycin, and calcineurin, These results confirm the role of two loop regions of FKBP12 (residues 40-44 and 84-91) as part of the effector face that interacts with calcineurin.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139	Vertex Pharmaceuticals								ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; ARMISTEAD DM, 1993, ANNU REP MED CHEM, V28, P207; ARMISTEAD DM, 1995, IN PRESS ACTA CRYSTA; BECKER JW, 1993, J BIOL CHEM, V268, P11335; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; DILELLA AG, 1991, BIOCHEMISTRY-US, V30, P8512, DOI 10.1021/bi00099a002; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HENDRICKSON BA, 1993, GENE, V134, P271, DOI 10.1016/0378-1119(93)90106-D; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; ITOH S, 1995, IN PRESS BIOORG MED, V5; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; KLEE CB, 1988, MOL ASPECTS CELL REG, V5, P225; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEPRE CA, 1994, BIOCHEMISTRY-US, V33, P13571, DOI 10.1021/bi00250a009; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; NIGAM SK, 1993, BIOCHEM J, V294, P511, DOI 10.1042/bj2940511; PARK ST, 1992, J BIOL CHEM, V267, P3316; PARTALEDIS JA, 1993, P NATL ACAD SCI USA, V90, P5450, DOI 10.1073/pnas.90.12.5450; PEATTIE DA, 1994, GENE, V150, P251, DOI 10.1016/0378-1119(94)90434-0; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; ROSEN MK, 1993, J AM CHEM SOC, V115, P821, DOI 10.1021/ja00055a082; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER SL, 1992, SCIENCE, V251, P283; SCHULTZ LW, 1994, J AM CHEM SOC, V116, P3129, DOI 10.1021/ja00086a055; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WILSON KP, 1995, IN PRESS ACTA CRYSTA; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	39	51	52	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18935	18940		10.1074/jbc.270.32.18935	http://dx.doi.org/10.1074/jbc.270.32.18935			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642551				2022-12-25	WOS:A1995RN95400039
J	SCHWARTZ, EL; BAPTISTE, N; WADLER, S; MAKOWER, D				SCHWARTZ, EL; BAPTISTE, N; WADLER, S; MAKOWER, D			THYMIDINE PHOSPHORYLASE MEDIATES THE SENSITIVITY OF HUMAN COLON-CARCINOMA CELLS TO 5-FLUOROURACIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADVANCED COLORECTAL-CARCINOMA; RECOMBINANT INTERFERON ALFA-2A; GROWTH-FACTOR; PHASE-II; FLUOROURACIL; EXPRESSION; METABOLISM; CANCER; RESISTANCE	Interferon-alpha (IFN alpha) potentiates the antitumor activity of 5-fluorouracil (FUra) in colon cancer in vitro, in vivo, and clinically. A likely mechanism for this action is the induction by IFN alpha of thymidine phosphorylase (TP), the first enzyme in one pathway for the metabolic activation of FUra to fluorodeoxyribonucleotides. To test this hypothesis, an expression vector containing the TP cDNA was transfected into HT-29 human colon carcinoma cells. Five stable transfectants were selected and analyzed. All showed increased sensitivity to FUra cytotoxicity, ranging from a 2-fold to a 19-fold decrease in the IC50 for FUra, compared to wild-type cells. Levels of TP mRNA, protein, and enzyme activity were elevated in the transfectants, and there was a significant correlation between the relative increase in sensitivity to FUra and both the increase in both TP mRNA levels and TP activity. Transfected cells exhibited increased formation of FdUMP, but not the ribonucleotides FUDP and FUTP, from FUra when compared to wild-type cells, The changes in TP activity, FdUMP formation, and FUra sensitivity in the transfected cells were comparable with those seen after treatment of wild-type cells with IFN alpha. These studies provide direct evidence for the role of TP in mediating the sensitivity of colon carcinoma cells to FUra, and further support the importance of the induction of TP in the biomodulating action of IFN alpha on FUra chemosensitivity.	ALBERT EINSTEIN COLL MED,DEPT ONCOL,BRONX,NY 10467	Yeshiva University; Albert Einstein College of Medicine	SCHWARTZ, EL (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN CANC CTR,DEPT ONCOL,111 E 210TH ST,BRONX,NY 10467, USA.				NATIONAL CANCER INSTITUTE [R01CA054422, P30CA013330, R55CA054422] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330, CA54422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNIE GD, 1963, BIOCHEMISTRY-US, V2, P566, DOI 10.1021/bi00903a031; CHU E, 1990, MOL PHARMACOL, V38, P410; EDA H, 1993, CANCER CHEMOTH PHARM, V32, P333, DOI 10.1007/BF00735915; ELIAS L, 1989, BIOCHEM BIOPH RES CO, V163, P867, DOI 10.1016/0006-291X(89)92302-4; FINNIS C, 1993, EUR J BIOCHEM, V212, P201, DOI 10.1111/j.1432-1033.1993.tb17651.x; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIEDKIN M, 1953, J BIOL CHEM, V207, P245; FURUKAWA T, 1992, NATURE, V356, P668, DOI 10.1038/356668a0; HARAGUCHI M, 1994, NATURE, V368, P198, DOI 10.1038/368198a0; ILTZSCH MH, 1985, BIOCHEMISTRY-US, V24, P6799, DOI 10.1021/bi00345a011; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; JOHNSTON PG, 1992, CANCER RES, V52, P4306; JOHNSTON PG, 1995, CANCER RES, V55, P1407; KRENITSKY TA, 1968, J BIOL CHEM, V243, P2871; LUCCIONI C, 1994, INT J CANCER, V58, P517, DOI 10.1002/ijc.2910580411; MAEHARA Y, 1989, J SURG ONCOL, V42, P184, DOI 10.1002/jso.2930420311; MARSH JC, 1964, J CLIN INVEST, V43, P267, DOI 10.1172/JCI104911; MARTINUSSEN J, 1994, J BACTERIOL, V176, P6457, DOI 10.1128/JB.176.21.6457-6463.1994; MOGHADDAM A, 1992, BIOCHEMISTRY-US, V31, P12141, DOI 10.1021/bi00163a024; MOGHADDAM A, 1995, P NATL ACAD SCI USA, V92, P998, DOI 10.1073/pnas.92.4.998; PAULY JL, 1978, P SOC EXP BIOL MED, V157, P262; PAULY JL, 1977, J NATL CANCER I, V58, P1587, DOI 10.1093/jnci/58.6.1587; PAZDUR R, 1990, J CLIN ONCOL, V8, P2027, DOI 10.1200/JCO.1990.8.12.2027; PETERS GJ, 1991, CANCER, V68, P1903, DOI 10.1002/1097-0142(19911101)68:9<1903::AID-CNCR2820680910>3.0.CO;2-9; REYNOLDS K, 1994, J NATL CANCER I, V86, P1234, DOI 10.1093/jnci/86.16.1234; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; SCHWARTZ EL, 1994, CANCER RES, V54, P1472; SCHWARTZ EL, 1992, BIOCHEM BIOPH RES CO, V182, P1232, DOI 10.1016/0006-291X(92)91863-L; SCHWARTZ EL, 1995, IN PRESS CANCER RES, V55; SHAW T, 1988, MUTAT RES, V200, P117, DOI 10.1016/0027-5107(88)90075-9; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SPEARS CP, 1988, CANCER RES, V48, P5894; Takebayashi Y., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P90; USUKI K, 1992, BIOCHEM BIOPH RES CO, V184, P1311, DOI 10.1016/S0006-291X(05)80025-7; WADLER S, 1989, J CLIN ONCOL, V7, P1769, DOI 10.1200/JCO.1989.7.12.1769; WADLER S, 1991, J CLIN ONCOL, V9, P1806, DOI 10.1200/JCO.1991.9.10.1806; YOSHIMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1034, P107, DOI 10.1016/0304-4165(90)90160-X; ZIMMERMAN M, 1964, J BIOL CHEM, V239, P2618; 1995, J CLIN ONCOL, V13, P921	39	110	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19073	19077		10.1074/jbc.270.32.19073	http://dx.doi.org/10.1074/jbc.270.32.19073			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642571	hybrid			2022-12-25	WOS:A1995RN95400059
J	WILSON, SA; WILLIAMS, RJ; PEARL, LH; DREW, RE				WILSON, SA; WILLIAMS, RJ; PEARL, LH; DREW, RE			IDENTIFICATION OF 2 NEW GENES IN THE PSEUDOMONAS-AERUGINOSA AMIDASE OPERON, ENCODING AN ATPASE (AMIB) AND A PUTATIVE INTEGRAL MEMBRANE-PROTEIN (AMIS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ALIPHATIC AMIDASE; BINDING PROTEIN; EXPRESSION; CLONING; PURIFICATION; COMPONENTS; PRODUCT; SUBUNIT	The nucleotide sequence of the amidase operon of Pseudomonas aeruginosa has been completed and two new genes identified amiB and amiS. The complete gene order for the operon is thus amiEBCRS. The amiB gene encodes a 42-kDa protein containing an ATP binding motif that shares extensive homology with the Clp family of proteins and also to an open reading frame adjacent to the amidase gene from Rhodococcus erythropolis. Deletion of the amiB gene has no apparent effect on inducible amidase expression and it is thus unlikely to encode a regulatory protein, A maltose binding protein-AmiB fusion has been purified and shown to have an intrinsic ATPase activity (K-m = 174 +/- 15 mM; V-max = 2.4 +/- 0.1 mM/min/mg), which is effectively inhibited by ammonium vanadate and ADP, The amiS gene encodes an 18-kDa protein with a high content of hydrophobic residues. Hydropathy analysis suggests the presence of six transmembrane helices in this protein, The AmiS sequence is homologous to an open reading frame identified adjacent to the amidase gene from Mycobacterium smegmatis and to the ureI gene from the urease operon of Helicobacter pylori. AmiS and its homologs appear to be a novel family of integral membrane proteins, Together AmiB and AmiS resemble two components of an ABC transporter system.	UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London				Pearl, Laurence/0000-0002-6910-1809; wilson, stuart/0000-0003-3073-258X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMMAR WJ, 1987, FEBS LETT, V215, P291, DOI 10.1016/0014-5793(87)80164-3; BRAMMAR WJ, 1964, J GEN MICROBIOL, V37, P307, DOI 10.1099/00221287-37-3-307; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; COUSENS DJ, 1987, J GEN MICROBIOL, V133, P2041; CUSSAC V, 1992, J BACTERIOL, V174, P2466, DOI 10.1128/jb.174.8.2466-2473.1992; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAY MJ, 1975, THESIS U LONDON; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREW R, 1989, J GEN MICROBIOL, V135, P817; DREW RE, 1980, MOL GEN GENET, V177, P311, DOI 10.1007/BF00267444; FERRERO RL, 1991, ITAL J GASTROENTE S2, V23, P3; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; KAGAWA Y, 1979, J BIOENERG BIOMEMBR, V11, P39, DOI 10.1007/BF00743196; KELLY M, 1962, J GEN MICROBIOL, V27, P305, DOI 10.1099/00221287-27-2-305; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWE N, 1989, FEBS LETT, V246, P39, DOI 10.1016/0014-5793(89)80249-2; MAHENTHIRALINGAM E, 1993, J GEN MICROBIOL, V139, P575, DOI 10.1099/00221287-139-3-575; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MORBACH S, 1993, J BIOL CHEM, V268, P18617; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PEARL L, 1994, EMBO J, V13, P5810, DOI 10.1002/j.1460-2075.1994.tb06924.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; Sambrook J, 1989, MOL CLONING LABORATO; SOUBRIER F, 1992, GENE, V116, P99, DOI 10.1016/0378-1119(92)90635-3; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; STIRK HJ, 1992, INTERVIROLOGY, V33, P148, DOI 10.1159/000150244; TAI JTN, 1994, MOL MICROBIOL, V12, P31, DOI 10.1111/j.1365-2958.1994.tb00992.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILSON S, 1991, J BACTERIOL, V173, P4914, DOI 10.1128/jb.173.16.4914-4921.1991; WILSON SA, 1993, EMBO J, V12, P3637, DOI 10.1002/j.1460-2075.1993.tb06037.x; WILSON SA, 1991, J MOL BIOL, V222, P869, DOI 10.1016/0022-2836(91)90579-U	41	25	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18818	18824		10.1074/jbc.270.32.18818	http://dx.doi.org/10.1074/jbc.270.32.18818			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642533	hybrid			2022-12-25	WOS:A1995RN95400020
J	PRASAD, ARK; DAILEY, HA				PRASAD, ARK; DAILEY, HA			EFFECT OF CELLULAR LOCATION ON THE FUNCTION OF FERROCHELATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTOPORPHYRINOGEN OXIDASE; SACCHAROMYCES-CEREVISIAE; PRECURSOR; MITOCHONDRIA; ORIENTATION; PROTEINS; SYNTHASE; SEQUENCE; LIVER; HEME	Ferrochelatase, the terminal enzyme of the heme biosynthetic pathway, is a nuclear encoded protein that is synthesized in the cytoplasm in a precursor form and then is translocated to the matrix side of the inner mitochondrial membrane, Since the product of the enzymatic reaction, protoheme IX, is utilized almost exclusively in the cytoplasmic compartment or on the cytoplasmic side of the inner mitochondrial membrane, it was of interest to determine if the intracellular location of ferrochelatase is crucial for its effective functioning, In a ferrochelatase-deficient strain of the yeast Saccharomyces cerevisiae vectors that coded for full-length ferrochelatase and a truncated form of the enzyme that lacked the mitochondrial targeting sequence were expressed, Both of these transformed cells produce approximately equal total amounts of ferrochelatase, as determined by enzyme assays and Western blot analysis, but only with the full-length construct was ferrochelatase properly localized. In cells containing the truncated construct, ferrochelatase activity was found in all membrane fractions but was not located on the matrix side of the inner mitochondrial membrane, Cells containing either construct produced heme, although the amount of heme synthesized by cells with the truncated construct was significantly less, Interestingly in cells with improperly localized ferrochelatase the amount of b-type cytochrome decreased by 80% as opposed to c- and a-type cytochromes where the decreases were only 60 and 40%, respectively.	UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032303, R01DK035898, R01DK032303] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 32303, R56 DK032303, DK 35898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADES IZ, 1981, J BIOL CHEM, V256, P9329; BORTHWICK IA, 1985, EUR J BIOCHEM, V150, P481, DOI 10.1111/j.1432-1033.1985.tb09047.x; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1983, J BIOL CHEM, V258, P1453; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEYBACH JC, 1985, EUR J BIOCHEM, V149, P431, DOI 10.1111/j.1432-1033.1985.tb08943.x; FERREIRA GC, 1988, J BIOL CHEM, V263, P3835; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HARBIN BM, 1985, BIOCHEMISTRY-US, V24, P366, DOI 10.1021/bi00323a019; Jordan PM, 1990, BIOSYNTHESIS HEME CH, P55; KARR SR, 1988, BIOCHEM J, V254, P799, DOI 10.1042/bj2540799; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; ROISE D, 1988, J BIOL CHEM, V263, P4509; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; YAMAUCHI K, 1980, FEBS LETT, V115, P15, DOI 10.1016/0014-5793(80)80716-2	17	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18198	18200		10.1074/jbc.270.31.18198	http://dx.doi.org/10.1074/jbc.270.31.18198			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629135	hybrid			2022-12-25	WOS:A1995RM64200007
J	SMITH, T; FERREIRA, LR; HEBERT, C; NORRIS, K; SAUK, JJ				SMITH, T; FERREIRA, LR; HEBERT, C; NORRIS, K; SAUK, JJ			HSP47 AND CYCLOPHILIN-B TRAVERSE THE ENDOPLASMIC-RETICULUM WITH PROCOLLAGEN INTO PRE-GOLGI INTERMEDIATE VESICLES - A ROLE FOR HSP47 AND CYCLOPHILIN-B IN THE EXPORT OF PROCOLLAGEN FROM THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; SIGNAL RECOGNITION PARTICLE; COLLAGEN TRIPLE-HELIX; PROTEIN TRANSLOCATION; I PROCOLLAGEN; OSTEOGENESIS IMPERFECTA; THERMAL-STABILITY; SECRETORY PATHWAY; PEPTIDE-BONDS; ALPHA-CHAINS	Hsp47 and cyclophilin B (CyPB) are residents of the endoplasmic reticulum (ER), Both of these proteins are closely associated with polysome-associated alpha 1(I) procollagen chains, Hsp47 possesses chaperone properties early during the translation of procollagen while the cis/trans-isomerase properties of CyPB facilitate procollagen folding. In this report, we further investigate the interaction of these proteins with procollagen I during export from the ER. To inhibit vesicular budding and retain procollagen within the ER, cells were treated with the heterotrimeric G protein inhibitor mastoparan or calphostin C, a specific inhibitor of diacylglycerol/phorbol ester binding proteins. To arrest procollagen in pre Golgi intermediate vesicles, cells were treated with guanosine 5'-3-O-(thio)triphosphate. Pulse chase experiments of cells labeled with [S-35]methionine followed by immunoprecipitation during the chase period with anti-procollagen, anti-Hsp47, and anti-CyPB antibodies were performed to reveal the relationship between Hsp47/CyPB/procollagen I. The distribution of procollagen, Hsp47, and CS PB to the ER and/or pre-Golgi vesicles was verified by immunofluorescence. Hsp47 and CyPB remained associated with procollagen retained within the ER, Hsp47 and CyPB were also associated with procollagen exported from the ER into pre-Golgi intermediate vesicles. Treatment of cells with cyclosporin A diminished the levels of CyPB bound to procollagen and diminished the rate of Hsp47 released from procollagen and the rate of procollagen secretion, suggesting that Hsp47 release from procollagen may be driven by helix formation. Also, these studies suggest that Hsp47 may resemble protein disulfide isomerase and possess both chaperone and anti-chaperone properties. During translation, high levels of Hsp47 are seen to limit protein aggregation and facilitate chain registration, Later, Hsp47 and/or CS PB and protein disulfide isomerase act as anti-chaperones and provide the basis for concentration of procollagen for ER export.	UNIV MARYLAND, SCH DENT, DEPT PATHOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore				Sauk, John/0000-0002-9208-5739	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008648] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41572] Funding Source: Medline; NIDCR NIH HHS [DE08648] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BERGMAN LW, 1977, BIOCHEMISTRY-US, V16, P4490, DOI 10.1021/bi00639a025; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOREL JF, 1976, IMMUNOLOGY, V31, P631; BOSE S, 1994, BIOCHEM J, V300, P871, DOI 10.1042/bj3000871; CARONI P, 1991, J BIOL CHEM, V266, P10739; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; CONNERN CP, 1992, BIOCHEM J, V284, P381, DOI 10.1042/bj2840381; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; FABBRI M, 1994, J BIOL CHEM, V269, P26848; FERREIRA LR, 1994, J CELL BIOCHEM, V56, P518, DOI 10.1002/jcb.240560412; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HOHMAN R J, 1990, New Biologist, V2, P663; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053, DOI 10.1021/bi00464a023; KIRK TZ, 1987, J BIOL CHEM, V262, P5540; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Mayne R., 1987, STRUCTURE FUNCTION C; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; PLUNTER H, 1992, J CELL BIOL, V119, P1097; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; PUIG A, 1994, J BIOL CHEM, V269, P7764; QUESNIAUX VFJ, 1987, EUR J IMMUNOL, V17, P1359, DOI 10.1002/eji.1830170921; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARKAR SK, 1984, P NATL ACAD SCI-BIOL, V81, P4800, DOI 10.1073/pnas.81.15.4800; SAUK JJ, 1994, J BIOL CHEM, V269, P3941; SAUK JJ, 1990, BIOCHEM BIOPH RES CO, V172, P135, DOI 10.1016/S0006-291X(05)80183-4; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SCHONBRUNNER ER, 1992, P NATL ACAD SCI USA, V89, P4510, DOI 10.1073/pnas.89.10.4510; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SHROFF B, 1993, CONNECT TISSUE RES, V29, P273, DOI 10.3109/03008209309016833; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SPIK G, 1991, J BIOL CHEM, V266, P10735; Stamnes MA, 1990, CURR OPIN CELL BIOL, V2, P1104, DOI 10.1016/0955-0674(90)90163-9; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; YOKOI H, 1993, BIOCHEM BIOPH RES CO, V195, P769, DOI 10.1006/bbrc.1993.2112	54	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18323	18328		10.1074/jbc.270.31.18323	http://dx.doi.org/10.1074/jbc.270.31.18323			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629154	hybrid			2022-12-25	WOS:A1995RM64200029
J	TRINKLEMULCAHY, L; ICHIKAWA, K; HARTSHORNE, DJ; SIEGMAN, MJ; BUTLER, TM				TRINKLEMULCAHY, L; ICHIKAWA, K; HARTSHORNE, DJ; SIEGMAN, MJ; BUTLER, TM			THIOPHOSPHORYLATION OF THE 130-KDA SUBUNIT IS ASSOCIATED WITH A DECREASED ACTIVITY OF MYOSIN LIGHT-CHAIN PHOSPHATASE IN ALPHA-TOXIN-PERMEABILIZED SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CA-2+ SENSITIVITY; PROTEIN; PHOSPHORYLATION; CALCIUM; CONTRACTION; MODULATION; INHIBITION; GIZZARD; ARTERY	Pretreatment of alpha-toxin-permeabilized smooth muscle with ATP gamma S (adenosine 5'-O-(thiotriphosphate)) under conditions resulting in minimal (<1%) thiophosphorylation of the myosin light chain increases the subsequent calcium sensitivity of force output and myosin light chain phosphorylation, The change in calcium sensitivity results at least in part from a 5-fold decrease in myosin light chain phosphatase activity, One of the few proteins thiophosphorylated under these conditions is the 130-kDa subunit of myosin light chain phosphatase. These results suggest that thiophosphorylation of this subunit leads to a decrease in the activity of the phosphatase, and that phosphorylation and dephosphorylation of the subunit may play a role in regulating myosin light chain phosphatase activity.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PHYSIOL,PHILADELPHIA,PA 19107; UNIV ARIZONA,MUSCLE BIOL GRP,TUCSON,AZ 85721	Jefferson University; University of Arizona					NHLBI NIH HHS [HL-50586, HL-23615, HL-20984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050586, R01HL023615, P01HL020984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BUTLER TM, 1983, AM J PHYSIOL, V244, pC234, DOI 10.1152/ajpcell.1983.244.3.C234; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; CRICHTON CA, 1990, J PHYSL, V437, P543; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GONG MC, 1992, J BIOL CHEM, V267, P21492; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HIMPENS B, 1990, PFLUG ARCH EUR J PHY, V417, P21, DOI 10.1007/BF00370764; HOAR PE, 1979, SCIENCE, V204, P503, DOI 10.1126/science.432654; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; ITO M, 1989, BIOCHEMISTRY-US, V28, P5567, DOI 10.1021/bi00439a034; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MORGAN JP, 1984, J PHYSIOL-LONDON, V351, P155, DOI 10.1113/jphysiol.1984.sp015239; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SHERRY JMF, 1978, BIOCHEMISTRY-US, V17, P4411, DOI 10.1021/bi00614a009; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; TRINKLEMULCAHY L, 1994, AM J PHYSIOL, V266, pC1673, DOI 10.1152/ajpcell.1994.266.6.C1673; VINCENT M, 1991, J MOL CELL CARDIOL, V23, P873, DOI 10.1016/0022-2828(91)90220-G	28	92	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18191	18194		10.1074/jbc.270.31.18191	http://dx.doi.org/10.1074/jbc.270.31.18191			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629133	hybrid			2022-12-25	WOS:A1995RM64200005
J	MARSHALL, GM; CHEUNG, B; STACEY, KP; CAMACHO, ML; SIMPSON, AM; KWAN, E; SMITH, S; HABER, M; NORRIS, MD				MARSHALL, GM; CHEUNG, B; STACEY, KP; CAMACHO, ML; SIMPSON, AM; KWAN, E; SMITH, S; HABER, M; NORRIS, MD			INCREASED RETINOIC ACID RECEPTOR-GAMMA EXPRESSION SUPPRESSES THE MALIGNANT PHENOTYPE AND ALTERS THE DIFFERENTIATION POTENTIAL OF HUMAN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article						DIFFERENTIATION; RETINOIC ACID RECEPTOR GAMMA; NEUROBLASTOMA; RETINOIC ACID	BINDING-PROTEINS; MOUSE; GENE; GROWTH; TRANSCRIPTION; PATTERN; CANCER	Human neuroblastoma (NB) tumor cell lines treated in vitro with the retinoid, all-trans-retinoic acid (aRA), form neurites and undergo growth arrest, Retinoids exert their diverse morphologic effects through a signalling pathway which involves the nuclear retinoid receptors, Defective retinoic acid receptor (RAR) function contributes to the malignant phenotype of several human and experimental tumors. Considerable evidence from gene disruption studies now suggests that one of the RARs, RAR gamma, may directly mediate some retinoid effects on embryonic and malignant cells. We, firstly, examined primary NE tumor tissue for a correlation between endogenous RAR gamma expression and clinical stage of the tumor and secondly, the effects of exogenous overexpression of the RAR gamma gene on a human NE tumor cell line. RAR gamma mRNA expression in 32 primary NE tumor tissue samples were significantly higher in clinically localised tumors compared with advanced or disseminated tumors. The human NE tumor cell line, BE(2)-C, was stably transfected with a mammalian expression (pREP4) over-expressing the human RAR gamma cDNA. Two selected clones over-expressing RAR gamma and 2) exhibited a reduced growth rate compared to control cells, Tumorigenicity was inhibited for BE/G1 cells and there was a delayed onset to tumor formation for BE/G2, cells. aRA caused growth inhibition but not neuritic differentiation of the BE/G clones, while 9-cis-retinoic acid caused both growth arrest and neuritic differentiation. Taken together these results suggest that reduced endogenous RAR gamma expression may contribute to the malignant phenotype of human NE. In NE cells the retinoid signalling pathway for neuritic differentiation may be distinct from that causing growth inhibition.	UNIV NEW S WALES,FAC MED,SCH PAEDIAT,KENSINGTON,NSW 2033,AUSTRALIA; UNIV TECHNOL SYDNEY,DEPT BIOCHEM & PHYSIOL,BROADWAY 2007,AUSTRALIA	University of New South Wales Sydney; University of Technology Sydney	MARSHALL, GM (corresponding author), PRINCE WALES CHILDRENS HOSP,CHILDRENS LEUKAEMIA & CANC RES CTR,HIGH ST,RANDWICK,NSW 2031,AUSTRALIA.		Greenwood, Kathryn/U-6965-2017	Greenwood, Kathryn/0000-0002-1556-0065; Norris, Murray/0000-0002-0632-4589; Cheung, Belamy/0000-0001-8784-860X; Haber, Michelle/0000-0003-2036-8817				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BASELGA J, 1993, ONCOGENE, V8, P3257; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; BORDOW SB, 1994, CANCER RES, V54, P5036; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; CLAGETTDAME M, 1993, ARCH BIOCHEM BIOPHYS, V300, P684, DOI 10.1006/abbi.1993.1095; Cushing H, 1927, AM J PATHOL, V3, P203; DAWSON MI, 1994, BLOOD, V84, P446; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIGUCHI T, 1991, CANCER RES, V51, P3958; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MACMILLAN RW, 1976, J PEDIATR SURG, V11, P461, DOI 10.1016/S0022-3468(76)80204-7; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARSHALL GM, 1994, ANTICANCER RES, V13, P437; MOASSER MM, 1994, ONCOGENE, V9, P833; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROUSSELOT P, 1994, ONCOGENE, V9, P545; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Sambrook J., 1989, MOL CLONING LABOROAT; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; WUARIN L, 1994, INT J CANCER, V56, P840, DOI 10.1002/ijc.2910560615; XU XC, 1994, CANCER RES, V54, P3580	42	35	36	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					485	491						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630632				2022-12-25	WOS:A1995RN53000008
J	NEVILLE, EM; STEWART, M; MYSKOW, M; DONNELLY, RJ; FIELD, JK				NEVILLE, EM; STEWART, M; MYSKOW, M; DONNELLY, RJ; FIELD, JK			LOSS OF HETEROZYGOSITY AT 9P23 DEFINES A NOVEL LOCUS IN NONSMALL CELL LUNG-CANCER	ONCOGENE			English	Article						LUNG CANCER; NONSMALL CELL; LOSS OF HETEROZYGOSITY; CHROMOSOME 9P; 9P23	REGION	Genetic studies have previously demonstrated cytogenetic deletions and allelic imbalance or loss of heterozygosity (LOH) on the p arm of chromosome 9, in a number of tumour types. We have analysed 45 Non-Small Cell Lung Cancers (NSCLC) with a panel of highly polymorphic microsatellite markers on chromosome 9. Our results indicate that loss on 9p is concentrated within the D9S156-D9S161 region with 44% (20/45) LOH, however the area with minimal loss in this set of lung tumours was found at D9S157 (9p23), with 30% LOH (10/33), whereas loss at the IFNA locus was only found in 6% (2/34) tumours. Five of the lung tumours in this study which demonstrated LOH at D9S157 retained heterozygosity at the adjacent informative markers lying centromeric and telomeric to D9S157. No correlations were found between any of the clinico-pathological parameters and LOH on 9p or at the D9S157 locus. The results of this study indicates the presence of a further putative tumour suppressor gene on 9p at the D9S157 locus (9p23) to be most likely involved in the pathogenesis of non-small cell lung cancer.	UNIV LIVERPOOL,DEPT CLIN DENT SCI,MOLEC GENET & ONCOL GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; BROADGREEN HOSP,DEPT PATHOL,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND; BROADGREEN HOSP,CTR CARDIOTHORAC,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust			Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				CAIRNS P, 1993, CANCER RES, V53, P1230; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; COLEMAN A, 1994, CANCER RES, V54, P344; DEVLIN J, 1994, ONCOGENE, V9, P2757; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HARMER EM, 1978, GENEVA UNION INT CAN, P41; HOLLAND EA, 1994, ONCOGENE, V9, P1361; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P531; MEAD LJ, 1994, CANCER RES, V54, P2307; MERLO A, 1994, CANCER RES, V54, P640; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1993, CANCER RES, V53, P2410; ORLOW I, 1994, CANCER RES, V54, P2848; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; TARMIN L, 1994, CANCER RES, V54, P6094; VANDERRIET P, 1994, CANCER RES, V54, P1156; WHITEHOUSE JMA, 1994, MANAGEMENT LUNG CANC	20	45	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					581	585						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630642				2022-12-25	WOS:A1995RN53000019
J	CHEN, CG; XUE, JC; ZHU, JM; CHEN, YW; KUNAPULI, S; DERIEL, JK; LIUCHEN, LY				CHEN, CG; XUE, JC; ZHU, JM; CHEN, YW; KUNAPULI, S; DERIEL, JK; LIUCHEN, LY			CHARACTERIZATION OF IRREVERSIBLE BINDING OF BETA-FUNALTREXAMINE TO THE CLONED RAT MU-OPIOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG BRAIN; OPIATE RECEPTOR; MOLECULAR-CLONING; HUMAN-PLATELET; EXPRESSION; SITE; MEMBRANES; COMPLEX; CELLS; ACID	Binding of beta-funaltrexamine (beta-FNA) to the cloned rat mu opioid receptor expressed in COS-1 cells or Chinese hamster ovary cells was examined. beta-FNA bound to the mu receptor with high affinity. Irreversible binding of [H-3]beta-FNA was defined as the binding that could not be dissociated by trichloroacetic acid. Na+ greatly enhanced the specific irreversible binding of [H-3]beta-FNA to the mu receptor, which was concentration- and time-dependent. Specific irreversible binding of [H-3]beta-FNA was potently inhibited by CTAP (a mu ligand), but not by ICI174,864 (a delta ligand) or U50,488H (a kappa ligand). These results indicate that [H-3]beta-FNA binds irreversibly to the cloned mu opioid receptor. SDS-polyacrylamide gel electrophoresis and fluorography showed that [H-3]beta-FNA-labeled receptors migrated as one broad and diffuse band with a mass of 80 kDa in Chinese hamster ovary or COS cells and as one band with a mass of 67 kDa in the rat brain preparation. Upon removal of N-linked carbohydrates, labeled receptors became a sharper band with a mass of similar to 40 kDa, [H-3]beta-FNA did not bind irreversibly to the cloned rat kappa receptor. [H-3]beta-FNA binding to four chimeric mu/kappa receptors was examined, The region from the middle of the third intracellular loop to the C terminus of the mu receptor is necessary for irreversible binding of beta-FNA.	TEMPLE UNIV,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST MOLEC BIOL & CANC RES,PHILADELPHIA,PA 19140; INDIANA UNIV,SCH MED,DEPT MED & MOLEC GENET,INDIANAPOLIS,IN 46202	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Indiana University System; Indiana University-Purdue University Indianapolis					NIDA NIH HHS [DA 04745] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA004745, R01DA004745] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; BARE LA, 1994, FEBS LETT, V354, P213, DOI 10.1016/0014-5793(94)01129-X; BUNZOW JR, 1995, J NEUROCHEM, V64, P14; CHEN Y, 1993, MOL PHARMACOL, V44, P8; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANKLIN TG, 1991, BRIT J PHARMACOL, V102, P718, DOI 10.1111/j.1476-5381.1991.tb12239.x; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; LAW PY, 1985, BIOCHEM PHARMACOL, V34, P9, DOI 10.1016/0006-2952(85)90093-0; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; LIUCHEN LY, 1993, MOL PHARMACOL, V44, P749; LIUCHEN LY, 1990, MOL PHARMACOL, V37, P243; LIUCHEN LY, 1987, MOL PHARMACOL, V32, P321; LIUCHEN LY, 1991, BRAIN RES, V544, P235, DOI 10.1016/0006-8993(91)90059-5; MATSUI H, 1989, BIOCHEMISTRY-US, V28, P4125, DOI 10.1021/bi00435a075; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; PASTERNAK GW, 1974, MOL PHARMACOL, V10, P183; PASTERNAK GW, 1988, OPIATE RECEPTORS; PORTOGHESE PS, 1980, J MED CHEM, V23, P233, DOI 10.1021/jm00177a002; RECHT LD, 1987, EUR J PHARMACOL, V140, P209, DOI 10.1016/0014-2999(87)90807-7; REGAN JW, 1986, BIOCHEM BIOPH RES CO, V137, P606, DOI 10.1016/0006-291X(86)91121-6; ROTHMAN RB, 1988, J PHARMACOL EXP THER, V247, P405; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; TAKEMORI AE, 1985, ANNU REV PHARMACOL, V25, P193; TAM SW, 1986, J PHARMACOL EXP THER, V239, P351; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; TOLL L, 1992, J PHARMACOL EXP THER, V260, P9; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; WANG JB, 1994, J BIOL CHEM, V269, P25966; XUE JC, 1995, J BIOL CHEM, V270, P12977; XUE JC, 1994, J BIOL CHEM, V269, P30195	33	58	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17866	17870		10.1074/jbc.270.30.17866	http://dx.doi.org/10.1074/jbc.270.30.17866			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629089	hybrid			2022-12-25	WOS:A1995RM26600037
J	JAGIELLO, I; BEULLENS, M; STALMANS, W; BOLLEN, M				JAGIELLO, I; BEULLENS, M; STALMANS, W; BOLLEN, M			SUBUNIT STRUCTURE AND REGULATION OF PROTEIN PHOSPHATASE-1 IN RAT-LIVER NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; INHIBITORY POLYPEPTIDES; KINASE-A	The activity of protein phosphatase-1 in rat liver nuclei (PP-1N) was decreased by up to 97% by associated inhibitory polypeptides, depending on the assay and extraction conditions. These inhibitors were rapidly degraded by endogenous proteases, resulting in the accumulation of active heat stable intermediates. Two major species of PP-1N could be differentiated by fractionation of a nuclear extract. PP-1N(R111) contained, besides the delta-isoform of the catalytic subunit, an inhibitory polypeptide of 111 kDa, PP-1N(R41) was found to be an inactive heterodimer between the delta-isoform of the catalytic subunit and NIPP-1, a nuclear inhibitor of PP-1, which in its undegraded form is heat labile and migrates during SDS-polyacrylamide gel electrophoresis as a polypeptide of 41 kDa. Native hepatic NIPP-1 displayed a reduced affinity for the catalytic subunit after phosphorylation by protein kinase A in vitro and after glucagon-induced phosphorylation in vivo.	CATHOLIC UNIV LEUVEN,FAC GENEESHUNDE,AFDELING BIOCHEM,B-3000 LOUVAIN,BELGIUM	KU Leuven								AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; ANTONIW JF, 1977, BIOCHEM J, V162, P423, DOI 10.1042/bj1620423; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BOLLEN M, 1993, ADV PROTEIN PHOSPHAT, V7, P31; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; CARDINALI B, 1994, FEBS LETT, V352, P276, DOI 10.1016/0014-5793(94)00973-2; CRESSMAN DE, 1994, J BIOL CHEM, V269, P26594; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; GOODWIN GH, 1973, EUR J BIOCHEM, V38, P14, DOI 10.1111/j.1432-1033.1973.tb03026.x; JAKES S, 1986, BIOCHIM BIOPHYS ACTA, V888, P135, DOI 10.1016/0167-4889(86)90079-0; JESSUS C, 1989, BIOCHEM J, V260, P45, DOI 10.1042/bj2600045; KURET J, 1986, FEBS LETT, V230, P197; MERCIER JC, 1968, B SOC CHIM BIOL, V50, P521; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; VAN EYNDE A, 1994, BIOCHEM J, V297, P447, DOI 10.1042/bj2970447; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; YANG SD, 1981, FEBS LETT, V132, P289; ZHANG ZJ, 1993, ARCH BIOCHEM BIOPHYS, V303, P402, DOI 10.1006/abbi.1993.1301	31	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17257	17263		10.1074/jbc.270.29.17257	http://dx.doi.org/10.1074/jbc.270.29.17257			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615525	hybrid			2022-12-25	WOS:A1995RK68900033
J	KIKUCHI, K; YAMASHITA, M; WATABE, S; AIDA, K				KIKUCHI, K; YAMASHITA, M; WATABE, S; AIDA, K			THE WARM TEMPERATURE ACCLIMATION-RELATED 65-KDA PROTEIN, WAP65, IN GOLDFISH AND ITS GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEMOPEXIN; MYOFIBRILLAR ATPASE; SEQUENCE; CARP; MECHANISMS	cDNAs encoding a warm temperature acclimation-related protein (Wap65) were cloned from the muscle and hepatopancreas cDNA libraries of the warm temperature-acclimated goldfish Carassius auratus, and their nucleotide sequences containing 5'- and 3'-noncoding regions together with their polyadenylation signal were determined, The deduced amino acid sequence of Wap65 was 31% homologous to rat hemopexin, However, goldfish Wap65 lacked a few possible glycosylation sites and presumed functional histidine residues, implying that it may have different functions from hemopexin, Wap65 contained a leader peptide of 30 amino acids and a mature protein region of 415 amino acids, Southern blot analysis demonstrated that the protein is expressed by a single copy gene in the goldfish haploid genome, In RNA blot analysis using isolated cDNA clones, a single transcript of about 2.0 kilobases was detected in the hepatopancreas but not in brain, muscle, or hemocytes, The abundancy of this transcript markedly increased in the hepatopancreas as a result of warm temperature acclimation, Electrophoretic analysis of plasma proteins revealed a good correlation of plasma Wap65 levels to those of the corresponding transcript in the hepatopancreas, suggesting that serum Wap65 concentrations are regulated mainly by transcript levels in the hepato pancreas via the secretion process.	UNIV TOKYO, FAC AGR, MARINE BIOCHEM LAB, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC AGR, FISH PHYSIOL LAB, BUNKYO KU, TOKYO 113, JAPAN; NATL RES INST FISHERIES SCI, YOKOHAMA, KANAGAWA 236, JAPAN	University of Tokyo; University of Tokyo; Japan Fisheries Research & Education Agency (FRA)								ALTRUDA F, 1985, NUCLEIC ACIDS RES, V13, P3841, DOI 10.1093/nar/13.11.3841; BARNES WM, 1983, METHOD ENZYMOL, V101, P98; GERLACH GF, 1990, AM J PHYSIOL, V259, pR237, DOI 10.1152/ajpregu.1990.259.2.R237; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GUO XF, 1994, J BIOCHEM-TOKYO, V116, P728, DOI 10.1093/oxfordjournals.jbchem.a124588; HAZEL JR, 1974, PHYSIOL REV, V54, P620, DOI 10.1152/physrev.1974.54.3.620; HEAP SP, 1985, J FISH BIOL, V26, P733, DOI 10.1111/j.1095-8649.1985.tb04313.x; HWANG GC, 1990, J COMP PHYSIOL B, V160, P233, DOI 10.1007/BF00302588; JENNE D, 1987, BIOCHEMISTRY-US, V26, P6735, DOI 10.1021/bi00395a024; JOHNSTON IA, 1975, FEBS LETT, V50, P293, DOI 10.1016/0014-5793(75)80512-6; KIKUCHI K, 1993, J COMP PHYSIOL B, V163, P349; KOJ A, 1974, STRUCTURE FUNCTION P, V1, P73; KUSHNER I, 1988, METHOD ENZYMOL, V163, P373; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Morimoto RI, 1990, STRESS PROTEINS BIOL; Muller- Eberhard U, 1974, STRUCTURE FUNCTION P, V1, ppp; MULLEREBERHARD M, 1983, METHOD ENZYMOL, V101, P536; NIKKILA H, 1991, BIOCHEMISTRY-US, V30, P823, DOI 10.1021/bi00217a036; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1994, P NATL ACAD SCI USA, V91, P8423, DOI 10.1073/pnas.91.18.8423; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P73, DOI 10.1073/pnas.82.1.73; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P2021, DOI 10.1073/pnas.81.7.2021; WATABE S, 1993, NIPPON SUISAN GAKK, V59, P151; WATABE S, 1995, BIOCHEM BIOPH RES CO, V208, P118, DOI 10.1006/bbrc.1995.1313; WATABE S, 1992, J BIOCHEM-TOKYO, V111, P113, DOI 10.1093/oxfordjournals.jbchem.a123706	27	69	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17087	17092		10.1074/jbc.270.29.17087	http://dx.doi.org/10.1074/jbc.270.29.17087			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615502	hybrid			2022-12-25	WOS:A1995RK68900009
J	LOHI, J; KESKIOJA, J				LOHI, J; KESKIOJA, J			CALCIUM IONOPHORES DECREASE PERICELLULAR GELATINOLYTIC ACTIVITY VIA INHIBITION OF 92-KDA GELATINASE EXPRESSION AND DECREASE OF 72-KDA GELATINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; SKIN FIBROBLAST PROCOLLAGENASE; PHORBOL-MYRISTATE ACETATE; IV COLLAGENASE GENE; SYNOVIAL FIBROBLASTS; MATRIX METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; CULTURED FIBROBLASTS; ENDOGENOUS ACTIVATION; RIBONUCLEIC-ACID	To understand the roles of intracellular calcium levels on gelatinase/type IV collagenase expression, we analyzed the effects of calcium ionophores on the expression of 92- and 72-kDa gelatinases (MMP-9 and MMP-2) in human fibrosarcoma cells (HT-1080). Calcium ionophores ionomycin and A23187 reduced the levels of pericellular gelatinolytic activity in both untreated and phorbol 12-myristate 13-acetate (PMA) or tumor necrosis factor-alpha (TNF alpha)-stimulated cells as determined by degradation of radiolabeled gelatin. Gelatin zymography and immunoblotting revealed a dose-dependent decrease in the levels of secreted 92-kDa gelatinase, which was paralleled by a decrease of its mRNA. Treatment of cells with thapsigargin caused similar decreases of 92-kDa gelatinase mRNA and protein. The decrease of 99-kDa gelatinase expression was due to lower transcription rate as determined by transfection assays with 92-kDa gelatinase/luciferase construct. The expression of 72-kDa gelatinase was only slightly decreased by ionophores. Treatment of HT-1080 cells with PMA, TNF alpha, or concanavalin A resulted in the conversion of 72-kDa gelatinase proenzyme to its presumed 64- and 62-kDa active forms as determined by gelatin zymography and immunoblotting. Simultaneous treatment with the ionophores or thapsigarin resulted in inhibition of PMA-induced gelatinase activation. The expression of membrane-type matrix metalloproteinase, a potential activator of 72-kDa gelatinase, was not affected by ionophores. The results indicate that calcium ionophores decrease gelatinolysis by repressing both the expression of 92-kDa gelatinase and the activation of the 72-kDa gelatinase.	UNIV HELSINKI,DEPT VIROL,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT DERMATOL & VENEROL,SF-00290 HELSINKI,FINLAND	University of Helsinki; University of Helsinki								BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRINCKERHOFF CE, 1982, BIOCHEMISTRY-US, V21, P2674, DOI 10.1021/bi00540a015; BRINCKERHOFF CE, 1981, BIOCHIM BIOPHYS ACTA, V677, P424, DOI 10.1016/0304-4165(81)90256-7; BROWN PD, 1990, CANCER RES, V50, P6184; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; KESKIOJA J, 1992, EXP CELL RES, V202, P471, DOI 10.1016/0014-4827(92)90101-D; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; KOHN EC, 1994, J BIOL CHEM, V269, P21505; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHI J, 1992, J CELL BIOCHEM, V50, P337, DOI 10.1002/jcb.240500402; Lohi Jouko, 1994, Matrix Biology, V14, P421, DOI 10.1016/0945-053X(94)90171-6; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MAINARDI CL, 1984, COLLAGEN REL RES, V4, P479; MATRISIAN LM, 1986, MOL CELL BIOL, V5, P1679; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; POSTLETHWAITE AE, 1983, J EXP MED, V157, P801, DOI 10.1084/jem.157.2.801; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; REPONEN P, 1995, DEV DYNAM, V202, P388, DOI 10.1002/aja.1002020408; RODLAND KD, 1992, J INVEST DERMATOL, V98, pS12, DOI 10.1111/1523-1747.ep12462100; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SAARINEN J, 1994, J BIOL CHEM, V268, P18134; SALO T, 1991, J BIOL CHEM, V266, P11436; Sambrook J, 1989, MOL CLONING LABORATO; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SATO H, 1993, ONCOGENE, V8, P395; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P61, DOI 10.1021/bi00270a009; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; TRYGGVASON K, 1990, CELL DIFFER DEV, V32, P307, DOI 10.1016/0922-3371(90)90044-W; UNEMORI EN, 1988, J BIOL CHEM, V263, P16252; WHITFIELD J F, 1992, Critical Reviews in Oncogenesis, V3, P55; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	53	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17602	17609		10.1074/jbc.270.29.17602	http://dx.doi.org/10.1074/jbc.270.29.17602			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615567	hybrid			2022-12-25	WOS:A1995RK68900084
J	PINES, G; ZHANG, YM; KANNER, BI				PINES, G; ZHANG, YM; KANNER, BI			GLUTAMATE-404 IS INVOLVED IN THE SUBSTRATE DISCRIMINATION OF GLT-1, A (NA++K+)-COUPLED GLUTAMATE TRANSPORTER FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; ESCHERICHIA-COLI; LACTOSE PERMEASE; HIGH-AFFINITY; EXPRESSION; PROTEIN; ASPARTATE; CLONING; CARRIER; GENE	Sodium coupled glutamate transporters, located in the plasma membrane of nerve terminals and glial processes, serve to keep its extracellular glutamate concentration below extracellular levels. Moreover, they help in conjunction with diffusion to terminate the transmitter's action in synaptic transmission. We have investigated the role of negatively charged amino acid residues of GLT-1, a cloned (Na+ + K+)-coupled glutamate transporter from rat brain. Using site-directed mutagenesis we modified these negative residues, which are located in hydrophobic surroundings and are highly conserved within the glutamate transporter family. Out of five residues meeting these criteria, three, aspartate 398, glutamate 404, and aspartate 470, are critical for heterologously expressed glutamate transport, This defective transport cannot be attributed to the mere requirement of a negative charge at these positions. After prelabeling of the proteins with [S-35]methionine, immunoprecipitation of all mutant transporters indicates that their expression levels are similar to that of wild type. No cryptic activity was revealed by reconstitution experiments aimed to monitor the activity of transporter molecules not located in the plasma membrane, Significantly, whereas all of the mutants at the glutamate 404 position exhibit impaired transport of glutamate, they possess considerable transport of D- and L-aspartate, up to 80% of wild type values. Binding of glutamate is not impaired in these mutants, Our observations indicate that the glutamate 404 residue may be located in the vicinity of the glutamate-aspartate permeation pathway.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT BIOCHEM, IL-91120 JERUSALEM, ISRAEL	Hebrew University of Jerusalem								Amara S G, 1993, Curr Opin Neurobiol, V3, P337, DOI 10.1016/0959-4388(93)90126-J; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADO M, 1993, J BIOL CHEM, V268, P27313; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; DUNTEN RL, 1993, BIOCHEMISTRY-US, V22, P3138; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; IGO RP, 1995, BBA-BIOMEMBRANES, V1233, P153, DOI 10.1016/0005-2736(94)00246-L; JIANG J, 1989, J BACTERIOL, V171, P5244, DOI 10.1128/jb.171.10.5244-5253.1989; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; POCOCK JM, 1988, J NEUROCHEM, V50, P745, DOI 10.1111/j.1471-4159.1988.tb02977.x; SAHINTOTH M, 1993, BIOCHEMISTRY-US, V32, P10027, DOI 10.1021/bi00089a019; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; WADICHE JI, 1995, IN PRESS NEURON; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	41	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17093	17097		10.1074/jbc.270.29.17093	http://dx.doi.org/10.1074/jbc.270.29.17093			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615503	hybrid			2022-12-25	WOS:A1995RK68900010
J	WONG, SC; PROEFKE, SA; BHUSHAN, A; MATHERLY, LH				WONG, SC; PROEFKE, SA; BHUSHAN, A; MATHERLY, LH			ISOLATION OF HUMAN CDNAS THAT RESTORE METHOTREXATE SENSITIVITY AND REDUCED FOLATE CARRIER ACTIVITY IN METHOTREXATE TRANSPORT-DEFECTIVE CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CARRIER; ANALOG TRANSPORT; BINDING-PROTEINS; TUMOR-CELLS; L1210 CELLS; LEUKEMIA; LINES; IDENTIFICATION; RESISTANCE; PLACENTA	This report describes the isolation, nucleotide sequencing, and functional expression of human cDNAs that restore reduced folate carrier activity in transport-defective cells. Based on homology to a partial murine cDNA probe, two functional cDNAs were isolated from a lambda gt11 library prepared from methotrexate transport upregulated K562 cells (K562.4CF). A 2.8-kilobase (kb) clone, KS43, contained a 1776-base pair open reading frame. The 2.5-kb clone, KS32, contained an internal deletion (626 base pairs) resulting a shortened open reading frame and 3'-untranslated region. KS43 and KS32 encoded proteins with multiple hydrophobic domains, one consensus N-glycosylation site, and predicted molecular masses of 65 and 58 kDa, respectively. The deduced amino acid sequence of KS43 is 79% and 80% homologous to the mouse and hamster sequences, respectively (Dixon, K. H., Lanpher, B. C., Chiu, J., Kelley, R., and Cowan, K. H. (1994) J. Biol. Chem. 269, 17-20; Williams, F. M. R., Murray, R. C., Underhill, T. M., and Flintoff, W. F. (1994) J. Biol. Chem. 269, 5810-5816). Northern blots identified one primary transcript at 3.1 kb in parental K562, R562.4CF, and transport-impaired K500E cells; transcript levels varied by 7-fold. The expression of both KS43 and KS32 in methotrexate transport-defective Chinese hamster ovary cells restored methotrexate sensitivity and transport. Certain transport characteristics of the transfected cells resembled both the wild type human (K562) and hamster ''classical'' reduced folate carriers, suggesting the expression of a hybrid system. For instance, based on K-i values, up to a 4-fold increased affinity for 1843U89 over wild type hamster cells (typical of human cells), and a 19-fold increased affinity for methotrexate over K562 cells (typical of hamster cells) was observed. Farther, a photoaffinity probe with high specificity for the reduced folate carrier labeled 94-kDa proteins in K562 cells and the transfectant containing the full length KS43, and a 85-kDa protein in the transfectant containing the 3'-truncated KS32. No specifically labeled proteins were de tected in wild type or mock-transfected hamster cells. Collectively, our results suggest that the KS43/KS32 cDNAs encode the human reduced folate carrier; however, additional modulatory/regulatory factors may be required to manifest the full spectrum of transport substrate activities typical of this system.	MICHIGAN CANC FDN, DEV THERAPEUT PROGRAM, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, DEPT PHARMACOL, DETROIT, MI 48201 USA; UNIV VERMONT, DEPT PHARMACOL, BURLINGTON, VT 05405 USA; UNIV VERMONT, VERMONT CANC CTR, BURLINGTON, VT 05405 USA	Wayne State University; University of Vermont; University of Vermont					NCI NIH HHS [CA 53535] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONY AC, 1992, BLOOD, V79, P2807; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P151; CHUNG KN, 1993, J CLIN INVEST, V91, P1289, DOI 10.1172/JCI116327; DIXON KH, 1994, J BIOL CHEM, V269, P17; DUCH DS, 1993, CANCER RES, V53, P810; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FREISHEIM JH, 1992, ADV ENZYME REGUL, V32, P17; FRY DW, 1982, J BIOL CHEM, V257, P1890; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; KESSEL D, 1965, SCIENCE, V150, P752, DOI 10.1126/science.150.3697.752; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, MOL CLONING; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MATHERLY LH, 1991, CANCER RES, V51, P3420; OVERVOORDE PJ, 1994, J BIOL CHEM, V269, P15154; PORTIN P, 1993, Q REV BIOL, V68, P173, DOI 10.1086/418039; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; PRICE EM, 1987, BIOCHEMISTRY-US, V26, P4757, DOI 10.1021/bi00389a024; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; TRIPPETT T, 1992, BLOOD, V80, P1158; UNDERHILL TM, 1989, SOMAT CELL MOLEC GEN, V15, P49, DOI 10.1007/BF01534669; WEITMAN SD, 1992, CANCER RES, V52, P3396; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; YANG CH, 1988, J BIOL CHEM, V263, P9703	37	173	177	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17468	17475		10.1074/jbc.270.29.17468	http://dx.doi.org/10.1074/jbc.270.29.17468			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615551	hybrid			2022-12-25	WOS:A1995RK68900065
J	EPSTEIN, RJ				EPSTEIN, RJ			PREFERENTIAL DETECTION OF CATALYTICALLY INACTIVE C-ERBB-2 BY ANTIBODIES TO UNPHOSPHORYLATED PEPTIDES MIMICKING RECEPTOR TYROSINE AUTOPHOSPHORYLATION SITES	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASES; ONCOGENES; NEOPLASMS; PHOSPHORYLATION; ANTIBODIES	GROWTH-FACTOR RECEPTOR; POSITIVE BREAST-CANCER; HER-2 NEU ONCOGENE; PROTEIN; AMPLIFICATION; EXPRESSION; CARCINOMA; CELLS; PHOSPHOTYROSINE; HER2/NEU	The c-evbB-2 tyrosine kinase is often overexpressed in human breast cancer, but correlations of receptor expression with tumour behaviour have proven elusive in patients without metastases at diagnosis. To address the possibility that receptor function may be more informative than expression, we previously developed function-specific cerbB-2 antibodies using synthetic tyrosine-phosphorylated peptide immunogens (Epstein et al., Proc, Natl. Acad. Sci. USA 1992; 89: 10435-10439). Here the converse approach has been taken to determine the functional status of c-erbB-2 receptors detected by antibodies to dephosphorylated (dep) autophosphorylation sequences. In contrast to antiphosphopeptide (apt) antibodies, dep antibodies to the Tyr(1248) autophosphorylation site exhibited preferential, but not exclusive, binding to tyrosine-dephosphorylated c-erbB-2, Consistent with this, catalytically active and inactive receptors could not be clearly distinguished by in vitro autophosphorylation experiments in which c-erbB-2 was immunoprecipitated using a monoclonal Tyr(1248) dep antibody, A dep antiserum recognizing autophosphorylation sites N-terminal to Tyr(1248) exclusively recognized tyrosine-dephosphorylated c-erbB-2 following antibody preabsorption with homologous phosphopeptides. Although indirect, these data are consistent with a model of sequential c-erbB-2 autophosphorylation in which Tyr(1Z48) iS the final residue modified, Moreover, since many studies of c-erbB-2 expression have used antibodies to dephosphorylated autophosphorylation sites, these results caution against automatically equating such receptor immunoreactivity with in vivo function or clinical significance.	CHARING CROSS HOSP,DEPT MED ONCOL,CANC RES CAMPAIGN LABS,LONDON W6 8RF,ENGLAND	Imperial College London	EPSTEIN, RJ (corresponding author), UNIV LONDON,CHARING CROSS & WESTMINSTER MED SCH,DIV CELL MOLEC & ONCOL RES,LONDON W6 8RF,ENGLAND.							AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARTKOVA J, 1990, HUM PATHOL, V21, P1164, DOI 10.1016/0046-8177(90)90154-W; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BERGER MS, 1988, CANCER RES, V48, P1238; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; BORG A, 1990, CANCER RES, V50, P4332; BORG A, 1989, LANCET, V1, P1268; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CAO HN, 1991, ONCOGENE, V6, P705; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; EPSTEIN RJ, 1992, CELL GROWTH DIFFER, V3, P157; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GUSTERSON BA, 1988, INT J CANCER, V42, P842, DOI 10.1002/ijc.2910420608; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HUANG SS, 1990, J BIOL CHEM, V265, P3340; IGLEHART JD, 1990, CANCER RES, V50, P6701; KURY F, 1990, EUR J CANCER, V26, P946, DOI 10.1016/0277-5379(90)90616-2; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; NAIRN AC, 1982, NATURE, V299, P734, DOI 10.1038/299734a0; OREILLY SM, 1991, BRIT J CANCER, V63, P444, DOI 10.1038/bjc.1991.102; OREILLY SM, 1990, EUR J CANCER, V26, P1035, DOI 10.1016/0277-5379(90)90045-U; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATERSON MC, 1991, CANCER RES, V51, P556; PERES R, 1987, CANCER RES, V47, P3425; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; RO J, 1989, ONCOGENE, V4, P351; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEVIJVER MJ, 1988, ONCOGENE, V2, P175; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILDENHAIN Y, 1990, ONCOGENE, V5, P879; WRANN M, 1980, SCIENCE, V210, P1363, DOI 10.1126/science.6254158	47	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					315	323						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624146				2022-12-25	WOS:A1995RK95700012
J	TSUDA, T; MARINETTI, MR; MASUELLI, L; CUTLER, ML				TSUDA, T; MARINETTI, MR; MASUELLI, L; CUTLER, ML			THE RAS SUPPRESSOR RSU-1 LOCALIZES TO 10P13 AND ITS EXPRESSION IN THE U251 GLIOBLASTOMA CELL-LINE CORRELATES WITH A DECREASE IN GROWTH-RATE AND TUMORIGENIC POTENTIAL	ONCOGENE			English	Note						RSU-1; GLIOBLASTOMA, TUMOR SUPPRESSOR	SACCHAROMYCES-CEREVISIAE; FACTOR RECEPTOR; TYPE-1 NEUROFIBROMATOSIS; ADENYLYL CYCLASE; HUMAN GLIOMAS; BRAIN-TUMORS; GENE; CHROMOSOME-10; HETEROZYGOSITY; MULTIFORME	Rsu-1, which was isolated based on its ability to suppress transformation by v-Ras, is a highly conserved gene which shares homology with yeast adenylyl cyclase in the region required for activation by Ras, Genomic DNA clones of human RSU-1 have been isolated and used as a probe for fluorescence in situ hybridization (FISH) to assign RSU-1 to 10p13, confirming the previous results of somatic cell hybrid mapping localizing RSU-1 to chromosome 10. Screening of more than 20 human tumor cell lines for RSU-1 expression revealed that most cell lines contained abundant RSU-1 RNA and protein. However, the p33 RSU-1 protein was undetectable in the U251 glioblastoma cell line and transfection of a rsu-1 expression vector into U251 cells yielded a cell line in which rsu-1 was under the control of a regulatable metallothionein promoter. Addition of Cd2+ to the U251-Rsu-1 transfectant resulted in transcription of rsu-1 RNA and the accumulation of p33 Rsu-1 protein. Appearance of the Rsu-1 protein correlated with a reduction in growth rate of the U251-Rsu-1 transfectant. In addition, reduction in anchorage independent growth and phenotypic alteration in U251-Rsu-1 transfectant agar colonies was observed. Two U251-Rsu-1 transfectant cell lines were non tumorigenic when injected subcutaneously into athymic nude mice. These results, in conjunction with the frequent deletions observed in chromosome 10 in glioblastomas, suggest that RSU-1 loss of function may play a role in the progression of this disease.	NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Masuelli, Laura/AGW-4259-2022; Cutler, Mary L/G-5735-2017	Cutler, Mary L/0000-0001-9727-4320; MASUELLI, Laura/0000-0001-8174-8034				AMBROSE D, 1994, J CELL PHYSIOL, V159, P92, DOI 10.1002/jcp.1041590113; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BERKMAN RA, 1992, J NEUROSURG, V77, P432, DOI 10.3171/jns.1992.77.3.0432; BIGNER SH, 1988, CANCER RES, V48, P405; CAVENEE WK, 1992, CANCER, V70, P1788, DOI 10.1002/1097-0142(19920915)70:4+<1788::AID-CNCR2820701621>3.0.CO;2-L; COLICELLI J, 1990, MOL CELL BIOL, V10, P2539, DOI 10.1128/MCB.10.6.2539; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; JAMES CD, 1988, CANCER RES, V48, P5546; JAMES CD, 1990, CANCER SURV, V9, P631; JAROS E, 1992, BRIT J CANCER, V66, P373, DOI 10.1038/bjc.1992.273; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KRANTZ DD, 1991, J BIOL CHEM, V266, P16801; MARK J, 1977, HEREDITAS, V87, P243; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RESNICOFF M, 1994, CANCER RES, V54, P2218; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; TROJAN J, 1993, SCIENCE, V259, P9497; TSUDA T, 1993, GENOMICS, V18, P461, DOI 10.1006/geno.1993.1503; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONDEIMLING A, 1992, J NEUROSURG, V77, P295, DOI 10.3171/jns.1992.77.2.0295; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YE Z, 1993, NEUROL RES, V15, P59, DOI 10.1080/01616412.1993.11740109	43	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					397	403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624154				2022-12-25	WOS:A1995RK95700021
J	BEGER, RD; BALASUBRAMANIAN, S; BENNETT, SE; MOSBAUGH, DW; BOLTON, PH				BEGER, RD; BALASUBRAMANIAN, S; BENNETT, SE; MOSBAUGH, DW; BOLTON, PH			TERTIARY STRUCTURE OF URACIL-DNA GLYCOSYLASE INHIBITOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-PBS2; PURIFICATION; ASSOCIATION; GENE	The Bacillus subtilis bacteriophage PBS2 uracil-DNA glycosylase inhibitor (Ugi) is an acidic protein of 84 amino acids that inactivates uracil-DNA glycosylase from diverse organisms. The secondary structure of Ugi consists of five anti-parallel beta-strands and two alpha-helices (Balasubramanian, S., Beger, R. D., Bennett, S. E., Mosbaugh, D. W., and Bolton, P. H. (1995) J. Biol. Chem. 270, 296-303). The tertiary structure of Ugi has been deter mined by solution state multidimensional nuclear magnetic resonance. The Ugi structure contains an area of highly negative electrostatic potential produced by the close proximity of a number of acidic residues. The unfavorable interactions between these acidic residues are apparently accommodated by the stability of the beta-strands. This negatively charged region is likely to play an important role in the binding of Ugi to uracil-DNA glycosylase.	WESLEYAN UNIV,DEPT CHEM,MIDDLETOWN,CT 06459; OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR ENVIRONM HLTH SCI,CORVALLIS,OR 97331	Wesleyan University; Oregon State University; Oregon State University; Oregon State University				Balasubramanian, Suganthi/0000-0003-2243-5948	NIEHS NIH HHS [ES 00210] Funding Source: Medline; NIGMS NIH HHS [GM 32823] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAN S, 1994, J MAGN RESON SER B, V104, P240, DOI 10.1006/jmrb.1994.1081; BALASUBRAMANIAN S, 1995, J BIOL CHEM, V270, P296, DOI 10.1074/jbc.270.1.296; BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BRUNGER AT, 1993, SCIENCE, V261, P328, DOI 10.1126/science.8332897; CONE R, 1980, J BIOL CHEM, V255, P354; DYSON HJ, 1994, 2 DIMENSIONAL NMR SP, P655; Hull W., 1994, 2 DIMENSIONAL NMR SP, P67; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; KESSLER H, 1994, 2 DIMENSIONAL NMR SP; LEMASTER DM, 1994, PROG NUCL MAG RES SP, V26, P371, DOI 10.1016/0079-6565(94)80010-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1988, J BACTERIOL, V170, P1082, DOI 10.1128/jb.170.3.1082-1091.1988; WANG ZG, 1991, GENE, V99, P31; WILLIAMS MV, 1990, J BACTERIOL, V172, P2979, DOI 10.1128/jb.172.6.2979-2985.1990; WINTERS TA, 1993, VIROLOGY, V195, P315, DOI 10.1006/viro.1993.1382	19	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16840	16847		10.1074/jbc.270.28.16840	http://dx.doi.org/10.1074/jbc.270.28.16840			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622499	hybrid			2022-12-25	WOS:A1995RJ34700060
J	CHUNG, SH; TAKAI, Y; HOLZ, RW				CHUNG, SH; TAKAI, Y; HOLZ, RW			EVIDENCE THAT THE RAB3A-BINDING PROTEIN, RABPHILIN3A, ENHANCES REGULATED SECRETION - STUDIES IN ADRENAL CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; PUTATIVE TARGET PROTEIN; ENDOCYTIC PATHWAY; KINASE-C; RAB3A; DOMAIN; SYNAPTOTAGMIN; EXOCYTOSIS; RECEPTORS; TRANSPORT	Rabphilin3a had been identified in brain as a Rab3a-binding protein and may serve as an effector for Rab3a function. We have cloned a splice variant of brain-Rabphilin3a from a bovine adrenal chromaffin cell cDNA library and investigated the function of the protein in regulated exocytosis in bovine chromaffin cells. The predicted amino acid sequence of chromaffin cell (c-) Rabphilin3a was identical with that of brain (b-) Rabphilin3a except for a 6-amino-acid insert VFSLSA in the amino-terminal half of the protein. An antibody directed against a carboxyl-terminal peptide recognized an 85-kDa protein in COS7 cells transfected with the cDNA in a mammalian expression vector. A band of similar mobility was enriched in a fraction of highly purified chromaffin granule membranes, consistent with the Rabphilin3a being associated with chromaffin granule membranes. Overexpression of either chromaffin cell or brain Rabphilin3a by transfection with the corresponding cDNAs in mammalian expression vectors enhanced DMPP-induced secretion of co-expressed human growth hormone (GH) approximately 30%. Chromaffin cells transfected with a plasmid with the entire coding sequence of c-Rabphilin3a inserted in the antisense orientation inhibited secretion of co-expressed GH by approximately 30%. Rabphilin3a mutants lacking one or both of the carboxyl-terminal C2 domains strongly inhibited DMPP-stimulated exocytosis. The single C2 domain deletion also strongly inhibited Ca2+-dependent secretion from digitonin-permeabilized cells. These data indicate that Rabphilin3a is a positive regulator of exocytosis. Because the C2 deletion mutants contain the aminoterminal Rab3a-GTP binding domain, they may inhibit secretion by competing with endogenous Rabphilin3a for interaction with Rab3a-GTP without being able to mimic the functional effects of full-length Rabphilin3a.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; OSAKA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN	University of Michigan System; University of Michigan; Osaka University					NIDDK NIH HHS [R01 DK27959] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BITTNER MA, 1992, J BIOL CHEM, V267, P16226; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FUJITA Y, 1994, FEBS LETT, V353, P67, DOI 10.1016/0014-5793(94)01015-3; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; HOLZ RW, 1982, J NEUROCHEM, V39, P635, DOI 10.1111/j.1471-4159.1982.tb07940.x; INAGAKI N, 1994, J BIOCHEM-TOKYO, V116, P239, DOI 10.1093/oxfordjournals.jbchem.a124512; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; MCKIERNAN CJ, 1993, J BIOL CHEM, V268, P24449; MIYAZAKI M, 1994, BIOCHEM BIOPH RES CO, V205, P460, DOI 10.1006/bbrc.1994.2688; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; MOLLARD GFV, 1990, P NATL ACAD SCI USA, V87, P1988; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WADA K, 1994, BIOCHEM BIOPH RES CO, V198, P158, DOI 10.1006/bbrc.1994.1023; WICK PF, 1993, J BIOL CHEM, V268, P10983; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	47	127	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16714	16718		10.1074/jbc.270.28.16714	http://dx.doi.org/10.1074/jbc.270.28.16714			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622481	hybrid			2022-12-25	WOS:A1995RJ34700041
J	COLIGE, A; BESCHIN, A; SAMYN, B; GOEBELS, Y; VANBEEUMEN, J; NUSGENS, BV; LAPIERE, CM				COLIGE, A; BESCHIN, A; SAMYN, B; GOEBELS, Y; VANBEEUMEN, J; NUSGENS, BV; LAPIERE, CM			CHARACTERIZATION AND PARTIAL AMINO-ACID SEQUENCING OF A 107-KDA PROCOLLAGEN-I N-PROTEINASE PURIFIED BY AFFINITY-CHROMATOGRAPHY ON IMMOBILIZED TYPE-XIV COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO TENDONS; PURIFICATION; ENZYME; DERMATOSPARAXIS; PEPTIDASE; BINDING; FORM	Procollagen I N-proteinase (EC 3.4.24.14), the enzyme that specifically processes type I and type II procollagens to collagen, was isolated from extracts of fetal calf skin. After two chromatographic steps on concanavalin A-Sepharose and heparin-Sepharose, the semi-purified preparation was used to produce monoclonal antibodies. One reacting antibody was found to recognize not the enzyme itself but type XIV collagen on which the enzyme was bound. This binding, highly sensitive to ionic conditions (pH, salt concentrations) but not affected by non-ionic detergents, was used for affinity chromatography that strongly improved the purification procedure. The enzyme is extensively characterized: 1) it has a molecular mass of 107 kDa as determined by polyacrylamide gel electrophoresis in presence of SDS and of about 130 kDa when estimated by gel filtration on a Sephacryl-S300; 2) in standard assay (pH 7.5, 0.2 M NaCl, 35 degrees C), the activation energy for reaction with amino procollagen type I was 17,000 calories per mole. In the same conditions, K-m and V-max values were, respectively, 435 and 39 nM per hour but varied strongly with pH and salt concentration; 3) the enzyme cleaved the NH2-terminal propeptide of type I procollagen at the specific site, the Pro-Gin bond in the alpha 1 type I procollagen chain; 4) the enzyme contained a high proportion of Gly, Asx, and Glx residues but no Hyp or Hyl; 5) partial amino acid sequences obtained from internal peptides of the enzyme displayed no significant homology with known sequences. The association of procollagen I N-proteinase with a FACIT (fibril associated colla gens with interrupted triple helices) collagen as found here might be of physiological significance.	UNIV LIEGE,CHU SART TILMAN,EXPTL DERMATOL LAB,B-4000 SART,BELGIUM; FREE UNIV BRUSSELS,INST MOLEC BIOL,CELLULAR IMMUNOL LAB,B-1640 RHODE ST GENESE,BELGIUM; VAKGRP BIOCHEM FYSIOL & MICROBIOL,B-9000 GHENT,BELGIUM	University of Liege			Beschin, Alain/L-2154-2014	Beschin, Alain/0000-0001-8478-6941				AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FONT B, 1993, J BIOL CHEM, V268, P25015; GOFFIN C, 1992, MOL BIOL, V11, P203; HALIA R, 1992, AM J HUM GENET, V51, P128; HANSET R, 1967, ANN MED VET, V7, P451; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOJIMA Y, 1994, J BIOL CHEM, V269, P11389; HOJIMA Y, 1989, J BIOL CHEM, V264, P11389; HORLEIN D, 1978, FEBS LETT, V89, P279, DOI 10.1016/0014-5793(78)80236-1; LAPIERE CM, 1971, P NATL ACAD SCI USA, V68, P3054, DOI 10.1073/pnas.68.12.3054; LENAERS A, 1971, EUR J BIOCHEM, V23, P533, DOI 10.1111/j.1432-1033.1971.tb01651.x; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; NUSGENS B, 1979, ANAL BIOCHEM, V95, P406, DOI 10.1016/0003-2697(79)90747-4; NUSGENS BV, 1980, BIOCHEM J, V191, P699, DOI 10.1042/bj1910699; NUSGENS BV, 1992, NAT GENET, V1, P214, DOI 10.1038/ng0692-214; SMITH LT, 1992, AM J HUM GENET, V51, P235; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WALCHLI C, 1994, J CELL SCI, V107, P669	22	65	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16724	16730		10.1074/jbc.270.28.16724	http://dx.doi.org/10.1074/jbc.270.28.16724			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622483	hybrid			2022-12-25	WOS:A1995RJ34700043
J	COVER, CM; WANG, JM; STLEZIN, E; KURTZ, TW; MELLON, SH				COVER, CM; WANG, JM; STLEZIN, E; KURTZ, TW; MELLON, SH			MOLECULAR VARIANTS IN THE P450C11AS GENE AS DETERMINANTS OF ALDOSTERONE SYNTHASE ACTIVITY IN THE DAHL RAT MODEL OF HYPERTENSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT-RESISTANT RATS; ADRENAL-CORTEX; CYTOCHROME-P-450; BIOSYNTHESIS; EXPRESSION; SEQUENCE; CDNA; MINERALOCORTICOIDS; MUTATIONS; CYP11B2	Dahl salt-sensitive (S) and salt-resistant (R) rats are widely used to study genetic determinants of salt sensitive hypertension. Differences in blood pressure under a high sodium diet in these two strains may be due to differences in the synthesis of 18-OH-11-deoxycorticosterone (18-OH DOC). This difference in 18-OH-DOC synthesis is due to mutations in the Dahl R rat's gene for P450c11 beta (11 beta-hydroxylase), an adrenal enzyme involved in the synthesis of both corticosterone and 18-OH DOC from 11-deoxycorticosterone. Aldosterone/renin ratios in plasma and in the adrenals are greater in Dahl S than R rats, suggesting an altered physiologic relationship between the renin-angiotensin and aldosterone systems between these strains. We demonstrate that the mRNA for P450c11AS, (aldosterone synthase), an enzyme required for aldosterone synthesis, is identical in the Dahl S rat and in normotensive Sprague-Dawley rats, but that P450c11AS mRNA from the Dahl R rat contains 7 mutations that result in two amino acid substitutions, These two changes result in a form of P450c11AS that has a greater apparent V-max and lower apparent K-m, resulting in an enzyme that catalyzes the conversion of 11-deoxycorticosterone to aldosterone at a greater rate in Dahl R rats than the P450c11AS in Dahl S rats or Sprague Dawley rats, Although plasma and adrenal renin are lower in Dahl S versus R rats, the regulation of P450c11AS mRNA expression in rats fed a low and high salt diet are identical in these strains, The current findings may explain both the reduced aldosterone concentrations and increased aldosterone/renin ratios previously reported in the Dahl S versus Dahl R rat.	UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD011979, R01HD027970] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-11979, HD 27970] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADLER GK, 1993, ENDOCRINOLOGY, V133, P2235, DOI 10.1210/en.133.5.2235; CICILA GT, 1993, NAT GENET, V3, P346, DOI 10.1038/ng0493-346; CONNELL JMC, 1991, J HYPERTENS, V9, P97, DOI 10.1097/00004872-199102000-00001; CURNOW KM, 1991, MOL ENDOCRINOL, V5, P1513, DOI 10.1210/mend-5-10-1513; DAHL LK, 1962, J EXP MED, V115, P1173, DOI 10.1084/jem.115.6.1173; DOMALIK LJ, 1991, MOL ENDOCRINOL, V5, P1853, DOI 10.1210/mend-5-12-1853; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FARDELLA CE, 1995, J CLIN ENDOCR METAB, V80, P1040, DOI 10.1210/jc.80.3.1040; FRASER R, 1985, P158; IMAI M, 1990, FEBS LETT, V263, P299, DOI 10.1016/0014-5793(90)81398-8; KUSANO E, 1986, J HYPERTENS       S5, V4, P20; LAUBER M, 1989, ARCH BIOCHEM BIOPHYS, V274, P109, DOI 10.1016/0003-9861(89)90421-9; LIFTON RP, 1992, NAT GENET, V2, P66, DOI 10.1038/ng0992-66; MALEE MP, 1991, P NATL ACAD SCI USA, V88, P4731, DOI 10.1073/pnas.88.11.4731; MATSUKAWA N, 1993, J BIOL CHEM, V268, P9117; MELLON SH, 1995, STEROIDS, V60, P59, DOI 10.1016/0039-128X(94)00020-D; MELLON SH, 1991, DNA CELL BIOL, V10, P339, DOI 10.1089/dna.1991.10.339; MELLON SH, 1989, J CLIN INVEST, V84, P1497, DOI 10.1172/JCI114325; MELLON SH, 1995, J BIOL CHEM, V270, P1643, DOI 10.1074/jbc.270.4.1643; MORNET E, 1989, J BIOL CHEM, V264, P20961; MUKAI K, 1993, J BIOL CHEM, V268, P9130; NONAKA Y, 1989, FEBS LETT, V255, P21, DOI 10.1016/0014-5793(89)81053-1; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OGISHIMA T, 1992, ENDOCRINOLOGY, V130, P2971, DOI 10.1210/en.130.5.2971; OONK RB, 1989, J BIOL CHEM, V264, P21934; PASCOE L, 1992, P NATL ACAD SCI USA, V89, P8327, DOI 10.1073/pnas.89.17.8327; RAPP JP, 1982, HYPERTENSION, V4, P753, DOI 10.1161/01.HYP.4.6.753; RAPP JP, 1973, ENDOCRINOLOGY, V92, P1286, DOI 10.1210/endo-92-4-1286; RAPP JP, 1972, NATURE, V237, P338, DOI 10.1038/237338a0; RAPP JP, 1978, ENDOCR RES COMMUN, V5, P35, DOI 10.3109/07435807809073634; RAPP JP, 1976, BIOCHEMISTRY-US, V15, P1235, DOI 10.1021/bi00651a010; SANDER M, 1994, P NATL ACAD SCI USA, V91, P148, DOI 10.1073/pnas.91.1.148; STLEZIN EM, 1994, HYPERTENSION, V23, P786, DOI 10.1161/01.HYP.23.6.786; TREMBLAY A, 1992, ENDOCRINOLOGY, V130, P3152, DOI 10.1210/en.130.6.3152	34	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16555	16560		10.1074/jbc.270.28.16555	http://dx.doi.org/10.1074/jbc.270.28.16555			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622461	hybrid			2022-12-25	WOS:A1995RJ34700017
J	KINLAW, WB; CHURCH, JL; HARMON, J; MARIASH, CN				KINLAW, WB; CHURCH, JL; HARMON, J; MARIASH, CN			DIRECT EVIDENCE FOR A ROLE OF THE SPOT-14 PROTEIN IN THE REGULATION OF LIPID-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S14 GENE-TRANSCRIPTION; RIBONUCLEIC-ACID S14; THYROID-HORMONE; MESSENGER-RNA; RAT-LIVER; MOLECULAR-CLONING; HEPATIC ZONATION; MALIC ENZYME; CARBOHYDRATE; EXPRESSION	''Spot 14'' is a nuclear protein that is rapidly induced by thyroid hormone (T-3) and dietary carbohydrate in liver, We used an antisense oligonucleotide to inhibit induction of spot 14 protein by T-3 and glucose in primary cultures of rat hepatocytes to test the hypothesis that the protein could function in the regulation of lipid synthesis. Spot 14 protein was undetectable in hepatocytes maintained in 5.5 mM glucose without T-3, and was induced within 4 h after addition of 27.5 mM glucose and 50 nM T-3 to the culture medium, reaching a maximal level within 24 h. Accumulation of spot 14 protein was markedly inhibited in hepatocytes transfected with a spot 14 antisense oligonucleotide, but not in those treated with a control oligonucleotide. Transfection of the antisense, but not control, oligonucleotide also abrogated the increase in lipogenesis induced by T-3 and glucose. Reduced triglyceride formation accounted for the diminished net lipid synthesis, In contrast to lipogenesis, glucose uptake was not significantly affected by the transfections. Antisense transfection inhibited the induction of both ATP citrate lyase and fatty acid synthase immunoreactivities, as well as malic enzyme activity, indicating that the observed reduction in lipogenesis could be explained by diminished cellular content of lipogenic enzymes. Reduced malic enzyme activity in antisense-transfected hepatocytes was accompanied by lowered relative abundance of malic enzyme mRNA, suggesting that the antisense effects on lipogenic enzymes were mediated at the pretranslational level. The oligonucleotides did not significantly affect lipogenesis in a rat hepatoma cell line that does not express detectable spot 14 mRNA or protein. These data directly implicate the spot 14 protein in the transduction of hormonal and dietary signals for increased lipid metabolism in hepatocytes.	DARTMOUTH COLL,SCH MED,DEPT MED,DIV ENDOCRINOL & METAB,LEBANON,NH 03750; UNIV MINNESOTA,SCH MED,DEPT MED,DIV ENDOCRINOL & METAB,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	Dartmouth College; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043142] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32855, DK-43142] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLIGH EG, 1989, CAN J BIOCH PHYSL, V37, P911; CAMPBELL JM, 1990, J BIOCHEM BIOPH METH, V20, P259, DOI 10.1016/0165-022X(90)90084-P; CARR FE, 1984, P NATL ACAD SCI-BIOL, V81, P974, DOI 10.1073/pnas.81.3.974; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; FREAKE HC, 1987, P NATL ACAD SCI USA, V84, P3070, DOI 10.1073/pnas.84.9.3070; GOTO Y, 1992, DIABETES, V41, P339, DOI 10.2337/diabetes.41.3.339; HSU RY, 1967, J BIOL CHEM, V242, P520; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; JUMP DB, 1984, J BIOL CHEM, V259, P2789; KINLAW WB, 1989, J BIOL CHEM, V264, P19779; KINLAW WB, 1988, ENDOCRINOLOGY, V123, P2255, DOI 10.1210/endo-123-5-2255; KINLAW WB, 1992, ENDOCRINOLOGY, V131, P3120, DOI 10.1210/en.131.6.3120; KINLAW WB, 1986, J CLIN INVEST, V78, P1091, DOI 10.1172/JCI112665; KINLAW WB, 1993, ENDOCRINOLOGY, V133, P645, DOI 10.1210/en.133.2.645; KINLAW WB, 1987, ENDOCRINOLOGY, V120, P1563, DOI 10.1210/endo-120-4-1563; LIAW CW, 1984, J BIOL CHEM, V259, P7253; MAGNUSON MA, 1983, J BIOL CHEM, V258, P2712; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARIASH CN, 1984, BIOCHEM BIOPH RES CO, V123, P1122; MARIASH CN, 1981, J CLIN INVEST, V65, P1126; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PEREZCASTILLO A, 1987, AM J PHYSIOL, V253, pE536, DOI 10.1152/ajpendo.1987.253.5.E536; SEELIG S, 1981, P NATL ACAD SCI-BIOL, V78, P4733, DOI 10.1073/pnas.78.8.4733; SHIH HM, 1992, J BIOL CHEM, V267, P13222; STRAIT KA, 1989, J BIOL CHEM, V264, P19784; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; YU K, BIOCHEM J, V268, P539; ZILZ ND, 1990, J BIOL CHEM, V265, P8136; [No title captured]	31	124	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16615	16618		10.1074/jbc.270.28.16615	http://dx.doi.org/10.1074/jbc.270.28.16615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622469	hybrid			2022-12-25	WOS:A1995RJ34700026
J	LIU, DH; POSTBEITTENMILLER, D				LIU, DH; POSTBEITTENMILLER, D			DISCOVERY OF AN EPIDERMAL STEAROYL-ACYL CARRIER PROTEIN THIOESTERASE - ITS POTENTIAL ROLE IN WAX BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UMBELLULARIA-CALIFORNICA; IMMATURE COTYLEDONS; ACP THIOESTERASE; PURIFICATION; EXPRESSION; PLANTS; SEEDS; DESATURASE; INDUCTION; SPINACH	Plant epicuticular, or surface, waxes are synthesized primarily, if not exclusively, by epidermal cells. The epicuticular wax constitutes almost 20% of the chloroformextractable lipids in developing leek leaf and is derived predominantly from saturated fatty acids. The significant requirement for saturated fatty acids in epidermal tissues led us to investigate whether or not epidermal extracts have thioesterase activities that prefer saturated acyl-acyl carrier protein (ACP) substrates, rather than the 18:1-ACP more commonly hydrolyzed by total leaf extracts. Epidermal extracts from Brassica, pea, and leek exhibited higher activities toward saturated acyl-ACPs relative to 18:1-ACP when compared to total leaf or leaf parenchymal extracts. We identified and purified a stearoyl-ACP (18:0-ACP)-specific thioesterase from leek epidermal extracts which could be separated from 18:1-ACP thioesterase using hydroxyapatite chromatography. The stearoyl-ACP thioesterase exhibited a high preference for 18:0-ACP, having less than 10% of the 18:0-ACP hydrolyzing activity when presented with 18:1-ACP, 16:0-ACP, or 18:0-CoA substrates. The stearoyl-ACP thioesterase was predominantly, if not exclusively, expressed in epidermis and may play a role in generating the saturated fatty acid pool required for wax production.	SAMUEL ROBERTS NOBLE FDN INC,DIV PLANT BIOL,ARDMORE,OK 73402	Noble Research Institute								CLOUGH RC, 1992, J BIOL CHEM, V267, P20992; DAVIES HM, 1991, ARCH BIOCHEM BIOPHYS, V290, P37, DOI 10.1016/0003-9861(91)90588-A; DORMANN P, 1994, PLANT PHYSIOL, V104, P839, DOI 10.1104/pp.104.3.839; DORMANN P, 1993, PLANTA, V189, P425, DOI 10.1007/BF00194441; ELHUSSEIN SA, 1988, BIOCHEM J, V251, P39; HELLYER A, 1992, PLANT MOL BIOL, V20, P763, DOI 10.1007/BF00027148; IMAI H, 1992, PLANT MOL BIOL, V20, P199, DOI 10.1007/BF00014488; JONES A, 1995, PLANT CELL, V7, P359, DOI 10.1105/tpc.7.3.359; KNUDSEN J, 1975, BIOCHEM BIOPH RES CO, V65, P921, DOI 10.1016/S0006-291X(75)80473-6; KNUTZON DS, 1992, P NATL ACAD SCI USA, V89, P2624, DOI 10.1073/pnas.89.7.2624; KOLATTUKUDY PE, 1985, J BIOL CHEM, V260, P789; KOLATTUKUDY PE, 1991, ARCH BIOCHEM BIOPHYS, V284, P201, DOI 10.1016/0003-9861(91)90284-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; OHLROGGE JB, 1978, ARCH BIOCHEM BIOPHYS, V189, P382, DOI 10.1016/0003-9861(78)90225-4; POLLARD MR, 1991, ARCH BIOCHEM BIOPHYS, V284, P306, DOI 10.1016/0003-9861(91)90300-8; POSTBEITTENMILL.MA, 1989, PLANT CELL, V1, P889; TAYLOR DC, 1990, ANAL BIOCHEM, V184, P311, DOI 10.1016/0003-2697(90)90686-4; VOELKER TA, 1992, SCIENCE, V257, P72, DOI 10.1126/science.1621095	20	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16962	16969		10.1074/jbc.270.28.16962	http://dx.doi.org/10.1074/jbc.270.28.16962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622515	hybrid			2022-12-25	WOS:A1995RJ34700076
J	WANG, CL; JAYADEV, S; ESCOBEDO, JA				WANG, CL; JAYADEV, S; ESCOBEDO, JA			IDENTIFICATION OF A DOMAIN IN THE ANGIOTENSIN-II TYPE-1 RECEPTOR DETERMINING G(Q) COUPLING BY THE USE OF RECEPTOR CHIMERAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; SITE-DIRECTED MUTAGENESIS; SMOOTH-MUSCLE CELLS; PHOSPHOLIPASE-C; PHOSPHATIDYLINOSITOL HYDROLYSIS; 2ND MESSENGERS; WASP VENOM; G-PROTEINS; EXPRESSION	The angiotensin II type 1 (AT1R) and type 2 (AT2R) receptors belong to the seven transmembrane receptor superfamily. Previous studies have suggested that the AT1R couples to a G(q) signaling pathway, whereas the AT2R does not associate with G(q). To identify the role that individual intracellular domains play in AT1R function, AT1R/AT2R chimeric receptors were prepared by substitution of intracellular loops. CHO cells expressing these chimeras were used to test angiotensin II-induced c-fos expression and Ca2+ mobilization which are involved in the AT1R signaling pathway through G(q) coupling. Substitution of the second intracellular loop (IC2) and the cytoplasmic tail between the two receptors did not affect AT1R function. However, exchange of the third intracellular loop (IC3) resulted in the loss of function in the AT1R and conferred to the AT2R the ability to constitutively activate the fos promoter. These findings suggest that the third intracellular loop of the AT1R is critical for G(q) coupling. Substitution of discrete amino acid sequences of the third intracellular loop indicate that its N-terminal and C-terminal portions, especially the seven amino acids 219-225 in the N-terminal portion, are important for AT1R function, and that the intermediate portion of this loop is not required for G(q) coupling.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DAIICHI RES CTR, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BERRIDGE MJ, 1989, PROC R SOC SER B-BIO, V238, P235, DOI 10.1098/rspb.1989.0079; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BLUML K, 1994, P NATL ACAD SCI USA, V91, P7980, DOI 10.1073/pnas.91.17.7980; BOTTARI SP, 1992, BIOCHEM BIOPH RES CO, V183, P206, DOI 10.1016/0006-291X(92)91629-5; BRECHLER V, 1994, RECEPTOR CHANNEL, V2, P89; CHANG RSL, 1990, MOL PHARMACOL, V37, P347; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KANG J, 1994, AM J PHYSIOL-CELL PH, V267, pC1389, DOI 10.1152/ajpcell.1994.267.5.C1389; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOSUGI S, 1994, MOL ENDOCRINOL, V8, P498, DOI 10.1210/me.8.4.498; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LANDAU EM, 1994, METHOD ENZYMOL, V238, P140; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MARIE J, 1994, J BIOL CHEM, V269, P20815; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OHNISHI J, 1992, BIOCHEM BIOPH RES CO, V186, P1094, DOI 10.1016/0006-291X(92)90859-J; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OPPI C, 1992, P NATL ACAD SCI USA, V89, P8268, DOI 10.1073/pnas.89.17.8268; REN Q, 1993, J BIOL CHEM, V268, P16483; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SONG KF, 1992, LIFE SCI, V51, pPL165, DOI 10.1016/0024-3205(92)90542-W; TAKAHASI K, 1994, BIOCHEM BIOPH RES CO, V198, P60, DOI 10.1006/bbrc.1994.1009; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; TAYLOR JM, 1994, PEPTIDES, V15, P829, DOI 10.1016/0196-9781(94)90038-8; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TSUDA T, 1990, J BIOL CHEM, V265, P1165; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V265, P6219	51	90	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16677	16682		10.1074/jbc.270.28.16677	http://dx.doi.org/10.1074/jbc.270.28.16677			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622477	hybrid			2022-12-25	WOS:A1995RJ34700036
J	MERCURE, C; THIBAULT, G; LUSSIERCACAN, S; DAVIGNON, J; SCHIFFRIN, EL; REUDELHUBER, TL				MERCURE, C; THIBAULT, G; LUSSIERCACAN, S; DAVIGNON, J; SCHIFFRIN, EL; REUDELHUBER, TL			MOLECULAR ANALYSIS OF HUMAN PRORENIN PROSEGMENT VARIANTS IN-VITRO AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGMENT-LENGTH-POLYMORPHISMS; RENIN-ANGIOTENSIN SYSTEM; BLOOD-PRESSURE; ESSENTIAL-HYPERTENSION; GENE; ASSOCIATION; CELLS; INHIBITORS; BIOLOGY; PEPTIDE	The aspartyl protease renin, an important modulator of blood pressure in humans, is present in the circulation not only in its active form, but also as an inactive precursor, prorenin, in which a 43-amino acid prosegment blocks access of the substrate to the active site of the enzyme, Site-directed mutagenesis of the prosegment has led to the following conclusions. 1) Maintenance of the enzymatically inactive state of prorenin requires a short peptide sequence between positions 10P and 20P (where P denotes prosegment and numbering is relative to amino terminus) of the prosegment; and 2) there is an inverse relationship between the ability of prosegment mutations to activate and their effect on the secretion of the various prorenins, suggesting that this same region of the prosegment plays a critical role in the biosynthesis of human prorenin, Since these results demonstrated that single amino acid mutations could activate human prorenin to varying degrees, mutations in this region of the renin gene could be clinically important in humans. To test this hypothesis, genomic screening was carried out on the corresponding region of the human renin gene (exon 2) in a cohort of patients selected for a likely familial component to their hypertension. While this study identified a novel polymorphism in exon 2 of the human renin gene, evidence was not obtained for either the presence of prosegment mutations or the association of the novel polymorphism with hypertension in the patient population studied. In conclusion, both structure-function studies and genetic screening suggest that mutation of the prorenin prosegment is an unlikely factor in activation of the renin-angiotensin system in humans.	CLIN RES INST MONTREAL, MRC, MULTIDISCIPLINARY RES GRP HYPERTENS, MONTREAL, PQ H2W 1R7, CANADA; CLIN RES INST MONTREAL, JA DESEVE LAB HYPERLIPIDEMIA & ATHEROSCLEROSIS, MONTREAL, PQ H2W 1R7, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Schiffrin, Ernesto L/AAB-9061-2019	Schiffrin, Ernesto L/0000-0002-4502-2823				ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BARLEY J, 1991, J HYPERTENS, V9, P993, DOI 10.1097/00004872-199111000-00003; BAXTER JD, 1991, RECENT PROG HORM RES, V47, P211; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; CHU WN, 1992, HYPERTENSION, V20, P782, DOI 10.1161/01.HYP.20.6.782; CREAGER MA, 1991, HYPERTENSION, V17, P989, DOI 10.1161/01.HYP.17.6.989; DAHL LK, 1962, NATURE, V194, P480, DOI 10.1038/194480b0; DANSER AHJ, 1989, J CLIN ENDOCR METAB, V68, P160, DOI 10.1210/jcem-68-1-160; DERKX FHM, 1987, J BIOL CHEM, V262, P2472; DERKX FHM, 1992, J BIOL CHEM, V267, P22837; FRITZ LC, 1987, J BIOL CHEM, V262, P12409; FROHLICH ED, 1990, AM J MED S6B, V87; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; HARDMAN JA, 1984, DNA-J MOLEC CELL BIO, V3, P457, DOI 10.1089/dna.1.1984.3.457; HARRISON TM, 1989, PROTEINS, V5, P259, DOI 10.1002/prot.340050402; HEINRIKSON RL, 1989, AM J HYPERTENS, V2, P367, DOI 10.1093/ajh/2.5.367; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HSUEH WA, 1991, HYPERTENSION, V17, P469, DOI 10.1161/01.HYP.17.4.469; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, HUM GENET, V88, P301; LINDPAINTNER K, 1991, CARDIOLOGY, V79, P32, DOI 10.1159/000174905; NAGAHAMA M, 1989, FEBS LETT, V259, P202, DOI 10.1016/0014-5793(89)81528-5; NEURINGER JR, 1993, AM J KIDNEY DIS, V22, P98, DOI 10.1016/S0272-6386(12)70174-9; OKURA T, 1993, J HUM HYPERTENS, V7, P457; PITARRESI TM, 1992, J BIOL CHEM, V267, P11753; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCHALEKAMP MADH, 1992, J HYPERTENS, V10, pS157; SEALEY JE, 1989, AM J HYPERTENS, V2, P358, DOI 10.1093/ajh/2.5.358; VILLARD E, 1994, J BIOL CHEM, V269, P30307; WARD R, 1990, HYPERTENSION PATHOPH, P81; WILLIAMS RR, 1989, HYPERTENSION, V14, P610, DOI 10.1161/01.HYP.14.6.610; XHIGNESSE M, 1991, ARTERIOSCLER THROMB, V11, P1100, DOI 10.1161/01.ATV.11.4.1100	35	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16355	16359		10.1074/jbc.270.27.16355	http://dx.doi.org/10.1074/jbc.270.27.16355			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608205	Green Submitted, hybrid			2022-12-25	WOS:A1995RH22600072
J	LAMANDE, SR; BATEMAN, JF				LAMANDE, SR; BATEMAN, JF			THE TYPE-I COLLAGEN PRO-ALPHA-1(I) COOH-TEMMINAL PROPEPTIDE N-LINKED OLIGOSACCHARIDE - FUNCTIONAL-ANALYSIS BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; EXTRACELLULAR-MATRIX ACCUMULATION; PERINATAL OSTEOGENESIS IMPERFECTA; CARBOXYL-TERMINAL PROPEPTIDE; EMBRYONIC LETHAL MUTATION; PROCOLLAGEN TYPE-I; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; INFLUENZA HEMAGGLUTININ; HUMAN-FIBROBLASTS	The C-propeptides of the pro alpha 1(I) and pro alpha 2(I) chains of type I collagen are each substituted with a single high-mannose N-linked oligosaccharide. Conservation of this motif among the fibrillar collagens has led to the proposal that the oligosaccharide has structural or functional importance, but a role in collagen biosynthesis has not been unambiguously defined. To examine directly the function of the pro alpha 1(I) C-propeptide N-linked oligosaccharide, the acceptor Asn residue was changed to Gin by site-directed mutagenesis. In transfected mouse Mov13 and 3T6 cells, unglycosylated mutant pro alpha 1(I) folded and assembled normally into trimeric molecules with pro alpha 2(I). In biosynthetic pulse-chase experiments mutant pro alpha 1(I) were secreted at the same rate as wild-type chains; however, following secretion, the chains were partitioned differently between the cell layer and medium, with a greater proportion of the mutant pro alpha 1(I) being released into the medium. This distribution difference was not eliminated by the inclusion of yeast mannan indicating that the high-mannose oligosaccharide itself was not binding to the matrix or the fibroblast surface after secretion. Subtle alterations in the tertiary structure of unglycosylated C-propeptides may have decreased their affinity for a cell-surface component. Further support for a small conformational change in the mutant C-propeptides came hom experiments suggesting that unglycosylated pro alpha 1(I) chains were cleaved in vitro by the purified C-proteinase slightly less efficiently than wild-type chains. Mutant and normal pro alpha 1(I) were deposited with equal efficiency into the 3T6 cell accumulated matrix, thus the reduced cleavage by C-proteinase and altered distribution in the short pulse-chase experiments were not functionally significant in this in vitro extracellular matrix model system.	UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,ORTHOPAED MOLEC BIOL RES UNIT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne				Bateman, John/0000-0001-8542-0730; Lamande, Shireen/0000-0003-2938-2711				BASSUK JA, 1989, MATRIX, V9, P244, DOI 10.1016/S0934-8832(89)80057-5; BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; BATEMAN JF, 1988, ANAL BIOCHEM, V168, P171, DOI 10.1016/0003-2697(88)90025-5; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BIRK DE, 1990, ANN NY ACAD SCI, V580, P176, DOI 10.1111/j.1749-6632.1990.tb17928.x; CHAN D, 1990, BIOCHEM J, V269, P175, DOI 10.1042/bj2690175; CHESSLER SD, 1993, J BIOL CHEM, V268, P18218; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; CHOGLAY AA, 1993, J BIOL CHEM, V268, P6107; CLARK CC, 1979, J BIOL CHEM, V254, P798; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DUBE S, 1988, J BIOL CHEM, V263, P17516; DUKSIN D, 1977, J BIOL CHEM, V252, P955; DUKSIN D, 1978, ARCH BIOCHEM BIOPHYS, V185, P326, DOI 10.1016/0003-9861(78)90174-1; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FENTON SP, 1993, BIOCHIM BIOPHYS ACTA, V1216, P469, DOI 10.1016/0167-4781(93)90016-7; FESSLER LI, 1974, J BIOL CHEM, V249, P7637; Fisher L. W., 1989, CONNECT TISSUE RES, V21, P43; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HARBERS K, 1984, P NATL ACAD SCI-BIOL, V81, P1504, DOI 10.1073/pnas.81.5.1504; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HOUSLEY TJ, 1980, J BIOL CHEM, V255, P121; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KESSLER E, 1990, BIOCHEM BIOPH RES CO, V173, P81, DOI 10.1016/S0006-291X(05)81024-1; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; LAMANDE SR, 1993, MATRIX, V13, P323, DOI 10.1016/S0934-8832(11)80028-4; LAMANDE SR, 1993, BIOCHEM J, V293, P387, DOI 10.1042/bj2930387; LEUNG MKK, 1979, J BIOL CHEM, V254, P224; LIPPINCOTTSCHWA.J, 1988, CELL, V54, P209; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MAHONEY WC, 1979, J BIOL CHEM, V254, P6572; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; OLSEN BR, 1977, BIOCHEMISTRY-US, V16, P3030, DOI 10.1021/bi00632a034; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PHELPS RG, 1985, COLLAGEN REL RES, V5, P405; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; SCOTT PG, 1976, CONNECT TISSUE RES, V4, P107, DOI 10.3109/03008207609152206; SEILBERG M, 1983, CANCER RES, V43, P845; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SMEDSROD B, 1990, BIOCHEM J, V271, P345, DOI 10.1042/bj2710345; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TANZER ML, 1977, BIOCHIM BIOPHYS ACTA, V500, P187, DOI 10.1016/0304-4165(77)90058-7; TAYLOR AK, 1988, MOL CELL BIOL, V8, P4197, DOI 10.1128/MCB.8.10.4197; TIFFT CJ, 1992, J BIOL CHEM, V267, P3268; TRELSTAD RL, 1979, DEV BIOL, V71, P228, DOI 10.1016/0012-1606(79)90166-0; WESTON SA, 1994, J BIOL CHEM, V269, P20982; WU CH, 1991, J BIOL CHEM, V266, P2983	59	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17858	17865		10.1074/jbc.270.30.17858	http://dx.doi.org/10.1074/jbc.270.30.17858			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629088	hybrid			2022-12-25	WOS:A1995RM26600036
J	TARLAP, A; KAPLAN, H; SYTWU, II; VLATTAS, I; BOHACEK, R; KNAP, AK; HIRAMA, T; HUBER, CP; HASNAIN, S				TARLAP, A; KAPLAN, H; SYTWU, II; VLATTAS, I; BOHACEK, R; KNAP, AK; HIRAMA, T; HUBER, CP; HASNAIN, S			CHARACTERIZATION OF THE S-3 SUBSITE SPECIFICITY OF CATHEPSIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASES; RAT-LIVER; CATALYZED HYDROLYZES; PH; INHIBITORS; INACTIVATORS; STABILITY; PROTEASE; ARGININE; CALPAIN	Five synthetic substrates containing different amino acid residues at the P-3 position (acetyl-X-Arg-Arg-AMC, where X is Gly, Glu, Arg, Val, and Tyr and where AMC represents 7-amido-4-methylcoumarin) were used to investigate the S-3 subsite specificity of cathepsin B. At pH 6.0, the specificity constant, k(cat)/K-m, for tripeptide substrate hydrolysis was observed to increase in the order Glu < Gly < Arg < Val < Tyr. Molecular modeling studies of substrates containing a P-3 Glu, Arg, or Tyr covalently bound as the tetrahedral intermediate to the enzyme suggest that the specificity for a P-3 Tyr is because of a favorable aromatic-aromatic interaction with Tyr(75) on the enzyme as well as a possible H bond between the P-3 Tyr hydroxyl and the side chain carboxyl of Asp(69).	UNIV OTTAWA,DEPT CHEM,OTTAWA,ON K1N 6N5,CANADA; CIBA GEIGY CORP,DIV PHARMACEUT,RES DEPT,SUMMIT,NJ 07901; NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA,ON K1A 0R6,CANADA	University of Ottawa; Novartis; National Research Council Canada								ACHER R, 1952, BIOCHIM BIOPHYS ACTA, V9, P704, DOI 10.1016/0006-3002(52)90236-9; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BROMME D, 1989, BIOCHEM J, V264, P475; BROMME D, 1987, BIOCHEM J, V245, P381; BURLEY SK, 1989, TRENDS BIOTECHNOL, V7, P354, DOI 10.1016/0167-7799(89)90036-X; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; ERNST JF, 1986, DNA-J MOLEC CELL BIO, V5, P483, DOI 10.1089/dna.1.1986.5.483; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P156; GOPALAN P, 1987, CAN J PHYSIOL PHARM, V65, P124, DOI 10.1139/y87-025; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; HASNAIN S, 1993, J BIOL CHEM, V268, P235; JIA ZC, 1995, J BIOL CHEM, V270, P5527, DOI 10.1074/jbc.270.10.5527; KATUNUMA N, 1987, REV PHYSL BIOCH PHAR, V108, P2; KHOURI HE, 1991, BIOCHEM J, V275, P751, DOI 10.1042/bj2750751; KOGA H, 1991, J BIOCHEM-TOKYO, V110, P179, DOI 10.1093/oxfordjournals.jbchem.a123554; KRANTZ A, 1991, BIOCHEMISTRY-US, V30, P4678, DOI 10.1021/bi00233a007; LAH TT, 1989, CLIN EXP METASTAS, V7, P461, DOI 10.1007/BF01753666; LEE X, 1990, J BIOL CHEM, V265, P5950; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; PLIURA DH, 1992, BIOCHEM J, V288, P759, DOI 10.1042/bj2880759; POHL J, 1987, ANAL BIOCHEM, V165, P96, DOI 10.1016/0003-2697(87)90205-3; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SLOANE BF, 1990, CANCER METAST REV, V9, P333, DOI 10.1007/BF00049523; VANNOORDEN CJF, 1989, J RHEUMATOL, V15, P1525; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WIKSTROM P, 1989, ARCH BIOCHEM BIOPHYS, V270, P286, DOI 10.1016/0003-9861(89)90030-1; WILLENBROCK F, 1985, BIOCHEM J, V227, P521, DOI 10.1042/bj2270521	30	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18036	18043		10.1074/jbc.270.30.18036	http://dx.doi.org/10.1074/jbc.270.30.18036			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629112	hybrid			2022-12-25	WOS:A1995RM26600063
J	VIITANEN, PV; SCHMIDT, M; BUCHNER, J; SUZUKI, T; VIERLING, E; DICKSON, R; LORIMER, GH; GATENBY, A; SOLL, J				VIITANEN, PV; SCHMIDT, M; BUCHNER, J; SUZUKI, T; VIERLING, E; DICKSON, R; LORIMER, GH; GATENBY, A; SOLL, J			FUNCTIONAL-CHARACTERIZATION OF THE HIGHER-PLANT CHLOROPLAST CHAPERONINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; SYNTHESIZED LARGE SUBUNITS; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE-CARBOXYLASE; BINDING-PROTEIN; MOLECULAR CHAPERONE; PEA-CHLOROPLASTS; ATP HYDROLYSIS; GROEL	The higher plant chloroplast chaperonins (ch-cpn60 and ch-cpn10) have been purified and their structural/functional properties examined. In all plants surveyed, both proteins were constitutively expressed, and only modest increases in their levels were detected upon heat shock. Like GroEL and GroES of Escherichia coli, the chloroplast chaperonins can physically interact with each other. The asymmetric complexes that form in the presence of ADP are ''bullet-shaped'' particles that likely consist of 1 mol each of ch-cpn60 and ch-cpn10. The purified ch-cpn60 is a functional molecular chaperone. Under ''nonpermissive'' conditions, where spontaneous folding was not observed, it was able to assist in the refolding of two different target proteins. In both cases, successful partitioning to the native state also required ATP hydrolysis and chaperonin 10. Surprisingly, how ever, the ''double-domain'' ch-cpn10, comprised of unique 21-kDa subunits, was not an obligatory co-chaperonin. Both GroES and a mammalian mitochondrial homolog were equally compatible with the ch-cpn60. Finally, the assisted-folding reaction mediated by the chloroplast chaperonins does not require K+ ions. Thus, the K+-dependent ATPase activity that is observed with other known groEL homologs is not a universal property of all chaperonin 60s.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY; UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721; INST BOT,D-24098 KIEL,GERMANY	University of Regensburg; University of Arizona	VIITANEN, PV (corresponding author), DUPONT CO INC,DEPT CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880, USA.		Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737; Vierling, Elizabeth/0000-0002-0066-4881				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BANEYX F, 1995, J BIOL CHEM, V270, P10695, DOI 10.1074/jbc.270.18.10695; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; BLOOM MV, 1983, P NATL ACAD SCI-BIOL, V80, P1013, DOI 10.1073/pnas.80.4.1013; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CANNON S, 1986, J CELL BIOL, V103, P1327, DOI 10.1083/jcb.103.4.1327; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN GG, 1994, P NATL ACAD SCI USA, V91, P11497, DOI 10.1073/pnas.91.24.11497; CHEN Q, 1990, J CELL BIOL, V110, P1873, DOI 10.1083/jcb.110.6.1873; CLONEY LP, 1992, J BIOL CHEM, V267, P23327; CLONEY LP, 1992, J BIOL CHEM, V32, P23333; DICKSON R, 1994, J BIOL CHEM, V269, P26858; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GATENBY AA, 1994, ANNU REV PLANT PHYS, V45, P469; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GHOSH S, 1988, ANAL BIOCHEM, V169, P227, DOI 10.1016/0003-2697(88)90278-3; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HARTMAN DJ, 1992, FEBS LETT, V305, P147, DOI 10.1016/0014-5793(92)80883-I; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HEMMINGSEN SM, 1986, PLANT PHYSIOL, V80, P269, DOI 10.1104/pp.80.1.269; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HUBBS A, 1992, PLANT PHYSIOL, V100, P272, DOI 10.1104/pp.100.1.272; HUBBS AE, 1993, PLANT PHYSIOL, V101, P523, DOI 10.1104/pp.101.2.523; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1995, FEBS LETT, V361, P55, DOI 10.1016/0014-5793(95)00151-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; ROY H, 1982, J CELL BIOL, V94, P20, DOI 10.1083/jcb.94.1.20; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SAXTON WO, 1973, ULTRAMICROSCOPY, V4, P343; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; Suelter C., 1974, METAL IONS BIOL SYST, V3, P201; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YUAN JG, 1993, P NATL ACAD SCI USA, V90, P8552, DOI 10.1073/pnas.90.18.8552; ZABALETA E, 1994, PLANT J, V6, P425, DOI 10.1046/j.1365-313X.1994.06030425.x; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	61	76	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18158	18164		10.1074/jbc.270.30.18158	http://dx.doi.org/10.1074/jbc.270.30.18158			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629128	Green Published, hybrid			2022-12-25	WOS:A1995RM26600080
J	KYRPIDES, N; TAVERNARAKIS, N; PAPAMATHEAKIS, J; THIREOS, G				KYRPIDES, N; TAVERNARAKIS, N; PAPAMATHEAKIS, J; THIREOS, G			A TRANSIENT GCN4 MESSENGER-RNA DESTABILIZATION FOLLOWS GCN4 TRANSLATIONAL DEREPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATOR; YEAST; GENE; STABILITY; TURNOVER; ELEMENTS; PROTEIN; REGION	Studies based on experimental strategies that utilized either inhibitors or structural alterations point to the existence of an inverse relationship between translation and stability of a given mRNA. In this study we have investigated the potential link between translation and stability of the yeast GCN4 mRNA whose translational rates change with respect to amino acid availability. We observed that under conditions favoring its translation, the steady state levels of the GCN4 mRNA were decreased, but this was not due to a measurable alternation in its decay rate. We have demonstrated that an extensive destabilization of this message is intimately coupled with its increased access to heavy polysomes, which occurs transiently in the process of translational derepression. This transient change in the stability is what readjusts the steady state levels of the GCN4 mRNA. This study demonstrates in vivo the existence of a mechanism of mRNA degradation that is coupled with the process of translation.	UNIV CRETE,DEPT BIOL,GR-71409 IRAKLION,GREECE	University of Crete	KYRPIDES, N (corresponding author), FDN RES & TECHNOL HELLAS,INST MOLEC BIOL & BIOTECHNOL,POB 1527,GR-71110 IRAKLION,GREECE.		Tavernarakis, Nektarios/B-9684-2013; Kyrpides, Nikos C./A-6305-2014	Tavernarakis, Nektarios/0000-0002-5253-1466; Kyrpides, Nikos C./0000-0002-6131-0462				AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P7920; DRISCOLLPENN M, 1984, MOL CELL BIOL, V4, P520; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PARKER R, 1990, P NATL ACAD SCI USA, V87, P2780, DOI 10.1073/pnas.87.7.2780; PELTZ SW, 1994, PROG NUCLEIC ACID RE, V47, P271, DOI 10.1016/S0079-6603(08)60254-8; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PELTZ SW, 1993, CONTROL MRNA STABILI, P231; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; TAVERNARAKIS N, 1995, IN PRESS MOL GEN GEN; THIREOS G, 1984, P NATL ACAD SCI-BIOL, V81, P5096, DOI 10.1073/pnas.81.16.5096; TZAMARIAS D, 1986, P NATL ACAD SCI USA, V83, P4849, DOI 10.1073/pnas.83.13.4849; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4	30	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17317	17320		10.1074/jbc.270.29.17317	http://dx.doi.org/10.1074/jbc.270.29.17317			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615533	hybrid			2022-12-25	WOS:A1995RK68900043
J	PORCHER, C; PICAT, C; DAEGELEN, D; BEAUMONT, C; GRANDCHAMP, B				PORCHER, C; PICAT, C; DAEGELEN, D; BEAUMONT, C; GRANDCHAMP, B			FUNCTIONAL-ANALYSIS OF DNASE-I HYPERSENSITIVE SITES AT THE MOUSE PORPHOBILINOGEN DEAMINASE GENE LOCUS - DIFFERENT REQUIREMENTS FOR POSITION-INDEPENDENT EXPRESSION FROM ITS 2 PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; BETA-GLOBIN GENE; NUCLEAR PROTEINS; TRANSCRIPTION FACTOR; ERYTHROID-CELLS; INVIVO PROTEIN; BINDING; ELEMENTS; ENHANCER; INVITRO	Porphobilinogen deaminase (EC 4.3.1.8; PBG-D) is the third enzyme of the heme biosynthetic pathway. In both human and mouse, the gene encoding PBG-D posseses two promoters, lying in close proximi ty. We have previously reported the mapping of six nuclear DNase-I hypersensitive sites at the PBG-D locus which could contribute to the regulation of the gene. In the present study, and in order to define all the elements necessary for a high level of expression and an integration site independence, we studied the pattern and the level of expression of a cloned PBG-D gene following integration into a host genome. The longest construct that we tested (12.5 kilobases) contained sufficient regulatory elements to promote expression levels similar to that of the endogenous gene, both in transgenic mice and in transfected cells. The overall contribution of individual DNase-I hypersensitive sites to the expression of the gene was then studied using a series of mutants that were stably transfected into mouse erythroleukemia cells. Two regions seem to play a critical role in the erythroid-specific expression of the PBG-D gene: the proximal promoter and a region situated at -1000 relative to the initiation site. Study of individual clones of mouse erythroleukemia cells revealed that the erythroid-specific expression of the gene was submitted to position effects in the absence of the upstream region, although the housekeeping transcription is not sensitive to such effects. The tandem arrangement of the housekeeping and tissue-specific promoters of the PBG-D gene raises some questions about the functioning of these two overlapping transcriptional units in erythroid cells. Previous data have suggested that in erythroid cells most of the transcripts initiated at the upstream promoter stop downstream of the first ubiquitous exon, between the two promoters. Here, we show that the deletion of a constitutive DNase-I hypersensitive site that is located in the region of the elongation block results in opposite effects on the steady state levels of housekeeping and tissue-specific RNA. This finding is consistent with the hypothesis that this region promotes premature termination of the housekeeping transcripts therefore preventing promoter interference.	UNIV PARIS 07,INSERM,U409,F-75018 PARIS,FRANCE; HOP COCHIN,INSERM,U129,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Porcher, Catherine/D-7026-2016					BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; CONCORDET JP, 1993, MOL CELL BIOL, V13, P9, DOI 10.1128/MCB.13.1.9; DYNAN WS, 1983, TRENDS GENET, V2, P196; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOGAN B, 1986, MANIPULATING MOUSE E; Kawasaki E. S., 1990, PCR PROTOCOLS GUIDE, P146; LACRONIQUE V, 1992, NUCLEIC ACIDS RES, V20, P5669, DOI 10.1093/nar/20.21.5669; MANTOVANI R, 1988, NUCLEIC ACIDS RES, V16, P4299, DOI 10.1093/nar/16.10.4299; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PORCHER C, 1992, BIOTECHNIQUES, V13, P106; PORCHER C, 1995, GENOMICS, V25, P312, DOI 10.1016/0888-7543(95)80145-C; PORCHER C, 1991, J BIOL CHEM, V266, P10562; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; SUN JM, 1992, NUCLEIC ACIDS RES, V20, P6385, DOI 10.1093/nar/20.23.6385; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794	27	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17368	17374		10.1074/jbc.270.29.17368	http://dx.doi.org/10.1074/jbc.270.29.17368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615541	hybrid			2022-12-25	WOS:A1995RK68900052
J	SELBERT, MA; ANDERSON, KA; HUANG, QH; GOLDSTEIN, EG; MEANS, AR; EDELMAN, AM				SELBERT, MA; ANDERSON, KA; HUANG, QH; GOLDSTEIN, EG; MEANS, AR; EDELMAN, AM			PHOSPHORYLATION AND ACTIVATION OF CA2+-CALMODULIN-DEPENDENT PROTEIN-KINASE-IV BY CA2+-CALMODULIN-DEPENDENT PROTEIN-KINASE-IA KINASE - PHOSPHORYLATION OF THREONINE-196 IS ESSENTIAL FOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; CALMODULIN BINDING DOMAIN; CAM KINASE; CA-2+-INDEPENDENT ACTIVITY; AUTOPHOSPHORYLATION SITES; RABBIT RETICULOCYTES; CATALYTIC DOMAINS; MOLECULAR-CLONING; ALPHA-SUBUNIT; RAT-BRAIN	Purified pig brain Ca2+-calmodulin (CaM)-dependent protein kinase Ia kinase (Lee, J. C., and Edelman, A. M. (1994) J. Biol. Chem. 269, 2158-2164) enhances, by up to 24-fold, the activity of recombinant CaM kinase IV in a reaction also requiring Ca2+-CaM and MgATP. The addition of brain extract, although capable of activating CaM kinase IV by itself, provides no further activation beyond that induced by purified CaM kinase Ia kinase, consistent with the lack of a requirement of additional components for activation. Activation is accompanied by the development of significant (38%) Ca2+-CaM-independent CaM kinase IV activity. In parallel fashion to its activation, CaM kinase IV is phosphorylated in a CaM kinase Ia kinase-, Ca2+-CaM-, and MgATP-dependent manner. Phosphorylation occurs on multiple serine and threonine residues with a Ser-P:Thr-P ratio of similar to 3:1. The identical requirements for phosphorylation and activation and a linear relationship between extent of phosphorylation of CaM kinase IV and its activation state indicate that CaM kinase IV activation is induced by its phosphorylation. Replacement of Thr-196 of CaM kinase IV with a nonphosphorylatable alanine by site directed mutagenesis abolishes both the phosphorylation and activation of CaM kinase IV, demonstrating that Thr-196 phosphorylation is essential for activation.	SUNY BUFFALO,DEPT PHARMACOL & TOXICOL,BUFFALO,NY 14214; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Duke University					NICHD NIH HHS [HD07503] Funding Source: Medline; NIGMS NIH HHS [GM07145-20] Funding Source: Medline; NINDS NIH HHS [NS24738] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024738, R01NS024738] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BLAND MM, 1994, GENE, V142, P191, DOI 10.1016/0378-1119(94)90260-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EDELMAN AM, 1985, J BIOL CHEM, V260, P1275; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1991, EMBO J, V11, P3995; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; ITO T, 1994, BIOCHEM BIOPH RES CO, V201, P1561, DOI 10.1006/bbrc.1994.1882; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KITANI T, 1994, J BIOCHEM-TOKYO, V115, P637, DOI 10.1093/oxfordjournals.jbchem.a124387; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LOU LL, 1989, J NEUROSCI, V9, P2020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEANS AR, 1994, ADV 2 MESSENGER PHOS, V30, P1; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MITSUI K, 1993, J BIOL CHEM, V268, P13422; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; REDPATH NT, 1993, EUR J BIOCHEM, V212, P511, DOI 10.1111/j.1432-1033.1993.tb17688.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; TAKIO K, 1985, BIOCHEMISTRY-US, V24, P6028, DOI 10.1021/bi00343a002; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	63	132	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17616	17621		10.1074/jbc.270.29.17616	http://dx.doi.org/10.1074/jbc.270.29.17616			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615569	hybrid			2022-12-25	WOS:A1995RK68900086
J	ONO, H; GRUHLER, A; STUART, RA; GUIARD, B; SCHWARZ, E; NEUPERT, W				ONO, H; GRUHLER, A; STUART, RA; GUIARD, B; SCHWARZ, E; NEUPERT, W			SORTING OF CYTOCHROME B(2) TO THE INTERMEMBRANE SPACE OF MITOCHONDRIA - KINETIC-ANALYSIS OF INTERMEDIATES DEMONSTRATES PASSAGE THROUGH THE MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MITOCHONDRIA; PROTEIN IMPORT; NUCLEAR GENE; SIGNAL; PRESEQUENCE; PEPTIDASE; TRANSPORT; PRECURSOR; CLEAVAGE; ATP	Precytochrome b(2) is targeted to the mitochondrial intermembrane space by a dual targeting sequence comprising 80 amino acids. A kinetic analysis of intramitochondrial sorting was performed. The intermediate-size form accumulated transiently in the matrix. When import was performed in the presence of metal chelators to prevent the first processing by the matrix processing peptidase, >40% of the imported precursor was localized in the matrix. A deletion of 13 amino acids in the intermembrane space sorting sequence caused partial inhibition of the first processing, and a transient accumulation of the precursor form in the matrix was also observed. The decrease in this matrix-localized precursor form paralleled an increase in the mature-size form in the intermembrane space. A point mutation in the mitochondrial targeting sequence (N-terminal to the sorting sequence) resulted in missorting to the matrix space. Furthermore, a chimeric protein consisting of the initial 85 residues of cytochrome b(2) fused to dihydrofolate reductase was partially targeted to the matrix at 15 degrees C, but not at 25 degrees C. Together, the results presented here indicate that cytochrome b(2) passes through the matrix on its sorting pathway to the intermembrane space.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY; UNIV PARIS 06,CTR MOLEC GENET,CNRS,F-91190 GIF SUR YVETTE,FRANCE	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay								ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; DAUM G, 1982, J BIOL CHEM, V257, P3028; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; JENSEN RE, 1992, MOL CELL BIOL, V12, P4677, DOI 10.1128/MCB.12.10.4677; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHLKE K, 1990, EUR J BIOCHEM, V192, P551, DOI 10.1111/j.1432-1033.1990.tb19260.x; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; OHASHI A, 1982, J BIOL CHEM, V257, P3042; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; ROJO EE, 1995, IN PRESS EMBO J; ROMISCH J, 1987, EUR J BIOCHEM, V164, P111, DOI 10.1111/j.1432-1033.1987.tb11000.x; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x	30	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16932	16938		10.1074/jbc.270.28.16932	http://dx.doi.org/10.1074/jbc.270.28.16932			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622511	hybrid			2022-12-25	WOS:A1995RJ34700072
J	YE, JJ; SAIER, MH				YE, JJ; SAIER, MH			PURIFICATION AND CHARACTERIZATION OF A SMALL MEMBRANE-ASSOCIATED SUGAR-PHOSPHATE PHOSPHATASE THAT IS ALLOSTERICALLY ACTIVATED BY HPR(SER(P)) OF THE PHOSPHOTRANSFERASE SYSTEM IN LACTOCOCCUS-LACTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOCARRIER PROTEIN HPR; BACILLUS-SUBTILIS; STREPTOCOCCUS-PYOGENES; ESCHERICHIA-COLI; ENZYME-II; PHOSPHOENOLPYRUVATE; PHOSPHORYLATION; EXPULSION; ATP; TRANSPORT	In the Gram-positive bacterium, Lactococcus lactis, nonmetabolizable cytoplasmic sugar phosphates, accumulated by the phosphoenolpyluvate:sugar phosphotransferase system, are rapidly dephosphorylated and expelled from the cell upon addition of glucose (inducer expulsion). Our recent studies have established that a metabolite-activated, ATP-dependent protein kinase that phosphorylates serine-46 in HPr of the phosphoenolpyruvate:sugar phosphotransferase system activates a sugar phosphate phosphatase, thus initiating the inducer expulsion process. A membrane associated, HPr(Ser(P))-dependent phosphatase has been identified, solubilized from the membrane, separated from other cellular phosphatases, and purified to near homogeneity. It exhibits a low subunit molecular mass (10 kDa) and behaves on gel filtration columns like a monomeric enzyme. It has broad substrate specificity, optimal activity between pH 7.0 and 8.0, is dependent on a divalent cation for activity, and is not inhibited by fluoride. It is stimulated more than 10-fold by HPr(Ser(P)) or a mutant derivative of HPr, S46D HPr, in which the regulatory serine is changed to aspartate, which bears a permanently negative charge as does phosphate. Stimulation is due both to an increase in the maximal velocity (V-max) and a decrease in the Michaelis-Menten kinetic constant (K-m) for sugar phosphate. The enzyme exhibits a K-a for S46D HPr of 15 mu M. Although the enzyme is thermally stable, activation by HPr(Ser(P)) is heat sensitive.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NIAID NIH HHS [5RO1AI21702, 2RO1AI14176] Funding Source: Medline; NIGMS NIH HHS [1F33GM16907] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702, R01AI014176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016907] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELOGRUDOV GI, 1995, J BIOL CHEM, V270, P2053, DOI 10.1074/jbc.270.5.2053; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P32, DOI 10.1021/bi00052a006; DEUTSCHER J, 1994, J BACTERIOL, V176, P3336, DOI 10.1128/jb.176.11.3336-3344.1994; DEUTSCHER J, 1986, BIOCHEMISTRY-US, V25, P6543, DOI 10.1021/bi00369a031; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; DEUTSCHER J, 1995, MOL MICROBIOL, V15, P1049, DOI 10.1111/j.1365-2958.1995.tb02280.x; DIEZEL W, 1972, ANAL BIOCHEM, V48, P617, DOI 10.1016/0003-2697(72)90117-0; HAGUENAUER R, 1971, BIOCHIMIE, V53, P99, DOI 10.1016/S0300-9084(71)80087-1; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HUECK CJ, 1994, RES MICROBIOL, V145, P503, DOI 10.1016/0923-2508(94)90028-0; KUNDIG W, 1971, J BIOL CHEM, V246, P1407; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL WJ, 1993, J BACTERIOL, V175, P2758, DOI 10.1128/JB.175.9.2758-2761.1993; PARVIN R, 1969, ANAL BIOCHEM, V27, P65, DOI 10.1016/0003-2697(69)90219-X; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1980, P NATL ACAD SCI-BIOL, V77, P5497, DOI 10.1073/pnas.77.9.5497; REIZER J, 1983, J BACTERIOL, V156, P354, DOI 10.1128/JB.156.1.354-361.1983; REIZER J, 1983, J BACTERIOL, V156, P236, DOI 10.1128/JB.156.1.236-242.1983; SAIER MH, 1977, J BIOL CHEM, V252, P8899; SAIER MH, 1985, MECHANISMS REGULATIO; SUTRINA SL, 1988, J BACTERIOL, V170, P1874, DOI 10.1128/jb.170.4.1874-1877.1988; THOMPSON J, 1981, J BACTERIOL, V146, P885, DOI 10.1128/JB.146.3.885-894.1981; THOMPSON J, 1983, J BACTERIOL, V156, P70, DOI 10.1128/JB.156.1.70-80.1983; WINKLER HH, 1971, J BACTERIOL, V106, P362, DOI 10.1128/JB.106.2.362-368.1971; WITTEKIND M, 1990, BIOCHEMISTRY-US, V29, P7191, DOI 10.1021/bi00483a006; WITTEKIND M, 1992, PROTEIN SCI, V1, P1363, DOI 10.1002/pro.5560011016; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; YE JJ, 1994, P NATL ACAD SCI USA, V91, P3102, DOI 10.1073/pnas.91.8.3102; YE JJ, 1995, P NATL ACAD SCI USA, V92, P417, DOI 10.1073/pnas.92.2.417; YE JJ, 1995, J BACTERIOL, V177, P1900, DOI 10.1128/jb.177.7.1900-1902.1995; YE JJ, 1994, J BIOL CHEM, V269, P11837; YE JJ, 1994, J BACTERIOL, V176, P3484, DOI 10.1128/JB.176.12.3484-3492.1994; YE JJ, 1994, MICROBIOL-UK, V140, P3421, DOI 10.1099/13500872-140-12-3421	34	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16740	16744		10.1074/jbc.270.28.16740	http://dx.doi.org/10.1074/jbc.270.28.16740			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622485	hybrid			2022-12-25	WOS:A1995RJ34700045
J	JUNEMANN, S; WRIGGLESWORTH, JM				JUNEMANN, S; WRIGGLESWORTH, JM			CYTOCHROME BD OXIDASE FROM AZOTOBACTER-VINELANDII - PURIFICATION AND QUANTITATION OF LIGAND-BINDING TO THE OXYGEN REDUCTION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D TERMINAL OXIDASE; ELECTRON-PARAMAGNETIC-RESONANCE; AEROBIC RESPIRATORY-CHAIN; ESCHERICHIA-COLI; D COMPLEX; NITRIC-OXIDE; C OXIDASE; RAMAN-SPECTROSCOPY; UBIQUINOL OXIDASE; CYANIDE	Cytochrome bd has been purified from Azotobacter vinelandii by a new simplified procedure. The heme and total iron content has been measured, as has the number of high affinity CO and NO binding sites. Spectral changes indicate high affinity binding of CO and NO to heme d only, with a stoichiometry of 1 molecule of gas per 2 molecules of heme b or per 3 atoms of iron. The results clearly define a stoichiometry of one heme d per complex. Low affinity binding of CO and NO to heme b595 also occurs at higher ligand concentrations. EPR heme-nitrosyl signals are seen with NO bound to both hemes b595 and d but with no indication of spin exchange coupling. Exposure of the air-oxidized complex to alkaline pH results in removal of molecular oxygen from heme d and a change in line shape of the high spin region of the EPR spectrum. Cyanide binds to both heme d and heme b595 in the air-oxidized complex, displacing molecular oxygen from heme d. The rate of cyanide binding to heme d as assessed by spectral changes at 650 nm does not correlate with the rate of binding to heme b595 as assessed by the loss of the high spin EPR signal. In addition, the cyanide binding rate in the presence of reductant is only 3 times that of the rate of binding to the air-oxidases where strong redox cooperativity makes these two rates differ by a factor of at least 10(6). The results do not support the idea of the presence of two strongly interacting hemes in a binuclear center.	UNIV LONDON KINGS COLL, DIV LIFE SCI, CTR MET BIOL & MED, LONDON W8 7AH, ENGLAND	University of London; King's College London								BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BONNER FT, 1991, BIOCHIM BIOPHYS ACTA, V1056, P133, DOI 10.1016/S0005-2728(05)80279-8; BRUDVIG GW, 1980, BIOCHEMISTRY-US, V19, P5275, DOI 10.1021/bi00564a020; DMELLO R, 1994, FEMS MICROBIOL LETT, V121, P115, DOI 10.1111/j.1574-6968.1994.tb07084.x; DMELLO R, 1994, MICROBIOL-UK, V140, P1395, DOI 10.1099/00221287-140-6-1395; EDWARDS C, 1981, FEBS LETT, V128, P205, DOI 10.1016/0014-5793(81)80081-6; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; GREEN GN, 1986, BIOCHEMISTRY-US, V25, P2309, DOI 10.1021/bi00357a002; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; HILL JJ, 1993, P NATL ACAD SCI USA, V90, P5863, DOI 10.1073/pnas.90.12.5863; INGLEDEW WJ, 1992, BIOCHEM J, V282, P255, DOI 10.1042/bj2820255; JONES MG, 1984, BIOCHEM J, V220, P57, DOI 10.1042/bj2200057; JUNEMANN S, 1994, FEBS LETT, V345, P198, DOI 10.1016/0014-5793(94)00372-6; Junemann Susanne, 1993, Biochemical Society Transactions, V21, p345S; KAHLOW MA, 1991, BIOCHEMISTRY-US, V30, P11485, DOI 10.1021/bi00113a001; KAHLOW MA, 1993, J AM CHEM SOC, V115, P5845, DOI 10.1021/ja00066a071; KAUFFMAN HF, 1974, BIOCHIM BIOPHYS ACTA, V333, P218, DOI 10.1016/0005-2728(74)90006-1; KAUFFMAN HF, 1975, J BIOENERG, V7, P215, DOI 10.1007/BF01558549; KELLY MJS, 1990, J BACTERIOL, V172, P6010, DOI 10.1128/jb.172.10.6010-6019.1990; KITA K, 1984, J BIOL CHEM, V259, P3375; KOLAND JG, 1984, BIOCHEMISTRY-US, V23, P1051, DOI 10.1021/bi00301a003; KOLONAY JF, 1994, J BACTERIOL, V176, P4177, DOI 10.1128/JB.176.13.4177-4181.1994; KONISHI K, 1986, J BIOCHEM, V99, P1227, DOI 10.1093/oxfordjournals.jbchem.a135586; KRANZ RG, 1985, J BACTERIOL, V161, P709, DOI 10.1128/JB.161.2.709-713.1985; KRASNOSELSKAYA I, 1993, FEBS LETT, V327, P279, DOI 10.1016/0014-5793(93)81004-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORENCE RM, 1986, BIOCHEMISTRY-US, V25, P2314, DOI 10.1021/bi00357a003; LORENCE RM, 1989, J BIOL CHEM, V264, P7135; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEINHARDT SW, 1989, BIOCHIM BIOPHYS ACTA, V975, P175, DOI 10.1016/S0005-2728(89)80216-6; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; MITCHELL P, 1987, FEBS LETT, V222, P235, DOI 10.1016/0014-5793(87)80378-2; MOSHIRI F, 1991, J BACTERIOL, V173, P6230, DOI 10.1128/jb.173.19.6230-6241.1991; NEESE F, 1993, THESIS U KONSTANZ GE; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; POOLE RK, 1988, FEBS LETT, V231, P243, DOI 10.1016/0014-5793(88)80740-3; POOLE RK, 1982, FEBS LETT, V141, P237, DOI 10.1016/0014-5793(82)80056-2; PUDEK MR, 1974, ARCH BIOCHEM BIOPHYS, V164, P682, DOI 10.1016/0003-9861(74)90081-2; ROTHERY RA, 1989, BIOCHEM J, V261, P437, DOI 10.1042/bj2610437; SMITH A, 1990, J GEN MICROBIOL, V136, P171, DOI 10.1099/00221287-136-1-171; WIKSTROM M, 1994, BBA-BIOENERGETICS, V1187, P106, DOI 10.1016/0005-2728(94)90093-0; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; YONETANI T, 1972, J BIOL CHEM, V247, P2447	44	62	63	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16213	16220		10.1074/jbc.270.27.16213	http://dx.doi.org/10.1074/jbc.270.27.16213			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608187	hybrid			2022-12-25	WOS:A1995RH22600051
J	TAKUMI, T; ISHII, T; HORIO, Y; MORISHIGE, K; TAKAHASHI, N; YAMADA, M; YAMASHITA, T; KIYAMA, H; SOHMIYA, K; NAKANISHI, S; KURACHI, Y				TAKUMI, T; ISHII, T; HORIO, Y; MORISHIGE, K; TAKAHASHI, N; YAMADA, M; YAMASHITA, T; KIYAMA, H; SOHMIYA, K; NAKANISHI, S; KURACHI, Y			A NOVEL ATP-DEPENDENT INWARD RECTIFIER POTASSIUM CHANNEL EXPRESSED PREDOMINANTLY IN GLIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG HEART; ION CHANNELS; FUNCTIONAL EXPRESSION; SEQUENCES; RECEPTOR; PROTEIN; OLIGODENDROCYTES; SUBUNITS; MEMBRANE; CURRENTS	We have isolated a novel inward rectifier K+ channel predominantly expressed in glial cells of the central nervous system. Its amino acid sequence exhibited 53% identity with ROMK1 and approximately 40% identity with other inward rectifier K+ channels. Xenopus oocytes injected with cRNA derived from this clone expressed a K+ current, which showed classical inward rectifier K+ channel characteristics. Intracenular Mg . ATP was required to sustain channel activity in excised membrane patches, which is consistent with a Walker type-ii ATP-binding domain on this clone. We designate this new clone as K-AB-2 (the second type of inward rectifying K+ channel with an ATP-binding domain). In situ hybridization showed K-AB-2 mRNA to be expressed predominantly in glial cells of the cerebellum and forebrain. This is the first description of the cloning of a glial cell inward rectifier potassium channel, which may be responsible for K+ buffering action of glial cells in the brain.	OSAKA UNIV, FAC MED, BIOMED RES CTR, DEPT PHARMACOL 2, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, FAC MED, BIOMED RES CTR, DEPT OBSTET & GYNECOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, FAC MED, BIOMED RES CTR, DEPT NEUROANAT, SUITA, OSAKA 565, JAPAN; KYOTO UNIV, FAC MED, INST IMMUNOL, KYOTO 60601, JAPAN	Osaka University; Osaka University; Osaka University; Kyoto University			Kiyama, Hiroshi/M-8867-2014	Kiyama, Hiroshi/0000-0001-5963-046X; Horio, Yoshiyuki/0000-0002-5021-5929				ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; Barres B A, 1991, Curr Opin Neurobiol, V1, P354, DOI 10.1016/0959-4388(91)90052-9; BARRES BA, 1990, ANNU REV NEUROSCI, V13, P441, DOI 10.1146/annurev.neuro.13.1.441; BARRES BA, 1988, GLIA, V1, P10, DOI 10.1002/glia.440010104; BREW H, 1986, NATURE, V324, P466, DOI 10.1038/324466a0; BRISMAR T, 1989, BRAIN RES, V480, P249, DOI 10.1016/0006-8993(89)90190-X; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P11235; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; ISHII T, 1993, J BIOL CHEM, V268, P2836; KARSCHIN C, 1994, FEBS LETT, V348, P139, DOI 10.1016/0014-5793(94)00590-7; KENNA S, 1994, MOL BRAIN RES, V24, P353, DOI 10.1016/0169-328X(94)90150-3; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MCLARNON JG, 1989, GLIA, V2, P298, DOI 10.1002/glia.440020503; MORISHIGE K, 1993, FEBS LETT, V336, P375, DOI 10.1016/0014-5793(93)80840-Q; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NEWMAN EA, 1993, J NEUROSCI, V13, P3333; NEWMAN EA, 1984, SCIENCE, V225, P1174, DOI 10.1126/science.6474173; NILIUS B, 1988, PFLUG ARCH EUR J PHY, V411, P654, DOI 10.1007/BF00580862; ORKAND RK, 1966, J NEUROPHYSIOL, V29, P788, DOI 10.1152/jn.1966.29.4.788; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P659, DOI 10.1113/jphysiol.1984.sp015089; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SONTHEIMER H, 1994, GLIA, V11, P156, DOI 10.1002/glia.440110210; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; SUZUKI M, 1994, NATURE, V367, P642, DOI 10.1038/367642a0; TAKAHASHI N, 1994, J BIOL CHEM, V269, P23274; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIHLE BA, 1994, NATURE, V371, P246; YOSHIMURA R, 1993, ENDOCRINOLOGY, V133, P1239, DOI 10.1210/en.133.3.1239	42	214	223	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16339	16346		10.1074/jbc.270.27.16339	http://dx.doi.org/10.1074/jbc.270.27.16339			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608203	hybrid			2022-12-25	WOS:A1995RH22600070
J	FUJII, M; CHUHJO, T; MINAMINO, T; MASAAKI, N; MIYAMOTO, K; SEIKI, M				FUJII, M; CHUHJO, T; MINAMINO, T; MASAAKI, N; MIYAMOTO, K; SEIKI, M			IDENTIFICATION OF THE TAX INTERACTION REGION OF SERUM RESPONSE FACTOR THAT MEDIATES THE ABERRANT INDUCTION OF IMMEDIATE-EARLY GENES THROUGH CARG BOXES BY HTLV-I TAX	ONCOGENE			English	Article						HTLV-I; TAX; SRF; TRANSCRIPTION	T-CELL LEUKEMIA; VIRUS TYPE-I; C-FOS PROMOTER; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; AUTO-REGULATION; PROTEIN ELK-1; ELEMENT; EXPRESSION; TRANSACTIVATION	Tax of human T-cell leukemia virus type I (HTLV-I) activates transcription at a CArG box of various immediate early genes such as the proto-oncogene c-fos. To do this, Tax does not directly bind to the CArG box, but instead binds to the CArG binding factor SRF. In this study, we investigated the domain of SRF required for the activation by Tax and studied the role of this domain on transcriptional regulation at the CArG box. Using a fusion protein of SRF with a yeast transcription factor GAL4, the 14 amino acid (aa) portion (aa 422-435) of SRF was identified as the domain required for Tax activation [Tax-responsive region of SRF (TRRS)]. By means of a two hybrid system, we showed that TRRS was essential for the interaction of SRF with Tax in vivo. The over-expression of SRF with a deletion of TRRS inhibited the Tax activation at the CArG box. Thus, TRRS is the domain of SRF that is essential for Tax activation at the CArG box. Unlike to Tax activation, TRRS was not required for TPA (12-o-tetradecanoylphobol-13-acetate) induction at the CArG box, but a TRRS deletion enhanced the basal activity at the CArG box both under serum-starved and TPA-stimulated conditions. These results suggest that TRRS negatively regulates the transcriptional activation function of SRF, and consequently contributes to the low basal activity at the CArG box before TPA induction.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC ONCOL & VIROL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,DEPT INTERNAL MED 3,KANAZAWA,ISHIKAWA 920,JAPAN; HOKURIKU UNIV,SCH PHARM,DEV MED RES LAB,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University; Hokuriku University			Seiki, Motoharu/K-9443-2015					AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DECAPRIO JA, 1988, CELL, V15, P275; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1994, J VIROL, V68, P7275, DOI 10.1128/JVI.68.11.7275-7283.1994; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P2349; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; NAGATA K, 1989, J VIROL, V68, P3220; NERENBERG M, 1988, SCIENCE, V237, P1324; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OSAME M, 1986, LANCET, V1, P1031; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; SUGAMURA K, 1993, RETROVIRIDAE, V2, P399; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; TSUCHIYA H, 1994, ONCOGENE, V9, P337; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; WHITE P, 1988, NATURE, V334, P124; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	55	37	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					7	14						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624133				2022-12-25	WOS:A1995RJ29500002
J	GU, Y; SARNECKI, C; ALDAPE, RA; LIVINGSTON, DJ; SU, MSS				GU, Y; SARNECKI, C; ALDAPE, RA; LIVINGSTON, DJ; SU, MSS			CLEAVAGE OF POLY(ADP-RIBOSE) POLYMERASE BY INTERLEUKIN-1-BETA CONVERTING-ENZYME AND ITS HOMOLOGS TX AND NEDD-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEATH GENE CED-3; INHIBITION; APOPTOSIS; ENCODES	The proteolytic cleavage of poly(ADP-ribose) polymerase (PARP) is an early biochemical event, which occurs during apoptosis. A recent study suggested that PARP cleavage can be mediated by a novel cytosolic protease (prICE) that resembles interleukin-1 beta converting enzyme (ICE), but cannot be mediated by ICE itself (Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. (1994) Nature 371, 346-347). We have used a COS cell co-transfection assay to investigate if ICE or any known ICE-like protease is active in PARP cleavage within the cell. Here we report that coexpression of human PARP with human ICE, or the ICE homologs TX and Nedd-2, resulted in a cleavage of PARP identical to that observed in apoptotic cells. Experiments with purified recombinant human ICE indicated that PARE polypeptide can be specifically cleaved in vitro by ICE in a time- and enzyme concentration de pendent manner. PARP cleavage, however, requires a 50-100-fold higher ICE concentration than does processing of the interleukin-1 beta precursor at an equivalent substrate concentration. The abilities of ICE, TX, and Nedd-2, when expressed at high intracellular concentrations, to cleave PARP are consistent with their induction of apoptosis in transfected cells.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139	Vertex Pharmaceuticals								AYALA JM, 1994, J IMMUNOL, V153, P2592; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAUCHEU C, 1995, EMBO J, V9, P1914; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GU Y, 1995, EMBO J, V9, P1923; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	22	169	173	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18715	18718		10.1074/jbc.270.32.18715	http://dx.doi.org/10.1074/jbc.270.32.18715			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642516	hybrid			2022-12-25	WOS:A1995RN95400002
J	HAYWARD, CPM; HASSELL, JA; DENOMME, GA; RACHUBINSKI, RA; BROWN, C; KELTON, JG				HAYWARD, CPM; HASSELL, JA; DENOMME, GA; RACHUBINSKI, RA; BROWN, C; KELTON, JG			THE CDNA SEQUENCE OF HUMAN ENDOTHELIAL-CELL MULTIMERIN - A UNIQUE PROTEIN WITH RGDS, COILED-COIL, AND EPIDERMAL GROWTH FACTOR-LIKE DOMAINS AND A CARBOXYL-TERMINUS SIMILAR TO THE GLOBULAR DOMAIN OF COMPLEMENT C1Q AND COLLAGENS TYPE-VIII AND TYPE-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; MYOSIN HEAVY-CHAIN; BETA-HYDROXYASPARTIC ACID; HEMOPHILIC FACTOR-IX; COAGULATION FACTOR-X; SUBCOMPONENT C1Q; B-CHAIN; VONWILLEBRAND-FACTOR; TYROSINE SULFATION; MOLECULAR-CLONING	Multimerin is a massive, soluble protein found in platelets and in the endothelium of blood vessels. Multimerin is composed of varying sized, disulfide-linked multimers, the smallest of which is a homotrimer. Multimerin is a factor V/Va-binding protein and may function as a carrier protein for platelet factor V. The cDNA for human multimerin was isolated from lambda gt11 endothelial cell libraries using antibodies, and the isolated cDNA clones were used to obtain the full sequence. The full-length multimerin cDNA was 4.2 kilobase pairs. Northern analyses identified a 4.7-kilobase transcript in cultured endothelial cells, a megakaryocytic cell line, platelets, and highly vascular tissues. The multimerin cDNA can encode a protein of 1228 amino acids with the probable signal peptide cleavage site between amino acids 19 and 20. The protein is predicted to be hydrophilic and to contain 23 N-glycosylation sites. The adhesive motif RGDS (Arg-Gly-Asp-Ser) and an epidermal growth factor-like domain were identified. Sequence searches indicated that multimerin is a unique protein. Analyses identified probable coiled-coil structures in the central portion of the multimerin sequence. Additionally, the carboxyl-terminal region of multimerin resembles the globular, non-collagen-like, carboxyl-terminal domains of several other trimeric proteins, including complement Clq and collagens type VIII and X.	MCMASTER UNIV,DEPT MED,HAMILTON,ON L8N 3Z5,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA; MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,HAMILTON,ON L8N 3Z5,CANADA; CANADIAN RED CROSS BLOOD TRANSFUS SERV,HAMILTON CTR,HAMILTON,ON L8N 3Z5,CANADA	McMaster University; McMaster University; McMaster University	HAYWARD, CPM (corresponding author), MCMASTER UNIV,DEPT PATHOL,HSC 2N32,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.		Denomme, Gregory A./T-5397-2019	Denomme, Gregory A./0000-0001-8727-1679; Hayward, Catherine/0000-0002-2843-0817				APTE S, 1991, FEBS LETT, V282, P393, DOI 10.1016/0014-5793(91)80521-4; APTE SS, 1992, EUR J BIOCHEM, V206, P217, DOI 10.1111/j.1432-1033.1992.tb16919.x; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHOO KH, 1982, NATURE, V299, P178, DOI 10.1038/299178a0; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DAVIS C G, 1990, New Biologist, V2, P410; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEGHALI R, 1989, J CELL BIOL, V108, P1791, DOI 10.1083/jcb.108.5.1791; Fourney R.M., 1988, FOCUS, V10, P5; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; GALAS DJ, 1980, J MOL BIOL, V144, P19, DOI 10.1016/0022-2836(80)90213-2; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HAYWARD CPM, 1991, J BIOL CHEM, V266, P7114; HAYWARD CPM, 1995, PLATELETS, V6, P1, DOI 10.3109/09537109509013255; HAYWARD CPM, 1993, J CLIN INVEST, V91, P2630, DOI 10.1172/JCI116502; HAYWARD CPM, 1991, BLOOD, V77, P2556; HOURNET AM, 1993, EUR J CELL BIOL, V60, P31; HUNH TV, 1985, DNA CLONING PRACTICA, V1, P49; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; JAGADEESWARAN P, 1984, SOMAT CELL MOLEC GEN, V10, P465, DOI 10.1007/BF01534851; JAYE M, 1983, NUCLEIC ACIDS RES, V11, P2325, DOI 10.1093/nar/11.8.2325; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KNOBEL HR, 1975, EUR J IMMUNOL, V5, P78, DOI 10.1002/eji.1830050119; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MITCHELL PJ, 1992, ONCOGENE, V7, P2329; MURAGAKI Y, 1991, EUR J BIOCHEM, V197, P615, DOI 10.1111/j.1432-1033.1991.tb15951.x; PETRY F, 1991, J IMMUNOL, V147, P3988; PETRY F, 1992, EUR J BIOCHEM, V209, P129, DOI 10.1111/j.1432-1033.1992.tb17269.x; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; REID KBM, 1979, BIOCHEM J, V179, P367, DOI 10.1042/bj1790367; REID KBM, 1985, BIOCHEM J, V231, P729, DOI 10.1042/bj2310729; REID KBM, 1982, BIOCHEM J, V203, P559, DOI 10.1042/bj2030559; REID KBM, 1986, ESSAYS BIOCHEM, V22, P27; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SAEZ L, 1986, NUCLEIC ACIDS RES, V14, P2951, DOI 10.1093/nar/14.7.2951; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMBROOK J, 1989, MOL CLONING LABORATO, P2118; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; STENFLO J, 1988, J BIOL CHEM, V263, P21; THOMAS JT, 1991, BIOCHEM J, V280, P617, DOI 10.1042/bj2800617; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YE RD, 1987, J BIOL CHEM, V262, P3718; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	58	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18246	18251		10.1074/jbc.270.31.18246	http://dx.doi.org/10.1074/jbc.270.31.18246			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629143	hybrid			2022-12-25	WOS:A1995RM64200017
J	JACOB, R; BULLEID, NJ; NAIM, HY				JACOB, R; BULLEID, NJ; NAIM, HY			FOLDING OF HUMAN INTESTINAL LACTASE-PHLORHIZIN HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; MICROVILLAR PROTEINS; PHLORHIZIN HYDROLASE; EPITHELIAL-CELLS; DISULFIDE BONDS; BIOSYNTHESIS; MEMBRANE; GLYCOSYLATION; MATURATION	The folding of human intestinal prolactase-phlorizin hydrolase (pro-LPH) has been analyzed in a cell-free transcription/translation system. In the presence of the thiol oxidant GSSG, disulfide bond formation in pro-LPH can be promoted concomitant with the binding of the molecule to a conformation-specific monoclonal anti-LPH antibody. Under these conditions, pro-LPH does not bind to the molecular chaperone BiP. In the absence of GSSG, on the other hand, pro-LPH does not bind to the monoclonal anti-LPH antibody, but can be immunoprecipitated with a polyclonal antibody that is directed against a denatured form of the enzyme. In this case, interaction of pro-LPH with immunoglobulin heavy chain binding protein can be discerned. The results demonstrate the existence of intramolecular disulfide bonds that are essential for the promotion of pro-LPH to a native conformation. Furthermore, BiP is involved in the folding events of pro-LPH.	UNIV DUSSELDORF,INST MICROBIOL,PROT SECRET GRP,D-40225 DUSSELDORF,GERMANY; UNIV MANCHESTER,DEPT BIOCHEM & MOLEC BIOL,DIV BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND	Heinrich Heine University Dusseldorf; University of Manchester				Bulleid, Neil/0000-0002-9839-5279				BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; BULLEID NJ, 1988, BIOCHEM J, V254, P805, DOI 10.1042/bj2540805; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; DANIELSEN EM, 1990, BIOCHEMISTRY-US, V29, P305, DOI 10.1021/bi00453a042; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MONTGOMERY RK, 1991, FASEB J, V13, P2824; MOSTOV K, 1992, J CELL BIOL, V114, P577; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1994, J BIOL CHEM, V269, P26933; NAIM HY, 1992, BIOCHEM J, V285, P13, DOI 10.1042/bj2850013; OBERHOLZER T, 1993, FEBS LETT, V333, P127, DOI 10.1016/0014-5793(93)80389-C; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	35	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18678	18684		10.1074/jbc.270.31.18678	http://dx.doi.org/10.1074/jbc.270.31.18678			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629200	hybrid			2022-12-25	WOS:A1995RM64200082
J	KAISE, M; MURAOKA, A; YAMADA, J; YAMADA, T				KAISE, M; MURAOKA, A; YAMADA, J; YAMADA, T			EPIDERMAL GROWTH-FACTOR INDUCES H+,K+-ATPASE ALPHA-SUBUNIT GENE-EXPRESSION THROUGH AN ELEMENT HOMOLOGOUS TO THE 3' HALF-SITE OF THE C-FOS SERUM RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED PARIETAL-CELLS; RAPID INDUCTION; RAT FIBROBLASTS; ACID-SECRETION; STIMULATION; PROTEIN; TRANSCRIPTION; INHIBITION; BINDING; ONCOGENE	Epidermal growth factor (EGF) acutely inhibits acid secretion; however, prolonged administration of EGF has been reported to increase acid production. We undertook these studies to examine whether the physiological effects of EGF on acid secretion are mediated by regulation of gastric H+,K+-ATPase, the principle enzyme responsible for acid secretion. EGF in concentrations equivalent to those in plasma increased H+,K+-ATPase alpha-subunit mRNA levels. Using H+,K+-ATPase-luciferase constructs transfected into primary cultured parietal cells, a significant step up in EGF inducibility was observed between bases -162 and -156 (5'-GA-CATGG-3') relative to the cap site, This EGF response element (ERE) conferred EGF inducibility when linked to homologous and heterologous promoters, The ERE is homologous to the 3' half site of the c-fos serum response element to which rNFIL-6, rE12, and SRE-ZBP bind. Electrophoretic mobility shift assays using an ERE probe and parietal cell nuclear extracts revealed a specific DNA-protein complex, the formation of which was changed by neither E12 and NFIL-6 consensus oligonucleotides nor antibodies for NFIL-6, SRE-ZBP, and E12, Our studies indicate that EGF induces gastric H+,K+-ATPase alpha-subunit gene expression via an interaction between a specific ERE and a novel transcriptional factor and that this may be a physiologic mechanism by which EGF regulates acid secretion.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIDDK NIH HHS [R01-DK34306, P30-DK34933, R30-DK33500] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R01DK034306, R01DK033500, R37DK033500] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BOULDEN AM, 1992, MOL CELL BIOL, V12, P4769, DOI 10.1128/MCB.12.10.4769; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CAMPBELL VW, 1989, J BIOL CHEM, V264, P11381; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, V1, P69; CARPENTER G, 1978, ANN REV BIOCH, V48, P193; CHATTERJEE AK, 1986, HORM METAB RES, V18, P873, DOI 10.1055/s-2007-1012461; CHEW CS, 1994, AM J PHYSIOL-GASTR L, V267, pG818, DOI 10.1152/ajpgi.1994.267.5.G818; DEMBINSKI A, 1986, J PHYSIOL-LONDON, V387, P347; DEMBINSKI AB, 1985, ENDOCRINOLOGY, V116, P90, DOI 10.1210/endo-116-1-90; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; HATT JF, 1988, BIOCHEM J, V255, P789, DOI 10.1042/bj2550789; KAISE M, 1995, J BIOL CHEM, V270, P11155, DOI 10.1074/jbc.270.19.11155; KONTUREK SJ, 1989, SCAND J GASTROENTERO, V48, P193; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LOGSDON CD, 1983, GASTROENTEROLOGY, V85, P339; LUND PK, 1985, J BIOL CHEM, V260, P7609; MARTI U, 1989, HEPATOLOGY, V9, P126, DOI 10.1002/hep.1840090122; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; METZ R, 1991, ONCOGENE, V6, P2165; MURAOKA A, 1994, GASTROENTEROLOGY, V106, pA145; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; OPLETAMADSEN K, 1991, AM J PHYSIOL, V260, pG807, DOI 10.1152/ajpgi.1991.260.6.G807; PODOLSKY DK, 1994, PHYSL GASTROINTESTIN, V1, P129; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SACHS G, 1987, PHYSL GASTROINTESTIN, V1, P865; SCHONBRUNN A, 1980, J CELL BIOL, V85, P786, DOI 10.1083/jcb.85.3.786; SHAW GP, 1987, BIOCHEM J, V244, P699, DOI 10.1042/bj2440699; SOLL AH, 1980, AM J PHYSIOL, V238, pG366, DOI 10.1152/ajpgi.1980.238.4.G366; SOLL AH, 1978, J CLIN INVEST, V61, P370, DOI 10.1172/JCI108947; SONG I, 1993, BIOCHEM BIOPH RES CO, V196, P1240, DOI 10.1006/bbrc.1993.2385; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WANG L, 1993, J PHARMACOL EXP THER, V265, P308	37	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18637	18642		10.1074/jbc.270.31.18637	http://dx.doi.org/10.1074/jbc.270.31.18637			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629193	hybrid			2022-12-25	WOS:A1995RM64200075
J	VASTRIK, I; MAKELA, TP; KOSKINEN, PJ; ALITALO, K				VASTRIK, I; MAKELA, TP; KOSKINEN, PJ; ALITALO, K			DETERMINATION OF SEQUENCES RESPONSIBLE FOR THE DIFFERENTIAL REGULATION OF MYC FUNCTION BY DELTA-MAX AND MAX	ONCOGENE			English	Article						MYC; MAX; DELTA-MAX; TRANSFORMATION; TRANSACTIVATION	MAMMALIAN EXPRESSION VECTOR; C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; PROTEIN; FORMS; COTRANSFORMATION; DIMERIZATION; DOMAINS; COMPLEX	The DNA-binding, transcriptional activation and transforming activities of the Myc protein require dimerization with Max. Max can form also homodimers which are able to bind the same DNA sequence as Myc/Max heterodimers and suppress Myc-induced transcription and transformation. We have recently identified naturally occurring truncated form of Max, Delta Max, which in a rat embryo fibroblast enhances transformation by Myc and Ras, Like Max, this Delta Max protein contains a b-HLH-Zip domain, except that the end of the leucine zipper is replaced by five Delta Max-specific amino acid residues. Delta Max also lacks the C-terminal sequences of Max including a nuclear localisation signal. Here we have dissected the regions responsible for the specific effects of Max and Delta Max in Ras-Myc cotransformation of rat embryo fibroblasts, Our results indicate that the suppressive activity of Max requires C-terminal acidic and basic regions and an intact leucine zipper. Replacement of the end of the leucine zipper with the Delta Max-specific sequence is responsible for the enhancement of transformation by Delta Max. Surprisingly, Delta Max does not require the DNA-binding basic region for enhancement of transformation and has no effect on Myc-induced transcription activation from Myc/Max-binding site-containing promoter construct.	UNIV HELSINKI,HAARTMAN INST,MOLEC CANC BIOL LAB,SF-00014 HELSINKI,FINLAND	University of Helsinki			makela, tomi/B-3734-2009; Vastrik, Imre/C-2690-2009; Alitalo, Kari K/J-5013-2014; Koskinen, Päivi J/G-8939-2014	makela, tomi/0000-0002-4869-8044; Alitalo, Kari K/0000-0002-7331-0902; Vastrik, Imre/0000-0001-6658-9311				ALITALO K, 1992, GENE AMPLIFICATION M, P371; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P1; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KATAGIRI F, 1992, MOL CELL BIOL, V12, P809; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; KOSKINEN PJ, 1993, SEMIN CANCER BIOL, V4, P3; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MCCLUTCHAN JH, 1968, J NATL CANCER I, V41, P351; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; Sambrook J, 1989, MOL CLONING LABORATO; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P2829, DOI 10.1093/nar/18.9.2829; VASTRIK I, 1993, ONCOGENE, V8, P503; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WECHSLER DS, 1994, MOL CELL BIOL, V14, P4097, DOI 10.1128/MCB.14.6.4097; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	32	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					553	560						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630640				2022-12-25	WOS:A1995RN53000016
J	XIAO, S; LI, DZ; VIJG, J; SUGARBAKER, DJ; CORSON, JM; FLETCHER, JA				XIAO, S; LI, DZ; VIJG, J; SUGARBAKER, DJ; CORSON, JM; FLETCHER, JA			CODELETION OF P15 AND P16 IN PRIMARY MALIGNANT MESOTHELIOMA	ONCOGENE			English	Article						MESOTHELIOMA; IN SITU HYBRIDIZATION; CYCLINS; CYCLIN-DEPENDENT KINASES	DELETIONS; 9P	The p15 and p16 CDK4 inhibitor genes map within the chromosome band 9p21 region deleted frequently in malignant mesothelioma and other cancers, p16 has been implicated recently as a potential target of 9p21 deletions in mesothelioma, but the role of this gene is uncertain because deletions have been detected more often in established cell lines than in primary tumor specimens. We determined p15 and p16 copy number by fluorescence in situ hybridization with a P1 contig in 50 primary mesotheliomas. Codeletion of p15 and p16 was found in 72% of mesotheliomas, including all cases with spindle-cell components (n = 21) and total deletion of p15 and p16 was found in several mesotheliomas that lacked cytogenetic deletion of the chromosome 9 short arm. Point mutations were not found, however, in exon 2 of retained p15 and p16 alleles from seven mesotheliomas. These findings demonstrate that p15, p16 and/or a closely neighboring gene, are the targets of frequent chromosome 9p deletion in primary malignant mesothelioma.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DIV GERONTOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NCI NIH HHS [1K11CA01498-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CARINS P, 1994, SCIENCE, V265, P415; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; CHENG JQ, 1994, CANCER RES, V54, P5547; CHENG JQ, 1993, CANCER RES, V53, P4761; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; FUSCO V, 1993, ANTICANCER RES, V13, P683; GRANADOS R, 1994, ACTA CYTOL, V38, P711; HAGEMEIJER A, 1990, CANCER GENET CYTOGEN, V47, P1, DOI 10.1016/0165-4608(90)90258-C; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MEAD LJ, 1994, CANCER RES, V54, P2307; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OELS HC, 1971, CHEST, V60, P564, DOI 10.1378/chest.60.6.564; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; POPESCU NC, 1988, CANCER RES, V48, P142; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAGUCHI T, 1993, CANCER RES, V53, P4349; WALKER DG, 1995, CANCER RES, V55, P20; WASHIMI O, 1995, CANCER RES, V55, P514; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737	27	146	148	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					511	515						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630635				2022-12-25	WOS:A1995RN53000011
J	FUKUHARA, T; MORIYAMA, H; NITTA, T				FUKUHARA, T; MORIYAMA, H; NITTA, T			THE UNUSUAL STRUCTURE OF A NOVEL RNA REPLICON IN RICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; NUCLEOTIDE-SEQUENCE; PHASEOLUS-VULGARIS; VIRUS	A linear, plasmid-like, double-stranded RNA (dsRNA) was isolated from rice, and its entire sequence of 13,952 nucleotides (nt) was determined. The dsRNA encodes a single, unusually long, open reading frame (13,716 nt, 4,572 amino acid residues), which includes an RNA he licase-like domain and an RNA-dependent RNA po lymerase-like domain. A series of Northern hybridization and primer extension experiments revealed that the coding (sense) strand of the dsRNA contains a discontinuity (nick) at a position 1,211 nt (or 1, 256 nt) from the 5' end. This discontinuity divides not only the coding strand of dsRNA molecule into a 1,211-nt fragment and a 12,741-nt fragment (or a 1, 256-nt fragment and a 12, 696-nt fragment) but also divides the long open reading frame into a 5' part of 1,045 nt (348 amino acid residues) and a 3' part of 12,671 nt (4,224 amino acid residues) or a 5' part of 1,090 nt (363 amino acid residues) and a 3' part of 12,626 nt (4,209 amino acid residues). It seems likely that almost all dsRNA molecules in rice plants contain such a discontinuity. This rice dsRNA appears to be a novel and unique RNA replicon.			FUKUHARA, T (corresponding author), TOKYO UNIV AGR & TECHNOL, FAC AGR, MOLEC CELL BIOL LAB, FUCHU, TOKYO 183, JAPAN.		Moriyama, Hiromitsu/F-9256-2013; Fukuhara, T./C-3208-2013					ALLISON R, 1986, VIROLOGY, V154, P9, DOI 10.1016/0042-6822(86)90425-3; BOCCARDO G, 1987, ADV VIRUS RES, V32, P171, DOI 10.1016/S0065-3527(08)60477-7; BROWN GG, 1989, INT REV CYTOL, V117, P1; DODDS JA, 1984, ANNU REV PHYTOPATHOL, V22, P151, DOI 10.1146/annurev.py.22.090184.001055; FUKUHARA T, 1993, PLANT MOL BIOL, V21, P1121, DOI 10.1007/BF00023608; GHABRIAL SA, 1994, ADV VIRUS RES, V43, P303, DOI 10.1016/S0065-3527(08)60052-4; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HILLMAN BI, 1994, 6TH REP INT COMM TAX; ISHIHARA J, 1992, PLANTA, V187, P475, DOI 10.1007/BF00199965; Joklik W.K., 1983, REOVIRIDAE; MACKENZIE SA, 1988, THEOR APPL GENET, V76, P59, DOI 10.1007/BF00288832; MINDICH L, 1988, ADV VIRUS RES, V35, P137; MORIYAMA H, 1995, IN PRESS MOL GEN GEN, V248; Nuss D L, 1990, Adv Virus Res, V38, P249, DOI 10.1016/S0065-3527(08)60864-7; PFEIFFER P, 1993, J GEN VIROL, V74, P1167, DOI 10.1099/0022-1317-74-6-1167; SHAPIRA R, 1991, EMBO J, V10, P731, DOI 10.1002/j.1460-2075.1991.tb08004.x; VALVERDE RA, 1990, PLANT SCI, V67, P195, DOI 10.1016/0168-9452(90)90243-H; WAKARCHUK DA, 1990, PLANT MOL BIOL, V14, P637, DOI 10.1007/BF00027512; WAKARCHUK DA, 1985, PLANT MOL BIOL, V5, P55, DOI 10.1007/BF00017873; WANG AL, 1991, ANNU REV MICROBIOL, V45, P251, DOI 10.1146/annurev.mi.45.100191.001343; ZABALGOGEAZCOA IA, 1992, PLANT SCI, V83, P187, DOI 10.1016/0168-9452(92)90078-Z; [No title captured]	22	19	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18147	18149		10.1074/jbc.270.30.18147	http://dx.doi.org/10.1074/jbc.270.30.18147			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629126				2022-12-25	WOS:A1995RM26600078
J	IWASAKI, T; WAKAGI, T; OSHIMA, T				IWASAKI, T; WAKAGI, T; OSHIMA, T			FERREDOXIN-DEPENDENT REDOX SYSTEM OF A THERMOACIDOPHILIC ARCHAEON, SULFOLOBUS SP STRAIN-7 - PURIFICATION AND CHARACTERIZATION OF A NOVEL REDUCED FERREDOXIN-REOXIDIZING IRON-SULFUR FLAVOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROCOCCUS-FURIOSUS; HYPERTHERMOPHILIC ARCHAEON; ELECTRON-TRANSPORT; 2-OXOACID-FERREDOXIN OXIDOREDUCTASES; HALOBACTERIUM-HALOBIUM; PYRUVATE; PROTEINS; ARCHAEBACTERIUM; ACIDOCALDARIUS; REDUCTASE	To elucidate the ferredoxin-dependent redox system of the thermoacidophilic, aerobic archaeon Sulfolobus sp. strain 7, a novel FeS flavoprotein, which can reoxidize the reduced 7Fe ferredoxin in vitro, has been purified and characterized (designated as IFP) using the cognate 7Fe ferredoxin and 2-oxoacid:ferredoxin oxidoreductase, a key enzyme of the archaeal tricarboxylic acid cycle. IFP consists of three non-identical subunits with apparent molecular masses of 87, 32, and 22 kDa, respectively, and contains at least two FMN (E(m),6.8 = -57 mV) and two plant-ferredoxin-type [2Fe-2S](2+,1+) clusters (E(m),6.8 -260 mV)/alpha(2) beta(2) gamma(2) structure. Both FeS and flavin centers of IFP are slowly but fully reduced by the enzymatically reduced cognate ferredoxin under anaerobic conditions at 50 degrees C, but not by NAD(P)H. Thus, the ferredoxin-dependent redox system of Sulfolobus sp. strain 7 is tentatively proposed as follows: 2-oxoacid:ferredoxin oxidoreductase (thiamine pyrophosphate and [4Fe-4S] cluster) --> ferredoxin --> IFP ([2Fe-2S] cluster --> FMN).			IWASAKI, T (corresponding author), TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN.		Wakagi, Takayoshi/AAJ-4145-2021	Iwasaki, Toshio/0000-0001-9562-4649				ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; BATIE CJ, 1987, J BIOL CHEM, V262, P1510; BLAMEY JM, 1993, BIOCHIM BIOPHYS ACTA, V1161, P19, DOI 10.1016/0167-4838(93)90190-3; BLAMEY JM, 1994, BIOCHEMISTRY-US, V33, P1000, DOI 10.1021/bi00170a019; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; DANSON MJ, 1989, CAN J MICROBIOL, V35, P58, DOI 10.1139/m89-009; Dutton P L, 1978, Methods Enzymol, V54, P411; FAEDER EJ, 1973, ANAL BIOCHEM, V64, P136; FUJII T, 1991, J BIOCHEM, V110, P472, DOI 10.1093/oxfordjournals.jbchem.a123605; GEHRING U, 1972, J BIOL CHEM, V247, P6963; HILLE R, 1992, CHEM BIOCH FLAVOENZY, V3, P21; HUNT J, 1993, J BIOL CHEM, V268, P18685; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; Iwasaki T, 1994, FLAVINS AND FLAVOPROTEINS 1993, P755; IWASAKI T, 1993, INT WORKSH MOL BIOL, P69; KERSCHER L, 1982, EUR J BIOCHEM, V128, P223; KERSCHER L, 1981, EUR J BIOCHEM, V116, P595, DOI 10.1111/j.1432-1033.1981.tb05377.x; KERSCHER L, 1982, TRENDS BIOCHEM SCI, V7, P371, DOI 10.1016/0968-0004(82)90118-9; KERSCHER L, 1981, EUR J BIOCHEM, V116, P587, DOI 10.1111/j.1432-1033.1981.tb05376.x; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; Koike M, 1976, Adv Biophys, P187; KOMAI H, 1969, J BIOL CHEM, V244, P1692; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA K, 1993, P NATL ACAD SCI USA, V90, P5341, DOI 10.1073/pnas.90.11.5341; MALIN R, 1973, IRON SULFUR PROTEINS, V2, P1; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MEINECKE B, 1989, ARCH MICROBIOL, V152, P244, DOI 10.1007/BF00409658; MOLL R, 1988, FEBS LETT, V232, P359, DOI 10.1016/0014-5793(88)80769-5; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1993, J BIOL CHEM, V268, P13592; MULLER M, 1988, ANNU REV MICROBIOL, V42, P465, DOI 10.1146/annurev.mi.42.100188.002341; ORTIZ ML, 1992, FEBS LETT, V296, P300, DOI 10.1016/0014-5793(92)80309-5; PALMER G, 1969, J BIOL CHEM, V244, P2614; PLAGA W, 1992, EUR J BIOCHEM, V205, P391, DOI 10.1111/j.1432-1033.1992.tb16792.x; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; SCHAFER T, 1993, ARCH MICROBIOL, V159, P354, DOI 10.1007/BF00290918; SCHICHO RN, 1993, J BACTERIOL, V175, P1823, DOI 10.1128/JB.175.6.1823-1830.1993; SHAH VK, 1983, J BIOL CHEM, V258, P2064; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; TSHISUAKA B, 1993, BIOCHEMISTRY-US, V32, P12928, DOI 10.1021/bi00210a047; UYEDA K, 1971, J BIOL CHEM, V246, P3111; WAHL RC, 1987, J BIOL CHEM, V262, P10489; WAKAGI T, 1986, SYST APPL MICROBIOL, V7, P342; WAKAO H, 1987, J BIOCHEM, V102, P255, DOI 10.1093/oxfordjournals.jbchem.a122049; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; WILLIAMS K, 1987, BIOCHEM J, V246, P529, DOI 10.1042/bj2460529	47	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17878	17883		10.1074/jbc.270.30.17878	http://dx.doi.org/10.1074/jbc.270.30.17878			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629091	hybrid			2022-12-25	WOS:A1995RM26600039
J	LI, XJ; SNYDER, SH				LI, XJ; SNYDER, SH			MOLECULAR-CLONING OF EBNERIN, A VON EBNERS GLAND PROTEIN ASSOCIATED WITH TASTE-BUDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONEBNERS GLANDS; MEMBRANE-PROTEIN; LINGUAL LIPASE; GROWTH-FACTOR; RECEPTOR; GLYCOPROTEIN; LIGAND; UROMODULIN; EXPRESSION; COMPONENT	Salivary secretions modulate taste perception. Taste buds in the circumvallate and foliate papillae are bathed in secretions of unique lingual salivary glands, von Ebner's glands (VEG). We have identified a rat cDNA encoding a novel protein of 1290 amino acids, Ebnerin, that is specifically expressed in VEG and released onto the tongue surface along the apical region of taste buds in the clefts of circumvallate papillae. Ebnerin possesses a putative single transmembrane domain at the C terminus with 17 amino acids in the cytoplasmic area. The extracellular region of Ebnerin contains a number of repeated domains with homology to the scavenger receptor cysteine-rich domain and to a repeated domain of bone morphogenetic protein-I and other related proteins. Western blot analysis reveals that Ebnerin exists in particulate and soluble forms in VEG and is present in secretions from VEG. In situ hybridization and immunohistochemistry demonstrate that Ebnerin is located in secretory duct epithelial cells of VEG and is released onto the tongue surface along the apical region of taste buds in the clefts of circumvallate papillae. The unique structure and localization of Ebnerin suggest that it may function as a binding protein in saliva for the regulation of taste sensation.			LI, XJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205, USA.							AMANO O, 1993, CELL TISSUE RES, V273, P467, DOI 10.1007/BF00333701; ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; ELAROUSSI MA, 1994, BBA-GENE STRUCT EXPR, V1217, P1, DOI 10.1016/0167-4781(94)90116-3; FENG P, 1993, J BIOL CHEM, V268, P21453; FIELD RB, 1987, AM J PHYSIOL, V253, pG217, DOI 10.1152/ajpgi.1987.253.2.G217; FRIEDMAN J, 1993, P NATL ACAD SCI USA, V90, P6815, DOI 10.1073/pnas.90.14.6815; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; FUKUOKA SI, 1991, P NATL ACAD SCI USA, V88, P2898, DOI 10.1073/pnas.88.7.2898; GURKAN S, 1988, CHEM SENSES, V13, P655, DOI 10.1093/chemse/13.4.655; HAMOSH M, 1973, J CLIN INVEST, V52, P88, DOI 10.1172/JCI107177; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HECK GL, 1984, SCIENCE, V223, P403, DOI 10.1126/science.6691151; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; HUMPHREYSBEHER MG, 1994, ENDOCRINOLOGY, V134, P963, DOI 10.1210/en.134.2.963; HWANG PM, 1990, P NATL ACAD SCI USA, V87, P7395, DOI 10.1073/pnas.87.19.7395; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; KINLOCH RA, 1992, P NATL ACAD SCI USA, V85, P6409; KOCK K, 1992, CELL TISSUE RES, V267, P313, DOI 10.1007/BF00302970; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOTHS K, 1993, J BIOL CHEM, V268, P14245; LEPAGE T, 1992, DEVELOPMENT, V114, P147; LI XJ, 1994, P NATL ACAD SCI USA, V91, P1814, DOI 10.1073/pnas.91.5.1814; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MACKINNON CM, 1987, EUR J BIOCHEM, V169, P547, DOI 10.1111/j.1432-1033.1987.tb13644.x; MATSUSHIMA M, 1994, J BIOL CHEM, V269, P19976; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; RINDLER MJ, 1990, J BIOL CHEM, V265, P20784; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SCHIFFMAN SS, 1983, P NATL ACAD SCI-BIOL, V80, P6136, DOI 10.1073/pnas.80.19.6136; SCHMALE H, 1990, NATURE, V343, P366, DOI 10.1038/343366a0; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WIJNGAARD PLJ, 1992, J IMMUNOL, V149, P3273; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	38	90	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17674	17679		10.1074/jbc.270.30.17674	http://dx.doi.org/10.1074/jbc.270.30.17674			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629065	hybrid			2022-12-25	WOS:A1995RM26600010
J	PETERSON, GL; TOUMADJE, A; JOHNSON, WC; SCHIMERLIK, MI				PETERSON, GL; TOUMADJE, A; JOHNSON, WC; SCHIMERLIK, MI			PURIFICATION OF RECOMBINANT PORCINE M2 MUSCARINIC ACETYLCHOLINE-RECEPTOR FROM CHINESE-HAMSTER OVARY CELLS - CIRCULAR-DICHROISM SPECTRA AND LIGAND-BINDING PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; MAMMALIAN BETA-2-ADRENERGIC RECEPTOR; PROTEIN SECONDARY STRUCTURE; GUANINE-NUCLEOTIDES; HIGH-AFFINITY; ALPHA-1-ADRENERGIC RECEPTOR; AGONIST INTERACTIONS; ANTAGONIST BINDING; RAT FOREBRAIN; MEMBRANE	The recombinant porcine m2 muscarinic acetylcholine receptor (rPm2R) from Chinese hamster ovary cells has been purified to homogeneity. Two mg of purified rPm2R, with a specific activity of 12 nmol of R-(-)-quinuclidinyl benzilate/mg of protein, were obtained from 30 mi of packed Chinese hamster ovary cells. The apparent molecular mass (78.5 kDa) and specific activity for the rPm2R preparation were the same as that for the Pm2R purified from atrial tissue, but the yield was 100 times greater. Purified rPm2R bound agonist and antagonist with the same affinities and coupled to the inhibitory guanine nucleotide-binding protein with the same efficiency as the purified native atrial Pm2R. Ligand binding studies were consistant with a single class of antagonist binding sites but two subclasses of agonist binding sites. The fraction of rPm2R having high affinity for agonists was increased by mM Mg2+, low detergent concentration, and low temperature. Circular dichroism spectra obtained for the purified rPm2R with and without agonists were indistinguishable, but spectra for the antagonist-occupied receptor showed reproducibly deeper characteristic negative deflections at 208 and 220 nm. Secondary structure analysis of the CD spectra predicted 53% alpha-helix for the free receptor and 49% alpha-helix for the R-(-)-quinuclidinyl benzilate-receptor complex.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, CTR ENVIRONM HLTH SCI, CORVALLIS, OR 97331 USA	Oregon State University; Oregon State University					NHLBI NIH HHS [HL23632] Funding Source: Medline; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM21479] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021479] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartfai T, 1979, Adv Cyclic Nucleotide Res, V10, P219; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BERRIE CP, 1985, BIOCHEM SOC T, V13, P1101, DOI 10.1042/bst0131101; BERSTEIN G, 1988, J NEUROCHEM, V50, P1687, DOI 10.1111/j.1471-4159.1988.tb02464.x; BIRDSALL NJM, 1980, PROC R SOC SER B-BIO, V207, P1, DOI 10.1098/rspb.1980.0011; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CREMO CR, 1981, ANAL BIOCHEM, V115, P331, DOI 10.1016/0003-2697(81)90014-2; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; GILLARD M, 1987, MOL PHARMACOL, V32, P100; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAGA K, 1983, J BIOL CHEM, V258, P3575; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HOMCY CJ, 1983, BIOCHEMISTRY-US, V22, P660, DOI 10.1021/bi00272a021; HULME EC, 1983, EUR J PHARMACOL, V94, P59, DOI 10.1016/0014-2999(83)90442-9; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KAHANE I, 1976, BIOCHIM BIOPHYS ACTA, V426, P464, DOI 10.1016/0005-2736(76)90391-6; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBIN P, 1978, ANAL BIOCHEM, V85, P114, DOI 10.1016/0003-2697(78)90281-6; LIU TY, 1989, ANAL BIOCHEM, V182, P383, DOI 10.1016/0003-2697(89)90612-X; LOMASNEY JW, 1986, J BIOL CHEM, V261, P7710; LYNCH CJ, 1988, FEBS LETT, V229, P54, DOI 10.1016/0014-5793(88)80796-8; LYNCH CJ, 1985, J BIOL CHEM, V260, P1593; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARTIN MW, 1984, J PHARMACOL EXP THER, V230, P424; MCMAHON KK, 1985, MOL PHARMACOL, V28, P400; NAKATA H, 1989, J BIOL CHEM, V264, P16545; NEUFELD G, 1983, P NATL ACAD SCI-BIOL, V80, P6441, DOI 10.1073/pnas.80.21.6441; PARK K, 1992, PROTEIN SCI, V1, P1032, DOI 10.1002/pro.5560010809; PARKER EM, 1991, J BIOL CHEM, V266, P519; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PETERSON GL, 1984, PREP BIOCHEM, V14, P33, DOI 10.1080/10826068408070612; PETERSON GL, 1984, P NATL ACAD SCI-BIOL, V81, P4993, DOI 10.1073/pnas.81.15.4993; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PHAN NT, 1980, EUR J PHARMACOL, V67, P497, DOI 10.1016/0014-2999(80)90195-8; PIKE LJ, 1978, MOL PHARMACOL, V14, P370; QUINTANA DG, 1993, J BIOL CHEM, V268, P2403; REGAN JW, 1986, J BIOL CHEM, V261, P3894; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3090; RUPLEY JA, 1964, BIOCHIM BIOPHYS ACTA, V83, P245, DOI 10.1016/0926-6526(64)90001-1; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARZ KR, 1986, BIOCHEMISTRY-US, V25, P7782, DOI 10.1021/bi00371a074; SENOGLES SE, 1988, J BIOL CHEM, V263, P18996; SHIOZAKI K, 1992, BIOCHEMISTRY-US, V31, P10634, DOI 10.1021/bi00158a028; TOEWS ML, 1983, P NATL ACAD SCI-BIOL, V80, P3553, DOI 10.1073/pnas.80.12.3553; TOTA MR, 1987, BIOCHEMISTRY-US, V26, P8175, DOI 10.1021/bi00399a023; TOUMADJE A, 1993, ANAL BIOCHEM, V211, P258, DOI 10.1006/abio.1993.1266; VOGEL WK, 1995, J BIOL CHEM, V270, P15485, DOI 10.1074/jbc.270.26.15485; WAELBROECK M, 1985, BIOCHEM J, V231, P469, DOI 10.1042/bj2310469; WEILAND GA, 1979, NATURE, V281, P114, DOI 10.1038/281114a0; WHEATLEY M, 1987, BIOCHEM SOC T, V15, P113, DOI 10.1042/bst0150113; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZAHNISER NR, 1983, MOL PHARMACOL, V23, P303	56	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17808	17814		10.1074/jbc.270.30.17808	http://dx.doi.org/10.1074/jbc.270.30.17808			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629081				2022-12-25	WOS:A1995RM26600029
J	POPIELARZ, M; CAVALOC, Y; MATTEI, MG; GATTONI, R; STEVENIN, J				POPIELARZ, M; CAVALOC, Y; MATTEI, MG; GATTONI, R; STEVENIN, J			THE GENE ENCODING HUMAN SPLICING FACTOR 9G8 - STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION OF ALTERNATIVELY PROCESSED TRANSCRIPTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-PROTEINS; CONSERVED FAMILY; NUCLEAR PHOSPHOPROTEINS; FUNCTIONAL-ANALYSIS; SITE SELECTION; FACTOR ASF/SF2; BINDING; INVITRO; SIMILARITIES; REGULATORS	The 9G8 factor is a 30-kDa member of the SR splicing factor family. We report here the isolation and characterization of the human 9G8 gene. This gene spans 7745 nucleotides and consists of 8 exons and 7 introns within the coding sequence, thus contrasting with the organization of the SC35/PR264 or RBP1 SR genes. We have located the human 9G8 gene in the p22-21 region of chromosome 2. The 5'-flanking region is GC-rich and contains basal promoter sequences and potential regulatory elements. Transfection experiments show that the 400-base pair flanking sequence has a promoter activity. Northern blot analysis of poly(A)(+) RNA isolated from human fetal tissues has allowed us to identify five different species, generated by alternative splicing of intron 3, which may be retained or excised as a shorter version, as well as the use of two polyadenylation sites. We also show that the different isoforms are differentially expressed in the fetal tissues. The persistence of sequences between exon 3 and 4 results in the synthesis of a 9G8 protein lacking the SR domain which is expected to be inactive in constitutive splicing. Thus, our results raise the possibility that alternative splicing of intron 3 provides a mechanism for modulation of the 9G8 function.	UNIV STRASBOURG 1,INSERM,CNRS,INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; FAC MED TIMONE,INSERM,U406,UNITE GENET MED & DEV,F-13385 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille				CAVALOC, Yvon/0000-0002-2837-8801				AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BLOOMFIELD CD, 1987, SEMIN ONCOL, V14, P372; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CACERES JF, 1994, NATURE, V265, P1706; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATTEI MG, 1993, GENOMICS, V16, P786, DOI 10.1006/geno.1993.1270; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; Moore M., 1993, RNA WORLD, P303; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SUREAU A, 1994, P NATL ACAD SCI USA, V91, P932, DOI 10.1073/pnas.91.3.932; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	48	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17830	17835		10.1074/jbc.270.30.17830	http://dx.doi.org/10.1074/jbc.270.30.17830			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629084	hybrid			2022-12-25	WOS:A1995RM26600032
J	WANG, XD; PAI, JT; WIEDENFELD, EA; MEDINA, JC; SLAUGHTER, CA; GOLDSTEIN, JL; BROWN, MS				WANG, XD; PAI, JT; WIEDENFELD, EA; MEDINA, JC; SLAUGHTER, CA; GOLDSTEIN, JL; BROWN, MS			PURIFICATION OF AN INTERLEUKIN-1-BETA CONVERTING ENZYME-RELATED CYSTEINE PROTEASE THAT CLEAVES STEROL REGULATORY ELEMENT-BINDING PROTEINS BETWEEN THE LEUCINE-ZIPPER AND TRANSMEMBRANE DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR PROMOTER; NUCLEAR-PROTEIN; CDNA CLONING; GENE; TRANSCRIPTION; EXPRESSION; SEQUENCE	We describe the characterization and purification of a protease that cleaves sterol regulatory element-binding protein-1 (SREBP-1) and SREBP-2 in vitro. Cleavage occurs between the basic helix-loop-helix-leucine zipper and the first transmembrane domain of each SREBP. This is the region in which the SREBPs are cleaved physiologically by a sterol-regulated protease that releases an NH2-terminal fragment that activates transcription of the genes for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl CoA synthase. The cleavage enzyme, designated SREBP cleavage activity (SCA), belongs to a new class of cysteine proteases of the interleukin-1 beta-converting enzyme (ICE) family, all of which cleave at aspartic acid residues. Like ICE, SCA was inactive in cytosol, and it was activated in vitro by incubation at 30 degrees C. SCA was resistant to inhibitors of serine, aspartyl, and metalloproteases, but it was sensitive to N-ethylmaleimide. The enzyme cleaved SREBP-1 and SREBP-2 between the Asp and Ser of a conserved sequence (S/DEPDSP). The activity was blocked by a tetrapeptide aldehyde, Ac-Asp-Glu-Ala-Asp-aldehyde (Ac-DEAD-CHO). A purified preparation of SCA from hamster liver contained a prominent 20-kDa polypeptide that could be labeled with [C-14]iodoacetic acid. Labeling was blocked by Ac-DEAD-CHO. Partial amino acid sequence of this polypeptide revealed that it was the hamster equivalent of human CPP32, a putative protease whose cDNA was recently identified by virtue of sequence homology to ICE. CPP32 and ICE have been implicated in apoptosis in animal cells, Whether SCA/CPP32 participates in vivo in the sterol-regulated activation of SREBP, or whether it activates SREBPs during apoptosis, remains to be determined.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; TULARIK INC,S SAN FRANCISCO,CA 94080	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	WANG, XD (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Wang, Xiaodong/0000-0001-9885-356X	NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYALA JM, 1994, J IMMUNOL, V153, P2592; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; SATO R, 1994, J BIOL CHEM, V269, P17267; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; STANFIELD CF, 1981, J ORG CHEM, V46, P4797, DOI 10.1021/jo00336a039; THHORNBERRY NA, 1995, PROTEIN SCI, V4, P3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	25	124	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18044	18050		10.1074/jbc.270.30.18044	http://dx.doi.org/10.1074/jbc.270.30.18044			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629113				2022-12-25	WOS:A1995RM26600064
J	KLOCKNER, U; MIKALA, G; VARADI, M; VARADI, G; SCHWARTZ, A				KLOCKNER, U; MIKALA, G; VARADI, M; VARADI, G; SCHWARTZ, A			INVOLVEMENT OF THE CARBOXYL-TERMINAL REGION OF THE ALPHA(1) SUBUNIT IN VOLTAGE-DEPENDENT INACTIVATION OF CARDIAC CALCIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROPYRIDINE RECEPTOR; SODIUM-CHANNEL; BETA-SUBUNIT; ACTIVATION; PHOSPHORYLATION; EXPRESSION; TRYPSIN; HEART; CELLS; RNA	Intracellular application of proteases increases cardiac calcium current to a level similar to beta-adrenergic stimulation. Using transiently transfected HEK 293 cells, we studied the molecular mechanism underlying calcium channel stimulation by proteolytic treatment. Perfusion of HEK cells, coexpressing the human cardiac (hHT) alpha(1), alpha(2), and beta(3) subunits, with 1 mg/ml of trypsin or carboxypeptidase A, increased the peak amplitude of the calcium channel current 3-4-fold without affecting the voltage dependence. Similar results were obtained in HEK cells cotransfected with hHT alpha(1) and alpha(2) or with alpha(1) alone, suggesting that modification of the alpha(1) subunit itself is responsible for the current enhancement by proteolysis. To further characterize the modification of the alpha(1) subunit by trypsin, we expressed a deletion mutant in which part of the carboxyl-terminal tail up to amino acid 1673 was removed. The expressed calcium channel currents no longer responded to intracellular application of the proteases; however, a 3-fold higher current density as well as faster inactivation compared with the wild type was observed. The results provide evidence that a specific region of the carboxyl-terminal tail of the cardiac alpha(1) subunit is an important regulatory segment that may serve as a critical component of the gating machinery that influences both inactivation properties as well as channel availability.	UNIV CINCINNATI,COLL MED,INST PHARMACOL MOLEC & BIOPHYS,CINCINNATI,OH 45267; UNIV COLOGNE,DEPT PHYSIOL,D-50931 COLOGNE,GERMANY	University System of Ohio; University of Cincinnati; University of Cologne					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, P01HL022619, R37HL043231] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 22619-17, P01 HL 41496-06, R37HL 43231-06] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; BOURINET E, 1994, EMBO J, V13, P5032, DOI 10.1002/j.1460-2075.1994.tb06832.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; GONOI T, 1987, J GEN PHYSIOL, V89, P253, DOI 10.1085/jgp.89.2.253; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELL JW, 1993, J BIOL CHEM, V268, P19451; HESCHELER J, 1988, J PHYSIOL-LONDON, V404, P259, DOI 10.1113/jphysiol.1988.sp017289; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KLEPPISCH T, 1994, EMBO J, V13, P2502, DOI 10.1002/j.1460-2075.1994.tb06538.x; KLOCKNER U, 1988, PFLUGERS ARCH, V412, P82; KUNIYASU A, 1992, J BIOCHEM, V112, P235, DOI 10.1093/oxfordjournals.jbchem.a123883; LEON M, 1995, BIOPHYS J, V68, P13; LORY P, 1992, BIOPHYS J, V63, P1421, DOI 10.1016/S0006-3495(92)81705-8; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MIYAZAKI J, 1989, GENE, V79, P269; NAKAI J, 1994, P NATL ACAD SCI USA, V91, P1014, DOI 10.1073/pnas.91.3.1014; NORMAN RI, 1994, BIOCHEM SOC T, V22, P492, DOI 10.1042/bst0220492; OBEJEROPAZ CA, 1991, J GEN PHYSIOL, V98, P1127, DOI 10.1085/jgp.98.6.1127; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; STIMERS JR, 1985, J GEN PHYSIOL, V85, P65, DOI 10.1085/jgp.85.1.65; STRYER L, 1988, BIOCHEMISTRY-US, P226; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1994, J BIOL CHEM, V269, P1635; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10905; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0	36	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17306	17310		10.1074/jbc.270.29.17306	http://dx.doi.org/10.1074/jbc.270.29.17306			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615531	hybrid			2022-12-25	WOS:A1995RK68900041
J	LIU, L; LASSAM, NJ; SLINGERLAND, JM; BAILEY, D; COLE, D; JENKINS, R; HOGG, D				LIU, L; LASSAM, NJ; SLINGERLAND, JM; BAILEY, D; COLE, D; JENKINS, R; HOGG, D			GERMLINE P16(INK4A) MUTATION AND PROTEIN DYSFUNCTION IN A FAMILY WITH INHERITED MELANOMA	ONCOGENE			English	Article						CDK INHIBITORS; P16(INK4A); MELANOMA	WILD-TYPE P53; GROWTH; SUPPRESSION; GENE; ONCOGENE; LOCUS; CELLS; MLM	The gene encoding the cell cycle inhibitor p16(INK4A) (also known as p16, MTS1, CDKN2 and INK4) has been mapped to human chromosome band 9p21, a region that also contains a putative melanoma susceptibility gene. Although germline mutations in the coding region of the p16(INK4A) gene have been detected in some families with inherited melanoma, many other families show no evidence of such mutations and hence the role of p16(INK4A) in the development of this tumor is still unclear. In this report, we describe a family with inherited melanoma in which a novel mutation in exon 2 of the p16(INK4A) gene segregates with the disease. The mutant gene encodes a protein with an in-frame deletion of two amino acids (Asp96 and Leu97). We show that the mutant protein is functionally abnormal: it is unable to bind cdk4 in vitro and does not inhibit colony formation in tertiary passage rat embryo fibroblasts. Moreover, in a metastatic lesion from one patient the wild type p16(INK4A) allele was deleted and the mutant allele retained. We conclude that family members carrying this germline mutation in the p16(INK4A) gene are predisposed to melanoma. By extension, these findings implicate the p16(INK4A) gene in the development of some cases of familial melanoma.	TORONTO GEN HOSP,DIV ONCOL RES,TORONTO,ON M5G 2C4,CANADA; TORONTO GEN HOSP,DEPT PATHOL,TORONTO,ON M5G 2C4,CANADA; TORONTO GEN HOSP,DEPT CLIN BIOCHEM,TORONTO,ON M5G 2C4,CANADA; TORONTO SUNNYBROOK REG CANC CTR,DIV MED ONCOL,TORONTO,ON M4N 3M5,CANADA; TORONTO SUNNYBROOK REG CANC CTR,DIV CANC BIOL RES,TORONTO,ON M4N 3M5,CANADA; MAYO CLIN & MAYO FDN,DIV LAB GENET,ROCHESTER,MN 55905	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Mayo Clinic								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BATTISTUTTA D, 1994, LANCET, V344, P1607, DOI 10.1016/S0140-6736(94)90408-1; BONETTA L, 1994, NATURE, V370, P180, DOI 10.1038/370180a0; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1994, CANCER RES, V54, P6041; CANNONALBRIGHT LA, 1994, GENOMICS, V23, P265, DOI 10.1006/geno.1994.1491; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COLEMAN A, 1994, CANCER RES, V54, P344; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUIS NA, 1995, IN PRESS AM J PATH, V146; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KAUFMAN DK, 1993, NEUROLOGY, V43, P1728, DOI 10.1212/WNL.43.9.1728; LIU L, 1995, IN PRESS ONCOGENE; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MYERSON M, 1994, MOL CELL BIOL, V14, P2077; NANCARROW DJ, 1992, GENOMICS, V12, P18, DOI 10.1016/0888-7543(92)90401-D; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTA M, 1994, CANCER RES, V54, P5269; PENG HQ, 1993, CANCER RES, V53, P3574; ROVINSKI B, 1988, ONCOGENE, V2, P445; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPRUCK CH, 1994, NATURE, V265, P183; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WALKER GJ, 1994, ONCOGENE, V9, P819; XU L, 1994, CANCER RES, V54, P5262	42	97	99	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					405	412						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624155				2022-12-25	WOS:A1995RK95700022
J	KANAI, Y; NUSSBERGER, S; ROMERO, MF; BORON, WF; HEBERT, SC; HEDIGER, MA				KANAI, Y; NUSSBERGER, S; ROMERO, MF; BORON, WF; HEBERT, SC; HEDIGER, MA			ELECTROGENIC PROPERTIES OF THE EPITHELIAL AND NEURONAL HIGH-AFFINITY GLUTAMATE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-GLUCOSE COTRANSPORTER; BRUSH-BORDER MEMBRANES; INTRACELLULAR PH; XENOPUS-OOCYTES; RAT-BRAIN; EXPRESSION; RELEASE; NEUROTRANSMITTER; CLONING; SODIUM	Active ion coupled glutamate transport is of critical importance for excitatory synaptic transmission, normal cellular function, and epithelial amino acid metabolism, We previously reported the cloning of the rabbit intestinal high affinity glutamate transporter EAAC1 (Kanai, Y., and Hediger, M. A. (1992) Nature 360, 467-471), which is expressed in numerous tissues including intestine, kidney, liver, heart, and brain. Here, we re port a detailed stoichiometric and kinetic analysis of EAAC1 expressed in Xenopus laevis oocytes. Uptake studies of Na-22(+) and [C-14]glutamate, in combination with measurements of intracellular pH with pH microelectrodes gave a glutamate to charge ratio of 1:1, a glutamate to Na+ ratio of 1:2, and a OH-/H+ to charge ratio of 1:1. Since transport is K+ dependent it can be concluded that EAAC1-mediated glutamate transport is coupled to the cotransport of 2 Na+ ions, the countertransport of one Kf ion and either the countertransport of one OH- ion or the cotransport of 1 H+ ion, We further demonstrate that under conditions where the electro chemical gradients for these ions are disrupted, EAAC1 runs in reverse, a transport mode which is of pathologic importance, Na-22(+) uptake studies revealed that there is a low level of Na+ uptake in the absence of extracellular glutamate which appears to be analogous to the Na+ leak observed for the intestinal. Na+/glucose cotransporter SGLT1. In voltage clamp studies, reducing extracellular Na+ from 100 to 10 mM strongly increased K-0.5(L-glutamate) and decreased I-max. The data indicate that Na+ binding at the extracellular transporter surface be comes rate-limiting. Studies addressing the cooperativity of the substrate-binding sites indicate that there are two distinct Na+-binding sites with different affinities and that Na+ binding is modulated by extracellular glutamate. A hypothetical ordered kinetic transport model for EAAC1 is discussed.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yale University			Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287; Hediger, Matthias/0000-0003-1946-027X; Nussberger, Stephan/0000-0003-3619-4452	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043171, R37DK030344, R01DK030344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43171, DK-30344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATO A, 1994, J PHYSIOL-LONDON, V479, P371, DOI 10.1113/jphysiol.1994.sp020302; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; BENNETT E, 1992, AM J PHYSIOL, V262, pC510, DOI 10.1152/ajpcell.1992.262.2.C510; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; DANBOLT NC, 1992, NEUROSCIENCE, V51, P259; DAVIS BA, 1992, AM J PHYSIOL, V263, pC246, DOI 10.1152/ajpcell.1992.263.1.C246; Fairman W. A., 1994, Society for Neuroscience Abstracts, V20, P925; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; HEINZ E, 1988, BIOCHIM BIOPHYS ACTA, V937, P300, DOI 10.1016/0005-2736(88)90252-0; Hille B., 1992, IONIC CHANNELS EXCIT; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; Kloeckner Udo, 1993, Journal of Biological Chemistry, V268, P14594; KOEPSELL H, 1984, J BIOL CHEM, V259, P6548; LEE WS, 1994, J BIOL CHEM, V269, P12032; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; POW DV, 1994, NEUROSCIENCE, V60, P355, DOI 10.1016/0306-4522(94)90249-6; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SIEBENS AW, 1987, J GEN PHYSIOL, V90, P799, DOI 10.1085/jgp.90.6.799; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; VANDENPOL AN, 1990, SCIENCE, V250, P1276, DOI 10.1126/science.1978759; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	38	159	164	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16561	16568		10.1074/jbc.270.28.16561	http://dx.doi.org/10.1074/jbc.270.28.16561			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622462	hybrid			2022-12-25	WOS:A1995RJ34700018
J	ZIONCHECK, TF; RICHARDSON, L; LIU, J; CHANG, L; KING, KL; BENNETT, GL; FUGEDI, P; CHAMOW, SM; SCHWALL, RH; STACK, RJ				ZIONCHECK, TF; RICHARDSON, L; LIU, J; CHANG, L; KING, KL; BENNETT, GL; FUGEDI, P; CHAMOW, SM; SCHWALL, RH; STACK, RJ			SULFATED OLIGOSACCHARIDES PROMOTE HEPATOCYTE GROWTH-FACTOR ASSOCIATION AND GOVERN ITS MITOGENIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; HEPARIN-LIKE MOLECULES; CELL-SURFACE; PROTEOLYTIC CLEAVAGE; EXTRACELLULAR DOMAIN; LIGAND-BINDING; SCATTER FACTOR; RAT PLATELETS; PURIFICATION; EXPRESSION	Hepatocyte growth factor (HGF) is a potent mitogen, motogen, and morphogen for various epithelial cell types. The pleiotropic effects of HGF are mediated by its binding to a specific high affinity receptor, c-Met. In addition, HGF binds to heparan sulfate proteoglycans on cell surfaces and within the extracellular matrix. Incubation of HGF with 0.1, 1.0, and 10 mu g/ml of heparin, heparan sulfate, or dextran sulfate resulted in a concentration-dependent increase in mitogenic potency in a primary rat hepatocyte bioassay, whereas sodium sulfate or fucoidan did not. Although co-incubation of HGF with sulfated compounds that enhanced HGF-dependent mitogenesis did not alter the binding isotherm of HGF for the c-Met receptor in a solid phase assay, an increase in autophosphorylation of the c-Met receptor in intact A549 cells was observed upon their addition. A series of chemically sulfated malto oligosaccharides varying in unit size and charge was tested in the bioassay in order to provide additional insights into the nature of the HGF-heparin interaction. While sulfated di-, tri-, tetra-, and pentasaccharides did not significantly potentiate HGF-dependent mitogenesis, larger oligosaccharides such as the sulfated hexa-, hepta-, or a sulfated oligosaccharide mixture containing decasaccharides resulted in an approximate 2-, 4-, and 7-fold enhancement, respectively. We observed a correlation between the sulfated oligosaccharide preparations that enhanced mitogenic potency and those that promoted HGF oligomerization in vitro, as measured by gel filtration and analytical ultracentrifugation. These findings indicate that heparin-like molecules can stabilize HGF oligomers, which may facilitate c-Met receptor dimerization and activation.	GLYCOMED INC,ALAMEDA,CA 94501		ZIONCHECK, TF (corresponding author), GENENTECH INC,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMOW SM, 1994, J IMMUNOL, V153, P4268; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FRANSSON LA, 1989, HEPARIN, P115; FUGEDI P, 1992, 16TH INT CARB S PAR; FUGEDI P, 1994, 17TH INT C S OTT; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHNSON ML, 1981, BIOPHYS J, V36, P578; KATO S, 1994, EXP CELL RES, V211, P553; LIU KX, 1992, HEPATOLOGY, V17, P651; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; LON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MARK MR, 1992, J BIOL CHEM, V267, P26166; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MICHALOPOULOS GK, 1992, HEPATOLOGY, V15, P149, DOI 10.1002/hep.1840150125; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; MIZUNO K, 1993, HEPATOCYTE GROWTH FA, P1; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1989, ONCOGENE, V6, P501; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TESSLER S, 1994, J BIOL CHEM, V269, P12456; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P397; ZARNEGAR R, 1989, CANCER RES, V49, P3314	43	146	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16871	16878		10.1074/jbc.270.28.16871	http://dx.doi.org/10.1074/jbc.270.28.16871			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622503	hybrid			2022-12-25	WOS:A1995RJ34700064
J	TAKAHASHI, K; YONEZAWA, K; NISHIMOTO, I				TAKAHASHI, K; YONEZAWA, K; NISHIMOTO, I			INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR-ACTIVATED BY A TRANSMEMBRANE MUTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ANTIBODY ALPHA-IR-3; PROTEIN-KINASES; POINT MUTATION; SIGNAL; DOMAIN; SUBSTITUTION; SPECIFICITY; ONCOPROTEIN; EXPRESSION	We constructed mutant receptors by mutating transmembrane Val(922) of the human insulin-like growth factor I receptor (IGF-IR). Assays of receptor kinase and autophosphorylation revealed constitutively augmented tyrosine kinase activity of V922E IGF-IR in both transient and stable expression. The constitutively active tyrosine kinase of this mutant was verified by promoted tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) in the absence of IGF-I. In CHO cells stably expressing V922E IGF-IR, both IRS-1 phosphorylation and the IRS-1-associated phosphoinositide 3-kinase activity were stimulated in the absence of IGF-I to the level attained by 1 nM IGF-I stimulation of wild type IGF-IR, whereas the Ras-mitogen-activated protein kinase pathway was not activated under the same condition. In these CHO cells, V922E IGF-IR significantly stimulated glucose uptake but did not promote mitogenesis in the absence of IGF-I. We thus conclude that the V922E mutation of IGF-IR switches on the intrinsic tyrosine kinase and differentially activates the downstream pathways. This mutant is extremely useful in clarifying the turning on mechanism of IGF-IR as well as the differential roles of individual downstream pathways of receptor tyrosine kinases.	MASSACHUSETTS GEN HOSP EAST,CARDIOVASC RES CTR,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								[Anonymous], 1991, INSULIN LIKE GROWTH; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IKEZU T, 1994, J BIOL CHEM, V269, P31955; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; KOZMA LM, 1990, MOL CELL BIOL, V10, P1301; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LONGO N, 1992, J BIOL CHEM, V267, P12416; MIURA M, 1994, CANCER RES, V54, P2472; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKADA T, 1994, J BIOL CHEM, V269, P3568; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STEELEPERKINS G, 1990, BIOCHEM BIOPH RES CO, V171, P1244, DOI 10.1016/0006-291X(90)90819-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VALENTINIS B, 1994, ONCOGENE, V9, P825; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XIAO S, 1994, J BIOL CHEM, V269, P21244; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; YONEZAWA K, 1992, J BIOL CHEM, V267, P23435; ZHANG B, 1992, J BIOL CHEM, V267, P18320	41	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19041	19045		10.1074/jbc.270.32.19041	http://dx.doi.org/10.1074/jbc.270.32.19041			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642566	hybrid			2022-12-25	WOS:A1995RN95400054
J	WANGE, RL; GUITIAN, R; ISAKOV, N; WATTS, JD; AEBERSOLD, R; SAMELSON, LE				WANGE, RL; GUITIAN, R; ISAKOV, N; WATTS, JD; AEBERSOLD, R; SAMELSON, LE			ACTIVATING AND INHIBITORY MUTATIONS IN ADJACENT TYROSINES IN THE KINASE DOMAIN OF ZAP-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL ANTIGEN RECEPTOR; ZETA-CHAIN; PROTEIN; PHOSPHORYLATION; AUTOPHOSPHORYLATION; PP60C-SRC; SITES; REPLACEMENT; PERVANADATE; EXPRESSION	ZAP-70 is a 70-kDa protein tyrosine kinase, expressed exclusively in T cells and NK cells, and plays a critical role in mediating T cell activation in response to T cell receptor engagement, The strong correlation between tyrosine phosphorylation of ZAP-70 and its acquisition of increased kinase activity suggests that it is positively regulated by tyrosine phosphorylation, Previously, we identified tyrosines 492 and 493 of ZAP-70 as being sites of in vivo phosphorylation in response to T cell receptor engagement, To determine the role of phosphorylation in regulating ZAP-70 activity, we mutated each of these tyrosines individually to phenylalanine, When expressed in COS cells, Y493F-mutated ZAP-70 demonstrated normal basal kinase activity, but, unlike wild type ZAP-70, could not be activated by tyrosine phosphorylation induced by incubation with pervanadate or by co-expression of constitutively activated Lck, This suggests that Tyr-493 phosphorylation is required for the tyrosine phosphorylation-induced activation of ZAP-70, The Y492F mutation resulted in 4-fold higher basal kinase activity, which could be stimulated further by tyrosine phosphorylation, These results reveal that critical tyrosine residues in the kinase domain of ZAP-70 are important in regulation of its catalytic activity.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA; UNIV WASHINGTON, DEPT MOLEC BIOTECHNOL, SEATTLE, WA USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Washington; University of Washington Seattle			Wange, Ronald/AAI-2505-2021	Isakov, Noah/0000-0002-1412-0957; Wange, Ronald/0000-0001-9593-3572				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHU HKG, 1994, MOL CELL BIOL, V14, P6868, DOI 10.1128/MCB.14.10.6868; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; ZHANG B, 1991, J BIOL CHEM, V266, P990	42	175	177	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18730	18733		10.1074/jbc.270.32.18730	http://dx.doi.org/10.1074/jbc.270.32.18730			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642520	hybrid			2022-12-25	WOS:A1995RN95400006
J	YAGI, H; KATO, T; NAGATA, T; HABU, T; NOZAKI, M; MATSUSHIRO, A; NISHIMUNE, Y; MORITA, T				YAGI, H; KATO, T; NAGATA, T; HABU, T; NOZAKI, M; MATSUSHIRO, A; NISHIMUNE, Y; MORITA, T			REGULATION OF THE MOUSE HISTONE H2A.X GENE PROMOTER BY THE TRANSCRIPTION FACTOR E2F AND CCAAT BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; RETINOBLASTOMA PROTEIN; MESSENGER-RNA; SITE; REPRESSION; INTERACTS; COMPLEXES; SEQUENCE; ELEMENTS; PRODUCT	We have molecularly cloned the genomic gene encoding the mouse histone variant H2A.X and characterized the promoter, The promoter region of the H2A.X gene was characterized by chloramphenicol acetyltransferase analysis using Balb/c 3T3 cells, Maximal promoter activity was found in the construct containing up to -282 base pairs H2A.X upstream region, Within this region, we found two sequences regulating the promoter activation: one was an E2F site and another was a CCAAT box, These sequences were also required for the DNA/protein binding activities, Thus, these activities corresponded to the promoter activities, implying that the promoter activity of H2A.X gene was controlled by both the transcription factor E2F and H1TF2 through the E2F and CCAAT element, The CCAAT box binding activity was constitutive when cell cycle was progressed by release from G1 arrest, but transiently transfected chloramphenicol acetyltransferase activity slightly increased when cells entered S phase, Similarly, the level of the smallest form of E2F (free E2F) became higher when cells reentered the cell cycle, indicating that the free E2F was one capable of inducing the promoter activation, Thus, the free E2F and CCAAT DNA binding activity correlated with regulation of the promoter activity.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC EMBRYOL,SUITA,OSAKA 565,JAPAN; KINKI UNIV,FAC BIOL SCI,DEPT BIOTECHNOL,WAKAYAMA 64964,JAPAN	Osaka University; Kindai University (Kinki University)			Habu, Toshiyuki/ABC-6644-2021	Habu, Toshiyuki/0000-0003-4131-3938; Kato, Tomohisa/0000-0002-3047-9847				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HUANG SY, 1986, P NATL ACAD SCI USA, V83, P3738, DOI 10.1073/pnas.83.11.3738; IVANOVA VS, 1994, J BIOL CHEM, V269, P24189; KEYOMARSI K, 1991, CANCER RES, V5, P3602; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; MANNIRONI C, 1989, NUCLEIC ACIDS RES, V17, P9113, DOI 10.1093/nar/17.22.9113; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NAGATA T, 1991, NUCLEIC ACIDS RES, V19, P2441, DOI 10.1093/nar/19.9.2441; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; RAJPUT B, 1992, BIOCHEM J, V285, P985, DOI 10.1042/bj2850985; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STEIN GS, 1994, J CELL BIOCHEM, V45, P393; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WU RS, 1982, CELL, V31, P367, DOI 10.1016/0092-8674(82)90130-1; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3; Zweidler A, 1984, HISTONE GENES STRUCT, P339	40	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18759	18765		10.1074/jbc.270.32.18759	http://dx.doi.org/10.1074/jbc.270.32.18759			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642525	hybrid			2022-12-25	WOS:A1995RN95400012
J	GREEN, BN; SUZUKI, T; GOTOH, T; KUCHUMOV, AR; VINOGRADOV, SN				GREEN, BN; SUZUKI, T; GOTOH, T; KUCHUMOV, AR; VINOGRADOV, SN			ELECTROSPRAY-IONIZATION MASS-SPECTROMETRIC DETERMINATION OF THE COMPLETE POLYPEPTIDE-CHAIN COMPOSITION OF TYLORRHYNCHUS-HETEROCHAETUS HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; EXTRACELLULAR HEMOGLOBIN; GIANT HEMOGLOBIN; MAXIMUM-ENTROPY; MYOGLOBIN; SPECTRA; PEPTIDE; HEME	Electrospray ionization mass spectrometry (ESI-MS) of the native, reduced, and carbamidomethylated forms of the extracellular, 3.38-MDa hemoglobin from the marine polychaete Tylorrhynchus heterochaetus, when combined with a maximum entropy (MaxEnt) analysis, provided a complete description of the polypeptide chain composition. This hemoglobin, a hetero-multimeric complex of approximately 180 polypeptide chains, consisting of globin and linker subunits in an similar to 3:1 mass ratio, is among the largest protein complexes investigated by ESI-MS. The globin subunits consist of a monomer subunit (chain I, 15575.4 La) and a disulfide-bonded trimer subunit, 50068.4 Da, consisting of globin chains IIA (16601.9 Da), IIB (16680.4 Da), and IIC (16,794.0 La). Linker subunits L1-L5, 23233.8, 24835.4, 25326.9, 28202.2, and 26317.2 La, respectively, were found together with a disulfide bonded dimer of L2, 52609.4 Da. Using the exact masses of the subunits, a plausible model of the hemoglobin consisting of 144 globin chains (36 monomers and 36 trimers) and 36 linker chains provides a calculated mass of 3.42 MDa.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201; VG ORGAN,ALTRINCHAM WA14 5RZ,CHESHIRE,ENGLAND; KOCHI UNIV,DEPT BIOL,KOCHI 780,JAPAN; UNIV TOKUSHIMA,DEPT BIOL,TOKUSHIMA 770,JAPAN	Wayne State University; Kochi University; Tokushima University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038674] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38674] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHOWDHURY SK, 1990, J AM SOC MASS SPECTR, V1, P382, DOI 10.1016/1044-0305(90)85018-H; CRESTFIELD AM, 1963, J BIOL CHEM, V239, P622; FERRIGE AG, 1991, RAPID COMMUN MASS SP, V5, P374, DOI 10.1002/rcm.1290050810; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; GOTOH T, 1990, ZOOL SCI, V7, P1; KIM JS, 1994, EUR J BIOCHEM, V224, P109, DOI 10.1111/j.1432-1033.1994.tb20001.x; Landon, 1977, Methods Enzymol, V47, P145; LOO JA, 1993, RAPID COMMUN MASS SP, V7, P186, DOI 10.1002/rcm.1290070304; PILZ I, 1988, INT J BIOL MACROMOL, V10, P356, DOI 10.1016/0141-8130(88)90029-3; SENKO MW, 1994, ANNU REV BIOPH BIOM, V23, P763, DOI 10.1146/annurev.bb.23.060194.003555; SUZUKI T, 1985, J BIOL CHEM, V260, P3145; SUZUKI T, 1985, J BIOL CHEM, V260, P1481; SUZUKI T, 1982, BIOCHIM BIOPHYS ACTA, V708, P253, DOI 10.1016/0167-4838(82)90434-4; SUZUKI T, 1988, J BIOL CHEM, V263, P18524; SUZUKI T, 1986, J MOL BIOL, V190, P119, DOI 10.1016/0022-2836(86)90081-1; SUZUKI T, 1990, J BIOL CHEM, V265, P12168; SUZUKI T, 1986, J BIOL CHEM, V261, P257; Vinogradov S.N., 1985, P9; Vinogradov S. N., 1982, ELECTRON MICROS, P135; YU W, 1993, ANAL CHEM, V65, P3015, DOI 10.1021/ac00069a014; ZAIA J, 1992, RAPID COMMUN MASS SP, V6, P32, DOI 10.1002/rcm.1290060108; 1993, J PHYS CHEM REF DATA, V22, P1571	22	34	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18209	18211		10.1074/jbc.270.31.18209	http://dx.doi.org/10.1074/jbc.270.31.18209			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629137	hybrid			2022-12-25	WOS:A1995RM64200010
J	PRASAD, MVVSV; DERMOTT, JM; HEASLEY, LE; JOHNSON, GL; DHANASEKARAN, N				PRASAD, MVVSV; DERMOTT, JM; HEASLEY, LE; JOHNSON, GL; DHANASEKARAN, N			ACTIVATION OF JUN KINASE STRESS-ACTIVATED PROTEIN-KINASE BY GTPASE-DEFICIENT MUTANTS OF G-ALPHA(12) AND G-ALPHA(13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; DNA-BINDING; GENE; PHOSPHORYLATION; TRANSCRIPTION; COOPERATION; EXPRESSION; FAMILY; DOMAIN; CELLS	Signal transduction pathways regulated by G(12) and G(13) heterotrimeric G proteins are largely unknown, Expression of activated, GTPase-deficient mutants of alpha(12) and alpha(12) alter physiological responses such as Na+/H+ exchanger activity, but the effector pathways controlling these responses have not been defined, We have found that the expression of GTPase-deficient mutants of alpha(12) (alpha(12)Q229L) or alpha(13) (alpha(13)Q226L) leads to robust activation of the Jun kinase/stress-activated protein kinase (JNK/SAPK) pathway. Inducible alpha(12)Q226L and alpha(13)Q226L expression vectors stably transfected in NIH 3T3 cells demonstrated JNK/SAPK activation but not extracellular response/mitogen-activated protein kinase activation, Transient transfection of alpha(12)Q229L and alpha(13)Q226L also activated the JNK/SAPK pathway in COS-1 cells, Expression of the GTPase-deficient mutant of alpha(q) (alpha(q)Q209L) but not alpha(i) (alpha(i)Q205L) or alpha(s) (alpha(s)Q227L) was also able to activate the JNK/SAPK pathway, Functional Ras signaling was required for alpha(12)Q229L and alpha(13)Q226L activation of the JNK/SAPK pathway; expression of competitive inhibitory N(17)Ras inhibited JNK/SAPK activation in response to both alpha(12)Q229L and alpha(13)Q226L. The results describe for the first time a Ras-dependent signal transduction pathway involving JNK/SAPK regulated by alpha(12) and alpha(13).	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; UNIV COLORADO,SCH MED,DEPT RENAL MED,DENVER,CO 80262; NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health					NCI NIH HHS [CA 58187, 5-P30-CA 12227] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058187, P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIRD TA, 1994, J BIOL CHEM, V269, P31836; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GRINSTEIN S, 1994, BIOCHEM SOC T, V22, P512, DOI 10.1042/bst0220512; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; KRYIAKIS JM, 1994, NATURE, V369, P156; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V10, P6683; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKA.T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKA.TA, 1994, ONCOGENE, V9, P2559; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAN MH, 1994, NATURE, V372, P798	34	172	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18655	18659		10.1074/jbc.270.31.18655	http://dx.doi.org/10.1074/jbc.270.31.18655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629196	hybrid			2022-12-25	WOS:A1995RM64200078
J	HSUEH, YP; LAI, MZ				HSUEH, YP; LAI, MZ			C-JUN N-TERMINAL KINASE BUT NOT MITOGEN-ACTIVATED PROTEIN-KINASE IS SENSITIVE TO CAMP INHIBITION IN T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CELLS; PHOSPHORYLATION; SIGNAL; ONCOPROTEIN; ANTI-CD3; RECEPTOR; MODULATE; PATHWAY; CALCIUM	The molecular mechanism underlying the cAMP inhibition of nuclear activation events in T lymphocytes is unknown. Recently, the activation of fibroblasts and muscle cells are shown to be antagonized by cAMP through the inhibition of mitogen-activated protein (MAP) kinases signaling pathway. Whether a similar antagonism may account for the late inhibitory effect of cAMP in T cell was examined. Surprisingly, extracellular signal regulated kinase 2 (ERK2) activation was resistant to cAMP inhibition in all the T lymphocytes tested. Different isoforms (ERK1, ERK2, and ERK3) of MAP kinase were poorly inhibited by cAMP. High concentration of cAMP also only weakly antagonized Raf-1 in T cells. The resistance of ERK and Raf-1 to cAMP clearly distinguishes T cells from fibroblasts. In contrast, another MAP kinase homologue c-Jun N-terminal kinase (JNK) was inhibited by cAMP in good correlation with that of IL-2 suppression. Moreover, JNK was antagonized by a delayed kinetics which is characteristic of cAMP inhibition. Despite that both ERK and JNK are essential for T cell activation, selective inhibition by cAMP further supports the specific role of JNK in T cell activation.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN; NATL YANG MING UNIV, GRAD INST MICROBIOL & IMMUNOL, TAIPEI 11221, TAIWAN	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University			Hsueh, Yi-Ping/ABH-5052-2020; Lai, Ming-Zong/AAA-4408-2021	Hsueh, Yi-Ping/0000-0002-0866-6275; Lai, Ming-Zong/0000-0002-3237-4803				ANASTASSIOU ED, 1992, J IMMUNOL, V148, P2845; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAI MZ, 1988, J EXP MED, V168, P1081, DOI 10.1084/jem.168.3.1081; LAI MZ, 1987, J IMMUNOL, V139, P3973; LEE MR, 1993, J IMMUNOL, V151, P5208; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LERNER A, 1988, J IMMUNOL, V140, P936; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARY D, 1987, J IMMUNOL, V139, P1179; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NEL AE, 1990, J IMMUNOL, V144, P2683; OSHEA JJ, 1987, J IMMUNOL, V139, P3463; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PARK JH, 1993, BLOOD, V82, P2470; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAN MH, 1994, NATURE, V372, P798; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	40	97	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					18094	18098		10.1074/jbc.270.30.18094	http://dx.doi.org/10.1074/jbc.270.30.18094			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629120	hybrid			2022-12-25	WOS:A1995RM26600071
J	PRYZDIAL, ELG; BAJZAR, L; NESHEIM, ME				PRYZDIAL, ELG; BAJZAR, L; NESHEIM, ME			PROTHROMBINASE COMPONENTS CAN ACCELERATE TISSUE-PLASMINOGEN ACTIVATOR-CATALYZED PLASMINOGEN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-X; FACTOR-VA; ENDOTHELIAL-CELLS; LYS-PLASMINOGEN; HUMAN PLATELETS; BINDING; SURFACE; RECEPTOR; INACTIVATION; TRANSITION	The enzymatic and cofactor subunits of human prothrombinase, factor Xa (FXa) and factor Va (FVa), respectively, were evaluated as modulators of Glu- and Lys-plasminogen (Pg) activation by tissue plasminogen activator (tPA). The data revealed that both FXa and FVa could accelerate tPA activity by as much as 60-fold for Lys-Pg and >150-fold for Glu-Pg. This function of FVa depended on pretreatment with plasmin (Pn), whereas the FXa fibrinolytic cofactor activity was endogenous. In the native state, FVa was observed to inhibit the acceleration of Pn generation by FXa. These effects were dependent on Ca2+ and procoagulant phospholipid. Interactions between plasminogen and prothrombinase components were quantified. The apparent K-d for binding to FXa was 35 nM. Strikingly, the affinity between FVa and Pg was increased by approximately 2 orders of magnitude when the FVa was Pn-pretreated (K-d = 0.1 mu M). These data cumulatively suggest a mechanism by which Pn production is coordinated with coagulation and localized to sites where procoagulant phospholipid is exposed on a cell surface.	UNIV OTTAWA, DEPT BIOCHEM, OTTAWA, ON K1G 4J5, CANADA; QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA	University of Ottawa; Queens University - Canada	PRYZDIAL, ELG (corresponding author), CANADIAN RED CROSS SOC, RES DEPT, 1800 ALTA VISTA DR, OTTAWA, ON K1G 4J5, CANADA.							ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; DAHLBACK B, 1978, BIOCHEMISTRY-US, V17, P4938, DOI 10.1021/bi00616a013; DUDANI AK, 1993, THROMB RES, V69, P185, DOI 10.1016/0049-3848(93)90044-O; DUDANI AK, 1994, BIOCHEM CELL BIOL, V72, P126, DOI 10.1139/o94-019; ELDERING JA, 1993, FEBS LETT, V318, P231, DOI 10.1016/0014-5793(93)80518-Y; ESMON CT, 1979, J BIOL CHEM, V254, P964; FAIR DS, 1975, BIOCHEMISTRY-US, V14, P5561, DOI 10.1021/bi00697a004; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; GONZ PR, 1991, BIOCH CELL BIOL, V69, P554; GONZALEZGRONOW M, 1991, ARCH BIOCHEM BIOPHYS, V286, P625, DOI 10.1016/0003-9861(91)90090-6; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; Jesty J, 1976, Methods Enzymol, V45, P95; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KELM RJ, 1994, J BIOL CHEM, V269, P30147; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KWAAN HC, 1991, SEMIN THROMB HEMOST, V17, P175, DOI 10.1055/s-2007-1002607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; LIJNEN HR, 1993, METHOD ENZYMOL, V223, P197; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1987, THROMBOSIS HAEMOSTAS; MANN KG, 1987, PROTEASES BIOL CONTR; MCGEE MP, 1991, J BIOL CHEM, V266, P8079; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1992, METHOD ENZYMOL, V215, P316; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OMAR MN, 1987, J BIOL CHEM, V262, P9750; PACKHAM MA, 1984, BLOOD PLATELET FUNCT; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; RADCLIFFE RD, 1972, J BIOL CHEM, V247, P7735; REINARTZ J, 1995, J IMMUNOL, V154, P844; ROBBINS KC, 1982, HEMOSTASIS THROMBOSI, P623; RODGERS GM, 1985, BIOCHIM BIOPHYS ACTA, V844, P320, DOI 10.1016/0167-4889(85)90133-8; SAKAI T, 1990, HAEMOSTASIS, V20, P125; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TRACY PB, 1981, J BIOL CHEM, V256, P743; TRACY PB, 1985, J BIOL CHEM, V260, P2119; TRACY PB, 1992, METHOD ENZYMOL, V215, P329; ZWAAL RFA, 1993, BIOCHEM SOC T, V21, P248, DOI 10.1042/bst0210248	59	21	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17871	17877		10.1074/jbc.270.30.17871	http://dx.doi.org/10.1074/jbc.270.30.17871			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629090	hybrid			2022-12-25	WOS:A1995RM26600038
J	CASTANO, EM; PRELLI, F; PRAS, M; FRANGIONE, B				CASTANO, EM; PRELLI, F; PRAS, M; FRANGIONE, B			APOLIPOPROTEIN-E CARBOXYL-TERMINAL FRAGMENTS ARE COMPLEXED TO AMYLOID-A AND AMYLOID-L - IMPLICATIONS FOR AMYLOIDOGENESIS AND ALZHEIMERS-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA-LIPOPROTEINS; RAT SCIATIC-NERVE; P-COMPONENT; CHOLESTEROL TRANSPORT; DENSITY LIPOPROTEIN; PROTEIN SAA; A-I; CONSTITUENT; BINDING; GLYCOSAMINOGLYCANS	Apolipoprotein E (ApoE) immunoreactivity is consistently present in the senile plaques and neurofibrillary tangles of Alzheimer's disease (AD) brain. In vitro, apoE, and in particular its apoE4 isoform, can bind to and promote fibrillogenesis of the amyloid A beta peptide, the main constituent of senile plaques. These findings, together with the strong genetic association between late onset AD and the E4 allele of apoE, have strengthened the hypothesis that apoE may have a central role in the pathogenesis of AD by modulating A beta cerebral accumulation. However, apoE immunoreactivity is present in all cerebral and systemic amyloidoses tested, and tryptic apoE fragments have been identified in association with amyloid A (AA). In order to further elucidate the interaction between apoE and amyloids, we purified AA and amyloid L (AL) fibrils from patients with familial Mediterranean fever and primary amyloidosis, respectively, and studied the association of apoE with AA and AL proteins. In each case, apoE fragments, detected by Western blot, co-purified with the amyloid fibrils. Microsequencing analysis identified COOH-terminal fragments of apoE, similar to the 10-kDa fragment produced by thrombin digestion that contains the purported binding region to A beta. In vitro co-incubation of AA with purified human apoE resulted in the formation of an SDS-resistant AA-apoE complex and a higher degree of polymerization of the AA peptide. These findings and similar results obtained from AD senile plaques suggest that 1) the carboxyl-terminal fragment of apoE is complexed to amyloid fibrils and resists proteolysis in vivo and 2) apoE may promote amyloidogenesis through a conformation-dependent interaction regardless of the primary structure of the amyloid precursors.	CHAIM SHEBA MED CTR,HELLER INST MED RES,IL-52621 TEL HASHOMER,ISRAEL	Chaim Sheba Medical Center	CASTANO, EM (corresponding author), NYU,MED CTR,DEPT PATHOL,550 1ST AVE,TH427,NEW YORK,NY 10016, USA.				NIAMS NIH HHS [AR02594] Funding Source: Medline; NIA NIH HHS [AG05891, AG10953] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR002594, R01AR002594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG010953, R37AG005891, R01AG005891] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENDITT EP, 1979, P NATL ACAD SCI USA, V76, P4092, DOI 10.1073/pnas.76.8.4092; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BUGIANI O, 1994, NEUROBIOL AGING, V15, pS156, DOI 10.1016/0197-4580(94)93095-3; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORIA F, 1988, LAB INVEST, V58, P454; DUONG T, 1989, ACTA NEUROPATHOL, V78, P429, DOI 10.1007/BF00688180; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GALLO G, 1994, AM J PATHOL, V145, P526; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LEBLANC AC, 1990, J NEUROSCI RES, V25, P162, DOI 10.1002/jnr.490250203; MA J, 1995, NATURE, V372, P92; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCADAM KPWJ, 1976, J EXP MED, V144, P1121, DOI 10.1084/jem.144.4.1121; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NICHOLS WC, 1988, BIOCHEM BIOPH RES CO, V156, P762, DOI 10.1016/S0006-291X(88)80909-4; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; PRAS M, 1968, J CLIN INVEST, V47, P924; PRELLI F, 1991, SCAND J IMMUNOL, V33, P783, DOI 10.1111/j.1365-3083.1991.tb02553.x; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGREST JP, 1992, J LIPID RES, V33, P141; SELKOE DJ, 1986, J NEUROCHEM, V146, P1820; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; SNOW AD, 1987, LAB INVEST, V56, P120; SNOW AD, 1988, ALZ DIS ASSOC DIS, V2, P232; SOUTAR AK, 1992, P NATL ACAD SCI USA, V89, P7389, DOI 10.1073/pnas.89.16.7389; STEINMETZ A, 1989, ARTERIOSCLEROSIS, V9, P405, DOI 10.1161/01.ATV.9.3.405; STENSTAD T, 1993, CLIN EXP IMMUNOL, V94, P189; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V20, P1977; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISNIEWSKI T, 1995, LANCET, V345, P956, DOI 10.1016/S0140-6736(95)90701-7; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1994, ANN NEUROL, V35, P245, DOI 10.1002/ana.410350223; WONG CW, 1985, P NATL ACAD SCI USA, V82, P8729, DOI 10.1073/pnas.82.24.8729; YOUNG ID, 1989, ACTA NEUROPATHOL, V78, P202, DOI 10.1007/BF00688210	47	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17610	17615		10.1074/jbc.270.29.17610	http://dx.doi.org/10.1074/jbc.270.29.17610			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615568	hybrid			2022-12-25	WOS:A1995RK68900085
J	HOHL, RJ; LEWIS, K				HOHL, RJ; LEWIS, K			DIFFERENTIAL-EFFECTS OF MONOTERPENES AND LOVASTATIN ON RAS PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-LIMONENE; SELECTIVE-INHIBITION; PROTEIN TRANSFERASE; CARCINOGENESIS; ISOPRENYLATION; FARNESYLTRANSFERASE; PEPTIDOMIMETICS; TRANSFORMATION; FARNESYLATION; CELLS	Limonene and related monoterpenes have been shown to impair the incorporation of mevalonic acid-derived isoprene compounds, that is farnesyl pyrophosphate, into RAS and RAS-related proteins. As farnesylation is critical for RAS's membrane localization and function, the isoprenylation pathways have received attention as potential targets of anti-RAS pharmacologic maneuvers. We have expanded on these prior studies and demonstrate that one of limonene's metabolic derivatives, perillyl alcohol, decreases the levels of antigenic RAS in the human-derived myeloid THP-1 and lymphoid RPMI-8402 cell lines. Both limonene and perillyl alcohol decrease levels of [S-35]methionine-labeled RAS proteins in cells that have been pulsed with radiolabeled methionine for 4 h. In contrast, lovastatin, which inhibits hydroxymethylglutaryl coenzyme A reductase and thus depletes cells of farnesyl pyrophosphate, does not diminish levels of total antigenic RAS but rather results in a shift in the RAS protein; levels of farnesylated RAS decrease whereas levels of unmodified/unfarnesylated RAS increase. As limonene and perillyl alcohol do not induce such a shift, we conclude that these monoterpenes decrease farnesylated RAS protein levels by a mechanism that is clearly distinct from that of either depleting cells of farnesyl pyrophosphate or inhibiting the enzyme farnesyl protein transferase that catalyzes the post-translational farnesylation of RAS. Perillyl alcohol decreases antigenic RAS levels but does not decrease levels of another membrane-tethered protein, the alpha subunit of the heterotrimeric G protein. Furthermore, perillyl alcohol decreases the levels of radiolabeled methionine incorporated into immunoprecipitable RAS to a greater extent than it decreases radiolabeled methionine incorporated into total cellular protein. Thus there is some degree of specificity for the activity of perillyl alcohol to depress RAS levels.	UNIV IOWA,DEPT PHARMACOL,IOWA CITY,IA 52242	University of Iowa	HOHL, RJ (corresponding author), UNIV IOWA,DEPT INTERNAL MED,C32-I GH,IOWA CITY,IA 52242, USA.							BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CROWELL PL, 1991, J BIOL CHEM, V266, P17679; CROWELL PL, 1994, BIOCHEM PHARMACOL, V47, P1405, DOI 10.1016/0006-2952(94)90341-7; ELEGBEDE JA, 1984, CARCINOGENESIS, V5, P661, DOI 10.1093/carcin/5.5.661; ELSON CE, 1988, CARCINOGENESIS, V9, P331, DOI 10.1093/carcin/9.2.331; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; HAAG JD, 1992, CANCER RES, V52, P4021; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JONES TLZ, 1990, J BIOL CHEM, V265, P19389; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KAWATA S, 1994, BRIT J CANCER, V69, P1015, DOI 10.1038/bjc.1994.199; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LEONARD S, 1990, J BIOL CHEM, V265, P5157; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTZMAN TH, 1989, CARCINOGENESIS, V10, P781, DOI 10.1093/carcin/10.4.781; NIGAM M, 1993, J BIOL CHEM, V268, P20695; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; WATTENBERG LW, 1989, CANCER RES, V49, P2689; WATTENBERG LW, 1991, CARCINOGENESIS, V12, P115, DOI 10.1093/carcin/12.1.115	26	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17508	17512		10.1074/jbc.270.29.17508	http://dx.doi.org/10.1074/jbc.270.29.17508			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615555	hybrid			2022-12-25	WOS:A1995RK68900071
J	NAKANISHI, M; ROBETORYE, RS; PEREIRASMITH, OM; SMITH, JR				NAKANISHI, M; ROBETORYE, RS; PEREIRASMITH, OM; SMITH, JR			THE C-TERMINAL REGION OF P21(SDI1/WAF1/CIP1) IS INVOLVED IN PROLIFERATING CELL NUCLEAR ANTIGEN-BINDING BUT DOES NOT APPEAR TO BE REQUIRED FOR GROWTH-INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-DIPLOID FIBROBLASTS; KINASES; DNA; P21	The cyclin-dependent kinase (Cdk) inhibitor p21(SDI1/WAF1/CIP1) has been found to be involved in cell senescence, cell cycle arrest, and differentiation. p21(SD11) inhibits the activity of several Cdks, in contrast to other inhibitors such as p15(INK4B) and p16(INK4A), which act on specific cyclin-Cdk complexes, Of interest were reports that p21(SD11) also bound proliferating cell nuclear antigen (PCNA), an auxiliary protein for DNA polymerase delta, and inhibited DNA replication but not DNA repair in vitro, To better understand the function of this interaction in vivo, we first determined the region of p21(SD11) that was needed for PCNA binding. Analysis of deletion mutants of p21(SD11), which covered the majority of the protein, revealed that deletion of either amino acids 142-147 or 149-154 resulted in loss of ability to bind a glutathione S-transferase-PCNA fusion protein. Site-directed mutagenesis in this region led to the identification of the PCNA binding motif RQXXMTXFYXXXR and demonstrated that mutation of either amino acid Met-147 or Phe-150 resulted in almost complete ablation of PCNA binding. Interestingly, when we determined DNA synthesis inhibitory activity of deletion mutants or point mutants that were unable to bind Cdk2 and/or PCNA, we found that loss of binding to PCNA did not affect inhibitory activity, whereas lack of Cdk2 binding greatly reduced the same. This result suggests that the primary mechanism for inhibition of DNA synthesis by p21(SD11) occurs via inhibition of Cdk activity.	BAYLOR COLL MED,DIV MOLEC VIROL,ROY M & PHYLLIS GOUGH HUFFINGTON CTR AGING,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NIA NIH HHS [AG05333, AG07123, AG11066] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG005333, R01AG011066, P01AG007123, R37AG005333] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HUPPI K, 1994, ONCOGENE, V9, P3017; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEREIRASMITH OM, 1982, SOMAT CELL GENET, V8, P731, DOI 10.1007/BF01543015; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SMITH JR, 1992, EXP GERONTOL, V27, P409, DOI 10.1016/0531-5565(92)90073-9; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	19	102	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17060	17063		10.1074/jbc.270.29.17060	http://dx.doi.org/10.1074/jbc.270.29.17060			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615495	hybrid			2022-12-25	WOS:A1995RK68900002
J	NELSON, RW; BATES, PA; RUTISHAUSER, U				NELSON, RW; BATES, PA; RUTISHAUSER, U			PROTEIN DETERMINANTS FOR SPECIFIC POLYSIALYLATION OF THE NEURAL CELL-ADHESION MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; MONOCLONAL-ANTIBODY EPITOPES; FIBRONECTIN TYPE-III; POLYSIALIC ACID; N-CAM; ELECTROPHORETIC TRANSFER; FUNCTIONAL DETERMINANTS; POLYACRYLAMIDE GELS; SIALYLATION STATE; NCAM	Expression of polysialic acid (PSA) involves its specific attachment to the neural cell adhesion molecule (NCAM), Here we identify the amino acid residues within NCAM that are polysialylated and structural domains of the NCAM polypeptide that are required for addition of PSA in cells, Chicken NCAM cDNAs containing amino acid mutations, domain deletions, and domain substitutions were expressed in the F11 rat/mouse hybrid cell line, which can produce polysialylated NCAM, Polysialylation of the chicken NCAM was evaluated by immunopurification and electrophoresis, Mutation of all three potential N-glycosylation sites within the fifth immunoglobulin domain (Ig5) abrogated polysialylation, Analysis of paired mutations revealed that Asn-459 is heavily polysialylated, Asn-430 has a lower level of substitution, and Asn-404 receives little or no PSA, Analysis of domain deletions established that the intracellular domain, Ig domains 1-3, and the COOH terminal fibronectin-type III (FNIII) repeat are not required for polysialylation, but that deletion of either the adjacent Ig4 or FNIII-type domain prevented addition of PSA, Accordingly, a minimal polypeptide for polysialylation was found to contain Ig domains 4 and 5, the adjacent FNIII repeat, plus a membrane attachment, These results suggest that although all PSA is located within Ig5, regions outside Ig5 also play a role in PSA addition to NCAM, Furthermore, molecular modeling indicates spatial proximity of Asn-430 and Asn-459 and a tight-locking arrangement between Ig4, Ig5, and FMIII#1 that would be consistent with their formation of a spatially discrete enzyme recognition site for polysialylation.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT GENET, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA; IMPERIAL CANC RES FUND, BIOMOLEC MODELING LAB, LONDON WC2A 3PX, ENGLAND	Case Western Reserve University; Case Western Reserve University; Cancer Research UK			Bates, Paul A/AAF-8561-2020	Bates, Paul A/0000-0003-0621-0925	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018369, R37HD018369, T32HD007104] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006107] Funding Source: NIH RePORTER; NEI NIH HHS [EY06107] Funding Source: Medline; NICHD NIH HHS [HD07104, HD18369] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; ALCARAZ G, 1991, EUR J CELL BIOL, V55, P165; BATES PA, 1992, FEBS LETT, V301, P207, DOI 10.1016/0014-5793(92)81249-L; BREEN KC, 1988, DEVELOPMENT, V104, P147; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CROSSIN KL, 1984, J CELL BIOL, V99, P1848, DOI 10.1083/jcb.99.5.1848; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIESENHOFER J, 1981, BIOCHEMISTRY-US, V31, P4996; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DOHERTY P, 1992, DEVELOPMENT, V115, P885; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FINNE J, 1985, J BIOL CHEM, V260, P1265; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; FREDETTE B, 1993, J CELL BIOL, V123, P1867, DOI 10.1083/jcb.123.6.1867; FRELINGER AL, 1986, J CELL BIOL, V103, P1729, DOI 10.1083/jcb.103.5.1729; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HE HT, 1987, J CELL BIOL, V105, P2489, DOI 10.1083/jcb.105.6.2489; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROG L, 1992, APMIS, V100, P53; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; REGAN CM, 1991, INT J BIOCHEM, V23, P513; REGLERO A, 1993, INT J BIOCHEM, V25, P1517, DOI 10.1016/0020-711X(93)90507-B; ROUGON G, 1993, EUR J CELL BIOL, V61, P197; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; RUTISHAUSER U, 1992, DEVELOPMENT, P99; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1988, J NEUROSCI RES, V20, P304, DOI 10.1002/jnr.490200304; SCHACHNER M, 1989, CIBA F SYMP, V145, P156; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; SEKI T, 1991, ANAT EMBRYOL, V184, P395, DOI 10.1007/BF00957900; SUNSHINE J, 1987, P NATL ACAD SCI USA, V84, P5986, DOI 10.1073/pnas.84.16.5986; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8; ZHANG H, 1992, J NEUROSCI, V12, P3107, DOI 10.1523/JNEUROSCI.12-08-03107.1992	52	112	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17171	17179		10.1074/jbc.270.29.17171	http://dx.doi.org/10.1074/jbc.270.29.17171			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615513	hybrid			2022-12-25	WOS:A1995RK68900020
J	VIAL, D; SENORALEPOSE, M; HAVET, N; MOLIO, L; VARGAFTIG, BB; TOUQUI, L				VIAL, D; SENORALEPOSE, M; HAVET, N; MOLIO, L; VARGAFTIG, BB; TOUQUI, L			EXPRESSION OF THE TYPE-II PHOSPHOLIPASE A(2) IN ALVEOLAR MACROPHAGES - DOWN-REGULATION BY AN INFLAMMATORY SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG; CELLS; INHIBITION; SECRETION; ENZYMES; CLONING	We have shown previously that guinea pig alveolar macrophages (AM) synthesize a secretory phospholipase A(2) (PLA(2)) during in vitro incubation. Here, we report the molecular cloning of this enzyme and show that it has structural features closely related to all known mammalian type-II PLA(2). The mRNA and PLA(2) activity were undetectable in freshly collected AM, but their levels increased dramatically to reach maximal values after 16 h of culture. Thereafter, the PLA(2) activity remained constant with a parallel secretion in the medium, in contrast to mRNA level which returned to near basal values after 32 h. Incubation of AM for 16 h with the inflammatory secretagogue peptide f-Met-Leu-Phe (fMLP) markedly reduced the PLA(2) activity and mRNA levels. This inhibition was prevented by preexposure of AM to pertussis toxin, an inhibitor of G-protein. In contrast, when AM were first cultured for 16 h and then incubated with fMLP, no significant change was observed in their PLA(2) activity. In conditions where the type-II PLA(2) was completely abrogated by fMLP, the latter did not alter the lipopolysaccharide-induced accumulation of tumor necrosis factor ru mRNA or the release of arachidonic acid induced by the subsequent addition of the calcium ionophore A23187. These studies show that the inflammatory peptide fMLP down-regulates the expression of the type-II PLA(2) by AM through a process mediated by G-protein. A possible negative control of the type-II PLA(2) expression during AM activation is suggested.	CNRS,URA 361,UNITE GENET BIOCHIM DEV,UNITE ASSOCIEE PASTEUR,F-75015 PARIS,FRANCE; INST PASTEUR,F-75015 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	VIAL, D (corresponding author), INSERM,U285,UNITE PHARMACOL CELLULAIRE,UNITE ASSOCIEE PASTEUR,25 RUE DR ROUX,F-75015 PARIS,FRANCE.		Vargaftig, Bernardo Boris B.B.J./C-3323-2013					BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BOUKILI MA, 1989, BRIT J PHARMACOL, V98, P61, DOI 10.1111/j.1476-5381.1989.tb16863.x; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DENNIS EA, 1989, J BIOL CHEM, V269, P3057; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; HIDI R, 1989, J IMMUNOL, V151, P5613; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MOUNIER C, 1993, EUR J BIOCHEM, V216, P169, DOI 10.1111/j.1432-1033.1993.tb18129.x; MOUNIER C, 1994, BBA-LIPID LIPID MET, V1214, P88, DOI 10.1016/0005-2760(94)90013-2; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; PRETOLANI M, 1993, BIOCHEM PHARMACOL, V45, P791, DOI 10.1016/0006-2952(93)90161-O; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Sambrook J, 1989, MOL CLONING LABORATO; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; YING Z, 1993, EUR J BIOCHEM, V215, P91, DOI 10.1111/j.1432-1033.1993.tb18010.x	25	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17327	17332		10.1074/jbc.270.29.17327	http://dx.doi.org/10.1074/jbc.270.29.17327			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615534	hybrid			2022-12-25	WOS:A1995RK68900045
J	COMBADIERE, C; AHUJA, SK; MURPHY, PM				COMBADIERE, C; AHUJA, SK; MURPHY, PM			CLONING AND FUNCTIONAL EXPRESSION OF A HUMAN EOSINOPHIL CC-CHEMOKINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN INTERLEUKIN-8 RECEPTOR; MOLECULAR-CLONING; RANTES; IDENTIFICATION; NEUTROPHILS; BINDING	Eosinophils undergo chemotaxis, degranulate, and exhibit [Ca2+](i) changes in response to the human CC chemokines macrophage inflammatory protein (MLP)-1 alpha, regulated on activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein-3 (MCP-3), but the receptors involved have not been defined. We have isolated a human cDNA encoding the first eosinophil-selective chemokine receptor, designated GC chemokine receptor 3 (CC CKR3). CC CKR3 is a seven-transmembrane domain G protein-coupled receptor most closely related to the previously reported monocyte- and neutrophil-selective receptor CC CKR1 (also known as the MIP-1 alpha/RANTES receptor). When [Ca2+](i) changes were monitored in stably transfected human embryonic kidney 293 cells, MIP-1 alpha and RANTES were both potent agonists for CC CKR3 and CC CKR1. However, MIP-1 beta was also an agonist for CC CKR3 but not CC CKR1; MCP-3 was an agonist for CC CKR1 but not CC CKR3, CC CKR3 may be one of the host factors responsible for selective recruitment of eosinophils to sites of inflammation.	NIAID,HOST DEF LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Combadiere, Christophe/I-5639-2013	Combadiere, Christophe/0000-0002-1755-4531				AHUJA SK, 1994, J BIOL CHEM, V269, P26381; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, IN PRESS DNA CELL BI; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAO JL, 1994, J BIOL CHEM, V269, P28539; GAO JL, 1995, IN PRESS J BIOL CHEM, V270; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MCCOLL SR, 1993, J IMMUNOL, V150, P4550; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MOSER B, 1991, J BIOL CHEM, V266, P10666; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHRAUFSTATTER IU, 1993, J IMMUNOL, V151, P6418; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VANRIPER G, 1994, J IMMUNOL, V152, P4055; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699	26	209	288	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16491	16494		10.1074/jbc.270.28.16491	http://dx.doi.org/10.1074/jbc.270.28.16491			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622448	hybrid			2022-12-25	WOS:A1995RJ34700003
J	CROTEAU, W; WHITTEMORE, SL; SCHNEIDER, MJ; STGERMAIN, D				CROTEAU, W; WHITTEMORE, SL; SCHNEIDER, MJ; STGERMAIN, D			CLONING AND EXPRESSION OF A CDNA FOR A MAMMALIAN TYPE-III IODOTHYRONINE DEIODINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS-OOCYTES; THYROID-HORMONES; RAT; 5'-DEIODINASE; SELENIUM; SELENOCYSTEINE; THYROXINE; PROPYLTHIOURACIL; SELENOPROTEIN; DEFICIENCY	The type III iodothyronine deiodinase metabolizes the active thyroid hormones thyroxine and 3,5,3'-triiodothyronine to inactive compounds. Recently, we have characterized a Xenopus laevis cDNA (XL-15) that encodes a selenoprotein with type III deiodinase activity (St. Germain, D. L., Schwartzman, R., Croteau, W., Kanamori, A., Wang, Z., Brown, D. D., and Galton, V. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7767-7771). Using the XL-15 as a probe, we screened a rat neonatal skin cDNA library. Among the clones isolated was one (rNS43-1) which contained a 2.1-kilobase pair cDNA insert that manifested significant homology to both the XL-15 and the G21 rat type I deiodinase cDNAs, including the presence of an in-frame TGA codon. Expression studies demonstrated that the rNS43-1 cDNA encodes a protein with 5-, but not 5'-, deiodinase activity that is resistant to inhibition by propylthiouracil and aurothioglucose. Northern analysis demonstrated a pattern of tissue expression in the rat consistent with that of the type III deiodinase and site directed mutagenesis confirmed that the TGA triplet codes for selenocysteine. We conclude that the rNS43-1 cDNA encodes the rat type III deiodinase and that the types I and III deiodinases present in amphibians and mammals constitute a family of conserved selenoproteins important in the metabolism of thyroid hormones.	DARTMOUTH COLL, SCH MED, DEPT MED, LEBANON, NH 03756 USA; DARTMOUTH COLL, SCH MED, DEPT PHYSIOL, LEBANON, NH 03756 USA	Dartmouth College; Dartmouth College					NICHD NIH HHS [HD-27706] Funding Source: Medline; NIDDK NIH HHS [DK42271, DK-08671] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042271, F32DK008671] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1992, J BIOL CHEM, V267, P18055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKMAN TD, 1993, BIOCHIM BIOPHYS ACTA, V1163, P176, DOI 10.1016/0167-4838(93)90179-U; CHANOINE JP, 1993, J CLIN INVEST, V91, P2709, DOI 10.1172/JCI116510; CHANOINE JP, 1993, PEDIATR RES, V34, P288, DOI 10.1203/00006450-199309000-00009; DAVEY JC, 1994, DEV GENET, V15, P339, DOI 10.1002/dvg.1020150405; GOSWAMI A, 1986, ENDOCRINOLOGY, V119, P916, DOI 10.1210/endo-119-2-916; HUANG TS, 1988, PEDIATR RES, V23, P196, DOI 10.1203/00006450-198802000-00014; HUANG TS, 1985, ENDOCRINOLOGY, V117, P2106, DOI 10.1210/endo-117-5-2106; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P2137, DOI 10.1210/endo-103-6-2137; MANDEL SJ, 1992, J CLIN ENDOCR METAB, V75, P1133, DOI 10.1210/jc.75.4.1133; MEINHOLD H, 1993, EXP CLIN ENDOCRINOL, V101, P87, DOI 10.1055/s-0029-1211212; MORENO M, 1994, FEBS LETT, V344, P143, DOI 10.1016/0014-5793(94)00365-3; OMARA BA, 1993, ENDOCRINOLOGY, V133, P1715, DOI 10.1210/en.133.4.1715; SANTINI F, 1992, ENDOCRINOLOGY, V130, P2325, DOI 10.1210/en.130.4.2325; SHARIFI J, 1992, J BIOL CHEM, V267, P12539; SILVA JE, 1984, J CLIN INVEST, V74, P1035, DOI 10.1172/JCI111471; STGERMAIN DL, 1989, J BIOL CHEM, V264, P3054; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P7767, DOI 10.1073/pnas.91.16.7767; STGERMAIN DL, 1994, THYROID HORMONE METABOLISM, P45; STGERMAIN DL, 1989, MOL ENDOCRINOL, V3, P2049; TOYODA N, 1994, J BIOL CHEM, V269, P20329; TOYODA N, 1994, 76TH ANN M END SOC A; VERONIKIS IE, 1994, 68TH M AM THYR ASS C, P69; VISSER TJ, 1992, ACTA MED AUST, V19, P18; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WU SY, 1991, THYROID HORMONE META, P293	32	170	177	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16569	16575		10.1074/jbc.270.28.16569	http://dx.doi.org/10.1074/jbc.270.28.16569			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622463	hybrid			2022-12-25	WOS:A1995RJ34700019
J	SHIKATA, Y; WATANABE, T; TERAMOTO, T; INOUE, A; KAWAKAMI, Y; NISHIZAWA, Y; KATAYAMA, K; KUWADA, M				SHIKATA, Y; WATANABE, T; TERAMOTO, T; INOUE, A; KAWAKAMI, Y; NISHIZAWA, Y; KATAYAMA, K; KUWADA, M			ISOLATION AND CHARACTERIZATION OF A PEPTIDE ISOMERASE FROM FUNNEL-WEB SPIDER VENOM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; CALCIUM CHANNELS; IVB	A novel peptide isomerase was purified from the venom of funnel web spider, Agelenopsis aperta. The complete primary structure of the isomerase has been established by sequence analyses of polypeptide chains, assignments of disulfide bridges, carbohydrate analyses, and mass spectrometry of sugar chains. The isomerase was found to be a 29-kDa polypeptide that consists of an 18-residue light chain and a 243-residue heavy chain connected by a single disulfide bridge. The heavy chain contains three intramolecular disulfide bridges and one N-linked oligosaccharide chain with a simple trimannosyl core structure. A sequence homology search showed a significant similarity of the enzyme with serine proteases, particularly around a putative catalytic triad of the isomerase. The isomerase specifically interconverts the configuration of Ser(46) of a 48-amino-acid peptide, omega-agatoxin-TK, and the conversion rate from L-Ser to D-Ser was approximately two times faster than the reverse reaction.	EISAI TSUKUBA RES LABS, DEPT PHYS & ANALYT CHEM, TSUKUBA, IBARAKI 30026, JAPAN	Eisai Co Ltd								ADAMS ME, 1993, MOL PHARMACOL, V44, P681; Bornstein P, 1977, Methods Enzymol, V47, P132; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P4; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3991, DOI 10.1021/bi00066a020; HECK SD, 1994, J AM CHEM SOC, V116, P10426, DOI 10.1021/ja00102a009; HECK SD, 1994, SCIENCE, V266, P1065, DOI 10.1126/science.7973665; HUANG HV, 1983, METHOD ENZYMOL, V91, P318; ITOH N, 1988, J BIOL CHEM, V263, P7628; JACOBSON J, 1984, J PHYS CHEM-US, V88, P4536, DOI 10.1021/j150664a018; KIMURA M, 1995, NEUROSCIENCE, V66, P609, DOI 10.1016/0306-4522(95)00023-C; KREIL G, 1994, J BIOL CHEM, V269, P10967; KUWADA M, 1994, MOL PHARMACOL, V46, P587; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; SHIEH JC, 1988, J BIOCHEM-TOKYO, V103, P596; STEINMAN HM, 1974, J BIOL CHEM, V249, P7326; TERAMOTO T, 1993, BIOCHEM BIOPH RES CO, V196, P134, DOI 10.1006/bbrc.1993.2225; WATANABE T, 1995, PEPTIDE CH, P253; YU HT, 1993, BIOCHEMISTRY-US, V32, P13123, DOI 10.1021/bi00211a022	20	79	86	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16719	16723		10.1074/jbc.270.28.16719	http://dx.doi.org/10.1074/jbc.270.28.16719			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622482	hybrid			2022-12-25	WOS:A1995RJ34700042
J	SRIVASTAVA, DK; RAWSON, TY; SHOWALTER, SD; WILSON, SH				SRIVASTAVA, DK; RAWSON, TY; SHOWALTER, SD; WILSON, SH			PHORBOL ESTER ABROGATES UP-REGULATION OF DNA-POLYMERASE-BETA BY DNA-ALKYLATING AGENTS IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; REPAIR SYNTHESIS; MESSENGER-RNA; DEOXYRIBONUCLEIC-ACID; MONOCLONAL-ANTIBODIES; DAMAGING AGENTS; BINDING-PROTEIN; CDNA CLONING; C-JUN; PROMOTER	Mammalian DNA polymerase beta (beta-pol), a DNA repair polymerase, is known to be constitutively expressed in cultured cells, but treatment of cells with the DNA-alkylating agents MNNG or methyl methanesulfonate has been shown to up-regulate beta-pol mRNA level. To further characterize this response, we prepared a panel of monoclonal antibodies and used one of them to quantify beta-pol in whole cell extracts by immunoblotting. We found that treatment of Chinese hamster ovary cells with either DNA-alkylating agent up-regulated the beta-pol protein level 5-10-fold. This induction appeared to be secondary to DNA alkylation, as induction was not observed with a genetically altered cell line overexpressing the DNA repair enzyme O-6-methylguanine-methyltransferase We also found that 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment of wild type Chinese hamster ovary cells increased expression of beta-pol protein (similar to 10-fold). Any interrelationship between this TPA response and the DNA-alkylation response was studied by treatment with combinations of MNNG and TPA. The beta-pol up-regulation observed with MNNG treatment was abrogated by TPA, and conversely the up-regulation observed with TPA treatment was abrogated by MNNG.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555; BIOMOLEC TECHNOL INC,FREDERICK,MD 21701	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NIEHS NIH HHS [ESO6839, ESO6492] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006839, R01ES006492] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARTEAGA CL, 1994, CANCER RES, V54, P3758; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUCKBINDER L, 1989, EMBO J, V8, P4239, DOI 10.1002/j.1460-2075.1989.tb08609.x; BUSCHER M, 1988, ONCOGENE, V3, P301; CHANG LMS, 1972, BIOCHEMISTRY-US, V11, P1264, DOI 10.1021/bi00757a023; CHEN KH, IN PRESS GENE AMST; DENG WP, 1994, MOL CELL BIOL, V14, P391, DOI 10.1128/MCB.14.1.391; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; DRESLER SL, 1987, BIOCHEMISTRY-US, V26, P2664, DOI 10.1021/bi00384a002; DUNN WC, 1991, CARCINOGENESIS, V12, P83, DOI 10.1093/carcin/12.1.83; ENGLANDER EW, 1992, NUCLEIC ACIDS RES, V20, P5527, DOI 10.1093/nar/20.21.5527; ENGLANDER EW, 1992, DNA CELL BIOL, V11, P61, DOI 10.1089/dna.1992.11.61; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; KUMAR A, 1990, J BIOL CHEM, V265, P2124; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MILLER MR, 1982, J BIOL CHEM, V257, P204; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; NELSON WG, 1994, MOL CELL BIOL, V16, P1815; NOWAK R, 1989, BIOCHIM BIOPHYS ACTA, V1008, P203, DOI 10.1016/0167-4781(80)90010-X; RANDAHL H, 1988, J BIOL CHEM, V263, P12228; RECUPERO AJ, 1992, BIOCHEMISTRY-US, V31, P7989, DOI 10.1021/bi00149a033; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; SENGUPTA DN, 1986, BIOCHEM BIOPH RES CO, V136, P341, DOI 10.1016/0006-291X(86)90916-2; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHOWALTER SD, 1981, INFECT IMMUNOL, V43, P684; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SMITH CA, 1984, BIOCHEMISTRY-US, V23, P1383, DOI 10.1021/bi00302a008; STEVENSON MA, 1994, CANCER RES, V54, P12; SWACK JA, 1985, ANAL BIOCHEM, V147, P10, DOI 10.1016/0003-2697(85)90003-X; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9587, DOI 10.1093/nar/16.20.9587; ZMUDZKA BZ, 1986, P NATL ACAD SCI USA, V83, P5106, DOI 10.1073/pnas.83.14.5106; ZU YL, 1993, ONCOGENE, V8, P2749	48	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16402	16408		10.1074/jbc.270.27.16402	http://dx.doi.org/10.1074/jbc.270.27.16402			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608211	hybrid			2022-12-25	WOS:A1995RH22600078
J	WU, ZN; JOHNSON, KW; GOLDSTEIN, B; CHOI, Y; EATON, SF; LAUE, TM; CIARDELLI, TL				WU, ZN; JOHNSON, KW; GOLDSTEIN, B; CHOI, Y; EATON, SF; LAUE, TM; CIARDELLI, TL			SOLUTION ASSEMBLY OF A SOLUBLE, HETEROMERIC, HIGH-AFFINITY INTERLEUKIN-2 RECEPTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICAL COILED-COILS; GAMMA-CHAIN; FUNCTIONAL CONSEQUENCES; LEUCINE ZIPPERS; AMINO-ACIDS; EXPRESSION; STABILITY; PROTEINS; ANTIBODY; BINDING	In this study, we report the use of coiled-coil (leucine zipper) molecular recognition for the solution assembly of stable, high affinity, heteromeric interleukin-2 receptor complexes, Co-expression of interleukin-2 receptor alpha and beta extracellular domains (ectodomains), each fused to seven coiled-coil heptad repeats, resulted in the formation of heteromeric complexes that bound interleukin-2 in a cooperative fashion and with much higher affinity than similar homomeric complexes, The dissociation constants for these solution complexes are within the range of values reported for the comparable cell surface ''pseudo high affinity'' interleukin-2 receptor. Ligand-induced cross-linking of homomeric or heteromeric receptor subunits is the common signal transmission mechanism employed by hematopoietin receptors. Individual receptor ectodomains, however, often do not bind ligand with measurable affinity, This is the first study to demonstrate the feasibility of coiled coil mediated preassembly of cytokine receptor complexes.	DARTMOUTH COLL,SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755; VET ADM MED CTR,WHITE RIVER JCT,VT 05009; CHIRON CORP,EMERYVILLE,CA 94608; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; UNIV NEW HAMPSHIRE,DEPT BIOCHEM,DURHAM,NH 03824	Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA); Novartis; United States Department of Energy (DOE); Los Alamos National Laboratory; University System Of New Hampshire; University of New Hampshire			Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035556, R01GM035556] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34331] Funding Source: Medline; NIGMS NIH HHS [GM35556] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; CALIGIURI MA, 1990, J EXP MED, V171, P1509, DOI 10.1084/jem.171.5.1509; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Efron B, 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; GILLIS S, 1978, J IMMUNOL, V121, P2077; GOLDSTEIN B, 1992, INT IMMUNOL, V4, P23, DOI 10.1093/intimm/4.1.23; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; JOHNSON K, 1994, EUR CYTOKINE NETW, V5, P23; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; LANDGRAF BE, 1992, J BIOL CHEM, V267, P18511; LAUE TM, 1994, PROG COLL POL SCI S, V94, P74; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MATSUOKA M, 1993, EUR J IMMUNOL, V23, P2472, DOI 10.1002/eji.1830231014; MINAMI Y, 1994, J IMMUNOL, V152, P5680; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; ONIEL KT, 1990, SCIENCE, V250, P646; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; ROBB RJ, 1987, J IMMUNOL, V137, P142; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SANA TR, 1994, BIOCHEMISTRY-US, V33, P5838, DOI 10.1021/bi00185a023; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; VANHOLDE KE, 1985, PHYSICAL BIOCH, P118; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WU ZN, 1994, PROTEIN ENG, V7, P1137, DOI 10.1093/protein/7.9.1137; WU ZN, 1995, J BIOL CHEM, V270, P16045, DOI 10.1074/jbc.270.27.16045; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P6190, DOI 10.1021/bi00075a011; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHU BY, 1993, PROTEIN SCI, V2, P383	35	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16039	16044		10.1074/jbc.270.27.16039	http://dx.doi.org/10.1074/jbc.270.27.16039			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608165	Green Published, hybrid			2022-12-25	WOS:A1995RH22600026
J	STEEGENGA, WT; SHVARTS, A; VANLAAR, T; VANDEREB, AJ; JOCHEMSEN, AG				STEEGENGA, WT; SHVARTS, A; VANLAAR, T; VANDEREB, AJ; JOCHEMSEN, AG			ALTERED PHOSPHORYLATION AND OLIGOMERIZATION OF P53 IN ADENOVIRUS TYPE 12-TRANSFORMED CELLS	ONCOGENE			English	Article						P53; ADENOVIRUS; PHOSPHORYLATION; COMPLEXATION; STABILIZATION	CASEIN KINASE-II; LARGE-T-ANTIGEN; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; PRIMARY RAT-CELLS; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; GENE AMPLIFICATION; E1B PROTEINS; CYCLE	Loss of function of the tumor-suppressor protein p53 is, in general, either caused by mutation, inducing a conformational change, or by binding to inactivating cellular (e.g. MDM2) or viral (e.g, SV40 large T) proteins. In adenovirus type 12 (Ad12)-transformed cells, p53 is stabilized without detectable binding to the Ad12 E1B/54 kDa protein and still present in a wild-type conformation but contains a mutant-like activity in cellular transformation, In this study we examined whether the changed characteristics of p53 in Ad12-transformed cells are correlated with changes in phosphorylation or complex formation of the protein, By making tryptic phosphopeptide maps we found a significant increase in the phosphorylation of the N-terminus of p53. Furthermore, expression of E1A was found to be essential for the altered phosphorylation, while expression of only Ad12 E1B/54 kDa is sufficient to increase the protein half-life. Additionally, we observed p53 to be present in increased molecular weight complexes in Ad12-transformed cells. We conclude that both the phosphorylation and oligomerization of p53 is changed as a result of Ad12 transformation.	LEIDEN UNIV, SYLVIUS LABS, MOLEC CARCINOGENESIS LAB, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University - Excl LUMC								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1993, ONCOGENE, V8, P1519; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GARVIN AJ, 1993, AM J PATHOL, V142, P375; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOCHEMSEN AG, 1987, EMBO J, V6, P3399, DOI 10.1002/j.1460-2075.1987.tb02663.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KRAISS S, 1992, BIOCHIM BIOPHYS ACTA, V1119, P11, DOI 10.1016/0167-4838(92)90227-5; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VAESSEN RTMJ, 1986, EMBO J, V5, P335, DOI 10.1002/j.1460-2075.1986.tb04217.x; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	53	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	1995	11	1					49	57						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624131				2022-12-25	WOS:A1995RJ29500007
J	PRATO, FS; CARSON, JJL; OSSENKOPP, KP; KAVALIERS, M				PRATO, FS; CARSON, JJL; OSSENKOPP, KP; KAVALIERS, M			POSSIBLE MECHANISMS BY WHICH EXTREMELY-LOW-FREQUENCY MAGNETIC-FIELDS AFFECT OPIOID FUNCTION	FASEB JOURNAL			English	Article						SNAIL; ELECTRIC FIELDS; OPIOID PEPTIDES; MAGNETIC FIELD DETECTION MECHANISMS	MORPHINE-INDUCED ANALGESIA; CEPAEA-NEMORALIS; ENKEPHALINASE INHIBITOR; ELECTROMAGNETIC-FIELDS; LAND SNAIL; EXPOSURE; MICE; ORIENTATION; INVOLVEMENT; SYSTEMS	Although extremely low frequency (ELF, <300 Hz) magnetic fields exert a variety of biological effects, the magnetic field sensing/transduction mechanism (or mechanisms) remain to be identified. Using the well-defined inhibitory effects that magnetic fields have on opioid peptide mediated antinociception or ''analgesial' in the land snail Cepaea nemoralis, we show that these actions only occur for certain frequency and amplitude combinations of time-varying sinusoidal magnetic fields in a manner consistent with a direct influence of these fields. We exposed snails with augmented opioid activity to ELF magnetic fields, which were varied in both amplitude and frequency, along with a parallel static magnetic field, When the peak amplitude (0-547 mu T) of a magnetic field of 60 Hz was varied systematically, we observed a nonlinear response, i.e., a nonlinear reduction in analgesia as measured by the latency of a defined response by the snails to a thermal stimulus. When frequency (10-240 Hz) was varied, keeping the amplitude constant (141 mu T), we saw significant inhibitory effects between 30 and 35 Hz, 60 and 90 Hz and at 120 and 240 Hz. Finally, when the static field was varied but the amplitude and frequency of the time-varying field were held constant, we observed significant inhibition at almost all amplitudes. This amplitude/frequency ''resonance-like'' dependence of the magnetic field effects suggests that the mechanism (or mechanisms) of response to weak ELF fields likely involves a direct magnetic field detection mechanism rather than an induced current phenomenon. We examined the implications of our findings for several models proposed for the direct sensing of ELF magnetic fields.	UNIV WESTERN ONTARIO, DEPT MED BIOPHYS, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, DEPT PSYCHOL, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, FAC DENT, DIV ORAL BIOL, LONDON, ON N6A 5C1, CANADA; LAWSON RES INST, LONDON, ON N6A 4L6, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	PRATO, FS (corresponding author), ST JOSEPHS HLTH CTR, DEPT NUCL MED & MAGNET RESONANCE, 268 GROSVENOR ST, LONDON, ON N6A 4V2, CANADA.		Carson, Jeffrey JL/C-7785-2014; Ossenkopp, Klaus-Peter/A-4810-2008; Prato, Frank S/C-9117-2014	Carson, Jeffrey JL/0000-0003-0683-6004; Ossenkopp, Klaus-Peter/0000-0001-7391-3239; Prato, Frank/0000-0002-4592-2522				ADAIR RK, 1994, P NATL ACAD SCI USA, V91, P2925, DOI 10.1073/pnas.91.8.2925; ADAIR RK, 1991, PHYS REV A, V43, P1039, DOI 10.1103/PhysRevA.43.1039; BATES MN, 1991, ENVIRON HEALTH PERSP, V95, P147, DOI 10.2307/3431121; BETANCUR C, 1994, NEUROSCI LETT, V182, P147, DOI 10.1016/0304-3940(94)90784-6; Bevington PR, 1969, DATA REDUCTION ERROR; BLANCHARD JP, 1994, BIOELECTROMAGNETICS, V15, P217, DOI 10.1002/bem.2250150306; CARSON JJL, 1990, AM J PHYSIOL, V259, pC687, DOI 10.1152/ajpcell.1990.259.4.C687; CHIPKIN RE, 1988, J PHARMACOL EXP THER, V245, P829; CHIPKIN RE, 1991, PHARMACOL BIOCHEM BE, V38, P21, DOI 10.1016/0091-3057(91)90584-O; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467, DOI 10.1093/oxfordjournals.aje.a116881; FREY AH, 1993, FASEB J, V7, P272, DOI 10.1096/fasebj.7.2.8440406; FREY AH, 1994, NATURE ELECTROMAGNET, P9; GRUNDLER W, 1992, NATURWISSENSCHAFTEN, V79, P551, DOI 10.1007/BF01131411; HAMILTON CA, 1988, MOL PHYS, V65, P423, DOI 10.1080/00268978800101141; HARKINS TT, 1994, SCIENCE, V263, P958, DOI 10.1126/science.8310292; Herz A., 1993, OPIOIDS; Herz A., 1993, OPIOIDS; KAVALIERS M, 1991, BIOL BULL, V180, P301, DOI 10.2307/1542401; KAVALIERS M, 1988, J COMP PHYSIOL A, V162, P551, DOI 10.1007/BF00612520; KAVALIERS M, 1987, N-S ARCH PHARMACOL, V336, P308; KAVALIERS M, 1986, BRAIN RES, V379, P30, DOI 10.1016/0006-8993(86)90252-0; KAVALIERS M, 1983, SCIENCE, V220, P99, DOI 10.1126/science.6298941; KAVALIERS M, 1984, PHYSIOL BEHAV, V32, P261, DOI 10.1016/0031-9384(84)90139-2; KAVALIERS M, 1993, J COMP PHYSIOL A, V173, P241; KAVALIERS M, 1986, PSYCHOPHARMACOLOGY, V89, P440, DOI 10.1007/BF02412118; KAVALIERS M, 1990, BRAIN RES, V517, P276, DOI 10.1016/0006-8993(90)91038-I; KAVALIERS M, 1991, BRAIN RES, V554, P65, DOI 10.1016/0006-8993(91)90172-R; KAVALIERS M, 1994, NATURE ELECTROMAGNET, P181; KIRSCHVINK JL, 1992, P NATL ACAD SCI USA, V89, P7683, DOI 10.1073/pnas.89.16.7683; KORALL H, 1988, J COMP PHYSIOL A, V162, P279, DOI 10.1007/BF00606116; LEASK MJM, 1977, NATURE, V267, P144, DOI 10.1038/267144a0; LEDNEV VV, 1993, ELECTRICITY AND MAGNETISM IN BIOLOGY AND MEDICINE, P550; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; LEDNEV VV, 1994, NATURE ELECTROMAGNET, P59; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; OSSENKOPP KP, 1978, NEUROSCI BIOBEHAV R, V2, P255, DOI 10.1016/0149-7634(78)90034-9; OSSENKOPP KP, 1987, BRAIN RES, V418, P356, DOI 10.1016/0006-8993(87)90103-X; PHILLIPS JB, 1993, J COMP PHYSIOL A, V172, P303, DOI 10.1007/BF00216612; PHILLIPS JB, 1992, NATURE, V359, P142, DOI 10.1038/359142a0; POLK C, 1994, BIOELECTROMAGNETICS, V15, P261, DOI 10.1002/bem.2250150308; POLK C, 1992, BIOELECTROMAGNETICS, P209, DOI 10.1002/bem.2250130720; PRATO F S, 1987, Magnetic Resonance Imaging, V5, P9, DOI 10.1016/0730-725X(87)90478-4; PRATO FS, 1992, ANN NY ACAD SCI, V649, P44, DOI 10.1111/j.1749-6632.1992.tb49595.x; REITER RJ, 1992, FASEB J, V6, P2283, DOI 10.1096/fasebj.6.6.1544540; SAKHAROV D, 1993, BRAIN RES, V620, P114, DOI 10.1016/0006-8993(93)90276-S; SAKSIDA LM, 1993, PEPTIDES, V14, P763, DOI 10.1016/0196-9781(93)90110-3; SCAIANO JC, 1994, PHOTOCHEM PHOTOBIOL, V59, P585; SMITH SD, 1987, BIOELECTROMAGNETICS, V8, P215, DOI 10.1002/bem.2250080302; STEINER UE, 1989, CHEM REV, V89, P51, DOI 10.1021/cr00091a003; THERIAULT G, 1994, AM J EPIDEMIOL, V139, P550, DOI 10.1093/oxfordjournals.aje.a117046; WALLECZEK J, 1992, FASEB J, V6, P3177, DOI 10.1096/fasebj.6.13.1397839; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WILTSCHKO W, 1993, NATURE, V364, P525, DOI 10.1038/364525a0	53	87	90	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1995	9	9					807	814		10.1096/fasebj.9.9.7601344	http://dx.doi.org/10.1096/fasebj.9.9.7601344			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RH982	7601344				2022-12-25	WOS:A1995RH98200014
J	CHAFIN, DR; GUO, HL; PRICE, DH				CHAFIN, DR; GUO, HL; PRICE, DH			ACTION OF ALPHA-AMANITIN DURING PYROPHOSPHOROLYSIS AND ELONGATION BY RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATED TRANSCRIPT CLEAVAGE; TERNARY COMPLEXES; CALF THYMUS; FACTOR-SII; DNA; INITIATION; INHIBITION; MECHANISM; PROTEIN; INVITRO	Using defined elongation complexes formed on dC-tailed templates with Drosophila RNA polymerase II, we have examined elongation, pyrophosphorolysis, and DmS-II-mediated transcript cleavage and the inhibitory effect of alpha-amanitin on these processes. Analysis of pyrophosphorolysis on soluble or immobilized DNA templates confirmed that NTPs are liberated instead of dinucleotides that are released during DmS-II-meditated transcript cleavage, 10 mu g/ml alpha-amanitin completely inhibited DmS-II-mediated transcript cleavage but allowed extended pyrophosphorolysis and nucleotide addition to occur. alpha-Amanitin dramatically decreased the V-max for nucleotide addition but only slightly affected the K-m for nucleotides. Although the processes are mechanistically distinct, both pyrophosphorolysis and DmS-II-mediated transcript cleavage frequently resulted in similar patterns of shortened transcript. Since polymerase molecules encounter similar kinetic barriers during both processes, it is possible that there is a common step in the reverse movement of the polymerase.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; DUPONT MERCK PHARMACEUT CO,EXPTL STN E4005435,WILMINGTON,DE 19880	University of Iowa; DuPont			Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; BHARGAVA P, 1989, FEBS LETT, V248, P195, DOI 10.1016/0014-5793(89)80460-0; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; FENG GH, 1994, J BIOL CHEM, V269, P22282; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JACOB ST, 1970, NATURE, V225, P60, DOI 10.1038/225060b0; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; PRICE DH, 1984, CELL, V38, P423, DOI 10.1016/0092-8674(84)90497-5; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; VAISIUS AC, 1982, BIOCHEMISTRY-US, V21, P3097, DOI 10.1021/bi00256a010; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	34	49	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19114	19119		10.1074/jbc.270.32.19114	http://dx.doi.org/10.1074/jbc.270.32.19114			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642577	hybrid			2022-12-25	WOS:A1995RN95400065
J	KNOL, JC; VANDERSLIK, AR; VANKESTEREN, ER; PLANTA, RJ; VANHEERIKHUIZEN, H; VREUGDENHIL, E				KNOL, JC; VANDERSLIK, AR; VANKESTEREN, ER; PLANTA, RJ; VANHEERIKHUIZEN, H; VREUGDENHIL, E			A NOVEL G-PROTEIN ALPHA-SUBUNIT CONTAINING ATYPICAL GUANINE-NUCLEOTIDE-BINDING DOMAINS IS DIFFERENTIALLY EXPRESSED IN A MOLLUSCAN NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING; ACTIVATION; SEQUENCES; CDNA; DIVERSITY; CLONING; GENE; SITE	We describe the characterization of a novel G protein alpha subunit, G alpha(a). cDNA encoding this subunit was cloned from the central nervous system of the mollusc Lymnaea stagnalis, The deduced protein contains all characteristic guanine nucleotide-binding domains of G alpha subunits but shares only a limited degree of overall sequence identity with known subtypes (similar to 30%). Moreover, two of the nucleotide binding domains exhibit salient deviations from corresponding sequences in other G protein alpha subunits, The A domain, determining kinetic features of the GTPase cycle, contains a markedly unique amino acid sequence (ILIIGGPGAGK). In addition, the C domain is also clearly distinct (DVAGQRSL). The presence of a leucine in this motif, instead of glutamic acid has important implications for hypotheses concerning the GTPase mechanism, In contrast to other G alpha subtypes, G alpha(a) has no appropriate N-terminal residues that could be acylated, It does contain the strictly conserved arginine residue that serves as a cholera toxin substrate in G alpha(s) and G alpha(t) but lacks a site for ADP-ribosylation by pertussis toxin, In situ hybridization experiments indicate that G alpha(a)-encoding mRNA is expressed in a limited subpopulation of neurons within the Lymnaea brain, These data suggest that G alpha(a) defines a separate class of G proteins with cell type-specific functions.	VRIJE UNIV AMSTERDAM,GRAD SCH NEUROSCI AMSTERDAM,NEUROSCI RES INST,1081 HV AMSTERDAM,NETHERLANDS; VRIJE UNIV AMSTERDAM,FAC CHEM,DEPT BIOCHEM & MOLEC BIOL,1081 HV AMSTERDAM,NETHERLANDS; VRIJE UNIV AMSTERDAM,FAC BIOL,DEPT EXPTL ZOOL,1081 HV AMSTERDAM,NETHERLANDS	University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam				van der Slik, Arno/0000-0002-8920-0118				Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLOEM LJ, 1990, NUCLEIC ACIDS RES, V18, P2830, DOI 10.1093/nar/18.9.2830; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BULLOCH AGM, 1992, TRENDS NEUROSCI, V15, P422, DOI 10.1016/0166-2236(92)90004-R; BURGOYNE RD, 1992, TRENDS BIOCHEM SCI, V17, P87; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; GERAERTS WPM, 1991, CURRENT ASPECTS NEUR, V3, P255; GIBBONS IR, 1991, P NATL ACAD SCI USA, V88, P8563, DOI 10.1073/pnas.88.19.8563; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; ILTZSCH MH, 1992, J BIOL CHEM, V267, P14504; ITOH H, 1988, J BIOL CHEM, V263, P6656; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; KNOL JC, 1994, BBA-MOL CELL RES, V1222, P129, DOI 10.1016/0167-4889(94)90035-3; KNOL JC, 1992, FEBS LETT, V314, P215, DOI 10.1016/0014-5793(92)81474-Z; KNOL JC, 1995, EUR J BIOCHEM, V230, P198; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OFFERMANNS S, 1994, N-S ARCH PHARMACOL, V350, P329; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; QUAN F, 1993, P NATL ACAD SCI USA, V9, P4236; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; SWNINDDALE NV, 1976, PHILOS T R SOC LOND, V274, P169; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; WENDELAARBONGA SE, 1972, GEN COMP ENDOCR    S, V3, P308; WU LJ, 1994, MOL BIOL CELL, V5, P691, DOI 10.1091/mbc.5.6.691	52	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18804	18808		10.1074/jbc.270.32.18804	http://dx.doi.org/10.1074/jbc.270.32.18804			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642531	hybrid, Green Submitted			2022-12-25	WOS:A1995RN95400018
J	CHUANG, TT; LEVINE, H; DEBLASI, A				CHUANG, TT; LEVINE, H; DEBLASI, A			PHOSPHORYLATION AND ACTIVATION OF BETA-ADRENERGIC-RECEPTOR KINASE BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-ADRENERGIC RECEPTOR; MULTIGENE FAMILY; BOVINE BRAIN; CALPHOSTIN-C; DESENSITIZATION; IDENTIFICATION; EXPRESSION; INHIBITION; SUBSTRATE; GAMMA	The aim of this study was to test the possible modification of beta-adrenergic receptor kinase (beta ARK) activity by second messengers and/or their downstream components. Using human mononuclear leukocytes (MNL), we found that calcium ionophores could elevate beta ARK activity by about 80% in a protein kinase C (PKC)-dependent manner. This was confirmed by the ability of the PKC activator phorbol 12-myristate 13-acetate (PMA) to produce a similar effect, suggesting a PKC dependent modulation of beta ARK activity. In vitro experiments with purified proteins showed that PKC could directly phosphorylate beta ARK1 with an apparent K-m for beta ARK1 of 6 nM. The ability of beta ARK1 to phosphorylate rhodopsin was 61% greater when it was phosphorylated by PKC. The level of phosphorylation of beta ARK1 immunoprecipitated from MNL and Sf9 cells overexpressing this kinase was enhanced by about 2-3-fold after PMA treatment. Functional significance of PKC-dependent increase in beta ARK activity was demonstrated by beta-adrenergic receptor (beta AR) homologous desensitization experiments in MNL. beta AR desensitization, as induced by exposure to 10 mu M isoproterenol (5 min at 37 degrees C), was increased from 42 +/- 10% in control to 68 +/- 8% in PMA-pretreated MNL. PARK inhibitor heparin (160 mu g/ml) prevented the augmenting effect of PMA on beta AR desensitization. These results show that beta ARK activity can be increased through phosphorylation by PKC, thus indicating that beta ARK can be preconditioned to modulate the subsequent cellular responsiveness to receptor activation, providing the cell with a mechanism by which specific homologous desensitization can be regulated heterologously.	CONSORZIO MARIO NEGRI SUD,IST RIC FARMACOL MARIO NEGRI,I-66030 SANTA MARIA IMBAR,ITALY; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT NEURODEGENERAT DIS,ANN ARBOR,MI 48105	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Pfizer					Fondazione Telethon Funding Source: Custom; Telethon [E.0062] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); Telethon(Fondazione Telethon)		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BELL JD, 1987, AM J PHYSIOL, V252, pE783, DOI 10.1152/ajpendo.1987.252.6.E783; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CHAMBAUTGUERIN AM, 1987, EUR J BIOCHEM, V170, P381, DOI 10.1111/j.1432-1033.1987.tb13711.x; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; DEBLASI A, 1985, J CLIN ENDOCR METAB, V61, P1081, DOI 10.1210/jcem-61-6-1081; DEBLASI A, 1995, J CLIN INVEST, V95, P203, DOI 10.1172/JCI117641; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PARRUTI G, 1993, BIOCHEM BIOPH RES CO, V190, P475, DOI 10.1006/bbrc.1993.1072; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TOUHARA K, 1993, J BIOL CHEM, V269, P10217; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	35	148	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18660	18665		10.1074/jbc.270.31.18660	http://dx.doi.org/10.1074/jbc.270.31.18660			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629197	hybrid			2022-12-25	WOS:A1995RM64200079
J	NGUYEN, H; MUSTAFA, A; HISCOTT, J; LIN, RT				NGUYEN, H; MUSTAFA, A; HISCOTT, J; LIN, RT			TRANSCRIPTION FACTOR IRF-2 EXERTS ITS ONCOGENIC PHENOTYPE THROUGH THE DNA-BINDING TRANSCRIPTION REGRESSION DOMAIN	ONCOGENE			English	Article						INTERFERON; TRANSCRIPTION; ONCOGENESIS; INTERFERON REGULATORY FACTORS	GENE REGULATORY ELEMENTS; IFN-INDUCIBLE GENES; PROTEIN-KINASE; BETA; INDUCTION; CHROMOSOME-2P21-P22; EXPRESSION; ACTIVATION; CELLS; PRKR	The Interferon Regulatory Factors-1 and -2 (IRF-1 and IRF-2) play a transcriptional role in the regulation of the IFN-beta gene as well as other immunoregulatory genes. IRF-1 serves as a transcriptional activator whereas IRF-2 acts as an antagonistic transcriptional repressor. IRF-1 and IRF-2 also play opposing functional roles in cell growth regulation, and are implicated as a potential antioncogene and oncogene, respectively. To analyse the relationship between DNA binding/transcriptional repression and oncogenic transformation, NIH3T3 cells expressing C-terminal deletions of IRF-2 were established and assayed for transformation by saturation density analysis, anchorage independent growth in soft agar and tumor formation in nude mice. Cells expressing an IRF-2 protein of at least 160 N-terminal amino acids were transformed in vitro and tumorigenic in vivo, thus mapping IRF-2 oncogenic activity to its DNA binding/ transcriptional repression domain, Overexpression of wild-type and truncated IRF-2 proteins resulted in reduced IFN-beta mRNA levels following induction by dsRNA. However, there was no effect of IRF-2 on IFN-beta inducibility by Sendai virus infection, suggesting the involvement of multiple IFN-beta induction pathways. In DNA binding assays, recombinant IRF-2 was found to preferentially bind to the IFN-beta PRDI site compared to IRF-1. These studies indicate that the transformed phenotype resulting from overexpression of IRF-2 may be due to constitutive engagement of the IRF-E recognition site, thus preventing DNA binding and transactivation of putative tumor suppressor genes by the IRF-1 anti-oncogene.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,TERRY FOX MOLEC ONCOL GRP,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University			Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				BARBER GN, 1993, GENOMICS, V16, P765, DOI 10.1006/geno.1993.1262; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COHEN L, 1992, VIROLOGY, V191, P589, DOI 10.1016/0042-6822(92)90234-G; COHEN L, 1991, CELL GROWTH DIFFER, V2, P323; DADDARIO M, 1992, J IMMUNOL, V148, P1222; DADDARIO M, 1990, J VIROL, V64, P6080, DOI 10.1128/JVI.64.12.6080-6089.1990; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; HANASH SM, 1995, GENES CHROM CANC, V8, P34; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1983, SCIENCE, V259, P971; HISCOTT J, 1995, IN PRESS SEMINARS VI, V6; KAMIJO R, 1994, CELL, V263, P1612; KIRCHOFF S, 1995, IN PRESS ONCOGENE; KOROMILAS AE, 1992, SCIENCE, V257, P1865; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LIN RT, 1994, J BIOL CHEM, V269, P17542; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SQUIRE J, 1993, GENOMICS, V16, P768, DOI 10.1006/geno.1993.1263; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WHITESIDE ST, 1994, J BIOL CHEM, V269, P27059; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; [No title captured]	34	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					537	544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630638				2022-12-25	WOS:A1995RN53000014
J	KNIGHT, PJK; KNOWLES, BH; ELLAR, DJ				KNIGHT, PJK; KNOWLES, BH; ELLAR, DJ			MOLECULAR-CLONING OF AN INSECT AMINOPEPTIDASE-N THAT SERVES AS A RECEPTOR FOR BACILLUS-THURINGIENSIS CRYIA(C) TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; KIDNEY MICROVILLAR MEMBRANE; AMINO-ACID SEQUENCE; LARVAL MIDGUT; DELTA-ENDOTOXINS; ECTO-ENZYMES; BOMBYX-MORI; PROTEINS; ANTIGEN; METALLOPEPTIDASE	The Bacillus thuringiensis CryIA(c) insecticidal delta-endotoxin binds to a 120 kDa glycoprotein receptor in the larval midgut epithelia of the susceptible insect Manduca sexta. This glycoprotein has recently been purified and identified as aminopeptidase N. We now report the cloning of aminopeptidase N from a M. sexta midgut cDNA library. Two overlapping clones were isolated, and their combined 3095-nucleotide sequence contains an open reading frame encoding a 990-residue prepro-protein. The N-terminal amino acid sequence derived from the glycoprotein is present in the open reading frame, immediately following a predicted cleavable signal peptide and a pro-peptide. There are four potential N-linked glycosylation sites. The C-terminal sequence contains a possible glycosylphosphatidylinositol (GPI) anchor signal peptide, which suggests that, unlike most other characterized aminopeptidases, the lepidopteran enzyme is anchored in the membrane by a GPI anchor. This was confirmed by partial release of aminopeptidase N activity from M. sexta midgut brush border membranes by phosphatidylinositol-specific phospholipase C. The deduced amino acid sequence shows significant similarity to the zinc-dependent aminopeptidase gene family, particularly in the region surrounding the consensus zinc-binding motif characteristic of these enzymes.	UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CB2 1QW, ENGLAND; UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND	University of Cambridge; University of Cambridge								ANGSUTHANASOMBAT C, 1993, FEMS MICROBIOL LETT, V111, P255; BIETLOT H, 1989, BIOCHEM J, V260, P87, DOI 10.1042/bj2600087; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P237, DOI 10.1016/0022-2011(92)90004-N; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; DELMAS B, 1994, J VIROL, V68, P5216, DOI 10.1128/JVI.68.8.5216-5224.1994; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FROHMAN MA, 1994, PCR METH APPL, V4, pS40; GARCIAALVAREZ N, 1991, EUR J BIOCHEM, V202, P993, DOI 10.1111/j.1432-1033.1991.tb16461.x; GARCZYNSKI SF, 1991, APPL ENVIRON MICROB, V57, P2816, DOI 10.1128/AEM.57.10.2816-2820.1991; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGH S, 1992, BIOESSAYS, V14, P535, DOI 10.1002/bies.950140807; HOOPER NM, 1988, FEBS LETT, V229, P340, DOI 10.1016/0014-5793(88)81152-9; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; Hooper NM, 1992, LIPID MODIFICATION P, P89; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KENNY AJ, 1987, MAMMALIAN ECTOENZYME, V14, P169; KLEIN JR, 1993, EUR J BIOCHEM, V217, P105, DOI 10.1111/j.1432-1033.1993.tb18224.x; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; KNOWLES BH, 1991, P ROY SOC B-BIOL SCI, V245, P31, DOI 10.1098/rspb.1991.0084; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LECADET MM, 1967, J INVERTEBR PATHOL, V9, P322, DOI 10.1016/0022-2011(67)90066-3; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; NISHIZAWA M, 1994, J BIOL CHEM, V269, P13651; NOREN O, 1989, FEBS LETT, V259, P107, DOI 10.1016/0014-5793(89)81506-6; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; Sambrook J, 1989, MOL CLONING LABORATO; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SODERBERG C, 1993, J VIROL, V67, P6576; TAKESUE S, 1992, COMP BIOCHEM PHYS B, V102, P7, DOI 10.1016/0305-0491(92)90263-Q; TAKESUE Y, 1989, J BIOCHEM, V105, P998, DOI 10.1093/oxfordjournals.jbchem.a122794; TURNER AJ, 1994, BRAZ J MED BIOL RES, V27, P389; VADLAMUDI RK, 1993, J BIOL CHEM, V268, P12334; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATT VM, 1989, J BIOL CHEM, V264, P5480; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0	51	159	190	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17765	17770		10.1074/jbc.270.30.17765	http://dx.doi.org/10.1074/jbc.270.30.17765			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629076	hybrid			2022-12-25	WOS:A1995RM26600023
J	XIN, H; WORIAX, V; BURKHART, W; SPREMULLI, LL				XIN, H; WORIAX, V; BURKHART, W; SPREMULLI, LL			CLONING AND EXPRESSION OF MITOCHONDRIAL TRANSLATIONAL ELONGATION-FACTOR TS FROM BOVINE AND HUMAN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST EF-TS; EUKARYOTIC RIBOSOMES; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ESCHERICHIA-COLI; FACTOR-TU; PROTEIN; ORGANIZATION; GENES; INITIATION	The sequences of the cDNAs for the mitochondrial translational elongation factor Ts (EF-Ts(mt)) from bovine and human liver have been obtained. The deduced amino acid sequence of bovine liver EF-Ts(mt) is 338 residues in length and includes a 55-amino acid signal peptide and a mature protein of 283 residues. The sequence of the mature form of bovine EF-Ts(mt) is 91% identical to that of human EF-Ts(mt) and 29% identical to Escherichia coli EF-Ts. Southern analysis indicates that there are two genes for EF-Ts(mt) in bovine liver chromosomal DNA. A 224-base pair intron is located near the 5'-end of at least one of these genes. Northern analysis using a human multiple tissue blot indicates that EF-Ts(mt) is expressed in all tissues, with the highest levels of expression in skeletal muscle, liver, and kidney. Both the mature and precursor forms of bovine liver EF-Ts(mt) have been expressed in E. coli as histidine-tagged pro teins, The mature form of EF-Ts(mt) forms a complex with E. coli elongation factor Tu. This complex is active in poly(U) directed polymerization of phenylalanine. The precursor form is expressed as a 42-kDa protein, which is rapidly degraded in the cell.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT BIOCHEM CB 3290,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; GLAXO INC,RES INST,DEPT BIOANALYT & STRUCT CHEM,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline					NIGMS NIH HHS [GM32734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AN G, 1981, NUCLEIC ACIDS RES, V9, P4163, DOI 10.1093/nar/9.16.4163; ARAI KI, 1978, EUR J BIOCHEM, V92, P521, DOI 10.1111/j.1432-1033.1978.tb12774.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; Carmichael G G, 1980, Methods Enzymol, V65, P380; CHEVALIER C, 1990, J BACTERIOL, V172, P2693, DOI 10.1128/jb.172.5.2693-2703.1990; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORMIER P, 1993, NUCLEIC ACIDS RES, V21, P743, DOI 10.1093/nar/21.3.743; FOX L, 1980, J BIOL CHEM, V255, P6018; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOTTESMAN MM, 1987, METHOD ENZYMOL, V151, P363; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KOZAK M, 1991, GENE EXPRESSION, V1, P117; KOZAK M, 1991, GENE EXPRESSION, V1, P111; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MILLER DL, 1970, BIOCHEM BIOPH RES CO, V38, P1016, DOI 10.1016/0006-291X(70)90341-4; MORALES J, 1992, NUCLEIC ACIDS RES, V20, P4091, DOI 10.1093/nar/20.15.4091; REINBOLT J, 1993, TRANSLATIONAL APPARATUS, P285; SANANGELANTONI AM, 1990, FEMS MICROBIOL LETT, V66, P141, DOI 10.1016/0378-1097(90)90272-R; SCHWARTZBACH CJ, 1991, J BIOL CHEM, V266, P16324; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; SPREMULLI GH, 1987, BIOCHEM BIOPH RES CO, V148, P1490, DOI 10.1016/S0006-291X(87)80300-5; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WITTINGHOFER A, 1983, J BACTERIOL, V153, P1266, DOI 10.1128/JB.153.3.1266-1271.1983	27	55	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17243	17249		10.1074/jbc.270.29.17243	http://dx.doi.org/10.1074/jbc.270.29.17243			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615523	Green Published, hybrid			2022-12-25	WOS:A1995RK68900031
J	CHEN, HC; APPEDDU, PA; PARSONS, JT; HILDEBRAND, JD; SCHALLER, MD; GUAN, JL				CHEN, HC; APPEDDU, PA; PARSONS, JT; HILDEBRAND, JD; SCHALLER, MD; GUAN, JL			INTERACTION OF FOCAL ADHESION KINASE WITH CYTOSKELETAL PROTEIN TALIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; STIMULATE TYROSINE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; BOMBESIN; FIBRONECTIN; VASOPRESSIN; ENDOTHELIN; IDENTIFICATION	The interaction of cells with extracellular matrix proteins plays a critical role in a variety of biological processes. Recent studies suggest that cell-matrix interactions mediated by integrins can transduce biochemical signals to the cell interior that regulate cell proliferation and differentiation. These studies have placed the focal adhesion kinase (FAR), an intracellular protein tyrosine kinase, in a central position in integrin-initiated signal transduction pathways (Zachary, I., and Rozengurt, E. (1992) Cell 71, 891-894; Schaller, M., and Parsons, J. T. (1993) Trends Cell Biol. 3, 258-262). Here, we report data suggesting a possible association of FAK with the cytoskeletal protein talin in NIH 3T3 cells. We have identified a 48-amino acid sequence in the carboxyl-terminal domain of FAK necessary for talin binding in vitro. Furthermore, we have correlated the ability of integrin to induce FAR phosphorylation with its ability to bind talin using a mutant integrin lacking the carboxyl-terminal 13 amino acids. These studies suggest talin may be a mediator for FAK activation in signaling initiated by integrins and may provide an explanation for the dependence on the integrity of actin-cytoskeleton of multiple intracellular signaling pathways converging to FAK activation and autophosphorylation.	CORNELL UNIV, COLL VET MED, DEPT PATHOL, CANC BIOL LABS, ITHACA, NY 14853 USA; UNIV VIRGINIA, SCH MED, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	Cornell University; University of Virginia; University of Virginia								AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; FORCE T, 1991, J BIOL CHEM, V266, P6650; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HORWITZ A, 1985, J CELL BIOL, V101, P2134, DOI 10.1083/jcb.101.6.2134; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TAPLEY P, 1989, ONCOGENE, V4, P325; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	37	320	324	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16995	16999		10.1074/jbc.270.28.16995	http://dx.doi.org/10.1074/jbc.270.28.16995			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622520	hybrid			2022-12-25	WOS:A1995RJ34700081
J	KLESS, H; VERMAAS, W				KLESS, H; VERMAAS, W			TANDEM SEQUENCE DUPLICATIONS FUNCTIONALLY COMPLEMENT DELETIONS IN THE D1 PROTEIN OF PHOTOSYSTEM-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; DNA; MUTATIONS; BINDING; SYNECHOCYSTIS-6803; INTEGRITY; DONOR	Obligate photoheterotrophic mutants of the cyanobacterium Synechocystis sp. PCC 6803 that carry deletions of conserved residues in the plastoquinone-binding niche of the D1 protein were used to select for spontaneous mutations that restore photoautotrophic growth. Spontaneous pseudorevertants emerged from two deletion mutants, Delta YNIV246-9 and Delta NN266-7, when the cultures were maintained long after the carbon source (glucose) had been depleted from the medium and cells had reached stationary phase. Most pseudorevertants were found to contain tandem duplications of 6-45-base pair DNA sequences located close to the domain carrying the deletion; none of them restored the wild-type sequence. Three pseudorevertants isolated from the Delta YNIV246-9 mutant contained a duplication (7-15 codons) of the DNA sequence immediately downstream of the deletion; the protein region encoded by this DNA may include part of the putative de helix, an important constituent of the plastoquinone-binding niche. Three pseudorevertants isolated from the Delta NN266-7 mutant contained duplications corresponding to 2-8 amino acid residues adjacent to the site of the deletion, In all six pseudorevertants carrying duplications, the length of the D1 protein in the modified regions was restored to at least the length present in wild type, suggesting that a minimal length of these protein domains may be required for functional integrity, In another photoautotrophic strain isolated from Delta NN266-7, no secondary mutations could be identified in the gene coding for the D1 protein; such mutations apparently reside on another protein subunit of the photosystem II complex, Photosystem II function in the pseudorevertants was altered as compared with wild type in terms of growth and oxygen evolution rates, photosystem II concentration, the semiquinone equilibrium at the acceptor side, and thermostability. A mechanism leading to tandem sequence duplication may involve DNA damage followed by DNA synthesis, strand displacement, and ligation.	ARIZONA STATE UNIV, CTR STUDY EARLY EVENTS PHOTOSYNTHESIS, TEMPE, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	KLESS, H (corresponding author), ARIZONA STATE UNIV, DEPT BOT, TEMPE, AZ 85287 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051556] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01GM51556] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; ETIENNE AL, 1993, PHOTOSYNTH RES, V38, P387, DOI 10.1007/BF00046765; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; KLESS H, 1992, BIOCHEMISTRY-US, V31, P11065, DOI 10.1021/bi00160a016; KLESS H, 1994, BIOCHEMISTRY-US, V33, P10501, DOI 10.1021/bi00200a035; KLESS H, 1995, J MOL BIOL, V246, P120, DOI 10.1006/jmbi.1994.0071; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; MAENPAA P, 1993, PLANT MOL BIOL, V22, P1, DOI 10.1007/BF00038991; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; NIXON PJ, 1992, PLANT PROTEIN ENG, P93; OHAD N, 1992, PLANT CELL, V4, P273, DOI 10.1105/tpc.4.3.273; RAO BJ, 1994, P NATL ACAD SCI USA, V91, P6161, DOI 10.1073/pnas.91.13.6161; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; RUFFLE SV, 1992, PHOTOSYNTH RES, V34, P287, DOI 10.1007/BF00033446; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STEPHAN W, 1989, MOL BIOL EVOL, V6, P198, DOI 10.1093/oxfordjournals.molbev.a040542; SVENSSON B, 1991, Z NATURFORSCH C, V46, P765; SVENSSON B, 1990, EMBO J, V9, P2051, DOI 10.1002/j.1460-2075.1990.tb07372.x; TREBST A, 1987, Z NATURFORSCH C, V42, P742; TRINH TQ, 1993, GENETICS, V134, P409; VERMAAS W, 1990, Z NATURFORSCH C, V45, P359; VERMAAS W, 1993, ANNU REV PLANT PHYS, V44, P457, DOI 10.1146/annurev.pp.44.060193.002325; Vermaas W.F.J., 1991, PHOTOSYNTHETIC APPAR, P25; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; YOON K, 1992, P NATL ACAD SCI USA, V89, P3840, DOI 10.1073/pnas.89.9.3840	31	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16536	16541		10.1074/jbc.270.28.16536	http://dx.doi.org/10.1074/jbc.270.28.16536			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622458	hybrid			2022-12-25	WOS:A1995RJ34700014
J	WAN, JX; BLAKELEY, SD; DENNIS, DT; KO, K				WAN, JX; BLAKELEY, SD; DENNIS, DT; KO, K			IMPORT CHARACTERISTICS OF A LEUKOPLASTID PYRUVATE-KINASE ARE INFLUENCED BY A 19-AMINO-ACID DOMAIN WITHIN THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER ENVELOPE MEMBRANE; CHLOROPHYLL-A/B PROTEIN; TRANSIT PEPTIDE; CHLOROPLAST ENVELOPE; SPINACH-CHLOROPLASTS; THYLAKOID MEMBRANE; RICINUS-COMMUNIS; BINDING PROTEIN; PRECURSORS; TRANSPORT	Two cDNA clones encoding distinct forms of plastid pyruvate kinase (designated Pka and Pkg) have recently been characterized. Pkg is found in both leucoplasts and chloroplasts, whereas Pka is present only in leucoplasts. The precursors of these proteins have different in vitro import characteristics. The Pkg precursor behaves like a typical stromal protein precursor with both types of plastid. In contrast, Pka precursors accumulate on the outer envelope membrane of leucoplasts under the same assay conditions and require a higher level of ATP for import into the organelle. Interestingly, the binding of Pka precursors to chloroplasts cannot be detected at any tested level of ATP even though the precursors are imported into the organelle at higher concentrations of ATP. Various N-terminal deletions and chimeric fusions were used to examine the translocation signaling mechanism of the Pka precursor. The N-terminal 83-amino-acid segment of Pka contains a transit peptide that is capable of directing dihydrofolate reductase and the mature body of Pkg into both types of plastid. Unlike the complete Pka precursor, these fusion proteins behave like typical stromal protein precursors. The behavior of the Pka transit peptide is influenced by a 19-amino-acid domain (-P-S-S-I-E-V-D-A-V-T-E-T-E-L-K-E-N-G-F-) located immediately downstream of the N-terminal 83-residue segment. Deletion of this domain from Pka alters its import properties such that it resembles a typical stromal protein precursor. Re-introduction of the 19-residue domain into the Dhfr fusion protein alters its import characteristics to resemble that of the complete Pka precursor. This Is-amino-acid domain can also influence the function of transit sequences from other precursors when it is placed immediately behind the transit peptide. These results suggest that this 19-amino-acid domain plays an important role in governing the import characteristics of the Pka precursor. We have named this 19-residue segment the ''import modifying domain.''	QUEENS UNIV, DEPT BIOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada								BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BLAKELEY S, 1995, PLANT MOL BIOL, V27, P79, DOI 10.1007/BF00019180; BLAKELEY SD, 1991, PLANT PHYSIOL, V96, P1283, DOI 10.1104/pp.96.4.1283; BOYLE SA, 1986, PLANT PHYSIOL, V81, P817, DOI 10.1104/pp.81.3.817; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; DRESESWERRINGLOER U, 1991, EUR J BIOCHEM, V195, P361, DOI 10.1111/j.1432-1033.1991.tb15714.x; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; GREENWOOD JS, 1982, CAN J BOT, V60, P1751, DOI 10.1139/b82-222; HALPIN C, 1989, FEBS LETT, V258, P32, DOI 10.1016/0014-5793(89)81608-4; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; JOYARD J, 1983, J BIOL CHEM, V258, P1; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KLOSGEN RB, 1991, MOL GEN GENET, V225, P297, DOI 10.1007/BF00269862; KLOSGEN RB, 1989, MOL GEN GENET, V217, P155, DOI 10.1007/BF00330955; KO K, 1992, J BIOL CHEM, V267, P13910; KO K, 1992, J BIOL CHEM, V267, P2986; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KOHORN BD, 1989, PLANT CELL, V1, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; LI HM, 1992, J BIOL CHEM, V267, P18999; PLAXTON WC, 1989, EUR J BIOCHEM, V181, P443, DOI 10.1111/j.1432-1033.1989.tb14745.x; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SIMCOX PD, 1979, CAN J BOT, V57, P1008, DOI 10.1139/b79-125; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBROECK G, 1988, PLANT SCI, V58, P171, DOI 10.1016/0168-9452(88)90006-4; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WU CB, 1993, J BIOL CHEM, V268, P19384; WU CB, 1994, J BIOL CHEM, V269, P32264	37	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16731	16739		10.1074/jbc.270.28.16731	http://dx.doi.org/10.1074/jbc.270.28.16731			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622484	hybrid			2022-12-25	WOS:A1995RJ34700044
J	MATSUGI, T; KREIDER, BL; DELWEL, R; CLEVELAND, JL; ASKEW, DS; IHLE, JN				MATSUGI, T; KREIDER, BL; DELWEL, R; CLEVELAND, JL; ASKEW, DS; IHLE, JN			THE EVI-1 ZINC-FINGER MYELOID TRANSFORMING PROTEIN BINDS TO GENOMIC FRAGMENTS CONTAINING (GATA)(N) SEQUENCES	ONCOGENE			English	Article						EVI-1; BINDING; GATA ELEMENTS	COLONY-STIMULATING FACTOR; RETROVIRAL INSERTIONS; VIRAL INTEGRATION; GENE; DNA; EXPRESSION; IDENTIFICATION; TRANSCRIPTION; DIFFERENTIATION; SPECIFICITY	The EVI1 gene is activated by chromosomal translocations and inversions in approximately 5% of human acute myeloid leukemia (AML) and by retroviral insertion in approximately 20% of murine myeloid leukemias, EVI1 encodes a nuclear DNA-binding protein having 10 zinc finger motifs in two noncontiguous domains consisting of an amino-terminal domain of seven fingers and a carboxyl domain containing three fingers, To evaluate the sequence specificity of Evi-1 binding and potentially identify genomic targets, whole-genome PCR was utilized to isolate multiple Sau3A fragments which specifically bind to the amino-terminal zinc finger domain, The majority of these clones represented single copy sequences and virtually all contained variable numbers of repeats of the GATA motif, the target sequence for the erythroid-specific transcription factor GATA-1, GST/Evi-1 fusion proteins containing the amino-terminal domain of zinc fingers bound the GATA motif in these clones as well as to those present in the human gamma-globin promoter, similar to the binding of purified GATA-1 protein, By obtaining corresponding large genomic clones for eight of these fragments, transcription units were found associated with two. One corresponded to the glyceraldehyde-3-phosphate dehydrogenase gene and its expression was not affected by Evi-1, The second is a novel gene whose expression is repressed in murine myeloid cell lines that express Evi-1.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; UNIV CINCINNATI, DEPT PATHOL, CINCINNATI, OH USA; ERASMUS UNIV ROTTERDAM, ROTTERDAM, NETHERLANDS; HUMAN GENOME SCI, ROCKVILLE, MD 20859 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University System of Ohio; University of Cincinnati; Erasmus University Rotterdam; GlaxoSmithKline; Human Genome Sciences Inc				Askew, David/0000-0002-6477-2515	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIDDK NIH HHS [DK 42932, DK 44150] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKEW DS, 1991, ONCOGENE, V6, P2041; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BELLOMO MJ, 1992, CANCER GENET CYTOGEN, V59, P138, DOI 10.1016/0165-4608(92)90208-P; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7344; DURBIN EJ, 1989, CHROMOSOMA, V97, P301, DOI 10.1007/BF00371970; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; KELLER AD, 1991, NUCLEIC ACIDS RES, V19, P4675, DOI 10.1093/nar/19.17.4675; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; SINGH L, 1984, CELL, V36, P111, DOI 10.1016/0092-8674(84)90079-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMPAYRAC L, 1990, P NATL ACAD SCI USA, V87, P3274, DOI 10.1073/pnas.87.9.3274	27	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					191	198						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624127				2022-12-25	WOS:A1995RJ29500022
J	GORAYA, TY; KESSLER, SP; STANTON, P; HANSON, RW; SEN, GC				GORAYA, TY; KESSLER, SP; STANTON, P; HANSON, RW; SEN, GC			THE CYCLIC-AMP RESPONSE ELEMENTS OF THE GENES FOR ANGIOTENSIN-CONVERTING ENZYME AND PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) CAN MEDIATE TRANSCRIPTIONAL ACTIVATION BY CREM-TAU AND CREM-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; REGULATORY ELEMENT; HEPATOMA-CELLS; PROMOTER; EXPRESSION; INITIATION; INDUCTION; SPERMATOGENESIS; LOCALIZATION; REPRESSES	The potential of the CREM family of proteins to activate transcription of the genes encoding the testis-specific isozyme of angiotensin converting enzyme (ACE(T)) and the gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (GTP) (PEPCK) (EC 4.1.1.32) were investigated. Both CREM tau and CREM alpha bind efficiently to the putative cyclic AMP response element (CRE) present in the ACE(T) gene (CRET) and to the CRE in the PEPCK gene, In HepG2 cells, the CRE was required for the strong stimulation by CREM tau of the expression of a chimeric PEPCK (-210 to +73)-chloramphenicol acetyl transferase (CAT) gene, The CRE could be mutated to the CRET sequence without losing the stimulatory effects of CREM tau. However, a similar chimeric gene driven by the regulatory region of the ACE(T) gene, which contains the CRET site, could only be stimulated by CREM tau when its imperfect TATA element was mutated to an authentic TATA. Surprisingly, CREM alpha, an alleged inhibitor of CRE-mediated transcription, stimulated the expression of both PEPCK-CAT and ACE(T)-CAT genes in HepG2 cells, a process which required the presence of the CRE and the CRET sites, respectively, In contrast, when the same CRE elements were used to drive the transcription of a chimeric gene containing the thymidine kinase promoter linked to the CAT structural gene, CREM alpha inhibited its expression in HepG2 and JEG3 cells, The expression of the same chimeric gene, however, was stimulated by CREM alpha in F9 embryonal carcinoma cells. These results demonstrated that the nature of the transcriptional effects of CREM isoforms on CRE-mediated transcription depends on the specific gene, the specific cell type and the promoter context of the CRE site.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48258] Funding Source: Medline; NIDDK NIH HHS [DK-07678] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERG T, 1986, J HISTOCHEM CYTOCHEM, V34, P753, DOI 10.1177/34.6.3009604; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; CALDWELL PRB, 1976, SCIENCE, V191, P1050, DOI 10.1126/science.175444; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; FRIEDLAND J, 1978, BIOCHEM BIOPH RES CO, V83, P843, DOI 10.1016/0006-291X(78)91471-7; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GORAYA TY, 1994, NUCLEIC ACIDS RES, V22, P1194, DOI 10.1093/nar/22.7.1194; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P873; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; LORIAUX MM, 1994, J BIOL CHEM, V269, P28839; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Safer R. L., 1981, BIOCH REGULATION BLO, P123; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3	35	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19078	19085		10.1074/jbc.270.32.19078	http://dx.doi.org/10.1074/jbc.270.32.19078			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642572	hybrid			2022-12-25	WOS:A1995RN95400060
J	JEOUNG, DI; TANG, BQ; SONENBERG, M				JEOUNG, DI; TANG, BQ; SONENBERG, M			EFFECTS OF TUMOR-NECROSIS-FACTOR-ALPHA ON ANTIMITOGENICITY AND CELL CYCLE-RELATED PROTEINS IN MCF-7 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; BREAST-CANCER CELLS; TYROSINE PHOSPHORYLATION; RAPID PHOSPHORYLATION; SUSCEPTIBILITY GENE; CARCINOMA-CELLS; MESSENGER-RNA; GROWTH; FIBROBLASTS; EXPRESSION	Tumor necrosis factor-alpha (TNF-alpha) demonstrated antimitogenic activity in MCF-7 cells (estrogen receptor-positive human breast cancer cells) in a dose- and time-dependent manner (EC-50 of 2.5 ng/ml). This antimitogenic effect of TNF-alpha was accompanied by a decreased number of cells in S phase in a dose- and time dependent manner. Based on growth arrest experiments using aphidicolin, it is apparent that TNF-alpha acted in early G(1) phase. It did not show antimitogenic effects once cells reentered the S phase based on [H-3]thymidine incorporation into DNA and cell cycle analysis. Specificity of TNF-alpha was established by using monoclonal anti-human TNF-alpha antibody. On the basis of Western immunoblot analysis of Rb, p53 and cell cycle inhibitory protein (Cip1) (p21) proteins, TNF-alpha decreased Rb protein expression in a dose- and time-dependent manner whereas it increased the expression level of tumor suppressor p53 protein, TNF-alpha also increased the expression level of Cip1 (p21) protein in a dose-dependent manner. This induction of Cip1 (p21) protein was preceded by the induction of p53 protein in MCF-7 cells, Cip1 (p21) protein associated with cyclin D was also increased, Tumor suppressor Rb protein expression was increased during G(1) to S phase progression. Cyclin D protein expression levels were not changed in response to TNF-alpha treatment, although serine/threonine kinase inhibitors such as H7 and the protein kinase C inhibitor staurosporine decreased cyclin D expression levels in MCF-7 cells. Based on experiments with staurosporine, it appears that TNF-alpha does not utilize a protein kinase C pathway in MCF-7 cells. Other cell cycle-related proteins such as Cdk2, CdcB, and Cdk4 did not show any change in response to TNF-alpha. TNF-alpha did not affect complexes between cyclin D and Cdk2, Cdk4, and Rb proteins in RICF-7 cells. Taken together these results suggest that Rb, p53, and Cip1 (p21) proteins mediate TNF-alpha antimitogenic activity, and TNF-alpha induces growth arrest in the G(1) phase in MCB-7 cells.	MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NATIONAL CANCER INSTITUTE [T32CA009512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041931] Funding Source: NIH RePORTER; NCI NIH HHS [CA09512] Funding Source: Medline; NIDDK NIH HHS [DK 41931] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BAUD L, 1989, FEBS LETT, V239, P50; BIRD TA, 1990, J BIOL CHEM, V265, P235; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHRETIEN P, 1988, J CELL PHYSIOL, V137, P157, DOI 10.1002/jcp.1041370119; DANFORTH DN, 1993, J ENDOCRINOL, V138, P517, DOI 10.1677/joe.0.1380517; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DONATO NJ, 1992, CELL GROWTH DIFFER, V3, P259; DONATO NJ, 1989, J BIOL CHEM, V264, P20474; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVA YH, 1988, SCIENCE, V241, P218; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HALL FL, 1993, ONCOGENE, V8, P1377; HARPER JW, 1993, CELL, V75, P805; HEPBURN A, 1988, FEBS LETT, V227, P175, DOI 10.1016/0014-5793(88)80892-5; HU QJ, 1992, MOL CELL BIOL, V2, P971; JAATTELA M, 1993, EMBO J, V11, P3507; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MARINO MW, 1991, J BIOL CHEM, V266, P2685; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V34, P760; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSEN OM, 1981, COLD SPRING HARBOR C, V8, P715; RUGGIERO V, 1987, J IMMUNOL, V138, P2711; SCHUTZE S, 1989, J BIOL CHEM, V264, P3562; SGAGIAS MK, 1991, MOL ENDOCRINOL, V5, P1740, DOI 10.1210/mend-5-11-1740; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TAM SW, 1994, ONCOGENE, V9, P2663; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910	52	76	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18367	18373		10.1074/jbc.270.31.18367	http://dx.doi.org/10.1074/jbc.270.31.18367			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629160	hybrid			2022-12-25	WOS:A1995RM64200036
J	KANG, KR; WOLFF, EC; PARK, MH; FOLK, JE; CHUNG, SN				KANG, KR; WOLFF, EC; PARK, MH; FOLK, JE; CHUNG, SN			IDENTIFICATION OF YHR068W IN SACCHAROMYCES-CEREVISIAE CHROMOSOME-VIII AS A GENE FOR DEOXYHYPUSINE SYNTHASE - EXPRESSION AND CHARACTERIZATION OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPUSINE; PROTEIN; SPERMIDINE; YEAST; PURIFICATION; CLEAVAGE	Deoxyhypusine synthase catalyzes the formation of deoxyhypusine, the first step in hypusine biosynthesis. Amino acid sequences of five tryptic peptides from rat deoxyhypusine synthase were found to match partially the deduced amino acid sequence of the open reading frame of gene YHR068w of Saccharomyces cerevisiae chromosome VIII (AC:U00061). In order to determine whether the product of this gene corresponds to yeast deoxyhypusine synthase, a 1.17-kilobase pair cDNA with an identical nucleotide sequence to that of the YR068w coding region was obtained from S. cerevisiae cDNA by polymerase chain reaction and was expressed in Escherichia coli B strain BL21(DE3). The recombinant protein was found mostly in the E. coli cytosol fraction and comprised similar to 20% of the total soluble protein. The purified form of the expressed protein effectively catalyzed the formation of deoxyhypusine in yeast eIF-5A precursors as well as in human precursor and in those from Chinese hamster ovary cells. The molecular mass of the enzyme was estimated to be 172,000 a 4,300 Da by equilibrium centrifugation. The mass of its polypeptide subunit was determined to be similar to 43,000 Da, in close agreement with that calculated for the coding region of the YHR068w gene. These findings show that this gene is a coding sequence for yeast deoxyhypusine synthase and that the product of this gene exists in a tetrameric form.	NIDR,CELLULAR DEV & ONCOL LAB,ENZYME CHEM SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; CHEN KY, 1988, FEBS LETT, V229, P325, DOI 10.1016/0014-5793(88)81149-9; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOE YA, 1994, J BIOL CHEM, V269, P25916; JOHNSTON M, 1995, SCIENCE, V265, P2077; LOWRY CV, 1983, P NATL ACAD SCI-BIOL, V80, P151, DOI 10.1073/pnas.80.1.151; MAGDOLEN V, 1994, MOL GEN GENET, V224, P646; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1994, J BIOL CHEM, V269, P27827; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1988, J BIOL CHEM, V263, P15264; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHUMANN H, 1989, SYST APPL MICROBIOL, V11, P103, DOI 10.1016/S0723-2020(89)80047-5; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; TAOY, 1995, J BIOL CHEM, V270, P383; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660	22	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18408	18412		10.1074/jbc.270.31.18408	http://dx.doi.org/10.1074/jbc.270.31.18408			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629166	hybrid			2022-12-25	WOS:A1995RM64200042
J	WIMALAWANSA, SJ				WIMALAWANSA, SJ			PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF NEUROPEPTIDE Y-2 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN PANCREATIC-POLYPEPTIDE; PEPTIDE-YY-RECEPTORS; RAT-BRAIN; CEREBRAL-CORTEX; BINDING-SITES; RABBIT KIDNEY; Y2 RECEPTORS; NPY BINDING; GUINEA-PIG; CELL-LINES	Neuropeptide Y (NPY) receptors consist of three subtypes, designated NPY1, NPY2, and NPY3. The Y-1 receptor tor has been cloned. The present study reports the purification of the NPY-Y-2 receptor from porcine brain and its biochemical characterization. NPY receptors were solubilized and purified by sequential hydrophobic interaction, ion exchange, and NPY-affinity chromatography. By use of SDS-polyacrylamide gel electrophoresis, high performance liquid chromatography gel permeation chromatography, and chemical cross-linking studies, the affinity-purified brain NPY-Y-2 receptor was identified as a monomeric glycoprotein with a molecular mass of 60 kDa. Following deglycosylation, the molecular mass of the Y-2 receptor was decreased to 45 kDa. Although the I-125-NPY binding to the purified NPY receptor was considerably decreased by N-ethylmaleimide, guanine nucleotides had no effect. Therefore, the purified NPY-Y-2 receptor is probably not associated with G-proteins, but may have intramolecular-free sulfhydryl groups. The specific activity of the isolated NPY-Y-2 receptor is 15.8 nmol/mg of protein. The isolated receptor retained its capacity to bind to I-125-NPY, specific to NPY and peptide YY, and showed no cross-reactivity with any other peptides. Highly purified (10(9)-fold purification) NPY receptor from the brain was identified as the Y-2 subtype as demonstrated by its affinity to C-terminal fragments of NPY, including NPY (13-36).			WIMALAWANSA, SJ (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV GEN INTERNAL MED,HYPERTENS & VASC RES LAB,GALVESTON,TX 77555, USA.			Wimalawansa, Prof. Sunil/0000-0003-1096-8595				ADAMO ML, 1990, ENDOCRINOLOGY, V126, P434, DOI 10.1210/endo-126-1-434; AICHER SA, 1990, NEUROSCI LETT, V130, P32; ALBERS HE, 1984, NEUROSCI LETT, V50, P163, DOI 10.1016/0304-3940(84)90480-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG RSL, 1985, LIFE SCI, V37, P2111, DOI 10.1016/0024-3205(85)90583-1; CHANPALAY V, 1985, J COMP NEUROL, V238, P382, DOI 10.1002/cne.902380403; CLARK JT, 1985, ENDOCRINOLOGY, V117, P2435, DOI 10.1210/endo-117-6-2435; COLMERS WF, 1991, BRIT J PHARMACOL, V102, P41, DOI 10.1111/j.1476-5381.1991.tb12129.x; DALSGAARD CJ, 1986, CELL TISSUE RES, V243, P477; DRUMHELLER A, 1988, Society for Neuroscience Abstracts, V14, P287; DUMONT Y, 1990, EUR J PHARMACOL, V191, P501, DOI 10.1016/0014-2999(90)94189-5; EDVINSSON L, 1987, TRENDS PHARMACOL SCI, V8, P231, DOI 10.1016/0165-6147(87)90069-1; GIMPL G, 1990, J BIOL CHEM, V265, P18142; GLOVER ID, 1985, EUR J BIOCHEM, V142, P379; GRAY TS, 1986, LIFE SCI, V38, P389, DOI 10.1016/0024-3205(86)90061-5; HEDO JA, 1984, RECEPTOR PURIFICATIO, V2, P45; HJELMELAND LM, 1984, RECEPTOR BIOCH METHO, V1, P35; INUI A, 1992, ENDOCRINOLOGY, V130, P3314, DOI 10.1210/en.130.6.3314; INUI A, 1992, ENDOCRINOLOGY, V131, P2090, DOI 10.1210/en.131.5.2090; INUI A, 1989, ENDOCRINOLOGY, V124, P402, DOI 10.1210/endo-124-1-402; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LI W, 1992, J BIOL CHEM, V267, P7570; LINDSTROM JM, 1978, NEUROTRANSMITTER REC, P91; LUNDBERG JM, 1983, NEUROSCI LETT, V42, P167, DOI 10.1016/0304-3940(83)90401-9; LUNDBERG JM, 1984, ACTA PHYSIOL SCAND, V121, P325, DOI 10.1111/j.1748-1716.1984.tb07463.x; MARTEL JC, 1986, PEPTIDES, V7, P55, DOI 10.1016/0196-9781(86)90061-6; MCDONALD JK, 1988, CRIT REV NEUROBIOL, V4, P97; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NATA K, 1990, BIOCHEM BIOPH RES CO, V171, P330, DOI 10.1016/0006-291X(90)91397-B; NGUYEN TD, 1990, J BIOL CHEM, V265, P6416; ODONOHUE TL, 1985, PEPTIDES, V6, P755, DOI 10.1016/0196-9781(85)90180-9; OKITA M, 1991, ENDOCRINOLOGY, V129, P2512, DOI 10.1210/endo-129-5-2512; PARROTT RF, 1986, PHYSIOL BEHAV, V36, P523, DOI 10.1016/0031-9384(86)90325-2; RIMLAND J, 1991, MOL PHARMACOL, V40, P869; SARIA A, 1985, European Journal of Pharmacology, V107, P105; SHEIKH SP, 1989, FEBS LETT, V245, P209, DOI 10.1016/0014-5793(89)80223-6; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SHEIKH SP, 1991, J BIOL CHEM, V266, P23959; SHEIKH SP, 1990, J BIOL CHEM, V265, P8304; SORENSEN MB, 1989, J NEUROCHEM, V52, P1545; STANLEY BG, 1985, BRAIN RES BULL, V14, P521, DOI 10.1016/0361-9230(85)90100-5; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485; TAYLOR IL, 1989, HDB PHYSL 6, V2, P475; UNDEN A, 1984, FEBS LETT, V177, P125, DOI 10.1016/0014-5793(84)80995-3; UNDEN A, 1984, EUR J BIOCHEM, V145, P525, DOI 10.1111/j.1432-1033.1984.tb08588.x; VOISIN T, 1990, AM J PHYSIOL, V258, pG753, DOI 10.1152/ajpgi.1990.258.5.G753; WAHLESTEDT C, 1985, J PHARMACOL EXP THER, V234, P735; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	53	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18523	18530						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629181				2022-12-25	WOS:A1995RM64200059
J	SHAO, ZM; DAWSON, MI; LI, XS; RISHI, AK; SHEIKH, MS; HAN, QX; ORDONEZ, JV; SHROOT, B; FONTANA, JA				SHAO, ZM; DAWSON, MI; LI, XS; RISHI, AK; SHEIKH, MS; HAN, QX; ORDONEZ, JV; SHROOT, B; FONTANA, JA			P53 INDEPENDENT G(0)/G(1) ARREST AND APOPTOSIS INDUCED BY A NOVEL RETINOID IN HUMAN BREAST-CANCER CELLS	ONCOGENE			English	Article						RETINOIDS; BREAST CANCER; APOPTOSIS	ACID RECEPTOR-GAMMA; D-TYPE CYCLINS; X-RECEPTOR; THYROID-HORMONE; RESPONSE ELEMENTS; NUCLEAR RECEPTORS; GROWTH; DEATH; GENE; IDENTIFICATION	The biological activity of a novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN) was investigated in human breast carcinoma (HBC) cells. Although capable of selective binding to the RAR gamma nuclear receptor, AHPN inhibited the growth of a number of HBC cell lines via RAR- or RXR-independent pathways. AHPN also inhibited the growth of the human leukemia cell line HL-60R which does not possess functional RARs. RA significantly inhibited AP-1 mediated gene activation in MCF-7 cells while AHPN displayed no such anti-AP-1 activity. Retinoids normally are cytostatic in their inhibition of breast carcinoma growth and permit cell proliferation upon their removal, whereas AHPN induced G(0)/G(1) arrest within 6 h followed by apoptosis. In MCF-7 cells that harbor wild type p53, AHPN-induced G(0)/G(1) arrest and apoptosis was accompanied by p53-independent regulation of WAF1/CIP1 as well as bar mRNA levels while bcl-2 mRNA levels were decreased. In MDA-MB-231 cells which possess a mutant p53, AHPN-mediated G(0)/G(1) arrest and apoptosis was also associated with a concomitant up regulation of WAF1/CIP1 mRNA while these cells did not express bar or bcl-2 messages. Thus, AHPN represents a novel retinoid that induces G(0)/G(1) arrest and apoptosis via a unique pathway which appears to involve activation of known downstream effecters of p53 in a p53-independent manner.	UNIV MARYLAND, CTR CANC, DEPT MED, DIV HEMATOL & MED ONCOL, BALTIMORE, MD 21201 USA; DEPT VET AFFAIRS MED CTR, BALTIMORE, MD 21201 USA; SRI INT, DIV LIFE SCI, MENLO PK, CA 94025 USA; CTR INT RECH DERMATOL GALDERMA, VALBONNE, FRANCE	University System of Maryland; University of Maryland Baltimore; SRI International; Galderma R&D SNC				Fontana, Joseph/0000-0003-3829-3358	NCI NIH HHS [CA 63335, CA 51993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051993, R01CA063335] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENBY G, 1994, J BIOL CHEM, V269, P16689; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEARD RL, 1994, BIOORG MED CHEM LETT, V4, P1447, DOI 10.1016/S0960-894X(01)80511-4; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; DAVIES PJA, 1993, MAR AM ASS CANC RES; DAWSON MI, 1983, J MED CHEM, V26, P1653, DOI 10.1021/jm00365a021; DAWSON MI, 1992, RETINOIDS NEW TRENDS, P205; DAWSON MI, UNPUB; DHRIKH MD, 1993, ANTICANCER RES, V13, P1387; DOMINIANNI SJ, 1977, J ORG CHEM, V42, P344, DOI 10.1021/jo00422a037; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HALDAR S, 1994, CANCER RES, V54, P2095; HERMANN T, 1993, ONCOGENE, V8, P55; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Isaacs John T., 1994, Current Opinion in Oncology, V6, P82, DOI 10.1097/00001622-199401000-00012; JAFFEY P, 1992, CANCER RES, V52, P2384; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG W, 1993, ONCOGENE, V8, P3447; JONG L, 1993, J MED CHEM, V36, P2605, DOI 10.1021/jm00070a003; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOHNES D, 1992, CELL SCI S, V16, P69; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MADER S, 1993, J BIOL CHEM, V268, P591; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOASSER MM, 1994, ONCOGENE, V9, P833; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REICHERT U, 1993, MOL BIOL THERAPEUTIC, V5, P117; ROBERTSON KA, 1992, BLOOD, V80, P1885; ROMAN SD, 1993, CANCER RES, V53, P5940; RUDD CJ, 1993, CANCER LETT, V73, P41, DOI 10.1016/0304-3835(93)90186-D; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SHEIKH MS, 1992, BIOCHEM BIOPH RES CO, V183, P1003, DOI 10.1016/S0006-291X(05)80290-6; SHROOT B, 1990, Patent No. 4940696; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	86	232	250	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					493	504						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630633				2022-12-25	WOS:A1995RN53000009
J	ZHOU, P; JIANG, W; ZHANG, YJ; KAHN, SM; SCHIEREN, I; SANTELLA, RM; WEINSTEIN, IB				ZHOU, P; JIANG, W; ZHANG, YJ; KAHN, SM; SCHIEREN, I; SANTELLA, RM; WEINSTEIN, IB			ANTISENSE TO CYCLIN D1 INHIBITS GROWTH AND REVERSES THE TRANSFORMED PHENOTYPE OF HUMAN ESOPHAGEAL CANCER-CELLS	ONCOGENE			English	Article						ANTISENSE; CYCLIN D1; ESOPHAGEAL CANCER; TUMORIGENICITY	RETINOBLASTOMA PROTEIN; NUCLEAR-PROTEIN; AMPLIFICATION; GENE; OVEREXPRESSION; EXPRESSION; FIBROBLASTS; CARCINOMAS; 11Q13; PHASE	The cyclin D1 gene is amplified and overexpressed in a significant fraction of human esophageal tumors, and several other types of human cancer, but the functional significance of this overexpression has not been established. To further address the roles of cyclin D1 in growth control and tumorigenesis, we have overexpressed an antisense cyclin D1 cDNA construct, either constitutively or inducibly, in the HCE7 human esophageal cancer cell line in which cyclin D1 is amplified and expressed at high levels. The expression of antisense cyclin D1 led to decreased expression of cyclin D1 at both the mRNA and protein levels, and this was associated with a marked inhibition of cell proliferation. Antisense cyclin D1 expressing cells displayed a decreased plating efficiency, increased doubling time, decreased saturation density, increased cell size, decreased cyclin D1-associated in vitro kinase activity, decreased anchorage-independent growth, and a loss of tumorigenicity in nude mice. These findings provide direct evidence that the overexpression of cyclin D1 in certain tumor cells contributes to their abnormal growth and tumorigenicity. The ability to revert the transformed phenotype of these cells with antisense cyclin D1 suggests that cyclin D1 may be a useful target in cancer therapy.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute				Jiang, Wei/0000-0002-2309-9571				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BANKSSCHLEGEL SP, 1986, CANCER RES, V46, P250; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BONHAM L, 1991, ONCOGENE, V6, P1073; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GILLETT C, 1994, CANCER RES, V54, P1812; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, ONCOGENE, V9, P2159; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; OSWALD F, 1994, ONCOGENE, V9, P2029; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHUURING E, 1992, ONCOGENE, V7, P355; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAM SW, 1994, ONCOGENE, V9, P2663; TOOSHIMA H, 1994, CELL, V78, P67; TSURUTA H, 1993, BIOCHEM BIOPH RES CO, V196, P1529, DOI 10.1006/bbrc.1993.2425; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	56	155	168	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					571	580						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630641				2022-12-25	WOS:A1995RN53000018
J	ATHERTON, JC; CAO, P; PEEK, RM; TUMMURU, MKR; BLASER, MJ; COVER, TL				ATHERTON, JC; CAO, P; PEEK, RM; TUMMURU, MKR; BLASER, MJ; COVER, TL			MOSAICISM IN VACUOLATING CYTOTOXIN ALLELES OF HELICOBACTER-PYLORI - ASSOCIATION OF SPECIFIC VACA TYPES WITH CYTOTOXIN PRODUCTION AND PEPTIC-ULCERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-LAYER PROTEIN; RICKETTSIA-RICKETTSII; CAMPYLOBACTER-PYLORI; GASTRIC-CARCINOMA; DUODENAL-ULCER; ANTIGEN; BINDING; GENE; METRONIDAZOLE; RESISTANCE	Approximately 50% of Helicobacter pylori strains produce a cytotoxin, encoded by vacA, that induces vacuolation of eukaryotic cells. Analysis of a clinically isolated tox(-) strain (Tx30a) indicated secretion of a 93-kDa product from a 3933 base pair vacA open reading frame. Characterization of 59 different H. pylori isolates indicated the existence of three different families of vacA signal sequences (s1a, s1b, and s2) and two different families of middle-region alleles (m1 and m2). All possible combinations of these vacA regions were identified, with the exception of s2/m1 (p < 0.001); this mosaic organization implies that recombination has occurred in vivo between vacA alleles. Type s1/m1 strains produced a higher level of cytotoxin activity in vitro than type s1/m2 strains; none of 19 type s2/m2 strains produced detectable cytotoxin activity. The presence of cagA (cytotoxin-associated gene A) was closely associated with the presence of vacA signal sequence type s1 (p < 0.001). Among patients with past or present peptic ulceration, 21 (91%) of 23 harbored type s1 strains compared with 16 (48%) of 33 patients without peptic ulcers; only 2 (10%) of 19 subjects harboring type s2 strains had past or present peptic ulcers (p < 0.005). Thus, specific vacA genotypes of H. pylori strains are associated with the level of in vitro cytotoxin activity as well as clinical consequences.	VANDERBILT UNIV,SCH MED,DEPT MED,DIV INFECT DIS,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System			Cover, Timothy/I-3814-2015	Cover, Timothy/0000-0001-8503-002X; /0000-0001-6180-0042	NATIONAL CANCER INSTITUTE [R01CA058834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045293] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58834] Funding Source: Medline; NIDDK NIH HHS [R29 DK45293] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON BE, 1990, INFECT IMMUN, V58, P2760, DOI 10.1128/IAI.58.9.2760-2769.1990; BLASER MJ, 1992, CLIN INFECT DIS, V15, P386, DOI 10.1093/clind/15.3.386; BUKANOV NO, 1994, MOL MICROBIOL, V11, P509, DOI 10.1111/j.1365-2958.1994.tb00332.x; CARL M, 1990, P NATL ACAD SCI USA, V87, P8237, DOI 10.1073/pnas.87.21.8237; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; COVER TL, 1993, INFECT IMMUN, V61, P5008, DOI 10.1128/IAI.61.12.5008-5012.1993; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1994, J BIOL CHEM, V269, P10566; COVER TL, 1992, J CLIN INVEST, V90, P913, DOI 10.1172/JCI115967; COVER TL, 1995, IN PRESS ADV INTERN, V41; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; FERRERO RL, 1992, J BACTERIOL, V174, P4212, DOI 10.1128/JB.174.13.4212-4217.1992; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; FUJIMOTO S, 1994, J CLIN MICROBIOL, V32, P331, DOI 10.1128/JCM.32.2.331-334.1994; GARNER JA, 1995, IN PRESS J INFECT DI, V172; GILMORE RD, 1991, MOL MICROBIOL, V5, P2361, DOI 10.1111/j.1365-2958.1991.tb02082.x; GOOSSENS H, 1992, MED MICROBIOL LETT, V1, P153; HAHN MJ, 1993, GENE, V133, P129, DOI 10.1016/0378-1119(93)90237-W; HALTER R, 1989, EMBO J, V8, P2737, DOI 10.1002/j.1460-2075.1989.tb08415.x; HAWRYLIK SJ, 1994, J CLIN MICROBIOL, V32, P790, DOI 10.1128/JCM.32.3.790-792.1994; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; OTOOLE PW, 1994, MOL MICROBIOL, V11, P849; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; POULSEN K, 1992, J BACTERIOL, V174, P2913, DOI 10.1128/JB.174.9.2913-2921.1992; PREWETT EJ, 1992, GASTROENTEROLOGY, V102, P829, DOI 10.1016/0016-5085(92)90165-U; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAUTELIN H, 1994, SCAND J GASTROENTERO, V29, P128, DOI 10.3109/00365529409090450; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; SMITH JM, 1991, NATURE, V349, P29, DOI 10.1038/349029a0; SPRATT BG, 1989, P NATL ACAD SCI USA, V86, P8988, DOI 10.1073/pnas.86.22.8988; TEE W, 1995, J CLIN MICROBIOL, V33, P1203, DOI 10.1128/JCM.33.5.1203-1205.1995; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; TUMMURU MKR, 1992, J BACTERIOL, V174, P5916, DOI 10.1128/jb.174.18.5916-5922.1992; TUMMURU MKR, 1994, INFECT IMMUN, V62, P2609, DOI 10.1128/IAI.62.6.2609-2613.1994; WALKER JE, 1982, EMBO J, V8, P945; WANG Y, 1993, J GEN MICROBIOL, V139, P2485, DOI 10.1099/00221287-139-10-2485	43	1263	1331	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17771	17777		10.1074/jbc.270.30.17771	http://dx.doi.org/10.1074/jbc.270.30.17771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629077				2022-12-25	WOS:A1995RM26600024
J	BENDIXEN, E; HARPEL, PC; SOTTRUPJENSEN, L				BENDIXEN, E; HARPEL, PC; SOTTRUPJENSEN, L			LOCATION OF THE MAJOR EPSILON-(GAMMA-GLUTAMYL)LYSYL CROSS-LINKING SITE IN TRANSGLUTAMINASE-MODIFIED HUMAN PLASMINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; AMINO-ACID-SEQUENCE; ALPHA-2-PLASMIN INHIBITOR; GLU-PLASMINOGEN; ACCEPTOR SITES; FACTOR-XIIIA; FIBRIN; ACTIVATOR; BINDING; FIBRONECTIN	Tissue and plasma transglutaminases cross-link human plasminogen into high molecular weight complexes (Bendixen, E., Borth, W., and Harpel, P. C. (1993) J. Biol. Chem. 268, 21962-21967). A major cross-linking site in plasminogen involved in the tissue transglutaminase-mediated polymerization process has been identified. The epsilon-(gamma-glutamyl)lysyl bridges of the polymer are formed between Lys-298 and Gln-322. Both the acyl donor Gin residue and the acyl acceptor Lys residue are located in the kringle 3 domain of plasminogen, i.e. cross-linking of plasminogen by tissue transglutaminase involves neither the catalytic domain nor the lysine dependent binding sites of plasminogen. This study documents that kringle 3 contains a novel functional site with the potential to participate in transglutaminase-mediated cross-linking interactions with plasma, cell-surface, and extracellular proteins.	AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS C,DENMARK; MT SINAI MED CTR,DIV HEMATOL,NEW YORK,NY 10029	Aarhus University; Icahn School of Medicine at Mount Sinai					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AESCHLIMANN D, 1992, J BIOL CHEM, V267, P11316; ALPERT AJ, 1988, J CHROMATOGR, V443, P819; BANYAI L, 1984, J BIOL CHEM, V259, P6466; BENDIXEN E, 1993, J BIOL CHEM, V268, P21962; CHEN R, 1970, P NATL ACAD SCI USA, V66, P472, DOI 10.1073/pnas.66.2.472; CHIN CCQ, 1993, ANAL BIOCHEM, V214, P128, DOI 10.1006/abio.1993.1466; COTTRELL BA, 1979, BIOCHEMISTRY-US, V18, P5405, DOI 10.1021/bi00591a023; CRIMMINS DL, 1989, ANAL BIOCHEM, V176, P255, DOI 10.1016/0003-2697(89)90305-9; DEGEN SJF, 1990, GENOMICS, V8, P49, DOI 10.1016/0888-7543(90)90225-J; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; GORMAN JJ, 1984, J BIOL CHEM, V259, P9007; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRIFFIN M, 1982, ANAL BIOCHEM, V124, P406, DOI 10.1016/0003-2697(82)90057-4; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HARPEL PC, 1985, J BIOL CHEM, V260, P4432; HOHL D, 1991, J BIOL CHEM, V266, P6626; KIMURA S, 1986, J BIOL CHEM, V261, P5591; KINSELLA MG, 1990, J BIOL CHEM, V265, P17891; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1991, P NATL ACAD SCI USA, V88, P82, DOI 10.1073/pnas.88.1.82; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1980, PROG HEMOSTASIS THRO, V52, P245; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARTINEZ J, 1989, J BIOL CHEM, V264, P20502; MATSUKA YV, 1990, EUR J BIOCHEM, V190, P93, DOI 10.1111/j.1432-1033.1990.tb15550.x; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MILES LA, 1988, BLOOD, V72, P628; MULICHAK AM, 1991, BIOCHEMISTRY-US, V30, P10576, DOI 10.1021/bi00107a029; NACHMAN RL, 1992, BLOOD, V79, P1897, DOI 10.1182/blood.V79.8.1897.bloodjournal7981897; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PONTING CP, 1992, BIOCHIM BIOPHYS ACTA, V1159, P155, DOI 10.1016/0167-4838(92)90020-E; PUCCI P, 1988, BIOCHEM BIOPH RES CO, V154, P735, DOI 10.1016/0006-291X(88)90201-X; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; REICH R, 1988, CANCER RES, V48, P3307; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SANE DC, 1991, BIOCHEM BIOPH RES CO, V174, P465, DOI 10.1016/0006-291X(91)91439-J; SCHALLER J, 1985, EUR J BIOCHEM, V149, P267, DOI 10.1111/j.1432-1033.1985.tb08921.x; SCHALLER J, 1987, Fibrinolysis, V1, P91, DOI 10.1016/0268-9499(87)90015-4; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TOYOOKA T, 1984, ANAL CHEM, V56, P2461, DOI 10.1021/ac00277a044; WU HL, 1990, J BIOL CHEM, V265, P19658	52	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17929	17933		10.1074/jbc.270.30.17929	http://dx.doi.org/10.1074/jbc.270.30.17929			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629099	hybrid			2022-12-25	WOS:A1995RM26600048
J	FREEDMAN, NJ; LIGGETT, SB; DRACHMAN, DE; PEI, G; CARON, MG; LEFKOWITZ, RJ				FREEDMAN, NJ; LIGGETT, SB; DRACHMAN, DE; PEI, G; CARON, MG; LEFKOWITZ, RJ			PHOSPHORYLATION AND DESENSITIZATION OF THE HUMAN BETA(1)-ADRENERGIC RECEPTOR - INVOLVEMENT OF G-PROTEIN-COUPLED RECEPTOR KINASES AND CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; HUMAN BETA-1-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; CYCLIC-AMP; HOMOLOGOUS DESENSITIZATION; ADENYLATE-CYCLASE; RHODOPSIN KINASE; EXPRESSION; FAMILY; CLONING	Persistent stimulation of the beta(1)-adrenergic receptor (beta(1)AR) engenders, within minutes, diminished responsiveness of the beta(1)AR/adenylyl cyclase signal transduction system. This desensitization remains incompletely defined mechanistically, however. We therefore tested the hypothesis that agonist-induced desensitization of the beta(1)AR (like that of the related beta(2)AR) involves phosphorylation of the receptor itself, by cAMP-dependent protein kinase (PKA) and the beta adrenergic receptor kinase (beta ARK1) or other G protein-coupled receptor kinases (GRKs). Both Chinese hamster fibroblast and 293 cells demonstrate receptor-specific desensitization of the beta(1)AR within 3-5 min. Both cell types also express beta(1)AR and the associated inhibitory proteins beta-arrestin-1 and beta-arrestin-2, as assessed by immunoblotting. Agonist-induced beta(1)AR desensitization in 293 cells correlates with a 2 +/- 0.3-fold increase in phosphorylation of the beta(1)AR, determined by immunoprecipitation of the beta(1)AR from cells metabolically labeled with P-32(i). This agonist induced beta(1)AR phosphorylation derives approximately equally from PKA and GRK activity, as judged by intact cell studies with kinase inhibitors or dominant negative beta ARK1 (K220R) mutant overexpression. Desensitization, likewise, is reduced by only similar to 50% when PKA is inhibited in the intact cells. Overexpression of rho dopsin kinase, beta ARK1, beta ARK2, or GRK5 significantly increases agonist-induced beta(1)AR phosphorylation and concomitantly decreases agonist-stimulated cellular cAMP production (p < 0.05). Furthermore, purified beta ARK1, beta ARK2, and GRK5 all demonstrate agonist-dependent phosphorylation of the beta(1)AR. Consistent with a GRK mechanism, receptor-specific desensitization of the beta(1)AR was enhanced by overexpression of beta-arrestin-1 and -2 in transfected 293 cells. We conclude that rapid agonist-induced desensitization of the beta(1)AR involves phosphorylation of the receptor by both PKA and at least beta ARK1 in intact cells. Like the beta(2)AR, the beta(1)AR appears to bind either beta-arrestin-1 or beta-arrestin-2 and to react with rhodopsin kinase, beta ARK1, beta ARK2, and GRK5.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT MED CARDIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021; liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL-16037, HL03008-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNER P, 1991, J PHARMACOL EXP THER, V259, P317; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H; BURGERMEISTER W, 1983, BIOCHIM BIOPHYS ACTA, V729, P219, DOI 10.1016/0005-2736(83)90488-1; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Colton T., 1974, STAT MED, V1; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; ESBENSHADE TA, 1992, MOL PHARMACOL, V42, P753; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GREEN SA, 1992, MOL PHARMACOL, V41, P889; HAMMOND HK, 1992, CIRCULATION, V85, P269, DOI 10.1161/01.CIR.85.1.269; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KONG GH, 1994, J BIOL CHEM, V269, P13084; KOPP U, 1983, AM J PHYSIOL, V244, pF418, DOI 10.1152/ajprenal.1983.244.4.F418; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PING PP, 1994, CIRCULATION, V90, P358; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; Sambrook J, 1989, MOL CLONING LABORATO; SEFTON BM, 1991, METHOD ENZYMOL, V201, P245; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; STRASSER RH, 1986, BIOCHEMISTRY-US, V25, P1371, DOI 10.1021/bi00354a027; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; ZHOU XM, 1991, J BIOL CHEM, V266, P7462; ZHOU XM, 1995, CELL SIGNAL, V7, P207, DOI 10.1016/0898-6568(94)00091-O	48	300	307	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17953	17961		10.1074/jbc.270.30.17953	http://dx.doi.org/10.1074/jbc.270.30.17953			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629102	hybrid			2022-12-25	WOS:A1995RM26600052
J	AZIM, AC; KNOLL, JHM; BEGGS, AH; CHISHTI, AH				AZIM, AC; KNOLL, JHM; BEGGS, AH; CHISHTI, AH			ISOFORM CLONING, ACTIN-BINDING, AND CHROMOSOMAL LOCALIZATION OF HUMAN ERYTHROID DEMATIN, A MEMBER OF THE VILLIN SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHEROCYTOSIS; PROTEINS; GENE; PURIFICATION; GLUTATHIONE; SEQUENCE; DELETION	Dematin is an actin-bundling protein of the erythroid membrane skeleton and is abundantly expressed in human brain, heart, skeletal muscle, kidney, and lung. The 48-kDa subunit of dematin contains a headpiece domain which was originally identified in villin, an actin-binding protein of the brush-border cytoskeleton. The headpiece domain of villin is essential for its morphogenic function in vivo. Here we report the primary structure of 52-kDa subunit of dematin which differs from the 48-kDa subunit by a 22-amino-acid insertion within its headpiece domain. A unique feature of the insertion sequence of the 52-kDa subunit is its homology to erythrocyte protein 4.2. The insertion sequence also includes a cysteine residue which may explain the formation of sulfhydryl-linked trimers of dematin. Actin binding measurements using recombinant fusion proteins re vealed that each monomer of dematin contains two Factin binding sites: one in the headpiece domain and the other in the undefined N-terminal domain. Although the actin bundling activity of intact dematin was abolished by phosphorylation, no effect of phosphorylation was observed on the actin binding activity of fusion proteins. Using somatic cell hybrid panels and fluorescence in situ hybridization, the dematin gene was localized on the short arm of chromosome 8. The dematin locus, 8p21.1, is distal to the known locus of human erythroid ankyrin (8p11.2) and may contribute to the etiology of hemolytic anemia in a subset of patients with severe hereditary spherocytosis.	TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT BIOMED RES,BOSTON,MA 02135; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	St. Elizabeth's Medical Center; Tufts University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			AZIM, ANSER/U-3483-2019	Beggs, Alan/0000-0001-8818-0568; Knoll, Joan/0000-0001-6691-1710	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL051445, P01HL037462, R01HL051445] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51445, HL37462] Funding Source: Medline; NICHD NIH HHS [HD18568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BECK JS, 1993, A J HUM ENET S, V53, pA974; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BRUNS G, 1987, HUM GENET, V76, P58; CHILCOTE RR, 1987, BLOOD, V69, P156; CHISHTI AH, 1989, J BIOL CHEM, V264, P8985; CHISHTI AH, 1988, NATURE, V334, P718; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KIDD GH, 1978, NATURE, V276, P733, DOI 10.1038/276733a0; KITATANI M, 1988, HUM GENET, V78, P94, DOI 10.1007/BF00291244; KNOLL JHM, 1994, CURRENT PROTOCOLS HU, V1; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; KORSGREN C, 1994, GENOMICS, V21, P478, DOI 10.1006/geno.1994.1304; KOURY ST, 1989, J CELL BIOL, V109, P3005, DOI 10.1083/jcb.109.6.3005; LUX SE, 1990, NATURE, V345, P736, DOI 10.1038/345736a0; MAHAJANMIKLOS S, 1994, CELL, V78, P291, DOI 10.1016/0092-8674(94)90298-4; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; RANA AP, 1993, P NATL ACAD SCI USA, V90, P6651, DOI 10.1073/pnas.90.14.6651; ROOF D, 1991, INVEST OPHTH VIS SCI, V32, P582; SIEGEL DL, 1985, J CELL BIOL, V100, P775, DOI 10.1083/jcb.100.3.775; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866	26	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17407	17413		10.1074/jbc.270.29.17407	http://dx.doi.org/10.1074/jbc.270.29.17407			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615546	hybrid			2022-12-25	WOS:A1995RK68900058
J	RAINES, RT; TOSCANO, MP; NIERENGARTEN, DM; HA, JH; AUERBACH, R				RAINES, RT; TOSCANO, MP; NIERENGARTEN, DM; HA, JH; AUERBACH, R			REPLACING A SURFACE LOOP ENDOWS RIBONUCLEASE-A WITH ANGIOGENIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID SEQUENCE; BINDING-PROTEIN; TUMOR-GROWTH; INHIBITION; NEOVASCULARIZATION; SPECIFICITY; DELETION; PEPTIDES; HYBRID	Angiogenin (ANG) promotes the formation of blood vessels in animals. This hormone is a small, monomeric protein that is homologous to bovine pancreatic ribonuclease A (RNase). ANG is a poor ribonuclease but its ribonucleolytic activity is essential for its angiogenic activity. RNase is not angiogenic. A hybrid protein was produced in which 13 residues of a divergent surface loop of ANG were substituted for the analogous 15 residues of RNase. The value of k(cat)/K-m for the cleavage of uridylyl(3'-->5')adenosine by this hybrid protein was 20-fold less than that of RNase but 10(5)-fold greater than that of ANG. The thermal stability of the hybrid protein was also less than that of RNase. Nevertheless, the RNase/ANG hybrid protein promotes angiogenesis in mice at least as extensively as does authentic ANG. Thus we present a protein endowed with st noncognate biological activity simply by replacing a single element of secondary structure. In addition, a 13 residue peptide corresponding to the surface loop of ANG inhibits endogenous angiogenesis in mice. These results support a model in which both a surface loop and a catalytic site are necessary for the promotion of blood vessel formation by ANG or RNase. The dissection of structure/function elements in ANG reveals a unique opportunity to develop new molecules that modulate neovascularization.	UNIV WISCONSIN,CTR DEV BIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	RAINES, RT (corresponding author), UNIV WISCONSIN,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706, USA.		Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044783] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44783] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA KR, 1994, P NATL ACAD SCI USA, V91, P2915, DOI 10.1073/pnas.91.8.2915; ALLEMANN RK, 1991, PROTEIN ENG, V4, P831, DOI 10.1093/protein/4.7.831; AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BALDISSERI DM, 1991, BIOCHEMISTRY-US, V30, P3628, DOI 10.1021/bi00229a006; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BEINTEMA JJ, 1987, LIFE CHEM REPORTS, V4, P333; BOND MD, 1993, BIOCHIM BIOPHYS ACTA, V1162, P177, DOI 10.1016/0167-4838(93)90145-H; BRAXTON S, 1992, BIOCHEMISTRY-US, V31, P7796, DOI 10.1021/bi00149a008; BRUNET AP, 1993, NATURE, V364, P355, DOI 10.1038/364355a0; Cleland W W, 1979, Methods Enzymol, V63, P103; DELCARDAYRE SB, 1994, BIOCHEMISTRY-US, V33, P6031, DOI 10.1021/bi00186a001; DELCARDAYRE SB, 1995, PROTEIN ENG, V8, P261, DOI 10.1093/protein/8.3.261; DELCARDAYRE SB, 1995, IN PRESS J MOL BIOL; EIJSINK VG, 1993, PROTEIN ENG, V5, P157; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; FAJARDO LF, 1988, LAB INVEST, V58, P718; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILL SC, 1989, ANAL BIOCHEM, V189, P283; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; HALLAHAN TW, 1991, P NATL ACAD SCI USA, V88, P2222, DOI 10.1073/pnas.88.6.2222; HARPER JW, 1989, BIOCHEMISTRY-US, V28, P1875, DOI 10.1021/bi00430a067; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HERMANS J, 1961, J AM CHEM SOC, V83, P3283, DOI 10.1021/ja01476a025; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU GF, 1991, P NATL ACAD SCI USA, V88, P2227, DOI 10.1073/pnas.88.6.2227; HYNES TR, 1989, NATURE, V339, P73, DOI 10.1038/339073a0; INGBER D, 1988, LAB INVEST, V59, P44; Ipata P L., 1968, FEBS Lett, V1, P29, DOI 10.1016/0014-5793(68)80010-9; KIM JS, 1995, J BIOL CHEM, V270, P10525, DOI 10.1074/jbc.270.18.10525; KNIGHTON D, 1977, BRIT J CANCER, V35, P347, DOI 10.1038/bjc.1977.49; KNOWLES JR, 1987, SCIENCE, V236, P1252; KUIPERS OP, 1989, SCIENCE, V244, P82, DOI 10.1126/science.2704992; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MARAGOUDAKIS ME, 1992, ANGIOGENESIS HLTH DI; MESSMORE JM, 1995, IN PRESS J AM CHEM S; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MUTHUKKARUPPAN V, 1979, SCIENCE, V205, P1416, DOI 10.1126/science.472760; OGILVIE KK, 1978, CAN J CHEM, V56, P2768, DOI 10.1139/v78-457; PCE CN, 1989, PROTEIN STRUCTURE, P311; POLAKOWSKI IJ, 1993, AM J PATHOL, V143, P507; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RAINES RT, 1989, STRUCTURE CHEM RIBON, P95; REYNOLDS LP, 1992, FASEB J, V6, P886, DOI 10.1096/fasebj.6.3.1371260; RYBAK SM, 1989, BIOCHEM BIOPH RES CO, V162, P535, DOI 10.1016/0006-291X(89)92030-5; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P1726, DOI 10.1021/bi00430a045; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; THOMPSON JE, 1994, J AM CHEM SOC, V116, P5467, DOI 10.1021/ja00091a060; TOMA S, 1991, BIOCHEMISTRY-US, V30, P97, DOI 10.1021/bi00215a015; UI N, 1971, BIOCHIM BIOPHYS ACTA, V229, P567; UNGER EF, 1994, AM J PHYSIOL, V266, pH1588, DOI 10.1152/ajpheart.1994.266.4.H1588; VUILLEUMIER S, 1994, EUR J BIOCHEM, V221, P1003, DOI 10.1111/j.1432-1033.1994.tb18817.x; WARSHAW MM, 1966, J MOL BIOL, V20, P29, DOI 10.1016/0022-2836(66)90115-X; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289; WLODAWER A, 1983, BIOCHEMISTRY-US, V22, P2720, DOI 10.1021/bi00280a021; WOLFSON AJ, 1991, PROTEIN ENG, V4, P313, DOI 10.1093/protein/4.3.313; [No title captured]	68	45	48	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17180	17184		10.1074/jbc.270.29.17180	http://dx.doi.org/10.1074/jbc.270.29.17180			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615514	hybrid			2022-12-25	WOS:A1995RK68900021
J	ZUBIAUR, M; SANCHO, J; TERHORST, C; FALLER, DV				ZUBIAUR, M; SANCHO, J; TERHORST, C; FALLER, DV			A SMALL GTP-BINDING PROTEIN, RHO, ASSOCIATES WITH THE PLATELET-DERIVED GROWTH-FACTOR TYPE-BETA RECEPTOR UPON LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; PHOSPHOLIPASE-C-GAMMA; T-CELL ACTIVATION; PDGF RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; TERMINAL REGION; GENE-PRODUCT	Ligand binding to the platelet-derived growth factor (PDGF) receptor initiates a complex and diverging cascade of signaling pathways. GTP-binding proteins with intrinsic GTPase activity (G-proteins) frequently link cell surface receptors to intracellular signaling pathways, but no close associations of the PDGF receptor and any small G-proteins, nor any such associations activated by ligand binding to the receptor have been previously reported. We demonstrate that a small GTP-binding protein binds specifically to the murine and human PDGF type-beta receptor. In response to PDGF-BB stimulation, there is an increase in the amount of labeled small G-protein associated with the PDGF type-beta receptor. The GTP-binding protein did not undergo ligand-induced association with a mutant receptor protein that was unable to bind ATP. Proteolytic cleavage analysis, together with two dimensional separation techniques, identified the small G-protein specifically associating with the PDGF type-beta receptor after ligand binding as a member of the Rho family. This was confirmed by demonstration that the small G-protein coimmunoprecipitated by the anti-PDGF receptor antibody was a substrate for the ADP-ribosyltransferase C3 exoenzyme. Thus, the PDGF type-beta receptor may form a complex with one or more small G-proteins upon binding PDGF-BB, and the Rho small G-protein is likely to be an important component of the proteins making up the multimeric signaling complex of the PDGF type-beta receptor.	BOSTON UNIV,SCH MED,CANC RES CTR,BOSTON,MA 02118; CSIC,INST BIOMED & PARASITOL,E-18001 GRANADA,SPAIN; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV IMMUNOL,BOSTON,MA 02115	Boston University; Consejo Superior de Investigaciones Cientificas (CSIC); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Zubiaur, Mercedes/AAC-5792-2021; Zubiaur, Mercedes/K-9390-2014; Sancho, Jaime/O-3228-2013; Sancho, Jaime/K-5989-2019	Zubiaur, Mercedes/0000-0002-4127-3027; Zubiaur, Mercedes/0000-0002-4127-3027; Sancho, Jaime/0000-0003-3852-7951; Sancho, Jaime/0000-0003-3852-7951	NCI NIH HHS [R01-CA50459] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AHN NG, 1990, J BIOL CHEM, V265, P11487; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P678, DOI 10.1038/348678a0; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CUI Z, 1991, J BIOL CHEM, V266, P20276; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P15; ESCOBEDO JA, 1988, J BIOL CHEM, V263, P1482; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; HUBER LA, 1994, ELECTROPHORESIS, V15, P283, DOI 10.1002/elps.1150150148; JONES PP, 1984, METHOD ENZYMOL, V108, P452; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KUMAGAI N, 1993, J BIOL CHEM, V268, P24536; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V89, P8232; Lacal JC, 1993, RAS SUPERFAMILY GTPA; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOW A, 1993, EUR J BIOCHEM, V215, P473, DOI 10.1111/j.1432-1033.1993.tb18056.x; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUI TG, 1989, P NATL ACAD SCI USA, V89, P8314; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PATTERSON SD, 1992, ANAL BIOCHEM, V202, P193, DOI 10.1016/0003-2697(92)90227-X; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETER ME, 1992, EMBO J, V11, P933, DOI 10.1002/j.1460-2075.1992.tb05132.x; PETER ME, 1993, ANAL BIOCHEM, V210, P77, DOI 10.1006/abio.1993.1153; PETER ME, 1993, EUR J IMMUNOL, V23, P461, DOI 10.1002/eji.1830230224; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; UEDA T, 1990, J BIOL CHEM, V265, P9373; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WIELAND T, 1990, FEBS LETT, V263, P195, DOI 10.1016/0014-5793(90)81372-U; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	75	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17221	17228		10.1074/jbc.270.29.17221	http://dx.doi.org/10.1074/jbc.270.29.17221			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615521	hybrid			2022-12-25	WOS:A1995RK68900028
J	KEMPF, B; BREMER, E				KEMPF, B; BREMER, E			OPUA, AN OSMOTICALLY REGULATED BINDING PROTEIN-DEPENDENT TRANSPORT-SYSTEM FOR THE OSMOPROTECTANT GLYCINE BETAINE IN BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; STAPHYLOCOCCUS-AUREUS; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; RNA-POLYMERASE; PROU OPERON; TRANSCRIPTION; BACTERIA; PROMOTER	Exogenously provided glycine betaine can efficiently protect Bacillus subtilis from the detrimental effects of high osmolarity environments. Through functional complementation of an Escherichia coli mutant deficient in glycine betaine uptake with a gene library from B. subtilis, we have identified a multicomponent glycine betaine transport system, OpuA. Uptake of radiolabeled glycine betaine in B. subtilis was found to be osmotically stimulated and was strongly decreased in a mutant strain lacking the OpuA transport system. DNA sequence analysis revealed that the components of the OpuA system are encoded by an operon (opuA) comprising three structural genes: opuAA, opuAB, and opuAC. The products of these genes exhibit features characteristic for binding protein dependent transport systems and in particular show homology to the glycine betaine uptake system ProU from E. coli. Expression of the opuA operon is under osmotic control. The transcriptional initiation sites of opuA were mapped by high resolution primer extension analysis, and two opuA mRNAs were detected that differed by 38 base pairs at their 5' ends. Synthesis of the shorter transcript was strongly increased in cells grown at high osmolarity, whereas the amount of the longer transcript did not vary in response to medium osmolarity. Physical and genetic mapping experiments allowed the positioning the opuA operon at 25 degrees on the genetic map of B. subtilis.	MAX PLANCK INST TERR MIKROBIOL,D-35043 MARBURG,GERMANY	Max Planck Society								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANAGNOSTOPOULOS C, 1994, BACILLUS SUBTILIS OT, P425; AUBLE DT, 1988, J MOL BIOL, V202, P471, DOI 10.1016/0022-2836(88)90279-3; BAE JH, 1993, APPL ENVIRON MICROB, V59, P2734, DOI 10.1128/AEM.59.8.2734-2736.1993; BARRON A, 1987, J BIOL CHEM, V262, P11841; BENSON AK, 1992, J BACTERIOL, V174, P749, DOI 10.1128/jb.174.3.749-757.1992; BOCH J, 1994, J BACTERIOL, V176, P5364; BOYLAN SA, 1993, J BACTERIOL, V175, P7931, DOI 10.1128/JB.175.24.7931-7937.1993; BRAUN V, 1994, N COMP BIOC, V27, P319, DOI DOI 10.1016/S0167-7306(08)60417-2; BRUCKNER R, 1992, GENE, V122, P187, DOI 10.1016/0378-1119(92)90048-T; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; CULHAM DE, 1993, J MOL BIOL, V229, P268, DOI 10.1006/jmbi.1993.1030; Cutting S., 1990, MOL BIOL METHODS BAC; DERSCH P, 1994, FEMS MICROBIOL LETT, V123, P19, DOI 10.1016/0378-1097(94)90268-2; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; FAATZ E, 1988, MOL MICROBIOL, V2, P265, DOI 10.1111/j.1365-2958.1988.tb00028.x; FURUSATO T, 1986, J BACTERIOL, V165, P549, DOI 10.1128/jb.165.2.549-556.1986; GONZYTREBOUL G, 1992, J MOL BIOL, V224, P967, DOI 10.1016/0022-2836(92)90463-T; GOWRISHANKAR J, 1989, J BACTERIOL, V171, P1923, DOI 10.1128/jb.171.4.1923-1931.1989; GRAHAM JE, 1992, J BACTERIOL, V174, P2711, DOI 10.1128/jb.174.8.2711-2716.1992; HAARDT M, 1995, MOL GEN GENET, V246, P783, DOI 10.1007/BF00290728; HANSON AD, 1994, P NATL ACAD SCI USA, V91, P306, DOI 10.1073/pnas.91.1.306; Harwood C., 1990, MOL BIOL METHODS BAC, P1; HASHIGUCHI K, 1986, MOL GEN GENET, V204, P36, DOI 10.1007/BF00330184; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HECKER M, 1990, FEMS MICROBIOL ECOL, V74, P197, DOI 10.1111/j.1574-6968.1990.tb04065.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1987, J GEN MICROBIOL, V133, P305; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HUTKINS RW, 1987, APPL ENVIRON MICROB, V53, P2275, DOI 10.1128/AEM.53.10.2275-2281.1987; IMHOFF JF, 1984, J BACTERIOL, V160, P478, DOI 10.1128/JB.160.1.478-479.1984; INUKAI M, 1978, J ANTIBIOT, V31, P421, DOI 10.7164/antibiotics.31.421; ITAYA M, 1991, J MOL BIOL, V220, P631, DOI 10.1016/0022-2836(91)90106-G; ITAYA M, 1992, BIOSCI BIOTECH BIOCH, V56, P685, DOI 10.1271/bbb.56.685; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; MANNA D, 1994, J BACTERIOL, V176, P5378, DOI 10.1128/JB.176.17.5378-5384.1994; MAY G, 1986, MOL GEN GENET, V205, P225, DOI 10.1007/BF00430432; MAY G, 1989, MOL MICROBIOL, V3, P1521, DOI 10.1111/j.1365-2958.1989.tb00138.x; MELLIES J, 1994, J BACTERIOL, V176, P3638, DOI 10.1128/JB.176.12.3638-3645.1994; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; OVERDIER DG, 1992, P NATL ACAD SCI USA, V89, P3140, DOI 10.1073/pnas.89.7.3140; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PLATT T, 1981, CELL, V24, P10, DOI 10.1016/0092-8674(81)90496-7; POURKOMAILIAN B, 1992, J GEN MICROBIOL, V138, P2515, DOI 10.1099/00221287-138-12-2515; Sambrook J, 1989, MOL CLONING LABORATO; SAURIN W, 1994, MOL MICROBIOL, V12, P993, DOI 10.1111/j.1365-2958.1994.tb01087.x; SCHNEIDER R, 1993, MOL MICROBIOL, V8, P111, DOI 10.1111/j.1365-2958.1993.tb01208.x; STIRLING DA, 1989, MOL MICROBIOL, V3, P1025, DOI 10.1111/j.1365-2958.1989.tb00253.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TRIEUCUOT P, 1983, GENE, V23, P331, DOI 10.1016/0378-1119(83)90022-7; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; VOLKER U, 1994, MICROBIOL-UK, V140, P741, DOI 10.1099/00221287-140-4-741; WANG JY, 1992, MOL MICROBIOL, V6, P1861, DOI 10.1111/j.1365-2958.1992.tb01358.x; WHATMORE AM, 1990, J GEN MICROBIOL, V136, P2521, DOI 10.1099/00221287-136-12-2521; WHATMORE AM, 1990, J GEN MICROBIOL, V136, P2527, DOI 10.1099/00221287-136-12-2527; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x	65	152	157	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16701	16713		10.1074/jbc.270.28.16701	http://dx.doi.org/10.1074/jbc.270.28.16701			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622480	hybrid			2022-12-25	WOS:A1995RJ34700040
J	NEGISHI, M; IRIE, A; SUGIMOTO, Y; NAMBA, T; ICHIKAWA, A				NEGISHI, M; IRIE, A; SUGIMOTO, Y; NAMBA, T; ICHIKAWA, A			SELECTIVE COUPLING OF PROSTAGLANDIN-E RECEPTOR EP3D TO G(I) AND G(S) THROUGH INTERACTION OF ALPHA-CARBOXYLIC ACID OF AGONIST AND ARGININE RESIDUE OF 7TH TRANSMEMBRANE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL TAIL; ADENYLATE-CYCLASE; G-PROTEINS; SUBTYPE; EXPRESSION; CLONING; BINDING; CDNA; STIMULATION; INHIBITION	Prostaglandin (PG) E receptor EP3D is coupled to both G(i) and G(s). To examine the roles of the interaction of alpha-carboxylic acid of PGE(2) and its putative binding site, the arginine residue in the seventh transmembrane domain of EP3D, in receptor-G protein coupling, we have mutated the arginine residue to the noncharged glutamine. PGE(2) with a negatively charged alpha-carboxylic acid and sulprostone, an EP3 agonist with a noncharged modified alpha-carboxylic acid, inhibited the forskolin-stimulated adenylate cyclase activity via G(i) activation in the EP3D receptor in the same concentration-dependent manner, In contrast, the adenylate cyclase stimulation via G(s) activation by sulprostone was much lower than that by PGE(2). On the other hand, both PGE(2) and sulprostone showed potent G(i) activity but failed to show G(s) activity in the mutant receptor. EP3D receptor showed a high affinity binding for PGE(2) in the form coupled to either G(i) or G(s). Although the mutant receptor showed high affinity binding when coupled to G(i), it lost high affinity binding in the condition of G(s) coupling. Furthermore, sulprostone bound to the G(i)-coupled EP3D receptor with higher affinity than the G(s)-coupled receptor. Among various EP3 agonists, ly-carboxylic acid-unmodified agonists showed both G(i) and G(s) activities, but the modified agonists showed only G(i) activity. These findings suggest that the interaction between the alpha-carboxylic acid of PGE(2) and the arginine residue of the receptor regulates the selectivity of the G protein coupling.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Kyoto University	NEGISHI, M (corresponding author), KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN.		Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X				ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BUNCE KT, 1990, ADV PROSTAGLANDIN TH, V21, P379; Coleman R A, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P467; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1992, J BIOL CHEM, V267, P15795; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FUNK CD, 1993, MOL PHARMACOL, V44, P934; HALUSHKA PV, 1989, ANN REV PHARM TOXICO, V10, P213; HARRISON JK, 1991, TRENDS PHARMACOL SCI, V12, P62, DOI 10.1016/0165-6147(91)90499-I; HONDA A, 1993, J BIOL CHEM, V268, P7759; HUNG DT, 1992, J BIOL CHEM, V267, P20831; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LAWRENCE RA, 1992, BRIT J PHARMACOL, V105, P271, DOI 10.1111/j.1476-5381.1992.tb14245.x; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; NEGISHI M, 1994, PROSTAGLANDINS, V48, P275, DOI 10.1016/0090-6980(94)90028-0; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; ROBB S, 1994, EMBO J, V13, P1325, DOI 10.1002/j.1460-2075.1994.tb06385.x; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STEIN R, 1988, EMBO J, V7, P3031, DOI 10.1002/j.1460-2075.1988.tb03167.x; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1994, AM J PHYSIOL, V266, pF823, DOI 10.1152/ajprenal.1994.266.5.F823; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TAKEUCHI K, 1994, BIOCHEM BIOPH RES CO, V199, P834, DOI 10.1006/bbrc.1994.1304; WATABE A, 1993, J BIOL CHEM, V268, P20175; WESS J, 1992, J BIOL CHEM, V267, P19313	37	77	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					16122	16127		10.1074/jbc.270.27.16122	http://dx.doi.org/10.1074/jbc.270.27.16122			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608175	hybrid			2022-12-25	WOS:A1995RH22600038
J	RODRIGUEZ, C; CHEN, F; WEINBERG, RA; LODISH, HF				RODRIGUEZ, C; CHEN, F; WEINBERG, RA; LODISH, HF			COOPERATIVE BINDING OF TRANSFORMING GROWTH-FACTOR (TGF)-BETA-2 TO THE TYPE-I AND TYPE-II TGF-BETA RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSION CLONING; 2 FORMS; KINASE; CELLS; RESPONSIVENESS; BETAGLYCAN; COMPLEXES; ISOFORMS; ACTIVIN; PROTEIN	TGF-beta 1 binds with high affinity (K-D = 25-50 pM) directly to the TGF-beta type II receptor serine-threonine kinase (T beta-RII) in the absence of expression of the TGF-beta type I or III receptors (T beta-RI and T beta-RIII). The serine-threonine kinase T beta-RI is essential for TGF-beta 1 signaling but not for binding to T beta-RII. TGF-beta 2, in contrast, does not bind directly to T beta-RII, although coexpression of T beta-RIII does allow binding and cross-linking of TGF-beta 2 to T beta-RII. Here we show that in transfected COS cells binding and cross-linking of I-125-TGF-beta 2 to T beta-RI or T beta-RII requires expression of both receptors. In cells transfected with the c-myc-tagged human T beta-RII cDNA, only low amounts of I-125-TGF-beta 2 cross-linked to T beta-RI and T beta-RII were detected even with high concentrations (700 pM) of ligand. Cotransfection of the influenza-hemagglutinin-tagged human T beta-RI cDNA dramatically increased the binding of TGF-beta 2 to T beta-RII; the concentration of I-125-TGF-beta 2 required for half-maximal binding and cross-linking to T beta-RI and T beta-RII was similar to 40 pM. Coimmunoprecipitation studies showed that the high affinity receptor for TGF-beta 2 is composed of a hetero-oligomer of T beta-RI and T beta-RII. Thus TGF-beta 1 and -beta 2 bind to TGF-beta receptors in different ways; TGB-beta 1 binds directly to T beta-RII, while binding of TGF-beta 2 to T beta-RII requires coexpression of T beta-RI T beta-RIII.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)				rodriguez, carlos/0000-0001-9593-8680	NATIONAL CANCER INSTITUTE [R35CA039826, R01CA063260] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-63260, 5R35 CA-39826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; CHEIFETZ S, 1988, J BIOL CHEM, V263, P10783; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1994, J BIOL CHEM, V269, P22868; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MITCHELL EJ, 1992, J CELL PHYSIOL, V150, P334, DOI 10.1002/jcp.1041500217; MITCHELL EJ, 1991, BIOCHEMISTRY-US, V30, P4350, DOI 10.1021/bi00231a034; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	36	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					15919	15922		10.1074/jbc.270.27.15919	http://dx.doi.org/10.1074/jbc.270.27.15919			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608141	hybrid			2022-12-25	WOS:A1995RH22600002
J	SAKAI, H; KUMANO, E; IKARI, A; TAKEGUCHI, N				SAKAI, H; KUMANO, E; IKARI, A; TAKEGUCHI, N			A GASTRIC HOUSEKEEPING CL- CHANNEL ACTIVATED VIA PROSTAGLANDIN EP(3) RECEPTOR-MEDIATED CA2+/NITRIC OXIDE/CGMP PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT PARIETAL-CELLS; NITRIC-OXIDE; BASOLATERAL MEMBRANE; ADENYLATE-CYCLASE; ARACHIDONIC-ACID; PERTUSSIS TOXIN; CONDUCTANCE; STIMULATION; METABOLISM; CA-2+	Prostaglandin E(2) (PGE(2)) has a cytoprotective role in the gastric parietal cell. PGE(2) opened a housekeeping basolateral Cl- channel of rabbit gastric parietal cells, the single channel conductance of which was about 0.3 picosiemens. In the present patch-clamp and Fura 2 fluorescence studies, we found that PGE(2) increased the intracellular free Ca2+ concentration ([Ca2+](i)) and that PGE(2)-induced opening of the Cl- channel depended on the increase in [Ca2+](i). A novel bifunctional prostaglandin EP(3) agonist/EP(1) antagonist, 5(Z)-7-[(1S, 2S, 3S, 5R)-3-(trans-beta-styren)sulfonamido-6,6-dimethylbicyclo(3.1.1)hept-2-yl]-5-heptenoic acid, also increased both [Ca2+](i) and channel opening. The PGE(2)-induced effect was mediated via production of nitric oxide (NO); that is, N-G-monomethyl-L-arginine, an inhibitor of NO production, markedly inhibited the PGE(2)-induced channel opening, and nitroprusside, a NO donor, induced the channel opening in the absence of PGE(2). Both PGE(2) and A23187, a Ca2+ ionophore, elevated the cGMP content of isolated parietal cells. The A23187-induced channel opening was abolished by methylene blue, a guanylate cyclase inhibitor. In conclusion, we found that the PGE(2)-induced opening of the housekeeping Cl- channel in the parietal cell involves the EP(3) receptor-mediated increase in [Ca2+](i) via a pertussis toxin-sensitive GTP binding protein, resulting in successive production of NO and cGMP.			SAKAI, H (corresponding author), TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,DEPT PHARMACEUT PHYSIOL,TOYAMA 93001,JAPAN.							ABOOLIAN A, 1989, AM J PHYSIOL, V3256, pF1135; ATWELL MM, 1988, BIOCHIM BIOPHYS ACTA, V971, P282; BARR DB, 1988, J PHYSIOL-LONDON, V405, P39, DOI 10.1113/jphysiol.1988.sp017320; BEAR CE, 1988, FEBS LETT, V237, P145, DOI 10.1016/0014-5793(88)80189-3; BERGLINDH T, 1980, AM J PHYSIOL, V239, pG90, DOI 10.1152/ajpgi.1980.239.2.G90; BREYER MD, 1993, KIDNEY INT, V43, P1372; CHEN MCY, 1988, GASTROENTEROLOGY, V94, P1121, DOI 10.1016/0016-5085(88)90002-9; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; FRIZZELL RA, 1986, FASEB J, V45, P2727; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; ISHII K, 1991, J CARDIOVASC PHARM, V17, pS246, DOI 10.1097/00005344-199100177-00071; KASHIWAGURA T, 1990, JPN J PHYSIOL, V40, P865, DOI 10.2170/jjphysiol.40.865; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KOIKE M, 1992, BIOCHEM J, V283, P265, DOI 10.1042/bj2830265; LACY ER, 1982, GASTROENTEROLOGY, V83, P619; MARUYAMA T, 1994, 9 INT C PROST REL CO, P88; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; NAMBA T, 1993, NATURE, V365, P165; NEGISHI M, 1989, J BIOL CHEM, V264, P3916; PINSKY DJ, 1994, P NATL ACAD SCI USA, V91, P12086, DOI 10.1073/pnas.91.25.12086; REISER G, 1990, EUR J BIOCHEM, V189, P547, DOI 10.1111/j.1432-1033.1990.tb15521.x; REISER G, 1990, BRIT J PHARMACOL, V101, P722, DOI 10.1111/j.1476-5381.1990.tb14147.x; ROBERT A, 1992, GUT, V33, P444, DOI 10.1136/gut.33.4.444; SAKAI H, 1992, J PHYSIOL-LONDON, V448, P293, DOI 10.1113/jphysiol.1992.sp019042; SAKAI H, 1994, J BIOL CHEM, V269, P23426; SAKAI H, 1993, J PHYSIOL-LONDON, V461, P201, DOI 10.1113/jphysiol.1993.sp019509; SAKAI H, 1989, PFLUG ARCH EUR J PHY, V414, P185, DOI 10.1007/BF00580962; SOLL AH, 1978, J CLIN INVEST, V61, P370, DOI 10.1172/JCI108947; WANGEMANN P, 1986, PFLUG ARCH EUR J PHY, V407, pS128, DOI 10.1007/BF00584942; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; YAMAGUCHI DT, 1988, J BIOL CHEM, V263, P10745; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	35	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18781	18785		10.1074/jbc.270.32.18781	http://dx.doi.org/10.1074/jbc.270.32.18781			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642528	hybrid			2022-12-25	WOS:A1995RN95400015
J	VANDERWOLK, JPW; KLOSE, M; DEWIT, JG; DENBLAAUWEN, T; FREUDL, R; DRIESSEN, AJM				VANDERWOLK, JPW; KLOSE, M; DEWIT, JG; DENBLAAUWEN, T; FREUDL, R; DRIESSEN, AJM			IDENTIFICATION OF THE MAGNESIUM-BINDING DOMAIN OF THE HIGH-AFFINITY ATP BINDING-SITE OF THE BACILLUS-SUBTILIS AND ESCHERICHIA-COLI SECA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION ATPASE; PLASMA-MEMBRANE; ESSENTIAL COMPONENT; PRECURSOR PROTEINS; CRYSTAL-STRUCTURE; TRIGGER FACTOR; PRO-OMPA; EXPORT; GENE; INVIVO	The homodimeric SecA protein is the peripheral subunit of the translocase, and couples the hydrolysis of ATP to the translocation of precursor proteins across the bacterial cytoplasmic membrane. The high affinity ATP binding activity of SecA resides in the amino-terminal domain of SecA. This domain contains a tandem repeat of the ''so-called'' Walker B-motif, hXhhD (Walker, J. E., Saraste, M., Runswick, M. J., and Gay, N. J. (1982) EMBO J. 1, 945-951), that in combination with motif A is responsible for the Mg2+-phosphate protein interaction. Two aspartate residues at positions 207 and 215 of the Bacillus subtilis SecA, and Asp-217 in the Escherichia coli SecA, that could be Mg2+ ion ligands, were individually mutated to an asparagine. Mutant SecA proteins were unable to growth complement an E. coli secA amber mutant strain, and the E. coli SecA mutant interfered with the translocation of precursor proteins in vivo. B. subtilis mutant SecA proteins were expressed to a high level and purified to homogeneity. The high affinity ATP and Mg2+-ion binding activity was reduced in the Asp-207 mutant, and completely lost in the Asp-215 mutant. Both SecA proteins were defective in lipid-stimulated ATPase activity. Proteolytic studies suggest that the two subunits of the mutated dimeric SecA proteins are present in different conformational states. These data suggest that Asp-207 and Asp 215 are involved in the binding of the Mg2+-ion when Mg2+-ATP is bound to SecA, while Asp-207 fulfills an additional catalytic role, possibly in accepting a proton during catalysis.	UNIV GRONINGEN, DEPT MICROBIOL, 9751 NN HAREN, NETHERLANDS; UNIV GRONINGEN, GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST, 9751 NN HAREN, NETHERLANDS; FORSCHUNGSZENTRUM JULICH, FORSCHUNGSZENTRUM, INST BIOTECHNOL 1, D-52425 JULICH, GERMANY	University of Groningen; University of Groningen; Helmholtz Association; Research Center Julich			Driessen, Arnold J.M./D-1876-2012; Freudl, Roland/N-4179-2017	Freudl, Roland/0000-0003-0743-1279; den Blaauwen, Tanneke/0000-0002-5403-5597; Driessen, Arnold J.M./0000-0001-9258-9104				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; DRIESSEN AJM, 1994, J MEMBRANE BIOL, V142, P145; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; KIM YJ, 1994, CELL, V78, P845; KLOSE M, 1993, J BIOL CHEM, V268, P4504; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2013, PRINCIPLES FLUORESCE; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OVERHOFF B, 1991, MOL GEN GENET, V228, P417, DOI 10.1007/BF00260635; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; SADAIE Y, 1991, GENE, V98, P101; Sambrook J, 1989, MOL CLONING LABORATO; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAKAMATSU H, 1992, J BACTERIOL, V174, P4308, DOI 10.1128/JB.174.13.4308-4316.1992; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARNER HR, 1978, NATURE, V272, P32, DOI 10.1038/272032a0; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	56	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18975	18982		10.1074/jbc.270.32.18975	http://dx.doi.org/10.1074/jbc.270.32.18975			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642557	hybrid			2022-12-25	WOS:A1995RN95400045
J	GUZDER, SN; SUNG, P; PRAKASH, S; PRAKASH, L				GUZDER, SN; SUNG, P; PRAKASH, S; PRAKASH, L			LETHALITY IN YEAST OF TRICHOTHIODYSTROPHY (TTD) MUTATIONS IN THE HUMAN XERODERMA-PIGMENTOSUM GROUP-D GENE - IMPLICATIONS FOR TRANSCRIPTIONAL DEFECT IN TTD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; DNA HELICASE; RAD3 PROTEIN; MUTAGENESIS; SELECTION; ENCODES; REPAIR; ATPASE	Mutations in the human XPD gene result in a defect in nucleotide excision repair of ultraviolet damaged DNA and cause the cancer-prone syndrome xeroderma pigmentosum (XP). Resides XP, mutations in XPD can cause another seemingly unrelated syndrome, trichothiodystrophy (TTD), characterized by sulfur-deficient brittle hair, ichthyosis, and physical and mental retardation. To ascertain the underlying defect responsible for TTD, we have expressed the TTD mutant proteins in the yeast Saccharomyces cerevisiae and determined if these mutations can rescue the inviability of a rad3 null mutation. RAD3, the S. cerevisiae counterpart of XPD, is required for nucleotide excision repair and also has an essential role in RNA polymerase II transcription. Expression of the wild type XPD protein or the XPD Arg-48 protein carrying a mutation in the DNA helicase domain restores viability to the rad3 null mutation. Interestingly, the XPD variants containing TTD mutations fail to complement the lethality of the rad3 null mutation, strongly suggesting that TTD mutations impair the ability of XPD protein to function normally in RNA polymerase II transcription. From our studies, we conclude that XPD DNA helicase activity is not essential for transcription and infer that TTD mutations in XPD result in a defect in transcription.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NCI NIH HHS [CA35035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA035035, R01CA035035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BROUGHTON BC, 1994, NAT GENET, V7, P189, DOI 10.1038/ng0694-189; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GUZDER S, 1994, NATURE, V369, P579; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; JOHNSON RT, 1992, MUTAT RES, V273, P97, DOI 10.1016/0921-8777(92)90072-B; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEHMANN A R, 1987, Cancer Reviews, V7, P82; MA LB, 1994, NUCLEIC ACIDS RES, V22, P4095, DOI 10.1093/nar/22.20.4095; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; REYNOLDS PR, 1992, NUCLEIC ACIDS RES, V20, P2327, DOI 10.1093/nar/20.9.2327; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUNG P, 1994, J BIOL CHEM, V269, P8303; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013	22	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17660	17663		10.1074/jbc.270.30.17660	http://dx.doi.org/10.1074/jbc.270.30.17660			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629061	hybrid			2022-12-25	WOS:A1995RM26600006
J	FRERE, V; SOURGEN, F; MONNOT, M; TROALEN, F; FERMANDJIAN, S				FRERE, V; SOURGEN, F; MONNOT, M; TROALEN, F; FERMANDJIAN, S			A PEPTIDE FRAGMENT OF HUMAN DNA TOPOISOMERASE-II-ALPHA FORMS A STABLE COILED-COIL STRUCTURE IN SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; SECONDARY STRUCTURE; PROTEINS; DESIGN; PURIFICATION; SPECTROSCOPY; DIMERIZATION; PREDICTION; BINDING; MOTIF	Results are presented on a peptide fragment (1013-1056) from human DNA topoisomerase II alpha. This was selected using the procedure of Lupas et al. (Lupas, A., Van Dyke, M., and Stock, J. (1991) Science 252, 1162-1164) for its potential to adopt a stable coiled-coil structure. The same theoretical treatment rejected the segment 994-1021 proposed by Zwelling and Perry (Zwelling, L. A., and Perry, W. M. (1989) Mol. Endocrinol. 3, 603-604) as a possible core for leucine-zipper formation. Our experimental studies combine cross-linking and CD analysis. Cross-linking establishes that the 1013-1056 fragment forms a stable hormodimer in solution. Effects of increasing peptide concentration on CD spectra confirm that only the 1013-1056 fragment can undergo a coiled-coil stabilization from an isolated alpha-helix. Unfolding experiments further show that the coiled-coil is more stable in guanidium chloride than in urea. Values of -6.8 and -7.4 kcal/mol for the dimerization free energy are determined by thermal and urea unfolding, respectively. These are strikingly similar to the value recently found for the dissociation/reassociation of the entire yeast topoisomerase II from sedimentation equilibrium experiments (Lamhasni, S., Larsen, A. K., Barray, M., Monnot, M., Delain, E., and Fermandjian, S. (1995) Biochemistry 34, 3632-3639), although their significance relatively to topoisomerase II undoubtedly requires further analysis.	INST GUSTAVE ROUSSY,DEPT BIOL & PHARMACOL STRUCT,CNRS,URA 147,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,SERV IMMUNOL MOLEC,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy								BALDWIN RL, 1986, TRENDS BIOCHEM SCI, V11, P6, DOI 10.1016/0968-0004(86)90219-7; BIOU V, 1988, PROTEIN ENG, V2, P185, DOI 10.1093/protein/2.3.185; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONEJEROLARA F, 1994, FEBS LETT, V344, P154, DOI 10.1016/0014-5793(94)00358-0; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; CURRAN T, 1992, TRANSCRIPTIONAL REGU, P797; ENGEL M, 1991, BIOCHEMISTRY-US, V30, P3161, DOI 10.1021/bi00227a002; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke R, 1986, Methods Enzymol, V131, P218; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LAMHASNI S, 1995, BIOCHEMISTRY-US, V34, P3632, DOI 10.1021/bi00011a018; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MONERA OD, 1993, J BIOL CHEM, V268, P19218; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; Pace C N, 1986, Methods Enzymol, V131, P266; RICO M, 1994, BIOCHEMISTRY-US, V33, P14834, DOI 10.1021/bi00253a023; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8816, DOI 10.1021/bi00085a012; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462; ZWELLING LA, 1989, MOL ENDOCRINOL, V3, P603, DOI 10.1210/mend-3-3-603	46	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17502	17507		10.1074/jbc.270.29.17502	http://dx.doi.org/10.1074/jbc.270.29.17502			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615554	hybrid			2022-12-25	WOS:A1995RK68900070
J	WEBB, HK; MATTHEWS, RG				WEBB, HK; MATTHEWS, RG			4-CHLOROTHREONINE IS SUBSTRATE, MECHANISTIC PROBE, AND MECHANISM-BASED INACTIVATOR OF SERINE HYDROXYMETHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSHYDROXYMETHYLASE; BENZALDEHYDES	Serine hydroxymethyltransferase catalyzes the cleavage of a variety of beta-hydroxy-L-amino acids to form glycine and aldehyde products. 4-chloro-L-threonine has been synthesized and shown to be both a substrate and a mechanism-based inactivator of serine hydroxymethyltransferase. k(cat) values for the formation of glycine in the absence of tetrahydrofolate were determined for 4-chloro-L-threonine and other beta-hydroxyamino acid substrates; an inverse relationship between the rate of cleavage of the amino acid and the electrophilicity of the product aldehyde was demonstrated. 4-Chloro-L-threonine inactivates serine hydroxymethyltransferase in a time- and concentration-dependent manner and exhibits saturation of the rate of inactivation at high concentrations. Our evidence suggests that 4-chlorothreonine undergoes aldol cleavage, and generation of chloroacetaldehyde at the active site of the enzyme results in inactivation. Serine or glycine protect the enzyme against inactivation by chlorothreonine, while tetrahydrofolate does not. The enzyme is also protected from inactivation by 2-mercaptoethanol or by alcohol dehydrogenase and NADH. These studies suggest that halothreonine derivatives that generate electrophilic aldehyde products will be effective inhibitors of serine hydroxymethyltransferase and might be potentially useful chemotherapeutic agents.	UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIGMS NIH HHS [R37 GM24908] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024908] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKHTAR M, 1975, BIOCHEM J, V145, P159, DOI 10.1042/bj1450159; BOIT HG, 1963, BEILSTEIN HDB O 2 S3, V4, P1623; BRADFORD MM, 1976, ANAL BIOCHEM, V22, P248; CHEN MS, 1973, J BIOL CHEM, V248, P3631; CHEN MS, 1973, J BIOL CHEM, V248, P7979; CIACCIO JA, 1986, TETRAHEDRON LETT, V27, P3697, DOI 10.1016/S0040-4039(00)83856-3; EICHLER HG, 1981, BIOSCIENCE REP, V1, P101, DOI 10.1007/BF01117006; FIESER LF, 1967, REAGENTS ORGANIC SYN, V1, P135; Finkelstein H, 1910, BER DTSCH CHEM GES, V43, P1528, DOI 10.1002/cber.19100430257; GREENZAID P, 1967, J AM CHEM SOC, V89, P749, DOI 10.1021/ja00980a004; GREENZAID P, 1973, J ORG CHEM, V38, P3164, DOI 10.1021/jo00958a019; GUTHRIE JP, 1975, CAN J CHEM, V53, P898, DOI 10.1139/v75-125; HANESSIAN S, 1984, TETRAHEDRON LETT, V14, P1425; KITZ RJ, 1965, BIOCHEM PHARMACOL, V14, P1471, DOI 10.1016/0006-2952(65)90180-2; LEHENAFF P, 1968, B SOC CHIM FR, V11, P4687; MATTHEWS RG, 1982, BIOCHEMISTRY-US, V21, P1230, DOI 10.1021/bi00535a019; MCCLELLAND RA, 1983, J AM CHEM SOC, V105, P2718, DOI 10.1021/ja00347a033; MUSCATE A, 1995, BURGERS MED CHEM DRU, V1, P733; SCHIRCH L, 1968, J BIOL CHEM, V243, P5651; SCHIRCH L, 1984, FOLATES PTERINS, P399; SCHIRCH LV, 1971, J BIOL CHEM, V246, P3961; SHAW KJ, 1985, J ORG CHEM, V50, P4515, DOI 10.1021/jo00223a019; SHIVELY JE, 1986, METHODS PROTEIN MICR, P155; SNELL K, 1989, CANCER LETT, V44, P217, DOI 10.1016/0304-3835(89)90064-5; STOVER P, 1992, J BIOL CHEM, V267, P17679; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5355, DOI 10.1021/bi00643a029; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5342, DOI 10.1021/bi00643a027; WEBB H, 1995, THESIS U MICHIGAN; WILSON EM, 1962, J BIOL CHEM, V237, P3180	29	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	1995	270	29					17204	17209		10.1074/jbc.270.29.17204	http://dx.doi.org/10.1074/jbc.270.29.17204			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RK689	7615518	hybrid			2022-12-25	WOS:A1995RK68900025
J	BUGGE, TH; SUH, TT; FLICK, MJ; DAUGHERTY, CC; ROMER, J; SOLBERG, H; ELLIS, V; DANO, K; DEGEN, JL				BUGGE, TH; SUH, TT; FLICK, MJ; DAUGHERTY, CC; ROMER, J; SOLBERG, H; ELLIS, V; DANO, K; DEGEN, JL			THE RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IS NOT ESSENTIAL FOR MOUSE DEVELOPMENT OR FERTILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; CELL-SURFACE RECEPTOR; ENDOTHELIAL-CELLS; HUMAN-TUMOR; GENE-EXPRESSION; STEM-CELLS; MEMBRANE; INVASION; LOCALIZATION; PROTEIN	The urokinase-type plasminogen activator receptor (uPAR) gene was disrupted in mice in order to explore the role of cell surface-associated plasminogen activation in development and hemostasis. Homozygous, uPAR(-/-) mice were born and survived to adulthood with no overt phenotypic abnormalities. There was no indication of loss of fetal animals based on the Mendelian pattern of transmission of the mutant uPAR gene. uPAR(-/-) mice carried no detectable uPAR in lung, spleen, and other tissues when measured both immunologically by Western blot analysis and functionally by ligand cross-linking analyses. In addition, activated peritoneal macrophages collected from uPAR(-/-) mice failed to promote plasminogen activation in vitro. The loss of the receptor also resulted in a redistribution of uPA in some tissues but had no impact on pro-uPA activation in the urogenital tract. Thus, in the absence of other challenging factors such as infection, injury, or other functional deficits, uPAR deficiency does not compromise fertility, development, or hemostasis. These mice provide a means to test the proposed function of uPA/uPAR in wound repair, atherogenesis, and tumor cell invasion in vivo.	CHILDRENS HOSP RES FDN,DIV PATHOL,CINCINNATI,OH 45229; THROMBOSIS RES INST,LONDON SW3 6LR,ENGLAND; RIGSHOSP,FINSEN LAB,DK-2100 COPENHAGEN O,DENMARK	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Thrombosis Research Institute; Rigshospitalet	BUGGE, TH (corresponding author), CHILDRENS HOSP RES FDN,DIV BASIC SCI,TCHRF 2025,3333 BURNET AVE,CINCINNATI,OH 45229, USA.		Ellis, Vincent/D-1860-2009	Ellis, Vincent/0000-0003-1956-073X	NHLBI NIH HHS [HL47826] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047826] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHT JC, 1992, VIROLOGY, V190, P527, DOI 10.1016/0042-6822(92)91247-R; APPELLA E, 1987, J BIOL CHEM, V262, P4437; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BELL SM, 1990, J BIOL CHEM, V265, P1333; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; COLLEN D, 1994, MOL BASIS BLOOD DIS, P725; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1980, BIOCHIM BIOPHYS ACTA, V613, P542, DOI 10.1016/0005-2744(80)90110-2; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; DVORAK HF, 1992, ANN NY ACAD SCI, V667, P101, DOI 10.1111/j.1749-6632.1992.tb51603.x; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ELLIS V, 1992, FIBRINOLYSIS, V6, P27; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FRIEDMAN GC, 1994, DEV BRAIN RES, V81, P41, DOI 10.1016/0165-3806(94)90066-3; FRIEDMAN S, 1990, IMMUNOGENETICS, V31, P104, DOI 10.1007/BF00661220; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KIELBERG V, 1985, FEBS LETT, V182, P441, DOI 10.1016/0014-5793(85)80350-1; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KRISTENSEN P, 1991, J CELL BIOL, V115, P1763, DOI 10.1083/jcb.115.6.1763; LARSSON LI, 1984, J CELL BIOL, V98, P896; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; MAGNATTI P, 1993, PHYSIOL REV, V73, P161; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOLLER LB, 1993, J BIOL CHEM, V268, P11152; MORIOKA S, 1987, J INVEST DERMATOL, V88, P418, DOI 10.1111/1523-1747.ep12469754; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; OSSOWSKI L, 1991, CANCER RES, V51, P274; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PALFREE RGE, 1991, IMMUNOL TODAY, V12, P170, DOI 10.1016/0167-5699(91)90086-9; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLOUG M, 1991, J BIOL CHEM, V266, P1926; RABBANI SA, 1990, BIOCHEM BIOPH RES CO, V173, P1058, DOI 10.1016/S0006-291X(05)80893-9; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; RENNUNG U, 1992, ARTERIOSCLER THROMB, V12, P1161; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SKRIVER L, 1982, EUR J BIOCHEM, V124, P409; SOLBERG H, 1992, EUR J BIOCHEM, V205, P451, DOI 10.1111/j.1432-1033.1992.tb16799.x; SOLBERG H, 1994, INT J CANCER, V58, P877, DOI 10.1002/ijc.2910580622; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STETLERSTEVENSO.WG, 1993, ANNU REV CELL BIOL, V9, P541; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; SUH TT, 1994, J BIOL CHEM, V269, P25992; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; VASSALLI JD, 1977, CELL, V11, P695, DOI 10.1016/0092-8674(77)90086-1; WEI Y, 1994, J BIOL CHEM, V269, P32380; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WILLIAMS AF, 1988, IMMUNOGENETICS, V27, P265, DOI 10.1007/BF00376121; ZINI JM, 1992, BLOOD, V79, P2917	68	189	196	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16886	16894		10.1074/jbc.270.28.16886	http://dx.doi.org/10.1074/jbc.270.28.16886			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622505	hybrid			2022-12-25	WOS:A1995RJ34700066
J	NELSON, CC; HENDY, SC; ROMANIUK, PJ				NELSON, CC; HENDY, SC; ROMANIUK, PJ			RELATIONSHIP BETWEEN P-BOX AMINO-ACID-SEQUENCE AND DNA-BINDING SPECIFICITY OF THE THYROID-HORMONE RECEPTOR - THE EFFECTS OF SEQUENCES FLANKING HALF-SITES IN THYROID-HORMONE RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; HIGH-AFFINITY; DOMAIN; ALPHA; SUPERFAMILY; ALTERS	The three P-box amino acids in the DNA recognition alpha-helix of steroid/thyroid hormone receptors participate in the discrimination of the central base pairs of the hexameric half-sites of receptor response elements in DNA. Using a series of variant receptors incorporating all 19 possible substitutions for each individual P-box amino acid of the human thyroid hormone receptor (hT3R beta), we demonstrated that the first P-box position must have a glutamate, and the second P-box position must have either an alanine or a glycine for high affinity binding to everted repeat elements with half-site sequences of AGGNCA. In the present study, the influence of half-site flanking sequence on the compatibility of P-box amino acids in hT3R beta with DNA binding was investigated. When a 5' sequence of CTG flanked AGGNCA half-sites in an everted repeat, several additional P-box variant receptors were able to bind to the DNA that were not able to bind when the half-sites were flanked with the 5' sequence GAG. Flanking sequence had the most dramatic effects on amino acid substitutions at the first P-box position, with smaller effects observed at the second P-box position and only subtle effects observed at the third P-box position. Expansion of the number of P-box sequences compatible with binding of hT3R beta to thyroid hormone response elements required the thymidine in the CTG flanking sequence, an everted repeat of the AGGNCA half-sites, and an intermolecular interaction in the C terminus of the receptor.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA,BC V8W 3P6,CANADA	University of Victoria				Romaniuk, Paul/0000-0002-5931-8879				ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1991, MOL ENDOCRINOL, V5, P1815, DOI 10.1210/mend-5-12-1815; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NELSON CC, 1995, J BIOL CHEM, V270, P16981, DOI 10.1074/jbc.270.28.16981; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YEN PM, 1992, J BIOL CHEM, V267, P23248; ZILLIACUS J, 1994, P NATL ACAD SCI USA, V91, P4175, DOI 10.1073/pnas.91.10.4175	27	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16988	16994		10.1074/jbc.270.28.16988	http://dx.doi.org/10.1074/jbc.270.28.16988			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622519	hybrid			2022-12-25	WOS:A1995RJ34700080
J	PENG, SB				PENG, SB			NUCLEOTIDE LABELING AND RECONSTITUTION OF THE RECOMBINANT 58-KDA SUBUNIT OF THE VACUOLAR PROTON-TRANSLOCATING ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; B-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; PUMP; BINDING; INHIBITORS; EXPRESSION; COMPLEX; PROTEIN; ISOFORM	Evidence suggests that ATP hydrolysis catalyzed by the clathrin-coated vesicle proton-translocating ATPase requires at least four polypeptides of molecular masses of 70, 58, 40, and 33 kDa (Xie, X.-S., and Stone, D.K. (1988) J. Biol. Chem. 263, 9859-9867). To further investigate the subunit requirements for ATP hydrolysis, histidine-tagged, 58-kDa polypeptide was expressed in insect Sf9 (Spodoptera frugiperda) cells. After purification by Ni2+-nitrolotriacetic acid chromatography, the 58-kDa protein was found to lack significant ATPase activity. However, the subunit was photoaffinity labeled with [alpha-P-32]ATP, [C-14]ADP, or S-35-labeled ADP and UV irradiation in a divalent cation-dependent manner. The labeling was saturable with an apparent K-d of 4 mu M for both ATP and ADP. ATP and ADP competition labeling experiments indicate that the two nucleotides share the same binding site. When reconstituted with recombinant 70-kDa subunit and a biochemically prepared catalytic sector (V-c) depleted of the 70- and 58-kDa subunits, the 58-kDa component restores Ca2+-activated ATP hydrolysis to a specific activity of 0.19 mu mol P-i x mg protein(-1) x min(-1), thus demonstrating that ATP hydrolysis in vacuolar type proton pumps is dependent upon the 58-kDa subunit as well as multi-subunit interactions.			PENG, SB (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ALPERN RA, 1990, KIDNEY, P318; ARAI H, 1989, BIOCHEMISTRY-US, V26, P6632; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; KEILY B, 1968, J BIOL CHEM, V243, P2273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MARQUARDT D, 1991, JNCI-J NATL CANCER I, V83, P1098, DOI 10.1093/jnci/83.15.1098; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; MATTSSON JP, 1991, BIOCHIM BIOPHYS ACTA, V1065, P261, DOI 10.1016/0005-2736(91)90238-4; MCCARTY RE, 1985, ENZYMES BIOL MEMBR, P383; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; PENG SB, 1994, J BIOL CHEM, V269, P27778; PENG SB, 1994, J BIOL CHEM, V269, P11356; PENG SB, 1993, J BIOL CHEM, V268, P23519; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; STUDIER FW, 1989, METHOD ENZYMOL, V185, P60; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SUN SZ, 1987, J BIOL CHEM, V262, P14790; SUUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555; TAKASE K, 1993, J BIOL CHEM, V268, P11610; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; WEBER J, 1994, J BIOL CHEM, V269, P11261; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1994, J BIOL CHEM, V269, P25809; XIE XS, 1988, J BIOL CHEM, V263, P9859; XIE XS, 1993, J BIOL CHEM, V268, P25063; XIE XS, 1989, J BIOL CHEM, V264, P1710; YU F, 1985, ARCH BIOCHEM BIOPHYS, V238, P61, DOI 10.1016/0003-9861(85)90140-7; 1992, QIA EXPRESSIONIST	47	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16926	16931						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622510				2022-12-25	WOS:A1995RJ34700071
J	VAUGHAN, A; HEMINGWAY, J				VAUGHAN, A; HEMINGWAY, J			MOSQUITO CARBOXYLESTERASE EST-ALPHA-2(1)(A(2)) - CLONING AND SEQUENCE OF THE FULL-LENGTH CDNA FOR A MAJOR INSECTICIDE RESISTANCE GENE WORLDWIDE IN THE MOSQUITO CULEX-QUINQUEFASCIATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANO-PHOSPHATE RESISTANCE; APHIDS MYZUS-PERSICAE; PEACH-POTATO APHID; SRI-LANKA; ESTERASE GENE; CULICIDAE; DIPTERA; ORGANOPHOSPHATE; AMPLIFICATION; CARBAMATE	Organophosphorus insecticide resistance in Culex mosquitoes is commonly caused by increased activity of one or more esterases. The commonest phenotype involves elevation of the esterases Est alpha 2 (A(2)) and Est beta 2 (B-2). A cDNA encoding the Est alpha 2 esterase has now been isolated from a Sri Lankan insecticide-resistant mosquito (Culex quinquefasciatus, Say) expression library. In line with a recently suggested nomenclature system (Karunaratne, S. H. P. P. (1994) Characterization of Multiple Variants of Carboxylesterases Which Are Involved in Insecticide Resistance in the Mosquito Culex quinquefasciatus. Ph.D. thesis, University of London), as the first sequenced variant of this esterase, it is now referred to as Est alpha 2(1). The full-length cDNA of est alpha 2(1) codes for a 540-amino acid protein, which has high homology with other esterases and lipases and belongs to the serine or B-esterase enzyme family. The predicted secondary structure of Est alpha 2(1) is similar to the consensus secondary structure of proteins within the esterase/lipase family where the secondary and tertiary structures have been resolved. The level of identity (similar to 47% at the amino acid level) between the est alpha 2(1) and the various Culex est beta (B-1 and B-2) cDNA alleles that have been cloned and sequenced suggests that the two esterase loci are closely related and arose originally from duplication of a common ancestral gene. The lack of a distinct hydrophobic signal sequence for Est alpha 2(1) and two possible N-linked glycosylation sites, both situated close to the active site serine, suggest that it is a nonglycosylated protein that is not exported from the cell. Southern and dot blot analysis of genomic DNA from various insecticide-resistant and susceptible mosquito strains show that the est alpha 2(1) gene, like est beta 2(1), is amplified in resistant strains. The restriction fragment length polymorphism patterns, after probing Southern blots of EcoRI-digested genomic DNA with est alpha 2(1) cDNA, show that the amplified and nonamplified est alpha alleles differ in the resistant and susceptible Sri Lankan mosquitoes.	UNIV WALES COLL CARDIFF,SCH PURE & APPL BIOL,CARDIFF CF1 3TL,S GLAM,WALES	Cardiff University				Hemingway, Janet/0000-0002-3200-7173	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALDRIDGE WN, 1953, BIOCHEM J, V53, P110, DOI 10.1042/bj0530110; AMIN AM, 1990, MED VET ENTOMOL, V4, P269, DOI 10.1111/j.1365-2915.1990.tb00439.x; CALLAGHAN A, 1993, BIOCHEM GENET, V31, P459, DOI 10.1007/BF02426878; CHANG CK, 1983, PESTIC BIOCHEM PHYS, V19, P190, DOI 10.1016/0048-3575(83)90139-6; CYGLER M, 1993, PROTEIN SCI, V2, P366; DEVONSHIRE AL, 1977, BIOCHEM J, V167, P675, DOI 10.1042/bj1670675; DEVONSHIRE AL, 1982, PESTIC BIOCHEM PHYS, V18, P235, DOI 10.1016/0048-3575(82)90110-9; DEVONSHIRE AL, 1986, INSECT BIOCHEM, V16, P659, DOI 10.1016/0020-1790(86)90009-0; DEVONSHIRE AL, 1989, ENZYMES HYDROLYSING, P181; FIELD LM, 1993, BIOCHEM J, V294, P569, DOI 10.1042/bj2940569; FIELD LM, 1988, BIOCHEM J, V251, P309, DOI 10.1042/bj2510309; FOURNIER D, 1987, PESTIC BIOCHEM PHYS, V27, P211, DOI 10.1016/0048-3575(87)90048-4; GEORGHIOU GP, 1978, J ECON ENTOMOL, V71, P201, DOI 10.1093/jee/71.2.201; HERATH PRJ, 1987, PESTIC BIOCHEM PHYS, V29, P157, DOI 10.1016/0048-3575(87)90074-5; JAYAWARDENA KGI, 1994, B ENTOMOL RES, V84, P39, DOI 10.1017/S000748530003220X; JAYAWARDENA KGI, 1995, MED VET ENTOMOL, V9; JAYAWARDENA KGI, 1992, THESIS U LONDON; KAO LR, 1985, PESTIC BIOCHEM PHYS, V23, P228, DOI 10.1016/0048-3575(85)90010-0; KARUNARATNE SHP, 1995, IN PRESS PESTIC BIOC, V51; KARUNARATNE SHP, 1993, BIOCHEM SOC T, V22, pS127; KARUNARATNE SHPP, 1993, BIOCHEM J, V294, P575, DOI 10.1042/bj2940575; Karunaratne SHPP, 1994, THESIS U LONDON; KETTERMAN AJ, 1992, BIOCHEM J, V287, P355, DOI 10.1042/bj2870355; KETTERMAN AJ, 1993, PESTIC BIOCHEM PHYS, V47, P142, DOI 10.1006/pest.1993.1072; KROETZ DL, 1993, BIOCHEMISTRY-US, V32, P11606, DOI 10.1021/bi00094a018; MALKENSON NCD, 1984, INS BIOCH, V4, P481; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATSUMURA F, 1968, J ECON ENTOMOL, V61, P598, DOI 10.1093/jee/61.3.598; MOTOYAMA N, 1984, PESTIC BIOCHEM PHYS, V21, P139, DOI 10.1016/0048-3575(84)90049-X; MOUCHES C, 1990, P NATL ACAD SCI USA, V87, P2574, DOI 10.1073/pnas.87.7.2574; MOUCHES C, 1986, SCIENCE, V233, P778, DOI 10.1126/science.3755546; MOUCHES C, 1987, P NATL ACAD SCI USA, V84, P2113, DOI 10.1073/pnas.84.8.2113; PARKER AG, 1991, PESTIC BIOCHEM PHYS, V41, P305, DOI 10.1016/0048-3575(91)90085-Z; PEIRIS HTR, 1990, B ENTOMOL RES, V80, P49, DOI 10.1017/S0007485300045910; PEIRIS HTR, 1990, B ENTOMOL RES, V80, P453, DOI 10.1017/S0007485300050719; PEIRIS HTR, 1993, B ENTOMOL RES, V83, P127, DOI 10.1017/S0007485300041869; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POIRIE M, 1992, BIOCHEM GENET, V30, P13, DOI 10.1007/BF00554424; RAYMOND M, 1987, J MED ENTOMOL, V24, P24, DOI 10.1093/jmedent/24.1.24; RAYMOND M, 1989, BIOCHEM GENET, V27, P417, DOI 10.1007/BF02399670; ROBBI M, 1992, BIOCHEM BIOPH RES CO, V183, P836, DOI 10.1016/0006-291X(92)90559-4; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; VAUGHAN A, 1995, BIOCHEM J, V305, P651, DOI 10.1042/bj3050651; WIRTH MC, 1990, J MED ENTOMOL, V27, P202, DOI 10.1093/jmedent/27.2.202	44	89	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					17044	17049		10.1074/jbc.270.28.17044	http://dx.doi.org/10.1074/jbc.270.28.17044			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622525	hybrid			2022-12-25	WOS:A1995RJ34700088
J	VERNET, T; TESSIER, DC; CHATELLIER, J; PLOUFFE, C; LEE, TS; THOMAS, DY; STORER, AC; MENARD, R				VERNET, T; TESSIER, DC; CHATELLIER, J; PLOUFFE, C; LEE, TS; THOMAS, DY; STORER, AC; MENARD, R			STRUCTURAL AND FUNCTIONAL ROLES OF ASPARAGINE-175 IN THE CYSTEINE PROTEASE PAPAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; CATALYTIC TRIAD; ION-PAIR; SERINE PROTEASES; TRANSITION-STATE; ALPHA-HELIX; SIDE-CHAIN; MECHANISM; PRECURSOR; STABILIZATION	The role of the asparagine residue in the Cys-His-Asn ''catalytic triad'' of cysteine proteases has been investigated by replacing Asn(175) in papain by alanine and glutamine using site-directed mutagenesis. The mutants were expressed in yeast and kinetic parameters determined against the substrate carbobenzoxy-L-phenylalanyl-(7-amino-4-methylcoumarinyl)-L-arginine. At the optimal pH of 6.5, the specificity constant (k(cat)/K-M)(obs) was reduced by factors of 3.4 and 150 for the Asn(175) --> Gln and Asn(175) --> Ala mutants, respectively. Most of this effect was the result of a decrease in k(cat), as neither mutation significantly affected K-M. Substrate hydrolysis by these mutants is still much faster than the non-catalytic rate, and therefore Asn(175) cannot be considered as an essential catalytic residue in the cysteine protease papain. Detailed analyses of the pH activity profiles for both mutants allow the evaluation of the role of the Asn(175) side chain on the stability of the active site ion pair and on the intrinsic activity of the enzyme. Alteration of the side chain at position 175 was also found to increase aggregation and proteolytic susceptibility of the proenzyme and to affect the thermal stability of the mature enzyme, reflecting a contribution of the asparagine residue to the structural integrity of papain. The strict conservation of Asn(175) in cysteine proteases might therefore result from a combination of functional and structural constraints.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL,PQ H4P 2R2,CANADA	National Research Council Canada			Vernet, Thierry/G-1118-2012; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; COREY DR, 1992, J AM CHEM SOC, V114, P4905, DOI 10.1021/ja00038a067; DIJKMAN JP, 1989, INT J QUANTUM CHEM, V35, P241, DOI 10.1002/qua.560350116; DIJKMAN JP, 1991, INT J QUANT CHEM QUA, V18, P49; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; Drenth J, 1971, Adv Protein Chem, V25, P79, DOI 10.1016/S0065-3233(08)60279-X; DRENTH J, 1975, P K NED AKAD C BIOL, V78, P104; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P156; GARAVITO RM, 1977, BIOCHEMISTRY-US, V16, P5065, DOI 10.1021/bi00642a019; Glazer A., 1971, ENZYMES, P501; GORDON CL, 1993, J BIOL CHEM, V268, P9358; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HUSAIN SS, 1968, BIOCHEM J, V108, P855, DOI 10.1042/bj1080855; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; LAVERY R, 1983, INT J QUANTUM CHEM, V24, P353, DOI 10.1002/qua.560240404; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; LI YS, 1993, J AM CHEM SOC, V115, P8523, DOI 10.1021/ja00072a001; LOWE G, 1965, BIOCHEM J, V96, P194, DOI 10.1042/bj0960194; MELLOR GW, 1993, BIOCHEM J, V294, P201, DOI 10.1042/bj2940201; MENARD R, 1990, BIOCHEMISTRY-US, V29, P6706, DOI 10.1021/bi00480a021; MENARD R, 1991, BIOCHEMISTRY-US, V30, P8924, DOI 10.1021/bi00101a002; MENARD R, 1991, BIOCHEMISTRY-US, V30, P5531, DOI 10.1021/bi00236a028; MITRAKI A, 1992, FEBS LETT, V307, P20, DOI 10.1016/0014-5793(92)80894-M; POLGAR L, 1974, FEBS LETT, V47, P15, DOI 10.1016/0014-5793(74)80415-1; POLGAR L, 1986, J THEOR BIOL, V121, P323, DOI 10.1016/S0022-5193(86)80111-4; RULLMANN JAC, 1989, J MOL BIOL, V206, P101, DOI 10.1016/0022-2836(89)90527-5; SLUYTERMAN LAA, 1976, EUR J BIOCHEM, V71, P383, DOI 10.1111/j.1432-1033.1976.tb11125.x; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; VANDUIJNEN PT, 1979, BIOPHYS CHEM, V9, P273, DOI 10.1016/0301-4622(79)85010-3; VANDUIJNEN PT, 1980, INT J QUANTUM CHEM, V17, P651, DOI 10.1002/qua.560170407; VERNET T, 1992, J MOL BIOL, V224, P501, DOI 10.1016/0022-2836(92)91011-D; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1993, PROTEIN ENG, V6, P213, DOI 10.1093/protein/6.2.213; VERNET T, 1989, GENE, V77, P229, DOI 10.1016/0378-1119(89)90071-1; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001	40	126	131	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	1995	270	28					16645	16652		10.1074/jbc.270.28.16645	http://dx.doi.org/10.1074/jbc.270.28.16645			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RJ347	7622473	hybrid			2022-12-25	WOS:A1995RJ34700031
J	TAGAYA, M; TOYONAGA, S; TAKAHASHI, M; YAMAMOTO, A; FUJIWARA, T; AKAGAWA, K; MORIYAMA, Y; MIZUSHIMA, S				TAGAYA, M; TOYONAGA, S; TAKAHASHI, M; YAMAMOTO, A; FUJIWARA, T; AKAGAWA, K; MORIYAMA, Y; MIZUSHIMA, S			SYNTAXIN-1 (HPC-1) IS ASSOCIATED WITH CHROMAFFIN GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; SYNAPTIC VESICLES; ANTIGEN; BRAIN; IDENTIFICATION; RECEPTORS; COMPLEX; FAMILY	Syntaxin 1 (HPC-1), a component of the receptor for SNAPs (soluble N-ethylmaleimide-sensitive factor attachment proteins), has been implicated in the docking and fusion of synaptic vesicles with the plasma membrane. It was reported that syntaxin 1 in rat brain and chromaffin cells (PC12) is exclusively located on the plasma membrane (Bennett, M. K., Calakos, N., and Scheller, R. R. (1992) Science 257, 255-259; Sollner, T., Bennett, M. K., Whiteheart, S. W., Scheller, R. H., and Rothman, J. E. (1993) Cell 75, 409-418). By means of biochemical and morphological analyses, we now show that syntaxin 1 is associated with chromaffin granules in the adrenal medulla. This finding raises the possibility that syntaxin 1 in chromaffin cells is a component of vesicle-SNAP receptor as well as one of target SNAP receptor on the plasma membrane.	MITSUBISHI KASEI INST LIFE SCI, MACHIDA 194, TOKYO, JAPAN; KANSAI MED UNIV, DEPT PHYSIOL, MORIGUCHI, OSAKA 570, JAPAN; KYORIN UNIV, SCH MED, DEPT PHYSIOL, MITAKA 181, TOKYO, JAPAN; HIROSHIMA UNIV, FAC SCI, GRAD SCH GENE SCI, MARINE BIOL LAB, HIROSHIMA 722, JAPAN	Kansai Medical University; Kyorin University; Hiroshima University	TAGAYA, M (corresponding author), TOKYO UNIV PHARM & LIFE SCI, SCH LIFE SCI, 1422-1 HORINOUCHI, HACHIOJI, TOKYO 19203, JAPAN.			Fujiwara, Tomonori/0000-0003-1369-7305				AKAGAWA K, 1986, BRAIN RES, V383, P110, DOI 10.1016/0006-8993(86)90012-0; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; DASCHER C, 1994, J BIOL CHEM, V269, P29363; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HODEL A, 1994, J BIOL CHEM, V269, P8623; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; HORIKAWA HPM, 1993, FEBS LETT, V330, P236, DOI 10.1016/0014-5793(93)80281-X; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; INOUE A, 1992, J BIOL CHEM, V267, P10613; KOH S, 1993, J NEUROCYTOL, V22, P995, DOI 10.1007/BF01218356; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYER DI, 1979, J BIOL CHEM, V254, P9854; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; NELSON N, 1988, METHOD ENZYMOL, V157, P619; OYER GA, 1989, J CELL BIOL, V109, P3039; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; ROTH D, 1994, FEBS LETT, V351, P207, DOI 10.1016/0014-5793(94)00833-7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	26	79	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	1995	270	27					15930	15933		10.1074/jbc.270.27.15930	http://dx.doi.org/10.1074/jbc.270.27.15930			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RH226	7608144	hybrid			2022-12-25	WOS:A1995RH22600005
